<SEC-DOCUMENT>0001628280-21-008878.txt : 20210504
<SEC-HEADER>0001628280-21-008878.hdr.sgml : 20210504
<ACCEPTANCE-DATETIME>20210504161716
ACCESSION NUMBER:		0001628280-21-008878
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210504
DATE AS OF CHANGE:		20210504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		21888700

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:2f8bb1a1-ab1a-4951-8c26-7b9e49d72adf,g:12312c6a-d00d-416f-b715-a9f74eefa2dc,d:4be9a0306d9c4f29ba82c2a83d136deb--><html xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20210331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF8yLTEtMS0xLTA_36d0feb9-34fa-4de9-9f62-e44e49d37ac7">false</ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF8zLTEtMS0xLTA_8a9dce33-38f0-4a11-b71f-32c2ae101f6f">2021</ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF80LTEtMS0xLTA_6cd9371a-0eab-4652-bc0a-338844c158b3">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF81LTEtMS0xLTA_b78f0396-d3ed-47c6-8f66-9a44750aafd2">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF82LTEtMS0xLTA_fccca1f6-af3b-4287-84f5-8829250d8161">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i002c88e9975348a9b63cef46a46fe8bd_I20210331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjY4_d3ea0c69-cbb9-4d34-80ee-4f04096945c8">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i453fc7e4d39e485696880a0068f3ac91_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55deba83f3ac420da3d9b6ec9427676b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iab4e0c85a3d84ffcab1a0012cecf66ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd883257c84a4687a5494a39e124d667_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53e0b5e6680f4291908d2acc03c5a95a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica34d212b8dc4e4eb77a34ebc1cc8e1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02e3ad207ffb4b27a99cbe2bb6344955_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b75390260714bd093b27d2888f6731f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i279bd903b27f4b1883910ef6730e4837_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d81ef37b6f41dc8f6b9d2391fe86ea_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c6e8db148e24765949ce24f00ae55c2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231e4a76d123433c8564b93e35aa1d22_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82edc27b271d404c8f4a64dd3f6d09f3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1bce859227c48ec937b364b0c755fb6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id569692232f44b089c8390de87c4cada_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c0f9028eede4cde8866b5ae5aa57301_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de66a8952c648ea9920beb1f440b1dd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ac77a17de44bb29cd358c8e38c4a67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81f6dd582b9643c0aaccfd23d753ec9b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14881f3db284ea58af6d0401f231170_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe452484de4488eb4d2377e776c52ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cfe10b5a20e4fa2b3b9874ee8383060_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd84aa923eee4c089192240132cbdce6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib311ed9a02b24bb49e4b526d0c3068c2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66fbbaa5c12e4acaa46d80bf7f899b95_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8adf3f5cfd514160ac3dc95f5c7ae73b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic79f4436f8484b2bbe53cd473de9e52e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67bf00db7caa48c4a6d8cf45da387715_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae1200701864b2592f8e63d6320339b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ebacde06924391a242a1ad5478841c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7af747e9403b4e1ba505b3f4ba6cee05_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563dfbe34ad4474ea0cf1df69ce7d40e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c16f4045ec2486c9655bc30dbea465c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i873c9f5644134b289bd2510df3750392_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i024dc19eb24b4daab222db22932603df_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91dfabbfcb6c42b6bb0bf2d326d97a54_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332314e60491404688c2fb0fef961934_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61dbb95b254048c5aba2eb7163863213_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i797c92907973403a9443e0c27091c0f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5b3cce32d374c0cbcc1ed41e9b476bc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ef830db3b5a4c42bce46b64a5716cf5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54f8c76b5c842219a02086497ccdcf2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d66e275ba74d119f72575fcbff978a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc652101e3c4c20b3cf3a98ba873683_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635047121e6c4458b824262db0945d4e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82295ac670bb4f48911ed7686079294d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd3e7b1c54840f38d767f4d886e6a20_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d2bc412b074d02b1f276ca18f76761_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8966338ebc438da839ad284fa2d835_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7db582e5de644bcb1b85a92b0e5f562_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i271e9f7a598345499ec311df587568ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78163204b2e442aea1bef8ca15bd3185_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e7ce110dc7a4abc917e9ff1f848c5c9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i106cafb1122d4c0e9f548d6e74623320_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e6eb66bd26477ab90813ade9edfb03_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46865ce5446e4b3581efb803f5308180_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89889f9b7a0f46bebb2b75f129454b9e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if04c5d46d250473194dd874c126bdbc8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dc8108057d44225a1ea75bd1ff54b19_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i419d0e887e054403af4e6b64c3884a5a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51edc4e56f8e4a7cb40c8d663d6c17d7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33962be218df46e4bb2551730a919275_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41dd293fb24a49c58c23d0ed05154696_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ef26cb1f0244fd88cc3a23ee2cb867_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bc5de5ccb1a4b8aaffe4d2996876f39_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if45973c1fb6444ea88b6e3c888274698_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2c1ad6d704e41659c0fd0df2e944744_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d4134488184de8a1fa41faf29af748_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8f6a626ca824ba0a50ba08002bf41f3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b36af6a83fa481bace8cd4e6fc87589_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1526a93629134bf5a457c273f64476aa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida4abef0acf44596a26f1a6b9c75bcdc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i049f3221e84245a9b058bae1da73bc95_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162a782c6f754612b1731de6c5d3c0d2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iceb962d8a3b8454e9d31307a65f31666_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic31c2d44d30d4f72b00d4d3dc2f0ea0e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2068f55b1b64c409a3faa26ee2644cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7da0f47f5194d899b2a75cec012f983_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9fa3dbd2e0444181f5a6e3e7046acb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e460cd7328340128515c28a0c9286b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ac6cc477e44273a668068859113a3b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ae0a19620647ba86b490ea19afde52_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eb74ef8efdf48d992458b94198588ac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09b72198ef2049a59d0032b521440eab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4829f8fd2ceb499a88d1a605878ef324_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad0091ec4e44a5c95e0c234a8797e30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6857d704b93459f901a1ad318f49bde_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa573862768c47788f0353badcc8a2c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if80129c7bc444c6c89ddf9cfc902a3bb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cbb561c5be14e16a7780931e372eeaf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i648e5da489e74498abd8b5eb03f88c29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17aabe1f736146ce8ab6b6adf624da61_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5951cf3812f84d1b880568d902f8ffb0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02a6ede247654801b23070be6fe9771f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i927cfac1568340718ec2370561ddff86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c77548671c64b518a9d84a96771bd0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieebfdbf5d1314dbf8980ccd6c0efeb45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba723c7ee42434e90ebc7232841e8db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15841938ea744133a39ee8f0276f4e94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a7cf6c983f4c9589afcfe337a84376_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85fee7acc1c942e3a814f2d4a0f959b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b7c87fda55463998db819047f79ca3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bc5cd0ff3e2431cb254b14fb4219da8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9866ab5b25c94734a96e173d3df99684_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cffbb4314d64ee4b5119c285bb1bdf8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i468e13f71bb44158bc1ebf6b962f54ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icce97d825f8b420eb0fba22b6d0a786f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1129259eb0a649868776568fa4898425_I20180720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b1a80eaeeb470bb98449ced38f5857_D20180720-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-20</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1087025adac9402fa10512e9bbce394b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i373acdae6305402aa0be5cf76855d613_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a2f2e458499460c9d2f8569ded9b145_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i3ad2a2e3a84b4100b7319b30812c47e6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icef8cccbf6ca4534ae5c619f394063a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6869d31d7a094145bfb28ac75b1e9b65_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i280b535896024bcd95cb6e05701ce4a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ad1dcdb92f74b6aa8153279f247ec2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i672e278ea9d9400fb2d871ecc0490a9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i096af9793db343b0815caa338ffd63a8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic336725f5f2a462798de6f9160210fdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1004bec248ae4ca1ba8a9c29ad354f09_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46c3138c0eba415ea37d06436df62854_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i859a69b7c32743829ed4f102732a1722_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39b2e0222b2542508d6cd3681b08a431_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i434d6421401646d8819ebb7f70ca4def_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie037112c32294882bba7e7dbbf15ae0a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddf917e0cbb043a6a5d13564bd385789_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b613add127642da88c0f1e731060ffd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53804a6be8344f08a5725ae1fe862146_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ad382cd550f476288b6b8449774030a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08febcafb084cb3800af6dd3c8ae060_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00b352c0d2ab458ebc5713e73ef66c30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic558cd205e844605965ec5e4461a1ba5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81c0ac6823a34b509afee459208f16b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c74fee69544d6fba7898340eefc923_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if88ebd43c71848c89734b2715f66361b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc2e857539f4ef4ba7daadf58df7f59_D20171201-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3acb6e7ece7c4264be4a73e7e4f9a1d1_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33584313d634d6ebb308bbe8e5d106b_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7809379654904198b0f40fede3b357a4_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f4f202adee470e8770f3ce345ea450_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757166e143b64a41ba577ebe4be02b45_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34fb2fbe43f84642b4ef2537c5369e1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a7d845e25d44dda4758f9bcaba97fa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0431659b3584e55b72f8e5b04fcf870_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ffb4ef28e24434bf448ba66f1f1afc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005c57a24e8f443ca9c1180106705ef2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54a4cf97110343f3a88212e70424cd96_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3542eb13ee6148b8b4bcdd99fef16454_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd855b9275c4a8eb8f323a68bbf1d77_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb99906f06b46e8b267391bde6b0830_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36d2806042d4050b552799fc92519e9_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4bf6163ffff418c83013f140a3d867b_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3274c4f79e0340a5ae43580f04c8e34f_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product_target"><xbrli:measure>sgmo:product_target</xbrli:measure></xbrli:unit><xbrli:context id="i1492cd406dd2436db6296241d9022d11_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e07997bca414cf2953b42b65cb1fefb_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f7ac715a9b948b18839034f530a5ddd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f78e88d6b69472e839f423e5b345307_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib69b2d9da4aa46f294f132d7d0fd52f0_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5f5ec067c64bd38439f1f0e454a1a3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ce08d1f25be4729bc3e45da23cef7b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2118dcb01a3143bb92d2503658c8e4de_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98afd062347644fe9caa179181f1d6bb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1f36c6406ec47d0a03002619c66f091_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i828c0aafea3d4fdfb8f588e64d921e4c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a6386cca364200a895bc9cda07eadd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cf45da81af341b5af253ace0465bd98_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i868c9fe32a52452dab9aa2f991f5ac1f_D20180405-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-05</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d691cfac5fc48f6ae86378e6b4a002a_D20180405-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-05</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5161917923e141dba34488ab948e41a6_D20180405-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-05</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad0d9faf81c84a81aa9b16164821cf1d_D20180405-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-05</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>sgmo:option</xbrli:measure></xbrli:unit><xbrli:context id="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ba008f3a5a42be83d38ba385bbc8d9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i184e9ab5d0b74ca68b16888bb4007dc0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3d9c81024248b1adfc4a25b7c4d391_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb423d0affaa4d709010389b445356c0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01acb0b530634a9f92961bce1668f40d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d076890fcfc4f4cae05e8d5e034c7b2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7559393313442091af1abf5c735f2b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d499b745bbd4aca82c6887941eb2f4b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9f9edf27124c6a8611cf6dcc485c06_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11db6cb00c9c4e91a017c15c76688b71_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607adea8b9544c9a857fd7049243e384_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if807a38abb434889be2ed63115c6d893_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b355d6fe77d457698c955bfed974e53_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0739b227da3b4bca85dcba2a54effd31_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:context id="ie9c5e3edd0db4669b6958fb4f83b506b_D20170501-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:context id="ia108ccb69cd546219ec3a5224afff3d6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="royaltyfee"><xbrli:measure>sgmo:royaltyFee</xbrli:measure></xbrli:unit><xbrli:context id="icc1d6a7d7d9648f297ef3f74c21f27f5_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02a2a6eb3a3422dbca515f54079ab86_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b75336922ca48acbeec35795e3f89c0_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc16c1fdcccf4d5798400ac9fd30c32d_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PhaseThreeClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibefa2eee1d224a5a8a3a002053b6b569_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PhaseThreeClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id906fae1befa40139b59199d084644fb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c5af769a3724b79ad162f6dc82b9325_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e53a9d7d29f4ca7a15cc2342c452633_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0794a490e25b4316b034257c060699e8_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9117357d274e389ec4bb2d954d40a3_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie71a3d375d8949d28e7d537186c4fba5_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i552e02bdf7ff40bd9f7d8d307d5ed4a0_D20171201-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12192197df6e4c748c74e75b895766dd_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i263f5e49eb104d2b951703a42c48374c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81052728a07f4234a17255473a25eb02_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>sgmo:program</xbrli:measure></xbrli:unit><xbrli:context id="i2b8e1d577cdc4e909e22ace81ac93119_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c2127ce4c454d39bf4876ba0fcacebf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bcae7d19c204753a2408edcca187aea_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85f4919f9c0c4473b1ebc3b0d83ed945_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic69d4938e11f4400912ca470c0f2df17_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d256269518436384e6a844f9460eb3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2f0c509626e41d2b12512c505830612_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3452b189334360b2eae0dc8a8f906d_D20140101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie081f263ba514369a864fc04ab2755ef_D20140101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i900c9e6b08d34f609332901a02f4e019_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70098c2ae44f43d0b6cc32e42dc76aff_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfb4fcf9f2374b178f3f64eb7492ba62_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8946000fa68f43baa5c040af17dd5bd5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cf33b15cb6f4155a7c06a66148748b1_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e1b297e2e824a43b69317d3cf60c21c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if64ca9e8294649218a45ade74be60132_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia042567c5f69499ca3310b43148a2dc4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a483e7e113b40b4932319e4d56036a0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412d6af141ea4a5eaff0bd4986d51146_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2a5a95ecafb44a7874d3bd37d807e3b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ec745d260041b8a59a2e8dc45ffa91_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie63bf8b36b024460a56259f11296d885_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51c2ae6d077473d8293fa2b46203655_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dae3ccf0cd54c5fb3e19ed6a18b06c8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f0be7b4249420ab4cc66f467c2f873_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic886d255bdf04e18ab350c75c4128994_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i31a1ce4b0e414b9186ddc9401df9e1ca_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08adf079a35e4e43a2b4ac18b46404b4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f2a73e9b4a48b496f08bbeb4ae0cda_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i002c88e9975348a9b63cef46a46fe8bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4389a31659b5435cbd086cba9f72cb06_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if674a30905aa4701b577fea5cdd38927_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49ed718922c34bacb4fe8ab46f011d3b_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb8843fb3d341009157555d58c1790d_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62fb65868a04407c87a0eefd5094126d_I20210129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied0c47637c5a4c5786b8ac57faeb569b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie59ea076e227497193dff8217d78482e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:LonzaNetherlandsBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21a9537a071b45a490485e4e675afbda_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7879f7c1ca14257a286f0937f160d6a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7121386b2ac42788064446ea02e0293_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i689dc02e331246b1b5c7ee22451f278f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d2cd66475ef461e9c805c9eaaaca699_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29077b179cb747c6af600e5610999238_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4031384af7314ae98be13e046f877228_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628ef7e645dc4f99a3b94a2aa9545377_D20181001-20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25f4525748b042cb9cf63d0d356cdd37_I20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-01</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.527%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjY5_20be905a-0f66-4e8d-9b33-3ffce6705d35">10-Q</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6ZmRhOGVhMjBmNmQ4NDZiMzkwOWM2ZTYwMTUwMDFhOTQvdGFibGVyYW5nZTpmZGE4ZWEyMGY2ZDg0NmIzOTA5YzZlNjAxNTAwMWE5NF8wLTAtMS0xLTA_d47931cb-fb74-43f1-b30f-38f6784ba2e3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMzM_027739b5-30ce-4484-aa49-66853c503aa4">March 31, 2021</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="margin-bottom:6pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6YTc1NmZiZmFkOWQyNDU3MjgxYmZmNmIwYWU4MjQxYmQvdGFibGVyYW5nZTphNzU2ZmJmYWQ5ZDI0NTcyODFiZmY2YjBhZTgyNDFiZF8wLTAtMS0xLTA_86d9d692-1a61-4f8c-8344-6a333c45adb5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjc1_30530f6d-1e3e-4505-9d4c-aeda873c7d73">000-30171</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjc3_6d3bbb03-cf5b-4dcb-acdd-6db4119b8c34">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-bottom:6pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:30.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18wLTAtMS0xLTA_1d905462-0bb8-4e6f-b31a-13d4a1210055">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18wLTQtMS0xLTA_d70f8ff5-c445-41da-8d57-d0ced463be90">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiOTEyOWI3MTcxZTc0N2M5YjhjZDgzYWI5YmZmMzRmMV80_e8a248ce-57a0-4ff7-9dff-9b8a9506c2e5">7000 Marina Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiOTEyOWI3MTcxZTc0N2M5YjhjZDgzYWI5YmZmMzRmMV84_b82405a4-b845-4405-8d61-032c22e2b3f8">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiOTEyOWI3MTcxZTc0N2M5YjhjZDgzYWI5YmZmMzRmMV8xMg_14fc50b2-0cda-408f-b2d5-211c1fd33192">California</ix:nonNumeric>, <ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiOTEyOWI3MTcxZTc0N2M5YjhjZDgzYWI5YmZmMzRmMV8xNg_f3c1f4d8-6fd0-4def-9b6b-ce449b88f59b">94005</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjcy_5dcb8e8f-1b55-4a3a-9358-a35ddfb99e49">510</ix:nonNumeric>) <ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjcw_6e585944-3795-419e-8a11-69560dbb8f35">970-6000</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:38.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6Mzc5YTgxOTM5N2VjNGNkY2JkM2MyYzdhMWRjOWUzMGIvdGFibGVyYW5nZTozNzlhODE5Mzk3ZWM0Y2RjYmQzYzJjN2ExZGM5ZTMwYl8xLTAtMS0xLTA_17afae51-4539-4cc9-80c9-80d0185dce81">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6Mzc5YTgxOTM5N2VjNGNkY2JkM2MyYzdhMWRjOWUzMGIvdGFibGVyYW5nZTozNzlhODE5Mzk3ZWM0Y2RjYmQzYzJjN2ExZGM5ZTMwYl8xLTItMS0xLTA_56b02673-d9ae-428a-aebf-ace3e634e450">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6Mzc5YTgxOTM5N2VjNGNkY2JkM2MyYzdhMWRjOWUzMGIvdGFibGVyYW5nZTozNzlhODE5Mzk3ZWM0Y2RjYmQzYzJjN2ExZGM5ZTMwYl8xLTQtMS0xLTA_415a3e59-ae5b-4ebe-a2e4-10d0c42768cd">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjcz_4a5eb67a-0928-4420-ba40-05d41226a4cc">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjcx_8cdcd4d5-ec9c-4c62-affd-7d7cb74011da">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:21.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6YWYyYjlmYzdlZWU5NDZhZTk3MmNiYTVhY2NlNDNmMDAvdGFibGVyYW5nZTphZjJiOWZjN2VlZTk0NmFlOTcyY2JhNWFjY2U0M2YwMF8wLTAtMS0xLTA_4209385a-a71e-4f68-8e93-2a36190d5dad">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6YWYyYjlmYzdlZWU5NDZhZTk3MmNiYTVhY2NlNDNmMDAvdGFibGVyYW5nZTphZjJiOWZjN2VlZTk0NmFlOTcyY2JhNWFjY2U0M2YwMF8xLTQtMS0xLTA_b5c755ce-1040-4de5-9f1f-6228985a28f6">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6YWYyYjlmYzdlZWU5NDZhZTk3MmNiYTVhY2NlNDNmMDAvdGFibGVyYW5nZTphZjJiOWZjN2VlZTk0NmFlOTcyY2JhNWFjY2U0M2YwMF8yLTQtMS0xLTA_3f71df62-f056-43fb-896d-135042812324">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjc0_d92a763b-be91-41d1-8a7d-750fe12f7841">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;&#160; &#9746;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of April&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i453fc7e4d39e485696880a0068f3ac91_I20210430" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMTgz_c98828f1-f3c1-4da8-9200-848a68ffeeec">143,881,477</ix:nonFraction> shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding.</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.527%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19">Condensed Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19">March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19"> and December 31, 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_22">Condensed Consolidated Statements of Operations for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_22">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19">March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_22"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_22">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_25">Condensed Consolidated Statements of Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_25">Loss</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_25"> for the Three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_25">Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19">March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_25"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_25">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_28">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19">March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_28"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_28">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_34">Condensed Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_34">Three</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_34"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_19">March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_34"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_34">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_34">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_37">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_73">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_73">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_91">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_91">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_91">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_94">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_94">36</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_100">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_100">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_100">37</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_103">Item&#160;1A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_103">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_103">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_106">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_106">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_106">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_109">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_109">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_109">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_112">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_112">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_112">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_115">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_115">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_118">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_118">40</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4be9a0306d9c4f29ba82c2a83d136deb_121">41</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to &#8220;Sangamo,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. and Sangamo Therapeutics UK Ltd.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This report contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development, manufacturing and commercialization activities, clinical trials, operating results and financial condition. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategy;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated research and development of product candidates and potential commercialization of any resulting approved products;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators and strategic partners;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of our product candidates, including the durability of therapeutic effects;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of technologies used by us in our product candidates, including our gene therapy and cell therapy technologies, our zinc finger protein technology platform, zinc finger nucleases and zinc finger protein transcription factors;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the impact of the COVID-19 pandemic on our business and operations and the business and operations of our collaborators, including clinical trials and manufacturing, and our ability to manage such impacts;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development and other expenses;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers or from our own in-house manufacturing facilities;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates and the timing and costs associated with obtaining regulatory approvals;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies required to develop and commercialize our product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments, including the impact on our competitive position of rival products and product candidates and our ability to meet competition from rival products and product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the growth of our business;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected operating and financial performance;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operational and legal risks; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by use of future dates or by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;project,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;goal&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with no approved products or product revenues. Our success depends substantially on clinical trial results demonstrating safety and efficacy of our product candidates and durability of therapeutic effects to the satisfaction of regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our product candidates are based on novel zinc finger protein technologies that have yet to yield any approved commercially viable therapeutic products.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We require additional capital to fund our operations and continue operating as a viable business. This additional capital may not be available to us on favorable terms or at all.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely heavily on collaborations with larger biopharmaceutical companies to generate revenues and develop, obtain regulatory approvals for and commercialize many of our product candidates. If conflicts arise with our collaborators or if the collaborations terminate for any reason, our revenues and product development efforts would be negatively impacted.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology and genomic medicine are highly competitive businesses. Our competitors may develop rival technologies and products that are superior to or are commercialized more quickly than our technologies and product candidates.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing genomic medicines is complex, expensive, highly regulated and risky. We currently rely heavily on third-party manufacturers and have limited experience manufacturing products ourselves. Manufacturing challenges may result in unexpected costs, supply interruptions and harm and delay to our product development efforts.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approvals for our product candidates, our approved products may not gain market acceptance among physicians and patients and adequate coverage and reimbursement from third-party payors and may not demonstrate commercial viability.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain, maintain and enforce necessary and desirable intellectual property protections for our technologies and product candidates in all desired jurisdictions, which could adversely affect the value of our technologies and our product development efforts and could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on hiring, integrating and retaining additional highly qualified skilled employees and retaining current key executives and employees, which may be challenging given that competition for these individuals is intense.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The evolving COVID-19 pandemic could continue to adversely impact our business and operations and the business and operations of our collaborators, manufacturers and other business partners. If such impacts become material, our revenues and product development efforts could be negatively impacted.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of any investment in our common stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional discussion of the risks, uncertainties and other factors described above, as well as other risks and uncertainties material to our business, can be found under &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on February&#160;24, 2021, and we encourage you to refer to that additional discussion. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect, and we cannot otherwise guarantee that any forward-looking statement will be realized. We hereby qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You are advised, however, to consult any further disclosures we make on related subjects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes discussion of certain clinical studies and trials relating to various product candidates. These studies typically are part of a larger body of clinical data relating to such product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical data are subject to differing interpretations, and even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_16"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMy0xLTEtMS0w_ca8f4747-5f9e-4901-aa3e-3ca93f590adf">122,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMy0zLTEtMS0w_b8137237-4f2b-4e7b-b059-d29f183c16c9">131,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNC0xLTEtMS0w_4aa9e00d-4087-4be9-97be-5a186d11601e">464,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNC0zLTEtMS0w_fa85f019-1aa3-42a1-aeb1-de6e92125607">510,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNS0xLTEtMS0w_d1204586-b44a-4357-a10a-c526bb1c56e4">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNS0zLTEtMS0w_21909382-e893-4572-966f-c26aa11d1410">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNi0xLTEtMS0w_78d5bf01-efb2-4e70-94f4-bd391a65caf3">6,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNi0zLTEtMS0w_8f00ab41-0fbf-47f4-8f24-5d25c40df162">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNy0xLTEtMS0w_ccacadb2-1292-43f1-af6e-d6ccf2c5ca66">12,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNy0zLTEtMS0w_2ebb503e-89f8-44c1-9c14-c0e328070684">11,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfOC0xLTEtMS0w_d5a8ab29-b5cf-4ae9-b41a-0238771d467f">606,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfOC0zLTEtMS0w_e3ad8b1e-b0da-4437-a5d1-fc6d991210b9">659,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfOS0xLTEtMS0w_48ff6d20-40ce-41b8-aa5f-bc039bb6fe45">42,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfOS0zLTEtMS0w_94e0fe59-3061-4e58-83fe-09b214a71ee2">50,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTAtMS0xLTEtMA_faa2b25f-e309-451d-9cc0-85ee177208ee">45,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTAtMy0xLTEtMA_e8b7a7d9-9dc8-434f-8271-81922235cb58">41,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTEtMS0xLTEtMA_5c22efb7-3554-474b-96d7-7d689ff6e0b2">55,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTEtMy0xLTEtMA_9d27fc08-a9ce-49e1-883c-0c2372e6acf2">58,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTItMS0xLTEtMA_4fe04845-cef2-4f14-bc84-b158dc81b59f">40,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTItMy0xLTEtMA_3ae3b7ff-20b6-43b3-a8b7-18b1935d3742">42,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTMtMS0xLTEtMA_3fbb9043-7823-4ab2-8891-a622471433d0">70,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTMtMy0xLTEtMA_a8ae27fc-9e24-45cd-aa9c-d11a0c8d8b8a">71,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTQtMS0xLTEtMA_6a087290-92ac-471c-a882-29275f11b158">14,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTQtMy0xLTEtMA_4baa94d2-41e1-4207-bc46-02d2c6f43ced">13,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTUtMS0xLTEtMA_d7e236f1-5b90-4411-a13c-e7516886e8b3">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTUtMy0xLTEtMA_5fd02efe-2992-4920-8a47-a63db78f65c4">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTYtMS0xLTEtMA_07b55dfb-7921-40d4-8141-e92b3da945e4">877,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTYtMy0xLTEtMA_f9c4383a-5939-4a4c-960b-c68cadb635fb">938,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTktMS0xLTEtMA_e1bfdd4f-0640-487b-a285-0ae0a4bcf6de">11,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTktMy0xLTEtMA_94852f02-8e20-47ec-ad1f-288a37e75b91">12,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjAtMS0xLTEtMTg0NQ_48c98c4f-53db-4770-b78e-8b6ba54b8365">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjAtMy0xLTEtMTg0NQ_181a0c8d-3247-4639-8cd0-ba42239adcae">20,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjAtMS0xLTEtMTQ1_0453a3f7-dde6-494e-b749-f36908103d8e">13,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjAtMy0xLTEtMTQ1_4b63e814-c4cc-4ef1-bb8f-b4ef8d084d89">18,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjEtMS0xLTEtMA_9b98b078-7ab9-49ef-9e4a-9c6805480c7f">94,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjEtMy0xLTEtMA_98ec157d-6cc2-4448-b217-df464a384005">91,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjItMS0xLTEtMA_1bb82e28-efb8-414a-983f-f94a69d4ed43">132,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjItMy0xLTEtMA_c0fbe4e4-c836-4d16-af48-dfc6058899ae">143,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjMtMS0xLTEtMA_c249307d-19d1-450e-80ea-2e72d6aa35aa">222,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjMtMy0xLTEtMA_3dcec622-c15d-470b-b454-5b96087a17db">245,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjQtMS0xLTEtMA_9fb24952-e77b-4f18-bf80-8de468c0e99f">38,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjQtMy0xLTEtMA_6a8be7de-79e4-466d-b21d-3526ce61d812">38,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjUtMS0xLTEtMA_2a9d62b4-0f85-406c-b1b9-25cdaccc7df3">6,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjUtMy0xLTEtMA_c3668feb-f735-4a7a-801d-0939006d6969">7,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjYtMS0xLTEtMA_0ef46ef0-a036-4dc7-bcd9-58d86dd7fcbe">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjYtMy0xLTEtMA_013022ac-47b7-4a18-ba2a-94d4e171b1af">7,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjctMS0xLTEtMA_eba99778-ce03-4fda-9c9a-90cada7930ad">407,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjctMy0xLTEtMA_e79bb91a-53f8-43b8-8127-28329816451c">441,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjgtMS0xLTEtMA_7243f50c-0707-4097-a72f-6c399747ec39"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjgtMy0xLTEtMA_84a364a1-c775-45d1-adea-6c8b6db64127"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzAtMS0xLTEtMA_db07df4c-56fa-4e9b-882a-2b4c03cc9ec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzAtMy0xLTEtMA_95ef544c-7daf-4e73-bea3-0462043527a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzEtMS0xLTEtMA_a4982fec-b731-4e39-8a2d-5493b8e3f81e">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzEtMy0xLTEtMA_fbc2aade-bc68-4524-974e-9a67c6185b0e">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzItMS0xLTEtMA_b9583a76-65ed-410c-bc2b-cefb17405857">1,292,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzItMy0xLTEtMA_66825401-f5a4-49b1-8b06-59cddc6831f1">1,269,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzMtMS0xLTEtMA_9b3b15c1-f6f0-4cb2-8732-3749caa8d1a6">823,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzMtMy0xLTEtMA_999f5b55-829e-4db8-99e3-71a140fecfa5">777,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzQtMS0xLTEtMA_be53a351-2e17-4e49-b241-393eee55019b">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzQtMy0xLTEtMA_b8f7deb1-1fde-476a-a1a6-aa9ada6e8ced">5,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzUtMS0xLTEtMA_57d75c0a-4fb6-4f42-8de5-d928e9835fcc">470,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzUtMy0xLTEtMA_aa19d098-e6e6-4e1b-81b2-99601d0abda3">498,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzYtMS0xLTEtMA_c0406e02-9364-42d7-85cb-91f38eed1555">938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzYtMy0xLTEtMA_69ab08d0-ca3d-478b-b3f2-d541bf674191">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzctMS0xLTEtMA_003da965-5bde-4253-a5ff-88dc00b38c0b">469,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzctMy0xLTEtMA_532f953f-da96-487d-819a-209656d11c2b">497,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzgtMS0xLTEtMA_caa82941-d98f-4113-86fd-2e8389cbf57e">877,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzgtMy0xLTEtMA_57d45cb0-2a3f-4596-96e3-28bbac321d82">938,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except per share amounts)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMi01LTEtMS0w_a5449d37-0cb2-440b-9a82-a8ab890dbe4f">26,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMi03LTEtMS0w_973cb0af-6dee-441b-990a-b4b18238e010">13,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNC01LTEtMS0w_ea55b675-d190-4685-ac18-c18fa4c1b40b">56,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNC03LTEtMS0w_954a76ab-ffd1-4c0c-9499-588b2a121937">41,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNS01LTEtMS0w_d101e201-588b-4fae-950c-feac63384b0d">16,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNS03LTEtMS0w_ec36b26b-ddec-4012-ac93-8a17867bd620">16,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNi01LTEtMS0w_6ca66601-2e7a-4777-9b2c-c457c8a5378b">72,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNi03LTEtMS0w_e8093038-29cf-46c2-806b-74a788895547">57,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNy01LTEtMS0w_6ab247bf-0215-42a2-ae6e-81cc60db6faf">46,302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNy03LTEtMS0w_2110cceb-faa3-4a6f-9f99-6fd7c64d1274">44,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfOC01LTEtMS0w_5e4a33c6-3821-4c7e-aaf6-efa3fb849c66">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfOC03LTEtMS0w_95678a7d-179d-4b5c-a346-6f2a5a6e1235">1,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfOS01LTEtMS0w_2b08d7c8-7b29-4012-b056-485b7f0c4144">45,677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfOS03LTEtMS0w_870b359a-e916-4fc2-8374-7aabf762878f">42,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTAtNS0xLTEtMA_3eaee0ad-1cc2-4199-8ac0-25d2ffba164b">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTAtNy0xLTEtMA_92b78116-6918-4b11-977a-2554b650eb33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTEtNS0xLTEtMA_684ea2c2-f277-4ae7-8c0c-88c6974bb243">45,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTEtNy0xLTEtMA_a77e1840-3707-469a-be17-b43097b8c163">42,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTItNS0xLTEtMA_2d8f9764-e786-4f39-8207-c40f63f54e76">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTItNy0xLTEtMA_da97e928-35de-44f1-84be-7fde6ddd253d">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTMtNS0xLTEtMA_6a4d2734-d152-4769-9073-f414ab8e3257">45,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTMtNy0xLTEtMA_8516d294-18c0-411a-a160-90f459ce4f6c">42,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTQtNS0xLTEtMA_f32e37da-1018-4e3e-b7c5-152208bd6406">0.32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTQtNy0xLTEtMA_e76735c0-c6a7-4aee-aac3-20e3eceb6796">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTUtNS0xLTEtMA_1da0c37e-fefe-4409-86b3-86717df66017">143,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTUtNy0xLTEtMA_a4fa6928-8446-4e1f-856d-68793927f71e">116,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfMi01LTEtMS0w_684ea2c2-f277-4ae7-8c0c-88c6974bb243">45,939</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfMi03LTEtMS0w_af1a3c1f-0a86-489a-90a5-133d95e27a54">42,974</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfMy01LTEtMS0w_f8d51b91-cab1-482b-bf53-3bdaec8bc8e3">4,749</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfMy03LTEtMS0w_1cb85838-736c-4065-8f95-a40b499b7bdf">1,633</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gain on marketable securities, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNC01LTEtMS0w_e55b730b-5434-4de6-8c66-ee0ac7082216">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNC03LTEtMS0w_84d0878f-44be-47f0-97ed-1d99fcf5b8a2">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNS01LTEtMS0w_ee9a7069-8876-4028-b104-134cf5b910e9">50,644</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNS03LTEtMS0w_3e15d444-95db-4cbe-814d-b9ce5b6a3116">44,353</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to non-controlling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNi01LTEtMS0w_f7f27081-b0c7-4561-8f87-5a4fecf2c875">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNi03LTEtMS0w_f8d502b3-3743-4715-9853-01150583d0bd">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNy01LTEtMS0w_ab828e88-7447-4c51-8d7d-04794ad15ea6">50,638</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNy03LTEtMS0w_c65fe698-da7d-47d3-8b9d-7cdb4b8be200">44,292</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.652%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.526%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab4e0c85a3d84ffcab1a0012cecf66ca_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy0xLTEtMS0w_f43e15b2-c1fe-4049-9e2e-0eb1359e1487">142,063,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab4e0c85a3d84ffcab1a0012cecf66ca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy0zLTEtMS0w_19752b17-0558-49d4-a66c-87428f5219f3">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd883257c84a4687a5494a39e124d667_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy01LTEtMS0w_d7524f9b-1e94-4c07-bf80-b0fbb68b179b">1,269,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53e0b5e6680f4291908d2acc03c5a95a_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy03LTEtMS0w_d87fb179-907d-4435-93ee-4eb7a7edff7f">777,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica34d212b8dc4e4eb77a34ebc1cc8e1b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy05LTEtMS0w_44bceb6b-5df6-4d22-8c14-0345031b18bb">5,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02e3ad207ffb4b27a99cbe2bb6344955_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy0xMS0xLTEtMA_45f9c08b-747b-4496-99e5-374b2a85e796">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy0xMy0xLTEtMA_5ee661e3-372d-40be-a2e4-27729fea492c">497,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock in connection with at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b75390260714bd093b27d2888f6731f_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0xLTEtMS0xOTAz_82f6ed45-155a-4add-8584-d70fa27c2bf3">1,034,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b75390260714bd093b27d2888f6731f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0zLTEtMS0xOTAz_686af727-1a12-4bed-a771-4f22612522a0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279bd903b27f4b1883910ef6730e4837_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC01LTEtMS0xOTAz_0959732b-50ee-4b7c-93c5-d4486338d579">15,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0xMy0xLTEtMTkwMw_7a80ed1d-5c68-4ed6-bd81-2893fe33aabb">15,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b75390260714bd093b27d2888f6731f_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0xLTEtMS0w_70cbf323-92ef-480a-8af6-95076d7323b6">615,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b75390260714bd093b27d2888f6731f_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0zLTEtMS0w_49cdcc3a-e48b-4239-9925-d90b1b38398c">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i279bd903b27f4b1883910ef6730e4837_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC01LTEtMS0w_48b63b92-302b-4104-ae66-feee4c66089d">422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0xMy0xLTEtMA_ea9f59d6-e96a-4881-b232-1eca25467a84">416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i279bd903b27f4b1883910ef6730e4837_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNy01LTEtMS0w_eca6d5ba-0595-45d5-bdc1-a0518c33f1d8">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNy0xMy0xLTEtMA_d3661b2f-e580-441d-8a2f-d283274adc8b">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of additional shares of Sangamo France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4d81ef37b6f41dc8f6b9d2391fe86ea_D20210101-20210331" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfOC0xMS0xLTEtMA_af7c6a45-67b4-4c2f-8b36-fed7cf5b5224">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfOC0xMy0xLTEtMA_58d98446-071b-44b6-ae72-b28bed46426a">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c6e8db148e24765949ce24f00ae55c2_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfOS05LTEtMS0w_7674cffa-afdf-4215-8443-f0d4b15dc3c7">4,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfOS0xMy0xLTEtMA_bf09e460-2047-488e-bf02-bedee39ad7b4">4,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c6e8db148e24765949ce24f00ae55c2_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTAtOS0xLTEtMA_86870d34-ff03-4b20-a5bf-a3745c599175">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTAtMTMtMS0xLTA_75e29756-0bb1-4a25-aacd-60b2819a9745">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i231e4a76d123433c8564b93e35aa1d22_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTEtNy0xLTEtMA_ddda627e-55df-459a-a65b-7999a1cebb6c">45,933</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4d81ef37b6f41dc8f6b9d2391fe86ea_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTEtMTEtMS0xLTA_2c3249e8-ed78-477b-870f-44df1779575c">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTEtMTMtMS0xLTA_7ffec78e-dd2f-4a9f-ad44-d916b560010a">45,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82edc27b271d404c8f4a64dd3f6d09f3_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItMS0xLTEtMA_e6359452-19ef-4375-929c-c0830c127df1">143,713,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82edc27b271d404c8f4a64dd3f6d09f3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItMy0xLTEtMA_a8f7e082-6248-49b7-a047-62d69f1bba81">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1bce859227c48ec937b364b0c755fb6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItNS0xLTEtMA_11faf270-923b-4e4a-ac52-d1ab3bcad7c5">1,292,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id569692232f44b089c8390de87c4cada_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItNy0xLTEtMA_5b456dc0-7395-4a5e-a6b5-2ea3f6a03545">823,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0f9028eede4cde8866b5ae5aa57301_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItOS0xLTEtMA_caf98dd7-5b61-41d9-afc0-0e2e45fc10a8">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de66a8952c648ea9920beb1f440b1dd_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItMTEtMS0xLTA_44a1b135-0c5f-485f-b82c-9959e454b74d">938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItMTMtMS0xLTA_223ae074-1270-4238-8e55-2ffa9f144582">469,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.652%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.670%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.244%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0ac77a17de44bb29cd358c8e38c4a67_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy0xLTEtMS0w_053ae366-3bb4-4459-87d5-1c97fcb94683">115,972,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ac77a17de44bb29cd358c8e38c4a67_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy0zLTEtMS0w_b3681633-db7a-4c80-9a6a-2965885d5743">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81f6dd582b9643c0aaccfd23d753ec9b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy01LTEtMS0w_8c576cc5-895d-4ea9-8d26-e42d0f5c8299">1,090,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib14881f3db284ea58af6d0401f231170_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy03LTEtMS0w_47996545-ef4b-4567-907e-2ea635962274">656,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fe452484de4488eb4d2377e776c52ca_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy05LTEtMS0w_51db46d0-4c89-44a8-afc3-cfdad906ac8a">2,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfe10b5a20e4fa2b3b9874ee8383060_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy0xMS0xLTEtMA_8e072042-19cb-4f5c-8a4a-4cde57ad23ea">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy0xMy0xLTEtMA_80069392-89a7-4fca-8fca-e9725c13a2f4">432,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd84aa923eee4c089192240132cbdce6_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNC0xLTEtMS0w_a8c76ede-f334-454c-8d10-2b278bce10e2">305,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd84aa923eee4c089192240132cbdce6_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNC0zLTEtMS0w_a8dc3b88-d823-4c5a-8233-d69315b80ff0">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib311ed9a02b24bb49e4b526d0c3068c2_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNC01LTEtMS0w_f41f678d-ebb0-4a04-8776-b16e55e43112">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNC0xMy0xLTEtMA_5364ee91-cc8f-45d9-b6d8-d70fc6e0f8c0">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib311ed9a02b24bb49e4b526d0c3068c2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNy01LTEtMS0w_df674349-b708-42b4-854e-f1e039f26751">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNy0xMy0xLTEtMA_de01cf1f-dc4a-4d8a-b1eb-393910e6823c">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66fbbaa5c12e4acaa46d80bf7f899b95_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfOC05LTEtMS0w_abd574ab-3f1a-4be8-9e46-e88e990df720">1,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfOC0xMy0xLTEtMA_9499faa3-3f2d-4c3c-a68c-7cc5ff2dc0df">1,633</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fbbaa5c12e4acaa46d80bf7f899b95_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfOS05LTEtMS0w_1437cd09-3e2a-4380-8d58-754bd0992642">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfOS0xMy0xLTEtMA_c6b359cf-ce32-4e6f-8105-a0c79a0ed113">254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8adf3f5cfd514160ac3dc95f5c7ae73b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTAtNy0xLTEtMA_095f9f5b-4206-4f45-aec9-836b3533378f">42,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic79f4436f8484b2bbe53cd473de9e52e_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTAtMTEtMS0xLTA_0cd37792-9199-41cc-9b6f-addb58595c46">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTAtMTMtMS0xLTA_d994d1ab-19e3-4bf3-834a-535815ffcf6f">42,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balances at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67bf00db7caa48c4a6d8cf45da387715_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtMS0xLTEtMA_a795ed95-b742-4f20-ba36-31acdcacb306">116,278,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67bf00db7caa48c4a6d8cf45da387715_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtMy0xLTEtMA_534bff49-3b54-4ba0-816a-c774e4ad44a0">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ae1200701864b2592f8e63d6320339b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtNS0xLTEtMA_efe09f8e-6a2c-4b34-b9fe-b0ac0952b464">1,096,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ebacde06924391a242a1ad5478841c_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtNy0xLTEtMA_6730a320-9ba6-4f8b-9e2d-27b3985089df">699,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7af747e9403b4e1ba505b3f4ba6cee05_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtOS0xLTEtMA_ea3a05fa-3222-42f2-ad7f-1f196cb2f07b">3,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i563dfbe34ad4474ea0cf1df69ce7d40e_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtMTEtMS0xLTA_fe69e9a8-404d-4a76-8cc8-f455efacd145">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtMTMtMS0xLTA_da0b17da-7d69-4ddc-b367-59ad0d96350d">394,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMy0xLTEtMS0w_a3a4903a-9c0e-4bbd-8d05-513ecf0941c7">45,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMy0zLTEtMS0w_7e1aed8b-83c8-430b-b72f-5c81532c726b">42,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNS0xLTEtMS0w_d311a144-5530-4bf8-bc2c-ab59427287f3">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNS0zLTEtMS0w_9e608cbf-3a26-416c-884e-0cba5ce18e44">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium (discount) on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNi0xLTEtMS0w_3b2c482a-fccf-4dff-a751-320bb274a973">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNi0zLTEtMS0w_7ba60adf-f9f2-479b-b57e-e6e901beaf9f">744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and other changes in operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNy0xLTEtMS0w_26a45d37-3d00-4293-8458-136fd926dea5">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNy0zLTEtMS0w_b5913dcc-9ed1-4e53-80c8-b5615b8f08cc">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on free shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="sgmo:GainLossOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfOC0xLTEtMS0w_19a80508-2ef9-4cc2-b087-2dd0bfbd33c2">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" name="sgmo:GainLossOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfOC0zLTEtMS0w_6673e5f8-e480-47de-a815-8b0d8e2b12a7">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfOS0xLTEtMS0w_20ce0974-bf0f-45ba-acb8-de9e7294de40">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfOS0zLTEtMS0w_e5d5faa0-dfc7-4ddf-9999-4b23c5b7885c">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTQtMS0xLTEtMA_fcb71a9b-67f7-43af-89e6-3a84a7a1cb03">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTQtMy0xLTEtMA_873363b3-ad9b-4ab9-89fe-23bb78e7d8b4">244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTUtMS0xLTEtMA_df14ac62-85e6-40c1-8273-6d25471b88f9">1,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTUtMy0xLTEtMA_afbc2f09-36b2-4293-91fb-ae16f16ef5a4">29,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTYtMS0xLTEtMA_822e1e93-dd48-4c26-bbb2-b0c26c9d4ef2">1,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTYtMy0xLTEtMA_204f68c6-5f65-4141-a6a8-f97f11933d28">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTgtMS0xLTEtMA_67de5709-d26a-4282-a2fc-97320bd070b2">3,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTgtMy0xLTEtMA_0f6327bb-7896-4d55-b9c3-500443cc5c2a">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTktMS0xLTEtMA_6b66436d-c8c2-4ed2-b4ea-5a61bb0f86ea">7,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTktMy0xLTEtMA_e3be6e26-3601-485b-b2ab-ecf8ca89d032">4,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjAtMS0xLTEtMA_a142d33a-bef2-4646-967d-20b4d478e1e1">20,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjAtMy0xLTEtMA_ee510cc4-e99e-4aed-adae-51c12f5b6581">8,319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjEtMS0xLTEtMA_20565221-9cfd-4cbe-811a-2ff5b289b456">1,045</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjEtMy0xLTEtMA_10b2ca00-7e59-4e1f-8f3e-5e285a36d53a">887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjItMS0xLTEtMA_fec4fbd2-8b41-43a6-a0b0-42c2182bb32f">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjItMy0xLTEtMA_a64224a4-2fc4-4caf-a003-8b5782e7ac73">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjMtMS0xLTEtMA_0f02c2a2-9444-4bcc-b90b-ea9e8f1551b0">68,550</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjMtMy0xLTEtMA_edb49f6a-39d7-45d9-90c3-5ab81444100c">18,890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjUtMS0xLTEtMA_3c4c6d36-890a-462b-8705-ed48a8b10f95">97,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjUtMy0xLTEtMA_1db0ca71-e27d-4f94-a16e-a869eb552656">43,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjYtMS0xLTEtMA_8b66cbf8-a98f-4f0a-bf78-686fccfe95c5">144,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjYtMy0xLTEtMA_af40d57d-f12b-48ad-a5cb-53e88ee368ac">71,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjQtMS0xLTEtMjMzMQ_1a34c233-07af-42cf-b9f1-b9312bcab9dc">6,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjQtMy0xLTEtMjMzMQ_b613c710-e5ab-463b-a88c-4e92a8100d3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjctMS0xLTEtMA_5d17216d-f314-42ff-9055-83f68169acbd">7,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjctMy0xLTEtMA_9bbc76b9-9217-4a7c-8620-dbd0954e402b">3,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of additional shares of Sangamo France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjgtMS0xLTEtMA_7591a3e2-f5e9-434e-ac07-be26ffa63a1d">65</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjgtMy0xLTEtMA_5d716608-0af6-4e84-bdbf-157bc17020fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzAtMS0xLTEtMA_0b8c151a-041c-46cb-a8c5-679e1c87225e">45,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzAtMy0xLTEtMA_793363dc-58be-4498-8623-832802b26399">23,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzItMS0xLTEtMA_edcb4284-49a5-417f-92ad-59e90ae5594e">15,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzItMy0xLTEtMA_1edfb66d-5c41-408a-a69c-26e28f641490">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzQtMS0xLTEtMA_71cf6a22-4493-457f-abbb-d50ce51805a8">2,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzQtMy0xLTEtMA_2a2d9c4f-c9be-4b9c-84f0-71a5ac30de70">411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzUtMS0xLTEtMA_a4047943-897c-4e03-a9dd-8b657caa8593">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzUtMy0xLTEtMA_cc1402db-ca97-4e8b-9361-ad88fe40682f">820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzctMS0xLTEtMA_87e6f0aa-c5e9-4029-8261-9f7dd8c69f79">15,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzctMy0xLTEtMA_6f3f86ce-78f1-4c1e-853a-1bb6a185da4c">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzgtMS0xLTEtMA_b3e01172-4469-4f1b-b6a4-c727c00ed387">328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzgtMy0xLTEtMA_34feb890-f0fc-4d3f-9ecf-224cd89ccb14">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzktMS0xLTEtMA_2d5927eb-4ef7-4b29-91b1-d8006dc39f84">8,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzktMy0xLTEtMA_6bb8b679-a2ca-497d-aa10-d1a0a4fa1c89">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDAtMS0xLTEtMA_3bfc90ee-1397-455f-9174-9460e9af0816">132,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDAtMy0xLTEtMA_8384f319-85a2-4cf4-805d-aa4773fb27b3">81,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDEtMS0xLTEtMA_9a3e66e3-b0ba-4790-a345-c570906f933d">124,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDEtMy0xLTEtMA_27415d17-eb97-4623-b576-6e569228b848">87,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in unpaid liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDMtMS0xLTEtMA_ae7664f9-616d-475f-9791-56e736dd5fc3">2,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDMtMy0xLTEtMA_ae0ecd19-c38f-4026-9dbc-3c234a8b86bb">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDQtMS0xLTEtMA_13169ca1-eb72-4d30-b262-f07fe03f2e11">1,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDQtMy0xLTEtMA_6e2ad12a-13e1-421a-b07e-15f93d93168e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March&#160;31, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_40"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTQ_0ab8b639-31c0-4f9a-9ff4-446a8b09486f" continuedAt="i1c5e7cf65c934f08af81f7aaf35c6a94" escape="true">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i1c5e7cf65c934f08af81f7aaf35c6a94" continuedAt="ifea30185d47d479fb36930254d2d568d"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.</span></div><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDU_de5758b9-fda7-4af2-bac6-9c76eae5e662" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;2020 Annual Report&#8221;) as filed with the SEC on February&#160;24, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#8217;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of March&#160;31, 2021 and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTI_52de2e73-e161-455c-9efa-784a86005118" continuedAt="i430f18e26c9f42729532b99d28f891e9" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="ifea30185d47d479fb36930254d2d568d" continuedAt="ib18a2b5acb8e41ad9466b7ff4247550a"><ix:continuation id="i430f18e26c9f42729532b99d28f891e9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in estimates during the three months ended March&#160;31, 2021.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#8220;Sanofi&#8221;) and Pfizer Inc. (&#8220;Pfizer&#8221;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i7c16f4045ec2486c9655bc30dbea465c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMTA5OTUxMTY2MDY0Nw_d271669c-d1c5-4e79-83da-547c99a44fcb">0.1</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i7c16f4045ec2486c9655bc30dbea465c_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMTA5OTUxMTY2MDY2Ng_babd330d-9a62-444c-8aa6-f51f7fc3d57c">0.1</ix:nonFraction>&#160;million and had <ix:nonFraction unitRef="usdPerShare" contextRef="i873c9f5644134b289bd2510df3750392_D20210101-20210331" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfNjU5NzA2OTgxMDIwOQ_f1d95512-027a-4173-b5d2-00cf0c7adb1e">no</ix:nonFraction> impact on the Company&#8217;s basic net loss per share for the three months ended March&#160;31, 2020.</span></div><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDc_96605206-4801-4ab6-839e-850a37c20a73" continuedAt="i9c134dc81d19461884e17cedfd513611" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="ib18a2b5acb8e41ad9466b7ff4247550a" continuedAt="i965f18c389b44276b8a9d1e3b710a86c"><ix:continuation id="i9c134dc81d19461884e17cedfd513611"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTc_02695ca2-9286-4743-a301-9f5620aef611" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i024dc19eb24b4daab222db22932603df_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfMi0xLTEtMS0w_80a8bc8b-bbec-453e-96ca-9e48db796ebe">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91dfabbfcb6c42b6bb0bf2d326d97a54_D20200101-20200331" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfMi0zLTEtMS0w_0f8a784d-13be-4450-87ff-daaabe8ebe39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i332314e60491404688c2fb0fef961934_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfMy0xLTEtMS0w_9925c68e-44b8-4de0-aa64-c3387659b71d">30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61dbb95b254048c5aba2eb7163863213_D20200101-20200331" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfMy0zLTEtMS0w_cd86b038-bcd1-416d-a956-3e1ce70035f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i797c92907973403a9443e0c27091c0f5_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNC0xLTEtMS0w_93a2ae52-3417-42ea-98f7-d78279e9aece">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5b3cce32d374c0cbcc1ed41e9b476bc_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNC0zLTEtMS0w_632d6a79-f0f6-4a6a-bb41-639f0a350c38">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ef830db3b5a4c42bce46b64a5716cf5_D20210101-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNS0xLTEtMS0w_f938517c-5f4e-4649-bb62-d82240054cde">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic54f8c76b5c842219a02086497ccdcf2_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNS0zLTEtMS0w_5cfef66a-2061-4664-a8b8-1746311e8bd5">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie0d66e275ba74d119f72575fcbff978a_D20210101-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNy0xLTEtMS0xNjg4_5c54b0a8-c45d-4266-8fdb-988730bb74cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fc652101e3c4c20b3cf3a98ba873683_D20200101-20200331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNy0zLTEtMS0xNjg4_c4752ed6-8fa3-49da-a2bd-8b50999c345c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of March&#160;31, 2021, the Company had not incurred any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTg_70f90c5c-682a-419f-8a68-cc9ed5a7b72e" escape="true"><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDg_220f0240-889b-435f-ae68-2fe380b1e642" continuedAt="i0923f89dce7d4416b0ea21de2193008e" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0923f89dce7d4416b0ea21de2193008e">Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.</ix:continuation> As of March&#160;31, 2021, <ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="10" format="ixt-sec:numwordsen" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfNjU5NzA2OTgwODE0NA_93495b9a-9f25-4ab2-a54f-5afb83b97d5d">no</ix:nonFraction> impairment of goodwill or indefinite-lived intangible assets was identified.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0Njg_46b7bf24-c13f-46e9-bf2c-1261cfb716d9" continuedAt="i2aba7f96297d4dc196c50c08d789ca6e" escape="true">Valuation of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2aba7f96297d4dc196c50c08d789ca6e">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</ix:continuation> As of March&#160;31, 2021, <ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfNjU5NzA2OTgxMTgzNA_e805b270-96a4-42ae-92dc-5b6ff3efcff2">no</ix:nonFraction> impairment of long-lived assets was identified.</span></div><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTk_4ea59db0-5067-4b18-9afc-94b24f53da39" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="i965f18c389b44276b8a9d1e3b710a86c" continuedAt="i861645262c754d0ab08fed7b19fb365b"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDM_96654823-6b15-4a4c-945a-777343753b7b" continuedAt="i41c7a4e3824746629383617960df55ee" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i41c7a4e3824746629383617960df55ee">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts.</ix:continuation> Restricted cash consists of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMTYyNTU_26804864-7dac-4ecd-876a-db188d74ca3e">1.5</ix:nonFraction>&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDk_1833ce89-748f-45ed-8075-86ce6a7135d8" escape="true"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDk_9e58a4e4-2c5d-4dc0-95f9-fb1e9eb68c0e" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"></td><td style="width:53.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.515%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMS0xLTEtMS0w_393efed3-3f3b-4a2b-8249-2227beb1dd0b">122,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMS0zLTEtMS0w_cd83ca78-91c2-4a7e-9563-8749ac117eef">131,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMS01LTEtMS0w_a0f7bb46-fa14-4904-8dd8-a44fee38e0c5">85,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMS03LTEtMS0w_05d82cee-2d4a-4600-b5bb-a9b5eee9c5f5">80,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMy0xLTEtMS0w_8d73c8c9-cf99-4c82-9fde-67cc97703ad8">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMy0zLTEtMS0w_7d179ab8-103d-4d0f-8b93-ab304eaedb93">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMy01LTEtMS0w_6db18224-dc84-4414-b860-fede9f3551ae">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMy03LTEtMS0w_b8a8935f-3d3e-4212-a41d-53b86e5bb6e7">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfNC0xLTEtMS0w_2f5bc009-8b71-4e3f-b997-e8c057233ae4">124,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfNC0zLTEtMS0w_cf58aed8-da93-44eb-b8b8-f0034d929965">132,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfNC01LTEtMS0w_29c9708f-440b-45d1-8799-374477450ef9">87,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfNC03LTEtMS0w_8a703f4e-d9ba-4757-bc0c-396be4d9fc75">81,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NjA_0b69d1e3-4a9d-4de3-b12a-9281a0898930" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDQ_e78ce17e-cd1c-4d5a-a8a7-3c52c16efccc" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#8220;IND&#8221;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0Njk_3894528e-8df1-4002-9c76-ed968c82b2aa" continuedAt="icde4da9176f14a219ffe9fb286979e3b" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="i861645262c754d0ab08fed7b19fb365b"><ix:continuation id="icde4da9176f14a219ffe9fb286979e3b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:continuation><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTU_538d9b9d-1336-4ebb-afce-62ec46c9d5e9" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NjI_4b24c084-06f0-41e6-bef3-6f2b3b46ccbd" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric></ix:continuation><div id="i4be9a0306d9c4f29ba82c2a83d136deb_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfNDA4Ng_fa58ec9c-9436-426c-86fc-696111d8c6b7" continuedAt="i238c526d53f146c6ba6c5c8033af9dbe" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i238c526d53f146c6ba6c5c8033af9dbe" continuedAt="i3022c63b5ce44e3a807053efb4cc768b"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfNDA4OA_50426843-bb1c-491b-bd69-2bf1f837227a" continuedAt="i8518880b959d4822a0471f850018cc7d" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i635047121e6c4458b824262db0945d4e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNS0xLTEtMS0w_b72ee3af-085e-4778-adb3-57fcc2c945bb">47,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82295ac670bb4f48911ed7686079294d_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNS0zLTEtMS0w_b8f05ddf-cc9b-4e69-8549-386d7e31abab">47,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd3e7b1c54840f38d767f4d886e6a20_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNS01LTEtMS0w_e9f67db4-9586-450b-b19a-c0d13ce8ed3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d2bc412b074d02b1f276ca18f76761_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNS03LTEtMS0w_df1075b8-b1a5-41c6-a3ad-321991300d42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNy0xLTEtMS0w_8c859faa-d037-4534-9412-d7c30f9df513">47,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8966338ebc438da839ad284fa2d835_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNy0zLTEtMS0w_bc4ce320-7e1d-4a35-b69a-363d0f765d64">47,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db582e5de644bcb1b85a92b0e5f562_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNy01LTEtMS0w_e896bbe0-4122-411a-8e30-00bd1db7c433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271e9f7a598345499ec311df587568ef_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNy03LTEtMS0w_701b0505-041f-4a14-9ffb-d312e8cb739b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78163204b2e442aea1bef8ca15bd3185_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfOS0xLTEtMS0w_8c0522ce-534b-4c92-8ad3-1667958df312">177,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7ce110dc7a4abc917e9ff1f848c5c9_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfOS0zLTEtMS0w_70f14404-1eaa-460c-b8f0-7efba4d4c4ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i106cafb1122d4c0e9f548d6e74623320_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfOS01LTEtMS0w_a5c48f5f-6bbc-4436-91bf-f01580f8b24e">177,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e6eb66bd26477ab90813ade9edfb03_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfOS03LTEtMS0w_be8a865d-4ed4-4db2-92bc-e8d39dc2638d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46865ce5446e4b3581efb803f5308180_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTAtMS0xLTEtMA_3bcb0e33-3335-4a5c-8a18-7f153fcc2b52">39,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89889f9b7a0f46bebb2b75f129454b9e_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTAtMy0xLTEtMA_8e4f9d62-1342-4ca8-87a2-0628f99f6945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if04c5d46d250473194dd874c126bdbc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTAtNS0xLTEtMA_b4f41d7b-4c06-4b58-ad9a-4598e569e78e">39,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc8108057d44225a1ea75bd1ff54b19_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTAtNy0xLTEtMA_8793ddc1-d342-4780-955b-afe59fdfa8b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i419d0e887e054403af4e6b64c3884a5a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtMS0xLTEtMzA1_838c8dc8-7016-437e-8519-1637e6be5dd6">11,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51edc4e56f8e4a7cb40c8d663d6c17d7_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtMy0xLTEtMzA1_414d5308-2075-4f35-b9dc-d59f2f14f19a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33962be218df46e4bb2551730a919275_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtNS0xLTEtMzA1_b2211be7-ab78-41e1-b887-a13aab422bb4">11,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41dd293fb24a49c58c23d0ed05154696_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtNy0xLTEtMzA1_c3867013-b684-4912-ac47-f3e38ca18fe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ef26cb1f0244fd88cc3a23ee2cb867_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtMS0xLTEtMA_8968da6f-57a7-4b0a-8d79-22c36a694a16">36,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bc5de5ccb1a4b8aaffe4d2996876f39_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtMy0xLTEtMA_edcad7d4-1eb6-4d44-8aeb-9e91ab012b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if45973c1fb6444ea88b6e3c888274698_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtNS0xLTEtMA_a3d08003-2044-4eee-8e2c-bb24419092c4">36,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2c1ad6d704e41659c0fd0df2e944744_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtNy0xLTEtMA_536e0d8b-0871-42ce-9dff-cb457294c72c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d4134488184de8a1fa41faf29af748_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTItMS0xLTEtMA_c9ff3469-0b10-4ddc-9e0c-eb61ea81502e">242,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8f6a626ca824ba0a50ba08002bf41f3_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTItMy0xLTEtMA_38ed92ed-172b-4a37-bba4-ead03592f501">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b36af6a83fa481bace8cd4e6fc87589_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTItNS0xLTEtMA_1d035658-b01d-4947-932e-2f9d7e9865f8">242,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1526a93629134bf5a457c273f64476aa_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTItNy0xLTEtMA_a665a338-6b3d-44e9-99a3-da1582c16a3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTMtMS0xLTEtMA_6dec7127-b00b-40e0-a6a7-7fa20ea9ca0b">506,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8966338ebc438da839ad284fa2d835_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTMtMy0xLTEtMA_3a6c41b2-9edf-4e46-b760-a26e57a65227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db582e5de644bcb1b85a92b0e5f562_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTMtNS0xLTEtMA_981f577d-e47c-4ffe-a582-f68612bfbd28">506,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271e9f7a598345499ec311df587568ef_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTMtNy0xLTEtMA_3314fcde-9050-4a15-9024-e320e83e2b2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTQtMS0xLTEtMA_b70f6234-f5a3-4031-b61d-56d04a547db9">554,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8966338ebc438da839ad284fa2d835_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTQtMy0xLTEtMA_3a33449f-8227-4c3c-8d33-c1e7f5f6435c">47,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7db582e5de644bcb1b85a92b0e5f562_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTQtNS0xLTEtMA_e3a0bb34-854d-43a1-b852-14ed764b4ad6">506,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i271e9f7a598345499ec311df587568ef_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTQtNy0xLTEtMA_ff705ad7-a493-4f13-9b33-ce4a7ad4cbde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida4abef0acf44596a26f1a6b9c75bcdc_I20210331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTYtMS0xLTEtMA_e077f391-8235-47d8-86e7-826024cf430e">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i049f3221e84245a9b058bae1da73bc95_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTYtMy0xLTEtMA_129e329d-80f9-4a51-925c-6b6f6b24bd0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i162a782c6f754612b1731de6c5d3c0d2_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTYtNS0xLTEtMA_31bb92b7-60c7-47ed-86ea-d3c3c54fe52c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceb962d8a3b8454e9d31307a65f31666_I20210331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTYtNy0xLTEtMA_efc375e6-2bb9-4ddf-8f25-e107547d5c22">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:6pt"><span><br/></span></div><ix:continuation id="i3022c63b5ce44e3a807053efb4cc768b"><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i8518880b959d4822a0471f850018cc7d"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31c2d44d30d4f72b00d4d3dc2f0ea0e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNS0xLTEtMS0w_da0fd66f-631d-4691-8adb-9de6ae9ae761">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2068f55b1b64c409a3faa26ee2644cd_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNS0zLTEtMS0w_4f0bc83f-d77d-4c22-a15f-ee7ab2f9948a">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7da0f47f5194d899b2a75cec012f983_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNS01LTEtMS0w_9eed939a-b734-4f8c-bae1-e1bd16a3bc47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9fa3dbd2e0444181f5a6e3e7046acb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNS03LTEtMS0w_34ce5469-3a49-4c27-a338-e6080294ddc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e460cd7328340128515c28a0c9286b0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNy0xLTEtMS0w_c8eda0dd-a34b-44ca-909c-38831128e4ea">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ac6cc477e44273a668068859113a3b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNy0zLTEtMS0w_bf6a9670-a2c8-48e1-bfff-089d94caf74a">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ae0a19620647ba86b490ea19afde52_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNy01LTEtMS0w_58f75636-bd4a-4d16-9d0e-97430b05fbf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb74ef8efdf48d992458b94198588ac_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNy03LTEtMS0w_942c149c-55ae-44fe-9029-2561c9f32a86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b72198ef2049a59d0032b521440eab_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfOS0xLTEtMS0w_95f084e7-3f6c-47e0-aeee-860bad3d59a6">213,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4829f8fd2ceb499a88d1a605878ef324_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfOS0zLTEtMS0w_51343a00-5d73-446a-b083-149d56dcb047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ad0091ec4e44a5c95e0c234a8797e30_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfOS01LTEtMS0w_461909a3-7ae0-4fbc-b717-eeb7e3b18ba0">213,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6857d704b93459f901a1ad318f49bde_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfOS03LTEtMS0w_a6955dcc-be8d-41b9-a097-b4669349ec10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa573862768c47788f0353badcc8a2c9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtMS0xLTEtMA_b9667772-c933-4883-8db7-e1572516807d">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if80129c7bc444c6c89ddf9cfc902a3bb_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtMy0xLTEtMA_255ac27d-295a-498e-be8d-48180c74763d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbb561c5be14e16a7780931e372eeaf_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtNS0xLTEtMA_d0ee3348-f3ca-4d3f-8e08-e0c333d8e19e">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i648e5da489e74498abd8b5eb03f88c29_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtNy0xLTEtMA_7c64facf-aa3c-4b21-8f50-3ae072ba73c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17aabe1f736146ce8ab6b6adf624da61_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtMS0xLTEtMzE5_b61b4c08-4678-436c-83ab-044acb567245">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5951cf3812f84d1b880568d902f8ffb0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtMy0xLTEtMzE5_fab8bd3a-ba87-4b26-8a34-4cab2f828989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02a6ede247654801b23070be6fe9771f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtNS0xLTEtMzE5_daf705ee-c113-4b49-996f-0085df347fb1">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i927cfac1568340718ec2370561ddff86_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtNy0xLTEtMzE5_c16f367c-4a13-4cce-97bd-78ff3635721c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c77548671c64b518a9d84a96771bd0a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtMS0xLTEtMzE5_8a17cd29-434c-4db0-b1d1-126fba316c31">17,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieebfdbf5d1314dbf8980ccd6c0efeb45_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtMy0xLTEtMzE5_2b8c3404-22e5-4afa-8af6-ba211d7a93d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifba723c7ee42434e90ebc7232841e8db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtNS0xLTEtMzE5_4dce357d-f2ca-491e-ada5-95eff7c95a57">17,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15841938ea744133a39ee8f0276f4e94_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtNy0xLTEtMzE5_4552b050-c47b-4600-a184-bad4266f414e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a7cf6c983f4c9589afcfe337a84376_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtMS0xLTEtMA_3238306d-9810-460e-b9ed-c5cfc65f7844">257,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85fee7acc1c942e3a814f2d4a0f959b0_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtMy0xLTEtMA_d8bdd229-b2e3-4b73-8745-1322acc39278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b7c87fda55463998db819047f79ca3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtNS0xLTEtMA_71957f5f-8955-459d-ac04-a8a2d6d9ed27">257,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc5cd0ff3e2431cb254b14fb4219da8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtNy0xLTEtMA_8e79b245-9ee0-4d3d-8054-3e2ea3a00d44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e460cd7328340128515c28a0c9286b0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTItMS0xLTEtMA_23c2bf34-e474-4f0a-bd9d-39410f1ec8fc">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ac6cc477e44273a668068859113a3b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTItMy0xLTEtMA_9aabfa28-b1fd-4ec2-a5da-5d045626cc21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ae0a19620647ba86b490ea19afde52_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTItNS0xLTEtMA_19b92929-d044-4ff3-be95-ee6823b4185a">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb74ef8efdf48d992458b94198588ac_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTItNy0xLTEtMA_cf9baf83-0d49-4d41-951d-ef79b2293c95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e460cd7328340128515c28a0c9286b0_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTMtMS0xLTEtMA_2494c29f-f728-40c4-bcbf-1446033bda8c">613,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ac6cc477e44273a668068859113a3b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTMtMy0xLTEtMA_67c2da4c-0a9e-433b-879b-89a6991e5a60">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ae0a19620647ba86b490ea19afde52_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTMtNS0xLTEtMA_655fb0a4-59f5-4a72-9581-4917ccf0b468">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb74ef8efdf48d992458b94198588ac_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTMtNy0xLTEtMA_cdae48e8-8382-4a42-8f57-51c511ac0e73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9866ab5b25c94734a96e173d3df99684_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTUtMS0xLTEtMA_5459cfb3-0a93-4da0-b995-991c22090faf">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cffbb4314d64ee4b5119c285bb1bdf8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTUtMy0xLTEtMA_af8a6c63-81a1-48b0-8f1c-ae7be7991e78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i468e13f71bb44158bc1ebf6b962f54ce_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTUtNS0xLTEtMA_241a5725-f4e3-4ea9-8f2a-cd68445e5161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce97d825f8b420eb0fba22b6d0a786f_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTUtNy0xLTEtMA_a44447bd-aa42-46ea-a17b-0d3746fa9330">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities and some cash equivalents as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Shares Asset</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 10 &#8212; Acquisition of Sangamo Therapeutics France S.A.S.), the Company entered into arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="i1129259eb0a649868776568fa4898425_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMTA5OTUxMTYzNjc4OA_af754001-f9fe-434a-bb35-f35b6928cf74">477,000</ix:nonFraction> &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). As of March&#160;31, 2021, the Company purchased approximately <ix:nonFraction unitRef="shares" contextRef="i91b1a80eaeeb470bb98449ced38f5857_D20180720-20210331" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMTA5OTUxMTYzNDE5Mg_6bf7b1f8-136f-4c27-92a2-6ca7602ca12c">453,000</ix:nonFraction> shares of the <ix:nonFraction unitRef="shares" contextRef="i1129259eb0a649868776568fa4898425_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMzU1OQ_9adea93d-c5ff-4eb9-a0f2-3354c59447c6">477,000</ix:nonFraction> total free shares, for a cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i1087025adac9402fa10512e9bbce394b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMzYyNA_e36257cf-f873-4081-b943-24cc4e63da10">1.1</ix:nonFraction>&#160;million, upon exercise of the put options. As of March&#160;31, 2021, approximately <ix:nonFraction unitRef="shares" contextRef="i1087025adac9402fa10512e9bbce394b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMzY5OQ_926bd635-04ce-4c20-93dc-b7602efcf126">24,000</ix:nonFraction> free shares remain outstanding and subject to purchase by the Company. The fair value of the free shares&#8217; asset is immaterial at March&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfNDA4Mw_38a4d4ab-a1b8-45cb-91ce-504215c75d10" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:73.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Free Shares valuation assumptions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i373acdae6305402aa0be5cf76855d613_I20210331" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMS0yLTEtMS0w_02622810-b424-4b61-acf5-e8dcc99f378c">11.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a2f2e458499460c9d2f8569ded9b145_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMS00LTEtMS0w_a03b5438-cd8d-4e91-85d8-8b8d6ca1a3fe">15.61</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="i3ad2a2e3a84b4100b7319b30812c47e6_I20210331" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMi0yLTEtMS0w_6e1ec399-c853-42f1-a8ef-1e4388dfc3df">2.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="icef8cccbf6ca4534ae5c619f394063a1_I20201231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMi00LTEtMS0w_2425f39e-bed8-4cb5-a20b-26e7a6c1dd54">3.85</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6869d31d7a094145bfb28ac75b1e9b65_I20210331" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMy0yLTEtMS0w_06742d19-79ce-4e80-ab3a-54f336284c9d">0.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i280b535896024bcd95cb6e05701ce4a5_I20201231" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMy00LTEtMS0w_1a4e2232-a828-40bd-a21c-442859d22796">0.82</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation between Sangamo and Sangamo France stock prices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0ad1dcdb92f74b6aa8153279f247ec2b_I20210331" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNC0yLTEtMS0w_ddaf990b-2977-4390-8185-9bb1a7092801">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i672e278ea9d9400fb2d871ecc0490a9c_I20201231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNC00LTEtMS0w_2f244093-e4f9-4c2e-a7ce-4ee24ecbba99">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i096af9793db343b0815caa338ffd63a8_I20210331" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNS0yLTEtMS0w_97b70b59-994c-4978-b6f7-f79bff541bb3">91.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic336725f5f2a462798de6f9160210fdb_I20201231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNS00LTEtMS0w_39bf3cfb-36c4-4e46-b212-e4292631db97">88.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1004bec248ae4ca1ba8a9c29ad354f09_I20210331" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNi0yLTEtMS0w_ce9386ee-dd21-4d7a-bb21-29d783135249">91.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46c3138c0eba415ea37d06436df62854_I20201231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNi00LTEtMS0w_6b4bb703-5b0e-48c7-9864-94e578f9ae52">88.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate volatility estimate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i859a69b7c32743829ed4f102732a1722_I20210331" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNy0yLTEtMS0w_e8ff0c83-6bea-4ee0-9dc1-3650317e7a95">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i39b2e0222b2542508d6cd3681b08a431_I20201231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNy00LTEtMS0w_cb7ba3d4-4d08-4b49-88a6-acaa787222a3">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTU2Mw_edb9eef0-3ad8-4922-bbcc-a2e02bd59f13" continuedAt="i3aa08689649a4d7a8e7e6c52c3842164" escape="true">CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i3aa08689649a4d7a8e7e6c52c3842164" continuedAt="i7ab3e9164d5c4fda9e656e4be30ba712"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTU2NQ_cf5939df-8e98-4868-8438-e4ba125b926b" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.565%"><tr><td style="width:1.0%"></td><td style="width:54.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434d6421401646d8819ebb7f70ca4def_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNC0yLTEtMS0w_02b2483d-83db-47f1-9c22-b4da5e230e6f">47,635</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434d6421401646d8819ebb7f70ca4def_I20210331" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNC00LTEtMS0w_0df09fc1-d356-42a1-8c66-21279964f7b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434d6421401646d8819ebb7f70ca4def_I20210331" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNC02LTEtMS0w_ceae51ea-aca4-420c-9536-9fbbc8676da2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434d6421401646d8819ebb7f70ca4def_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNC04LTEtMS0w_ecb00d35-4f7d-4e5f-a1fe-5404d27db749">47,635</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie037112c32294882bba7e7dbbf15ae0a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNi0yLTEtMS0w_ec3b6e8e-e427-4fbf-9e65-d1ea0940cb32">47,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie037112c32294882bba7e7dbbf15ae0a_I20210331" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNi00LTEtMS0w_fb6216b1-fe67-4b9a-aad5-e469c03c1e42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie037112c32294882bba7e7dbbf15ae0a_I20210331" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNi02LTEtMS0w_3283866c-ea65-4c75-8ef6-d142dbb7a92f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie037112c32294882bba7e7dbbf15ae0a_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNi04LTEtMS0w_15deeae9-e101-46b6-bff8-e3d15049f7e8">47,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf917e0cbb043a6a5d13564bd385789_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOC0yLTEtMS0w_09eb9f9b-59d7-44eb-a679-58b6213e2567">177,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf917e0cbb043a6a5d13564bd385789_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOC00LTEtMS0w_7d5ce0e8-0e7f-4d17-9bd6-d2d6a8f9c891">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf917e0cbb043a6a5d13564bd385789_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOC02LTEtMS0w_9e1951d0-f143-4913-a888-2fa106c3f8d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf917e0cbb043a6a5d13564bd385789_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOC04LTEtMS0w_e3353e7e-caed-44c9-ab60-1c4dd1a702c0">177,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOS0yLTEtMS0w_a93e8346-b802-4597-baa6-a630a7b285e3">39,031</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOS00LTEtMS0w_d9b1ae35-f9e9-42fe-b35d-4b1ede454488">5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOS02LTEtMS0w_42a9a9a7-6201-42ab-bb49-9c95b5c9abeb">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOS04LTEtMS0w_4c50210d-3f45-49e2-aa07-a12d5941a17b">39,022</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b613add127642da88c0f1e731060ffd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtMi0xLTEtMzgz_c24e239c-b11e-4574-9363-6b848d866097">11,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b613add127642da88c0f1e731060ffd_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtNC0xLTEtMzgz_e6bcb4c5-947a-4568-9f4b-9d9b2cae348d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b613add127642da88c0f1e731060ffd_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtNi0xLTEtMzgz_f910c3aa-3f95-4c53-8306-b991ad789b42">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b613add127642da88c0f1e731060ffd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtOC0xLTEtMzgz_9377e2ef-cdd1-4313-ae0d-16c6a6fd079a">11,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53804a6be8344f08a5725ae1fe862146_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtMi0xLTEtMA_dbb46eed-5f44-4b6b-93c3-5571c63c855b">36,419</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53804a6be8344f08a5725ae1fe862146_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtNC0xLTEtMA_2162c242-f620-47a1-8496-56b35c44ea49">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53804a6be8344f08a5725ae1fe862146_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtNi0xLTEtMA_ecd38838-ea95-439e-bd7a-590f14c9d850">16</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53804a6be8344f08a5725ae1fe862146_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtOC0xLTEtMA_4da345cc-cc18-4929-9f5b-18d6308d614b">36,410</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTEtMi0xLTEtMA_73684941-5f0e-4399-b042-e36a639c2619">242,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTEtNC0xLTEtMA_715c389f-1c75-4435-9339-2fe322875c4e">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTEtNi0xLTEtMA_c8b89999-6d2d-4792-8714-0949de36c845">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTEtOC0xLTEtMA_d194716b-acb1-4cf6-86c3-8165c220faa0">242,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTItMi0xLTEtMA_915d8135-9c1a-4131-808b-a9edcf76be41">506,447</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTItNC0xLTEtMA_b4056541-3dd6-4139-be2f-03d62ea92afb">124</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTItNi0xLTEtMA_bed9ff98-70ca-4187-9597-6c8f5aee74a3">31</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTItOC0xLTEtMA_2714db83-fdee-4fd5-8d83-0e268dc1e2ec">506,540</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTMtMi0xLTEtMA_d6bd36d2-26df-46ab-9206-c1f8fb33171b">554,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTMtNC0xLTEtMA_e8e46b62-9d0f-4543-a70f-7af62bf4d496">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTMtNi0xLTEtMA_ececd9a6-1957-4fe0-9acb-e184a10f56b3">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTMtOC0xLTEtMA_53aabeef-a99f-4a5a-94c8-d14502232635">554,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad382cd550f476288b6b8449774030a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTgtMi0xLTEtMA_630cb017-f416-4c67-b8ad-3fe7cfa767d1">53,165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad382cd550f476288b6b8449774030a_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTgtNC0xLTEtMA_813dbcd0-c0a6-446f-9aea-e8925ec991ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad382cd550f476288b6b8449774030a_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTgtNi0xLTEtMA_524a7c1d-d21a-4dc4-a4b3-d50f2ab7926a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad382cd550f476288b6b8449774030a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTgtOC0xLTEtMA_1c587fcb-5a6e-4658-a577-605975ff92a0">53,165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08febcafb084cb3800af6dd3c8ae060_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjAtMi0xLTEtMA_ccdc8002-6dbe-460c-868f-924c50d20e3b">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08febcafb084cb3800af6dd3c8ae060_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjAtNC0xLTEtMA_04bb42ab-284f-4972-a0d9-1495f05c6c9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08febcafb084cb3800af6dd3c8ae060_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjAtNi0xLTEtMA_c7f2adc3-1de2-41fa-8d68-537437d31d11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08febcafb084cb3800af6dd3c8ae060_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjAtOC0xLTEtMA_4c52d209-0d58-4aa0-a8b2-e4100918924a">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b352c0d2ab458ebc5713e73ef66c30_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjItMi0xLTEtMA_d7b6de10-4dcf-457c-a7b7-4718ccc0590f">213,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b352c0d2ab458ebc5713e73ef66c30_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjItNC0xLTEtMA_f55ebd5f-48f7-42ad-b93f-6500291d633e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00b352c0d2ab458ebc5713e73ef66c30_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjItNi0xLTEtMA_da344757-9b87-4bf8-ae37-cbe277571c0e">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b352c0d2ab458ebc5713e73ef66c30_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjItOC0xLTEtMA_514d5990-f808-4ef2-a87a-0f2a919a2f34">213,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic558cd205e844605965ec5e4461a1ba5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjMtMi0xLTEtMA_36f05169-6cfb-48d6-baa3-59843072ecc3">59,575</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic558cd205e844605965ec5e4461a1ba5_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjMtNC0xLTEtMA_497ff521-5f8e-43ad-8bbf-01adfec96fcf">16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic558cd205e844605965ec5e4461a1ba5_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjMtNi0xLTEtMA_09de1191-3807-4c1f-9f75-d0cf3606df72">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic558cd205e844605965ec5e4461a1ba5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjMtOC0xLTEtMA_5a048071-54c8-4e7c-984b-83aaee921a98">59,574</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c0ac6823a34b509afee459208f16b2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtMi0xLTEtMzg5_9d0ba7aa-5002-4366-b628-8975b0f6e471">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c0ac6823a34b509afee459208f16b2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtNC0xLTEtMzg5_5d6d4a96-2007-42ce-a5b3-187b2876895f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c0ac6823a34b509afee459208f16b2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtNi0xLTEtMzg5_665e6401-c2ea-4caf-bb34-7328f9435674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c0ac6823a34b509afee459208f16b2_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtOC0xLTEtMzg5_a1e81276-6521-42b7-86cc-77f19ca3cad0">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c74fee69544d6fba7898340eefc923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtMi0xLTEtMzg5_ed9a8167-8acb-40c9-b9ef-19883b779aca">17,905</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c74fee69544d6fba7898340eefc923_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtNC0xLTEtMzg5_1654576a-08a8-4c5c-bc90-b11c9e1a1759">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c74fee69544d6fba7898340eefc923_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtNi0xLTEtMzg5_fcff054d-71d7-4ba3-b1cf-0a6d6fd46497">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c74fee69544d6fba7898340eefc923_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtOC0xLTEtMzg5_d745c12f-43d9-4f65-8ce4-2b790262ec77">17,908</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtMi0xLTEtMA_8e51fc0c-165b-4cff-bdb4-cae6dd48ff5e">257,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtNC0xLTEtMA_97f4115e-fef8-481d-b674-2e77e5495be4">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtNi0xLTEtMA_9277ed18-e715-440e-92bf-2480ee6f157d">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtOC0xLTEtMA_f13288de-b65c-427a-b734-8d40cd1b4a3a">257,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtMi0xLTEtMA_68e0a300-c26b-4ae5-b45b-55a6134d5fea">560,575</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtNC0xLTEtMA_994638e8-0787-478d-9e89-dc2237b6a081">86</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtNi0xLTEtMA_68a143ca-3eaa-4544-ac6b-1d2dfcdd7a87">37</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtOC0xLTEtMA_1459898b-9897-466e-bb5c-43ca35c9dbac">560,624</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjYtMi0xLTEtMA_35ef8173-8ba6-4b06-94e7-e2e269f43afe">613,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjYtNC0xLTEtMA_f9c105d8-e41c-4c63-a6c2-0190b43b9187">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjYtNi0xLTEtMA_77b93e9a-5383-45be-a55c-732f289a1969">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjYtOC0xLTEtMA_a9a501ec-e484-433a-b735-b38610d80e3c">613,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTU2MQ_89c62e11-a401-4b38-8eab-246f9abab4a4" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:73.065%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMS0yLTEtMS0w_ec1235bc-044c-49f8-b06d-490e5af713c7">464,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMS00LTEtMS0w_077ce745-e869-4a41-a161-4bbbac0de334">510,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMi0yLTEtMS0w_22705731-098c-4bab-a185-13afe88677be">42,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMi00LTEtMS0w_dc1df223-d8d8-46a5-a5ec-00152aed21b1">50,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMy0yLTEtMS0w_e1a6260a-19f4-4c75-ad5e-61564dc7b7fc">506,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMy00LTEtMS0w_60a066d5-3017-4fde-9774-e0fe49838114">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2021 and 2020. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews the marketable securities for other-than-temporary impairment losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7ab3e9164d5c4fda9e656e4be30ba712">not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, there were <ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTM3NDM4OTUzNTIxODA_e6b7e5ba-c7d8-458e-89b6-15bae8d8a97f"><ix:nonFraction unitRef="usd" contextRef="if88ebd43c71848c89734b2715f66361b_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTM3NDM4OTUzNTIxODA_f625b17b-d73f-40ac-a177-d9d62e5e54a8">no</ix:nonFraction></ix:nonFraction> other-than-temporary impairments for these marketable securities at either March&#160;31, 2021 or December&#160;31, 2020.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80OS9mcmFnOjkyNzQ3ZTkyYjA0NTQ0ZTc4NWNkYWNiOTgxMjUzMjAwL3RleHRyZWdpb246OTI3NDdlOTJiMDQ1NDRlNzg1Y2RhY2I5ODEyNTMyMDBfMTA3NA_0b832f53-659b-40c6-b9af-9774e4a2bd28" continuedAt="i2e9a13c069df453e86bcedc57da0e3d3" escape="true">BASIC AND DILUTED NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i2e9a13c069df453e86bcedc57da0e3d3"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of March&#160;31, 2021 and 2020 totaled <ix:nonFraction unitRef="shares" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80OS9mcmFnOjkyNzQ3ZTkyYjA0NTQ0ZTc4NWNkYWNiOTgxMjUzMjAwL3RleHRyZWdpb246OTI3NDdlOTJiMDQ1NDRlNzg1Y2RhY2I5ODEyNTMyMDBfMTA1MA_1c17aafa-cc3e-4074-8b16-052beb07d609">17,614,376</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80OS9mcmFnOjkyNzQ3ZTkyYjA0NTQ0ZTc4NWNkYWNiOTgxMjUzMjAwL3RleHRyZWdpb246OTI3NDdlOTJiMDQ1NDRlNzg1Y2RhY2I5ODEyNTMyMDBfMTA1Nw_f2050796-3fe1-4bea-97c7-67e83eff4544">14,849,728</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="i4be9a0306d9c4f29ba82c2a83d136deb_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5&#8212;<ix:nonNumeric contextRef="i7dc2e857539f4ef4ba7daadf58df7f59_D20171201-20210331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjI_ad7493e4-6c9e-4384-aef6-1ba627a50dce" continuedAt="i1ef1dd1ddbbc448d8410a8ed6ee130f4" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="i1ef1dd1ddbbc448d8410a8ed6ee130f4" continuedAt="if12f1dff4f394f549916c7c5496cb43b"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#8220;ZFP&#8221;) transcription factors (&#8220;ZFP-TFs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company will perform early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, IND-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid the Company a $<ix:nonFraction unitRef="usd" contextRef="i3acb6e7ece7c4264be4a73e7e4f9a1d1_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTc4NA_65fa7973-a583-4f2b-a1d6-45a6d0f81068">75.0</ix:nonFraction>&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $<ix:nonFraction unitRef="usd" contextRef="id33584313d634d6ebb308bbe8e5d106b_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk1OA_079702a3-ff71-4cd3-9f30-231718ba2fe5">420.0</ix:nonFraction>&#160;million in development milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i7809379654904198b0f40fede3b357a4_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk5Nw_a208f736-3e45-4abf-886d-0bd18d09ecd9">300.0</ix:nonFraction>&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement, when earned are non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="if7f4f202adee470e8770f3ce345ea450_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjk0MA_54afdc98-26e0-4c04-9bc1-3c47ae066490">95.1</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="if7f4f202adee470e8770f3ce345ea450_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementLicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjk3OQ_717bc127-453d-45a3-b230-390762ce4342">75.0</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="if7f4f202adee470e8770f3ce345ea450_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzAxNA_cf8dd13f-cb62-4d90-baf3-69d5d9a3c71e">20.1</ix:nonFraction>&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i757166e143b64a41ba577ebe4be02b45_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDYyNw_9440c3ba-4a4f-4ade-afcd-7c28208c04f6">64.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i34fb2fbe43f84642b4ef2537c5369e1e_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjI3MQ_4bf2ada3-f3bc-47c3-91d1-1a8d4b45297f">70.9</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="if12f1dff4f394f549916c7c5496cb43b" continuedAt="icdd9b98c8d7e4bc2a0dc23f060abbb87"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, the Company recognized revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="ib3a7d845e25d44dda4758f9bcaba97fa_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NTQyNg_5963fc08-ad7b-43cb-af56-6c6f5f1a26de">6.2</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="if0431659b3584e55b72f8e5b04fcf870_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzYxOA_82b308b9-8c22-4b50-8e7b-aa23250bc546">none</ix:nonFraction>, respectively, related to the upfront license fee and approximately $<ix:nonFraction unitRef="usd" contextRef="i15ffb4ef28e24434bf448ba66f1f1afc_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NTQ0Ng_549de850-2a93-42af-9a1f-0d45a6894c11">1.7</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i005c57a24e8f443ca9c1180106705ef2_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzY4MA_ecd7889a-4204-49de-89d1-9faf015a2d1b">none</ix:nonFraction>, respectively, from research reimbursement costs related to the Novartis agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczNw_0687e4f3-6bab-4297-a871-55274530e247">1.5</ix:nonFraction>&#160;million for financial advisory fees during the year ended December 31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDgwNg_d0eb9294-eb19-4d6e-8140-8e951350e776">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDgxMg_d55666bf-a09a-4e41-acbd-4c8e7f5ffcb9">75.0</ix:nonFraction>&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0MQ_0687e4f3-6bab-4297-a871-55274530e247">1.5</ix:nonFraction>&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic 340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company amortized $<ix:nonFraction unitRef="usd" contextRef="i54a4cf97110343f3a88212e70424cd96_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NTYyMw_ff14de3a-fc58-4d0c-887a-ab5576552bd7">0.1</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i3542eb13ee6148b8b4bcdd99fef16454_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTk4Mw_1430c7c8-e74a-4bf4-8e0e-48c87ced1ec5">none</ix:nonFraction> during the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase <ix:nonFraction unitRef="shares" contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNTg5NA_2b956dc5-5df9-4993-a620-d65e35e405b8">24,420,157</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="idcd855b9275c4a8eb8f323a68bbf1d77_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNTk4MQ_509534f2-90ea-497d-bb6a-84e6fa394aed">9.2137</ix:nonFraction>, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjAzNA_02a24daf-a32f-48c6-b667-14263af58fef">225.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $<ix:nonFraction unitRef="usd" contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjMwMg_803d7282-ba7c-4da4-a3d5-130b1f4530bd">225.0</ix:nonFraction>&#160;million for the purchase of the Biogen Shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i9cb99906f06b46e8b267391bde6b0830_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjQyOQ_a69ac5d8-66b5-4e13-b790-d2b9c396f942">125.0</ix:nonFraction>&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="ic36d2806042d4050b552799fc92519e9_I20200229" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjU5MA_196dd90c-9441-48a8-b32d-27685c06d7c7">2.37</ix:nonFraction>&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $<ix:nonFraction unitRef="usd" contextRef="ia4bf6163ffff418c83013f140a3d867b_I20200229" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjc1Mw_a0980b52-4a6a-4f71-9071-b575ad5e483e">925.0</ix:nonFraction>&#160;million in pre-approval milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i3274c4f79e0340a5ae43580f04c8e34f_I20200229" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjgwMQ_5efd2ee6-7c7e-4eb2-a3a6-d5d193271bd3">1.45</ix:nonFraction>&#160;billion in first commercial sale and other sales-based milestone payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to <ix:nonFraction unitRef="product_target" contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNzUxMg_15af1a1b-3920-4665-9ee1-1d06e38bfc8e">12</ix:nonFraction>&#160;neurological disease gene targets selected by Biogen. Biogen has already selected <ix:nonFraction unitRef="product_target" contextRef="ic36d2806042d4050b552799fc92519e9_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNzU5Nw_00c892c1-f7be-4dcd-b083-ac71a701c36e">three</ix:nonFraction> of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to <ix:nonFraction unitRef="product_target" contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAgreementNumberOfAdditionalProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNzgyNA_bee6a386-61ab-42ff-bf41-53559af91dec">nine</ix:nonFraction> additional targets over a target selection period of <ix:nonNumeric contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborationAgreementTargetSelectionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNzg4MA_3a139834-58b3-4266-9fa3-acc97260ed02">five years</ix:nonNumeric>. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first <ix:nonFraction unitRef="product_target" contextRef="ic36d2806042d4050b552799fc92519e9_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfODQ2Ng_f699eac4-daac-4adb-9cc9-00b096677399">three</ix:nonFraction> products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first <ix:nonFraction unitRef="product_target" contextRef="ic36d2806042d4050b552799fc92519e9_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfODcxNw_0b7b97a1-c25f-4cd5-9dfa-c41c368cf81a">three</ix:nonFraction> products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed <ix:nonNumeric contextRef="i3e07997bca414cf2953b42b65cb1fefb_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborationArrangementResearchPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfODgyOA_b296b354-3543-4850-b9c3-234752ab6230">seven years</ix:nonNumeric> from the effective date of the agreement (i.e. through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to <ix:nonFraction unitRef="product_target" contextRef="i4f7ac715a9b948b18839034f530a5ddd_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfOTQ1Nw_6a89725b-2a56-40e1-a698-816d772fb499">ten</ix:nonFraction> targets. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the <ix:nonNumeric contextRef="i1f78e88d6b69472e839f423e5b345307_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborativeArrangementStandstillRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjU_baa00ea5-9d95-4029-b9a4-3a4eebf3a1aa">three-year</ix:nonNumeric> anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="ib69b2d9da4aa46f294f132d7d0fd52f0_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA0MjE_2323b309-3660-415c-b3f6-9cc1e032f47b">5</ix:nonFraction>% of the Company&#8217;s common stock.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="icdd9b98c8d7e4bc2a0dc23f060abbb87" continuedAt="i545654081fe54b9d917f820dfe027838"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock purchase agreement also provides that from the first anniversary of the effectiveness of the collaboration agreement, through the second anniversary, Biogen will hold and not sell at least <ix:nonFraction unitRef="number" contextRef="ib69b2d9da4aa46f294f132d7d0fd52f0_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA3NDE_ab0c0934-d2c0-4b41-ad41-f94ecb0ad238">50</ix:nonFraction>% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule&#160;144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i)&#160;the <ix:nonNumeric contextRef="i1f78e88d6b69472e839f423e5b345307_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMTk_58f628c8-fe4a-40c7-b66a-6c9e2d562c86">two-year</ix:nonNumeric> anniversary of the effectiveness of the collaboration agreement, (ii)&#160;the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="ib69b2d9da4aa46f294f132d7d0fd52f0_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTE2MzY_293b1140-37f8-4df8-abfb-50fb28906a8a">5</ix:nonFraction>% of the Company&#8217;s common stock and (iii)&#160;the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjE5Ng_1d398edf-04c4-4238-bada-2c32d6cd8367">204.6</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTIwODc_cb04605c-f574-4a13-9d13-ed6d15301479">125.0</ix:nonFraction>&#160;million and the excess consideration from the stock purchase of $<ix:nonFraction unitRef="usd" contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTIxNDY_af3299c7-f15d-4254-9724-0005c1e24d85">79.6</ix:nonFraction>&#160;million, which represents the difference between the $<ix:nonFraction unitRef="usd" contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTIxOTQ_19cf3cd2-3687-4043-b757-90b7001269f5">225.0</ix:nonFraction>&#160;million received for the purchase of the Biogen Shares and the $<ix:nonFraction unitRef="usd" contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationAgreementEquityIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTIyNTI_2b194fc4-3fbe-40a5-b800-cb60d82bcabe">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i7f5f5ec067c64bd38439f1f0e454a1a3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQyNjU_99e09286-18d2-408d-bcda-677fdd48d4ac">175.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0ce08d1f25be4729bc3e45da23cef7b0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjIzNA_77c9bd3e-73a2-47cd-b4a1-8429cdaa722b">183.2</ix:nonFraction>&#160;million, respectively, related to this agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, the Company recognized revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i2118dcb01a3143bb92d2503658c8e4de_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjE2Ng_fee621c4-d802-4e80-b9f7-0ab4e6c3532c">7.3</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i98afd062347644fe9caa179181f1d6bb_D20200101-20200331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzQ2MA_895bec06-b666-4958-a0da-03b33d59ed80">none</ix:nonFraction>, respectively, related to the upfront license fee and the excess consideration from the stock purchase, and approximately $<ix:nonFraction unitRef="usd" contextRef="if1f36c6406ec47d0a03002619c66f091_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjE4NQ_324940a6-353e-4d3b-af84-d36c3d64c49b">3.1</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i828c0aafea3d4fdfb8f588e64d921e4c_D20200101-20200331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzQ2OQ_d7b048b8-4095-457f-bd89-1ac842d6e12e">none</ix:nonFraction>, respectively, from research reimbursement costs under the Biogen agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ0MzM_fb16a5dd-56b7-41f4-82e6-4d172db63c0d">7.0</ix:nonFraction>&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ1MDY_a391ecd9-c3f0-4ccb-85d9-d615a43063d0">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ1MTI_19cf3cd2-3687-4043-b757-90b7001269f5">225.0</ix:nonFraction>&#160;million received for the sale of shares and <ix:nonFraction unitRef="number" contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ1NTE_71d3c437-00c4-4ef5-8b9d-9748a55894dd">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ1NTc_cb04605c-f574-4a13-9d13-ed6d15301479">125.0</ix:nonFraction>&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i53a6386cca364200a895bc9cda07eadd_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ4Njk_840681c0-87c5-444e-b2dc-956783cf3324">4.1</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ4OTA_5b40cd5b-57b2-411e-bbaa-5f6252677e9d">2</ix:nonFraction>% of the transaction price of $<ix:nonFraction unitRef="usd" contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTY2Mg_2320af8d-2c2c-4cbd-afd2-203c5f15b345">204.6</ix:nonFraction>&#160;million, as a contract asset. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company amortized $<ix:nonFraction unitRef="usd" contextRef="i4f7ac715a9b948b18839034f530a5ddd_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTUyNTk_77b1c9e1-9c12-4a72-8ec5-8b340496f466">0.1</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i6cf45da81af341b5af253ace0465bd98_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTkzMw_edacfe5c-22a1-4cde-8640-5ab363b8f4f5">none</ix:nonFraction> during the three months ended March&#160;31, 2021 and 2020, respectively. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTUzNDY_d09b6420-44b5-4c3c-9a4a-56a11d1943d3">2.9</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTUzNjc_37e6dd58-aa3e-4b50-96fb-915ed9359e43">2</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationAgreementEquityIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTUzNzc_2b194fc4-3fbe-40a5-b800-cb60d82bcabe">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in proceeds.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), which became effective in April 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="i545654081fe54b9d917f820dfe027838" continuedAt="i5b40096a34ce4dfead70a759825b6e95"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the effective date, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i868c9fe32a52452dab9aa2f991f5ac1f_D20180405-20180405" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTc3MDA_af62d61b-0f42-4b03-9939-96b9f5b33db7">150.0</ix:nonFraction>&#160;million upfront payment from Kite. Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $<ix:nonFraction unitRef="usd" contextRef="i6d691cfac5fc48f6ae86378e6b4a002a_D20180405-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTc5MzA_732e0026-1cc0-408b-a5a1-dd33afd71b50">3.01</ix:nonFraction>&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $<ix:nonFraction unitRef="usd" contextRef="i5161917923e141dba34488ab948e41a6_D20180405-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTgwNDA_09417a48-acea-4c79-9222-296bfbf08141">1.26</ix:nonFraction>&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $<ix:nonFraction unitRef="usd" contextRef="iad0d9faf81c84a81aa9b16164821cf1d_D20180405-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTgxODI_1e37da87-45b2-4164-ad8b-eaddfe40f6e4">1.75</ix:nonFraction>&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term in the agreement is <ix:nonNumeric contextRef="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331" format="ixt-sec:durwordsen" name="sgmo:InitialResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTkxMzY_ef5e6340-6264-45d0-890c-bbdc3b637a33">six years</ix:nonNumeric>. Kite has an option to extend the research term of the agreement for up to <ix:nonFraction unitRef="option" contextRef="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfOptionsToExtendInitialResearchTerm" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTkyMTQ_d29aa5ec-b46e-47a4-a08c-569313fb7ab1">two</ix:nonFraction> additional <ix:nonNumeric contextRef="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331" format="ixt-sec:durwordsen" name="sgmo:ExtendedResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjA_917b356b-fab0-4dca-b9f4-e139a3de0f05">one-year</ix:nonNumeric> periods for a separate upfront fee of $<ix:nonFraction unitRef="usd" contextRef="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SeparateUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTkyNzQ_dd8b5b70-0c89-4ea6-88ae-c4fb72b624c3">10.0</ix:nonFraction>&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $<ix:nonFraction unitRef="usd" contextRef="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk1ODc_8e9d9e2d-a994-461a-98e0-7cf549a97b3e">3.4</ix:nonFraction>&#160;million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk3MzQ_f9120245-0ce1-44db-a883-b69b8b5d482b">189.3</ix:nonFraction>&#160;million and includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk3Nzc_db8ebdaa-9028-4015-8fd5-381403b42365">150.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk3ODQ_3eeec428-af18-4332-bdcd-46083f774759">39.3</ix:nonFraction>&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ia8ba008f3a5a42be83d38ba385bbc8d9_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjIyODE_c7e4b3ab-1712-48fb-b9f0-34cea7ef11f6">75.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i184e9ab5d0b74ca68b16888bb4007dc0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjIyODg_cb5eaeb4-8c06-4167-97ef-c1544a4846d8">81.4</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="i5b40096a34ce4dfead70a759825b6e95" continuedAt="ib7e49c3b4bd64708bf4f8c673afd2230"><ix:nonNumeric contextRef="i2a3d9c81024248b1adfc4a25b7c4d391_D20210101-20210331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjc_c3847f46-7b40-40de-8c8b-310d6349c148" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb423d0affaa4d709010389b445356c0_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfMy01LTEtMS0w_5a5277eb-6b0f-481f-a0b3-b351d7c46447">6,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01acb0b530634a9f92961bce1668f40d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfMy03LTEtMS0w_2fdeed6c-74e8-43f8-83f2-77bd72fced94">6,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d076890fcfc4f4cae05e8d5e034c7b2_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfNC01LTEtMS0w_2fb373b4-576c-40e6-8e69-ffa91b209d80">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba7559393313442091af1abf5c735f2b_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfNC03LTEtMS0w_64e449e5-508f-42da-a8e8-dd43463e0b55">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3d9c81024248b1adfc4a25b7c4d391_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfNS01LTEtMS0w_9156eb22-1561-4559-92e9-99c583a542c5">6,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d499b745bbd4aca82c6887941eb2f4b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfNS03LTEtMS0w_f168f1ab-cfed-49a2-95f9-1f7eb5fa566c">7,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia&#160;A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia&#160;A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;<ix:nonNumeric contextRef="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331" format="ixt-sec:durwordsen" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjQyNzM_bcd5a05e-ec39-4625-8743-a9111e194bdd">fifteen years</ix:nonNumeric> after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="iad9f9edf27124c6a8611cf6dcc485c06_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjUxNTI_4e68f986-98c3-4f60-acbb-fdc9d25b91c0">70.0</ix:nonFraction>&#160;million and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i11db6cb00c9c4e91a017c15c76688b71_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU0NDI_3834b228-f549-4394-9aa8-e512acee5fbe">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i607adea8b9544c9a857fd7049243e384_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU1NzE_4209e013-acf3-471e-b063-3659dee35fb0">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="if807a38abb434889be2ed63115c6d893_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU4Nzk_bafd5bd0-e1f2-4380-b1ca-b9427b65cd12">475.0</ix:nonFraction>&#160;million, which includes up to $<ix:nonFraction unitRef="usd" contextRef="i2b355d6fe77d457698c955bfed974e53_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU5MDQ_66afe849-c93e-4e18-9e04-dd8dd98f6d34">300.0</ix:nonFraction>&#160;million for giroctocogene fitelparvovec and up to $<ix:nonFraction unitRef="usd" contextRef="i0739b227da3b4bca85dcba2a54effd31_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU5Mjg_fe829ab6-61b6-4dd5-88c9-a415fb00fb59">175.0</ix:nonFraction>&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, <ix:nonFraction unitRef="milestone" contextRef="ie9c5e3edd0db4669b6958fb4f83b506b_D20170501-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY1MDc_a9c06782-402a-459e-bea8-63925472505e">two</ix:nonFraction> milestones of $<ix:nonFraction unitRef="usd" contextRef="ie9c5e3edd0db4669b6958fb4f83b506b_D20170501-20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY1MjQ_5e77f5c4-e319-4e60-b5a5-2dea1fbf94ad">55.0</ix:nonFraction>&#160;million in aggregate have been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="ia108ccb69cd546219ec3a5224afff3d6_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY1Njg_6e4d4ec4-c6a9-4424-8aa1-5accf783f3e4">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="royaltyfee" contextRef="ia108ccb69cd546219ec3a5224afff3d6_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY2MTM_0e392f5b-9b3d-472f-92d1-f51257a3a1e4">no</ix:nonFraction> royalty fees have been earned under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY4NTA_1af649f1-9ced-4d5c-b3e6-c7ac85ccf9b4">134.0</ix:nonFraction>&#160;million, which represents the upfront fee and research services fees of $<ix:nonFraction unitRef="usd" contextRef="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementResearchServiceFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY5MTc_1ad26e8f-d6b3-48af-8625-504bf213358f">79.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="milestone" contextRef="ie9c5e3edd0db4669b6958fb4f83b506b_D20170501-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjU5NzA2OTgzMTcwMw_0ad206e8-6451-4bf4-96a5-875245b16138">two</ix:nonFraction> unconstrained milestones achieved of an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY5ODg_ced4270d-d383-408c-8d24-005ce79c23fb">55.0</ix:nonFraction>&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="ib7e49c3b4bd64708bf4f8c673afd2230" continuedAt="i12f58321e0a646b7bc5b1c9f862010d5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into an amendment to the agreement, pursuant to which the Company transferred the IND for giroctocogene fitelparvovec to Pfizer. Upon this transfer the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="icc1d6a7d7d9648f297ef3f74c21f27f5_D20191201-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjg4OTY_8f4d4946-98c5-452a-b824-e46882041308">25.0</ix:nonFraction>&#160;million milestone as the conditions for achieving the milestone were met. The cumulative revenue recognized in connection with this milestone was $<ix:nonFraction unitRef="usd" contextRef="ib02a2a6eb3a3422dbca515f54079ab86_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3OTA5NA_b7da49d9-99b7-497f-911f-4f2b2cb298c5">25.0</ix:nonFraction>&#160;million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia&#160;A collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the giroctocogene fitelparvovec product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i6b75336922ca48acbeec35795e3f89c0_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NDUyMA_fecf2a9d-f39d-4c66-9bb0-f83ecd226b3e">2.4</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i6b75336922ca48acbeec35795e3f89c0_D20200301-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NDU0Nw_217ddf25-7b14-42dd-883c-1288d39869a1">2.4</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i6b75336922ca48acbeec35795e3f89c0_D20200301-20200331" decimals="INF" sign="-" name="sgmo:CollaborativeArrangementNetIncomeLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NDYwOA_89603dd6-de7c-433f-b913-5335f4ef0985">0.02</ix:nonFraction> for the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company determined that there was a high probability of achievement of a $<ix:nonFraction unitRef="usd" contextRef="idc16c1fdcccf4d5798400ac9fd30c32d_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjkzNzE_05d4db1f-e79a-4737-afb4-0db400b05bb4">30.0</ix:nonFraction>&#160;million milestone with Pfizer for giroctocogene fitelparvovec. The milestone was subsequently achieved upon dosing of the first subject in a Phase&#160;3 clinical trial in early October 2020. The cumulative revenue recognized in connection with this milestone was $<ix:nonFraction unitRef="usd" contextRef="ibefa2eee1d224a5a8a3a002053b6b569_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjk1OTE_d5203b87-60a7-49da-ae66-a90416ce1d4c">30.0</ix:nonFraction>&#160;million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three months ended March&#160;31, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="id906fae1befa40139b59199d084644fb_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NTYxMA_4977adb3-1ddb-4034-85a9-e763fa1bfcd6">2.2</ix:nonFraction>&#160;million of upfront license fee and research services and $<ix:nonFraction unitRef="usd" contextRef="i2c5af769a3724b79ad162f6dc82b9325_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NTY2Mw_f192e2c2-090b-4e89-939b-407e19087ab5">1.0</ix:nonFraction>&#160;million milestone achievement as revenue related to this agreement during the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;<ix:nonNumeric contextRef="i5e53a9d7d29f4ca7a15cc2342c452633_D20210101-20210331" format="ixt-sec:durwordsen" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzI2MjU_6f7660c4-14d4-4d2f-b20b-0057960ed1b5">fifteen years</ix:nonNumeric> after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="i12f58321e0a646b7bc5b1c9f862010d5" continuedAt="i29b8d4134f9f4ffdba60ccb9dee24f98"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $<ix:nonFraction unitRef="usd" contextRef="i0794a490e25b4316b034257c060699e8_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzQ0NDI_c24336cf-b831-4ebd-b577-601b29dfaad6">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="iad9117357d274e389ec4bb2d954d40a3_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzQ1MDY_39f1d009-e90f-4b24-9e49-b64edd0fb80d">60.0</ix:nonFraction>&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="ie71a3d375d8949d28e7d537186c4fba5_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzQ2OTI_ba14a468-eba5-4860-aa3b-cb0cb24935f4">90.0</ix:nonFraction>&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $<ix:nonFraction unitRef="usd" contextRef="i552e02bdf7ff40bd9f7d8d307d5ed4a0_D20171201-20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTg3OQ_5f6334ec-ef83-42e3-848c-9d0ffc869630">5.0</ix:nonFraction>&#160;million has been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="i552e02bdf7ff40bd9f7d8d307d5ed4a0_D20171201-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjU5NzA2OTgzMTc1MA_3b624a7c-eb78-4509-aca7-45b719086259">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i552e02bdf7ff40bd9f7d8d307d5ed4a0_D20171201-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjU5NzA2OTgzMTc1MQ_30af641c-2edb-4063-bf4c-f877ef2f3e7f">no</ix:nonFraction> royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="i12192197df6e4c748c74e75b895766dd_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzU0ODk_070c1eb8-df1b-46f8-8350-cd29b62fceca">17.0</ix:nonFraction>&#160;million, which represents the upfront fees of $<ix:nonFraction unitRef="usd" contextRef="i12192197df6e4c748c74e75b895766dd_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzU1MzA_9e1813ab-af93-48a5-a486-56b128d64c9f">12.0</ix:nonFraction>&#160;million and one unconstrained milestone in the amount of $<ix:nonFraction unitRef="usd" contextRef="i12192197df6e4c748c74e75b895766dd_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzU1ODI_0e6b1f08-19d3-4b10-b10e-bef6cdfa4ff2">5.0</ix:nonFraction>&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $<ix:nonFraction unitRef="usd" contextRef="i263f5e49eb104d2b951703a42c48374c_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzgzMQ_2f455116-33bc-4cc5-bd36-5f8d2675a5d6">5.0</ix:nonFraction>&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December&#160;31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three months ended March&#160;31, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i81052728a07f4234a17255473a25eb02_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MTM5NA_4ab090ed-c8d4-4386-bea4-06ccc6c78530">0.4</ix:nonFraction>&#160;million of upfront license fee and research services as revenue related to this agreement during the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Genzyme</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting <ix:nonFraction unitRef="program" contextRef="i2b8e1d577cdc4e909e22ace81ac93119_D20140101-20140131" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfResearchProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzg4Nzg_1681ffd2-2b16-42bd-b8d5-1a26284420ff">two</ix:nonFraction> research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="i29b8d4134f9f4ffdba60ccb9dee24f98" continuedAt="i9d2aba4e85e44543af6897c96d7d1848"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon <ix:nonNumeric contextRef="i2c2127ce4c454d39bf4876ba0fcacebf_D20210101-20210331" format="ixt-sec:durday" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDA5MDI_09cf16ca-5c94-4f40-a820-a6795c66c7a1">180</ix:nonNumeric> days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i2b8e1d577cdc4e909e22ace81ac93119_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDEyMTk_f58164fd-0fb9-4b98-bf5a-ad3493fb9747">20.0</ix:nonFraction>&#160;million and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i4bcae7d19c204753a2408edcca187aea_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDE0Mzg_d6d16117-191a-4b2f-9276-76ee8b7d9ed2">115.8</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $<ix:nonFraction unitRef="usd" contextRef="i85f4919f9c0c4473b1ebc3b0d83ed945_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDE1NTI_2734d90f-a6f0-4e12-8e2f-8687fe3abc28">160.5</ix:nonFraction>&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="ic69d4938e11f4400912ca470c0f2df17_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDE3OTI_7cd188f6-1fce-404c-97d9-09af1846ae07">276.3</ix:nonFraction>&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $<ix:nonFraction unitRef="usd" contextRef="ia3d256269518436384e6a844f9460eb3_I20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDIxMDE_b1ed2490-243e-41e2-a052-d24409173fa1">6.0</ix:nonFraction>&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $<ix:nonFraction unitRef="usd" contextRef="id2f0c509626e41d2b12512c505830612_I20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTkxNA_ac918ce0-7e5f-46b8-811f-af44d805bf27">7.5</ix:nonFraction>&#160;million milestone has been achieved related to SCD, however <ix:nonFraction unitRef="product" contextRef="icb3452b189334360b2eae0dc8a8f906d_D20140101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDIyMzg_1ebcf43c-6248-4faa-8f07-7a9f8b872075">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="ie081f263ba514369a864fc04ab2755ef_D20140101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDIyODM_ea6dcbf8-2459-4160-9153-a428b65bf009">no</ix:nonFraction> royalty fees have been earned under the Sanofi agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i900c9e6b08d34f609332901a02f4e019_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDI0NzA_bff5ae7a-729d-47a3-93ed-e041d590896e">93.3</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i900c9e6b08d34f609332901a02f4e019_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDI1MDk_5929e5bd-8537-4e49-8a10-08f6a2591d4f">20.0</ix:nonFraction>&#160;million, two unconstrained milestones in the amount of $<ix:nonFraction unitRef="usd" contextRef="i70098c2ae44f43d0b6cc32e42dc76aff_I20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDI1NTk_957dcf11-a2c7-47cc-ab15-8a0b341f4e56">13.5</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="i900c9e6b08d34f609332901a02f4e019_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDI1OTQ_1bcf6653-a611-41cd-bd6f-7a73f4a0efd7">59.8</ix:nonFraction>&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ibfb4fcf9f2374b178f3f64eb7492ba62_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ0Mjc_88483716-ca66-4918-8984-83462cf4be8a">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8946000fa68f43baa5c040af17dd5bd5_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ0MzQ_e09f3fae-fa77-4569-8621-e9270ff0d8bd">1.2</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i3cf33b15cb6f4155a7c06a66148748b1_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ1MTg_4f818673-4f65-41a9-8f5a-dc270c660dfd">6.0</ix:nonFraction>&#160;million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $<ix:nonFraction unitRef="usd" contextRef="i3e1b297e2e824a43b69317d3cf60c21c_I20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ2OTA_a343282f-aded-4e71-9c21-6c14096a6435">5.9</ix:nonFraction>&#160;million as of March&#160;31, 2021 and included $<ix:nonFraction unitRef="usd" contextRef="i3e1b297e2e824a43b69317d3cf60c21c_I20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMilestoneRevenueReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjU2OA_66da8893-83b3-48b3-a71e-4e237bb0deed">0.1</ix:nonFraction>&#160;million recognized during the three months ended March&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="if64ca9e8294649218a45ade74be60132_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ4OTM_d1d8d634-cb47-4360-97a0-034a03f6a9b7">7.5</ix:nonFraction>&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $<ix:nonFraction unitRef="usd" contextRef="ibfb4fcf9f2374b178f3f64eb7492ba62_I20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDUwNDU_f11b6dca-377a-4718-8aa8-31fd05c52b44">7.3</ix:nonFraction>&#160;million as of March&#160;31, 2021 and included $<ix:nonFraction unitRef="usd" contextRef="id2f0c509626e41d2b12512c505830612_I20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMilestoneRevenueReversal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjgzMg_6f5977f7-67fc-4cac-b5b0-3c53ea0342e6">0.1</ix:nonFraction>&#160;million recognized during the three months ended March&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i2c2127ce4c454d39bf4876ba0fcacebf_D20210101-20210331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjE_c5fad739-0269-47a8-a876-e244f32c973f" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia042567c5f69499ca3310b43148a2dc4_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfMy01LTEtMS0w_835f885f-97c6-4baa-879f-afa39f460771">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a483e7e113b40b4932319e4d56036a0_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfMy03LTEtMS0w_83551598-e553-4ace-b051-2350d515c5e6">729</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412d6af141ea4a5eaff0bd4986d51146_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNC01LTEtMS0w_a9ca4d13-887f-4aff-8efe-225820e53c12">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2a5a95ecafb44a7874d3bd37d807e3b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNC03LTEtMS0w_a7aeee02-4849-4acb-95a8-540f76a9c7a4">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ec745d260041b8a59a2e8dc45ffa91_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNS01LTEtMS0w_f5bb98f8-10a0-4a08-a7d7-a05da5dff1a1">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie63bf8b36b024460a56259f11296d885_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNS03LTEtMS0w_cc260216-57a4-4254-8668-a48b52c35dd0">492</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2127ce4c454d39bf4876ba0fcacebf_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNi01LTEtMS0w_811554b0-dc37-4291-870d-6636f4ea6b6b">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNi03LTEtMS0w_6be83e0d-0e31-4883-9083-1e80e0df316c">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="i9d2aba4e85e44543af6897c96d7d1848"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment decreased revenue by $<ix:nonFraction unitRef="usd" contextRef="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDU3MjI_304413b1-1cd3-42eb-b55f-b839ca206b64">2.2</ix:nonFraction>&#160;million, increased net loss by $<ix:nonFraction unitRef="usd" contextRef="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDU3NDg_fd831f0b-339e-4828-a639-d4b5b05aa6f6">2.2</ix:nonFraction>&#160;million and increased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331" decimals="2" sign="-" name="sgmo:CollaborativeArrangementNetIncomeLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDU4MDg_d3564f5b-6367-47ae-aff0-98b5a566613e">0.02</ix:nonFraction> for the three months ended March 31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Institute for Regenerative Medicine</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $<ix:nonFraction unitRef="usd" contextRef="ic51c2ae6d077473d8293fa2b46203655_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:GrantFundingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDYwMDE_c1ba8d41-b2f3-4f91-9542-7975dbdbd50b">8.0</ix:nonFraction>&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of March&#160;31, 2021, the Company had received $<ix:nonFraction unitRef="usd" contextRef="i6dae3ccf0cd54c5fb3e19ed6a18b06c8_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDY0MTM_7b989f22-8530-4af1-bc09-abfc94d83f92">5.2</ix:nonFraction>&#160;million under the award.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of March&#160;31, 2021, and December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i55f0be7b4249420ab4cc66f467c2f873_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDcwNjE_6451eecf-31d2-422a-af3f-c3557a16c683">6.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic886d255bdf04e18ab350c75c4128994_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDcwNjg_d9d07b91-2662-4dce-90d1-eca15edf095f">6.4</ix:nonFraction>&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.</span></div></ix:continuation><div id="i4be9a0306d9c4f29ba82c2a83d136deb_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81NS9mcmFnOmE3OGUyOTc1OWE3MTQyOGJiODZkNmY0NjY5ZjlkZWI1L3RleHRyZWdpb246YTc4ZTI5NzU5YTcxNDI4YmI4NmQ2ZjQ2NjlmOWRlYjVfMTM1OQ_19ba4026-b6ee-4b38-89ca-9039f074a96b" continuedAt="idd410b8554864d7f9d879db8c075b6ec" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idd410b8554864d7f9d879db8c075b6ec">The Company&#8217;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. During the three months ended March&#160;31, 2021 and 2020, the Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81NS9mcmFnOmE3OGUyOTc1OWE3MTQyOGJiODZkNmY0NjY5ZjlkZWI1L3RleHRyZWdpb246YTc4ZTI5NzU5YTcxNDI4YmI4NmQ2ZjQ2NjlmOWRlYjVfNTEx_6750f9a2-4916-4331-99f6-6d459c9fb207">0.3</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81NS9mcmFnOmE3OGUyOTc1OWE3MTQyOGJiODZkNmY0NjY5ZjlkZWI1L3RleHRyZWdpb246YTc4ZTI5NzU5YTcxNDI4YmI4NmQ2ZjQ2NjlmOWRlYjVfNTE4_053993fe-806e-4716-9bc7-d36989488a9c">nil</ix:nonFraction>, respectively. The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three months ended March&#160;31, 2021 was primarily due to foreign income tax expense.</ix:continuation></span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMzM4Nw_a798d60f-ecd7-4ce3-83d6-ae0e27be1607" continuedAt="ideb78e2bdf54451f970ca75ac0372e9c" escape="true">COMMITMENTS</ix:nonNumeric></span></div><ix:continuation id="ideb78e2bdf54451f970ca75ac0372e9c" continuedAt="i4462dd19793344f4b283be39d6345a3f"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo occupies approximately <ix:nonFraction unitRef="sqft" contextRef="i31a1ce4b0e414b9186ddc9401df9e1ca_I20210331" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfODA_f06b7e0f-8d78-4c8f-a6b7-e2884e6bdccd">87,700</ix:nonFraction> square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately <ix:nonFraction unitRef="sqft" contextRef="i08adf079a35e4e43a2b4ac18b46404b4_I20210331" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMjU3_3ae64539-9f46-4f9f-b8ed-ebe7b36d0d82">59,200</ix:nonFraction> square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i53f2a73e9b4a48b496f08bbeb4ae0cda_I20210331" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNDE5_7abe622d-7811-4d6b-ab56-f80c28c4045c">25,600</ix:nonFraction> square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through January 2030.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjY4_d3ea0c69-cbb9-4d34-80ee-4f04096945c8">five</span> to <ix:nonNumeric contextRef="i4389a31659b5435cbd086cba9f72cb06_I20210331" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjc0_0264dc6f-f5fc-4562-b386-b57c40c36d97">ten years</ix:nonNumeric>. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the three months ended March&#160;31, 2021 and 2020, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA3OQ_e98f7405-454a-4afe-a9fa-e52283653e5b">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTE2NQ_fe1cc423-7365-4617-9cce-1bc069752974">2.6</ix:nonFraction>&#160;million, respectively, of lease costs in relation to these operating leases. These lease costs were included in operating expenses in the Condensed Consolidated Statements of Operations. For the three months ended March&#160;31, 2021 and 2020, variable lease expenses were $<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTMxMA_fe91038c-09a8-450d-bdb0-6ab5eaf29810">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTMxOA_0b229076-31c6-44a0-b4be-4926648ca331">0.5</ix:nonFraction>&#160;million, respectively, and were not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. This variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March&#160;31, 2021 and 2020, was $<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTc2Nw_8adad3a0-1073-4056-b167-ec45b50c3e42">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTM2Nw_03858125-f5ce-4dcf-addf-c98c65ec778c">1.6</ix:nonFraction>&#160;million respectively, and was included in net cash provided by operating activities in the Company&#8217;s Condensed Consolidated Statements of Cash Flows.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><ix:continuation id="i4462dd19793344f4b283be39d6345a3f"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMzM4OA_402decbf-379c-40b4-9dd7-10c1c16daa34" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ending December 31, 2021:</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMS0xLTEtMS0w_52bf8b47-3ada-406e-bc6d-5a701841320b">4,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMi0xLTEtMS0w_00647a82-7522-40ea-b263-4c0a582cc26b">6,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMy0xLTEtMS0w_c750ba63-7dcd-4348-a86e-4483fdaa6fc8">7,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfNC0xLTEtMS0w_9964d017-9fa3-4c75-bd8a-8ed7b6a5fc82">7,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfNS0xLTEtMS0w_9f684cfb-ddf8-4388-b1e5-42ce0e551899">7,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfNi0xLTEtMS0w_7522f705-a920-4841-b3c1-c32ef0970984">20,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfNy0xLTEtMS0w_b2602aee-8d20-4ca6-8b5a-e97fda69cd1e">53,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfOS0xLTEtMS0w_356dbbf8-a7af-411d-9c80-022650aa2c57">10,980</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMTEtMS0xLTEtMA_b468a24d-1c48-41ae-89fe-39cb566c07f2">42,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of March 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities - current (included in other accrued liabilities on the Condensed Consolidated Balance Sheet)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMTQtMS0xLTEtMA_b0fca8d9-5310-4456-ae92-5b27816813ca">3,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMTUtMS0xLTEtMA_f8ed2baf-ec63-4a43-8c28-dd079ba89c50">38,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMTYtMS0xLTEtMA_81721604-7c6a-4a78-8aae-93237ff1d80b">42,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the weighted-average remaining lease term is <ix:nonNumeric contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMjA1Nw_20567e2a-af47-4cd4-a104-865a98f92a0f">7.5</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMjE2NA_581bc419-439a-4c2a-9621-c6c6b99dc013">6.2</ix:nonFraction>% for the Company&#8217;s operating leases.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an amendment to an existing lease to acquire approximately <ix:nonFraction unitRef="sqft" contextRef="if674a30905aa4701b577fea5cdd38927_I20210131" decimals="-2" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAreaOfRealEstate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjU5NzA2OTc3NDI2MA_1d03b1ac-ee37-46eb-9177-c9013552f8ba">5,000</ix:nonFraction>&#160;square feet of research and office space in Richmond, California. With this amendment, the existing lease expires in August 2026. Total lease payments over the life of this amended lease are approximately $<ix:nonFraction unitRef="usd" contextRef="if674a30905aa4701b577fea5cdd38927_I20210131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMjQ3Mg_b15036c5-2ff5-47cc-9ed2-d3d3b24ec852">0.9</ix:nonFraction>&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On February&#160;1, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="i49ed718922c34bacb4fe8ab46f011d3b_I20210201" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNDM1NQ_b6881517-02cf-4641-b1c8-248ce249ec4a">0.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company also entered into a new lease to acquire approximately <ix:nonFraction unitRef="sqft" contextRef="i4bb8843fb3d341009157555d58c1790d_I20210131" decimals="-2" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAreaOfRealEstate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjU5NzA2OTc3NDI1Mw_16b2dd43-f736-4427-85e6-fac25c26365a">5,800</ix:nonFraction>&#160;square feet of research and office space in Valbonne, France, that expires in January 2030. Total lease payments over the life of this amended lease are approximately $<ix:nonFraction unitRef="usd" contextRef="i4bb8843fb3d341009157555d58c1790d_I20210131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTEwOQ_ce6b9e61-856a-4ee0-8241-e3ad7ee272f5">0.8</ix:nonFraction>&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On January&#160;29, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="i62fb65868a04407c87a0eefd5094126d_I20210129" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTEyNw_3fe8542f-aa72-4fe6-a3bc-d9f1fb359221">0.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any financing leases.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Commitments</span></div><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:OtherCommitmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMzM5MA_1a2ff623-2650-4d9c-adc5-f47966f90173" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of March&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied0c47637c5a4c5786b8ac57faeb569b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOmExZTI5NTUxOTQwZDRlYTE4NzAxNGRmZGRmMmYxOTIwL3RhYmxlcmFuZ2U6YTFlMjk1NTE5NDBkNGVhMTg3MDE0ZGZkZGYyZjE5MjBfMS0yLTEtMS0w_1a070a7d-e513-4066-a936-3b47d460c665">6,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59ea076e227497193dff8217d78482e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOmExZTI5NTUxOTQwZDRlYTE4NzAxNGRmZGRmMmYxOTIwL3RhYmxlcmFuZ2U6YTFlMjk1NTE5NDBkNGVhMTg3MDE0ZGZkZGYyZjE5MjBfMi0yLTEtMS0w_16838e2a-c445-42df-9720-e401ef34b1a3">11,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOmExZTI5NTUxOTQwZDRlYTE4NzAxNGRmZGRmMmYxOTIwL3RhYmxlcmFuZ2U6YTFlMjk1NTE5NDBkNGVhMTg3MDE0ZGZkZGYyZjE5MjBfMy0yLTEtMS0w_c2df82b3-c509-48eb-a8ed-98f6f4aac61f">17,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had $<ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LicenseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMzEwOA_717484a3-e142-4ec6-bcdf-57eebec2eb53">0.9</ix:nonFraction>&#160;million of license obligations related to its intellectual property as of March&#160;31, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RleHRyZWdpb246Zjg4NWI4NzZjNDEzNGQwOWI2ZDM0NDcwZjlmYmFmMDdfMjE5_78f775f6-b99b-4f52-ba46-dd5cab044a1a" continuedAt="ic0101d45c4ec40888e8b762c52c03e0a" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="ic0101d45c4ec40888e8b762c52c03e0a"><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RleHRyZWdpb246Zjg4NWI4NzZjNDEzNGQwOWI2ZDM0NDcwZjlmYmFmMDdfMjE4_5cc92469-d4b1-4474-aa65-1e10f947dd0f" escape="true"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three months ended March&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a9537a071b45a490485e4e675afbda_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfMi01LTEtMS0w_63f11ca6-fa79-4ab3-97a4-7ad6e9f20fd0">4,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7879f7c1ca14257a286f0937f160d6a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfMi03LTEtMS0w_fe615d90-e0ae-4245-bc55-149e38d4dcb3">2,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7121386b2ac42788064446ea02e0293_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfMy01LTEtMS0w_1aac2692-cdf3-4b9c-a735-1f1fe0e54178">3,272</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689dc02e331246b1b5c7ee22451f278f_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfMy03LTEtMS0w_f7afe84e-9851-4edc-9567-71a2bce19961">2,781</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfNC01LTEtMS0w_17c94131-dd7c-4084-8d12-42a14c9eb44a">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfNC03LTEtMS0w_310de181-8203-4503-b60c-075d2ed7866e">5,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82NC9mcmFnOjRlM2IyMmUzODg5MjQyY2JiNzAwMGJhOTFkZThjZTg3L3RleHRyZWdpb246NGUzYjIyZTM4ODkyNDJjYmI3MDAwYmE5MWRlOGNlODdfMjYyNg_43127351-1a85-4c4e-84e3-cd78bee33f94" continuedAt="ic74bb3d1a7b1457bada6250d87010bad" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ic74bb3d1a7b1457bada6250d87010bad"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i5d2cd66475ef461e9c805c9eaaaca699_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="sgmo:StockOfferingProgramMaximumValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82NC9mcmFnOjRlM2IyMmUzODg5MjQyY2JiNzAwMGJhOTFkZThjZTg3L3RleHRyZWdpb246NGUzYjIyZTM4ODkyNDJjYmI3MDAwYmE5MWRlOGNlODdfMTE3OA_5caa2402-aee5-4395-9849-1075cc0d45f0">150.0</ix:nonFraction>&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i29077b179cb747c6af600e5610999238_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82NC9mcmFnOjRlM2IyMmUzODg5MjQyY2JiNzAwMGJhOTFkZThjZTg3L3RleHRyZWdpb246NGUzYjIyZTM4ODkyNDJjYmI3MDAwYmE5MWRlOGNlODdfMTA5OTUxMTYzMzE3Mw_39025409-520f-4fbf-b6a3-f04cf9b54fbf">1,034,762</ix:nonFraction> shares of its common stock for net cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i29077b179cb747c6af600e5610999238_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82NC9mcmFnOjRlM2IyMmUzODg5MjQyY2JiNzAwMGJhOTFkZThjZTg3L3RleHRyZWdpb246NGUzYjIyZTM4ODkyNDJjYmI3MDAwYmE5MWRlOGNlODdfMTA5OTUxMTYzMzIwOQ_fb2ec7e5-f9c2-427b-8ec6-1ee9a3f6004d">15.7</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i4be9a0306d9c4f29ba82c2a83d136deb_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10&#8212;<ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMzM1MQ_d44e6332-ed4e-43b3-9d24-e32a2b4cc038" continuedAt="i17c78c1869844bd9a372a34c724135f4" escape="true">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</ix:nonNumeric></span></div><ix:continuation id="i17c78c1869844bd9a372a34c724135f4"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Sangamo entered into various agreements with the goal of eventually acquiring <ix:nonFraction unitRef="number" contextRef="i1129259eb0a649868776568fa4898425_I20180720" decimals="INF" name="sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMTYy_eca2201a-0394-4755-8266-fd92e10dc1ed">100</ix:nonFraction>% of Sangamo France&#8217;s share capital, including arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="i1129259eb0a649868776568fa4898425_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMTA2Mg_1d69ea2f-1987-4ec6-bcab-49bc204b75a8">477,000</ix:nonFraction> ordinary shares of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders, and such holders have the right to sell to the Company such shares from time to time through mid-2021. As of March&#160;31, 2021, the Company acquired approximately <ix:nonFraction unitRef="shares" contextRef="i91b1a80eaeeb470bb98449ced38f5857_D20180720-20210331" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfNTQ5NzU1ODE0NTQ4OA_6bf7b1f8-136f-4c27-92a2-6ca7602ca12c">453,000</ix:nonFraction> of the <ix:nonFraction unitRef="shares" contextRef="i1129259eb0a649868776568fa4898425_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfNTQ5NzU1ODE0NTQ5OA_9adea93d-c5ff-4eb9-a0f2-3354c59447c6">477,000</ix:nonFraction> shares, increasing its ownership of the ordinary shares of Sangamo France to <ix:nonFraction unitRef="number" contextRef="i4031384af7314ae98be13e046f877228_I20210331" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMTc4OQ_8c06c933-4e03-429a-b123-943491d76846">99.9</ix:nonFraction>%. The fair value of the option to acquire the remaining shares was estimated to be an asset with immaterial balance as of March&#160;31, 2021. See &#8220;Note 2 &#8212; Fair Value Measurements-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Free Shares Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for information regarding the valuation method.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic&#160;805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for total consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i628ef7e645dc4f99a3b94a2aa9545377_D20181001-20181001" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMjQxNg_4afaa552-9a51-4b31-b3b5-a3a3a78b3fb3">45.9</ix:nonFraction>&#160;million at the October 2018 acquisition date. The operating results of Sangamo France after the October 2018 acquisition date have been included in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMjYwOA_1ffe8611-19de-49d9-867c-7da20a378610"><ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMjYwOA_224bc123-9b9f-4ffe-9bf4-0c6a831edadc">no</ix:nonFraction></ix:nonFraction> goodwill impairment during the three months ended March&#160;31, 2021 or during 2020 and, as noted below, substantially all of the non-controlling interest on the October 2018 acquisition date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of March&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining non-controlling was determined based on the number of outstanding shares comprising the non-controlling interest and the $<ix:nonFraction unitRef="usdPerShare" contextRef="i25f4525748b042cb9cf63d0d356cdd37_I20181001" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMzA4Ng_b73b931a-76ae-4c7d-8dc6-bc2473070fe2">2.99</ix:nonFraction> acquisition price per share as of the October 2018 acquisition date. The non-controlling interest is presented as a component of stockholders&#8217; equity on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" name="sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMzM0OA_ec94d9af-0429-4a10-b410-ac017d5ef9a9" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of March&#160;31, 2021 was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RhYmxlOmUyN2JkZWU4MWM1MzQyNGE4OTlmNTRkODIwODgwZjY2L3RhYmxlcmFuZ2U6ZTI3YmRlZTgxYzUzNDI0YTg5OWY1NGQ4MjA4ODBmNjZfMS0xLTEtMS0w_54b177cd-e3f5-4e82-8d53-2e14767db852">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RhYmxlOmUyN2JkZWU4MWM1MzQyNGE4OTlmNTRkODIwODgwZjY2L3RhYmxlcmFuZ2U6ZTI3YmRlZTgxYzUzNDI0YTg5OWY1NGQ4MjA4ODBmNjZfMi0xLTEtMS0w_cae56ae8-a1d4-4eef-82ed-f6b465598994">64</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RhYmxlOmUyN2JkZWU4MWM1MzQyNGE4OTlmNTRkODIwODgwZjY2L3RhYmxlcmFuZ2U6ZTI3YmRlZTgxYzUzNDI0YTg5OWY1NGQ4MjA4ODBmNjZfMy0xLTEtMS0w_48d83f86-9e6c-4400-8886-f73453f8ebca">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RhYmxlOmUyN2JkZWU4MWM1MzQyNGE4OTlmNTRkODIwODgwZjY2L3RhYmxlcmFuZ2U6ZTI3YmRlZTgxYzUzNDI0YTg5OWY1NGQ4MjA4ODBmNjZfNC0xLTEtMS0w_3dfbfa57-9d0d-42a1-a20c-f662ee81e460">938</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risks and uncertainties summarized under &#8220;Special Note Regarding Forward-Looking Statements&#8221; that appears in the forepart of this report and as discussed in more detail under &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the SEC on February 24, 2021, or the 2020 Annual Report. You should also read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and accompanying notes included in this report and the Consolidated Financial Statements and accompanying notes thereto included in our 2020 Form 10-K.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases. We plan to deliver on this mission through development of (i)&#160;our clinical and preclinical product candidates, (ii)&#160;our novel science and (iii)&#160;our growing in-house manufacturing capabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical-stage product candidates are:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Giroctocogene fitelparvovec, also known as SB-525, our lead product candidate, is a gene therapy for the treatment of hemophilia&#160;A and is currently being evaluated in the registrational Phase&#160;3 AFFINE (efficAcy and saFety Factor vIii geNe thErapy) clinical trial. We are developing giroctocogene fitelparvovec with our collaborator Pfizer Inc., or Pfizer;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, is currently being evaluated in our Phase 1/2 STAAR clinical study;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SAR445136, formerly known as BIVV003, our cell therapy product candidate for the treatment of sickle cell disease, or SCD, is currently being evaluated in our Phase 1/2 PRECIZN-1 clinical study. We are developing SAR445136 with our collaborator Sanofi S.A., or Sanofi;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ST-400, our cell therapy product candidate for the treatment of transfusion dependent beta thalassemia, is currently being evaluated in our Phase 1/2 Thales clinical study. We are developing ST-400 with our collaborator Sanofi; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TX200, our wholly-owned Chimeric Antigen Receptor, or CAR, engineered regulatory T cell, or CAR-Treg, cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection is currently being evaluated in our Phase 1/2 STEADFAST clinical study. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we are focusing our preclinical development in emerging areas for us, including CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Indications for our other preclinical programs include neurodevelopmental disorders, cancer, inflammatory bowel disease, or IBD, tauopathies such as Alzheimer&#8217;s and neurodegenerative diseases such as amyotrophic lateral sclerosis, or ALS, multiple sclerosis, or MS, and Huntington&#8217;s disease, some of which we are developing with our collaborators Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, Kite, Novartis Institutes for BioMedical Research, Inc., or Novartis, Pfizer and Takeda Pharmaceutical Company Limited.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our zinc finger protein, or ZFP, technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal to bring our medicines more rapidly to patients. We believe these collaborations reflect of the value of our ZFP technology platform and will potentially expand the addressable markets of our product candidates. To date, we have received approximately $815.0&#160;million in upfront licensing fees, milestone payments, and proceeds from sale of our common stock to collaborators and have the right to earn up to $7.0&#160;billion in future milestone payments from our collaborations, in addition to potential product royalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current and future in-house manufacturing capacity provides us a competitive advantage. We currently operate an in-house adeno-associated virus, or AAV, manufacturing facility in our Brisbane, California headquarters, and we are building cell therapy manufacturing facilities in Brisbane, California and Valbonne, France, which we expect to be operational by the end of 2021. Our manufacturing strategy is to provide greater flexibility, quality and control by building a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">balanced and necessary capacity achieved through our in-house manufacturing and contract manufacturing organization, or CMO, partnerships, investing in manufacturing processes and analytics and developing a strong supply chain.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and Pfizer have completed enrollment in the lead-in study to the registrational Phase&#160;3 AFFINE clinical trial of giroctocogene fitelparvovec, our gene therapy product candidate for the treatment of severe hemophilia&#160;A. This lead-in study will follow patients for six months to establish a baseline prior to treatment with giroctocogene fitelparvovec. We and Pfizer expect to present a pivotal data readout from the AFFINE trial as early as 2022, as well as a two-year update from the Phase 1/2 Alta clinical study in the fourth quarter of 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have enrolled the fourth patient in our Phase 1/2 STAAR clinical study of ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease. We plan to present initial clinical data from this study in the fourth quarter of 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. Food and Drug Administration, or FDA, granted Fast Track Designation to SAR445136, formerly known as BIVV003, our cell therapy product candidate for the treatment of SCD. In addition, the European Medicines Agency, or EMA, granted Orphan Designation to SAR445136. According to minutes of the EMA&#8217;s Committee for Orphan Medicinal Products, the grant was based in part on the following preliminary clinical observations from the three patients treated out of the six patients enrolled in our PRECIZN-1 study as of December 2020:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">As of December 2020, these patients had 52 weeks, 13 weeks, and 29 days of follow-up, respectively.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The first patient treated was on standard of care hydroxyurea daily for several years and had frequent hospitalizations due to 10 severe vaso-occlusive crises, or VOCs, including hospitalizations within the two years prior to study enrollment.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The second patient treated also had numerous VOCs and received chronic red blood cell, or RBC, transfusions since the age of seven.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The third patient treated also has a previous history of chronic RBC transfusions and a VOC in the two years prior to enrollment.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">None of these three treated patients experienced recurrence of previous SCD symptoms as of December 2020.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The minutes stated that the preliminary clinical observations of SAR445136 as well as the potential of long-term effects that may obviate the need for continuous treatment, suggested a potential clinically relevant advantage versus hydroxyurea.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Sanofi expect to enroll a total of eight patients in the PRECIZN-1 study evaluating SAR445136 and expect to present initial clinical data from the study at a medical meeting by the end of 2021. The initial data we expect to present will reflect a more mature and more comprehensive data set than the preliminary clinical observations shared by the EMA in the committee minutes.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have initiated and opened for enrollment our Phase 1/2 STEADFAST clinical study evaluating TX200, our wholly-owned autologous CAR-Treg cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection. Patient recruitment is now open in two clinical sites in Belgium and the Netherlands, and we plan to enroll up to fifteen patients to receive TX200 and up to six patients in a control group. We expect to enroll the first patient in this study by the end of 2021, and to dose the first patient several months after enrollment. The primary objective of this study is to assess the safety and tolerability of TX200, and secondary objectives include the incidence of biopsy-confirmed acute graft rejection, incidence of chronic graft rejection and localization of TX200 CAR-Treg cells in the transplanted kidney. We also plan to evaluate the ability of TX200 to reduce systemic immunosuppressive therapy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our collaborator Kite Pharma, Inc., or Kite, a Gilead company, recently decided not to submit an investigational new drug application, or IND, at this time for KITE-037, our allogeneic anti-CD19 CAR-T cell therapy product candidate for the treatment of cancer. This program and the underlying collaboration to develop cell therapies to treat cancer remain active.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recently published preclinical data on tau- and alpha-synuclein targeted zinc finger transcriptional repressors in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Science Advances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and at the 15th International Conference on Alzheimer&#8217;s &amp; Parkinson&#8217;s Diseases Conference, respectively. We also expect to present preclinical data on repression of alpha-synuclein and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> repeat expansions at the upcoming 24th Annual Meeting of the American Society of Gene &amp; Cell Therapy on May&#160;11,2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Estimated Impacts of Evolving COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to experience impacts from the evolving COVID-19 pandemic on our business and operations and could continue to experience these or potentially more severe impacts for the rest of the 2021 if the pandemic persists in the United States, United Kingdom, France and locations of our clinical studies and trials. We continue to conduct business operations pursuant to a modified operating plan that includes enhanced workplace safety protocols and modified working schedules in our laboratories. Employees who are able to fulfill their job duties working from home are required to work from home, and have been doing so since March 2020, although we are currently planning a phased return to the office for most employees. These protocols and modifications have slowed our productivity and disrupted our business to a moderate degree and are likely to continue doing so through 2021. For example, we have experienced periodic short-term disruptions to our onsite laboratory and manufacturing operations while addressing positive cases of COVID-19 by onsite workers, and our laboratory and manufacturing operations could experience longer term disruptions in the future in the event of a significant outbreak of COVID-19 among our onsite workers. Moreover, from time to time, we have been required to reorganize and prioritize our research resources to mitigate moderate COVID-19 impacts arising from travel restrictions, laboratory density restrictions and laboratory supply constraints. If our research programs encounter longer-term disruptions, it could impact our ability to support our biopharmaceutical partners as contemplated in our collaboration agreements and could result in adjustments to our research timelines, although we do not believe that the short-term disruptions to date have resulted in any such impacts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our Phase 1/2 STAAR clinical study evaluating ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, has experienced delays in its timeline due to COVID-19 impacts and the diversion of healthcare resources to fight the pandemic. For example, we estimate that the opening of the clinical trial sites in the United Kingdom for this study experienced a delay of approximately one year due to the significant prevalence of COVID-19 in the United Kingdom. Additionally, we have experienced delays in recruiting, enrolling and dosing patients for this study at our U.S. trial sites, due in some part to the understandable hesitation of patients to travel by plane to trial sites not within driving distance and to enter medical facilities during the pandemic and in other part to trial sites prioritizing COVID-19 clinical care over research activities such as the STAAR study. Moreover, we have experienced some short-term delays in sourcing the necessary raw materials to manufacture supplies for the STAAR study due to COVID-19 impacts. We estimate that these challenges have set back our STAAR study timelines three to six months. While we currently still expect to present initial clinical study data by the end of 2021, this timeline could be revised if COVID-19 impacts to our enrollment and dosing of patients and to our sourcing of raw materials for this study intensify because of vaccination delays, new COVID-19 variants or unexpected events.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our STEADFAST study evaluating TX200, our wholly-owned CAR-Treg cell therapy product candidate for the treatment of kidney transplant rejection, has experienced delays in its timeline due to COVID-19 impacts related to manufacturing and technology transfer challenges with our CMOs. We estimate that these challenges set back our clinical study timeline by approximately three months. While we have now initiated this clinical study and expect to enroll the first patient in this study by the end of 2021, this timeline could be revised if COVID-19 impacts result in additional delays.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our partnered programs, the timelines for the studies and trials managed by our collaborators are also subject to potential delay in the future if these studies and trials experience similar challenges that we have experienced in our STAAR and STEADFAST studies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward, we will continue to monitor the impact of COVID-19 on our operations, research commitments and clinical trials and those of our collaborators, clinical trial sites and CMOs. The magnitude of these impacts will depend, in part, on the length and severity of the COVID-19 pandemic and related government orders and restrictions, and how the pandemic limits the ability of us and our business partners to operate business in the ordinary course. Disruptions to these operations, and possibly more severe disruptions in the future that could arise due to the extension of government orders or new government orders applicable in the places we operate or our industry generally or to us and our facilities specifically, could impede our ability to conduct research in a timely manner, comply with our research obligations to our collaborators and advance the development of our therapeutic programs. These delays and disruptions could result in adverse material impacts to our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate any material negative impact on our financial condition in 2021 as a result of the COVID-19 pandemic. We believe we are well positioned financially in the near term to execute on our wholly-owned and partnered research and clinical programs. As of March&#160;31, 2021, we had $629.5&#160;million in cash, cash equivalents and marketable securities. Although we believe we are well capitalized currently, the effects of the evolving pandemic could result in disruption of global financial markets, impairing our ability to access capital, which could negatively affect our liquidity in the future. We do not currently anticipate any material impairments to the valuation of the financial assets or goodwill on our balance sheet as a result of COVID-19. We do not believe that the remote workplace arrangements we have implemented for our office-based employees have affected our financial reporting or control systems.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic will impact our business, operations and financial condition, either directly or indirectly, will depend on future developments that remain highly uncertain at the present time. These developments include </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ultimate duration and severity of the pandemic, the impacts of new COVID-19 variants, travel restrictions, quarantines and social distancing requirements in the United States, France, United Kingdom and other countries, business closures or business disruptions and the effectiveness and timeliness of actions taken in the United States, France, United Kingdom and other countries to contain and treat the disease, including the effectiveness and timing of vaccination programs. Although certain government orders and restrictions have eased, and phased re-openings are underway, it is not certain when such restrictions and orders will be fully lifted, and the surge of new variants of the virus may result in the return of prior orders and restrictions or new quarantine and shelter-in-place orders or other restrictions. As our understanding of events evolves and additional information becomes available, we may materially change our guidance relating to our revenues, expenses and timelines for manufacturing, clinical trials and research and development.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Certain Components of Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues have consisted primarily of revenues from upfront licensing fees, reimbursements for research services, milestones achievements and research grant funding. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner reimbursements will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception and expect to incur losses for at least the next several years as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our product candidates from research stage through clinical trials. Pursuant to the terms of our agreements with Biogen, Kite, Novartis and Sanofi, certain expenses related to research and development activities will be reimbursed to us. The reimbursement funds to be received from Biogen, Kite, Novartis and Sanofi will be recognized as revenue as the related costs are incurred and collection is reasonably assured.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our Condensed Consolidated Financial Statements and the related disclosures, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition and valuation of long-lived assets including goodwill and intangible assets are the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three months ended March&#160;31, 2021, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our 2020 Form 10-K.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_79"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three Months Ended March 31, 2021 and 2020</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,076&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Biogen, Kite, Novartis, Pfizer and Sanofi as we continue to recognize upfront and milestone payments received under such agreements over time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $13.2&#160;million in revenues for the three months ended March&#160;31, 2021, compared to the same period in 2020, was primarily due to the recognition of upfront license fees and research revenue of $10.4&#160;million and $7.9&#160;million under our collaboration agreements with Biogen and Novartis, which became effective in April and July 2020, respectively. These increases were partially offset by a decrease of $3.2&#160;million in revenue related to our giroctocogene fitelparvovec collaboration </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement with Pfizer, as no revenue was recognized in 2021 due to completion of activities under this collaboration as of December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,434&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,955&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,119&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,582&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,984&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted primarily of compensation related expenses, including stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing clinical supply, contracted research, allocated facilities and information technology expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $15.0&#160;million in research and development expenses for the three months ended March&#160;31, 2021, compared to the same period in 2020, was primarily driven by a $7.3&#160;million increase in clinical and manufacturing supply expenses due to the timing of our trials and increase in activities attributed to our new collaborations, a $5.3&#160;million increase in compensation expense as a result of increased headcount to support our programs, clinical trials and start-up of our manufacturing operations, and a $1.8&#160;million increase in overhead costs as we ramp up our internal manufacturing operations. Stock-based compensation expense included in research and development expenses was $4.3&#160;million and $2.8&#160;million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our clinical programs and if we are able to progress our earlier stage product candidates into clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required to complete our development programs and our development costs for those programs may be impacted by the scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, and whether we pursue development of our product candidates with a partner or collaborator or independently. For example, our product candidates are being developed in multiple therapeutic areas, and we do not yet know how many of those therapeutic areas we will continue to pursue. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with our development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. The full extent of the impact of the COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part I, Item 1A of the 2020 Annual Report.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation related expenses including stock-based compensation for executive, legal, finance and administrative personnel, professional fees, allocated facilities and information technology expenses, and other general corporate expenses.</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses remained consistent for the three months ended March&#160;31, 2021, compared to the same period in 2020. Stock-based compensation expense included in general and administrative expenses was $3.3&#160;million and $2.8&#160;million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to build out our product portfolio and advance our product candidates into the clinic, we expect higher general and administrative expenses to support the growth of the business.</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net, decreased by $0.9&#160;million for the three months ended March&#160;31, 2021, compared to the same period in 2020, primarily due to a decrease of $1.4&#160;million in interest income reflecting the decline in market interest rates.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, we had cash, cash equivalents, and marketable securities totaling $629.5&#160;million compared to $692.0&#160;million as of December&#160;31, 2020. Our most significant use of capital was for employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Our cash and investment balances are held in a variety of interest-bearing instruments, including commercial paper, money market funds, corporate debt securities, certificates of deposit, asset-backed securities and U.S. government-sponsored entity debt securities. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an Open Market Sale Agreement with Jefferies LLC, or Jefferies, providing for the sale of up to $150.0&#160;million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under an existing shelf registration statement. During the three months ended March&#160;31, 2021, we sold 1,034,762 shares of our common stock under the sales agreement for net proceeds of approximately $15.7&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we currently believe that our available cash, cash equivalents and marketable securities and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund our currently planned operations through at least the next 12&#160;months from the date the Condensed Consolidated Financial Statements are issued. During this period of uncertainty and volatility related to the COVID-19 pandemic, we will continue to monitor our liquidity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $68.6&#160;million for the three months ended March&#160;31, 2021, primarily reflecting our net loss of $45.9&#160;million, a decrease in deferred revenues of $20.0&#160;million, a decrease in accrued compensation and employee benefits by $7.6&#160;million mainly attributed to bonus pay-outs, and a decrease in account payable and accrued liabilities of $3.8&#160;million due to timing of payments. These decreases were partially offset by $9.4&#160;million of non-cash expenses related to stock-based compensation and depreciation. The majority of the increase in cash used in operating activities during the three months ended March&#160;31, 2021, compared to the same period in 2020, was primarily due to less cash provided by accounts receivable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2021 consisted of $45.3&#160;million mostly related to a net maturities, sales and purchases of marketable securities. The increase in cash provided by investing activities during the three months ended March&#160;31, 2021, compared to the same period in 2020, was mostly due to an increase in net maturities, sales and purchases of marketable securities, partially offset by purchases of property and equipment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2021 consisted of $15.2&#160;million, mostly related to $16.2&#160;million proceeds from at-the-market offering offset by the offering expenses of $0.5&#160;million. The increase in cash provided in financing activities during the three months ended March&#160;31, 2021, compared to the same period in 2020, was mostly due to proceeds from our at-the-market offering.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital and Capital Expenditure Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate continuing to incur operating losses for at least the next several years. While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we currently believe that our available cash, cash equivalents and marketable securities and expected revenues from collaborations, strategic partners and research grants, will be adequate to fund our currently planned operations through at least the next 12&#160;months from the date the Condensed </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Financial Statements are issued. Although we believe we are well capitalized currently, the effects of the ongoing COVID-19 pandemic could result in significant disruption of global financial markets, impairing our ability to access capital, which could in the future negatively affect our liquidity. Future capital requirements beyond the next 12&#160;months will be substantial, and we will need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates through equity or debt financing. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. We regularly consider fund-raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities, including sales pursuant to our at-the-market offering program, may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many forward-looking factors, including the following:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration agreements;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and terms of future in-licensing and out-licensing transactions;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of procuring clinical and commercial supplies of our product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of potential disputes and litigation.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements as defined in Item&#160;303(a)(4)(ii) of Regulation S-K.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future minimum contractual obligations as of December&#160;31, 2020 were reported in the 2020 Annual Report. Other than as described below, during the three months ended March&#160;31, 2021, there have been no other material changes outside the ordinary course of our business from the contractual obligations previously disclosed in our 2020 Annual Report.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into an amendment to an existing lease to acquire approximately 5,000&#160;square feet of research and office space in Richmond, California. With this amendment, the existing lease expires in August 2026. The contractual obligations during the lease term are approximately $0.9&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we also entered into a new lease to acquire approximately 5,800&#160;square feet of research and office space in Valbonne, France that expires in January 2030. The contractual obligations during the lease term are approximately $0.8&#160;million.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_91"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk relates to our cash, cash equivalents and marketable securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities in our investment portfolio are not leveraged and are classified as available-for-sale. The majority of these available-for-sale securities are short-term in nature and subject to minimal interest rate risk. Our investments currently consist of commercial paper, corporate debt securities, certificates of deposit, asset-backed securities and U.S. government-sponsored entity debt securities. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments have a fixed interest rate and are carried at market </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. We do not believe that a change in interest rates would have a material negative impact on the value of our investment portfolio. Our market risks at March&#160;31, 2021 have not changed materially from those discussed in Item&#160;7A of our 2020 Annual Report.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatile market conditions arising from the evolving COVID-19 pandemic may result in significant changes to exchange rates relative to the U.S. dollar and may affect our operating results as expressed in U.S. dollars.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_94"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of March&#160;31, 2021. Based on that evaluation, as of March&#160;31, 2021, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the three months ended March&#160;31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_100"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_103"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors as previously disclosed in Part I, Item 1A of the 2020Annual Report.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_109"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_112"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_115"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Seventh Amended and Restated Certificate of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Incorporation,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm"> as amended (incorporated by reference to Exhibit 3.1 to the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm"> Quarterly Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm"> filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">August 9, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">Fourth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">(incorporated by reference to Exhibit 3.1 to the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm"> Current Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">8-K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm"> filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm"> May 22, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">Fourth</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm"> Amended and Restated Bylaws </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">(incorporated by reference to Exhibit 3.1 to the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">Company&#8217;s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm"> Current Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">8-K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm"> filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm"> 15, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828021000921/leeconsultingagreementfinal.htm">Letter Agreement between the Company and Sung Lee dated as of January 22, 2021 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed January 28, 2021).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex102.htm">Ninth Amendment to Triple Net Laboratory Lease</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex102.htm"> between the Company and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex102.htm">Point Richmond R&amp;D Associates II, LLC,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex102.htm"> dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex102.htm">January 4, 2021. </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3#+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex103.htm">Letter Agreement between the Company and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex103.htm">Jason Font</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex103.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex103.htm">not </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex103.htm">dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex103.htm">January 28,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex103.htm"> 2019</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4#+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex104.htm">Letter Agreement between the Company and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex104.htm"> Robert J. Schott</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex104.htm"> dated as of January </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex104.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex104.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex104.htm">21</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex311.htm">Rule 13a &#8212; 14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex312.htm">Rule 13a &#8212; 14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210331xex321.htm">Certifications Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from Sangamo&#8217;s Quarterly Report on Form 10-Q for the three months ended March 31, 2021 is formatted in Inline XBRL and it is contained in Exhibit 101</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">#&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Indicates management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">+&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4be9a0306d9c4f29ba82c2a83d136deb_7">Contents</a></span></div></div><div><span><br/></span></div><div id="i4be9a0306d9c4f29ba82c2a83d136deb_121"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May&#160;4, 2021 </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ALEXANDER D. MACRAE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Alexander D. Macrae</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Duly Authorized Officer and Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PRATHYUSHA DURAIBABU</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prathyusha Duraibabu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Vice&#160;President, Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>sgmo-20210331xex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7ac9ccf80726419baa2417904322aa91_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NINTH AMENDMENT TO LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS NINTH AMENDMENT TO LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ninth Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of January 4, 2021, by and between POINT RICHMOND R&#38;D ASSOCIATES II, LLC, a California limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and SANGAMO THERAPEUTICS, INC., a Delaware corporation (formerly known as Sangamo Biosciences, Inc., a Delaware corporation) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), with reference to the following facts&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Recitals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">Landlord and Tenant entered into that certain Triple Net Laboratory Lease dated as of May 23, 1997, together with an Addendum thereto dated May 28, 1997 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Original Lease</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as amended by those certain letter agreements dated June 15, 1999, April 21, 2000 and November&#160;3, 2000, that certain First Amendment to Lease dated March&#160;12, 2004 (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Amendment</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), that certain Lease Addendum dated December 12, 2006, that certain Second Amendment to Lease dated March 15, 2007, that certain Lease Addendum III dated April 2, 2012 , that certain Third Amendment to Lease dated August 1, 2013 (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Amendment</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), that certain Lease Addendum dated December 1, 2013, that certain Fourth Amendment to Lease dated June 10, 2016, that certain Fifth Amendment to Lease dated July 10, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fifth Amendment</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), that certain Sixth Amendment to Lease dated May 11, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Sixth Amendment</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), that certain Seventh Amendment to Lease dated May 20, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Seventh Amendment</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that certain Eighth Amendment to Lease dated May 29, 2020, pursuant to which Tenant leases certain premises consisting of approximately 46,488 rentable square feet known as Suites A, B, C-1, C-2, F, G, H and J (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Original Premises</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in the building located at 501 Canal Boulevard, Point Richmond, California (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Building</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Original Lease, as so amended, is collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Existing Lease</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25pt">Tenant has requested that additional space containing approximately 5,000 rentable square feet described as Suite K within the Building as shown on </font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suite K Expansion Space</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) be added to the Original Premises, and that the Existing Lease be appropriately amended, and Landlord is willing to do the same on the following terms and conditions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and adequacy are hereby acknowledged, Landlord and Tenant hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Agreement</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;text-decoration:underline">Definitions&#59; Recitals</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Unless otherwise specified herein, all capitalized terms used in this Ninth Amendment are used as defined in the Existing Lease.  The parties acknowledge the truthfulness of the foregoing Recitals, which are hereby incorporated into this Ninth Amendment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Inconsistencies</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent that there are any inconsistencies between the terms of the Existing Lease and this Ninth Amendment, the terms of this Ninth Amendment shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;text-decoration:underline">Expansion and Effective Date</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Effective as of the later of (i) February 1, 2021, and (ii) the date the Suite K Expansion Space is delivered to Tenant in the condition required by this Ninth Amendment (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suite K Expansion Effective Date</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Premises, as defined in the Existing Lease, is increased from approximately 46,488 rentable square feet to approximately 51,488 rentable square feet by the addition of the Suite K Expansion Space, and from and after the Suite K Expansion Effective Date, the Original Premises and the Suite K Expansion Space, collectively, shall be deemed the Premises, as defined in the Existing Lease, for all purposes under the Existing Lease, including, without limitation, Section 8 of the First Amendment (as amended by Section 2 of the Third Amendment, Section 14 of the Fifth Amendment, and Section 6 of the Sixth Amendment).  The Term for the Suite K Expansion Space shall commence on the Suite K Expansion Effective Date and end on the Second Extended Expiration Date (as defined in the Sixth Amendment) (hereinafter, the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Termination Date</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, the Suite K Expansion Effective Date shall be delayed to the extent that Landlord fails to deliver possession of the Suite K Expansion Space for any reason (other than Tenant&#8217;s early occupancy of the Suite K Expansion Space pursuant to Section 7 below), including but not limited to, holding over by the current tenant&#59; provided, however, that Landlord will use commercially reasonable efforts to deliver the Suite K Expansion Space to Tenant by February 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Target Suite K Expansion Effective Date</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Additionally, if the Suite K Expansion Effective Date has not occurred by April 1, 2021 (which date may be extended, but not past June 1, 2021, due to delays caused by Force Majeure events, as defined in this Section&#160;3 below), Tenant may terminate this Ninth Amendment (but not the Existing Lease) by providing notice to Landlord within ten (10) days after such date.  A &#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Force Majeure</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; event is any accident, casualty, act of God, war or civil commotion, strike or labor troubles, or any cause whatsoever beyond the reasonable control of Landlord, including water shortages, energy shortages or governmental preemption in connection with an act of God, a national emergency, or by reason of Law, or by reason of the conditions of supply and demand which have been or are affected by act of God, war or other emergency.  Except as provided above, any such delay in the Suite K Expansion Effective Date shall not subject Landlord to any liability for any loss or damage resulting therefrom.  The Suite K Expansion Space is subject to all the terms and conditions of the Existing Lease except as expressly modified herein and except that Tenant shall not be entitled to receive any allowances, abatements or other financial concessions granted with respect to the Original Premises except as otherwise expressly provided for herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Base Monthly Rent</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to Tenant&#8217;s obligation to pay Base Monthly Rent for the Original Premises, commencing on the Suite K Expansion Effective Date, Tenant shall pay Landlord Base Monthly Rent for the Suite K Expansion Space as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.891%"><tr><td style="width:1.0%"></td><td style="width:41.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.802%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Period</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Base Monthly Rent</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">02&#47;01&#47;21 &#8211; 08&#47;31&#47;21</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$12,500.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">09&#47;01&#47;21 &#8211; 08&#47;31&#47;22</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$12,813.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">09&#47;01&#47;22 &#8211; 08&#47;31&#47;23</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$13,133.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">09&#47;01&#47;23 &#8211; 08&#47;31&#47;24</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$13,461.00</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">09&#47;01&#47;24 &#8211; 08&#47;31&#47;25</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$13,798.00</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">09&#47;01&#47;25 &#8211; 08&#47;31&#47;26</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$14,143.00</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All such Base Monthly Rent shall be payable by Tenant in accordance with the terms of the Existing Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Landlord and Tenant acknowledge that the foregoing schedule is based on the assumption that the Suite K Expansion Effective Date is the Target Suite K Expansion Effective Date.  If the Suite K Expansion Effective Date is other than the Target Suite K Expansion Effective Date, the schedule set forth above with respect to the payment of any installment(s) of Base Monthly Rent for the Suite K Expansion Space shall be appropriately adjusted on a per diem basis to reflect that the payment of any installment(s) of Base Monthly Rent commences on the actual Suite K Expansion Effective Date, and the actual Suite K Expansion Effective Date shall be set forth in a confirmation letter to be prepared by Landlord.  However, the effective date of any increases or decreases in the Base Monthly Rent rate shall not be postponed as a result of an adjustment of the Suite K Expansion Effective Date as provided above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt;text-decoration:underline">Operating Expenses</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the period commencing with the Suite K Expansion Effective Date, Tenant shall pay for Tenant&#8217;s Pro Rata Share of Operating Expenses applicable to the Suite K Expansion Space in accordance with the terms of the Existing Lease.  As of the Suite&#160;K Expansion Effective Date as to Suite K Expansion Space and ending as of the Second Extended Expiration Date, Tenant&#8217;s Pro Rata Share of Operating Expenses (exclusive of Taxes) shall not increase by more than 5% per calendar year on a compounding and cumulative basis (e.g., Tenant&#8217;s Pro Rata Share of Operating Expenses (other than Taxes) for calendar year 2022 shall not exceed 105% of Tenant&#8217;s Pro Rata Share of Operating Expenses (other than Taxes) for 2021&#59; Tenant&#8217;s Pro Rata Share of Operating Expenses (other than Taxes) for calendar year 2023 shall not exceed 105% of the maximum allowable amount of Tenant&#8217;s Pro Rata Share of Operating Expenses (other than Taxes) permitted for 2022, etc.).  For the period commencing with the Suite&#160;K Expansion Effective Date and continuing through the Second Extended Expiration Date, Tenant&#8217;s Pro Rata Share for the Premises (including the Suite K Expansion Space) is 63.32%.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.01pt;text-decoration:underline">Improvements to Suite K Expansion Space</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:60.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Condition of Suite K Expansion Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Tenant has inspected the Suite K Expansion Space and agrees to accept the same &#8220;as is&#8221; without any agreements, representations, understandings or obligations on the part of Landlord to perform any alterations, repairs or improvements, except as may be expressly provided otherwise in this Ninth Amendment.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Landlord represents and warrants that the structural components of, and mechanical, electrical, plumbing and drainage systems within and serving, the Suite K Expansion Space are, and will be as of the Suite K Expansion Effective Date, in good working order and free from defects.  Should Tenant determine that there is any noncompliance with the foregoing representation and provide Landlord with a written notice thereof, Landlord shall promptly after receipt of written notice from Tenant setting forth with specificity the nature and extent of such noncompliance, rectify the same&#59; such noncompliance shall not, however, entitle Tenant to an abatement of rent or to terminate the Lease, or otherwise release Tenant from any of Tenant&#8217;s obligations under the Lease.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:57.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Demising of Suite K Expansion Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Prior to the Suite K Expansion Effective Date, Landlord shall separately demise the Suite K Expansion Space (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suite K Expansion Space Demising Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Tenant acknowledges and agrees that Landlord may complete the Suite K Expansion Space Demising Work (which shall include finishing all walls and trim, including painting) subsequent to the Suite K Expansion Effective Date&#59; provided, however, that Landlord shall use commercially reasonable efforts to complete all of the Suite K Expansion Space Demising Work by the Suite K Expansion Effective Date (and, for the avoidance of doubt, at a minimum the Suite K Expansion Space must be physically demised by a wall as a condition of the occurrence of the Suite K Expansion Effective Date), and if it is not so completed, Landlord will use commercially reasonable efforts to complete all of the Suite K Expansion Space Demising Work as soon as possible after the Suite K Expansion Effective Date.  Landlord and Tenant agree to cooperate with each other in order to enable the Suite K Expansion Space Demising Work to be performed in a timely manner and with as little inconvenience to the operation of Tenant&#8217;s business as is reasonably possible.  Notwithstanding anything herein to the contrary, subject to Section 3 above, any delay in the completion of the Suite K Expansion Space Demising Work or inconvenience suffered by Tenant during the performance of the Tenant Improvements shall not subject Landlord to any liability for any loss or damage resulting therefrom (other than as a result of Landlord&#8217;s gross negligence or willful misconduct) or entitle Tenant to any credit, abatement or adjustment of Rent or other sums payable under the Lease.  Landlord shall make commercially reasonable efforts to minimize disruption of Tenant's use and enjoyment of the Premises during such period&#59; provided, however, that such efforts shall not require Landlord to complete the Suite K Expansion Space Demising Work outside of standard business hours for the Building unless Tenant pays for the additional cost thereof.  Tenant shall be responsible for all costs of removing and repositioning its furniture, equipment and other personal property in the Suite K Expansion Space, if any, in order to accommodate the completion of the Suite K Expansion Space Demising Work.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Responsibility for Improvements to Suite K Expansion Space</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Tenant may perform improvements to the Suite K Expansion Space in accordance with Section 7.3 of the Existing Lease and at Tenant&#8217;s sole cost&#59; provided, however, that Landlord shall not unreasonably withhold its consent to any proposed Alterations.  Landlord shall respond to any request by Tenant for approval of proposed Alterations within seven (7) business days, and if Landlord disapproves of the proposed Alterations, it shall provide Tenant with written notice of the reason for such disapproval.  If within such seven (7) business day period, Landlord informs Tenant that Landlord has submitted the proposed Alterations to an outside third party for review, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">then Landlord shall make diligent, good faith efforts to have such outside third-party review completed, and to deliver to Tenant an approval or any written notice of additional required revisions to or comments regarding the proposed Alterations, within not less than twenty (20) business days.  In the event Landlord fails to respond to Tenant&#8217;s request for approval of the proposed Alterations within the original seven (7) business day period, Tenant shall send a reminder notice to Landlord, and if Landlord fails to respond to the reminder notice within three (3) business days after receipt thereof, the proposed Alterations shall be deemed approved.  Provided that Tenant is not in breach of any of its obligations under the Existing Lease beyond any notice or cure period(s), Tenant shall be entitled to an allowance (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suite K Expansion Space Improvement Allowance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in an amount not to exceed the sum of $150,000.00 (i.e., $30.00 per rentable square foot of the Suite K Expansion Space) for the costs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suite K Expansion Space Improvement Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) relating to the design, permitting and construction of Tenant&#8217;s improvements which are permanently affixed to the Suite K Expansion Space (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Suite K Expansion Space Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  As used herein the term &#8220;Suite K Expansion Space Improvement Costs&#8221;&#160;shall mean payments to contractors, subcontractors, architects, engineers and material suppliers for services, labor and materials with respect to the Suite K Expansion Space Work.  Landlord shall be entitled to deduct from the Suite K Expansion Space Improvement Allowance a construction management fee for Landlord&#8217;s oversight of the improvements in an amount equal to 3% of the total hard costs of the improvements.  The Suite K Expansion Space Improvement Allowance (or so much of same as qualifies for disbursement under this Section&#160;6(b)) shall be paid to Tenant in a single-lump sum following the date that Tenant has satisfied all of the following conditions&#58; (i) Tenant has delivered to Landlord reasonable evidence of the amounts so incurred and paid by Tenant in connection with the refurbishment of the Suite K Expansion Space&#59; (ii) Tenant shall have provided Landlord the final unconditional lien waivers and releases from all parties providing labor or materials on behalf of Tenant at the Suite K Expansion Space in a form reasonably satisfactory to Landlord&#59; (iii) Tenant shall have provided as-built drawings (.pdf and CAD formats) for the Suite K Expansion Space Work&#59; and (iv) the Suite K Expansion Space Work shall have been completed in compliance with the requirements imposed on Alterations pursuant to Section 7.3 of the Existing Lease.&#160; If Tenant does not submit a request for disbursement of the entire Suite K Expansion Space Improvement Allowance in accordance with the provisions contained in this Section 7(b) by January 31, 2022, the Suite K Expansion Space Improvement Expansion Space Improvement Allowance, or any unused portion thereof, shall be forfeited and shall accrue for the sole benefit of Landlord&#59; provided however that such date shall be extended on a day for day basis for (x) each day following February 1, 2021 until the Suite K Expansion Effective Date, and (y) each day following the Suite K Expansion Effective Date where construction of the Suite K Expansion Space Work would not be permitted in the Suite K Expansion Space as a result of applicable governmental laws, regulations, orders, directives or similar governmental action. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Early Access to Suite K Expansion Space</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Landlord shall use commercially reasonable efforts to provide Tenant access to the Suite K Expansion Space as of January 1, 2021, for the sole purpose of having its architects and contractors inspect the Suite K Expansion Space in preparation for Tenant performing Alterations therein.  Tenant acknowledges and agrees that&#58; (a) Tenant shall make commercially reasonable efforts to not disturb the occupancy of NCE in its premises within the Building during any early occupancy of the Suite K Expansion </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Space, and (b) Landlord is not obligated to separately demise the Suite K Expansion Space until the Suite K Expansion Effective Date.  During any period that Tenant shall be permitted to enter the Suite K Expansion Space prior to the Suite K Expansion Effective Date, Tenant shall comply with all terms and provisions of the Existing Lease, except those provisions requiring payment of Base Monthly Rent or Additional Rent as to the Suite K Expansion Space. If Tenant takes possession and occupies the Suite K Expansion Space prior to the Suite K Expansion Effective Date for any reason whatsoever (other than the performance of work in the Suite K Expansion Space with Landlord&#8217;s prior approval), such possession shall be subject to all the terms and conditions of the Existing Lease and this Ninth Amendment, and Tenant shall pay Base Monthly Rent and Additional Rent  as applicable to the Suite K Expansion Space to Landlord on a per diem basis for each day of occupancy prior to the Suite K Expansion Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">h.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Parking</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the period commencing with the Suite K Expansion Effective Date and continuing through the Second Extended Expiration Date, in addition to the parking spaces available to Tenant for the Existing Premises in accordance with the Existing Lease, Tenant shall be entitled to up to fifteen (15) unreserved off-street parking spaces (i.e., 3 spaces per 1,000 rentable square feet of the Suite K Expansion Space) in the surface lot serving the Building at no additional cost to Tenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;text-decoration:underline">Inspection by a CASp in Accordance with Civil Code Section 1938</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Pursuant to California Civil Code Section 1938, Landlord hereby notifies Tenant that as of the Effective Date, the Premises have not undergone inspection by a &#8220;Certified Access Specialist&#8221; (&#8220;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CASp</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to determine whether the Premises meet all applicable construction-related accessibility standards under California Civil Code Section 55.53.  Landlord hereby discloses pursuant to California Civil Code Section 1938 as follows&#58; &#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&#8221;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">j.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.67pt;text-decoration:underline">OFAC</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Tenant represents and warrants to Landlord that Tenant is currently in compliance with and shall at all times during the Term of the Existing Lease remain in compliance with the regulations of the Office of Foreign Asset Control (&#8220;OFAC&#8221;) of the Department of the Treasury and any statute, executive order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism), or other governmental action relating thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">k.</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:60.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)This Ninth Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein. There have been no additional oral or written </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">representations or agreements with regard to the subject matter of this Ninth Amendment. Under no circumstances shall Tenant be entitled to any Rent abatement, improvement allowance, leasehold improvements, or other work to the Premises, or any similar economic incentives that may have been provided Tenant in connection with entering into the Existing Lease, unless specifically set forth in this Ninth Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:57.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)Except as herein modified or amended, the provisions, conditions and terms of the Existing Lease shall remain unchanged and in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)Submission of this Ninth Amendment by Landlord is not an offer to enter into this Ninth Amendment but rather is a solicitation for such an offer by Tenant. Neither Landlord nor Tenant shall be bound by this Ninth Amendment until each of Landlord and Tenant has executed this Ninth Amendment and delivered the same to the other party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)Tenant hereby represents to Landlord that Tenant has dealt with no broker in connection with this Ninth Amendment.  Tenant agrees to indemnify and hold Landlord, its members, principals, beneficiaries, partners, officers, directors, employees, mortgagee(s) and agents, and the respective principals and members of any such agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Landlord Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) harmless from all claims of any brokers claiming to have represented Tenant in connection with this Ninth Amendment.  Landlord hereby represents to Tenant that Landlord has dealt with no broker in connection with this Ninth Amendment.  Landlord agrees to indemnify and hold Tenant, its members, principals, beneficiaries, partners, officers, directors, employees, and agents, and the respective principals and members of any such agents (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tenant Related Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) harmless from all claims of any brokers claiming to have represented Landlord in connection with this Ninth Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:58.02pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)This Ninth Amendment shall be binding upon and inure to the benefit of the parties, their respective heirs, legal representatives, successors and assigns.  Each party hereto and the persons signing below warrant that the person signing below on such party&#8217;s behalf is authorized to do so and to bind such party to the terms of this Ninth Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:54.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)This Ninth Amendment may be executed in counterparts each of which counterparts when taken together shall constitute one and the same agreement. Any facsimile, PDF or other electronic signature shall constitute a valid and binding method for executing this Ninth Amendment. Executed counterparts of this Ninth Amendment exchanged by facsimile transmission, PDF email, or other electronic means shall be fully enforceable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have executed this Ninth Amendment as of the date set forth above.</font></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.429%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Landlord&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">POINT RICHMOND R&#38;D ASSOCIATES II, LLC,<br>a California limited liability company</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt 2px 26.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 26.9pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Wareham-NZL, LLC, its Manager</font></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Richard K. Robbins<br>&#160;&#160;&#160;&#160;Its Manager</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Tenant&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SANGAMO THERAPEUTICS, INC.,<br>a Delaware corporation</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58; &#160;&#160;&#160;&#160;<br>Name&#58; &#160;&#160;&#160;&#160;<br>Title&#58; &#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div><div id="i7ac9ccf80726419baa2417904322aa91_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OUTLINE AND LOCATION OF SUITE K EXPANSION SPACE</font></div><div style="text-align:center"><img alt="image_01a.jpg" src="image_01a.jpg" style="height:563px;margin-bottom:5pt;vertical-align:text-bottom;width:787px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:6pt;font-weight:400;line-height:120%">00051072.9 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-</font><font style="color:#000000;font-family:'Times',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</font></div><div><font style="color:#000000;font-family:'Times',sans-serif;font-size:8pt;font-weight:400;line-height:125%">38139&#92;13852735.2 </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>sgmo-20210331xex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>sgmo-20210331xex103</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- sgmo-20210331xex103001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103013.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103013.jpg" title="slide13" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sgmo-20210331xex103014.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sgmo-20210331xex103014.jpg" title="slide14" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>sgmo-20210331xex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i9e4878d7f90042b58247d40a595e0fc3_1"></div><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.8pt;padding-left:1.4pt;padding-right:1.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div><font><br></font></div><div style="margin-top:8.85pt;padding-left:45pt;padding-right:56.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employment Agreement (&#8220;Agreement&#8221;) made as of the 6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of January 2021 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Robert J. Schott (&#8220;Executive&#8221;) (collectively, the &#8220;Parties&#8221;).</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:1.55pt;padding-right:1.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">R E C I T A L S</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:45pt;padding-right:41.7pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company desires to employ Executive, and Executive desires to be employed by the Company, on the terms and conditions set forth in this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:69.1pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the mutual promises set forth herein, the Parties agree follows&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:81pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Employment.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:47.65pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company hereby agrees to employ Executive and Executive hereby agrees to accept such employment, on the terms and conditions set forth in this Agreement, with a start date of 1st day of February, 2021  (the &#8220;Effective Date&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:81pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">At-Will Employment.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:41.7pt;text-indent:39.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive shall be employed on an at-will basis. Either Executive or the Company may terminate employment at any time, with or without cause, and with or without advance notice.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:81pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Position, Duties and Obligations.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:46.15pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt">Executive shall be appointed as the Senior Vice President, Chief Development Officer and shall serve in such position, and in such other positions as the Board and the Company may from time to time reasonably determine, including but not limited to working with medical affairs and drug safety, product development and management, regulatory affairs, and development operations, subject at all times to the direction, supervision and authority of the Chief Executive Officer (collectively, your &#8220;Duties&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:64.35pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.07pt">During Executive&#8217;s employment, Executive shall perform Executive&#8217;s Duties faithfully and to the best of Executive&#8217;s ability, and shall devote substantially all of</font></div><div style="padding-left:45pt;padding-right:79.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive&#8217;s business time, attention, knowledge, skills and interests to the business of the Company (and its affiliates or subsidiaries).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:50.05pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.75pt">During Executive&#8217;s employment, Executive shall not, whether directly or indirectly, render any services of a commercial or professional nature to any other person or organization, whether for compensation or otherwise, without the prior written consent of the Chief Executive Officer.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:48.85pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.07pt">The foregoing in this Section 3 shall not preclude Executive from serving on any corporate, civic or charitable boards or committees on which Executive is serving as of the Effective Date and discloses to the Chief Executive Officer prior to the Effective Date or on</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_4"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:45pt;padding-right:65.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which Executive commences service following such date with the Chief Executive Officer&#8217;s prior written approval, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:153pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.73pt">Executive&#8217;s principal place of business will be located in Brisbane,</font></div><div style="padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">California.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:153pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.05pt">Executive represents that Executive may enter into this Agreement, and as</font></div><div style="padding-left:45pt;padding-right:46.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of the Effective Date, 1) accept employment with the Company under the terms of this Agreement, and 2) perform the Duties and responsibilities contemplated by this Agreement without violating any other agreement or agreements with other parties including but not limited to and any prior employers.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:81pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Compensation and Benefits.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:42.1pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.73pt">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Company shall pay to Executive an annual base salary of $440,000 Dollars, prorated for any partial employment period and payable in equal monthly installments in accordance with the Company&#8217;s payroll schedule. The Compensation Committee of the Board shall annually review the then-current level of Executive&#8217;s base salary (for increase only) to determine the amount, if any, of change to such salary.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:42.05pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.05pt">Annual Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive is eligible to earn an annual performance bonus commencing with the 2021 calendar year performance period. The target amount of Executive&#8217;s annual cash bonus shall be 35% percent of Executive&#8217;s annual base salary. The Board shall have sole discretion to determine whether any annual cash bonus will be paid based upon achievement of both corporate objectives and Executive&#8217;s personal objectives, and the reasonable discretion to determine that actual amount of any such bonus.  Executive must be an employee in good standing on the date that the Board makes such determination in order to earn any such bonus, which determination shall be made by the Board no later than March 31 of the calendar year first following the performance period calendar year. The actual bonus may be more or less than the target amount based upon the Company&#8217;s achievement over the year. Any bonus to which Executive becomes entitled for a particular calendar year shall be paid in accordance with the terms of the applicable bonus plan, but in no event later than the second payroll period following such Board determination. The Compensation Committee of the Board shall annually review Executive&#8217;s then target amount for the annual cash bonus (for increase only) to determine the amount, if any, of change to such target amount.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:50.85pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.73pt">Executive Severance Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive shall be deemed an Eligible Employee and an Executive Officer and entitled to receive certain severance benefits under the Sangamo Therapeutics, Inc. Executive Severance Plan dated February 6, 2019 (the &#8220;Severance Plan&#8221;) subject to the terms and conditions of the Severance Plan. A copy of the Severance Plan has been provided to Executive concurrently with this Agreement. Notwithstanding the foregoing, in the event that the Company withdraws this offer after it is signed by Executive or terminates this Agreement prior to the Effective Date for any reason other than Executive&#8217;s </font></div><div style="height:85pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="padding-left:45pt;padding-right:50.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">failure to successfully pass the requirements for a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States</font></div><div style="height:85pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_7"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:45pt;padding-right:48.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">required under Section 8(a) herein, then Executive shall be entitled to severance under the Severance Plan as though his employment was terminated by the Company other than for Cause to the same extent as he would otherwise be entitled had such termination occurred after the Effective Date&#59; provided, however, that Executive shall not be entitled to such severance if he has not notified his current employer of his intent to resign his employment at the time the Company informs him of the withdrawal or termination of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:46.05pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.73pt">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive will be entitled to the employee benefits generally provided to other executive officers of the Company pursuant to the terms of the applicable benefit plans. Executive will not be subject to a formal paid time off program. Executive is free to take paid time off from work for vacation, medical appointments, and other short-term absences due to illnesses or other personal reasons. If Executive desires to take time off for a duration longer than two (2) weeks manager approval is required. Unlimited paid time off is available from the first day of employment.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:43.95pt;text-indent:71.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18.05pt">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Effective on the second Friday of the month, or if not a trading day, the trading day prior (the &#8220;Grant Date&#8221;) in which the Executive commences employment, as long as the first day of employment with Sangamo occurs between the prior Grant Date and the day preceding the Grant Date, the Compensation Committee of the Board shall grant you non- statutory stock options to purchase up to 80,000 shares of the Company&#8217;s Common Stock subject to the terms and conditions of the Company&#8217;s 2018 Equity Incentive Plan (the</font></div><div style="padding-left:45pt;padding-right:44.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Plan&#8221;),with an exercise price per share equal to the fair market value of the Company&#8217;s Common Stock on the Grant Date (the &#8220;Option&#8221;). If the first day of employment is Grant Date, the equity incentive award will be received on the subsequent Grant Date. The Option will be evidenced by the standard stock option agreement under the Plan and will be subject to the terms and conditions of that agreement and the Plan&#58;</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:117pt;padding-right:48.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.8pt">1&#47;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (one-fourth) of the Option shares will vest on the first-year anniversary of the Grant Date, and</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:117pt;padding-right:83pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.8pt">1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (one forty-eighth) of the Option shares will vest in equal monthly installments for thirty-six (36) months thereafter,</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:41.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided Executive remains a full-time employee through each such vesting date. Vesting of the Option and any subsequent equity grants will cease upon termination of Executive&#8217;s service by either party for any reason.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:42.85pt;text-indent:65.62pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.05pt">Also, subject to approval by the Compensation Committee of the Board, we intend to grant you 40,000 restricted stock units (&#34;Restricted Stock Units&#34;) under the Plan. Each Restricted Stock Unit represents the right to receive one share of the Company's common stock upon the specified issuance date following vesting. Your Restricted Stock Units will vest in a series of three (3) successive equal annual installments upon your completion of each year of service to the Company measured from the Vesting Commencement Date. The issuance of the underlying shares of common stock in settlement of vested Restricted Stock Units will be subject to the Company's collection of all applicable withholding taxes. The Restricted Stock Units will</font></div><div style="height:85pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_10"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:45pt;padding-right:42.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">be evidenced by the Plan's form of Restricted Stock Unit Issuance Agreement and will be subject to its terms and conditions and the Plan.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:44.05pt;text-indent:65.62pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Advance for Relocation Assistance. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive shall be advanced relocation assistance (the &#8220;Relocation Assistance&#8221;) in the amount of seventy-five thousand dollars ($75,000), subject to required deductions and withholdings and payable in the first regularly rescheduled payroll after Executive relocates to the San Francisco Bay Area. Although the Relocation Assistance is advanced upon relocation, it is expressly conditioned on Executive not terminating employment prior to the first (1st) anniversary of payment under any circumstances other than a termination that would entitle Executive to receive benefits under the Severance Plan, and such advanced Relocation Assistance shall not be deemed earned by</font></div><div style="padding-left:45pt;padding-right:46.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Executive until such service condition has been met. If Executive&#8217;s employment terminates at any time prior to the first (1st) anniversary of the Effective Date and Executive is not entitled to receive benefits under the Severance Plan (such termination, a &#8220;Disqualifying Termination&#8221;), then, Executive shall at the time of such Disqualifying Termination promptly repay the full Relocation Assistance to the Company. In the event Executive does not earn and fails to promptly repay the Relocation Assistance in connection with a Disqualifying Termination, then the Company shall be further entitled to recover from Executive its costs and expenses incurred in enforcing Executive&#8217;s repayment obligation, including reasonable attorney&#8217;s fees and costs. If the Company has implemented a formal relocation policy at the time of your relocation and it is more favorable to you, you will be eligible, at your option, for relocation per the policy instead of a lump sum Relocation Assistance</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:51.65pt;text-indent:62.29pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary in this Agreement, all compensation paid to Executive by the Company (whether payable pursuant to this Agreement or otherwise) will be subject to reduction, recovery and&#47;or recoupment to the extent required by any present or future law, government regulation or stock exchange listing requirement (or any policy adopted by the Company which ensures compliance with the requirements of any such law, government regulation or stock exchange listing requirement).</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:44.8pt;text-indent:58.96pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Resignation from Positions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of this Agreement to the contrary, upon any termination of employment (whether voluntary or involuntary), Executive, upon written request from the Board, shall immediately resign from any positions Executive has with the Company (or any subsidiary), whether as an executive, officer, employee, consultant, director, trustee, fiduciary or otherwise.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:46.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive agrees to abide by the terms and conditions of the Employee Confidential Information and Invention Assignment Agreement between Executive and the Company, a copy of which is attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Executive further agrees that at all times both during Executive&#8217;s employment by the Company and after Executive&#8217;s employment ends, Executive will keep in confidence and trust, and will not use or disclose, except as directed by the Company, any confidential or proprietary information of the Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="height:85pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:62.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any and all cash compensation and other benefits (including without limitation, base salary, annual bonus and sign-on bonus) paid to Executive under this Agreement shall be subject to all applicable tax withholding requirements, and the Company</font></div><div style="height:85pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_13"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:45pt;padding-right:47.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall make such other deductions as may be required and&#47;or allowed by applicable law and&#47;or as authorized in writing by Executive.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:43pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any dispute, controversy, or claim, whether contractual or non-contractual, between Executive and the Company shall be resolved by binding arbitration before the Judicial Arbitration and Mediation Service (the &#8220;JAMS&#8221;), in accordance with the JAMS Employment Arbitration Rules and Procedures, available at www.jamsadr.com. Executive and the Company each agree that before proceeding to arbitration, they will mediate disputes before the JAMS by a mediator approved by the JAMS. If mediation fails to resolve the matter, any subsequent arbitration shall be conducted by an arbitrator approved by the JAMS and mutually acceptable to Executive and the Company. All disputes, controversies, and claims shall be conducted by a single arbitrator, who shall&#58; (i) allow discovery authorized by California Code of Civil Procedure Section 1282, et seq., or any other discovery required by applicable law&#59; and (ii) issue a written award that sets forth the essential findings of fact and conclusions of law on which the award is based. The arbitrator shall have the authority to award any relief authorized by law in connection with the asserted claims or disputes. Judgment upon the arbitrator&#8217;s award may be entered in any court having jurisdiction thereof. If Executive and the Company are unable to agree on the mediator or the arbitrator, then the JAMS shall select the mediator&#47;arbitrator. The resolution of the dispute by the arbitrator shall be final, binding, non-appealable, and fully enforceable by a court of competent jurisdiction under the Federal Arbitration Act. The arbitration award shall be in writing and shall include a statement of the reasons for the award. The arbitration shall be held in San Francisco, California. The Company shall pay all JAMS, mediation, and arbitrator&#8217;s fees and costs, irrespective of who raised the claim and the outcome of arbitration.</font></div><div><font><br></font></div><div style="padding-left:81pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Miscellaneous.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:50.95pt;text-indent:65.62pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Conditions to Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement is contingent upon a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States.  Executive agrees to provide any documentation or</font></div><div style="padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">information at the Company&#8217;s request to facilitate these processes.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:84.35pt;text-indent:62.29pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of California.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:46pt;text-indent:58.96pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. In the event of any controversy, claim or dispute between the parties, arising out of or relating to this Agreement or the breach hereof, or the interpretation hereof, each party shall bear its own legal fees and expenses. Notwithstanding the foregoing, in the event of a finding by any court having jurisdiction over such matter that any party initiating an action under this Agreement failed to have a reasonable prospect of prevailing on its claim, the arbitrator shall have discretion to award the prevailing party attorneys&#8217; fees and costs incurred by it with respect to such claim or action. The &#34;prevailing party&#34; means the party determined by the arbitrator to have most nearly prevailed, even if such party did not prevail in all matters, not necessarily the one in whose favor a judgment is rendered.</font></div><div style="height:85pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_16"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.6pt;padding-left:45pt;padding-right:47.7pt;text-indent:65.62pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by the Parties hereto.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:44.45pt;text-indent:62.29pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If any provision of this Agreement as applied to any party or to any circumstance should be adjudged by a court of competent jurisdiction (or determined by the arbitrator) to be void or unenforceable for any reason, the invalidity of that provision shall in no way affect (to the maximum extent permissible by law) the application of such provision under circumstances different from those adjudicated by the court or determined by the arbitrator, the application of any other provision of this Agreement, or the enforceability or invalidity of this Agreement as a whole. Should any provision of this Agreement become or be deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision will be stricken, and the remainder of this Agreement shall continue in full force and effect.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:45pt;padding-right:54.85pt;text-indent:58.96pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company. Executive shall not be entitled to assign any of Executive&#8217;s rights or obligations under this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:43.95pt;text-indent:59.62pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.05pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement, along with any other agreements set forth herein, including without limitation, the Proprietary Information and Inventions Agreement, constitutes the entire agreement between the parties with respect to the employment of Executive.</font></div><div style="height:85pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_19"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.8pt;padding-left:267.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:4.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></div><div style="padding-left:9.75pt"><font><br></font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"><div style="padding-left:9.75pt"><font><br></font></div><div style="padding-left:10.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Whitney B. Jones</font></div><div style="padding-left:12.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Whitney B. Jones</font></div><div style="margin-top:10pt;padding-left:12.45pt;padding-right:53.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Senior Vice President, Chief People Officer</font></div></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:267.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ROBERT J. SCHOTT</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Robert J. Schott</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_22"></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.8pt;padding-left:81.45pt;padding-right:81.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-top:6.05pt;padding-left:134.32pt;padding-right:134.32pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT AGREEMENT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:9pt;padding-right:19.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In consideration of my employment or continued employment by Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221;), its direct and indirect subsidiaries, parents, affiliates, predecessors, successors and assigns (together with Sangamo, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and the compensation and benefits provided to me now and during my employment with the Company, I hereby enter into this Employee Confidential Information and Invention Assignment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), which will be deemed effective as of the first day of my employment with the Company&#58;</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:6.25pt;padding-left:30.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.35pt">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ONFIDENTIAL </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NFORMATION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ROTECTIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-top:5.95pt;padding-left:9pt;padding-right:1.9pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.77pt">Recognition of Company&#8217;s Rights&#59; Nondisclosure. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I understand and acknowledge that my employment by Company creates a relationship of confidence and trust with respect to Company&#8217;s Confidential Information (as defined below) and that Company has a protectable interest therein. At all times during and after my employment, I will hold in confidence and will not disclose, use, lecture upon, or publish any of Company&#8217;s Confidential Information, except as such disclosure, use or publication may be required in connection with my work for Company, or unless an officer of Company expressly authorizes such disclosure. I will obtain Company&#8217;s written approval before publishing or submitting for publication any material (written, oral, or otherwise) that discloses and&#47;or incorporates any Confidential Information. I hereby assign to Sangamo any rights I may have or acquire in such Confidential Information and recognize that all Confidential Information shall be the sole and exclusive property of Sangamo and its assigns. I will take all reasonable precautions to prevent the inadvertent accidental disclosure of Confidential Information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), I shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that&#58; (1) is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt;padding-right:1.9pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.15pt">Confidential Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Confidential Information&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">shall mean any and all confidential knowledge, data or information of Company. By way of illustration but not limitation, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Confidential Information&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">includes (a) trade secrets, inventions, mask works, ideas, processes, formulas, software in source or object code versions, data, programs, other works of authorship, know-how, </font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"><div style="padding-left:9pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">improvements, discoveries, developments, designs and techniques and any other proprietary technology and all Intellectual Property Rights therein (collectively, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Inventions&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">)&#59; (b) information regarding research, development, new products, marketing and selling, business plans, budgets and unpublished financial statements, licenses, prices and costs, margins, discounts, credit terms, pricing and billing policies, quoting procedures, methods of obtaining business, forecasts, future plans and potential strategies, financial projections and business strategies, operational plans, financing and capital-raising plans, activities and agreements, internal services and operational manuals, methods of conducting Company business, suppliers and supplier information, and purchasing&#59; (c) information regarding customers and potential customers of Company, including customer lists, names, representatives, their needs or desires with respect to the types of products or services offered by Company, proposals, bids, contracts and their contents and parties, the type and quantity of products and services provided or sought to be provided to customers and potential customers of Company and other non-public information relating to customers and potential customers&#59; (d) information regarding any of Company&#8217;s business partners and their services, including names, representatives, proposals, bids, contracts and their contents and parties, the type and quantity of products and services received by Company, and other non-public information relating to business partners&#59; (e) information regarding personnel, employee lists, compensation, and employee skills&#59; and (f) any other non-public information which a competitor of Company could use to the competitive disadvantage of Company. Notwithstanding the foregoing, it is understood that, at all such times, I am free to use information which is generally known in the trade or industry through no breach of this Agreement or other act or omission by me. Further, notwithstanding the foregoing or anything to the contrary in this Agreement or any other agreement between the Company and me, nothing in this Agreement shall limit my right to discuss my employment or report possible violations of law or </font></div></div></div><div style="height:39pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="padding-left:9pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">regulation with any federal government agency or similar state or local agency or to discuss the terms and conditions of my employment with others to the extent expressly permitted by Section 7 of the National Labor Relations</font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"></div></div><div style="height:39pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_25"></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:3.7pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Act.</font></div><div style="margin-top:5.95pt;padding-left:9pt;padding-right:1.9pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.77pt">Third Party Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I understand, in addition, that Company has received, and in the future will receive, from third parties their confidential and&#47;or proprietary knowledge, data or information (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Third Party Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) subject to a duty on Company&#8217;s part to maintain the confidentiality of such information and to use it only for certain limited purposes. During my employment and thereafter, I will hold Third Party Information in confidence and will not disclose to anyone (other than Company personnel who need to know such information in connection with their work for Company) or use, except in connection with my work for Company, Third Party Information unless expressly authorized by an officer of Company in writing.</font></div><div style="margin-top:6.3pt;padding-left:9pt;padding-right:2.1pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.15pt">No Improper Use of Information of Prior Employers and Others. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During my employment by Company, I will not improperly use or disclose confidential information or trade secrets, if any, of any former employer or any other person to whom I have an obligation of confidentiality, and I will not bring onto the premises of Company any unpublished documents or any property belonging to any former employer or any other person to whom I have an obligation of confidentiality unless consented to in writing by that former employer or person.</font></div><div style="margin-top:6.05pt;padding-left:30.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.35pt">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SSIGNMENTS OF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">NVENTIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-top:5.75pt;padding-left:9pt;padding-right:1.9pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.77pt">Definitions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As used in this Agreement, the term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Intellectual Property Rights&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means all trade secrets, Copyrights, trademarks, mask work rights, patents and other intellectual property rights recognized by the laws of any jurisdiction or country&#59; the term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Copyright&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means the exclusive legal right to reproduce, perform, display, distribute and make derivative works of a work of authorship (as a literary, musical, or artistic work) recognized by the laws of any jurisdiction or country&#59; and the term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Moral Rights&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means all paternity, integrity, disclosure, withdrawal, special and any other similar rights recognized by the laws of any jurisdiction or country.</font></div><div style="margin-top:6.3pt;padding-left:9pt;padding-right:1.9pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.15pt">Excluded Inventions and Other Inventions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Attachment 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is a list describing all existing Inventions, if any, that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development and that were made by me or acquired by me prior to the commencement of my employment with, and which are not to be assigned to, Company (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Excluded Inventions&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">). If no such list is attached, I represent and agree that it is because I </font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"><div style="margin-top:6.3pt;padding-left:9pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">have no rights in any existing Inventions that may relate to Company&#8217;s business or actual or demonstrably anticipated research or development. For purposes of this Agreement, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Other Inventions&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">means</font></div><div style="margin-top:3.7pt;padding-left:9pt;padding-right:5.55pt;text-align:justify"><font><br></font></div><div style="margin-top:3.7pt;padding-left:9pt;padding-right:5.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inventions in which I have or may have an interest, as of the commencement of my employment, other than Company Inventions (defined below) and Excluded Inventions. I acknowledge and agree that if I use any Excluded Inventions or any Other Inventions in the scope of my employment, or if I include any Excluded Inventions or Other Inventions in any product or service of Company, or if my rights in any Excluded Inventions or Other Inventions may block or interfere with, or may otherwise be required for, the exercise by Company of any rights assigned to Company under this Agreement, I will immediately so notify Company in writing. Unless Company and I agree otherwise in writing as to particular Excluded Inventions or Other Inventions, I hereby grant to Company, in such circumstances (whether or not I give Company notice as required above), a non-exclusive, perpetual, transferable, fully-paid and royalty-free, irrevocable and worldwide license, with rights to sublicense through multiple levels of sublicensees, to reproduce, make derivative works of, distribute, publicly perform, and publicly display in any form or medium, whether now known or later developed, make, have made, use, sell, import, offer for sale, and exercise any and all present or future rights in, such Excluded Inventions and Other Inventions. To the extent that any third parties have rights in any such Excluded Inventions or Other Inventions, I hereby represent and warrant that such third party or parties have validly and irrevocably granted to me the right to grant the license stated above.</font></div><div style="margin-top:6.3pt;padding-left:9pt;padding-right:5.7pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.77pt">Assignment of Company Inventions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Inventions assigned to Sangamo, or to a third party as directed by Sangamo pursuant to Section 2.6, are referred to in this Agreement as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8220;Company Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to Section 2.4 (Unassigned or Nonassignable Inventions) and except for Excluded Inventions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Attachment 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and Other Inventions, I hereby assign to Sangamo all my right, title, and interest in and to any and all Inventions (and all Intellectual Property Rights with respect thereto) made, conceived, reduced to practice, or learned by me, either alone or with others, during the period of my employment by Company. To the extent required by applicable Copyright laws, I agree to assign in the future (when any copyrightable Inventions are first </font></div></div></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:6.3pt;padding-left:9pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">fixed in a tangible medium of expression) my Copyright rights in and to such Inventions. Any assignment of Company Inventions (and all Intellectual Property Rights with respect thereto) hereunder includes an assignment of all Moral Rights. To the extent such Moral Rights cannot be assigned to Sangamo and to the extent the following is allowed by the laws in any country where Moral Rights exist, I hereby unconditionally and irrevocably waive the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to</font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"></div></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_28"></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:3.7pt;padding-left:9pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Company&#8217;s customers, with respect to such rights. I further acknowledge and agree that neither my successors- in-interest nor legal heirs retain any Moral Rights in any Company Inventions (and any Intellectual Property Rights with respect thereto).</font></div><div style="margin-top:6pt;padding-left:9pt;padding-right:1.9pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.77pt">Unassigned or Nonassignable Inventions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I recognize that this Agreement will not be deemed to require assignment of any Invention that is covered under California Labor Code section 2870(a) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Specific Inventions Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as detailed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Attachment 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:6.25pt;padding-left:9pt;padding-right:2pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.15pt">Obligation to Keep Company Informed. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the period of my employment and for one (1) year after termination of my employment, I will promptly and fully disclose to Company in writing all Inventions authored, conceived, or reduced to practice by me, either alone or jointly with others. In addition, I will promptly disclose to Company all patent applications filed by me or on my behalf within one (1) year after termination of employment. At the time of each such disclosure, I will advise Company in writing of any Inventions that I believe fully qualify for protection under the provisions of the Specific Inventions Law&#59; and I will at that time provide to Company in writing all evidence necessary to substantiate that belief. Company will keep in confidence and will not use for any purpose or disclose to third parties without my consent any confidential information disclosed in writing to Company pursuant to this Agreement relating to Inventions that qualify fully for protection under the Specific Inventions Law. I will preserve the confidentiality of any Invention that does not fully qualify for protection under the Specific Inventions Law.</font></div><div style="margin-top:5.85pt;padding-left:9pt;padding-right:2pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.77pt">Government or Third Party. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree that, as directed by Company, I will assign to a third party, including without limitation the United States, all my right, title, and interest in and to any particular Company Invention.</font></div><div style="margin-top:6pt;padding-left:9pt;padding-right:1.95pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.15pt">Ownership of Work Product. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree that Sangamo will exclusively own all work product that is made by me (solely or jointly with others) within the scope of my employment, and I hereby irrevocably and unconditionally assign to Sangamo all right, title, and interest worldwide in and to such work product. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within the scope of my employment and which are protectable by Copyright are &#8220;works made for hire,&#8221; pursuant to United States Copyright Act (17 U.S.C., Section 101). I understand and agree that I have no right to publish on, </font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"><div style="margin-top:6pt;padding-left:9pt;padding-right:1.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">submit for publishing, or use for any publication any work product protected by this Section, except as necessary to perform services for Company.</font></div><div style="margin-top:3.9pt;padding-left:9pt;padding-right:5.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.37pt">Enforcement of Intellectual Property Rights and Assistance. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I will assist Company in every proper way to obtain, and from time to time enforce, United States and foreign Intellectual Property Rights and Moral Rights relating to Company Inventions in any and all countries. To that end I will execute, verify and deliver such documents and perform such other acts (including appearances as a witness) as Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such Intellectual Property Rights and the assignment thereof. In addition, I will execute, verify and deliver assignments of such Intellectual Property Rights to Sangamo or its designee, including the United States or any third party designated by Sangamo. My obligation to assist Company with respect to Intellectual Property Rights relating to such Company Inventions in any and all countries will continue beyond the termination of my employment, but Company will compensate me at a reasonable rate after my termination for the time actually spent by me at Company's request on such assistance. In the event Company is unable for any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified in this paragraph, I hereby irrevocably designate and appoint Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted acts to further the purposes of this Agreement with the same legal force and effect as if executed by me. I hereby waive and quitclaim to Company any and all claims, of any nature whatsoever, which I now or may hereafter have for infringement of any Intellectual Property Rights assigned under this Agreement to Sangamo.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="padding-left:9pt;padding-right:5.65pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:34.99pt">Incorporation of Software Code. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree that I will not incorporate into any Company software or otherwise deliver to Company any software code licensed under the GNU General Public License or Lesser General Public License or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">except </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in strict compliance with Company&#8217;s policies regarding the use of such software.</font></div></div></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:6.05pt;padding-left:9pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ECORDS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that is required by Company) of all Confidential Information developed by me and all Company Inventions made by me during the period of my employment at Company, which records will be available to and remain the sole property of Company at all times.</font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"></div></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_31"></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:3.7pt;padding-left:9pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UTY OF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OYALTY </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">URING </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MPLOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree that during the period of my employment by Company I will not, without Company's express written consent, directly or indirectly (a) engage in any other employment or (b) engage in any other activities that are competitive with, or would otherwise conflict with, my employment by Company.</font></div><div style="margin-top:6.25pt;padding-left:9pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">O </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OLICITATION OF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MPLOYEES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ONSULTANTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ONTRACTORS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree that during the period of my employment and for the one (1) year period after the date my employment ends for any reason, including but not limited to voluntary termination by me or involuntary termination by Company, I will not, as an officer, director, employee, consultant, owner, partner, or in any other capacity, either directly or through others, except on behalf of Company, solicit, induce, encourage, or participate in soliciting, inducing or encouraging any employee, consultant, or independent contractor of Company to terminate his, her or its relationship with Company, even if I did not initiate the discussion or seek out the contact.</font></div><div style="margin-top:5.75pt;padding-left:9pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EASONABLENESS OF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ESTRICTIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree that I have read this entire Agreement and understand it. I agree that this Agreement does not prevent me from earning a living or pursuing my career. I agree that the restrictions contained in this Agreement are reasonable, proper, and necessitated by Company&#8217;s legitimate business interests. I represent and agree that I am entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.</font></div><div style="margin-top:6pt;padding-left:9pt;padding-right:1.9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">O </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ONFLICTING </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">GREEMENT OR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">BLIGATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I represent that my employment by Company does not and will not breach any agreement with any former employer or third party, including any noncompete agreement or any agreement to keep in confidence or refrain from using information acquired by me prior to my employment by Company. I further represent that I have not entered into, and will not enter into, any agreement, either written or oral, in conflict with my obligations under this Agreement.</font></div><div style="margin-top:6.05pt;padding-left:9pt;padding-right:1.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ETURN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">F </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OMPANY </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ROPERTY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subject to the nondisclosure requirements of Section 1.1 above, upon termination of my employment or upon Company&#8217;s request at any other time, I will deliver to Company any and all of Company&#8217;s property and equipment and any and all drawings, notes, memoranda, specifications, devices, formulas and documents, together with all copies thereof, and any other material containing or disclosing any Company Inventions, </font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"><div style="margin-top:6.05pt;padding-left:9pt;padding-right:1.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Third Party Information or Confidential Information of Company. I agree that I will not copy, delete, or alter any information contained upon my Company computer or Company equipment before I return it to Company.   In addition, if I have used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, I agree to provide Company with a computer- useable copy of all such Confidential Information and then permanently delete and expunge such Confidential Information from those systems&#59; and I agree to provide Company access to my system as reasonably requested to verify that the necessary copying and&#47;or deletion is completed. I further agree that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time with or without notice.</font></div><div style="margin-top:6.25pt;padding-left:30.6pt;text-align:justify;text-indent:-21.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.4pt">L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EGAL AND </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUITABLE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EMEDIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-top:5.75pt;padding-left:9pt;padding-right:5.6pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:33.77pt">I agree that it may be impossible to assess the damages caused by my violation of this Agreement or any of its terms. I agree that any threatened or actual violation of this Agreement or any of its terms will constitute immediate and irreparable injury to Company, and Company will have the right to enforce this Agreement and any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that Company may have for a breach or threatened breach of this Agreement.</font></div><div style="margin-top:6pt;padding-left:9pt;padding-right:5.85pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:33.15pt">In the event Company enforces this Agreement through a court or arbitration order, I agree that the restrictions of Sections 5 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.</font></div><div style="margin-top:6pt;padding-left:9pt;padding-right:5.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OTICES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Any notices required or permitted under this Agreement will be given to Company at its headquarters location at the time notice is given, and to me at my address as listed on Company payroll, or at such other address as Company or I may designate by written notice to the other. Notice will be effective upon receipt or refusal of delivery. If delivered by certified or registered mail, notice will be considered to have been given five (5) business days after it was mailed, as evidenced by the postmark. If delivered by courier or express mail service, notice will be considered to have been given on the delivery date reflected by the courier or express mail service receipt.</font></div></div></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:6.15pt;padding-left:9pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:18.75pt">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OTIFICATION </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">O</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">F </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">EW </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MPLOYER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If I leave the employ of Company, I consent to the notification of my new employer of my rights and obligations under this Agreement, by Company providing a copy of this Agreement or otherwise.</font></div><div style="margin-top:6.2pt;padding-left:30.6pt;text-align:justify;text-indent:-21.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:13.4pt">G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ENERAL </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ROVISIONS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div style="margin-top:5.7pt;padding-left:52.2pt;text-indent:-21.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.02pt">Governing Law.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement will be</font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"></div></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_34"></div><hr style="page-break-after:always"><div style="min-height:50pt;width:100%"><div><font><br></font></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="margin-top:3.7pt;padding-left:9pt;padding-right:2.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">governed by and construed according to the laws of the State of California as such laws are applied to agreements entered into and to be performed entirely within California between California residents.</font></div><div style="margin-top:6.05pt;padding-left:9pt;padding-right:1.95pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.77pt">Severability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement. If moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.</font></div><div style="margin-top:5.95pt;padding-left:9pt;padding-right:1.95pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.15pt">Successors and Assigns. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement is for my benefit and the benefit of Company, its successors, assigns, parent corporations, direct and indirect subsidiaries, affiliates, and purchasers, and will be binding upon my heirs, executors, administrators and other legal representatives.</font></div><div style="margin-top:6.05pt;padding-left:9pt;padding-right:2.05pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.77pt">Survival. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement shall survive the termination of my employment, regardless of the reason, and the assignment of this Agreement by Company to any successor in interest or other assignee.</font></div><div style="margin-top:5.95pt;padding-left:9pt;padding-right:1.9pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.15pt">Employment At-Will. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree and understand that nothing in this Agreement will change my at-will employment status or confer any right with respect to continuation of employment by Company, nor will it interfere in any way with my right or Company's right to terminate my employment at any time, with or without cause or advance notice.</font></div><div style="margin-top:3.7pt;padding-left:9pt;padding-right:5.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:19.37pt">  Waiver. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No waiver by Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach. No waiver by Company of any right under this Agreement will be construed as a waiver of any other right. Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.</font></div><div style="margin-top:5.95pt;padding-left:9pt;padding-right:5.75pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:34.99pt">Export. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I agree not to export, reexport, or transfer, directly or indirectly, any U.S. technical data acquired from Company or any products utilizing such data, in violation of the United States export laws or regulations.</font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"><div style="margin-top:6pt;padding-left:9pt;padding-right:5.55pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:33.15pt">Entire Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Agreement is the final, complete and exclusive agreement of the parties with respect to the subject matter of this Agreement and supersedes and merges all prior discussions between the parties&#59; provided, however, prior to the execution of this Agreement, if Company and I were parties to any agreement regarding the subject matter hereof, that agreement will be superseded by this Agreement prospectively only. No modification of or amendment to this Agreement, or any waiver of any rights under this Agreement, will be effective unless in writing and signed by me and an authorized officer of the Company. Any subsequent change or changes in my Duties (as used in my Executive Employment Agreement), salary or compensation will not affect the validity or scope of this Agreement. If no other agreement governs nondisclosure and assignment of inventions during any period in which I was previously engaged or am in the future engaged by Company as an independent contractor, the obligations pursuant to sections of this Agreement titled &#8220;Confidential Information Protections&#8221; and &#8220;Assignment of Inventions&#8221; shall apply.</font></div></div></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_37"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.55pt;padding-left:14.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OBERT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">J. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SCHOTT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#58;</font></div><div style="margin-top:5pt;padding-left:14.35pt;padding-right:323.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">I </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">HAVE READ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNDERSTAND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AND </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CCEPT THIS AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Robert J. Schott</font></div><div style="margin-top:1.35pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">(Signature)</font></div><div><font><br></font></div><div style="margin-top:9.35pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  By&#58; Robert J. Schott</font></div><div style="margin-top:0.1pt;padding-right:482.1pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:14.35pt;padding-right:291.55pt"><font><br></font></div><div style="padding-left:14.35pt;padding-right:291.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Title&#58; Senior Vice President, Chief Development Officer Date&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:400;line-height:133%">Jan 14, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="margin-top:4.6pt;padding-left:9pt;padding-right:365.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:161%">SANGAMO THERAPEUTICS, INC.&#58; A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:161%">CCEPTED AND AGREED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:161%">&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="padding-left:10.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#47;s&#47; Whitney B. Jones</font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">    (Signature)</font></div><div style="margin-top:9.35pt;padding-left:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">By&#58; Whitney B. Jones</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:9pt;padding-right:325.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:141%">Title&#58; Senior Vice President, Chief People Officer Date&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:15pt;font-weight:400;line-height:141%">Jan 14, 2021</font></div><div style="height:47pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_40"></div><hr style="page-break-after:always"><div style="min-height:68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.8pt;padding-left:229.62pt;padding-right:229.62pt;text-align:center;text-indent:0.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:217%">TTACHMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">1 P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:217%">RIOR </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:217%">NVENTIONS</font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:312.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:217%">TO&#58;&#160;&#160;&#160;&#160;Sangamo Therapeutics, Inc. FROM&#58;&#160;&#160;&#160;&#160;Robert J. Schott</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.756%"><div style="padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DATE&#58;</font></div><div style="margin-top:1.75pt;padding-left:16.6pt"><font><br></font></div></div><div style="display:inline-block;max-width:6.486%;min-width:5.486%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.758%"><div style="margin-top:1.75pt;padding-left:16.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Jan 14, 2021</font></div><div style="padding-left:14.65pt"><font><br></font></div></div></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBJECT&#58;&#160;&#160;&#160;&#160;Prior Inventions</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:45pt;padding-right:52.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by Sangamo Therapeutics, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by Company&#58;</font></div><div style="margin-top:0.05pt;padding-left:117pt;padding-right:282.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:217%"> &#9744; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">No inventions or improvements. </font></div><div style="margin-top:0.05pt;padding-left:117pt;padding-right:282.5pt;text-indent:-45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:217%"> &#9744; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">See below&#58;</font></div><div style="margin-top:0.2pt;padding-left:72pt"><img alt="image_141.jpg" src="image_141.jpg" style="height:0px;margin-bottom:5pt;vertical-align:text-bottom;width:528px"></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font><br></font></div><div style="margin-top:0.5pt;padding-left:72pt"><img alt="image_141.jpg" src="image_141.jpg" style="height:0px;margin-bottom:5pt;vertical-align:text-bottom;width:528px"></div><div style="margin-top:0.4pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:73.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additional sheets attached.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:81pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.05pt">Due to a prior confidentiality agreement, I cannot complete the disclosure under</font></div><div style="padding-left:45pt;padding-right:86.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1 above with respect to inventions or improvements generally listed below, the intellectual property rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div><div style="margin-top:0.25pt;padding-left:73.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Invention or Improvement&#160;&#160;&#160;&#160;Party(ies)&#160;&#160;&#160;&#160;Relationship</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font></div><div style="padding-left:45pt"><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:73.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9744;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additional sheets attached.</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9e4878d7f90042b58247d40a595e0fc3_43"></div><hr style="page-break-after:always"><div style="min-height:34pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3.8pt;padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TTACHMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:1.4pt;padding-right:1.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIMITED EXCLUSION NOTIFICATION</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:53.55pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This is to notify you in accordance with Section 2872 of the California Labor Code that the foregoing Agreement between you and Company does not require you to assign or offer to assign to Company any Invention that you develop entirely on your own time without using Company&#8217;s equipment, supplies, facilities or trade secret information, except for those Inventions that either&#58;</font></div><div><font><br></font></div><div style="padding-left:45pt;padding-right:41.75pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.73pt">Relate at the time of conception or reduction to practice to Company&#8217;s business, or actual or demonstrably anticipated research or development&#59; or</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:117pt;text-indent:-36.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.05pt">Result from any work performed by you for Company.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:45pt;padding-right:44.15pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent a provision in the foregoing Agreement purports to require you to assign an Invention otherwise excluded from the preceding paragraph, the provision is against the public policy of this state and is unenforceable.</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:45pt;padding-right:51.95pt;text-indent:35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This limited exclusion does not apply to any patent or Invention covered by a contract between Company and the United States or any of its agencies requiring full title to such patent or Invention to be in the United States.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:1.47pt;padding-right:1.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A-2</font></div><div style="height:14pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>sgmo-20210331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8ca60ae7dda9447592a2fc6715d6c5a7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alexander D. Macrae, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>sgmo-20210331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i5aad95467d6244ed8f873b0a88e21fc8_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Prathyusha Duraibabu, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice&#160;President, Finance</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>sgmo-20210331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib8c7ae03d36e45fe8977aa2740690c4c_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in his or her capacity as an officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;the Company&#8217;s Quarterly Report on Form 10-Q for the period ended March&#160;31, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice&#160;President, Finance</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 4, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sgmo-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f8bb1a1-ab1a-4951-8c26-7b9e49d72adf,g:12312c6a-d00d-416f-b715-a9f74eefa2dc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
        <link:definition>2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
        <link:definition>2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail">
        <link:definition>2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2107102 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail">
        <link:definition>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSNarrativeDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail">
        <link:definition>2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail">
        <link:definition>2411406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES">
        <link:definition>2112103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables">
        <link:definition>2313303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails">
        <link:definition>2415408 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail">
        <link:definition>2416409 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSPERSHARE" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE">
        <link:definition>2117104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail">
        <link:definition>2418410 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES">
        <link:definition>2119105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
        <link:definition>2320304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail">
        <link:definition>2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail">
        <link:definition>2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sangamo.com/role/INCOMETAXES">
        <link:definition>2123106 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESDetails">
        <link:definition>2424413 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTS" roleURI="http://www.sangamo.com/role/COMMITMENTS">
        <link:definition>2125107 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSTables" roleURI="http://www.sangamo.com/role/COMMITMENTSTables">
        <link:definition>2326305 - Disclosure - COMMITMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail">
        <link:definition>2427414 - Disclosure - COMMITMENTS - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail">
        <link:definition>2428415 - Disclosure - COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1">
        <link:definition>2428415 - Disclosure - COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail">
        <link:definition>2429416 - Disclosure - COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2130108 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2331306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail">
        <link:definition>2432417 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2133109 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetail" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail">
        <link:definition>2434418 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS">
        <link:definition>2135110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables">
        <link:definition>2336307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail">
        <link:definition>2437419 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail">
        <link:definition>2438420 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" abstract="false" name="CollaborativeArrangementVotingProvisionsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_LicenseObligations" abstract="false" name="LicenseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PropertySubjectToOperatingLeaseOneMember" abstract="true" name="PropertySubjectToOperatingLeaseOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ResearchAndOfficeSpaceMember" abstract="true" name="ResearchAndOfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" abstract="false" name="CollaborativeArrangementIncreaseDecreaseInRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" abstract="true" name="CaliforniaInstituteForRegenerativeMedicineAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" abstract="false" name="CollaborativeArrangementNumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockExcessConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" abstract="false" name="CollaborativeArrangementCumulativeMilestoneAchieved" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" abstract="false" name="CollaborativeArrangementNumberOfProductTargetsSelected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesMilestonesMember" abstract="true" name="AchievementOfSpecifiedSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborationAgreementTargetSelectionPeriod" abstract="false" name="CollaborationAgreementTargetSelectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementResearchServiceFees" abstract="false" name="CollaborativeArrangementResearchServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ValbonneFranceMember" abstract="true" name="ValbonneFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SeparateUpfrontFee" abstract="false" name="SeparateUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargets" abstract="false" name="CollaborativeArrangementNumberOfProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborationArrangementResearchPeriod" abstract="false" name="CollaborationArrangementResearchPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BrisbaneCaliforniaMember" abstract="true" name="BrisbaneCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" abstract="true" name="SharePurchaseAgreementAndTenderOfferAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementMaximumMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementLicenseFee" abstract="false" name="CollaborativeArrangementLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" abstract="false" name="CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" abstract="false" name="BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesHeldByHolders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_FreeSharesAssetMember" abstract="true" name="FreeSharesAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementPercentOfInitialRecognition" abstract="false" name="CollaborativeAgreementPercentOfInitialRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfSharesAcquired" abstract="false" name="BusinessAcquisitionNumberOfSharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_SangamoFranceMember" abstract="true" name="SangamoFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MeasurementInputExchangeRateMember" abstract="true" name="MeasurementInputExchangeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ExtendedResearchTermOfAgreement" abstract="false" name="ExtendedResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" abstract="false" name="ScheduleOfNoncontrollingInterestTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNetIncomeLossPerShare" abstract="false" name="CollaborativeArrangementNetIncomeLossPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="sgmo_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_StockOfferingProgramMaximumValue" abstract="false" name="StockOfferingProgramMaximumValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_GrantFundingAmount" abstract="false" name="GrantFundingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneAxis" abstract="true" name="CollaborativeAgreementMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MeasurementInputStockPriceCorrelationMember" abstract="true" name="MeasurementInputStockPriceCorrelationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveMember" abstract="true" name="SBFiveTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionPeriod" abstract="false" name="CollaborativeArrangementStandstillRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveAndOtherProductsMember" abstract="true" name="SBFiveTwoFiveAndOtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" abstract="true" name="ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneDomain" abstract="true" name="CollaborativeAgreementMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" abstract="false" name="CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" abstract="false" name="CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAgreementEquityIssued" abstract="false" name="CollaborationAgreementEquityIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseAreaOfRealEstate" abstract="false" name="LesseeOperatingLeaseAreaOfRealEstate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="sgmo_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" abstract="false" name="CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_PreApprovalMilestoneMember" abstract="true" name="PreApprovalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMilestoneRevenueReversal" abstract="false" name="CollaborativeArrangementMilestoneRevenueReversal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NumberOfOptionsToExtendInitialResearchTerm" abstract="false" name="NumberOfOptionsToExtendInitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" abstract="true" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_PhaseThreeClinicalTrialMember" abstract="true" name="PhaseThreeClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_GainLossOnFreeShares" abstract="false" name="GainLossOnFreeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" abstract="false" name="CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_InitialResearchTermOfAgreement" abstract="false" name="InitialResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_BrammerBioMAMember" abstract="true" name="BrammerBioMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseAmount" abstract="false" name="LesseeOperatingLeaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AmortizationAndOtherChangesInRightOfUseAssets" abstract="false" name="AmortizationAndOtherChangesInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ChangeInCollaborationAgreementScopeMember" abstract="true" name="ChangeInCollaborationAgreementScopeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" abstract="false" name="CollaborationAgreementNumberOfAdditionalProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_NumberOfResearchProgram" abstract="false" name="NumberOfResearchProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" abstract="false" name="CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_LonzaNetherlandsBVMember" abstract="true" name="LonzaNetherlandsBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sgmo-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f8bb1a1-ab1a-4951-8c26-7b9e49d72adf,g:12312c6a-d00d-416f-b715-a9f74eefa2dc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20210331.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_32ee1673-ca45-48b2-96ce-c7ef1916b4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0e64a1bd-3aa6-4cd3-b35e-0ae1880b349d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_32ee1673-ca45-48b2-96ce-c7ef1916b4ab" xlink:to="loc_us-gaap_AccountsPayableCurrent_0e64a1bd-3aa6-4cd3-b35e-0ae1880b349d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_542801fd-921d-4844-8688-b3fc9145ded8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_32ee1673-ca45-48b2-96ce-c7ef1916b4ab" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_542801fd-921d-4844-8688-b3fc9145ded8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_74f7f910-107a-434f-957b-1c30df480a0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_32ee1673-ca45-48b2-96ce-c7ef1916b4ab" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_74f7f910-107a-434f-957b-1c30df480a0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_07615844-a4fc-4b66-ac06-c76af3388c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_32ee1673-ca45-48b2-96ce-c7ef1916b4ab" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_07615844-a4fc-4b66-ac06-c76af3388c52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b07d22af-600f-46fc-bac0-37384167c8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35a5728c-36a3-4651-a60c-faedf68b269f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b07d22af-600f-46fc-bac0-37384167c8c2" xlink:to="loc_us-gaap_StockholdersEquity_35a5728c-36a3-4651-a60c-faedf68b269f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ac108113-b95e-4ab3-9ef4-d4f5e4217c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b07d22af-600f-46fc-bac0-37384167c8c2" xlink:to="loc_us-gaap_MinorityInterest_ac108113-b95e-4ab3-9ef4-d4f5e4217c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_335f88b0-b08d-4fe9-9939-fa23de14eb5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_508e1b15-fa52-47b7-a779-55efc01427d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_335f88b0-b08d-4fe9-9939-fa23de14eb5a" xlink:to="loc_us-gaap_PreferredStockValue_508e1b15-fa52-47b7-a779-55efc01427d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_17a29558-4395-4839-9b99-ea294e80c314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_335f88b0-b08d-4fe9-9939-fa23de14eb5a" xlink:to="loc_us-gaap_CommonStockValue_17a29558-4395-4839-9b99-ea294e80c314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b511c1d2-5efb-4b36-98da-e6a0064e9ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_335f88b0-b08d-4fe9-9939-fa23de14eb5a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b511c1d2-5efb-4b36-98da-e6a0064e9ab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2f5a379f-c79e-4916-ac49-2783b6079ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_335f88b0-b08d-4fe9-9939-fa23de14eb5a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2f5a379f-c79e-4916-ac49-2783b6079ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c3b8284-c290-4672-a442-8c67b0e8545b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_335f88b0-b08d-4fe9-9939-fa23de14eb5a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0c3b8284-c290-4672-a442-8c67b0e8545b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_780c5602-045e-4677-9fe1-8a0c31af19c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:to="loc_us-gaap_AssetsCurrent_780c5602-045e-4677-9fe1-8a0c31af19c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f383cef4-7d40-420b-9666-cf5e3ae1e0ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_f383cef4-7d40-420b-9666-cf5e3ae1e0ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cc078215-eb77-4843-b1e2-3f5fed1333b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cc078215-eb77-4843-b1e2-3f5fed1333b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3d7cd1be-551d-4f31-8eb9-c6db2c8ec855" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3d7cd1be-551d-4f31-8eb9-c6db2c8ec855" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ad305b34-b6ec-4f5a-ae4a-ae414110f4c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:to="loc_us-gaap_Goodwill_ad305b34-b6ec-4f5a-ae4a-ae414110f4c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1c8bca08-540c-4f90-b3ba-37334cc78eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1c8bca08-540c-4f90-b3ba-37334cc78eda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_25b66f53-cdcb-48f0-83a6-d05e2d87ab56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_25b66f53-cdcb-48f0-83a6-d05e2d87ab56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3af1cf84-ec4d-491d-b438-d77a8ec5d3ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_29bdf56b-a86a-4918-9bcd-d8b278c27c4c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3af1cf84-ec4d-491d-b438-d77a8ec5d3ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2b024b6f-f6bf-420b-90a6-461f356e183e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7bc02ffe-5bea-44af-ac80-40751ce20461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2b024b6f-f6bf-420b-90a6-461f356e183e" xlink:to="loc_us-gaap_LiabilitiesCurrent_7bc02ffe-5bea-44af-ac80-40751ce20461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8e34c870-851c-4e36-beac-e19e1faabddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2b024b6f-f6bf-420b-90a6-461f356e183e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8e34c870-851c-4e36-beac-e19e1faabddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e111ce6-2cf7-412b-b27e-3d0403919364" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2b024b6f-f6bf-420b-90a6-461f356e183e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e111ce6-2cf7-412b-b27e-3d0403919364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_18870a8a-76b9-4ce5-be65-7e20cd2e2977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2b024b6f-f6bf-420b-90a6-461f356e183e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_18870a8a-76b9-4ce5-be65-7e20cd2e2977" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_daf4f012-35f9-49d8-bff4-31f04ec6afdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2b024b6f-f6bf-420b-90a6-461f356e183e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_daf4f012-35f9-49d8-bff4-31f04ec6afdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae990148-c379-427e-b2f2-5fe418053d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8f640d57-9aec-4b74-8f85-b0dd2fa8c01a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae990148-c379-427e-b2f2-5fe418053d8e" xlink:to="loc_us-gaap_Liabilities_8f640d57-9aec-4b74-8f85-b0dd2fa8c01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ac17ef28-a64f-4600-856c-90ad36ab7bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae990148-c379-427e-b2f2-5fe418053d8e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ac17ef28-a64f-4600-856c-90ad36ab7bc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b87e32a7-67df-4b76-aafe-10dfd35bedb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae990148-c379-427e-b2f2-5fe418053d8e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b87e32a7-67df-4b76-aafe-10dfd35bedb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8bba1348-81e7-496c-bb2f-c736d8e11487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1314ec0c-df65-4e4a-a787-2ca57b70d2a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bba1348-81e7-496c-bb2f-c736d8e11487" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1314ec0c-df65-4e4a-a787-2ca57b70d2a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0ec165aa-3593-4089-b3fe-9559d06c3c45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bba1348-81e7-496c-bb2f-c736d8e11487" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_0ec165aa-3593-4089-b3fe-9559d06c3c45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_425bab34-2ee8-4080-8674-075426c5bf0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bba1348-81e7-496c-bb2f-c736d8e11487" xlink:to="loc_us-gaap_InterestReceivableCurrent_425bab34-2ee8-4080-8674-075426c5bf0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_80afb1fe-e526-4961-be43-d2fddb3759a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bba1348-81e7-496c-bb2f-c736d8e11487" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_80afb1fe-e526-4961-be43-d2fddb3759a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_12d159fc-cd97-4eba-904b-f3c912f90b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8bba1348-81e7-496c-bb2f-c736d8e11487" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_12d159fc-cd97-4eba-904b-f3c912f90b15" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d5480f08-9531-4ba1-95a3-ae141242dced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5f390f06-92e9-4137-a704-b02b11281917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d5480f08-9531-4ba1-95a3-ae141242dced" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5f390f06-92e9-4137-a704-b02b11281917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_35cceab1-9e4c-4fc8-9adc-c70607936b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d5480f08-9531-4ba1-95a3-ae141242dced" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_35cceab1-9e4c-4fc8-9adc-c70607936b63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_c8548a48-8d44-4211-b439-5c2905d1fa3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f0b6d692-53a0-4c36-a79e-81e651428057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_c8548a48-8d44-4211-b439-5c2905d1fa3f" xlink:to="loc_us-gaap_OperatingIncomeLoss_f0b6d692-53a0-4c36-a79e-81e651428057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_8fd7612e-549c-40cb-aafd-28a920862c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_c8548a48-8d44-4211-b439-5c2905d1fa3f" xlink:to="loc_us-gaap_InterestAndOtherIncome_8fd7612e-549c-40cb-aafd-28a920862c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_98a925fd-b9d4-4d55-bd0a-2c7b9b013cc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_4cddc689-c42c-4def-8dca-76021a5663c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_98a925fd-b9d4-4d55-bd0a-2c7b9b013cc6" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_4cddc689-c42c-4def-8dca-76021a5663c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1602cd1e-7e90-4aac-9a42-59709e3b3569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_98a925fd-b9d4-4d55-bd0a-2c7b9b013cc6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1602cd1e-7e90-4aac-9a42-59709e3b3569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c35c2b87-1772-4d1c-b611-2d611d011dd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b25d68a7-5401-4dc4-8986-19663a45e62b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c35c2b87-1772-4d1c-b611-2d611d011dd2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b25d68a7-5401-4dc4-8986-19663a45e62b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bd3b5521-8305-4f6c-aac0-37f522665ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c35c2b87-1772-4d1c-b611-2d611d011dd2" xlink:to="loc_us-gaap_OperatingExpenses_bd3b5521-8305-4f6c-aac0-37f522665ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8708ace2-e5bc-4e72-9294-2481c632d56a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c838adbd-78eb-473a-af02-67fb1753eda1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8708ace2-e5bc-4e72-9294-2481c632d56a" xlink:to="loc_us-gaap_ProfitLoss_c838adbd-78eb-473a-af02-67fb1753eda1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_153e3156-bf5b-4fc8-a3a6-a6326d300bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8708ace2-e5bc-4e72-9294-2481c632d56a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_153e3156-bf5b-4fc8-a3a6-a6326d300bee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_add735e3-9a67-4f20-b91e-f223657b98d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e8ad012-2caf-4475-863b-6915e4c7633b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_add735e3-9a67-4f20-b91e-f223657b98d8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e8ad012-2caf-4475-863b-6915e4c7633b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1c31d30d-984f-4757-9ea0-88146414eaae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_add735e3-9a67-4f20-b91e-f223657b98d8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1c31d30d-984f-4757-9ea0-88146414eaae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f6245772-d0a9-474a-9998-f3cd3bbfffdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b944d41d-8e81-4378-9730-939408da884e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f6245772-d0a9-474a-9998-f3cd3bbfffdb" xlink:to="loc_us-gaap_ProfitLoss_b944d41d-8e81-4378-9730-939408da884e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ef4a3a17-84ea-485e-9482-1c004317480c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f6245772-d0a9-474a-9998-f3cd3bbfffdb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ef4a3a17-84ea-485e-9482-1c004317480c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_61762ef5-a47d-4710-b9e4-984066acbcc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f6245772-d0a9-474a-9998-f3cd3bbfffdb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_61762ef5-a47d-4710-b9e4-984066acbcc5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca8fef3d-f6fe-427f-a3e7-1726abd0c54f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4578e1ce-f9c9-4d94-ada6-387b52c4b732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca8fef3d-f6fe-427f-a3e7-1726abd0c54f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4578e1ce-f9c9-4d94-ada6-387b52c4b732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_13de7700-7e00-47f6-9454-d814714e4043" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca8fef3d-f6fe-427f-a3e7-1726abd0c54f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_13de7700-7e00-47f6-9454-d814714e4043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e68a3531-47f4-4539-9cf9-4f513f4564c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca8fef3d-f6fe-427f-a3e7-1726abd0c54f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e68a3531-47f4-4539-9cf9-4f513f4564c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7d355677-c80c-42c0-a65f-c6b4cc769532" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7ab85385-cdad-4af9-895d-ca53fa8c783b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7d355677-c80c-42c0-a65f-c6b4cc769532" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7ab85385-cdad-4af9-895d-ca53fa8c783b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99f617ec-d6b7-4d40-aba0-7a9bb12467c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7d355677-c80c-42c0-a65f-c6b4cc769532" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_99f617ec-d6b7-4d40-aba0-7a9bb12467c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad9d2da0-0c61-40db-8493-71d6ed1df9d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7d355677-c80c-42c0-a65f-c6b4cc769532" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad9d2da0-0c61-40db-8493-71d6ed1df9d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1710b85b-65ab-4d7e-b274-fd2ba296f2c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7d355677-c80c-42c0-a65f-c6b4cc769532" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1710b85b-65ab-4d7e-b274-fd2ba296f2c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49525828-b5f7-48dd-9d87-2026bceff0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_547b7743-6796-4e8a-af46-7f047a8cd337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49525828-b5f7-48dd-9d87-2026bceff0d0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_547b7743-6796-4e8a-af46-7f047a8cd337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_fe0665be-d3d7-4534-b6c3-54c3e0fa26d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49525828-b5f7-48dd-9d87-2026bceff0d0" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_fe0665be-d3d7-4534-b6c3-54c3e0fa26d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b92110e6-91b0-40e7-904d-db2c53adf899" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49525828-b5f7-48dd-9d87-2026bceff0d0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b92110e6-91b0-40e7-904d-db2c53adf899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_9b100d87-b000-4515-98dd-5f94ff1c31f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49525828-b5f7-48dd-9d87-2026bceff0d0" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_9b100d87-b000-4515-98dd-5f94ff1c31f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_ad29c749-cd15-49ee-aaef-6e8e99d04e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_49525828-b5f7-48dd-9d87-2026bceff0d0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_ad29c749-cd15-49ee-aaef-6e8e99d04e74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3b07c831-9d97-48f4-aa7f-2452a95e8cc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3b07c831-9d97-48f4-aa7f-2452a95e8cc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_ec2d34d1-4249-48a2-bc74-dc80e899fbad" xlink:href="sgmo-20210331.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_ec2d34d1-4249-48a2-bc74-dc80e899fbad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_8137bcb1-b271-4a73-89b5-feba7bb34075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_8137bcb1-b271-4a73-89b5-feba7bb34075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ccbf5225-6d7a-4c72-b5de-23a992616365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_ShareBasedCompensation_ccbf5225-6d7a-4c72-b5de-23a992616365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_cc8ac856-eb33-4942-86fd-d29fb34dd5b6" xlink:href="sgmo-20210331.xsd#sgmo_GainLossOnFreeShares"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_sgmo_GainLossOnFreeShares_cc8ac856-eb33-4942-86fd-d29fb34dd5b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_41b4459f-7724-45c4-95c4-246005e3b131" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_41b4459f-7724-45c4-95c4-246005e3b131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e2bdf90e-2e72-4156-8b61-5eb9ce2a9c29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e2bdf90e-2e72-4156-8b61-5eb9ce2a9c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94251ab4-a77f-4b33-b2da-d0079a2d7db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94251ab4-a77f-4b33-b2da-d0079a2d7db1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_5ca9b6bd-4a01-4f6a-8459-f6d5ce53a39d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_5ca9b6bd-4a01-4f6a-8459-f6d5ce53a39d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_44c13d16-8f12-4fab-8573-c9154a2d0d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_44c13d16-8f12-4fab-8573-c9154a2d0d71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9f3683a2-5a00-42b4-9f59-df2492988d6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_ProfitLoss_9f3683a2-5a00-42b4-9f59-df2492988d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_6835ce3a-91d7-449a-97d3-39dddb957e3a" xlink:href="sgmo-20210331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_6835ce3a-91d7-449a-97d3-39dddb957e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cc2f07a9-7477-4f1b-89d8-6c914bb38d17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_cc2f07a9-7477-4f1b-89d8-6c914bb38d17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1e2c359d-c5b7-4efe-af2c-bb2d9bea496d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_dd7e86fd-ebc8-41dc-b305-aa65335ebbb4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1e2c359d-c5b7-4efe-af2c-bb2d9bea496d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c41f3805-f4c6-4630-a876-091ed91b79f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_836d71d7-7e91-4e6a-8f35-cb7cdb9afd29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c41f3805-f4c6-4630-a876-091ed91b79f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_836d71d7-7e91-4e6a-8f35-cb7cdb9afd29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a7b4ac9f-9377-4b52-b014-b5beef5d7bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_c41f3805-f4c6-4630-a876-091ed91b79f7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a7b4ac9f-9377-4b52-b014-b5beef5d7bb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_273a186f-168c-45c9-8f35-f3b430a5f103" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11e971a1-98c3-4fd9-ad2b-2ffd2c81170a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_273a186f-168c-45c9-8f35-f3b430a5f103" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_11e971a1-98c3-4fd9-ad2b-2ffd2c81170a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3e3cddd-5c54-4a6a-a424-5b0e2be502e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_273a186f-168c-45c9-8f35-f3b430a5f103" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b3e3cddd-5c54-4a6a-a424-5b0e2be502e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_1a23175d-fad2-425d-bee4-0fe2971011f4" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_21b1ca59-cac1-4dbf-8528-d120c24a607b" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_1a23175d-fad2-425d-bee4-0fe2971011f4" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_21b1ca59-cac1-4dbf-8528-d120c24a607b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b26f3c78-506c-44c9-8a2e-3cf4477b5aeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_1a23175d-fad2-425d-bee4-0fe2971011f4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b26f3c78-506c-44c9-8a2e-3cf4477b5aeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4bf4347e-8c43-4c4d-a185-341e872d72d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829a18b0-a505-4c67-a0ec-dc1b7dc21a8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4bf4347e-8c43-4c4d-a185-341e872d72d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829a18b0-a505-4c67-a0ec-dc1b7dc21a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45cf407c-18d9-42cb-a5e3-43c36c17654c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4bf4347e-8c43-4c4d-a185-341e872d72d5" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_45cf407c-18d9-42cb-a5e3-43c36c17654c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_93d5c76d-c01b-4a32-bd56-073e3a823bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4bf4347e-8c43-4c4d-a185-341e872d72d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_93d5c76d-c01b-4a32-bd56-073e3a823bfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2dc6902a-0b39-4928-ab45-d7220b4e524c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_cea59b73-8a85-4634-87dd-707cb54277d1" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2dc6902a-0b39-4928-ab45-d7220b4e524c" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_cea59b73-8a85-4634-87dd-707cb54277d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_302f460d-cafb-40c0-9d34-bd55a2a17eae" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2dc6902a-0b39-4928-ab45-d7220b4e524c" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_302f460d-cafb-40c0-9d34-bd55a2a17eae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8e84c103-c36d-45d4-9a25-f2987a29aa0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2dc6902a-0b39-4928-ab45-d7220b4e524c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8e84c103-c36d-45d4-9a25-f2987a29aa0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_fa66a98e-56c5-40bc-8b02-441e82568320" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_70567af1-9298-49e2-8ba5-7d1b72863660" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_fa66a98e-56c5-40bc-8b02-441e82568320" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_70567af1-9298-49e2-8ba5-7d1b72863660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d7def790-ec37-4c1d-96ac-b037ce768611" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_fa66a98e-56c5-40bc-8b02-441e82568320" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d7def790-ec37-4c1d-96ac-b037ce768611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_58f51b7a-115b-48f9-b966-dcb5de863878" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_fa66a98e-56c5-40bc-8b02-441e82568320" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_58f51b7a-115b-48f9-b966-dcb5de863878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_423730ec-dd2f-4193-acff-8009bd3557e3" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_9393c764-e17f-4a55-b9ad-87b4dccae868" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_423730ec-dd2f-4193-acff-8009bd3557e3" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_9393c764-e17f-4a55-b9ad-87b4dccae868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96c74a23-7d31-4d11-9697-095a95306641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_423730ec-dd2f-4193-acff-8009bd3557e3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_96c74a23-7d31-4d11-9697-095a95306641" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b599bc6-fbe3-4be4-928d-4b61d7643e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_03eb4504-fea6-4a95-8110-441d19f8411a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b599bc6-fbe3-4be4-928d-4b61d7643e91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_03eb4504-fea6-4a95-8110-441d19f8411a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d6668fa8-05cb-419e-bf5f-807eb994c71b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7b599bc6-fbe3-4be4-928d-4b61d7643e91" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d6668fa8-05cb-419e-bf5f-807eb994c71b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20210331.xsd#BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#INCOMETAXES"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/INCOMETAXES" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="sgmo-20210331.xsd#INCOMETAXESDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bc2a5406-2854-469e-a932-27ce97301d29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d10c8c73-eb8d-49a9-b301-67f9cee44ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bc2a5406-2854-469e-a932-27ce97301d29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d10c8c73-eb8d-49a9-b301-67f9cee44ce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cd993ec9-e402-463d-aa93-c8de67cccba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bc2a5406-2854-469e-a932-27ce97301d29" xlink:to="loc_us-gaap_OperatingLeaseLiability_cd993ec9-e402-463d-aa93-c8de67cccba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a07d8638-3a51-419e-89bf-553a4dd66f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a1e0f57a-c282-4afd-bdd1-a431238d203d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a07d8638-3a51-419e-89bf-553a4dd66f2d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a1e0f57a-c282-4afd-bdd1-a431238d203d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_85be6e3d-186e-4d00-ba25-1b1ed24978fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a07d8638-3a51-419e-89bf-553a4dd66f2d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_85be6e3d-186e-4d00-ba25-1b1ed24978fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17f56a8e-bc97-4fad-a9ee-12f4ac3fba81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_27e019a1-c64e-430b-bbba-332e5dbb39f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17f56a8e-bc97-4fad-a9ee-12f4ac3fba81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_27e019a1-c64e-430b-bbba-332e5dbb39f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_271484a0-6436-49e2-86b9-c58973e44700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17f56a8e-bc97-4fad-a9ee-12f4ac3fba81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_271484a0-6436-49e2-86b9-c58973e44700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_359cf2e4-7c77-4a55-ad01-ef3f6529a8db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17f56a8e-bc97-4fad-a9ee-12f4ac3fba81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_359cf2e4-7c77-4a55-ad01-ef3f6529a8db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e8e6af2e-e3e4-4b8e-8f2e-ede139c12aba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17f56a8e-bc97-4fad-a9ee-12f4ac3fba81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e8e6af2e-e3e4-4b8e-8f2e-ede139c12aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_66d21f7c-36c3-48bb-a272-c1e5e4706337" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17f56a8e-bc97-4fad-a9ee-12f4ac3fba81" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_66d21f7c-36c3-48bb-a272-c1e5e4706337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_111b0c62-9ea2-4f3f-ba38-72878d104389" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_17f56a8e-bc97-4fad-a9ee-12f4ac3fba81" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_111b0c62-9ea2-4f3f-ba38-72878d104389" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKHOLDERSEQUITYNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sgmo-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f8bb1a1-ab1a-4951-8c26-7b9e49d72adf,g:12312c6a-d00d-416f-b715-a9f74eefa2dc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20210331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended" id="i4bcdfc5d41a74f2fa0016311074281db_Cover"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i05425da0df784f8ba6d2b6d3c2519600_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i7df1d675f0da4f8a8acf007eb6acc96b_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended" id="i1b3829a2cdea412b8789b629963d3935_CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="id20498a91b9548f692ba3eb6afd2f997_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f051e642-5039-416f-ace0-ddc9bc8d492e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f051e642-5039-416f-ace0-ddc9bc8d492e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f36c2a4b-d330-4ddd-a623-010e083e5091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_CommonStockSharesIssued_f36c2a4b-d330-4ddd-a623-010e083e5091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfbbaec-bdd1-4421-8205-2f9bdc3bc122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfbbaec-bdd1-4421-8205-2f9bdc3bc122" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_282409b1-1fe9-4179-8e92-3abe56107447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_282409b1-1fe9-4179-8e92-3abe56107447" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f1ef6100-88d3-4b45-8152-4ee349804c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f1ef6100-88d3-4b45-8152-4ee349804c4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5e48d35d-907c-4807-990f-6bdf254295d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5e48d35d-907c-4807-990f-6bdf254295d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4bcee0eb-0725-477d-b963-03ba08105a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4bcee0eb-0725-477d-b963-03ba08105a8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dddb0369-bd6e-4087-aed2-e62e335cd190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dddb0369-bd6e-4087-aed2-e62e335cd190" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_29ccfc19-33c6-4972-8a95-77e0a95a1908" xlink:href="sgmo-20210331.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_29ccfc19-33c6-4972-8a95-77e0a95a1908" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_882dcecb-a0c7-46f6-8cbd-01105393db0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_882dcecb-a0c7-46f6-8cbd-01105393db0c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_135b47b5-2893-4292-91da-d26360a9912a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_135b47b5-2893-4292-91da-d26360a9912a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7a8045d5-d979-4ad4-aad2-af4aa8960c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_ProfitLoss_7a8045d5-d979-4ad4-aad2-af4aa8960c07" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_51a2d7dc-3446-448e-99b7-eb5cf17bd4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_038f451d-b7bb-4842-8b42-84e0dd0e81fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f06ba7ef-845e-470e-96fa-279b3e759bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f051e642-5039-416f-ace0-ddc9bc8d492e" xlink:to="loc_us-gaap_StatementTable_f06ba7ef-845e-470e-96fa-279b3e759bad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a53880a4-a848-44be-a434-ffcd2d874bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f06ba7ef-845e-470e-96fa-279b3e759bad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a53880a4-a848-44be-a434-ffcd2d874bea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a53880a4-a848-44be-a434-ffcd2d874bea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a53880a4-a848-44be-a434-ffcd2d874bea" xlink:to="loc_us-gaap_EquityComponentDomain_a53880a4-a848-44be-a434-ffcd2d874bea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a53880a4-a848-44be-a434-ffcd2d874bea" xlink:to="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_87643d08-2c8a-43b2-9076-f0484b06d5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_CommonStockMember_87643d08-2c8a-43b2-9076-f0484b06d5ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12ff45ce-b8d4-4972-a91d-dfdaf4a38374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12ff45ce-b8d4-4972-a91d-dfdaf4a38374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3904cfbb-fb88-43d9-9867-45d5cd95955a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_RetainedEarningsMember_3904cfbb-fb88-43d9-9867-45d5cd95955a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_550ffc11-f881-4270-a13b-4df2bd619ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_550ffc11-f881-4270-a13b-4df2bd619ead" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d6ed9c72-7ec2-444c-b9b6-d10f4701ca57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d6ed9c72-7ec2-444c-b9b6-d10f4701ca57" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="id3b772b473064579a88f4bd2194a8c02_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended" id="i89d79baf26ac4c2f92a54686bce827f4_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended" id="i3be68214dcf4457abee0485f9a458765_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended" id="i6a3d92d56a7847e0a26cfa091c22573e_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended" id="i0f1c581e2c5846379664db32ebbe3d0f_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:href="sgmo-20210331.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e7a9fc1-fd6a-4b61-9b32-1d531ba016a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e7a9fc1-fd6a-4b61-9b32-1d531ba016a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c1c74eaf-6865-49a1-a618-2a275a627a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_ProfitLoss_c1c74eaf-6865-49a1-a618-2a275a627a36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_96aaa2e9-a79a-4391-b27f-89af2af3763a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_EarningsPerShareBasic_96aaa2e9-a79a-4391-b27f-89af2af3763a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_5d822197-ba62-448c-bedc-088c71503bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_5d822197-ba62-448c-bedc-088c71503bff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_bca180db-3a7a-4ebb-9290-45bb9375256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_bca180db-3a7a-4ebb-9290-45bb9375256a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_c343af93-b0dc-41e9-aaa0-3c6cadf16b69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_c343af93-b0dc-41e9-aaa0-3c6cadf16b69" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:href="sgmo-20210331.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ce100ef5-63ff-4f80-a99f-e494f2a8c082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ce100ef5-63ff-4f80-a99f-e494f2a8c082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ce100ef5-63ff-4f80-a99f-e494f2a8c082_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ce100ef5-63ff-4f80-a99f-e494f2a8c082" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_ce100ef5-63ff-4f80-a99f-e494f2a8c082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5a7832ab-27f0-4957-982f-da57705db696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ce100ef5-63ff-4f80-a99f-e494f2a8c082" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5a7832ab-27f0-4957-982f-da57705db696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_fd752f75-1153-4bbd-b161-2f1605d8426e" xlink:href="sgmo-20210331.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5a7832ab-27f0-4957-982f-da57705db696" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_fd752f75-1153-4bbd-b161-2f1605d8426e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ec1dc180-97b2-462c-9242-d6926901205f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ec1dc180-97b2-462c-9242-d6926901205f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec1dc180-97b2-462c-9242-d6926901205f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ec1dc180-97b2-462c-9242-d6926901205f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ec1dc180-97b2-462c-9242-d6926901205f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb7fc86c-0382-4240-95d6-aa308ee9c4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ec1dc180-97b2-462c-9242-d6926901205f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb7fc86c-0382-4240-95d6-aa308ee9c4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_0aad393e-6d17-4a49-a69b-41af756c7378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb7fc86c-0382-4240-95d6-aa308ee9c4d5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_0aad393e-6d17-4a49-a69b-41af756c7378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2aa6a8f0-3741-4e9e-87f7-d31132478b42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:to="loc_srt_CounterpartyNameAxis_2aa6a8f0-3741-4e9e-87f7-d31132478b42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2aa6a8f0-3741-4e9e-87f7-d31132478b42_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2aa6a8f0-3741-4e9e-87f7-d31132478b42" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2aa6a8f0-3741-4e9e-87f7-d31132478b42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a4a13d8-07f7-4385-88c6-7c66a96e42cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2aa6a8f0-3741-4e9e-87f7-d31132478b42" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a4a13d8-07f7-4385-88c6-7c66a96e42cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_4c87bf65-25f6-400a-9065-bf5996c7f9b3" xlink:href="sgmo-20210331.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a4a13d8-07f7-4385-88c6-7c66a96e42cc" xlink:to="loc_sgmo_PfizerSB525Member_4c87bf65-25f6-400a-9065-bf5996c7f9b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended" id="i9e29af517ff4490a91883bf4babcd460_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_53b2ec18-b23c-41e2-a813-198de28ac732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_34ca735d-7d9d-45f1-983f-5c7c5ac837f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_53b2ec18-b23c-41e2-a813-198de28ac732" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_34ca735d-7d9d-45f1-983f-5c7c5ac837f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_53b2ec18-b23c-41e2-a813-198de28ac732" xlink:to="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9438e47-5e40-47ef-b28b-54368ec28e5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:to="loc_srt_CounterpartyNameAxis_a9438e47-5e40-47ef-b28b-54368ec28e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9438e47-5e40-47ef-b28b-54368ec28e5e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a9438e47-5e40-47ef-b28b-54368ec28e5e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9438e47-5e40-47ef-b28b-54368ec28e5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a9438e47-5e40-47ef-b28b-54368ec28e5e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_fe0ae050-1c1c-4761-bab0-7d888f60fe08" xlink:href="sgmo-20210331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_BiogenMAIncMember_fe0ae050-1c1c-4761-bab0-7d888f60fe08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c88ce60f-27f7-427e-ace3-e8b4d8719bbf" xlink:href="sgmo-20210331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c88ce60f-27f7-427e-ace3-e8b4d8719bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_f3daa514-6ed9-446f-801b-bdf3035e8782" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_KitePharmaIncMember_f3daa514-6ed9-446f-801b-bdf3035e8782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_2283b721-dadc-4570-b2ae-ac5021fc5d57" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_SanofiMember_2283b721-dadc-4570-b2ae-ac5021fc5d57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_e29978a2-8293-441c-b01f-56a583ef893b" xlink:href="sgmo-20210331.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_PfizerMember_e29978a2-8293-441c-b01f-56a583ef893b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20ffecee-3ca4-43f4-9108-c2a2729fff83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20ffecee-3ca4-43f4-9108-c2a2729fff83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8b771641-7bac-4bf3-a1f4-6fe000ca1e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20ffecee-3ca4-43f4-9108-c2a2729fff83" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8b771641-7bac-4bf3-a1f4-6fe000ca1e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_132bea6d-e262-487a-82e0-331f155c8134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_132bea6d-e262-487a-82e0-331f155c8134" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_132bea6d-e262-487a-82e0-331f155c8134_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_132bea6d-e262-487a-82e0-331f155c8134" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_132bea6d-e262-487a-82e0-331f155c8134_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8fd4a2ad-caa0-484d-a7a6-c73a04d12fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_132bea6d-e262-487a-82e0-331f155c8134" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8fd4a2ad-caa0-484d-a7a6-c73a04d12fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_d141bf12-43e9-4fcd-a5ed-5d6685c37eb8" xlink:href="sgmo-20210331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8fd4a2ad-caa0-484d-a7a6-c73a04d12fee" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_d141bf12-43e9-4fcd-a5ed-5d6685c37eb8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="extended" id="i755b0f9888724772a139aca388bfe1f4_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended" id="i53286189b46147fe93a815d0e540e20f_FAIRVALUEMEASUREMENTS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended" id="ie633314269ea4867b7e424b81fe03a46_FAIRVALUEMEASUREMENTSTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended" id="i2582b5633e8b43388e944c4b3a9e1ba1_FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7ce24f3c-d180-4a2f-a17d-0dd608aa2c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7ce24f3c-d180-4a2f-a17d-0dd608aa2c2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8adf38b-7c9b-47cd-8ea4-e0f0843d84ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8adf38b-7c9b-47cd-8ea4-e0f0843d84ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6e31b4f5-a485-46ba-a5e9-2d65b0744464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6e31b4f5-a485-46ba-a5e9-2d65b0744464" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6d69fa4-63a4-437d-aa23-fb76cd509576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6d69fa4-63a4-437d-aa23-fb76cd509576" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6d69fa4-63a4-437d-aa23-fb76cd509576_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6d69fa4-63a4-437d-aa23-fb76cd509576" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6d69fa4-63a4-437d-aa23-fb76cd509576_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7eb19522-67d5-49da-a383-b4f9ed8c106e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6d69fa4-63a4-437d-aa23-fb76cd509576" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7eb19522-67d5-49da-a383-b4f9ed8c106e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_58de6d90-78ff-45e4-8df5-83535f44dab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7eb19522-67d5-49da-a383-b4f9ed8c106e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_58de6d90-78ff-45e4-8df5-83535f44dab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_45329ffb-00be-4e0c-a15d-bd32e56badda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_45329ffb-00be-4e0c-a15d-bd32e56badda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45329ffb-00be-4e0c-a15d-bd32e56badda_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_45329ffb-00be-4e0c-a15d-bd32e56badda" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_45329ffb-00be-4e0c-a15d-bd32e56badda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_45329ffb-00be-4e0c-a15d-bd32e56badda" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b8fab84f-3eb6-4ca5-8e1d-2f38debd40ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b8fab84f-3eb6-4ca5-8e1d-2f38debd40ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_357367f5-3b22-4240-9fe8-77cd03a5b649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_357367f5-3b22-4240-9fe8-77cd03a5b649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_95b1382a-150b-4521-bdf2-e4950b43bdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_95b1382a-150b-4521-bdf2-e4950b43bdfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_31c5d7ee-de06-4b72-84e2-e056fde01f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_31c5d7ee-de06-4b72-84e2-e056fde01f84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31c5d7ee-de06-4b72-84e2-e056fde01f84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_31c5d7ee-de06-4b72-84e2-e056fde01f84" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31c5d7ee-de06-4b72-84e2-e056fde01f84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_31c5d7ee-de06-4b72-84e2-e056fde01f84" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9d0a47fa-4e45-4d53-b41b-8b2c5adc86bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9d0a47fa-4e45-4d53-b41b-8b2c5adc86bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_226c8a9a-306a-4ba5-892a-94ef967920ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_CommercialPaperMember_226c8a9a-306a-4ba5-892a-94ef967920ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_03a39a77-05ea-4c11-afa1-6b5d83753066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_03a39a77-05ea-4c11-afa1-6b5d83753066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_cc364918-53bf-4f76-bf1e-1ba7de1b879f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_cc364918-53bf-4f76-bf1e-1ba7de1b879f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_aa62a8b3-f4bf-44b6-b601-b2cd6dc2a4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_aa62a8b3-f4bf-44b6-b601-b2cd6dc2a4c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2411dadc-d822-4aff-9ac9-8c6596499911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2411dadc-d822-4aff-9ac9-8c6596499911" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_6c78e18e-8943-486b-8616-773c51b523c1" xlink:href="sgmo-20210331.xsd#sgmo_FreeSharesAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_sgmo_FreeSharesAssetMember_6c78e18e-8943-486b-8616-773c51b523c1" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="extended" id="i85ab7e9918d64f909ca64e886d42123a_FAIRVALUEMEASUREMENTSNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_e6748284-a6b5-4bb2-a177-9bd438cd2d22" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_e6748284-a6b5-4bb2-a177-9bd438cd2d22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_fd15e9c5-18af-4030-92d5-96cb46eedc14" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_fd15e9c5-18af-4030-92d5-96cb46eedc14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1352a2ac-92b5-4de8-b506-9764b6c02faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1352a2ac-92b5-4de8-b506-9764b6c02faf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_22433eac-83fc-41d8-8048-650191d9c2d2" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_22433eac-83fc-41d8-8048-650191d9c2d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_045c4065-5f3f-4938-abd6-8288594cdedd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_045c4065-5f3f-4938-abd6-8288594cdedd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_045c4065-5f3f-4938-abd6-8288594cdedd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_045c4065-5f3f-4938-abd6-8288594cdedd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_045c4065-5f3f-4938-abd6-8288594cdedd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_830adf65-e77b-49bf-8e58-bb8eaa20bf83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_045c4065-5f3f-4938-abd6-8288594cdedd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_830adf65-e77b-49bf-8e58-bb8eaa20bf83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_12b74c9b-673f-408a-adcc-4b3c11a2e55f" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_830adf65-e77b-49bf-8e58-bb8eaa20bf83" xlink:to="loc_sgmo_SangamoFranceMember_12b74c9b-673f-408a-adcc-4b3c11a2e55f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4a18cf98-6e00-448b-8d0c-76f5ecab5681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4a18cf98-6e00-448b-8d0c-76f5ecab5681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a18cf98-6e00-448b-8d0c-76f5ecab5681_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a18cf98-6e00-448b-8d0c-76f5ecab5681" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a18cf98-6e00-448b-8d0c-76f5ecab5681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d354b02b-173b-4927-8583-458c08cf3450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a18cf98-6e00-448b-8d0c-76f5ecab5681" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d354b02b-173b-4927-8583-458c08cf3450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_99efc5b6-c2b9-4ccb-92ee-e72cf0b4f363" xlink:href="sgmo-20210331.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d354b02b-173b-4927-8583-458c08cf3450" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_99efc5b6-c2b9-4ccb-92ee-e72cf0b4f363" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="extended" id="iddb56f8e98044da18829564a2d9df195_FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0c5a16f3-9d80-4075-bc84-0b32979ba4eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_SharePrice_0c5a16f3-9d80-4075-bc84-0b32979ba4eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_bf1a2728-f813-428c-8439-58c5ad3fea9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_bf1a2728-f813-428c-8439-58c5ad3fea9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_fe624ef8-4997-4238-94fd-c53659161c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_fe624ef8-4997-4238-94fd-c53659161c48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_38d86878-d648-4ce8-bb9f-170cb5f6af5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_38d86878-d648-4ce8-bb9f-170cb5f6af5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_eef66926-8c17-4cb8-9da3-7b2ef8e1754d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_eef66926-8c17-4cb8-9da3-7b2ef8e1754d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b9fa858c-54f8-4068-a516-23de894004c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b9fa858c-54f8-4068-a516-23de894004c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9fa858c-54f8-4068-a516-23de894004c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b9fa858c-54f8-4068-a516-23de894004c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b9fa858c-54f8-4068-a516-23de894004c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43508ac2-4778-4518-b67a-ce1cdf162cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b9fa858c-54f8-4068-a516-23de894004c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43508ac2-4778-4518-b67a-ce1cdf162cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_3682c2cb-61f0-4665-acd8-858518d745c8" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43508ac2-4778-4518-b67a-ce1cdf162cee" xlink:to="loc_sgmo_SangamoFranceMember_3682c2cb-61f0-4665-acd8-858518d745c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_8e5b900b-02d8-4728-a960-fe88cb3430d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_8e5b900b-02d8-4728-a960-fe88cb3430d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_ac20f374-b9ba-4c00-be44-0ea58d4cfe09" xlink:href="sgmo-20210331.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_sgmo_MeasurementInputExchangeRateMember_ac20f374-b9ba-4c00-be44-0ea58d4cfe09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_09605455-f4d5-4d8b-a75c-276b63695968" xlink:href="sgmo-20210331.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_09605455-f4d5-4d8b-a75c-276b63695968" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_ab9db789-b36a-4f5f-804b-066fe75c36c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_ab9db789-b36a-4f5f-804b-066fe75c36c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b595fb47-abed-4f2e-a2e9-5d4a1d9838e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b595fb47-abed-4f2e-a2e9-5d4a1d9838e6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended" id="i2bd6b1b3bed547f48bd1664cdb9af1b7_CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended" id="ia8b034f70baf4e1b8933bd94d0647f9e_CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="i4fe261e71784414e929754a695e0df1b_CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_070e807a-6eb7-4bd0-97e9-3a978b97b394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_070e807a-6eb7-4bd0-97e9-3a978b97b394" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_66197ca8-c555-43c3-a10e-27e94de7e69a" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_66197ca8-c555-43c3-a10e-27e94de7e69a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6c769474-d759-4eb9-99a2-78a8afca4306" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6c769474-d759-4eb9-99a2-78a8afca4306" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97b6996b-e41a-4865-9467-51a461161a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97b6996b-e41a-4865-9467-51a461161a43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_adb6c637-05c4-486c-9caa-f42e5985dd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_adb6c637-05c4-486c-9caa-f42e5985dd06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2a40acc0-2d73-4692-b3b8-5da467d53c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2a40acc0-2d73-4692-b3b8-5da467d53c15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_afb3f280-aeb0-4c5e-b5bc-7f36bdc4ebc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_afb3f280-aeb0-4c5e-b5bc-7f36bdc4ebc3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1823f506-f93a-45a8-917c-ca753cfc45a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1823f506-f93a-45a8-917c-ca753cfc45a3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_279f50d3-d0ca-41fe-a81c-e4a751bdfa49" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_279f50d3-d0ca-41fe-a81c-e4a751bdfa49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_551780bc-b759-4d9c-bb7f-42d34d17b686" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_551780bc-b759-4d9c-bb7f-42d34d17b686" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_59aebc95-94c5-4bfb-9c93-122bdc30c618" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_59aebc95-94c5-4bfb-9c93-122bdc30c618" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3bb8a5f4-3186-48c7-bb95-295d78e6d42c" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3bb8a5f4-3186-48c7-bb95-295d78e6d42c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9e4d6e21-5f2e-4b50-a4eb-c6bb272ff833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9e4d6e21-5f2e-4b50-a4eb-c6bb272ff833" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_59588efc-9703-4757-a885-5ff2277c268a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9e4d6e21-5f2e-4b50-a4eb-c6bb272ff833" xlink:to="loc_us-gaap_FinancialInstrumentAxis_59588efc-9703-4757-a885-5ff2277c268a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59588efc-9703-4757-a885-5ff2277c268a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_59588efc-9703-4757-a885-5ff2277c268a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59588efc-9703-4757-a885-5ff2277c268a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_59588efc-9703-4757-a885-5ff2277c268a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_02340082-0b27-4ab8-81ee-f4ae56460ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_MoneyMarketFundsMember_02340082-0b27-4ab8-81ee-f4ae56460ffc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_19b40382-8ecc-489f-9803-79807b6c8b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_CommercialPaperMember_19b40382-8ecc-489f-9803-79807b6c8b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9a79fef4-2ea1-41f0-896f-ffb927bdc291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9a79fef4-2ea1-41f0-896f-ffb927bdc291" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a62a119e-6836-4dd0-9458-ddd965dfc195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a62a119e-6836-4dd0-9458-ddd965dfc195" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b7a7245b-d884-40b0-b0e5-f60f59e3ce14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b7a7245b-d884-40b0-b0e5-f60f59e3ce14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_edaaa586-85b2-41fe-8770-550a5713b741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_CashEquivalentsMember_edaaa586-85b2-41fe-8770-550a5713b741" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_be29a8a6-d992-4d8e-baa9-5af7cf929e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_be29a8a6-d992-4d8e-baa9-5af7cf929e32" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended" id="i3abf368ef5f44045a47b7f120a3dba6a_CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended" id="i384a465af0d24fcabd929b8663d38256_CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20210331.xsd#BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="extended" id="iedfb4f271d6448b399cf0d18fba167fc_BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="extended" id="i017ca112e0854ef4a4c040cb3860b444_BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended" id="iba4626c7552e465c86314b752d4870f9_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended" id="i812f4409dbd841fc932be62603c16efc_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_24dae7e2-dbb0-4856-86b0-aec0d560cd24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_e548435b-5e84-4739-8357-583cf406e1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_24dae7e2-dbb0-4856-86b0-aec0d560cd24" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_e548435b-5e84-4739-8357-583cf406e1f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_390c2842-90b4-4283-b5e2-911071e8d8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_24dae7e2-dbb0-4856-86b0-aec0d560cd24" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_390c2842-90b4-4283-b5e2-911071e8d8d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_78edcfe8-9046-451d-91b2-9ffe7c855a89" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_390c2842-90b4-4283-b5e2-911071e8d8d9" xlink:to="loc_srt_CounterpartyNameAxis_78edcfe8-9046-451d-91b2-9ffe7c855a89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78edcfe8-9046-451d-91b2-9ffe7c855a89_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_78edcfe8-9046-451d-91b2-9ffe7c855a89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_78edcfe8-9046-451d-91b2-9ffe7c855a89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6058117-e176-41ee-9d2a-4e3c1ac00e0d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_78edcfe8-9046-451d-91b2-9ffe7c855a89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6058117-e176-41ee-9d2a-4e3c1ac00e0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_97db0897-964c-4e59-a869-fb5e0ac39634" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6058117-e176-41ee-9d2a-4e3c1ac00e0d" xlink:to="loc_sgmo_KitePharmaIncMember_97db0897-964c-4e59-a869-fb5e0ac39634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_9ca961e9-6d37-4977-89f9-8e39a2a872da" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6058117-e176-41ee-9d2a-4e3c1ac00e0d" xlink:to="loc_sgmo_SanofiMember_9ca961e9-6d37-4977-89f9-8e39a2a872da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="extended" id="i1f4fb6fd09144a3cbc89e02a3102319d_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_8611f586-84c3-44c3-a5e0-68cc63af5f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ProceedsFromCollaborators_8611f586-84c3-44c3-a5e0-68cc63af5f47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c0fe180f-80a6-4797-93db-c6b3405469b2" xlink:href="sgmo-20210331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c0fe180f-80a6-4797-93db-c6b3405469b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_5e960bef-0eb3-488a-825e-fd9c725a8a1e" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_5e960bef-0eb3-488a-825e-fd9c725a8a1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_e6c79a0f-2dc0-42a7-b5fa-f91cfbd33ec2" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_e6c79a0f-2dc0-42a7-b5fa-f91cfbd33ec2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_a3c0a003-8774-44fa-9903-5799e74cbbd4" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_a3c0a003-8774-44fa-9903-5799e74cbbd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43545ee3-31f2-46a8-b2e7-d7d8744eff25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43545ee3-31f2-46a8-b2e7-d7d8744eff25" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12d02a2c-f0f7-43c7-8c77-fada67138bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12d02a2c-f0f7-43c7-8c77-fada67138bee" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0f4d678e-9b45-4737-88ad-5966a5c6cd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0f4d678e-9b45-4737-88ad-5966a5c6cd4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_47681df4-5df5-443d-96cd-7bcf10375b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_47681df4-5df5-443d-96cd-7bcf10375b9e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8fb894c5-62e7-4f7e-9bea-0b9eafb9a9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8fb894c5-62e7-4f7e-9bea-0b9eafb9a9d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_240cf9cb-9272-4392-8983-4c80fcd8b283" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_240cf9cb-9272-4392-8983-4c80fcd8b283" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_126fce9e-76aa-4827-b6ec-f322cba3e809" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_126fce9e-76aa-4827-b6ec-f322cba3e809" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_5faa0721-4fde-46fe-8577-cb3d6a2d3525" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_5faa0721-4fde-46fe-8577-cb3d6a2d3525" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_155b10d6-cea9-45b0-95a8-95cd00ee0b7b" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_155b10d6-cea9-45b0-95a8-95cd00ee0b7b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_da90bfa5-ff11-4d96-8117-b2802c3f2853" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_da90bfa5-ff11-4d96-8117-b2802c3f2853" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_d310804b-2d29-44f9-b076-eb528e34cc40" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_d310804b-2d29-44f9-b076-eb528e34cc40" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_9b6b9977-a4f0-40b8-9e5d-cef52bd61d67" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_9b6b9977-a4f0-40b8-9e5d-cef52bd61d67" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_1d822a30-2f21-4c1b-bd48-5eeaef0c30e4" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_1d822a30-2f21-4c1b-bd48-5eeaef0c30e4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_53bbcae0-ebc7-4888-9124-df9159277e84" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_53bbcae0-ebc7-4888-9124-df9159277e84" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_ffac8350-fb28-422e-8ac3-aef5dac558d5" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_ffac8350-fb28-422e-8ac3-aef5dac558d5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_c455aaf1-3520-4c80-b641-5bb876fad35f" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_c455aaf1-3520-4c80-b641-5bb876fad35f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d060df59-94ba-4e5f-b8a6-86d9c910fe25" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d060df59-94ba-4e5f-b8a6-86d9c910fe25" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_49f90424-535f-4142-bb2b-e69ae3b34eca" xlink:href="sgmo-20210331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_49f90424-535f-4142-bb2b-e69ae3b34eca" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_fb995580-e1e7-4ed9-89ab-18fb2c2ab098" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_fb995580-e1e7-4ed9-89ab-18fb2c2ab098" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_089fc26b-3a7d-4532-bab0-c1dde19774c5" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_089fc26b-3a7d-4532-bab0-c1dde19774c5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_1186e382-dcee-459c-9cab-e9f722c7bf42" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_1186e382-dcee-459c-9cab-e9f722c7bf42" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_49f43552-efa6-4f43-bed8-1e500bcf9a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_49f43552-efa6-4f43-bed8-1e500bcf9a04" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_45e5145c-b8dc-49d8-aba8-e227a910b86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_45e5145c-b8dc-49d8-aba8-e227a910b86a" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_9bf811f8-8d7c-440d-ad13-f2129a0055bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_9bf811f8-8d7c-440d-ad13-f2129a0055bd" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_5068ab3d-ef93-4f28-a6cf-92d2f5c216a0" xlink:href="sgmo-20210331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_MilestonePaymentsReceived_5068ab3d-ef93-4f28-a6cf-92d2f5c216a0" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_257e4132-091e-4a9a-9a0f-9c3f9cac3d68" xlink:href="sgmo-20210331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_257e4132-091e-4a9a-9a0f-9c3f9cac3d68" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_79218a89-cf7b-4544-8579-24845a9a249a" xlink:href="sgmo-20210331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_79218a89-cf7b-4544-8579-24845a9a249a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_e297a7ff-6944-4752-9ead-8650887a0cb7" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_e297a7ff-6944-4752-9ead-8650887a0cb7" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_511601e9-2da0-4122-9820-601c8b0a5212" xlink:href="sgmo-20210331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_511601e9-2da0-4122-9820-601c8b0a5212" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_3d6444bf-05af-46e1-8629-8d5fd0f131ea" xlink:href="sgmo-20210331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_SeparateUpfrontFee_3d6444bf-05af-46e1-8629-8d5fd0f131ea" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_edf571c0-c01e-43df-820c-76c3b346d2d5" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_edf571c0-c01e-43df-820c-76c3b346d2d5" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_9a2a57c6-3650-4cc6-9f68-d401a8fbaa48" xlink:href="sgmo-20210331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_AgreementTerminationTerm_9a2a57c6-3650-4cc6-9f68-d401a8fbaa48" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8aa5f3f8-9389-4f63-9f3f-bbb6e048106d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8aa5f3f8-9389-4f63-9f3f-bbb6e048106d" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_39d69764-1796-4710-92bb-f328c7d32ae9" xlink:href="sgmo-20210331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_39d69764-1796-4710-92bb-f328c7d32ae9" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_f6decf39-9a76-466d-808e-8a6d29541c2c" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_MilestoneRevenueReceivable_f6decf39-9a76-466d-808e-8a6d29541c2c" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_1c4fd515-46b2-4cdc-95b0-60710307c83a" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_1c4fd515-46b2-4cdc-95b0-60710307c83a" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_1003f9d4-463c-40b4-bc88-e7ce0c6eee74" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_1003f9d4-463c-40b4-bc88-e7ce0c6eee74" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_896c83cd-2320-448d-9240-f42e89b59dce" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_896c83cd-2320-448d-9240-f42e89b59dce" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_96aa1d01-d97e-42ac-bf93-8e8fd9b0cb1e" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_96aa1d01-d97e-42ac-bf93-8e8fd9b0cb1e" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_4f1d6c18-faf6-42e6-8810-1ebaf2f70506" xlink:href="sgmo-20210331.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_4f1d6c18-faf6-42e6-8810-1ebaf2f70506" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_3d55f2da-94d6-46be-bdc6-c738e4e0f67f" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_NumberOfResearchProgram_3d55f2da-94d6-46be-bdc6-c738e4e0f67f" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal_65a34fcd-9f05-4ffe-b409-b06606117bec" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMilestoneRevenueReversal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal_65a34fcd-9f05-4ffe-b409-b06606117bec" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_55257662-18a1-4528-b825-57ad96f4ec0f" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_55257662-18a1-4528-b825-57ad96f4ec0f" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_c18759ea-bdda-4192-8147-0c50e7ded8ec" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_c18759ea-bdda-4192-8147-0c50e7ded8ec" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_301dccff-1bc4-409f-b446-7ed85dea3fe0" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_301dccff-1bc4-409f-b446-7ed85dea3fe0" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_493044c7-84db-4a4b-b9b0-ef1c4903f044" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_493044c7-84db-4a4b-b9b0-ef1c4903f044" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_edc57c8a-5b95-4561-88ed-b72fd103f572" xlink:href="sgmo-20210331.xsd#sgmo_GrantFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_GrantFundingAmount_edc57c8a-5b95-4561-88ed-b72fd103f572" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce466267-b940-4076-9d2e-96210c15dcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2893e604-b3aa-4fbe-863b-eef47247f06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2893e604-b3aa-4fbe-863b-eef47247f06a" xlink:type="arc" order="53"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3a829b6c-afaf-4f7a-886c-5a9812b39cc3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_srt_CounterpartyNameAxis_3a829b6c-afaf-4f7a-886c-5a9812b39cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a829b6c-afaf-4f7a-886c-5a9812b39cc3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3a829b6c-afaf-4f7a-886c-5a9812b39cc3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a829b6c-afaf-4f7a-886c-5a9812b39cc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3a829b6c-afaf-4f7a-886c-5a9812b39cc3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6914cc92-63e7-414f-8cca-c02c6e7a99c0" xlink:href="sgmo-20210331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6914cc92-63e7-414f-8cca-c02c6e7a99c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_d3dbf7a1-9487-42ce-8bb7-1ae53f688d31" xlink:href="sgmo-20210331.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_BiogenMAIncMember_d3dbf7a1-9487-42ce-8bb7-1ae53f688d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_f923039b-b433-426e-9f59-4c281869f84f" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_KitePharmaIncMember_f923039b-b433-426e-9f59-4c281869f84f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_beee8be9-05d5-4bc5-a9b1-db77d3cd0053" xlink:href="sgmo-20210331.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_PfizerMember_beee8be9-05d5-4bc5-a9b1-db77d3cd0053" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_10df3d11-4b8d-4c06-99b9-afdba6d6dbfd" xlink:href="sgmo-20210331.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_PfizerSB525Member_10df3d11-4b8d-4c06-99b9-afdba6d6dbfd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_f5ce96e9-e322-428d-bc35-0644f9f45954" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_SanofiMember_f5ce96e9-e322-428d-bc35-0644f9f45954" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d16cc420-46ca-407f-87a9-70c7352c975e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d16cc420-46ca-407f-87a9-70c7352c975e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d16cc420-46ca-407f-87a9-70c7352c975e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d16cc420-46ca-407f-87a9-70c7352c975e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d16cc420-46ca-407f-87a9-70c7352c975e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2b0f5d7-c1f9-43df-875b-390a62b40de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d16cc420-46ca-407f-87a9-70c7352c975e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2b0f5d7-c1f9-43df-875b-390a62b40de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_6fb1d236-3611-454f-8da0-b7b9407c9bac" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2b0f5d7-c1f9-43df-875b-390a62b40de9" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_6fb1d236-3611-454f-8da0-b7b9407c9bac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_4ca61d62-1249-4b0e-a254-e3ae34fdefd0" xlink:href="sgmo-20210331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2b0f5d7-c1f9-43df-875b-390a62b40de9" xlink:to="loc_sgmo_StockPurchaseAgreementMember_4ca61d62-1249-4b0e-a254-e3ae34fdefd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c9d8cbff-31fb-4321-a8f3-03a0734817aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c9d8cbff-31fb-4321-a8f3-03a0734817aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c9d8cbff-31fb-4321-a8f3-03a0734817aa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c9d8cbff-31fb-4321-a8f3-03a0734817aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_c9d8cbff-31fb-4321-a8f3-03a0734817aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c9d8cbff-31fb-4321-a8f3-03a0734817aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_56751186-dced-4ca8-b56a-c0e5710e3078" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_56751186-dced-4ca8-b56a-c0e5710e3078" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_e6718451-7ce2-490d-a121-fff5b3b074e4" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_e6718451-7ce2-490d-a121-fff5b3b074e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_c9a269ef-4806-4388-92a8-e2e21dfcc31b" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_c9a269ef-4806-4388-92a8-e2e21dfcc31b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_856b0cdb-93b3-49fa-9420-ae258de8e35f" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_856b0cdb-93b3-49fa-9420-ae258de8e35f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_8334cca6-fd50-4c64-9257-73efc5198505" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_8334cca6-fd50-4c64-9257-73efc5198505" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_12af563c-39f3-4b09-a650-94ab25fc31e4" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_12af563c-39f3-4b09-a650-94ab25fc31e4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_02dc45fc-11e0-4fbd-acfc-fe1ad6d7844f" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_02dc45fc-11e0-4fbd-acfc-fe1ad6d7844f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_6625e70f-bc71-4a35-b656-40429f3a47e6" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_6625e70f-bc71-4a35-b656-40429f3a47e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_7e19ea46-8c8e-45f2-8d51-2d3099ca012f" xlink:href="sgmo-20210331.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_7e19ea46-8c8e-45f2-8d51-2d3099ca012f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_9945277f-ac24-4f61-98c7-65f341f67a97" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_9945277f-ac24-4f61-98c7-65f341f67a97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_9945277f-ac24-4f61-98c7-65f341f67a97_default" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_9945277f-ac24-4f61-98c7-65f341f67a97" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_9945277f-ac24-4f61-98c7-65f341f67a97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_9945277f-ac24-4f61-98c7-65f341f67a97" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_c26bb025-70a3-4e3c-87a8-a3b613e8b751" xlink:href="sgmo-20210331.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_PreApprovalMilestoneMember_c26bb025-70a3-4e3c-87a8-a3b613e8b751" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_92b86916-c1e3-41f4-9d0c-25f877148077" xlink:href="sgmo-20210331.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_SalesBasedMilestoneMember_92b86916-c1e3-41f4-9d0c-25f877148077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_34e38217-2db4-4ef8-b88a-1906b03e0cf0" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_MilestoneTwoMember_34e38217-2db4-4ef8-b88a-1906b03e0cf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_316d65cb-64e5-41bf-9d3e-863c6c8de4e7" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_MilestoneThreeMember_316d65cb-64e5-41bf-9d3e-863c6c8de4e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_47305399-1c9a-46c2-a335-e2893261a5af" xlink:href="sgmo-20210331.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_47305399-1c9a-46c2-a335-e2893261a5af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PhaseThreeClinicalTrialMember_07ba53bf-f918-4912-b51a-69192abcae6e" xlink:href="sgmo-20210331.xsd#sgmo_PhaseThreeClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_PhaseThreeClinicalTrialMember_07ba53bf-f918-4912-b51a-69192abcae6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_74a41027-74b2-4d81-a220-d79751940b46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_srt_RangeAxis_74a41027-74b2-4d81-a220-d79751940b46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74a41027-74b2-4d81-a220-d79751940b46_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_74a41027-74b2-4d81-a220-d79751940b46" xlink:to="loc_srt_RangeMember_74a41027-74b2-4d81-a220-d79751940b46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c0c956c-bd12-40c5-88fe-a8c346a5fdda" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_74a41027-74b2-4d81-a220-d79751940b46" xlink:to="loc_srt_RangeMember_8c0c956c-bd12-40c5-88fe-a8c346a5fdda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7cb45341-524f-4aaa-a997-c8b8e215c5eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8c0c956c-bd12-40c5-88fe-a8c346a5fdda" xlink:to="loc_srt_MaximumMember_7cb45341-524f-4aaa-a997-c8b8e215c5eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_srt_ProductOrServiceAxis_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c" xlink:to="loc_srt_ProductsAndServicesDomain_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c" xlink:to="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_3f929a1e-3567-4f43-83ea-8db3679a400e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_us-gaap_LicenseAndServiceMember_3f929a1e-3567-4f43-83ea-8db3679a400e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_e210ade7-c1a8-460d-8c1c-298cabbb8bf7" xlink:href="sgmo-20210331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_e210ade7-c1a8-460d-8c1c-298cabbb8bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_8519bd05-b282-4475-8641-fde6cae4bfd8" xlink:href="sgmo-20210331.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_SBFiveTwoFiveMember_8519bd05-b282-4475-8641-fde6cae4bfd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_10b20771-4c8a-49ad-a3db-4e35f417d79b" xlink:href="sgmo-20210331.xsd#sgmo_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_OtherProductsMember_10b20771-4c8a-49ad-a3db-4e35f417d79b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_63a0de69-40c7-4818-aca8-c25c3fd215bf" xlink:href="sgmo-20210331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_CNineORFSevenTwoMember_63a0de69-40c7-4818-aca8-c25c3fd215bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_60940aca-9b4a-43f7-aef2-167467ef0c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_us-gaap_GrantMember_60940aca-9b4a-43f7-aef2-167467ef0c38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_9815a48a-3f8e-4d8a-882e-b234e30abc73" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_MilestoneAchievementMember_9815a48a-3f8e-4d8a-882e-b234e30abc73" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_39918ce6-f2f9-443c-b1ae-3bec77756cf5" xlink:href="sgmo-20210331.xsd#sgmo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_ResearchServicesMember_39918ce6-f2f9-443c-b1ae-3bec77756cf5" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended" id="i6818ae1b2e7443b8a13fcc26f6bb9400_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_38a2e688-2447-498d-b9ef-5e76ce4dc03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54fdb0c-6363-4515-b260-0985b4de1da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_38a2e688-2447-498d-b9ef-5e76ce4dc03a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54fdb0c-6363-4515-b260-0985b4de1da3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_38a2e688-2447-498d-b9ef-5e76ce4dc03a" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:to="loc_srt_CounterpartyNameAxis_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d250c98f-7908-4847-bca6-785cbbc380af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d250c98f-7908-4847-bca6-785cbbc380af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_723e63be-a385-4cba-9557-446fcf96aff7" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d250c98f-7908-4847-bca6-785cbbc380af" xlink:to="loc_sgmo_KitePharmaIncMember_723e63be-a385-4cba-9557-446fcf96aff7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_a402e632-bbc1-4e01-bd0c-a0dcdcda8809" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d250c98f-7908-4847-bca6-785cbbc380af" xlink:to="loc_sgmo_SanofiMember_a402e632-bbc1-4e01-bd0c-a0dcdcda8809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe80141c-a041-4669-b73f-6bcd26a2fd94" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:to="loc_srt_ProductOrServiceAxis_fe80141c-a041-4669-b73f-6bcd26a2fd94" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe80141c-a041-4669-b73f-6bcd26a2fd94_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fe80141c-a041-4669-b73f-6bcd26a2fd94" xlink:to="loc_srt_ProductsAndServicesDomain_fe80141c-a041-4669-b73f-6bcd26a2fd94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fe80141c-a041-4669-b73f-6bcd26a2fd94" xlink:to="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c720854e-6e12-48b1-b367-580de87d8fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:to="loc_us-gaap_LicenseAndServiceMember_c720854e-6e12-48b1-b367-580de87d8fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_5c6674a1-a503-4f04-a5bc-74f3983ae3ee" xlink:href="sgmo-20210331.xsd#sgmo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:to="loc_sgmo_ResearchServicesMember_5c6674a1-a503-4f04-a5bc-74f3983ae3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_ad41b2a6-ac05-4fea-9ba7-9c020c6cdca3" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:to="loc_sgmo_MilestoneAchievementMember_ad41b2a6-ac05-4fea-9ba7-9c020c6cdca3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#INCOMETAXES"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/INCOMETAXES" xlink:type="extended" id="i13b87dc5e65541428592d65d7619e5af_INCOMETAXES"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="sgmo-20210331.xsd#INCOMETAXESDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="extended" id="i56cb85f751ec47d1a980bc134e1c3984_INCOMETAXESDetails"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTS" xlink:type="extended" id="ica40422e4604411d8216a250490fc825_COMMITMENTS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSTables" xlink:type="extended" id="i7e5ddc78ccd0402dbef1454e1176563f_COMMITMENTSTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="extended" id="i52bfd7f3aa014a04b20d3d18ed6aa6bb_COMMITMENTSAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:href="sgmo-20210331.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_e8aa4c22-6989-44ac-97f2-60160343e332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_e8aa4c22-6989-44ac-97f2-60160343e332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_645daa1b-cb05-43dd-b168-026efe4cbbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_645daa1b-cb05-43dd-b168-026efe4cbbd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cefeefbc-252a-463c-a1f3-22e7368ae48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_OperatingLeaseCost_cefeefbc-252a-463c-a1f3-22e7368ae48c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_df7ebcc1-d15c-4c0d-b7a5-400074551ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_VariableLeaseCost_df7ebcc1-d15c-4c0d-b7a5-400074551ff9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_af01ba84-72da-4d81-b26b-d09565e2be04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_OperatingLeasePayments_af01ba84-72da-4d81-b26b-d09565e2be04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_110c3195-0d40-4c33-a0b3-19b46728c9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_110c3195-0d40-4c33-a0b3-19b46728c9da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_59f497ed-d756-445a-981e-08425ae1a410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_59f497ed-d756-445a-981e-08425ae1a410" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate_01bdf273-54ed-4713-96d9-b39358b1b840" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseAreaOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate_01bdf273-54ed-4713-96d9-b39358b1b840" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAmount_4a9a859f-0c83-425a-8b6f-5a3a5312f46e" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_sgmo_LesseeOperatingLeaseAmount_4a9a859f-0c83-425a-8b6f-5a3a5312f46e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_e52afbba-8451-46b3-957e-a9c004fa6724" xlink:href="sgmo-20210331.xsd#sgmo_LicenseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_sgmo_LicenseObligations_e52afbba-8451-46b3-957e-a9c004fa6724" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:href="sgmo-20210331.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_e51ed51a-a1b1-4f35-86ea-5d65a77b25c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_e51ed51a-a1b1-4f35-86ea-5d65a77b25c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_1978eca0-dbc6-4522-8a65-eb9facf0aa11" xlink:href="sgmo-20210331.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_e51ed51a-a1b1-4f35-86ea-5d65a77b25c5" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_1978eca0-dbc6-4522-8a65-eb9facf0aa11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5d7ba94b-4fdc-4488-b120-3abec2d4508b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5d7ba94b-4fdc-4488-b120-3abec2d4508b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5d7ba94b-4fdc-4488-b120-3abec2d4508b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5d7ba94b-4fdc-4488-b120-3abec2d4508b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5d7ba94b-4fdc-4488-b120-3abec2d4508b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56c36292-f4f5-4e2d-8a98-a43c68a9ea8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5d7ba94b-4fdc-4488-b120-3abec2d4508b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56c36292-f4f5-4e2d-8a98-a43c68a9ea8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_b1327567-9cb3-4f3c-8d1d-42d7e8518a86" xlink:href="sgmo-20210331.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56c36292-f4f5-4e2d-8a98-a43c68a9ea8f" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_b1327567-9cb3-4f3c-8d1d-42d7e8518a86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_ef863f08-f072-4e34-b1a2-25bfdce86843" xlink:href="sgmo-20210331.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56c36292-f4f5-4e2d-8a98-a43c68a9ea8f" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_ef863f08-f072-4e34-b1a2-25bfdce86843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_srt_StatementGeographicalAxis_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f" xlink:to="loc_srt_SegmentGeographicalDomain_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f" xlink:to="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_da4db150-2bfd-486a-bfcc-b2af98595cf4" xlink:href="sgmo-20210331.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_da4db150-2bfd-486a-bfcc-b2af98595cf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_28a8dc4f-7720-4dd5-9f76-eb76149fb357" xlink:href="sgmo-20210331.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:to="loc_sgmo_RichmondCaliforniaMember_28a8dc4f-7720-4dd5-9f76-eb76149fb357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_65621243-b38f-4483-82e0-8a085d929e0a" xlink:href="sgmo-20210331.xsd#sgmo_ValbonneFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:to="loc_sgmo_ValbonneFranceMember_65621243-b38f-4483-82e0-8a085d929e0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_755752f2-2438-424e-9ef5-f4030a5f547f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_srt_RangeAxis_755752f2-2438-424e-9ef5-f4030a5f547f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_755752f2-2438-424e-9ef5-f4030a5f547f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_755752f2-2438-424e-9ef5-f4030a5f547f" xlink:to="loc_srt_RangeMember_755752f2-2438-424e-9ef5-f4030a5f547f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8a559f0-7ed1-4092-97f9-58a93d03d807" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_755752f2-2438-424e-9ef5-f4030a5f547f" xlink:to="loc_srt_RangeMember_e8a559f0-7ed1-4092-97f9-58a93d03d807" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b99cabcb-2481-4c20-a767-064365e878ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8a559f0-7ed1-4092-97f9-58a93d03d807" xlink:to="loc_srt_MinimumMember_b99cabcb-2481-4c20-a767-064365e878ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c32c2ff1-5fba-4492-9363-a5f2ed306147" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8a559f0-7ed1-4092-97f9-58a93d03d807" xlink:to="loc_srt_MaximumMember_c32c2ff1-5fba-4492-9363-a5f2ed306147" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="extended" id="if24d167230bf454eab1e7da17fab9b08_COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="extended" id="i3bf9a45c49bf4e23bed3576b7afbf7fa_COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_13bb3c48-a738-4a47-904b-6960827c509b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_5631a8e3-85bd-4cef-8ae0-c0cf4ff3edd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_13bb3c48-a738-4a47-904b-6960827c509b" xlink:to="loc_us-gaap_ContractualObligation_5631a8e3-85bd-4cef-8ae0-c0cf4ff3edd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_042b5429-6936-4ecc-b245-6a32cf0d260c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_13bb3c48-a738-4a47-904b-6960827c509b" xlink:to="loc_us-gaap_OtherCommitmentsTable_042b5429-6936-4ecc-b245-6a32cf0d260c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_377699c6-8f40-4d67-a246-f9393ba25db4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_042b5429-6936-4ecc-b245-6a32cf0d260c" xlink:to="loc_srt_CounterpartyNameAxis_377699c6-8f40-4d67-a246-f9393ba25db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_377699c6-8f40-4d67-a246-f9393ba25db4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_377699c6-8f40-4d67-a246-f9393ba25db4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_377699c6-8f40-4d67-a246-f9393ba25db4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82a599a7-1de9-4baf-9b23-d8799be86cb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_377699c6-8f40-4d67-a246-f9393ba25db4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82a599a7-1de9-4baf-9b23-d8799be86cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember_d9d9b52f-6908-4b3e-bc1d-223ed4baf8da" xlink:href="sgmo-20210331.xsd#sgmo_BrammerBioMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82a599a7-1de9-4baf-9b23-d8799be86cb8" xlink:to="loc_sgmo_BrammerBioMAMember_d9d9b52f-6908-4b3e-bc1d-223ed4baf8da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember_7725ae5f-314a-46b4-b95d-73598a3e6c12" xlink:href="sgmo-20210331.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82a599a7-1de9-4baf-9b23-d8799be86cb8" xlink:to="loc_sgmo_LonzaNetherlandsBVMember_7725ae5f-314a-46b4-b95d-73598a3e6c12" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended" id="i7952251e4b134d7493a92ee1245cd144_STOCKBASEDCOMPENSATION"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended" id="id476f1d3936b4a10bb22f7e0e8f1f11b_STOCKBASEDCOMPENSATIONTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended" id="i82547a3bb8c94e10848295d7427d2ad2_STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a1c7f1ac-31d8-4481-ba46-ded21a17cf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_487b5b7c-6b31-4041-9cb4-2e613be38a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a1c7f1ac-31d8-4481-ba46-ded21a17cf4e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_487b5b7c-6b31-4041-9cb4-2e613be38a11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_48e89b56-b629-43e9-8203-c98bf40de4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a1c7f1ac-31d8-4481-ba46-ded21a17cf4e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_48e89b56-b629-43e9-8203-c98bf40de4d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6e438eaa-fccc-449a-b50e-6458a75daab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_48e89b56-b629-43e9-8203-c98bf40de4d4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6e438eaa-fccc-449a-b50e-6458a75daab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e438eaa-fccc-449a-b50e-6458a75daab9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6e438eaa-fccc-449a-b50e-6458a75daab9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e438eaa-fccc-449a-b50e-6458a75daab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_39dbab0d-e81e-411d-b102-6011e2c8e175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6e438eaa-fccc-449a-b50e-6458a75daab9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_39dbab0d-e81e-411d-b102-6011e2c8e175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d976d36e-28ac-4024-a609-e9fb82b6c492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39dbab0d-e81e-411d-b102-6011e2c8e175" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d976d36e-28ac-4024-a609-e9fb82b6c492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6fd42e79-d9e9-4b47-889d-c32ff51b325b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39dbab0d-e81e-411d-b102-6011e2c8e175" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6fd42e79-d9e9-4b47-889d-c32ff51b325b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended" id="i5cfcf986303e46f2a19ed58a7bc7ddcf_STOCKHOLDERSEQUITY"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKHOLDERSEQUITYNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="extended" id="ic16d0fce461645559aa37688ca538310_STOCKHOLDERSEQUITYNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ff116ad3-3455-4721-9fc4-c6996f84015c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ff116ad3-3455-4721-9fc4-c6996f84015c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_6a0d1ae0-a19c-4f37-9e46-b83876dc7eb8" xlink:href="sgmo-20210331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_6a0d1ae0-a19c-4f37-9e46-b83876dc7eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_71089fd9-df89-427a-8b9d-88b7af2956d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_71089fd9-df89-427a-8b9d-88b7af2956d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2cc7e2c0-7f45-4cfc-87ae-20a7a9ec5c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3fbaca0b-401b-477f-96e9-86b39aae94ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:to="loc_srt_CounterpartyNameAxis_3fbaca0b-401b-477f-96e9-86b39aae94ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fbaca0b-401b-477f-96e9-86b39aae94ce_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3fbaca0b-401b-477f-96e9-86b39aae94ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3fbaca0b-401b-477f-96e9-86b39aae94ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c71cc22d-666d-42b8-8e21-a9105c527d18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3fbaca0b-401b-477f-96e9-86b39aae94ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c71cc22d-666d-42b8-8e21-a9105c527d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_286dc002-8908-4fb0-808c-9976d8bca139" xlink:href="sgmo-20210331.xsd#sgmo_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c71cc22d-666d-42b8-8e21-a9105c527d18" xlink:to="loc_sgmo_JefferiesLLCMember_286dc002-8908-4fb0-808c-9976d8bca139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_875ef221-905c-49df-9b12-297ff7cbd7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_875ef221-905c-49df-9b12-297ff7cbd7ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_875ef221-905c-49df-9b12-297ff7cbd7ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_875ef221-905c-49df-9b12-297ff7cbd7ea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_875ef221-905c-49df-9b12-297ff7cbd7ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee639a8a-f466-401a-8117-ad3ed9aac74b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_875ef221-905c-49df-9b12-297ff7cbd7ea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee639a8a-f466-401a-8117-ad3ed9aac74b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_2db8d2c0-78c9-49f5-8f67-8c2d3f1912a9" xlink:href="sgmo-20210331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee639a8a-f466-401a-8117-ad3ed9aac74b" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_2db8d2c0-78c9-49f5-8f67-8c2d3f1912a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="extended" id="i1743f42f1f254cc08254acee55ae4fb9_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="extended" id="ibe60e25f98994489abc90968a0d04c08_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="extended" id="i9baf1be99211409591db422af5ff6786_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_eb419b8a-7baf-4357-841c-2de350a821cd" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_eb419b8a-7baf-4357-841c-2de350a821cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_ff6372b7-5d03-47ed-a00f-10a2b9112612" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_ff6372b7-5d03-47ed-a00f-10a2b9112612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_8ee7652b-1e43-43f6-9ac2-201d399cbbd2" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_8ee7652b-1e43-43f6-9ac2-201d399cbbd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1f87754f-c1c7-4b2c-85df-2d79b187a072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1f87754f-c1c7-4b2c-85df-2d79b187a072" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_815c9ee1-dae3-4e94-ae85-51a8a1a196ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_815c9ee1-dae3-4e94-ae85-51a8a1a196ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_535bbbc8-1503-44f3-9118-f30331d79c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_535bbbc8-1503-44f3-9118-f30331d79c1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_393b81a8-ef56-41b3-86da-daf101271cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_393b81a8-ef56-41b3-86da-daf101271cd0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_887830bf-c5f5-47ca-a117-5bbffbe5f3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_887830bf-c5f5-47ca-a117-5bbffbe5f3fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887830bf-c5f5-47ca-a117-5bbffbe5f3fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_887830bf-c5f5-47ca-a117-5bbffbe5f3fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_887830bf-c5f5-47ca-a117-5bbffbe5f3fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6cad6f27-6e7b-4c6f-a5e3-5933dfb6861c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_887830bf-c5f5-47ca-a117-5bbffbe5f3fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6cad6f27-6e7b-4c6f-a5e3-5933dfb6861c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_b1c86043-5301-40c0-86dd-ff85822b8a5c" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6cad6f27-6e7b-4c6f-a5e3-5933dfb6861c" xlink:to="loc_sgmo_SangamoFranceMember_b1c86043-5301-40c0-86dd-ff85822b8a5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_cba46a54-842b-43ce-bd05-74beb2ba6614" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:to="loc_srt_OwnershipAxis_cba46a54-842b-43ce-bd05-74beb2ba6614" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_cba46a54-842b-43ce-bd05-74beb2ba6614_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_cba46a54-842b-43ce-bd05-74beb2ba6614" xlink:to="loc_srt_OwnershipDomain_cba46a54-842b-43ce-bd05-74beb2ba6614_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f19be0fd-4e59-45cf-911d-71adff78d95d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_cba46a54-842b-43ce-bd05-74beb2ba6614" xlink:to="loc_srt_OwnershipDomain_f19be0fd-4e59-45cf-911d-71adff78d95d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_9d114417-6f3a-4858-ac52-82025ce8733c" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f19be0fd-4e59-45cf-911d-71adff78d95d" xlink:to="loc_sgmo_SangamoFranceMember_9d114417-6f3a-4858-ac52-82025ce8733c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44d98811-e8d7-4eed-82e4-d1e1045def96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44d98811-e8d7-4eed-82e4-d1e1045def96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44d98811-e8d7-4eed-82e4-d1e1045def96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44d98811-e8d7-4eed-82e4-d1e1045def96" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44d98811-e8d7-4eed-82e4-d1e1045def96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3b27201-ae74-4f62-aeaf-9c4c382a6183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44d98811-e8d7-4eed-82e4-d1e1045def96" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3b27201-ae74-4f62-aeaf-9c4c382a6183" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_21462841-c2c4-4dae-8da7-51addb048008" xlink:href="sgmo-20210331.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3b27201-ae74-4f62-aeaf-9c4c382a6183" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_21462841-c2c4-4dae-8da7-51addb048008" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="extended" id="i1a86300f755d497dab4690f57ec8f8ce_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sgmo-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f8bb1a1-ab1a-4951-8c26-7b9e49d72adf,g:12312c6a-d00d-416f-b715-a9f74eefa2dc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_0b270278-663f-404b-bd26-44c2ad251dc6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ccecce02-f035-43e3-802b-532b8a8714e9_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_b0dde2b8-1006-40f1-8389-08116190515e_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fedeafd6-f72b-40ec-a8aa-2560105d8e85_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_970e58b3-6725-490f-958f-769a34354508_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_ea1589a1-9875-4ae5-9ef2-95e750a661e4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_49b381a4-6c17-45e0-8dbd-63d3264c0cfa_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price correlation</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_label_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Stock Price Correlation [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Stock Price Correlation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:href="sgmo-20210331.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:to="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_06319f03-bf99-42cf-a857-a73e9779d0ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherProductsMember_94ab20be-d791-47c5-bc6b-f465decb072f_terseLabel_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_label_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember" xlink:href="sgmo-20210331.xsd#sgmo_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherProductsMember" xlink:to="lab_sgmo_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_2c75666f-2f1e-4eed-96ec-c8d3e96c4047_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_8ff3aa74-0509-4a20-8e10-41bbdc9ab8c1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_e0f3e041-ed40-4950-845e-e8c27c2dd205_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_JefferiesLLCMember_af078daa-4d6f-4b16-9421-a0c4d9db96fc_terseLabel_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_label_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_documentation_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember" xlink:href="sgmo-20210331.xsd#sgmo_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_JefferiesLLCMember" xlink:to="lab_sgmo_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTableTextBlock_d63f0c68-f9db-4fdd-adca-facb16af1f74_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTableTextBlock" xlink:to="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a53b29a9-4858-4992-afa2-39445cfd5cbb_verboseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_e62e9fa4-eb49-4a1a-af2f-841654c2ed80_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fd3aa481-634b-445e-9d86-606da52b974c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d059ee0-b27d-4c7f-a464-1bd82dfed26b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bf1ba996-657b-42d4-a8ba-40dffa6cc1df_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_cc1ebb80-ed39-4db0-908c-36a888d3dba0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_660de902-5190-4416-aa52-f6496dcf19d8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_083b81af-85cd-4189-8b34-7fe2fce515dc_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SanofiMember_3b574fdc-97aa-45b9-90a8-60eae2d8ef2c_terseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Genzyme</link:label>
    <link:label id="lab_sgmo_SanofiMember_bfc1b6bc-94ac-4e33-8b36-94a6ee2d104e_verboseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sgmo_SanofiMember_label_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_SanofiMember_documentation_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SanofiMember" xlink:to="lab_sgmo_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7096f8cd-382a-45cf-af3f-e0ccb0a91f45_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ab58bf1c-9b48-400c-9882-60950c3d3aa7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a84ade8c-19ac-4ed3-9d27-f508b2dd50c6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a27006da-0ce4-41d7-a0de-1b43bc27f368_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_031cdb12-9ac4-477b-b8b0-792441b739de_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_11f5ad96-bebb-4b62-9128-e692821faa38_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6df6ce18-b6ec-4444-a7ba-19ae5212f2da_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_f96cc8da-a9eb-4666-a66d-0d404b56e3e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_b1a01bbb-c69d-4369-9c45-6f00857eaf40_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments Due After Year Four</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9b6d011f-5f1e-4438-a632-26f373af9770_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_779cb21a-b41c-400b-a85e-3186a7de7da5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_27db461c-c8e3-493c-891b-d51c08c69fb8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities included net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a7590131-4765-4404-bd74-6914b81ba43a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_c01ff905-708f-40af-8c9d-c1cbcd0ee442_terseLabel_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_label_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California [Member]</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember" xlink:href="sgmo-20210331.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondCaliforniaMember" xlink:to="lab_sgmo_RichmondCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_52ae14c3-11e6-47e5-babc-91a9ce5be64c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payment receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:to="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_d9fe47d0-f717-4c67-a4e9-9a78ccc9abbb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_acbae566-f97b-4756-af7a-7273abc2c8c8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_962347b9-d418-483a-b5a3-8d1387ea0a9a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_5517d164-b08c-4854-887b-205924be9505_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_c3c46db9-4d28-4b7b-b2d2-3195b7019262_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_389fa099-de30-4f34-ad28-957ff2fbb0e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_64812533-8427-4e7b-a903-ea73083b0df4_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20210331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_91f9b13a-7bd8-4228-9ffd-a8a66a712a06_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2f86a252-127f-4210-a0ce-f0bb65d7331b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_9ed1aa3a-d31c-43f1-88ea-b4e30e3bdafc_terseLabel_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of additional shares of Sangamo France</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_label_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:href="sgmo-20210331.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:to="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e6134b17-a55e-434e-9d7e-bb1174a51afe_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_f531f783-fe71-4ee4-85a0-41cfd8fdb61b_verboseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_69103d05-6a75-426c-9bf3-b5824ece8018_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneThreeMember_6124b641-8853-4e6e-8ec2-cf21ed293756_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone three</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_label_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneThreeMember" xlink:to="lab_sgmo_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_6f2df4bf-991b-47ea-b855-99cce1e5d69e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_4ae76e2a-db48-42bc-af0a-902322affd42_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange rate</link:label>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_label_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Exchange Rate [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Exchange Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember" xlink:href="sgmo-20210331.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputExchangeRateMember" xlink:to="lab_sgmo_MeasurementInputExchangeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_e32153a5-7c38-4fc8-a230-f3522c933788_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-controlling Interest</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Noncontrolling Interest Table [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of noncontrolling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:href="sgmo-20210331.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:to="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_3a24099b-cdcd-4cd2-965b-9d572f5d1a85_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_83534646-8db0-432c-910a-b5dbb9d7c3a3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility estimate</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7011c21e-f796-4679-8e3c-4a8df83d3617_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_58b32c65-267c-4bb1-9eb1-8e75ab5445b4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a87dc595-8cc8-4f64-ad76-8384362a015b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b755cb62-7c4a-4010-b6ef-1d051c56df2d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_deec1313-8549-4a43-b33b-0fcb15488517_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_06477a34-5d10-4cb6-b0f7-c6a901a8e27e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b6fd8bc0-f3ed-4f4c-a136-5cfb5e98ce4a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_5243f9a4-b7d1-40d8-9c96-2ee0fad3d6d3_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo stock price (USD) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d3535045-ddbd-43e9-813c-756d8f0b6bb0_negatedTotalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_3f656e81-03fe-402a-945d-28e5df1cc3bb_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_770cb306-0784-444b-8672-506b3ed76e8e_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Income (Loss) Per Share</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Income (Loss) Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:to="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_8520b218-9b20-4731-8a00-3e5af0fc1c9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_da4ec174-fa3a-43ce-baef-f68a6d176808_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_b12788c2-7240-4df7-8a71-048ece2fec16_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_41ffbe6a-fa7e-444d-a6c0-f658e836070a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfResearchProgram_c8ee1a21-a6aa-459d-a164-2b035e076038_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_label_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Research Program</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_documentation_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfResearchProgram" xlink:to="lab_sgmo_NumberOfResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_ca886d31-9262-4104-8cdb-d97b8d07febd_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_125c9670-11e6-4d40-9d72-2e41e149323f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ab04ad94-2be8-4d21-9dd7-678e5e85c749_verboseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_9f904227-c26c-46c0-8519-f35287421a1a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_15bd6c3c-0472-4426-9dcc-a1cfa575205e_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_43205e98-8d06-4c98-afbd-3c246e8a8beb_terseLabel_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V.</link:label>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_label_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V. [Member]</link:label>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_documentation_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember" xlink:href="sgmo-20210331.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LonzaNetherlandsBVMember" xlink:to="lab_sgmo_LonzaNetherlandsBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_e9d41824-8938-4002-a5d7-10150597b510_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_9b8ab899-df6f-4c95-888b-091074f014c0_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in net loss</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:to="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_9c6e96a3-4ffb-4d13-8e84-c50f784aa8f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional shares of Sangamo France</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_f109b53b-854a-4e43-bfd3-1ffff1c0c7ee_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional Sangamo France shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_f6ade1c4-d740-46be-b774-154ce8a10709_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_273adb26-06e1-420b-b541-bc5dbefb1329_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_7ad8b340-7408-40ed-bc50-f5af76258c45_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1b612031-a1a8-4599-b16f-8aeee6c7784b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_c1db2ba3-ec8c-43c1-91cd-f599296ba1f7_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_2ce4eaf0-2162-492e-b049-fb8388288468_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20210331.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7b1ea670-23a3-4db3-ad64-440e2fac4233_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_7712a207-12bc-4353-8699-541c5ad7784f_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of free shares held by the holders (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Free Shares Held By Holders</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of free shares held by the holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f9c13fa7-8843-462c-adc8-273ab56ef7e9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3d76c450-4246-46dc-8741-738b352e6122_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_3940c6f6-e985-454f-858b-4ba2abbf2af8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ee129969-7d59-4235-b3be-2b91ccf3ae29_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at-the-market offering, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_de261f07-d5fd-4f9c-8806-7f2068bfd6fe_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_70c2d9de-8c84-4b31-b32c-73734436c588_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price volatility estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_3d7bd487-3df6-479e-91a0-29d30d1612b9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EUR / USD exchange rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0b4d18d2-ccb1-4d4f-83db-f649b9d76b26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d38892f7-7db7-468d-be98-0db3a4e41bfc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_b680aa70-3714-4108-a17d-487b026bdb57_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_6d12dea6-fcad-4b1c-875c-56531f0e52e3_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_12598896-4f4f-4b6c-b916-619df0eb5b4e_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of equity interests agreed to acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Percentage Of Equity Interests Agreed To Acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage of equity interests agreed to acquire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:to="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b3b21073-361a-4d94-8501-f782ce7618cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e4388ae2-398c-4f68-9ecc-5f8035f52132_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ce352a8c-1f6c-457b-9363-30e8d339bd02_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_a1917a96-ff8f-4221-b820-34e280ea43a8_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_44df96b9-9827-4c95-8de9-b11472dfd78c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cbb7739b-9629-4082-9c65-42851f3b1976_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_016ad980-414e-4907-95d6-83870ce5e0cc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_775c7bc6-fb6d-44b5-adb1-8727a0305f97_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_96dcb9c1-2434-4453-81fb-0b6e004a200d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_beeb36a2-711a-4f78-bd01-67cc72dbe938_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement, extendable lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_17d99a63-4580-4838-b922-ec27484d9fc7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ff9334d1-4dfe-4ffb-80ac-f60c82e308b7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_846bea3c-aa21-45f5-a67e-6aee424fc759_terseLabel_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease one</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_label_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject To Operating Lease One [Member]</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_documentation_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property subject to operating lease one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:href="sgmo-20210331.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:to="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_baddb9cd-1e36-4fb6-8c51-25e42404a481_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1b75088c-575c-4c74-8a41-19bbb08239e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6157c7db-2c06-4fb2-9d73-342f8383a8db_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8fb3d1c2-c161-410e-b549-fd30b9454697_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e90b0255-e1d6-49a0-bd49-f75a65087593_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_5bfe01e0-3338-401c-be29-d63ecfb3af6e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_70c7d392-5fd4-4fb7-8a71-f11e8dfe6541_terseLabel_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 clinical trial milestone</link:label>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_label_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone [Member]</link:label>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:href="sgmo-20210331.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:to="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f6e43c5d-ddd7-4e77-bbc0-a6d82b6d01a4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_58b7c1ee-5bd9-4d6c-9b74-17c293fdcc57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_f26513af-19ba-4496-a082-63915426a3ba_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5c9b7c39-2286-4ec1-9bca-6952d50d50d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_cd4d080f-3142-4de3-b05e-d6949c61b655_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with at-the-market offering, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3d454711-099d-4ec6-8426-40075257c35c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0e573db9-0100-4eea-8b2b-167f8597c665_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_bede1d57-7f82-4432-ba2d-1f0128b578ee_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fc7f0d4e-5f8e-4897-ad58-1805cb4dcd34_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_34fa011b-a3e0-475e-a0f4-dab932111fa0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6bfee784-e536-49d5-be2a-bc37bad53ad9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_75add937-7198-42e7-8dcf-895a86fcc9ac_terseLabel_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc.</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_label_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc. [Member]</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_documentation_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:href="sgmo-20210331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_aa4f8ac7-56a7-42d9-bda9-6a0b90a1a34a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ca1c33ac-a6f1-41fb-8705-ac536596c3dc_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_cea2b3ea-f67a-4112-9cf7-7d62e523dc02_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_93fc2c84-e2ef-474d-973f-dd56980c0d03_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ac14fdc0-fc18-4264-b2a3-08b31d64e2e7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_568246fc-5512-4cc6-b911-2475405cf867_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional product targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:to="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d22146f8-9f30-4d9d-98f5-f5cce2f123b0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e826e728-c793-4705-9014-4994e649452f_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_529ce40e-10e5-49f8-9249-0439d8eda319_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="sgmo-20210331.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c187ca47-9bba-4968-83d9-ec3875f2fd88_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_cfbaf927-82c2-42b6-8057-52e6d068e915_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_eb2975e5-2c98-4002-b721-d4a50d166e16_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting provisions, ownership threshold percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_70016d2a-ffdf-49e0-8e2f-78786b5a96ad_negatedLabel_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other changes in operating lease right-of-use assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_label_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_documentation_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:href="sgmo-20210331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:to="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c190e4cf-16ae-43d9-94ea-02a76453bd1b_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bac4119a-180a-47df-bb2f-dea49aeaedf3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2fe81fa9-5cd0-4614-bc70-d925e3c64e48_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_b5a085ba-f455-494d-83fb-7190d2c2ee28_terseLabel_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and laboratory</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory [Member]</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and laboratory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember" xlink:href="sgmo-20210331.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OfficeAndLaboratoryMember" xlink:to="lab_sgmo_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_a8a4bf5b-6c3d-4e8b-bce6-2413b5b5c1c3_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_9e390261-1689-4022-8189-eb66ac952ad4_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial advisory fees</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:to="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9daa381d-7e03-41ee-b71d-075810f501e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0deca745-085c-42b5-8895-0d4cf9b2dc88_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4fb44e72-cd83-436e-b956-98d5d1686371_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_98330366-2296-4c17-b91c-7a8c897980aa_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target selection period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:to="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_3636f81a-d41d-4d97-a5f5-a2affba067ac_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting provisions expiration period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_32cab11f-7f4c-4029-83b8-1e86856fc755_terseLabel_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval milestone</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_label_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone [Member]</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember" xlink:href="sgmo-20210331.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PreApprovalMilestoneMember" xlink:to="lab_sgmo_PreApprovalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_660126a1-8b72-454f-b2ea-06a2fe6fe890_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesMember_6045200e-c1ef-4bf4-b709-dd207f7a801c_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_label_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember" xlink:href="sgmo-20210331.xsd#sgmo_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesMember" xlink:to="lab_sgmo_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_24f17d0a-27aa-4038-a98a-b681eceacb47_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_1c913dde-5048-43be-be6a-dd43909989e9_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering Agreement</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:href="sgmo-20210331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:to="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d75f9250-2adf-4b8e-8b60-fe8530647572_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_4c21f1c1-2d42-4f56-ba99-b09b936cdbef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of additional shares acquired</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_1e936b19-7a90-4809-8b00-4abe0c8ddf0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_10669e36-5dce-4e88-bfed-d909c8937040_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_020d2b77-0a6f-492c-b444-5d3bebd52280_verboseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares acquired (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_f32abd6d-4a08-4c05-8043-125dfa151218_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares acquired (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Shares Acquired</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of shares acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FreeSharesAssetMember_ccdb5a6d-9d49-47c0-b82d-5754b66b6a00_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_label_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Asset [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_documentation_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember" xlink:href="sgmo-20210331.xsd#sgmo_FreeSharesAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesAssetMember" xlink:to="lab_sgmo_FreeSharesAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_0efe0bc9-4d73-4e4c-8851-651e3aee058b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_88afcab2-b8bd-4928-a9f1-c3e56d17e5ed_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_f4761445-2f66-42d2-8f5e-79ed1932b3f7_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit established as a deposit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_15198fe3-11fb-4593-9b0a-075d4e02bf90_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_2bf26a5a-be58-44d6-a855-f29d78b9ac65_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_9c744985-5dd6-4e29-82cd-7a9884a0f360_terseLabel_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock offering program, maximum value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_label_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_documentation_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue" xlink:href="sgmo-20210331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockOfferingProgramMaximumValue" xlink:to="lab_sgmo_StockOfferingProgramMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_9114b223-28c6-411e-9cb1-583191607a78_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_81fe4475-f5ad-42bd-9323-4d6851f08f82_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea08adfa-f899-40b0-b2ae-c91527729c02_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e5c07a56-f9d1-4b3d-99b9-f37b4d1e62cb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c37c78ae-97e7-4696-8dfe-c7b208189794_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a84b781d-1707-481f-8db6-47a830d399a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_544b1033-bc1a-4cbc-86da-c04e13921517_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of space leased (in sqft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_ea3866df-709b-4c4a-b76f-581f699bfc59_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20210331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7836ac53-9554-4440-940c-92e10671808a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_542d03fd-d35c-4a5a-8c65-4b2d283da450_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_a686c51d-2e96-4ccd-83bc-9c0f5cbe5c3f_terseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement and tender offer agreement</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_label_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement And Tender Offer Agreement [Member]</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_documentation_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement and tender offer agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:href="sgmo-20210331.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:to="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_deaf41b8-d0c2-4e39-8de1-cea3ca505125_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8b8dea24-4625-44be-be89-11ff6560e509_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_b7cfd4b3-b4aa-497b-91d3-18120b0c8dbf_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development And regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Clinical Development and Regulatory Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6e638547-cd13-4e7b-8618-ea56d18111a0_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_eb2d8c8d-80a3-481d-a4e6-237d3d0be3ec_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess consideration received on transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:href="sgmo-20210331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:to="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_e643ddfd-3133-48ce-a275-98f17297a038_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction, percentage of shares held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:to="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a108fbc0-b7b6-42d9-80ca-736f27645905_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bfe406c6-6ff7-49bf-ac34-8fef72a7f4b8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d3674c89-c0f5-4a6b-83a3-bd6f835dc5e4_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ecc8fc41-2188-4f69-86f6-84ea49cf7e63_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_c63fd1f6-80b9-4891-b647-aec82115fd8e_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc. [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20210331.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SeparateUpfrontFee_88940de3-26c9-4892-804f-9ae716fb573e_terseLabel_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_label_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Upfront Fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_documentation_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee" xlink:href="sgmo-20210331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SeparateUpfrontFee" xlink:to="lab_sgmo_SeparateUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_381a35c9-a341-4da1-9884-eed57bfcd35e_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_5323269e-45a0-4632-b7aa-b978687d5fab_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_ed2e8e52-2091-4add-b2b5-a58d2a137b3d_negatedLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a1a0077f-4127-40d9-8311-f697da71c179_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_689985a9-cb73-4ba3-9d4e-fc4cce9a658a_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of free shares outstanding subject to purchase (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_a0c933f2-7421-4e59-9956-df83df864d18_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4bd4c2c0-1b77-4885-82e5-2f78473283f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GainLossOnFreeShares_3cfa4c5a-aba9-406e-a486-ef9a39567575_negatedLabel_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on free shares</link:label>
    <link:label id="lab_sgmo_GainLossOnFreeShares_label_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Free Shares</link:label>
    <link:label id="lab_sgmo_GainLossOnFreeShares_documentation_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on free shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares" xlink:href="sgmo-20210331.xsd#sgmo_GainLossOnFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GainLossOnFreeShares" xlink:to="lab_sgmo_GainLossOnFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1cb82119-260c-4673-afef-862d954abbdf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6bc26e45-a366-4ce8-bb81-7d3f08e7756c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_b92c087a-fbfd-4e2e-a320-341764fd1611_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_f7298ece-f9af-447b-99e9-1bf7023dc642_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend initial research term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_label_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_documentation_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:to="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_fafb88e3-2046-4ca3-879e-101047f3b25f_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Sales Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f1efb187-8f05-485f-a20a-05afc261c518_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_485b97fb-7e27-4fec-8541-c714e377e1bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ff094d3d-74ad-4f1d-a73d-4ebba5c2cb7d_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium (discount) on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b9378ce0-6eca-41cb-8337-c7928f147c66_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92b8e0c6-5512-47af-ada1-02128ece376b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_167c4a96-948a-4a39-b67c-3929463e0e13_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d6c804da-f0e2-4aef-a5a1-8f712d45c681_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5888d7b5-9fbf-4c7e-a7b8-2faa8c6c3e2f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5ea11e08-0847-4b3a-bc72-100a55d97d26_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da6d1c72-ad76-4e48-a2f3-7bd15b51e8bc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BrammerBioMAMember_3ca0226b-a00a-4b98-8ad3-d90c30c44240_terseLabel_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</link:label>
    <link:label id="lab_sgmo_BrammerBioMAMember_label_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA [Member]</link:label>
    <link:label id="lab_sgmo_BrammerBioMAMember_documentation_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember" xlink:href="sgmo-20210331.xsd#sgmo_BrammerBioMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrammerBioMAMember" xlink:to="lab_sgmo_BrammerBioMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8d3c3b04-b81a-45a7-93d0-716acf3228a8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_92f7a397-ce64-4d0d-bea8-84fed812152c_terseLabel_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember" xlink:href="sgmo-20210331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockPurchaseAgreementMember" xlink:to="lab_sgmo_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9a55c764-e870-4718-b58d-12d09ab214ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current (included in other accrued liabilities on the Condensed Consolidated Balance Sheet)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_70049bc8-42c5-42fb-bcbe-0cb7f41a728e_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_41595e36-37fc-4552-97ed-62589802f301_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in revenue</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Revenue</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:to="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_69030e4e-5bf6-4d92-b89f-d921e5c4840d_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restriction period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_04d5989c-3eb0-42b3-9d28-d8af7a8a65d3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_bdb7214b-47b1-4d68-b764-ed1b8b24fa49_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0e044e1a-fe6e-4ab7-80ba-44d2dcabfab8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_5a9c217f-7651-42a8-a9b7-470045b24b3b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_94928f68-93d3-417c-aa96-9a5721deb395_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_d516e516-f990-444e-b505-8bb0c0a7a28e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e0ba985d-c6cc-45ad-95e8-4ee34eda247c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6951f96a-e1db-497d-854c-fe1760a08391_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_16b447b9-ed8b-4ee8-a9bb-c9d81da8d1cd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PhaseThreeClinicalTrialMember_875a781f-d87d-4c83-84bb-bec390023f32_terseLabel_en-US" xlink:label="lab_sgmo_PhaseThreeClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase 3 clinical trial</link:label>
    <link:label id="lab_sgmo_PhaseThreeClinicalTrialMember_label_en-US" xlink:label="lab_sgmo_PhaseThreeClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Three Clinical Trial [Member]</link:label>
    <link:label id="lab_sgmo_PhaseThreeClinicalTrialMember_documentation_en-US" xlink:label="lab_sgmo_PhaseThreeClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Three Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PhaseThreeClinicalTrialMember" xlink:href="sgmo-20210331.xsd#sgmo_PhaseThreeClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PhaseThreeClinicalTrialMember" xlink:to="lab_sgmo_PhaseThreeClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_a91a146f-b1d3-49b4-afa3-76255bdfa8d9_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_label_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_documentation_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:href="sgmo-20210331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:to="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_873fcd0e-2fc8-4ac9-bd7e-f5a0810ff8bb_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_b2fb433e-eb1b-4e92-9bee-9ee86bf0d286_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative milestone achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cumulative Milestone Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cumulative Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:to="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6d7db8c1-6a70-4efa-8864-efedf517c367_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_626e8830-4e00-4e1e-8869-ae969b485197_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_7ea352cc-e096-46c9-97a5-04ae35c09037_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restriction, ownership threshold percentage ownership percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_86035f93-c444-4904-ba89-d95be023affe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f572ce14-f2e0-42a1-8af1-1c6ab5ddd2e0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_c07b25c8-ddcb-43f2-9edd-440d3dff01a9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_f2ab74d3-c100-41f9-805d-b1d67fa61d8b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_cf5087b8-8a2d-4a15-b15d-f7055ba3e2dd_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_a969d8d0-cd4b-4bcb-b5be-36374b374104_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB-525 and other products</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:href="sgmo-20210331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:to="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0107a55a-e6c1-42fd-ad25-636576d509c0_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_13e010ec-6598-41ba-83ce-9508e782f151_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_add663ce-4a37-439e-84a0-57141315e294_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_25be0f14-1a7c-4851-a0f1-65e10906a7c0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_fb5875a8-9d24-4961-bcae-93a2d9811811_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_9ef63b50-94d1-4561-a19b-7b449a14b62d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f275568d-e5a0-4ac2-842b-16ec2e923143_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_d8f3546a-ba1d-49cb-9b34-1d9da67865f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporarily impaired investments</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_b4de7a1d-83cc-4a9f-ac64-d1fb6f5dba90_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc.</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_c36a923e-9b72-43ef-aa2d-84afc29af7ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_9e9f6a35-fa4c-4905-8a1e-c1ae6ff2e98d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_b0071af3-aa19-4e94-ac33-93e93e3ee503_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e6abb47e-42a1-4f03-bbf3-90aae4b4bab9_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_c7f9d5dd-af39-42fa-a63f-7eeb58139fa8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5ed32b8d-3fcb-429b-8d87-dfc3d425069f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a866bc05-e301-43a1-be52-a567f7adaa23_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_5730ba72-eb78-4a1f-898f-78c1ef2737b9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_f5a94058-ee6d-41bf-9d64-a516d5515d29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_10fd68db-28da-4bf7-aa05-c37eb4e566e1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dcbc26b5-ba5a-4c5f-ae4c-24b260385a2f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c6abc341-3134-47a8-b462-61880457e359_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Value of Free Shares Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_372a0c87-3160-4192-98a4-90fea7683cb1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5c33d3d0-4b1e-41c0-af73-018e2c0d56a2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ff4c6d2f-233b-4272-be04-207930144df2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_511b12ae-029e-48aa-9de7-b9984382dc1c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ff84f938-d5ed-4648-a3a0-30fa3427b9b6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b2520cf6-0258-47cf-891f-1499d6aa4450_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_725e6c0b-02a1-43d3-8ec7-a5c668bd4dc4_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_876268af-1fbb-4453-8a8d-ecec17108763_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities and free shares asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_8119abb7-0e57-4919-9fcd-3e55a3595ab7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized portion of equity issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_59224521-96a8-4d4a-aebb-20094d8b5d67_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_a8c04349-dfa3-4cfa-a22b-f79bb745cb58_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b4232585-a25a-491f-b467-e243b66f0ca1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a0d6c780-b7bc-455d-8243-f0a0a000af0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_554324f2-ebe2-4d36-98c6-6689b40426ee_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_a44fead4-3cd3-42ba-a3fd-ac7959f12803_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3bec8f7b-6481-4007-be0f-82597938546e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8003054c-09e2-4561-81a6-06731bc3055d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_78785a68-568b-49e4-8ebb-d673e42de6dd_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and office space</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_label_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Office Space [Member]</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_documentation_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and office space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:href="sgmo-20210331.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:to="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LicenseObligations_d9759931-cd34-4ed5-a508-ed0b343026c5_terseLabel_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_label_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_documentation_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations" xlink:href="sgmo-20210331.xsd#sgmo_LicenseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LicenseObligations" xlink:to="lab_sgmo_LicenseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_8e8503dc-c53b-4a7e-9d0b-f47788fdff27_terseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement" xlink:href="sgmo-20210331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_InitialResearchTermOfAgreement" xlink:to="lab_sgmo_InitialResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_964a8f2d-9fb7-4c81-b18b-101f1d73cdd2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3086e4e9-999b-4dfb-b602-e8f117b5eacd_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_99356baf-3df3-48f4-9230-28e96a7fd441_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_42fe8958-2427-4b6a-b686-8941852825cd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a067cd39-688b-45c6-a21b-473ef207ffca_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_332ef934-2b57-488c-b6c6-08b42fed38e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_bd3e5a14-fd46-4a14-9bcc-a04a8eb09eb9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1da0eb5a-cede-4301-b096-44ac391ae4c3_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_d9aee1d3-3cf5-4890-ba38-ad2acfb15627_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_15c89a54-5712-4a7d-8da3-4582f6fe3457_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs for new research plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_cdf86f3f-367a-4a87-98f9-9ebed158a54c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_a654bd68-2325-43cf-8bc7-b1c34c776abc_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_200db5e8-d05e-48b3-b7d2-b394d1ce4165_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0e17695b-3a9a-4b31-bb2c-6d9917f4446c_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ValbonneFranceMember_3616b1ff-71a5-41d8-99c4-758bc311cd1e_terseLabel_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_label_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France [Member]</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_documentation_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember" xlink:href="sgmo-20210331.xsd#sgmo_ValbonneFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ValbonneFranceMember" xlink:to="lab_sgmo_ValbonneFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_73c3bf29-3de6-4fba-b7d7-91b53bd0e157_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_33d51e8d-e5c2-41be-9b6f-3150d1a751f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_06c8587c-7bfb-4b01-b0d1-8c64fb3eb15f_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at March 31, 2021</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_6695ce74-5bd4-4dab-94ab-083d5a437892_verboseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of commercial milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_b5e81bed-8749-447c-8f94-00a08943a65b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France stock price (EUR) (in euros per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_10bfde10-05b7-40b6-bc61-41c8813d8599_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_cff46db4-f9b5-4882-b5a4-5da63743522c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4721c2ad-53a6-443c-940c-59e3dfca659a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_54e84b6c-b8b8-43e2-8411-a9e4c5daee22_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_12c03417-e332-44f2-b327-f735fdbdc0da_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ab3aee8b-3af8-43c3-b603-5fb84d403049_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e0fb0619-f151-4fe5-ae82-431def96dbcf_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_c01f642b-939d-4de2-8b94-207c5a18dd6f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cdaa9791-d6f2-4d6f-9ce4-e9f604b93a74_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_9b7fee4c-50b7-4e11-92c1-eb20647c6d76_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20210331.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_19676afb-6939-45d8-ad21-45ed0ed75df8_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b100b91a-cda2-49cc-bbc5-2e9725faad86_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_aefc16db-cc4e-4bbb-88ac-ebbc01c5737d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_225f578f-41c1-4f09-bc02-73fb64add8c2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_87cef453-a0aa-4467-9d7e-54de0b2b9666_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_870277b8-2d91-43fd-b13f-5c0d87c990a6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SangamoFranceMember_c2e1ff8c-8055-45e7-a17d-ec6827a127ae_terseLabel_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_label_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France [Member]</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_documentation_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SangamoFranceMember" xlink:to="lab_sgmo_SangamoFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f81962e7-2690-43fd-a807-eaa25ca8b71d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dd717085-1333-43bc-b5b2-f1553cd359bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4dff9761-e3a6-4bf6-8695-abe65fffab91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_19d1265f-85f4-4d68-ad79-19fea851ae9c_terseLabel_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California institute for regenerative medicine agreement</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_label_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Institute For Regenerative Medicine Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California institute for regenerative medicine agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:href="sgmo-20210331.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:to="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e0fa19c6-1069-4f68-9d1e-dd7fd107769e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_038f7b00-ab72-44f0-9304-a8a6c70acab1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_16761609-e9fa-4514-beef-92a0b9569eae_terseLabel_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_label_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California [Member]</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember" xlink:href="sgmo-20210331.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrisbaneCaliforniaMember" xlink:to="lab_sgmo_BrisbaneCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_12f23353-572a-4d43-ad3e-925c333eb6f3_verboseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20210331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_571f6abe-d2b2-4758-8ef7-001fdedf3fe5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e369f35c-5c1f-4b9b-9b2e-521489d2495a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_033865a9-05e1-4b65-999d-c1957671c272_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2f838bad-d8eb-4902-a92a-baee5b2294b5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_9b61c514-549b-4437-a08d-4e4c9a9363df_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in collaboration agreement scope</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_label_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_documentation_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:href="sgmo-20210331.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:to="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_0d1130de-03b1-4d18-a2a5-fa26d157bc66_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_304f0a0b-737e-4bb3-a391-9ca044f41ab2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_8edb745f-5188-4847-ac5e-48469657d587_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_fda56e8b-f38d-4778-b92f-28fd328f999a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_47efb99e-7a1c-4276-b063-39eed17d2ca7_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e4df62a8-74fc-4285-823e-29e911253e9b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_49b6fb92-4752-4ebc-86a0-41c179996a9a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_00126e05-7636-4449-8956-7cde8f3706e7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_3485e327-29a8-4b3b-8285-63c74e99f7f1_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:to="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_65cff964-cc50-4f47-967e-ae9b93c923bd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_badfc07f-6141-4d1f-bbaf-f21985e950fd_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development - and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments To Be Received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales based milestone payments to be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:href="sgmo-20210331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_27f713e8-3a11-4afe-8db5-b2b1d889f991_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_dbbba4d9-c54a-4854-a22f-76fb4510c1ff_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_860a87ba-63dc-4473-96a6-2fbeb99ff526_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20764e8-f68b-40d8-8cfb-9b93165d9a25_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nine months ending December 31, 2021:</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GrantFundingAmount_7eca1727-47d5-4b0f-8022-b6d0f8a24e13_terseLabel_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds due under the agreement</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_label_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Amount</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_documentation_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount" xlink:href="sgmo-20210331.xsd#sgmo_GrantFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GrantFundingAmount" xlink:to="lab_sgmo_GrantFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_88fa55a6-75ca-4421-b629-20f58d8b53b5_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_16c9ddcb-cd4b-4a2a-a46d-ce151e839736_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d6325b46-7d2f-417f-90cc-67dea4a7af73_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_aae6a945-921e-4194-b4b4-e4a5e5173f27_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5f448440-9dee-479d-8485-5001a02074ae_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1d31d67d-9178-4e8c-b53e-66c353416287_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1ab44417-edd9-4ff0-84d0-e429817bfcde_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_c59c949b-3fe3-4302-a1df-0f16ac66e946_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneTwoMember_1f5c59b8-8125-4e84-8d2d-c3ff797a711f_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone two</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_label_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneTwoMember" xlink:to="lab_sgmo_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3029d15e-7a96-44c3-8726-343fd402fa7e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_543e358c-d5ac-47bb-80f9-c8ac9fd56e20_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in long-term portion of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:href="sgmo-20210331.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:to="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_81d0284d-77e8-474b-b311-c2f15c745fb5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill or indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate_172fbf46-f972-4d56-82bb-dcc309c2f5fe_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of real estate</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Real Estate</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseAreaOfRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:to="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_eb668da1-d77c-4948-83fe-8cc52e203745_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_166ee105-0275-4f3f-9a61-40a02f96d898_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_f3a28172-82a9-47c0-8da6-e04dc0ff896e_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable" xlink:href="sgmo-20210331.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable" xlink:to="lab_sgmo_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c74af94c-12d8-4fdc-a496-84d00adecd29_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ab0e6a3f-2bef-4aaa-92f9-1b5cd70e1ec7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1b6fa830-d378-4022-b2ab-06e1cd439fd1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1da3430c-4606-40aa-a2fa-6457d69433c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_76a72186-60e0-4ed5-a240-72a1484b747c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_48f78007-1497-4554-a2fa-f91218aecd8e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_0bed84a8-fff7-4ee2-ae26-5a898dde2df2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized under Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_66c226da-cef6-4b67-b084-fc06953fb976_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_c627c85e-efc0-4096-bec0-6a5f841c8fce_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_851ca7a3-63fa-4f79-8954-ad4d6ed451f3_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20210331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f3475097-f378-4d26-b014-b11a94679bf8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with at-the-market offering, net of offering expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c3dfac08-9123-4035-8e8f-5950e59299a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_4cc1eb35-e423-453b-adb8-ae50f7026742_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_712d1c28-070b-40f6-9729-e10c6d6144e9_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_4d32ecf2-71d0-426e-a381-7bf814da020a_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:to="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_f92b6082-f7f0-47e2-9c06-a172c951471f_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:href="sgmo-20210331.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:to="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_f3d0d574-d2f8-4452-b11d-10ed7d0989ea_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_95b4f55e-5a9b-4ced-9f6c-864181553c2f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_34ed9b57-b819-464b-be42-988b2c7069a9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e7c36d00-de62-4335-95bf-d79a229cfe00_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8faf62b2-34da-49d9-8d0d-c1e7774fa321_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_05ad954d-e8b2-45ce-80b9-7c4ed18d9bb9_verboseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_17f85ca6-ca25-43fa-afbf-5e4fa51b1d8e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6781bd32-a15c-47c0-9ba5-839ef3ae16bc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_059a2e38-3cb5-4fb5-aa61-a12c6bc8c939_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_584016ad-85a6-4ac4-a184-0cccbe1e0259_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2d8ab0f1-1740-4f81-abd9-145f9ce06f7f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_5a7881ff-00db-46c4-bfd4-8ea71ab6ce6d_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAmount_b6ecee2d-7d0b-4fba-b716-f8d42c6cfdc8_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payment amount</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAmount_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Amount</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAmount_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAmount" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseAmount" xlink:to="lab_sgmo_LesseeOperatingLeaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_1fdaa705-140d-40f3-8251-3e1bff38be36_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of product targets replaced</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:to="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_2d7dbbd7-d017-45dd-8ac4-1ba6a731dcde_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_a71188e2-dd90-4873-a3c2-75ee2a2b3c21_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research service fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:to="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e3c978fe-4683-45ce-bb84-47aea934a248_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_09717ff0-6c49-42ae-9b02-d128bad5260d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_287a0a68-d96c-48b7-aa18-9d521e09cb57_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ab90c405-6645-45ca-a13f-6cb3e81c7e73_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_98cd9173-4809-4388-b3eb-009bf30481a3_terseLabel_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone [Member]</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember" xlink:href="sgmo-20210331.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SalesBasedMilestoneMember" xlink:to="lab_sgmo_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_219d952e-aca4-49d7-a873-769c20fe164d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f1326776-202b-4d4b-a941-599dd59e7049_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1a9c6530-7a75-418f-bd73-4741742aa0b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_81e8a68d-df2f-4d11-b10b-dc8ea36859b7_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20210331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef53cd6e-f57f-44f4-8746-857e6ba4a203_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4942251-f296-4b1e-a46b-96383713b53b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0eb08ade-70ed-44ae-ad9b-08575115a01d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_beaf45fc-5311-436b-aa51-988c09d388a1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f79dd97d-d7ac-4e44-9b69-426d0e9b8526_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_f6406725-ce09-4e0f-a6a6-f040f9aadd52_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of license and stand-ready fee</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9cd7921d-1b4c-415a-99fe-eae33428d1a4_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_328a2590-c10b-44eb-aac4-6aa1575e37d6_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, equity issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementEquityIssued" xlink:to="lab_sgmo_CollaborationAgreementEquityIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_255f45fb-d9f4-4778-8718-d84d1f1e7973_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_d68e2c46-1448-45f0-b059-3455df12d36c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2c20ec52-0d71-4660-9f5f-377710340924_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated correlation between Sangamo and Sangamo France stock prices</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1d8f9404-3821-47d2-90ca-eda5d2e6c2b5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_fab060f0-9a32-425b-a862-9adc08e77748_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract to perform for others, cumulative compensation earned</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_label_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_documentation_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:href="sgmo-20210331.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:to="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_012f314b-9c82-4b3b-a542-ada39b8be1c8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_98037266-039e-4f5c-b605-74de5677f228_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_00df1e0b-8c44-498a-ab43-b3a3720dbfaa_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_a184c641-aba4-42ac-beb7-bc8a99d32315_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_c3e6b07c-83d4-4f92-9ebb-e190ec2c6a4c_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB-525</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB five two five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember" xlink:href="sgmo-20210331.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveMember" xlink:to="lab_sgmo_SBFiveTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c593f752-aeff-468c-9e1a-6563d4d095f7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_08fa6186-3d73-4188-afe1-5586f6536397_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_5e6437dd-3183-4906-b704-cf4da08384e4_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="sgmo-20210331.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9334ccd0-0915-4c04-9ecb-7478e1cec3f6_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a95bccb8-aaa8-41a1-9e7c-b9857ddf9083_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_19a12032-5486-4759-91ba-c7b50c7f999f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3586db4f-a550-4b02-b1fb-edade84fd534_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_58a2e9f3-cf1c-4566-b6d0-f6a55b36d595_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_e5099a51-f5f7-452c-99e0-19e18e9928ab_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20210331.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_0bd1f23f-5cae-45e3-b873-bff26d56c7f2_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0d3ec6cf-21a4-4a31-8301-9429f88b3e18_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneAchievementMember_ec4637cd-4ad2-4fed-8e84-a9c06007235f_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_label_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneAchievementMember" xlink:to="lab_sgmo_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_01fae1c1-c2ab-428c-8851-0bb33344f36c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal_e3ba8b44-c260-4c2b-8eb8-cc4a5b1a5060_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue reversal</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Revenue Reversal</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Revenue Reversal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMilestoneRevenueReversal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:to="lab_sgmo_CollaborativeArrangementMilestoneRevenueReversal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_ed2b7bf0-1a75-4ac0-adfa-85b349827a3a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of contract asset recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_36aca5e6-6ec8-4206-a71a-1bb7503af67f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIC AND DILUTED NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0c815523-7cfb-47ea-bb38-e2957a9ebd72_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_ec85e19f-8c31-49ac-87cd-7fb4988bad26_terseLabel_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended research term of agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:href="sgmo-20210331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:to="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_09025a43-b35d-448a-9a2a-50f271edbe8f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b293e7cc-0518-4e49-a419-d521178839ba_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e10e28fd-c16f-446e-9b9f-29e893e55e88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_77aea9c3-89b1-4f27-b21b-4d1e7256bd12_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_953cb751-5f44-4f39-8314-6ad003e4ed49_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_5d9b1703-1f8b-467a-bfcf-614fca4c6ef4_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of initial recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:to="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3073a67e-f6ba-4953-a0a6-3ff226c3c96e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sgmo-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f8bb1a1-ab1a-4951-8c26-7b9e49d72adf,g:12312c6a-d00d-416f-b715-a9f74eefa2dc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20210331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_13dcb246-9668-4a34-a946-f308f02a6de8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_DocumentType_13dcb246-9668-4a34-a946-f308f02a6de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d7c1867b-fa04-4572-8262-3eeaa1e4a17c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_DocumentQuarterlyReport_d7c1867b-fa04-4572-8262-3eeaa1e4a17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d00d7415-4354-4896-abd0-d8f56ef210b0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_DocumentPeriodEndDate_d00d7415-4354-4896-abd0-d8f56ef210b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_defd38b5-17be-44d2-9eee-1820e335584f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_DocumentTransitionReport_defd38b5-17be-44d2-9eee-1820e335584f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ce32e4b4-e11f-4fe3-864e-72a567e0114f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityFileNumber_ce32e4b4-e11f-4fe3-864e-72a567e0114f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_24715758-140a-4e0c-a5f3-0f4b01c7f33e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityRegistrantName_24715758-140a-4e0c-a5f3-0f4b01c7f33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_061c1d91-930f-4c53-8653-14c2937c9a0c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityIncorporationStateCountryCode_061c1d91-930f-4c53-8653-14c2937c9a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c6cdfa16-9acf-4a03-9023-6cd3f5ad2d14" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityTaxIdentificationNumber_c6cdfa16-9acf-4a03-9023-6cd3f5ad2d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_76765de7-4960-46e8-a150-401123a254a8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityAddressAddressLine1_76765de7-4960-46e8-a150-401123a254a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a8b0620f-c1e6-4ed9-b84f-498c24090a76" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityAddressCityOrTown_a8b0620f-c1e6-4ed9-b84f-498c24090a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_65745f4c-d818-4b35-ba1d-6dd03737baab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityAddressStateOrProvince_65745f4c-d818-4b35-ba1d-6dd03737baab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_456d2c1e-334a-4147-8959-4af3ea2a0ba3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityAddressPostalZipCode_456d2c1e-334a-4147-8959-4af3ea2a0ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_85f5dcfa-b26b-44c6-8063-e85fe5c0024c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_CityAreaCode_85f5dcfa-b26b-44c6-8063-e85fe5c0024c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_686aa6c3-c3b1-4434-9f01-a1d0e6d1dc55" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_LocalPhoneNumber_686aa6c3-c3b1-4434-9f01-a1d0e6d1dc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_18940870-ceb5-45f1-90fd-852cdf786ebe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_Security12bTitle_18940870-ceb5-45f1-90fd-852cdf786ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_eb9a9526-0e80-4ce1-9fa2-67a1045cd91e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_TradingSymbol_eb9a9526-0e80-4ce1-9fa2-67a1045cd91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b034f84c-0fa3-4648-bb81-cf71f397659e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_SecurityExchangeName_b034f84c-0fa3-4648-bb81-cf71f397659e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_39e4ea79-92cd-4e1a-a798-51d222e90a5c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityCurrentReportingStatus_39e4ea79-92cd-4e1a-a798-51d222e90a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d9470a6d-5c83-4420-a0f2-5b460b1a02c2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityInteractiveDataCurrent_d9470a6d-5c83-4420-a0f2-5b460b1a02c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_959b81c9-72dd-42a9-8b57-407fa670e866" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityFilerCategory_959b81c9-72dd-42a9-8b57-407fa670e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_35094279-d72b-4f02-92fe-ba45012f7b0e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntitySmallBusiness_35094279-d72b-4f02-92fe-ba45012f7b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9a833ec5-6273-4646-bb68-6b82725bceb1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityEmergingGrowthCompany_9a833ec5-6273-4646-bb68-6b82725bceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0c4ca466-aa2b-4606-a967-ff43d0218be4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityShellCompany_0c4ca466-aa2b-4606-a967-ff43d0218be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2ca293b1-0284-4b8d-8d3b-9663a9e065d4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2ca293b1-0284-4b8d-8d3b-9663a9e065d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4344f359-864d-4576-8608-91ad6ba2c228" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_AmendmentFlag_4344f359-864d-4576-8608-91ad6ba2c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a6b92f13-d8ef-480e-b6bb-6802073ede8f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_DocumentFiscalYearFocus_a6b92f13-d8ef-480e-b6bb-6802073ede8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0cab4baa-ddb4-4bcf-8880-91075f44c252" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0cab4baa-ddb4-4bcf-8880-91075f44c252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_60937ddd-3513-4fe0-823f-49d4a4674dac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_EntityCentralIndexKey_60937ddd-3513-4fe0-823f-49d4a4674dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_af9567cb-dcbc-4ca8-8d16-fab409a03211" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_86ccff34-db34-419f-a5a4-3f2b4cfb3004" xlink:to="loc_dei_CurrentFiscalYearEndDate_af9567cb-dcbc-4ca8-8d16-fab409a03211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2d815037-f10c-401d-ae32-88cd02a2eb93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d815037-f10c-401d-ae32-88cd02a2eb93" xlink:to="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3084b7f4-e93d-494d-a17f-4a2fcd6ead97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3084b7f4-e93d-494d-a17f-4a2fcd6ead97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4be59269-4c32-401d-9746-28a4c9ff6c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3084b7f4-e93d-494d-a17f-4a2fcd6ead97" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4be59269-4c32-401d-9746-28a4c9ff6c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a76edbca-3086-4e64-b6c2-568e6d9840e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3084b7f4-e93d-494d-a17f-4a2fcd6ead97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a76edbca-3086-4e64-b6c2-568e6d9840e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_2bc8ca73-1f89-4f7c-b5ce-d0758d7fdb63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3084b7f4-e93d-494d-a17f-4a2fcd6ead97" xlink:to="loc_us-gaap_InterestReceivableCurrent_2bc8ca73-1f89-4f7c-b5ce-d0758d7fdb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c6427e23-d014-42f4-bb1a-6af2b82b4feb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3084b7f4-e93d-494d-a17f-4a2fcd6ead97" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c6427e23-d014-42f4-bb1a-6af2b82b4feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9280e9ab-6545-4f5f-9238-5071570a4e72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3084b7f4-e93d-494d-a17f-4a2fcd6ead97" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9280e9ab-6545-4f5f-9238-5071570a4e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ec4e723f-1a69-498a-bcb4-cf6d54284639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3084b7f4-e93d-494d-a17f-4a2fcd6ead97" xlink:to="loc_us-gaap_AssetsCurrent_ec4e723f-1a69-498a-bcb4-cf6d54284639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4a437a98-1e1a-4327-99c3-0de0dda47a1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4a437a98-1e1a-4327-99c3-0de0dda47a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9ffe08b9-c35c-4d00-a3eb-86e1efe759b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9ffe08b9-c35c-4d00-a3eb-86e1efe759b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8919866d-3f5a-40a5-a669-b21290cd1c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8919866d-3f5a-40a5-a669-b21290cd1c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_793857bb-ff9d-4b7c-ac2b-2db3309d99b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_Goodwill_793857bb-ff9d-4b7c-ac2b-2db3309d99b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfee44c7-0849-48c4-9074-1515c51d7e51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bfee44c7-0849-48c4-9074-1515c51d7e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_301e777f-563c-40aa-9388-ae869397d460" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_301e777f-563c-40aa-9388-ae869397d460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c84c5fa3-ab7f-4a8e-8081-11ae62c91ae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c84c5fa3-ab7f-4a8e-8081-11ae62c91ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_281441c6-5f7a-42e4-a58d-84c5d3c754ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b376b9ee-d923-4301-a7eb-55b52479dee1" xlink:to="loc_us-gaap_Assets_281441c6-5f7a-42e4-a58d-84c5d3c754ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2d815037-f10c-401d-ae32-88cd02a2eb93" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_76f39822-2132-4133-929c-bbaa4c1e66ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_76f39822-2132-4133-929c-bbaa4c1e66ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_804fc8de-34cb-496f-a1c0-a961d051f2d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76f39822-2132-4133-929c-bbaa4c1e66ec" xlink:to="loc_us-gaap_AccountsPayableCurrent_804fc8de-34cb-496f-a1c0-a961d051f2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1a088bb0-8aa1-4a6d-93f9-a258bc5a51cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76f39822-2132-4133-929c-bbaa4c1e66ec" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_1a088bb0-8aa1-4a6d-93f9-a258bc5a51cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cea907d0-7e71-4ee6-9ba2-e4ec664872fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76f39822-2132-4133-929c-bbaa4c1e66ec" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cea907d0-7e71-4ee6-9ba2-e4ec664872fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b133e72e-53d7-4a4a-bd6b-ea63100fbe38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76f39822-2132-4133-929c-bbaa4c1e66ec" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b133e72e-53d7-4a4a-bd6b-ea63100fbe38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f1e37aba-5905-4335-acc0-634b28eaef2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_76f39822-2132-4133-929c-bbaa4c1e66ec" xlink:to="loc_us-gaap_LiabilitiesCurrent_f1e37aba-5905-4335-acc0-634b28eaef2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_035d24f0-f7fd-449b-b12b-6874dac6f40d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_035d24f0-f7fd-449b-b12b-6874dac6f40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16469974-1633-4c51-be76-5aaf55d27a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16469974-1633-4c51-be76-5aaf55d27a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_278f2d83-8cd5-4d56-8a61-2bf846240322" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_278f2d83-8cd5-4d56-8a61-2bf846240322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_462f137b-74c6-4a37-b1d5-8e83bd1ff596" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_462f137b-74c6-4a37-b1d5-8e83bd1ff596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_164a4518-4c10-48ba-a8fa-0cea226a930d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_Liabilities_164a4518-4c10-48ba-a8fa-0cea226a930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8aa1c141-c175-447f-92f6-94f60c557f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8aa1c141-c175-447f-92f6-94f60c557f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1a9b2130-ed03-4e32-b948-beb8d19a4fd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:to="loc_us-gaap_PreferredStockValue_1a9b2130-ed03-4e32-b948-beb8d19a4fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b07690a1-ff5b-4992-bfd0-0f090fde3eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:to="loc_us-gaap_CommonStockValue_b07690a1-ff5b-4992-bfd0-0f090fde3eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6921c211-a105-440a-bf68-91a3b81a5cca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6921c211-a105-440a-bf68-91a3b81a5cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae6b1709-c142-4526-b15f-534f5fbfbb14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ae6b1709-c142-4526-b15f-534f5fbfbb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c6153946-97cf-454b-ae16-2bac5fb60f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c6153946-97cf-454b-ae16-2bac5fb60f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77024046-b6bc-4f55-81c7-a560a0f87e58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:to="loc_us-gaap_StockholdersEquity_77024046-b6bc-4f55-81c7-a560a0f87e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_36c56048-c26c-4cc6-936a-555fec7bb502" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:to="loc_us-gaap_MinorityInterest_36c56048-c26c-4cc6-936a-555fec7bb502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_384c70fe-d9d4-4079-9d7e-a15a34ba4a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_c8e6981f-cc2c-461b-af43-e57d19946b41" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_384c70fe-d9d4-4079-9d7e-a15a34ba4a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e76e865f-a49a-4eba-84cd-2b73368f5c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d4f02c74-5b2e-4e9c-84d1-b807f0f543f5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e76e865f-a49a-4eba-84cd-2b73368f5c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_858efa8c-a5ca-4172-ae6e-19441299b886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_858efa8c-a5ca-4172-ae6e-19441299b886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7d8f7046-d5df-449b-aff5-ca0efe5ddc2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7d8f7046-d5df-449b-aff5-ca0efe5ddc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d6e46465-8682-4106-818f-8a5579715952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7d8f7046-d5df-449b-aff5-ca0efe5ddc2e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d6e46465-8682-4106-818f-8a5579715952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_251a4879-708a-4098-9a2e-2807193f7ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7d8f7046-d5df-449b-aff5-ca0efe5ddc2e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_251a4879-708a-4098-9a2e-2807193f7ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a1cd9fc0-7b0a-493b-aa9f-5e43c7246042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7d8f7046-d5df-449b-aff5-ca0efe5ddc2e" xlink:to="loc_us-gaap_OperatingExpenses_a1cd9fc0-7b0a-493b-aa9f-5e43c7246042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bab93b84-835a-42a3-9bcf-fb06a671df8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_OperatingIncomeLoss_bab93b84-835a-42a3-9bcf-fb06a671df8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_d6b806a5-610e-4ac0-9de1-43c1e4928922" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_InterestAndOtherIncome_d6b806a5-610e-4ac0-9de1-43c1e4928922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_a2874967-6eba-49a7-a550-3672620d6e40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_a2874967-6eba-49a7-a550-3672620d6e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c4b7f16e-0624-4a68-b5fa-575777be543c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c4b7f16e-0624-4a68-b5fa-575777be543c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1d66a042-9ea1-4edc-a8a4-1bcd18b4c4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_ProfitLoss_1d66a042-9ea1-4edc-a8a4-1bcd18b4c4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_957e8f64-fb00-4ce3-956d-a99ed72a7c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_957e8f64-fb00-4ce3-956d-a99ed72a7c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d65797a7-cedc-4bac-8094-4b955279670b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_NetIncomeLoss_d65797a7-cedc-4bac-8094-4b955279670b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_b5a109bb-89a2-4492-b4ab-44e47887e1d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_b5a109bb-89a2-4492-b4ab-44e47887e1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_eb8acee2-8409-4f85-98e3-bb24159ef2a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_eb60376c-ed8b-4797-b92d-5f5e116d9a51" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_eb8acee2-8409-4f85-98e3-bb24159ef2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f07c4512-c91d-4e0c-9cbb-6d85d385dd89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_13b1af90-bbd5-475e-ab4c-9f9ca0063154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f07c4512-c91d-4e0c-9cbb-6d85d385dd89" xlink:to="loc_us-gaap_ProfitLoss_13b1af90-bbd5-475e-ab4c-9f9ca0063154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a30af5de-755d-4400-b748-dc3f9d9542a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f07c4512-c91d-4e0c-9cbb-6d85d385dd89" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a30af5de-755d-4400-b748-dc3f9d9542a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bcd38130-c07d-4a66-aa33-574fba5d7380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f07c4512-c91d-4e0c-9cbb-6d85d385dd89" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_bcd38130-c07d-4a66-aa33-574fba5d7380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_57b22dbd-4f02-4ab0-8857-bb4617954faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f07c4512-c91d-4e0c-9cbb-6d85d385dd89" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_57b22dbd-4f02-4ab0-8857-bb4617954faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_642a3c82-c5c5-472a-a689-ffe23496abb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f07c4512-c91d-4e0c-9cbb-6d85d385dd89" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_642a3c82-c5c5-472a-a689-ffe23496abb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0e70a6c4-57a4-4f63-9e0d-51d83b5d8eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f07c4512-c91d-4e0c-9cbb-6d85d385dd89" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0e70a6c4-57a4-4f63-9e0d-51d83b5d8eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_403174b7-62f9-4a55-b3a3-a9828ed280e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f06ba7ef-845e-470e-96fa-279b3e759bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_403174b7-62f9-4a55-b3a3-a9828ed280e6" xlink:to="loc_us-gaap_StatementTable_f06ba7ef-845e-470e-96fa-279b3e759bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a53880a4-a848-44be-a434-ffcd2d874bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f06ba7ef-845e-470e-96fa-279b3e759bad" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a53880a4-a848-44be-a434-ffcd2d874bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a53880a4-a848-44be-a434-ffcd2d874bea" xlink:to="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_87643d08-2c8a-43b2-9076-f0484b06d5ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_CommonStockMember_87643d08-2c8a-43b2-9076-f0484b06d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_12ff45ce-b8d4-4972-a91d-dfdaf4a38374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_12ff45ce-b8d4-4972-a91d-dfdaf4a38374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3904cfbb-fb88-43d9-9867-45d5cd95955a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_RetainedEarningsMember_3904cfbb-fb88-43d9-9867-45d5cd95955a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_550ffc11-f881-4270-a13b-4df2bd619ead" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_550ffc11-f881-4270-a13b-4df2bd619ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_d6ed9c72-7ec2-444c-b9b6-d10f4701ca57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8a400c2e-bff5-4eab-8309-e1845f97ec3d" xlink:to="loc_us-gaap_NoncontrollingInterestMember_d6ed9c72-7ec2-444c-b9b6-d10f4701ca57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f051e642-5039-416f-ace0-ddc9bc8d492e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f06ba7ef-845e-470e-96fa-279b3e759bad" xlink:to="loc_us-gaap_StatementLineItems_f051e642-5039-416f-ace0-ddc9bc8d492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f051e642-5039-416f-ace0-ddc9bc8d492e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f36c2a4b-d330-4ddd-a623-010e083e5091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_CommonStockSharesIssued_f36c2a4b-d330-4ddd-a623-010e083e5091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfbbaec-bdd1-4421-8205-2f9bdc3bc122" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0cfbbaec-bdd1-4421-8205-2f9bdc3bc122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_282409b1-1fe9-4179-8e92-3abe56107447" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_282409b1-1fe9-4179-8e92-3abe56107447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f1ef6100-88d3-4b45-8152-4ee349804c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f1ef6100-88d3-4b45-8152-4ee349804c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5e48d35d-907c-4807-990f-6bdf254295d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5e48d35d-907c-4807-990f-6bdf254295d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4bcee0eb-0725-477d-b963-03ba08105a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4bcee0eb-0725-477d-b963-03ba08105a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dddb0369-bd6e-4087-aed2-e62e335cd190" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_dddb0369-bd6e-4087-aed2-e62e335cd190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_29ccfc19-33c6-4972-8a95-77e0a95a1908" xlink:href="sgmo-20210331.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_29ccfc19-33c6-4972-8a95-77e0a95a1908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_882dcecb-a0c7-46f6-8cbd-01105393db0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_882dcecb-a0c7-46f6-8cbd-01105393db0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_135b47b5-2893-4292-91da-d26360a9912a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_135b47b5-2893-4292-91da-d26360a9912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7a8045d5-d979-4ad4-aad2-af4aa8960c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_ProfitLoss_7a8045d5-d979-4ad4-aad2-af4aa8960c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_51a2d7dc-3446-448e-99b7-eb5cf17bd4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_CommonStockSharesIssued_51a2d7dc-3446-448e-99b7-eb5cf17bd4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_038f451d-b7bb-4842-8b42-84e0dd0e81fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_19ee557c-ac12-449f-87ce-d067d42be59c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_038f451d-b7bb-4842-8b42-84e0dd0e81fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_72ae2fb0-32f2-4289-850c-4ad828754e56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_72ae2fb0-32f2-4289-850c-4ad828754e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1314d93a-4d57-42ec-a13d-d7e4459feac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_72ae2fb0-32f2-4289-850c-4ad828754e56" xlink:to="loc_us-gaap_ProfitLoss_1314d93a-4d57-42ec-a13d-d7e4459feac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59f0e440-14c2-4409-9464-2057bc548662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_72ae2fb0-32f2-4289-850c-4ad828754e56" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59f0e440-14c2-4409-9464-2057bc548662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_21768a73-fe2f-4256-a64a-7ff8a5835478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59f0e440-14c2-4409-9464-2057bc548662" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_21768a73-fe2f-4256-a64a-7ff8a5835478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f3e15ca5-a653-4168-832e-512824fb4eb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59f0e440-14c2-4409-9464-2057bc548662" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f3e15ca5-a653-4168-832e-512824fb4eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_f4175e80-2617-4cca-b93b-dd1799e1ac7f" xlink:href="sgmo-20210331.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59f0e440-14c2-4409-9464-2057bc548662" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_f4175e80-2617-4cca-b93b-dd1799e1ac7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_5b2e9104-ea1c-4ce1-acbc-7d2bc4e5de5d" xlink:href="sgmo-20210331.xsd#sgmo_GainLossOnFreeShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59f0e440-14c2-4409-9464-2057bc548662" xlink:to="loc_sgmo_GainLossOnFreeShares_5b2e9104-ea1c-4ce1-acbc-7d2bc4e5de5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4dedc1c5-1ca2-4190-81d1-8bc49d7ff7fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_59f0e440-14c2-4409-9464-2057bc548662" xlink:to="loc_us-gaap_ShareBasedCompensation_4dedc1c5-1ca2-4190-81d1-8bc49d7ff7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_72ae2fb0-32f2-4289-850c-4ad828754e56" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_507d5360-6628-4f3d-b915-496abe94f115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_507d5360-6628-4f3d-b915-496abe94f115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_05b9c3c7-77b3-462a-bf66-537b7247dd07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_05b9c3c7-77b3-462a-bf66-537b7247dd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3818430e-f5ee-416e-b595-7c3c6eb29f7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3818430e-f5ee-416e-b595-7c3c6eb29f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a86581c6-6ca4-4401-8340-f77eaf15d392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_a86581c6-6ca4-4401-8340-f77eaf15d392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ec75d00f-6805-4ec9-a1b2-eedb027d9be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ec75d00f-6805-4ec9-a1b2-eedb027d9be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_741744f2-9b62-41c5-bd1d-271c20bac22d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_741744f2-9b62-41c5-bd1d-271c20bac22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_83c7c5d5-ebe8-458a-9362-41cb9887d868" xlink:href="sgmo-20210331.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_83c7c5d5-ebe8-458a-9362-41cb9887d868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f908e81b-2546-4bb5-a3ca-41282378b9c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22835765-adf0-4203-98fb-b067b2cb2dbd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f908e81b-2546-4bb5-a3ca-41282378b9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_842b079a-384c-44e2-a4ca-76f1e16f4ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_72ae2fb0-32f2-4289-850c-4ad828754e56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_842b079a-384c-44e2-a4ca-76f1e16f4ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068dc802-b7e2-4f22-a379-4318193ed4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068dc802-b7e2-4f22-a379-4318193ed4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8ded7c43-4a9b-4f45-a41e-9088d9d91eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068dc802-b7e2-4f22-a379-4318193ed4e3" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8ded7c43-4a9b-4f45-a41e-9088d9d91eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_785c523a-677f-422a-ad58-e0485f6f52e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068dc802-b7e2-4f22-a379-4318193ed4e3" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_785c523a-677f-422a-ad58-e0485f6f52e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_ed91ee23-9be0-4d2a-9bf3-aedb07f647a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068dc802-b7e2-4f22-a379-4318193ed4e3" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_ed91ee23-9be0-4d2a-9bf3-aedb07f647a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7686f821-87d4-4e0d-b270-c1b39db4b00e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068dc802-b7e2-4f22-a379-4318193ed4e3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7686f821-87d4-4e0d-b270-c1b39db4b00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_b4ff683a-2908-4461-9e6d-9e7db4aa930a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068dc802-b7e2-4f22-a379-4318193ed4e3" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_b4ff683a-2908-4461-9e6d-9e7db4aa930a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eedb2c8b-9bca-49d8-9864-621c635f0dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_068dc802-b7e2-4f22-a379-4318193ed4e3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eedb2c8b-9bca-49d8-9864-621c635f0dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_89732904-9963-43f8-9bfb-6c20d41e060e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_89732904-9963-43f8-9bfb-6c20d41e060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_225742a2-7f8a-4a2f-98e3-56065fdf95e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_89732904-9963-43f8-9bfb-6c20d41e060e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_225742a2-7f8a-4a2f-98e3-56065fdf95e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7980a09f-38bc-4e86-87f1-4ea814f31869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_89732904-9963-43f8-9bfb-6c20d41e060e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7980a09f-38bc-4e86-87f1-4ea814f31869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1400afc-0479-4af7-9c04-1aa1e434d17e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_89732904-9963-43f8-9bfb-6c20d41e060e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c1400afc-0479-4af7-9c04-1aa1e434d17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_67ee601c-bff3-45ee-825b-535a9b75722a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_89732904-9963-43f8-9bfb-6c20d41e060e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_67ee601c-bff3-45ee-825b-535a9b75722a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15db5e86-39a2-41f7-93b9-2c83955086cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15db5e86-39a2-41f7-93b9-2c83955086cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85ae1907-77e7-4b2f-828e-bac4829c0996" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85ae1907-77e7-4b2f-828e-bac4829c0996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bd8ec24-99ec-41c9-8c73-1621d4538bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bd8ec24-99ec-41c9-8c73-1621d4538bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e5bfaf1-466b-4425-a516-74b1fa96e06c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e5bfaf1-466b-4425-a516-74b1fa96e06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_dfdf7486-61ce-495d-a905-a035e667683a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c84fc2f9-def7-4f85-b6d4-f6205b74981a" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_dfdf7486-61ce-495d-a905-a035e667683a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_158915d2-43df-4d3c-b172-67ac6a16c34d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_dfdf7486-61ce-495d-a905-a035e667683a" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_158915d2-43df-4d3c-b172-67ac6a16c34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_34a19202-9fc9-4ab0-b2d5-1325faf8cf60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_dfdf7486-61ce-495d-a905-a035e667683a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_34a19202-9fc9-4ab0-b2d5-1325faf8cf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_22e6e008-f4d8-4adb-9ba0-31fdb58d9ea6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_695c431d-1f37-4251-982e-0b7e4631c419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_22e6e008-f4d8-4adb-9ba0-31fdb58d9ea6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_695c431d-1f37-4251-982e-0b7e4631c419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3673393-1101-4a3b-9371-d45d4d36fb3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3673393-1101-4a3b-9371-d45d4d36fb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f0c77fbc-362e-4ea8-9b84-40d8d91dc2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_UseOfEstimates_f0c77fbc-362e-4ea8-9b84-40d8d91dc2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_df898237-5282-453f-9bfc-e33d9d9345ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_df898237-5282-453f-9bfc-e33d9d9345ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_fd539bbf-1d07-4f15-8584-d3c1b393ebd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_fd539bbf-1d07-4f15-8584-d3c1b393ebd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_5e746268-f0c0-4793-a356-881dc6b879a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_5e746268-f0c0-4793-a356-881dc6b879a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a4614668-dbfb-46c4-9218-cbd9497f0e76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a4614668-dbfb-46c4-9218-cbd9497f0e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5a52aff2-6bdb-4029-b80e-a98a66c5a49b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_5a52aff2-6bdb-4029-b80e-a98a66c5a49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ea41053f-46c5-4e25-b0ac-582a857e3760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ea41053f-46c5-4e25-b0ac-582a857e3760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_3589ca08-eda5-41c7-afda-a73a46a9c7b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_3589ca08-eda5-41c7-afda-a73a46a9c7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_4e27b0a3-20b1-4fb3-9eba-75a79a9c3d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_4e27b0a3-20b1-4fb3-9eba-75a79a9c3d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_afedb381-a71a-48d1-a2a4-738fbbb11e39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_afedb381-a71a-48d1-a2a4-738fbbb11e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cff7e902-70e8-47da-b022-2ce31d18be54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cff7e902-70e8-47da-b022-2ce31d18be54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df4a5c16-935c-4339-a746-76296a897e91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da50c830-047e-4b0b-9e61-de84155af669" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_df4a5c16-935c-4339-a746-76296a897e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_54d4e1d6-2ce8-435d-bcf6-c959a001de00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_ad3a26db-929a-4654-90a3-260f67a64fff" xlink:href="sgmo-20210331.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54d4e1d6-2ce8-435d-bcf6-c959a001de00" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_ad3a26db-929a-4654-90a3-260f67a64fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_082bf95e-0c7c-4c61-b48c-8fc629478df2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54d4e1d6-2ce8-435d-bcf6-c959a001de00" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_082bf95e-0c7c-4c61-b48c-8fc629478df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3c295700-853e-4d68-8f4b-43d8b7ffc838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_54d4e1d6-2ce8-435d-bcf6-c959a001de00" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_3c295700-853e-4d68-8f4b-43d8b7ffc838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_daa70fcc-43e4-44fb-9861-e4e1dda86e52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:href="sgmo-20210331.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_daa70fcc-43e4-44fb-9861-e4e1dda86e52" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ce100ef5-63ff-4f80-a99f-e494f2a8c082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ce100ef5-63ff-4f80-a99f-e494f2a8c082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5a7832ab-27f0-4957-982f-da57705db696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_ce100ef5-63ff-4f80-a99f-e494f2a8c082" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5a7832ab-27f0-4957-982f-da57705db696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_fd752f75-1153-4bbd-b161-2f1605d8426e" xlink:href="sgmo-20210331.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_5a7832ab-27f0-4957-982f-da57705db696" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_fd752f75-1153-4bbd-b161-2f1605d8426e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ec1dc180-97b2-462c-9242-d6926901205f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ec1dc180-97b2-462c-9242-d6926901205f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb7fc86c-0382-4240-95d6-aa308ee9c4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ec1dc180-97b2-462c-9242-d6926901205f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb7fc86c-0382-4240-95d6-aa308ee9c4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_0aad393e-6d17-4a49-a69b-41af756c7378" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb7fc86c-0382-4240-95d6-aa308ee9c4d5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_0aad393e-6d17-4a49-a69b-41af756c7378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2aa6a8f0-3741-4e9e-87f7-d31132478b42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:to="loc_srt_CounterpartyNameAxis_2aa6a8f0-3741-4e9e-87f7-d31132478b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a4a13d8-07f7-4385-88c6-7c66a96e42cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2aa6a8f0-3741-4e9e-87f7-d31132478b42" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a4a13d8-07f7-4385-88c6-7c66a96e42cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_4c87bf65-25f6-400a-9065-bf5996c7f9b3" xlink:href="sgmo-20210331.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9a4a13d8-07f7-4385-88c6-7c66a96e42cc" xlink:to="loc_sgmo_PfizerSB525Member_4c87bf65-25f6-400a-9065-bf5996c7f9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:href="sgmo-20210331.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_76716816-b4f4-421d-b594-79924e3568ee" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e7a9fc1-fd6a-4b61-9b32-1d531ba016a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e7a9fc1-fd6a-4b61-9b32-1d531ba016a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c1c74eaf-6865-49a1-a618-2a275a627a36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_ProfitLoss_c1c74eaf-6865-49a1-a618-2a275a627a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_96aaa2e9-a79a-4391-b27f-89af2af3763a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_EarningsPerShareBasic_96aaa2e9-a79a-4391-b27f-89af2af3763a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_5d822197-ba62-448c-bedc-088c71503bff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_5d822197-ba62-448c-bedc-088c71503bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_bca180db-3a7a-4ebb-9290-45bb9375256a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_bca180db-3a7a-4ebb-9290-45bb9375256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_c343af93-b0dc-41e9-aaa0-3c6cadf16b69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_8af7e14b-867c-411a-97d5-6f84923e7e8e" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_c343af93-b0dc-41e9-aaa0-3c6cadf16b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b006fad-1b5a-4bdc-adf2-5279bf345045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b006fad-1b5a-4bdc-adf2-5279bf345045" xlink:to="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9438e47-5e40-47ef-b28b-54368ec28e5e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:to="loc_srt_CounterpartyNameAxis_a9438e47-5e40-47ef-b28b-54368ec28e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a9438e47-5e40-47ef-b28b-54368ec28e5e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_fe0ae050-1c1c-4761-bab0-7d888f60fe08" xlink:href="sgmo-20210331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_BiogenMAIncMember_fe0ae050-1c1c-4761-bab0-7d888f60fe08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c88ce60f-27f7-427e-ace3-e8b4d8719bbf" xlink:href="sgmo-20210331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_c88ce60f-27f7-427e-ace3-e8b4d8719bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_f3daa514-6ed9-446f-801b-bdf3035e8782" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_KitePharmaIncMember_f3daa514-6ed9-446f-801b-bdf3035e8782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_2283b721-dadc-4570-b2ae-ac5021fc5d57" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_SanofiMember_2283b721-dadc-4570-b2ae-ac5021fc5d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_e29978a2-8293-441c-b01f-56a583ef893b" xlink:href="sgmo-20210331.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f5e70c8b-7123-4ff4-86ef-a707ffd4f419" xlink:to="loc_sgmo_PfizerMember_e29978a2-8293-441c-b01f-56a583ef893b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20ffecee-3ca4-43f4-9108-c2a2729fff83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cfb5a310-7d9f-459f-ab64-3a9aa1613a0a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20ffecee-3ca4-43f4-9108-c2a2729fff83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8b771641-7bac-4bf3-a1f4-6fe000ca1e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_20ffecee-3ca4-43f4-9108-c2a2729fff83" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8b771641-7bac-4bf3-a1f4-6fe000ca1e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_132bea6d-e262-487a-82e0-331f155c8134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_132bea6d-e262-487a-82e0-331f155c8134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_8fd4a2ad-caa0-484d-a7a6-c73a04d12fee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_132bea6d-e262-487a-82e0-331f155c8134" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_8fd4a2ad-caa0-484d-a7a6-c73a04d12fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_d141bf12-43e9-4fcd-a5ed-5d6685c37eb8" xlink:href="sgmo-20210331.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_8fd4a2ad-caa0-484d-a7a6-c73a04d12fee" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_d141bf12-43e9-4fcd-a5ed-5d6685c37eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_53b2ec18-b23c-41e2-a813-198de28ac732" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_7245eb81-1b5f-428d-9099-85ce17e3f302" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_53b2ec18-b23c-41e2-a813-198de28ac732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_34ca735d-7d9d-45f1-983f-5c7c5ac837f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_53b2ec18-b23c-41e2-a813-198de28ac732" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_34ca735d-7d9d-45f1-983f-5c7c5ac837f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfd2751d-99e0-4eef-bcbe-1a049477b0ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cf9d423b-7752-4eaa-8d74-db006ac78d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfd2751d-99e0-4eef-bcbe-1a049477b0ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cf9d423b-7752-4eaa-8d74-db006ac78d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a3b8c884-04ac-4e0a-84d6-951bf389fde4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfd2751d-99e0-4eef-bcbe-1a049477b0ed" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a3b8c884-04ac-4e0a-84d6-951bf389fde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7cae8a40-9b14-4ba2-bd2b-5ab7b9d7043f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfd2751d-99e0-4eef-bcbe-1a049477b0ed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7cae8a40-9b14-4ba2-bd2b-5ab7b9d7043f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0f7e7a6a-d75a-49c7-97a3-f56601134af2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0d6cd50a-8af7-4500-bf25-0c7bb2f9f301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0f7e7a6a-d75a-49c7-97a3-f56601134af2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0d6cd50a-8af7-4500-bf25-0c7bb2f9f301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d1d6b5dc-1c20-453f-b6ef-4851e5af0c7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3f8458cd-6aae-4e80-9d09-ee4797b33182" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d1d6b5dc-1c20-453f-b6ef-4851e5af0c7a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_3f8458cd-6aae-4e80-9d09-ee4797b33182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cd85cb2e-e633-456e-9990-88fc86b5d73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d1d6b5dc-1c20-453f-b6ef-4851e5af0c7a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cd85cb2e-e633-456e-9990-88fc86b5d73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2b4e5a8f-847c-4e38-996c-b35d57a0fedb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2b4e5a8f-847c-4e38-996c-b35d57a0fedb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6d69fa4-63a4-437d-aa23-fb76cd509576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6d69fa4-63a4-437d-aa23-fb76cd509576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7eb19522-67d5-49da-a383-b4f9ed8c106e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d6d69fa4-63a4-437d-aa23-fb76cd509576" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7eb19522-67d5-49da-a383-b4f9ed8c106e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_58de6d90-78ff-45e4-8df5-83535f44dab8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7eb19522-67d5-49da-a383-b4f9ed8c106e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_58de6d90-78ff-45e4-8df5-83535f44dab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_45329ffb-00be-4e0c-a15d-bd32e56badda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_45329ffb-00be-4e0c-a15d-bd32e56badda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_45329ffb-00be-4e0c-a15d-bd32e56badda" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b8fab84f-3eb6-4ca5-8e1d-2f38debd40ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b8fab84f-3eb6-4ca5-8e1d-2f38debd40ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_357367f5-3b22-4240-9fe8-77cd03a5b649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_357367f5-3b22-4240-9fe8-77cd03a5b649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_95b1382a-150b-4521-bdf2-e4950b43bdfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b6be6919-2203-43b6-9ce6-5af87d423c1c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_95b1382a-150b-4521-bdf2-e4950b43bdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_31c5d7ee-de06-4b72-84e2-e056fde01f84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_31c5d7ee-de06-4b72-84e2-e056fde01f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_31c5d7ee-de06-4b72-84e2-e056fde01f84" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_9d0a47fa-4e45-4d53-b41b-8b2c5adc86bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_9d0a47fa-4e45-4d53-b41b-8b2c5adc86bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_226c8a9a-306a-4ba5-892a-94ef967920ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_CommercialPaperMember_226c8a9a-306a-4ba5-892a-94ef967920ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_03a39a77-05ea-4c11-afa1-6b5d83753066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_03a39a77-05ea-4c11-afa1-6b5d83753066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_cc364918-53bf-4f76-bf1e-1ba7de1b879f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_cc364918-53bf-4f76-bf1e-1ba7de1b879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_aa62a8b3-f4bf-44b6-b601-b2cd6dc2a4c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_aa62a8b3-f4bf-44b6-b601-b2cd6dc2a4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2411dadc-d822-4aff-9ac9-8c6596499911" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_2411dadc-d822-4aff-9ac9-8c6596499911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_6c78e18e-8943-486b-8616-773c51b523c1" xlink:href="sgmo-20210331.xsd#sgmo_FreeSharesAssetMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d567959b-1dcf-4dfe-a0cc-9988f78bafb2" xlink:to="loc_sgmo_FreeSharesAssetMember_6c78e18e-8943-486b-8616-773c51b523c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8706622e-994c-4a36-b72c-ab97b16a1ee6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7ce24f3c-d180-4a2f-a17d-0dd608aa2c2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7ce24f3c-d180-4a2f-a17d-0dd608aa2c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8adf38b-7c9b-47cd-8ea4-e0f0843d84ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8adf38b-7c9b-47cd-8ea4-e0f0843d84ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6e31b4f5-a485-46ba-a5e9-2d65b0744464" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_21c1a140-e2ff-4ee1-b028-0181e08318ab" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_6e31b4f5-a485-46ba-a5e9-2d65b0744464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2170117d-4920-434c-af7b-51b191057be1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2170117d-4920-434c-af7b-51b191057be1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_045c4065-5f3f-4938-abd6-8288594cdedd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_045c4065-5f3f-4938-abd6-8288594cdedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_830adf65-e77b-49bf-8e58-bb8eaa20bf83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_045c4065-5f3f-4938-abd6-8288594cdedd" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_830adf65-e77b-49bf-8e58-bb8eaa20bf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_12b74c9b-673f-408a-adcc-4b3c11a2e55f" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_830adf65-e77b-49bf-8e58-bb8eaa20bf83" xlink:to="loc_sgmo_SangamoFranceMember_12b74c9b-673f-408a-adcc-4b3c11a2e55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4a18cf98-6e00-448b-8d0c-76f5ecab5681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4a18cf98-6e00-448b-8d0c-76f5ecab5681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d354b02b-173b-4927-8583-458c08cf3450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a18cf98-6e00-448b-8d0c-76f5ecab5681" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d354b02b-173b-4927-8583-458c08cf3450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_99efc5b6-c2b9-4ccb-92ee-e72cf0b4f363" xlink:href="sgmo-20210331.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d354b02b-173b-4927-8583-458c08cf3450" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_99efc5b6-c2b9-4ccb-92ee-e72cf0b4f363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_95ba4f08-8a00-483d-9846-47b8255ec056" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_e6748284-a6b5-4bb2-a177-9bd438cd2d22" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_e6748284-a6b5-4bb2-a177-9bd438cd2d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_fd15e9c5-18af-4030-92d5-96cb46eedc14" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_fd15e9c5-18af-4030-92d5-96cb46eedc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1352a2ac-92b5-4de8-b506-9764b6c02faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1352a2ac-92b5-4de8-b506-9764b6c02faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_22433eac-83fc-41d8-8048-650191d9c2d2" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fd55f56e-0154-415a-9be7-604b0a7fb07c" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_22433eac-83fc-41d8-8048-650191d9c2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_adeb6c30-0763-427b-ae31-5ec5587fc3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_adeb6c30-0763-427b-ae31-5ec5587fc3f3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b9fa858c-54f8-4068-a516-23de894004c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b9fa858c-54f8-4068-a516-23de894004c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43508ac2-4778-4518-b67a-ce1cdf162cee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b9fa858c-54f8-4068-a516-23de894004c6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43508ac2-4778-4518-b67a-ce1cdf162cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_3682c2cb-61f0-4665-acd8-858518d745c8" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_43508ac2-4778-4518-b67a-ce1cdf162cee" xlink:to="loc_sgmo_SangamoFranceMember_3682c2cb-61f0-4665-acd8-858518d745c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6d487a4e-5fb5-421a-ab7e-6ec72c3b005e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_8e5b900b-02d8-4728-a960-fe88cb3430d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_8e5b900b-02d8-4728-a960-fe88cb3430d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_ac20f374-b9ba-4c00-be44-0ea58d4cfe09" xlink:href="sgmo-20210331.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_sgmo_MeasurementInputExchangeRateMember_ac20f374-b9ba-4c00-be44-0ea58d4cfe09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_09605455-f4d5-4d8b-a75c-276b63695968" xlink:href="sgmo-20210331.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_09605455-f4d5-4d8b-a75c-276b63695968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_ab9db789-b36a-4f5f-804b-066fe75c36c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_ab9db789-b36a-4f5f-804b-066fe75c36c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_b595fb47-abed-4f2e-a2e9-5d4a1d9838e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a39a9ff-2016-4feb-8ee4-05e6e8b6f61f" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_b595fb47-abed-4f2e-a2e9-5d4a1d9838e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_12a0bac1-a04a-4ef3-9a87-168af0a6d36c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_0c5a16f3-9d80-4075-bc84-0b32979ba4eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_SharePrice_0c5a16f3-9d80-4075-bc84-0b32979ba4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_bf1a2728-f813-428c-8439-58c5ad3fea9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_bf1a2728-f813-428c-8439-58c5ad3fea9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_fe624ef8-4997-4238-94fd-c53659161c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_fe624ef8-4997-4238-94fd-c53659161c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_38d86878-d648-4ce8-bb9f-170cb5f6af5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_38d86878-d648-4ce8-bb9f-170cb5f6af5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_eef66926-8c17-4cb8-9da3-7b2ef8e1754d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_66c48a22-8f70-419a-91f6-d83fcdf9a3ee" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_eef66926-8c17-4cb8-9da3-7b2ef8e1754d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f180bc8-3f7f-4f3a-ac2f-b35ae27efe57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9dec8664-e91b-4051-944b-cccd0d426c72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6f180bc8-3f7f-4f3a-ac2f-b35ae27efe57" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9dec8664-e91b-4051-944b-cccd0d426c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_999df9df-2c9b-4369-bb91-8abe10b94158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_95934df5-0bdb-4991-8a30-a59ebeea0e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_999df9df-2c9b-4369-bb91-8abe10b94158" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_95934df5-0bdb-4991-8a30-a59ebeea0e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_171af8e2-1691-4edd-a4c2-8338ae8f5584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_999df9df-2c9b-4369-bb91-8abe10b94158" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_171af8e2-1691-4edd-a4c2-8338ae8f5584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_84c3ee36-aec9-47c4-9ccd-db507042cae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9e4d6e21-5f2e-4b50-a4eb-c6bb272ff833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_84c3ee36-aec9-47c4-9ccd-db507042cae2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9e4d6e21-5f2e-4b50-a4eb-c6bb272ff833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_59588efc-9703-4757-a885-5ff2277c268a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9e4d6e21-5f2e-4b50-a4eb-c6bb272ff833" xlink:to="loc_us-gaap_FinancialInstrumentAxis_59588efc-9703-4757-a885-5ff2277c268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_59588efc-9703-4757-a885-5ff2277c268a" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_02340082-0b27-4ab8-81ee-f4ae56460ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_MoneyMarketFundsMember_02340082-0b27-4ab8-81ee-f4ae56460ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_19b40382-8ecc-489f-9803-79807b6c8b35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_CommercialPaperMember_19b40382-8ecc-489f-9803-79807b6c8b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9a79fef4-2ea1-41f0-896f-ffb927bdc291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9a79fef4-2ea1-41f0-896f-ffb927bdc291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a62a119e-6836-4dd0-9458-ddd965dfc195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a62a119e-6836-4dd0-9458-ddd965dfc195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_b7a7245b-d884-40b0-b0e5-f60f59e3ce14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_b7a7245b-d884-40b0-b0e5-f60f59e3ce14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_edaaa586-85b2-41fe-8770-550a5713b741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_CashEquivalentsMember_edaaa586-85b2-41fe-8770-550a5713b741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_be29a8a6-d992-4d8e-baa9-5af7cf929e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_92115bab-85a2-4325-8f4a-b3d63f762779" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_be29a8a6-d992-4d8e-baa9-5af7cf929e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9e4d6e21-5f2e-4b50-a4eb-c6bb272ff833" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_070e807a-6eb7-4bd0-97e9-3a978b97b394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_070e807a-6eb7-4bd0-97e9-3a978b97b394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_66197ca8-c555-43c3-a10e-27e94de7e69a" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_66197ca8-c555-43c3-a10e-27e94de7e69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6c769474-d759-4eb9-99a2-78a8afca4306" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6c769474-d759-4eb9-99a2-78a8afca4306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97b6996b-e41a-4865-9467-51a461161a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_97b6996b-e41a-4865-9467-51a461161a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_adb6c637-05c4-486c-9caa-f42e5985dd06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_adb6c637-05c4-486c-9caa-f42e5985dd06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2a40acc0-2d73-4692-b3b8-5da467d53c15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2a40acc0-2d73-4692-b3b8-5da467d53c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_afb3f280-aeb0-4c5e-b5bc-7f36bdc4ebc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_afb3f280-aeb0-4c5e-b5bc-7f36bdc4ebc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1823f506-f93a-45a8-917c-ca753cfc45a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_39b868e8-3c61-4a21-9d3e-c3ce556422a2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1823f506-f93a-45a8-917c-ca753cfc45a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_279f50d3-d0ca-41fe-a81c-e4a751bdfa49" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_279f50d3-d0ca-41fe-a81c-e4a751bdfa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_551780bc-b759-4d9c-bb7f-42d34d17b686" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_551780bc-b759-4d9c-bb7f-42d34d17b686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_59aebc95-94c5-4bfb-9c93-122bdc30c618" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_59aebc95-94c5-4bfb-9c93-122bdc30c618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3bb8a5f4-3186-48c7-bb95-295d78e6d42c" xlink:href="sgmo-20210331.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09bf8bb4-1f0c-4df4-849e-d91c9fe4cf26" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3bb8a5f4-3186-48c7-bb95-295d78e6d42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8e0bd841-c48c-4c57-9769-b827793d4286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0f35e743-e5a8-4953-afe9-198f9d75cfca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8e0bd841-c48c-4c57-9769-b827793d4286" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0f35e743-e5a8-4953-afe9-198f9d75cfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3810ceb0-03e5-41d4-a0dc-81a3116091ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8e0bd841-c48c-4c57-9769-b827793d4286" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3810ceb0-03e5-41d4-a0dc-81a3116091ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_df4061f3-2e62-450b-bb93-8acd696c95d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8e0bd841-c48c-4c57-9769-b827793d4286" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_df4061f3-2e62-450b-bb93-8acd696c95d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e0006b82-709a-4007-9c47-03067731b2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9ad5724e-860d-4b95-8e70-6d3f947bec07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e0006b82-709a-4007-9c47-03067731b2f3" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_9ad5724e-860d-4b95-8e70-6d3f947bec07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20210331.xsd#BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6debbb40-a3f6-42e1-b133-85fa356528da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_aff735ea-2695-4dae-a43a-738683680d02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6debbb40-a3f6-42e1-b133-85fa356528da" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_aff735ea-2695-4dae-a43a-738683680d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4869693c-c29d-47af-b243-ca86913d4070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a39501de-85c7-4201-93be-9238631b4946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4869693c-c29d-47af-b243-ca86913d4070" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a39501de-85c7-4201-93be-9238631b4946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd926156-de2c-4fcd-8b4f-e3dcf6de3cb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8f5bfc55-d55a-4b52-8070-2c1485c727ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fd926156-de2c-4fcd-8b4f-e3dcf6de3cb5" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_8f5bfc55-d55a-4b52-8070-2c1485c727ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541d26b6-a9c1-4ab6-9cb9-7b3502264029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_390c2842-90b4-4283-b5e2-911071e8d8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_541d26b6-a9c1-4ab6-9cb9-7b3502264029" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_390c2842-90b4-4283-b5e2-911071e8d8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_78edcfe8-9046-451d-91b2-9ffe7c855a89" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_390c2842-90b4-4283-b5e2-911071e8d8d9" xlink:to="loc_srt_CounterpartyNameAxis_78edcfe8-9046-451d-91b2-9ffe7c855a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6058117-e176-41ee-9d2a-4e3c1ac00e0d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_78edcfe8-9046-451d-91b2-9ffe7c855a89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6058117-e176-41ee-9d2a-4e3c1ac00e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_97db0897-964c-4e59-a869-fb5e0ac39634" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6058117-e176-41ee-9d2a-4e3c1ac00e0d" xlink:to="loc_sgmo_KitePharmaIncMember_97db0897-964c-4e59-a869-fb5e0ac39634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_9ca961e9-6d37-4977-89f9-8e39a2a872da" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b6058117-e176-41ee-9d2a-4e3c1ac00e0d" xlink:to="loc_sgmo_SanofiMember_9ca961e9-6d37-4977-89f9-8e39a2a872da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_24dae7e2-dbb0-4856-86b0-aec0d560cd24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_390c2842-90b4-4283-b5e2-911071e8d8d9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_24dae7e2-dbb0-4856-86b0-aec0d560cd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_e548435b-5e84-4739-8357-583cf406e1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_24dae7e2-dbb0-4856-86b0-aec0d560cd24" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_e548435b-5e84-4739-8357-583cf406e1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41434d91-4a16-448b-acf3-931a52cf3c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41434d91-4a16-448b-acf3-931a52cf3c24" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3a829b6c-afaf-4f7a-886c-5a9812b39cc3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_srt_CounterpartyNameAxis_3a829b6c-afaf-4f7a-886c-5a9812b39cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3a829b6c-afaf-4f7a-886c-5a9812b39cc3" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6914cc92-63e7-414f-8cca-c02c6e7a99c0" xlink:href="sgmo-20210331.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6914cc92-63e7-414f-8cca-c02c6e7a99c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_d3dbf7a1-9487-42ce-8bb7-1ae53f688d31" xlink:href="sgmo-20210331.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_BiogenMAIncMember_d3dbf7a1-9487-42ce-8bb7-1ae53f688d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_f923039b-b433-426e-9f59-4c281869f84f" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_KitePharmaIncMember_f923039b-b433-426e-9f59-4c281869f84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_beee8be9-05d5-4bc5-a9b1-db77d3cd0053" xlink:href="sgmo-20210331.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_PfizerMember_beee8be9-05d5-4bc5-a9b1-db77d3cd0053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_10df3d11-4b8d-4c06-99b9-afdba6d6dbfd" xlink:href="sgmo-20210331.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_PfizerSB525Member_10df3d11-4b8d-4c06-99b9-afdba6d6dbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_f5ce96e9-e322-428d-bc35-0644f9f45954" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_22cb4dc7-dcbe-4ab8-ad1d-48286141d28d" xlink:to="loc_sgmo_SanofiMember_f5ce96e9-e322-428d-bc35-0644f9f45954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d16cc420-46ca-407f-87a9-70c7352c975e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d16cc420-46ca-407f-87a9-70c7352c975e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2b0f5d7-c1f9-43df-875b-390a62b40de9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d16cc420-46ca-407f-87a9-70c7352c975e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2b0f5d7-c1f9-43df-875b-390a62b40de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_6fb1d236-3611-454f-8da0-b7b9407c9bac" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2b0f5d7-c1f9-43df-875b-390a62b40de9" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_6fb1d236-3611-454f-8da0-b7b9407c9bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_4ca61d62-1249-4b0e-a254-e3ae34fdefd0" xlink:href="sgmo-20210331.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d2b0f5d7-c1f9-43df-875b-390a62b40de9" xlink:to="loc_sgmo_StockPurchaseAgreementMember_4ca61d62-1249-4b0e-a254-e3ae34fdefd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c9d8cbff-31fb-4321-a8f3-03a0734817aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c9d8cbff-31fb-4321-a8f3-03a0734817aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c9d8cbff-31fb-4321-a8f3-03a0734817aa" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_56751186-dced-4ca8-b56a-c0e5710e3078" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_56751186-dced-4ca8-b56a-c0e5710e3078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_e6718451-7ce2-490d-a121-fff5b3b074e4" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_e6718451-7ce2-490d-a121-fff5b3b074e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_c9a269ef-4806-4388-92a8-e2e21dfcc31b" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_c9a269ef-4806-4388-92a8-e2e21dfcc31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_856b0cdb-93b3-49fa-9420-ae258de8e35f" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_856b0cdb-93b3-49fa-9420-ae258de8e35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_8334cca6-fd50-4c64-9257-73efc5198505" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_8334cca6-fd50-4c64-9257-73efc5198505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_12af563c-39f3-4b09-a650-94ab25fc31e4" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_12af563c-39f3-4b09-a650-94ab25fc31e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_02dc45fc-11e0-4fbd-acfc-fe1ad6d7844f" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_02dc45fc-11e0-4fbd-acfc-fe1ad6d7844f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_6625e70f-bc71-4a35-b656-40429f3a47e6" xlink:href="sgmo-20210331.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_6625e70f-bc71-4a35-b656-40429f3a47e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_7e19ea46-8c8e-45f2-8d51-2d3099ca012f" xlink:href="sgmo-20210331.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9c4c33eb-11f7-42dd-ac38-184517f2fef2" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_7e19ea46-8c8e-45f2-8d51-2d3099ca012f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_9945277f-ac24-4f61-98c7-65f341f67a97" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_9945277f-ac24-4f61-98c7-65f341f67a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_9945277f-ac24-4f61-98c7-65f341f67a97" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_c26bb025-70a3-4e3c-87a8-a3b613e8b751" xlink:href="sgmo-20210331.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_PreApprovalMilestoneMember_c26bb025-70a3-4e3c-87a8-a3b613e8b751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_92b86916-c1e3-41f4-9d0c-25f877148077" xlink:href="sgmo-20210331.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_SalesBasedMilestoneMember_92b86916-c1e3-41f4-9d0c-25f877148077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_34e38217-2db4-4ef8-b88a-1906b03e0cf0" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_MilestoneTwoMember_34e38217-2db4-4ef8-b88a-1906b03e0cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_316d65cb-64e5-41bf-9d3e-863c6c8de4e7" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_MilestoneThreeMember_316d65cb-64e5-41bf-9d3e-863c6c8de4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_47305399-1c9a-46c2-a335-e2893261a5af" xlink:href="sgmo-20210331.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_47305399-1c9a-46c2-a335-e2893261a5af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PhaseThreeClinicalTrialMember_07ba53bf-f918-4912-b51a-69192abcae6e" xlink:href="sgmo-20210331.xsd#sgmo_PhaseThreeClinicalTrialMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_5dd08379-c8a4-4a90-9e7e-eac27ef28f2d" xlink:to="loc_sgmo_PhaseThreeClinicalTrialMember_07ba53bf-f918-4912-b51a-69192abcae6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_74a41027-74b2-4d81-a220-d79751940b46" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_srt_RangeAxis_74a41027-74b2-4d81-a220-d79751940b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c0c956c-bd12-40c5-88fe-a8c346a5fdda" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_74a41027-74b2-4d81-a220-d79751940b46" xlink:to="loc_srt_RangeMember_8c0c956c-bd12-40c5-88fe-a8c346a5fdda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7cb45341-524f-4aaa-a997-c8b8e215c5eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8c0c956c-bd12-40c5-88fe-a8c346a5fdda" xlink:to="loc_srt_MaximumMember_7cb45341-524f-4aaa-a997-c8b8e215c5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_srt_ProductOrServiceAxis_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c15bc5f2-9558-49a6-a8ec-2b1e5d94003c" xlink:to="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_3f929a1e-3567-4f43-83ea-8db3679a400e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_us-gaap_LicenseAndServiceMember_3f929a1e-3567-4f43-83ea-8db3679a400e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_e210ade7-c1a8-460d-8c1c-298cabbb8bf7" xlink:href="sgmo-20210331.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_e210ade7-c1a8-460d-8c1c-298cabbb8bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_8519bd05-b282-4475-8641-fde6cae4bfd8" xlink:href="sgmo-20210331.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_SBFiveTwoFiveMember_8519bd05-b282-4475-8641-fde6cae4bfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_10b20771-4c8a-49ad-a3db-4e35f417d79b" xlink:href="sgmo-20210331.xsd#sgmo_OtherProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_OtherProductsMember_10b20771-4c8a-49ad-a3db-4e35f417d79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_63a0de69-40c7-4818-aca8-c25c3fd215bf" xlink:href="sgmo-20210331.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_CNineORFSevenTwoMember_63a0de69-40c7-4818-aca8-c25c3fd215bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_60940aca-9b4a-43f7-aef2-167467ef0c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_us-gaap_GrantMember_60940aca-9b4a-43f7-aef2-167467ef0c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_9815a48a-3f8e-4d8a-882e-b234e30abc73" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_MilestoneAchievementMember_9815a48a-3f8e-4d8a-882e-b234e30abc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_39918ce6-f2f9-443c-b1ae-3bec77756cf5" xlink:href="sgmo-20210331.xsd#sgmo_ResearchServicesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_157acf2a-af8a-4321-af80-e2749ae333e9" xlink:to="loc_sgmo_ResearchServicesMember_39918ce6-f2f9-443c-b1ae-3bec77756cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fad2a911-3b5d-42a5-99e7-e5563fad60a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_8611f586-84c3-44c3-a5e0-68cc63af5f47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ProceedsFromCollaborators_8611f586-84c3-44c3-a5e0-68cc63af5f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c0fe180f-80a6-4797-93db-c6b3405469b2" xlink:href="sgmo-20210331.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_c0fe180f-80a6-4797-93db-c6b3405469b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_5e960bef-0eb3-488a-825e-fd9c725a8a1e" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_5e960bef-0eb3-488a-825e-fd9c725a8a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_e6c79a0f-2dc0-42a7-b5fa-f91cfbd33ec2" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_e6c79a0f-2dc0-42a7-b5fa-f91cfbd33ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_a3c0a003-8774-44fa-9903-5799e74cbbd4" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_a3c0a003-8774-44fa-9903-5799e74cbbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_43545ee3-31f2-46a8-b2e7-d7d8744eff25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ContractWithCustomerLiability_43545ee3-31f2-46a8-b2e7-d7d8744eff25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12d02a2c-f0f7-43c7-8c77-fada67138bee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12d02a2c-f0f7-43c7-8c77-fada67138bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0f4d678e-9b45-4737-88ad-5966a5c6cd4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0f4d678e-9b45-4737-88ad-5966a5c6cd4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_47681df4-5df5-443d-96cd-7bcf10375b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_47681df4-5df5-443d-96cd-7bcf10375b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8fb894c5-62e7-4f7e-9bea-0b9eafb9a9d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_8fb894c5-62e7-4f7e-9bea-0b9eafb9a9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_240cf9cb-9272-4392-8983-4c80fcd8b283" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_240cf9cb-9272-4392-8983-4c80fcd8b283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_126fce9e-76aa-4827-b6ec-f322cba3e809" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_126fce9e-76aa-4827-b6ec-f322cba3e809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_5faa0721-4fde-46fe-8577-cb3d6a2d3525" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_5faa0721-4fde-46fe-8577-cb3d6a2d3525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_155b10d6-cea9-45b0-95a8-95cd00ee0b7b" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_155b10d6-cea9-45b0-95a8-95cd00ee0b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_da90bfa5-ff11-4d96-8117-b2802c3f2853" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_da90bfa5-ff11-4d96-8117-b2802c3f2853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_d310804b-2d29-44f9-b076-eb528e34cc40" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_d310804b-2d29-44f9-b076-eb528e34cc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_9b6b9977-a4f0-40b8-9e5d-cef52bd61d67" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_9b6b9977-a4f0-40b8-9e5d-cef52bd61d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_1d822a30-2f21-4c1b-bd48-5eeaef0c30e4" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_1d822a30-2f21-4c1b-bd48-5eeaef0c30e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_53bbcae0-ebc7-4888-9124-df9159277e84" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_53bbcae0-ebc7-4888-9124-df9159277e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_ffac8350-fb28-422e-8ac3-aef5dac558d5" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_ffac8350-fb28-422e-8ac3-aef5dac558d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_c455aaf1-3520-4c80-b641-5bb876fad35f" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_c455aaf1-3520-4c80-b641-5bb876fad35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d060df59-94ba-4e5f-b8a6-86d9c910fe25" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_d060df59-94ba-4e5f-b8a6-86d9c910fe25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_49f90424-535f-4142-bb2b-e69ae3b34eca" xlink:href="sgmo-20210331.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_49f90424-535f-4142-bb2b-e69ae3b34eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_fb995580-e1e7-4ed9-89ab-18fb2c2ab098" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_fb995580-e1e7-4ed9-89ab-18fb2c2ab098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_089fc26b-3a7d-4532-bab0-c1dde19774c5" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_089fc26b-3a7d-4532-bab0-c1dde19774c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_1186e382-dcee-459c-9cab-e9f722c7bf42" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_1186e382-dcee-459c-9cab-e9f722c7bf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_49f43552-efa6-4f43-bed8-1e500bcf9a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_49f43552-efa6-4f43-bed8-1e500bcf9a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_45e5145c-b8dc-49d8-aba8-e227a910b86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_45e5145c-b8dc-49d8-aba8-e227a910b86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_9bf811f8-8d7c-440d-ad13-f2129a0055bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_9bf811f8-8d7c-440d-ad13-f2129a0055bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_5068ab3d-ef93-4f28-a6cf-92d2f5c216a0" xlink:href="sgmo-20210331.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_MilestonePaymentsReceived_5068ab3d-ef93-4f28-a6cf-92d2f5c216a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_257e4132-091e-4a9a-9a0f-9c3f9cac3d68" xlink:href="sgmo-20210331.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_257e4132-091e-4a9a-9a0f-9c3f9cac3d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_79218a89-cf7b-4544-8579-24845a9a249a" xlink:href="sgmo-20210331.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_79218a89-cf7b-4544-8579-24845a9a249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_e297a7ff-6944-4752-9ead-8650887a0cb7" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_e297a7ff-6944-4752-9ead-8650887a0cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_511601e9-2da0-4122-9820-601c8b0a5212" xlink:href="sgmo-20210331.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_511601e9-2da0-4122-9820-601c8b0a5212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_3d6444bf-05af-46e1-8629-8d5fd0f131ea" xlink:href="sgmo-20210331.xsd#sgmo_SeparateUpfrontFee"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_SeparateUpfrontFee_3d6444bf-05af-46e1-8629-8d5fd0f131ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_edf571c0-c01e-43df-820c-76c3b346d2d5" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_edf571c0-c01e-43df-820c-76c3b346d2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_9a2a57c6-3650-4cc6-9f68-d401a8fbaa48" xlink:href="sgmo-20210331.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_AgreementTerminationTerm_9a2a57c6-3650-4cc6-9f68-d401a8fbaa48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8aa5f3f8-9389-4f63-9f3f-bbb6e048106d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_8aa5f3f8-9389-4f63-9f3f-bbb6e048106d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_39d69764-1796-4710-92bb-f328c7d32ae9" xlink:href="sgmo-20210331.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_39d69764-1796-4710-92bb-f328c7d32ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_f6decf39-9a76-466d-808e-8a6d29541c2c" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_MilestoneRevenueReceivable_f6decf39-9a76-466d-808e-8a6d29541c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_1c4fd515-46b2-4cdc-95b0-60710307c83a" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_1c4fd515-46b2-4cdc-95b0-60710307c83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_1003f9d4-463c-40b4-bc88-e7ce0c6eee74" xlink:href="sgmo-20210331.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_1003f9d4-463c-40b4-bc88-e7ce0c6eee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_896c83cd-2320-448d-9240-f42e89b59dce" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_896c83cd-2320-448d-9240-f42e89b59dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_96aa1d01-d97e-42ac-bf93-8e8fd9b0cb1e" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_96aa1d01-d97e-42ac-bf93-8e8fd9b0cb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_4f1d6c18-faf6-42e6-8810-1ebaf2f70506" xlink:href="sgmo-20210331.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_4f1d6c18-faf6-42e6-8810-1ebaf2f70506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_3d55f2da-94d6-46be-bdc6-c738e4e0f67f" xlink:href="sgmo-20210331.xsd#sgmo_NumberOfResearchProgram"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_NumberOfResearchProgram_3d55f2da-94d6-46be-bdc6-c738e4e0f67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal_65a34fcd-9f05-4ffe-b409-b06606117bec" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementMilestoneRevenueReversal"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementMilestoneRevenueReversal_65a34fcd-9f05-4ffe-b409-b06606117bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_55257662-18a1-4528-b825-57ad96f4ec0f" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_55257662-18a1-4528-b825-57ad96f4ec0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_c18759ea-bdda-4192-8147-0c50e7ded8ec" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_c18759ea-bdda-4192-8147-0c50e7ded8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_301dccff-1bc4-409f-b446-7ed85dea3fe0" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_301dccff-1bc4-409f-b446-7ed85dea3fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_493044c7-84db-4a4b-b9b0-ef1c4903f044" xlink:href="sgmo-20210331.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_493044c7-84db-4a4b-b9b0-ef1c4903f044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_edc57c8a-5b95-4561-88ed-b72fd103f572" xlink:href="sgmo-20210331.xsd#sgmo_GrantFundingAmount"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_sgmo_GrantFundingAmount_edc57c8a-5b95-4561-88ed-b72fd103f572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce466267-b940-4076-9d2e-96210c15dcf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2893e604-b3aa-4fbe-863b-eef47247f06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="54" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_b85967b9-f3b3-45b2-8ecc-f22c008b3514" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2893e604-b3aa-4fbe-863b-eef47247f06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8598ad98-d467-4a0c-81f4-b2e1b33a117a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8598ad98-d467-4a0c-81f4-b2e1b33a117a" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:to="loc_srt_CounterpartyNameAxis_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d250c98f-7908-4847-bca6-785cbbc380af" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_00f43531-03ef-40d7-ae3b-9d29c7b7d9ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d250c98f-7908-4847-bca6-785cbbc380af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_723e63be-a385-4cba-9557-446fcf96aff7" xlink:href="sgmo-20210331.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d250c98f-7908-4847-bca6-785cbbc380af" xlink:to="loc_sgmo_KitePharmaIncMember_723e63be-a385-4cba-9557-446fcf96aff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_a402e632-bbc1-4e01-bd0c-a0dcdcda8809" xlink:href="sgmo-20210331.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d250c98f-7908-4847-bca6-785cbbc380af" xlink:to="loc_sgmo_SanofiMember_a402e632-bbc1-4e01-bd0c-a0dcdcda8809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe80141c-a041-4669-b73f-6bcd26a2fd94" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:to="loc_srt_ProductOrServiceAxis_fe80141c-a041-4669-b73f-6bcd26a2fd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fe80141c-a041-4669-b73f-6bcd26a2fd94" xlink:to="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_c720854e-6e12-48b1-b367-580de87d8fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:to="loc_us-gaap_LicenseAndServiceMember_c720854e-6e12-48b1-b367-580de87d8fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_5c6674a1-a503-4f04-a5bc-74f3983ae3ee" xlink:href="sgmo-20210331.xsd#sgmo_ResearchServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:to="loc_sgmo_ResearchServicesMember_5c6674a1-a503-4f04-a5bc-74f3983ae3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_ad41b2a6-ac05-4fea-9ba7-9c020c6cdca3" xlink:href="sgmo-20210331.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbf29c3a-ab2c-4723-9d8d-d05674fa5c36" xlink:to="loc_sgmo_MilestoneAchievementMember_ad41b2a6-ac05-4fea-9ba7-9c020c6cdca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_38a2e688-2447-498d-b9ef-5e76ce4dc03a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_96020676-45da-44ea-861a-2ff11c34e71e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_38a2e688-2447-498d-b9ef-5e76ce4dc03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54fdb0c-6363-4515-b260-0985b4de1da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_38a2e688-2447-498d-b9ef-5e76ce4dc03a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f54fdb0c-6363-4515-b260-0985b4de1da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sgmo-20210331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f3ee6c15-3f87-4947-a883-a6eb254328c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_61016727-983a-4c49-92a9-f8953300d656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3ee6c15-3f87-4947-a883-a6eb254328c7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_61016727-983a-4c49-92a9-f8953300d656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="sgmo-20210331.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_12699337-69c7-48f3-a98a-5d20e139be96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e0c73032-582c-45d6-9b67-57ae0e7435b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12699337-69c7-48f3-a98a-5d20e139be96" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e0c73032-582c-45d6-9b67-57ae0e7435b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2952472b-4842-4250-8bc6-6ab231b93cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f79333ab-82f5-46dd-a7b3-d28881b348b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2952472b-4842-4250-8bc6-6ab231b93cfa" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f79333ab-82f5-46dd-a7b3-d28881b348b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e53fe59-a0e9-43fb-b39b-cc3a9dcc3361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4f424b24-8560-4e7e-bd5c-6603c4c1c941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e53fe59-a0e9-43fb-b39b-cc3a9dcc3361" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4f424b24-8560-4e7e-bd5c-6603c4c1c941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTableTextBlock_bfdae53b-ac75-4b3a-9fb1-f094cfcad3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0e53fe59-a0e9-43fb-b39b-cc3a9dcc3361" xlink:to="loc_us-gaap_OtherCommitmentsTableTextBlock_bfdae53b-ac75-4b3a-9fb1-f094cfcad3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_efb30e0b-46e6-4509-a105-a4b900b3bc39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:href="sgmo-20210331.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_efb30e0b-46e6-4509-a105-a4b900b3bc39" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_e51ed51a-a1b1-4f35-86ea-5d65a77b25c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_2df30a23-6ac4-4fe1-b00a-2aac94b36ad2" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_e51ed51a-a1b1-4f35-86ea-5d65a77b25c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_1978eca0-dbc6-4522-8a65-eb9facf0aa11" xlink:href="sgmo-20210331.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_e51ed51a-a1b1-4f35-86ea-5d65a77b25c5" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_1978eca0-dbc6-4522-8a65-eb9facf0aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5d7ba94b-4fdc-4488-b120-3abec2d4508b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5d7ba94b-4fdc-4488-b120-3abec2d4508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56c36292-f4f5-4e2d-8a98-a43c68a9ea8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5d7ba94b-4fdc-4488-b120-3abec2d4508b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56c36292-f4f5-4e2d-8a98-a43c68a9ea8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_b1327567-9cb3-4f3c-8d1d-42d7e8518a86" xlink:href="sgmo-20210331.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56c36292-f4f5-4e2d-8a98-a43c68a9ea8f" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_b1327567-9cb3-4f3c-8d1d-42d7e8518a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_ef863f08-f072-4e34-b1a2-25bfdce86843" xlink:href="sgmo-20210331.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56c36292-f4f5-4e2d-8a98-a43c68a9ea8f" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_ef863f08-f072-4e34-b1a2-25bfdce86843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_srt_StatementGeographicalAxis_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8a617a94-bcf0-4163-96e4-c3a9ec3d7a9f" xlink:to="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_da4db150-2bfd-486a-bfcc-b2af98595cf4" xlink:href="sgmo-20210331.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_da4db150-2bfd-486a-bfcc-b2af98595cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_28a8dc4f-7720-4dd5-9f76-eb76149fb357" xlink:href="sgmo-20210331.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:to="loc_sgmo_RichmondCaliforniaMember_28a8dc4f-7720-4dd5-9f76-eb76149fb357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_65621243-b38f-4483-82e0-8a085d929e0a" xlink:href="sgmo-20210331.xsd#sgmo_ValbonneFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8fe85665-e2f6-4e1b-94ff-bc5eb1abbe18" xlink:to="loc_sgmo_ValbonneFranceMember_65621243-b38f-4483-82e0-8a085d929e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_755752f2-2438-424e-9ef5-f4030a5f547f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_srt_RangeAxis_755752f2-2438-424e-9ef5-f4030a5f547f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8a559f0-7ed1-4092-97f9-58a93d03d807" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_755752f2-2438-424e-9ef5-f4030a5f547f" xlink:to="loc_srt_RangeMember_e8a559f0-7ed1-4092-97f9-58a93d03d807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b99cabcb-2481-4c20-a767-064365e878ed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8a559f0-7ed1-4092-97f9-58a93d03d807" xlink:to="loc_srt_MinimumMember_b99cabcb-2481-4c20-a767-064365e878ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c32c2ff1-5fba-4492-9363-a5f2ed306147" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8a559f0-7ed1-4092-97f9-58a93d03d807" xlink:to="loc_srt_MaximumMember_c32c2ff1-5fba-4492-9363-a5f2ed306147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:href="sgmo-20210331.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_f1ff4594-0d3e-4bfd-82aa-abf9e0d9366e" xlink:to="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_e8aa4c22-6989-44ac-97f2-60160343e332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_e8aa4c22-6989-44ac-97f2-60160343e332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_645daa1b-cb05-43dd-b168-026efe4cbbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_645daa1b-cb05-43dd-b168-026efe4cbbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cefeefbc-252a-463c-a1f3-22e7368ae48c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_OperatingLeaseCost_cefeefbc-252a-463c-a1f3-22e7368ae48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_df7ebcc1-d15c-4c0d-b7a5-400074551ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_VariableLeaseCost_df7ebcc1-d15c-4c0d-b7a5-400074551ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_af01ba84-72da-4d81-b26b-d09565e2be04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_OperatingLeasePayments_af01ba84-72da-4d81-b26b-d09565e2be04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_110c3195-0d40-4c33-a0b3-19b46728c9da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_110c3195-0d40-4c33-a0b3-19b46728c9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_59f497ed-d756-445a-981e-08425ae1a410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_59f497ed-d756-445a-981e-08425ae1a410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate_01bdf273-54ed-4713-96d9-b39358b1b840" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseAreaOfRealEstate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate_01bdf273-54ed-4713-96d9-b39358b1b840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAmount_4a9a859f-0c83-425a-8b6f-5a3a5312f46e" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_sgmo_LesseeOperatingLeaseAmount_4a9a859f-0c83-425a-8b6f-5a3a5312f46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_e52afbba-8451-46b3-957e-a9c004fa6724" xlink:href="sgmo-20210331.xsd#sgmo_LicenseObligations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_b83a27e7-4765-436e-a8c6-59a394d2104a" xlink:to="loc_sgmo_LicenseObligations_e52afbba-8451-46b3-957e-a9c004fa6724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ff271a6e-ed6a-40b7-9e90-542719b4f7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ff271a6e-ed6a-40b7-9e90-542719b4f7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8cfc62c0-05b4-4645-853d-6706d8282ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8cfc62c0-05b4-4645-853d-6706d8282ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9bc9a9e3-fd42-471f-b680-23c4ff215665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9bc9a9e3-fd42-471f-b680-23c4ff215665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_981082aa-9860-4ebe-a5db-d5837b816476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_981082aa-9860-4ebe-a5db-d5837b816476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_04f79ec8-3e76-4ed4-91aa-7207c187690d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_04f79ec8-3e76-4ed4-91aa-7207c187690d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_9c3cd6e2-4ab9-48ca-a528-5ffcc9767b71" xlink:href="sgmo-20210331.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_9c3cd6e2-4ab9-48ca-a528-5ffcc9767b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b430c339-9c93-400a-82f7-f1e1594c4d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b430c339-9c93-400a-82f7-f1e1594c4d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c4297f52-ed4b-4d9d-8587-e33498fc740f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c4297f52-ed4b-4d9d-8587-e33498fc740f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_84e1de5e-6c32-4d8f-857d-ad9005ed108d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_OperatingLeaseLiability_84e1de5e-6c32-4d8f-857d-ad9005ed108d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3ef4e905-a2f8-44fc-b9ad-202ee4dce74e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3ef4e905-a2f8-44fc-b9ad-202ee4dce74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_350436fe-1ffa-4ebb-9958-83f5a01b9ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_350436fe-1ffa-4ebb-9958-83f5a01b9ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7f0bb63b-360c-44e8-a6dc-a6f48fa1fffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0316d45-b66d-4a42-bae9-c10794c2dc16" xlink:to="loc_us-gaap_OperatingLeaseLiability_7f0bb63b-360c-44e8-a6dc-a6f48fa1fffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3f20d31c-1806-49d8-87a9-15115db9a475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_042b5429-6936-4ecc-b245-6a32cf0d260c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3f20d31c-1806-49d8-87a9-15115db9a475" xlink:to="loc_us-gaap_OtherCommitmentsTable_042b5429-6936-4ecc-b245-6a32cf0d260c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_377699c6-8f40-4d67-a246-f9393ba25db4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_042b5429-6936-4ecc-b245-6a32cf0d260c" xlink:to="loc_srt_CounterpartyNameAxis_377699c6-8f40-4d67-a246-f9393ba25db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82a599a7-1de9-4baf-9b23-d8799be86cb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_377699c6-8f40-4d67-a246-f9393ba25db4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82a599a7-1de9-4baf-9b23-d8799be86cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember_d9d9b52f-6908-4b3e-bc1d-223ed4baf8da" xlink:href="sgmo-20210331.xsd#sgmo_BrammerBioMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82a599a7-1de9-4baf-9b23-d8799be86cb8" xlink:to="loc_sgmo_BrammerBioMAMember_d9d9b52f-6908-4b3e-bc1d-223ed4baf8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember_7725ae5f-314a-46b4-b95d-73598a3e6c12" xlink:href="sgmo-20210331.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82a599a7-1de9-4baf-9b23-d8799be86cb8" xlink:to="loc_sgmo_LonzaNetherlandsBVMember_7725ae5f-314a-46b4-b95d-73598a3e6c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_13bb3c48-a738-4a47-904b-6960827c509b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_042b5429-6936-4ecc-b245-6a32cf0d260c" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_13bb3c48-a738-4a47-904b-6960827c509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_5631a8e3-85bd-4cef-8ae0-c0cf4ff3edd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_13bb3c48-a738-4a47-904b-6960827c509b" xlink:to="loc_us-gaap_ContractualObligation_5631a8e3-85bd-4cef-8ae0-c0cf4ff3edd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_656010a6-6cdf-4feb-b615-6348a483887c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ebdf08ea-f283-45da-a14b-5dd64a5f0253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_656010a6-6cdf-4feb-b615-6348a483887c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ebdf08ea-f283-45da-a14b-5dd64a5f0253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8b7e0ca-fa34-48a5-b747-c175fc4cd9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_97c1e1ce-1007-4a77-a51c-041c60606fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8b7e0ca-fa34-48a5-b747-c175fc4cd9bd" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_97c1e1ce-1007-4a77-a51c-041c60606fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fa9ceb6-23a6-4e51-bf80-5e01f33d39e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_48e89b56-b629-43e9-8203-c98bf40de4d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3fa9ceb6-23a6-4e51-bf80-5e01f33d39e4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_48e89b56-b629-43e9-8203-c98bf40de4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6e438eaa-fccc-449a-b50e-6458a75daab9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_48e89b56-b629-43e9-8203-c98bf40de4d4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6e438eaa-fccc-449a-b50e-6458a75daab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_39dbab0d-e81e-411d-b102-6011e2c8e175" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6e438eaa-fccc-449a-b50e-6458a75daab9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_39dbab0d-e81e-411d-b102-6011e2c8e175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d976d36e-28ac-4024-a609-e9fb82b6c492" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39dbab0d-e81e-411d-b102-6011e2c8e175" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d976d36e-28ac-4024-a609-e9fb82b6c492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6fd42e79-d9e9-4b47-889d-c32ff51b325b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_39dbab0d-e81e-411d-b102-6011e2c8e175" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6fd42e79-d9e9-4b47-889d-c32ff51b325b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a1c7f1ac-31d8-4481-ba46-ded21a17cf4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_48e89b56-b629-43e9-8203-c98bf40de4d4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a1c7f1ac-31d8-4481-ba46-ded21a17cf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_487b5b7c-6b31-4041-9cb4-2e613be38a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a1c7f1ac-31d8-4481-ba46-ded21a17cf4e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_487b5b7c-6b31-4041-9cb4-2e613be38a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a776a0c6-71c0-4f28-aa35-3f35d1991566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9f7a2af1-165f-46cc-8d7f-401a62d377fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a776a0c6-71c0-4f28-aa35-3f35d1991566" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9f7a2af1-165f-46cc-8d7f-401a62d377fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#STOCKHOLDERSEQUITYNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_05a40c60-b160-40a3-8498-1d0f805fc47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_05a40c60-b160-40a3-8498-1d0f805fc47a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3fbaca0b-401b-477f-96e9-86b39aae94ce" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:to="loc_srt_CounterpartyNameAxis_3fbaca0b-401b-477f-96e9-86b39aae94ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c71cc22d-666d-42b8-8e21-a9105c527d18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3fbaca0b-401b-477f-96e9-86b39aae94ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c71cc22d-666d-42b8-8e21-a9105c527d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_286dc002-8908-4fb0-808c-9976d8bca139" xlink:href="sgmo-20210331.xsd#sgmo_JefferiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c71cc22d-666d-42b8-8e21-a9105c527d18" xlink:to="loc_sgmo_JefferiesLLCMember_286dc002-8908-4fb0-808c-9976d8bca139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_875ef221-905c-49df-9b12-297ff7cbd7ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_875ef221-905c-49df-9b12-297ff7cbd7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee639a8a-f466-401a-8117-ad3ed9aac74b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_875ef221-905c-49df-9b12-297ff7cbd7ea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee639a8a-f466-401a-8117-ad3ed9aac74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_2db8d2c0-78c9-49f5-8f67-8c2d3f1912a9" xlink:href="sgmo-20210331.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ee639a8a-f466-401a-8117-ad3ed9aac74b" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_2db8d2c0-78c9-49f5-8f67-8c2d3f1912a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b42dcabd-1507-4dd4-850e-d08ef9b15414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ff116ad3-3455-4721-9fc4-c6996f84015c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ff116ad3-3455-4721-9fc4-c6996f84015c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_6a0d1ae0-a19c-4f37-9e46-b83876dc7eb8" xlink:href="sgmo-20210331.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_6a0d1ae0-a19c-4f37-9e46-b83876dc7eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_71089fd9-df89-427a-8b9d-88b7af2956d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_60849c95-e0f2-43df-ba9f-372efce4d3e6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_71089fd9-df89-427a-8b9d-88b7af2956d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2cc7e2c0-7f45-4cfc-87ae-20a7a9ec5c43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_580027bd-5eb2-4488-b8e7-fc9d4a366ce9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c2a475ed-ce52-483a-af8d-5c266d2ee7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_580027bd-5eb2-4488-b8e7-fc9d4a366ce9" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_c2a475ed-ce52-483a-af8d-5c266d2ee7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_792e40fc-d0ea-4bb4-831e-5ae3ab904355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_13eff6e3-0910-4d4f-a4c1-351d01ac0e85" xlink:href="sgmo-20210331.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_792e40fc-d0ea-4bb4-831e-5ae3ab904355" xlink:to="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_13eff6e3-0910-4d4f-a4c1-351d01ac0e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1a34283c-76e4-4e37-b3eb-9fc5708d7d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1a34283c-76e4-4e37-b3eb-9fc5708d7d9e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_887830bf-c5f5-47ca-a117-5bbffbe5f3fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_887830bf-c5f5-47ca-a117-5bbffbe5f3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6cad6f27-6e7b-4c6f-a5e3-5933dfb6861c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_887830bf-c5f5-47ca-a117-5bbffbe5f3fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6cad6f27-6e7b-4c6f-a5e3-5933dfb6861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_b1c86043-5301-40c0-86dd-ff85822b8a5c" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6cad6f27-6e7b-4c6f-a5e3-5933dfb6861c" xlink:to="loc_sgmo_SangamoFranceMember_b1c86043-5301-40c0-86dd-ff85822b8a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_cba46a54-842b-43ce-bd05-74beb2ba6614" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:to="loc_srt_OwnershipAxis_cba46a54-842b-43ce-bd05-74beb2ba6614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f19be0fd-4e59-45cf-911d-71adff78d95d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_cba46a54-842b-43ce-bd05-74beb2ba6614" xlink:to="loc_srt_OwnershipDomain_f19be0fd-4e59-45cf-911d-71adff78d95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_9d114417-6f3a-4858-ac52-82025ce8733c" xlink:href="sgmo-20210331.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f19be0fd-4e59-45cf-911d-71adff78d95d" xlink:to="loc_sgmo_SangamoFranceMember_9d114417-6f3a-4858-ac52-82025ce8733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_44d98811-e8d7-4eed-82e4-d1e1045def96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_44d98811-e8d7-4eed-82e4-d1e1045def96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3b27201-ae74-4f62-aeaf-9c4c382a6183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_44d98811-e8d7-4eed-82e4-d1e1045def96" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3b27201-ae74-4f62-aeaf-9c4c382a6183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_21462841-c2c4-4dae-8da7-51addb048008" xlink:href="sgmo-20210331.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3b27201-ae74-4f62-aeaf-9c4c382a6183" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_21462841-c2c4-4dae-8da7-51addb048008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4d00bcec-99ec-44dc-a296-0ff9befcf7c2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_eb419b8a-7baf-4357-841c-2de350a821cd" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_eb419b8a-7baf-4357-841c-2de350a821cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_ff6372b7-5d03-47ed-a00f-10a2b9112612" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_ff6372b7-5d03-47ed-a00f-10a2b9112612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_8ee7652b-1e43-43f6-9ac2-201d399cbbd2" xlink:href="sgmo-20210331.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_8ee7652b-1e43-43f6-9ac2-201d399cbbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1f87754f-c1c7-4b2c-85df-2d79b187a072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_1f87754f-c1c7-4b2c-85df-2d79b187a072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_815c9ee1-dae3-4e94-ae85-51a8a1a196ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_815c9ee1-dae3-4e94-ae85-51a8a1a196ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_535bbbc8-1503-44f3-9118-f30331d79c1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_535bbbc8-1503-44f3-9118-f30331d79c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_393b81a8-ef56-41b3-86da-daf101271cd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0c5c574f-b22e-44e9-927a-50f892b2c750" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_393b81a8-ef56-41b3-86da-daf101271cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20210331.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_c4965f9f-78eb-48b6-ad78-2370902ef018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_4e5e097a-7bfd-41de-a32d-482bdab899ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_c4965f9f-78eb-48b6-ad78-2370902ef018" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_4e5e097a-7bfd-41de-a32d-482bdab899ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_009268b9-4bb1-4ba4-aef1-4c52bbc77ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_4e5e097a-7bfd-41de-a32d-482bdab899ce" xlink:to="loc_us-gaap_MinorityInterest_009268b9-4bb1-4ba4-aef1-4c52bbc77ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c22086d8-daeb-46f6-9cc3-bc2e3ba92abf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_4e5e097a-7bfd-41de-a32d-482bdab899ce" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_c22086d8-daeb-46f6-9cc3-bc2e3ba92abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_770d2fe9-b119-4117-834e-92efca5bb517" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_4e5e097a-7bfd-41de-a32d-482bdab899ce" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_770d2fe9-b119-4117-834e-92efca5bb517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_9b1070fe-a8fa-47c8-ba4c-b47413ddee2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_4e5e097a-7bfd-41de-a32d-482bdab899ce" xlink:to="loc_us-gaap_MinorityInterest_9b1070fe-a8fa-47c8-ba4c-b47413ddee2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_01a.jpg
<TEXT>
begin 644 image_01a.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M /KXH_\ !2O_ ,=H ^XJ*^'?^'PWP!]?%'_@I7_X[1_P^&^ /KXH_P#!2O\
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M#Z^*/_!2O_QV@#[BHKX=_P"'PWP!]?%'_@I7_P".T?\ #X;X ^OBC_P4K_\
M': /N*BOAW_A\-\ ?7Q1_P""E?\ X[1_P^&^ /KXH_\ !2O_ ,=H ^XJ*^'?
M^'PWP!]?%'_@I7_X[1_P^&^ /KXH_P#!2O\ \=H ^XJ*^'?^'PWP!]?%'_@I
M7_X[1_P^&^ /KXH_\%*__': /N*BOAW_ (?#? 'U\4?^"E?_ ([1_P /AO@#
MZ^*/_!2O_P =H ^XJ*^'?^'PWP!]?%'_ (*5_P#CM'_#X;X ^OBC_P %*_\
MQV@#[BHKX=_X?#? 'U\4?^"E?_CM'_#X;X ^OBC_ ,%*_P#QV@#[BHKX=_X?
M#? 'U\4?^"E?_CM'_#X;X ^OBC_P4K_\=H ^XJ*^'?\ A\-\ ?7Q1_X*5_\
MCM'_  ^&^ /KXH_\%*__ !V@#[BHKX=_X?#? 'U\4?\ @I7_ ..T?\/AO@#Z
M^*/_  4K_P#': /N*BOAW_A\-\ ?7Q1_X*5_^.T?\/AO@#Z^*/\ P4K_ /':
M /N*BOAW_A\-\ ?7Q1_X*5_^.T?\/AO@#Z^*/_!2O_QV@#[BHKX=_P"'PWP!
M]?%'_@I7_P".T?\ #X;X ^OBC_P4K_\ ': /N*BOAW_A\-\ ?7Q1_P""E?\
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ME?\ X[1_P^&^ /KXH_\ !2O_ ,=H ^XJ*^'?^'PWP!]?%'_@I7_X[1_P^&^
M/KXH_P#!2O\ \=H ^XJ*^'?^'PWP!]?%'_@I7_X[1_P^&^ /KXH_\%*__':
M/N*BOAW_ (?#? 'U\4?^"E?_ ([1_P /AO@#Z^*/_!2O_P =H ^XJ*^'?^'P
MWP!]?%'_ (*5_P#CM'_#X;X ^OBC_P %*_\ QV@#[BHKX=_X?#? 'U\4?^"E
M?_CM'_#X;X ^OBC_ ,%*_P#QV@#[BHKX=_X?#? 'U\4?^"E?_CM'_#X;X ^O
MBC_P4K_\=H ^XJ*^'?\ A\-\ ?7Q1_X*5_\ CM'_  ^&^ /KXH_\%*__ !V@
M#[BHKX=_X?#? 'U\4?\ @I7_ ..T?\/AO@#Z^*/_  4K_P#': /N*BOAW_A\
M-\ ?7Q1_X*5_^.T?\/AO@#Z^*/\ P4K_ /': /N*BOAW_A\-\ ?7Q1_X*5_^
M.T?\/AO@#Z^*/_!2O_QV@#[BHKX=_P"'PWP!]?%'_@I7_P".T?\ #X;X ^OB
MC_P4K_\ ': /N*BOAW_A\-\ ?7Q1_P""E?\ X[1_P^&^ /KXH_\ !2O_ ,=H
M ^XJ*^'?^'PWP!]?%'_@I7_X[1_P^&^ /KXH_P#!2O\ \=H ^XJ*^'?^'PWP
M!]?%'_@I7_X[1_P^&^ /KXH_\%*__': /N*BOAW_ (?#? 'U\4?^"E?_ ([1
M_P /AO@#Z^*/_!2O_P =H ^XJ*^'?^'PWP!]?%'_ (*5_P#CM'_#X;X ^OBC
M_P %*_\ QV@#[BHKX=_X?#? 'U\4?^"E?_CM'_#X;X ^OBC_ ,%*_P#QV@#[
MBHKX=_X?#? 'U\4?^"E?_CM'_#X;X ^OBC_P4K_\=H ^XJ*^'?\ A\-\ ?7Q
M1_X*5_\ CM'_  ^&^ /KXH_\%*__ !V@#[BHKX=_X?#? 'U\4?\ @I7_ ..T
M?\/AO@#Z^*/_  4K_P#': /N*BOAW_A\-\ ?7Q1_X*5_^.U[=^S3^V#X!_:N
M;Q'_ ,(,=4(T'[-]L_M*T$'^O\W9M^8Y_P!2^?3B@#W2BBOGG]H[]M[X<_LL
M^(-*T;QP=6%YJEJUW;_V;9B=?+#E#N)<8.1Z4 ?0U%?#O_#X;X ^OBC_ ,%*
M_P#QVC_A\-\ ?7Q1_P""E?\ X[0!]Q45\._\/AO@#Z^*/_!2O_QVC_A\-\ ?
M7Q1_X*5_^.T ?<5%?#O_  ^&^ /KXH_\%*__ !VC_A\-\ ?7Q1_X*5_^.T ?
M<5%?#O\ P^&^ /KXH_\ !2O_ ,=H_P"'PWP!]?%'_@I7_P".T ?<5%?#O_#X
M;X ^OBC_ ,%*_P#QVC_A\-\ ?7Q1_P""E?\ X[0!]Q45\._\/AO@#Z^*/_!2
MO_QVC_A\-\ ?7Q1_X*5_^.T ?<5%?#O_  ^&^ /KXH_\%*__ !VC_A\-\ ?7
MQ1_X*5_^.T ?<5%?#O\ P^&^ /KXH_\ !2O_ ,=KZ9^ _P =?#7[1GP_MO&G
MA(7G]BW$TMO']NA$,NZ-MK97)XS[T >DT444 %%%% !1110 4444 )CG-+11
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4@4+T%+10
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6>:&V*RW/[B:,Y@2U&_RW_?Z'Q#\->$_B9X@UG3=2\<:AI\^H:=#X$FNM?\
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MK^'2(="W?VC<R)):Q2O,GFQO(4EE$DLS>>ZM*3+)ESO;/<T4 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"B^?&S_P *M?\ XS7V+10!\=?\.V['_HOGQL_\*M?_ (S7T)\%_A/'\&/
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M* "BBB@ KF-1\&Q/>SW^F74VBZG. );BU"LLVW.WS(V!1CDCYL!\# 85T]%
M'*7EYXHTNUD<V^DZJ(U9VD\Z6S. ,\+LEYQ_M=L]\!MG>>*=6LXY5@TC2EF1
M7CE\V6].",\IMBYQ_M=_;!Z#6/\ D#WW_7!__033/#__ " =-_Z]H_\ T$4
M9>G^$X5O+>]U2XDUK4H0?*N+E558<]?+C4!5/^U@O@X+$5TE%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8GA'_D%S_]A"^_
M]*I:VZQ/"/\ R"Y_^PA??^E4M;= !1110 4444 %%%% !1110 4444 <WX^_
MY =K_P!A73?_ $N@KI*YOQ]_R [7_L*Z;_Z705TE !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M %+6/^0/??\ 7!__ $$TSP__ ,@'3?\ KVC_ /013]8_Y ]]_P!<'_\ 033/
M#_\ R =-_P"O:/\ ]!% &A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &)X1_Y!<_\ V$+[_P!*I:VZQ/"/_(+G_P"PA??^
ME4M;= !1110 4444 %%%% !1110 4444 <WX^_Y =K_V%=-_]+H*Z2N;\??\
M@.U_["NF_P#I=!724 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 4M8_Y ]]_UP?\ ]!-,\/\
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M^,?_ $9Q\1O^^+W_ .0*/^'C'QC_ .C./B-_WQ>__(% 'WO17P1_P\8^,?\
MT9Q\1O\ OB]_^0*/^'C'QC_Z,X^(W_?%[_\ (% 'WO17P1_P\8^,?_1G'Q&_
M[XO?_D"C_AXQ\8_^C./B-_WQ>_\ R!0!][T5\$?\/&/C'_T9Q\1O^^+W_P"0
M*/\ AXQ\8_\ HSCXC?\ ?%[_ /(% 'WO17P1_P /&/C'_P!&<?$;_OB]_P#D
M"C_AXQ\8_P#HSCXC?]\7O_R!0!][T5\$?\/&/C'_ -&<?$;_ +XO?_D"OJ?]
MGWXJ:]\9/AO;>)O$?@35?AQJDT\L3:!K(D%Q&J,0KG?%&V&ZCY?SH ]0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-8M[B=U7EF"(Y8@9&2!QD5W-?/?Q44+^V9\ L?\ 0&\4_P#H&GU]"4 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M((RI&#@@'ZBKU% '.?\ "N/"?_0KZ-_X+X?_ (FC_A7/A/\ Z%?1O_!?%_\
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M_P#"3NO_ )'KZ0_X9H^$/_1*O!?_ (3UG_\ &Z/^&:/A#_T2KP7_ .$]9_\
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M_#-'PA_Z)5X+_P#">L__ (W0!\W_ /#P[]C[_H*:?_X2=U_\CT?\/#OV/O\
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M[]C[_H*:?_X2=U_\CU](?\,T?"'_ *)5X+_\)ZS_ /C='_#-'PA_Z)5X+_\
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M(?\ HE7@O_PGK/\ ^-T?\,T?"'_HE7@O_P )ZS_^-T ?.'_#PW]C[_H)Z?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI?\ 7G;?^ED%>@?!K_DHGQV_['.V_P#4>T:@#U>BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *^$OV_O^14_:)_[$KP5_P"G
M[5*^[:^$OV_O^14_:)_[$KP5_P"G[5* /NVBBB@ HHHH **** *6L?\ ('OO
M^N#_ /H)IGA__D Z;_U[1_\ H(I^L?\ ('OO^N#_ /H)IGA__D Z;_U[1_\
MH(H T**** "BBB@ HHHH ^>OV^/^38-?_P"POH/_ *>;*N]^%7_(]?&/_L:X
M/_3'I5<%^WQ_R;!K_P#V%]!_]/-E7>_"K_D>OC'_ -C7!_Z8]*H ](HHHH *
M*** "BBB@ HHHH **** /+?VI'CC_9F^+C2J&B7PAJY=<9R!939&*\T_83\<
M> /B)X5^)&O?#'1X- \%W'BXK96%MIT=@D972M-60B%/E7,@<\=<Y[UZ-^UC
M_P FL_&3_L3-9_\ 2*:OE;_@BK_R:SXI_P"QSNO_ $AL: /T HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS3
MXH_"V]\>ZA;ZAIVL0Z7?6^DWNDI]JM9YHBEU/92.S>3<02<+:%<+(N?-SG"E
M6]+HH \/M/V>;[0[?Q=9Z'XFMM.M/$EP1<2MHZO<P6DC74EQ'$5E6)93+>2O
M&_E>6O5X9I'EDDZC0_AOJ=GJ.K'5]5T_7-*O=9&J)9W5G=3&!%D>:%%,]Y+&
MDD<P@D$D<:*/*.V-259/2** /#--_9QE\.^(/"VI:-XB\A])@M;6\>\%]-->
M11LK/&LBWJ>7$=GR0E7A0R2YC?< I_PS3''X!D\+PZ\G^D7HDN[^;34>2XM%
M22VBA9-PC=TLS!;[Y5DCD%N#+#*KO&?<Z* /*;SX&VVH75O%<7=L-,BMH0?L
M]F\%^UTGD*9OM22@A2EK;X0)E9(HY-Y,<82[X)^%M]X=\8-XAU/6[;4[C^RX
M;".*VT\P*K".%9Y 7EE*AVMXR%C*<8$IG*1-'Z310 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >.?&;_DV'XN_]@3Q%_P"@W5<3_P $X?\ DS?X=_\
M7FW_ *&U=M\9O^38?B[_ -@3Q%_Z#=5Q/_!.'_DS?X=_]>;?^AM0!],T444
M%%%% !1110 4444 %%%% 'S1_P %)/\ DR/XI?\ 7G;?^ED%>@?!K_DHGQV_
M['.V_P#4>T:O/_\ @I)_R9'\4O\ KSMO_2R"O0/@U_R43X[?]CG;?^H]HU '
MJ]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5\)?M_?\BI^T3_V)7@K_ -/VJ5]VU\)?M_?\BI^T3_V)7@K_ -/VJ4 ?=M%%
M% !1110 4444 4M8_P"0/??]<'_]!-,\/_\ (!TW_KVC_P#013]8_P"0/??]
M<'_]!-,\/_\ (!TW_KVC_P#010!H4444 %%%% !1110!\]?M\?\ )L&O_P#8
M7T'_ -/-E7>_"K_D>OC'_P!C7!_Z8]*K@OV^/^38-?\ ^POH/_IYLJ[WX5?\
MCU\8_P#L:X/_ $QZ50!Z11110 4444 %%%% !1110 4444 >6_M1M''^S/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-QX'OO$7B5-0MM(NK^VO9!;QZ5I]H',EN[I\SVLG&<X'3H:]!\>*!H=K@?\
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MQ6TJYMY(K7X>^-[XV%W8K&Y&G:[*S/#=(>5CBNSNBD7 !N6@8#?/,S>X YH
M6BBB@"EK'_('OO\ K@__ *":9X?_ .0#IO\ U[1_^@BGZQ_R![[_ *X/_P"@
MFF>'_P#D Z;_ ->T?_H(H T**** "BBB@ HHHH ^>OV^/^38-?\ ^POH/_IY
MLJ\5T'2Y?'W_  4>^,GA/4M?\36OAR'3--U%=-T7Q'J.E0_:6LK9&E86D\6Y
MRB(N6SPJ^E>U?M\?\FP:_P#]A?0?_3S95Y+\+/\ E*I\:_\ L7M+_P#26"@#
MWS6/AQX_\(R"]^'?C>:]MXP%7PKXW)OK%U+*S[+X#[;'(</B262Y1=Y BVA
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'GOP._Y$W5/^QG\0_^GB\IOP2_Y%S7O^QGUO\ ].-Q3O@=_P B;JG_ &,_
MB'_T\7E<3\-OC/\ #_PC8^(])U[QUX;T35(?$NLM+8ZCJ]O;S)NOYV4LCN&
M*D'D="* />**\[_X:.^$W_14/!G_ (4%I_\ '*/^&COA-_T5#P9_X4%I_P#'
M* /1**\[_P"&COA-_P!%0\&?^%!:?_'*/^&COA-_T5#P9_X4%I_\<H ]$HKS
MO_AH[X3?]%0\&?\ A06G_P <H_X:.^$W_14/!G_A06G_ ,<H ]$K$\6>*-/\
M%>%]7\0ZO/\ 9-)TFSFO[R8@GRX(D9Y&P.N%4G\*Y;_AH[X3?]%0\&?^%!:?
M_'*\O_:2^.W@GQ%\#?&6C^%O&7@GQ+K&IV+:?_9#^*K"U-S;S,L5RB322;(Y
M/(>78S@J'"Y##((!Z9\#?#=UH_@=-4U6&6#Q+XEG;7]:2<L7CNYU0^1EE5ML
M$2Q6R;E!\NW3(SFO2*^%T_X*'>.(UVK\'?"0 _ZK)X?_ /BZ7_AXEXZ_Z(]X
M1_\ #R>'_P#XN@#[#\??\@.U_P"PKIO_ *705TE?GKXZ_P""CGB/2_#XO]?^
M%.A66BV=]9W5W-I/Q/T74[I8X[J)V\NVB;?*V%QM'KDD $C[,^%?Q0;XEP^(
M4N/#>J^%-4T'4AI5]INL/;/*DIM;>Z5@UO-+&5,=U%T?.<@@8H [ZBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^"O^"A__
M "(O[27_ &(W@W_T^ZI7WK7SI\;/@OXF\>>+_&?E^$O"OC7P?XL\.:5HM[I^
MN>(KS298Y+.[OYPRF"SGW*3>1D,'0@Q'CD4 1_\ !//_ )--\*?]A'6__3Q>
MU]'UYE^SK\*_^%)_!'P7X*<1M>Z7IT:ZC-!<2SQSWTF9;N97E^<J\[RN,@8W
MX 4# ]-H X7XR^!)?B3\+?$WARVDCM]3O;)_[.NI'9!;7J8DM9]P!(,<Z129
M"GE!P>AT_A]XTL_B1X!\-^+=+BN8-/U_3+;5;:.Z15F2*>)945PK$!@K@'#$
M9S@GK72N-RD5^=_PY_8E^/'@OP-H^A:AXRU"_N-/A^S++I/Q<UK3;41*Q$4<
M=LNFNL2I'L0*&Q\F>.E 'Z)45^?'BS]CO]H;4]-$.B>.M3TFX99EDDO_ (P:
M[>QL'MY8T^0:?'RDKQ2\L0WE%",/D>F_\,W^+_\ H0[7_P /WXM_^0Z /JW6
M/^0/??\ 7!__ $$TSP__ ,@'3?\ KVC_ /017R9J/[.GBY+&Z9O MJH$3$G_
M (7QXK;HIYP;/G\:9I/[.OBV32[-E\#6K*T*$-_PO?Q6F<J/X19X'T'2@#[&
MHKY%_P"&;_%__0AVO_A^_%O_ ,AT?\,W^+_^A#M?_#]^+?\ Y#H ^NJ*^1?^
M&;_%_P#T(=K_ .'[\6__ "'1_P ,W^+_ /H0[7_P_?BW_P"0Z /KJBOD7_AF
M_P 7_P#0AVO_ (?OQ;_\AT?\,W^+_P#H0[7_ ,/WXM_^0Z .U_;X_P"38-?_
M .POH/\ Z>;*O)?A9_RE4^-?_8O:7_Z2P5O7'[,?B*_\I;[X::/JL$4\5P+7
M4OC=XGN[=I(I%DC+Q2V+(X5T5L,I&5'%=_\ "CX&ZMIO[0WCCXM^*O#NB:%K
MNO:3I^F1QZ'XBO=35FA,PFED$MO;HI:-;)%"H<>2YR#(^X ^@J*** /)OAV(
M_#OQD^)WAF%,PW(TWQ8K*2JPF\CFLWA5.0/WFE23EP1N:Z?*Y!9_6:^2OVC?
MV<?B7\1/C0GBSP;K3Z7I4NBV.F7*6/C;4?#MS(]O-J$A#?9K699$/VR,AG^9
M3&X& Y)XC_ADGXV=_$_B#_P^.MG_ -Q5 'W917PYX#_96^+>AV^KKXNB3QS=
M7%\9[.ZN/C3XFLWM;7RHU6W;RK/;(0ZR/YA )\S& %%=3_PS?XO_ .A#M?\
MP_?BW_Y#H ^NJ*^1?^&;_%__ $(=K_X?OQ;_ /(='_#-_B__ *$.U_\ #]^+
M?_D.@#ZZHKY%_P"&;_%__0AVO_A^_%O_ ,AT?\,W^+_^A#M?_#]^+?\ Y#H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*/\ AC!_^@!\ ?\ PSA_^6E?55% 'RK_ ,,8/_T /@#_ .&</_RTH_X8P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!XY\9O^38?B[_ -@3Q%_Z#=5Q/_!.
M'_DS?X=_]>;?^AM7;?&;_DV'XN_]@3Q%_P"@W5<3_P $X?\ DS?X=_\ 7FW_
M *&U 'TS1110 4444 %%%% !1110 4444 ?-'_!23_DR/XI?]>=M_P"ED%>@
M?!K_ )*)\=O^QSMO_4>T:O/_ /@I)_R9'\4O^O.V_P#2R"O0/@U_R43X[?\
M8YVW_J/:-0!ZO1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %+6/^0/??]<'_P#033/#_P#R =-_
MZ]H__013]8_Y ]]_UP?_ -!-,\/_ /(!TW_KVC_]!% &A1110 4444 %%%%
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M &P=#\;RW/Q;U77_ !#X4-G(B6F@Z]8Q7 N"R;'+%T^4*'S\W<?6NN_X*-?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %?"7[?W_(J?M$_]B5X*_\
M3]JE?=M?"7[?W_(J?M$_]B5X*_\ 3]JE 'W;1110 4444 %%%% %+6/^0/??
M]<'_ /033/#_ /R =-_Z]H__ $$4_6/^0/??]<'_ /033/#_ /R =-_Z]H__
M $$4 :%>,Z/??\*5^)5UH.IRPP>#_&FJ/=>'IDBVI9:I*K2W=E*V?^6\BR7,
M3G[TDMQ&2I$"R>S5SOC?P3H?Q(\)ZGX:\2:='JFB:E$8+JTE+*&7J"&4AE=2
M RNI#*RJRD$ T = K!AD'-.KQ>&S^)_PHN)8K!&^*'@R-%%M9SW,</B.S&Y%
M$8GF=8+U%4LV^9XI0%^9[AR2;>F?M,>"I-/CNM<.O>"1]F6XF;Q?X?OM)AB8
MJ&:(W,\*P/(H)RL<C?<<C*J30!Z[17-^$_'WASQU#=2^'=;L=:CM9!%.UE.L
M@C8J&"M@\$@@\^M=)0 4444 %%%% !1110 4444 %%%% 'YE?\%EW:/PCI!5
MBF9K('!(SS>\5^FB_=%?"_\ P46^#5G\<+:XT6Z\3P>&)]/T<:S:^= LS7\M
MN+MS;1J9$^8H9'R"Q"Q,=I )'W0OW10 M%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117C/QK_:Z^$_[
M.NL:=I?Q"\5_\(]?ZA ;JVA_LZ[N?,C#%2V88G Y!X)!]J /9J*^5/\ AZ-^
MS)_T4W_R@ZG_ /(M'_#T;]F3_HIO_E!U/_Y%H ^JZ*^5/^'HW[,G_13?_*#J
M?_R+1_P]&_9D_P"BF_\ E!U/_P"1: /JNBOE3_AZ-^S)_P!%-_\ *#J?_P B
MT?\ #T;]F3_HIO\ Y0=3_P#D6@#ZKHKY4_X>C?LR?]%-_P#*#J?_ ,BT?\/1
MOV9/^BF_^4'4_P#Y%H ^JZ*^5/\ AZ-^S)_T4W_R@ZG_ /(M'_#T;]F3_HIO
M_E!U/_Y%H ^JZ*^5/^'HW[,G_13?_*#J?_R+1_P]&_9D_P"BF_\ E!U/_P"1
M: /JNBOE3_AZ-^S)_P!%-_\ *#J?_P BT?\ #T;]F3_HIO\ Y0=3_P#D6@#Z
MKHKY4_X>C?LR?]%-_P#*#J?_ ,BU[G\)?C#X1^.O@V#Q7X'U?^VM!GED@CNO
MLTUOEXVVN-DJ*W!]5H [BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO2O!*7-M-<+;7,]O865U#9L\S0Q,TL$DD<R/*K(7MVE6-E<2F+RY-DNE^-/
M.M_$+QCX,TSP/;W^N>&8C)<P1Q:8KSN(H)0D43SK+\RW,8$CHD6[(+@]?1M9
M\ ^'_$7VD:GI-M?I=.DD\=PF])F39L+J3ABIC0C(^5D5A@C-"^ -$CFOWCLV
MC-_-%<77ESR+YTT8B$<S8;F51!$-_P!["+SQ0!SOA/3]$\3W$B3?"Z30;58U
MEAN]5LK!5G!QPL<<KRHP!Y$B(1T//%=3_P *]\+?]"SH_P#X 1?_ !-:.DZ5
M:Z'I=II]C;16=E:0K;P6UN@2.*-%"JBJ.B@   =@*T* .>_X5[X6_P"A9T?_
M , (O_B:/^%>^%O^A9T?_P  (O\ XFNAHH Y[_A7OA;_ *%G1_\ P B_^)H_
MX5[X6_Z%G1__   B_P#B:Z&B@#GO^%>^%O\ H6='_P# "+_XFC_A7OA;_H6=
M'_\  "+_ .)KH:* .>_X5[X6_P"A9T?_ , (O_B:/^%>^%O^A9T?_P  (O\
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M$W5/^QG\0_\ IXO*;\$O^1<U[_L9];_].-Q0!Z)1110 4444 %%%% !1110
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M^$O_ &P_]2_PC7U70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113=P'4
M_I0 ZBH]X]?YT!@RY'(SC]: )**9YJ^M.R* %HINX'O3?,7U_2@"2BF>8/7]
M*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?M$_]B5X*_\ 3]JE 'W;1110 4444 %%%% %+6/^0/??]<'_ /033/#_ /R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/^B'>/?_  .\/_\ RUJ/_AFCPB?^8OX__P##C>(?_DZE_P"&9_"'_07\?_\
MAQO$/_R=0 __ (7!XL_Z(=X]_P# [P__ /+6D_X7%XL_Z(?X\_\  [P__P#+
M6F?\,T^$ ,_VOX__ /#C>(?_ ).KS[X(_!+1?&'@W4;_ %?Q!X^N[J'Q-X@T
M])/^%A:^F(+;6;RV@3"WH'RQ0QKG&3MR222: /1?^%P>+/\ HAWCW_P.\/\
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MSV\D2,Y74RP4,XSA2<=C7;?\,S^$/^@OX_\ _#C>(?\ Y.KSS]H3X*:+X(^
MOQ*\1Z+X@\?6.M:/X:U/4+&Y_P"%A:])Y4\-K))&^U[TJV&53A@1QR"* /5?
M /\ R4_XF?\ 7W8_^D<=>B5YYX!_Y*=\3/\ K[L?_2*.O0Z "BBB@ HHHH *
M*** "BBB@ HHHH ^5/VNO^2Q?"7_ +8?^I?X1KZKKY4_:Z_Y+%\)?^V'_J7^
M$:^JZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM?">K3QI=^/-<N82RV<K /%+>,DBY'*.I4C(((XH ]?\!_\ )4/B9_U]V/\
MZ1QUZ'7G?@'_ )*?\3/^ONP_](HZ]$H **** "BBB@ HHHH **** "BBB@#Y
M)_;!GN(_C-\'%@@$T3RPK-(7VF)/^$K\*$.!CYLN$7 _O9[5];5\J?M=?\EB
M^$O_ &P_]2_PC7U70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <#\=/!^H?$/X(
M_$'PMI/D_P!J:YX?U#3+3SVVQB::VDC3<V#@;F&3CCFHO _P1\*^ /$$^OZ;
M%J]YK4UK]A_M#7=>O]7GC@WAS%&]W/*8T9PK,J$!BJDYVC&YXUL/%=]I<<?A
M'6M(T345G#27&M:3+J,+1!6!01QW-N0Q8J=Q<@ $;3D$?.^L?'[QUX5^%OPB
MU_Q%XS\ >')?'EY&UQKFJZ-/;Z9I5M)I4UXD;(^I#?(985C$AF0'S!\F>H![
M_P##'PU>>$_"[Z?>^7]H;4]2NQY3;EV3WT\\?/KLD7/OGZU\VQ_LAZU::#XF
MUNT@TG_A/(?B+J'C325N"DMIJ-L]X\L5G=AXGVJ\;MAE7=#,L4BG,8KN]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** //?@=_R)NJ?]C/XA_P#3Q>4WX)?\BYKW_8SZW_Z<;BG?
M [_D3=4_[&?Q#_Z>+RO!=#_9RN/'^I>+-<CTWX3W"7'B35E$GBCX='5[\[+V
M9#YES]OBW@;>/D&!@<XS0!]>45\M_P##'MW_ - ?X#_^&?/_ ,M:/^&/;O\
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M3^(%U:.RT749;^&")--L;,*9I;>!BQ:S9N(\ .HR: /4**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX2_;^_Y%3]HG_L2O
M!7_I^U2ONVOA+]O[_D5/VB?^Q*\%?^G[5* /NVBBB@ HHHH **** *6L?\@>
M^_ZX/_Z":9X?_P"0#IO_ %[1_P#H(I^L?\@>^_ZX/_Z":9X?_P"0#IO_ %[1
M_P#H(H T**** "O*?VL/^36/C'_V)FL_^D,U>K5Y3^UA_P FL?&/_L3-9_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /H)IGA__D Z;_U[1_\ H(I^L?\ ('OO^N#_ /H)IGA__D Z;_U[1_\ H(H
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M HHHH **** "BBB@#SWX'?\ (FZI_P!C/XA_]/%Y3?@E_P BYKW_ &,^M_\
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M964@@KP0010!IT444 4M8_Y ]]_UP?\ ]!-,\/\ _(!TW_KVC_\ 013]8_Y
M]]_UP?\ ]!-,\/\ _(!TW_KVC_\ 010!H4444 %>4_M8?\FL?&/_ +$S6?\
MTAFKU:O*?VL/^36/C'_V)FL_^D,U &GX#_Y*A\3/^ONQ_P#2..O0Z\\\!_\
M)4/B9_U]V/\ Z1QUZ'0 4444 %%%% !1110 4444 %%%% 'RI^UU_P EB^$O
M_;#_ -2_PC7U77RG^UP?^+Q?"7ZP?^I?X1KZLH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "J&H:E:Z3:/=WUS#9VT9 ::XD"(N3@98G R2!^(J
M_2$9H YS_A9'A'_H:-%_\&$/_P 53O\ A8_A/_H:-%_\&$/_ ,57144 <[_P
ML?PG_P!#1HO_ (,(?_BJ/^%C^$_^AHT7_P &$/\ \57144 <[_PL?PG_ -#1
MHO\ X,(?_BJ/^%C^$_\ H:-%_P#!A#_\57144 <[_P +'\)_]#1HO_@PA_\
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M11A(3EB=T3;OFS6K_P %,O"ND:S^R#XYU>]TVWGU71[:.2POI$'FVQEN(8Y
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MHO\ X,(?_BJ/^%D>$?\ H:-%_P#!A#_\57244 <W_P +(\(_]#1HO_@PA_\
MBJ/^%D>$?^AHT7_P80__ !5=)10!S?\ PLCPC_T-&B_^#"'_ .*H_P"%D>$?
M^AHT7_P80_\ Q5=)10!S?_"R/"/_ $-&B_\ @PA_^*H_X61X1_Z&C1?_  80
M_P#Q5=)10!S?_"R/"/\ T-&B_P#@PA_^*H_X61X1_P"AHT7_ ,&$/_Q5=)10
M!S?_  LCPC_T-&B_^#"'_P"*H_X61X1_Z&C1?_!A#_\ %5TE% '-_P#"R/"/
M_0T:+_X,(?\ XJL[3]:T_P 4>.(IM+U:TOX++3Y%86<RR@-++&<L58@$"+C(
M_B-=K7+W<C6/CG3V)46]Y931;FX/FHZ,J YY+*TK8 _Y9DT =16%JRZK?7T5
MI:.VGVFW?-J"[&DZD".-6##.0"69<8P "6RF[7*ZK/J&K>(CI%C?/I<=O;QW
M=U=0HCS.)&E6-$#JRCF)BS$'@  <Y4 <MU>^']8T^RNKR35;34)&ACGG6-9H
MIEC>3!V*JE"D;=@01_$&^3J*YK3?"8M-474+[4KS6KN,;8'OA$/(R,,46.-%
M#,."V,XXS@G/2T %<M%LL?'T\8C9?[1TY9592-I,$A5RPS]XBXBP<<A2#T%=
M37+6H%]X[OIR'<6-E%;Q29(5&E=WE4#/)*I;G..P]Z .IHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** //?@=_P B;JG_ &,_B'_T\7E-^"7_
M "+FO?\ 8SZW_P"G&XIWP._Y$W5/^QG\0_\ IXO*;\$O^1<U[_L9];_].-Q0
M!Z)1110 4444 %%%% !1110 4444 ?-'_!23_DR/XI?]>=M_Z605Z!\&O^2B
M?';_ +'.V_\ 4>T:O/\ _@I)_P F1_%+_KSMO_2R"O0/@U_R43X[?]CG;?\
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M;;);P1E\NY6- %&YV9C@<EB>] '3T444 %%%% !1110 4444 %%%% !1110
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MHW2(GWG53\J?'KX(^+_$'AO]H/QCX(T"?_A,M:FDTZWM9;8(^NZ+<Z!IMM/
M=Q!S%,LLT?\ $LMO)&,":4,C? 3XL?%+PK/-HVO6G@;4]!T'0]"T2U\1:'<S
M;;JP2TU+[7$QN!'%OOA'!(S6TV5T],!P,$ ^Q=%\4Z9X@U+7+&PN?M%UH=ZM
MAJ">6Z^3<-;07*IDC#9AN86RI(^?&<@@;E?/GP7\8W^F^*O'%UX@\(^)-"O/
M%FMZ?JUO;KI-S<0PK)H>E0NCSI'L!CFAFC;=MP8V) %?00Z#M0 M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK#1O^BS? [_PID_^/4?\-8:-_P!%F^!W_A3)_P#'J /IFBOF;_AK#1O^BS?
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M^&__  :0_P#Q5'_#0_PP_P"B@^&__!I#_P#%4 =MK'_('OO^N#_^@FF>'_\
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M_"X\,?\ R97W;10!\)?\*)\;_P#01_:Q_P#"X\,?_)E'_"B?&_\ T$?VL?\
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MO_T$?VL?_"X\,?\ R97W;10!\)?\*)\;_P#01_:Q_P#"X\,?_)E'_"B?&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'GOP._Y$W5/^QG\0_^GB\IOP2_Y%S7O^QGUO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=+))^\9<X+K\JY8YX%?H70 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!Y[\#O^1-U3_L9_$/_ *>+RN'^
M&OC#Q-I=EXDM].\(+JMHGB;6-ET=6A@WYOYR?D<9&"2.?2NX^!W_ ")NJ?\
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M:Q_R![[_ *X/_P"@FF>'_P#D Z;_ ->T?_H(I^L?\@>^_P"N#_\ H)IGA_\
MY .F_P#7M'_Z"* -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M/7_@J?\ %7Q1\(_#_P!M\+:DNF7&K6<&CWCM;Q3>9:RM=-)'B16QDHOS 9&.
M"*_0A<]Z_/?_ (*H_"OQ3\6/#XLO"FE_VK<Z39P:O>I]HBA\NUB:Z$DF9&4'
M!=?E7).>E?H2OW10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7C/QK^&?Q:\<:QIUQ\/?C/_PK"P@@
M,=S9?\(K::O]ID+$B3?,P*8&%VCCC->S44 ?*G_#/'[3O_1W'_F-=+_^.4?\
M,\?M._\ 1W'_ )C72_\ XY7U710!\J?\,\?M._\ 1W'_ )C72_\ XY1_PSQ^
MT[_T=Q_YC72__CE?5=% 'RI_PSQ^T[_T=Q_YC72__CE'_#/'[3O_ $=Q_P"8
MUTO_ ..5]5T4 ?*G_#/'[3O_ $=Q_P"8UTO_ ..4?\,\?M._]'<?^8UTO_XY
M7U710!\J?\,\?M._]'<?^8UTO_XY1_PSQ^T[_P!'<?\ F-=+_P#CE?5=% 'R
MI_PSQ^T[_P!'<?\ F-=+_P#CE'_#/'[3O_1W'_F-=+_^.5]5T4 ?*G_#/'[3
MO_1W'_F-=+_^.4?\,\?M._\ 1W'_ )C72_\ XY7U710!\J?\,\?M._\ 1W'_
M )C72_\ XY7N/PE\*^,/!_@V#3?''C@_$'7TED:36_[*ATSS$9LHGD0DJ-HX
MR#DUW5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M65E\QL+DD;F.,9J]_P *9\6\_P#%]?'_ #_TX^'O_E52_P#"F?%O_1=?'_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y[\#O\
MD3=4_P"QG\0_^GB\IOP2_P"1<U[_ +&?6_\ TXW%.^!W_(FZI_V,_B'_ -/%
MY3?@E_R+FO?]C/K?_IQN* /1**** "BBB@ HHHH **** "BBLW6-8L?#^F76
MI:I?6^G:;91-<75Y>2K%#!$HRSN[$!54 DL3@ '- 'SU_P %)/\ DR/XI?\
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MZ\#GG@&OT.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \]^!W_(FZI_V,_B'_P!/%Y3?@E_R+FO?]C/K
M?_IQN*=\#O\ D3=4_P"QG\0_^GB\IOP2_P"1<U[_ +&?6_\ TXW% 'HE%%%
M!1110 4444 %%%5[BYCM(9)I6V1HI9F[  9)H XKXB?$9_"=QIFC:-IS:_XN
MUAG73='23RE*IM$MQ<2[6\FVBWIOEVM@NB*KR/'&_+:5^SGINK:L=;^).H/\
M3=>,K2Q)JL(72+#(P$L].+-%$%4D"1S).02&E84S]GKPY)K5A>?%/6T,OB;Q
MH!=PM,"6T_222UA8QAE5HU6$I)(F.9YIF[C'M- ',>/(U_L2U('/]J:</SOH
M,UTRJ%Z5SGC[_D!VO_85TW_TN@KI* "BBB@ HHHH \L_:0_Y)[I'_8X^%?\
MU(-/KA/V.?\ D+?M"?\ 95-4_P#2.QKN_P!I#_DGND?]CCX5_P#4@T^N$_8Y
M_P"0M^T)_P!E4U3_ -([&@#Z.HHHH **** "BBB@ HHHH **** "OEBW_P"2
MJ?%3_LJ/AW_TSZ57U/7RQ;_\E4^*G_94?#O_ *9]*H ^IZ*** "BBB@ HHHH
M **** "BBB@ HHHH I:Q_P @>^_ZX/\ ^@FF>'_^0#IO_7M'_P"@BGZQ_P @
M>^_ZX/\ ^@FF>'_^0#IO_7M'_P"@B@#0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /@K_@I=\;M=^!>C7.HZ#:Z?=3ZWI4>@W*ZC%(ZK!.URS,@
M1UPX,:X))')R#7WFN=O-?G;_ ,%8/AUXD^(_AV"T\,Z1/K%QIUO;:G=I!MS#
M;1M=AY3DC@%USCUK]$U^Z* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M, Z%_P!&[_#W_P .IKW_ ,K:/^& ="_Z-W^'O_AU->_^5M 'W9D49%?"?_#
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M_P"N#_\ H)IGA_\ Y .F_P#7M'_Z"*?K'_('OO\ K@__ *":9X?_ .0#IO\
MU[1_^@B@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@G_ (*7
M?&[7?@7HMSJ.A6FGW4^N:5%H-RNI1NZK!.URSL@1UPX,:X))'7@]OO11M4"O
MSG_X*U>!?$/CWPS;6_A[1[S69[&*UU"ZCLXB[0VZ&[#RL!T52RY)_O"OT:H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH \]^!W_(FZI_V,_B'_P!/%Y3?@E_R+FO?]C/K?_IQN*=\#O\
MD3=4_P"QG\0_^GB\IOP2_P"1<U[_ +&?6_\ TXW% 'HE%%% !1110 4444 %
M<-\:?">I>.O@_P".?#6C&W35]8T*^T^S:Z8K")YK>2./>0"0H9AG /&>*[FB
M@#FO /BV#Q]X*T/Q';0R6\.J6<5V+>8,KPEU#&)P0"&0Y4@@$$$$ \5TM>$:
M9'-^S[\1M2MKE%3X:>+M2>^MKW<PBT+5IC&KVTFYR%@NY2\J/A%6X=T.3/$*
M]U5MU '.^/?^0':_]A73?_2Z"NDKF_'W_(#M?^PKIO\ Z705TE !1110 444
M4 >6?M(?\D]TC_L<?"O_ *D&GUX[\!_ T7Q@\4?&V^\4^(O&EU)I7Q"U#2;"
M.Q\9ZO806UHEO:ND20VUU'&%#2N?N_Q>@%>Q?M(?\D]TC_L<?"O_ *D&GUPG
M['/_ "%OVA/^RJ:I_P"D=C0!V_\ PS/X0_Z"WC__ ,.-XA_^3J/^&9_"'_06
M\?\ _AQO$/\ \G5ZO10!Y1_PS/X0_P"@MX__ /#C>(?_ ).H_P"&9_"'_06\
M?_\ AQO$/_R=7J]% 'E'_#,_A#_H+>/_ /PXWB'_ .3J/^&9_"'_ $%O'_\
MX<;Q#_\ )U>KT4 >4?\ #,_A#_H+>/\ _P .-XA_^3J/^&9_"'_06\?_ /AQ
MO$/_ ,G5ZO10!Y1_PS/X0_Z"WC__ ,.-XA_^3J/^&9_"'_06\?\ _AQO$/\
M\G5ZO10!Y1_PS/X0_P"@MX__ /#C>(?_ ).KR?P_:OH7BKQQX<AOM1O-+T7X
MDZ#;V/\ :NH3W\Z))IVGSN&GG=Y9"9)G.7=B 54855 ^KZ^6+?\ Y*I\5/\
MLJ/AW_TSZ50!]3T444 %%%% !1110 4444 %%%% !1110!2UC_D#WW_7!_\
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M^V]U\:=0B\$?#;X)Z/X?\.7=CYDFH>"%?4B[(D[O#-%(BHP#?*=G! /-?7-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD]TC_L<?"O\ ZD&GUPG['/\ R%OVA/\ LJFJ?^D=C7=_M(?\D]TC_L<?"O\
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MH=>>> _^2G?$W_K]L?\ TABKT.@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY8\#<,U^D"T +1110 5Y3^UA_P FL?&/_L3-9_\ 2&:O5J\I_:P_Y-8^,?\
MV)FL_P#I#-0!I^ _^2G?$W_K]L?_ $ABKT.O// ?_)3OB;_U^V/_ *0Q5Z'0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y[\
M#O\ D3=4_P"QG\0_^GB\IOP2_P"1<U[_ +&?6_\ TXW%.^!W_(FZI_V,_B'_
M -/%Y3?@E_R+FO?]C/K?_IQN* /1**** "BBB@ HHHH **** "BBB@#YH_X*
M2?\ )D?Q2_Z\[;_TL@KT#X-?\E$^.W_8YVW_ *CVC5Y__P %)/\ DR/XI?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>_ [_D3=4_
M[&?Q#_Z>+RF_!+_D7->_[&?6_P#TXW%.^!W_ ")NJ?\ 8S^(?_3Q>4WX)?\
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M-[X*?\%6]7^-'B"^TO\ X1WP!X$^R6WVG[9XV\:OIUM-\X7RXW^R-N?YMVW
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M^$6\!^.OM%FM[_:/@OQH^HV<>Z21/*>3[(N)1Y>XKCHZ'O0!^D]%?EU\/_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y[\#O^1-U3_L9_$/_IXO*;\$O^1<
MU[_L9];_ /3C<4[X'?\ (FZI_P!C/XA_]/%Y3?@E_P BYKW_ &,^M_\ IQN*
M /1**** "BBB@ HHHH **** "BBB@#YG_P""DG_)D?Q1_P"O.V_]+(*^6/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SWX'?\B;JG_8S^(?_
M $\7E-^"7_(N:]_V,^M_^G&XIWP._P"1-U3_ +&?Q#_Z>+RF_!+_ )%S7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM+@L4\)7GV0Q,TS%F!U7S-V9W^[(!P..N>]_X9;\?_\ 0]^"_P#PC]1_^75
M'O'_  L[P?\ ]#9H?_@RA_\ BJ/^%G>#_P#H;-#_ /!E#_\ %5X/_P ,M^/_
M /H>_!?_ (1^H_\ RZH_X9;\?_\ 0]^"_P#PC]1_^75 'O'_  L[P?\ ]#9H
M?_@RA_\ BJ/^%G>#_P#H;-#_ /!E#_\ %5\WZ/\ L=^-M#U+7[V'Q]X2EDUJ
M^6_F2;P??[8W6V@M]J8U@$*5MT/S$G+-SC &Q_PRWX__ .A[\%_^$?J/_P N
MJ />/^%G>#_^ALT/_P &4/\ \51_PL[P?_T-FA_^#*'_ .*KP?\ X9;\?_\
M0]^"_P#PC]1_^75'_#+?C_\ Z'OP7_X1^H__ "ZH ]X_X6=X/_Z&S0__  90
M_P#Q5'_"SO!__0V:'_X,H?\ XJO!_P#AEOQ__P!#WX+_ /"/U'_Y=5B^$_V-
MO&W@_2'TZV\?^$KB)[R[O3)<^$+\ONN+F2X<?+K"C"M*RKQG:!DDY) /I+_A
M9W@__H;-#_\ !E#_ /%4?\+.\'_]#9H?_@RA_P#BJ\'_ .&6_'__ $/?@O\
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M_P#0V:'_ .#*'_XJO!_^&6_'_P#T/?@O_P (_4?_ )=4?\,M^/\ _H>_!?\
MX1^H_P#RZH ]C\1?%CP78Z#J5Q<>,-!@MXK6222634X%5%"DEB2W  YR?2F>
M%_BMX*O?#>DSP>,-!F@EM(I(Y(]3@964H"&!#\@CO[UX!XQ_9 \;>(-)C%QX
M]\)1BRN(M03R?"-^07A<.%97UAE93MQ\RG'#+M=4=3P/^R%XUT'PW#!:^.O"
M!BN)I]0/F^$+_<'N)GN'7Y-85<!I6 XZ 9R>: /I?_A9W@__ *&S0_\ P90_
M_%4?\+.\'_\ 0V:'_P"#*'_XJO!_^&6_'_\ T/?@O_PC]1_^75'_  RWX_\
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M/_RZH ]X_P"%G>#_ /H;-#_\&4/_ ,51_P +.\'_ /0V:'_X,H?_ (JO!_\
MAEOQ_P#]#WX+_P#"/U'_ .75<GIWP7\?:A\5/$/@S_A*_!<?]DZ-INK_ &S_
M (1;4CYOVN>_B\O9_;/&S[#G=N.?-Q@;?F /J3_A9W@__H;-#_\ !E#_ /%4
M?\+.\'_]#9H?_@RA_P#BJ\'_ .&6_'__ $/?@O\ \(_4?_EU1_PRWX__ .A[
M\%_^$?J/_P NJ />/^%G>#_^ALT/_P &4/\ \51_PL[P?_T-FA_^#*'_ .*K
MP?\ X9;\?_\ 0]^"_P#PC]1_^75'_#+?C_\ Z'OP7_X1^H__ "ZH ]VC^)'A
M.XECBA\3Z-++(P5(X]0B9F8\  ;N3FNHKYKT/]FSQQINM:?>7'C3PC-#;W$<
MKQP^$]0C=E5PQ56;5V"L0#R5;&>AQBOI2@ HHHH **** "BN?7PUJ &/^$IU
M;_OU9_\ R/2_\(]J'_0T:M_WZL__ (Q0!OT5@?\ "/:A_P!#1JW_ 'ZL_P#X
MQ1_PCVH?]#1JW_?JS_\ C% &_16!_P (]J'_ $-&K?\ ?JS_ /C%'_"/:A_T
M-&K?]^K/_P",4 ;]%8'_  CVH?\ 0T:M_P!^K/\ ^,4?\(]J'_0T:M_WZL__
M (Q0!OT5@?\ "/:A_P!#1JW_ 'ZL_P#XQ1_PCVH?]#1JW_?JS_\ C% &_16!
M_P (]J'_ $-&K?\ ?JS_ /C%'_"/:A_T-&K?]^K/_P",4 ;]%8'_  CVH?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SWX'?\
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M% !1110 4444 ?._Q<_Y'_XA?]@3P=_Z>M1KZ'6OGCXN?\C_ /$+_L">#O\
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M.)B/]$ZA7./<#KTKZ\_9U_9T\.?LR>"[WPQX8O+^]T^ZO5OG?4%ME<.+:"V
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MIMDB%-8TA<K))*I_Y;6B.UPDB_.5A>'D2\ 'LVL?\@>^_P"N#_\ H)IGA_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML<_\A;]H3_LJFJ?^D=C0!]'4444 %%%% !1110 4444 %%%% !1110 4444
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M:[7JU>4^&_\ DZ?XA_\ 8F>&O_2[7: /5J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $WRUZQK'_('OO\ K@__ *":\G_:2_Y,\^*?_8AZI_Z;Y: -7X0_\E ^-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR2;]F'P'-?7]VD?B2RDO
MKRXOYXM/\7:O:0&>>5YIG6&*Z5$WR2.Q"J!EC7K=% 'DO_#+O@;_ )^/&/\
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MC\ ?^%18_P#QVC_AK#X(_P#18_ '_A46/_QV@#U6BO*?^&L/@A_T6/P!Z_\
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M^Q#U3_TWRUZQK'_('OO^N#_^@FO)_P!I+_DSSXI_]B'JG_IOEH U?A#_ ,E
M^-O_ &-]O_Z8-(KU"O+_ (0_\E ^-O\ V-]O_P"F#2*]0H **** "BBB@ K
M\??\B-XB_P"P=<?^BFK?K \??\B-XB_[!UQ_Z*:@#S;X*?\ (Z7?_8D>&?\
MT+4:]HKQ?X*?\CI=_P#8D>&?_0M1KVB@ HHHH **** "BBB@ KRGPW_R=/\
M$/\ [$SPU_Z7:[7JU>4^&_\ DZ?XA_\ 8F>&O_2[7: /5J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M588'_"7?%CP=-'#K7@K3_'UH/,W:AX-O8[&Y8[B4S8WTBQH-A7+"\?)5B%'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO4*\O^$/_)0/C;_V-]O_ .F#2*]0H **** "BBB@ K \??\ (C>(O^P=<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH ^=_BY_R/_P 0O^P)X._]/6HU]#K7SQ\7/^1_^(7_ &!/!W_IZU&OH=:
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M2?\ )D?Q2_Z\[;_TL@KT#X-?\E$^.W_8YVW_ *CVC5Y__P %)/\ DR/XI?\
M7G;?^ED%>@?!K_DHGQV_['.V_P#4>T:@#U>BBB@ HHHH \L_:0_Y)[I'_8X^
M%?\ U(-/KA/V.?\ D+?M"?\ 95-4_P#2.QKN_P!I#_DGND?]CCX5_P#4@T^N
M$_8Y_P"0M^T)_P!E4U3_ -([&@#Z.HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^=_BY_R/\ \0O^P)X._P#3UJ-?0ZU\\?%S_D?_
M (A?]@3P=_Z>M1KZ'6@!:*** *6L?\@>^_ZX/_Z":\G_ &DO^3//BG_V(>J?
M^F^6O6-8_P"0/??]<'_]!->3_M)?\F>?%/\ [$/5/_3?+0!J_"'_ )*!\;?^
MQOM__3!I%>H5\Z^%_C=\._AO\5/C-IGB[Q[X8\+:E+XIMKB.TUK6;:SF>(Z%
MI2B14D=6*ED==P&,JP[5VO\ PUC\$/\ HLGP_P#_  J+'_X[0!ZK17E7_#6/
MP0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\ _P *BQ_^.T ;WQ<\:7/@'P)J
M&IV$4-QK4KPZ?I-O<[O)FU"YE2WM(Y"OS",SRQ[F'W5W'M3_ (8_#VS^&OA2
M'2H76]U":62^U75#$J2ZEJ$K;[FZD X#22%CM7Y4&U%"HJJ/*/$WQ=^&GQB^
M*WPGT#PMX[\,^+=1L]=N-;FL=)U>VN_W,&FWD0=@KD%EFN;=E0?/\ID48B=E
M^BE^Z* %KY?^,'_)W&D_]DM\0?\ I59U]05\B?M%>-?#_@/]J30]0\3:_IGA
MVQN/AOKUI#=:M>1VL<LS75F5B5I" 7(!PHY.#0!R'QJ_Y P_[$>R_P#4>\4U
M]U5^?G[0'B_0/#YL-(U36].TW5K[P38K:V%Y=QQ3W!;1/$D"B.-F#,3--%&,
M#[\J+U8"OT#H 3:/2O%_A7H[_"/XCZY\.XIE3PM?VS>(/"MG@ 64(D6._L8U
M!^6""22UD3(4 7_EH"L''M->.?'K6-+\$ZQ\-_&.M:KIVA:9H_B!H[W4-2FC
M@B6WN+&Z@*&60[8QYSV[DY&?+QWH ]CHKRK_ (:Q^"'_ $63X?\ _A46/_QV
MC_AK'X(?]%D^'_\ X5%C_P#': /5:*\J_P"&L?@A_P!%D^'_ /X5%C_\=H_X
M:Q^"'_19/A__ .%18_\ QV@#U6O*?#?_ "=/\0_^Q,\-?^EVNTO_  UC\$/^
MBR?#_P#\*BQ_^.UR'P_^*W@KQ5\>/BEXHT7QCH.K^&].\&^'Q>ZQ8:G!/9VW
MEW6N22>9,KE$V1LKMN(PK G - %']C'_ )"?[0__ &5?5_\ TELJ^DJ^7/V&
M=<T[Q,GQYU71[^UU72[SXHZK/;7UC.LT$\9M;(JZ.I*LI'0@XKZCH \I^.OA
MFZ708?'6@Z:VI>-?!<=QJ>DV\*MYMZAC_P!)T\;021<1KL'RMB00R;6,8%=W
MX5\4:=XV\,Z1X@T:[%]H^K6D5_972HRB:"5 \;[6 895E." 1GD5L29\LXZU
M\W_!WXY_#'X7^$+OPEXD\<^#O!>H:)KNM6$6A:CJUK82VEG'JETMH/(=U9$:
MV$++A0I5E*C:10!])T5Y98_M0?!S5+ZWLK'XM>!KR[NI%A@M[?Q+9O)+(Q 5
M%42Y+$D  <DFO4Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M " =-_Z]H_\ T$4 >>K\(?%6T?\ %[/'?_@%H'_RKIW_  J'Q5_T6WQW_P"
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MJZ/^%0^*O^BV^.__  !T#_Y5UZA10!Y?_P *A\5?]%M\=_\ @#H'_P JZ/\
MA4/BK_HMOCO_ , = _\ E77J%% 'E_\ PJ'Q5_T6WQW_ . .@?\ RKIC?!_Q
M2W_-;?'@^EEH ]_^@77J=% ')?#OP0GP]\,#2(]5U#6V-W=7LNH:GY/GS2W%
MQ)/(S"&*.,?/*V J 8 ^M=;110 5Y3-\%M4AUG6+[1OBAXO\.V^IWDE])IMA
M;Z1+!'(X4,4,]A))@[<_,YZUZM10!YA9_"KQ1:W]M/)\8O&U[%'(KM;7%GH8
MCE ()1BFFJVT@$':P//!'6O3Z** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\C_:.A2W\(^'-4B41:E9^,?#:VMXO$T GUFSMIPC]5\R">:%\?>CED0Y5B"
M=5X9\?:'\3_AS#XH\,:E#J^A:E:22VMW"" P *L"I&Y65@RLC ,K*RL 00.B
M\/\ _(!TW_KVC_\ 017F?P-&WX4^(P/^AI\6?^GW4*],\/\ _(!TW_KVC_\
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M,:]I'A.V%UI=UJ4-UX7\52:OM\B6VC9)5>RM]F[[2I4@M]QA@=:]CH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M16LXTTWP?JLMU*D2"PUIRGSB-@[-(B>6I5]W[P(5\R-7".MTEI^D>T>E&T4
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M_1[<,+5'3 \N69Y)[ET;YD^T)$W,->QT <[_ ,*[\*?]"QH__@!%_P#$T?\
M"N_"G_0L:/\ ^ $7_P 37144 <[_ ,*[\*?]"QH__@!%_P#$TG_"NO"G_0L:
M/_X 1?\ Q-='10!SO_"N_"G_ $+&C_\ @!%_\37Q1\>M%T./XVRZ/*O@[2+.
M+QQX-N;/3K[2=VH:I,][:1RQV<I9(T$<19I%19G*2-O$2E6D^^:^%OC_  :U
M)\>KN2:[\51^&X_'/@<V]OI,%J=*DO#?6PD-^^TW 41E-G*0^8(\EG*@ 'V1
M_P *]\*_]"SH_P#X 1?_ !-'_"O/"G_0LZ/_ . $7_Q-=#10!SW_  KSPI_T
M+.C_ /@!%_\ $T?\*\\*?]"SH_\ X 1?_$UT-% '/?\ "O/"G_0LZ/\ ^ $7
M_P 31_PKSPI_T+.C_P#@!%_\370T4 >+:YI^G^!_VB/AS-9Z19Z=I^K:/K>C
M^?:QQ0EKQFLKJ&,J"&;,-E>-D*V/+YQFO9U;<H([UYW\;O &J?$#P5Y7AZ\M
MM.\6:5=P:OH=W>B3[.E[ X=%EV'=Y,@WPR;>?+F?'.*UOAK\0K#XF>%(-9L4
MDM95EEL[ZPFQYUA>0NT5Q:R=M\<JNI(RK8#*2K*2 =A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[0=0\*^-/!<<MQI>LR7\4[RZQH]P0N^VA("K<(,D<D-P._URJA<XKX5\5?\
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M;3_XY0!Z117F_P#PTI\(_P#HJ?@K_P *&T_^.4?\-*?"/_HJ?@K_ ,*&T_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M -!%>5_ "\M]2^$.N75I/%<VL_B7Q5+%/#('216US4"K*P)!!&.0:]4\/_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SWX'?\B;JG_8S^(?\ T\7E
M?'W[)YG_ .'B?QX\Z>Z>+[!<^2MPI"1I_:C96(ESE"VYB5"C>SC&06;[!^!W
M_(FZI_V,_B'_ -/%Y7Y4>.&\.^%_VUOBW<^(_B'XR^%PUI+XZ9J7A74CI[7M
M\;V:*".2218D\@F!@6:3R5=?WEQ#AE0 _9FBO+OV9M7O=>_9P^%6IZE>7&HZ
ME>^%-*N+F\NY6EFGE>SB9W=V.69F))).222:]1H **** "BBB@ HHHH ****
M /FC_@I)_P F2_%'VM+;_P!+(*ZC]G/PGH?@?Q/\:]$\.:/I^@:-:^,H?(T_
M2[5+:WBW:#I#MMC0!1EF9C@<EB>]<O\ \%)/^3(_BE_UYVW_ *605Z!\&O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M -;B+*Z:;O;/]X\R?:SE?X?+')SQZG110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRCNYWE6V@%A9.(HPQ.Q SNP5>,LQ[U[M0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!112,P7K0 M)N'K7C^L_'*X\0>)-3\+_  VT#_A--=T]Y+:\U6:?[+H.F7,9
M7?;W5X%=C,,_ZF".5U;:)!$#O%./X.^/_%?FR>-?BUJD*3KL;2? UE#HUFBF
M$H0)7$]YN#,6$BW"<A<(N* /;-P]:-P]:^<O$GP#\.VGQ,\%Z;#K?CQ;.^AO
MWN$/Q UYBYC2(H0QO<C!9OND=:ZBZ^ >IZ'#<OX*^)WC3P_<.LC16^K:A_;]
MIYK1HJM(M^)9RBM&&VQSQ\L^"-U 'LU%>%77QD\9?"&:;_A:OAF&7PS%@_\
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M0+=KM)*^:8&;:X5LDY1<@5],444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UF"C)
MKP?7M<O?V@?&FN>"-#O)+/X>Z'.UAXHUNRG*SZC=!07TNUD1@8@@8"XF4AUS
MY2;7WO'V'QU\=7W@OP/Y6BW,=MXJUZ]@T'03+#YP%]<OL24QY^=(4\RX<?\
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M_P#$#Q?\)+J]9X],VZ_X:@F:)=NC7+N!;0HK;C':7"2P@;56.)[1!_#GW"@
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M_P ^[;USQ0!W5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVO/_ )44 >G45YC_ ,)!\9/^A"\#?^%M>?\ RHH_X2#XR?\ 0A>!O_"VO/\
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M_H0O W_A;7G_ ,J*/^$@^,G_ $(7@;_PMKS_ .5% 'IU%>8_\)!\9/\ H0O
MW_A;7G_RHH_X2#XR?]"%X&_\+:\_^5% 'IU%>8_\)!\9/^A"\#?^%M>?_*BC
M_A(/C)_T(7@;_P +:\_^5% 'IU%>8_\ "0?&3_H0O W_ (6UY_\ *BC_ (2#
MXR?]"%X&_P#"VO/_ )44 >G45YC_ ,)!\9/^A"\#?^%M>?\ RHH_X2#XR?\
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M )44 >G45YC_ ,)!\9/^A"\#?^%M>?\ RHH_X2#XR?\ 0A>!O_"VO/\ Y44
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MMKS_ .5% 'IU%>8_\)!\9/\ H0O W_A;7G_RHH_X2#XR?]"%X&_\+:\_^5%
M'IU%>8_\)!\9/^A"\#?^%M>?_*BC_A(/C)_T(7@;_P +:\_^5% 'IU%>8_\
M"0?&3_H0O W_ (6UY_\ *BC_ (2#XR?]"%X&_P#"VO/_ )44 >G45YC_ ,)!
M\9/^A"\#?^%M>?\ RHH_X2#XR?\ 0A>!O_"VO/\ Y44 >G45YC_PD'QD_P"A
M"\#?^%M>?_*BC_A(/C)_T(7@;_PMKS_Y44 >G45YC_PD'QD_Z$+P-_X6UY_\
MJ*/^$@^,G_0A>!O_  MKS_Y44 >G45YC_P )!\9/^A"\#?\ A;7G_P J*/\
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M3/()Y+@:I+\0]4;4_-DC6*23[>=,^T[FA1(2WF9,2+$?W8VT <I)XZ\6^(O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;X6T>TTK1]/M=*TNSB$-M8V,*PPPQKPJ(B@!5 [ 5JT %%%% !1110 4444
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M -%C\ ?^%18__':/^&LO@C_T6/P!_P"%18__ !VC_ADWX(_]$<\ ?^$O8_\
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M^"/_ $1SP!_X2]C_ /&J #_AK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\
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MH_X9-^"/_1'/ '_A+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\
MT6/P!_X5%C_\=H_X:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&
MJ/\ ADWX(_\ 1'/ '_A+V/\ \:H /^&LO@C_ -%C\ ?^%18__':/^&LO@C_T
M6/P!_P"%18__ !VC_ADWX(_]$<\ ?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_
M /&J #_AK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/
M_1'/ '_A+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5
M%C_\=H_X:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX
M(_\ 1'/ '_A+V/\ \:H /^&LO@C_ -%C\ ?^%18__':/^&LO@C_T6/P!_P"%
M18__ !VC_ADWX(_]$<\ ?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_ /&J #_A
MK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/_1'/ '_A
M+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5%C_\=H_X
M:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\ 1'/
M'_A+V/\ \:H /^&LO@C_ -%C\ ?^%18__':/^&LO@C_T6/P!_P"%18__ !VC
M_ADWX(_]$<\ ?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_ /&J #_AK+X(_P#1
M8_ '_A46/_QVC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/_1'/ '_A+V/_ ,:H
M_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5%C_\=H_X:R^"/_18
M_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\ 1'/ '_A+V/\
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M!_X5%C_\=H_X:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\
MADWX(_\ 1'/ '_A+V/\ \:H /^&LO@C_ -%C\ ?^%18__':/^&LO@C_T6/P!
M_P"%18__ !VC_ADWX(_]$<\ ?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_ /&J
M #_AK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/_1'/
M '_A+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5%C_\
M=H_X:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\
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M (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\ 1'/ '_A+V/\ \:H
M/^&LO@C_ -%C\ ?^%18__':/^&LO@C_T6/P!_P"%18__ !VC_ADWX(_]$<\
M?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_ /&J #_AK+X(_P#18_ '_A46/_QV
MC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/_1'/ '_A+V/_ ,:H_P"&3?@C_P!$
M<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5%C_\=H_X:R^"/_18_ '_ (5%C_\
M':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\ 1'/ '_A+V/\ \:H /^&LO@C_
M -%C\ ?^%18__':/^&LO@C_T6/P!_P"%18__ !VC_ADWX(_]$<\ ?^$O8_\
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M^"/_ $1SP!_X2]C_ /&J #_AK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\
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MH_X9-^"/_1'/ '_A+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\
MT6/P!_X5%C_\=H_X:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&
MJ/\ ADWX(_\ 1'/ '_A+V/\ \:H /^&LO@C_ -%C\ ?^%18__':/^&LO@C_T
M6/P!_P"%18__ !VC_ADWX(_]$<\ ?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_
M /&J #_AK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/
M_1'/ '_A+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5
M%C_\=H_X:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX
M(_\ 1'/ '_A+V/\ \:H /^&LO@C_ -%C\ ?^%18__':/^&LO@C_T6/P!_P"%
M18__ !VC_ADWX(_]$<\ ?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_ /&J #_A
MK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/_1'/ '_A
M+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5%C_\=H_X
M:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\ 1'/
M'_A+V/\ \:H /^&LO@C_ -%C\ ?^%18__':/^&LO@C_T6/P!_P"%18__ !VC
M_ADWX(_]$<\ ?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_ /&J #_AK+X(_P#1
M8_ '_A46/_QVC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/_1'/ '_A+V/_ ,:H
M_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5%C_\=H_X:R^"/_18
M_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\ 1'/ '_A+V/\
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M!_X5%C_\=H_X:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\
MADWX(_\ 1'/ '_A+V/\ \:H /^&LO@C_ -%C\ ?^%18__':/^&LO@C_T6/P!
M_P"%18__ !VC_ADWX(_]$<\ ?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_ /&J
M #_AK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/_1'/
M '_A+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5%C_\
M=H_X:R^"/_18_ '_ (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\
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M (5%C_\ ':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\ 1'/ '_A+V/\ \:H
M/^&LO@C_ -%C\ ?^%18__':/^&LO@C_T6/P!_P"%18__ !VC_ADWX(_]$<\
M?^$O8_\ QJC_ (9-^"/_ $1SP!_X2]C_ /&J #_AK+X(_P#18_ '_A46/_QV
MC_AK+X(_]%C\ ?\ A46/_P =H_X9-^"/_1'/ '_A+V/_ ,:H_P"&3?@C_P!$
M<\ ?^$O8_P#QJ@ _X:R^"/\ T6/P!_X5%C_\=H_X:R^"/_18_ '_ (5%C_\
M':/^&3?@C_T1SP!_X2]C_P#&J/\ ADWX(_\ 1'/ '_A+V/\ \:H /^&LO@C_
M -%C\ ?^%18__':/^&LO@C_T6/P!_P"%18__ !VC_ADWX(_]$<\ ?^$O8_\
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M^"/_ $1SP!_X2]C_ /&J #_AK+X(_P#18_ '_A46/_QVC_AK+X(_]%C\ ?\
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MH_X9-^"/_1'/ '_A+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\
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M\ ?^%18__':/^&3?@C_T1SP!_P"$O8__ !JC_ADWX(_]$<\ ?^$O8_\ QJ@
M_P"&LO@C_P!%C\ ?^%18_P#QVC_AK+X(_P#18_ '_A46/_QVC_ADWX(_]$<\
M ?\ A+V/_P :H_X9-^"/_1'/ '_A+V/_ ,:H /\ AK+X(?\ 18O '_A3V/\
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MH_X9-^"/_1'/ '_A+V/_ ,:H_P"&3?@C_P!$<\ ?^$O8_P#QJ@ _X:R^"/\
MT6/P!_X5%C_\=KM_"/C;P_\ $#1X]8\,:[IOB/2G=HTO])O([J!F4X8"2-BI
M(/49XKB/^&3?@C_T1SP!_P"$O8__ !JNW\(^"?#W@#14TGPOH6F^'-)C=I$L
M-(LX[6!68Y9A'&H7)/4@<T =!1110 @8-T-+5'2]+LM)L_)L;2"SBDDDN7CM
MXEC5I9':220@#EG=W=FZEF)/)-7J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_141.jpg
<TEXT>
begin 644 image_141.jpg
MB5!.1PT*&@H    -24A$4@  "K\    %" 8   #V%&61    "7!(67,  $SE
M  !,Y0%USO"5    :4E$051XG.W:P0D (! #P?3?](E6X$\#LS#_%) D&0
M          #XW2ZO1P            # #>=7             &HXOP(
M      !0XYQ?1Y(D29(D29(D29(D29(D22II 7IYLOC*T4K6     $E%3D2N
#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>sgmo-20210331xex103001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WFZ :W*L
M064$'OR*F'2H+LX@_P"!I_Z$*GH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"%K6%V+/%&Q/4E0<TJV\2,K+&@91@$*,@5
M+10! ;*U))-M"2>Y04AL+,_\ND'_ '[%6** *W]GV1_Y<[?_ +]+_A2?V;8_
M\^5O_P!^E_PJU10!4.EZ>3G[#;?]^E_PJ-]#TF1MTFF63GU:W4_TJ_10!G?V
M#H^,?V58X_Z]T_PH_L#1O^@38?\ @,G^%:-% &>="T@]=*L3_P!NZ?X4IT/2
M#UTNR_\  =/\*OT4 9XT+2!TTNR_\!T_PH_L'1S_ ,PJQ_\  =/\*T** ,_^
MP='_ .@38_\ @.G^%']A:01@Z58X_P"O=/\ "M"B@#/&@Z0OW=*L1]+=/\*#
MH6D$Y.E6)/\ U[I_A6A10!GG0='(P=*L<?\ 7NG^%(- T8# TFP'_;LG^%:-
M% &?_86D8Q_95C_X#I_A3)/#NBRIM;2K+'M H_D*TZ* ,U?#VBJH TFQX];=
M#_2H?^$4T'<6&D68).3MB _E6Q10!C'PGH!_YA5M_P!\4G_"): <_P#$JMN?
M]FMJB@#%'A'P^H &DVP [;:4>$M '_,*MO\ OFMFB@#&_P"$3T$_\PJV_P"^
M:!X3T # TJV _P!VMFB@#&'A+0!_S"K;_OBGKX8T1!A=,MP/0+6M10!C/X3T
M"0Y?2;5OJE*OA304&%TJU4>R5L44 8H\(^'P,?V3:\_[%.7PKH2+M72K95]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** ,OQ%_P @"[_W1_Z$*U!63XF(7PY>D] G]16L
M.E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 87C0[?!FK'
MTMV-;@Z5@>./^1'UG_KU:M\=* %HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .?\<\>!M9_Z]7K?'2N?\=_\B)K?_7H_\JZ!>5% "T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '.^/"%\!ZVQZ"T<_I6U8G
M=86S$Y)B4_H*QO'8!\":V#T^QR?RK8TXYTRT/K"G_H(H LT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '.^/ 6\!:X!U-G)_*MC3/^059_\
M7!/_ $$5D>//^1#US_KSD_E6KI)SHUB3U^SQ_P#H(H N4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 % .1FD/0TD6#$A7IM&* .>\?<^ -=_Z\Y/Y
M5I:!N_X1S3-[;F^R19/J=@K.\> GP%KH'7[')_*K_ATY\,Z43_SYP_\ H H
MTZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?!VB'_IP@_\ 1:T :]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>6:UX>
MUZ;XJ0^(X=*>:QM]J$>8FYP%() STYKU.B@#C+*36;:^2.TT*>UTBRMG,=OY
MB[IY"1@=> ,DUA:IX3U#Q3X3U6XU;3I$UR63-LI<'RU!&U5YQCDY]>:]0HH
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M^5.\!_\ (AZ'_P!><?\ *CQV,^ ]< [V<G\J;X!R/ .A ]19Q_RH Z.BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDL[:XM["/RVM!=32S2;5''W%]352^\>7:Z?HUQINDFXDU,E41I.C D$?IUH
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MG<0LRQ'*\@GK^-=Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6O[?16LI=,OIFN!)<$AK=VZ\#K7?$XJAI^LVFIW=[;6S.9+*013;E(&[V]:
M.<72=:@\?-JZP)-;?V<+3S#*H9V'S9(QQEN*PD\(^(HO"]K"L%L;^TU<:BD?
MF\.,YVY[$9KU"B@#)U73Y=9\-75A<!8YKFV:-@K$JK%>Q],U1\"SM)X2LK:;
MY;JS3[-/&1@HR<8(^@%=)6!;:SH+^(Y[*"9!JQ&V5 C!B!Z\8X]: -747NH[
M"9K*)9;H(?*1FV@MVR:YS1O"ML?#WEZKI=NVH2*_GLQ#%V)/.[MG]*ZVB@#R
M.;2M;T;X:7&B:E';AGN4BLR\H/#-G&>V/7ZUIZ/-KFE:G"-4T99;J]3[-'<_
M;%D8*!D#V7N37?:CIEGJ]FUI?0)/ W)1AW]:IZ1X8TC0W+V-H$D(P9&8LV/3
M)Z4 <UHOA._;P!?>'=21;>65G*.CAQRVX'\P*FTO3O%-]8'2]<%G!9I T+20
M'<\^5*CV YS^%=M0>E '!^&=*\6:4UOI%RMD--M'^6\7!DEC!R%QV^M59?#.
MNOX<\4:<;:'S=5N6GB(F& &(R#[C'ZUU(\8Z";J:V%^#/!_K8Q&Y9/J,<5HZ
M?JMCJT)FL+J*XC!P61LX/H?2@#D)-#UB2^\)2FR41Z9$Z7'[Y<C<H3CUP #^
M-0Z)H?BC0F?1;1+(Z9YK-%?/S)&A.<;>[5Z 3@50TS6[#5Y+I+*;S#:R>5+\
MI&UO3F@#EK70=7@UCQ9=?9H]FI1[;;,H^8A=HSZ>M4(O"^O6]MX5GBMH&NM)
MW12Q/* "IXW9'\NM>D44 (N=HW8W8YQTS7'^-K9M9O-$T>$;F:\6YEP?N1IR
M2?Q(%=C5>.RMXKF6Y2)!/+C?)CYFQP.?PH R_&%A=ZKX6OK"RC62>X0(H9MH
MZC)S6))H^L2ZCX3E^QQJFEH5G8S ]4"' _#]:[>B@#S6Z\,^))&\3"VABA_M
M*X2:-O/ W*N<IQTSZ\5&W@W6KW4KQWLK&PMKVP%LR129$1!SP!U.17IU% 'G
M$FC>++T:%;W%E:*-*N5D\[S^)0HP#@<CBK5MH7B/0]3O8-,CLI[&]G:83SGY
MX2W7CO7>T4 9VIVMW<:!<VEK<%+MX"B3$X^;&,UPMAX6\2PWNB7B6NG6\FGK
M)&P+DE]PP78@<YKTNB@#A/\ A&M4NM;TS49;6ULKJWEWW5S;R?Z]?[NW'4UM
M>+=!FUW3(!:2K%=VLZW$+-T+#L:Z&B@#EX]'O[WQ+;:YJ$44+V=NT4,,4F[<
M[=6)QP.P%+X,TC4='M]0BU".$&XNWN5:)]WW^H_#%=*\BH"2>@R1[53TG5;;
M6;!;VT+F%F*@NNTG!P>* ,/Q'I.JW'B#2-6TM;=WL_,1TF8J,,,9K+M_#FN1
MV7B6*6&V,NKN70K+\J9&.>/>N^HH \]_X1OQ#I-WINJ:6EK-=16*6=Q!*_RD
M+T(/%=GI$=]'IZ_VC)&UTQ+,(AA4_P!D?2K]5K>^M[LRBWD63RGV.5Z!O3-
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MQ7\5\;^SN8$(\N0]00>HX% #+GQ3XNTWPYK=[=6:)]B9&MI[FWV&9"V""H.
M1D5<FU?Q;8Z/;75]<:8@NYXAYR*?W$;(23M)^8YQ@<]ZGO?"&O:GX;OK'4-:
MBN;V\5(F<Q;8XT4Y^51_$3WJQJ_A34M1L-",-_!#J&E,&#&,M$_ '(Z]A^M
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MGQ%I3PV%QK,4NC6[ Q*B$3, <A2>P]?RJM<>"-3N;+Q# ;V!#JEPMRA0-\K
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M5ZM\;ZVGB4_(YZ@Y[4 ;/AO4];O+Z]@U6Q:**,@P3^64$@[\$U/>^'#=Z_\
MVD-0N(D>W,$L$?"R#!P<]L9J71;#5+5I)M6U 74[@*%C3:B 9Z#U.:V* /+O
M$&DR6$_A7PW=7TEU82WC/(THQN"XVH?;DUZ'?:7::E9?9;F,&+@J!P5(Z8]*
MI>)?#L?B"SB7SF@N;>02P3J,E&J&&Q\07,*6VH7MLD(X>2V5A+(![GA<]\4
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M^EO(L;N,HP;;G(&<^_6LG3M3U.V.N>&;G5;F36#>)'932-\WDM@AAD=E!)H
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MXM9!-EY!-H\KJTH'HQ7@_6EN-2U'0=,\)ZD+UTT=TAAO(@JX3*_*V2,X]?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%)FC/- "T4=** "BDSDTI.* "BDS03B@!:*3- (- "T
M4F12T %%&>:.E !13/-CW;=ZYZ8S3Z "BFLZH"68 #N:575QE2"/44 +1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!6U'G3+K_KB_\C3[48LX!_TS7^5,U'_D&7?_
M %Q?_P!!-26O_'I#_P!<U_E0!A>/21X!UPCK]CD_E1X"_P"1!T+_ *\X_P"5
M'CTX\!:X?^G.3^5+X$&/ >AC.<6<?\J .AHHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%%
M!1110 4444 %%%% !1110 4444 %&*** "BBB@ HHHH **** "BBB@ HHHH
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M(AR,\9(/WA2^-O%_B#0O&&F:1836?D:@4VF6 DQY;;@\\^O:@#TRBN/TN_\
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M7VMG5I[(FY)!<!R$<CNRC@_C4UUX/TF\O;BYF6X/VDJ9XA.PCDQ@#*@X/04
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MWS7$\A'#Q#E<_4D#Z5Z#9>']+T_4);ZUM_+N91M=]Y.1Z<GVJW'86D5Y+>)
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M56F8$&-3VQ@8S[5UU5K+3[33H?)L[:*"/KMC4*/TJS0 4444 %%%% !1110
M4444 %%%% !1110 4444 4]5#'2+P*<$P/@^GRFIK3_CS@_ZYK_*H=5<1Z1>
M,3@""0D_\!-36G_'G!_US7^5 &#X_P#^2?Z]_P!><G\JN^%?^1/T3_KP@_\
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M/#UG>S#3IS9SNE]=*6V0LQVHJGC=QD9[&@#U^3Q%HT-E;WDFJ6B6UP<0R-*
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M?%7AL>*-(;39+R2VA=@SF-02V#D#GWK6LX)+>SAAFF,[QH%,A4*7QWP*L44
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MB1\RE2"#@@@]#0!>HK,O-?L++5;'39FD^TWQ(A C)4X!)^;IV^M:= !1110
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MZWK-UJ5W;2VFJ6PMY(XD964*, @DT 4+OQ5KFDZ;HVN7C6UQI]^Z+-!#$0T
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ML-5U_5]0U'34O+:UN-+B032)%O$TS GOT7CMS[U8'@R6UO\ 09+"[C2VTE7
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MYT+6Y-/MKD#[1#LWY(XRN>AJWJ?A?4;NWELH-3C-A+ L+0W,1D*X&-P.?O4
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M$-W=>-]4T*XMHHXK2!)HW5RQ<,>_IQVKIJ\UO;R73OB!XLOK>/S+BWT9)(E
MSR!6/J$'V?P!I/B_3[RX.M%XI'F\YF\]G;#(1G'X>V* /8J*\EUIXO#/BW44
MOH9FL-<L"88P[9%P",HO/&20?RJ/P5-<7Z6/A:^%S%J&E74DUT2[ [ ,KDYY
MRS#\J /7J*\BTF2?3?%>GVVN?:TN+B\9[75+><R0WP).$<9P.HZ=/UKTC1M%
MCTB6_>.\N;C[7<&9EF?<(R>R^@H U:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ JM#I]I;SM-#:P1RO]YTC 9OJ1UJS10 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^GW%M=V5O!8_-'Y@8LS$@G.!T^44 7?#;KXGO9-9O[%[6]TR]F@MT< /&A0
MJV.O4FN,/Q3\5FTUFY2QT@Q:7,L<IQ("V6*C W>U=O)HOB6[U"T>>;2K>UBN
MENITM5<-<,HXR3[@?D*X_P#X5=X@2PURU6[TXKJSK(Q+./**N6P/EYZ^U &A
M8?$G6I/$N@VE]IMG'8ZS$KPF)V:1<\ DGCJ.F/QI;CQSXK?QKJ?ANPL-+FFM
MD>2)GWC<H 8 \\D@X[<U OP^\2+J?AB\,FF8T6-(BHE?]Z%;.?N\=:S(VU ?
M'K5?[.6!K@P$ 3L57'EKW /\J ,_QMXM_P"$R^&5M>26ZP74&H+'/&IR =C<
MCV-=DWC74$U&S\.:%;6CW,&FK<SRW3-L $8(4!><\CGWK)NOA/J@\$1:+:7=
MHUW)>?:KF21F5!\N JX4D_CBM9O VKV6N6^NV!LGO)+ 6=W!)*RINVA=ZMM)
MZ <$=J ,^^^+-^/!MKX@L-+MW1IC;72R.W[F3J#QU4CWKHW\6:G.+^YL(K":
MPMM-6\$NYL[RA;8>W;\ 16)%X:T3PKX"F\+:WJ4*W.I)+,9&R%,B@'Y?]W"_
M7]*TO"/A>?2?ABUC#&DE]>VS2,LAV@LZ\ ]<8&* .9B^,6LKI5CJL^@6_P!B
MN)VA+).0S$#H!VZCDUTNA>/[Z\\6:CH>L:4EBUK 9\I)O(4 ,<^O!!XKD7^&
MOBD^#;#1!#9;[6]>X+_:/O C _AXQ70Z?X0U^3XAW^O7UO:PV=[;-;R(MP79
M04"Y''^S0!!;?%])[^VD-E"NESW36P(FS.HXPY3LO-%[\4-:@U76[*W\/PSK
MI.YII/M!7Y <;L$>]+X2\%^*_#%W<:;'-IQTF282BZ*[I5 QP%/<@ <].HJM
M=^"O$TFM>*[J.SM3%K,30Q_Z2 4&1@GCN!T]Z (O&OCW5+OP+HVH:9 +:'4W
M*RL9/G5E/*#V.T\^E>IZ7+=3:9;RWL*0W+Q@R(C[@#]>]>5WOP\\177PXTO1
MA';"^T^\:4*9OE=#DY![<MT]J]!LV\317&E17$%@UL8#]N=78,DG8(.XZ?K0
M!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 9OB$9\-:J/6TE_P#0#5NRXL;<?],E_E53Q!SX;U3_ *])?_0#5RS_
M ./*#_KFO\J ,+Q\,^ == Z_8Y/Y5LZ:,:7: ]1"G_H(K(\=D#P)K9/3[(_\
MJV-/_P"0;:_]<4_D* +-%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %9:^'-&353JBZ;;B_+;OM 3Y\_6M2B@ HHHH
MH:CHFEZN\+:C86]TT#;HC*@;8?;/TJ_T%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWK<KOA6)2[.OJ !G%5Y_&OAVVL[>[EU.)8;C(B;!.['7@#(_&@#?HKEV\?\
MA]].NKRVNGG^SC+1)$V\_@1T]^E:7AS6X_$.BP:C'%)$)!RKJ1@^Q(Y'O0!K
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9XC_Y%C52/^?.;_T
MU<LCFPMS_P!,E_D*I^(_^18U;_KSF_\ 0#5RQ_X\+;_KDO\ (4 8OCPX\!ZY
MC_GT?^5;&G_\@VU_ZXI_(5B^/CCP#KI_Z<Y/Y5M:<<Z9:G_IBG\A0!9HHHH
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MKZ9H \TU2TLD\/\ @O4/#R1QW[W<$<<D(PSJRGS Q[C(YS73?$VXN;;P3/)
M\B)YL0N&C&2(MPW<5T%CX=T?3;EKFRTVU@F;.7CC //7'I^%:$T,<\+Q2HKQ
MNI5E89!!Z@B@#REM&\/SKJ6HVFNPWLD^EREK:VB1(RBKP7"<*0<=<'-8D.B:
M2GASP)*MFD<][=A+B56(9U/#*3Z&O6[?PGH%K93V<&DVD=M<$&:-8P ^.F?6
MHSX,\.,D2'1[4I%DQJ5X3Z#M0!P=UINGVFH^/].M[:*.S338Y5@4?*'$9.X#
ML<XJBN@Z;8>'_!FI:.@75Y[B#+Q/EY5(S)GGH.]=]K?A:S32=4?2-*@.IWEN
M\&_=M+;Q@DL?S_"F^#_"MGH^F6;S:3;VNI11>7)(A#$GH6![9H XC4[JYM].
M^(KV+'S!>1!BG4)@!_TS5_6+6P37O!5WH$<"/<OY<JP@8DM]HW;@.HY(Y]Z]
M L_#VD:?-/-::?;PR3@K*RI]\'DY]:;9^'],T@.^F:?:V\Q4@,L8'X9ZXSVH
M \X72Y=+\3WW@N.U_P")=J\ZW<<BKQ'$#EU_, "O655(8U1%"(HP !@ #M7.
M>'--ULW4NI>(I+1[W9Y,*VRX$:9R>3W)Q^5=%/!'<P/#,@>*12K*>A!ZB@#R
M+P1H-IK6@:XMQJ5U:YOYXP([DJ@'')7.#^-;7BA+#7]$TV317\S6H)]NF3*%
M#,T?WCS_  <'GIT]:ZE/!7AF,Y70K#\8 ?YU<70=*2YMKA-/MDEM5V0,D87R
MUYX7'0<G\Z /*]0U"VN?A;/)9^9#>?;4_ML*H\T,6/F%AZ9QCMV]:-3LM+BT
M[4]3\/Z[->ZC+I[;DLHT1!&",[E4#:<'Z\&O4K?PYH]K)/)!IEHC7"E9B(A^
M\!Z@^HJ73M%TW2(7AT^RM[:-SEA%&!N^OK0!Q/AQO!U^^C76GF(ZA]C,'D0G
MD#:=_F+[<\GUKBY;S3H_A1]DEFMQ=IJOR1%AO4>8,G'4#&:]HL-"TO2I99;"
MPM[:27[[11A2WU-,;PYHTD\TSZ59/)/S*S0*=Y]3D4 <1IITG_A:VM+/]B$-
MQ8PF$-MQ)E025]<CTJAHNA0>(/A-?6EO%')/#<SR6V,?*ZMD >F1Q^->E3:)
MIEQ<">;3[6258_*#M$I(3^[TZ5+9:98Z:C)8V=O:JQRP@B"!C[X'- 'FUI?Z
MCXA\&ZKXD6U,-W'IYM(%Q\P*C]XR_7M]*B\,VWAN_F\.WT6N3SZA %6.UB6-
M70X^8. H.T8.2?ZUZI%;Q01^7%&D:9)VHH YZ\54LM#TO3;B6XLM/M;>67[[
MQ1!2?RH YKXC7EG%INF6ERB%[F^C6%I7V1(XS\SG^Z,]*\\FFM'L/'UO+>V<
M[.L3QF(!$=QU*+GMTXKVZ_TZSU2U-M?6L5Q"2#LE0,,^O-56\-Z&^=^C:<V0
M%YM4/ Z#I0!YW+86>C^(?!\FF0Q6\TUE*6:->96\K(!]<FL6[O=(N_A.C2S6
M_P#;"W8:<28\XR^9R3GGIC\J]>/AO1?.@F&DV2R0?ZIE@4;/I@4V7PSH<]S+
M<S:18R32G,CO;JQ8^IR* +L,J26"2(ZLC1 A@<@C'7->4^!] L=5\'7K7.JW
M%L7NYMP2YVQ@ \$KTKUB2T@EM6M9(D:!EV&/;\NWTQ62/!GAL# T2R ]/*%
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M1S)90V["*V&>F<99C]3UKW"DP/2@#RG0M7M-)35-"US2KJ:[N;MKB&%K<O\
M:-Q&WMQTZFI_[5'AOQEJY\16<AMM4@C\IHHC*I 7'E@#ZD5ZA@>E&!0!Y+J#
MV]AXAL=5UC3+RRT>:R$-O]F9@8.20&"\C(/(]Z=KZ:/8^&M!FM[%[73!JRR!
M;@'+KSEB#R <=#VKU.:X@MU!FDCC4G +L ,_C6%XF\.W.OR:<T%[';I:7 N,
M-%OWL.G?IUH YB\CAUK6]:U/1XS)9KHS6[RHA EE.2 /7  KHO -[#=>$+&.
M+?NMXQ%)N0KAAVYZ_A73 8&*7&* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH S/$?_ "+&K?\ 7G-_Z :MV/\ R#[;_KDO\A53Q'_R+&K?]><W
M_H!JY8_\>%M_UR7^0H P_'__ "(&N_\ 7G)_*MG3?^07:?\ 7%/_ $$5D>._
M^1#UO_KT?^5;&G<Z9:'_ *8I_P"@B@"S1110 4444 %%%% !1110 4444 %%
M%% !6#XL\1CPUI<=T8E8RSI &D8K'&6_B<@' %;U8?B>#4+G3XXK&QM;]6E
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M'\.(KBU\&6UK=6L]O/$[ADFC*'EB1U]C7">)+'6M1BUV*?1M3DNS>"2#R$Q
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M;2X].NK1Y+?4&U*[DN0P\^8GG 4<#K^0KT.B@#D?$?AS5[_7=&UO2KFSBO+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!F^(#CPYJ9/:TE/_CAJW9'-C;G_IDO\JJ>(?\
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M,E_D*J^("!X<U,GI]DE_] -6K+FQM_\ KDO\J ,+X@?\D_UW_KSD_E6UIO\
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M1\4+IWBG2]$DL9F_M -Y=R&&P%021CKV_6GZ'XF36M7UC3OL4UM+IDB1OYC
M[]P)!&.V!^M &[16'J'B1-/\3Z7HCV<S-J <I."-BE021CJ3Q^M;E !1110
M4444 %%%4]6U :5I5S?M!+.MO&9&CB +$#KC- %RBL[0M7AU[1;35+=&2*YC
M#JK]1[&M&@ HHHH **S]:U5-%TFXU&2WGGC@0NR0KEL#J?PIVC:G%K6CVNI0
MH\<=S&)%5\9 /KB@"]1110 4444 %%%% !1149GB$X@+KYI4N$SR5! )QZ<B
M@"2BBB@ HK/UO5?[%TJ6^^QW-YY>W]S;+N=LD#@>V<U0N/%4%MXET[1'L[@2
MWT32QRD * H)(ZYS[>] &_16)X?\30>(3?K%:W%N]C<FWE2< '</H339/%$$
M?C"#PXUI<"::!IUG( 0@>G<T ;M%%% !15'6-0?2M*N+V.SGO'B7(@@&7?GH
M!5BTG-U9PW!BDA,B!S'(,,N1T(]: )J*** "BN;U/QE;:9KT>BMIVH3WLL9E
MA6&-2)%'4@[O8]:D@\5Q3&[A?3-0AN[:V^TFVEB&Z1>?NX)R<C% '045FZ?K
M$5YI-G?3Q/9&ZVA8;CY7#'HI]ZJZ?XGM=1\2:CHD=O<1W%BJM(TB@*P/3'-
M&Y1110 44A.%)P3CL*YBU\<6E[=WEK;:5JLLUF_ESHL"_(WH?FH ZBBJ&DZM
M#K%JT\,4\6R1HG29-K*PZ@BK] !1110 445$]S#',D+R(LLF2B%N6QUP* ):
M*S-)UE=6DO46SNK?[+,829X]HDQW7U%:= !1110 4444 %%137$4&SS9%3>P
M1=QQECT ]ZR]-\1P:EKVI:0EM<136 0NTJ@!@V<%>>G% &S1110 45C:SXEL
MM%GM[619;B^N3B"T@7=(_J<=@/4U#!XIB;5K73+O3KVSNKG<8A*JE6"C)^8$
MB@#?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#/UY#)X?U*-1DM:R@?]\FK-D,6-N/^F2_RJOK
MC%-!U!QC*VTA&?\ =-6;/_CQM_\ KFO\J ,/Q[_R(6N?]><G\JV=/_Y!MK_U
MQ3^0K&\>@'P%K@/3[&_\JV=._P"09:_]<4_D* +-%%% !1110 4444 %%%%
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M5-3SIAS;AI58#/7JO0CC%:NE>%X-)UW4=6CO;N6:_(,R2LI7(^Z0 !T''T-
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M&$.T]!@?YYK@O#TFMGQAXV31TL"?MBDM=,XPVTXP%&.U>FI&ZP*C2%G"X+D
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M/#*D,DH1BH 9@0#QDX%=GX,3Q#!;75MX@=7:.7-LS2K))Y9Z!RO4CU[UGO\
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MR**76U\$Z-KH\3:I]LN+L0%7EW(%+,.A')XSDU[#?V8O[&>U,LD0F0H7C(#
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M?_7H_P#*MJQQ_9]M@8'E+Q^ K&\=DCP'KA'7[')_*MC3_P#D&VO_ %Q3^0H
MLT444 %%%% !1110 4444 %%%% !1110 5FZWK=EX?TR:_OY5CAC&0">6/8
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M9/09I"ZKG+ 8ZY->%K9)9>!O"OB2.>X;57O8XS</,S'R]S+L )QC '&*VO\
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MG6M+N+G4)(=7M!)IH6XD!2?.-B'/'S$'Z4 >L9K#LM=N4TV]OM<L?[,CMI6
M+R!@Z \-QZUPO@^]N]<.F^'KV2^CO=&><ZBXN7#,02$!8'YLDY_X#Z5AZB);
MWX9:^][=7D[VFM%(FFG9F5=R#!YP>": /49_$LL'C:T\//8$1W,#S+<F08.T
M<C;70UYCK>CPW?C[PQIT-Y>6\'V";][%,1*5QG&\Y/-;?PYGG?2=4MY[J>Y%
MGJD]M$\[[WV+MP">_4T =G17 0R-XI\<>(M,N[RZ@CT^**.VCMIWBQN!+2'!
M&3G'7BN3&H:QK.B^&HI]7OX))-7;3Y)X9BIFC'\1QU;MGVH ]KS1D5E:9HHT
M[11IC7MY=+AE,\\I,I#9_B'<9ZUY3=3ZI;:9K/A47=_)KEO>>;92"ZDWR0D;
MLDY^[M'YF@#V:YDDBM99(8O-E5"4CSC<<<#/:LZSUHG3;*?5+?\ L^ZNG$8M
MG;<=Y/ R.OK7':5>KXPL+G58+F^M(K73Q#^YN70^?MW,>N#@8'/J?PY][?\
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M,YE,K&4R'J^\G)-4-5^'FFOX1ET73X'+R2B3SI+A@^\ @.[8); [?RZUVU%
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M+;92,'D4.VYV!SDMG)Z>M;<420Q)%&NU$4*H'8#I3Z* "BBB@ HHHH ****
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MNF7*W%ON*;P".1U'- &A1110 445F:QXATO0(XY-4NA;12$A9&1BN1V) XH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK@KGX5^)+^QTBQN]=L3;Z6Q\@+ V0"0<GU/%>K7%K'>V,EK=(LD<T9CE7'#
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MU?3]62,WT4FBQ6:0Q0E/WGF+@;BWN*W: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SO$'_(N:G_UZ2_\ H!JU
M9?\ 'C;_ /7)?Y55\0?\BYJ?_7I+_P"@&K=G_P >-O\ ]<U_E0!B>.@3X%UH
M+U^R/C\JWHEV1*N,8 &,YK#\<$#P/K)/3[*_\JWAT% "T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*XM;>[A
M,-S!'-$W5)%# _@:BL]-L=/5ELK*WM@W)$,03/Y"K5% !1110 4444 %%%%
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M9W5G=3QF6W$VTB51G/*DX/'0UI:YX@BT1K2'[-/=75XY2"WAQN<@9/+$ 8%
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MM<2^3\D)+12#JKCL?;OVS6SH6OVOB73&N[6&YBCWM$R3QF-P1UXH UZ*\TT
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M6A;S(RGS+P<9Z\T 7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\#_VY!<W3SV=XJ!@ W179A\H&._OUKTZ[BO[;PE)#8P0?VA'9[(HD'[OS F
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M,6:WE,D4JY X) Y!(K$^)L=G!XD\'W5Q:"8&^99 L.]G7"X7'\77I73^&_\
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M^AJ#X1C;X#C&S81=3_)_=^<\4:AI7B+1O&MUKFB6<&H6^HQ)'<0RR^4T;*,
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M_P!,7_\ 034EI_QYP?\ 7-?Y4 8OCK_D1M:_Z]7_ )5OCH*P/'7_ "(VM?\
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M>Z+;6L>G^*+V)K<.JAX4>,JQSC9_B:>OPTLK>SLC8WT]MJ=G,\Z7X4$LSG+
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M$GC1QY4DT29E8C&TDY!/)Z<GFH-'M)M*L_ 6IVE_?,U[,L$\<DQ\LH1]T+T
MX/:O0+OP#HMY>W]TWVN)[\?OUAN616.,$[0<9(XIG_"OM)\G3X?M&H^5I[;K
M5/M;8C/J* ..T])?%OAWQ+K=Y=W46J6D\PM=D[(+41KE0 #CUR2.:HNU_P"*
M]2\%B\U+4;4ZG9R&Y$$[(&* X8#H"<9/UKT6Y\"Z+<7MU<[+B+[9_P ?44-P
MR1W'^^H//X8J6X\&Z7<:O8ZE_I$<]BH2V6*8JD:CC 4<8(X/K0!R>GZ4-/\
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M3]>N-:U1K36+347Q.9"&M(U(VA1D +PPK6L+:T_X6G?QG#6=YHBR2%S@3 L
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MDZ99_P!J_P!I_9T^V>5Y'G?Q;,YQ^=9.L>!_#NO:E'J&HZ9%-<H -^YEW =
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M?6MRLDAN,S72^63OEQP"3@CDD>M5M!TB.S\(>(_$EG)='5=.N[J.V?SF8(N
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M6-E\1_%MM8B)(,0%4C(P#MRV!]2?I7HM !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $%ZI>QN$ )+1L !W.*=:_\
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M$D=%9XR2C%<E<\<>E17FGV>H1K'>6L%PBG($T8< ^O-6:* &HBQHJ(H55&
M, 4DL4<\31RHKHPPRL,@CW%/HH 8\:21F-U5D8892,@CTQ5>/2]/AADABL;:
M.*3_ %D:0J%?ZC'-6Z* (+>RM;2 P6UM##$>J1H%7\A26EA9V",EG:P6ZL<L
M(8P@)]3BK%% %2[TRPOG5[NRMKAE& 98E<@?B*E:U@>V-L\$30$;?** KCTQ
MTQ4U% %:'3[.V@:"WM8(8G^]''&%5OJ!4-OHNF6EI):6^GVL5O)]^)(E"O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (WW3]*9;
M_P#'M%_N#^5/;[I^E,M_^/:+_<'\J ,+QV<>!-:/I:/_ "KH!TKGO'@SX#UL
M?].C_P JZ%2&4$'((X- "T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 (WW3]*9!_Q[Q?[@_E3S]T_2F0?\>\?^Z/Y4 87CS_D0];S_P ^C_RK:LF#
MV,#*NT&-2!Z<5B>/?^1"US_KT?\ E6SI_P#R#;7_ *XI_(4 6:*** "BBB@
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MJ:+9:CX9AMKJ.><*YN7V8C#$%ASUXX_E7':];V4_Q$UZV"1M&_A^22>-3P9
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MF6YC%P^)W#'ECG)[4 >N!U*[@PV]<YH#H5W!@5]<UX2;ZXM?"-OI0O!!IO\
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M<(O!( [9(!/TKSGP]XAU5O%5II^LZM>6>I^?)YUC=1*L-Q'A@ODL%[<'&>:
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MH=+C22SQ]G82/^[YSQS3[KP5X=O;JYN;C2H'GN?]<_(+_D: /-+;2[#1M+\
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M$7DOCL) !P0JCH<=:]ABAB@C"0QI&@Z*B@#]*1H(7D\QHHV?;MW%03CTSZ4
M>-V]]I,LWPXN+V2$V$5O-#,\ZXC601J "6X^]CGI5?58+--&\?ZA9+''I%T8
M8[0X"I+*OWC&._.>17M3VEM)"L,EO$\2]$9 5'X4K6T#PK"\$;1+C"% 0,=.
M* /+)]0T^?QQ\/@MY X2S<':X."8P%!^I&,52LY;2>P^)T%F\4GF,\D:1$'<
MNTY(QU&?2O718V@96%K &3&T^6,KCTHAM[1=TD,$*[^K(@^;\1UH \QO4BUW
MX8:1J^B.)-0T%(IXV"D?,BCS$YZ\>GI78>"8+B32&UB]C"7FJO\ :I%Q]Q2
M$7\% _.H]>\/7^K7UO:VFK)8Z.(BEW9Q0KNE!.>#VR./S]:Z5&BCB 4J$7Y>
M.@[8H \U\8:K9P>.I[:XE33G.DL#>;"\DZDG]T@Z ^^,UQ^BW^D7-C\/K2>6
M"1[:[F6Y24#Y 3E0V>V?PKWIH())4F>&-I$^ZY4$K]#VIGV"S^7_ $2#Y?N_
MNQQSGCCUH \-UEEENO'$.FE9(Q=6\\D-N<^9"I_>8 Z@=ZZ4^)= U7XG^%;K
M2[F-XOLLT)\N,Y0L,(IXX[_2O3TM+:)R\=O$CMU94 )IL5C9P/OAM((V]4C
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MSH]B899/-=/(7!?UZ=::_A+P])YN_1-/)E #G[.O( P.W'% 'G L--TSQ)X
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M!(8$"11J%55'  Z"I*;&@C14!)"C R23^9ZTZ@ HHHH **** "BBB@ HHHH
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MA6\\YI2X"X"ECSSVQ[UR_C8P/KUYK6CH9-/L_+BUU(9 JSKN'R?[1 X/U^M
M'J<GB'2(M/BOY-0MTM9O]7*7 #_3UIW]OZ4=+_M,:A;_ &'IY_F#;G.,9]<U
MYMX@UG2W\9:%J<^HSVN@RV#+;7-J0%CD)Y!X..,#&*R=0&A:*^AZEIBWEQX?
MCU5Y+J>7+H[[5PX&,;1SSCL<4 >K#Q?X?:Q>]&KVGV9)/*:3S!A6]#Z5//XA
MTBVO%M)M0@2X:,RK&6Y9 ,DCU&!7GWB2YT+6/!WBRY\.VC3M-%')<W<2'9(X
M8' SU(&2<#O5>;7](U'Q]X+-I=QRB&W:.1U!*AF0 +GUSV[=Z .B7QSI?B/P
M[JSV6KC2FB9HH[J5<;1V?GUYXZUMP>(M*TZ/2K"]UB.:[NH$,,C#'VC@?,.W
M/UKS33]3TR+X9>*-*FGA2\2>Y?R7&#RP"]>^>G>MO6[1K[X6:'J^ELK7ND0P
M7,3)S]U0'7_'Z4 =XWB#2DO+RT>\1)K./S;@."!&GJ2>*@L?$NE:VT]KIFH1
MM=K'N",I5ER.&VL 2.17GWB2*^U'X:3:V;207&H74-W<QQ??6!?NC\  ?QK3
M\'2^%M4\21ZAHQU.]OE@(FN+IW(A4\!6SQD]@,]Z -KPOJ%]IOAFXNO$NH"2
M.&9]EW+&8R\>>"5//)SCN1BMG2?$6EZY)/%I]PTDD&WS5:)T*YSCA@/0UG>/
M!I;>%KA-8>:.T=T4RPC+1L6 5OP-8G@&\NSKFIV,MW#JL,,<9358TP9!V1CW
M(!H =XCUTZ#\1M):]UB>WTN6UE>6%F'E[E&!P!DDY]ZVU\>>&WT@:JNHYLO,
M\HRB)SM?T8;<C\:P?%=Q:6/Q-\.W>HA4LQ:SH9I%RBN>F3T%<QK>G2W/ASQG
MJNG6KC3KNZMY+<+&5\Q8_P#62*OH2>O?!H ]2_X272_[<&CM.5O3%YRHT; ,
MF,Y#8QC\:I0>-]"N[E+:.ZD7S5=HI6A=8W"#+%6(P< &N&F\2Z7JGCK1[R*.
MZGLDTF:.4K;O\Q(.5''MUZ>],\-7<&G>(--AT74I;[1)4EDDMKJ$[]-&PG.X
MCY?2@#J-#\2:!H/A/[=-K]U>V373QK<W*L6W9^Z!C.!6MI/CC0-:OY;*RO"9
MHT\S$D;(&3^\I8#(KRA;VVD^$EQ8 .US)J9=(O*8EE\P'/3TS6_XC\O5/'L4
M-ADB70I;2*18SL61MVU<@8'!_6@#M[?QQH5S?VUHEQ*ING9+>5X66.9AU"N1
M@T\>,]':[6W1[APUS]E$R0,8O-_N[\8S7GOA1M$NUTS2)_"]^^N6+HLGG[_+
MA*GF0L3@#C.,<G IT4IM_$L5QX9-\CS:CMO-(N(&:,\_-,K$84=\YH [Z/QK
MI$NH+:1_:7#7/V19U@;RC-GE-WK^E'C;Q,WA/PY-J:6DERZD(JJ/E4GH6/8?
M_6%<!$PA\1VESX;%_$]QJ6+W2+B F,8)S*I(PO3.0?Y5V7Q.M;B\\ :E#;1/
M+)A&V(,L0'!. /:@"K<ZKI6J:_X:DO)M6M-0?+P6JQLD;G&3OXY''KTJ>X^)
MWAVW>[3_ $Z1K1]LXCM'.P?WCQP/K7-ZMJZW_B3P3=6]K>I%;LQE\RU<%5("
M@D8Z'!J""]$=E\06%K<[KV5S;YMG/FJ5*C''J>_K0!VEC\0-#U'5K;3[=KD_
M:@?L]P\)6&4@9*JQZG\*2^^(.AZ?<NDYN?L\<WD2WB0EH(Y/[I;U^@-<:USL
MM/AXGV6[Q:,&G(MWQ& NTYX]:HZ=I2:3+J.E:KX,O-3O'NG:UN%C+0R*QX+-
MG"@9ZT >T(ZR('4@JPR"#D$5DZUXDLM$GM;:6.XN+NZ8B"VMDWR/@9)P2!@?
M6JVF^(X'\0R^&S87-O-;0!UD9,1.HP#L/H,BL3QQ=7D/B'1HS97KZ8XD\Z:P
MBW3;\<(".5![XQG\* $U_P"(T<'A#^U]&L[F=WG^SG?&!]G<, 1(,\'GCWJ:
M'QQ<S^-;711HFH0QO;F63S8U#@D@!OO8"CG)KA8M*U<_#S5M/BT74HI8]56Z
M\IXLL\6X'"]V(P.E=5<W%XWQ"L=771M2^SWNEFV7$/S1N7S\_.%XYYH V9/B
M-HD5[%$R77V268VZ7PB_<-(., YR><C.,5#<_$W1[>;4818ZM*^GMBX$=H3L
M'=CSP![XKC?#%E_9T*>'M0\$R7&JP2D)=M$#"REB0[/VQSTSG JXJWGF^/W_
M ++U$C4%VVO^B/\ O?E*\<>I% '0ZEX]*>(M"L-.L;FYMM04S&9$'[Q-A("9
M(Z'!.<8Q4FC:EH%MXA\47D<M[#-;LK7S79Q&N >4'7''^%<I:P:A82^!-0.C
MZA,EC;26]Q'';G>CD #(.,#GJ>*ENM&U'7-3\?6L-C=0_P!HQP_99)HBB2&/
M (#'CDCCZT =C:>/+">_LK:XL[VS2_&;.>XC 2?V&"2"1C -4+CXIZ/"UYMT
M[5I$LIO+NW6VPL(SC<V3P/;K6/<PWWBK3O"^G#2KZTFT^>*:\EGA,:QB-<$*
M?XBQZ;:IR17TOAWQ[&NDZCOU"[9[53:L#(&X!''M0!ZQ;7,5Y:Q7,+;HI4$B
M-CJI&0?RKBOBK$#X:M9PSK)'?P!2KD#EP#D#K^-/T'Q2]I_PC^A7&C:A%YUJ
MD7VF2(JBR*G*X//\)J/XK6\U_P"%H].M[2[N))KF-C]GA9RJJ?F)QTXH VF\
M6V_G:BL6GZA/!IX/G7$4:LA(&2J_-ECZX''>LFR^)^D7TVG[+#5([6_E$,-W
M+;[8_,)P%SG^6:PM!O=3T#2]3\-7FF:E=644,@L;R&S?]XK*<(PQP<G_ !K/
M2"^3P!X/L#I&I?:;#4HIKB/[(^516<D]/<4 =UJ'CNQLKB]6*PO[R"P;;>7%
MM&&2$]2#SDX[X'%2CQOIKZQIFG0P74QU.(S6DZ*OE.H!)Y+ @C'3%<GIWV_P
MZ/$^CW6DW]W'J,\MS9R6\!=)/-7&UC_"1P#GWI]_X-U2P^'&AK9J)-=T5UGB
M"\Y8MET]QS^.V@#HK/Q]8WMEK<ZV%]')HYQ<P2!%?OT^;'8_TS6+IMP$^+5Y
M=2K-;13:,EP\<[Y*?,,Y&2!C';TK,3P+JUIXKTUO->:UU.,2ZU(>5:5&\P_0
M$X ]LU;U32[[5?B+K426MVEO=Z.UG'=-$PB$F,_>QT]Z .@M_B+I$^HV5L\-
MU#%?-MM;F15$<I[=#D9[9 KF/B5XDM]6\&Z@+&RO9H()UC%^AVQ!PX# <Y8=
M1G&,U#X6LIQ;V>C3>"?LVI6I$<VI30CR@%XWJW\3'MCZUG7$'B"S^'NH>"V\
M.ZA-=))B*Z@3=%(AE#[LYZ^U 'HTWBF#3Q;:?!9W5_>BS6X>&W"Y2/ &26([
M]J@A^(>CW&B6^J117A6YE,-O"T8625QUQDXP.YSBN*UN]U.R\:PS:=IVHI,=
M)BANQ;P+.R@DXRH. 1CCFH[C38+G0-!GT;1KN]CT&X=+W3;N'9,_F $L5YR>
MXZ]?:@#TCPWXLL?$OVN.WCF@N;.01W$$P&Y">AR"00<'OVK<DD2&)Y9&"HBE
MF8] !U-<'8ZS<:5H%]K5KX->SB3RT2SCC"3R8)W.V!]T9XZGK77P7O\ :&@Q
MW\,!;[1;"9(7."=RY"G\\4 8&G^-+/Q#);68TN_2TU-94AN7"A'"J<\ALKQ^
M-<Y\/O$L6E>#-'T\6UU?7MS-.%AM]K,BB0_,VXC ]S5'PY8W=AX@TZ_T32]8
MTZR=))-5L9XF\I3MR/+SU)/ QSTK,\(6&O>#&L]5AT?49Q=R20ZC9F$[D ;<
MCI^!_,&@#O+2;1+WQYK5LEM?Q:JU@HN6E)6,Q\#Y,'KTY'IP:\[\@2?!<7+R
M2^9#JQV'S#WD (/K7<V;W3?$S4]6.E:@EE)I8A21K<C<ZG<5QZ]OK7))I>L#
MX4-HW]BZC]N?4?-$7D'A-X;/TQ0!Z1K'C.VT>^ELDL+R]FM[<7%P+95/E(>A
MY(ST/2MQ]0@CTHZE(62W6'SV)'*KC=T'M7F7C:S.J:I-<VFCZQ:ZK#!&UCJ%
MG$Q$I*Y*2>F"<<^]=Y(=77P6Q$:/K L?N<8,VSIZ=: ,W3/']AJ.H6-J;"_M
MAJ$;264LT:[9PH).,$D' SS5#_A:VDFUENAIFK?9H)_(N)C;@+ <@98YXY/3
MK7':=#J=MK7A?5'\-ZY))9K(E[(\>2S%",(N<!1VZ"I9;;4)OASXHTY='U,7
M5YJCSPQFU?+([*P/3T4Y].* /0=?\2V2?:-+BL[W49S;&6:*R S'&1P2Q(P3
MV YK-^$<CR_#VS=W=R99>7.3]\UDV%YJ6@>*[_4&T'4[NQUBT@9/)@)>*1$V
M['4XQW_2MCX4VU[8^"H[._L+BSFBFD.V==I8,V00.O>@ M-2T*U\8>)+J*'4
M_P"T+:!'NPRDH4 X,:YR> .<?2G:?\3M&U&:P"6FI16]\_E174UOMB\SLF[)
MY^E8LDTT'C_Q;=2:9J36]U8)!#(MG(RR.JX(&!SSWZ5D):ZA'\._"5FVD:D;
MJPU%9)XA:ON15=F)Z>C#'XT =?HOCB6]\0^(+:^L9[2QTS'[V55 C !+%R#W
MQD8SQ5B'XBZ4]]':W%IJ%JT\)GMFE@R)T S\NTDYQV.*Y>ZTW4[G5_&^F1Z7
M=YUF)'M;DQXB^6,\,QZ$D@8J;PGM5K)7\#26-YI\9-U>2P<?*I'[HCEV;T%
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MJJ?N" R>6^XYZ87&2..HH Z6*UA@A\F**..+^XB@#\J2*RMH HBMXHPN=NU
M,9ZXK$N/'/ANTTRSU*XU2)+2\R()-K'<1U& ,C'O2:1XZ\/:X;L6.H*QM$,D
MPD1DVH.K?,!D4 ;9L+1C(3;0GS""^8Q\Q]3ZU)'#%#%Y4<:)&/X57 _*L"P\
M<:'J-TEM#<2K))"9XQ+"Z"6,=60D?-^%45^*/A-@&74'*F7RBWV>3"G..3C
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M[C\R!L;DW$!L=CCJ/;O4Z(L:!$ 55&  , "G44 %%%% !1110 4444 %%%%
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MJ%Z+G!QGMS33>6K_  IURVB1VNKK56DCA$9WE2ZL#CTP*]V$:CMTZ4H4#H*
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M3>"UNIH[6],T[Q0LZHIP 20/K7>44 >7(MWI7BKQ@EQX?O=1AOP)$$<?[N1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKN(G6146==WRLHSSD$=/6M2/4;*:[EM(KR![F+_60K("Z?4=1UKS?75T+4?
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M&O-;*2QC'A*_M9K2"#^U_EW$?:BA?EI6';M7>6&'^(GC<*X7=9088'I^ZZT
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MG:R^:K7<J%_-F+, 8W!8J23QC Q5_P "Z$+_ ,3:]=3ZGJ9?3=680Q_:F*L
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M<6<G\JN>%_\ D4M&_P"O&#_T6M &M1110 4444 %%%% !1110 4444 %%%%
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MPLEY,MJZQSS0P%HXV;H"WXBEU#QUH^F7T]K.+MA;R)%//% 6BC=@"%9AWY%
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MW\ME=:JJ7$3!701N<$G'4#%3W?C?P]8WAMKB_",L@B:3RV,:N>BEP-H/L30
M#P)X5!8C0K+YI!*?W?\ $/Z>W2IU\):"EQ<3KID*RW*%)F&1O4]CSTJYJ^JV
M^C:1<:E<B0P0(7;RD+L1[ ?_ *JQ-$\<:=J/A6#6[MFM4?".K(W^L/\ "O'S
M?AF@#;TO1]/T2U-KIMJEM 6+^6F<9/\ ^JJ8\):")[N?^S8O,O 5N&R?W@)R
M<\U/I'B'2]=64Z?="5H6VRH5*.A]U(!%-U?Q'I6A>4-0NA$\QQ'&%+.^.N%
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MLQ>)-$N+I;:'5K*2=F*K&DZEB0,D8S3[/7](U"X:WLM3M+B=1DQQ3*S8^@-
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M$="* %(RN*Y-? &GQ?:H8+V_AT^[E\V>PCD40N3U&-N0#W (KK:* .>_X1.
M>)H-=2]NXYH(1;I A3RA%_<QMSC//7-=#110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!SGC[_D0-=Q_SYR?RJ[X6.?".BG_ *<8/_1:
MU2\??\B!KO\ UYR?RJ]X8&/">C#_ *<8/_0!0!JT444 %%%% !1110 4444
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M=J /+?&-KX:C\%>(#H6R9?M<,LTB$/$KLPR$/0<=<>HK4U6\M&\=^!5LC"\
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MJR@J1@@C@T >':;K>G1>._#MY<:S;S6JV#HVR+RX;?*D"(>N,CJ2:HPG3O\
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M  SR7!D"6FT$L^22.2. !R3VJCX;TZ76/AKXJLK* _;Y;F1XU9=KLI(/&?4
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M  @<4 ><Z&L>J_%V^UO2GWZ:-/6.:>,?)+(2,#/<X'Z4>.M4MK+QEHD5PZ6
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M* "BBB@ HHHH **** .<\?<> -=_Z\Y/Y5>\,?\ (IZ-_P!>,'_H JEX^&?
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M0W\.:K]ILM26:0_9R595=F.,<]&';F@#T33_ ![875SJ4%Y:7>G/80BX<72
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M'CK79T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTK^T?,N! +C[-(# VZ*3CAACCK5N\\8:;9ZO<:4Z73WL-N;DQI QW(.ZGH:
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M&-MR1(K>JJ!3I(DE&)$5AZ,,BGT4 0?8K7_GWA_[X%(]C:R0- ]O"T+?>C9
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M9[U&GTZT*K.T '.6&.2?3D"O3** /%O[$U^&'Q=!%X6N(8M8AC^SI$ZD18!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<988&,8W>F2>/7FLCP1XHN=>TZ\EU,V\5Q#?26H6/Y5.W& ,G)-8NIV&G_\
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MD:[=>+K+Q->(FHBYP)I2$D2%/NF//3IVH ]+?Q'IB^(4T,7*F^:$S% 1\H!
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MU<+:R*T!\Y@(BT98MC///K65INE)XBN_ <6LM+(;JWNHY6:1@9(X]Q0$Y]*
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M_P %Z#X8FEFTNQ$,DHP79V<@>@))P*GU_P +Z9XF@CAU2*26*-MRHLS(,^I
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M-<EU&*^TK[%J-E:0&XVW*7/WIE/\*?[57I]6TZUN%MKB_M8IVQMBDF56.>F
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ML0E&TA1_>88SFO;+_3[35+)[.^MX[BW?[T<BY!K*_P"$(\-$@_V)99">6,1
M<?Y[]: /)(M+T^P\$>"M7M84BU)]2C#W"GYV&YL@^W XK:UVQG\*>,KZUTRT
M#VWBF+R4 &!%*3AC],%CCW]J]"/@WP[Y$,)TBU\J%BT:[.%)YS5#2-)\07FN
MC4?$4ECY=H9!906H)QNXWL3WV\?B: -^RL(M(TF&RLHU6."()&O3.!W^IKR3
M0F\+ZAX;E_X2*80ZY;ZF\L^PA;EY=YP!W((XP/2O::R&\,:*^K_VLVF6IO\
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MH+$&@#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB*Y:V0RQ 8".5Y7'L>*\>LX;Z;P/H26]A>.^@:AYU[ 8"-P\PGC/WB!U ]:
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M())F>*VQAMIQAG'9CZ=N* .-$'_",?&*V6XN;E]/U2!OLBO,Q6.;C*\GG/\
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MGPE\1;(K43IJC"-EQOQO&WWQC.*TGO-*3Q;JJ^)M6U"SM]1M(3;SP29CFBV
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M3NY.>!C\:UKCQE9"*P&GP3ZC=7\!N+>W@ #&/'WF+$!1GCGO0!TE%<I;^/\
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M:ZII\%]9S++;SH'C<=P:LT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <YX^Y\ ZY_P!>;_RK9TS_ )!-G_UP3_T$5C^/!GP'K8];1_Y5
MLZ<,:9:#_IBG_H(H LT444 %%%% !1110 4444 %%%% !1110 5YY\3)XK75
M/"EQ,CO''J&Y@BEC@ = .M>AU@:_X;?6]2TN\6_>V.GR^<BK&&W-[Y]J .%U
M^REU67Q-KUC;W!M;G3ELH5^SL&N'R#D+C.!@#)'\JE\0P7%S\&K"SM[&Z:YV
MP1F$0-N!4_-D8XZ'DUZF!1B@#S>WDN=$\=OK=S9W<NG:CI\<:R0V[.874#Y2
MH&1G![=ZYC5="OXO"MY<C3[K.HZ^MY%;B$LZPC/S,!TZ]#[5[?@48H CMW26
M%)45E5U# ,I4\^H->03Z=J=X_CSP[%8W*W-_<F[MG,>(V4,&^]_M8 %>R4FT
M4 >5WAF\76_A33K6QN8+NPGCFO3/"R?9E1<$9(YW8XQUKL/B!:7-]X%U:VM(
M&GG>(;8T&2V&!X'T!KI-HH(S0!Y-_:$E]XH\&72:;J4=O8P-'</+:. I,8 Z
M ]ZR=1TG4=83Q+/;Z;<NZ:K'>Q0O"R"XB7(.,@9.,>]>WXHQ0!P7@QM-U#51
M>Z?X4GTTI#B6ZNE*MN./D3.=PZ\\=/>F?%1)+FQTFWAM;BY>._BGD2&!G_=C
M.<X&/PKT# %+CF@#C3JFF1ZO:-H^BS/>RL(&F^Q20I'$3EB25 XQ65X3O_LG
MB[Q;<SVE_%!=3I) [VLA$@4,#CY??@5Z/BDQ0!XK8:-J6I?"S5-+CL+I-0CO
MVNU@EB9/-3<#P2.>,\=>*OQVD/BO1[R#2O"4NFW?V22.6YNEV['QQ'&2<G)X
M[8KUO HP* //?"FNWU];Z1I5QX8NX;VR41RW%S!MBB51@LK==Q QBL2T-Y9^
M"_%FB3:3J*W,EU<21,+=F23>1M (^A/I[UZZ !1B@#SG6='GU3X6:=);0SKJ
M>G113P*8V5Q(F 1@C/3/Z57UOP_K-]\-TN);4W&KRW,>H7=OC!D_V,#T7 Q[
M5Z=M%!&: .#\'FROM56\LO!\^E&.$K-<7*;&W''R)S\P]3Q4?Q2-Q+:Z+%;V
M5U<M'J$=Q(((&?"+G/(&/PKT #%+0!YYXLO]3\8:4VA:'I=Y&MTRI<7EU"8H
MXTR"<9Y)K)UJUO[2_N="DTG4KC3HM,2WL391_+.X7!,KCL#VZ>U>LTA&: /'
MK*#4;;P[X%G;1M0?^S+IUN(UA^<9'! ]/<XHDT^71O$VJQZKX0N-9BU&<SVL
M\:[B-W\#GH,?I[U[#@48% &3]@EN/"+:>8([6:6R,/E1GY8F*8P/89KS>.SU
M2^^'4/@J32KM-5BD$6]XB(E57W>9OZ8Q7KXXHQSF@#S[0(YK?XG:KOM;S[.]
ME#!%</ P1VC'S<D?KWK4^(NC7VM>$VAT]/,N8)X[A8^[[#D@>]=;1C- 'G-T
MUQXG\4:!JL6FWUM;Z7')/<O- 4;<5&(U!'S'/I7-QV.H_P#"K=6T[^R=2%[<
MZBT\<9M'RR%U;=TQT!KVG H(S0!6T]UFT^W95D5#&N!(FU@,=P>AKS%_ .I7
MNH:[HDA>/P_YK7EH!QNF=> /93G/X5ZQC%% 'EJ:7K2?"W4O[0L[F?6+]!%Y
M4<)9PJ (@(Z]%)S_ +7O1)%>KK7@FZ&D:CY6GVS+=%;5SY9*;0,8]1VKU*B@
M#QAM"U;6=$\51V]A=0W3ZJ+ZWCN(63S44G !/<^E==9Z_JVN6-Q+)X:N[***
MU=)C-'F61RN D8')&3G-=Q@4H&* /'7L]2'P]\,Z9_8^IO=VM_'+<)]E?,:*
MS$\XYZBO3M=F=?#M\T<$\S/ RK'%&6<EA@?+U[UJ44 >8^$9CI/@2RTS5?#&
MK375MN8QBQ+;FWEEP?RJ?Q!8:AXVL[+2-0TV>Q;R#>2W(@+*DF/EB4^O(W?3
M%>CT4 >1747B+7?"&ES7'AZ47^AW*22V<\)1;N, CY!CDXZBI=4T2]\5>';U
MM*\++HKQA)(EGB5);AU;=MXZ+CUZFO6",T4 <?HVLZWX@;9<>')]*C6%EFDN
ML9=B,!4[XSSFN!,&N#P5I.@)X;U)[C3=322:01@(P#LPV<Y.0>O0?C7MU)M%
M 'GUFNI:;X\\174NCWSVNH01/'-&@95VI@J<'[V>,#/Y5!X5\.W.I?"B7P_J
M5E-:W.)559XBA5BQ96'KR>M>DT4 >9:9X6US5OAWJL.K[EUF^A$*"0X*I%Q&
MI^I!/_ J=X2$TMSIUH_@==/O+3 N;Z>%0B[1@F-AR6/'Y]Z]+HQB@#C/B-I>
MIWFF:??Z3";BZTR\2[$ SND Z@>]8>O0>(?'WAJ\2WT:7255$81W0 EN9%.=
MO;"CU/4UZ?1CB@#S6ZCO/%NH^&9/[,OK(Z3(;F\DGB*E2%'R)_?)([=A6%'8
MZJW@#Q=I_P#8FI+=7EZTMO&;5AO5G!X^@4Y_"O9@ *6@#S*^:]?Q%X+OCI6I
M&.RMW%T5LW_=LR!<8QZ@UC-9ZE+\/O%>FC1=3%U>Z@T]NAM'_>(SJ01QZ*>M
M>S$9HH \GU2VO-0\1>%3!I6IQ116$EK/,]JP$+/'L&<CL>353PO:SZ?#!X>N
M_ R3ZI;RE!J$L(,!4-D2%R.<#L.N!7L=)@4 >3PM<0WOQ!9M-U B_0K:_P"B
M/B4[&3T]2*HZ2NK^&I_#OB!-&OKNW73/[.N[=(CYT+AB<A3VZ<].M>S8HP*
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M"\4#KMD88'S,.Q/IGIBN9N;V%_C.P'G*/[+-IYOE-M$I<MC./0@YZ5Z128%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@# \;_\
MB1K'_7LU;PZ5@^-AGP3K ];9JWQTH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#%\7*7\):FH&28" /6MD=*R_$G_(NWO^Y_45JB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,SQ N[0;M?51_,5IU0
MUI&ETBXC09=@ !ZG(J\.E "T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% $%V,P?\#3_T(5/45P"T. ,G<I_45(.E "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIW_C_P#\5110 X?'O6SUTC3_ ,W_ ,:3_A?FMC_F$:?^;_XT44 2CX]:R?\
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MM'D7^RH3L7/^M//Z4I^+%X(D?^RX/F[>:?\ "BB@!O\ PMN\WX_LJ#_OZ?\
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MQYS?X5'_ ,+ZU#@?V';9(S_KV_PHHH DD^.VHQHC?V+:G<,_ZYO\*3_A>NI
MY.BVN#T'FM110 DOQXU"- PT2U/_ &V;_"HS\?-1'_,#M>@/^N;_  HHH ;_
M ,+^U+_H!VG_ '^;_"E'Q]U+./[#M?\ O\W^%%% "?\ "_M2_P"@':_]_F_P
MH_X7]J7_ $ K7_O\W^%%% "'X_:GNXT.TQCIYK4'X^ZGG_D"6F/^NS?X444
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MM\<O$QC0+;:>K#.6\MN?_'J:?C=XJ 8^78<'_GB?_BJ** (V^.'BO;PE@/\
MMB?\:C/QO\6^EA_WX/\ C110 UOC9XO.<262_2WZ?K4?_"Y_&6,_:[;_ ,!E
MHHH !\9O&>-WVRV^GV9:F3XO^,I(]WVZW!_Z]DHHH B/QD\9C_E]M_\ P&2G
MK\8?&1!_TVWX_P"G9*** 'CXO^,N,WMMTS_Q[+3#\9?&,;8-S:OGUMQ_2BB@
M"U;?&CQ7*S!OL/R_],#S^M.'QN\4>9M\JP_[]'_&BB@"TGQP\11)A['3I"#U
M*./Y-0/CQKH/.E:<?IO_ /BJ** )8_CUJH)\S1;-O3;(P_QJ?_A?%_@$Z';?
M]_V_PHHH LVGQVG<MYWA^-O39=E?YH:E/QRD\^-1X? 4YR#><_\ H%%% %V'
>XS^:N?[ Q_V^?_85ZG#)YL$<F,;U#8],BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>sgmo-20210331xex103002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M &/X1-)@_P#CU2?\*O\ !V[)T9.F,>=)Q_X]77T4 <<WPJ\$O][0HS]9Y?\
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M_P"?6#_OV*L44 5O[/LO^?2W_P"_0_PH.GV1ZVEN?^V0_P *LT4 5O[/L_\
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MBB@"O]AM/^?6'_OV*7[%:C_EVA_[X%3T4 0?8[;M;Q#_ ( *G' HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BHV/^D(O8JQ_45)0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%,C8L\@/\+8'Y _UH 8_P#Q]Q_[C?S6
MIJA<_P"F1#_IF_\ -:FH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "HHO\ 63_[_P#[**EJ*'_63_\ 70?^@K0 U_\ C^A_ZY/_ #6IZI7#$:M9
MJ"?FCE_]EJ[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %10_ZR
M?_KI_P"RK4M0P_ZVX_ZZ#_T%: *MR?\ B=V _P"F<W_LE:%9MT<:]IP]8IO_
M &2M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI,BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I:?\
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M;7AWP7;:%H]_IS2&=+QG#,>"(R" OX FJNB^%M?TN2&REUU7T:W?='&D>)6
M.0I;L,^A]J -]=,BM+Z\U6*/?=RQ;0  !@<X]R3W/M7+^$O$FI:QJ<27&HQ2
M-MD^U69A$;P$?=QW85V\T;R6TD:/Y;LI57'\)QUKE[3PG=MXAL=7U*ZMI)[.
M-D#P0[&F)&,N<\XH =XZU?5M'L;"72I8$DGNT@82INSNSCZ#CFLN77/$=OJ\
M'A^67S[M86GGNK2V5CM)P@VL0![FM[Q5X=N/$ T\07<=N+2X%P2\9;<1T'4>
M]5]=\*W=_JUMK&EZF;#4XH_*:3RPZ2+Z%30!B7FO^*=.T'3YM6B-GNN2EU=0
MPK(R1X^4[<D#)Z^F*AU+Q#XABTC2)M/UFSG>^O?(67R0<J<X)XXQW&,UTPT'
M5X8[8PZT995+M<_:(]R3[@!C:", 8X%<CXCT5?#VF:)8Q7:+=3:N+@R%,(I(
M.2%[*,CB@"74?&6L^#K^]L-7GCU%OLHGM9%C"?,3C# =JT[O5=9T"31+J?4/
MML&H2)#/$\:KL9AD%, ''7KFM%O!\6HO>W&LSK>7-W"(-R1[!$@YPHYYSSFB
MV\*7+2Z<-2U$7=OIQW6\8AVY8#"LYR<X% ',G5/%$L?B6Z&MK'#I,SA%$"_/
MM&<'T'^-7=6\2:FD.EWTUS-9Z9<68=KBVC#@3D<;\@X7Z"M1/!<ZV&MVK:KN
M&K2&21OLX&PGKCYO2G1>$M1ALQ:+KI-M]G%L8FM@5*CC."W!]Z *D>K:BNM^
M&(?[32YM[Z&3S3&@VR%5SG.,_P NE8UCI^L7.J>++C3M8>R$%^[+$J B1@N?
MF)[5U:>$(8;K19+>ZECCTI"D:8!W@]<GWI'\)'[5J+0:G/#:ZBY>Y@5%)8G@
MX8\@$4 8-CXDU+4=6\)RFY,<5_%(9X%4 ,RY&[/OZ=JDTJ65-9\="&5XIE<2
M)(H!*D(<<&N@F\*6\FL:7?Q3/ FFIY<$$:C9COGO4<'A)8)]8G_M"8R:H")3
MM4;>W'X<4 <9>)<:WI7@F>ZO[KS;J?#L'QSR=WU[9KH+K5;[3?&FIQBZFGMX
M-)-S' Q&T,"?IZ?6M!O!5LVC:;IPO+E?[/D\R"=2 Z]>.F.]6H_#$(U^;5I;
MF::26W^S-&^-I3TZ?YS0!RFCCQ=?IIFK1W@$<K;[@37 ,;H3T" ?+^!I;>ZO
M;+Q-';ZU=7UM=RW?[N97)MYH^R =!6YIW@.PTZ^$T=W>/;)(98K-Y?W2-V('
MM4\7A"%6MTFO[RXMK:?SX8)64@-VR<9('I0 WX@+O\#:GR01&I'UW"L.V^U>
M'M7T;&HW=VEW8RR31S-N!*1AAM':NQUK2(=<TR33[B25(9"-YB(!..<<@U3_
M .$8MSJ5E?/=73R6<?E1(S+MVD8.1CG(ZT <=H\'B+5[2TUU-4AMR\VZ9Y)R
M5*9QLV8P/2I[*PN;OQ7XAGEU;4##ILJR0PK-A2Q4M@^W&,5OVW@/1[341=Q"
MX""3S1;&4F$-V.WVK1T[P_;Z;J5]?137#RWK;I5D?*Y[8&/PH XC1K37=:M+
M'7QJ,%O(92TTS3,04S@IL^ZH [59M&"VGC>VDFF\JW=C'NE)*@(2,'.>HK>M
M_ >B6VK-J$<,N2_F" R'R@W7.WI4NH>"])U.]GN;A9O](4":..4JDF.Y ZF@
M#CQ#-JLG@VUFOKM$NK1_.\N4KOVKG]>F:C74;K2=.UK3(+J5+>/54M(Y2^YX
MHWSNP3[#]37;6O@[2K.ZLKB)9]]DNV -,S!!]":>/".D[;]9('E6_?S)P\A.
M6SG(]#SVH Y>\L+30_'UC)8*P?\ LV=\,Y?)4'!Y/>L_0M*U#5K2RU^37+>W
ME:XW22;F+-\WW#DX'IBNSL_!6BV-_%?1PRO<1#"/+,S8'IR>GM3K;P7H5IJ_
M]IPV*K<ABPRQ*AO4+TS0!S6E>';74O'>M37%Q>.+&>(Q1_:&VY*YY[GGWKT-
M75\[6!P<'!Z&L^RT.QTZ_NKVVB9)[HYF8R,VX^O)J73=*L])ADBLX1&LDAD?
MDDEC[F@"[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'3
M_P#67W_7R?\ T%:O52T__67O_7R?_05H S=6('BWP\/7[3_Z+%;]<]K#8\8>
M&QZ_:?\ T6*Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ P*,"BB@ HHHH **** # HP*** "BBB@ P*,"BB@ HQ110 8'I1110 48H
MHH ,48HHH ,"C%%% !@48%%% !@48HHH **** $P*7 HHH ,4444 &!1@444
M &*SM6T.PUR..+48#-%&VY4\QE&[UP",FM&B@!D<:Q1+&N=J@ 9))P/<\FGX
M%%% !BC%%% !1@444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %1R00RL&DB1V7H64$BI** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "JED5,EYM7;B<@\]3M7FK=4M
M/_UE]_U\G_T%: ,?751O%WAG<VW#W!'N?+Z5TM<QXAQ_PEWA;_KM/_Z+KIZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **QO$.MG2+6!((UEOKN86]K$QP&<]S[ <FIY-2MM&LHCJ
M^IP(Y&#+*1&&/L* -*BN;U[6Y]'A@UJ*6*XT<;5N57DJK' D1AUQD9'ITKHD
M=9$5T(96&01T(H =1110 4444 %%<+_:GB.X\>WOA^+4K.*&*U%TDAM"QP6
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MRX XSTKJO""S+X/T<7!S+]CBS_WR,?IBDU;0O[5A@TPB.+25PTT2#!D"D;4
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MC'3U^T3W;3*1,FT*7#<G/7BO2** .(32=?T?5;F]TJV@F34(D\V*64 P2*N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JG8?ZR]_Z^#_ .@K5RJUIN\RZW?\]N.,
M<;5H Y?Q?N'BSP>5Z_;)?R\OG]*[&N'\;$CQ=X*_Z_Y/_0*[B@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BJ>J:G;:/I\E[=L1$G8#)8GH .Y)K)U3Q'+IFG64DMD!?7\ZP6]LTF
M &8\;VQQ@=< T =%17-:/XGN)]5DTG6=-;3;[),'[S?%<J.I1L#)'<=:Z6@
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MTH NT5C:-XGTS6]+;4+:XC$"E@Y=P-@!(R?0'&>:OV6I66HH7LKN"X5>"8I
MV/KB@"U16+X@\3:?X<CMS>RJK3RK&B[@#R<%OH.M88\4/9^/+NSO]3MDTE;%
M9XB^U "2,8;^+C- ';45@:W>&>PLKBQURVLHY)T;S6VL)DS]U<]SQTJY>^(-
M)TVX%O>:A;P3$;MCN <>I]* -.BD5@ZAE(((R"#D&N)\9^,IO#VJZ?!;PM)"
M'#WS!<A(R< 9[$G)_"@#MZ*B-Q$EM]H:11"%WER> N,YSZ5DCQ?H!D6,ZG"C
MN,H'RNX>HR.1[B@#;HK!M_&GAV[O%M+?5K>2=B0%!/;KSC%36OBC1;V[2UM[
M^-YGSL7! ?'7:2,-^% &Q16&_B[18]06R:['F/)Y2OL;87_N[L8S4-UXZ\.6
MD\T$NI)YT#;9(U1B5.<=A0!T5%8,'C/0+J^@LX-0226?B,A3M)]-V,9]J?J'
MBS2-,GDAN)VW1$"4I&S+%GIN(&!0!MT5SEUXYT"TNS:O>%Y@@D58HF?>/]G
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MAX9T[3M;O=5MQ*MQ>'=(I<[,\9(7U..30!RWQ-,HOO"WV>7R9O[2 23;NVG
MYQWK<@L+VRU2XDU?61=VUY$+>)-OE$,2?E 7U!ZYS5C6O"6G:_>6]U?271>W
MYB6.8HJG.=P [^]-C\'Z>MZMW)<7\\J!A'YUT[>7N&"5YX..] 'GD,,4/BUO
M"=]?32Z'+=&6"<N^YI0O^H+YZ#//TJS?V>I>+/$WB'3EN;6#[ R1VHFGD1H5
MQ]] IP<]R<]A7<3>"=%GT:VTJ2&4VMM+YL0\UMP;DYW9SWINI^!= UB[ANKV
MU>2>-!'Y@E96=1TW$'YOQH XW2IQX@\4MH&O:G]NAM=.!MWC)C29^C29S\S#
ML?8FIKFVCL-7\')!J\U_)'>R6LMRTAS(H!.TC."!G'>NOUCP1H&NBV%[8J3;
M+LB,;%"J_P!W([>U27WA#1M0TBVTR2V\NVM6#P")BAC([@CGZT >;:];P/#\
M1(,L8+<P2Q)YC;5<J,D#/J36OJ]I'IG_  @C6#RQ1M<HC*LS;3N3)^7/)///
MX5UEOX%\/6R7JQV/%['Y5QND8[U_$]>^?6FKX#T%([)$@F5;-_,@ G?Y6_O=
M>O% ''ZMY7@OQQ=.+=YK36K-T@BR6_TC/W!SP&./S]J;J.FR0ZUHGA26[@2U
M%@TQ2Z+%)IRQ!^ZPR1V&:],O-,L[^:UFNH$EDM9/-A9OX&]15+7?#&D^)(8X
M]4M1-Y1RC E67Z$<T 4O!&F2Z+H\NFRZHNH?9YRJLH/[H$ [.2>F?UKA[K0;
M/5/%OC..Z:X9+:W$\2^>^%?83GKZUZAI>E66C6"65A L,"=%'KZD]S6;_P (
M=HWVB]N/)F\V]!$["=QO![<&@#S*WM([3P]X-\0+/<MJDU_' TK2L<Q98;<9
MQC@?F:/%WDW5KXEU2PV3M;7D:F]N)")(V!4&.$#L/4X[]>M>E?\ "#Z#]CMK
M4VLAAMGWPJ9W_=G.<CGBFR^ O#4]S<7$NE1.]QS("3@GUQG@^] '*^(57PSK
MFD^,88//MYHO(O HW$NR_*X]R>"?\:[3PMI_]GZ%%OB2*XN"UQ.JKMP[G)&/
M88'X5D3:9J5YJ46BKI=K:^&[5HY%D#Y:3;A@H7M\W4^WO78 8% 'D5Q80^)O
M$WBBTU?5K:SDBE$<(GB!>.%>0R,6 7WQ4L6@:5?>/-#LYY'U"W.D;S*[,/.*
MG )!/3 Z5Z!J/A/0M7ODO;_38)[E, 2.#GCIGU_&GR>&M(EU)=1>S3[6J;%E
M#,"JXQ@8. ,4 >0O#"_P_F@D4/#::\(X _/EH6Y4$]JV]52PO_'M[IM]?VME
M81V*1V8DC1HPI'S;"?E5O?VKOE\(Z"EA/8C38?LT[!Y(SDAF'0]>M/NO"NA7
ML%O!<:7:R16XQ$K1CY1Z?2@#SF]\/:1)>^"M/,S:E;-)/";ASCS44G"\'H#G
M'MCFO4K;3+.QTM=.MX52S1#&(LDC;W'-03^'M)N98)9K"!G@ $3;/]6!TV^E
M:#QK+$\3@,C@JP/<&@#P];6VD^$3AXT(75R$QU4%P./3BNF73=/TOXD)8V%M
M%#;3:/)YD8 (?N,^IXKM/^$2T#R?)_LFU\K=NV>6,9]<5/'H&DPW274=A;K<
M(,+*$&X#&.OTH \@MKFUC\">'8QL-JFI;M41.2%\P[=^.<5VWEH/BK82Z4%\
MF2P=KXPXV$<^66QWSC'MBNLAT33+:&>&&PMDBG.94$0PY]QWJ2QTNQTQ&2QM
M8;=6.6$: 9^M '(?$H01V^A7$^ D>J0[F;H%Y)S[<500Z3J7Q5NII!:W<"Z6
M"C$AUZX..W3->A75G;WT7E74$<T60VR10PR.G!JN-$TI22-,L@2,$^0O/Z4
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M]<T >QQRI,@>-U=#R&4Y!I]<+X.31_"NGWT/_"0P7-NUV '8A(HW8?<3G'X
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MG6[@\8'H:Z[P;%JL&@)'JS2-,';RO-_UGE?P[_\ :H Z"BBB@ HHHH ****
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M%96F^+-%U>_-E9WJO<;=XC9&0NO]Y=P&X?2M#4-1M=+M&NKV9885P"S>IX
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MI311M.&<A 0%RP&%'7KB@#N[GPYHM[-#+=:9:320J%C9X@2H'0?2M-0%&!@
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M!L*^8L9&[!/^>:]A*@]:21DC7=(ZHH[L<"@#RO1;KP[JL0FA\/:C<7EG:/\
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M#JG@ZR\(7^F-"89(XY;X.AB\F,@@K@Y+$ #I0!=BUO4]9\1>)=*NK*!M.MH
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MB;X>FD@\B>33)F>,G.UO0GOBFCPSXHTO7;^[T.\L8[;5'\VXCN0S&&0CYF3
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M9:,@L%N-\4T^<A\* %';U^E=QIK7KZ;;MJ,<<=X4'G+$<J&[X]JM44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5.P<O+>Y.<7! ^F
MU:N51T[_ %E]_P!?)_\ 05H Y3QRV/%7@I<$[M1;\/E%=S7$^-_^1H\&_P#8
M0;_T$5VU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4449H **,T4 %%%% !1110 4444 %%%% !111G% !1110 4444 %%%% !
M11FC- !11FB@ HHHH **** "BDR*6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU_PC'PYTJ[\07R&";8EMY4!S&K#Y5;'4\'FO0@<B@!:*** "BBB@!&.U22<
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M17>FS'_CY!52"G/SCIQU!Y%0^/-1BD\6ZO%#%+8W4FFA+K>#)YS;4.P#HH
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M)10!&D$4>=D:+GKM&,T]55%"J  .@%+10 4444 %%%% !1110 4444 %%%%
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M5S7C'Q-<^&[.RNK>UBN(Y[I+=R\FW;N]!CGH>] '344U6![BD\Q2"%()],T
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M[FLVZ\3Z9:ZY9Z0]U&;FZ4LH#C"@=,\]^WK0!M45@6.H3VMUJLVJZMIS623
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M#T)(J230])E%L)--M&%L<P PKB,_[/'% '&>&--L+W5/&VEM##]FEO IB"C
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M'KG->=M:G_A47B**7:]G;Z@RZ<S')5/-4?*?3D_K7KVD1PQ:3:+#&B+Y*'"
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M,G:/EV^GM0!V/AG6WO= TVYU2\M?MM]&)4C3"9![ $DG'K6M_:NGD3$7UL1
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M-A;:Q\8M2M9+VXMS_92 &UN#&Y.[D9'7@YQ4GC_2K;1OAU96982?9+F!8I9
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M.YM+F._W#3+:U(0@,/WTCX^;(]QSCB@#U"+QM;3^-G\/1VUQB.+<TYB;&_/
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M\'*>INYL?]^C77UQOBP$^,_!GI]KG_\ 11KLJ "BBB@ HHHH **** "BBB@
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MQ&6^N-.^'FM^%K_3=176#/(RF*W9UGRX(?<!C''\J]5TR>8>#+62.VE,Z6(
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M2C!QYJ*=R#WR>#["CPIX5N?#^M:M-(Q>R#M_9\08$(CG<P [<X'X5V,\T=O
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M'I\8U"5)+LY:0QC"@DYVK[#ISZ5<HK%7Q5I+?VIB>3&F8^U'RF^3.?;GH>E
M&U15/2]3MM8TV#4+-B]O.NZ-B,$CITJY0 4444 %%%5[^\CTZPN+R97:."-I
M&"+EB ,G [F@"Q15;3[V+4M/@O85D6*= ZB12K 'U!Z59H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *HZ<<R7WM<G_T%:O50TW_ %M_
M_P!?1_\ 05H Y[Q4?^*S\'#&?]*GY]/W1KL*Y'Q0<>,O!XYYN9__ $4:ZZ@
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ML(1,U[?V0N[B:VC1F"X_A#D+R:KWNI^-K3PC>WUT3:W-C/O#>5&3<6_<E02
MPZUJS> YVT[1_L^KM:ZII4?E07D47#1]-K(3SQ6YIFARV^FW-OJE_)J4UWD7
M$LBA 05V[54<*,?UH Y23QJUOXVT]'U%CHMW;J_^J7;'(RY4,^,^_P"-=5X9
MDO[G2OM=_<F4W$C20@H%V19^4<#DXY_&L=OASI?_  B"^'ED81B<3F8CYBV?
M_B?EKKXHEAB2)!A$ 50.P% #Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ JE8(R2WVX8W7)(^FU:NU7MPPEN=S9_>\<=MJT <WXG"GQAX1)ZBYG
MQ_WZ-=97)^)LGQAX2_Z^)_\ T5764 %%%% !1110 4444 %%%% !1110 444
M4 %(S!%+,< #)-+7GFKSZ[_PMO2K&"_@6T-H\ZQ-$2 N<,#SRQQP>,4 =CI&
MNZ;KT,TVFW*W$<,IB=ES@, "1S]:TJ\6TS5O$6A:/XGU32H[ V=IJLTDXN"Q
M>09&0H' X]\UTNJ>.[V;4#8Z/"ZR1V*74C?8Y+@EW *QX0\<'EC0!Z)534M2
ML])L9;R^G6"VC&7D;H*SO"FK7^M>'H;K4]/DL+S)26%U*\CN ><&N"LKC6+K
M5/'Z7FI1SP6UN\3*(2N?W3;=O/RXY]<T =I::)I.M:K:>+;:ZNWE>$>2PE(3
MRR.FWT/4CUKI1TKR3POKOB/1=-\(1W*6#:/J&RU2.,-YR9'#$GCWP*LW/C_7
MKHW5YH]A)-!!<F&*U%A+(9T5L,QE7Y5/MSTH ]2ILD:RQM&WW6!!^E>>W/B3
MQ9=>+;O1=.CTRV6.Q6[4W*N60''! /+<X]*M>'_B-ILOA>QU#7[RWL;F>1X2
M#D*S(<$CK@<CKZT =#H'A?2?#,,L>EVWE"5MSL6+,WIR3T%;-<7+XLEUSQ!'
MI'AF[M"/LANY;QU\Q<9VJJ@$9.>IJC?>(O%6E6FA2:E!:6]S=7XM;B$#>'0G
MAU(/'':@#T*JFIZ=%JNG36,\DJ13+M<PN4;'<9'KTKC+[Q/K=GKOB:PC-FZZ
M?8"\MF>-AUY(;!YXS6%-XQ\=6W@K_A)I$T4VDD<9C0+)Y@+-MZ=/UH ],T;2
M+;0],AT^T:4V\(P@E<L0/3)[5?KS2\\5>*]*FL]-U.*S^VZ@[/#+90O-Y404
M$CR^K$$X]*I7?C?QC8^'-0O)=/A22WO4BBFN;9X1/$QP"%)X.1SGUH [VS\)
M:-8:]=:W;VN-0N22\K.3C/7 S@=*V@0>G->?1:UXLA\42:#J$VG"6\L7N;2:
M"-BL+#C:03\P'K4_PGEU&Y\(_:[^\6X\Z>1E^3#*=YW9.><GVXH Z<>(=-;7
MSH8N,ZB(O-,6T\+QSG&.]:E<'JD\=M\7K&>3A(]%F=C[!R?Z5DV?CKQ-J9T^
M_L-+EN+2YGP]NMFP58LX!$Q.">_3% 'J5%>?6_BC6+'7?$6F:S<6X-G:_:;-
MDAQYBG.#C/)S@8JO>>*_$"7%KH\?F'4ELA=7DMK8^:49ONH%+   =3F@#M-7
M\1:=H36JW\K1M=2B*$!"VYC]!QUK5KRC7=1UC4_!.AW&NZ>;*^_MJW5DV[0P
M!.&QDXS7HVNZHFB:'>ZG(A=;6%I-H_BP.E &C6)K?BK3= .V\,[,$\UU@B,A
MC3.-[ =%SWKD+SQ1XCT/3]&\07\UM<Z=J+QK-:1P[&@$@W*5;.6P/6ET^WU2
M3XP:NIU&,*EI$S#[.#OB)X3KP?>@#L+[Q3H^G:5;ZI=W?EV-PH:.?RV*D$9&
M<#C/O5"/Q_H$DL"&6Y03NL<;R6LBJ6;H,D8YK.^*T:1?#B^1%"HIC"JHP!\P
MJ6QO-:O7T.QOO#\<>FR(#+,9A-@K'N3@ ;?F Y_"@#M**\SUKQ/XD\/^))M&
MN)(I_P"TEQI$ZQJ-LA8#$F2.!G\?>KFK^(M9L-7LO#D$DUQ?&U-S<W5O:*['
MG"A4)  SU)H ] HKS2W\4^*I(-(T>]MAI^LWUR\?VF6)2ODH,EP@)^8YQCIQ
M4NMZKXP\/>%=4O;RYMS-:7:BUF$2GSX2P'S*/NGGVZ4 >C5G:SK5IH6DSZE>
M;_L\&-_EKN/) Z?4US%[K&L#QKINDV]]%%;ZCI\DV#"&:&0+P1ZC/.#[UR>E
M:QKVF?"2_P!=BU!)I_M3L5N(0W63:V/4DG//% 'L$,JW$$<R9V.H9<C!P1FI
M*\^U+Q#K6F:_X9GN+R,:-JJJDR^2H\N4ID#=Z$G]#4&J>+=6LK<36T[7(U34
MC:Z<%MU)2)20S@9&XYR "1VH [_4;^WTO3KB_NW*6]O&9)& S@#VJ+2-6LM<
MTR'4=/F$MM,"5;&.AP>*YOPU=>);Z]U*RUFTE6P*9M;J>&-'.>"K(I*GK^GO
M4?B2>X\$^&;./2DE%LMQBZNDA$K0HQ)9]F,'D^F!0!VQX%8^G^)=.U/6[W2;
M9I3=60!F#QE0,^A/6J7@W4KC5-/N+B75+?4X#.1;W$2A"4P.&48PP.>U<E>V
MVOW/Q2\0KX?OK:SN!8P%GGBW[N. .P^M 'J5,FB6>%XG+!74J2K%3@^A'(KS
M&S\::UJ&DZ6]Q=0:>PN)K6_F2,2R/*G01Q\YW'K@''M4-MX[UV7P0FI3(ZM#
MJ;6MY=0VP+Q0J,[_ "SP#R ?2@#T+1/#NF^'898=,@:&.5][J9&?+>OS$UJU
MY:?&^I+IMC%9ZE%JLNHW[16]S;0J)%A503F-L /VP?7Z5TG@Z_\ $MS>:A;Z
M[9S);QL#:7,T:1O(I[,J$C(]J .NHK@/&7B:^T7Q##;37\FE:9+;9BOA:B9&
MGR1MD)!V@#';G/6J6L>)]:LEMDEU6*,_V6LZM80+</<3XY.W!Q&.N[@>_:@#
MM=4\26&D:II^GW7G>??R>7#MB)7/NW05KUY/=ZS<:[IOPZU2Z""XN=24R;!@
M$C(X_*D\4^,M=TBYU::._0/9W*+#:V\ EB\HD F9\?(Q],Y]J /6:*\TOM1\
M8:CXXN=#TK6;2TB%DEXA>U#;02!MSSGZU7'BG7M*O/$>C:OJ0EU.&.,Z:R0I
M&)0Y"J0,<G+#(YQSZ4 >IU1_M6V.K'34+27"IYD@09$8[;CV)["BW6XLM(0W
MMS]HN(HLRRE0NX@9)P, "N.^'4<E_P"!9]3%R\-]J=Q-<2W(4,RG>0,9&#@
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M]>Z:LNHV!L;G<RM%O##@]0?0UI4U%"*%'0<"G4 %%%% !1110 4444 %%%%
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MSN9&SNYSC.2>W2LO1_ VN:.W]FP^)&_X1X2%UMA%B8*3G8'[ GKCU/K7H%%
M'*^(/!=OKOB31]8>0(U@Q\Q,?ZU,Y"GZ'FJ_B3PAJ-[K\&O:!JXTW45B\B8M
M$'25.HR/45V5% '"ZKX+U?4-'LK,ZS'-/%>+>W%Q<1$F21>@4*0%7VKK+_3H
MM7T>XTZ] :.XA,4NWCJ,$BKDC[$9MI; S@#)-9'AOQ+:>*+">[M(;B%(9VMV
M6=0K;EQG@$^M '-VW@74);#3='U74X+C2--E62(1PE99=N=H<DD #/;K6A9>
M'-5MO&UYK\E]:-%<QB%H5A8$1K]W!W?>]376T4 <YXU\/W7BC07TJWNH;=)6
M!D=T+' .1C!'>JDVA^*;C3H=.?6K&&W"K'(]O:NLK(,9 )<@$@$9QWKKJQM!
M\1V_B"34$AMKF![&X-O(MPH4[L9Z F@#G-5\!76NV^K#4KZWEN;@H+&80'-F
MJMD!>>_<CK4=]X#UB[&G:C#XA-MK]E'Y!O(XODGCSP'4GK_/TKT"B@#A-6^'
M]QJNG6LKZW,->MIO/74?+ ^;@;=@X"X P!]>]69O!=WJ?AG4-/UK69+R^O54
M&Y$018]IRH5!VSR?7)KLJ* .&T_P5J\>OZ9K.H^(C<S6431>6MJJKM/&%YXR
M.IZU2'PXU%/#-]X=CUY?[-N)=R(]J"T:EPQ^;(R>/IUKT:B@#F-9\(KKO@Q-
M"N[D>9&B!+A(\;63HV,GM[]Z;KW@JUU?PY9Z;;W$ME-I^U[*XB^]$ZC /O74
MT4 <[X;\/ZCIKO=ZQK4NIWK)Y:L4V)&G7 4=R1R>M6M=T[4K[[))IFIBRFMY
M=[*\9>.88QM< CCFMBB@#GO"WAA/#R7LAE1I[V;SI5AC\N)3Z(N3@?CS5.]\
M+:D/%=UKFE:M';/=P)!-'+;^8 %Z%2&'-=;10!P#?#A[2?2+G1M8>SN;!9%>
M62!9?-\PDNV#P"23^GI3-+^'^LZ,C+9>*I,?:GN?+DM04D+#!#X89S_^JO0J
M* //'^%=M+I\K?VBUOJSW?VQ+RUA$8A?CA4S]WCUKI/#>@WNDB6?5-8GU2]E
M 7S9%"*BCH%4<#U)K?HH Y;7_#FJZI?7#VVKPQV5U;BWFM+BV\U !N^=?F&&
M^;]!6)%\,'T^X_XE.OW%I;RV0L[E#"DCR*!U#'[I/TKT2B@#SRV^&U]!8:':
M_P#"1EH](F\Z &R7[V<XSN''7KFDOOAE<7B:Q:1^(IX-.U*Y-TT MD8B0G/+
M'DCCIQ7HE% '':1X,O\ 3/$JZW/KWVN3[*MHR-:!-T8.1R&ZY'7%9ME/IGCG
MQK8:K;Z=<JND)*))YXB@,F<*G/7'S-[9%>ATBJ%S@ #.>!0 CH)(RC=",&N*
M\+V-UX>MKSPKO\AEDDETZZ,9=7B8[O;YE).1D=CTKMZ* ."L_AHD?A&?P[>Z
MJUU;/+Y\,JP".2&7.=P.XY_^N:T[;PE=_P!H0:GJ.L?;=0M+=H+27[,$2+<.
M7*[CN8\=P..E=510!SW@[PQ)X3TEM..H&\B\PR(3"(RN3DC@G/--U_PQ/K>L
M:5?)J9METZ7SHXA 'W/TR23Z5T=% '$1^ ;J--?']ON3K1S.?LJX7.0<#/H<
M57E^& ^RZ4UIKUW::GIT9@COH8P&>+LK+G!Q_P#KS7?T4 <7=?#X31:4L6M7
M<;V%R;PS.BR23SG'SL6_+'3'TJ7Q'X$76]6MM8LM7N]*U2&/RFN+;_EHGH1G
MZUU]% '$S?#J/S]/N[/6]0MM0M$='N_ED>?><L6W \GU[<>E5[/X:2:9$%T_
MQ/J<+I=FZC9E1P&((.1CYLYYSUKOJ* ."N?A9IU[97/VJ_N7U2>Y%V=0C58W
M20# V@< >WZUO>'/#+:$DTESJ=WJ=[-@/<W39;:.B@=@,G\ZWZ* .;U?PA%?
MZ[;ZY97TVGZI#&8O.B16$B'LRL,&LZ]^'%G>:"-+&HW,8>Z-Y<S[5,EQ+G.Y
MLCCZ"NUHH Y*3P5,_B,:Z->NUO1;?9@?)CQMQUQCKGFLT1P_#?0HM)$&IZVE
M[*ZPQQVZMAB,E6(['/?/>N_HH YKPWIL/@[P5;V\J,OD1F698U+'>QR0 ,YY
M../2F^$='N+634]9OT:.^U6?S7B8Y,4:C"(?<#^==/10!SNL>$HM7\0V.LC4
M;RTGM8S$1;.%\Q"<[2>N,^E43\/K0?;K:#4KV#2KZ4RW%A&5V,Q^\ Q!*@]P
M*["B@" 6D LOL8B46_E^5Y>/EV8QC'IBN&?X3V#6_P!B&N:PFFI*)8;-9QLB
M;.?ER/<XKT"B@#C=1^'5G>ZS_:EMJVJ:=<R1B.Y>SGV&X &,L<=>!DU9N? F
MG37^E7=O=7MFVG0FWC%O)C?'_=)()^IZ\FNIHH XI/AEI,.L37=O>:A!9W#^
M9-IT4VV"1LYY _A]JU-/\)PZ=XCOM:BU"[:6]&)8FV;..%P-O\(X%=#10!QD
M/PYM(]-U33WU?4GMM2F\ZX4-&"6/7G9QGCIZ58?P%:/+IDIU;5-^F)Y=J1)'
M\HQC^YSQ75T4 <:?AQI[:?J-BVJ:JT&HR^=<@R1DN_7/W..@Z5</@FT>]TN[
MDU'4))-,79;AFCQMQ@@C9SD<&NFHH XRS^&6AV.J-=PRWPMR_F_8?M!^S[^N
M2O?MQGM74:GIT&K:7<Z?=!C!<1F-]IP<$=JMT4 <>OPZTY3I[?VIJ[-I[A[<
MO<!MI& .JXZ # XP*L#P)I37FJ7-Q+=W7]IKMN8YW4JV/NXP 1CMBNHHH YC
MP]X%TKPY<">VEO+B15*1&ZF\P1*>H0< 9JUXA\)V'B0VLEU+=03VKEX9[67R
MW3/7GGVK=HH XB3X6Z$\-Y"MSJ:179#3(MT<,1@\Y!SD@'GTK3?P99R:K8:D
MVH:C]IL8O*@;SA@+C!R-O.>]=)10!S%KX$TFWM]3@D>ZNHM2;?<K<2!MS_WA
MP,'WJSIOA.RTZ^BO3<WEY<0QF*&2[F\PQ*>H7@>G7K6]10!QMQ\,?#]T]T9#
M>^5<R^<\*W!$88G)(7WJ];^"=,M-5.I0SWXN?)^SAC<LVV/& HSV':NDHH Y
M9/A]H4>CR:7LN#:O.+@ SME9!_$IZ@U%;>$(;3Q;;ZI:>=#'!!Y3%IR_G\8
M(/IUR>IKKJ* ,CQ!X<L?$MK%;:@T_DQR>9LBD*!B.F?I51_!NG2ZO;:I+/?/
M>6RA8I&N&^4>GX]_7-=%10 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[7/FW61_RVX_[Y6K%
M0P_ZVX_ZZ#_T%: ,#7&V^,O"_*Y+7(Y./^6==+7-ZV@;QCX9)'0W1_\ (==)
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %(5#=:6B@  Q1110 4444
M %%%% !1110 4444 )BEHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(4:42I,G<$],_P#UZ=X)OIH-9U[PU-(9(]+F4VK,2S"%QD*2>NWI0!VE%%%
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MGG3M$[Q0A&QP <DGZ]C0!ZS16-X5U:XUOPY:ZA="W$LN[)MR3&P#$ KDYP0
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M&6P3P,^@^M:@.1TQ7E-_KEWK_P +([R_*?:%U&.)V V[MLHY(['':O5P0>E
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5##_K;
MC_KH/_05J:H8?];<?]=!_P"@K0!A:R/^*R\,\=[K_P!%BNCKG-9_Y'+PS_V]
M?^BQ71T %%%% !1110 4444 %%%% !1110 4444 %%%% !111D4 %%1SSQ6U
MO)/-(L<4:EG=C@*!U)K$TCQCHVM:D^GVEQ)]I6/S0DL+1[T_O+N R* -^BBC
M- !1110 449HH **,T9'K0 44R:58(7E?.Q%+-A23@<]!R:S=!\0:?XDL&O=
M-D:2!9&B+,A0[AUX/- %#Q[H\VN^"]1L+<9G9 \:_P!YE(8#\<5CZO;W?C3X
M?:=+IGE274<D%PT3MM#/']Y,]CG/6N[.#WJO;6-K9RSRV\"1-.VZ0H,;F]2/
M7W[T <Q::;J6K>*K?7]8L%T]+"W:*VMS,LC%WQN<LO   P!^/%0>"K?[;XC\
M2^(T_P"/:]N%AMF[2+&-I<>Q/3Z5V-U;07MK);7""2&12KH3]X'M3HHHH(UC
MB14C4855& !Z 4 2449HH ***,T <9XHTG5-?U[3;:?28;C0;>0RS!KG:TCE
M<*=N.BY/&>:Y?6OA[JMAXXLM:\(Z;:00VP5G62Y*B5N_&,C(.*];S1D4 >4W
MWA7Q7<^.[_Q#'IUH([JR:U\IKOE<Q[<YV^M9"_#GQ4OP\E\-?9;3SFOUN1*+
MGY=H7&.G6O;<T9'K0!Y/9>#/$R^.- UJ>SM$@T^UBM9%6YW$A5*EA\OOG%9V
MH?#;Q6EQXBM=/.GR6.K2B0R2R,K@!BP&,<'G%>TYHS0!Y#J'@3Q?=:!X<TV.
M2R$%@"MQ;/(3&[;B0[8 W#!Z5'IOPZ\3:;X2\2:,%TZ4ZC(ODN)&4X!Y)XX&
M ./?K7L6165K>N1:'!!+):W=R)IEA5;:(N02>IQT% %#P/I6HZ%X0M-,U%(1
M<VP91Y3EE8$D@YQQUKEO#_A7Q)8_$N^\37EE:+;WP9&CCN2S1 [>?NC/W?;K
M7I@-+D>M '&_$;P;-XQT6&*TG6&]M9/-A+YVMQ@J?3MS[54;0_&&H>#-1L=3
MN+%[VYM3;10IE44'@NS8)+$?A7>YHS0!R'A70]7T+P ='FBMGO8DE2+;*=C[
MB2,G''7TKD=%^%^J_P#"$:IX>U-[:)IIEN+>:-R^''9ACIQU![UZYGBL@:\I
M\4?V']BN]WD>?]I,1\KKTW>M ''Z5X(UB?Q3INL:U]DB_LFT2WMX[=V83,H(
M#$D#:/;FI_AWX.UGPK?:M/J#6;1Z@XD AD9F0@MP<J!_%ZUTOB'Q38^'=)DU
M&9);F&.40N+8!RC$X^;G [=?45LQR"2-7' 8 @4 >2R?#KQ,=8\4W:-I>S6H
MY(E#3R QAV!S]SG XJ+_ (5IXG6U\-H)-++:*6;B>3,V9-^/N<>G6O7IIH[>
M(R2R)&@P"SL .3@5BVWBB&Y\73^'1:7*3PV_VAI7 "%<@<<Y/)H \^\2_#7Q
M-X@\0ZS=M?V36US$!;><"[1@8(1?[G(P6'K[U+JGP[\27OAOPQ8)+IIET=B[
MY=QO.X8 X/8<GCZ5ZU1F@#S&P^'6JOXJU[4=4EL?L6L02121P2.7CW8P1E0#
MTJ;P=X*\5^&XFTJXU:PDT0R,VQ(V:5E/5>0 H/?KCM6[X@\>66@7\EG_ &?J
M5])#&)+@V=N9%@!Y&\\ <<U;F\9Z/'X9CU]+CSK.;"PB-3OE<G 0+UW9XQ0!
MQWAKP#XH\+ZC<6%AK-LFA32B4OY>9P!V (P"0,9R?7VKO/$=C>:EX<OK"Q$'
MGW,+0@SL550PP3P"> :AT3Q);ZR]S;_9Y[.^M<>?:7( D0$9!X)!!'<4FA^*
MM.\07VH6MD)P]BRI(98FCR3Z \]NX% 'GEO\-_%D/@N3PJ+O1DLYY_-FN 9&
MD(R#@ KCM6E_PJ^71O[!OM"N8Y=1TG<&%T2J7"L6)Y .TY8X^M=!>^/]/M)[
MW997US9V,@BNKV",-%"W?/.3CO@'%=5#-'/"DT3J\;J&5@>"#T- 'EH^%^HK
MX1URR^U6;:KK%TLTTF7$4:A]X5>,GG/8=?:F1?#KQ,-4\+W<USI3)H2)&%5Y
M,RA6S_=XXKUC(]:,CUH \HUKX9:Y=:]X@NM-U*QCM=9CVR"=&+KR&P,<8R.O
MH>E6K;P'K]OX8TS1)FTB\M;9)H[BWG+[)=S!E96VY5U^;GM^-=?!XGCG\8W'
MAPV<\<T-M]I\YRNUUR!Q@Y[]_2M[- '#>'_"FN^&-$TC3--U&V,<5RTM_P":
MC-O1N=D?H!ZG'K[5W-&:BN)C!!)(L;RLJDB-,;FQV&>] ''^+/#FO:SXAT;4
M-.ET](=+D,R)<%\R.>#G:.!@>M6!9^,[F^BFNKG288H$=DBMC*1)*5(7>3_"
M,YP.X%:/A7Q)%XJT<ZC#;2VRB9XO+E(W J<'.*W,CUH \VF\!ZY%/I6LV5Y9
MCQ'#*[WUU*[E+E6_AP!]W& !QC'%6&\&^)=.UV^O/#VM6MG::FWG7<$\1D\N
M4CYFC]<^^*]!HR* ."O/ ^KV6MPZQX=UE8;QK9+6[^VQF03*H #G'\7'_P"J
MEU7P7J\\.B7=GJR2ZOIMQ).TMVI\N9I/O<+]T>@':N\R*,B@#S.'X<ZR^G>*
M+:]UBWD;6RL@*0E=L@(;<>>!G(P >,<U=N_"OB>]OO#UY<7NER2:4YD?"2(&
M)&W QGC'YGMBN_R/6C(]: .3\2>"K?Q#X@T;57D\MK%SYJ[?]<G4*3[,/U-5
M_$WA/5[GQ!#X@\.:I'9:DL'V:5;A-\<D><],=>?_ -5=ID>M&10!EZ#87NGZ
M8(]1OWOKV1C)-,1A=Q[*O91T KG!X3UU-<U_5(=5M89=4B6.-DA;="4&$/7G
MCK7;Y'K6/K^OIH<=JJPFXN[R<6]M"&"[W/J3T [F@#%T?PC>0>+O^$AU%[ 3
MK;&#%C"8_.)()>3)Y/'2I/%GA&\UC5+'6M&U+^S]6LD9$D>/>CH?X6'Y_G6Q
MH.K7FJ6DC7^ES:=<Q2F-XI#N!Q_$K#AA[UK9% ' :OX)UW6?#BV-WKD4M[+<
MI<7$SQ'8-GW4C4$8'KZ]:OS^']5_X3*V\37%]:>7;6A@>".!\E?O,0=W7/2N
MPS1QZT >!:%=LLDNM6OB#03=33RRBUO;<M<>86RHVC'S' ''3/%>D67AW6+K
MQ?9>*[F:U@;[$L$EGY;%D! +#=GJ#[5U TK35O#=BQM1='GSA$N__OK&:N#
M[T <#;>!-3M])N?#YU*W;1+J=Y96$3+<;6.XH#G;@],^E7)O!4TWBQ]2-S -
M.?3SIS6BQMN,6/[V[KGVKL\BC- '#:%X+US1YH+-_$DD^AV\@>&U\D"7 .50
MR==HXX%=%XET4>(?#5]I)F\G[3'L$FW.TY!''U%:^:,CUH X4^"-56ZTK58]
M;C_MBQC\EI&ML12Q=D*A@?QS6[X?\/G2KK4-0NIUN-1U"027$J1[%&!A54<G
M 'J36[D>M&1ZT <9KW@[4;GQ(-?T#63IE\\0AN \/FI*HZ9!/456N? NJ#4-
M-U*RU]EU"WC=)[BY@$OF;SDLJDX4]AZ#%=Q,[I"[1IO<*2J9QN/89JEHE]>:
MCI4-U?Z>^GW#YW6SN&*<D#D>HYH X/\ X5EJT>F)IZ>((GMX[[[;&)+3D/G/
M4-SG-=%K?AO4]6U[1=234+:$:82^PP%M[,,-_%P,#BNKR*YW7O$[Z'K&CV)L
M6FCU*?R!,) !&?IU- $>@>&[W1]>U?4Y[^*X&I.KO&L!385X&#N/&*JZMX.N
M[SQ--J]CJ[6?VFU^RW"^0)#M_P!@G[IKL!TILC^6C.02 ,\4 >=VOPZU>TAT
M6)?$,<D>DW!FA5[/U/(X;-;^C>&KW3/%.J:U+J$4HU$*)($@*A=O"D'<>V>W
M>LFZ\?:O9?V9]I\+R1'4I1%;J]TH;)Z;ACY?QI^J^/=3T:WDDOO#4T/EW$<)
M8W"E"'Z%6 YZ'CMWH N:WX4U"]\50:[IFK"RF6W^S2AX!+E-V<KGH:PX?AMJ
MMK965C'X@C>SL[[[9#'):\[@21DAAG.3FO20P*@^HI<T <3>>"]1N];U;4?[
M6@0ZE9_8W3[(3L3'4?/UZTUO ^HG2-$T\:M!MTB99XF^R'+E?NAOGZ8)Z5V-
MY>06%I+=7,BQ01*6=VZ "I@P8 @\$9% '$7W@6]GO]8FL]=DM+?5U NHEMPQ
M+!2.&)R!STJK:?#J_P!+N+"XT_Q%*DUM;&S9Y+=7_=%LX4=C^=>A9%&10!YY
M'\.+Y/#$VA_V]F![K[0K-; E,'( PPY)QG] *[ZV65+>-9F5I0H#LH(!/<@&
MI<CUI"P4$D@ =230 M%5[&]M]1LX[NTE$L$@RCKT858H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *AA_P!;<?\ 70?^@K4U0P?ZVY_Z
MZ#_T%: ,35Q_Q5_AP^GVG_T6*Z&N<UDX\9>&AZ_:O_18KHZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "N#U_P 0>*8O&]OX>TF/3 MS:M/'+.')0 X);'TZ
M#U%=Y7F?B:;4?^%O:7_8[V37::8X9+EB%P6/'R\@]_PH J+\2]6L[>71M0MH
MCXB2_%GF&,M&5(SO"@Y)QV[\5+/XL\9V%AK<DVGCR;2'SK>]N;5H0PX!7;GE
MN?TJ]>?#66_TR:XDU!8_$4MV+W[=&F%20# 4#KM  JQ=>$?$NJ:#?VVJZ]!<
M7ES#]G3;"4AC0D$G:#RQQUH YS6[CQCJGPTU#4M4O-.BLI[1)5BMX2793C()
M)X[>M;D&IZG:7.@>'8;NV.HW5KYYO)+; B@"_=49^9LCO6C?^%=6O?A_'X;%
MY9QR^4L$DWE,5*#I@9X/ J.]\':E<MHNIQ7UM#K>EIY:R")C#+'TVL,Y''H>
MYH RK[QCX@TZS\2Z=*]HVJZ1&+F.<Q';-"?]D'AAD>U4=1\2^/M+\(PZ[/-H
M[1W0@,2)$VY?,QUYQ6_?>"-0U#3M;>6^MAJVL(D,TPA/EQ1*,;4&<_B34FK^
M#]4U;P7IV@MJ%K');-%YDPA8AEC^[@;NO S0!E'6O&D?C./PW+>:7YMU:?:%
MF6W;;!CJ ,_-T[T[3_&&NWG@Z>X=[.*\M-2-G<W3 !%C'WI I/)P?NCK6U_P
MBVJOXTB\12:C:%XK7[,(Q:G!!Y)SOX.:Q)/AIJ0M-D6NQ><NHG4D)M/E\P]F
M&XY'''XT 58O&^N26/BM(+B&6728UGM[F:U,9=""3E/PX-6K+Q#XILM7\+R:
MK=6=Q:ZU'M,$,.TQ':&#;N_45))\.M9EN]8F;Q*C'5H%BN2UD"3@8X&[@ =*
MT)_!FJ3R>'G;5[8'11B/%F?W@VA>?WGH.U %:PUGQ3XATQ-=T>:T^SO=E$L)
M$',*MM)+YR&X)Q6;?>+/$>L7.J/X<BN7%C<>1 D5LDD<Q&-Q=V8$=\ #\ZT+
M+X<WVF7=Q!8>)+F#1+B4RR6(B&[!/*A\\ ].!4D_P^O;;7KN^T#Q!-I=M?$&
MZMDA#@GN4.>#_+]* .RTZ:YN--MI;VW%O<O&K2Q!L[&QR,UXQX;N?%6A^!;_
M %S3+NS%A;WDLKVLL6YI%#88[L\?3V->U6EJEE90VT18K$@0%SDG ZD^M<99
M?#^ZM=*N=$;62^CW$[321>1B4AB"4W[L;3W^7- %;3O$>J^-KZ]CT:^72X+*
M&(Y,2R/)*Z[L'/11TXK(;Q[XAU/2-">REM+2\N=0;3[E7A++O'\0YX'M76?\
M(9/I^OW&J:!J$>G_ &J%8IX'MO-0E1A67YA@@#WJG<_#K_1M&@L-2^SC3;@W
M9=X-[33$Y+'Y@!]* ,UO$/B/3/\ A*].N]0BN+O2[9+N"Y$"J"&&2I7I5BZ\
M2:Q#>^!7%XGE:NB+=1&(88E Q(/4')^E:?\ PA,]QK.M7U[J22QZM;?9I8H[
M?9L4#"D'<>16;%\-]2$^C2S^*9Y/[(.+8"U7"KC ').3VR<\4 4M/\4:O/XM
M_LZ]U%["\^WE?L%Q JQR6^>#')CEL>IYSQ76>-=?FT'2K8VH075Y=1VL4DGW
M(RQ^\?H*SO\ A![ZZ_L^'5-;^VV]C="YB8VP6<D$D*9-QXY]*W/%'ANT\4Z,
M^G7;21C<'CEC/S1N.A% '-ZMJWB/P7::O?7MQ%J>GI K6DDH5)!,6"["% &W
MG.?:H+_6-=\-W?A^\NM3%_::I,D%Q"T*IY;.,AD(YP.>#GI6C;^ C<V-S;^(
M=8NM8:: VZM(HC$2DYRH'\60.3Z4ZP\$7*S:9_:^L2:C;Z6V^TB,(CPP&%+G
M)W$#ITH Y277?%[:3XHOQKD*+HUXT<:I:+^]VD9!ST&,>IK5M=8\26GB?PU]
MNU.*XM=;A=FMD@"K"0@8;3U/7O5W_A +O^R]=L/[;!36)S-*QM!E6)RV/F[U
M9?P7?2W.AW+ZRGG:.A2 BT&'R IW#=Z =,4 <A+K?BW^PO$VJ+X@4+I%Z\4:
M"U3]X%(!!]!S6S;ZWKFG^(O#LVHZHES9ZS!*\EM' %6$J@8;#U/4=3ZU>'P\
MF_L;6-,.MN8M5G,]PWV9=P8D$XYX' JS)X*NIM1T.[EUIV.CKMB3[.,29 !+
M<]2 !0!S%CKWC;7=/M];TJ&X*2W186[>0+<P!B",EM^[CKQ4LU_XHU#6/%EK
M#XA^S0:6JR1%;9 3\I8+GL..O)-:UI\-18:G)]DUV_AT660R2:6I^0D\D;LY
MV^V.G>K:^![F.\UNYCUIE.KKLE4VJD(H&!MY[#B@#'TWQ/J7B>ZT32$O6L)+
MC3?MUQ<0(N]SN*[5SD#H2?Z4:W>>*]!\/Z6]YJ\+78U2.WE>",'SHG;C=D<'
M [#O5N;X9*=-TN.UUFYM=1TQ3';WT2 -Y9).UAG!ZGFK-]\/C>Z1:V']M70:
M*Y%W-<2()))YAT8D] /04 9\]QXCU3XB:MH5MKSV5G#9I/&4MD9ESC@$_7K5
M"S\7ZQ=^%/#+W5QY#7UZ;6\OD 7:JDC// +8ZX]:ZB+P?>P^([W7%UR3[7=V
MXMV_T9=J@#@@9Z@\UQ/B3PP/#NEZ-HLVH:F=-CNI+A[Z*W#B$[3A60=<L<Y/
M3F@#JO!-]JM[KNNQ7&HR7NF6<P@M961/G/4_, ,D<?G2^-=2U'0=>T+4UOYH
M]'DN%M[R$*I49Z,>,^N?I4/@5M0.H2>1J5QJ&B>1\LEQ9BWQ+NZ( !D8SD_2
MNJ\0Z%:^)-$N=+O"PBG4#<N,J0<@C/O0!YI9>,+R&^\3Z?)JEW.\H_XDTD@5
M3)ES'\G&#\Q'/<"MZ!]9M_'AT"?7+J>VDT@S!MB*Z/NVY! Y/&>?6MV;P9I<
MNIZ)?+'Y;:0AC@0#@KMP ?H>?K2/X5D?QF/$G]IS!Q#]G^S>4NSR^I&>O7G-
M 'ED$$X^">L7$MY/,9;[&R0@A6$RY;IG)[\UVVDW&L:1X_T_2+G6);^UO=.:
M=EE15\MU_NX' ITGPNB.CW6DQ:[J$=A//YP@VH53Y@V.F3R!S6J/!\Q\2V&N
M2ZS<R7%G!Y 0Q(%=#U!P.] &3\5;=Y;#17%U/$C:I#$4C8 '.?FZ=1CBJ%UI
M=[=_%BYL[/5[FS*Z*F^Y4*TK#?ZD8SG&3CM79>*?#47BG28[*6YFM6BG2>.:
M'&Y77.#S]36;:>")K37I-8&OZA)<M;?9MTBHQV=1DXY.>: ..L?&6NW>B>'=
M.\V2:ZO[JXADN(W6*1UB/ #-D GCFNV\&Q^([=]0@UY@\0D#6C23+)*$.<AR
MH /;FLL?"O3QH,>F?VG?[H)C<6MR"HD@D/WB"!T)YP:Z3P[X>708)/,O;F_N
MYL>==W+9=P.@]@/2@!^O:C!HNG33QP"6\N#LA@11NN)2,*/?H,D] *\WU#PX
M_AT_#W29F$BIJ3/<,OW#*2K 8].6 ^E=EK'@7^UM>.KKX@UBTGV[$6WE4+&O
M&0H*\9QS4Q\$VCZ"=,GOK^XD^T"Z6]FD#3K*""&!QCC&.G2@#'MRP^.-VL9^
M0Z0GF8'^UQFG>#G+^/O&@Y.+B+KS_"170Z'X:CT>XN[V2ZGO=1O"OGW4X 8A
M1@*    /2J^@^$O[#US4M5&I7-Q+J#;I8Y%0+GMT';I0!P%^FK^!_"WB?3;W
M2Q=Z?=RR-;W@F0 F48P5)W$@]@*] T".ZT3X?V*SHTES:V 8H>I8)G;_ $J:
M?PQ#J&JQWVJW$MZ()#);6[@+%$>QVC[S#U-;CHKH48 J1@@]Q0!YSX?_ +>U
MK1]%\2Q^) AEE,E[!+CR/++8V*,<$8 R3^-<[K7B'6+6>?4K35;ZX>+6!;M+
M"0+-(M^!%M/WF]2,_6NQL?A?I.G:@98+S4?L/FB9=.,_[@/G/3'(Z<'TJM/\
M)=+EM);1-5U:.U:?[1' LR^7$Y.20-O\\T 5]4OFTOXI:Q?I'O:W\.F4+ZE7
MS5;1AXSU&/0]=@OU2WN-K7BSW@9)$8_P($PA&3@9)Z UU%IX%M+776U5]1U"
MY=[7[(\5PZNCQ8^Z?ER>>>M5-+^&>EZ3>QRV]_J;6T,IFALI)P8(W[,%QS@\
MC.: .-DE\32>'/$^JOXFOU?1K^58$VIA_+/(; &1@].GM726NHWGB[Q+/I;:
MC<V$%GI]O.PM&"/)+(H;.>NT9''YU?'PYMUTC4M,_MO53;ZC*9K@%H\LS'+'
M.SC/&?I3I_AU9RW-I=Q:KJEK>V]N+8W-O*J/-&.@?"X.!QG'84 </X<N9[7X
M?V%O'JTEOYVL2QS+ ";FZ&[E8\=&/4GC'K23ZWKT?@SQ>@U._MYM*O(UA,DB
MM,L;$+L9A]<Y!Z]ZZU?A/I$-E;06VH:I#+;7!N(;A9QO1CUQQ@9^E$GPGTN2
M._B75M82&_*M<Q_:%82%3D$Y4Y.>: .A\*Z9?:=8,]]K-UJ37 21?/ 'E?+R
M!CMFN/U#5;KP?XOU*WU'4;R>QU&T:730\A.R8'F,>^2,?A7HNGVIL;&&U,TD
M_E(%\R7&YL>N !^E<9.DWC'Q3:0W?A^XM;31;MIOM5R,"9@,*$]03\Q_W10!
MFW]WKL6LZ+X3CNI9YVL6NKJ:2Z,+S/G& X4D ')P!Z>E5I9/$FF:58:9KFM
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MRW,QEOY!+-YDA8 @8^4=A6G0!P'Q#V_V]X-R3C^U!T_"G_%E5;PA"K.45K^
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MN-+FM9Y5C8Q,TG[LL!QN(Z"O,_$L9TW1]&O+M?L<.IZI]KU%Q&&"!N45QT(
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MH]!OI+.X^SSQPLZ2[ ^,#/0_3%<[X,\9Z??Z'HUKJ&KP2:S=0!VC+#<QY].
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M-5N9+:WN'6>.(3-'-$T;>6?XOF R* -JC-<];>*M)UF9+"TNIUEND?R)/)=
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M3;&\@2"ZL[>>%""D<L095(Z8!&!B@#Y^N+_36\%^+;(ZA#=2/J230$J$,@R
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MK:1:_%K5O-,2P0Z4(2?+^564Y91QZ?X5Z<-K*&!!!Y!ID,L%PA>&1)%!P2C
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M"Q(0L1R<$<UUWCJ:2U\#ZG);V*7C+#@0,F]2,@$E>^!S^%;0OK)F"BZ@+'@
M2#)JSU% 'B%MK5G%XZM=3-QJ-W:R:6\;7$EFRJ6Z850.%'L,#WI(+VUC^%NA
MVVR075OJB/,@@?<H60L2>/[I!KV_ ]*-H]* /-_&&G7T/B73M5T @'6D_L^[
M8#^$C<LGU"AOIBO0[:WBL[6*WA4)%$@1%'8 8%85AX6EMO$EQJ]WJ]W>@N[6
MMM*?DMMW4+SSQP/:NCQQ0!X#XAO9;_2]726"]@NX-3,KV%O;E88TWC]X[8RQ
M/U_"NITS5M-N?B5J%X7=(GT<+OEA92K#!88(ZA1FO4I'BBC:21E1%&69C@ >
MYI(I(IHEDB97C8!E93D$>H- '@=IJ%M%X-\.6S%S-;:T9YHS$Q*Q[B=Q&.F#
M757,\.H>._%,%B3+)>Z/Y4("$"20 Y .,'BO5=H]*, 4 >&?VXEQX?\ !-@E
MK?R7&F7T2W0%LW[LKD;>G)^GI4'B/4UO]"UZ%[>_L[B/4/,_L^&V*Q[=X_>2
M'')./7KC KWA&CD&Y&5@#C*G/-.VCTH \TT[6;6]^+%E/$\PCFTCR0)HF0J^
M[=MY'IS6G\2XKV.RT?5+6U>ZBTW4$N9X4&24 /..^*[C:/2EQF@#R_7/$6FZ
MKX<UG5-'T%KM7BC6XN+BW90Y#  8/+;1R<>U96GZQ8CQTEZ\NHZE#/I#Q,TE
ML5#L#DJJX&%P#]/6O9-H]*-H]* /(_#FH1:?KVEQ:1J#W^B%))7MKJ$^;IP"
M')W8X'.,?7KUK%%U:CX-7%L&'VLZB6$80[S^\#9QC^[SFO=L#THP/2@"KIEQ
M'=:;;3Q/OCDC5E;U&*MT8Q10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !447^LG_WQ_Z"*EJ*+_63_P"^/_010!B:L/\ BK_#OL+G_P! 6N@K
M%U% WBG12>JQW!'Y(/ZUM4 %%%% !1110 4444 %%%% !1110 4444 %>>W?
MBD:#\3KRWUG6A#I1T]98HI0%5'+ 8&!DG )_&O0J\WU :5%\8Y9M9%JL!TD"
M)[L+L+A^<%N,XS0!VH\1:.VCC5AJ5L=//2XWC:>V/KGC'6H;/Q9H5]8W%Y!J
M4!@MAF=F.WRQ_M \BO'DLY](N=-U[[.Z>&#KTEQ%!M($<9PJ2%<<#N/_ *]=
M#JC6M[XUUG7;"2(Z5%HDD%U<KCRY)6SM4'NWW>GL* .YMO'/AB\O;>TMM:M9
M9KG_ %2JV=Q],]C['FK">*M$DCOG34(V6P(%U@']UDX&>*\D,^E)\/? \:O;
M+*NI1/.%P",$[BWI@$9/TK8O-:L=&\3^.HKMY%FOK9#:HL3-YH\DC(P,=Z /
M0)_%VB6UA:7CWH,5VAD@V(S,Z@9+!0,X'<UH:=J5IJVG0W]E+YMM,"4< C(!
MQT^H->,V5QI<OAOP[]GUJ;1M:LK!S%/,A$+Y/S1MGKGKZ?RKTOP'=W-]X,T^
MXNK.*TE=6/EQ)L4C<?F"]@W7\: 'CQUX>;3+G41>L;6UE$4S^2_R-[C&:L7'
MBK2+:.R>:>1%O8S)"3"^"H&23QQQSS7 ZQH&I_\ ";ZEX>LUV:5XAB%Q/,%R
M(=OWR.V2<#_@57?AY#J, NI]>Q'!H<3Z? S]" VYW.?8(/H* *^N7LL?PMN=
M1T;Q/J%WY5YN%V7V.P,@4H#C.!GM_+BMJ[N[Z/XC^&[=;VX^SW-E*\MOOQ&2
M$ZX Y/US7!&^MV^"]U;(_P"_;5&Q'CYL&7<#C_=YKL;[4[2;XI^&)!<"0"QD
M!<#C<Z_+G'<T :_Q*N+NS\#7MY9WT]G- 48/ VTG+ 8SUQSVJQX>\;:%K,L6
MFVNI":]6$,0Z,OF8')!(Y_"H?B7;S7?P^U.&"%YG(0[$4L2 ZD\#VS7,:Y;P
M^-+_ $8>&P0UE;RF6Y$91(P4PL><=<]NU '8)XYT%]3BL?M3AII#%#,T3"*1
MQ_"KXP36IK6M6&@::]_J,_DVZ'!;!.3Z "O(_#$>CW-KINB7VA:M-KEE* 89
MGD\F-@W+Y)V@8&>G/2O0_B,Q7X=ZT0A?-L1@=LD<_AUH -)^(/AW6=633;.\
M9IY$W1EXRJR8ZA2>I_PI\7CO0YM1BM$FFQ-.;:*X,+"&24?P*^,$UQJS6GB.
M+P;;:- \TNG>7//*D;(L*K'RI8C^(XX%<U+?27%OHEW-::@L]GJZR7%E;63)
M;VJ!\X"@8+G\30!ZAI=]ILGCG6(X=9O9[J*%?.LY6/D0 'JH/&?\37+^,/%L
M6H76@/H]YJD22:@D?F1H\=O<)GYOFXW<C^=1W/G:QXL\8)817"R7NE+#;EXF
M3<ZK\RY(Z]JRM6UHZGH/A6PATC4TN],NX1<Q"S?$90;2,XP2<$@4 >G^-49O
M!FK,D\L+QVKR*\3E6! )ZBN;\&_$'1)M-T72);J?[;);QQ^9)&VQY, $!SU.
M:ZGQ5%+=^#]6AMXGDFELY%2,#YF)4X&/6O/EB_M_P]X3T6RLKC[;ITL$EVTD
M+Q?9Q&/F&Y@!DD8 &: .S?Q]HD=YY#/<F/[3]D-R+=C"LN<;"_KFG:AXXTK3
MKRZMY$O)!:,B7$L-NSQQ,V,!F'3J*\HU"34-2TX-)H^K1WMKJRRRV=K:E+:)
M _4*/ON>.>3S6MK$C7>KWFJZ!:ZOINN&X6-[&6V9X;\#;RW&T8!YR>,4 >AZ
MKXUTK2)KI)OM,JV84W4D$1=(-W3>1T/M2ZGXJTH(EK$UW=RW%MYX6P1G=8B.
M'R/N^W>O.UT^/2_%&M6OB/PG>:J+^Y:YM;BVB:17W<[#S@8]^F/2M2QFOO!O
MC&[N+K0+DV&HVENL0T^,S"!T7'E\?C0!L_"6XDNO!7FR3339NYMKS,6?;NXR
M36X/%E@VIZGIPCNC=:=%YLT?DG)4]"O]ZL3X5QW5OX6F@O+"[LY1=RR;;B(I
MD,V1C/6LS49[S1OB'KUU_9&H7D>H:?&ELUK"75F48()Z+S0!LW7Q-\/VECIU
M[(;PP:@&,#+;,<[25(/OD=.M6-)^(.AZI::C.SSV?]GC=/'=Q^6ZJ>AQ[UYK
M#/<:3I'P^BO["\MWM;^7S(GA.\_-G*KU(PWI6EXG\)ZAXMU'7=9TVTG@7RH4
M@CGB,373(<MP<''  SUH [VP\:V-YJ,5C+:WUE-/&9;<74!7SU')V>IQSCK6
M2/BOH1225;;4VMXIO)FG^RD)"<XRQ[<_C56Y>Z\2:SX9N(=,O;0:86N+N2XM
MV39\N-BY'S$D=LUSSP7S_#CQ59C2=2%U?:D\D$7V23<RM(&!Z=,*: /8VF1+
M=IV<"-5+ENV,9S7+:;X_TW4]0L+:.VO8H]0W_8[B6(!)]O7'.1T/45J)-</X
M.,MK:LUU]A)CMYHRI+A.%93[\<UY380:H=1\+:@V@:])<VTKB[>2(*JEE(V1
MID!%&>N /K0!Z%??$#2[&21FAN9;**Y%K+>QJ#$DA[=<G'<@&N0BUZ/PQ\2_
M$SQV>H:@DD44I2#,A1=NYF.3P!FI?#4VO>'+2\\,W/AF[NY7N7DMKDJ'MR'.
M09&)P,'GUJYI[WEOXY\47=UI]\T<]I'%%+':/ME9%P=O'KG% &AJ^M>']:?P
MI>S-?NMU=*]D8"53S#QB0CCCTZ]:T-7\=V&DRW@%K=7,%@RK>3P!2L)...2"
M3SSCI7!6%KJ4'A[P59G1=4,^F:@9;I!:M\J@DYST/6K3:;=:+XHUA+WP7_;D
M6I73W-I<K&K!-W.URWW0#Z_K0!V]KXWL+OQ);:)#;W)DNH/M$-QM7RG3;G(.
M<^W3K37\<6D<,K26=VLGVLV<$1"YN)!UV<XP.Y-9'C+0=6;1]&U/1+:*/6M,
M90D-NOR;' 5U'^R.OT!JAXN\+7EGIGANYL].75?[*<_:;,KN\\.!O;!ZG.3^
M- &J/BAI:Z;J-U-97Z3:=(([JW6,.T>3@'(.,=LYI?\ A9MDM]':2:-K,<MQ
M'YEFK6O-R./NC.>_?M6'K-I>7_@;5X[#P:VF/>+'%!;Q0KYSD/N9GV\*O'&:
MNS+?/XZ\+7XTC41:VEB\4[F#A&=< 'GVYH V;7XAZ7<:!/J<L-S!)!<_9'M'
M4>;YW9 ,XS40^(]@@U6.XL+Z&[TV,336VQ7<H<?,"I(QR,\\5PUUX=UO4K+6
M)H-%G,J:V=3@M[N+:MQ%R-O)Z\]#6\8;J]\+ZO):^"?[)::Q:W$:0IY\TK<<
M =$'OUS[4 ;6G?$>TU#4M.M?[*U*WBU%";6XN(@BRL!DJ.?UZ4[P7XIU/Q#J
MFM17FGR00VMV88\LA$6T %#@Y)SD]QSUKFY+?5<> #_8FHEM+'^E_NO]7\H3
MU]B?IBM[P5::GI?B/Q);76F3);W6HR7<=T67RV1ON@<Y)_#B@#=U;Q)'IVIP
M:7;VLM[J,T;2K;PD K&.K,2< 9X'J:Y?7_'@O_AWJ^HZ/!<I=P!K>>-L)):/
MT);GMVQWJ76-/U+2/B5#XE@L)[^QN+3[).EN-TD1!R&V]Q6+>:#JR>#_ !;,
M-+G-WK]T7M[.)07C7/!?L..30!TG@;P[80V]KK::5+IU]+:+%(GG9648!WD
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%%_K)_\ ?_\
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M[6"_:2=TE$>Q0,85>YX)X]ZV+[4K35_'?@76;90D=U;7+[G&&"[!P3[$G]:
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M11U"_P \\5J6OC'7HM<T,ZI:V4>E:U$6@$+,TL1"!AO)X/7M0!Z#28%>=?\
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M-Q_[)6M65>?\C'I?_7&?_P!DK5H **** "BBB@ HHHH **** "BBB@ HHHH
M#TKS*75[;3OC/J3W,,I"Z7&@,,+2'.0<X4$C@XKTT]*X^PT6Q3XA7>JQ:\)M
M2>(K/9#8=L7&T8'(Q\O/?\: //9O"^I6$-IXB_L.:ZMFU*XN)=*8?/'#)@*=
MH_BP/Y5IZ_;P7W@75Y=*\)SZ>+MHHHA]G_?SD.&8LHSM4;>I/)KU[ ]*7 H
M\_\ %<5AJFC:+!?:;J#VLB;EN;2)O.LW"C!P!D \@_2N8M=.\5Q)HFO7D%U?
MPZ5>RX21-MQ);L !(5ZD]?>O9\"C H \OU"QN]7UCQ#XBM[*^2W;238V\9@9
M9+EV'78><#CJ/Y55N(+X:#X%A&D:DTFF7$+W2BU<&,* #VKUK HP* /"M?L]
M>U?2;]+SP]JKZF;\3(47%O'$&XVJ#@L1U/)]Z[71VO;CXE#4YM)O[:V?25M0
M\T! $@?<1GIT[UZ!@5E7GB30].NC:WFK65O<#_EE+,JM^1- '/>/M*U"YN]
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MUQ/;ZBVI7<IE,:M(QR548/&,#/MTK<T70]9M_B!JNNW5K;16M] D05)RS(4
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M'UZU@VVN^.KCPIJ/B)=8M2FFW$H-L;8?OD0_-D]O8>U=C+X6NXM>TW7KK7(
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MN'2?Q)#-X2E'B:Y=M<0I,'C0JGR!LJ,=><9KT37]%37]!N=*DN)(8[A-CR(
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MV\/WFF6UQ;74C:A<+;QO$HV(Q('S$FO/])UCQ0NE:WXEO-?>>UTFZN(A9F!
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M!89BL:E?FR1W)QBMOPO=W/CGQ!/:^();B/[-IL+PVR2-%N9P-TORD9/3'UH
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MC@N]WE3REL8.TC) !(&: /8M1U6RTJV6>\E6-'D2)<]69F"@#UY-6C(B@$D
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M8)--DWK'(4W8+'!(YQ7)W,U_HHNO#T-\5T)=;6W%S<,Q55*[C&Q!!VYQG!%
M'NZNKC*D$>QI2P!P37&>$- _X1_6[]%U:"5+J)9180(P2+!QO&YF.#69XNTR
M'4OB?X=M)I;E8;FVG$RQ3L@8*N0.#P#GG'6@#T3S4V[@P(]<TK2*OWB!]:\+
MA\/VO_"+>-SY]WMTF\E6R07#A8MH!SC/)^OI707@7Q#<Z-;R>9J%Z-%6:2UF
MF\N&,LH_?,PY+<]/Y4 >JL0%SG KF?#OB6[U;Q#KVEW=I#!_9CQ!&BD+[PX8
M@G(&. /SKSSPYJMQJ^G^#-$U*[=K&Z:X,Y\TAI3&6V1L>N.G'>G32'PO)\1?
M[(8V[1_9/**DL8PVX,1GL-Q^G% 'LX8,3@YQ7-^+O$EUX;339(;-+B.ZO$MG
M+2;2FXX! QSW[BN?T'0'TSQ%IFK6FM68L;N$Q-;P&0BZ)0L'^9FYXSGC@5-\
M6H3<>'=-A!93)J4*!E.""<CB@#O0P/0YQUI<UY;+X;BTKQ[!H=C/>-IVK6,K
M7<;W#,T;+TD#$Y!SCO47AH/?/:^#;OSFN=*O9)KN7>PWQ+]PYSSN+#\ : /5
M)IXK:!YIG6.)%+.[' 4#J37,:EXP-M>^'A:6R7%CK$PC2X,A4KD9^[CT[YJS
MXZL8K_P1J\<JAA':R2KDD8*J2#Q]/I7GCZ=;'P_\.[>,RQ+=7*/(T<A#9*#)
M!SQ^% 'L@(/2@$'I7CNHW]YX27QG8:9=7 @M_L[0^;(7,/F8#D,>?6NBT#0-
M0T[Q#9ZK%JMI'I]W%L>VBEDD%P=I(8%R>>,Y'8&@#H/&/B2;PIHIU1+!;R%&
M"RKY_ELN2 "/E.>OM5&]\;2Z+-9'7-):SL[QUCCNHK@3(KD9 88!'UP:K?%S
M/_"N=0Q_>C_]#%<Q\1=,UFW\-:;J=]J<>H:=92Q2S6GDB$L> """<]2/QH ]
M?SBDR*\]MKJ'QEXPU"PO9+B.UM[&"6V@CE:,YD7<SG'4C('I6%9:G=3Z(VB:
MCJ5V6L]9-E%Y.?-O47_EGNR,>Y^E 'L .:3/%>/6LNI0:'XZLS<W=G]@*RP1
MK<EVA^4G ?J0<"K/D7FBZ/H/_$\U&1_$4UM%<RRS9\I2N3L/\).<9H [B#Q*
M\GC2;PX]DR&.V^TK<&4$.N0/NXXY)[]JZ&O.M*TJ#2/B^\,$D[H^D[P)I3(5
M_> 8!/..*]%H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M SKK_D.Z?_URF_\ 9*T:H7*YUBS;<!MBEX/4\ITJ_0 4444 %%%% !1110 4
M444 %%%% !1110 'I7!7G@G6[77M5O\ P]K-O:0:K\US#<0>9A\8W*?Q/YUW
MM% 'ER?"S4X-"TF*VUY(=5TN1C;W*1$*%8Y*D9YYS^=;=WX,U?5?">H:=JNO
M&ZU"\,;"?R@L46Q@P"H.V1R>]=M10!Y[J'@/7I;VQU>Q\2"WUF*#R+B;R (Y
M$[#:/3WS4]_X$U.]DT>9M;1[C3[@W;S30%C-,<=@P 4   #TK7\0>*O[!US1
MM/>QDDCU*;R1<!P%C/TY)KHQR* .3U#PIJ%UXVLO$<6H6Z-:VYMUA:$D$'.3
MG=ZDUECX?:I_8FN::VMP,-8N&GFD^RD$%CE@!NQ7;MJ-HFI1Z<TRB[DC,JQ=
MR@(!/YFK5 '$'P7JK:QHFHMK%MOTF P1)]E.&!7:2?FZXQ^558_A[J2:/KNF
MG6H3'J\IED;[*?D)/./F^E>@U7O+ZWL+<SW4HBB! +'U)P!^9% '!Q?#?48+
M[[5!XD:!I+%;&?R[8$M&J[5VDD[3@#)I(/AE>6NF:-;P^(I!/I4[26\AMU*J
M#U 7U]R371?\)+*/':>'&L=BO:-=+<&4'< <8"XXYSU-='0!QMOX)N3XAU#4
M;_5%NX+^U%I/"8-I9 N!\P/![GBH+?X>R"QM-(OM6:[T2TF$L5JT(#M@Y56?
M/*CZ"NYI,\XH XR'P5J$&KZYJ$6LQJ^JQ^6R_9LB, 8&/F["MGPKH#^&O#]O
MI)N_M*6^1&YCV$*3G!Q[DTGBK79O#>A7&JQV0NX[<;I(_.\LA?4<'/TJ;PWK
M]OXE\/VFK6Z&-+A,F,G)1@<%3]"* .<;P%>O>Z_<?VYM&LC;*JVJ_*O08YZX
MXS3G^'\TEIH5NVMN!HS*UN1;+R1@#=SSP*GTWQN=9\<7^@6%DKP6*YGNS-CG
MH0JXYYXZ]JZ\'- &;KVAVOB+1)]+OMQBF7!93@J1R&'N#S6/8>#[B*^L[S4M
M9FU"6PC:.SWQ*HBR,;CC[S8[FNJS2,3M.T G' )Q0!RVB^"(M+TC4]+NKZ2_
MM-0D>619(U4AG^\<CUX^F*R?^%7LQL4F\3:G+!I\JR6D;!3Y6.@!QST')K<\
M(^(KS7AJPO;6&W>RO7M0L3E@=H'.2!GKZ"ND9MH).?PH X>Y^&EO)KES?VFL
M7]C;WC!KRTMWVI/_ 'LGJ,\YQZUIVGA#[%XJ.N0ZC*!Y M1;>6NP1#[J@]>#
MSGK67+XRUVSUK34O_#WV;2M1N1;0RF<&968_*73MGKCMZUJ>+O$]SX<_LTQ:
M?Y\=W=QVS2F0*L>Y@.G4G&?:@#9U?3(-9TJYTZZW>1<1F-]IP<'TKEXOAS:P
MV5@%U2]_M&P;_1KXD%XUZ; O3;CM7:U&\\49422*I8X4,0,GVH R]%\/0:.]
MS<&:2ZOKM@]Q=2XW28X P.  .@%9OB7P+9>(M0M]26\NM/U&%=@NK1]KE/[I
M_,_G5CQ=XD_X1[3[<Q")KN[N$MX%E;"AF/WC["G^'Y]>VWBZ\+,I&X-O=6[8
M65,9)(R=N* ,R?X<::\.F_9[V_M;JQ9G6[BE_>NS_?+$@Y)]:H-\)M,-M<VR
M:OJRVUQ.)Y(O.# N.YR.3GG/6K/B#QV(_"KZSH!@N$CNQ;.9<X/S[25 /(]"
M:[-)XW=HUD1G3[RAAD?6@#GM4\'+JL^ESSZO?+)II#PLFP9?^\?EZXX]*DTC
MPE'I&O7VKKJ-W/<7H'GB4KM;'"\ #H*W%NH'F,*RHTB]4# D?A4I( ))P!0!
MS.M^"-/UO68M4>YO+6Y6(PR-:S&/S4_ND_X5EP_"K2;>P@LX-1U-(H+G[3$H
MN.$<="!CMGK79P7UK=%Q;W$4Q3 81N&VYZ9QTID=_;7@E2SN[>6501\KA]I]
MP#0!S%[HP\-7U]XJMQJ>JZ@\*Q-;(P)D7(P  .W6K/A#3)!)J&O7=@;&]U64
M2- Q^:- H"AO]KJ3]:9X'\0WFMZ)>W>JM LEO>S0%D78H5,<\GZUT,&IV-S
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M$-O<SW*":56^=\K\VX]QG\NE13:AI%U\-_%/]K-;#7VNIC,DQ42[]_R!0><
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M28?L-KY1.2GDKM)]<8KC+_P5K \17FHZ;=:3+;72H/(U&S\SR HP F.@[XH
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M']R1D!9?H>U L[83F<6\7G$Y,FP;C^- 'G%M=6[_ !;UZWLKB 3'2%@@56
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M;:XGALM5BGF\B,NRJ/8?E67IVJQM\4-;U6>TOH[.338XD\RT<'<N"R8QUZT
M=:WC?2/[.TR\A,]Q_:1(M888]TCD?>X[8QS5:;XB^'[?0_[6EDN$MQ<&V93
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MGLK:1(?]6KQ*0GTXXI\EA9RSI/+;0/,O"R-&"P^AH \8:\TU;'XEQ*]KY;R
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MX+ZU2YM9DF@<922-LJP]C44&I6=U=3VL%S#)/;D":-'!:,GID=J .(T?2?\
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MH,3_ -F7D3I=)<*%E1"<<=N.]>MRSS1Z<T_V9GG$>[R$8$EL?=!/'7C-6:*
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M4 %%%% !1110 4444 1/_P ?,8_V&_FM2TTH"X;N 1^>/\*=0 4444 %%%%
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M<#V_K6I))XLF\1>)M9TSPS=P->V"1V_VE4!4J.I!/)X/R\]LT =GIOCNVO\
M4X]/ETS4+2>>V-U;":-3Y\8&?EVD\X[&H= ^(MGXCU5;*STG5%&]T:>2$"-&
M7LQ!.#_]:N'TQ-:M?%^CZVOA/6F6&U>&X>X??+(Y7ECD\ =AQ["NO^%D.H6F
MAWMMJ.F75E)]LDF7STV[U<Y&/I0!KZUXOBT37M-TJ;3[IVU!Q'#.NT1[B<8)
M)[<?G3KOQC96#ZLUY#-#;Z:422<[2)'8 A% .2>157XB:3!J?A&[=YA#<68^
MUV\O=9$Y&/KT_*L.^\&ZE?\ PK%@&$FLS.M]/YO_ "UFR&(/X8'X"@#9@^(6
MFF\N+2^MY[*:*U-V%D*/OC')QL)Y]NM+IWCVWOM1L[*;2[ZUEOK9KFU$@4^:
M@&>@)P<#H:YBU?Q)=Z7=2:9X-M-$OH+5U:=[9 \TF,8C&.AZ\Y':LG1M.URT
M\0>'-87PEJ.ZWBDCNI))099G*8W$,?E YQTSVH [?0?B-:>(M52RLM'U0(9'
MB>X>$>7&RC.&()P?Y9K6UWQ,FC7MC816<MY?7I;R88V5>%')+,0!6'\+['4-
M,TG4K?4-/N+1I+^2XC\X ;D?&.A//%2>/+&/49;*WN= O-0M@'?[39?ZZW?C
M;MY'7G\J ,#Q;K$%U?>$-=_LN\2=-2>$V_E@S';D%0,X/(KIK;X@6CV.KSWN
MG7ME-I05KBVD56<AON[=I(.:Y./2_%@MO##ZA8WM_+8ZB]P2S(9$@QA0QW<M
MW[_6I=0L/%2ZWXNN])TJYBDU".)+2X+(I^3AB/FX)&<=^G2@#J-,\7)K6LR>
M']1TB:RN);7SUCED5P\9X(..AP>E>>FWB?\ 9^U F)6\N]9DS_ ?M 7(_ D?
MC6GHVCZ[IGC2UUR'PI<QVQM#!*KW:/*6XW.Q+<DXZ4P:!XB7X1WOA\:)/]OG
MO"P7S$P$,HDW9W>V/QH ]5MHHY]*ABD4-&\*JRGH05Z5Y+X.\72>%O#NH!-
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M1U_"N'GN[KQC%XJD&HW=C;::KV]O! VPDB,EFD]<],>E;_PRY^&VAY_Y]_\
MV8T 6-8\6FPU&YT_3],GU*[M8!<7$<3JNQ"<#&>K<9P!6]9W(O+&WNO+DB\Z
M-9/+D&&3(S@CL1FO,["S^P?%/Q3=?:[Z06=E%<;?.R9?E+;3QR.P%4GU'67^
M'B>/(]:N3J&X2O;;A]G\OS-OEA/IWZT =^WBD+XRE\.?V?/YJ6GVI9MR[9!T
MPH^O'..0:E\*^)$\4Z5)?1VLEL$G> QR,"<J<'IQ7+VES]M^+]A=E"GG>'ED
MV-U7=(3@US6B:U=:5X(BMK24V[ZCXCDM&N1C,2,WS,,\9P.* /:<T9KS:=[_
M $3QW;>&HM4O)K'5[21@\TFZ6WD4'YE;WQTKE;[Q%K<'A*?3O[4U!_$^G7\J
MRB.3YF@4;F8_[.T=?6@#V?5;V33M*NKR&UDNI(8RZP1_>D(["G:==O?:=;74
MEN]N\T2NT,GWD)&<'Z5YS?:Q=:[HFM^(-%UF]M[6SL4$/EN"C3!-[Y!'4 J/
MKFJFH:IKEW%X"B@UJ[MFU2)1<O'M^8[02W3D\_2@#UNBO)?[9U[1M.\;V%G>
MS7TNEM&]M-<$-(BN,N2>^!DU?T.[O;OQGIT.FZ[>W>EOIZW-[N=9 )<X"DD?
M+GT&#Q0!Z71FN6\?-K:>'5?0A*TRSHTZ0-ME>$9+!#_>Z?AFN"O_ !#*O@F\
MO=(UW4_-@U.&/RKEBLUNK *8WSUY#$&@#V;(IK-M4D MCL.]>:^)-<U/1/'U
MZ;>\E>UCT66\^RN_R>8H(&!^ _6K7AO3M3N+30/$8\2S/]H0/?17#@QS;QPJ
M#HI!X% '1^%?%$?BBWOI4M)+4VETUJRR,"2R@9/'UK=D8JC,J[V )"CO[5X9
M E\NB>-]>L=6N[!K/5998K>!@$9@P/S<<^F*]HTBY>\T:QNI,>9/;QR-CIDJ
M"?YT <MI_C^YU&"]G@\-7S16,SP7.V6,LCK]X!<Y.*Z30M=L?$>DQ:EITIDM
MY.F1@J1U!'J*\X\+6WB.Y;Q@FBWEC;H=9NE'GQ%FWG'0@X';L:Q/#?B(Z7X)
ML="L_-L[B36!87EQO!*;C\[(<<<#'M0![I1FO,[J\O/"/C1-)CU:9M.U#3YI
M@]X_F?99(U)WYZ[>!Q6-X=U34X?$OA3-SJ$L>HQS)<7%S*2ET0N[<J$_*!Q@
M\9]* /9<USOBCQ4/#,NEJ]E)/'?726QD5@!&6/4CJ?R[5Y]IDVJV]MXDU^;7
M]2F31;^<16K,&24*N,/^8Z=,&H->M)VT3P9KSZA=W=[>:A;2R*\A,99CNPJ]
ML=!B@#V*YLK6^55NK:&=5.0)8PP!]>:PM8UR#3=>T?P_)I?FV^IEHUDROEIM
M4G;M[\ >W-2>-M<F\.^#M2U2V4&:&,",GHK,P4'\,YKA=3TK^S/%?@6\;4[V
MZ>XG8R//)O!8IG*CMG)'':@#U.VLK2R0I:VT,"$Y*Q(%!/T% O;=KY[)9D-P
MB"1H\\A22 ?T->265YXM\5V$VN:;<B">.[;8[7@2&*-3@HT>/3DDFI+5WTCQ
MSXOU;SIYIK+3X[D)YQ*.Q3.T^J@G@4 >OYHKRG0H_&%X^BZY%?(MM=%&O&FO
M0Z3(V.%3;A&&< #O3?#-GKNM1:OJ,WBG4D6PO[B!(UVG<JKWR,9Y';M0!ZQF
MFNQ5&*KN8#(7UKQ**7Q"?!'A_P 1/XFOUO9[]+<>8RF+RW<J21CD\=374:>V
MIZ=\0=5T)M:O;FWETK[4DD[!GBDW;<KQC\,>E '9Z!JESJ^DQWEWITVGRLS
MP3$%A@D _C6IFO%(];UR;X6:7?+K%TMZ^L>0TX8992[#!]:W([O4M \6>(M*
M.NS/;+I'VZ.XOSO\B3.W/ Z=\8]* /3\UE:IK7V/2;Z\L;9]1EM#M:W@/S,P
MQE?J <UYSH6H7T/B[0+0WNIM:ZG82>=-=2<3R!,[XQU7GD?6J6BI>:7\,O%6
MIV6J7L5W#>7 0^9N'RLO/(/S'N>M 'L5I.US9PSO"\+R(',3_>0D=#[BIJ\Y
M&MWNJ^)_#_AXWMQ;PRZ2+Z>:!]LDSX  W8X'4G'6L+5?$/B'3M%\8::NJ3F?
M1987M[W:"[QR$?(QQU ;KUH ]CHKSJQNM8TSQ_H5K<:Q/>P:K8R23Q3*H5'1
M<@H !MKT6@"KJ5]'IFFW-]*KM'!&9&5!EB ,X'O7#W7B#1;CQ-I\=WX2O&UF
MZC\^V,D4/F%5&<YW\8QT->@LH88(R*\[\1(5^-/A-R/E-K<*#[A6_P 10!JQ
M_$.P.I65A+INI03W5T;0>=$JA)  <'YO0@\>M=AFO.?B7#-+K?A!+:46\TFI
M[5G"ABA( S@]?_K5F3^+=:\+_P#"5:?=7IU&33S ;6XF4 @S <-CC S0!ZS2
M$!A@]*X70CXOB\20BZCN)=(FA_?M=O$6CDQG*;/X2<#%=W0 @&*6BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)JE]I&B3WNG:?]OGB&[R?,"?+W.?85;TN_&I:19W_EF+[3"DOEMU7< <'\Z
M.1M?AI;6UYI-V^M:K-/IIQ$TDH^YV0<<+@8XZU(?AQ9B#5[:'5-0AM-3D+R6
MZ.-B;CE@ 1WQU[5VV16#K'B-;/3=8EL$CNKK3(M\L1?: =N[!/K@9Q0!1G\#
M6\L&E/'J-W%J&EKLM[X!3)LZ;&&,,,>HJ.\\ VMYH5]IKW]R)-1E$M[=;5,D
MY'0'C  P.!Z5N^'=4;6O#NG:FZHCW4"2LJ'@$CD"M+(]: .3E\$^=J^CZF^K
MWGGZ7$(HL(GS#&&W<=Q6QH>COHT-Q&^H75[YT[3!KEMQ3/\ "#Z"M7(]:,CU
MH *Y?5_",FJ^*++75U:>WFL5*P1I$C*H88;.1DYK=AU*UN-1N;"*96N+95:5
M!_"&SC^56\CUH YKQ%X4;Q!J6E7IU*>V.FS>?$D:*59_4Y]N*SI_A]%?:IK=
MSJ%^]S;ZO&J30^4%*; -A5@>HP.W/>NVR/6C(]: ./\ #G@JYT:\AEO?$%]J
M45JI6TAF "Q C'/]XXXKL*,CUJNUY"E[':&1?/D1I%3N54@$_FP_.@"Q111D
M>M !11FC(]: "BC-&1ZT %%&14<\\=M"\TSJD4:EG9C@*!R2: )**:C!U#*0
M01D$5SNI>+X[*ZO8+33KK4&L51KK[-M)CW=!C.6. 3@4 =)145O,+BWCF"LH
MD4,%<8(R,X([&I<CUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*\R^&Q.L^)O%.N
MWJE[Q;TVT7F#F&-<_*/3C _"O33TKAO^$1U?0O$M[JWAFXM%AU!@]U:78;;O
MY^92O3J: +_B-M-\*&_\8O"3/':>2Z( /-^8;<GUS@9]*R9_$7B+0;O0YM7-
MI<6>JS) Z01%6MW<?* <G<.WX5HW_A74/$NEWUMX@OD'VF+RXX+0$10D'(;G
MECD#KCCBJ<'A'6[XZ-;:[>6DMEI$BRQ>1N#W#H,(7SP,>V: ,1O%/C.=?%,L
M<VF0QZ+(1@PEB^ 3@<^G<UH6OBKQ%#J/AFYU%K#[!KF$$$2-OB)0,#N/7Z8I
MZ>"]?6S\30_;-.WZY(7+;'_=9X(]^*+CP7K]PGAA#>:<JZ$58 *_[TJ !GTX
M H SH]>\=ZG/XC^P7.F)'I%PT8W0',FT$E1SQQCD^M,@^(^H>(Q8VFD1303R
M6)N+I[>U-PT;Y*A0I( &1G//457\.PZOJFN^-;;1M4L8(I[]UD\Q"[*#QO3!
MQTX_"MB]^&EQ8S:7=>%=4_LV[L[?[-(\B;A,G7+ =3DG_(H H77B[QM::9H!
MN;2TL[V]O3:2)/$<L.S8SP#_ $JS:>*O$ME+XKTZY$&HWVEQ+/;O%$4#!NVW
MN!U]:O:EX'UJ]CT<MJ\-Q<65T;R::>,@RR^@ .%4  8H?P;XBB\0:WJUEJUI
M;RZD$"D1L3&%((_/&#]: *ND>+-4U'2]4OK/5K"_$%AYB1/$('AG[AP3]T<\
M]*A\.^*=6O\ Q*=#&K_:XI]/-PEZ;01E). =G9U'/-+?_"^\UDZE=W^I00WU
MU;K"OV*$QQM@AMSC^+) J[IW@77H/$]AK5YX@BD:"V^RR116NP>7_=7GCOSU
MH Y;3-4\0Z1\()=;@U2.5OM+L5F@WM@S$$[B>22<\BNSN=;U35_%K^&]/NDT
M]K6S6YN+CRQ(S,V,*H/&.>364/AIK \)7'AS_A(8_L+3%XU-KT&[=@G=GK6W
M>^$M177;;7M*OX(=3%L+:Z\V(F.=>.< Y!&!0!R6H>/O$-OX5NW5K>+4M.U1
M;"=S%E903PV/X>AS73:3JOB"S^(!T#5KRVO(I[ WB/%#Y9C(?;MZ\CZU4U/X
M:R7GAM]-@U)4N;B]^WW=S)#N,TO8  _*OMS6PGAC4SXVA\1S:G QCM/LA@2V
M(RF=QP=QP<T <_\ %1Y)=3\*:?)G[!<ZB/M /W6P1@'\S7H-_8V^I:?/8W*[
MH)XS&X!QP1CBL[Q/X8L?%.E?8KS>I5A)%+&<-&XZ$5FP^'O$DL"6>H^(TELQ
MA7,-KLEF3'0ONX/N!F@"E;ZEJ6N>(-8T32=0_LZWT:..%7$:NTLC XSN'W1M
MQQS7,R^-_$EYX4TJ:UN8;?4#JQTVX;R@PD(_B] .>0*[&?P;<6VOSZOH6IC3
MY;J%8KB-X/-5]OW6&2,$5GW7PV)TS2;&PU0VZV%P;MI'@#M-.3G>>1CZ?2@#
M.BF\72>+=7\.-X@4Q1VJW?VH6ZB1 > JCH.?\YJC+XH\2WO@SPM>VVI)!=WE
M_P#8YF\H$.=Y4,?^^>0.N:ZV+P?J47B;4=;76D\Z]@$!3[(,(HZ8^:LV#X:7
M5OHVG:<FOOLT^[^UPDVH/SYSSSTY/YT 483XJ;Q/K/AS_A)7,4%LMW]K-NOF
MC(^XO8#_  JFOBS7;SP3X<U+[?Y4TFJQV5SL09F7?C)/;@<X]:ZV+P;?1^(+
M_6?[<8W%Y!Y#K]E7:%[8Y[5F1?#&6/1K+2O[>D^S6=V+N+_1ESO!R,\^YH J
M)IUQ<?%_6H_[5OHP-,21#&X!4%L;1D'@'FN=\-ZOJ&A?#U;FSN;J:\U'5FM%
M$C*1&2YRRYZL0.I[_2O29_"/F^+4U]-2N(7:!8)X8U $RJ<C)Z@9QP*RD^&%
MB-'O=)EU"[ELY9#+;1G ^RN3G<N.I^M &/?:IXO\):?K6H78=K+R5%F+NX2:
M1)20/X<<<D_@*TM#M/%]OXCL)Y99VTF2+%TMW=)*2^.&0+T[<"M&R\ 6_P!B
MNK?6M3O-8\^'R%:Y/^J3KA1V.0.?84[P[X&&@WD4TNL7]_';J5M8;A_DASP3
MCN<'&: $\=:U=6,VB:593FVEU6]6W:X4#,:?Q;<]&.0 :R[>6_TSQ^?"[ZE>
M7.G7UDTT;R29F@8=2'Z\X/YUU7B7PW:>)K!+:Y9XY(I!+!/'P\3CH15?3O"H
ML[NXU"XU"XN]3FA^SB[=5!C3KA1C YY[T <W\(]/2+0+NX%S<MF^G3RWDRG#
M=<>OO4/B#34G^-.@AKF[026<DG[N8C!7/ ] <<XZUUOACPM#X6M9K:UO+F>&
M60RE9RIPQZD$ =:C\0>#[/7]4LM1>YN[6[M%9%EMI-I*'JIH \T;3KIU^(.K
M6VK:A:265_*\4=M,8U9@,Y;'7CBM635-9\4>(K;3(9V4)HL5R4%RUN'F< E\
MJ,L!D<=.M=.GP\LX[#5K,:IJ1CU5_,NB77+'OSM[]Z;=?#72;J*P_P!*U"&Y
ML8A!%=0S;)/+'120/?% &GX,AU2U\/BUUC4(;Z\@E:-I8GW8 QA6/=A7(6L>
MJ7?QA\2C3KZ&U9+2 ,9(?,R-HQW&.:]#TK2[71].CL;-&6),G+,69B>223R2
M?6L5/ ]@FL7>K)>ZE%?7?$TD=SMW#L, =!0!YMINJWW@MO'D$F+G7(U6\-X.
M4<,0!E>Q&_./\*U-1$_AS1?"OB'2[R[GN[N:%+I'F9Q=&49;()ZYSC']*[[3
M/!VBZ5!>QPVS3-??\?4EPYD>8<\,3VY-5=-\":1IL]LX^TSQVCE[6&>8O' ?
M55]1V- 'F_B.^O!;ZGK5A<75R(-554OS<%$0!@/*C3/S 9Y-;3Z'+K_Q/U6S
MFU?4X+>.S@N5CAN" &8YQ]!Z5TD_PP\,W NE>"Y$=Q)YAC6X8(CYSN4= ?>K
M^E>"=)T?5O[2M#="Y,?E$O.S!E[ YZT ><Z@J>)/AGXC\07\\KWPFD6-/.;;
M JN L87.,8]1SG->IZ$2/"6F'>$/V*+YCT7Y!S6/J/PW\.:G=7<TT$Z?:CNF
MCAG9$9O[VT<9KHK+2[6PTJ/3+=&%JB&-5+$G'U/- 'E'AXOI/BO2K;7%N5O)
M[AV@U*"X,D%_N!P&&< \C'X5B+IB6?P]U'Q'!=7<=_!J[>3MF(1/WP'W>AR"
M:]7LO >BV+VQB-VRVF[[,DEP66 L,%E'8^]1+\.M &DRZ65NVLYIO/DC-PV&
M;W_'GZT </XSE&H77B22W>>]ELK2)FD>8QQ:<VTD[ #\SMC/2M._GENM5^%L
M]PY>>5&=W)R68PH2371M\-?#4D\LLMM/(9HQ'*KSL5? P&89Y;WJ:#X?Z%;R
M:;(BW>[3B3;9N7.TGJ>OL/RH R/"94_%#QIL)(W6_7UV<U!XW9+WQEI6F*);
MU_LTLIT_SO*B/I([9[<\>U=9IOA;3=)UF[U6V\\7=W_KV>8L'],CVZ"F:SX1
MT77K^WOK^W9[B ;5=)&0E>I4X/(]J /)2]S=_#+07:^N8W36_L@:*<CY"S#&
M<\XQQ6Q/IBZ/XM\4Z/9W=VEG)H1O,&8DB4'@@GGM^M=>/AEX8"HBVDRQI-YZ
MHMPX56]AGC%7KOP3HM[J$]_<1W#7,\ MY7^TN-T?]TX/2@#RG3[4V&B>!?$$
M=[=M?W5ZL4K23,RLA8C;@G&/\:WHF"VOQ+BDF98K>0M &E($9V,1MYX^;'2N
MRD^'^@26-E9^5<+!92>9;*MP_P"[;.<CGVHU#X?>'=4U*XOKNUD>2X4+,HE8
M))@8!(!Y/O0!P$3KK-OX<M1--J%RFB^:]H\QCB0]/.=NI(Z8]JHQWEY?_#CP
MG-=3O.R:_'&79LG 9L?7O7I!^&OA;S+9TL'0P(8QLF<;U_NMSR*CC^&/AF&T
M2VC@N4B2;ST"W+C8_8CGMVH S7@CN_C+J-K+_JY=!$;88J<&0="*Y_14G-Q-
M\/KQKE[J+4?M#3M(=S6H 8-NSU/"_C7H-WX;L[/4KCQ':6UQ<:LD!55^T,/.
M '"'/&,@?C57PO:7^H:G<^)-8TQ=.NYH5MHK;=N9(U))+'U)/Y 4 :OB6(/X
M5U-!))'MM)"K1N5884D8(Y[5X^MG)HWPVTC78-1O!=ZJ\-K=32SGRXXF<L?<
M?= SGH3ZU[=J%A!J>GSV-R',$Z%) C%25/49'-9=MX0T:V\.-H'V9I=-88\J
M9R^/H3TYYXH Y'3?!<@U+4+:?5K1;+4K/BRLW<!2I7$JY/4''/O6;X0<ZQ;Z
M=X3O%<7>BWLDU\V]LL(S\ASWW%_R4UWWA[P=HOA@RMIENRR2 *TDDA=MH[ G
MH/:M&UT>PL]1O-0M[=4NKS9Y\@_CVC _G0!Y#?ZA?:._Q&EL+B<2)/"%;>S-
M&&.&8'M@$_2M[2/#%LVK:9?_ -M61M;VT:W>UM58?;5,9.YCN/S#J3[5V5KX
M0T6TN[ZZCMF:2_!%UYDC.)<^H)Q4.A>!] \.7<EUIMEY<S @,SEM@/4+GH*
M/)KF"YD\/:CX.MK=I=;TF]DGCE#$-]G4;@V>^<A<>XKT+P7>6_BK4IO%,,3Q
MH+>.SC4G W ;I..^"0N?:NKCT>PBU:?5$MD%[/$L4LO=E7H/\^@I=*TFRT2P
M6RT^ 0VZLS!!ZL23^IH X3XH127&M>#889FAD?4\+(HR5.!R!6[;:5<:9KTU
MUJVM&\M;V!+.*.90IWEB< * #D'ZU?UGPCI&OWMO=ZA%-)-;?ZDK.Z;#G.0
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M0K#P+X>TZ>>:"S/F7$)@F9Y6;S%(P<Y/.:KK\.O#BV5O9^1<&&WE\V)3<O\
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M2S71V;A)MR0G."._-=]>^ ]!U'5KO4;FWE:6[C\N=!*PC?C )4=QZU17X8:
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MYM&(,+1LV-BC'!&1SGUJP[^)-7\<ZCIMEX@>UMHK:&Y13"K8W'.W_/6M>U\
M16UK_99U.XDT,2B5+!E'!#;MN_J5SVK2L_#+VGBVZUX7[L;F(1/;F(!0J_=
M/M0!T"@A1GK2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %9.MZ]!HNE7M_P"6UT+-0TT4
M+ NHZ\Y/''-:K#*D D<=17BUG9RQZ)\2)I=0O)S#-/"5D<$/A?O,,=>WI[4
M>O:7J":KI-GJ$:,B74*3*K=0& .#^=7,BO(="76- OO!#-KES<VVJ0>7):.
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M* .*B^&NGQZ->Z0VIZDUC>3F>9#(F6;.>NW/4 _A5JR\"V]IJ:ZD=6U22\6
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MTF[\G[1IMI+Y  BWPJ=@'0#C@>U:%% ";1Z5GKH&CH) -+L\22>:X,"G<_\
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MDT?SA'=3^9*''_+0<D*W7C-4/#-CJY^'=[XIAU[4IM06VG5(GGW1C!QG![@
M_C7;P_#32X[P7SZAJ\EZ8?)>X:\.YQCO_AT]J@U;P>=%^'6IZ+H:7=V)1\D,
MD@+#+#=MX';)QZT <WH]L+_6_#=UH<^IR6Z6QFU3]\X7S  5#9XW%L\#M533
M+76O%VDW6O\ ]N6MA=PW;LUP9I T"*?N%0=H7ZCFK?AWPY,+BT71+?Q5ITL4
MJM/)J,ZB!0#\PV_QDC(QBNPF^&?AF?6GU1K)UE=P[PI*5B9ASDH./PZ4 87A
MG1;1?BUKUP[-++#;6\JN)#@LZG<>O(]!VK6^($L3/HUD9;MY)[KY;&V.TW8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )@4M%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJEM<SZ=);)-#?2VPA^; RH  !!R<=^*I_$SPYJ6KZMIFH^'KU%UO3T,J6QD
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MK\GB2TCU#2K/R;EGU-#)"RQY50%!.\YXX-<IXN%\_P (-9FU6WCAU"2,M.J
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=S@"L&'QWK-^;BWL/#C_ -H64:R7EK/,%9=Q.%3CDD#- &EX.\)7_AR%4O\
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M;U[5<^'UI)8_$+QA;2W<UVZ& &:8Y=N">:OGX80+H6GV,.KW,5WILS2V5ZJ
M/$&.2I ^\,Y//K6EX:\$_P#"/:S?ZJ^KWE[<WJJ)3-M 8CN<#KZ>E %#QG>7
MIUZQL8-4NH8F@>0VNG?\?4K] ?0(.Y.!Q7&GQ3XFN_ >AWR:O+#>'5#9R,$!
M\P;L MZX[^M>AZ[X*&L:_!K,&K7>GW*0?9Y#;XR\>2<9/3D]:PX_A-!#9Q6<
M6O7XMH;G[3'&P5@KYR#]??O0!/X:O-7LOB1JOA^^U2;4+<6:72/,H!5BP!
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M.O:@;$3"1(CM*H 20 ,<<G\:Z37O"UGXET%=)U.222,,C^:,!MR]^F.>1^-
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MIX@-_?K>HGEH%D78J9R4 V]#4=IX+M;'5K_4X=0U#[5?#$[&48;@@<;<<=J
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M)-:1R:>L2Q"%N@4#CGKGCK6-IWPZ\.Z78WEI:VTJI=Q^5*YF8OL_NANH'TH
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M<HZ$D=\=:W*I:3IL>DZ?':1R2R[22TLK;G=B<DD^M7: "BBB@ HHHH ****
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MDG6)-":\5))&DQ-N W\]\9H ]=#J3@'D=J=7G'A;3-#-MX:UVVU62.\DC"S
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M'Q-;H;4J,+!<'Y6( XP 2WY58T6TM/#WQ4U*U60B"RT%=[K]XX"EF^IY/XT
M>K)>6TDIB2>)I%ZHK@D?A2_:[??L\Z/?G&W<,YKP+39;>*7P3J$+6EO$^IL
M3)FY>,MRTS<#';'ZULZ!X?TZ?5?&VH6]NTE]I5X\NG[7.U&"L5 &>>1_*@#V
M3[5 TQ@6:,S@9\O<-P_#K7*>%/$M[?ZCKUKK,UG&;"]^SQ&/*@C&>YYKD/"R
M>%K[PSX=U2XU!XM7MY_G,,H\^:9FP5<=6!P/PK.N=#TV\M_B3>3VZRSVMPQ@
MD9CF,[<Y'OF@#W#.1Q7(R>)]3C^)-KX<>QA2RFM7N!/O+.P'MT7D8[UJ^$97
MG\&:++*Y>1[&$LQ.23L&:YC4\GXXZ)M8 #2921G&?F;C_/I0!TOBSQ%'X9T&
M>^*&6XVD00@9,CX)Q]  2?8&G^$]6FU[PKIVJ7"(DUS"'=4SM!]LUQ/C.+Q.
M-6UB]72(KS35T^2"W=K@+Y*E,R/MY.[J/IQ6A\-M8^S?#S2GU80V$7$-L\DP
M_?#G!]B3GCVH [74KF6STVXN8+:2YFCC+)#']YV["N&3Q-XLT/Q%I%GXDMM/
M>SU:7R8WLRVZ"0]%;/7_ #S7H$DT<,+32NJ1H"S,QP /4FN#_M+2?$?B&VUF
MZO[:/3--=A8HTJYGF)VF3;G.!T7UZT 27?BW5[S4-=_L2&U>TT,;9Q,&W7$@
M!+*I'3 !&>>:L:UXQNH_AZ/%&C6L4ZM )=LSE=@/!X'7!XQD5SGAF5-%@^(=
MK?'8\-Q-<9?@O&ZMM(SZX_6F16<]A^SO-#<[A(;)GVM_"&?('Y&@#N+G4]8;
MPA;7NFV<-QJMQ#$RQDD1AF ))/7 R:YVS\1>-H/&&F:-J]GH_EW:O*YM3(S)
M&O4G/3G %==X;F27PQI4BG*FTBY_X *Y[PPHUGQMX@\0$[HH7&FVI[;4P7(^
MK']* .FUK6+70='N-2O&(AA7.!R6/0*/<G K+'B3^R[?3DU]X8+_ %"8)%;Q
M'.S/0$D]AU/Y"L/XI-(+;0$8$V;:M"+C(X(SP#[9J'XC6=G+XF\&R7,$+!]0
M,4C.HY3'0GT]J -C1O$MY<>,]>TF_:V6VL5B:%T^7ALGYB3R>E=6TL:)O9U5
M.NXG KR-=%TK7/B7XM2]@2>**QC:+#8"_(.1BL;3-5NYK;P+97=Y!%I\EO-E
M[Q-\3R*S*JL,C.!C'/>@#W6.5)5#1NK*>A4Y!KD+_P =VME>:]"6B+Z7$&$!
M)\R0X&6/8+E@/7@TO@+2(=$CU.S@UA-04W'FE(DVQP%AG:O)_+/%=)+I&GS7
M$UQ)96[S3Q^5*[1@ET_ND]Q0!RUSXTDEGT#3],FL9;O58FE%Q(6$*JHYVC@D
MD@@#CI6GH.K:Q/K.HZ;K%I;Q-:I$\4L#$K,&+9(STQM'%97BGPUX;UI[#P].
MOV&Z$3R6$L ">7M(R%]>N<5Q]QK?B?PYI_B;PW=WJW]Q9:>+BVODR9 A<+AN
M^0&)]L4 >RB:-B0KJ2.H!Z4HD0@D,,#OFO*_#_ARR_M#1-437[-XY83 ;:WA
MP;I60Y5_F.?<D=JSH+<Z)K6O>!4BESJ\\<EG*"3MA;[_ #VV@'% 'LAE1<9=
M1GID]:4NHZFO(KJQ77?&FL^'I[VVM8+&VCAL8;I"Q1"@S(F&'S9[\]JKW6C1
M7OB/P;I4^LW.H02PW,,MS&[1^:J X'7\,]Q0![+YB<?,.>G-!<#K7C.OZ?:6
MQ\0V>GM-?'2]/1#->3[18X!($>.69O7C&.IJ<P-K5Q\.9+R[N2UY:RI.R3,I
M<+&#V]<\GJ: /7PX(R#D4!U(R#GZ5XM/>S>'--\7:;9W4\-C;ZI;PH2Y8PQR
M#Y\$\CI70ZQ9VGA&SU/6M"U.7=+IS>59+)O4L,?O1UZ#DT >DA@3@=12UY;X
M>T:^_M#0]>AUZR6WD41R*DDC-=Y'1MQ(W#GZ8KU*@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH 8T>95?/0$8^N/\*?2$XI: "BB
MB@ HHHH **** "BBB@ HHHH ****  ]*Y&W\$36%E-I]AX@OX;&;?NA94<KN
M)+!&(RHYKK6SM.,9QQFO.[7QSXBNWUX1:-8L-%<I./M+ R8R3L^7'0=Z -*?
MX;:8MQ83:9>7NEO:0&W#6LF&>,DD@DYYR3S5*+X3Z='IWV#^V-5^RBY^TI$L
MBA5<=#@J>?>FCXB3WS>%KG3;6$V.LS^1+YS'S(F!PP '! ]:[YIXT94>159O
MN@D GZ4 <EJ/A)K:ZOM?M[R^N]3-B]N(F9 )5QPO"@YS@Y!!K@-$L+F"R@L=
M#O/%EKJXVYAGB"VZ-G)W9& O/XU[:TJ("78* ,G)QQZUS7BW7=6T:#3[G2;"
M"^AFN$BF#/A@&( V#/)- %&Z^&.D7K7X>[U"."_<S3VT4^V(RG^/&.N?7BK5
MGX!LK#4X]1@U+4Q<Q6_V:-VF#;4QTY6JMOXB\2RZIX@LSI5L3I[H]OMD)\Z(
MY^7(Z.0,C/KTKIM$UBTU[2+?4;)F,,RY 88*D<$$>H.10!S:_#;31H%UHIO]
M1-G=3^?(IE7);J>=O<X/X"KMUX&T^>ZL[V*ZO+6_MH1 +NWD"22(!C#\8/3T
MK>GU&SMIA%/=012$9"/(%)'K@T_[7;DN!/'E!EQO'R_7TH K:1H]GHED+6RC
MVH6+NQ.6D<]68]R?6J_B+P[:>)],;3K^2=;9F#.L,FS=CH#[5A^+O$E]I&J^
M'#9W%J-/OKY8+AVY.T^AZ 8S6]<ZBM]H]W)HNH63SJA"3&0/&C]MV* &2>'+
M:7PV=!DN+IK0Q^46,O[S9_=W8Z8X^E9+?#S2FBTZ(W>I%-.8-:@W)/ED>G%;
M.GWQMM!MKC5]0LFD$8\ZYC<+$S=R">,5:BU2QGLC>PWD$EJ,YF60%!CK\V<4
M <Y<_#;PW=:P^I/;2+)(P>6%)2L4K#NR#@_RJ_9>$-.L/$-SK<$ER+NY4K*&
MERC+V7;V P,>F*FNO%.B6VD7.I_VG:26MOG>\4RL-V,A>#U/858T;6+76]'M
MM1M71HYHU8A7#;"0"5/N,T <S)\*?#$HF5X;HI))YBI]H8+$2<G8.@K M/#:
MZA\2M4WVVM6-B+5+>&>)GC638,-ECU!QQ7<:7XPT;6-;OM)LKM)+BSQN^88<
M\YV^N.YJW:^(=&OKLVMKJEG/<#(\J.968XZX /- &;J/@/P]J>BVVDS6(6VM
M3F#RV*M&3U(;KSWIT7@;0(O#TNABR#64K!Y-SDN[?WBW7/%:>M:Q9Z%I,^I7
M\PB@A7<23RQ[ >I-</JWCJ66\\)7NF:C;QZ5J5P%N0P!*XY8%B<#&<&@#>T[
MX>>'=,U"._@M)&NHXS&)99F<D'@YR>>.*KGX8^&_[/FL1#<BWFE\QE%R^!SG
M YX'-=)::QIU_:27=I?6\]O&2'ECD!5<=<GM4=AX@TC5+F2WL-1MKF:,9=(I
M Q ]>.U &5K/@'0=>2U%_;R/):J$CF$S"0KZ%LY/XU+<>"M'FALXX8YK/[&A
MCMWM)FB9%/49!YSWS3O$GB_2O#+6:7TZK+<S)&J9P0I."Y]AS5N\\3:)IXC^
MUZK:0^:@D3?*!N4]"/;WH P=1\!6#S:$FFP+:1Z=.9?-25@RKD$@#^(L>I-=
M/JFF6VL6$EE>*[6\@PZI(R;AZ$J0<>U5;OQ1H-C(([O6+&%RF\*]PH.WUZU$
M_C'PU&&+Z[IP"J&/^DIT/3O0!3D^'_AZ738-.>VN&L[=]\,)NY=J'U W5:B\
M(:/%JYU7R)9+QHC"TDL[ON0C&T@D@CVJ1/%OAZ2:WA36;%I;C'E()U)?/3'-
M.OO%&AZ;=&VO=5M()QC=&\H!&>F?2@"EH_@/P[H.I-J&G:<D5P<X;<S!,]=H
M)XK3TG0]/T1+E-/@\D7,S3R_,3N=NIY-79)HXHFED=4C52S,QP !W)K+LO%6
MA:C<O;V>JVLTJ)YA59!]T=6![B@"OJ/@K0]6U,ZE>VKO>8 $HG=2HQCC!X_"
MD@\$:#;_ &@I9LS7$)@D>29W;8>H!))&?:AO'7A9613KU@2[^6N)@>?PJUK>
MOZ9I,#1W>IQ6<\L3&(M\S#C[P7N : *UUX+T*]M].@GLR8].'^B[974Q=.A!
M]A3-1\"^'-5U9=4O=,BFO!C+DGYL=-PS@_C5+X9ZQ?:[X+AO]1N?M%PTTJF3
M &0&('3VK:U/Q-HNC3+#J.I6]M(V#L=^0#T)]![GB@"MK/@OP_X@GAFU/3(9
MY81M1N5.WT.",CVJ;4_"NBZQ86]C?:?#);6Q!AC VA,<8&,8'M4FI>)=&T>&
M&6_U&"%)ANBRV2X]0!R1[U'/XLT"VT^"_FU>S2TG)$4S2C:Y'4 T 00^"?#=
MM;7EO#H]JD5XNR=0OWU]/;H.GI38/ WANVDM9(=)@1[3'DLI8%#Z]>OJ>]7-
M)\3Z+KLT\.EZC!=20?ZQ8VR1[^X]QQ7%>,O&MM+?:);Z%KI\Q]3BAGB@'$B%
ML-\^.<=, ]Z /0+C3;2[N;6XN+>.6:U<O [#F-B,$C\*J:WX:T?Q%$D>JV$-
MRJ'*%Q\R_0CD5C+K5A:>(M:O)O$WGPVMNIET]1D6V#@MQU)/&/>LR3QE8^)?
M!27\>N#0&DN GFGEAAONC/<KCIZT =S8Z?:Z98Q65E D%O$NU(T& !69?>$=
M"U&XDN+C3H3/*<R2IE'?C')4@GI4VI^)-(T01KJ-\D3NA=5P69E'5MJ@G'OT
MJ*Y\7^'[33[:_N-6M4M;HXAD+\/SCCZ9Y]* )W\.:/)HHT=M.MSIX&!!L^7Z
M_7WIVBZ!IGAZS-II5G';0%B[*F>3ZDGDU7T[Q=H&K"Z-CJD$PM%+SD'&Q1_%
MSV]QQ1I?BS1-:O?L>GWPFN/*\X)Y;+E,@;AD $<CF@#0M=.M+*>ZFMH$BDNI
M/-F91C>V ,G\!6</"'A\:T=8&DVO]H%M_G[.=WKCIGWJYJ>M:?HT22:A<K L
MC;(P02SMZ*HR2?H*H+XOT:YT2[U2TNUEBM01*H5@R,!]UEQD'\* )['PQHVF
MWT][9Z?#%<SY\V09R^3DYS5,> O"P5E_L*QPTHE(\K^(?T]NE<OX"NKSQ0+/
M7O\ A([S[1EWO=/*GR,$D(J@X P #D9]ZW;GQI9R>,G\*Q-*DYMF+7"QL=DA
M("@<>Y.3QQ0!=C\#^&X1<"+2+=!<KMF"Y <9S@\TL_@GP[<Z7%ILVDV[V<+E
MXXCG"$]<'.17)>!?'NFV^C"UU_Q KZ@UY+&IN');:&PN3C _'%=GJOBW0M%F
M:&_U".*5$$CH%9RBGHS!0<#W- $D_AK1KG1ETB73;9M/486#RP%7Z>A]ZL:3
MH^GZ'9"STRTBM;<$D)&,<GN?6I[>Z@O;:.YMI4EAE4,DB'(8'N#7F&C^(+KQ
M-K>LP-XDGTS5X+F2&ST_"A-J\#*L/G)[T =[=^%-$OM575+G3XI+Y""LY)W+
MCICFKVI:99ZO9-9W]ND]N^"T;YP<5C66NIH_AK39?$=UY-[+$!(KH2[28RV%
M49./84LWCSPQ;Z;;ZC+JT0M+AF2.4(Q!8=0<#(//0XH FF\&^'KBWLX)M(MI
M(K//V=67.P$YQ],]CQ59OA[X4;.="M.7+\*1\WKUK5?7=-CN[>UDN0DUQ"9X
MU92,Q@9+$XP />J-KXU\.WERMO!JD1D969-RLH<+U*D@!NAZ9H GM_"VBVNJ
MC5(-.ACO@,><N=V,8_E5G5M$TW7;3[+J=G#=0@[@L@Z'U!ZBL:'XB^$KBX$$
M6N6S2?/Z@#:,GDC'^/:K6G^,] U2X\BTU!6D,1G :-TW1CJP+ 9'TH (O!?A
MN&.XCCT6R5+A DH$0^90 ,?H.E.M/!_AZQGMI[71[.*6V!6)UB&Y<]>>Y]S6
M>OQ,\'.5"ZW"=S[,^6^ ?<[>/J:T]3\5Z)H\HBOKY4D\KSBJ(TA$?]X[0<+[
MF@!D7@_P_#:W=K'I%H(+MMTZ>7D.?\],=*L:;X;T;2+&6RL--MH+:;/F1JF0
M^>/FSU_&H)O%VA065K=MJ"-%=+O@\I6D:1>Y"J"<#OQQ5[2M7L-<L$OM-N4N
M+9R0LBYZCJ,'D4 9=GX%\,6$L<MMH=DDD;^8C^7DJWJ"?I6GJND6&MV?V34;
M9+BW+!C&^<9'TK@KJXUF;XL3Z%'K][;V#67VL*@0[&SC RI^6N=N/&FMZE\.
M]<G_ +3>.[TF_CABO;8[/M2E]N/R.>/:@#V"'2;&".U2.UCQ:Y\@L-QCSUP3
MR*HGPCH1U9]4_LV+[<[%FFRV6)]>>?I4=UXLT?1T@AU*_6.X:$2L@5G8+CEB
M%!P/<TZZ\9^'++[+]IUBTC%W&)("7X=3T.?3@T 5%^'7A)8]@T*TV^8).A/(
M]\]/;I6CI'A?1M"FFETRQ2V>88D*,WS?4$T_1O$6D^(8))M*O8[F.-MCE005
M/H0>16I0!@VG@SP]8ZN=5M=)MHKXDGS57D$]2!T!^E,7P/X=6.Z0::@6[.;A
M1(^)><_-SSS70GI7G8\>2GXH1:0?ET:1'M8IB/EDN5P6P?;(7ZT =SIVFVFD
MV*65C"(;>/[D8)(7Z9JI-X9TBXUE-8ELE;48\;;C<P88[#GI[5JYXK$U+QAH
M&D7+6]_J<,,J8WJ<G9GIN(!V]>^* -B:".>"2&50\<BE&4]P1@BN<UWP5IVK
MZ%::/';6\-K;N#'P<PKW*8/WOK6AJ/B?1=),2WE_&CRIYD:*"[,G]["@G'OT
MJ"Z\9^'++3[2_N-7MDM;O_42;B0_KC'IW]* -2[TZUO]-DT^[A6:VD38\;=&
M'O6':_#[PI9W,5S;Z':I-$P=&P3M(Z'DT^V\>^%[RWO)[?5X9([-=\Y56^1<
MXSTY&>XS5A?%VA/I5OJBWZFQN)?)BFV-AWR1@<9['\J )=0\-:/JMPMQ?:?!
M/* !N9?O '(!]1]<U8U'1[#5[$V5_;)/:D@F(Y XZ=*MR31PPO-*ZI&BEF9C
M@*!U)-8UAXPT#4[]+*SU*.2YD4O&A#+Y@'4J2 &_#- &CI^FVNEV<=G90K#;
MQYV1J20._>DTW2[/2+7[-8VZ00[F?8OJQR3^)->>77B)O%'C35=!MM;NM+:U
M6..Q:W5L22G)<OCJ!@  X'6ND\2>+K?P;IFG)J,C7%W.\<.\(5#<@.YQG'&3
MB@#6\2:';^(M"N=,N"564 JZ]4<'*L/H:I_V(GB'2(;;Q1IUO// ^<@Y5F ^
M^I'(SZ5S4OBQ-)^)MU'JFM^7I!TM;B&.3A=Q8= !DG&3ZUV(\2Z,='CU8:C!
M]@EX2?=PQSC [DY[=: *T/@SP_;37$T&FQQR7$9BE9&8;T/!4\]*9+X'\.2Z
M+_8[Z7$; /YBQ9;Y&]5.<C\*TM*UO3=;A>;3;R.Y1&VOL/*'T(/(/UKD/%'B
MB:U\<Z=X?DU/^R+*XMS*;O8"99,X"!F!"].OX4 =?I&C6&A6"66FVR6]NO(1
M>Y]23R3]:OUS.@SZS;7VK1:S=+/8VZQ/:79C"!T*DL21P2,<_P#UZN6_B[0+
MLW @U6V8VZ&24;\;4_O<]O?I0!-J?AW2]8N(KB^M%EFA!$4FXJR9]"",=*;8
M>&]*TY;D6]FFZZ&)WD)D:4>C,V21[4L?B31I=+?4X]2MGL8VVM.) 4!R!C/X
MBFWWBC0],*"]U.V@+[2 \@'!Z$^@/J: *VC^"/#N@7SWNF:9%!<."-X).T'J
M!D\?A6E)I%E-JT.J26Z->PQM%',1RJGJ*J7WBS0-,N#!?:Q9V\H4,4DE (!Z
M&B7Q9H$,OER:M:*V%8YD& &&5)/;.1U]: (M<\&:#XBN8KG5+!)IXAA9 S*V
M/0D$9'L:=<>$=&N=0L[Y[0K/9*$MBDC((@.P ( JQ=^)-%L+IK:[U2T@G5-Y
MCDF56"^N*?#KVE7&F-J<6H6[V*D@W D&P$<=: ,W4/ OA[5-2FU"[T]7N)U"
MRD2,HD &!N .#45M\/O#MH]D\-K*KV1W0-]ID^0]R.<<XYK7L=>TK4HYI+/4
M+>=(/]:4D!V<9Y]*2P\0:1JEP]O8:E:W,R#<T<4H9@/7'I0!23P9H:OJ+-9F
M0ZB/]+$LKN)?<@GJ.Q'2DT7P5H.@+,MC8J/.0QN96,A*'^'YB>/:L_XD:SJG
MA_PU_:FEW21212HC(\:L'#$#OZ>U4I/$FL:!XKT;2M3N(=0M]67;'(D0CDA<
M =0."O- &QHO@/0- OS>6%HR2@DH&D9ECSUV@G KI:X_P?K]U=V^O2ZO?0O'
M8ZC);K,5$:JBA>OIR:Z&VUS2KN&66WU&UECA&96292$'JW/'XT 7Z*SHM?T>
MXGC@AU6RDFDX2-+A"S?0 \UHT %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 1-_P ?<?\ N-_-:EJ%_P#CZC'^PW\UJ:@ HHHH **** "B
MBB@ HHHH **** "BBB@ KR+0-(O->UKQS86VMR6$$NIND\<< 9F4YZ,3QD B
MO7&&Y2/6L;1_"FCZ#>3W6FVIAFN,^:WF,V_)SSD]: .(\1Z-9^'=7^'^F6*;
M;>"^91GJ2=N2?<FN7\6/:7.F>(=5T]XV,6I ?:[J;]_O##Y(%'W5'J>HS7LF
MI>'-*U>]MKR^M1-<6Q!A<NPV$'.0 <9JA<> ?"]W<W%Q/HUN\MR296.?F)Y)
MQG /N* .&BT;1O$/Q3GCN8S/;R:,EQ(/-;:\A(RQY]"./45O?"?9<^"8TD;S
MOLMY,D6_YC& W&/3@_K6W;^ _#-I,9K;2TAD*&/<DK@[3U'#=*TM&T#2_#\#
MPZ7:);12-N95)()]>30!=C@BAWF.-$WL6;:N-Q/<^]<%\*3-]@UY6+&!=7G$
M//&,\X_&NTU?[<^FS1:<(_M4@V(\APL>?XCZXZX[U!X>T.#P_H=MIMNQ98E^
M9SU=R<LQ^I)- 'F/C"T^R:QK.M/#::SI+21QWL60MS9LH4#8Q_#ZYJ[:W.F6
MGC_Q2TK06UM<Z1#*%E(4-E<G@]3S7=W'A'0;O43J$^EV\ET6#F0K]XCN1T/X
MU/>^'-'U&]CO+W3;:XN(UVK))&"0* /%K=+74?!GP^@N"LMH=5DCN59_E&9#
MP?3@_D:W+W0;&Q\4>*K;2[>-=+_L;?<PJI\M9NJ@=MW&?SKTH^%M#.GK8'2K
M3[(K;Q%Y0P&]?K6/K>C:A!I[:1X>TVP33KF"2.;+^6R,PP&'!S0!YLUR;71/
MA^M[=_8]*\J3?<-$LB+)D@;@P(_$CN:;JT&EZ'9Q_P!F7]SJ6B'589=2<1J8
M!U.!M&._(''2O7M/\,6%OX7LM#NX(;NWMX50B1 0S <G!]\U>CT?3X=._L^.
MRMUL\8\@1C9^5 'FNMKX1NM \53>'DBGEFL \[P#,,97[HQT#'D\>G:NU\"3
MZ?/X,TK^SW@9%M8UE\G'$@0;@V/XL]:U;31M.L+-[2TL;>&V?.^)(P%;/7([
M_C4MCI]IIELMM96\5O"O1(E"C]* /&;^1K>;XC66GJJ:E),KPJFT2&/'S[1U
MZ$YQ5K46TV]\->";CPZ(AJJ74"Q) H#X _>;@.W&3FO6AI=BNHMJ(M81>,FQ
MIP@WE?3-1VVB:997;W5K86T$[C#21Q!21^% &/\ $.-9?A_K890V+5F&1GD5
MYUJ%SHNK1_#FWCDM9X5E2.YB!& VQ,AA]:]IEB2:)HY$5T8896&01Z$5GQ^'
M=%B5532+ !1A?]'3C]* /%=9VPS_ ! L])VQ1+);,8;7 S&"=^%'ZUT_A'_A
M%K[Q5I^HZ;K%]J.IFW*%-H40H$Y\S"COP/ZXKTF'2--MG=[?3[2%G!5S'"JE
M@>QP.13K/2['3C(;.SM[<R'+^5&%W'WQ0!Q?Q/:U@/ABYNQ$+>/683*\@&%3
MG.?:N*EN]!NO%_B(>)=6O+&UOE3[(R+A)X,8&"4)Z8QC%>W7-I;WL7E7,$4\
M><[)4#+GZ&H[G3;&\:-KFSMYFB_U9DB5BGTR.* /(X-'\-R>-?"-FEJKV;6$
MQV7H4R/U\O?ZGTSVQ6C:Z;X=B^*FM02VFG+!!ID82-U0*I_BX/&<=:]*DTNQ
MEN1<R65L\ZX(E:)2PQTYQGBFOI&G23/,]A:M*^=SM"I9L^IQS0!X2%TN'X,:
M?/ +9+_^TP7D&!(")6[]>%Q6SXJN+>TU/6M6TG5+.^MGEC34='N",S$!0&C(
M.>XP1[UZW_8>DXQ_9=ECT^SI_A0FBZ5',LT>FV:2J<JZP*&!]CB@#(\6WL$/
M@+4;J]L9)H3:9DM0Q5CN &TD<CD\FO+--UG3D\<>%[RXUJUEMULBC1PQ;(K7
M*X$6>K>Y))KW=T61&1U#(PP5(R"/2JBZ1IR(BI86JJA)0"%0%)ZXXXH \)4:
M3_PJ3Q#(OV8W9U5L-QOQO&W'?&,]/>NGTCQ!8:7XRU677YT$5WIUO]BFFRT;
MQB,;E4\C!8G/N#WKU'^S[*2(Q&TMS'GE#&I'Y4YK"T<1![6!A%_JP8P=GT]*
M .%^#=W!+X%6"-AYD-Q+O3!&W<Y(_2L&'6=%TKQ3XQTSQ@I OY@\/F1,1-#C
M"JI49STKU]$2-=J*JCT Q4,UC:W$\<\UM#)+%]QWC!9?H3TH \PT>]M=,^(Q
MFU2!=.T^?2(TTX7)PL: @E,D\-UXKD]7MEA\":G(=HL+OQ%OT^-N T0)RR _
MPGV]*]\N;.VO$"75O%.@.0LJ!@#^-.:VA<(&BC8(,*"HX^E 'COB.2)_'^H0
M:*\/G2>'Y$@%L1\S\D!<=3BLS4_$>AW'A7P9:6;B.ZT^\@-S;B%LQ[?OD\>H
MS[YKW800J^]8D#_W@HS2+;0(25AC!+;R0HY;U^M 'EUE>6UY\3?%PMIHI?-T
MH*GED'>P49QCJ:YZ35=,?X&P6 N8FO+>:-7C*X96\W) SU..N/QZU[HL,2.7
M6)%<]6"@$TW[- 1@PQXSG&P=: /,['4K72OB?JM[K,L:6>I6,1L+N0CRVC"C
M*AN@SUQ7&RPI9>"++[4A6TN?$GGVD,B\_9QU.&[?6O?9K6WN(A'-!%(@Z*Z
M@?A3VAB< /&C =-R@XH \CU34M#7XA>(?M#K)8/H0BD^S,,GU"XX)VFIO L\
MUKXRM=.M]2MM<TW[ _D7:1XEM8\C$;D=,D#@UZJ;>$L6,,>2,$[12QQ1Q B.
M-$!Z[5 H \\\;3OI7Q#\+ZU>@_V/")87DQE89'& Q],\?D:H6$EO_P )1XS\
M26\R+H,MB(_/'$<LVT9(_O$'(^IQ7J4B(Z%9%5E[AAD4V.&!;=8DCC$('RHJ
MC;CZ4 <=\)IX)/ASI444J-)"C+*JGE"78X([<&LG4=5M-$^-+76IS&WMY=)$
M4<CH=K-OS@$#ZUZ4D<<0Q&BH/11BD:*-V#/&K$# )&: / 6ETQO@[>_\>YO7
MU1B!M'F',F0?7&W/X5I3W6B6/C+Q##XINKR.PU1(Y;6>VD?RIXMN I\OKZ#Z
M&O:_L\&,>3'C.<;12&.!W56CC+*,J"!D#VH R/"=O;VWABRAL[*6SME4^5!,
MQ9U4L2"<\Y(P<=LXKSC61X/\8Z1J&HW\L&D:[:R2(LJ/LD<J2%('\8.!TYKV
M)F"C+$ >]1/:V\FTM!&2O()0'% 'ACW>I6.H^%=8\9/J4%H;%H'N(F9'C<L<
M%RO.2N,]ZZRT\,Z-KW@?6[+0;.XAM;J3S;:YN&8F:4 $2*&Y R,9[\UZ6\:2
MKMD177T89%("BD1KM&!PH["@#R;1K;6?%/@'6-6NH6_M&33SIUJF"&*Q@[VY
M[NW_ *#4/A"]\):B-"0IJ<NL6  ,,\DA6TVCYW.?E"<=*]?)2-1]U1GZ<T"&
M)2Q$: M]XA1S]: /&?"\FCI\.?$UVFG6M_>07%P[1&/+%&.%/KMQGIV!JAHV
MM:=!XV\)7\NJRSV\5E+#+(;8QPP'80(U 7MGD\^I->ZK#$@(6-%!X.% S0(8
MEQB-!C.,*.,T >!?:],;X0>* K0BZGU9C$-OSMF167W^Z&_6MFPUVP\/>,-4
MF\0JTFFZU80&VN0AD1D"8*<9[DC'M[U['Y$.W;Y28SG&T4IBC8*"BD+TR.E
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M@$,5 Z_,>WK7IUE>0ZA907ELQ:"=!)&Q!&5(R#@T_P B'+'RH_F&#\HYJ0
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M"C !P,9ZD5Z/:V-K91M':VT,",<E8HPH)^@I+33K*P+FTL[>W+_>\F)4W?7
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MTD40;42A6-?;/->H:- VC^&;&VNGR]I:(DKCGE4 )_2O*?"$WARW'B(^([,
MW=_(\)GLW9GC/]T[<B@#M[77['P?H>EP:G?7EXEXQ^SW31ELACE S'O@CK6M
M!XMTJ>;4TWR1IIO%S-)&5C4^@;N:X[5]7M/$GA>UT*'2Y8UU&;[-8&9&Q'&F
M )CQQSG ]JP+1+R\^'VM>"TMBVJV$I972-@MVJR!B=V.6[?E0!Z-IWCS1M1U
M,:>/M-M<-%YT:W41C$B8SN&>V.:B@^(>C3WUI;JEV(KUF2UN6A(BG<?PJ?\
M(KA],M=&\3Z?-:Z+X7NK?4OLLB2W5[O"P,5(VJS$Y)/TQUK1\'Z[>2:=I'AV
M?PO=_P!I:?(J/-<08AA5>#('/0XR !WH ZM/'NDOI.IZCY-Z(M,E,5TAAPZ,
M.O&>@K*N/B&6\5Z-IUIIEY):7UN9S)Y)W,I VE1GH.I-<EJ<E_IMOX\T<Z+J
M<UQJ=Q)<6[PVY:,QM_$6J]:27FF:WX)U.XTK4GC32WM9$CMV9T?H 5[>OTH
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M:&P>&67['(%C9P, G'&._I0!J_$'Q;=^%=*MIK.QDG>XG2+S0 5CR1V[L1G
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M3X_#(U^67;8?9Q<%^ORD9Z>O.*PX_B+9_P!H6%E/I6I0RZA'YMK^[#>8AZ'
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M:FJ%_P#C[C_ZYO\ S6IJ "BBB@ HHHH **** "BBB@ HHHH **** $90ZE6
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M=0758; NXPPB:,'J%_B/^'K52+XL:++!'<K9:D+,S^1)<M;XCB;.!N.?T'-
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M5NU9HH /E3JQ)P!^9KE-1\6?;_#VLQZUX;F:UBLTG=(IUD2:)\\JXP.,9X-
M'?1R)+&LD;!D895@<@CUIU<7;>*K73_#WARWTK2V>;4H5%G9>:%VHJY.YCV
MQ]:J/\37BTW5[J3P[?!]*81W2"1"%<^^<X]P#0!W]%<+IOQ'^U:YIUA?:)=:
M=%J4)DM9YF!#D#.,#H,>M4[CXMZ?!<I*+(OI;7)MOM23J7!!QN\L<[?>@#T1
MW6-"[L%51DDG  H1TE171E9&&0RG((KA/&7B,WNEZ]I5AI#ZC':6Y%Y*7")$
MQ4D 9^\P&#@5H?#/YOAMH>3_ ,N__LQH ZI)8Y&94=6*'#!3G!]#3Z\;TCQ*
MOA#Q'XQAM-"O+V..]$CFV VPQA>22?QXKK8_B59SZKHEI!I\[PZP@:WN3(H3
M_:!]U/!% ';U#+<P1MLDGC1NN&< UFZ+KPUF]U2!+22*.PN#;^<S K*PZXQZ
M<?G7GOC^#2H?BEX;EU&&$6L\<AN6=<A\#"[@.O:@#H+'P*]K+=+I/BS4(-/F
MD:1K>+8VUF.3AB#CK]:Z_3=.M]*T^&RM$VP1+M4$Y/U)[D]:X[1E\/G5M0U7
MPQ9N\UC!Y,MO;IY2SEOF&-V.1MZ^]3Z=\1+?5(+,6FFSR7D]TUM)9^8HE@V]
M6<=@* .UHKB=;^)-AH]S?1I9R74-@RK=2QS(NQCU"J3EB,\XZ59N?'MHSA-(
MLY]59;,7LOD, (HCTR3_ !'GY1SQ0!UM%<=;_$.RN;G0DCL;GR=9R()6P-K
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MHH **** "BBB@ HHHH A?_C[C_ZYO_-:FJ%_^/R+_KF_\UJ:@ HHHH ****
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M)I\WV;Y+EHF\O=_"^.,_C7B:>&_%;Q:-<R^&GFU.RU(7-U=S7*[Y\-D!?[J
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M;XRL=.\1VNB^&I+R%M>MKB*-TMGRT2%?WAYY VC/UQ7IL4200I%&-J(H51Z
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M ,?D7_7-_P":U-4#_P#'[%_US?\ FM3T %%%% !1110 4444 %%%% !1110
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ML7FT:[6)': C<AP.F[&>1^M 'J>:*\NE\4^,-)_LZSU1+.>YU=@;9[.)G:%
MH+?*<!FY&.?K70>"]7\1:A<ZE:ZY9ND=NP^S7+0&$S*<]5R1GITH [ LH(!(
MR>@SUI<UYCJC:N?C-8Q#5-EM%9/.L8A!"I_$O7DG'6D;Q?XCO?#5WXOL)K1-
M.MIFQ820Y:2)3@DN#D-^&* /3Z*S=.U1=4\/6VJ6T9(N+<3)'GG)&=OY\5PG
MA;Q3K?B*^2+^V+.*?$OVJPDM=DML1G;C)^<9QF@#TVC->6/XUU\?#6R\0B2W
M%U]L\F5?*RLJ>85X&?E-:MUKWB/6[[6[?PXUK =)98]D\>YKB0C)7.<*/?\
ME0!WU%<%)XCU[4==M_#MD;:PU*/3Q=WLCIYBHYP!&!GID]>:J:CXN\1Z=;:/
MI5[:>5K5X9#,]M%Y^V-#C<J9Y)Z]>/Y 'I%%>5-XW\4V/AF\N-0TN>)H;M8E
MOC:X_<DG+F+/4 =,XY%6)O%VM6OA>YU2*_L]1M?M:(M]:P[C#"1\S-&#]X'L
M: .S\1:%H>L6#-KEI!-! K/YDG!B'4D-U'2L7PAJ?A:*\;2-"L9K21H1.#);
M,GGQ]G#'EASW]:YS6]0U35OAGKUT->L[RW4CRY[:( R18 *LO\!R?T]*FM]1
MUOP^W@JV.H0W%OJ/EP.C6JJR)L7 # Y[_I0!Z'JVJ6^BZ7/J%UYA@@7<_EH7
M;'T%8TOCS2(K+1KO%RT6KNJ6Q6$]2<?-Z=:YVZUK4KQO'NE7DZ2V]A:YMR(P
MK*&1C@XZ]JQYHC%X"^',9().H6K?@<G^M 'L.:*\WN?%&J^'_&VHV.MZE'_9
M[6;W-CB!5W$?PY_O#I[UV/AHZFVA6TNKS"6\E7S'Q&$VYZ+@>@H UZ*\K;4/
M'FKZWXBLK#5["!-)D7:/LW,F5+!>_IS49\:ZQJ^CZ->B\73()X)&G:"(2RR3
M*Q7:B'G;QG/ZT >L45Y&OCO6KGP'I&J2RO;K+=R07U[!;B0Q(IP&V=!GC\JO
MZGXKU2U\-6%Y%JHN[*:\D2XU2SMPYBA'W24Q@'U],4 =]JVC:?KMG]CU.V6Y
MM]P;RV) R/I]:9)-8Z!I3K&C""SAW>3$"[A!Z#J>E9_@R]N-0T-[F?5(-35Y
MW\FYA  :/C;D#H?4>]<CI,6I#XA>,7EU266*VMTRC(OS*59E7V"\].M '>^'
M]=M/$FBP:K9"1;>;=L$JX;@D<C\*TZ\.\-ZEXC\/>"M#U>"_MVTQKW[/]@\G
MEE>1@6+]<YS6[J'BWQ5JM[JW_"/6UUBQN3:Q1I;(\<A7[Q=F.0?0 4 >J49K
M-M9;^\T&*1XULK^6 %E==XBD([C(R ?>O,=(\6^,$\)7'BW4+VSNK*%9(EM%
MAV,S[@JMD?[7Z4 >P9HKRVP\1>,K&]2^U"SNIM(^SM-=-<01Q>40N?W>UB2O
MUJGJFO>)_P#A"].\4Q:SY+WMS&BV<<*>6D;L0!DC)/'6@#U[-9.N:]%H2VC2
MVEU<"YG6 ?9X]^PGNWM7,P:KJDGCSQ%HLFH2?9(K!;F!E1=T+'TXYQGO6!:^
M+/$4O@OPUJ1U!/-N]3%K<$PC<ZF0@8/0<#TH ]:!I:\OO[CQ?J'Q"U+1K#7X
MK2WMX$N1NMP0$)''N>>M9R^(_&WB"UEU30H;IO+O#''&!%Y#1J<'.?G)/X4
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ML%G<?:$<6N2Q#$@'YO<UJOXZEDU)XM/T.ZOK&*\^Q374+CY).,X3J0,]>*[
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M'6)O%DTVH10-!O>T3;L/8+GCK7HF17/6_BCSO&]SX;:QDC:"U%R+AG&'!('
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M'E0<X)'O@_E3/LEL+K[5Y$0N-NSSM@W[?3/7'M0 6=G#864-I;ILAA01HOH
M,"IZCCGBE,@CD1S&VQPISM; .#[X(_.I,B@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** (7_P"/R+_KF_\ -:FJ%_\ C\C_
M .N;_P UJ:@ HHHH **** "BBB@ HHHH **** "BBB@!DH=H7$3!9"I"L1D
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M>]FT6)I;]4_=JHRV,C) [D#.*X#2_$L\NAZ[/9^*)!-%!&JQ:JH66UDW8<X
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M![9]#U#3A>W(EU)]]Y=X4R3'\L >PK7T+2#HFDPZ>+J6XC@4)&T@ (4=!P*
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MPF4!@?H/UKK/ 6IS>+9CJ/\ :5Q;6UDL=NNFJX!RJCYY!C.&[ >E:,GP_4^
M1X2CU6=;;=S,8E+%-VXK^?>BR\ ?8/$5MK=OJT\=S' D$X6)0MRJ\98>N .?
M:@!?BA?:AI?@>[OM-OI+2>%D.Z,#)!8 C/;K^E96O7&O77C_ $72++7)K*UO
M-/>639&I*E1R1D<D^_2NJ\6>&QXKT)]*ENY+:&1U:1HU#%@#G'/OC\JHKX-F
M_P"$DTW6Y=8FDGL;<P*AA4*RD8.<=S0!!\.-4U#4-.U6VU*[:[ET_49;1)W
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M10 4444 %%%% !1110 4444 0O\ \?<?^XW\UJ:@C-% !1110 4444 %%%%
M!1110 4444 %%%% !29'K39HQ+"\99E#J5W(V",]P>QKP[3;*ZM? &I>+H]7
MU1]5M9)H8BUR60+Y@3D'.>"30![ID4F1ZUY%I>E7VE1P>*+;6K18S9._V>&:
M23[:PC9OF#G[V?3T[50OXK6X^'FD^(UOIIM9N+R'SKD7#!MQ?YDP#@ =,8H
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M\R5F*LL9(Y)R<>YH ['Q'XUGTRUT"^TZUAN;'5;B*+S9'(90^",+],]^#79
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M&-71XY"A!W =0?0F@#K\BDR/6O+KZYNV\3?#^47MPB7]H5G1)F ?]T#DC/\
MM=:Y(VMX? .OZV=;U0W.FZF\=K_IC;4"LHY'?@T >\W4LL-I-)!%YTJH62+=
MMWG' SVS6'X,\22^*= _M*>U6U?SY(C$&W8VG'6N7TRXD\8>+;JRU&YG2WLM
M.MW2&"=HM[RIEG.TC..@["N0TN^O+/PAH6C6EP(;>^UJYAFD>4Q[E5N%+CD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH Y;7K_ ,5/?M:>';&TV0H'DN+UB%D8Y^1
M.O;)Z<U8\&>(I?$VA?;+BV%M<Q3/;S1JV5#J<'!]*E\1Z]%I-NEO"\9U*ZRE
MM$[A1G^\Q/11U)_"F^$[+3],TD:?8W<-U)$Q>YDC8$M*_P S$XZ9ST],4 ;U
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@ZMX,\/:[>_;-3
MTU+FXVA-[NXX'08!Q5[1]"TO0+5K;2K..UA9MS*F>3ZDGDUH44 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 =*YC4/&=O;:TVDV5C=ZC=1C,ZVJAA$/<^M:OB#5DT/0+W4W7<+>(N%SC<>
MP_$XK$\):5%X8T@RZG=1?VAJ,WGW$DC@;I&YV@GKC_&@#JHG\R)'VLNX [6&
M"/8T^@=** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \P^,_B;6/#6FZ5+I%Z]J\TSK(5 .
MX #'45X[_P +2\:]?[>N/^^4_P *** %_P"%I^-1_P QZ?\ [X3_  H_X6IX
MU_Z#LW_?"?X444 .'Q7\:@?\AN0_6-/\*:/BIXU'_,=F_%$_PHHH L0_%_QM
M""!JX;/]^WC;^:U+_P +F\<?]!2+_P !8_\ XFBB@!?^%S^-_P#H)0_^ L?^
M%.7XT^-5!S?V[>YMD_H*** '?\+K\:<?Z7;?^ R\U.OQR\7C_GP/U@/^-%%
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M)^W>3VSLW>^.N*** ,__ (2?_IS_ /(O_P!:I9O$'E",_9<[T#_ZSIG\***
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CU;&FW_\ :%L9O*\OYBN-V?Z444 7:*** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>sgmo-20210331xex103003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ I&4,,'D4M% "*H5<   =A3##&QR44\8Y':I** (S!$0 8TP.@VC%.V+D'
MR!C.*=10 T1HJ; H"^F.*9]F@_YXQ_\ ?(J6B@!BQ(K%@H!/4@=:!$@)(503
MU..M/HH ;Y:X VC Z#'2G444 (1FEHHH **** "BBB@ HHHH **** $ P,"@
M@$$'H:6B@ '%,:-'(+*I(Z$CI3Z* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY]A0!LT5R5EXO:/0-'EO8)'U*_BW1P+M!DP,ENN ,<U5E^)VD1Z6E\+:\?\
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MY ^XG.3V&>M>A44 <=\2K&:\\"W5A86LDLTK1K'%#'GHP/0=!Q7.^((-1O\
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MYE%S:P/&(H2V<+T(ZC.:],KEX=%CT7Q/>^(;O60$O%6%HI55%&/N '/;G\Z
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M?^"=9?3?#4]A]I6**-3#B65@X)R!T4 =:OYG;QIX5G6TNEB33FCDD,1 1F
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M6]DAR(D )]3W/XG)K+U73="T_5!XEU*01RQ*$#RR'8#V(7UK>BD6:-9$(9&
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M4M]7L4N8-R@\-&XPR'T([5=H XR+POJMY::;IVJ7-LUA8R*_[LL7EV_=!R,
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M_P!(2_T\+,)H1+ &)4-D9&?2O(]4U75-=^%EUJ.JP1&2/408&5LL/WN"N,<
M=!S7K.AZ;_8^AV.FA_,^RP)%O_O8&,UYG-X<\4)X*O?#1T8.3>&6&Y2X3# O
MNY!.10!U-GXXGBUFXT_7=+.F[+$WT;^:) 8Q][..A'I52P^)D-YK&F6QM(Q:
MZD2L,D4X=XVSA1(@'RY^M5=8T#6-<\46\KZ=+!:2:4]A/*TJ$J7S\V >0#4W
MA*T\66GV/2-2TFQ@AL<+_:"E6:6-3\H4=B1W/\Z .H\3^(%\.:9%=M&C&6=(
M%,DFQ%+9^9C@X Q67+XMU&WT\/-HV+E[U;2/9+NA8, 1)O X7G\_QQI>*8+F
MXTN."'2H=3A>4+<VTI W1X.2"3C(.*\^_P"$2\1Z?I;+IMM*VF?V@DZ:1/<
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MCTF^\0>)H-;N[-]/2TM)+>..0AG=I!@GCL/UH 7_ (3S.AZ!JG]FL8=6G$#
M3#,+$D#M\W0^E9NCW-IH?COQO=3*L-O!%!/)M'^P23]3_6L-- \5IX=TG1TT
M5?\ B6:@)_.,Z_O &.,#/ YK7N_#FJ:SKOBZ.:RDMK?5K6*.&9G4@/& !G'8
MF@"IK5_?ZGXM\&7]UI*V<4MUF&7S0[,K $!L=..?SKT'7]<MO#VDR7]R"RJ0
MB(O5W)P%'U-< T'BO4CX8@GT!H3I-RAFE\Y=LFT;=P]L9/>NN\=>'[CQ'X::
MTM&"W44J3P[C@,RGH?KS0!'_ ,)9<PZO%I&H:7]DO;J!I+0?: Z2L!]PL -I
M_"O/=6U?4==^%=YJ6J0QM+'J(\AU;) W\J!CC'3KS7:+I^H>(_$6AZE?:?+8
M#2U=W#L#OD8 87';C.:Y:70/$<?@:^\.#1'D?[89(YUE7##>&R!GV_6@#L=.
M\;E]1>QU?2YM-D6S-XK.X8-&.IP.0>#Q5.T^)MK=:E9VXT^3R+TE8)4E5VSV
M#(/NY]S575=(U/6_%\5RVG3V]I/I$EE)*Q4^6[@]0#T!.*?X3A\0V<=KI-YX
M?MH19?*^H#;^\5>FT8^\>.<^M $EI\1KW4(KB6R\*WLT=O))'*XD&T%.2,XZ
MU9?XA(FD:%JATX_9=5F$)8SC]RQ)'/'/0T_X?6%_I]CJD&HV,EL9;Z2>/>00
MRN?;Z?K7/CX:7$Z:]:2SL++<[:5$6^6%F(;<!GC&-OYT ;?BGQ##_9NM0WVA
MO>6%B\:2,LX 8D!O3(QD>O6KE]XM-C>QZ;8Z;]IE6R6ZV-.(_D[!<@[CQVK)
MN]#U4?"F33?LTEQJUTH:<%AN+E@222>P 'X57\1Z7=ZS80Q3>'KD74=I&+:\
M@=1)%*!R#S]W- &KK/Q BTZ?[-;V0ENH[=;F>&681%%(!"C/5O:NCT35H-?T
M6WU&!&6*X3.QQR.<$'\0:X"/1?$V@:TNJ/IL.NO>VL<5R&95:.10!G)[>]>B
M:7'<QZ=$+N.&*?!+1PCY$R<X'TH \O\ #GB*[\,_\)$MOH4USI]MJ4KS2QN%
M\I2<8 [XQ73ZA\1K&%RNGQ1W92V%S('F$7RL,A5SG+=\50ATW6K0>)]*73'D
M75;F62"Y#@1JL@QEN_ /3':J4/A;5O!NM>?I>EQ:S9W%LD4BR%5='4=1G/!Y
M_P B@#O]%UF#6]%M]3MU9(IDW;7&"N."#]"#7)#XGP-=P/'9+)I\US]F65)P
M90<X#F/&0M=?ID%T-)CCOEA6=E/F+ ,*N<\#Z XS7%>'=+\1:$PT,:1926\4
MQ,>IL1Q&3G)7J6H M3?$&^\S6?L_AV1X](D*W#O<JO [@8ZX'3FEN?$FJW7C
M+P]!811_V;?6S7&&?!==H)W<<$9X'>J(T;64M_&H.F2$ZI(QML.O/!7GG\:E
M@T;6K6\\)7\6G>8]E9M:W,32A2F0!G]": $D\2&'2/%USI6D)9WUE,1,SR<R
M-@Y<X&,CTJKJ<UW>VW@"\U!$^U/>QDL&W9! .<^^ 35J'0M7O+;QE#)8&W_M
M4[K<LZ\D+C!^OK3+C2_$-UIWA1/['(?2YXWE'VA.50!?;DXS0!=U?XCPZ?=7
MRVUFEQ%8RB&8&;;(S=]BX.0/6K%UXH;7(KRRTBP6Z6.T\RX:=_+"[UR%Q@Y;
M'X5GQ:5XF\.:YJ$6DZ;9WFGW\YG665@K0LW4'N0/\]:631_$>A:WJ,]A;1ZG
M%JL*B5V<1F*0+C./3DT :/PP+'P!I^Y2I&\<]_F-<U9ZO?Z!XD\92Z;I*W4$
M,RS3$R",* N>/4\DUV/@;2[_ $7PI;:?J,:)-"6 "-NX)SS[\FL(:)K:MXQ)
MTXDZKQ;8E3!&"O//'7- &I<>,9FALYK&Q5H9[(WCS7$AC1!V3.#EB>*2T\;?
MVE8:,UC9AKW5-Q2&1\+&J??9B >/3CG-<];>&?$T9TX36-O/##IYM5AEF&V"
M3!^?'<_YXIFF>%/%.D6NC7T4-O)=Z;YD7V4R >9&Y))W= >?TH UO 9G_P"$
MG\6BYBCAF^UQEDC.5'R]C^M:>N^*+K3]?ATBS@M6F>W,P-S*4$ASC8I_O?6H
M_"ND:Q8ZUK6HZE#!$-0D20)')NVD#&/RIGBW1[[66EMFTJ"\MFAQ!+YHCD@E
M_O9].G2@"U;^)+UO$EKH]S81PO<6/VH'S"2IZ%2,>N:SK;QS<SZ;%FQB&HSZ
M@]C#&'/EEEZL3UP*CD\/>(-/U#1-1M##?W5M9&SG,TA7J<[L]^N*SK;P1K\6
MCP.)K==4L]0>\@RQ9'W8R&].E %OQ9?:C=^!=?BU;3T@FMF01O&24E!9<,N:
MNZ'XEU&/6--T74;"&%+JS$MN\;EF 4#[W:F:MHWB;7/"M_:7_P!C^U7)18X8
M7*I&JMDDDYR34G]@ZN_BK0M2\F"."QM?(EQ+ECD<]J %^(M]J=AI5@VFSK#Y
MU[%%(QSDY/ !';(YJIK/CB]L]1NK"RMHI9[&-6F!1V\UR!\J8' YZFMOQEHE
MWKFD0PV1C^T074=PHD. VTGC]:Q!X?\ %FFZ]<ZGIEQI\AU!5-RDP(6-QQE>
M^ * "Z\::Z;_ $>RLM&@$^HVQF"7$A4J1U!'&*#XH\43ZKJ.F1V&FQS6-N)I
M',CD#(S@>IK0E\/ZJWBG1-1:2"=+*!XYY7;:[ENI  Q@=A2)H&J1^(M=U%1;
M&._MQ#$ID(*D# )XH R[7QKK4EGHVJW%C:1Z??W"VY178R9)QN] ,@\5J)X@
MO!KOB.T%K;!K"V6:)AG+_*2-QK./@_63X;T32\VF_3KD3L_FMAP"2!]WCK^E
M7&\/:T-<UO4$%F!J-J(%3S&^0@8!/R\T 9VG^,M>^RZ'J5];67V+4IA!LC+;
MP3G#>G;I3]9\9ZEI$]U),;-1#>K EE@F1XSCYRP/&<^E//A#6?\ A'M#TY9+
M,/IL_FERS8;!X[>YJM/X!UN:QO;(ZC:&.XNA<F5T8R.0<X)]!0!;T^?59?B9
MK$ OD>*&U5DA=3M )X''3GJ:CMO&UZ?#4$S06XU"ZOWLX0 1&N#C<?I^M:<'
MAO5K/Q/-K,%[;.]Q;K',)(S\S#TP>!5.'P'<#P_'927D8NX+TWD$R*2%8G."
M#VH LOKNJZ=K4^CW9@GF>R>YM)U0J&*@Y##)]*R+3Q7XD%CH>IW@LC:ZA<"
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MN(Q?A<2^6<@G/7\JT*JZ=8QZ;816D3R.L8QOD;<S'J23ZU:H **** "BBB@
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MR_.4^JY.#TK/UWQ-J0\0W.C:1&WFVUL)6<0&7<Y^ZO48&._/6@#M*1F"C).
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M-62W)MK@QQ36P.R1?;/7'2NEXK&O?$5CIFOZ?HLD<HN+[<82J?)P"3D_A^M
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M-5B\J/=(P*_+M!/'IS5*R\'>([.;3)%GTY_LMF;7;*&94R?OJ./FYKT:C(H
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MZC(S5;2M0FU&*=YK*6T,<[1*LO5U'1A[&@"OH=AJEM&\NKZC]KN7 &V--D:
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M*,4.#@]<5SLWB.>/QE:67FVPTR>T,_F-P?S)Q73K<0M!YRRQF+&=X8;<>N:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!"VV08W*<<'ZUY/-J^N7/@/PA<KJUW#<75]]GGE1AF0%V&3],4 >Q,P52S$
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MB@#%\/,"VK ')&HR@^W"UM5A>&\>;K?_ &$Y?_04K=H **** "BBB@ HHHH
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M]BQ:4][?FUBG\]%$BC#YS_=J[_PB-N-6GU(:AJ N9X/(D;S%Y0#@8V\5T-%
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MHK$L/$<=]XEO]%%K+'):(',CD8<$]A6W0 4444 %%%% !1110 4444 %%%%
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M]>*L5Y:I\0RZAXETW_A);L1:7&)XY-B[V;;G!./N\=*FO=?UJ?PQX?U5VO\
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M 4444 %%%% '/^%_^/CQ!_V%I/\ T7'705S_ (7_ ./GQ!_V%9/_ $7'704
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M%_/6;4TWVV86"D;=W)Z X[=>14ND>(['6K[4+.U\X36$@CG66,I@G.,9Z]*
M.4TSPIKUE\.;OPVRZ?\ :)=\:2^:VW:Y.2?ESD=O_K5)J/A77K[0O#UF#8"?
M2I8W9C*^UPB@+CY._>N^HS0!P'_"+^)]*\2:A>:%?V4=GJC^;<)<*6,,AZLH
M&,^WZBF2^$?$>C^(I-4\.:E;NMW&B7:7^YMS+QO&*]"R/6FAU9<JP8=,@YH
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MCIRLME:06RN<L(8P@/UQ6/K'BR+3+N>VM["YOY;5%DNEMP"8E;IP3R>^!VH
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MVB=I'DD:::5@ 9)&Y)P.E9-UX/NGU[4M3L]9>V74(1'+#Y <$A=H.2:ZO-%
M'$+X G&BZ5I9UG]UIT_GQM]F&2021GYO<U(? 3PZM<7%AK=W965V^^YLX@,.
M3UP?X<UV>1ZUFZ[K,.A://J,R%UB P@."Q)P!^9H LS644VG/8D;86B,6!V7
M&*Y!/ARO]A6UA)K-T;FSDWV=TBA6M_90.WKS4\_C'4K2_ATZZT!HKNZD"6K"
M?=#)D9.6VY&._%;^BWU]?6CMJ.G-8W"2%"A<.K8_B4^AH P[GP.UYX>FTRYU
MFZFFN71[BZD 9G"\JH'0 &K.I>$Y-2_L=FU22.33&#HZQ+\[#')'X5TN:,T
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MSGA4_P"E^(AZ:M)_Z+CKHZ "BFIOYWXZ\8]*=0 4444 %%%% !1110 4444
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M>&>1VB.9R9 2V0,  #IV%;NJ> TO-:75K#5KS3+MHA%.UMC]\H&!G/0__6H
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MIKKIO#6BW&J#4I=-MWO 0?-9<G(Z'TS4M[H6E:C<1W%[I]O/-&,*\B D#TH
M\BTY-.DT/PA<3K;E%U-UE=P,!<YPQ/;ZUUUA!8W/Q1UF%%AD@GTU-ZC!5\E<
M_7BNN_L#2#9+9?V;:_9E?>(O*&W=ZX]:?;Z-IEK>&[M[&WBN"-OF(@!QZ4 >
M=Z#:W*ZRW@R:U!L[&Z:\:4CAHNJ+CW)K/F@TJ]O?$4'B#6VLYA>LQB,:^8Z
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M)[ULW^H6FF6;W=]<)!;QXW2.< 9XK/@\6:!<V,]Y%JUJ;> @2N7QL)Z9SR*
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M[M+@P3V\#2HX16Y49P0>,5R$GC&\TWX60:Y>WL<FIW<0,.Z,*-Q(&  .PR:
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MT/\ 9R'[)_Q[Y=CY?.>.?6IH/#&BVSW;PZ?$K7:E+@\GS >N<UCZ/XCTG2-
MCGO_ !&;^.:YD1+MXV.6S]S@=OU[5ORZU80WL5G)/MFEA,Z@HV-@ZDG&!^-
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M+Z*+,NI%A!#)(L8!4X;<QX ![U<\+>*K?Q/:W$D<+0RVTGE31L0P!]0PX(H
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M*$V04SG!!(//X5K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '+>$1C5O%77G5F/_D*.NIKEO")SJWBKI_R%3_Z*CKJ: "BBB@
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M3"L2A#^&,4 >1P)I6GO\/985MHR4=II$PI8E!PQ^I[UBW>J6+:9I,MM=6]I
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M/\97'S<?Y%=I10!S/@;2M2T3PZFGZC' CQ2/L,3[MP))R?3DUTU%% !1110
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M/+>.-=SEU)7: .^15+PKXLTS4M=625;J;6M0^4I]G94M8E!(4%L<=R1U)^E
M&]X?UB==?U#PW?R-+<V:K-!.V,RPMT+?[0/!/>M*]\2:7IVLVFDW,[)>W?\
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MX9WB5EQ<E5^X03T&<\\4W2O$^G>&+^[\.Z9X:UG?'()I(D E$>_&2,,<*.*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<KX1.=7\5>VJG_T5'755RWA'_D+^*O\ L*G_ -%1UU- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%)D4M !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1129% "T444 %%%% !111D4 %%&0:* "BBB@ HI,BEH *
M*** "BD# ]#FEH **** "BBB@ HII=58*6 )Z#UH5T?.U@V#@X/0T .HHHH
M**;)(D2%Y'5%')+' %.!!&1R#0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!RG@__ )"WBO\ ["S?^BHZZNN6\(*!
MJGBH^NK-_P"BHZZF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAJ\\+W,9NYO#<=S<XN+E,J)&"[7&!]WKCCL:D\4SZ OA47N@QD6G]NPSR7+
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MU[;P]<6=MJ&FF-#-,&;?C.6)).2>WYT-I.M'2?#FH#PXT\FDH;>>QN"I,RD
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M))&3CG SQ6RFHQSZ.NI6B/<1O#YT:(,,X(R ,]S0!:2*.-=J(JKZ 8%.  Z
M#Z5YSI7Q+E7PQ>Z[J^DWBV\=T\:&%%8!=V I.>W3)[UHVWQ)M+R2W@@TC4S>
M7,QC@MY(A&SJ%W%\L0-N/>@#M2 >HZ4W,8)7Y<XR1[5S5MXYTZZT%M42*XR+
MDV8MM@,K3YQL !P3R.]<KIMWN^)/B&>ZTR\ML:2#-;E_,=CN7)7!(Z>AH ]/
M1HY45D*NAY!!R*?7G6D>+M$\->#]#:TT_439WLK10KQ(X;>1\W/4]@*VK'QU
M:30ZLVHV=QILNEH)9X9P"VPC((QUSTQ0!U=%<C;>.?-U73;"XT>[@?4HQ+:M
MN5@R=23SP0,''O6YKFM6V@Z<;RY#L"RQQQH,M(['"J!ZF@"_YL?F^5O7S,9V
M9YQZXI]>8V5])%\6;N]OM,DTXQZ*\LB^8)/, =3N&WCH,8]JW;#QZMY>Z=;R
M:7- -3C>2R9I%)DVC.& Y7('>@#L:IZKIL&L:7<:?<EQ#.FQS&V&Q[&N9LO'
MOVS1M6OCI4T4VG3B![5Y5WLY(&!^?'K7337K6NDRWUS%Y9B@,KQ@YVX7)&>]
M '.V7@YXIHX=0\1ZAJ%O'\T=I,RA2 1C=CE@.*ZIIH8Y$C>5%=^$5F +?0=Z
M\X@U?48/AW=^,HX%GU6\1Y"SO@6\6XA0H/90 <=R>:IZM?7IUCP-JEQII?4I
M%<&*-U+2GR^/FX '.?;F@#U>BN*B^(EO'H^HW6I6,EE=V%P+:6U,@?+L/EPP
MXP>>?:K.@>-H]9UVXT>:VBAN8HA,CP7*SQR+P.&4=1GI0!:T/PM::#?W-V;^
M[O+JY)"M=S;BBYSM7V_PKH0ZL"0P(!P<&N9U/2=:G\66=_9SVHL5MWBD69,O
M&3GYD]SQ^5<9K \0Z%X:TKPU=7=O'=:KJ/V87-L""(21DD_WB3R: /4!J>GL
MY1;ZV+CJHE7(_6K0((R*XGQ/HGA;2?"<L5WIP@M%7;]HM[<N\1QPY(YZXY/7
MO56X\?7=G-I5AIWA^YO_ +9;>9;N\@A:0*.3M() ^M 'H%%<!JGC[5=/M[FZ
M;0D@@LTC-PMU<;&=F )6/C#8SUJW=^-=0.M6FF:9H7VI[RT%U#(]TJ#;C^(8
M..N* .TILDB11M)(P5%&69C@ >M>::OXTUJ_\(VU]86L5I<G4DLKE#*<JX<9
M"D#H>Y]#7HT0DELU%U%&LC+^\C4[ESW&2!D?A0!27Q'HKL%75K(L3@ 3K_C6
MFCK(@9&#*1D$'(->=_#O1=,NM)UE;BQMID?4IE_>1*?E&,#IQ530=4N_"NL>
M*-&MX;G4+.PV2VELO)3>1\N>2!R/7H30!ZA17$6OC*^N[S5M(6*Q;4;.T^T)
M)!*7B[ J>,Y!-9VD>,KW2O!.E76IM#-=7\K+ [%^FXDL^ 3QZ#VH [Z^U"TT
MV#S[VXBMXMP7?(VT9/05S\MGX77Q3-J\]U#_ &E"BLZR3Y$8(P&VYP..]9MM
M?/X[L-3T>_L(HWB93'.T+F)US]Y=P!##G_.:VK?PE81:R+\P0X6T%J1L^:48
M RY[\* !]: .A4AE!!!!'44M<GX*NY1)K.CRL673+QHH"W)\H\J,]\=*ZR@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<
M\*?\?7B/_L+R?^BXZZ.N<\*?\?7B/_L+R?\ HN.NCH **** "BBB@ HHHH *
M*** "BBB@ HHHH YGXA#/P^US'7[(U<:DMOXG@\%FQMYT;2C'=74C6S*(D11
ME<XY+$<!<UZ#XFT63Q#H5QI:WAM$N!MDD6,.2O<8/\Z32(K?0M/L-%N-0CFN
M$C\N+?M1Y .F%SV _2@#S?1--NM:\!>+],M(9HKRXO9IH5EB:/>K,"H!8#J
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M#4;QIHE>,AO*7.&V]><U#\+?*/@26RO83&(YIO.CF0KE&).3D=,9_*O0<"C
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MX3\-Q:>SK)<,YFG=>AD;KCV& /PKHR!Z5D/XK\/QR/&^M6"NAPRFX7(/H>:
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M\'*PK_=W?Q'N3[UR4>BZ_P"&]5U^+3=.74-/U=VFC;SUC-O(P(8,#U'/4>E
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M-KVS EL[*W2U&GB]^T7TIC1\C(C3CE_;W%8NJ:K'K^L?#S6$@$374[L0>6'
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MFZ. J1*,<GGA>,=SW]JL7?A+Q%<2:%J2:G8#5M,#H286\ED8 8 ZY 'MU[4
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M\BWA5LF0G 8<< ,._84 ;.@7U[J4^HW,D\,E@+@QV9C3!*KP23GGG@?2N?\
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M[/5[!XUM7'D7?V=X5G4_[+<@T =A17*7>OZG;?$"UT "U-K=V<D\;E&WHR]
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MT*"::,73S"!MLTD$#R)&?]IE! _.MC3M2M-6L8[VQG6>WDSLD7H<'!_45A>
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M_P!IOFNGCEMBJS!A\P?K@>P^N:]%) &345I=P7ULMQ;2K+"^=KJ<@X.#^HH
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M[B^@U>2YU5'U'4X5MY+@6V%CB'\*)NX]<DFNSHH X?\ X074#-X>D.MPG^Q
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M-:1HWRJ%R!@@$>YK(\3ZL]G\0]6!,JZ7>6UK#>W<:_/#$P'S#TSTSVKTNY\
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M(NH6\EV-2,('V3 NXN.F0-H'S<D#@9SZY44^DP>)OARUJ]I'_HC+(8BHY:(
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MJ*0W,4*?)(FX!OG(P<=.#CFNQU+Q=H6CW7V6_P!1BAF! ((8A2>FX@$+^.*
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M[7-N(4:1I1C.54 D\<UQW@;Q5''I6M:AJ^KS36L>HF*"6XSNP1\JA0,Y]@*
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MNKPR2RPW4GDP1(F97DR?D"^O!H VKFPM+UD-U:P3F,[D,L8;:?49Z58(!!!
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M#<?K7HFH64EQI=Q:V5P;&61"L<\: F,GN!TJEX;T%]#LI$N;^74+V9]\]W*
M&D. !P.@ '2@"OXZA:7P)K:(A=C:2851DGBO.7U_1]1N/A^/M".EJ0MP)8F
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MIG.FLRDEA+RV/4@#''<FO2<5FW.OZ-9W!MKK5+*&<8!CDG56&?8F@#R>"WU
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MRVPL+S5O >F>$AIUU#J-O<(UP\\#(D"JY;=N(P<C@ =<U+J>EW6MZYX_T^R
M^T20VIC!XW$+G;GWQ7I^HV7V^PFM1<36YE4KYL#[73W![&J6A^'[?1%N'6::
MYNKE@T]S.VYY"!@9^@H X72K<Z[:26MOX(.D7QM9(Y;VY@"!&,;*/+/4Y)'X
M9J?P?J.M066F>'+OPO<17=BVQKV>/,"H#]]6[L1Q@5Z3@4N!0!PO@B*\T[7/
M$5E<Z==Q"?4);E+ADQ$R$C&&[D^U+XG2]M?'WA_4XM-N[RV2*:%S;)NV,PP,
M^@YZFNXP*6@#RK3;:_\ #_A_Q#X8FTB\N)[N6=K.6*(M%,)1@9;HI'4YKO\
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M-0M$(D$@7_5N!T&?6O0M 74$T&R752IOQ$//VXQN_#BM# I: "BBB@ HHHH
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MT>*&UE$%];3I/;S'C80>>?IG\A0!EW/CJXLH@]S#;*+N]DMK%UWE61"0TC
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M[) -SH RJY7J!T(S7D.A76N:3X"\1ZQ!>VL[6VHS,T5S:[@S@K\X.>#TXZ4
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MZ]@: /2<BC(KR.+6O'6O6]W?Z+YK2V]V8(XE:W%NP0@-O#_/D\],=L58>_\
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M>>&_AQ;W-MJ$KSZCJ#64,<H4I 6<YD QDGZG&37M5]#/<64T5M<?9IG7"3;
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M+._#>?%+.6!8]6''!XZT <9<_;+C5?#WABQF\NSDTI;IH;J\E0R.W&-RY8X
MSMSBJVJZ5KVGZ-H=A?>)[F2Z?619M):7+?(CKG#$X)8>_8UV=S\+_#EUIEI9
MN+Q6M"3%<K<'SAGMN]/;M5B?X?:)/86-F&O(XK*3SHO+N""9/[['J6]Z -G0
M]+&B:7%8&^NKPH2?.NI-\AR<]?;-<G\5$N?[+T=K74+JSDDU2" M!(5&')Y(
M[D$ BM2]\+-=>.=.UU'DB%I"4=_.)\T<@)L[=<DYY].]9?Q5L+S5M%TZQL]/
MO+L_;HYI3;+RB+G//8\\4 <[J.F7WA_Q%J>BVFN:K+97&BRWVZ2Y+212H3@A
MNP)'ZFJKI?:/X5\.W0U[5)#XADM8+N6:X)$*'YCL/\)(XSZ5Z%:>"-,6PNT>
M;49)K^%8IYY[@F;9_<W=AR<@5/\ \(7H[^&!X>G2:XT]<;!-*69,=-K=1CM0
M!R,FG&P^(;^%[62[.D:GIK221&X=O(<$_.I)R.<=^IJAX=EN=3A@\&7=Q=G4
M]/U)Y+R?SY-[0IR&W9R-VY5%>B:1X8T_1KJ2[B:XN+N2-8C<74ID?8.B@GH*
ML6^A:?:ZW=ZQ##MO;N-(YGS]X+T_S["@#S&^U6_\,3?$*2TO+F9K4VOD&XE:
M0Q>8 "1D]MW'T%2ZKH]GHWC3P7=V4MQ</.LS.\D[2^<PC!W<DC)SVKMH? VC
MQW>IW$GVFX;4TV7:3S%UD';CVZ#TJC8?"[PUI]W:W")>226K;H?-NG8)[ >G
MM0!P^B6NM^)-)MO%,6M6=G=1732W%Q)<RY"AR/*9/NA<8 '^-)J,,7BOP3XM
MU[4IYCJ-K-+#%&DS!;=$/RH%& 0><Y'-=[!\-/#-MKYUF*UD$YE\[RO,/E;^
MN=G3KS2ZG\-O#>JZA=WMQ!.CW8_?I#.R)(W]XJ.": -GPR2?"ND$G)-E"3_W
MP*\X\*Z=K.H2>-DTG618N=5N%53 'RW/.[J/P'%>FV6D6FGZ/'I=H)(K:.,Q
M(!(=RCV8\YYKGK7X;Z/9"7[+>:M!YSF23R[YUWL>I/J: ,;QC!(OAVRU*QU*
M1];TN6*#RH97*W<HQNB*@Y8]_7BN?N=3-O\ #B77M/U"5+_6+Y(K^7S65;0E
MCN0#)* =,]<'/I7HUKX)TBSETV2#[4AT]F>$>>Q!9L[F;^\3D\U!!\/?#\']
MI*89Y8=2):YAEF+(S$YW =CGH>M '$ZC::WX)TS6-4M=5MEAFL/]'L8)I)=K
M;D!F7>3T#9)]Q6]IOA_3A_9^I6VMS^1?V#136S7!<7CE<[\Y^\.2<>G:MS0O
M 7A_P_;W4%I:M(MTGERFX<R$I_=YZ#VI- \ >'O#5Y)=:=:N)F!"F24OY:GJ
M%!Z"@#SA;J[D^&W@R_>]N'NVU9$:9IVW,IE8$'GD8 K6\.Z#8GQ3X[2-[BW,
M#IY;PW+HRY1B3D-S^-=%_P *G\);R6LYV3S?-6,W#[4.2<*,\#G]!6C-X$T*
M?6+C5#%<)<SQ")_+N&4$!=N< ]=O&?<T ><O87>I_!/2-=CFN)-0T\-.Y\Y@
M9HA*V]6(// S^%:&N:S)<>'M=\::3<211RQPV5K)N887>HDDQZY.T'K\M>B:
M-X:T[0]&;2+196L3NQ%-(7 #=5&>W7CW-.M_#>E6_AY=!6U5M.$7E>2_.5]_
M?WH Y'PUHNH:;XEM+_\ M>Q6PO;<@VD%Q+(+A@,^8N\GGIDC^M)\0M-:_P#%
M'A:V74;^UCO+B2&86URR J$+<#IGJ,^AKH/#?@70O"L\L^F6\@ED&W?+(7*K
MG.U<]!5G5O"VF:UJ=IJ%X;G[1:<P&.X= A]0 >M 'FPTB_U7Q#K/A2#45,6E
MP1167VVYD$J[@6,HV$;F!(&2.!@=*D?2[F^\3^$=.O/$-Y=I<6=PES-;7#(D
MWE@CCZC@GJ?7FN\U_P ">'_$M]#>ZC:,;F(;1+%(8V9?1B.HJ2?P9H\VHV-^
MJ3PSV,8BMO)G9%C3&-H .,8H \EDTV1/"'BB]&IZGOT+4#'IRF[8B$!Q[\GG
MO6UXB:;5[RZG2YGO)[71$G:(3F"*Q<KN$FY3EG."0,?CBNQ3X;Z$FG7]AOOS
M;7\@EN$-TWSL#G-)-\,_#=Q/'-/#<R.L MV+7#?O$ P-W/.!T^@H Y:SNKI[
MOX9WDM]=M)=P.LZM,Q60B+@E<X)Y/-9%YICW-AX\N9=4U1CI%TS66;M]L; 9
MSUY/0?2O0;?X:^';3[%Y$=XC63%H"+I_E8]3UZGI4P^'VA"'4(B+UDU!MUT#
M=R?O3[\T <-XBEO[BWL=:NH;C5],?2(A<16<Y6>S=EW&8*#W]3Z&O0[6]MV\
M#QWD%^_V<6&];N13N "??(]>]46^'6B&-46748\0"V+)>."T0SA#ZCFN@32K
M)-)_LM8%%EY/D>3VV8QC\J /)=%EO+#Q#X+FMQ<1P:CYJS327#,UXN =[IDA
M?O9')//:NS^*EM;7'P^U22<$F&,/&=Q&&R!VZ]>]%M\+/"UJ]JZV]R[6LGF1
M%[ESM_V>OW>.E=#K>A6?B#3FL+\S&V?[Z1RE-X]#CJ* //I;.'2/$_@%=.EN
M(H;I9/-0W#LKCRP1P3CJ:S;YMGASXFVT=Q)+;PSKY:NY8)D L!D^N?RKT&_\
M"Z+J6CV6F7(N6BLFW6\@G;S(_8-UQCBJR_#3PU':WMO#;W$4=Z%$X2X<;@,<
M=?:@#$NP#KWPT;G/DR]_^F"UIG7-8U>:[TO4_"=U:V#QRJUTTXVD ''W>><?
MK6F_@G27ETN4R7H?3!BT/VEOW8_KQQ]*Z(@.I4C((P10!X=;:?':? NVU"TN
M+FWN#<*[&*=PKGSMO(SCIZ>E=/J6D)J_Q8?3[G4=02TETGS6AAN656.\+CCH
M,<\8Y%;J_#7PVNG3:>MO<"UEE\UHQ<. #V YZ G.*MIX*TQ-634UGO\ [8D/
MD"0W3$[,8QS^?UH \LC@N4^&D/B$:KJ+ZC87_DV[-<-M1!+MVD=^#U_#H,5O
M7,6J^,?%'B'3Q=6\,MB8TM=]Q(C0@C/F($/.3W/M74I\-] 31GTD&]-D\WGF
M,W+8W^M3:K\/?#^LW=O=W<,YN88Q&94F96D4=G(ZT 6K"YN[3P1]IDO(M0N[
M>T<FXCY69D!Y]^1S7GV@:?JFM6&C>)XM;M+67SE-W-]IE+39;!C92=H/8 >V
M*];M[:"UM8[:")8X(U"(BCA0.,5S5C\.O#>G:T=5MK1TFWF18_,/EH_]X+T!
MY./2@#S:2PGD\->,+]]8U4S:5?/]D_TM\(1CD\\G!Q6_;6LVD^,?"S_VG?3-
MK%E(MZ7N&82-Y8(8<_+R>,=*ZD_#S0S97]F&O1!?2"2X0738=AW-22^"]+BE
MT^\W7\DNE)BU G)( _A [YZ?2@#SBWT6XO?!VN:]_;VJK>:;>SFV8W)*@(1U
M'?-;Z:A>'QQ9:K)&&N6\+FX\OL7SNQ^=.\%^$6N[743KEIJ5L9K]KAK:1]L,
MRDY7*@\^X^E=DWA73V\2)KV^Y%XD?E*!*=@3^[M].] 'G&^Z/PQ@\9P:E=G6
MTD$LDOGMM<&7:8BF=NW!Z8J]J-[)X0\6#4[N6]FL-7LG$$+RNWDW!P2@&>-Q
MQCTKKX/ ^C6LQ,*SK:F;S_L7FGR/,SG=L^O..GM5*:+5/$/B:*UO]%%KIFEW
M7VB.Z>4,;AE'R;5QP,DD_04 8.HPW]IJGAWPJ;K>L]M)-<&YN9%$\O==RG<0
M.<#Z51O6UOP['IWAV?7+:5;O4-I)GD'DQ[05B9_O $XKT/Q%X5TKQ39I;ZE$
MS>6V^.2-MKH?8U5D\!^'Y?#IT.2T9K4OYA8N3)O_ +V[KGM]* *GA#1M3T34
MM2MKW5()X)=DL%FDKR&V!R#R_.TXX^E9>K:5;2?&72)#YJL]C)*Y65ERRG Z
M'I[=#75^'_"^F>&;>2+3TES*09))I"[OCH"3V'84S6O">FZ[J-I?W1N$N+4%
M4>"4QDJ>QQVH \K6QDB\)>*M=@U*^@N;/596@2&<K&#O4$E1UR#CFMN\L+OQ
M!\1%L3K>J6=M/I:7;);7+* Y(' Z 5U*_#W1ETJ[TWSK_P"RW<OG3)]I/SMW
M)^O'Y5:L/!FG:?JT&IQW%\]U#%Y"M+.6'E]E([B@#D[&*3Q1:^);RZU&^ANM
M/N)(;01SLGD"->&P, EN<YINA:M?ZIJ?@F]N9IEEO(;I;E5D(2;RU(5BN<=L
M]*ZZ^\%Z5>W]S>![JWDNU"72V\Q19P/[P[_6I-6\'Z1K%G96TL<D"V1_T9K9
M_+:,8Q@$=L"@#A9K[5K32_&WV&ZN6^S7ZHFZ5F,41/S!,G@X-:VB6K7'C>.X
MTJ[U%]#6R$CJT\GE>>3T^8_,<9)'8TSQ-X(MM.T"[31-*N+LWEQ&UW&MPWF%
M <DIDXW<=?<U2\.^&KM]8BFLH_$^EVZ@_:3J-VI#C& B+R2<\[N,8H P[&TN
MM/\ A]%X@MM6OXKB'43Y<*S$0A3-M(*=#GD\U[=7*#X?:0-%;2!/J LFE\XQ
M_:/XLY]/7GZUU$,?DPI'O=]H W.<D^Y]Z 'T444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% &1H(_Y"?_7_ "_TK7K&\/YSJO)/
M_$PE_#I6S0 4444 %%%% !1110 4444 %%%% !1110 4T.I) 8$CJ/2N=\?Z
MA=Z5X$U>]L6*7,</R,!DKE@"1[@$FO/--T>RT[^S?$8\5VUI ;4B2*RB823C
M822V7;YASR1U% 'LHD0L5# D=1F@R(#M+ ,>@)KP?3W%EJ_@W4+9(K>&YN'S
M<O<9N;I3U:;' !],FM'08-"\3>'IM8UG56M=;MK]II;A9<31[6^5%!_AQ@ "
M@#OM$\37U]XPUW1[Z&VABT\1&)XV)+!\GDGVQVKJ\C&:\<U#1-.U[QKXXEOH
M7<6MC')$N]EP_E$[B >O ZUVWPUNIKOX<Z++<2-)+Y)4LQR2 Q _0"@#JC+&
M&VEU#>F>:/.CQGS%QTSFO&?L<>F^([6\U6UAU+3;K50]MK-LP,JN20(I0>2N
M1@CVJE<?V?;^ _'=I(8$,&J/]FB)'R'< -H[<<<4 >XRSP0@-+*B G +,!DU
MS.I>([ZQ\?Z-HJI:_P!GWT,KM(<^8"BD\<X X%<%I<VD:]XDFTOQ+/%Y T:W
M%CYS!40% 79,\;LGK[5:N=+T74?$7@;2EEFU"P6&Z7S9F/[Y%!VC/&1E3[$8
MH ];BFBGC$D4BR(W1D.0?QI/M$/F^5YJ>9_<W#/Y5P7PQC2TN/%&G0#9;6NJ
M2)#'V1?0?E6=XZB@\'^,M+\9Q6>^&0M;WH1 221\K#W[9]J /3/M=L8GE$\7
MEIG<^\87'7)[4"\MFM_M"W$1@QGS0XV_GTKQO6;)M(_X1>ROI;?3K349I;N]
M>6#?#Y[<JKKD# R!SP.O:GMX9M!I]U8Z7XLMIW?48YXX&A"V<DQ5F\H8)7D#
M.!P./6@#TS6/%FC:-IPO9[V%XVD6)!'(K%F) XY]\GVIKW.K/XFM!;7.GMHS
MV[,ZDYF9^Q7!Y'(KR#5!87'A>Z%SHD&GZC;:W EVB[6B4L.=A'12!R,UULMI
MI:?&32TLHK86LVE2JRPXV,.1CCCIQ0!Z-_:-CO5/MEOO9MBKY@R6]![T76H6
M5F4%U=P0%_NB60+N^F:\";0](@^&>L:U%#&+^#5F$$ZD[HU$@  ]L9-=)XAN
MK1?&^N6U]'!J37>E1Q6JO+&/(8KP"7("Y/S97UH ]A5U<95@1ZBN6\=>)9/#
MWAZZN+*\L([]$WQQ7+<N.^U<@DU-X&TA=#\&V-B&MWE2/,KVY!5W[G(Z^F?:
MO+Y;S2=3\#>+[C5EM1KWVJ7Y;@CS4P0$"YYP.G% 'KMKKEI%HUA=ZG>VMM)<
M0(Y\R55!8@$XR?4U%J?BS1]+U*PL+B]A$]Z?W8WC 7!.XG/ /0>N:\LU2\TJ
MYDVPSV#7%MH"))/>N'CP4R%A3C+DXR<\>E0Z7-I+I\.)+R2S<+'<+<R3%<#
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MET.%/[)^RVX)MU_=><'4MMQQP,YQTS6WJ6I:1=>)_A[<6=Q:.0S1O(N ?]6
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MMW,7B62\CC16>S<%8[0 =<GZ'/ZU?TSQGH.L7R65E?A[AT,D:-&Z>8HZE2P
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ME92W6E7%I9W+64TB%8YXP"8R>X%4_#F@G0K%TGO)KZ]F?S+B[F^]*V !QV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% &%X;SYNM<_\Q.7O_LI6[6!X8_UVN_]A27_ - 2M^@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXZY/TS7D$=Y/=_##P@UQ<--*NN1)N9MQ #M@?E7K'C/'_"$ZWZ?8I?\ T$T
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M^--0_??:M-U23[&_GO\ N<,O09Z\]3[5U%@]AXJ\5ZA:>(G23[/IUNUI!,<
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M7-J%TS+;PIO<A23CZ#FL/0?'&EZKX836[B9;2+.)%DR-A)(4#(^8G':@!_\
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M5#X@M]%-W$;N9&?:''RXQ@'GJ<\#VH RK[X;Z%?W-]+*;Q5O6WRPQW#+'O\
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M7>[?##IL;,8_F.%C&0/?@UX_:W]A$_@^]M[FPMK<ZD6V!PURJDG<TTG'7/3
MZ]Z]YMK.VL[1+6V@BAMT&U8HT"J!Z #BLJ'P;X:@W>7H=@-TGFG,"GYO7D4
M>127FEVOAOXAV<T]K'))>%K:)B 6_NE!^/:M;2+C2(/'/A:[FELHX6\/)F5B
MH4R@XZ_WLC'KQ7IESX5T&\O9+RZTBRGN)5"O))"&) ^M2S^']'N4MTGTNSD6
MV&( \"D1C_9XXH \1>RTN3X9^*=2:&W?4!JS;)S@R*-Z8VGMU;IUKK=(ELKG
MQWKL6OM \;Z?!]E:Y(V^3L&[:6XZDYQWKNAX1\.",QC0].V,<E?LR8)_*I9O
M#NBW,,$,^EV4D< Q$CP*0@] ,<4 >&VMA!<Z)X.M]4B5X)M:D2/S>"]MN&!G
MKMR37;76D:1I'Q;\.6FGP6MG%]BG+1QJ!N)S@'USD]:[^\T+2=0,37FFVEP8
M1MC,L*ML'H,CBG/HNERWRWLFGVK7:8VS-"I<8Z8.,\4 >9>%-(TSQ%H'BKP]
M<&W6ZDU&Y94P/,C 8;7QUP#C^5:7PY:]UJ:*ZU2!D?1(3IT989WRY^=@?H$'
MXFNHU[2-12VEF\+#3[+5)Y5:>XFA!\Q!G.<#D].M:&A:6='TF*UDF\Z?+23S
M$8,LC'+,?J30!QGQ?$2:-H\\JH$CU2$N[#A5YSD^E4])U/3;CXC:^=3GM7L[
MJRB-C))C8T 'S!">,=<_2O2KJSMKZW:"[@CGA?[T<BAE/X&H+K2--OEB6[L;
M:=8?]6)8E8)],CB@#E/A/#/#X+Q+N^SF[F-H&_YX[OE_#.3^-<+K6H6J:EXT
MT%[NR=M1NDQ=7<PC\GCD8/+!<8&*]Q1%10J@!0, #H*\\D\$Z\FIZC(I\/W\
M-Y.TOF:C:,\J9Z 8Z@   9[4 8=YIN@R_$7P?8?Z%>68TUT)PI64A2%)'0D]
M17/>+;K2X;3Q;86,EOI:13QP_9 I>:[9,#//W(QVQ^=>S:+X6TO1K""!+2W>
M6([O.:%0Q;.<CCCGH!TK1DTRPFEDDDL[9Y)%VR,T2DN/0G'(H \IT*ZT'5/B
M/93.UC<0KH" M+M($@QGK_$!G\,US]M=V:>"/#DIEC6"U\0MYS'[L:[B1GT&
M*]T_LC30V[[!:AL;<^2O3&,=/3BE&E:<(#!]AMO)9@QC\I=I(Z'&,9H S?$M
MS:3^"-4N-\;6\EC(R.V-IRAVGGWQBO(KK2[)/A;X:UBUM5"PS1C4IK-1YOEA
MB?F('.#@\^U>[36\-Q$8IHTDC/5'4$'\#0EM!'&8TBC6,]550 ?PH \A:#P7
M?6FNW\.KZK=V]S:QQWU^SY6,F10@QM'(.#CL :S;RXO'T+Q7I<TEIJ[Q:9&R
MZM:CYI$#C:CX.,@9/K@5[8FGV:6S6R6L"P-UB$8"G\.E.@L[:VB,4$$449ZI
M&@4?D* /';K4/#VLZ[\/U#V4\$<;QW <#&X1J &!Z\].V:U-0MK2+XF:AIVD
M-;VMQ)X<D@AB@VQ@3%B57 Z'&#7IR6=K&H5+>%57@!4  IWD0^:)?+3S!GYM
MHS^= 'DO@_6/#E[H_AW2+G3WF\0:=-Y:VVQE>%LG=(3TVXY.>]8$LK'PAXHT
MVW,ANH-<>ZN;>($2?9U<9/MV_*O>$MH$F>9(HUE?[[A0"WU/>E6WA1W=8T5Y
M/OL%&6^I[T >(ZG'H^KZ7JFH>%;G5]4U-M.99YII3^ZBW+E#\HRQ7=QGH#5N
M[\3:!J>N^ )--EB06LC+-&$(, *J IX]0?YU[%#:P6Z%(8DB4G)"*%&?PHCM
M+>)BT<$:$G<2J 9/K0!R_P 1(]-G\/P0ZE>36*O=Q""[BQ^XEY*NV?X1CFO,
M=7U"\O/"OB".Y%K=M::C:--JEHGR72C^(XXR,#./6O>7C208=58>A&:8MI;K
M;FW6"-82,&,(-I'TZ4 >86>O6$'Q7N-3N[E/[+U33D73[N;Y8P%^\H+8QD@_
M7\:Y*S@N/#T>DZ[/%,_AR+79Y8XRA^2-AA)<>G!(^GO7O<EG;31+%+!$\:XV
MJR @8]!4CQI)&8W560C!4C((H \<\;:KX?O_  9KD^API$EW>6Y:["E1=2A@
M6*J>NT=3ZDUN?#K7([._O?#>JR0-JXD\Y+Q6S]N1_F#;NYP1QZ?2O1O(BV!-
MB;1T7 P*!#&&#!%!'0XH X;XDS+8W/A?4IV*65IJJ27$FTG8-IP3CM_C7G^L
MZUIU]-\198I@4OH+<6I92OFE0.F1^(KWJ6*.>)HY45XVZJXR#^%)Y,6,;$QQ
MQ@=J /(GO])M_%GP^DCGM8HX[!Q,RD!5S& -Q[<YZ^]83R1W7PN\8K:LLNW6
MFGVIR1&77#8]#@\^U>\^1#_SS3TZ"G"&, @(H!Z@#K0!Y!XCU32-2U3^U]$\
M0+8:G%IP_P"/E,6][%SF/#8YR,?C78>&O%^GB/0]"N[?^S]4NK)98[01D(BC
M.%!/3A2<>E=<8(F #1H<<#*CBJ4^C6USK%OJ4[-));*1 AQMC8Y!8<9)(..3
MQ0!D_$#1'UWP;>P09%W !<VQ49(D3YA^>,?C7FUQ)XEGET[QK%!LN-:7^S&M
M<$!$=<1R$_[P+?E7M^.,48& .PH \:UV/3?#'CD)KOV^#1YM,CM;:XM7=5&W
MAD;;U!/)'^->B>"K6PL_"MNFF6L]M8%G>!)V)<H6)#'/(SUQZ&M]T20 .%8
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M&_BMG#6TJCJ  20<D9Q0!U=\UWXLNM%U30[G4K5;:\*7$+XC0!2-_F+G)/4
M<]:J6V@:WI.E:[?1ZA?M-;7+W=C]KDW&0*OSJP!QL;D#N.#Q6W\/6U9O#C_V
MMYC2"YD$,TL?ER31 X5W7J">>O-;6OW,-EX>U&XG8+%';2,Q)_V30 S0-:CU
MSPW9ZO$A"W$(DV#D@]Q^8(K&_P"%B:/_ &%=ZSY-[]DM+DVTY\GYHW& 21GI
MR*7X:64^G_#G1[>XC*2B)G*D<@,[,/T(KS?4+?5;'PIXM\.#0]2FN[K4GN4D
MBMRT7E%E(8-WZ=!S0!Z-J/Q'T;3M2DT\PZA<721";R[>U9BR''(Z<<]>E6QX
MWTB30[#58&FG34'\NU@CCS+*^2"H7U&#G)P/6N.TJZF3X@3:A-IFJ16[:(EN
M"]E)GS%P2N /:L'0(M8T6P\+ZRVCWT\&F/=07=M]G?S(Q*^X.JGKP>H^E &Y
MX,UZVL-?\;ZA?R7=M9V\\9V7C%GC)W?+C)ZD\ >HKJ8OB%I1N[NTN+:^M;FV
MM_M1AEARSQ<?,H4G/7I7G-]I6L^(/^$S>UT._B%Y-;W5NMS"8_-6,@E>>Y'.
M*WM*-O>6E[=:?X(N=*=+"6.6=[9O-,C+@)$!RW.23Z"@#K_"_CO2O%L[Q:=#
M>KLB\W?/!L4C., YY.:SY_%\\_Q#/A==,O/L_P!E<RR*H!)+* X.1A ,\]<D
M<5;^&R2P> ]+M;BUGMI[>,Q213Q,C!@3V/4<]:R=5DN='^+*:JVEW]U:7&E?
M95DM8#( _FACG'3 &: ,'P%XTT_P[HDUKJ7V]U?59HS=>4SQQ98!=[D_XUV^
MM>/-*T2>ZBEBN[C[&JM=O;QAE@#8QN)(YYS@9KS4V>HK\+=5TQ]'U07D^JM/
M'&;*3+(7#9Z>@-7;BT&G^*M6N-4\&76L6NK2+<6<J6Y8H2,>6X/W?QZ4 >LP
M3VFMZ0DT3^;:7<6Y64E=RL/S%>&6L\%GX!UW4_[:NH-9LM4ECLS]L;>0"H5=
MA/(Y;M7MNEJ=.\.VRS6B6YA@&ZWM4+!,#[J@9)QTXZUPOPST6W\K5/[5\/R1
M7AU&6YAFO+$J?+8C;M9AUZ\4 0V5Q=7'Q+\)7-X)8;N\T9Y+F+>0N_;_ '#T
M[UTMK\0=-NKRSC6TO4M;VX:UMKQHU\J24$@C[V1R."1S65KD=]_PMS2;VVTV
M\E@M["6$SK QB$C9V@MTQTR>U<2UKK,D.B7DOA[7'U.TU3S[LK"5BC&XX6%,
M[<=#D#KU/- 'H$_Q4T6#[=_H6K.+"7RKHI:<1>[9/ _7VKM;>>.YMXIX7#Q2
MJ'1AT((R#7C]LFH_V/X_231M6#ZK*[VB-8N&<,"!T'&,BNY\/ZS<1#0=%;2+
M]%?3E:2XDB*+"R *48'G.1^HH ZNO)]2&DP?&.[MM6O6AT^731/Y<MV\:><7
MZCYAS@'BO6*\SN99K;XO76K2:+JD]@-/%J)H[%W!D#9...1C(S0!HZ9J^@>'
MM'U37;34+FXTF2X$<<(W2%91\A6,L>0QQCM6E:>.M.D34Q?PW&F3Z;$)KF&Z
M495",@@J2#G^9Q7+^(+O6'T348?#OAVZMM/2:.23?;%9Y2S%I&C1O0 =NIXZ
M5S-]X9U35=2\26^G:'JEK'J%C"UN]X2=QC8,=[,3RQ7 &<Y(Z"@#T9O%5CKS
M76A7%EJ%E<3V37,2S+L,D6.H*L2#GL<5S/PY\<V5CX6T'2[V'4 \\C6Z7DD.
M86D+L0N_/7D#I6QI'B#6-5M%%SX7N[)K6T=+J6>#+,VW 2$#DY(R:Y%;/4HO
MAQX9TT:-JL=Y8ZHD]PJV;DJH=B6''/WA0!ZEXNMX[CPEJN_=F.UEE1E<J594
M)!!'H:\>$YM? OAV^T'5[R3Q3/(N;=+II3*"QW!D)( Z>E>Q>*)';PEJ0AMY
MYY)K22-(HHBSLS*0!MZ]3^%>8:=X7U.Q\(Z%K^BZ;<6OB+2 8[FUD@,;7<>2
M67!'S<'@CW]!0!Z3J?BB#1OL]O<6\]SJ$D)E:VLU#,J@?,WS$ +G@<Y-5(/B
M!H]WIVFW=DMS=OJ#O'!;0HOF[E&6# L ,=^>XKBM=,UWXFL_%%YX0O;_ $R>
MS%K<VDMJ?/MI Q8,%/4=LCCDU9U/2;*XT73(;CPQ?Z9;23S7$,NF1-YUB<*%
M9PH/+=Q[#TH U=4^)+*=&_L[1]0D2]O&@D#1*'782&0+G[W'KTJW-\4=#@U:
M33)+75!<Q2)'(OV0G9NZ$C.<<CMWXS7*>3XABT?PO?:C8WU[]@U=WRD!\]X<
M$([IUR??\:WO"DTS?$CQ+<S:;?6\5]# \3SVK*/D7#+G&,Y/3OB@"SX9USP[
MI>B:WJ%I=7[6L=_(9_M@._SCC*(IYZD #UJQ??$*U@LM7$>G7RZEIT'GR6<T
M0#[".'R"1MYYYS[5PKZ'K-SX=\0-9Z=>+>0Z[_:D$$T#IY\8/& 1R>#QUKJ)
M-5U#Q?H6LFU\-7%B9--EB9[N'9++*5.U$[D#GKZB@#6TSQO$_AK2KR^M;H7U
M[&OEVJ1#S)FV@LR#.-O.<DBK$'CS1+G1FU*.28A;@6IM_*/G><3@1[?[WZ>]
M>;W-K<S6GA76+OPO?WMAIUG]@N[22 B0$*O[Q5SDC/&?:KM]8W-M_9/B/1O"
M]Q:Z?9Z@9GL4C(GE0J 963/7K@=?SH VO!NHM?\ Q,\2_+J$,8@A86]Z3NC8
MDYP,D >F*E^)>K2:9?Z%]NDNX?#\DKB^EM'*OG V D<A<\G'7FH_#-_/?_%'
M5M0&E:C;V=W8PI'+<6S1C*YZYZ9S70>)M2EL]5T^UN-,FOM'N8IA=^7:F<(1
MMVE@ >.O^10!D:5<Q:)!JFO:?J5WK.A_95DAC$_G-&ZEMRC)R!C!YZ<^E7=$
M\=07?A2QU74H989[HA(XDB.9G).!&.K<#K7,:/X;-MK'B>3P[:W4.AW6F/&D
M,J/&'N"#]Q7P<=>??%9]HNH)H_@O6%TK42F@,T-[ ]N0^&4+O1>K >H_QH ]
M(L?&>C7MO?R&X:V?3QF[AN$*/#]1_AFJ$GBW2]<6\T>-[ZRO'M&GB$B&%W3'
MWT/IQ]:XOQ#H5[XLOO$VLZ+#-Y$NGPP0%XVC^TNKJYP& )X7'3K6]IGBR/7;
M03?\(]=0W-M:2)=W$]J08L+C8C8RQ+8X';- #_ OBF&U\%^'H+Y[FXOKR.0H
M$1I68!R,L1T_&NF\71O)X0U62*>>WEAM9)HY(7*,&52PY';BO*OAZ;[PA)I]
MW<6-Y/8ZE$8KC_1',MG(K''&,["&!_\ U5[%J]J=3T"^M(3AKJVDB4GU92!_
M.@#"\#+)??#_ $^6YNKF::[AWR2O*2^3QP>W2LW0_$6G^&/#,-SK>JW3M<W<
MT227!:4G;(5 X'' '7WJ+P;XBMM#\'V>D:G#=0:G9*87M#;NSR')P4P,,#ZC
MBLCQ+:R:5X(\,6VHQ.9_[7BNKF-8R^ 7=VS@'H& - '9)XQT+6++58H=0DA^
MR0GSW,3H\:D8#J",GV.*QE\:6/ASP]X<BMIKS5$OI$B2ZDB8LZ;L,QXY;KA>
MM4+K4[.W^(VOSL72*;1UB20Q-M9QDX!QR<$5@><(/A]X'O9DG,6F:FGVL^4V
M8L,3R,9QTH ]DO-2M;#39-0NI?*MHTWN[*?E'N,9K"LOB'X7U".5[?54811>
M:X:-U(7..XY.2!@9-:&MW<)\)7]TV](GM'(WH0PW*< KC(/(XKS":SDO?@SH
M<MC9R326$T;74,*E92JL2P&.>X/ZT >ACQUH/V:]FDNVA-D UQ%-$R2(#T.T
MC)!]JCT_X@^&M4U**PM-1#SRH7CW1LH; R0"1R<=JX[S/#>JZ#KNI:'IE]YH
MTR:.:]NGER#MXC^=CD_3IBH1/IOB'1_ ]GI#*UY8SP33ND97[/&B9D+''&3^
M= '=V?CWPS?WR6=MJT4D[LR!-C#E1D\D8'%6+7Q=H=[J$5C!?*;B92T2M&ZB
M0#J5) #?@37!>&K5-4\-^-;2SCB>_EO;I[<E<,RNN%()['D9JMX8N?"VHOI,
M3:;JLVM6( >"5YBMN5&&;D[0O'3\* /1[;Q=HEWJ$5A!>[KB5F6,&)PKE<YV
ML1M.,'H:1?%VAMJ,5@+]//F<QQ91@DC#@JKXVD^P->9Z9,UO?Z?;>&K\ZC8W
M+RA=/NH_WVG,58%E;&57DCGCFE\*-H5Q9Z9HFJ6.K/KUC."+)WFV*X;/F#G:
MHQR>E '?R?$3PI#OWZU -DGE-A'.&_+I[]*2[\<6%KXMLM"VR,UQ&7:81L5&
M<; ,#G.>O0<5P<EWITVB?$)?,MS-/=L8AQF0< %?7D=JO6VJVUAXG\'7]Q.1
M9R:*;=76-F'F@ %> 3G(QB@#O$\6Z))J:Z<E\#=-*857RWPSCJH;&TGCUI/%
M7B:U\+:*]_<@NWW8T /SMZ9 XKSBQNX[+7].;P_J*WUA<ZD?-T>Z&9K20D[I
M$_B ')STY[UV7Q/5C\/M1*(SE?+8A1G@.I)_*@"E?^*$LO&^E7$NKF+1+NQE
MD*2#:@=3@'D9_ UU=MXATF[TG^U8+^!['D>>&^7.<8^N>U<%=>(M"U7XC^&;
MN&\MY+=;:9=\GRA7(^7[V.<]*YB6=!INI3VSR2:?:^(#<74=H_S+$1@.,=L]
MZ /9]+US3=:64Z?>1SF)MLBKD,A]P>16A7"^#O\ A';W7KK4]$NK^_EDMU2X
MNYW8J2#PIW 9;'IT'UKNJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#"\-_Z[6_^PG)_P"@I6[6!X9),VNY[:I)_P"@)6_0 444
M4 %%%% !1110 4444 %%%% !1110!%<VT%Y;O;W,,<T+C#QR*&5A[@U7M-)T
MW3XY([/3[6W27_6+%"JA_K@<]33-;UFS\/Z3/J=^SK;0C+E$+'\A7G^N^/\
MPEXG\/7-O-+K$-LC1N9;>%D8\\8;IC/!S0!Z&='TPZ?]@.GVOV/_ )X>4NS_
M +YQBI8K2TM+06L-O#%; ;1$B!4 /;'2L>^\4Z?I<T%C'#=WEPUM]H$-LF]U
MB'\39(_Q-<'X\\3:?XA\'Z;K>FS7L=O!JT49<JZ!AR6^7^+&* /4(=*TV"WD
M@AT^UCAE.9(TA4*_U '-(='TPHB'3K0HA)5?(7"D^G'%<O!\1[&ZMM5^SZ;J
M(N["#[1]FGB$;RIV89/3U]!5_P ">(+OQ'X4M-1O;=XYY 2S%0JOR<%<'IC
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MK.]%$MQM,<BY!4\= <'/?TKH?!_B2]UQ]4M-3M(;>_TVY\B80.61LC(()YH
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M@#G_  Q_K]>Y_P"8K+_Z E=!6!X8'[_7O^PI+_Z E;] !1110 4444 %%%%
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MEO86EG]H#$L^0SLPX ^8\5Z16)=>*;"S\3V?A^03?;KM&>/$?R8 )/S?AVH
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MHHH **** "BJDNJ6,&H0Z?+=Q)>3@M'"6^9@.N!^%6Z "BBB@ HHHH ****
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M&OK>;_B97!8[IT;EAGOR  /2M?7]%UNY\?:-K-A802VFG1.GSW 0N7&.!@X
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M:]TJW>VD-XK%71^3C'/!S@4 16/Q U6739(YH+1]3DU@Z5;E%98\]=[ DG@
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M7B/Q1;:OX5;5KVUN;77H"?(B@"&(A P.[N>1GM0!Z5!!%;0)#!&D<2#:J(N
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M4T<&DG4;.X)'FQ%3]UFQ\P/O4R:QJIA^']S_ &K,6U(B.[ QME^3=DC'7/\
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M?45"0B/RRAQM7VX[U%HVK>-[RYT?4(K:>XL;P![Q)Q L2(PR&C*G< !V.2:
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M]<?1/#UY<VES9QWT<+2Q1W+#Y]O)P,@DT 95E\,M&L-7:\@FO5M3*)Q8"8B
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MN/O>GU]J *^L:/8Z[IDVGZC;K/;2C#*>WH0>Q'K6#:>"IK>V6PF\0ZG<Z8@
M6UD* E1_"SA=Q7VS769&,U!+>VL43R27$2I&"SL7 "@=2: .?N_!L;>(3K>F
M7\^F7;P"WF\E$994&-N58'D  9]A56\^'EG/::5;6M[<6::;-]HC\L*Q>7.2
M[$@Y)/\ .M_1==LM=TF/4[.7=;2%@&;CHQ'/ITK161'7<C!AZ@YH Y!O \HU
M36-1CUF99]5@\B<>0A &,# ]A7'^(-#3PZO@S0(M9E5[.]=TNO)!,*L#M)'3
M&[CGUKUF>=_LTYM3&\Z*=JL>-V. <<U@^!O$-QXE\+PZE?QPQ7#RR1LD>0!M
M<@#GZ4 9U_\ #J'5=.U!+[4[B74+UXW>]"!2IC^X%0< #)XJO)\.+R74)[]O
M%%Z;NXM/LL\C0(?,4]1CL/8?G7<W+3+:2M;(KS!"8U8X!;' /XU3T*XU*YT6
MUFU>"*"_=,S1Q-N53GL?IB@#EC\/KH:3HE@->81Z-*)H#]D!+,I^7/S=AD57
ML'TKQSXULM6@LKA?[%1TDFGB,>^0G"J >NW#-[9%>A@YIH5$X4 #KQ0 V9'>
M"1(G\N0J0KD9VGL<=ZX)_AM='PI+H"Z[B&2Z-R7^R#=N)W8^]Z\UZ!N%4[[5
MK+3I;2.ZF"/=S""%>[.: .?E\&W%]XACU74=42X7[$UE+;K;;%D1ASSN)!R<
MU1T;X?7NE/':R>)+RXT:!]\%B4"[><J"W4@'M733ZU$SZC:V!2XO[*)7>$MM
M&6!*@GG'2JW@[Q#)XF\,6NK30+ \Q?,:G(7#$=?PH Y)/A9?)I]M8IXHG6WL
M[O[5:H+9/W9SGGG)/XX]JTK[P'?:G$]C?ZX;K37NOM.R6V!F3YMVU9,\#\/T
MKN-PHW"@#AM3\ WMU?ZO+8:]+96FJH!<6X@5\L%VYW$Y QU%-L? .HV.J:)>
M?V\LXTF$P1+): %D(P02&].A_G7=Y%&X4 </>^ []/$5UJN@^(9]*6^(:[@6
M(2!V_O+D\'DTZ[\"WMOK$.J>'];DT^X,"V]SYL8F$RKT8Y_BKMLBH+6^MKWS
MOLTJR>3*89"O0.,9'X9H Q/!WAFX\+:9+93:B;U7F:4$Q!-I8Y(X/-='29K.
MUW6;?0=&N=3N0QB@7)51RQZ ?F10!I45@:/JVLW6IW%GJ>C&TC1%DBN8Y1)&
MX/\ #G .X5OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!SWA?_7Z__P!A67_T".NAK \,8\_7O^PK)_Z E;] !1110 44
M44 %%%% !1110 4444 %%%% &5XDM1>^&]1@:6:(&!SNA?:W )QGT]:\9BM[
M_3/@WHVI:;K6I6T]Q<K&8TN"$&Z1@-H[>M>VZQIW]KZ5<6'VJ:V$Z[6EA(#@
M=P,^HX_&N5D^&5@_AZVT+^U]4%A;2B6*/?'P0<]=F>I)H P?LE_9^,--\%7>
MN:C=65PDMY+.\I667@XCW#D*"">#WK#UB_U;3M \9:/'JU]LTBY@:UN/-/F;
M9#RC-U(%>HZUX0L];%C+-=7<-]8_ZF]@<+,.,')Q@Y^E4I_AUH]SH5QI4EQ?
M;+J83W,_F@RSN.FYB#^0 H XRYTF\A\=:'I?_"2:J1JM@SWK-<'+8&?D[+G&
M.*Z/X57-X^E:O9W5W-<K8ZE+;PO,VYM@P0"3]:U'\!V+ZOI^J-J.IFZL(A#"
MWG+C:/4;>_>K?AOPE9>&)+Q[.ZO9OMDGFRBXE#@OW88 Y- ')#3()/CU-(S3
M973%G&)6Y;>!Z]/;I7&?9)=/\$:AXBM-4OH;RVUJ0111RXB&90#E>^1Z^U>N
M:QX)TG6M:AU>X:ZBO(X_+WP3&/<N<@''7%9W_"L=$&CR:4+K41927'VAXQ<#
ME_R_&@#D[Z'7/&7B/Q):07MM$]@Z0VOFW4D36XQGS%5.#GGDUZ!;KJ,G@(I]
MLCO-2-BRBXMVR))-I *GZUFZK\,M U?4(;Z=KU+E(UCDDAN"IG4#'[P]2??B
MNLMK6&SM(K6W01PQ($1%Z*HX H X#X-RPR?#V*VA;9<PS2I.".5<L3DCZ8KE
M=5UG7-3\/^.//U9T.D3B*,6D8A,IW!=SD<G@8Q7H]UX#TN74IM0L[C4-,NK@
MYG>PN3'YI]6'(IB_#S0ET.\TG%T8+V42W<AG8R3L.?F;OS0!P]_H:Z-HFBQ?
MVSJM[<:O<02/8F7FYPH)3=D;%YY-9$\M]#X!\;6[SRVQL-2C$,4-RS"+<R@I
MNZLN#W]*]1U'P#I&J:5I]A=2WK_8#^XG%P1*H]-WIT'X50;X3^%66X18+I([
M@@R(MT^"1^/////>@#G;31HM,\=Z=I8N[J>VU31I'O$N)V?SF Z]>/P]*U/@
MQI]M;^"4NXX@)YI9%D?)Y 8X'M70)X%TI=8L]5::_DN[1!'$\ETS83^Z1Z'N
M*M>'O"6E>&&NCID<B"X?<RM(6"]\*#T'- '+:@I'QWTAL<-I4N/S-4?B(\>H
M?$'P;IUF2U]#="XE*')BB!!)/IT)_"NLU#P)I&IZRVK3RWPO2-HDCNG0HO\
M=7!X'M5[2/"NC:'-)/8V:K<RC;)<2,9)''NS$F@#Q>ZG?_0M<L)W=9=>"#4Y
MI2L\V6P45 2!&!QR>?2M&9H-!U+XAZEIT217EKY2VKH>8_,7#$?GFN]D^%GA
M&02@Z:0))/, $SX0YR=HSQG':M%/ _AU-7?4QIL7VAXA$0<E"NW;]WITXZ4
M<+X4T&6TUG0M;@\0V"P7$7EM! 7W79*DG=DG+#J3[5ZQ#-%.F^&19$Z;D8$5
MSFC?#_PWH-[-=V%ALFD5E!9V;8IZA<GY<_G6MHNB6/A_3EL-.B,5NK,P4L6Y
M)R>30!HUYOII8_'G5]V<#2HP,^F5Z?K7I%8-OX.T.UUU];AM9%U%R2\_VB0E
MO8@M@CVQB@#CO%6D6NN?&'2+&\$AMWTJ0NL<A3=AFX)':N-BU&XB\.Z5HRWP
MCT]]>N+>5[@EHPBD&-'.1\A))(SVKV6[\(:+>ZS_ &Q/;2G4-FP3K<RJ0O3
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M*A_X5SX5^Q)9_P!F?Z.DOG)']HEPK_WA\W!H V-9MH+C0+VWERL)@8':Q7
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M]>O8XTO-6O(KJ(28+1J74(H/7A!^IK=U*\MIOC9X=:*XB=?[-EY5P1SNQ^=
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M(VGQZC"U^J=X<\Y]LX_2JERMO+\6=%N]&:)K>33Y/[0,)'E^5C]V6[=3Q]*
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M#. 2YVAGZ#-=MJ_CG0]%N98+N:8F#;]H>*%G6#=TWD<#- '0QQI%$L<:*D:
M*JJ,  = *RY?"V@SWAO)='LGN"<EVA4DGU/J?>KR20ZCIXD@F+07$>4DC8@E
M6'!![=:\6LKVZ_X1;Q)JESXMU.WO-/O)8K0/=E@VW[J[#][)XH ]EO=)T[44
MC2^L+:Y6/[BS1!POTSTJJWA?0&=G;1=/+,,%C;)DC\JR-#\5/#X%TK5O$(>*
M\N45?*1"7E<DA0JCDD@ X]ZEB^(&@2:9?WS3RQ)8R"*>*6(K(KDX V]<D\4
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MSW$TYOI82\TI<;5/ &34>GZG8>$+GQ7JEZU]);6]\L*HK-+L4HK< G Y)YH
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M%% !1110!SOA7_CY\1?]A>3_ -%QUT5<YX4_X^?$7_87D_\ 1<=='0 4444
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MY5Q;20&-KE,Y88(^;KP>_/I0!Z)J_BN+1OL]HUM+>:I)%YIM;<KD*/O,2Q
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MVE5*CD#CDG&/>@#I+;QC?6OB/3]'UW38K-M2C+VLT,Q==PY,;9 PV,>V:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S_A?_
M %^O_P#85D_] CKH*YWPKG[1XA_["TG_ *+CKHJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH12U7L(WBL+>.0DNL:JQ/<@#-6* "BBB@ KROQ-XTU?4_B!;>#/#EPMFX/\
MI5YL#L/EW$*#QP/UKU2O#]8TZX\$_&6/Q+=PR/I%Y(Q:X121$77!W>F#S]*
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MXQZT >IO\0?#<6D_VE)?[+<3&W8-&P99!U4KC((R*M:-XQT37[VXM-.O!+-
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MGTCQ )?[+O$N##@2J 04)[$$<'BO%HM<M-$TOX?ZM$Y::UAGAE216V#C# D
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MG(P,DGWKIO#/C'1]7MK2QCU6&XU 6B22KNY)V_,<]#@YSBO,Y-5L].\*>/\
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M>V:DU/Q)H^BB,ZCJ-O;"093>_4>OT]Z\E+:!:ZYXIT?Q5>7UB)[G?#$G$<\
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M)Z]J[[P]XN\-)9:-I<&IVHN+B!%BC3HS!1D9 QG/ZT =?1110 4444 %%%%
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M@L[J)@%>VD)X# GGOT]*U;KQG;V>MZCI<MA>>=96?VW**K"6/(&5YZY/?T-
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M7*>1%>21?N7D&?E#9R?3I6GI6N>'M/U;Q;J*"^ADM6C?4#<9VYP0H1<_YR*
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MFN+U DL<@0)@?=QA0>*Z*@#R#6K/4KBW\/3V_A.2Q5-6CO'M;.VYCA7C,FT
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M=U/?ZG<1)<!1Y";B 2S9XP.>GI2ZUX<\0(][HTVAW&K6B:=%;:;-&X2*(K&
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M)[5M>(]+U"?P+X9U.VBDT_7=.>""))L"1M^(RN!Z\''H#7J]<\W@S3)/%?\
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M(90P((/((H 6BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110 4444
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M$+?)\I*A ?KR33O&^IZ];>+_  Q8V$ENEK=7#'#,P+NHY#X_AP1T[_2M#1M
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M5=%@TV]O7S;>=/NC\K;DLVT%L@X&,=_:MCXCZ+J7B'P;<Z7ID*2SS.A^>0(
M P/]*SO$_A_Q#=OH.OZ1%;+K&FH4>SE?,;JP 8!N/3]?:@""P^)TUYIJK_96
M-5DU 6$,.YEBD8C(?<1]W&<]ZNW/CR]T73M9GUW1V@DL)$C@:)B8[LO]T(Q
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M&N990I+-)D="1P!CK69_PF&LW7AKPYXJ^WRP67VE;;5(4C7&-V-X)&0#W^M
M'KE%>::[XIU2QMM3U.PO&GM[F^CT[3UPA56QB1QTSR& R<5##<^.K&VUWS7N
M8;&*R:XM;J_$4DJR(,E2$."",\D<4 >HT5XQJ&J^.--\ 6_B63Q)"_VI+<I
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M"S5'TA]&C\2;-+6Z^T00FU!8<Y^9L\XK6_X0O61XBU36/[8M6DOK,6;(UJV
MH  ;AQSQGTYKNLBLB#5-0D\3W6G2:5(FGQ0J\=\6&UV/5<?C^E '.VGP^8_#
MT>%M1O5E\IBUO<0QE#&V2RGKS@D_@?QI;+P+J%YIES9^*==EU57@,$*A BQ#
M^]Q]Y^G)_K7<9%&10!YK#\-]=-SH[W7BPRQ:1(&M4^QKE0..3GDX '.:[+Q1
MH$?B;PW>:1+,T(N% $BC.T@@@X[]*V,CUHR* .*MO#ESIYMM8\2:DM__ &-
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M<&@Q:/'#]LMFN5O$VC?CKP!G\ZZO(H 6BC.:* "BBB@ HHHH **** "BBB@
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MBU.)[W4RFJ,'NQ]HQYASGT_R*?J_PYT/6]/L;:[-UYMBNR&Z27$P7^Z6QR*
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MI9BK-$O\/F8R,GOC->AVWP]L+;4K'45U/5FNK*/RXG>Y#?*>H.5Y!)/%0O\
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M.O3'3-=#>^&;/Q!\8M2LKJZO4@73X[D+%<,/GW#]/:@#UO<H."1GTS064=6
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M %%%(2 ,D@"@!:*S=3\0:5H\5M+?WT,$=S((X69N'8],8_GTK1!R* %HHHH
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M_A%2-2\4,>AU9\?]^XZZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4UY;QVD;*RLN<)DDYSC&<>E5+CX:Z^VB:IH=OK%DNF7EVURBO =ZDL&Y(/\
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M*^U)"S1><P5 V.,D]!0!?HKRG1/%FN7'BFTT==8^W)>:>\S7#VBJD<P!),9
M&] 1CTK+L?%OC >%['Q/<ZS#);#41;2VBVJ@R*6P26[>P% 'M5%>:3>)=5\/
M^,]7L]<U1S8/9-<::?*09/'' R6!X%=OH,6H)H%JNIW+37[1!II"BJ0Q&<8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[NK=7M9-2D>X3S1DPQG/E@CV!SCWJ]X$;6GT6<ZU=M=R?:7\B=HO++Q<8.W
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M(A<R7%C* =DD+G.W/9E.<BKD/@/2(KS7[G9N?6E*39 ^12,$+]3\WUKJ<44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %;4/M9T^<6!B
M%V5Q$9<[0WJ<5Q_A^X\16'CBXT74M735[3[$+DR^0L30,6P%(7UP3^%=A?W]
MKIEC+>7LZ06T0!>1S@+SCG\37G=CINGK\5;34?#5VTT%Q;R2:F(I3)&.,1DG
M)Y))X]J /3:*!THH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH P/#/^NUW_L*2_\ H"5OU@^&O];KG_84E_\ 04K>H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH CF@BN86AFC22-QAD=001[@TVWM
M+>TC\NV@BA3.=L:!1^0J:B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Q] 15;52.K:A*3]<*/Z5L5DZ&,?VC_U_2_T
MK6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#,T88%_P#]
M?DI_45IUGZ4I7[9D'!NI",]^:T* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH @M?\ 5-_UTD_]#-3U% NU&'^VQ_-B:EH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **3(I: "BBB@ HHHH **** "BBB@ QS1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M7KNL)HNG^?L:6>1A%;PJ.99#]U:S+_X@^&M.NWMIM0W2H2'$2,X4^A(&*P_B
M!KUFOA_2_$&G31W9M+U)HD0Y$@ .X''3B@#2MK632576O$VKSF[=LK!'(PB0
MGHBH/O?Y^M==$YDB5RK+N .UNH]C7(^&M*GU>6'Q-J]PEQ-<1K):P)S';HPR
M,>K8[UV- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MER/<;B<'Z4 4?!>DSP^"+;3]7BW@AP()OFVQ%B50Y]%P*Z6""*VA2&"-8XD
M5448 'H*DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHIKRQQXWNJYZ;CB@!U%5IM1LH%W37EO&O3+R@"D74;)V 6[@8E=P
MQ*.GK]* +5%(K*ZAE((/0@]:6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#PWQC\8]>\/^+M2TJUM;)H+:78
MC2*Q8C ///O6%_POOQ/_ ,^>G?\ ?MO\:** #_A??B?_ )\]._[]M_\ %4?\
M+[\3_P#/GIW_ '[;_P"*HHH 4?'WQ)C_ (\=/_[Y;_&G#X^^(^^GZ>?^ M_C
M110!*W[0&N'[ND6"\Y^\YX].M2C]H36>^B6'_?;_ .-%% "C]H35^^B6/_?Q
MZ</V@]5_Z 5G_P!_6HHH !^T)JF>="L_^_S5*G[0E\#^\\/VS?[MPP_]E-%%
M $W_  T%<\_\4[#_ .!9_P#B:LQ_'FXD(_XI^(9_Z>C_ /$T44 6Q\<FW$'P
M\#]+S_["FI\<W8.3X>7CIB\]_P#<HHH LI\:]Z!O^$?QG_I]_P#M=/'QGRN?
M[ [_ //Y_P#8444 68_B[YFW_B1XW?\ 3W_]A6CIOQ(_M"[$']D^7\I.[[1G
M_P!EHHH T-/\:_;[=Y?[/V;7*X\[.?\ QVK\?B/S,?Z+CC/^L_\ K444 /&O
MY;'V;_R)_P#6J0:WG_EW_P#'_P#ZU%%  NM;O^7?O_?_ /K5JHVY%;&,C-%%
M "T444 %-=MB,V,X&:** .=U+Q9_9]E+<_8O,\L9V^;C/Z5R<_Q@\G'_ !(M
MW&?^/O'_ +)110!D-\=IP0!X?C_\"S_\133\=[@8_P"*?C_\"C_\3110!!)\
M?KE" /#T7/\ T]'_ .)I3\?;D-C_ (1Z+_P*/_Q-%% #3\?[@-C_ (1V+_P+
M/_Q%2I\>KAO^9?B'_;T?_B:** )'^.UPFW_B01'*Y_X^C_\ $U$_Q[N%Q_Q3
MT7_@4?\ XFBB@!G_  O^XY_XIV+_ ,"S_P#$4G_"_P"X_P"A=B_\"S_\1110
M!(/CW<$?\B]%_P"!1_\ B:0_'RY!Q_PCT7_@4?\ XFBB@!7^/=PH)_X1Z+_P
M*/\ \34#?M!70./^$=A_\"C_ /$T44 (/V@[K_H78?\ P*/_ ,31_P -!W7/
M_%.P\?\ 3T?_ (FBB@!#^T)= C_BG8?_  +/_P 32/\ M!W@R%\/0 ]B;HG_
M -EHHH /^&A+L]/#L'_@4?\ XFF2?M"7^1L\/VP'?=<,?Z"BB@!I_:$U$@;=
M M0<<YG8_P!*:?V@M5[:'9_]_6HHH 8?VA-7SQH=C_W\>F2?'_7)&4)I-@G_
M  )S_6BB@!G_  OGQ#U%A8 >F&_QI/\ A>WB3&19Z?\ ]\-_C110 UOCMXF!
MP+33^N/]6W_Q51GXZ^*6.!;Z>.>HB;_XJBB@"(_'#Q:TP %BH8XP(.GYFKD7
MQB\5RK< R6@:(9!$ YYHHH SA\;?&)DV^=9_>Q_Q[BI+KXP^,!.D(N[<*W=;
M=01110!+'\3O%[L%_M51D9SY"?X5<T?XC>*[O6[6UEU,%"<M^Y3YL<XZ444
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/W=.V-HHHH [&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sgmo-20210331xex103004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK9?2;=C[Y_QK>HH P(_!/AN+[FDP+],C^M//@[P^2"=,BX_VF_QK<HH P_\
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M]FV>1R#Y"\?I0!PGCS37\-W>E>*M"M(DEL<VDL,8VAXW^51@>C&NCBTR/1/
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ME7]Y:L<AG'H ,GFO4-,TZWTG3X;&U7;#$NU1_6I5L[9)6E2WA61NKA "?QH
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M"-(O[?7+NRNSNL=#D>&R)[^9S^BX'_ JT/BE;2S^"Y'B!(M[B*9P/[H;G^=
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MXM']F7LRZA:HL#P0EE)$94Y/U-4?LM^= \%VBZ;>>;:7*R7 \ELQA3CGCWH
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MO6</BGX?,/G+'?F+<J;_ +/\N3T&<T =K@>@K*U[2+K5[2."SU2?3B) TCP
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MEMK$G SC\ZUM3U:'QAX2\07&CZ+.HELF1KB6$)),X(P@'5@!FO2L#THP!T%
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ME6M3M+6+QAJMO:(BZ<^CO)>1J (Q(,[#CH#Q0!Z!#JNGW$R0PWMO)(Z[E1)
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M3A\,6ULHFM(=16V$LJC]XB 9^J\_2GV\&DIXW\6B6WM?)@LQLR@PAVD$ >M
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MJFNOAKX9N_$!UJ2T<7+/YCHLF(W;KEE[Y[UT,FKZ;!O\[4+6,QL%?=,HVD]
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M2>;''Y*X5O6@#S6[\S3]6^()T,K%+]CADBCA& <C+,,=P"?SJ35+73_^$?\
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M*W2_5-L4_EC*$#"_@../:O/+'P)J36SZ?>^'-(,CELZIYI+<DG=M');GCH*
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M[9[N=-JH0,?(?XB3^5>@T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!#:_P"I;_KH_P#Z&:FJ"T.821_ST?\ ]#-3T %8
M/BG_ %6D_P#84MO_ $*MZN?\6N([;2F/0:I;9_[[H Z"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#@;'4]2\:>(M4M[74)M.TG3)?L^ZVV^;/+W.X@X4
M>WM6MI4>MZ3KM[%JFIF[T9;998+B9$1HR#AE=@!DXYSZ5RWAJ\M_ 'B36]*U
MQC:VU]=&ZLKR7_52 ]5+=F'O5WQOJTGB7P;JD/AU);J.-%:2>(?+( P+(O\
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MYM/\/O)-#,W 8R?<)]@I8^V:Y=CITOPO\3L_V8WG]JLR/QO/S @@]>F['XT
M>O"X5_&Y1?$$9"VNUM*&TL#G._U'!JRGBC1)]1&FPZI;->,2JQALY(Z@'H3[
M5Y[JEU;S>/8WTN>%KN?P[(J/"X+/-SM&1U; 'O3/".N>&;S0M"TJ\LW?7M/G
M"I:^6RR)+NY?.,8QR<^E &SX5\:0VMSK=KXDUV'S8=2:" S;4)48[#H*]!,B
M>49-R[,9W9XQZYKQ&1M*NO#_ ,1&8VIF-VQAD8*2WH%/7J.WK7JOA:>*?P9I
MDAE22/[(@=RP(X7!R: *F@:C#9:)=WE_XEM]3MTN'_TH!5$8)&$X)R1G]<5L
M:7K>FZU'(^G7:7"Q-M?;GY3Z'->2:1_9%QX*U:TGU(:>IUUC;7$0R(7SE&([
M+P:[#X=WUW<SZU!>I9SSQ3KOU&S $=U\HP>.-P'7'K0!TFJ>)]%T:98=0U"*
M&0@':<D@$XR<=![FLW4O'6D:;X@L-)DF4M=QF3S@?D1<94YQSFN#\9ZG;'7_
M !-:K,--D^Q+&^8R[WIQD 9X '3(HTS5=/CUCP!?2SHL*:?) \I!XDVXV_7)
MQ^- '=:+X]T;6+C5$6X2%+"0@O(=H9 !E^1P,G'_ .NM;2_$>CZT\B:??Q3O
M& SH,A@/7!P<>]>57VLZ=I</CFRO+7[3/-J.];?#+E,C#DCHH.#[U56\6X\2
MZHEGJXO[FZT1H()8(2@:3C"* /0=: /6X?$FC7]VVGVFJ6[7;!@BJ<Y(Z[>S
M8]JY7P9XWMAITD/B'6HO[0:_EA0285B 0 , 8 JGX4UWPQJ6G^';<P$ZQIZ;
M1%L93;G&'=CC&,9//K7)L^G3?#/Q#._V?[;)JY=22/,/SJ1SUZ;OUH ]GU+Q
M%I&CNJ:A?PP,PSACR!ZG'0>YI=0UO3+"T2:YOX84F'[I\[MWNH'7UKRBZN-(
M7Q;K">(K^^M;'48(9+9X')CGBV#Y3@'/-7=+O+'PSXPTR2^BN;31VTSR=/DO
M"6V'<2<GL2/IU% '4?#;6+K6=*U*6[U WK1ZA)''(5 _=@#;@ ?6M[4O$VBZ
M1<"WO]1A@E*[MC9) ]3CH/K7(?"FYMID\0);L"AU%Y$ ! V-T-8?B[4;=]>\
M5VQN1I\GV)(ROEEY+TA3C']U1P./K0!Z;?\ B/1],6%KS4(8Q,GF1\EMR_WN
M,\>]78IXKVS2>VF#Q2INCE0@@@]"*\;:^L[G3-,O]+UN.SU>STE8Y8+M/W5T
M@',?S<9R"./6O4O#5V;CPIIUS+:BRS;J6AZ", =L]!Q^5 '*^&[S7=7GUY+O
MQ+) NG7KVZL+>$#:N>3E:Z"QUR'2=/LH->U:"2[N6(AF"X$X+?*1@8!P17G_
M (4M_#.J7/BEM8N;0//J,OER2SA,J<\KR,UM:Y=:/KGA.TT:Q;S)VG6UTR7<
M%)>, >:#_='(SW[4 ;GBW7U/AG7/['U(1ZAI\>Z3RU!*'T.1]>E6O#OBO2=4
MMK*S35(9M1-LCR1[OF)VC=]3ZXK@+;6K5/AOXDT>^D2+6K994N6>3+7#YP&!
MZMV%3BXTJ/5OA])!):1%(6$IC*@#Y%'S'ZYZ^] &IK.J7=GX)U[4=.\4?;IH
MKDLLL2K^Y!('E]_7J*Z70_%NBZLD=K#J<$MXL*O(F<=N3SUKS>(13^$O'T%F
MR2#[8SHL?.4SU ]*V5@T[4-4\&MHAMS-8H);N2WQB.+8-P<CH2<\'WH UD\5
M67ASPU?ZE-K9UD?:I%B*KT;C$>>>!GKTKL=/OX-3L(;RW;=%*H8'!'\Z\;CE
MBG^%GBN*(H^S4VD 0Y(4R+@_3@_K7K>CZG9WF@6]]!.K6WD@F4Y484<GGMP:
M .<^(7BRZ\.6EM_9RA[DN)95VYVP*?F)],D@9KKK"[BO]/M[R$YBGC$BGV(S
M7!V=C-XRFU?5+;6(X;>Z#62Q^0)2L(X[D;=QR?RJO\.?$MMI^AZAHU[<[VT8
MR%74%O,A!SE?7']10!Z97/>-Y[BT\(:C=VEU+;3V\)E1XR,Y';D=*UM-U&#5
MM.@O[4L8)T#IO7:<>XK"^(<T47@754D<*983'&.[,>@'Y4 8^F137/AK2[@>
M*;Q-2NXXRBRS!E>0C.TKC..#73CQ1I(U"\T]KDK=641EGC,3#:@ZD<<CGM7$
M:)>^$=/\-:1=-'$VJ6L2,L=NA\UY<8VG YY/>H?&\)UN]>]T^!%NM(A5[T,Y
M7SE."8>,;@.?Y4 =\_BC28],M]0,[^3<G$($3EY/HF,G\J2+Q7HDVDC4X[Y#
M:E_*SM.[?_=VXSN]L5P&N:K:WFH^'/$KQ7@T86[P3+:EE>VD/8[<$>GN*AO8
M;/3X])\0Z-I-TND6FH--.7W%Y@5QYNUN<#D T =ZWC;05LIKLW;B*"413?N7
MW1L>FX8R/QJ>\\4Z79:D-/EDF-T83.L:0.Q=0,\8'-<?X@NK;Q%X+U^ZT;2W
M6*41N9S%L>X96!) ZD #K4$6LQZQ\1-$O+&"Z:T&GO TIMW +G/'(Z=.: +T
MOC/3?$/@VXN[N\O-(C,_E^=%&^X8;Y0"!R2!SCI73#Q-IMOK%GHC23M=W$0>
M+,9(=<9SNZ=J\T%P/^%0:CH[6]PM]'<;3&8&^\90V <<\ UU/C"UO'\/Z/XA
MTA3)>Z;L=%"\NC !@1U_R: .CD\5Z9%'=N[RK]FN/LS+Y39>3^Z@_B/TJ71O
M$>G:Z]S%:22">V;9-#+&4=#[@UQ'BC1KVTT#0KN6UFO#;71NM0CA8[F9QEB,
M<\$D9K>\&?V;<7-Y>Z5H]Q:6\H4-<76X23.,Y&&).!Z]\T 4/&^NO%XFT;1&
MAOC97+L;C[.K RC;PJE>3@\G%:.@ZKIVE6FHZ?'-J,S:</-ECN8R9(T;D >H
M JEXLNTC\?\ A=BDS);-,TS)$S! Z@+R!ZUGZG=2Z3XP\3&33[R;^TK*-+4P
M0EP[",@Y/;F@#>G^(N@06UE<-+<LEXA>';;L=V,\?7CI5/3O'@UWQ,FD0:?>
M16LUJ7\UD*."?XNORKUY]<5RND_:(?\ A!H)M.O4:Q>4W&ZV;"YZ'I73WTMQ
MI7Q0.H/8W<UI/8"(/;P&0 AL\XZ=* ,GP9XRL]&TC['?+>R?Z?+$UUY9:./+
MX4,YKK]6\96&DW%Q"T-S<&U0/<M FX0*>1N.?3G KSLP7S_#.\T]=.O!=OJ9
ME6,VKY*%PV>G%7WL'TWQ-?RZAX:GU:VU,)+;ND9)0[0-C _=_&@#IKWXDZ-:
M3V\4<-]<M<0^=%Y%N2'7VSU_^M71W.K6]IHC:K.)(X%B$S H=P&,XQZUQR0S
M0?$#0G_LJ2W@@T]H7$,1,43MSM# 8P/6NF\6-?CPKJ!TN%9KSRL1HRAL^O!Z
MG&: *VE>+K?4M16PDM+BSN'M_M2+.!\T?KD'CKWJC)\0[..**Y&FW[V4\_V>
MWN$0$2OG' SG'7!KE=&LKRV\5V.H1Z'J:VC:?)#/)=2#<[<9+$GY5K*T6^N(
M[6Q75=/U,Z-87!NX!%;Y4'<2"S]U&2>!0!WEQ\1;:'6)=+CTG4I;B)E$@$6
MJG^(^@I9?B/I<4\)\F9K*:?[.EV"-I;.#\N=V,]\57T(7%WX\UO4?L-U'8WU
MK$L%Q)$55MJ@'K^E8OAS2]5T8?V+)X1MIYEF)34I54Q["<[CQDD>@.: .DU;
MXA6.ERW@6VDN(;-Q'/*DBC:Q[!2<G'L*=/X]MO/F2QL9[U+>%9YG5E3:K#(P
M#R?PKGX--U70]>U.V/AF+6(KV8S0W;JH"D]0Q.< >E+XGT>]U&X<1Z-<IJT"
M1BUOK$;(G.!D-D] <B@#T&_O)K;2);RWMS/*L6]8MP7=QG&3TKR[6=:O-8^'
MNC:SJ-J1<+J490H0?,&6^Z!TZ8_"O3UANGT(0W+*]VUOLD*\ N5P?UKS8Z1X
MB;P7I&C'0IA+87B2E_-3#JK$D@9XZT =;9>-4DFU""^TRZL)[.W^T^5)AF>/
MU&/Y4RQ\:RW6H1:?+I3P7EQ:FYMHC.K;U'0-_=)]ZR=;LO$<WBG4K_2M.EC,
MFG"UAF9T'S;MQ/)].!6?I>@ZU#XGTG4$\/M;1I;/!.\MTKNS$$%V//X"@#J/
M 6OZGXATB:[U"V6/]\X21&&",_= Z\>IZU)K?B]M)N[N&+3GN([.$37$IE$:
MJ#T49'S'VJMX!T_5M%TV;2]0L1#'%*[).)0PER<\ =!]:R/$NC>(-0UO4\Z8
M-0M9K;R[(O.JQVYQRVT]6SGF@"S?>+]4N/$?AR/3;,/8ZA$9L-*%:0;<\^@7
MK[UU^M:H-&TF:^,$DY0 +%$,L[$X _,UP5GHOB2TF\+W9TI)'TV!K=X1<*#@
MKC<3T'T&>E=7XUM]8NO#4L&B[OM3LH8(X1BG\0!['M0!3M_$2:Y+JNAWVGK#
M<P6OF2H)1(I!'J!UZ5Q<D4<GPL\.SE5WQWL84D<@%SG'Y"M+2=&U[3M=O[^W
M\,QVUM<V @6%+E,J1W//S$D<TC>'?$+> =(T=-,_TBWNEEF#3(,*K9X.>^?T
MH ]$U:YN+/2+NYM8EEGBB9T1VP"0.]>=Q^(9KWP#I^H>(M$:]5KE-K^:JAB6
MX;'4=<8Q7I%W$]UID\(&UY864 GH2N*\X;0_$LO@2ST+^QP);:XCP_VE/F56
MW$X_EUH W;_QI?6FOW&BV?AV:YGAA\[=YZHNSUZ55MOB/+/;6]\V@W,6FR2B
M![EI5^5R<8"XR0#QFI(K+6V\;7^KR:0R6\MAY$:^?&26'///&:Q_^$=\1_\
M""VFB_V3_I,=Z)W/VB/:%WEN/FZ\T ;>N?$.'2;^\MH+1;H66!/^_"-D]D7!
M+8[TZZ\>'SHHK"P$S-9B[;SY?*.",[5!'S'Z5GG2/$FC^(=0NM.TFROH-1<2
M$SNJM WH3W SVZXJ?Q'HFIZK%]FN-&AO72W40WL,RPM'+WX)SMSB@#MK*=KJ
MQM[AHS&TL:N4/\.1G%3UGZ':W=EH=E;7T_GW4<0623.=QK0H **** "BBB@
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M=+ATC4[F[M 'D6.$8V?W@<]*>WCVR9M$:"SN98-7.V";"JJMD@J<GJ,=/RH
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M; S6MY'N9GM6BC@)Y'S$Y84 >B49%>61>,O%;:&VNRG3OL=M>&WEA1&#R?,
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M:NT %<UXU_Y!^F_]A2U_]#%=+7,^-O\ D':;_P!A2U_]&"@#IJ*** "BBB@
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M[@L16G+IFL?\)QH%])I^^&TM6BGD@VJBL^>%&>@S7>T4 5=1DDBTVX>&!YY
MAVQ(0"Q].>*X?PFNN:!X5CTR?PY//,C.PQ+&$.6)&<GW]*[VXN(;2WDN+B1(
MX8QN=W. H]367_PE6B_8;2]%\AMKN;R() #AWR1CI[4 8.H:+K'B6QMM,UR
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M;34%TSPK=^(O#>@ETN)GEFLB_E%0A*%E4+U.W)%06UIX@M/B%JVNIH+26EQ
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MMIJ(MO!&3A&<<NV/Q _.NHK+\.:1'H>@6=A&BJ8HQOV]"YY8_GFM2@ HHHH
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M"XUV?26'B& QWB2LJL0H\Q.Q(7@&N:\'C[1\3O%\]V<W43I'#NZB+G&/;@4
M=7IWB>SU'5&TP6]Y;7BQ^:8KF$H=N0,YZ'K6W6#XHNK?1-*N?$!@\RYLK=Q&
M<XSN(&#[9Q7+7>K:SHFG:!KLFIRWD-]+$EU;LBA?WHR-F!D8_6@#T>BO)KNY
M\27:^+I1XDN88]'D+0K'$B[L*6P3C.,<8JU97VNV6I^%+V]UN>Z&LJ5EM_+5
M8TR@(P!W&1S0!Z?17DEM'XFU)?$]Q_PE-W&=*NI/)544!]@)PV.W'3I4USXA
MU#6+*WN$O[T2OI0G%II_RNDO.9)#T"^@S^% 'JM%>3+JFN:K%X+ UNYMSJ,;
MK<-&%&XKQGIU-3V\&N7NG>*=)MM;OVNM*N0;6;S3YC@J3L)[@T >I45PWA76
M/^$IO+&Z@N;E8;"S5;E/,(#SMQAO[V "?Q%=S0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 4=(&-,C'^T__ *&:O52TK_D')_O/_P"A&KM !7/^
M+"%@TDDX']JVW_H==!7/^+?]1I/_ &%;7_T.@#H**** "BBB@ HHHH ****
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MN]0DUC49[)]3CM6MK58E811AOO,<\DG-9(\":TGAK1=(2]L?^)9<_:%D*O\
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M_84MO_0J -^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH)Q10 4444
M%%%% !1110 4449H **** "BBC(H **,BC/.* "BBB@ HHHH **** "BBB@
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M93&UM2_0YY9E'N-G/O658,)?BSXMB@^=KJSN(H_E)#/MSC]#0!>U'XD7&O>
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M,?AO5O#,?@^6WL9=0?3_ #UN([=@-IE''7L"3S[4MM8ZR'\:22:+>*^K*1;
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MF$9)Q\Q(Z;<\TG@R:\TS6[6TBN-#OQ<C;,]BTCRHB@X)8D@*/3WH ]3HHHH
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MH **** "BBB@ H/2BB@#+\.'.@6A Q\IX]/F-:E9^AH(](A0=%+@?]]&M"@
MK#\3#,>E?]A.W_\ 0JW*P?%/^JTG_L*6_P#Z%0!O4444 %%%% !1110 4444
M %%%% !1110 4444 <)XR\(7^JZ_IVH:3-Y#3*UEJ#J<$V[<D_7C'XBJWA;P
M3=:!XVU"158:#"/-T^(OD+*Z@.0.O !'XUZ%)(D4;22,%1069B<  =338)XK
MJWCG@D62&10R.AR&!Z$4 >5PZ-K%YH7CNS&CW4$FI3O<6@E"J'!QA>O!XIJK
MX@NO$/@^ZN/#>H00:9%Y<Q^5^J!=W!XZ=/2O6J* /&;[PSKNL?\ "0FWTNX@
MG.JIJ=F;@!5F"@J4SG@X.?PKIS9ZAXI\8:+JTFE7>FV^FQ2&7[7M5G=A@*H!
M.0/7BN_HH \0N=+\40^!KKPJGAN[FDCOC*+E778Z>8&&WG)_I77:?!JMG\3Y
MM0;0[K[-J-C"C2JR;8&'+!SGGIVKT&B@#B/B=:7NH>'K6VL-/N+R7[9%*4A3
M=A5.3FJD[7K?$^VUA-'U$V*Z:T#R>01AR2P&/TKT*B@#Q4Z7K?\ PJV^T0Z'
MJ OI-0,L:"+.4WJV2?P-=%="^?XEZ5KBZ/J)LH-/:&1O(.58@G&/Q%>D44 >
M,QZ#K,OPKN]/72+M;Z+4Q=+;NF&=-X/R^O%7-<N->UC7I!>^&=4:RN;'9:P1
M.J8D(.?.8$=#V)X]*]9) &2<"JFGZMI^K)*^GWD-TD4AC=HFW!6';/XT >26
M=EK=AHG@F>;P_?EM(N)EGB507(;&& SP/KZ5IW.F7OB#Q-XNC6PO;1=1TV.&
M"2:(JID0<@L.,9_.O5*IW>K:?8W5M:W5Y##<73;((W<!I#Z =Z /-'M]1\2>
M%=#\+S:1>VM[93PBZEECVQQ+$,;E?HV0.,>M)$MQ#-\0(Y-+U KJ*D6I%JY$
MAVLG''J0:]-M]4L+J]GL[>[AEN;?'G1(X+1Y]?2BYU2PL[J"UN;V"*XN&"Q1
M/( SD^@ZF@#A_#/B:;1=+\+Z)<Z+J"_:(E@>XDC*+%)R I!'/3\JUOB5IM[J
MO@B[M;"W>XN"\;B-.I"N"<?@*Z*33K6:_BOI$+SPJ5C)8D)GJ0.@/;/6K= '
MFFJ0:CXEU"QU;2M,GC.EV,VW[9#Y9FE9<+&%;J..>W-<K:PZL=:\,:J=!UV:
M:W9ENS,G&['W47.%4=N *]UHH \7L--O)-3MSX:@U72Y;QV&HZ;<Q-]FB1@0
M74D8'J,<\TSPMI7V5X_#U[X%$VJVTI']HS1Y@9=V=[,>O'3'6O8[V^M-.M7N
MKVXBMX$^])*P4#\34L4L<T22QN'C=0RL.A!Z&@#"\8K"_A:[BN-,FU*%]J26
M\(.\J6&2N.XZUYBT/B;3='UBVT2/4;[0PL2Q"_MS]HBYRP0,,G'TP.U>R6.I
M66I1-+8W<-S&KE&:)PP##J..]6J /&M(,^G>,-0OXM&UXV%YIGEB6XB:21FX
M^9N2>O8<^U16\FJ6G@[PM;2:7J8M+>65+T6]N5N$.25"DC(!#=1],U[510!X
M#)8ZC;>%]8TE/#VKQ^;JR7,*M"9 $!'!8=3CO^M>F>/K"+7/!,E["Q@N+,"]
MM9'4JR,O."#R,C(Q]*[*N>UGPA9:YK-IJ-W<7A6W4+]E27$,F#D%E[\_R% %
M"UN;SPIX'&H36-QJ6H2$7%U%  &:1R"Q^@_I6Y'J,NI^&5U&P@_>W%KYL,4O
M]XKD _C5N]L(-0M6MK@,T+XW*K%<@'.#CM[5*3%;098I%%&O). J@?R% 'B-
MO!J_VOPYJ4OAS69+RPO&^U$J G(.$B0'"J/7 'O6G%]JE\-^.86TK40^H7<D
MELIM'RX;A>W'->EGQ)H@TY-0.J6@LW?RTF,H"LV<8![FM2@#RC17NX/&6@W$
MVE:BD-KHXLYG-J^%E&>.G(XZBLU]+U.Z\':F\6EW9EAUXWZP20LK2Q%AT!Z_
M2O::* /'=0N?$M_XEU;6+#PS>QBXTH00?:$7@9R2PSUQG"\]N*KZ*M_;>,-$
MU:/PWKABCM7@N);CYI'DQ@M@G@#L./85[55.^U73]->%+V\AMVG<)$LC@%V]
M!ZT <G\,8[J#1=1BO;.XM9FU"68)-&5^5R",9Z]#45Z;G1?B=/K$VG7LUC<Z
M>MNDEM"9?W@;."!R/J:[(:I8MJ3::+N$WJH)&@W#>%/?%6Z /'[3PGK'AW4M
M+\3K92S.+N>:ZLH2&:&.7I@=R!G.*LZYHM]K!\4ZY!IUW&+^SCM+2 Q'S)2,
M$N5ZJ.,<XKU>J=GJVGZA/<06=Y#/+;,%F6-PQ0^A_(T ><S?;9M5\![=+U "
MPBVW3- P$9*JG/XJ?PK(O-.UZ+POKOAJ'P]?3ROJ37*W";1&T9<$8.<D\=*]
M;N=9TZTU&WT^>]A2\N<^5 6^=OPJ]0!Y#K>EZEJL\EW'H6K:;KL$<:VE[:X(
MF.T964@XP/7T_*O0-;366\$W*6JQRZN;3&, JTFWYL \>N,^U;U% 'CVC66J
MV?B/1-77POJNV"UDANGDD5I)'(P3RW '8<>U-.E:Q_PK.'2/[%OC>C4//,?E
M=%W[LYSZ&O8Z* /+6C\0:+J/B:"#0+N_M=:W7$$L6T&)G4@J^3QC^GO76^ ;
M6]L?!6G6>H6;VMQ A1HW()ZD@\?7I72T4 >50Z-?R>)[/4]-T._TC4/MN;UU
M8"UG@!.21GJ1CC'6HKRVN[?P]XZDO]*GCBU"?S;8387?DA5Z'.[.#7IAUBP&
MLKI!N4^WM#YXAYSLSC/IUK/\7OX?_L&2+Q)+&EA*X3+D_>[8QSF@#A= U'4=
M.U;3[G7_  _K!G6$6%O<2&,JF>@VKCDD8R:K?V#X@_X5SJ&C'0KHWL^HFXC'
MF1@!2P;).[V(Q[UW&F^%-"\.9U0SW$@AC+++>7!D$2XY*YX''>MS2M5L]:T^
M._T^836TA(20*0&P<'J/44 <T?A_H>J72:Q>VETE_(%DD#3D%6 '8'';M7/V
M6A^(-%\/ZQX3BTMKJ*[>0VMZ'41A7QG?DY!'T->I5F7OB#3=/U2STRYN0EY>
M'$$6TDM^0X_&@#C-/T;5-#\9V4T.E7%U86>DBQ\]7C&]@0V0"P..U:GPYT[4
M=*T>\MM2L)+21[V2= SJV5?![$],5TFK:O9:)I\E]J$PAMH_O.5)Q^ JJ/$^
MEFZTVV%P?-U*,R6R^6WSKC.>G'XT <Y)9ZUHWCG6=4MM)>^M]0AC6)HI44(R
MC&&#$<?3-8]AX&U/PEJ.D:SI\7]H31))'?6Z,%)#G.4W8'!/?TKU,=** /+-
M7\):U?Z3XCO(]/\ ]/UJ6();&5 8(T(.6)."3CH,UI/I6MW7C/0-4;1Y(;:S
MM&MYV:XC)!9<9 #<@5Z#10!XW+X1\7_\(P/#4>F6S6\%_P#:$NC<@>8N[(^7
MJ.M:VN^'-=\0W$AN-!MX+])E-IJEO=*AA48^]_$V.>W?M7IU% '$:Y8R:MXU
M\-622&1=,W7ETXZ@X 3/U(-'Q59U\$.8P#)]J@V@]"=XQ776NGVEBTS6T"1M
M.YDE8#EV/<FL7QG'HXT0W&MVT]S:Q./W418_,3@' (Z>IZ4 8>I^'_$'B2[_
M +1N8XM+N+6SEBM$CFWL97&"Q8<!?3O61I?A/Q5;7WA^\73=)MFTX21NHD):
M3<,%W(ZD\]*]0M1&MK$(@PC"#:&SD#'&<\_G4U 'F7_""ZQ=Z/KMM.8+:XNM
M1&H6KK*7 <'(5N/UJY;:)XOO/%^C:UJ8TR,643Q2+$SDL&X)^I[=J]!HR* .
M;\;Z'=^(/#QM+%HQ<I-',@D.%)4YP365%H'B/3?$,FNVC6<\U] J7UJSLB"0
M#AE.#D#IS[^M=SFC(H P?"?A_P#X1S2'MGE$MQ-,\\[J, NQR0/8=*Q/^$?\
M21>.[WQ#;C2RDUN+=(Y)7S@8YR%Z\5V[R)$A>1U11U+' I<B@#DKC3O%]S#?
M.;W3X+B95BA2)Y/+B3G<V<9+GC!QQ5*T\$W>E^(9Y=->UBT6]A$5Y:.[EG.,
M%AQUZ]Z[NB@#A=#\+>)M):#36UR!M$@DW($0B<IG(0GH!].:BM?!6O:3J%W;
MZ1KD=OHMW*9)(V0F://WMAZ ^]=_D49% '$ZIX3UA_$=WJ.D:G!;17UJMO<^
M=&7<;1@%/PQUJI#X#U6VT70;:'5;?[5I%P\D4C0$J5;L1GD_XUTGB+Q*GAW[
M"9+.:=;NX6W#1D (6Z9R:W"0!DD 4 <KI?AW4[3QE>:Y=7EK*ES L#(D;!L+
MT/7&>.:FL?!]I9>,[[Q$C?O+F(*(\<*W\3?4X'ZU)J/BN"QO]&@BMWN8-4E$
M<5S&R[ 3^I_*N@S0!PS>!]4M-9O)='U^2PTZ^E\RXMUC#,"?O;">A/K79):1
M1V L_F,0C\ODY)7&.M6,BLW7-<LO#VFO?7SD1J0JJHRTC'HJCN30!Q7_  K;
M4&L+;3V\1.MG9W(GMHDMU^7!S\WJ?TK5@\'ZE#=ZU=?VS$TNJQB.0_9<;,#&
M1\WH34EWXNU33M.&H7OAFXBM21R+A&= 3@%E[=?>NM# @$$4 <,GP]N+>VTM
M[/6Y+;4=/C,"7*0@AX\_=92>>IHA^&L!T_4[:]U6YNGOKC[3YI55,<@Z,,=_
MTKN<CUI<B@#D++P7>1:?>0WWB"[OKF> VZ33*"(8SUVKGJ?4UM^'M(;0M#M=
M,-QYXMUV*Y3;QVXK3R*,CUH YW4_"8OO$<6MV^I7-E=)%Y+>4%(=<YYR*S%^
M'BKX>NM%_M>X^S7-Q]H<^4N[=G)'T)Q^5=J&!&00:-RYQD9]* .5'@N1M9CU
M.;6;AY4M3:8$2+\A&/3KWJ2R\'B*_L+J_P!3N;\Z>I%JLJJNPD8R2!ECCU-=
M-N7.-PI0<]* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV_\ %4MPEG!%K-L(XPLQ<HRC"Y^4<&NK\*VNK6/AZUL]8%J+B!%B46Y)&U0
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M*L;ZRLD;4T=DMXYF\^W(&Y1*".,BLX_$CQ*]EJ&H0>%X6L=-N7ANG-V"PVD
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M[C:WU336FF01 %7" [@?<]JQ[CQ3XCA\%Z[?)J$3W&G:JUMYDENN6C!4  #
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M %%%% !1110 4444 %%%% !1110!2TH8TY!_M/\ ^A&KM5-,_P"/!/\ >?\
M]"-6Z "L'Q2,Q:3SC_B:6W_H5;U8'BK_ %.D_P#84MO_ $*@#?HHHH ****
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MV>YA1)X9-V'#C;RI[$5OWVO:E8>(?"D[7\K6E_92/=6^U=K%(M^X<9!)/Z4
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M;:]NYET2Z62P=Y&)8;26B)SR. /_ -===X/NK;Q3J/\ PD,,,D<5O;):QY)
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MET^[L;NV56>*X5>5;."I4D$<5LT <7IG@B^%C=P:]XANM4:>V:U0[0@B1NI
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MJU0I',]VQ;'89]!V P/7-=C10!QR_#C25T2XT<7FI?8[B7SI4^T?>;.<]/4
M_A5RZ\$Z==/:3"XO8+RUA$"WD$VR9TQC#MCG\JZ6B@#-LM"T[3](;2X+=1:N
MK+(K<F3=]XL>Y/<U6/A/1SI=AIWV-/LUC*LT"_W64Y!_Q]:VZ* .?\1>#-&\
M3O!)J$#^=#PDT+E' ],CM4=WX%T&\T:VTM[0I#:G="\;E9$;NP8<Y/>NDHH
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MHRW=Y="WD$]ZI2X?SWS(#V/-(/!N@_V*='.GHUAN+B)V+;6]5).1^%;U% &
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MWL;7JA;B*&Y9(Y2!@$J.I'Y4Q_AKHITW3[..?48#8%C!<17)68!NJ[O3V&*
M/-/$4$DOA#Q3;R7EY,FG:T(K;S+AVVJ<#!R>?QKI=;T;?\1/"NE1ZAJ%NOV"
M;=*MPQF(Y)'F')_^M711?"_0(=.U*Q5KTQ7Y#2[K@G:P((9??CJ<FGV?PZLK
M/4;+4/[7UB6\M%*QRRW(?@]>&4]: .$M/$NKV6A2:,=1N&#:_P#V:M]*^94B
M(R<-Z^_;-;U^^H:!XU70+75-0?3]2L9)AYLQDDMG0'E';) .T<'UK>3X;:(+
M"_LII+RXAO9OM$@EE&5E_OJ0!AJMVG@RV@,LUQ?WUW>O;_9ENYI 9(X^X7C
MSW.,F@#SS2-/UJ3X:7'B>3Q=K#2R6<I$/F9"E7(&"<D?=Y(P>:U]4NHK?P-I
M&NZCK&J>8UA'%#:V]T\;W$Y&<DJ<D_TKJ[;P19V?A.?PY!?7PLI05!:12R*3
MDA3MZ'G\S5*7X::9,NFB34]6/]FKMM<7"CR_<?+U]Z .0D7Q'H-EH&C76IW$
M^I:Q.\ER)[YD,:JN5B$@R5SGDCDD8J6\O?$WA#3+NVU#54*WUY#%;$W1FELX
MW)W$LP!(P, GO767WPVTG5+>==1NK^[N961Q=2S#S(BH(&P@#'7I4MO\/-&3
M0;K2KHW%\+I@TUQ<REYB1]W#=L=J .9ATA=%^->E1P7%U<QRZ;(S-=3M*R_>
M'!//)'3W-;/Q5FN[/PO'>V6H75I)#<Q ^1)LWAF (..:L:=\.--T[6K/5?[1
MU:XNK5=L9GNRPV^A]NO'2MCQ+X9M/%-@EE?3W,<"N)"L#A=Q'3.0>E '$ZC8
M7VI?$[4M+;7M6MK(Z>+A([>?;@DXP..!D?7WKH/AGJ5YJG@FVFOIVGG222'S
M'^\P5B!D]SCO5A?!%LNL2:M_:VJF]D@-NTAE0_)Z?<]\_6K_ (:\-6GA;3WL
M;*>YD@:0R!9W#;2>N" .M '!:G<2^'/%6N:;?ZIJ9MM1LO.TW;=.763=CRTY
MZ[L8]JK^%=0O?$UEI6@W.HZI:ZG833G4'2=EEVK]W<>G)('.?NFO2M2\/Z?J
MNI:=?WD/F3Z?(9(#V!([COT!^HJ.U\-Z?8ZKJ>IVJ-%=:B%$SJ>F 1E>.#SG
MZT ><^&=-US4K'5-5?Q?JW^A7-U$MN&5]P4'&2<C/X?2LVZ6XUKX?^#+V^O[
MR6YDU5(7D\X@D&1N?]X8&#VKTK1_!=OHMCJ-I;ZC?M'?NSN7=2R,W4J=O4YJ
MB?AQ8'PK#H']H7OD6]P+FWE#@20L.>"!ZD_G0!EQ2ZA:?$?4-&&L7[VQT@R0
M"5PQC;@;AD8)Z\FN5M=0U^'P/8^)W\1ZA+<1:D(1 [CRF3S""'&,MGZ\#BN_
MC^'R0:Q_:<6N:G]H^SFVW2,CG81R,E?7FH#\,K4^'%T+^V+\62S_ &@*!'G=
MG/7;GKS0!C^(=8NSXA\26UWJUUI\EC:)+I4<,GEK,2N2<?\ +0[L#'/TKN/"
MAU)O"UA+J\LDFH2Q"28R*JD$\XPH &*\MUJR9?&U_-J-UXDL;H>6EO/96YF6
M=%4#=E1@$D9P.!7IG@Q-37PW#_:L\\TQ=S&]PNV4QD_+O'9L4 >:66CZI>ZC
MXWN]+UZZTU[.^>1(X@ LC $_/WQ@8Q5Z#Q)JD,OA?Q3J6HW":-J*^5>1"3;%
M#,,JK8QPIVYQ]:ZZ?P&C:AJ<UKJUW;6NJ,6O;9 I$A/7#$97/3BLWQ$EMJ3Q
M> [70KH6^(B;GRL011@@DANY X^IH W_  @E[)I;ZA>W-Q(U[*T\44QSY,9)
MV*/^ X/XUS.N/J"_&:Q73&M5N6T=@/M2L4QYA)^[SGBO18XUBB6.-0J( J@=
M !7+WO@R>Z\4?V_%KUY;W8B\E D<95(\YVX*G//K0!#'I_B&_P!(U*UU+4X[
M#59)F:UN+-@ (PHQ@'G;G.0>>:YKP1KVIZ[=.=1U*5'T2 K/!#/O^V."3YAX
M^[CCC.374S>"I[EKR6X\0ZA)<W, MQ/A%,29R0@"@#/&:&\"6XUS3]6@OYK:
MXM(%MW$$:(LZCKO '?I^% '%Z9J/CG7=/M/$6G/MWSL\@EO4%N8@Q!3RBN5Q
MCKNSU_#1L9]=\9V^L7]IK$VF7]C>>1!;AL0QJN,^8/XB>>3Z5KV_PQTZUU.2
M:#4-0CTZ27SFTQ)B("W7D=QGM4E_\-M/N]=N-2AU'4+-+LAKNUMIMD<Y[[A[
M]Z *%E=:@_C;7M,?6+B2T;3$N8BD@_=N<<H<<#K^E<IFZUW3OA]=7^IWSW%U
M>/%(RS%?NLV&&.C=L^E>B:IX$M-0UA=1@O[W3W-N+:9+*01B6,= 3C(]*IK\
M,["/0[#38M3U*/[#<&X@G64;T)ZA>.!0!6L7O[KQUXAT!M9OO(CL8F@<LNZ%
MCW4@#VZ\UBZ'JVJZG8P^&9]4NUUZWU1H[N592'\A<DMGT(P![D5VFF^#TTSQ
M-/KB:G=S2SQB*2.7:P9 /E!.,\8'.<G'-7[;PY86OB.[UR*,"\NHEBD/; /7
MZGC/T% 'G(O/%GBK^T+S1[B2![2^>.%OMHCC1%(^5XMOS9'.2>_M7J]HTC6D
M)F*&4QJ7V'*[L<X/I7(W7PUTVXUZ?4X;Z_M$N6WW-K;S%(ISWW#W[UNVF@QV
M>OW.JI=W)\^%8?LS/F) O0JO:@#7HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"IIG_
M !X)_O/_ .A&K=4],_X\$_WG_P#0C5R@ KF/&Y T[3,YQ_:MKT_ZZ"NGKEO'
M?_(,TS_L+6G_ *,% '4]J*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXF;A3<.RN!&K<J3C R: /4,BH;J9X+266*,2.B%E0MMW$#IGM7E]Q>>0WC.
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M20>)M/N/$\WA^,S?;H8?.<&,A=N0.">O7M6S0 #I12,P52S' '4FEH ****
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MGVB21YG+N=P;+''(XZ5[S02 ,F@#S4^$/$5K\69?$MD+/[#<1*DNYSN V*&
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MH8]4O'\2S::VES+9I )%OB?D9C_!CUJ]:WMM?0F:UF26,.R%D.1N4X(_ @T
M<(/AG<V\.F367B*YMM4L8OLZW:PKAHO[NSIQ[DUJ:AX*EO-%LK6/6)TOK:\6
M]^W/&'9Y1GDKTQS@#H,"NNR*@NKZVL8TDN9EB5W6-2W=F. ![DT <E>>!KN;
M6KC4;7Q!=6QN[5;>[40HS3;1@'<?NGZ"J=C\-+C3)--ELO$EY%+91/"&,*-F
M-CDJH/3DGDYKJSJ.H?\ "2C3UTMSI_D>8;[S!C?G[FVM7- 'GO\ PK&1=!N-
M(3Q#=?9IKK[3AX58ALYZ]>O)]:[LVJS:?]DNL3*\?ERY4 /Q@\>]3Y%!/'%
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M/,1DW;LC!!!SBLR_^&<5SI$?D:E-#K<=T;T:D%^9ICUR/[O08[8H Y;Q)?\
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M8@]!CBIC\,;QK+6K0^)96CU:023E[12=V<D\$<Y_#VH =><>/? /'6RG&?\
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M-7&_LW7-,\;WFJI#)J=O++'&)L9AC1<1[,].0>G4UW"_#WPHK,?[%MR6??\
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MI0!D>&Y8Y?B+XK,;JP(MNAS_  5VM9MEX?TG3KQ[NSL((+B08>1%PS#W-:5
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 4]+_X\$_WG_\ 0C5R
MJFF?\>"?[S_^A&K= !7+^.B1INED=?[6M/\ T8*ZBN7\<_\ (-TS_L+6G_HP
M4 =11110 4444 %%%% !1110 4444 %%%% !1110 R::.WA>:5U2.-2S,QP
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M&CN'<.CAB<%6'4<=<>OI6]D5Y$OB_P 2:'9Z_8Z]:6_]N6-@);>_C4$31[L
MGZ%B>W0Y%6-+T3Q +K3]3?78;6RNH?+FV:C)*URS*2&3>N%;/8>E 'JN11GC
MBO'_  7X7O\ Q5X4?4KSQ-K8N)#-#&OVHA%(;AO4\BK'A"^D\26>B:+-->1W
MNER3-J)6=U8;25 8YR=S,#^!H ]!TV[N]6_M"'5-(^S013F*(2L'%P@Z/CTK
M2M[:WM$*6T$<*$Y*QH%&?PKQV?7=2T?0_$\!U&Z8_P!N)9BYFE+-!&W4@]N!
MCMUKH-<MG\"Z7K.IZ;K,\BS6@\BRN)#(4<$ RJS$G@-TQB@#T?(JEJ^K6VC:
M=+>W1.Q, *HRSL3@*!W)/%<#X;TC6[/6M)U<ZQ:+8W<026#[;+/]J)4L&&\8
M#=^/2M#QTS2>+/!5J[D027[NXSP6505_4T =1#J"$VBWT,4&I3H[Q6V_<W R
M1NQZ$9[?6L_PCXFG\26^H2W-D+-[2]>U,8DW_= Y)QZD]*YG6])LI_C-HGF&
M3=+9RRL!.XRR_=Q@\#@\#@XKE;C2@WASQCJZ7VH0W%CJLK0I#,4C5MZG<0.I
MY[^@H ]SR*1Y%CC:1CA5!)/H*\AN)=8\:>(;[3TNK:(P6$+0K+<2Q%&=,F50
MG4@GOP.*]$\)1W">%[2"]U&+4KB)6CDNHSN60AB.O? X/TH S$^(&FR6>GW
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M$ENO/O6O;^)-)FL+>[DO[:W6>%9@LTJHP5NF03[XJQ/K.EVMY'9W&HVL5S(
M4BDF56;/ P">: ,NR\'VMEXEDUX7^H2WDL8B<22J49!T! 4=*EUWPK9:_>6E
MY//=P7-F&\B6VEV,A;&3TYZ=^*T[W4[#345[Z]MK5&.%:>54!/H,FEGU&QMK
M474]Y;Q6S8Q-)*%0YZ?,3B@#*L?"6FVIO'G,U_/>1^5/->OYC.G]WH ![ "L
MC2_A=H&CW$LUI)?AV5EBW7&1;[A@F/C@X/4YKK%U&R:Q^VK>0&TV[O/$@\O'
MKNZ8KB](\9^?XRUR"[U?3Y-&M((Y(IHBH12QQ@ODY/;K0!T7AKPO9>%=.:QT
M^6Y: N7Q/)NP3UQP,5/8>'[#3=3U'4+5"EQJ#*\YSP2HQD>G6IQJ^F&2WC&H
M6A>Y7= OG+F4>JC//X4U-<TF2[^R)JEDUSN*>2LZE]PZC;G.: ,.'X?:,D&J
MP7#W=Y%JC;[E+B7<"V<[A@#!]Z=H?P_T'0K.ZMH8IKA;J/R96NI3(3'_ '!V
M ^E;=OK6EW=X]G;:C:37,8R\,<RLR_4 YJ.#Q#HUSJ'V"#5;.6[R5\E)E+Y'
M)&,^U &1X<^'VA>%[Q[JP2=Y3D)Y\I<1 ]0@[?7K[U8\6^'WUNRMIK4HNHV$
MZW-HS]-RGE3[$<?E70UF7OB/1=.O%L[W5;.WN6QB*695;GIP30!EWOAC3O%;
MZ?JFJ6=U:WENI 02E&7)Y4E3R/Q[U73X;Z(EE>V8FU#R+UQ)<H;IOWC9SDUO
MC7=).J?V8-2M3?\ _/OYHW],_=Z]*A?Q1H,<$T[ZO9+%!)Y4CF9<*_\ =/O[
M4 9&I_#?PWJ\=DMY;S.]I&(HY1,RN4'16(ZCZUTUG9V^GVD5I:Q+%!$H1$4<
M*!6#KNM07GA2:]T?Q%8V8+*$OF97C4[AD=QDCC\:S[C5]4MOB+H&E&_22RN[
M*226-80-S*I^;=UY/.!B@#M3R*Y[2?!6AZ+JD^HV-JR7$S,W,A*QEOO;!T7-
M6O\ A*-".K?V4-6M#?YV^1Y@W;O[OU]NM<KHOC2/3_$/B*R\2ZY;1I;721VO
MFJL7RD$D#N>HY.: .LT?P[IVA/=/8K,K73^9,9)WDW-Z_,3S5!_ NA/JESJ?
ME7*W]SD2W"7<JL0>W#8P.,#VK.U?5]1A^(GANSMM0']EW\<S/"B*0^U"0=W7
M!R.GI6]/XIT&VU5=,FU6U2]9@@A9^=QZ#V/M0!':^$M%L]+&F1V>ZR$HF$,L
MC2 .#D$;B<<]J9J'@[1=4U>+5;NWF>]BP(Y5N9%V?0!@!6S<7,%I;27-Q*D4
M$2EGD<X50.I)K%C\:^'9[6ZN(=5@DCM(Q)-MSE5/0XQDCIT]: (YO OAZ:6Y
ME-G(CW3,TYBN94\TL<G<%89Z]ZW;6U@LK6.VMHEBAB4*B(,!0.PK$\(>++/Q
M=HXOK;Y'#,'BYRGS$+DX[@ _C4__  ENA&2_C&HH7T\9N@$;,0SCGB@!OB:U
MU#5-/.DV2B..\!CN+IB/W41^]@=2Q' [5FW'@BSEUO0[J*"&&+28U$<JEO-;
M;T3TV]R3D_2M)_&&@IIUI?\ ]H*;6[8I!(L;L)".H&!5=_'OAI-*.J'4T-B)
M?),PB<KOQG'2@#4UG0]/U^R^QZG!Y]ON#>7O902/7!&:H#P5X>6[BNQIX%Q$
MNR.7S7W*N,8!STJ2_P#%VAZ64%]?" O")UW1/_J_[W Z4QO&.A+/IL/V[Y]2
M -G^Z?$O..#C^= %O1_#VE: LRZ79I;+,VZ0*Q.X^O)ZU3O/!/AO4=0N+^[T
MBVFN;A-DLC+]X8Q^?OUK2M-5L[V\NK2"4O-:L%F78PV$C(&2,'CGBL*QO[/_
M (3?5@/$;SF*V#2:<W^KMMN 7SC\^>Y_  L7O@7PSJ%O:07.CVSQ6@VP* 1M
M'IP>1]:N:IX9T;6K*&TU'3X)X(?]4C+C9QCC'3BJ=CXY\.ZC=BUM]20RM&TJ
M;XW0.@SEE+ !AP>GI57_ (65X/+(!KML=[[ <-@'W., >YH U9?"^BS:-'I$
MFG0'3XN8X-N IZY'<'WIA\):$=*?3#IT1LY&#R1Y/[QAW8YRQ^IIFE^,-!UF
M^N++3M3AGGMU+2*N<;0<$@D88>XS3;+QGH6HWBVMM>EI'1I$+0NJ.J_>8,0
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MZO+<3+:2S&#/DL61P<$,,?+^- '1W5I;WL#07,,<T+?>210P/X&J8\/Z*/\
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MQ]T<Y]LU8T_QO'?6^LR-IMS;/I/^NBF9 S'!.!S[=Z .KHJO8W#W=C#<20-
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MSUT01ZO'<3,YGP7P%_=%<\X!'&*]7.AZ4=0^WG3K7[9G=]H\I=^?7=C--NM
MTJ]OX[ZZT^VFNHQA)9(@6'XF@#R;2-6%AXATO_A-V"V]QHBQP278RH8GYL^A
M(X)/-17MUIEAJ?AR."^O;#PM'%-%9W<B+*ID+G+D.#\IR0"1G ]*]EO]+L-4
MB6*_LX+J-3N"S1AP#Z\TEQI5A=V8L[FSMYK88Q"\8*C'3CI0!XO*=*T"'2?L
MEY=ZAX7_ +6\R]GEB7R"Y48P%'*@\D8QD<5>6XT:]\:>,K72Y;.6.\TD>2D)
M7;)($RVW'!/>O7&TVR;3_P"SS:0&SV[/(,8V8]-O2H[/1M,T^3?9Z?:V[[=F
MZ*%5.WTX'2@#Q@Z_H,NC_#Z-[NW>XM9U%Q&2,QK@J2Q[#..M6M%\/Z7?0>-I
MM-M;=M5M;V8V#0MAHQM^78!T')Q7K$?AW1H6+1Z59*2YDR(%^\>,].M36>D:
M=I\TDUG8VUO))]]HH@I;ZXH \=\+Q>&M3?0+HZ_?R:K:J$6QA@1'BX^<$A 2
MHYR23^=2>&;B'1-8T%4>QUC2I9I/L-U%\MW:94[A(HZ@ G.<^OI7L,&F6-M<
MRW,%G;QSR_ZR1(P&;ZGO45KHNFV,SSVEA:P3,-I>.%5)'ID4 1Z+XATOQ%8M
M>:3=K<PJY1F4$;6'8@\UXSXQU33IF\9P)+:V,PG17BF4R3W3J1RA/")WXR>*
M]DT/0K?0X)TA(9[B8S2L$" L0!PHX P!5M]-L9;A[B2SMWF==C.T8+%?0GTH
M \P\0W"VFF^'?B#I*QWDMG&D%U@_ZU&7:><=0Q(S[T:V]MH>F>%9=12&"_N[
MQ[N2]N"?+MY7&YF91C<?F  /'R_6O5?L\/D"'R8_* P$VC;CZ4DUM!<J%GAC
ME4'< ZA@#Z\T ?/IO]*?P5XWM'O8;FY_M!9[=W0(9,NOSJ,<9YZ=J[:ZU2R_
MX3_P3=?;(9&?3Y58!QU*?+WZDD@#VKTA]/LI"Y>SMVWD%LQ [B/7CFA=.L4=
M72RMU9?ND1*"/IQ0!\_W6N:>^GZ:R3P6<%MKOG-IRQLTD2[R3)(YR<^PQ^.*
MZ:.;PS)XE\<'6ULR)UCDMS.H\QT,?_+///7'3GI7K?V&T)<FU@S(P9_W8^8C
MH3ZFG/:6TLJRR6\3R)]UV0$K]#0!X[IADTK5OAU:ZI.L5W%#<(8V?YXPZ_NP
MP[=0/PK+T\:-/:W?A_Q->ZTNL1:@\@LHC\MQ(6.UD^4\G/4GWKWEX8I&#/$C
M,.A*@XI#!"9A,8D,H& ^T;L?6@#E_'=Q%9_#^^>?3VO8UB4- SMCJ.6*D$@=
M3BN!T/6+2[^(<<D6L-?/>Z.UM'(ML8T63(PB@#. !U/XFO:6574JP!4C!!'!
MIJ0Q1A1'&BA1A0J@8'M0!P?PDU.WN?!-MIP8FZLBZ3)L8;,R,1DD8SSTK/\
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M5[2]_L\H^ZZTZ'?<;SP(PW5 1UQUKB4^UV_@Y=(DT?54FCUQ;GY[=GR@;)Y
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MZ4KG"_VK:DG_ +:"NDKF_&:L]EI2J<$ZM:C/_;04 =)10.E% !1110 4444
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MW$D*2.2RQ[<X///..:V_#4$5M\7?%L</RJT%O(R9)RS#)/YG]:QIM,UJ?0?
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MYV=;&W,FU8D;EADCCD_DM5M%\.>*M.\(V&F0BUM[VROA.':X)26,ER5.%SW
MH C\.Z_I7B7Q3I[75G_9/B'3UD22UDCP95*$$*WH.N#SUK2^*RC_ (0:X?:&
M998BOK]X=*?/X?U/7?$^D:K?V-KIZZ<Q<O%-YDDS=ER ,+]?6M+QMH-SXC\,
MSZ=:21QS,R.ID)"G:<X)% &);>+_ !#;ZG!I>IZ);6\M[ SZ>ZW!=6=5SL?W
MZ<TNE^-]3U+P\;D6=HFIG4!9"U+-A3GOWZ9/T%6X].U&_P!6LM=\0QVVGP:5
M&YBA2;?\Q&&=VP   .!^=4=!TC3=0^(6I:]IURD]FJ*1Y;[H_/8?,P[$[?\
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M8_-8,!\J+&"&8GVS7,)X[\17/A;1-2MDT\7%YJ7V"42QN%8[B PYRHP.>IH
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M:QF!A,I,<L9[$#TR?\BM&[\60V^NZ'I\5K)-#JP9H;M77R\!=WU/&.W>NBH
MR= L-1L;%_[6OQ>7LS^9(Z+MC7@#:B]@,?SKF+GP=KT6O>(+K3=0L%L]9B"R
MQSQL7!V%>". /F)KO:Q_$NOKX:TB74Y;.>Y@AYE\DJ"@]?F(S^% ''OX'\0?
MV)X:TY;C2S_8MPLVYMY$NT\#&..,YJ6R\$^)='U"\MM)UV"#0KR8RM$\9::'
M=RPC/0>QSZ<5V>DZI_:FD0:@UM+:I,@D5)F7(4C()P2.G-0^'_$5AXEM)[G3
MW+1PW#P,3W*GJ/8C!'UH 77].NM0\-WNF6,D22W%NT >?) ##:2<<YP3^-<B
M/!>O^1X4C-UIW_$B;)^_^]P /3C@?G6Y'XVLO^$R/ABZMKBUO67?"TFTI*.<
M;2">H!Z^E7/%7B:S\)Z')J=XKNBNJ+&GWG)/0?AD_A0!R.I> M>U2Y\1227]
MC"-5>&1/+#G:8ONJX/52.M36_@?Q"^O3ZG>:MIX^U6!LIHK>V(55Q@!,GIT.
M?TK:G\9JD.E1PZ7=3:CJ:&6"R#H&$8&2S-G:!@CO5S0O$G]LWM]92Z==65U9
M;/.CGQU;.-I!P1QUH Y=/ FO+X2TW2SJME]JTN[BN+1A"WEX3. W.23NS^&/
M>I)_!?B6RUJ;5-!\06\$U\JB_2>WRC.!C>BCH?0'\S7H-% '&0^$]5@\5:7J
MQU&">.QM3;-YRL9)=W+L3G .<X%6=-GUQO'6HPR7:W.C+$"J^5M\B3C"[L?,
M2,D]<<=*ZJN>U#Q,=/\ %>EZ*UA(5U /LN3(H4%1DC'4GIZ=: *?B/PSJ]_X
MEL-:TC4X+6:WA:!DN(C(NUCDLHS]ZN<3X<>(K?3K2QCUNQDAM-0^WQA[9E)8
M$GD@^YKU"B@#A7M)O"WB'5?%^N:C:)9W$"12)%"^4VX"XY.>?:I/ 6BZ?!/J
M^O:?$5MM3N"]ON4@^6.I /(#-N./3%=E-!%<0M%/$DL;##(ZA@?J#3OECC[*
MBCZ "@#,U^RU.^LH5TF_2SN8YUDWR*65U&<JP!&0<URLOPX:[TK7XIKJ""ZU
M<QL?LL16*(H01A2><D9)]Z[>RO;?4;2.ZM)1+!(,HZ]&&<58H X2S\%:Y_PD
M]IKFHZ_#/)#;&W:..UVC8>R_-QZYIEAX O8-$3P[=ZG#/HBS>:R+ 5ED&[=L
M+;B ,^@S7=3N\=O(\<9D=5)5 0-Q],GI7$_\+#D_X09O$W]C2%4G,,D'V@?)
MA]F2V.><=!WH ?K?@S5-<%S8W&IVC:5-.)55[8M-;CCY8VW8'3KCN:CG\"ZM
M:ZY<W>@^(I=.L[U_,NK<Q!_F/5D)Z$UW2L&4,#D$9!I: ."OO ]SI^J-JFA:
M\=*C:W$5V)(A('"CAR2<9]3^-8'@_P /CQ/\,;6VMK\07EIJ#7$4V VQU;(W
M#W!KUIT61"CJ&4C!!&0:;#!#;J5AB2,'DA% _E0!PJ?#FXNM3U"\UG79+X:A
M:BWGC6W6/@<C:<G ! (_7-6=%\&ZSIY07OB::^BM59;*)X0%0D;07P<O@=!F
MNUHH \\'PZU+_A$O^$>.NP?9_M'VCS/L9W9W;L??]:W(?#%]%XN&NC5MHFMX
MXKN!( !*4!P023M'/3]:Z>B@ HJM9W]MJ"RM;2;UBE:%B <;E."/?FJVOZC-
MI.AW>H6]NMQ);QF3RVDV @#)YP: -*BL[0M1DU;0;'49(A$]S DI0'(7(S6;
MX>\0W6KZWK>GW-I' =.E1%*2%]X8$Y/ ]* .CHHJK?ZE::7"DUY,L2/(L2D]
MV8X H M44A8#K2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4
MTP8L$'^T_P#Z$:MU3TLYL$/^T_\ Z$:N4 %<UXT3S++2D]=6M.O_ %T%=+7.
M^+R!;:1G_H+6O_HP4 =%11VHH **** "BBB@ HHHH **** "BBB@ HHHH X+
MQEXFUK2=0G@M9+.QMHK,SQ3W$9E:YD!_U:*&!''4X-9=SX\\375EX6?2K#3Q
M-K2-E9RQ"L,YZ'A<8/<UK:QX+UF[\4ZAJEAJMK%#?VGV607$!D>%<8(CY YZ
M_CTK,T[P#XGLG\.^9J.ER)HKL8P(W!=6X()^G>@"E.WBQOB59+%'I:ZTVB'S
MRY?R4_>GICDGI^9IUWX^UH^%KB6\TW3Q?Z?J*V5['*C.A)/#(,_7O74:IX9U
M=/&B^)=&N+/SFMA;2P7:MM(S]X%3].*S-5^'NH7?AJ?3X+ZW:]O;[[=>74RD
M OG("*.@[<F@!EU+XAF^+7V>VU"S$2:8TT,<L+%=I<#!PWWN.OIVJIH7BOQU
MJUM>:@+#2I+6SEFADB5F1W9!P 22 ,XZ]:WM0\+Z]+XIL]?L-1LH)TLA:SQR
M1,ZGYMQ*G/<\<]JI6'@35XO!^NZ%=:C:AM2E>9)H48;&8@L"">G&/Q- &?HO
MC;6K_P 3VFB'4-.GDO;-Y?,AMFVVTH&=N=Q$@&,<&LG1M;\26OPTUG7I+JQO
M1]ID9HKFW)R=P!/!P>HP,8&*WM/\!>)(=;T74KK6=/\ ^)=$;80P6A"B+&"!
MSR3SD\8J-/AYX@M_">H^'(-7L&LKJ4E-]NP95+!B20>O &.E &F?$VIZKK%E
MH.CR6MM=?V>E[=3RQEU0,!A57(YY'4]#6%>_$'Q!;^'-4(CT\:MI5\MI<DJQ
M20,V%9!GC/.<UNR^#-6@U;2]=TV\M(]6M[46MV)58PW"@8!P#G/ []A5;4OA
MU>7NAWEM'?VR7VHWHO+V<PG:6!R%09R /<F@"QH^O^([?QXOA[7OL,HN++[7
M$]HK*(\,05.>O0U;\?>)KKPU:V#PL((+B?RY[UH#*MNN.I4$9S_0T+X8UB3Q
MS9^([C4+,K!;?9F@2W8;E.22"6ZY-:?B'3-6OI;232[RVB6+>)[>ZC+Q7"D#
MA@".F,T <#XCO=3U30/#LCW=A>7<NMI]EGAXBD3G:Q )(]QU%;%KXG\26EWX
MFTV_73[J]TVV2XMWB!BC;<,X;<>@^M1?\*VOH8+%+/4+*%K;46U(J+4^7YA(
M^15#?*@ '%+K/P]UG6K[6[B76+2%=4@CB=8K=OE\O&WJW0XYH /"_C'4-2\4
MG2+B]M[Z!]/^T^=';-#L?/*KDX=>>HKEHV_XL1=$]]18?^1A756W@3Q/%K-K
MK#^)+3[7%:&U*+8CR]G90-PXZ<TP?#G5_P#A"F\-?VQ9^2UQYYE^RMNSNW8^
M_P"M 'HEO_QZQ?[@_E7B7A_5/%?A[P"^M6$VGOI-M=R-+;O&QE=3+@G=T'6O
M:[1)HK.&.X='F5 '9%VJ3CG )./SKAK+X?:A;Z,_A^;5X9-$>Y\]U6V*S.N[
M<4+;L 9[XS0!D7/C[Q!K5QJ#>&+.>2&TV+&JV8E$KD98.Q8;1V& :] CUB:#
MPK_:^HV;6\T5H;B>WSRI"Y*_I7*W/P[U"TUVZOO#>OMI%M>A?M-LD <9 QE#
MG@]:[*/1[5=$_LEM\EL83 V]LLRD8))]3F@#DM(O_&&I)HNM)/8R:;>_/=6N
MP+]GB/*E7SECCK[]JSV\4>(M3\-:CXJTV\MX+2SED,=C) &\V.,X;<^<@GD\
M=*M^'OAWJ.B7$-M)XDGN-$MIO.AL?*"G.<@,V>0#SC^5/7X?7MM;ZCI5CK2Q
M:'J$IDDMFM]TD88_.J/NP ?<'% %%O$_B76O$VG6&CWEA:VFHZ6+Y&D@,C0Y
MX(SG#,#]!46E^.]6O=&TRQ:6#^V;S4I;'[48ODV1GF0+QS@C K?/@V^@\4VN
MKV&IVT$%K9?88+=[0MLC[<[QDYY[5D#X6W*Z,MJNN[;VWO3>VEY':[6B<_>!
M&XY!X].G>@#)C;5])\<>,9VU)9[ZUTE)DN&@49"@, 5''08K47Q7K;0>!KEK
MJ,?VO*([N(0KM;OD'J/PK0TWX?7D6JZEJ&J^(9;Z74;0VMPJVZQ@J1CCD].U
M4;;X8:C$VDB;Q9<21:5*'M8Q:( @';J<GW.?I0 ZQU?Q7XHTYM<T.^MH85O#
M&EA+&NUHE.&+.>0W?C%9T&IZAH_B[QIJUUJ,]U%ID$>+=E4"0%257./E )/3
MKFM:'X9S6FI72V?B&[M]$NI?-GTU$&&)Z@/G@'O@=.*N7'P]%SXBU._;59ET
M_4HA'<V"1* ^%VCY\\ =>GXT 86G^)/'$$MKJE_82RZ.T#37?F+ @C7;N!C*
MMN/T;DUE^*;O6=9\":7KUWJ6(+R^A;[!'$H1$+G;\WWBPQR<X]N*ZG1OAM)9
M*EKJGB&\U33(5*P6,B[$3.1\W)W8!..F*HO\*;LV$>EKXLO1I,,XF@M6@5C'
M@YQNSSU/;'M0!W7B$X\-:J?2SE_] ->5:3?>*O"WA#PQJG]HV]QI4QB@>P%N
M%94?H0_))_SBO79K(7.ERV,\DCK+"8G?C<01@GIC/X5R>F^!)[.#3K34=9;4
M-,TQ_,M;4VP0[AG;O8$[MN>.!0!BKXGUW2[WQ#HFJ:FTNJH8SI1$$:^:KMA2
M!MY.3SUZ&O1;>.YMM+5)KD7%RD7S32*$#MCJ0. ,^E<3IK6/C7QM;:Y!IUS%
M'I"20F6YBV%Y"<  '^Z,GVS7=7MJE]8W%I*6$<\31,5/.&&#C\Z /*]+\7:]
M_;_AY)M2>Z34)W@NE6V46JD9P(I  6([G)'N:AN]>\8-IOBJ_37XDCT2^,4<
M:V: RA6 P3V&#[GWK8C^%=W''IB?\)9?;=,E+6@$* 1H>PYZ^Y_*K0^'-X=+
MUNQD\0%UUB?S[EQ9J"&)R<?-QG H Z^UO9+C0(;[,:2R6JS9<X125SSZ"O+-
M)\7>()-<T",ZK-<KJ<TL-PYME%J".@A; +8[GH:]-@T0+X9_L2YN7G0VQMFE
MVA6*E=O0<9Q7&1_"JX6'3$/BO42^F.?LK"- (DQ]T#U_VN>.,4 9NC77BS5[
M#7=1O-?5].L)[RWDMOLRAI0L9[CIC(P/K6=H\WB7PMX.\-:U'K,<^FRR10OI
MWD 821CT;J6YKT+0/!G]B:=JEA+J<][;ZB\DDOF(JL&<88@CUJMI?@(V<5A:
M7VK37^G:=)YEI:/$JA"/NEB/O[<\=* .;O=4UB]T[XA6MUK$RKIH7[.T2(A"
ME&)7IT/ ]:JRR>(--T3P18Z9XAGA7551&\V)'\K]VIP#@' ST/YUV%MX$$<^
MOO/JD\R:VA6X3RU7:<$ J1Z FJ2?#65!I&[Q)J$G]E.'MQ(D;;2,  <<#  Q
M0!@:S?>)-+:]L+GQ'<WES8V!EC738 '+<G?/D850 .,Y(YIB27WB+Q3X&N;C
M4[ZWDN["69Q"ZJ%94Y*C&/F[YSP:ZO5_AW!JNM7^H)K&HV:ZA"L5W#;.JK+M
M7:"21TQV[U%%\-8((-%6+6M22?2]ZI.C@,T;=4Z?*,<<>] &(NL:YKGA76_$
MUKK,UI)I\TPMK-%0Q[(L'$G&6+ 'N.M02:KXD\4>(=&MM/UZ;2HM3TC[8R"!
M6$;9P=O0G)&02>AKIW^'5LMQJ"VFJ7MMIVHOON[%"NR0G[V"1E0>^*M?\(5&
MGBJSUR#4)X19P"VAM$C3RUB_N=,_CUH N:]<7>D^#+J8:C!%>06N/MEPN$W@
M8W$#/4]AGFN#TC6-9A\2S:<-0U<6EQI#W<<E^$:3S%XWH"/E4\\,/PKT?Q%H
M5MXDT*YTJ[9UBG4 LAP5(.01]"!7&S?#VWT>4Z]<:]K%S/;6C1-N<MYH[*0H
MSMZ?*.M '*0ZKXML/!&F>-I/$D]R&G59+%XQL>,N5()'\7'7WK4BA\5:WK'B
MRWM_%EY;II<JO;H(TRS%"P4D 87MCO4_P[\+_P!H^$],&IWNH-!9RF1M,GBV
M1K*'+*3E067D'&2,G\*CT727U_QKXK:/4M6T^VNY$P(H#&MQ&%PW+IP03C(Y
MY- &=:ZUXE\57?A.%/$%UI_]J6<[3&!%P&C)&X# Z[<\GC/&*V]*&L^(KCQ!
M:3>(KZ"71&6U@>W(3S'523+(.=VXCITKHSX"L5US3=2M[V\MAIL0AMK:$H(U
M7^('*DD-WY_&EU'P+!=:U<ZI9:G?Z9->H([Q;5U"S@#&2"#AL?Q"@#A+CQ)K
M-[X1\.^+Y[V_ABBNU@U.&W<QQR1AR/,P/P!^N*T=9U_4;>QO-=TW4)_L^J:E
M'IUB))_W4:=&E7((7)1@#V'-=^_AK3#X9?P^D'EZ>T!@V)U /<9[YYSZU7O?
M!^D:AX43PY<0$V,<:I'@X9"HX8'^][T </<7_B[P78ZQJ5]<++9_9@UM!<7G
MVF1)=RKNSM4[/FR1]*=J.CW%EXQ\#W+ZQ?7QGF<R>?+N0MY9)91_#G.,#CI7
M2Z9\.],L]+N[*]N;W5/M47DO)>S%V6/J%7^Z,@'CN!56S^%NE6EW8W!U76YS
M8G-LDMY\L8]!@ @?0T 2?%I@OPVU/D DQ ?7S%K DLM>T;Q5HVFOXCU"]M-<
MMY8Y-S[7@D5-V^/'"@<?K7H6OZ%9^(]&GTN_$GV>;&[RVVL""",'Z@5DQ: G
MAV*;67DU'6[^UMRD F*M($Z[4 4#)[GJ: .,T#4M1U!%\(7>J:@NN6VI/]LN
M5G;=Y"#.X'^ZPPH'OFNT^(<1?P#JY6:>(QVS.#%(5+8'0GN#W'>H/"5O)J.J
MZAXGO-'DTRYO$2!(IAB3RT_B8=B2?R45TNI:?!JNFW-A=*6@N(FB<#K@C% '
MDTNERF+X<6=MJ%S#+,DC_:2X=XP85)5<]!C('I2R^)M7T33-;TI-2FN9HM:C
ML8;J[D^>**0 Y+XXZ$ XXZXKK+3X:V=I)ILJZWK+/II)MB\Z,$R,8P5/&T 8
M''%/_P"%:Z1(FKI=W-]=KJK![@32+PX.0ZX48(H C\+67B33=?GCU*Z3^S;B
M+?#;S7QN95D!&2K%0=N#R.W%6?B:X_X5UK:AAN\@'&><;A5OPSX,T_PN9'M[
MF]NYG01B6\F\QD0?P+P %SSBH]=\"Z7X@U=-1NYKQ'$0ADBBEVQS(&W;7&.1
MGZ4 9>K:G)8_#S2=/LHI9;W4+6*WACA7=)M\L&1@/4)D_7%<YX/N%\-?$632
MX].O=.TK5H%-O%>($(FC7G&"1SS^)%>AS>&H)?$-IK O+Q'M8S%%;HRB%5(P
M1MVYYP._856\1^#+/Q/=V5S=WE]!)9-O@^S2*FULYW<J3G@?E0!POCK2Y[GQ
M%K.N6,6;_0H[.YA8'JH+LX_+G_@-4?&VJ)XU\'ZCK<2D:=I\$:P9Z/<.R[S_
M ,!!V_4FO2['PG#9:O=ZD^HW]U+=Q"*=+AT*.H&!P%'0$_G56\^'^CW7AJ/P
M]&]U:Z:K%FCMY #(2<_,2#GF@##USPRNMKH4FE:N;#Q)96*R6[GD/'@ AO;)
M_4\&K7@37]2OM9U72M?TZ*WUNS2/SYX?NSISM/ZGIZ]JTV\"V;/8S#4M42[L
MK<VT-TEP%D"9S@X7![#D=JT=$\-6FB2W5PDUS<W=T09KJZDWR.!T&<  #T H
M Y?QG=SS^)8=/M;F]G\NQDF:RL9C"P;/$DDF1A0.@[GM7+'4]<U/PIX'E&MW
M\-Q?7AM9WBDP74.0">.2 .IKT/6O ^GZUK<>JO<7EM<",0S?9IC&)X\_=?')
M'XUG6_PMT:UBM(XKW5@MI-YT ^U<1OG.0,8% ')WOB+5?",_B^P@O[N\2V-N
M+:6\D\QX6E W-GTYSCZ5H7^CC3OB9X/":A=W1E29Y'NKAI,D+]X9X&?0<=*Z
M?_A7VER7NJ75W<WUX=3C$=RD\JE2!C;C"C!&.*AL?AIHUE?6%X;K5+B:QSY#
M3WC-L'8#T'L/QS0!#\5I[RT\'&YL;^YLYEN(QN@?;D$XP>^*QHM)OE^(+Z _
MB76&M;K3?M$Y-Q\Q<,!\AQ\@Y[?2NX\1^&K/Q/8I97TEPMNKARL,FW<1TSQV
MJK_PA5C_ &RFK_;M2^VI#Y D^T?P8Z=/Q^M 'FYU74V\ V%RVIWGVFTU_P"Q
M+-Y[!FBW='P?F_&M[78GF\7^)].DNKK[&V@M<^2+EMH<-U S\O3I_C71?\*\
MT3_A'[O16:[>TN9?..^;+))UW*<<&EL?AYH=C>M>C[9-<20&"5Y[EG\U2"#N
MYYX/\J .#TV/^R/#G@.[L[F^5[N]C69!<N4=.<KLSM Z=O6KNI:K=:;XB\<P
M_P!M7-G;PVT+PNS-+Y3OC.Q2>"2<#'3/M75K\.-$70?[(W7K0+,)HG-P=\+#
MIL/\(&3QCO3#\,/#;+>"2.[E:[C$<KR7+,QQC#<]6R,Y.: ,/PK/?VWQ!>RE
M2^M[672/M'V:[NFF)?>!O.2=I//&>*Q(CN^ FI-ZW;<>G^D+7>6OPZT.UO(K
MV-[_ .UQQ&+SC=OO8=LG/..W;CI2+\.M%30GT59M0%A)+YKQ?:3\S=?Y@'ZT
M 87B2YD\&^,M-URXO+QM'NT>&:#SG,<4H7*D+G&#C&/J:Z_PM8W%IH<<EW).
MUU<DW$JRR,_EEN0@W$X &!^%8FHVNHZUJL/AR?17.C6LT4SZC<3!_." , !C
M.XMP3Z9KML<8H \?\7W5W)_PDU]8W=_<O8NBK.ERT$5D1@%%4']XW/)P.M;*
MSGQ/XPDT35+R:..#3(IH8X)C'OE< M)E2,E<C Z=ZW+WX<^'M0NKZ>>&Y_TU
MB\T:W#!"Y_CVYQN]Z;?_  U\-:C#9I-:RJUJFQ)8Y2LC+Z,W4T <[%<O+XCT
M7PE>Z[/>6:V\K2W".8VNI5) 0L#G"@'OR:CUF2[TA])\,P:[Y\5UJ$JR37+N
MOEH K+ 7!R?O>N>0*[+5? ^@:QIEKI]Q9!(+3_CW\EBC1^N"/6BX\#>'[GP\
MNB26(^QJV]<,=X;NV[KD^M '":YI>K>'/"/B$/K[G88IK>WM9Y ;8,VTC).[
M:<\#/:K$FB2:%XC\.-!JFHW2ZO'+%?)<7#,)!Y8.X>G7MTXK2\4^$;;2?AY?
M:-X>TRXFFO'083YW8A@<LQ[ "M[P[X9L;)+6_=;R2[6 1K]MF:1H1CE5!)"_
MA0!YYHD=K8?#221;N[MY;W4F@6.&1F:3]YCRU!("Y P6J:R>YT^\\<Z8\/V6
M)-,$J6J7#2K&2AS\Q/4Y&<<5VTGPW\,2P7,36+XGE,N1,V8V)SE.?E_"I;/X
M?>&K&ZDN8M.!ED@,#F1V;<I&"3D]2.IH X--$?0]$\(Z_INH7S7]Q-;12127
M!99$<#*!>@ %2WNKWFDS?$.]L6V3I<6Z+(!G8"-I/U )KO\ 3?!VCZ5/%+#'
M/)Y'_'ND\S2+!Z[ QPM/M?"6CVD]_*EN[M?@BZ$TK2++]03C/O0!R/AO2+NS
M\1:9J(\06!ANH"K6MOYA-W\I;>=SGYAUS5KXFZ=:WS>'5N(MX?4XHF.2#M)Y
M%;^A^!_#WAR]EO-,L%BN) 07+%BH/4#/05H:UH6G>(;#[%J=OYT(8.!N*D$=
MP1R* .,LK:WU_P 9:YH^J+FVTZ&.*RMM[ *A'+CGD_=Y[<5I?#6]OKSPPRWT
MSW'V>YE@BG<Y,B*< GU],UJW/@_1+EH&^RM"\$7D(]O*T3>7C&TE2"1CL:UK
M.SMK"UCM;2%(8(AM2-!@ 4 3T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %+2O\ D'I_O/\ ^A&KM4]*&-/3_>?_ -"-7* "N<\8JK6ND!@"#J]I
MD'_KH*Z.N>\6KNM])&/^8M:G_P ?H Z&BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#F]8\:6>BZW;:1-8:C-=7*EH!;PJXD ZX^;M5G3?$T&HZJ=-;3]1
ML[CRC,HNX0@=00#@Y.>2*Y#QS]N'Q)\)'3!;F\V7 07!(3ISG'/3-;]A#XAN
MWU2+6Y+>RE8+'8W%EAMH();:6&<Y R".U '5T5Y)X<UCQ!J?B5O".HZS)%>:
M=+)--=Q.N;J/C:BC;P1G)].>*DN-8\7>)+O7'T!IT-A>FVMO+GA6(;,9+JPR
MV[KZ4 >KT5YE9ZGK_BW6M2TIM3_LJ?3K2,A+212))V&2S-@Y0'C IZ7WB#3_
M !CX3LM2U@S/>03)>QQ%?*9T4X(^48.<?B* /1IYXK6%YIY$CB099W. H]2:
MS;W67M-;T[3UT^[G2\W9N(DS'#@9^<]LUY-XEN-2N?"?C"WN=7O98].U-(H0
MS@%D) VM@<CO^%=1>7.J:3XO\(:=%K5Y+9W<;B6.?:Q;"YY8*"?;- 'H]%>4
M/K>H^'?$'B71]1U.^N'DMUDTG=(-S;SM 7CE@Q'X TEW>>);K7!X8MI[V>2Q
MT]))IH[Q;>625^K%B#N4'@ ?G0!ZQ16!X/&MKX=BC\0R12:C&S([1,&R!TR1
MQN]:\SUSQ#K%JU[JMGJ]_=R0:J(A) VVRBBW8$94@;VYP2,_6@#VNBO,+^UU
MK5_B+K.E)XEU*SLX;))U6!@I4GH!@# !_$CO5'0O$^J:_:>%M"FU&>*2]6=K
MN[C;;)(D1.%#=03CD]?SH [O0_%2ZUK^KZ4+*:WDTUE5FD8'?G." .G3]:VI
M[V"">&"215FG+"),\N0,G'X5Y_\ #ZS^P>.?&-L;F:X\N6$"2X??(1ACRW?_
M /52^*=-2[^+/AE'N[V,2PSMB*X9 NU<_+CIGOZT =+X7\4?\))-JD1L);-[
M"X^SNLCAB3SGITZ>]=%7A=S9W\5OX]UFRUN_LGL-1=XX;:38KMNZOW88[5M7
M6J^(O$VO)I5E.R^3I<-P5BO6M2TDB E\JI+ 9^[P* /6JYK4?%RQ:Q)HVD:?
M-JFI1*'FBC=8TA4]-SMP#[5-X136(O#T,&N7<%U?Q,T;RP/N! .!N.!\V.M<
MI\*V8:IXNCNVS?\ ]I%I0WWL<XZ]NM '4:'XH;5M8N]*N=,N;"]M(UDD28JR
MD-_=93@CWKHJX_Q]JR>'- OM5LUB&J^2L228!=4+8W$=P"?SK NXK[PUK7AB
M:QU34+B#5W%M>1W%PT@)8 ^8N<[2,D\<<4 >GT5X44U)_!'B/6V\2:R;C3-1
M=;9/M9P &4?-_>Z_3CZUTMG;7]EXXTJS_MO4IH]9TR22Z:6;.' !W1C&$(SQ
MB@#U"BO";6TUEOAW+XO7Q/J[W]E.QBCDN"T919-NT@]<^]6O$^IWU[9:[JMG
M>:C=26L<+"6WNFMX; [064 -^\;)YX_&@#VRBO*+NVOM<^(&C6<NLZC;VM]H
MPN)X[>X*!CW"X^[DXK'2'6=4^&MQ?1:C?O=:)?RJI^T.#/ A!9&P?F//4\\8
MH ]OHKB?"%W'XDU6\\2PM<I9&)+:W1Y7VM@ NVTG&<G;G'\)KM000"#D4 +6
M WBW3AXS'A@O_I9MO/SGC.?N?7'/TK6U"]AT[3KB]N&"Q01M(Y]@,UXCK5GK
M5I96GB]O#MU;ZG!=_;KF\,L;*8FX"; V<!=HY'K0!ZEXG\33>';O28TL!/#?
MW2VS2F;;Y98\<8.>_P"5&G>)KF[\;:EX>FL%A6TMUG282[C(I.!QCBL'Q[?P
M7^G>$KRV=7MY]5MY4?I\I!-6;%3_ ,+IU4AB!_9,19<?[= '<GI7'67B_5=1
MD\26MOHBF^TEE2*'[0#YY;)'. !P,U!XPNS=^,/#WAR>:6'3[WS9;@HY3SBB
M_+'N&#C/4#KQ7'VVFQ:9:_$FTL9KF!;;RWB:.9@ZX5B!NSDCMSVH ]>TZ>YN
M-.MYKVW^S7+H&DAW!MC8Y&1UJUD5Y'JUOJU]X;\+7<41U>S@T]9+S3%N62:7
M*@>:,'+$?CS]:SH+&UUF_P#!5M9ZSJXL;N"YCD_TED<!/X2,D _PDCJ!0![;
MD4C2*BEF(50,DGH!7@>LVTVCZ;XGTE+NZFM=)O[1[*5Y&+0F1OF7=GIC_/-=
M1J=K:W/Q/EM9"7BN] =[B/S#AV]2,]< ?E0!Z3I>K6>LV"7UC+YMM(6"/@@-
M@D'KVR*N9XS7@.GRBQ\"^$[*VDBM8=7NW6^ED9PCA6PJN5((4YZ C./K70S^
M&-1L]'U;2+'Q#93-<30S0Z:KND2@L28@Q8D!\8QGG% 'KV<T5YU\.KVPM)-;
M@DL)=%NXYHS<V4\F8XB1@&-C_"Q!('Y9KK/%=]=:;X3U6^LO^/F"UD>,@9P0
M.N/;K0!L9!HW#..]>5Z%9:&;/PYXCLM:9=5:'9,J2;WOI67)20=3A@?H!]#6
M#-:Q:C\*KKQ@]Q+_ ,))%<&8W8D(='$H7R\ \+MQA: /<6D5%+,P51U)/2J.
MH:U8:8]I'=3!7O)U@@4<EV;IQZ>]>3G1+?Q)\0=1M]7%R0^B17<D(N'"B8@9
MXST!)P.GM65;V=MJ>@?#R;4(UN9)-1>UD>;YBT2R'"$GL* />R5 R:3>F_;D
M;L9QWQ7D6C^$-)U#XB>)=S76S2Y+:6T2.X<*#LW>N2,CUK-%O;ZG\)[OQ;)(
M4\20W#SF\5R)4D63 3.>!MP-O3I0![@74,%)&3T'K31/$4+B12HZMD8%>1:N
MP\)>)M$\;75CMBU"T\F^C5<E+ADR& [$XQ^=5=5TLZ7<^%M$G:RL;?4?/N;O
MSX2T,EP<%4D4,H(7( Y_"@#VCSH]H;>NT]#G@TTW$*H',J!"<!BPP37@_B#P
MS;Z3X3:V&N#4-FKPA!;,R1VV_)9%&XCT/J/QKH->\&1Z#>VZZ':VVKVMO!++
M-H=],7;:QYECST/&,_XT >A7UUK8\0:;'806<FDR*WVJ623$BG'&P=_U_"M<
MS1JXC:10YZ*3R?PKQNU_LZ?6OAO?Z9YZH\<L(69OF"HI&".G!+#/>LS3;&+Q
M-IE_J.I^);'3=5M]0>665[;_ $N$J?E57,@.W' 4#'XT >[-<PHX1Y45CT4L
M 34O45XCXML#:ZIJNJ:A:6^M:-)-&;BZA(6\L& 7 &>@Z'&,<]J]CM-1L[R2
M2*VNH998\>9&D@+1YZ!@.1^- $\DT4(S)(B#U8XI?-3Y3N'S?=YZ_2O,O',=
MOJ'C5;40VUW<0:8\C1ZA(!:P(6/SXQDN>G&,<'-<?;V\&K>%/AXMU*SR-J)M
M799"&$9;[N0<CC% 'OL<T<JEHW5P#C*G-<C?>*KV#XB:3H4(LY-/O8I&,BL6
MD5D4DCK@=O6O.-2D_P"$97Q[I^CF2TLXY;0>7&Y/EH_$C#TR.,UOFP\/Z9\4
MO"$FBI:Q036<V6B( D&P[6/J3GJ>30!ZNS*B[F( '4GM7/\ B[7;K2/"5[K&
ME?99WMEW?O"2I&<'[IZ\UA_$^]^S1Z!#=N4T:XU%$U YPI3J%8_W2>OTK%\0
M:=H.F^%_&(T.]$JW5JD\EO ZF"#)P-H7@%N3CVH ](TW41<:+87ET\<;W%O'
M(W.T;F4$@9^M5M9N=9CET[^R$LGBDN +IKAR,1_[&.IKSC4C87E_HELT<%Q=
M0:"KE-18?984*CYPN"6<],#'0<UCZ>8+CPGX"N'D$EU#K"P!M^2B>82%QGIP
M,4 >YR74$08R3(@7&XLP&,],TOGQ>8(_,3>1D+N&<?2O()_"FBZGXT\=?:[7
MS!;VL<T2^8P"NT98MC/7(_"J5MI=M8:-\/\ 7+??_:=S>PQS7)D9F="""IR>
MF.,4 >U-=VZS>2T\8E_N%AN_*I'=8T+NP50,DDX %>-:I;)I?B&74;NTM-6T
M>?65?^T86"W=G,' \MLY)4$8QZ>G%>@>/K/^T/"<]F+Z*SDFDC6-YAF-WW#:
MC?[+' /UH B\<>);S1/"T^K:,]E.T++O\TEAM)QQM/7)%=%:7L-S&JB:-I@B
MM(BL"5R.X[5XKJD@A\'^+K&ZT:'2M61;4W,=KM^SR+NPCH!TR,Y'-;4VFZ3X
M6\<:1)9(;.WFT:X>Z:$G<X5<[N>K=\T >I1WMK-*\,-Q"\J?>17!*_4=J\_@
M\9>()-$\77!&G_:]&F9(\1ML*JN3D9SGCBN/TDVEGK'@J\M#8VL,DL@W+*#<
MNAZM.PP.3GC''3)K<MP!X<^)F"/^/F8_^.4 >E:%>S:GX<TZ^EV^?<VL<KX&
M!N903^&36#X0\4W6I2:M#K4]E%/:W[6L8C.P-@#IN.36KX08MX)T,Y&?L$(X
M_P!P5Y9#X>T35+'Q]>ZG#&UY;7DYAEWD-$0"5Q]6_.@#V>XO+:T56N;B*%6.
M 9'"@GTYJ8$,H(.0>0:\)T[[5JVJKIWBO5;?3YCI4*VPO[99%9"OS$%R K].
M>OY5ZGX*M(;#PG;6MKJ$NH01%UBN)%QO 8CY?]GT- &Y)?V<5RMM)=0I.W2-
MI &/X=:)[^SMI4CGNH(I'^XLD@4M] >M>1>'SX8UGPY(WB*Z$.NPZ@TT[%PM
MTT@;Y0N1N(Q@;1^E7-/MM.UN+QO_ &_#"VHQ328:X4;X80G[LJ3RH&,\4 >I
MRW=O P6:>.,D$@.X&0.O6DBO+:>W^T13QR0]?,1P5_/I7BMAIL6M:G\/QKUN
M)I;FUG$IESNE50QCW'J>,5#<M'H^G:YI\),6AIXCCBN8T)PL!&2..@) H ]&
MC\3SOX_.F+>:?+I)L6N2\9RR$,%^9LD=?IP:Z=M2L52)VO( LO$9,BX?Z<\U
MYU''H(^+"16 L&MKO161XX0A1VW\# XR5 X]!7)K>6"?"?1K:2:W^UQZL/W;
M,N] )"3QU QB@#W*XU&RM98XKB[@ADD^XDD@4M] 3S6=<>*-+M_$4&B/<H+R
M6,R8+@!<8 !YZG/ KSNWN/#6JZSXOL?%5S!%-+<8AEG8(WV<<IY;'Z9XZY[U
M8=='M_B5HT^R&.!]%WQ/=A59Y-V%+%NKX YZT >FMJ-DMTMJUW +END)D&\_
M\!SFLKQ7K)TG0KV6VOK.WOHX6EB6X(._:,X"Y!).,5Y/HR:3K.A[M7\1&TU.
M&],LD"V\?VDS%N-C8WMGVK6BNM)N]'\<KKK6XU@33A5NB X14_=!,]LYQB@#
MT?PW?7.K>%-.OIW4W-Q;+(S;<#<1Z5A^#O%,]X=5@UV_LUN+:_>VBQB(,!_=
M!.36CX GCG\":,8Y$?;:HK;6!P0.1]:\]CT?0+[3_'EUJ4-NUU'?W BD<_O$
M(R4V^F6].M 'K@U.P:[-HM[;FY!QY(E7?_WSG-26]Y;7>_[-<13;#AO+<-M/
MH<=*\GO;6]\,VGACQF;-YKN*U2UU"(+AW#+A6/?<"0.?:O1?#&F_V=HD/F1J
MES<9N+C"X_>.=S#\,X_"@"W=ZUI>GS)#>:A:V\K_ '4EF52WT!-75(8 @Y!Z
M$5XUXQO;"XO/&"13VEK*D*1SM>D/+.RKPL*DC:/?GGM7IGA&ZBN_".DR13I,
M!:1*S*P;Y@@R"?7- &U1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!2TK_ )!Z?[S_ /H1J[5+2?\ D')_OO\ ^AFKM !6!XK.(-*_
M["MK_P"AUOUSWB[_ (]](_["UK_Z'0!T-%%% !1110 4444 %%%% !1110 4
M444 %%%% '(ZWX.O=7\2V6M1ZX]I)8@BWC6V5PNX8;))YS3V\*ZI/?\ VV[\
M1S3SQP/';?Z*BK [?\M HX+ 9 SZUU>:RY;G5AXAMX(K.!M):$M+<M+AUDR<
M*%[CI0!S,WPWB:/1FMM3EM;S3&9_M<<">9,2<G<>_P".:6]^&T,^NW&I6.M:
MCIHO#F\@M7VK,>Y]B:[C<*7- '#:O\-;2[U>#4])U*\T:YCA6!VLSCS$' !]
M\8Y]A5G5/A_:7D.E"ROKO3[C32?)N(FW.0WWL[NI)R<^]3^.O$E_X8T>"^LK
M:"96N$BE,K$; QP" .OYUTS2*B@NP4>I.* .&B^%U@FDZQ82:GJ,ZZHXDD>6
M0$JX((;IR<CO5A? +_VAI5[)X@U"6;30?*,@1LD\-DD=".,=J[3.:C\^+S?*
M\Q?,QG9D9Q]* ,;4_"NGZKX@TO6;A";G3BQC]&R.,_0\BL_Q+X"LO$.J0:K'
M?7FFZC$GEFXLY-K.GH:Z>>1EA;RC'YI!$8D. 6["N:\#^*+CQ#H\EQJ)MHKM
M+J6#RXC@$*>,9Y- &YH^DV^BZ:EE;F1E7):25BSR,>K,3U)-<;/\)].FM[FV
M&K:I':2S_:([=91Y<3DY) QS^-=,UUK$?B=DD^PKHHMM^XOB8..IQTVU-I'B
M+3-;M9[FRND>&&5HF?<,94XR.>A[&@#$A\"?9]3NM0AUW4O/N+86S-)Y;G8.
MF25Y/OUJFOPNTU-(L[*/4+^.>QF:6UNXV59(MV,@8'(..]=JUY;(C.UQ$J(V
MUF+@ -Z'WK/UGQ)I>AZ8+^\ND$#,$38P)<D@?+SSUH H^'O!5GX>U2[U**^U
M"YNKL#SFN)]P;W(P,GK]*=XB\(6OB+4;&^DO+VTN+/<$DM)=C%6ZC./:MJ6_
MM((%GFNH(XF^Z[R *?H34CW4$<2RO-&L;8PQ8 '/3F@#D(?AO81V.J6;:KJC
MP:F_F7(:1"7;.<Y*9]/RHO?AGI%ZUC)]LU.&ZM(A EU!<".5HQT5B!S@<9QT
MKL(+B&Y3?!*DJ D;D8$9'4<4D]S!:H'N)HXE)QN=@H_6@"OI.E6FBZ;#862,
ML$0.-S%F))R22>I))-8^J^"=.U'61J\%Q>Z=J)79)/8S>69%]&&"#^5;0U.P
M:Y2V%[;F=P&6(2KN88SD#.3QS7+>)O%=QI^KZ FFWEE)9W=^MK=$8=ESUY!P
M.* -:+PAI0L;RVNEFOC>(([B:[D,DCJ.@SVQU&,<\U7T[P/IVG2V\@NK^Y:T
MC:.T^TS!Q; ]T&,9]SFMVUU"SOHFEM+J&XC4X9XI P!]"13+/5=.U!W2ROK:
MY9/OB&97*_7!XH YK_A7&E?V9?Z<U]J;6U_-YUPIG7YVSD_P]SS^%32^$-/L
MM0L]::\U:6?3H?+B59#(2@ZKM"Y;/I73W%Q#:0//<2QPPH,M)(P55'N37&>.
M/%<^G^&X]3\/ZA8R@74<,C "8'<>@(. ?KF@#%^'_@Y+C0 FL)J\.VZ:5K"X
M+1PL=V5.PCGMQG&:Z#4/AGX?U*\O[B;[:@OOFGABN62)G[/M'&?KQ[5TEIJN
MGWWFBUO;><P\2>5*K;/K@\5%:Z[I>IR2P:=JEG<7" Y6.57*]LD ],T 85G\
M.=(L-1@OK>\U198(3!'F[)"H>H&1GWZU1O-.N?!5F-/\-:)=ZI'J,C^;YMSN
M2%R,;FR.A[].E9*^+_$;_#O7]7^VVPOM.OI(A)]G&THI48"YX//4YKT&QU.W
M>UT]+JZ@6\NH%D6-G"M(=N257J>_2@"KI?AJULO"$6@,#Y'V<PR^6VTG<#N(
M/;))J]I.E6NB:5;Z=9AQ;P+M0.Y8XZ\DU%X@UNV\.Z'<ZI=9,4"Y"KU=CP%'
MN3@5AW<^N?V9ILL^NZ?IMY/=([QR(NTQD?ZE<G+'D<_RH V]>T&S\1Z<;"_:
M<6Y8,RPRF/=CL2.H]J=>Z):ZAH;:1<R7#6SQB-R)2'9?0MU.>]9R:U=:?XM7
M1]3>-H;X-+83*-OW?O1,/4#D'O6Y=WEM86SW-W/'!!&,O)(P55^I- ',#X;Z
M$+&TL@^H?9[.3S;=/MCXC;U'/%:%IX1TZS\0OKB2WKWSIL=I+EF5E]".F.^*
MAU;Q##=^%]4O?#^JVLD]K$7\R/;*$(&<$9[BN8E\2^(%T?P-??;T7^T[F*&]
M3R5S*'YR/3@=AWH [+Q%X6TKQ1;10ZG"[>2^^*2.0H\;>H(K)A^&GANWAO(X
MHKQ3>*$N'^V2%I%]"<\YK<U#Q'HNDW,=OJ&J6EK-)RJ32JI(]<'M[TZ77](@
MOXK&74K5+N4!HX3*-S ]"!0!CMX T3R;..-K^$V<30P/%>2*ZH3DKD'D5RWB
M/PMN\4>&=/L=(U"/2-/#B2XM&VD%\8(;.[J,L?>N[A\4:%<6]S/#J]G)#:X,
M[K,"(L\?,>U:,%U;W5JEU!*DL#KO213E67U!]* ,=?!^B?V!<Z,]JTEI=,7G
M\R1F>1S@[BY.=W Y]JI:=\./#&F7\5];V3M=1(4626=W//<Y/)QQ6/K'C82^
M,O#UCH6N6T]O<7+0W=O$JL2 ,YW'M]/3K6[HNHB.]UZXN_$EK?6D4H8(@55L
MUP?E9@>>GZ>] $47PW\*Q:3<:9_9@:VG?>P>1F93VVL3E<9/3UI\/P]\,P:*
M=*CT\K;&59F(F<.SKT8N#NX^M:EGXCT74$G>SU2TF6W7?,4E!$:^K>@X--TW
MQ/HFL/.FGZE!.T S(%;[H]>>WOTH P=:^'^G77AV?3+2U\R2YG666>ZN9&?<
M!@.6R2VT=%) KJK6S2#38K)_WL:0B([QG> ,<_6L^R\6Z!J-Z]G9ZM;37"@G
M8K\L!U*_W@,=LTEGXOT#4+>\N+34HIHK-=]PZAL1CGKQ[&@"IHWP_P##.@:J
M^I:;IJQ73 @,79@F>NT$X%2'P-X>.IM?BQ*N\HF>)96$32#HYC!VD_A4MSXR
M\/6EA;WL^JP);W*EX6Y)=1U8 #./?&*6\\9^&]/6)KK6K*,2Q^;'F4'<F,Y&
M/T]: (Y?!6AS:M<ZHT$XO;E#'+*MU*I92,$<-P/855;X<^%WT=-*;3F:SCF\
MY$,\A*/W*G=D?0<5;TKQMX<UN[-KINJ17,X0N416X4=^1TK1TO6+#6K/[7IU
MPL\&XKO4$#(Z]: ,[1_!FA:!?RWNF6CP3RKM<^>[!AV&"2..WI3/^$%\.?VF
M^H?V:OG22><Z^8WEL_\ >,>=I/X5)<^-/#MGJ?\ 9T^J0I<B01,,$JKGHI;&
M ?8FI1XKT0S7\(OE,NGKOND\MMT2^I&.1]* +U_I=EJD"0WMND\:2+*JOT#*
M<@U6UOP[I/B.R^Q:M9I<P@[@&)!4^H(Y'X5@ZG\2-$LI]'2"<W,>I/\ +)&C
MD+'\PW<#GYAC'6L?2O&MMHWBKQ1#XCU[_1HIX%M!,,;0R,Q"JHZ=,G'IF@#I
M'^'_ (7DTN#3#I:"S@8ND:R.!N/5C@\GCJ:LZCX.T/59(9;NT=Y88A#'(L\B
ML$_NY# U9OO$6D:;;6]Q=7T:QW'^I* N9.,_*%!)X]*JR>-/#<.D1ZK)K%JM
ME(VQ)=W5AU&.N1Z8XH &\&>'FGLYO[-C62R4+;,C,OE '(Q@_P#ZZ;/X'\-7
M6MC6)M(MGO@=WFE>I]2.A/N16'>^*M#U_4M(&E>+Q;.E]L,$*EOM1Z;"/[OO
MTK9OO'7AW33<K=7[)]E<QS$6\C*C#J"P7&>1WH EN/!?AZZOYKV?3(Y)YG$D
MI9FQ(PZ%ES@].XJOHOA*WTGQ/JNMQQQ0O??+Y<6<$9R6;/\ $3Z8 ]Z?=>._
M#EG!!--J&$FB6==L3L5C;HS #Y1[G%6=5\3:3I]A!--?86\0FW:!#*SC&=RA
M0<@ @YZ4 +JGA70M;OH;W4M,M[JXA&U'D7.!UP1T(^M4%^'GA)!$$T6W7RF+
MIM+##$YSUZUF_"W5;K5]#U&:YU":_5-0ECAGF^\T8QCZ?3WK-G\70>&/B7K,
M.NZU,-/^R1201298(S'D*JCT[_G0!V,7A'08;JZN4TV+SKM2EPS$MYJGJ&!.
M#56P^'_A73;B.>UT2V66)B\;L"Q4^V2?_K4]O'/AQ9=/C&H>8VHC=:^7$[B0
M9QP0.N>HZCO6E9ZW87VJ7FG6\KM=6>//0QL N>G)&#^% $NI:;9:O8R66H6T
M=Q;2##QR#(-9<7@OPY!H[Z3%I4"6+L&>)<C>1T+'.3^-8_B/7M1N_&-CX1T:
MY%I-+$;F\NP@9HHAT"@\9/KVR*LMI6NZ5K^E2VVL7M[I;.R7D%QL9A\C8?=@
M'&<9'TH N3^!?#-TUFT^D02_8EV0!\D*O7&">1[&F?\ " >%!%'&-%ME6.0R
M*%R,,>_!Z_RJ2U\;:!>ZC%8V]ZQEF=HX7,+B.5EZA'(VL?H:Y*RU.XCU#QY;
MZIXAN;>VMWC6&Z=LFV#AN4 Z<D=/2@#KQX+\.B:ZE_LV/S+I=D[;VS(OH>:8
M/ OAD000C2HO+MVW0KN;Y#UR.>*Y?Q%XJ&B>$M MK74KRZ>_>",W_DOYCQ$C
M<P.W[Y'0?>Y_&M+3=5L?"L4KZAX@O[Z"\_TBU@N()))X(AUSP6V\CE@,4 ;<
M/@SP[;WPO8M*@%P)/.WG)^?^]@G&?>M'4]*L=9LFLM1MDN;9B"T;C@D'(K*N
MO''ANST^ROIM6A%M>G$#KEMW3/0<8SSGI5!?BCX.?9MUA27#%1Y+Y..HQMZ^
MU &@W@GPT;)K-M)MS S!V4Y)8@8&3G)P.@-/_P"$-\/&YAN6TN%Y84"1L^6V
MJ.,#)Z5B>(/$VAZSX--_;>)9]-MGF"+=VZL) X/*;<9_"MG4O%NC:&4@O+J5
MI5@\YQ% \K+'_??:#M'N<4 ,B\!>%8%18]"L@$D\Q<QY.[ZGK].E2)X+\-Q1
MW$::1;*ESCSE"\28.>1]:U[.]M]1LH;RTE66WF0/'(O1@>AKA-$OK_Q_J.HW
M8U*ZL-&L[@VUO'9MY;S,!\SL_7'3 % '<6&GVFEV<=G8PK#;QC"1KT6J$WA+
M0+C4CJ,VDVKW9(9I"GWCZD="?<U0TM-1\/7.KRZYJS7&DQK&]M<7!4%%P=P;
M&,D''/?(J[IOBW1M5O\ [!;W$B79C$JPSPO$SH?XE#@;A]* )]7\.:-KOE_V
MKIUO=F,Y0RH"5_'T]JT8H8X(4BA14C0!551@*!V KS;XA^+[=M*C31]4O(KF
M.]2+S+='6*0YPR>9C!QZ ]C76ZKXOT?0W:*\GE+QH'F\F!Y1"IZ%RH(4?6@"
MPWA?0VUC^UVTNV;4,[O/* MG&,_7WI;_ ,,:'JEXMY?:7;3W"C'F.F21Z'U_
M&M&"YAN;>.X@D62&10Z.IR&!Z$5A?\)QH'VN*#[6X66;[/'<&%Q"TG]T28VD
M_C0!?N/#VC7=Y'=W.FVLMQ&H5)'B!9 .F#VID7A?0H8;F&+2;-([E=LZK"H$
M@Z\^M<=XEUL:EX[M_#KRZK#9+:.\ALXY4<RDX5LJ,E1Z_=SUK6UW5KCP%X $
MTUW)J5["!!%+/]Z:1CQN^@_E0!LV'A;0-+ECELM(LH)8QA)$A7<OT.,TT>$O
M#OG3S'1K%I+AM\K-"K;CG.>?>L9/"NL2Z+YTGB74QK3P[C(LF(5D(S@18VX'
M2H(+B.+7O#5MJNLWT.L1V69+%"QCG;8=Q<CY21@_I0!TMWX:T2_N8;F[TJSF
MF@ 6-Y(5)4#H!QT%376C:7?7EO=W=C;SW%O_ *F21 Q3Z9K/TWQCI&K07\UF
M]RZ6&?M&;:12I'48(Y/'0<UE1ZUI.K>,]'DMM9OXYY+9VCL/+=(YD()WL"!S
MCD?04 =!_P ([HIU4:I_9EI]OSG[1Y0WY]<^OO27OAK0]1O!=WNE6=Q<8QYD
ML*LQ'3G(YKG? =Q=2:MXIM[B[N+E;;4C'$9Y"Y5<=!Z?A5?QFEU_PFOAJV@U
M74;6#4'ECGCM[ED!"*"" .AYH [BTM+:QMUM[2"*"%.%CB4*H^@%4G\.:*^H
M?;VTNT:[SN,QA7<3ZDXY/O7#:+XLET#Q'X@TS5-3FOM(TY%DCNW0R/&2?]6S
M*.3R>OI7267Q#\-W]O=3P7KF.V";RT+ DOPH48RQ)XP* #4-)U[5O$ ANIK-
M?#J,DOEH&\Z1EY"D],;L'\*ZD=*Q=-\4Z7J=Q<VR22P7-LGF2P7431.J?WL-
MV]ZKV?C;1;[4K>QBEG5[D,;>26!DCGV]=C$8- &C/H&D7-X]W/IEG+<R+L>5
MX5+,N,8)(]*MVUK;V-NEO:PQP0H,+'&H55'L!6!+X[T.&]6W>6?RVF^SBZ$#
M&#S/[OF8QG/%4?&OB2S@TC5;&&;4!=0P%GEL8V/D,1E=SC[N>/PH [.BN-\,
M^)K2UTGPYI=]+=-?WUDCQR/&S"0[<D;O6K4_Q T&VL[VYGDN8TLIA!.&MGW*
MY&0,8]J .HHKE[3X@^'[^VDFM9IY=LHB6-;=]\K$9 1<9;@5I:'XBT_Q DYL
MGD$EO)Y<T,T91XV]"IH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"EI7_ "#T_P!]_P#T,U=JGIG_ !X)_O/_ .A&KE !7/>+?]1I'_86M?\
MT.NAKG_%BEH-)QVU6U/_ (_0!T%%%% !1110 4444 %%%% !1110 4444 %%
M%% 'F'CVVOAK%QJ'V./6M+BM!'<V:S;9K,<GS$'J1SG&>/2HM)6QE\?Z";*Y
MN9+2ZT%L&61MY .T'_9.!V[BNVU/P;HFKW\M[=V\QN)D$<K1W,D8D0?PL%8
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M,]<&G]10!XG>^(?#U[>_#UM/GM0UM,BS*H^> ;5&UO3G-313:%<)\0;2YO\
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M]DERIP$&X\EL<8&*DT#PW?P>)['4+'2;K1%E1_[5MS(IMG)7C8 Q_BYZ#&*
M-T_$*$^$[3Q$NFSFUFG\AT\Q=T9W[0?<9I-<^(MEI%Y>01P+<K8D"Z;[2D;
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M6UK## <YBCC"KSUX'%8NM^---T2^:Q>*[NKF. W,L=I#YABB'\3<C J ^/\
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MPKMJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *>E_\
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M ]4J.X@2YMI8)03'*A1L'!P1@\UG:3)K;W>H#58;1+=9L6;0,2S1^K9[UJT
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MMC. .0?I6:WBCQ#':Z19K/<W%YK$DUQ')#;Q&6&V7E JDJI8C!)/3)KI-?\
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MTRQ6D4"NL+/ECGIG/3G\NM;_ (%T!?#_ (9A@, AFG9KB6,?P,YSM_ 8'X4
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MM0NHX+A9IR8VC8'Y=G3MU]>:?>3WFD>*O,\0M?B&;50]IJMM<,\)0/Q"Z!L
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MD+ &&=@))XYSC/% '6T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)XQ(9688<D=/H.@KMJYKPUXHDU[5M9L9;!K-]-E6,AI0Y;()SQP.GO0!E0>
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MOAGHL]Y!<R3ZAOCMUMI-MR4^T(HP!)M )XP.,=*Z=M5T](XY&OK94D!*,95
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M3+YK'3]+ 6ZN(E'FRR'^%2P( &#DX[5IV%MKFE>)S%<:C/?Z+):LRO.J!H9
MPX9@!D$$X^AH T+?PMHMIIT]A#8JMM<?ZY=[$R?[S$Y/XFH7\%^')-'327TJ
M%K!)/-2$EB%;U'.119>,] U'4%L;;44:=P3&"K*),==K$8;\#52;XC^$H"X?
M6H"4?RVVAC@_@.GOTH OZ=X2T+2;\WUCIT<%R4V&16;.W&,<GIP.*I'X=^$6
M$H.@VO[UP[]>H].>![#@U<M?%^@WNJMIEMJ<$MVJE]BGJ!UP>AQ[&J$GQ(\(
M1R+&VN6VXOY?&2,_4#I[]* -)?"F@IJS:HNEV_VUD\LR;?X<8QCITXZ=*;I_
MA'0=*N5N++3(895)*$$D(3UV@G"Y]L4:IXMT/1I/+OK](W\L2E55G(0G&X[0
M<#W-,N_&?AVPEBBN=7MHWFB$T8+9W(1D'CU% %C3/#>D:/=SW6GV2P33_P"M
M968[^<Y.3R?>K>HZ=::M836-]")K:8;9(R2-PSGMS6.WCKPRFF)J3:M#]C>0
MQ+*%8C>.J],@_6M :_IAO[2Q^T_Z5=Q^;!&4;+IZ]./QH 32_#VE:*[R6%H(
MI'4*9&=G;:.@W,2<>W2HM4\*:%K5_#?:CIL-Q<PKM1WST]" <$?7-6M4UBPT
M:!9]0N5AC=@BY!)9CV ')/TJA_PF7A[^RO[3.JVXL_,\KS&)'S_W<$9S^% $
M^G^&=%TK3I]/LM/AAM+C/FQ#)#Y&#G/M5AM'T]ULE:TC*V+!K88XB(4J,?@:
MH1>,O#\UE)>1:G"\"2^067)^?KM QDGZ5?TO6-/UJS^UZ==)<0[BI9.Q'4$'
MD'ZT 4-2\&>'=8U(:CJ&E0W%UL\OS')Y7W&<'ZFJL7P[\*0/ \.CQQM;G,12
M5QM/K][D^YK1_P"$ETC[7>VGVP?:+)/,N(]C91?7IR/I5<>-?#AMK6X_M>V$
M5TQ6%F;&\C@]: 'ZQX0T#7[N*ZU/38[B>(;5<LRG'H<$9'L:LZ-X?TKP]:M;
M:591VL3MN8*22Q]R234-AXJT/5+&XO;/4[>6VMSB:3=M$?USTJJ?$NFZUI^H
M0Z-JJ?:X8"^47YDX.&PPY'% $C>#=">\O+LV<GVB]4I<.+F4&13V.&Z5$_@3
MPV]I:VC:>Q@M7+P)]IEQ&QQDCYO:L;P+XXL+S0-*MM5UJ"369U.Y'8!F.XXS
MC@'&.*M:%J.H/X_\26-W?M/:6T<,D*$ "+=DD<#]?:@"Y<?#WPI=W5S<SZ-#
M)-<\RN6;D^O7@^XP:SSI.IW>L0:(=&M+7PSI\J2Q2!\M+M&54+_O<DGTK>L/
M%.AZGJ+6%EJ4$UT 6\M6Y('4CU_"H/%GBJQ\)Z5]LO,EG8)%& <N<COVQG-
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MS2EE!\P#Y1VXX^E>J1_#?PE&A4:0A+1^6SF5]S+[G=6DGA;1H] DT)+,#39
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M%=[X=L7=91%)-=K&RBXD5@2 ",G:!S]:@_X2C2];^)?AF73;B2:(6$L#.(F
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MK*&>98@Q9,'*_P C^%7](TR+1]*@L(2S)"N-[=6/4L?<DDT <C\1-6ATR]T
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M%%% !1110!#;?ZH_]='_ /0C4U0VW^J/_71__0C4U !7+>._^09IG_86M/\
MT8*ZFN5\>Y_LO3,?]!:T_P#1@H ZJBBB@ HHHH **** "BBB@ HHHH ****
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MMV*1^%/%%O!M;2;?6XQ8MGA"3API].E 'OEOJ%G=S2PVUU!-+"<2)'(&*'W
M/'XUG>(/$^F^'$MOMLZ))<S+%$A8*6)(!//0#.2:XRPTW3]$^,.GVVFP0VT<
MVCEI$AX#L&/)]>@JQ\4DM5N/#$URD/E_VK&LCR 8V=P2>U %ZS\5SP^/-5T[
M4]1L4TN&UBGMY#B,#>>,L3SQ76RZE90V8O);N!+4@$3-(H0@]/FSBO-'LM$U
MCXF^('NH+6]MK?2(WC!PRCCJ.W3\JX_2;L)8>"/[2U*2STE$N!Y_EADCFWL%
MSN!7ICJ.,T >_6E[;7]NL]I<13PMT>)PRG\156YUW1[.5X[K5+*"2/&]9;A%
M*Y]03Q7._#_3M%T]-5&B:A<7T,ESODF8KY6\C)$>T =^<>U<S)I.B7WQ,\8?
M;+:R<1Z?&ZF15(1ROS-]<]30!Z./$.C-<PVRZK9-/.,Q1BX4LX]AGFB]\0:1
MIMPEO?:E:V\S]$EE"G]>E>)VEOI=I\._"-]#%;QWKZM&7G&!(0'.<MUP!BK4
MC:)>ZUXJL/%&M75C)+>%Q$%7$\0_U>TE23@= #WH ]>UC7-.TVT_TG5;:R>9
M2(9)&!YQPP7/('6N(T37]3UCP!:WUQXEM["ZDU J;J5%_>QA\;%7U/%97AZ\
MTO1?&^HC7Y)+>$Z;#'8-J6,F +ROIGID=<Y%8$-QI[?"/32LD!FBUL;<D;E!
MDR<=^F* /:M0\3:+H\ZVVHZI;03E=VQW ;'J1VK,U3Q_HVF>([#1I)PTET"S
M2@G;$-N5Z#G=D8Q7GGB[6=.N]8\7);WUM8YM4CD=AYDE\P3Y5C'15'0D<]Z?
MIVN:9%XB\#7D]TJ6T.E/"TC*=HEVA=HXY.>.* /4+WQ;H.G7_P!AN]4MXKG(
M!1C]TGH&/1?QQ2:EXO\ #VCS-#J&KVD$JIYA1I!NV^N!7ENDW=@G@'Q7H^K,
MG]LO<3L8YQB2>1O]65!Y)SC&*GL[.R'CGPCIVN"UGGCT7RYHY@&_>G[JL#_%
M@XYH ]@CNH);1+M)5-NZ"19,\%2,YSZ8K)T_QCX?U2^^Q6>IQ2SD$J,$!P.I
M4D8;\":J>/+2YE^'NK6FF1/YQMMD<<(YV\9  _V<C%</J%W:>(]'\%66AR*^
MHVL\+O&OWK:-%Q(7Q]T9 ^M '>P>//#%SJ$5A!K%O)=2R^2D:Y)+^G3]>E0^
M+O&MCX4^PQW*R-+=SH@ C8A4)^9B0.PS@=<US/PY&D7WB'Q/(%M9KI=2:6)]
MH+!.@93Z=>1ZU<^*SB"RT"ZD+1P6^K0R2RJI/EJ <GB@"J?&,&D?$?4SJ>K7
M TK^SHY8(9%. S$'Y4 SG&>HS79R>*]%CT>VU4W@:TNO]041F:4^BJ!DG@\8
MKS^RU[1I_BQJNIR748M#I2JDDBE03P2,$9SCM7':=/#;Z%X5U.[%V^DV<MS%
M=&T9E>W9V)5LCD<$?A0![QHNO:;XALS=:;<":-6*,"I5D8=0P/(/UJCJWC70
MM$O)+2\NI!-$@DF$4+R"%3T+E00N?>LWX?QZ.8-0N]#L+N&RN95;[3=,VZY;
M!RP#<X&<9[G/I7!^-=36?5?%]@\=Q:2^0@B@M+<E[W '[R1\'Y .V1QZT >C
M:I\0_#&D7 M[S4PLK1"90D;ON4\@@@8.0<UQUMXXL]"^(.MOJ.KWUQILUK!/
M:QD-(%W@/\J@?* #^76J&C:K97_C;PCNAE:*WTC[+,9+=L+(00 <CH?6M9K^
MT\/_ !3\0W.JQRQVMU8P1V^(&82X !5< Y],4 ;6KZ]X>U6\\-W UZ[@\Z<2
MVB6P8+<9^7:_'3@CGWJ&S^)EH^O:U;7MI>6]CI^U1,;5S@\Y+XY7/&!BN%.E
MW.AZ3X/CO(94E_M9[YX%B9C!$V,!L#@C X]_:MQ[PZ/X@\?VUU8WN[48]T#Q
MV[,A'EL,Y'NP'XT =/#\5?"DUO-.MW.$BB63F!@7W':%7CDY[#^AIUS\1M-3
M1M4NHK2^%YIZ!I;*6 K*N[[I(_N^ISQ7)27=S9?!C1A9Z8TTL3QQ7!:UWO;X
M)+.$8<MGH<=367;0RSZOXLBM-.UR7^T-*VV\][$Q>4@$EB3C&<# H ]$TSQU
M;/X6T[4M0@NEN[L*B6T=N?,GDV@GRU[KSUZ<5(?B+H":/=ZC*UU$+.3RKFW>
M!O.B;G 9>V<=>GO7"6D]]!)X+\1IIE^UAI5L;*[4P,'4E-I<)U*C/7':E\06
MDVHQ^-->@M+S[+J5M#9V:?9W#SNNW+;,9 XX)Q0!Z-X9\8Z7XL^TG3!<[;?;
MN::$H&#9P1GKT-7/$6L?V!H-WJ?V::Y^SQE_+B&2?\!ZGTKG#XNM_"_@S0KF
MXTV_DC>**"3RX"IA*J 2X;! S^=;WBB&2^\'ZM#:HTDDUE*L:J.6)0X H \U
MUWQ/->Z=X(\0WHOK3?>I]HB7<$E  ;<J G<,].]=UIGQ T34=/U*\)N+1--(
M%REU$4=,]/EY//0#K7G1OY[[2O ,2Z-JR_V7<PM<NUF^ J  L, Y&0:=KFEZ
MAK>H^-8K+3[MFN7M9H!-;NBSB(Y=02!^ [T =]#\1=(,MW#=6]_9S6]O]J$4
MT!W2Q?WE"YS[@X(_ X@TWXH:%J=[I]O'%?1)?G;!/-;E8V?^YN]?TKE["2UN
M]*OKFP\"W&ER16,L4LLMLV\NZ%52,#ELD\G& /K6>5NU\(^!;0:7J)FT^]26
MZ464F8PI.3G'OVZ_A0!Z9XU\1R^%_"]WJD%H]Q)&N$ QM4GHS<CY<^E<!K>M
MG_A*?!6OW-KJ,3SPS%[;!9I2$&W8BDC+%C^8S7<_$&RGU/X?ZQ;6L#S3O!E(
MU&6)!!X'KQ7$_P!JW-SX@\$73:%K$$&G0RQSO)9OQNC5 <+DXR#_ (4 =?9?
M$71;O09]487-N8)_LSVLL>)O-[(%]3_GI5O0?&=AKNJW>E+#<6FHVJAI+>X"
MAMI[@J2#U'YUY5=Z/JFK1>(I[?1[N9TUI=3BM[BV>-;F%=P(&1R?F''7K7>>
M!5BN[V2]M/!Z:#;+&8VDGA"3RN2#A>^P8[]>/>@ ^+L6WP#>7L<DL5Q;,C1/
M%(R$9=0>AYX-:S7]MX8\")>HI*PVJM&A8L99&'"Y/))8_K7/?$FXU;6+>[\)
M6F@W<HO(XF@ODYBW!U+!O[H !Y)JQK-E-JNN:)X<FM-2CTRR59I;RWB94:95
M C4..@'))]<"@"'X9:OJ8DU;PWKLA;5;&8S$DYRDGS<'N 2?S%<_J6HS^#_B
M\]XDLRZ+,\5O=AY&9(VE7(;!Z<KG\#6CK6CWOA7XAZ5K6BV>KZDDT1BU'AYR
M8\X'S'N,9QGL/6K-YI)\6ZCXKL)],O[>'4((/LMS<6K(@DC4\Y/3DCZ\T 5_
MC)KE[#HO]FZ=-)$RJMS=2QM@K'NVJN1SRW_H-5?%=['H-YX:;5;2ZF\*_9,2
MI$S%1.W\4@S\PP>A]3]*IZGX=UY?A=<Q7EC>7OB#4YHS((XB[(D9 521T&%S
M]3777&JZB;RV6Z\/W]SX?GTY5N(F@#-%)O(.Y#RW [9[&@"WX'LK*%]2O=(U
M 7>C7CQO:*)F?R<*0RX/*C/05=USQ:FDZI'I=MI]Q?WS6[730PLJD1 XSEB,
MG/89-87@#PV=*U_7-1L[.XT_1[LH+6TFRIR/O/M/*C/3/.#5;XAZ9#JFJJMQ
MHFINT5IOM=3TU"TD<N6_=MCMT/XT 9-_K,*?$[0=>LM.O;E[_26D6VC&9&8Y
M &"<+@#GMQ760?$6PN= MM1AL;Q[BXO#8K9A1YBS]U)) Z<YKG=.M_$%MXO\
M-WVK:;?3R6NEM!=W$4.Y?,;) XZX!&2.^:QX+3Q%:Z1-;1Z#JWV.779;FYAB
M4++);N!M"MUZ@YQC]: -WQ?KUIXJ^'7B:.6SEMKO2Y DL,K E) 1@@J<$<FH
M[NU@'BGX:WBIB:6V9&;/55A4@?AN/YUB+HNN6VB^,=-B\*W\$.ILCVJ*ZR!.
MG!YYZ<G)Q717<&IS:MX!F31]0V:=&1=GRL>5N14P>?52?IB@#M_$FOVWAK19
M=2N49T1E144@%F9@ ,G@=>IK&_X3J*VL[Z;4],N[&6U:)!$S(_G-)G9L8'!'
M'7(J[XTB:X\.2Q?V,=7C=T$MH/O,FX9*\CD=17FC^"]?N]#OX]/@O?[.M+N"
MYTW3M5(WG:#O3!)^7GCGG% '4:CXNLO$NB^)=#N;*2VO;73WG,32+(K*%R&5
MD)'!Q3]"\4V^A>!_"]H(6NKZ[L4,4*R(G"J"Q+,0 /YU5MUU*\\/ZQ,G@I-)
M#V#VZP11H9YY6X&, 80<]>N?:L67P_KMO8>%-63PVU^VFV)L[W3KC;N([,H.
M<]3ZGCI0!V-E\2=,O]*2>"UN7OWNOL:Z>-OFF7N,YQC'.[..*SM=^(UW;^%M
M8NK+2;B#4M/F%O/%.5Q"6X5\YPP^G\JS=5T;Q%<6NE^)K#P_;65WI]V9DTJ$
M*KO"5 .XC@L>>.P/KQ6AK\?B7Q=X UH2Z*;&258_LMDSYF;8P+%NG7& /;WH
M [73+Z\NM BO+BPDBNS%O-MO4L6QP 0=O/\ 6O*-=\07WBOX6>(+O4K!H1;W
MO[A_,4A<2*NS@Y) )Y/!S7JWAZZN;O0[:6[T^:QEV!?(F(+@ 8R<=,^E>4SZ
M/XB@\">(?#3>';V626_::*>)E*2!I%88&<XP#S0!VNA^.K>6_ATB]TZ[T_%A
M]JBGN0H66-1RV <CN>?2FP?$O3I=4T^W:TG2TU&3RK6[\Q&#MG RH.Y0>V16
M!K6E:MJWBC2'32;V*U?1Y=/FE=!^Z>1" 3@] 2,_C4?A#3]8M38Z->^";2*\
MLY%#ZL\2>68U.=P(&2Y'3GKS0!Z!XI\1P^%M$EU2XM;BXBC(#+  2,]SD\#W
MKGT^)*OJ*6!\/:LMS<0">SC9%S<#VY^7ZFK7Q-LKS4O U]8V%I-<W,Y142)<
MG[P.3[<5D7']HR>/?#6I+H>H_9K6Q>*=O*'R,ZX //;O0!L6OQ#TR?0!J4D$
M\,QNOL7V1\"03Y^[DG';.<TS3_B-I5U#JINXIK.?3 &GB8J^0> 4*DALG _&
MN!/AW7[K2K^>+0IS<6VN-J<=K>1 +<1,"-HR>3ZBMN\T35?$OA?419>%K?0G
M C>&W9566XD1@QR0!A>, 'O0 ]K][WXO:!=7&D7.GS/93D":16,J[3MX4G!'
M/!YYK0T+Q'H.A^'-8U.TT^]MT74GBE@E.Z1YR1P.<#D^O%4C>>(]9\9>'=5/
MA6_M([.*9+CS60?>P#C)Z>F<$UFP6_BBT\+Z[%::3J"7%QJQNF&W;)+;N1D(
M1G#<?4 T =3>>/Y8++6T&BW,>J:7"LTEJ\B$;&&0^X$@@=QUIVE^-IE\,Z-+
M?V,\FJZ@ EO;QLF;@[<EP<X5<<\XQ7(V>A:P^L>(S:^&;RRM=4TDQQ>=*IVN
M%.-QR3N)[=>>:EMM/U^*W\):ZN@7BOHH:UN+-@/,>,@ R(N?KQU_"@#KU^(5
ME'IVJ3W=A>P76F$"ZLMJM(@/1A@X*^^:J)\01J?AW5[ZTTN_MC!"IMGN(]HF
M:3A-OKR16%K.CZGJC>*]=CTN\5=2LDLK2V,?[YR,9=E[#COS706=G>ZCIOA*
MQELKFWAM0L]V)4V[6B4!5/U?!^BYH 2+Q!#X1L(]#@L;K4)=+LEFO6A*KY:X
MR3\Q&XGDX%.U'XF:;8S:?%%I^HW9O[?[1!Y$.=ZXS@#.2>,'TK"\5VNN7WB/
M6;.?1;^_L[BS"V'V>39"I"\LYR,D'. ?RYJGHL6LPZQX,:?P[JD"Z=;R07$A
MB!&&& >">,]0>10 67B"/2/B-K.I0:/JEQ]LL()S:Q1%I$+ ,Q8$_+6]JOB/
MPWXAM?#6HRV]_-'-?+]F:+Y1%-TQ)SV].:DG2_T3XFZAJ[:3?7=C>6,<,<EI
M&)"'4C((SQ]36!?>&]2TO1]&5--NIKAM:.J3PVT9<0(3]W(XR!C]: .BM_&U
M]_PF.LV$VCWK6EA"AQ"$=AU.\_-T(Q@#/2FVWQ7TFXLY;TZ;JD=HD6]9FM_E
M=MVW8"#C.<>U5I#J.D^/==N5T6_NK74K.,QS6\>0I52"#G'/3CK699V_B"Q^
M#(L+72[Q-0ADV30O#^\,9?+% >IP>O;GTH ZU?&X(U.W?2+V+4;&V%R;1VCR
M\9_B#!L<=^_UJIX?\<O/X5L-0U6SG6[O'\NWCC"DW+$G&P \ =RV*Y[0].U!
M/&-W/'X<U*&RU#2C!YEU(&8-U+.2>IZ8Z^U4K*RUR'0/#-Y'H%ZL_ARY:.>!
MD&Z=&X9HQ_%@?S[T =['XYL/+U1;FSOK:[TQ/,N+1X@TFPCAEVD@CWS3_#'C
M2S\4RR):V-_ J1)*)+B+:CALC@YYP0:YC5;"[U;5-<\0PZ?>I VD&PMHS;L)
M9W;/.S&<#.,FMG0=1OM%^&UC,VBWTMY9PI"]F(RLC$$*2 1R.] '9UD:QH$.
MM75F]S/,L%N79H(Y&02D@ ;B"#@8/'O6G!(TUO'(T;1,ZABC=5)'0^].D<1Q
MLY#$*"2%!)_ #K0!Y9X1\,VNM+XDAFNKU)+?4I8+>1;J3,2C[N!NYQ[U7T;Q
M!;>#?%'B])K;4[V-;B-V:%&F*+M.YF8G@<]S6]\.OM$%_P"(EN+"]MUNM0DN
M86GMV170GU(Z].*R[<3B]\?LVG:B4OTQ;D6<G[PA&7CCU(H [2Z\76$,%HUK
M'/?2W</VB&"W4;S'C.X[B !]>]6O#_B&Q\2Z6M_8,^S<4=)%VO&PZJP]:\H7
M3[NQ'A_6[SPM<:K9)IRV%S:/;DRPR(>'",.A]?KS7IWA.)$TMYH]%31XII"Z
M6H0*X& ,N!QD^GIB@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@"&V_U1_P"NC_\ H1J:HK?_ %1_WW_]"-2T %<KX]_Y!>F?]A:T_P#1
M@KJJY7QY_P @O3/^PM:?^C!0!U5%%% !1110 4444 %%%% !1110 4444 %%
M%% &%?\ @SP[J>I/J-]I%M/=.H1I'7.X=.1TS[UQ7B3P(T&M63:;X3L-4T:"
MW,2V8G\AD<MN+%B>?_KUV^H>+_#NE736M]K%G!.@!:-Y!N7ZCM2W?B[P_8WR
MV5UJUK%<-MPC/TSTR>@S[T <SH'PZL"EU)J^CVMO!<%2FF12M)'$5_B)SRQS
MV'%=9=>&]&O=*CTRZTZWFLH@!'%(N0GT[BJVI^,O#VCW9M;_ %2&&=5WLG+;
M0>F< XS[U)JOBS0]$=$U#48H790X7!8[?[Q !P/<\4 21^'-%AT=M(CTVV73
MV!#6XC&TY[GW]^M2:1H6E:#;-!I5C#:1,<L(EQN/J3U-<CX[UJ]B'AFZT;5"
MEM>ZA%"_E8*RJW.<]<<=*Z5/%FALU^BZ@A?3QFZ4*VZ+G'(QG\J +.JZ#I6M
MQHFIV,-T$.4\Q>5/L>HJ*?PWH=U80V$VE6DEI <QPM$-BGU KG]4^)NB6D^D
M1VLQN4U"4?O5C?:L?.6'')R,8%6=(O[.?QIK#Q>(VNPD*;]/((2UQP3GIGC]
M: ->#POH5M>QWD&DVD=U$ $E2(!E &.#]*MZAI=AJUM]GU"S@NH0<A)D# 'U
MYK)T_P ;^'M3U);"UU -/("8MR,JRXZ[&(PWX53G^)O@^WDD1]:B+1R>6P6-
MVP?P'3WZ4 :B>$O#J322KH>GB20%6;[.O(].E2#PUH8TYM/&DV7V-FWF#R5V
M%O7&.OO6E%-'/"DT3!XW4,K#H0>017/MX\\-+J"V1U-?-:7R0WE/Y9?^[YF-
MN?QH W+2SM=/MDMK.WBMX$&$CB4*J_0"J)\-:"TLLK:-I[22DF1VMD+.2<G)
M(YKA_%'B47_C^T\,FZU*ULE@=I7M$D61Y3PN"HR5'7(XK=U;5V^'O@@2WMS<
MZI/ I5)7C),C$_+O(S@<@9)[4 ;1\,>'RJI_8FF[5.57[)'@?I4TVA:3<W,-
MS/IMI)/" (I'A4L@'3!(XQ7G.H^*G@\7>$]7N-3NH--O+65I[<JZ(75".$QD
MY8C'7/%=M:>-M O=$FU>.]VV<,GE2%T*LK_W=N,Y.>!B@#5NM+L+Z2.2[LK:
MX>(YC:6)7*?0D<4QM%TIK=8&TVS,*$E8S NT$]<#&.:I:-XLTG7;N>TLYI5N
MX%#26\\+12*IZ'# <5+K?B'3]#$$=VTS3W)*P001F220@<X4>GK0!:.F:<9C
M,;*V,I3RR_E+G;TVYQT]J=_9UCM@7[';[;<YA'EKB,^J\<?A7D>@ZO:W/AWQ
MC+JVK:O!8F^$:3Y=KB->H' ..G/&*[^3Q5I>C6>FVB_;[UY;-9HUAA,LAB51
M^\?T_P : -]K"S>Y%RUK"TXZ2F,%A^/6E-G;--YQMXC+G/F%!NS]:Y2Z^)_A
MNS%GYCWA>[B\V)$M7+$>G3K]*!\3O#YT<:H@O&@$_P!GD40?/"YZ!QGC/:@#
ML<<8J-+>&)W>.)$9SEBJ@%C[^M8&H^,K+3]9GT@V=]+?16QN42.'(E0?W3GG
MGC\#61X;^(::AX4@U74[2XCGGN#!#%%%GSF);:J<\X Y)P.* .WCMX869HHD
M0N<L54#)]Z<VQL*V#W /M6%X<\6Z?XDDNH+=)H+NT8+/;SIM9,]/8UQ/BK51
MH'QCTV\,5[=+)IS_ .CVX:1F;) VKT'2@#U3:*1D5E*L 5(P0>AK@G^*^DC1
MTU%+#4'3[1]FF3RP##)V5LGC-=/'KPD\1KHPLYS(+87$DH*E(P20 ><YR/\
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MUIQ<6LA_<J24!VC'(!Q@<5V.H^+]?C\5:?H.DZ98M]KT_P"TQR32E57CN!T
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M;S01F3RRJX*E>GY^E65$EEXZ\*RG0KBR@M;299HK:U=XX#)DJN5!R>1G'?-
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M:'ANRU>UTN1S>78M8[;SE#@YQD^G3IZ<UTFLZK#HNC76I3I(\=NA<K&N6;T
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M2UM5M+RT+6M_%)(=T7(!V$#G.?;O75>$])$=A9ZE>Z=807PM4AC>VR3Y6T$
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MR0-$$VG! +')+8!(&: *'PB%[+X4>[NKZ6<RW,N4=1PVX[FW=3GWKT&N$L?
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M*ZOK6Z,4\1M[86GE0S,B21#HC =0/_UUN7FL:;I\L<-YJ%I;RR8VI+,J%NW
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M&\!(^SB=?,R.HVYS5?Q'KMMX;T&[U6Z!,5NF[:#RS= H^IP* ,+_ (5KH_\
M8EOHXNM2%E!/]HC07/W7ZYZ=CS]2:T8?!^G0>)CK\<ET+QXU20><=DA5=H9E
M[G'^-9-I-XTU'P^FLQW>GV\\T/G0Z>;8LN",J&DW9SCVK=TK7$/AC3]2UJ:W
ML)9H4:43.(U5R.1\WOVH /$/AC3_ !)';_:_-CN+5_,MKF!]DD+<<J?P%0?\
M(=8?V;?VGGW?F:A_Q]77F_OI1C&"V.F., =*UFU33TLTO'O[5;63&R8S*$;/
MHV<&F#6M*99V74[,K;_ZXB=?W?\ O<\?C0!!X?T&W\-Z7'IMG/<26L7^K6=P
MQ0>@.!Q6?J?@?3-4UM]7:>^M[N2(12-;7!C#@=,@=<5L#5]-:TBNAJ%K]GF.
MV.7SEVN?0'.#3[74K"^\S[)>VUQY9P_E2J^P^^#Q0!R__"MM)_L:TTE;W4EL
M[2?[1"@G&5?J#G;V.2/J:6^^&NAWVL-J;/>12RX^TI!.8UN".[@>O?&,YKI+
M76-,OI'CM-1M+AT&66*=7*CU(!XI1J^F%X4&HVA>8E8E$RYD(."%YY(/I0 ^
MXL8YM/>R1G@B:/RP82%*KC''IQ6):>"-)M?"\OAQO/N--DS^[G?)7)SP0 1S
MS6PFKZ;+++%'J-H\D2EI$6924 ZDC/ %36UW;7L GM;B*>$])(G#*?Q% ')6
M'PQT"SL;JTD-W=I<0F FYG+&.,G.$Z;>@_*F0_##1HY[2XDO-4FN+:,Q+(]V
MV2A&-I]AZ#\<UU3ZIIZW?V(W]JMV>! 9EWY[?+G-<MX0\53W;:O%KU_91R6N
MHM:0MD1!\ < $\G\Z +FG>!-/L'LC+=7M['8!EM8KJ0,L088/0#/''.:AM?A
MWI-HXC2>\;3EG%PFG-+F!7SGIC)&><9Q72W>I6%@%-[>VUMN^[YTJIGZ9-<U
MXEU_4--\5>&;6TEMVL=3G:*4%,L<+G(;.,<B@"W_ ,(9:C5=2U)=0U!;C48_
M*G(D7&T<  ;>,#@53M?A];::EK_9NL:I:R6L;10MYB-A&;<5(*\C//-/\.Z]
MJ5]XT\1:1>F$PV!B,)C0J<,">>>3TKJ)KF"W"F::.,,<+O8#)]LT 4M"T.S\
M/:3'IUBK")"6)8Y9F)R2?<UF6/@RUL==O]4^W7<[:@FRYAFV%)!C S\HZ#TK
M=@OK2YMC<074$L SF6.0,HQUY'%-BU.PGMVN(;ZVDA0X:1)5*@^Y!Q0!SMGX
M!T^TCAM3=W<VFVTWGV]C*X,<;Y)'.-Q ). 35S2_"J:5XBO]8CU"ZDDOCF>)
MPFPX^[T7(Q6R+ZT*(XNH"DC;4;S!ACZ#U-2LZ(A=V"J!DDG % &9XBT"U\2Z
M+-IEXTB1R%6#QG#*P.01^594'@F.WURVU9=9U-[FW@,"F5T?*G).25]3FMN>
M_2?3+F?3;FVFDC1MK!MZ!@.AP:X!O'6N?\*^T7Q L=H)[J\$%P"AQ@N5!49]
MJ -@?#/3)-'NM-NKR\N$FN3=I*[ /#*>K*0._?-;/A[PQ#H'FR&]O+^ZF $E
MS>2EW*CHH]!R?SK</2N.T3Q+K&H>-]4T&YBL1!IZJ[2QJX:0,/EP"2![T 6=
M5\#VNIZ[-JBZA?6CW,(@N8[:3:)E P,\9'X4_3_!=E9>$IO#DMS<W=I*C)F=
M\E0>@4=!@\CWJ+Q/XVM?#>MZ/ITR!OMTNV5\X\E#PK?BW\C5[Q?JM]HGAN[U
M33XX)9;5?,:.8'#+W P>#0!%+X,TF5-$1H?ET=PUL/H,<^O(!^HJGJ7@*UU'
M7;S4AJ5];+?0B*ZMX'"K* NT$\9Z5?\ !_B6/Q5X:M]42,1R-E)H@<[)!P1_
M7\:P],\>3:QXVU32;2&#^SM.A:5YB&+R;3@A1G'WL_E0!)8_#E+"XTN:/7=1
M;^S"?LROL(4'&Y?N]"!BK>K^!X[_ %XZQ8ZI>:7=RH([EK4C]\HZ9ST/'6LF
MV\9Z_J/A.?Q+I]CITMM&TA^RF1O-5%)Y+=-W?;@<=Z[RTE,]I#,P ,B*Q [9
M&: .8L? RZ9HUGIMGK6HQ1V]V+DN'&7YR4.!]TUUM%% !1110 4444 %%%%
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M?C7L>I^"=!UB.Q2_LO/^Q+MA=I&WA?0L#DCCO5#_ (5?X1!8KI07,AE^29U
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M'J?KS48\&^&Q!/"-%LQ%.095$8PY'3- 'F.JWEC?ZA=(K6C7D/A^,3SZDX9
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MV\DTLDY979CG;MS@ $8&,8KUGQ==I9>$=3GEO7L5$##[0B[FC)X! ]<GCWH
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MO7G5[_Q(=%^'>GZI+Y=W;72S3H_6)#G&?3&<?A7L\J1W-NT; /'(N"#R&!H
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M<52U'QQHEA::G)]J$DVG+^^A5&W!N<#IW(Z]*\MBMY]$\&^&+V^22*RBU\W
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M 0HK8RH.TY&1TILL,<R[98U=>N&&13Z*  # P.E,:&)W5VC1G7HQ&2/I3Z*
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M."Z6P%QLNCF9)92ZL>YP>]5],\ :'I5W%- EPT4#&2"VEG+Q1.?XE4]^>^:
M.1:W%WXK\>:==23RVK:?'-Y4DK$*Q3=QSP >U<U<:1;)\+_"$]O-<6\M[>11
M3F*=@'#%L\9QG@5ZU!X-TJWUN]U91<-<WJLD^^9BKJ1C&/0#IZ5E_P#"K/#/
MV2"V$-T(X'\Q/]*?@]N_&/:@#EM2\-6%AKL>@VDVH:HT5E).+2ZN2D-N"?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 10?ZL_P"^W_H1J6HK?_5'_??_ -"-2T %<7\3O^18MO\ L)6O_HP5VE<7
M\3_^17ML_P#01M?_ $8* .THHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% $-M_JF_ZZ/_ .A&IJAMO]4W_71__0C4U !7%?%$$^%K;'_0
M2M?_ $8*[6N)^*;%?"=N1U_M&U_]&"@#MJ*** "BBB@ HHHH **** "BBB@
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M,/(< L>@JZ#D9'2@ HHHH **** "BBJ,.KV$^J7&F1743WMNH>6$'YD!Z$T
M7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWX4\4)XIL[BX2TDMO(F\HJ[!LG:#D$=N:XOQ!XXUN#XKZ=H%IITK6\1+&%)
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M\<R>)=5U#39[2..2T =+B!F:*53QP6 />NS8[5+8)P,X% "XHXK@O#GCR_\
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MJZM[NWETZ2<.MN(W9@3U.3CD=N*RO#/BS7=8U^&SN-5MX;L22QWNES6PC>
M-L:,DY<9VY_PH ZS4_'FAZ5J#6EQ).WERK#--%"SQ0NW178< ^U=-7C7A-=;
MLXO'-U#>V]S);7TV8IXD1)90/]86)PH'7'3CK5S1/B!J%KKD]G?Z@NK6J:6]
M\TRVOD;70994(&'7WH ]9IJNK,P5@2IPV#T/6O/M)N_&^I0:+K,%W:366HC?
M<VOE*HM8VY5E;JY ZCUKE=&\2:IX7T/Q7J]UJ!OIDU5[2.*2( /,<!7+#D#
M^[TXH ]MHKSRXUKQ'X>\1Z-8:AJ$%_;ZRK11R?9A&;>8 $<*?F7)'7GWK$T'
M5?B/XHT^]O;/5--MTM9IH=GV8%G=.0.<@#MU_.@#UZBO,_#OBG5_$FG>'8+?
M5$74Y)96U1?(0E(XS@J5_AR2H!]ZZ/XA:GJNB^#;S4](N(H9[8!V,D>_*YQ@
M=@<D=<]* .IZUSM]X%\,ZGJ7]H7FC6LER3N9]N-Y]6 X;\:XZ+Q%XRTO6]"3
M5;JQGM==0I"L<&/LTA4%<X(+#D9Y]>E4]%\:>+?^$7O/%6HW-C+IMEY\;6R0
ME7D<$!.>PR0/H.] 'KJ(D<:HBJJJ %51@ >@IU>:7?B/Q#X9_L#4]5U&"^T_
M5)$BGA2V$9@+KN!0@Y('OZ57?Q5XDU?P[K'BG2;^""SL)I%BL6MP_G)'C<6<
M\@D9/% 'H.L:Y9Z)%";KS'DG?RX884+R2MC.%4=> 32:%KMCXAT_[98-)Y8=
MHW61"CHZ]5(/0UYAK=[?^(O%7@74[/4C:PZ@CR01^0KFW?8-W7[V>1STKT'Q
M7K7_  B?A"]U;RUFE@08'W0[L0N3^)S0!T-<+X@U#PEI?B1M3OK2YGU*R5'E
MN;=9)!;*W"[\'"@^F/YU5GUOQ#X=U7P\VIZE!?V6L2+;R(MN(C;R,,@J0>5Y
M[^E4?!EC?GXE>+%FU+S8XYHC<*T"_O\ *':/]D#V]* .TUGQ?I&@06LU_).L
M-SCRI$MW=6)Z#('4^G6H[7QII%WJ%O8JM[%/<L4B\^REB#$ G&64#H#7-_&)
MC#X7TZ2-0S1ZG RKT!(S@5MV=WKNH^(HH-5T**RLXX'FAF$JSD3 JHYQA3AF
M^N3Z4 =717E3^(_%=GXGF\(W>H1G4KJ5)-/OO(C">1SNW+ZX!X]:NZQXC\0W
M6OW^A:')<>?IMJA>>*UCD\V9AG#;V 5?IGOZ4 >D45YQ#XC\2ZCJFC>'+C9I
M&J2V;W5[+L60\$JH09(&<9-1:AKWB_0[7P^=5EMEN)]3^R7"QJI$T1(VM_LG
M&>E 'IA.!FLK5O$%EHXL3<"9UO9U@B,,9<;FZ$XZ#WK@]?U779K_ ,:Z0FK-
M%!8V"W4#+"H95*EBF1^6>M01ZOK>@>"O!4D.H1RQWD]O#)YD*[A&RC"@^P!&
M>O/6@#UBBN E\0:GHGQ"N-.UC4=VDSV<ES9$PHN"O+*6 YP ?TJH?$7B%3H6
ME--.]_J%O)>S2P6\1>./C:@5B%SSR30!VGB#Q'IOAC3UOM4E:*W:01AE0MR?
M8?0UIQ2I/"DT3!HY%#*P[@\@UQV@V^M^)/#5YIWBJWDMY!.8_,V(K3Q9!S@9
M )&1D?A5+QAKU[X=U73[,7<NDZ(UN5^VQ6JSA9 0%5@0=JX_.@#T&BLWP_<3
M7>@6$]Q<17,\D*M)-%C8[8Y(QQBM*@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** (;;_5'_ *Z/_P"A&IJBMO\ 5'_??_T(U+0 5P?Q>./ XXS_
M *;;_P#H8KO*XCXJ*'\(1(V<-?VP./\ ?% ';#H*6@=** "BBB@ HHHH ***
M* "BBB@ HHHH **** //KHWFB?%"^U>72K^ZL[O3TABDM(?-^=2,@XZ=.]<Y
M%HFO:%;Z7'<:9=SZ==7<]U>0Z</WT;/PL98$$+@#.,=Q7JR:OITFJOI:7D#7
MZ)YCVX<%U7CDC\1^=7L#TH \$M-"\465H;RS\/7$;:5K#7T4,C<RHP **.2V
M .H]:ZCQ-?:UXC\%:QCPS>69NA%%#!Y6Z>1PP9F? X4 8&>]>IX%&* /*/!;
MZKX4NY=$NM-O[C1+B+SX;DVS PLP^9)#V[\GI7*:#?W$.G:?#K6DZQ_PCUA<
MM>0&"RW(/F)7,N1E!DG(KW#4-0TH3KI%Y=PI<7J,B6Y?#R*00<#KZUSME\.;
M2S5;<:SJ\FFJ>+![D^7C^Z>Y7VH R_#4LE_\2M>U%;&^CL-0M8EM[F2W9$;:
MH!PQ''J*P].L=3TKP5K'@JXT>\FOIY9!;2I"6AD5R,,7Z+CKS7K%YJ%AI,,)
MO+B"VC=UBC\Q@H+'HHJY@>E 'E;Z7J7A/Q?H-ZNF7NIP0Z.MBS6D>_$JGO\
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M$A-)\11V>@+>(=:%Y%Y4<39EB!/S,0.0-F3^5=_9VT5E906L"[8H4$:+Z #
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MUNZ^'-GX7%W8B2%U$DQ#;613N QCKGK]* -'PIJ^I>)KE]3M;V%- 7$<$'E
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M[,)$D7E0.P ]/KVH ]QSS1N%>&:9I!M]+\4^)([W49;_ $74;@6B/<%E^50
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5Q7Q1&?"UN/^HC:_\ HP5VM<7\3SCPM;G_ *B-M_Z,% ':4444 %%%
M% !1110 4444 %%%% !1110 4444 <GJ7A2_N_%\?B"UU6.WDBM3;1Q/;;P
M>2?O#G-8:_#&\7PD_AT:^OV9[K[27-I\V<YQ]_IGFO2** ..C\'ZD/&%MXBF
MUJ-Y88!;&%;7:K1]Q]_KGG/K51/AU+;6FI:79:S)#HVH2F26V,(9TS]X(^>
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MG# '.#[T .HHHH **1F5%+,0J@9))P *I0ZWI-S.L$&IV4LK<+''.K,?H :
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MZMT %%,FEC@@DFE<)'&I9F/0 #)-5-(UBQUW3DO]-N%N+5R0LBYP2#@]?<4
M7J**,T %%%% !1110 4444 %%%9>D^(M+URXO(=-O([EK-@DQCR0I.<#/0]#
MTH U**** "BBB@ HHHR* "BBB@ HHHH **S+#Q#I>IZI>:;9WD<]U9X\]$YV
M9)&,],\5IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7%_$_ \+6^1Q_:-K_Z,%=I7$_%+_D5+?_L(VO\
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MIYGLKT7#2FX;!"L6 'R>K$?A71:5X?UW3?B#J.KJ+$Z=JB1M/EV,D3(N-JC
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M7%RMN8T:=\;VVX!8@'KWKS!/ 7BJ/P;I&@B/3<V.H?;'D-PWS@$D ?)Q]XT
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MZ_;0?:+95E/D7*<=">0?8_I46D^.]2UGPSI5_:V=D;^]O3;-;F1L1@9))X[
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MMA<::\T82(;T;.,DG.2"#[<]*Y#PWJ=YX<\/^,==N+][M+74YT^SO$@668E
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MNHKZ1@690 '# $YXY'N:[RB@#S&^^'VKC0["ULI;*2Y75/[4NY)795:3GY5
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M MU:F26W4]E8, <>XKN:* .%U'P#=G4]+U'2-;EMKVT22.6>XC$S2B0Y9N>
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MK0_&=EK_ (EU;1[*,LNG!=UQNRLA)(( ]B,9[U!\0=6U#2_#NW3;2[GFNI1
MS6L9=XD(.Y@!WP,#W-<-\/\ 6;<?$S5+:UT6_LX;BVACCCDAVF$(O63GC/KW
MS0![+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7$?%3_D4[?/_01M?_1@KMZXCXI_\BI;_P#82M?_ $8* .WHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *RK3P_966OW^LQ>9]KOE1)=S97"#
M P.U:M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7$_%+_D5K;_ +"5K_Z,%=M7%_$\9\,6H_ZB5K_Z,% ':4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7%_$[_D6;3'_ $$[7_T8*[2N
M1^(BJ^AV",,JVJV@(![>8* .NHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "N3^( SI&F_\ 86M/_1HKK*Y3Q]C^R=-S_P!!6T_]&"@#JZ**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***1F55+,0 .22>E "T52L=7L-3DF2RNDN/).',?*@_
M7H:NT %%%% !1110 4444 %<KX]&=*TW'_06M/\ T8*ZJN7\<_\ (-TW_L*V
MO_HP4 =11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%17%S!:0F:XFCBB7J\C!0/Q- $M<3KD-WXE\
M6MX>>X:VTJVMTN+D1G#W&XD!<]EXKI;#7M)U5V33]2M+EUZK#,K$?@#7!^+D
M\0)X]LI=.9=.AO(AI[7S8<-DEQ@=CP0* .\L/[*T]ETJQ,$3QKG[/%C*CU('
M3KU/6M&L;P]X;L_#ULZ0%YKB8[I[F4[I)6]2?Z5LT %%%% !1110 4444 %<
MSXV!;3], &3_ &I:]/\ ?KIJY_Q:H>WTI6Z'5+;_ -#H Z"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJA
MJ]G<W^GR6UK>-9R2<><BAF4=\>^.] '*>(_B.FC^(_\ A'[/2;C4+]E4H(W
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M10 4444 %%%% !1110 4444 %%%% !137?85&UCN..!T^M.H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ).?_84I^,>!G^PNW_/Y_P#8444 1_\ "Y_^H!_Y.?\ V%#_ !GV+G^P,_\
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M%% %I/CWXI50&L]+;W,3_P#Q=+_POWQ1_P ^&E?]^Y/_ (NBB@!?^%^^)O\
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L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sgmo-20210331xex103005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M +X%344 0_9;?_GA%_WP*46T _Y8Q_\ ?(J6B@!JHJ<(H4>@&*=110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !0>1110 BJ%4*  !T I:** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4WP[DN?#,FO2.TNH:/;0JT=Q%$=['/"@'GH3D=!BO8::[I&A=V55 R68X H
MAL+Q-0L(+N-)$2:,.JR## $9Y%<Q\39D7P#J<!)\V>,)$H!)9MP/]*ZX$,H9
M2"#R".]+0!Y=J&KVEP/ OEL9!!,AFPI)CP@7D8]?Y5I^%;M9OB9XJ")A'$6T
M[3@E!M.#]:[P2(9"@==X&2N><>M.H X/Q5,NG?$/P[J<Z2_95AFB9T0M\Q'
MXK"BO[671OB#AOFN)I&B#*<N"F%P._->LT4 >,"6PT_4M+U'6+*YGTJYTB&W
M62#?^[E0?,I"D5Z7X4@LX-!3[!IS6%H[L\<+D[B"?O,#R"?3TQ6Y10!XQ8#1
M[&XU'1/$6C7UQJ+7CR0I&7V3ACE3P0!]:Z;QM9:E87NC:[HL'^EQ8LY(UY&Q
M^!^ ->@TA8 @$C)Z"@#S'Q?IL.AW7AN\N[6>ZTJR1X;CR2P96;'S\'/7)K-\
M0-HK^"Y9M&TZ6TM[F_@97EW;K@J<L<$DX'KWYKU]]A0A\;3P<]*4  8'2@#S
MFZO+>\^)$QM9%D$FC/"A09#.3D+]<5I_#"]BE\'6MB%D6>S#),'C*A6+L<9/
M6NTHH \YL+^#PYXU\3)K2M''?LL]O*REA(@!&T>_/3VKGKVUDTCX9:/:WF^.
M>351<K"X.Y(]['IVP"#^->RLBOC<H.#D9'0TZ@"I<7*/I,US @N5\EG1$Y\S
MY<@#ZUXK!JMM))X4O&DNBUI>DW$*PE8;49/RJ .OYU[K3%B1/NJH&<\#OZT
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MGE26<1\RX8C[A;J%'I6)8W@3PIX1LI(;A)[74Q),#$W"AR21QSU%>V$@ DD
M#N:1'25 \;JZ,,AE.0: /.;>_MO^$V\6W0#>4;)%1RAPQ5<$#\:PC,H^&WAB
MU\J3STU-6=!&<@*[$G\F7\Z]C=UC0N[!5 R68X I00P!!!!Z$4 8/C&QN=6\
M(:C9V8_?S0X4'OR#C\0*Y%]_B72_#.G6L$R7%C/')=%XRHA6,<Y)[GL*]-HH
M X?P.Y?Q%XIE>&2/S[P/$7C*[T QD$T_Q\+FVNM"UB."6>VTZZ,DZ1#)P0 #
MCVYKM:* /,['51J'C+6M56POH[233!%$[P$!B.3G^0JG806<W@+1K/5;:^MY
M%EE*W$49W6S@Y#$>G(KU:26.&-I)75$49+,< ?C3+>Y@NXA+;S1RQDXW(P8?
MF* /(M5N;R'P78R:LS2QKK*&"22'#S0CHS+W)YZUT,L+>)/$6H:II\,@M8M*
MDM5=XROG2.#@+GKBN@\3^'9O$#6.R\%N+283C]UNW,.G<<5T Z#/6@#QX75W
M<Z5X2L(M+U$-IUVAN7$)&W:?X?7UJUJ&GZA<S>,=+AT^=Y[Z9)HV"XC**<GG
MU/3'O7K%&10!P7A*6PO;ZS-KX9FM)[:(K-<3J0(N,83));)^G%=[4<,\-PA>
M"6.50<;D8,,^G%24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ][;&W-M<PQ$>8HYPR@]:R]2\'ZIJ6B^*KU8!#>:K+%)!:LPR%CQ@$YQN/-
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M_IPMO_0YJW:P+4_\5[J@_P"H?:_^AS4 ;]%%% !1110 4444 %%%% !1110
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M^GZ3]KD>RBDE191&J<9))(Y)_6MH^.TET[1KBVM%,NIE@JS3B-(]O4%L<G/
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M^Z 31H7C:34]=33)[2/][#YJ36[ET7OM8XZT =E1110 4444 %%%% !1110
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MAM-.%IA)U8DCOR:SK3PIXAAL1>+9QIJ%KJCWL,+2 AT<<C([\=Z]2I"0.IH
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M?V%Y-;317,0^0C#JS $'(]Z .PHK@=4O=3@^(ATV#4YX[:XTJ2?RSM81R D
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MMXXY/W[#.&+GA1[<T >E*H10H  '0"EKS277?%\FI^'--FEM].NM0@E^T*8
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M/?/6M34-9TW20AU"^M[;?]WS7"Y_.EFU?3K>&&::^MXXIR!$[2 !\],'OU%
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MVSC'WE]O\: .=N/ U[#XAN]2T779].AOG#W<"H'W'N5)Z$\TNH>!;E=534M
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MMQ]I6^*#EC@$;>FW ''M5K0?"M_IGB2[UJ^U?[7-=0K%(H@5 =O3ITQ75T4
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MRQ:?=S>>(/)5B'X/S-U(X]JT+OPCJMW:W5E+K?GVEW&L<JSP!BN!@E.<*?\
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M8:=+OMQO \M>ZCCCZT <_<ZAJ=B/$^AW6KZDVI1R))I;I*?,D5L[5&,9]_\
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MF625=LPBE*"7W8#J:UM'T>ST+3TL;!&2W3)568MU^M %^BBB@ HHHH ****
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M3#?Q/?Q@EH5SD ?I5C3=7L-8BDDL+E)TC?8Y3/#>G->::WI^J>&--\,>);:
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MK^?0%U;52IO[T+N8?\\T&U?Y%O\ @59OQ&>:SUGPKJBVUS-;V5ZS3&",N0"
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MQ0!POA'2="U7QUXFN3!;3_9[J*6V93PO!)9<>]1:-H4/B7PWXOT\A6E.JSO
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MK_QKH>F7C075VRA)1"\PC8Q1R'^%G P#[9XK3U:XMH-(N9KFY-O;B([IU/*
MC&X>_->/65KIUA-J>A>)=&U:\O)KMY;?R3(8KH$Y4\' /N:]=OFCM/#LV]#&
MB6Q&Q<OM^7&!CKZ4 8.F^*- T'PWI7VO6Y9X;@%8+FX5B\N"<D\<8Z<UL:'X
MHTCQ&)_[,NO-: @2(R%&7/3@@<&O*X+F!? _@ZUD@E$UIJ<<D\9@8E$#-DGC
MI@BNNT.[@E^+&N-&&V36D(1Q&0KE>N#T- '4W?B/3;'6[72+B5TO+H9A7RFP
MW_ L8[56MO&.BW<&I317$A73>+K,+@Q]>V.>AK)^(NFW<NEVNLZ9&SZCI,ZW
M$2KU9<C>OOD#I[5RO]A:[;^);/>'-OXF02:FNWB!E.\J,=/E^7GWH TK/QK:
M:5XWULZGK$[::UO#-:QRHV5W<G"A01^73O7;2^)=)ATJWU)KM3:W./)906,F
M>R@<DUQ4=U90?$[Q)]JB"12:?'&DCIA6VK\P!]>1^5<WX>NFTV#P=JL\4QTZ
MP%Q;W;!&/V=W)VEAV&".: /5[?Q1HUSI,^IQWJ"UMR5F9@5,9'8@\@^U):>*
MM&O(+F:.\"):J&G\Y&C,8/3(8#KVKSR]ALKZ_P#%6K3^>/#=X+>/SH%(9I@5
M!D4=P,\GO[UFW_\ ;&HZ5JD$4QUFVLY+:;[?;H5EGB4D^62/O,H.?;% 'K.F
M>(]*UBYFMK.Z#7$(!>)U*. >AP0#CWK#^('B4Z'IUK!#++%/=7,<9>-"2L9/
MS$'&,X_&L_PA+X<U;7SJ6CVNIRW*0%)KJ[>0A <?)\Y.3]/2G_$^[@AL=&5W
M ==3AE(&20BGYFX[#- %JPUS3O#TLXO_ !#<W4-R%N(8[B%B]M%T^8@9QGUQ
M6[)XHT6/4+6Q;4(_M-VJM;H 3Y@;H00,$5YUXLUB"76M;MD:2T%Q8*(I+>!I
M'U#Y20 V" HZ<8SSS0J/=?"S0M=TZ-VO]"*R@,A4L%_UB\]1CT]* /2F\0:4
MAOM]XB"QQ]I+@J(\],DC'Y5%;>*=#NUN#%J,.;9/,F5\HR+_ 'B&P<>]<'XC
ML-2/@W3]4DA9Y)=1CO\ 4(XT+-L[# [*,<5;NY]/U?QY9ZYIMPDEE;Z=*+^<
M?ZO:1\BMGOSTZT ==I?BW0=;N_LNFZG!<S["^Q,YP#C/2K&I:]I>D21QWUVD
M4DBEE3!9B!U. "<#UKD/A';V!\&V\\<$'VQ'D620(/,&6)P3U]*A\8ZG#:>-
M;6&5GL#)8,@OXX&EDDRQ_=(,$9[YQGF@#O[.^M=2L8[RRG2>WE7<DB'(85SN
MG:K8VFI:]<2^)#>00.K20%,BRZC&0.1_+%9_PEN8I? UO;+O\RWD=) R%<'<
M3CGV]*IK;M+XK^(-O;Q R264(5%'+,8F_4DT =B?$FCJU@#?Q_\ $PQ]E.#B
M7/H<5S?Q#\4V^G:#>P66K/:ZE$ 5,*;L-V1C@A<CZ&N-CU^PFT3P-:1-*\]C
M>(+E5A<^65!!!XZ^PI\VL6]IX(\2:!JD<RZS+/-($:!B9=Q!5P<8Z#\,4 >D
MQ>(;#3=#TZ74;S,TULDG"EG?Y06; &<>IH?QOX92V2X;6K3RG8*K!\Y/I7G5
M_P"(8O#VM^'M5!+M+HXMY$GC=0N,#.0I.=PYXZ?6HKZYT2'X:6-I:W]O?LNJ
M)+,B*1C+EF&UAD* <<B@#T0>/_"YCN7&KPG[.<.H!W'_ '1C+#Z5H'Q)I/\
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M7AOPUIT]K>I/<0"$9MV"HR+SN)Z#T-=I0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7G\QS\=[<9'&B9_\B-7H%<!*A;X[PL.BZ'D_P#?
MQA_6@#OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 0C(J*VM8+.%8;:&.&)>B1J% _ 5-10 4444 %%%% !1110 44
M44 %%%% !BBBB@ IDD8DB9,LH8$94X(^AI]% &%X=\+VWAU9BEU=WD\N T]W
M)O<*.B@]AR?SK=HHH **** "BBB@ HQ110 F 3G I:** "C ]*** "BBB@!"
M >H%&Q<8VC![8I:* &[%V[=HV^F.*4*JC"J /0"EHH 155?NJ!]!045OO*#]
M12T4 -V)D':N1TXZ4H10NT*-OICBEHH ,#&,<4Q8HT4JL:A3V XI]% "*BH,
M*H4>PQ2-&CLK,BL5.5)&<'VIU% %2^@N)-.N(K"9+6Y=#Y<I0,$8]R.]9GA_
M09]-N;S4=0N8[C4KT1B>2)-B81=HP/S)^M;U% #%BC7[L:#G/"CKZTI1"<E5
M)QC)%.HH Y36/#&IW'B%=8TK6$M96B$$D5Q;B:,J#GCD$'O6EHN@)I9N)YYA
M=7ETRM/,8U0-@8 "C@ 5LT4 -\M,YV+GITHV(%*A5P>HQ3J* &^6FT+L7 [8
MH\M,@[%R.G%.HH 0 #. !GK1M7.<#/KBEHH 0*H.0!GUQ2D ]1110 A56&"
M1[BC:, 8''2EHH ,#TI H&< #// I:* $VKG.!GUQ1M .<#)[TM% ";1G.!G
MUHP"0<#(Z4M% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N'P/^%W9QS_87_M8UW%<,#_Q? CUT$?\ HXT =S1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1C- "T54L=2M-1CEDM)A*D4K1,R]-R]15K(H 6BDR*-P]: %HI-PQF@$'I0
MM%(2!U-&10 M%&:3<,XSS0 M%)N&<9HW"@!:*3((SVKFI?$ES'X]M_#_ )$/
MV>6U:<2[B6..V.W- '345AVVKW=CI-U?>)([:Q6*1MOEON!0=#]3SQ5FYN-3
M.HV LH(7L9"QN9)&PZ#'R[1]: -.BD+*#@D9HW#UH 6BDWKC.>* RMT(- "T
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5PP_Y+>W_ & 1
M_P"CC7<UPX(_X7:_K_82_P#HXT =Q1110 4444 %%%% !1110 4444 %%%%
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M"#43%$QN#M5?,VG([YKHI)[OPEXRNX[6\O+N)]%DO'CN)B^Z53U'IT[5T?\
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MS4W94L%P.>O(K9TW5K'48E%O>6\TPC5I(XY%9DR.X!XKG?BG@_#?5L],1?\
MHU*XS6]&M],U/0KOP=$D6HM92M<);GAHQ']YAGKD\>^* /6TU&QDNVM$O+=K
ME>L*RJ7'X9S4EQ<V]K&)+B>.%"<!I'"C/IDUXKX8M]#U.U\/7LOB7R]5MYE/
MV:*W03F0GYE8@;F![DYXS7K'B?0X/$?A^\TR=%/FQGRV89V/CY6'I@T :'VV
MU'E?Z3#^^_U?[P?/]/6FK?6DLS01W4#S#K&L@+#\.M>8^%KI=;L([C5;1H%\
M,6DL$C(@!\X @E?=57/U-<_ILUK;:AX*N[673K>%[I]H+@W+1D\M,_ ]1C%
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%175S%9VLMS.XCAB4N[MT
M'4T 2T51TK4&U.R6[^S2V\4AS$)<!F3LV!TSZ5'K&LQ:+#%<7,4AM6<)+.N"
M(0>C-WQGC/:@#2HI%974,I!4C(([TM !1110 445S]WXMMH-9FTFVLKV_O((
MQ),EK&I$0/3<68<GT% '045DZ#XAL_$5K-<60E5(9F@<2IL8. ,C!^M:V10
M449HR* "BC-&10 45@:YXPTOP]J-C8Z@TR27S;8&6,LI.0,$]NH_.MJXN([6
MWDGE8+'&I=SZ #)H EHKCYOB7X<@T.VUB2><6=Q*T4;>0Q^9>H/I6K'XKTF7
MQ''H27!-_);BX5=AP4(SU]<<T ;=%1QW$,TDD<<J.\3;753DJ<9P?3@BI,T
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M>EZI::SIL.H6,OFVTP)1\$9&<=#]*AL]>T^_UB]TJWF+7=EM\]-A 7/3GH:
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MO?)ILTGFR:<&PC,#D9(YP/3]: .8AUKQUK?CCQ!H.D:Y;PI9,[1M<6Z':H8
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M<6GB1?'V@6VIZ^AN6MYI 8+<>6A'! !ZDC')J_#XJU;3KC7]-U:]C?4+<*+
M+"J^:'X4@=SDC(K=UWPW>ZAX@TW6+'4ELY;5&BDS$'W(W)QGO6);OI'C7QS8
MZG81O+%I2/YTS(55GSA%Y')'+?E0!W-BEPEC MW*)K@(/,D"[0S=\#M5BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB4./C3*/70
MT_\ 1S5VU<2G_):IO^P$G_HYJ .VHHHH **** "BBB@ HHHH **** "BBB@
MHHHH H:IK6GZ-$DE_<"+S#MC4*69SC.%4 D_A5*/QAH$FERZD-3@6TA?RY7<
ME2C_ -T@\@^V*YOQA.VC^/O#^N7P;^QXHY8))%4L('88#-Z \<^QKD]8EM+F
M/Q[JU@R?V3=6\4$<BKA9K@ 9V^IZ\^] 'K&D^(](UUYETN_ANFAQY@C/W<]*
MS+3QQI=YXOG\/0R$SQ)G>00&?)R@X[ 9SFI/!,&F+X7T^XTZ*W7S+6)97B0
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MT/6]1@N=4M);6=%EAL8)'<0\X)&\D@'Z_P J .V=%D4JZAE/!!&0:7 1<*H
M X KSKQG_P 3'Q)/8Q/<7CP:8TALUG,$4#9XF=P>3C@#!_"L;P]K%UK\7A#1
MM3O;H07-K--,ZRE&N61MJH6')P 21GGB@#K;7Q?JE]9:ZUMH+/?:9<"!;07
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M+:>1=I+#>^&/'4 8]*Z-8]6T3QEX7TF77KR]@FBN/.\T*/,*J6!/&3U'4]J
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MZHBCY5/8G/6@#MJ*\QO[[5='U;Q#H<>JWDEO'I9O[:>1P\L+#@KN(Y!.:W?
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MEZ1K\8OY@QA,0.05YSR,$<=.XJSX3U^36[&XBO%6/4K&8VUXB?=WC^(>QZT
M6KGPOH5[>RWMUI-I-<RQ^6\DD0)9?0U3_P"$"\*A8U&A60$>=N(\$9]^M02>
M.-.C\:+X<);S1$6>38V ^0 HX],G/2K\GB[0(M1%A)JD"W!D\H*<XW_W=V,9
M]LT 0'P-X9-K]E.D0?9]^_RN=N[UQGK2WW@GPUJ<UO->Z1;SR6ZA(V<'(4=
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M&G:RVHWD4]@"(T39M.?O9^7N.#^F*SM'\4:SK-CXA$-A:C4-.N&@@B\PE)"
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MGERS6<NPRIZ-5%/AGHBZ!)I+27LD9F,\<KS?/$_JI[>_K79[E'>D+J!DL *
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M-&RX;:JA]O SR?Q% '?T4R%S)#&YQEE!./I3Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *XR,D?&2X Q@Z''GGD_OFKLZXI,_P#"Z)^./[#3
MG_MLU ':T444 %%%% !1110 4444 %%%% !1110 4444 <+\0["[FO/#>I06
M<UU!IVH+-<+ F]PG'(7J>E&EZ6VM^-;[Q$]G+;:?+8BR$=S$8Y)SGYF*GD#&
M!SUKK=0U:PTKR?MUU%;^?((HO,;&]ST J#Q!HD?B'1I=.EN;BV27!,EN^UA@
MYZT <5\.M!O]/U?4XKNX,UCI4LEIIP(^ZK$,QSZ\*/SK>^)-G<7W@'5+>UA>
M:<HK*B#+'#J3@?0&MS1M'M="TN'3[-6$,0ZL<LQ/5B>Y)J_0!Y1;:C)J/C;P
ME>+I.JPV]I:/#+)-9. &*X'0'@GO7.WFD:E?VFM7-OI=Y,D.N?;?LSPR1FXA
MY!V\#/T'/->\T4 <'X%&CW>I3:AH_ANZTY#!Y<MS=AE9VR/D4$G(&.3["J7C
M:Y>#QG8"YMK^&S-JZI=Z=#NGE<G_ %6X#*C\J])HH ^?K*[CA\-:#IMS8WR2
M66N>=<>=;.0(]Y)R<<\8S7=^)Y8=.^)'AO5[B)DTM+:5&N!$2B,V<9P..HKT
M:@@$8(H \5UZQ8^&O&6K16LD=KJMU"+.,QL#)M(W.%QQDY(S6QJNKVMCX^\+
M:W*LS:?)IKQ+*D+-ESGC&,YYKU*D(!Z@<4 >3>&+BSDT_P :2Q:>E_=?;)[B
M&&6$YFC*_+@$9QUZ>M86EZM:-X@\&7GVB^N$BWQ21K:E8;=RH"Q1@#L>#R3Q
MFO<;FZM[.(S7,T4,8ZO(X4#\343W]A##'+)<VZ12']V[2*%8GT/>@#Q.Z>X?
MP]KVD6L%P]Y:ZTU]/;&%OF@!!R3C';./:NIO]0LO$_C7PQJFCW*M%912S7LP
M'$,17[K^A/(Q^->F+M/S #GN.] 15! 4 'K@4 ><_"./39M%O9(XK9KN._F;
M>$&]58\'/4 @5<\"H9/%OC2Z3<('OUC7C@LH.[^8KL[N":2SECLYDMIV&%E,
M>X+[XR,U#H^D6NB:>EG:*0@)9F8Y9V/)9CW)- '!:W=Q:;\62\TCQ/>:.8+9
M@OWI2YP.!]*YM)K.Z^$$WAN>,#Q#;SF-;-A^^,QER&5>O0]?K7MI2-V5RJLR
M_=;&2/I1Y,7F^;Y:>9C&_:,X],T 9UQ#./"LL,F9+G[$4;')9]F#^M>.VUKI
M.I?##0]-TY;=O$8NDVK$ )XW$AW,V.1A1R3Z"O=JA6VM8)&F6&&-V^\X4 GZ
MF@#P^T;1E_MS0_%]]JL-\]ZTOD)]VZR?D*_*3G_$5[39VT1T:"U>)S%Y"QM'
M,=S8VX(;U/K5EK>%Y5E:&-I%^ZY4$CZ&I* /*/"NFW<'B*7P=/$QTS2+MK^.
M1AD/&W^J0_BQ;_@/M6=87EG#H'CG2-?DCCU62::3;/@-*&'[O;GEN0,?45[/
MM4,6VC<1@G')J*2TMI95EDMXGD7[KL@)'T- 'DUKFQ\1?#F#46CCOH[203&0
M@/\ -&0JGO[#WK*EUC3H_AUXETG69HX]>-Y*[PSK^\=MPVL/PZ'L*]NDM+::
M599;>)Y%^Z[("1]#44FF6,UP;B6SMY)BNTR-$"Q'IF@#+MIVO? 22Z7*))7T
M[$#H?X_+P/UKS"9[/4/@]I]C;[5UVWNU18.DZW'F'/'7)'.?\*]M5%1 B*%4
M#  & *K+IMBMZ;U;.W%T1@S",;R/KUH \WTC1]$U'XJ>(8K^TLKB1(;=T4@'
M$F,N<>N1S6S\6HPWP^NV\O/ER1-G;G:-XR?:NP%A:+<_:5MH5GY/F",;N>O/
M6I9H8YXFBE17C8896&01[B@#R?4]:T'4?B79O'?64UN=%EAD8NI4L=V%)Z$X
MQQ7.PV&EV_PV\/:I!#!'??VO&'N%.' W-QGL.!7MB^']'2,1KI5D(PNP*(%Q
MM].G2HSX7T$IL_L;3]H.<?9DQ_*@#R)H-+U34_%=AXFUTZ9.UZTACEBCS)$/
M]649@2> , '^=:MKHFBWGQ,C@N;99X&T-),70&]W! #/ZMMKTRY\/:1>74%S
M<Z;:S30*%B=X@2@'0"B7P]H]Q=O=3:7927#C#2O I8\8Y.,T >*R"WF^"0$G
MENUOJA2+=@F-3(,@9Z#%=@T-B?BM!I]];6W]F'2RUA$R*(2Y(WD#H6(S78OX
M.\-O&(SH6G; <X%LHY_ 5/=^'-'O[*&RNM-M9;:$YBB:,;4^GI0!XEJ^GP_\
M(CK-N55M-M-?$6G2$Y"(S?.J'^[TZ5TUYI?A_P +_$32M/N;2&#0I[>62%9V
M+0_:#P6.XD9VC'XBO1;GPSHEY8P65QI=K):V_P#JHFB&U/H*?>^'M)U*PBL+
MW3[>>UBQY<4B JN!@8H \KUF;1],BT/3M,OV3PY_:4QGN9E$T DP"%&>"@)/
MMGUQ5>]MO#FCV=U;0:L^JPWFH0L(+<K%:)(22 [#*@<<@=L5ZZ^@:5)I TE]
M/MCIX&!;&,;.N>GUJ!?"FA+HO]CC2[8Z=G=]G*97/K]?>@#R'S8H;;XB6HN;
M [[:-UCLCMA+;>=BY[=ZU(]!T[1Y_ >HZ%$(M4O)(A<%)&;S8C'F0L,G@5Z9
M;>%]"M)6EM])LXG>(0L5A493IM/M1IWAC1=)D:2PTVVMW92A9$P=I[>PH \C
MO;JYM?!WB4Q2O% _B-H[N1!DK$<9X].F:ZWPII.E6GB_[?I6OP77VJSS):V<
M")&5&,,P4X4\CL">:Z^U\+:'8QW,5KI=M%'=+MG14XD'N.]/T;PYI'A])4TJ
MPAM1*<OY:\L?K0!Q?Q0LK2;4/"TLEM"\CZFD3,Z ED/53ZCVIEG::=JGQ)UW
M2=8M;=X+>TB2PM9$ 18BN6*#MSW%=MJ?AK1M9FCFU+3X+J2,81I%R5^E-U'P
MQHVKF W]A#,T"[8V8$,H],CG'M0!XN;0ZAX?\+PWS22PC7)+2"3><FWR !GZ
MYY]J]GM-+T_PUX=DM+,2065O'(XVL691RQ()_'%%WX5T._AMHKG3+=X[48@7
M;@1_[N.E:IB0Q>45!3&T@\@CTH \&TTPP7W@N\M!##!/?R!97<&[G0MAFE(X
MQVQS]:>_A_2Y_"_CN_> M<V.H2_9I/,;]WC!!'/OUKU$_#KPD4*_V':X,GF\
M*0=WUST]NE/C\ ^&(K6YMDTJ-8;D@S('?#D=,C- '%:UY?AF\\.>./LWGB:V
M6"_VIEF=X\K)['.03[UW?A'1TTG08_W*Q7-TQN;@*,?O'Y(_#('X5BR:-K5S
MK$.A+86MMX4M6CD602;Y)-AW!,$GC=C\!7<8XQ0!Y0/"6F:Q\3_$@N4N'-K%
M;SPJD[##D;CW]>WO6'I.G'Q!H1URX\06=EJ-O>-+/.T3&YC8-@(3NY&.@V_U
MKUNU\+:19:U-K%O:E+^;/F2^:YW9]03C].*K#P+X<&OMK?\ 9D1ORV_S"3C=
M_>VYQGWQ0!Y1XJEAGL==UC3V+O%J2*+^ZD*W".& \N%1T4>^.,\5M>,K.5M5
MU#6)[:+6=*%M%'="*7%QI^%R63MSG=7;W7P\\+7EU=W-QI$3S79)F8LW))R2
M!G .>XIS_#_PR\K2?V:$WJJ.L<KHKJHP R@X(X[T <=HT>F>,=4\2+J:/*MM
M#$EBDV5,4!CRKJ.Q/7/TK$MHI_$&G^!GU26X:6:\EMS*LK R1)G:>N,]LCG%
M>J:EX-T+5;E;BYL@)EC$6^)VC)3^Z=I&1VP:=>>$-#OY;.2>S^:R4+;".5T$
M0'3 4@"@#FO!,-KX?U[Q;I\4BV^EVMS"T:RR\1ETR>6[9]Z[N:&"^M'AE598
M)D*L#R&4BN5U;P!HT]E?BUT]'N;W'FF>YEVL<YW'D\CK^E=#HVG+I&BV>G)(
M9%MH5B#D8)P,9H \3L;"TB^"VO3VZ(EP;TI(5/.P3+M'ZUOWEO\ \(IXUB&C
M-<*;C1)YY-\S2>=(BDJQW'D@@5V;?#GPLPN0=+4+<R>9*JR.H)Z]CP,\XZ59
M3P5H4>HVNH+:R_:K5!'#(;F0[4'\/WN1[&@#SWPOI#WMOH'B1/$5G!*TR_:&
MC1_.N69N8Y"7.XYXZ<5VOQ,A$OP^U9MSJT4/F*4<KR#[=?I5JP\"^'-,UDZM
M9Z9%#=DDAE)VJ3U*KG /T%:FKZ/9:[8-8ZC$TMLY!:,2,F['KM(R/:@#S2]T
MFVU+QGX2M;I[CR;G2")D2X90V$&!UX!YSC&:JV?AU=9\%>)](A,ADTK4I_[/
MRQ)CV\A0>X/(Q[UZ&G@C08[JVN5M9A/:IY<$GVJ7,:^@.[@5:T?PUI>@M<-I
ML,D)N&WRYF=PS>N&)Y]Z .%TO4;+Q)IG_"0RR26<&DZ7]G\Y0<Q3E?G('?:
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M#3_T<U=M7%)_R6B;_L!IG_O\U ':T444 %%%% !1110 4444 %%%% !1110
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M%QJ$04QHP."0,Y(!."15?Q5::E#X]T+6K+3)[^!+>6VD$! *%^A)/ '/7VK
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M=C9W-U<2W$95((R^ IW$G'08%46DNV^)>GZJ=*U(646EF!Y/LK\.3NQC'X4
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M-GJEFEW8W,5Q;O\ =DB8,#7B.D:C9Z<?"M]JE[=6NFG2WMUN;5C^[F\PEE?
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MF./6LC4/$VO6?B#Q98Q7D+QZ=8+=VYE@'RDC..",\>M 'HU4-9UFQT#3GO\
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MUO(@>3>V&"D+^?4_E6Y9^+->A\5V>F:QI]I%!?VKW%NMN[-(A49*MG@G'H*
M.[I.#7GFA>-=:\13P"Q&E'S'D2>V/F>=:$9VEQGD' Y '6J/A/Q%XD7P;J.K
MR10ZA*]\ZQJNX>62^&9O1%'/% 'J.!45U:P7MK);7,2RPR*5=&&00:\^MOB#
MJ+V?B/$.FWD^CQI,LMK*PAE0@Y&3DY&#]:ET_P =ZS_:.A#5]*M;:PUE"8'A
MG+NAV@Y;C&#F@#NK&S2QLXK9'D=(QA3(VYL=AGOCI5BN$B\9:Y?VT6K:7HT=
MWI+W9M]JNWV@H#@R8Q@#.>*J:M\2;FWGU(Z98PW,.GS>0\;F3S9F!PQ3:I4
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M;Y _=! W'N,UE:GH>LZO_P ).\&E71DDU2&_MXKF$HMS%&"I7Z\CCJ:]JHH
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MC>M=RZDS"/[*^2#-OST_N_X5[;10!YK=:E WQ8TN^2WNOLD6F-&7^ROA6;+
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M #''./Y5ZO\ VQI9LY;P:C:?986VR3><NQ#Z%LX!Y'YU<5U=0RL&4C((/!%
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M8\#VVK>(/[934K^QN3#Y+_99 H=0>,Y!H \QT9=5T?P!8:]8ZY=1K%J7E&R
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MXC65L]\SZ9+ILL_V58U&&0>O4TZ]^'5O>>'IM*.I7 :YN?M5W<E%,D[]L\8
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MLY9+H1F+83N=1@YR_?C[M.LO$%_J?P;U1%G^RZOIL+VD[,VTJR8!Y[$KQ]:
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M0MG!QW(Q6O\ #^7[/XBO=.O;"ZTW54M4\VV>8RPRA6QYJ$D]<X/_ .N@#TH
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M:G\E9)'4>4<D8(&23Q]/>L*_\.ZK;:MJ'B/P#J:[WF9;W39E/ERRJ?FQGO\
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M6WBCAMXXX8EBC50%C50 H],"O+M;U;7K?P9>^)++7+B*.;4 ;6*2-&'D&38
M,KGG.[Z8J;QKKNK:1KA-S?W^GZ5+:*+6\MXU:)+CG/F_*3CI0!W3:ZB^)4T7
M[%>%V@\_[2(_W(&2,%L]>*U:\WD\1:IIWC&!)=3^V::NA-?O$B* [*#RK8R<
MD9_&J$VO>(+;P1:^.QJDDI>59)M/VJ(! S[=BC&=PR/FSF@#U>BO*KC4?%&I
M>)O$=G9^)&M;6RM4NX0+2,D!EW!.?R)YKL_!.M7&N^#--U.\P;B6']Z0,!F!
M()Q[XH Z*LO6==M=%%LDL<T]S=.8[>W@4%Y2!DXR0. .YK@EU_Q!K/AC6/%>
MGZLULEE-+]GL?)1HVCCZAR1N)89Z$8JKJLUQX@\6^!M2CU"ZM!J$,DL<:!#]
MG/E@G;E><]\Y_"@#TC0]<MM?TXWEM%<1*LC1O'<1['5AU!%5=6\2:9I=_I=M
M<Q2RR7\PCMI(XMR!C_M=!^'-,\7I=1>"]4>UO9H9XK5W$L87<=JG/;C/MCVQ
M7F]_;7Z>#? "QZ@9+F6]A:!YHQMAS'\HP ,@>_)H ]>U&_CTS3+B_E21XH(S
M(RQKN8@#/ I-+OX]5TRVOX8Y(X[B-9%65=K $9P1ZUYW%K7B.R7Q?I4VL)<W
M6E0)<07<EJH."A8J5'';@\TR^\6ZQ;>'_#%_=7=S:V%W:[[V_MK99&60@;<@
M@@+WX% 'J6*I:KJMEHNGR7VH3+#;1E0SD=,D ?J:J^&+J>]\.6=S<7L5[+(A
M)N(@ LG)P0!P.,<5QGQ N-/U[5?^$<O;B>&U@MVGE:*)WS,PQ$IVJ>F2U 'I
M*E74,,$'D$4M<#X$\4R7OPY>=HWGO]*B>*6+!W.R E?S&/QS69!XB\1W4'A>
MXM-<@E?6I"LT/V16$&!D[<8;Y<$')- 'J-%>96&K>,KOQ)K4!U:S%CH\Z&8?
M90&FCVEBHY..!4&G^)_&>JKIVK:?:3SVEQ<$RVQAC6(0[L?*^=VX8ZGOVH ]
M4HKRR3Q5XOU=;N^T&UG>."\:&*W$$9BD1#AMSD[@QZ\8 ]ZM7.J>+=0\:ZAH
MMIJ=O81I8I=*K6RR-$3CY<]SGOT]!0!Z3@48KR*#Q?XL/A;2_$DVH6ODF\2T
MFM%MA^^&\J7+9X/'08%:&H^*?$VI:CK">'HIREA-Y$*1VJ.LDBX+>8S$$#TP
M* /3::S*B%F("CJ3TKSJ\U?QE<^*-*TN"YM-.-]I_P!HEC>W$A@<#YN<_,<]
M.WUKG=?U[7-4\!O]IU 1SVNK_8+DPQ!1< ,"&/I]!P: /9)YX[:WDGER(XU+
M,0I)P/8<FJ>B:U9^(-,34+ N;=V95+IM/!(/'X59MDEM[)$NKGSY47YYB@3=
M[X' KQKP_J/BK1/ ,6NV5S:/I5K<.9+(Q?/(AD(8E^W)[4 >VX%&*\MN/&?B
M'79]1D\-07(BLRJ0HMJLBSO@%@[%@5'/:M6/7O$&N:LFC6S1Z1>PZ>MU=%XQ
M*1(W 0 \ =R>>M '>TA%<%_PD'B/[1H?AVZ%M9:W?1RR7$ZJ)%C1,X*KG!+8
M^@JG<>+?$&GVWB33)Y;634M)A%S%=-"0LT1]5!P&&1[4 =KI/AO2-#FN9M.L
M8H);EM\SKDESUZGZ]*U:\N;Q#XS@O/#Q>]TV0:Y$1'%]G*K VQ3N)SENN<<>
ME30>-M6TC3?$<.JM%?7VEW$<$,L46P2F3.W*CTQ0!Z7BBN'\/ZKXK?Q)';:A
M:S3Z9-"6:XDM! 8) /N@!CN!]^>:T?%&O7-CJ>DZ-I[)'>ZG*5$TB[A"BC+-
MM[GL* .GHKSRY\3:]I5[K.B75Q;37EK8F^M+QH" \8ZAE!P#GI6EX)N_$^IV
M=OJ>L7%D]G=6JO%'!&5=6/=NW(Y_&@#</B'3QXB70O,D^WM$9=GEL%VCONQ@
M_A6K7F_BI-6E^)NEQ:+<V\%X=.D^>X0LJKN.3@=350?$/6+&&;1KZWCEUY+T
M6JR6\1964C.\)GDX_AR,\4 >IT5Q_A+4_$=QJ=Y::Q:3M:(H>VO9;<0,_JK(
M"1G_  KL* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M("C_ (78[=_["4?^1C7;UQ*M_P 7KD7_ *@2G_R,: .VHHHH **** "BBB@
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M.+=M3)GTQP;5_LZ?(-I;&WOP .<UTF@>(X5\$Z1JFMW\4<MS C/))A=[D9X
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M3?8SNW;MP'W\8R34T_@/58-9EU'1O$4FG&\PU]&L(97?NZ G@GGUKN\BC(H
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M0 4444 %%%% !7$JO_%ZY&_Z@2C_ ,C&NVKBES_PNB7T_L-?_1S4 =K1110
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MVP_O%W#C:3U/4G\:LZU+X7F\)^*-1T=[RY-U;QI)>W<C%9)=P*HN[JP&<^E
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MB;?6MGH%FUS"CJ]_"$FESY<# Y$C@=0,'CO7G$VK:65\?I/JL%V]W;Q-;R%
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MB*2,,HQTX-)9:5I^FES8V-O;%_O&&,)N^N*Q-"\:Z3JVH)I47VJ.Z\@2Q^?
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M)DATO)W>1$26&?JQ!/\ NUTUYXDTNPUBRTJ><B[O?]0@C8AN,_>QCMZUK9H
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MNX+ZTBNK:5)8)5#I(AR&!Z$4 >?Z./&&K:.OA[4](3388K5K:XOFD5_.&PH
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MN>Y^E=4Z)(-K@,#V/-.5510J@ #H * /+?&4MO:>(-8O-.UJ*TU%+9%N]/O
M&AODV_*%!YS@XXY_.G:#JOV#QO/=>((8],BU#3(?LWG_ "H@"C='ENX.>#Z5
MZ8]M!(^YXHV;KDJ":=)%',H61%<#G##- '&_#2UEMM(U-MCI93:E-)9JP('E
M'&"N>Q.<5VM(!@8%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %<C /^+N7I_Z@L/;_IL]==7(P'_B[EZ.W]BP_P#HYZ .NHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH Y#Q]>2066G6\6HS6C7%XJ,EMG[
M1.N#E(\#@GCDX ]:X./6-?/A#QC&=3U&VETJY4P&616F53_ S\Y[=/SKTSQ+
MX5M_$@LWDN;FTN;.3S(+BV?:Z$C!KGIOA382K?QKK.JI%?D-<IYH82,.YR.3
M0!D20Z_:>)]!L?\ A*=08:U:NURS!#Y950W[L8PIYQGK5/\ X2S7-(T'7[(7
MTEW/;:NMA;W-PRB15?/);ID8X)Z9KM&\"E[_ $N].MWQFTR/R[<[8\!>AS\O
M.1Q4,?PVTXVVK6]Y>W5Y'JC^;,)-H*R Y#J0.",_2@#(:T\86,&L2S:C/;V!
ML'DA,MVD\R2H-V5.P<$ @UEZ7J&OVEOX-U:Z\0W=RNJ3B&>WE"^6%.<=LY]S
M75Z=\.HK#3;VU?6M1N9;F$VZSS.&,,1ZJ@/ R!@FFM\.D:RTFT_MN]$6E/YE
ML D>0>V?EYH Y76;J^\6> ?$>O2:G=6\4<DD4%G$P$8C0@8<8R2>N<T^+5]<
MU.ZL] TG[2L=GI,,I%M<) [.RC!+,#E0".!WKH;_ .%UG>7.H&#5]0LK/4#O
MN+.!P(V?.2>??G%37WPULIX;!K/4[^QOK.+R5O89!YCIZ,>,X[>@H Q=/U7Q
M)<ZII/A'6+TVMZ8WFNKJUD4R.JY*J#C /J:O_#JTDM/$'B^":YFN98[Y%\Z9
M@7<;3@G'&<5?OOAS87%IIZVE[=V5]8L62_C;,S;N6W$]<DFK7A?P5%X9U"^O
M5U2^O);P@R_:'!!;^]P.30!C>*;Z_P!!\=Z5<SZM<Q:#?*T,R%P$BDVD @XX
M['ZBN<T3Q5J%W;:QHQU343J-S=1?V7)-@2&!FX8<?W02?6O3?$GARR\4:2=/
MOPWE&19 4/(*G/\ B/QJ-_"NFOXDL]<\D+=6EN;>,#IM/0_4#('UH XN2XUE
M/%7B'0I=>O9+>WTGSH9 $1T/!SD+R>V>O-<XMO<)\'-!D2]G>:XU.%D\WYUB
M.]L;1CUYYZFO2QX-4^*+[6Y=0FD-Y;FVD@**%\LC  (YX]:Q4^%H32[;31XB
MU'[);7 GBC(7"$$E0/H3^- &?)KVM^#]6\16U[J3:K%;::M] ;A0I#EMN/EQ
MQG/%+>:IKGA_3?#_ (@.L3ZA%J$D,=W;2JOEYE&1LP,KCFNAD\"+=Z_<ZIJ&
MIRW:75M]EFMGB55:/TR.1SSQWIFG> C:2V,5WK-S?:=I\GF6EI*B@(P^[N8<
MMMSQF@#GXM7UA=)\=QG5KIGTJ<FTE)4L@ )P3CD<54M/[1U3QOX/FN-:OMUQ
MI9NF"[  V!N  7&&QS73:K\.8]0U#5)X-9O;*VU-<W-K#C8[XQN/^'?GFGGX
M=QK)HTMOK6H0S:9";<2J5W/&?X<XX]/I0!9^(]_J.E>#+O4-,O6M;B H=P16
MW L!CD>]<M)-XJB\6Z/I2^)I&76+)I9'>V3]R5&3Y8'0XXYKN/%/AUO$VA/I
M)O7M8I2ID=4#E@#G'/3G%9G_  A5V=>TK5FUQVETV#R(U-LN&7&&SSW% '+6
M7B/78_!^K12ZU$EUI^K&U:_G0%VBR/NK@[G]!BL^YUW6KG1/&.FR:CJ*1V$"
MS6\EQ&L=P48<JV!T.<]C].E=$_PKD>"=#XCN5DDO1?JZVZC;-S\V,^]6H/AE
M&)]5DN]>U&Z_M*#RK@/M&XX^\3CMV% &'!K.L6EKX9\-Z9<7<\MU8"ZEE3R5
ME5-HVHA<!0!SUR:BU?5O'VC>'K#[9>QVEV^HK:HS)%(TL;?=9\9 (QVZUN77
MPP,VE6$::_>KJFGG%M?D<HG9 H.,?K5F_P#AY)?:59VK:[<&YBN1=SW<L0D>
M>4#"DY/  X % %&[NO%/A_Q%X9LK[7TOH;^ZDBF M$CRH (Y_'MBL37/%NNZ
M==W-W#K#SF'5%@\BW@5K5(2V-KR%<[_8'(KN=;\*7>LZIHU^=7,,FF?.H%N"
M'D(PS'GC([=JP9_A7-+8S6">)[V.R:?[1';B)2J/NW$G^]S]* +<'/QMN?;1
ME_\ 1E<;I=SKNG?#&75]$OI8?LNHSM<PI$C>9'O&X_,#@BN^M_!NH6WB5M<&
MOM)<FT%I^]M5.5'()P1DYYK*"6OPT\/'3+Y[O6$U&:3RHH;7!+,/F4X/0Y_G
M0!L>'M7F\0:_<7EEJ3R:/#!$BQ[$VR2LNYCN SP"N1GJ3Z4WQCJFH6.HZ5;V
MU]]DMKAW$IMXQ+<R$#Y5C0@Y&3R<<>W>[X(T!/#?A2SL50I(099E)SAVY(_#
MI^%5O$G@^XUG7;+6=/UB;3;VVC: ND8D#1MU !X!YZ_X4 <+JFMWVN_!J>YU
M*0R7*:BL#.R!&8+*,;@. :U9);VV^*UU-)JUQ]FL])^U"'8A&S<"4'' X'/7
MWJ>/X5W$?A^[T;_A);AK:XN?/(DMU;!#;O7J3U/?T%;-QX)N;CQ';ZQ_;,D;
M_9!:7B1P@"X0'/&2=N?QH Y?1O$_C767TK4[2QN9+2YES<1R11+;K"6QE&SO
MR!Z]<59T6Y\<:QXEUB!-?L4M]-O!"Z-9@AU()X'7T[_C5_2/AO<Z3=K OB*\
MDT*.7S8]-*@#KD*6SRN><8YK5\/>%+_0M0UJ[.K13-J<AF(^R[1')V/WN1CM
M0!Q3>,/%+_#C^V8;^W-XFJFVD9H!@IN"@ =!R?<X[UNV>N>(]$\5ZAIFL7L&
MI1KI3:A%Y4'E%2IQL'J/_K5!_P *OO\ _A&/[#_M^,0_;?MN_P"Q_-NZX^_T
MS5O5/#FL6&IWOBJ75!<W$>FO;>1;69#,N,_+\QPV[GH?I0!BVOB?Q-=IX6N;
M?6K>1];E99K?[,K" #DE0.< #!R:Z_XB/?0^ ]5FL;MK:6.$LS*H)9>A7GID
M'J.:\H\*EM,%M<>'_$%K>ZLY53I[:21(Q8_,IDZ@=<MD#BO;]=TD:[H%]I<L
MAB%U"T1<#.TD=<=^: /,=5M=3MY?AU!!?12W;;O*EFAPJ Q)P54\X&?K5K_A
M/=;TFRUVUOGBO=0L]1BLK>6.#:&\P$Y* \X"GC/I6I#X!UT3Z!-<^(X)FT<D
MPJUCQ@J%QD,,C 'OFDN/AG-J!U[[=JR$:I,EPI@M]C02H?E(.XY&"010!:\*
M:SXHNO$=U:ZG8W1TOR0\-U<VJP,'XRI )!Z_I5SQ)JNHZ?XL\-6\7V4V=[</
M$^Z+,@(0GALX Z=LT[PUX:UG3KD7.N:_)JDL<9B@7RPBQJ>I./O,<#DU+XC\
M.:AK.L:1?6VH06RZ;*9D22W,F]B,')W#C% ''W'BCQF[>+&AN]+CCT-]W_'N
MQ+KM+;1SZ#J:2XU?6=5\:>$)DU%+:"ZTYKTQ+"&5&\OY^_.1D#/3-;*^!-6
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MFT6TAMYBI=N<LS;21CL.35;PMX/N]&\5ZE(YQI$,C2Z='D$*TN#)],;<?B:
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MU[<IY@,@/$:H&!)/6L _$#6Y_"V@:K:65D9=0N_LDJ2NX&_<5!'H#C//3WH
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MYBD4@[MN1DL/\^X!Z!@45A^#Y;Z?PIILNH&)IGMXV#QNS;E* @MD?>/>MR@
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M' R>!3Z "BBFR2)#&TDCJB*,LS'  ]2: '44R*6.:)98G5XW&593D$>H-/H
M**** "BBD9@H)/04 +157^T[#_G]MO\ OZO^-2-=VZ/&C3QJTIQ&I< L?;UH
M FHHHH ***C^T1>=Y/F+YNW=LS\V/7'I0!)113!*AD,89=X&2N>0/7% #Z**
M* "BBB@ HHH)Q0 44=:* "BBB@ HI,\XI: "BBB@ HHHH **** "BBB@ HI&
M;:I."<=AWI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N0M_P#DKU]_
MV!(?_1SUU]<A!_R5Z]_[ D/_ *.>@#KZ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?'>M3>'_  7J
M6HVQ N(XPL1/9F(4'\,Y_"NBK!\9Z(WB'PCJ.F1D"66/,9/]]2&'YD8_&@#D
MO%]C<V'P<>.REB1/LT;W3.A+S%MI8@YX)8Y).:/$EG=6W@2'Q*ZVB:U81Q31
M3VL9CQ'Q\AR3D8)S_*KMS!?^,_ALFE6/V6&[:);>Z6Z9@863&> "<Y'?M3?%
M27\G@B'PPPADUF^5+9(X&+C8"-TAR 0 !R?6@#MM,NOMVEVEWC'GPI+CTW*#
M_6K55M/M18Z=;6BG*P1+&#ZA0!_2K- !1110 5Y#\0X_$.@>-;?Q;I5N+^W@
MM_+DB9=XAZYX'*@]<COFO7JXV[T7Q)9^+K[6])N+*2VN8HD:RG++O*C&=P'!
M&?>@#C=+\>6"^&_$/B/0[**WU<"&2\LY^8SSM++MP3G=S[U<M_B;K,M_X2C>
MSL1!K87S-H?<A\PH<<^P/>K4?PPFN;/Q'-=/:VU]K"A4CM@?*MP&#8[9R0,G
M%8MA\,_%UO?>'+JXNM-ECT>1?+A5F4A0^XY.WDF@#4U/XE:[-JFL1^'M*M[N
MTTF18YPX=I926VDJ%/ !!]:GU?XBZS+K5YIOA_2H9)M/LA=7*708N6^4F-54
M]1NY]P:K1?#_ ,3^'O&5]J7AC4+*.SORQD%RI8QY.>F.<'I^M2W_ ("\2:?X
MX'B3P[?6C37$>VZ%V" 6( 8X Z' .!TH 9KGQ4N[&?3+""RM[6_N+47-Q]N+
M;(<J6"87!+''ZBJEW\8;K[%H[PV=M:27:.9Y;M7,:,IQM&,'G@Y[9%7O$7@#
MQ#/XBTOQ+I-_:R:M BK<F=-J2,!C<  <#'&/I4WB#P=XEURTCAU%]/U-#;-O
M20F+RIV8D-&0N< 8'/7% %36/BAJ>F6V@J]I907.H6QN)GG+^4O)"JI'/..I
MSC(K1O?'^HB?P[I%G8VZZWJT2S2+.6\J!3GTY.<'\JR;KX<:U_85AHSQV&I6
MD-H5/G2-&T4Y9CN1@,X&0,=P.E6/^%;ZII<WAG4]/F@NM1TF'RIHYG95E&6(
MPV#C&XCIT H )/BC?S>"=1U>UL;9+_3+I8+J&5F9""<!E(P>OKZ&JI^*7B>/
M1VUN;PNJ:4;4/'-O.&D+;0<_W<YXQGWI1\,M9@\!:MIJ26LFJ:M=)/-\Y6.)
M0<X!QR?\:Z4>'M<A^&]EHENED+^%8XY$D.Z*1 WS*>.XH D\!^++_P 4B[>Y
M2R,,2QF.:T+%6+ D@AN01QQ57QIXZO= U=-,L;.'>;9[EKJ\++" H)"@CJ3C
M'7J11X"\$S^&=8U:_:&.SM[O:L5E',91'CDG<0._3VJAXZ\$^(_$GBFVNK2X
MLY-,C@*+!<EML;D$%MH')Y!!]J ('^*MXWPZC\46^FP&1+G[-<0O(P&<=5/X
MCK4WAOXDZIJ'B^WT76-)AM%NK3[3"T4A<@;"X+>Q4'Z&L!/AIXH'PYD\-F.P
M$K7_ -H#^:?N@?3N<5JZ?X(\1)XXTC6;BUM%MK6R2RE07&YB!&8RP^7WSB@#
MG_&WB_4/&7@C5[FUL+:/1K6\CA$KN3,Q!!W8Q@ Y'OS7K/@@Y\"Z$<8_T&+_
M -!%>82?#?Q=::!J_AFR2QETVZNEGCN))2KX!'&/P&?I7J7ANQOM)\)V%A=1
MQ-=6MNL6V)SM8J,#DCO0!P'QDO\ 4+JS&G:42PT]5O[XJ>4&X",?7.YL>@S7
M36OCR%OAE_PE9B\YHH 98D./WN0I7V&X_E65I?@=]5_MB]\6:)%-J5S,9(V6
M[.&3&%08QC  &3ZUC^&O"'C;P[H.K:,EM8RV]T0\ EF#JAW#<K CD,HP: -+
M3OBI//H&J:O<Z= \5E;QR+]EF9@[NQ&QB0-I&.>M5W\<3^(_!?B"2^TNTN+2
M"TC=_LMVP617/*[BN590.GK[55TOX?:[I1UJZTVPMK6.\CBB33)IQ-&XW*9"
M2?X<!@._-1V?PYUJPTOQ.MA9"VBU*V6&WT][H/M;(+,6Z8'.._- %O1O'L.D
M^%O"VEZ-HY-UJ89+>":Y.R,"1ERSXR<G)QBGQ?%G4Y-(UB__ .$>@"Z3(D=S
MF]/S,6VX4;/8UR.N:;K6B:9X/T2?22^I6AGD3[%-FX(W%AM90<#YOTJW8";5
M_"VL^#M-\+W5CK%P$N9#<S9,HW@EF9\8_P#KT =9H_Q9GU+7=&L;OP\]G!JJ
MYMYC<!R>2,XVCC((JS9?%#^TO$YTVRTU)+<7JV99KC;,O.#)Y>W[GX]N<5S-
MIX(\51ZKX/N'TE%CT6-4FS=1_/B0MD8/H:M-X#UR]\5:=K#:6ECJ$-_YUU>1
M7">5-$'R#L'(8C Z<]30![#5>^M$O["XLY'=$GC:-F0X8 C!P?7FJ.CW6LSW
M>HIJFGPVMO%-MM'CDW&6/U/H>GYUK4 >4Z]X<T.P^(_@_3XM*MTM)([A738"
M),(-N[UP>>?6H?%VAZ;X2\3>&+G2M.9Y9M2DE$$(&YOE4;%)X"YYP>F36YXH
MT_6[GXA^'M2M-(EN+#3M_F2++&I)< ' )SQ5GQII^KWOB+PW=:?I;W4&G7)N
M)G61%.",;0&(Y[T -M?B3 FF:Q<:QILNG7.E2I'-;>:LA8O]S:> <X_K4_AW
MQ_!K?B270Y;>&*X$(GB>WNEN$=>X+*!AAZ5R=]X0\0ZQ>>*S_9[VSWMQ!=64
MD\B,K&$G"L QQD'CM76>%W\276H))JOA^STB&&,AS&R.T[G&,8^ZHY- $WBO
MQK)X9U+3K&+1+K4);XE8O)=1EAV'?/Y<5E:;K5CJ7C^QEO/#EYI^KR::[B:Z
M?&V,-RNT'USR0#5CQA8:M=>,/#5]9:5-=6VG2O+,Z2(/O#;@!F&2,9I-0M-2
M;XJ6.K?V3*=-M[%[:2Z+Q@ L=V[&[.!T/'K0!'=_$V.WT[^UH]&N)](>Z-I'
M<QRKN=P2,[#_  D@X.:P?[3E\/\ Q7URXL]&NKR6XTZ*8V\+#*="Q8DX'2L'
M2&U :7')=>'=1N_#JWDE_%%:RQM"H#L1R1N*@Y.">:[.P_M.[\=:CX@71KUM
M,O=*6"V<; S'[W(+9&><9]J &:C\1+VZMO#-UHVF2O;ZK<!7+.H;*DAHAGH<
MCJ>U:UW\0/(O;R&'1+JXCL#&EZZRH#"S8X"YRP&>2*Y"ST#Q%IWA#PP/[#N9
M+K1]4:>:W#IN=&+$%2"1_$*G\2Z3J^J:C/>VGAV_TSQ"LJ?9;VRE!BE3Y<B5
M@<<<]NPH ].UC5K;0](N=3O"PM[="[[1D_0#U)XKG;'Q]'<7DEG<Z-?VUR++
M[?#'\KF6+VP>&YZ&KWBV+6Y?!=[%I(6353 %& /F/&[;GOC.*\\TVPU?3_%5
MIJ\'A/54MY=->VG,DBR3-(3DNV6SZ8!QGL* .HT_XJ:??KITPTC4X;2]N/LR
MW4D8$:R$X49SSGVIOCCQ+;W6@Z]IMKI][>BTA*W,]NX1('(R.<@D@X) 'UKE
M;73]:M?ASH.DMH&I->V6J)<2((>-BR%LYSZ,/UJZ8=>T=/%>DG0+^^CUEI;F
MTN+<#"^8I^5\_=(XXH [OP*Y?P)H;,22;./)/TJC=?$/3+:&>[%G?3:9!,()
M=0BC4PJV<$YW9(!."0,5;\$6]W#X(TRSO[26TN(;<1/'(1NX&,\=*X:QT[5=
M+\":IX)GTF[EO9'DCM)TBW0RK(V0Q?HN,DG..E %S4=?AT7XK"ZBCO[Z&[TA
M9$@M-TQ=BY^8+G &T?YS2>+O$5EXE\(:7K&E3W,?EZK!$Z;F1D);#*Z@X/;U
MJ8:?=^%?&>CWLUA=W5C%HJ:>\]K"9<2*>X'..!SCO6-JFB:C:^'+F<Z;=F?4
MM=2_6TBA+M%$K9^;;D XYQ0!VWVS2#\36@WZBNJK8<JQ(MS'G.1GJ>>HXZTD
MWQ'T>&&.Y-O?O82S_9HKR.'='))G&!@Y/(/;M65.\L_Q>M;T6-Z;-M*,!F-L
MX0.QW $D<<'\#7$Z1?(-.M]/U&RU:+0K._:^B$-B9/E5B0#*#@J,Y) H ]/U
M3X@Z3I=Q=1/;7\WV)$>[>&#(MPXRN_)!!]NU0R^.-WC/3M&MK"XEMKJU^T?:
M%BR&!P59>?NC)R:XKQ0]]JUUXE@DTS49(Y[9'TW[%"RQ3KMSOD9<;R,C ;..
MF*NZ?<WEEKWA'5)]'U+[.FC_ &$A;<EUE&!R.P.,@GM0!TWAS5]#M(?$.H1:
MI?20073-=O?$@1-CH@(''_UJTK+QIIEYJ*V!BO+:XDB,\*W-NR>>@Y)3UX[=
M:\RN=.OM;L_&\-C;7/G2ZBE[;QR0NGVA%/(&X#/TKI;VY3Q9KWA:ZLK2Y@;3
MG:ZO'DMG3R%"C]WR.23Q@9Z4 :J_%/PPP#>=="/SO)>0VS!8V[;CCY0?Z&M+
M5?&VD:1<30S?:9C;QK+<-;P-(L*-]TN1TS7FAD+_  Q\5:?]FO/M5QJ3RPQ&
MU?+JTBL"/E]%/Y5+K3VTTTNHZ3+J&G:S%9PQX-J[PZB/+'[ME*]1RN#_ /J
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MMJOB#4M&CMKF*XT\*96E4!6W="N"<CO7GT^J7.N:'\.]0NVWW,FHJ)'_ +Q
M()_2NA\.?\E;\6^GD6W_ *#0!TVKZ\FD7NG6ILKNX:^F\I6@CW"/U9CV'^!K
M6##%<5X[U+5M+U/PXVGWS10W6H1VTT"QJ?,#<]2,CICCUKFKJY\4WFN>,+>/
MQ/-!;Z3"LT82WCRWR%PN<<#C'J: /6Z*\OTGQ1K-]JW@B62^81:K;2FZ@5%V
M,R*?F'&0<\]:S-4\3^)+/1?%S0:U+YNEZDD,#O#&6V$XP?E_6@#V.BO*[[4/
M&.G:C8>'WU9]0N]05[EI;>*.&2.-0,HA;Y>O?&:ZCP1)XH^R7D/B9%$D<O\
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MJ44\VC21$F:Z, DCD]A$?NGTH W]5\466CZSINF7,=R9M1D\N%DCR@/NV?\
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M%EJ5@8A;X:&ZCMY(HYE/H).016/XRDU&#XF^'7T>V@GOFL[D*L[[$Q@<DCG
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M;71+J[M8M0\R5H,*D*<YZ]_85W-]X[T^ 6B6BBYGN;47:QM,D.(STR7(&2>
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M!.<F@#/U;PG=:AXRTR_%EICZ39Q/$T$I.6#\EMNW;D'IZ^U=6VFV+67V)K.
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M23@"HY;J"*TDN6E3R44LS[AC YH R="\-1:+=7EZ]U->7UZRF>XE !8*,*
M   *;#X:\OQ;+X@?4;B61X?(6!PNQ$SG XR.>:Q_#_B'Q#X@-AJ=M!I[:-<R
M2!T!(FA0$A23G!)QG&.]=!-KMH-7.BPRH^I?9VG6,GA0, ;CVR2/UH S-9\%
MKJ_BBRUX:K=VT]FH6)(E7&,DGJ.<YKS6.R^S^)=3N+J\\2:;J<MW(4BM;7S0
MZD_*0^.<_E7I?@GQ)<>(-%EN]1%M#.MY);A8C\IVG QDG-=,\B1C+NJ_4XH
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MS93FZ\UBLCS3''SN2.3P!4[> 8)M2UB[NM3NYQJL(AGC*HO ^[@@=JZT2(2
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M#; KC#';N^9B!C)-5?\ A7%^-&T/2QX@B\G2+@3PM]AY<@D@-^\Z<GI7H-%
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M6>%M,U XT>XG=IP<A9' ^16]LD<5G0:=#:>,_%.D0Q1MHITX7+6Q4&.*8CC
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M-0>*=*6QN)YX-DJ31RPD!D=>AYH Y@37VN^--3\.IJ]]9VVDVL6V2%P)9I'
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MC;VGVNWBEN 5FCS@DL!\I]JI:%XZOH_!FGZEJEK&TU[<^1;N9PJN69N6./D
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M6B@"E;Z1I]I?->V]E!%<O&L32)&%)0=%X[# _(5=HHH **** "BBB@ HHHH
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M6VU*SO+NZM;>X22>T8+.BGF,D9 /X5:H **** "BBB@ HHHH **** "BBB@
MHHZ53LM5L-1EN(K*[AN'MVVS"-PVP^AQ]#0!<HHHH **** "BBB@ HJ*&Y@N
M#((9HY#&VQPC [6]#CH:5YXHY4B>1%DDSL4L 6QZ#O0!)1110 4444 %%%%
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M9L]),NFW_P!J>8S-ON3DG<[8S[>M:;>"=:U5?%T%_%!;)K)CE@D2?S/+DCZ
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M"56"2,I3<"P ) )'8'&16U7 ?".XLI/!D4,,D)N8Y)/.12-Z_.V-PZ_2N_H
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M<^E'7+U9=/UU;!+Q'^:5'[,>I*X!Z_Q8H ]>N]1.DZEIFG6FCSRVUR65IK=
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M6YD&4A:0!V'LO4T 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8-C).,5[%_8&C[67^RK+#G+#R%Y/OQ4T>EZ?#9M9Q65NEL^=T*Q (V>N1C%
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MI>F^']*TB*6.QLHXQ+Q(3EF<>A+9)'M5+1O!/AW0+V2\TS3(X+AP07R20#U
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MDA<^<VZ1LLHZ8!X_"NFUSXC7%M?:C!I-O;SKIQ"2+*LA:9^I5"HP,>_>L]O
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M81/I]OG6F9X +D?(67;AN/3FH[K0?$36W@U%TI"VBLIN,7*88!0ORY]AG\:
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M86 1P1G=TQ@'IWK(U;4$T+Q[X?U?4+"6UMFTLP%(8RXC<GB,;1U' KDP9IO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ Q1110 4444 %%%% !1110 4444 %%%% !1110 5%/;074?EW$
M,<R9SMD4,,_0U+10 R*&*"-8X8TCC7@*@P!^%/HHH **** "BBB@ HHHH **
M** "BBB@ I&&X8I:* ,K2_#FF:-=75S80/'-=-NG9IG?>WJ=Q/-:M%% !6.?
M"^DMXE/B!K4-J)0)YA8D  8!QTSCC-;%% !1@444 &*3 ]*6B@!,"EQ110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SUI_R4'5?^P;
M:_\ HR>NAKG;0_\ %PM5'_4-M3_Y$GH Z*BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!" PP0"/0T;%V[=HV^F.*6B@! JK]T ?04AC0G)12?I3J* &A$
M ("J >O%*54XRH..G%+10 FU=V[:-WKCF@@$@D#(Z&EHH 0J&QD XZ9H(!&"
M,BEHH 3:N<[1GUQ2T44 (55L9 ..F12X&<XY%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7.V@_XN'JI_ZAMK_P"C)ZZ*N;M)%'Q&U2//S'3+5@/823?X
MB@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF;611\3-
M3BQ\S:5;,#["2;_$5TU<G;_\E7O_ /L#0?\ HV2@#K**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KD[?_DK%_\ ]@:#_P!&R5UE<I;_ /)5
M[_\ [ \'_HV2@#JZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KD[?\ Y*O?G_J#P?\ HV2NLKE+<_\ %U;\?]0>#_T;)0!U=%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5REO_ ,E6O_\ L#P?^C9*ZNN4
MM_\ DJU__P!@>#_T;)0!U=%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M,VT1/Q,U*;(PNE6ZX^LLI_I735REO_R56_\ ^P/!_P"C9* .KHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N7MMG_"T-0))W_V3;X';'FRY
M_I745SEH/^+B:J?^H;:_^C)Z .CHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N>M/\ DH6J_P#8-M?_ $9/70USUH/^+@ZJ?^H;:_\ HR>@
M#H:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG[0?\ %?ZJ
M?^H=:_\ H<]=!7/VG_(_:I_V#K7_ -#FH Z"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *P+3_D?=4_[!]K_P"AS5OU@6@/_">:H>W]GVO_
M *'-0!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6):J?^
M$TU-NWV&V'_C\U;=8MJQ_P"$QU1>WV.U_P#0IJ -JBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *S+?_D9-0_Z]K?\ ]"EK3K.@4C7[
MY\<&W@&?H9/\: -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *IP_\ (6NO^N47\WJY52+_ )"MU_USC_FU %NBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *JQ#_B9W)_Z9Q_S:K558O\ D(W'_7./^;4
M6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *K1_\A&X_P"N<?\ [-5FH$5A>S,0=K(@!]<9_P : )Z*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** $/2N1N?!VH7U]>+>>([R;2+MRTE@5
M7H?X _4+VP.U=?10 R&&.WA2&)%2-%"JJC  '0"GT44 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%11O*9)!)&$4-A#NR6&.I].
M<U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %'4H);JVD
M@MY%CN"N8W.?E/K5R(,L2*YRP4 GU-!C4R"0J"P& <<BG4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5-3N;BSTZ>XM;4W
M4T:[EA#8+^P/K7'W'B/5?$RKI^AZ?=V1DP+BZNDV>2.X'J:[NB@"AH^E6VC:
M;%96RX1!R3U9N['W-7Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% $3?&; /_$AZ?\ 3Y_]A48^-) R= SSC_C\]O\ <HHH :OQJ<A\Z",C./\
M2_\ ["F1_&R5GPVA)CVNB/\ V2BB@!+GXW30W+Q+H*$+W-T?_B*@_P"%YW _
MY@,?_@4?_B:** '+\<;ACC^P8Q_V]'_XFG-\;[A03_84?'_3R?\ XFBB@"/_
M (7I<;B/[ C_ / H_P#Q-.'QQG/_ # 8_P#P*/\ \3110 \_&Z=03_84?_@2
M?_B:DA^-DC,=^@J?3%WC_P!DHHH M#XRY_Y@/_DY_P#84YOC%M./["_\F_\
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M110!87XJ[O\ F#8X_P"?K_["NEM_%'GQ!_L>,YX\W/\ 2BB@"8>(LG_CU_\
M(G_UJD&NY_Y=O_'_ /ZU%% &NK;ESC%+110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+ %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>sgmo-20210331xex103006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 R%B\$;GJR@G\J?4-KS9P'_ *9K_*IJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:<L<]!P!C\:YSP%K5UX8\):CX?NM$U-M5,TA@A2V8B0LH'WL8 !')]*]LHH
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MCG.V,'_:4=?]H5)4-U_J5_ZZ)_Z&* )1TI:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH **** "J>JL4TB]=3AE@<@^^TU<JEK'_(%OO^O>3_T$T &D?\@2P_Z]X_\
MT$5=JEI'_(%L/^O>/_T$5=H *PO&1QX3OSZ*O_H:UNU@>-O^1.U'_<7_ -"%
M &_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M HHHS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 52UC_ ) M_P#]>\G_ *":NU#>?\>4_P#U
MS;^5 $&D?\@2P_Z]X_\ T$5=JEH__($L/^O>/_T$5=H *Y[QTVWP5JC9QB('
M/_ A70US/Q"./ &LG_IW_J* .E!! (.0:6F0_P"HC_W1_*GT %%%% !1110
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MV?ADGM^\FKMZ* .)^T?$S_GR\,_]_)J//^)G_/GX9'_;2:NVHH X4R?$_/\
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M4 %<Q\1/^2?:U_U[G^8KIZYCXB?\D^UO_KW/\Q0!T<'_ ![Q?[@_E4E1V_\
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MG_D#6/\ U[Q_^@BKE !7,?$7_DGNM_\ 7L?YBNGKE_B+_P D\UO_ *]C_,4
M=';?\>L/^X/Y5+4-FP>R@93D-&I!_"IJ "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *CG_X]Y?]P_RJ2F3?ZB3_ '3_ "H KZ6,:39#_I@G_H(JW573?^07
M:?\ 7%/_ $$5:H *Y?XC_P#).]<_Z]C_ #%=17+_ !'_ .2=ZY_U['^8H V]
M&_Y >G_]>T?_ *"*NU0T3_D Z=_UZQ?^@BK] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %,F_U$G^Z?Y4^F3?ZB3_ '3_ "H AT[_ )!EI_UQ3_T$59JMIW_(
M+M/^N*?^@BK- !7+_$?_ ))WKG_7L?YBNHKE_B/_ ,D[US_KV/\ ,4 ;6B_\
M@'3O^O6+_P!!%7JS/#DHG\,Z7*!@-:1''_ 16G0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !3)O\ 42?[I_E3Z9-_J)/]T_RH @TW_D%VG_7!/_015JJNF_\
M(+M/^N"?^@BK5 !7+_$?_DG>N?\ 7L?YBNHKE_B/_P D[US_ *]C_,4 7_"1
MSX/T;_KRB_\ 0!6S63X6(/A/2"H 'V.+ '^Z*UJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *1E#(5/0C%+10!7L!C3K8>D2?R%6*@L?^0?;?]<E_D*GH *Y?
MXC_\D[US_KV/\Q745R_Q'_Y)WKG_ %['^8H O^$CGP?HQ_Z<HO\ T 5LUB^#
M_P#D3-%_Z\H?_0!6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN2_R%6*@LO\ CPM_^N2_R%3T %<O\1_^2=ZY_P!>Q_F*ZBN7^(__ "3O7/\
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MCL[E)FM9?)G"<['P#@_G6'XX\4KX;T;$"&;4[L^39P*,EW/&?H,U)X(\-_\
M"+^&XK21S)=RL9[J0_Q2MU_+@?A0!TE%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 067_'C;_\
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M63X;T2+P_H5MI\;%R@+22'J[GEF/XUK4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 06?_'C;
M_P#7-?Y5/4%G_P >-O\ ]<U_E4] !7+_ !'_ .2=ZY_U['^8KJ*Y?XC_ /).
M]<_Z]C_,4 +\._\ DGFA?]>JUT]<Q\._^2>:%_UZK73T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !0>E%% 'GPN(],^%?B&'EOL?VVW(8X
M.2S8_P#0A6_X#@^S> ]$BQC%HA(QW(S_ %K%^)T-OIWPXUTQ+L-TR,V#U<N@
M)_(5V&D1"WT:QA&<1V\:<^R@4 7**9++'!$TLLBQQKR68X _&G @]* %HHHH
M ***R-:\3Z-X?A$FIZA#;Y.%0G+L?91R?RH UZJ:AJEAI-J;G4+R&V@!QOE<
M*,^G-<4/$GBSQ3E?#FE?V98DX_M#4AAB/]B/^IXJYI_PXTY;M-0UVXGUS4%Y
M\V\.4'TCZ ?7- $/_">WFM3FW\*:+-J S@WMQF*W7WR>6[]*>?!>J:[A_%.N
MS3QDY^PV(\F$>Q/WF[CK7:I&D:A44*HZ # %.H HZ9H^GZ/:+:Z=9Q6T*_PQ
MKC\SW_&KU%% !1110 4444 %<UXZ\2?\(QX7N+R/YKN3$%JF,EI6X&![<G\*
MZ-W5%+,P50,DGH*\RT=F^(GCQM;?<= T9S'9*P^6>;N^/;@_]\^] '3> /#1
M\,^%K>WFYOIR;B[<]3(W)'X<#\*ZF@#%% !1169XAUF'P_H-YJ<Y^2",L%_O
M-T51[DX% &)K+?\ "0^);?0%.ZRM0+G4,=&[I&?KU/M72WMW#I]C+<2$*D2Y
MQTSZ ?7I6%X)TN6QT5KV]7_B8ZBYNKDGJ"W(7\!_6DU&8ZMXML](C.8+)1>7
M>#_%_P LU_/G\* -O3H&AMMTG^MF8RR?[Q[?@,#\*N4#I10 UW6-&=V"J!DD
MG@"N%\.*OB_Q//XJD5S86C-;:8&& P'#R_B<@4OCW49M3N+7P9I<F+[4N;F1
M3_Q[VX^\Q^O0?C78:7IUOI&EVVGVB!(+>,1HH]!W^O>@"WTHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ H/2BB@""R_P"/"W_ZY+_*IZAM/^/*#_KFO\JFH *Y?XC_ /).]<_Z
M]C_,5U%<O\1_^2=ZY_U['^8H =\.QCX>Z%_UZK735S'P[.?AYH7_ %ZK73T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P'Q8C%YH>
ME:6/OWVIP1 >V3FN^484#TKB?%OEW?CSP=8. =L\UR>>FQ../K_*NV/ H \F
M^*5S/KMU>:'%<&&QTNP?4+QA_')@B)#^//X^U=WX(:1_ ^B-*Y>0V418DY)^
M45Y=KKLW@?QGKRXWZOJ*VT+ _>B20*,?4!J]BT:S_L_1+&SP!Y%ND>!VPH%
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M !1110 4444 %%%% !1110 4444 %%%% !1110!#9_\ 'E!_US7^535#9_\
M'E!_US7^534 %<O\1_\ DG>N?]>Q_F*ZBN7^(_\ R3O7/^O8_P Q0 OPZ_Y)
MYH?_ %ZK_6NGKE_AS_R3O0_^O5?YFNHH **** "BBB@ HHHH **** "BBB@
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MGCK@<]:T-)^$GABP@C6\@EU%T& ;A\(#W(1<#GWS756_A_1;2(1V^DV,2 8
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M0_\ KU'\S745R_PYY^'>A_\ 7L/YFNHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#)UWQ)I?AN"*;5)GBCE8JA6%Y,G_@(.*PC\5?!X_YB<O_ ("2_P#Q
M-=)K&LZ?H&G/?ZG<+;VR$ NP)Y/0 #DFJND>*M"UX#^S-4MKAR,^6'PX^JGD
M?E0!B?\ "UO!HZZHX^MK+_\ $TH^*W@PL =7VYZ;K>4?^RUV=-:-'*ED5BIR
M"1G!H Y%?BGX+8L/[<C&/6*0?^RTY?BAX+8 C781D=XW'_LM=,;"S)R;2 D^
ML8JKJ$&GV.GW-V]G;!88FD),2]AGTH \X\$>./"]D==O+W5HH)K[5)9E5U;F
M/C:>!]:Y+P[XGT>'Q[<-<WD46GG59[T3L"5;Y2$Q^)->J?#O2[3_ (0/2Y)+
M6!WFC,S,T0ZNQ;T]ZUH/"&@V^LW.K)IL'VNY4+(S+D$#T4\#H.E '%>(/&GA
M:;Q'X>UBUUJVD:RG>.8#=D12(5)''8XKI?\ A9G@W_H/VWY-_A70#2=-'33[
M3_ORO^%']DZ;_P! ^T_[\K_A0!@?\++\&_\ 0?MOR;_"LKQ!\0-$N]/6/1?%
M]C8W0D#>9)$9%*\Y!&/\XKM#I.FGKI]I_P!^5_PI!H^F*<KIUF"?2!?\* /+
M]%O/ MIJ:ZQK?BR/6M77D3W"MY<7IY:8POZ^V*[$?$SP81QK]MCZ-_A70#2=
M-'33[3_ORO\ A0-)TT=-/M!_VQ7_  H P/\ A9G@W_H/VWY-_A2?\+,\&\?\
M3^VY]F_PKH?[*T[_ )\+7_ORO^%)_9.F_P#0/M/^_*_X4 8'_"RO!O\ T'[7
M\F_PH'Q+\&G_ )C]K^3?X5T']E:<.EA:_P#?E?\ "D_LG3?^@?:?]^5_PH Y
M\?$WP:6*_P!O6_'^RV/Y4O\ PLOP:/\ F/VOY-_A70#2M.'2PM?^_*_X4?V7
MI_\ SXVO_?E?\* .?_X67X-_Z#]M^3?X4'XE^#L'&OVN?HW^%=!_96G?\^%K
M_P!^5_PH_LO3\Y^P6N?^N*_X4 >0>&O'NDZ-H3RQWEO)KVKW4EQ<-.Q$<!).
M-Y S@+C &?PKHM,\3^![2Y%]J'B2#4-3_P"?F="?+]HQM^4?K[UW46C:7 A2
M+3;.-2<[4@4#/Y4_^R]/QC[#;?\ ?E?\* .>_P"%E^#!_P QZV_[Y;_"FGXG
M^#!_S'8#]$?_  KI!IMB.EE;#Z1+_A1_9MC_ ,^5O_WZ7_"@#G3\3?!H_P"8
M];_]\O\ X4UOB7X*=2KZY;,IZ@H^#_X[72_V=8XQ]CM\?]<E_P *46-F.EK!
M_P!^Q0!S0^)O@P#C78,#_8?_ .)I/^%G^#/^@Y#_ -^W_P#B:Z?[%:DD_9H<
MGD_NQ3DMK>/.R")<@CA .#0!R<_Q)\$3Q/#/J\$L;C:\;0.P8'@@C;R*CLOB
M/X%M[=(+34X((4&$CCMI%51[ +79"*-6W"-0>3D#UZTJHB+M554>@&* .07X
MI^#6; U?\3;RX_\ 0:5OBCX/5L?VJQ]Q;2D?^@UUX51G"@9.3@4N* .._P"%
MI>$/^@E)_P" DO\ \32?\+3\(8S_ &C+_P" DW_Q-=E10!QI^*7A(*2+^<^P
MLYN?_':AB^+'A:1L-)?1C^\UE)C] :[BC% '$M\5?#2S&+_B8EL]K&3G\,9H
M/Q5\-&4I$=0FQWCL9#_2NVQ1B@#BC\4-!'_+MJY_[A\G^%'_  M#1.<6.LG'
M_4/>NUHH XD?%#13P-/UK/I_9[T'XH:.#_R#=<_\%[UVU% '$_\ "S](_P"@
M9KG_ (+WJ)OBEIAD5(]&U]R3C(L#Q^M=W10 V-]\:N 1N&<$8-.HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (;3_ (\X/^N:
M_P JFJ&U_P"/.#_KFO\ *IJ "N7^(_\ R3O7/^O8_P Q745R_P 1_P#DG>N?
M]>Q_F* (_AEYG_"N=%\WKY''TW''Z5UE<C\,-_\ PKC1O,.3Y1QSGC<<5UU
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M^E)G?J%_#$/H&W'^0H Z;2+-=/T:RLUQM@@2,8&.B@5=I!2T %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%;?\ 'I#_ +B_RJ6H
MK;FUA_W%_E4M !7+_$?_ ))WKG_7L?YBNHKE_B/_ ,D[US_KV/\ ,4 5?A3M
M_P"%;:1M! V/U/?>U=E7%_";_DFND_23_P!&-7:4 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <CJ+G1?B%IU[S]EU>$V4N.@F3+QD_4;U_*NN'2N
M>\::)+KGAR:*T(74(&6YLWS]V5#D?GR/QIWA/Q/;>)=*\Z/='=0'RKN"1=K1
M2CJ"/KG% $7C1_.TB'2T9A+J5PEJNWKM)W.?^^5:NAAB2"%(HQA$4*H]A7':
M7.OBGQK-JL+"32])1K:V?'#W#?ZQAZ@#"Y]Z[2@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% #8\&)-I)7:,$TZF0J5@C5A@A0"/PI] !7+_ !'_
M .2=ZY_U['^8KJ*Y?XC_ /).]<_Z]C_,4 4OA-_R372?I)_Z,:NUKB_A-_R3
M72?I)_Z,:NTH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N7^(_
M_).]<_Z]C_,5U%<O\1_^2=ZY_P!>Q_F* *7PF_Y)KI/TD_\ 1C5VM<7\)O\
MDFND_23_ -&-7:4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+
M_$?_ ))WKG_7L?YBNHKE_B/_ ,D[US_KV/\ ,4 4OA,<_#72?I)_Z,:NUKBO
MA-_R332?I)_Z,:NUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN7^(_P#R3O7/^O8_S%=17+_$?_DG>N?]>Q_F* *7PF_Y)II/TD_]&-7:UQ7P
MF_Y)II/TD_\ 1C5VM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5R_Q'_Y)WKG_ %['^8KJ*Y?XC_\ ).]<_P"O8_S% %+X3?\ )-=)^DG_ *,:
MNUKB_A.,?#72?I)_Z,:NTH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N7^(_\ R3O7/^O8_P Q745R_P 1_P#DG>N?]>Q_F* *?PH_Y)KI'^Z_
M_H;5VE<9\*?^2;:1_NO_ .AM79T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/AO_ ,D[T/\ Z]A_,UU-<O\ #GCX=Z'_ ->J_P S744 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7+_$?_ ))WKG_7L?YBNHKE_B/_ ,D[US_K
MV/\ ,4 'PY_Y)WH?_7J/YFNHKF/AU_R3S0_^O5?ZUT] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5R_P 1_P#DG>N?]>Q_F*ZBN7^(_P#R3O7/
M^O8_S% #_A]C_A7^AXSC[(G6NEKG/ !+> =$)_Y]4KHZ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KE_B/_P D[US_ *]C_,5U%<O\1_\ DG>N
M?]>Q_F* '_#X$?#_ $//7[*M=+7/^!G63P)H;*<C[%$/R4"N@H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N7^(_\ R3O7/^O8_P Q745R_P 1
M_P#DG>N?]>Q_F* )/A^"/ &AY&/]%6NDK \#_P#(BZ'\V[_0HN?^ CBM^@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?XC_\ ).]<_P"O8_S%
M=17+_$?_ ))WKG_7L?YB@"WX+4+X(T, <?88O_016[6'X-_Y$G1/^O&'_P!
M%;E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R_P 1_P#DG>N?
M]>Q_F*ZBN7^(_P#R3O7/^O8_S% %SP8,>"=#'_3C#_Z *W*Q/!PQX+T3_KRB
M_P#0!6W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<O\1_^2=Z
MY_U['^8KJ*Y?XC_\D[US_KV/\Q0!>\'_ /(F:+C_ )\HO_016U6)X._Y$O1,
M_P#/E%_Z *VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE_B/
M_P D[US_ *]C_,5U%<O\1_\ DG>N?]>Q_F* +_A'_D3M&_Z\HO\ T$5LUD^%
MI&E\)Z0[G+&SB)/_  $5K4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7+_ !'_ .2=ZY_U['^8KJ*Y?XC_ /).]<_Z]C_,4 ;.B#&@:<!_SZQ?
M^@BK]4=$_P"0#IW_ %ZQ_P#H(J]0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<O\1_^2=ZY_U['^8KJ*Y?XC_\D[US_KV/\Q0!J^'9#+X:TN1D
M*%K2(E3V^45IU1T;_D!:?_U[1_\ H(J]0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<O\ $?\ Y)WKG_7L?YBNHKE_B/\ \D[US_KV/\Q0!M:-
M_P @/3_^O:/_ -!%7JI:-_R ]/\ ^O:/_P!!%7: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KE_B/_ ,D[US_KV/\ ,5U%<O\ $?\ Y)WKG_7L
M?YB@#;T;G0]/_P"O:/\ ]!%7:I:/QHEA_P!>T?\ Z"*NT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7+_$?_DG>N?]>Q_F*ZBN7^(__).]<_Z]
MC_,4 ;>C?\@/3\_\^T?_ *"*NU2T?C1+#_KWC_\ 015V@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *Y?XC?\D\US_KV/\ ,5U%<O\ $7_DGFM_
M]>Q_F* -O2!C1; '_GWC_P#015VJNF;O[*L]^=WD)G/7.T5:H **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "N8^(O_)/=;_Z]C_,5T]<Q\1?^2>Z
MW_U['^8H Z*V_P"/6+_<'\JEJ*V_X]8?]P?RJ6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YCXB?\D^UK_KW/\Q73US'Q$_Y)]K?_ %[G^8H
MZ.W_ ./:+_<'\JDJ*W_X]HO]P?RJ6@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *YKXA#/@'61_TP_J*Z6N:^(7/@'6<=?(_J* .AM_^/:+_<'\
MJDJ.W_X]HO\ <'\JDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N<\? GP+JP R3#Q_P!]"NCKGO'/_(E:GSC]V/\ T(4 ;L (@C!ZA0#^524V
M/B-<G/'7UIU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWCE=
MW@K5%]8P/_'A70US_C?_ )$S4O\ KF/_ $(4 ;R+M15QC QBG4BC"@9S[TM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S_CCGP9J8SC]V/_0A
M705S_C?_ )$W4O\ KF/_ $(4 ;X&% SGWI:** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K \; GP=J0'78O\ Z$*WZP?&G_(H:C_N+_Z$* -Z
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *PO&8SX1U ?["_
M^A"MVL'QI_R*&H_[B_\ H0H WJ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K!\9C/A'4!_L+_Z$*WJPO&7_ "*6H?[J_P#H0H W:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'\51K-X;NHG<(K[%+'L"
MZ\UL5E^(D$NB31GHSQ@_]_%H TQTI:!10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %9VM_\@I_^ND7_HQ:T:S]:_Y!CY_YZ1?^C%H T**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJD7G6)C!QNEBY_X&M7
M*J:F6%D=A ;S(\$]OG6@"V.E%(.E+0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %5-2C\VR*9QNDC'_ (^M6ZKWA @!/3S8_P#T,4 3CI2T#I10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %077^I7_KI'_Z&*GIL
MD8D7:<XR#Q['/]* '#@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%5[V^M].M)+JZE6.&,9
M9F/2N:T7QJ_B'4O+TW1[F2P5MKWCL%5?P[_A0!UM%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU<<'1[(D=][444 +_P +]U;_ * ME_W\>@?'W5O^@+9?]_'HHH 7_A?NJ_\
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M^-%% "'XZ^)CTM-/'_;-O\:/^%Z^)\?\>NG_ /?MO_BJ** $'QT\4=[;3O\
MOTW_ ,52-\<_%# @6]@N1U$9R/UHHH 7_A>GB?'_ ![:?_W[;_&C_A>GB?\
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M+-M&A)MST^U'/_H-%% $R?&IO+!;0 3WQ>8_]DJ8?&3)Q_8/;_G\_P#L***
M$D^,+[!Y>B*IS_%=9_\ 9!39?C'(D!(T1=XQR;KC\ME%% #A\8VV#.A#=CK]
MK_\ L*1_C*5X_L'GU^U__8444 02_&B4$;-#0#_:NL_^R"FCXTW!(_XDD?\
MX$G_ .)HHH >?C1*I8'0T/7'^E'C_P =J-/C9,=P;0D)QQBZ(Q_XY110!'_P
MNZXR1_847_@2?_B:='\;)W< Z''C('%R?_B:** +T'Q@=]V[1%]L76/_ &2I
MX?BR[*-^C D^ESC_ -EHHH M)\4-W_,'Q_V\_P#V%2CXDY'_ ""?_)C_ .QH
MHH VSXH/E0/]D_UI4?ZSID9]*AU'Q<;"U2;[%YFYMN/-QZ_[/M110!TD$GG6
/\<N,;U#8STR*DHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>sgmo-20210331xex103007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLP/00+_A5ZB@"BVC:6WWM-LS]8%_PI$T32HSE-,LU/J(%']*OT4 0?8K4?\
M+M#_ -\"E^RVX_Y81?\ ? J:B@",01+G;&@R,'"CFG@8&!TI:* "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J.63RD#8SEE7\SC^M257O/]2G_76/\ ]#% %BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K7W^I3_ *[1_P#H8JS5
M347"6\9/_/>(?G(HH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M512$A5+$@ #))[5YCX>\=7%Y\3+_ $^YD<:?<_+9;L[?EXR/][F@#T^BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JAJ__'I%_P!?4'_HU:OU
MGZQ_QYQ?]?5O_P"C4H T**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\8\=-#/\6-,FGMV
MEL;542Y)C++UR>G7@U[,>E<!JGPRDU/4[F]_X234(?.<MY8Y"CT'/2@!^D^)
M+#3[NWT?2(9FTNVCEGN+B2-OD7E@%X]37/>)-/3Q[H.JZUNECN+$E+* )A@H
M(.6'4EO;IBM)?A),A)7Q9J:D]<9&?_'J>OPIN5)*^+]5!/7!//\ X]0!F:1X
MNEO?AIJ&G:NDR:FEL]O&&C.905PO_P!>J/AC3[)?A'J276GQ_P!H#S%4M!F0
MLW"X.,_E6^WPFF;KXLU(\Y^8$\_]]5.OPPO%4K_PF&J[3U&3_P#%4 <IH-PE
MM\%M1T>XWQW[,ZK 4)8Y(Q_(U:L)XX?@9/IS!A>.K1"':=Q8L#T^E;C?">1L
MY\4:B23DDCK_ ./4U_A-,R*A\5ZCM7H,$@?^/4 <-/;#4?!&AZ-I.G3'7HY0
M[RQ0E2@SW;\ORK8\>+<#7/"<,[-<7%A&@O)%RV&^7.3^M=$OPGG3E/%FI*W3
M*@C_ -FI3\*;EASXNU,\YYR>?^^J -7XE7$<WP]OD0EVND58@H)+G(/\A1\+
M9 ? EC 05DAW)(K#!4YS_6LIOA7>.I5O&&IL#V()_P#9J!\*KJ-<1>+M37O@
M9 _]"H Z#QUK T[1/LJ.RW%\?(1@N=BGAF_ &O.O'?AV?PY_8FK65_+=W,#J
MD2B(*0B\YX_#\ZZ5_A;>LF/^$NU)CT^8$\=_XJ'^%=Y*BI+XOU-U7[H(X'_C
MU '=Z/J":KI%K?(I431AMI&"#W'YYJ]63X<T5] T>/3WOI;PQDD2R]<$].M:
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML*3OPTJQ@,>_)ZU*T4;'+1J3@KDCL>HH \$T'0;+Q+X_\46]Q+Y;/)(]LX?
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MKG+:38L?4P*?Z5-:Z/IEC-YUII]K!)C&^*)5./3(% '$_&:55\"-%D;I+B/
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MB*]0'A[1@,#2K(=^(%_PJ_Y4>,;%QC;C';TH \A\#SV\/Q4\2R[XX[?#[&R
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MB!"]3T[&O6[:$6]K# I)$:! 3WP,4L5O# NV&)(U]$4#^524 %%%% !1110
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MK'U->0_$OP))#J4?B31U9 \BB]B3OD_?Q[\9KV":5(())I6"QQJ69CV &2:
M.%^(OCB3PG-I<=MAGEF#SC&<1 \CVS_2MWQ'KTEAX*N]:TY1,RV_F1=QST/X
M9K@=0TFZ\<Z7KFJIJ%I%:RL56.2(EXXXL[3G^'/7I3/!?C.6W^'L]C=VXGN[
M#]VL,JD^=$3^N 2/RH VO#VLZCKNE65WI'B07EV'0WEI*B!@,_-@8!&*A7Q?
M+?\ CO5M%N]<_LA;5_+LU"+ME8=2Q;K]*Y?7=#TJTU/3-8\$W<D%_).JFRCR
M6&>N>X]"#Q6[J^F^'O&;ZA'KABTK6K-VB%PK;5D"]#SPWTZT :'B[5_$^A>
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M^)&G:5I>IK/IUP5>7RHU<(,\C(]A6%XDMO[3^-D,$5Y+:@PK']HA;!1MO3-
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M%G9FQY<?=O<U);ZA:74]Q!!.DDENP655_@)&<&@"S135=7&58$>U.H ****
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M2#YG'*]^:]B@MX+2$1011PQ#HD:A0/P%1QZ?9Q7;W<=I EQ)]^58P';ZGJ:
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M5]21=/NT,=L)\I@@G:P[CM761>$-$AOC=QVF&,GG>7O;R_,_O;,[<_A5K3M
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M4 >8+:7L%OXNUJQU>ZM)+2^9EAB.$<C'WAWSG%:2>(-1T'5;>\U6ZO)K74[
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ME]=:5:6QCB^QS 2(V>^2,C&*MZ9X(M[RV!U3[=LCDWVL<UR3)"N.06'KZ=J
M.837-;O/!UAG4[B"X;6/LCR(^7V'/!/?%2WCZM:_\)0$\0ZBR:2%>#=+DL2
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M$\+Z0DM]*+8[[X%;DF1OW@/XT <#I\]YI'_",WD=]?74]];R23Q33EE;"Y
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M:)+Y(TYD$<8N$0<J"2ZD?,#^E=IK6MWFD^ YM781->1VRN=GS)O. 2/49.:
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MU-0\0ZT+*PU"*:W%M>WZQ1(T.6$9; .2>IH [;4-0M=+L9;R[D\N")=SM@G
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M3P*[%94>'S5=3&1N# \8]<UR&G>(]9\4-<W.@QV<.GP2F));L,6F8=<!3PM
M$B^!Q:W=M>Z=JD]I>QVZVTLH16$T:C RIXR,#FD_X0*WCGTB6UO98/[,+/&"
M@;>S'+,Q]\UIZ+K-Q/I<UQK,<-E-;S-%+\Q"#'0@MV-:BW]H]NMPES"T#=)
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M<GJ3Z\G-6X[B&5"T<J.HZE6! KG[+Q)-=^-[O1 D!M8;59TF1]S,20,'MWH
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M\D9IOGZ@=:6-8H#IIAW&7=\_F9Z8],5>$T;.45U++U /(H X>+X?7T5Q'/\
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MJW5C]D6,QDX]R<U1@\%S6<'AY&U%&BT5W?/DD&0'\>*[,,"< C-(67.#U]*
M.&TR'2_%7C5-?LXI&ALX?+,K*5$DN>..^!_2NKUO28-<T:YTVX++'.N"RGD$
M'(/Y@4ZPU/3[Z2XAL9HY#;2>7*$Z*W7%+J^I0Z/I-UJ-QGRK>,N0.I]!^)H
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ML9P&P>/<"O5[:QM+*'R;2VA@BSGRXD"KGZ"J@\.Z&N\#1]/&_AL6R?-]>.:
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MZ8'M27^FV6J0B&^M8;F('(65 P!]>: /*SI%F]SX4L3J$NI6K7<T9D8LJN@
M.U>>5SWK,U&TLT\+:I$T2M!9^(?+B4\B.,]0/05[$^B:5*(!)IUJX@&V$-"I
M$8_V>.*%T32D@F@33;18IB#*BPJ%<CH2,<T >?WICM/&\KZ#Y7_("D> 0ME=
MP/&.W:JGEVHT3PSJ.B,!K,US&D^R0[Y<Y\SS!G)&1WKTZ/2=.AN$N(K"V2=%
MVK(L*AE&,8!QD#'%-M]%TRTN6N;>PMHIV))D2(!CGKS0!XS-IUO#X>U74TWI
M?6VLB..3S3E%ST'->U7=[#I^FRWEPX6**,NQ)]!59O#VBM$T9TJRV,VX@0*
M3Z].M6[JRM;RT-K<P1RV[  QNH*D#IQ0!Y'J^E:U#I%KXLDM[))8;H:@[K(3
M,48C"GC& ,<9K>\7SG4H-.UBT6VU"UCMFFEL))=K,C8^=<'J.E=W+IMC/8?8
M9;6)[0 +Y+*"N!T&*J-X8T-TC1M*M"L8P@\H849S0!YOJES!-;6^M) ;[2EM
M(H7A:8I<V9&,, >#GV'-; G?_A.M?DM9GB+:,LB&1B C$9!.>F*[*X\.:-=W
M45S/IMM)+$ J$H. .@QT..V>E1ZMH<5U;7\EE%!%J-S T/VADR2",8)]* /-
M_",5OKFJ:3+ \]O';6S_ &X_:2AGE.<$8;)]<U5L;>&#0M-U=)YS?-KODB0S
M,<Q[CD8SCTKI;#P&)I[/[5H.G:?]G92\]M.S/*!VP  ,]R:Z[_A&-#-ND!TN
MV\I',BIL& QZD>] 'ENK:?%)IWBZ_:>Z-S9WX6W/GM\G(]_>MHM-H7B.^CTJ
M29C)HIN-KNTADEYPW.>:[D>&=$\B6$:9;>7,P:1?+&'(Z$U8BT?3H+L7<=G"
MMP$$8E"_-M QC/IB@#RGP];P75O!J)\1*+N2"3S[>V#^;*=I)WDMQCUP!4>A
MPI:6G@_4$DG^U7UX\4[M*QWQYQMP3TYKU2V\.:/9S7$MOIUO')< B5E3E@>H
M^GM2IX>TB/[/LTZW7[,VZ'"#]V>N1Z4 <G\.+2QM[SQ!Y*1I.M_)'@'Y@@/
M^E:/B:6?5=:LM"LXX)PF+N\CE<JI0'"J< ]20<>U=';Z78VMU-=6]I#%/,<R
MR(@#/]31%I=C#?R7T=K$MW(,/,%&YA]: ."\$S7.AZUK7AJ^,<+@FZM@IR@5
MNN,]NA_"N<T/['KFJ:7;%D2YANI9+VY>XVFY7/"CG)S7K-UHEE-/->1VL"Z@
MZ%5N3&"RDC .:XNV\!W4RQ6=YIVCPPQL"U["K&>3!Z]@": ,:#1+6>+QCJ%D
MLGVZSN7%H\4K90#/3!YJE8Q01:<+[0-;DN-6-H5:WM+?:1Q\Q?GJ/7KG%>PV
M>F6-@C+:6D$ ;&[RXPN['KCK2VNFV-B\C6EG! TG+F*,+N^N* /)?#UAHUY%
M!<+K<C7_ -CE$MK!%L(^4D^8?ZGK5;3]'TUM(\'2/ IDN[MTN&#X,B[NA]J]
MBBTO3X6E:*QMHVF!$I6)07!Z[N.?QH72]/5(T6QM@D9)11$N%SUQQQ0!Y#>O
M-::+XCM+!Y(;"+541A$-P2([MW'IP*??Z5HT7A;6)]-U:6^!2-B$7RXD8L .
M/[V.U>NII]G&DJ1VL*++_K L8 ?Z^M-&EZ>MM]F6RMQ!NW>4(EVY]<8QF@#R
MV]TK3[36KNTM((UA?0O->,<@R=CSWZ5V?@$6:>"K!;(P[_*!E$1'$A'.?>N@
M73;%9O.6S@$N-N\1@''IG'2I+>UM[2(16T$<,8YV1J%'Y"@#S?1K=I?AEXB2
MXBW7!FN3(KC)W#!Y^G6LI+72+[_A"--1;>:(Y-Q$A[D#.['>O3[?1TM=2NYH
MF7[-=C=- 5R"_3</J.HJ=='TQ"A33[52GW<0J-OTXXH \<NA-;Z%=V\4K0Z2
MFLE)EC3<J)VX[CCI7>> 8-,A%_\ V5J,]] [*S.8]D2M@\*/7U_"NK33K*.%
MX4M(%B<Y=%C 5OJ.]206T%K$(K>&.*,=$C4*!^ H :]G;2&0O;Q-YF-^4!W8
MZ9]:X;Q5'+XMUK_A'[ VLD5E'YMR)G( <\*. <X'\Z] JO%8VD$[SPVT,<LG
MWY$0!F^I'6@#Q[P;J;6'AWQ%X8O+X6UQ )/)E+' XY"__6]:I^"] MM1UK1;
MB5]/AALT+M&9T:2X;M\N<_G7L6IZ':W^G75LD,,4D\93S1$"1GO7$:?\*K>W
MO;*:1+2%;5PS- &+SX_O%C@?A0!C>$/#>CZ_XV\32WMJ)$AN 8%#D*/F/3'7
MH*P-'L#/JU_'?:A-9:E#=;H8HX&>:4]@#GITKWR*U@AR8H8XR>NQ0,_E2_9H
M/.\[R4\WIOVC=^= '@WAZP%[KMS%K&ISVFHK=APH@9YI#Z;O2JVK6%@NI^,F
M9%+PL!;,3DD[P#CUXS7T$;: S><84\W^_M&[\Z8;"S))-K 2>I,8YH \)T"(
M6_BO0FTU%CG>R8L8R?FD*G&[WJ3P?IL5UKF=2U">#48KTOY,<#&6;)YR_I_*
MO<TL[6-PZ6\2,.A5 "*>MO"LIE6)!(>"X49/XT ?-.KPP++XAE2 &47@6 A>
M=N?X:[G5([1/&WA&]NK7=;M9)YK&(MO?:0,C')Z5ZVMI;H^]8(U?^\$ -2&-
M&96*@E?NDCI]* !0-HX [CBN(\23)%\0M&N#PEK:333LO.U/I7<GI65;:)%!
M>7MZTC27EV-K2D#Y$'15'0 ?J>M %G2]4M-8T^.]LI/,MY,[6P1T.#P?I5RJ
MNGZ?;:99I:VJ;(ER<>I)R2:M4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !6)XK.-%CXS_IMI_Z41UMUB>*_P#D"I_U^VG_ */CH VZ*** "BBB@ HH
MHH K:A%<3Z?/%:W!M[AD(CE !VMV.#Q7D/\ PL'5;2QT>6YU.0W5M>-!K$'E
M)\J*X!8\?+UQQ7L]<])X*T65]:9K<DZP,71S[?P^G//UH X?Q5>7^MZ7I]]#
M?Y@FUZ-+ F)=JJ"0'XP6YSU[5K1^(==M8?%NG7ES;W=WI4*S03M;A5963=AD
M!K?U'P;:WNEZ5I\-W/:0:;*DL(C"G+)]W=D'/K^-5)/ QDO=;NFUBXWZO"(9
MOW2_* ,<?A_.@#,T[Q%K.MQZ;I5A<VUE>/I*7\LYA#;F)P%5>@&>IK,UI?$<
MWBOP=)/]CM=7>.X1B<O$& Y.!ZC'YUM3_#5#!I3V>M7=EJ&G0?9TO(5&YXN<
M*R].,]:MCP,T>H:1>1:M*9-.\QLS1;S-))]]V.1UXX]J )O OB"_U_2KPZFD
M0O+.[DMI&B&%8J>N.U<_JWC+6])U7Q!I]S<V,<MK;BZL-T)'G*3]WKR>W%=1
MX4\,/X:BOU>^-T;RZ:Y8F/9M9NO>C6O!]AKGB'2]7N>9+#=A,<29Z9^AYH Q
M-#\8:AXEAL&L&M2WV%Y[Q7B;:L@.T)D'C)R?H*YR^U4:QX9\&:D]I;6I;64S
M';IM1/F(.!7=Z+X.M?#T.K#3'$<M_(T@++D19' QGD#DUA)\.KU/#FDZ3_:M
MN1I]W]I$AMS\YSD#[WN: )] )7XM>*54J$-M;DKW)V]?Y_G5+Q/_ &I%\5=/
MDT2"TDO6TM\BY)52-YZD<^E=+I_ANYL_&NI:\UU$T=["D1A6,@KMZ'.>34.N
M^'-2N?%%EK^E7MO%<6\#6[17,99'4G.>"#F@#F[;XH7=Q96]J=/CCUIYY(98
M@KR1QA.K84%C]*ZOPAK]_KVES3:EILEC<Q3&,JR,JR =&7<,X-<[>_#25+"U
MGTC5/LFN07#W!O-GRNS_ '@5[#T'^-=;X?TW4+"Q;^U=1-]?2MNEEVA4'& %
M4=!0!P'C;Q!>>(?"GB%;.TM6TVRF$#RR.?,9@PRRC&!@XZUI7/CFYTX#3;"S
M2>6QLH99@X<E]R A5VJ<'!ZGBF:EX UDPZWI^EZE9QZ9JLOGO'/$Q>)B<D*1
MQC/K4MQX+\1V6L0ZGH.M6UO<2VT=O?>=#N5R@ #*N#@X% %>[^*F[*6&G$31
M6ZS31W6]6W'^!0JGGW.!5A_B!JUSJEO8Z;H*LUQIXO8_M,YC('.01M[$$>])
M<^"?$6FZT-3\.:[&DUQ$J7HO4WB1A_&,#K[5<'A768_%%MJWVRWN?(TTV9:9
MF#R.226.!@#)_*@"CI?Q'U"\_L6ZNM$CM].U.?[,LJ7.]UDY'W=HXS3+SXI&
M'4ITM]/2:TM[K[/)B1O.;!P650N,#W-0VW@37[?1M"T\S:<W]F7_ -K+[W^<
M9S@?+[FKEKX0\3:3K=\FDZO;0Z)?7!GD5U)GB+<ML.,?B30!E>.O$EQX@\*:
MVNG:?#-IEFZ1R74LF'#9!)1<=LXZ]Z]!_M&#2O"D>H7)(A@M%D?'7 45PU]X
M \0Q6FN:5I-[IYTG5'$N+K?YL39!."!@].]=K+HC7_A Z+J$BL\EJ())(@0,
MXQD9_"@#F-)^(\VK:C%8Q:?$TEU TMNT<Q948 D++\ORGCMFN%:"^O?AO?ZU
M)IMHUS%<RR+?"Y99@2^&X"\^@R:]"\-:'XQTR&.SU'4;&:RM$9+=8@0TORD*
M'.. ..GI5.S\%Z[;_#W4?#<DEB9[B1FCE65]H5FR0?ES_P#KH S[+7+/PLFG
M.=&L(-:N=.5Y"MUY:-$ -I)VX+L0>W;K6[I_Q!.N6MJFCZ8\VHS1O(]O-*(U
MB5>"2V#G)(QQS[53U#PCXCCET;5=)N;%-5LK-;*>*?+0RH.X.,YSS1?^$?$T
M5_8:_INI6K:U&ACN8Y5(@="<[5 &0!_]>@!EYXS\1RZCX:CM=)%LM_(XF@N'
MVNS(/F7D<#N#WIX\31:7=^*[ZT\/G[;8M$UYBYYF7!^8<$# [59U'P[XEG?0
M=1^U6=UJMA<223"3*1%7 &%P,X %6M!\.ZC;>(?$%YJ<5J;;5 @*1R%N@((Y
M X()H LP^,898;*X\E?LTU@]]-(),^2B@<=.><CMTK.T7XCV^KZ[9Z?]D5([
MQ&:&6.<2$$=G4#Y20/4TWPSX!.DZ)K&FWDP=;TO%$R-DQP'.T<CJ,FF^$]"\
M7:5):66I7.G'3K/(62!/WLRXPH/' H VO%'B>3P_)90P6!NIKHOC=*(D4*,G
M+$'%9EO\0XKW2]*N+6RS<ZB[QQQ33"-%9.H+D8],<<YJ3QEX>U76=6TRYLUM
M+FUMPXDM;IV5"Q& _ .<>E8&G>"]<MO#$6A:EIVF:A9"61F03LC@G[K*V.".
M?SH ]"T[4'NM+2\N[=[)L,9(I3RF"0<GTXS7,R?$&.*.VU"33+A=$N)_(2_W
M#&<D!BG4*2#S6EX=T"XL?!\>BZI<M<.8FCD;<3A6S\H)ZX!QFN9MO".N_P#"
M/1^$KE+9M+CG#?;1)\S1!]VW;C(;/?I0!!*LGB?XD:II6IZ;YUG#;HJ'S\&
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M"2BF&6,*&+J >A)I3(B_>8#ZF@!U%,$J,<*ZD^QI^: "BDR*,B@!:*3(HR*
M%HI,BEH ***3(H 6BD)"@DG ')-9EKXDT2]N?LUKJ]E-<9P(DG4L3[#.30!J
M44F12YQ0 449XHSF@ HHHH **** "BBB@ HHHH ***AGN[:U -Q<10@\ R.%
MS^= $U%00WMK<'$%S#*1V1PW\JGH **** "BBB@ HHHH *S+?P]I-IJ\^K06
M,27\_P#K)P.6_H/PK3HH **** "BBB@ K+MO#FE6FM7&KPV:+?7'^LFZD_3T
MK4HH **** "JFIZ;:ZOITUA>(7MY@ ZAB,C.>H^E6Z* (+.TBL;.&U@#"*%
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M0N,JZ'(- $]%%% !1110 4444 %%%% !1110 4444 %87B[_ ) <?_7]:?\
MI1'6[6%XO_Y <?\ U_6G_I1'0!NT444 %%%% !1110 5Q>EC_B[FO?\ 8/M_
MYFNTK)@\.:?;:]<:U$)Q>W"A)6,S%64=!M)Q@4 :U%9VF:+::3/?36WF[KV;
MSI=\A8;O;/05HT %>2?'&:X6TT.(M)]@DN3]H Z,1MP#^&ZO6ZSM<T+3_$>E
MR:=J< FMI,$C."".A![&@!KZ5I]]H":=) C6+0J@3L% &,'^M>:Z%;IXL^*7
MB*VUR,W-MIR>5:VTK':@R!NVYY) SGWKK;+X?P6L<=K+K>KW6G1',=E+.-@'
M920 6'L35J_\&6MQKIUNPO;G3-1:+RI);8*1*O;<K @XQUH \HA2;4+/Q-X3
M$KFTL[^,64CN6-N6D"[0>N,'^=6]'O;]M>TGP7XFB$EY8WN8II.1-#M/&3US
M@8]>E>BVO@"PL=(:PM;R[C>6Y6ZGN25:2:0'(W$@\9&:U-1\,:?J>L:=JLZL
MMY8.6BD3 + ]F]1WH \1T6.VD\8:OI<UC<RI/J*VL=Q'(ZK:JSD<$'@],?2N
MHMM/BC^,EWI#R3/9QZ:K!&E;!;8OS=>M=KX=\$P^'M8U+4$OYKEK^3S94EC0
M -G((P.,9-1R^!V/C&?Q+%J\\=U-%Y.PPHRJF,8_2@#RO1ENE^&>J^);?4KV
M+5-/O#Y4HN'(9,J-A4G:1\WI3_$/B-KKQ)X=U6X@NY(;S3!-<6MM*Z"1\,,_
M*PP,C\A7<V?PGBM]+ETB37KR32YIQ/+;+$B>8>."W7'%7]2^'[7/B2QUG3M4
M%@;& 6\$ M5D15P01R1G@F@#GO$.@7Z>%=&@T;4[V&[N[DS6Y:X<&,/'N\O.
M>1D=_6J6@Z]-XSU6RT;49[ZQUJU@GANS'*R D ;7P"!D<YKLH/!>I1ZC#>S^
M(6N)$N5N"K6@"D*I4* &^48)K2;PE8CQC%XFA+1W@A:*90/EE!& 3Z$8H \\
MBTAQ\6)_#:ZMJJV'V/S$"WLFY7*YSG/K5S2Q=V?QH.C-J=_-:062R!)+AR&?
M8,L1GU[5U2>"Y$^(#^*AJ0+/'Y1MC;\;<8^]NZ_A44_@B[;QM<>)[;6(X;B6
M'R%B:TWA%QC.=XR: .=O?B%<6OQ4MK1IBNB.39=>#+GEB/9N,^E3Z]=W</QF
MT6T2]NEM9X@[P+.P1F&<'&<=AQWJ[K7PPM]5\.VFGB>VAOHI1))J*6F)9.22
M3\V<\]S^5.NO >K7'B#3-;.LVWVRPMQ$NZT8K(1W;Y^_J/RH [XGM7C'A>WA
M;XM>-EV[ L$NTQ\,GS+RI'(/TKT;P]H>IZ;<:E>:GJ,=W=WKJV8XBJ1A1@ #
M/2N:L/A]K>G^)M5UR'6+,SZFCQS*;9L*&(/R_-GL* .-L_%FM^'].GT7Q%>7
M;I?VHN-.OED.Y6(R 6'/7C';\:T/%6L-I'C:QM+K5-9_LMM/\V:*"ZD+-)M;
M!SG(Y S7<:EX%BUGP;::'?RHUQ:*HANDCP59>AP3W YJ*[\#3W/C>QU\WL7E
M6T @,#0D[UP0<\]\F@#E#?:NWBS2/"?]L7QL;M?M<DYF/G,C+D1[^N!@C(]:
MOMJ5_P"'_'MUX8_M"ZN=.O+)IH#).6EMWVD\/U_A]>]=/X@\&KJ>J:;J^G7"
MV.I::-L+&/=&R?W&4$<=>GK5:U\$W!UF]U_4;V&?5YX#!$4B*Q0#&.!G)X]Z
M /*]'\8ZS+9:3]CU[4;K7I;_ ,M[260M&\7&,@\=<UT_C#Q'KOAGQ[!?QW5T
MVC(T(N[<R$QJ7!]>G0X^E7(?@^T>A06ZZG''J=I<F>VO8H2" <?*PSSR,CTK
MH+GP9>ZS;:I;ZY>6TJ7\$49>"(JR/'G#8)]Z .6G\3ZKJGQ5TF&WO[F/1;DY
MACC<JDRKP6]P6!K2\3^/I]'^(>EV22[=)1O(O&[>8W_Q(P?SJ[=^ +P:_HVH
MZ;>VT,6DVZP012Q,=_J6(/<D]*AU/X9)JWAF:TN3:?VS),93J 1LG+9SC/X4
M 1?$J/6-)T74=>M-?O8</"L$$,FU$4X#9'<GK6?XG76="^'LFN6_B/4WDEBM
M7C#S9,9;[_/<'</IBNDUKPAJNM^ H?#MQJ-O]H78)+GRSA@IXP,]>!3_ !!X
M0OM=\"6WA[[7;Q2QK$CRE&*D)TP,Y["@#GEUK5-6\5Z-X5M]2N[>W6Q2ZN[A
M'_?2ED#8W'H.1T]:KWOB'6=,\1^(/"K:I=2HEF;FSNV(\V(A-^TG'([>M=#-
MX'OH[[1M:L;JVCUFPMUMI=RMY,Z 8Y[CCO2-X&O;F?6=6N[BV?6=0A\B/:&$
M,*8 P.Y.!UH X^P\<:W'8R>'?$-W=6FM":%K:Y10IFC9AD'CT)[5V/Q:MXV^
M'%ZTB"1XMFUV4%@=P&<]JM^(O \/B.STJ2<Q1ZG8&-A,JDJ0,;E]=I[5;\;Z
M'J'B7PU/I%C+;P_:,"228MP 0>, ]Q0!Y1H^BZCJ]SX6N?#VGW5@UO;@7=]Y
M?EHYSUS_ !<9^M2'QMKD,?B$/XHD2_L;L165JT49\\;B""-N37KGA+2KW0_#
M=IIE\T#R6R>6KPEL,!TSD=:X(?"6XNH]:^W3VHN+R;[3:SPEMT$F2<'(&1S]
M>* +MUXJUS4?%/A_PTLK:9/<VHN;YT0%Q\I.Q=P./NG\_:FMJWB2W\;7/@Y=
M7\S[1$L]O?2Q+YD*]67 &#P#VJZ_@O7'O=%UQ[RS?7M.0PRN2_E7,?(&<#(;
MD]JT-&\)7?\ PEMSXHUJ:)K]T\J"&W)*0IC'4@$GKVH YK2;OQ/J/C;7M"3Q
M).!IZ!X':&,[CD<-\O3FJ;^*M63QQJNAW7B.Y@6-TBM/+@C8L[8ZY7H,FNLT
M+PKJFF>/M7U^=[0VVH J$C=BZ $8ZJ!V]:R?^$*U^V\8ZMKJ6VD7B7K QQ33
M2#RBI!5N%Z\4 3WWB'6W\5:5X.M;]([PP>;?7HB!/0G"@\ X'IWK2N]'\8_V
MI%%:^)B--*YDDDMXS*I]!A<'/K6=)X)UJ/5;#Q)!>6[Z]$K+=)(6\F8$G@'&
M5PIQT[5UVG?VU()Y=2CM8LKB*"!R_//)8@=>.U '!^"]2\8>)H[V637U06=_
M]G9/LL7S(#\QSMZ^E9EG\2-;LO"NM7U[<)=WD5^+*U#1*H4G/S$ #/ KK/ '
MAC5O"T6J1WJ6S_:IS/&T4A//]T\?K6%8_#'4)O#FM:9J4EO%+=7?VRVEB<L$
M?G@C XYH MZ]K^O^#+31M5O=4_M&"[=8KJ!H40 L,Y0J 1CWJK=>.]9\/>-)
MAJ[/+X:DF\B.X$*@PL5##) YP"/PK3U+PEKOBFWTG3M<^R06=BRR2R6\A=YV
M48& 5&VM;_A%VU2QUS3M7@B^RWLYDA*2%BHVA0<$#!&T&@#E-1\;ZE8Z=IMU
M)JDJZ==7DR2ZA';(QCC4X0 8QSU)QFNZ\*7UQJ&D&XGU"WU!&D;R;F$!=Z=L
MJ.C>HKFM/\*:UH>@V>DQ6]EJ=E$)EN+>=]HE5F!0C*G!QG\ZAT7P?XG\.Q6Z
M:/=VEM;S7AGN;1R75(ST16(R>/I0!Z11110 4444 %%%% !1110 4444 <7J
M'CY[+7KW3(]"O;A;+:T\Z,-J(>=V/3'-)I_Q'TZ_U&RMQ"8X+TE8)3,K-N'9
MT'*9[9J>W\.WC>)O$=Q<1QK8:K D2E),L-JE22,=\DUE>&M#\1Z&8K"^CTQ-
M*L6+K?(@,LB D[2#T]S[4 71\1(F-O-%I-U-9W5R;6WEC=2TD@[;"1@?C3G^
M(=O'JRVLNFW26[WGV)9RRY\WT*9SCWK@M"@UG3XHM=ETR*[T:*Y>ZA07JJ(V
M+8W!3SGVK5N_"'BFZOA>/86MQ<Q:@MVEW+<_,\><A N/E []* .F3XA(^M7U
MC_8U]Y%C*8[FZ&"L8&?F(';BL+5M:GUKQ9X0O!I\]M:273&"5YA^^7C^$=.Q
MYZYK8T;PSJ;_ /"5IJ4$=L-88F-XW#X!4C^M9]KH7BI[[PW%=:;:+;Z+(5\]
M;C_6I@*#MZC@?GZ4 7D\5Z7H5AK.I0Z5?ADU#R;A"P),A YY/ K3L_&]N\NI
M1:E8W&G26,(N&64ABT1Z$8[Y[5S-]X7U^XT;7+%=.!>^U,74;^>FW8".O.<\
M58UJPO+34/$.MWMA'%8SZ4+=?-E4[G&,9 /<T ;ECXW2ZUBQTZ72KR&2^B$]
MNV58&,_Q-SQ].:E\2>,HO#VHVE@-,O;VYNU+1+;J"#CJ.N?TKC/!\6M:+JFE
MRZWI,LHEC6SM;DW*MY2$9 "@=/?TKK=<TO4+KQUH.H06C/:6BR":3<HV[N.A
M.: *UU\2]-MMQ-G=;82JW6XJIA)[;2<DCOBKL7C>TN[UH["SNKNWC=(Y+B(#
M"LV,?*3G'/7%<[<^'-?TWQ1J4ECH^EZE9ZE-YPGNU!,#'KD'DC_"I-6\+ZI=
M:Q#-8V!L;^.5!_:5M*J1R1 <[TSUZ\ 4 :MQ\1](@OQ#Y<SVPN/LS7*E=H?Z
M9R1[XJ2;X@:=#J @-I=M ;H68N0J[/-],9SCWQ7.Z9X7\0Z->76EP:5IEQ:S
M3F6+4YE4O&"<G(.23Z>]9U[X3\5W%^TTVF1W=U%J"W"WC7(4-&#PJKT';- '
M7_\ "QK#^T+NU.F:F([20QW$_E I&1W)!J0>+(M462Q>QO;3[7:R2VLKX D4
M*3G(.5-9NC>&]3NK#Q3;:G:FS?596>,B0.HR/8]C4VC1>,38"PU&PM88+2W:
M(/'(&>Y.PJH'9>Q/2@"CX$\7^3H^B:9?V=V@N=\4-W(<K*X8G'//?&:](KS.
MV\.Z['I?A.'^S2)-)G:6<&9,$$\8YKKO"^L7^KP7G]HV*6LUO<-#B-]ZL![^
MM '(^/O$3:EX<U*'3K2XDMK:98I;U'VJK@\C'4@=/3)K8U#Q[8:*JVHC:ZDM
MH(VN-LJKM! Z!CEF[X%8=WX9\3P:1K&@6EE#/:7MR9X[DS!=JE@Q!4\YX%69
MO#GB32]<FOM-T_3;Z.^BC$RW)&8750,@G&1Q0!O6'C:VOM6:R^R30(;3[7%-
M*R@2)C/ J"\\>0V=M8L]F1<W<)G$+SJ@6,="6/&3V%0^)O!UUK)T62&X"7%L
M1%<RH A>(@;L#TZ\>])XE\.:K_;=CK&A06<[P0?9GM;D84IG(P?QH SM8UBV
M\12>#M2M$D3S=1QAC@KM^\".AY'6MJY\;>5;SZA;Z=+/I%O*8IKI7&00<$A.
MX!/6JU[X;UF^/AV69K7S+*[-Q<K'\B*"1\J #G ]:KQ>%]:M](U#PY'';MI]
MU,72\,GS(C,"P*8Y;]* +%YX_F&I7EEI>AW%^;6%9WE6554H1G(Z]J0?$![J
MYTZ#3-'FNY+ZV:>,&94P5SD'Z8-8MO!?6GCK7]/T.SAE'V*"#=-+L$0V@9]3
MWK4TOP=J.BZWHL\ @FM]/LWA=FD(9W?)) QP,F@!UG\1);I;&>319H;2YNOL
M;3-*#MESC  '(]Z=J7Q(M;'4[BWCMO.@MIA#*PE D+=]J8Y ^HJK#X0UF/0K
M#3VCMMUOJGVYF$QP5R3@?+UYJS'X<\2:;K=^NEW%B-.OYC,TLR$RPD]=H[GT
MSQ0 MW\0+F*;41!H,\D-@%>:5YE7"MT..>>>E2+XFU6[\<6%A:P1_P!G360N
M?FD 9E;'S=.H]/K4-WX5U>4^)@GV=AJBHL3-(01MP,L-OIDU*/#FM66K:9J=
MFUB7M]-6SF6=F"@J!R"!STH [4DA,X)/IZUP47Q%N7$ER^ANEA#=_999S."5
M;./NXYKH_#%_J6I:1]HU2&&.?S653#G8Z@\,,]C7(_\ "#ZU_P (W<:;FU\R
M74OMF?,/W<DX^[UZ4 :.K?$:WT_4KJV@M5G6T<1S$S;7+'KM7!SC\*>?'-RK
M:HLFEK$]G;+=(LEQ@RQGG/3TJ,^&?$6G:Y?3:/=V2V>H/YDOVA"SPL>I7U]L
MU>USP7#K>MZ9?S3,4MT\NX0_\MU'(!Q[]: )](\5#63I?V6%&^UVYGFQ+GR
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M_$/BBTT+5&?2XK6>WC#+<K(6CP>.,CDC-59/A[J.HOJMQJ6H0"[NV22)K=2
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M/::C$C)'<QB15;J ?6L_7O$]MH%W807-O<O]MF6%)(X\HK'U;^E &[10.E%
M!17$Q?$JPDUFZTA=(U=[^UR988X%<J!WX;D<BMSPYXITKQ5:27&ESLXB;9+&
MZE7C;T(- &U1110 4444 %%%9.I^)-+TC4K#3[VX\NYOWV0)M)W'W]* -:BJ
MMSJ-I:1W$DTR*+>/S91G)5.>2.O8_E46CZS8Z]ID6H:=-YMM+G:V".AP>#0!
M?HHHH **** "BBB@ HHK"U[QAH?AIXX]4O1#)(-RH%+-CUP!P* -VBH[>XBN
M[:*X@</%*H=&'<$9!J2@ HHHH **R=8\3:-H'EC4[Z.!Y#A$P69OHHR:32?$
M^C:Y*8=.OXYY53>T8R'5<XR5/(Y- &O1110 4444 %%%% !114-U=6]E;27-
MU-'#!&-SR2,%51[DT 345#:7EO?6T=S:3QSP2#*21L&5A[$5-0 4444 %%%4
MK_5]-TLH+^_MK4O]WSY53=],F@"[15&TUG3-0<I9ZA:W#@9VQ3*Q_0U-'?6D
MUW+:QW,+W$(!DB5P60'ID=10!8HI"0H))P!R2:K66I6.I1F2QNX+E%.TM#('
M /IQ0!:HHSSBB@ HHHH **** "BBB@!,B@D$$&O(O&.M:E#JVK7.GW][(ME/
M FZ*7RXK;)PRE?XR?I4NK2ZG<ZYXL*:[J,4=A91W4$<,VU0Q0-C@=* .\3PM
MH%C.U];Z1 )TS(-B\YZ\ \ U/X=UV'Q%I":C;Q/%$[,H63&>#CM7%VNH7OBO
M5[33+G4+FSA72$NF%M)Y;3R-QG/H/3UK6^%:[? EJNXMMEE&3W^8T =I29!J
M*Z,HLYS 5$PC;87Z!L<9]LUY+'XLU#1+74!?3:A#K$5J?]&O&\R*1RW^MC;H
M% SQ0!ZS=W(M;2:X*,XB0N50<G SQ7+S^+-)U32-)-S83RVFM2&!$D0$#DCY
MN?:LK0XO$$+RSWVH1S:?=6#LJ/>>>S2 9W)P,#V&:Q;1E_X0_P  @'D:@,_F
MU ':^'M)T:QU>]BL=&FM9+4A1<2@E7##_EF23QQ74YKRG6==UFW;QF(]4F4V
M;PBV*@?NPQY X]^O7BKVEW>N:;XADL1J4^HF71_M:K<$';+VQZ#/\Z /2**\
MM\.:IJNIZOH;6NLWDZS(\FJ1N RQ,.B]/E!Z5ZD#F@!KML1FP3@9P!DFLW0M
M=MO$%B]W:K(L:2O%^\7!RIP>*U#TKQ?3CJFE>&;OQ#8:Q-&D.J2+]A('E.#)
M@\>IS0![/D49%>9WVL:FFF^-774+E'LGB>W.[!BR,E1[4WQ%K&IV,]G<WESJ
M-MITEG#LN[0Y1)2,DRKCG- 'H*:D)-8ET[[-<#RXA*9RF(SDXV@]S5J***!-
MD2*B#^%1@5P&IZMJ2Z]XAC@U.401:,+JW"@81O4<=3Z^]9^EZEK&EWGA^XGU
M>ZOEU'3IIY89N0&6/>,4 >I9%&17F/AR[\4:FFFZP-0A$,TI$ZRW8*."<!0@
M7Y3^.:?H^K:G#XA:RU6ZO[;4F28HLS[K68X.TH?X0./6@#TS-%>>^!]2N$UJ
M73=5FU&+4Q 6DM[IRZ2'=_K(SZ>U>A=J $R*R+W7XK+Q#IVCM;R-)?*[)("-
MJ[1DY[]JX;4H=3U/Q7XH@_M_4;2&PMTGACBEVJ#LW=NU+8:C/J6J^![^]?\
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MKW4+J_U%+F_C"70BD0*PXR "O3(I[_##2I$TA6U#42-)_P"/;YTX^;=S\G-
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MF8>P!YKP?2]3TJ'6-'FEN;7[*=.N(V@2 D0Y5MJ.V/G;)ZFK>DKIL.B^"KB
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MU[(ZQW0C"CJ=N\=F/)KN\#TK-CETO4=6D6.1)KRP.UER?W18>G3/O0!>N?\
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M64C..>,5:\9V>I>?I6KZ9:_;)=.E9VM@V"ZL,''O6ZNL6#:PVDK.#>K'YK1
M'A?7/2G7NJ6=A<6L%S*$ENI/+A7!.YO3B@#B+^T\0ZLFGZW)I"6_V6[$_P#9
MJL#(XQ@LQX!;T%+?Z/)K&H:AKEYHMS);/ EO'9.=LS\\O@9QCL/:NID\5:-&
MNH,UV,:>0+D[&^0GMTY_"IAK^G,^GH)&+:@NZWQ&?F&,\\<?C0!P"Z!XAG\-
M:E9I%>-:K-"]C;W3KYVU3EAGL.F,GM4VOZ=K&IWL=]:Z+J%CJRJBPSQ3HR,H
MZB3GC%>FXHH P-(UC4)]9GTG4+%8GMX%D^T))N67/&0,<=^OI4/CRPO-4\*S
MV5A;F>>22/"A@, ,"3R?:NA2"*.1Y$B19),;V"@%L=,GO4E ' 2Z9K1\47-]
M_9TK0OI7V;(D3YI,<_Q=,UE1^'/$O]C:/93Z6+FUMDD\VU^TK$2Q/!9@<E>>
M@KU3%&* /*--\->*+:ST*Q;2(8HK"^-Q)(MPC<$YX&>U/\8PZKJ'C*2/1+<S
M*EJL-Z(KA8F=22=I+<=/2O09-=LX]?BT4B4W<D1E&(SMVCWK*CTCPYXKFEU"
M72W,L<AB9Y5>(L5[X!&1[T 8*0WNM6F@)IVC_9K?2KL>?&9T8)LX(4Y^;ZTR
MX\-:]/I?B2'[$HDU*Z62(&9?N@YYYX-=S=W%KH.E[UM9#!#A1%;1;B 3C@"K
MT;"2-7"D!@#AA@CZB@#SO5/#.K:I) RZ7;VE]#Y8BU"*YP550 0X')Z=O:NF
MT;4M4FUR_P!.O88#!;*OESPDG<3V;L#WQ708I%15SM4#)R<#O0 M%%% !111
M0 4444 %%%% !1110 5S/CW_ )%1_P#K[M/_ $HCKIJYCQ^<>$I/^ONT_P#2
MB.@#IZ*** "BBB@ HHHH **J:K?+INDW=\ZEEMXFD*CO@9Q7G>C:WXYU%=,U
M&&(O97@+3FX6 10JWW3'M?><>C<F@#T^BO&8O%OC3_A'++73JEG(D^H&S-NU
MH  ,D!B0<]N@K<C\4>);%/%FGW-Q:75_I,"7$-P8=BE2NXJ5!].E 'I+L$4L
MQ 4#))[52TO5[#6K=[C3KJ.YA20Q,Z= PZC]:\^TSQ;XJMI?#=YK#6$^G:VR
MQ!+>,J\+,,J22>:I>&]?DT'P_>06B1F^OM?EMH6E!**3MRQ Y./3WH ]<HKS
MZX\2>*=/U#4=#D&GW6II9F]LYEA8)*HX*,N[AO0YJ?1_&=_X@T_1CIK6+7MS
M%)+=I)&^V((<$<-E?FXYSZT =U17DT'Q#\6/I%CJSV.CM;7=Z;-8E\P/NY .
M22 ,CTK37XA:AIEOXABUNUM6O=*:,)]DW>7+OX4<Y/!ZT >C45YHGC[Q&MMJ
M+-I,,A@M#=13FWFAB&T99&W<DXZ8QFI;#QIXFN+C2X;JPTQ/[7LWGLVB=VV,
MJY^?VY'3I0!Z,,=J*X7X7:GKFK^'&O=6N;>='FD\ME#>9G<<AL\8] .U=U0!
M UW:1WB6KW$*W4@)2(N [ =2!U-3@ =*\U\:F^M/B9X;NM'L8;G4&MKA0DC[
M PQW;V!--E^)FIV^F+=SZ/%$UK>_8]31I#^X8GAE(ZKC]: /3*0JK=0#]163
M9:M->Z[>6D<4365O'&?/5SDNPSMQC'3!Z]Q6O0 F0/2JZ-9W3N4>"5P-C;2&
M(]C7%?$&[N)];\.>'DE:.TU.X876PX+HNWY<]0#FM>?P+HPO-/O=/M8[&XLI
MED5X%QO4'E6'?([T =+Y:?W1^51_98/+\OR8]F<[=HQGUQ7%S_$"XCTZ;6X=
M(\[0H9S"]RLP\S .TN$QTS[YJ#4?B+J$%_JL%CX?-S#IT*SR2M<JNZ-@""!C
MT.<4 =[Y,9C*%%V'.5QP<TPV=LT:QF"(HOW5*# ^@KCM)\>W=_JMA:W.AO;0
MZE;-<64OGJQ<*,X8#[O%9\'Q2N7LH]4N/#EQ#I'VDVTMWYZML;=C.WJ1ZT >
MA/:P2,K/#&S+]TL@)'TIS0QLX=D4N!@,1R/QKA=1^)/]G7[^9I;_ -GI=+;&
M8RA9&)'WE0]5]\U'J'Q+N;2YU6*+P[<2+I94W+F=!M0XYQSD\]* .Z^PVFT+
M]FAP,X'ECBC[!9C&+6 8Y'[L<5R]EXY6Y\4P:1-9>1#=6@O+:Y:08D3&>F."
M,'//:M_0]3?6-+2^:W\E9&;RUW;MR D!NG?&: ++V-K*Y>2VA=SU9HP2:L45
MR6I^-);:[OX]/TJ;4(=-*B\>-P&4G^%5QEB!R: .E:PLW9F:U@9F.6)C!)-)
M_9UES_H=OSU_=+S^E<?<_$29-<;2[3PWJ-U*D23.5*@JC8^8C)QUJ!/BQI3W
MD*F!A9S3&!)A(I<$?Q-&.0I]: .XEL+2=$2:UAD5/NJ\8(7Z>E2QQI$@2-55
M1T51@"N*M_B/#-JMG9OI-S$E[,\%M([KEF4XY3JH)[UEZ/\ $:\ALM9U#7+(
MQV\-[]G@"2+P_ $?Z$[NG6@#T.>PL[F999[6"611M#O&&('IDTV32[":WCMY
M;*VDAC.4C:)2J_08P*XQ/BKIGV6_:>UDCN+,H#$LJNLFX@ AP=O4\UU&AZQ-
MJR3^?I\ME)"X4J[JX8$9!5EX(H N2:;8RSQSR6=N\T8 21HE+*!TP<<5!_8&
MCYS_ &38YSG/V9.OKTK1KF?$GC"/P]=+;+I]S=R>0US)Y1"JD:G!))/Z4 ;4
M>E:=$93%8VL?G#$FV%1O'H>.:=9:98Z:K+96D%NK'+"*,)D_A3=)U.WUG2;;
M4;4MY%P@=-PP<'UJY0!";6 K(IACVRG,@VC#GW]:AO-+L-0$8O;."X$9W)YL
M8;:?;/2N8N/B+90:Y>Z7_9>IR&R<+<3)""D8/\1YSBGZ?\0=+U/4;2R\BYA2
M_P!PMIG*8DQ[*Q93Z9 H Z"71-+GODOI;"U>[3&V9HE+C'3!ZU'=^&]%O[EK
MF\TJSN)V&#)+"K,1]2*X+P5XE71/#%\]Y]INY&U>2WMXU.^21CC"Y)QV[FK^
MK?$DIHL=WINF732F_%C,D@7,+@C(//)(.!B@!VM^$;Z37Y+JWTC1-3LY8XXH
MX;U2AM@O]W ((.<^M;FD^#M-M=#73K^SM+I/-:;RS$#'&S=D!S@"LM-:TO\
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M%#Z@GH: ,3P-H9T#PI9VDI9KAE\R9G^\6/K]!@?A71U@:3XE_M/Q)JVC-9-
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M:3X>EM-2M)+>?[5)* Y4Y#'CH378444 %%%% !1110 A(%&X5Y/K%U;:I?\
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M7#&VA6X)3[N<%3U ]/:K<US<Z9I7AK6]'O+JZOKW"3Q/,TBSEE);*D]0?3%
M'JU%>6^';JWO]+L/$,VOW2:FD[_:+;S2_G-D@1>7G@=,8%9&CW6K:C;)K_\
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MVVTW5Y]/%Y>?9Y6A Y!'7\*[VL?6?#EEKMQ93W;3A[*3S8?*D*X;CGCZ?J:
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MBBB@ HHHH *Y7XC*'\&3J>ANK7_THCKJJY+XE,5\$7# $XNK0\?]?$= '6
M  # I:13E0<8S2T %%%% !1110!7O[@VFG7-R!DPQ-(!ZX!->>?#K1K3Q)X=
MEU_7K2#4+_497+27$8?:@. H!SM YZ8KTET61&1AE6&"/45P>F>&/$GA*:ZM
MO#TVGW.DS2F6."]+HUN2>0"N<B@"TGV?P%:0Z/IB?:KC4;US96CR;!&& )RW
M.%7!/3O56X^(TFG6NL1ZAH[)J>E*LDMO'."LD;$ .C$=.1QC/-2ZUX1UK4%T
M[4X]3A?7+"X,Z%T*P%3UC '(&._)ZU0UKP9K.M6NNW\T5JNJ:G;1VD4"3'9#
M&K DEL?,20#T% &II7CB[U#5DTZ?0I+2:YLOMEF)+E6\X>AP/EKSNQM;35/"
M>LZYXB\.27S07LKM<QW864X(!0G@[1^/L*[2+0?$<'B70]4&GVS1V&F?8Y$%
MU@LV",CY>E5+'PGXBA^'>MZ#+:0"[O)GEB<7(P=[ D$X[8_&@#2N?$\9TN#1
M=(T6:\9M+6:2$3A%MX63"@N>K8K&\%^+(/#_ ,/M$@D19;R[>80Q/,L0P';)
M9V. .U6+;PYXJT/48=0T^QM;HW6FQ6=[;R7 38\:[5=6P<C SC'?\:S8_ GB
MC3]"T2XMK6PGU/37F1[.9P\4L<C;NIP : -Q/BYITFG6EQ!I5]/-/<&U:&+:
M=D@[;LX;/;%1ZQ\2YQX7U6YL-+G@U*PG%O/#,RGR"QP&/.".WUJOJ?ASQ3>6
MNBS/IED)[?41=R6MHZ1I"@ &T$XW'@DFJE]X.\1WMMXS5=/2)M6FCFM@TZ'=
ML?.TX/!(]>* -R'5K*_\9>'_ .T]-U*UUA[5V@S*OE;<$DD*W)./2KFG_$6R
MU#5K.S_L^[A@OG>.TNGV[967K\H.5_$5FSZ9XEN_$?AC43HZVYLK>6*=A<HX
MC+KM!Z@MCJ0!7.6?A'Q9'K6CZI<Z"LM[9WCR7=TU^A:X!/RD#^%0.WZ4 =7\
M-99GN?%"37$TPCU1U4RR%RHQTR:[P]*XOP+I6IZ7J'B&2_TY[6.]O3<0YE1P
M5(Z?*3S7:GI0!YCH.J2Z=XM\9W%]?:C<66E;7C@-Q)*$4Y)PI)ST[]*W=%^(
MVF:U?V5I'9:A!]MC9[:6XA"I*5ZJISR:Y^#1];BU?QQ*=$NO*U:$I;'?'\QV
ML.?FXSNS45AHNNV[>!V?1KD?V6KI=Y9#LSQV;GUH KZ?K#Z_K6NWNKSZQIJ:
M9=!HKB*3;';HHYC=02"3]#G-=K9>.].N;P6EQ:7]E,\+7$ N8,>?&!DE,$Y.
M!TZUR2>%M:U+3?&5B]C-:-J5T+FT:4KM;!!P<,<$XK0FM-5\3ZIH5Q=:+=V!
MTA9)9_,*XDDVX"1G/S D YH G7XP>&F@DG6'5# @),OV1MO!QC/XBK(^*6@>
M=-#Y.I^;'&)53[&VZ1,9W*/3W.*YM-"UJ+X,76C/I-R-0,^! H!)'FAL\'IB
MK[66I_\ "9+J#:/>F Z(;4-L!Q+CIU_"@#I)?'FC)ING7L/VFZ&H@FVAMXBT
MCX^]Q[5DZK\2[2"WT2XTRTN;R+4I]A(B.5 X90.[^U<K::3XAC\.>&+.;0K\
MP6S3K<);XCG#,6V_,2"J$$9/YU#9:)XAM?#FAHWAR\,NDZLTKQY4LZ-W49YQ
MQSTH [O2]>TR3Q%K=R=6U!1;P1O/:WBE(K<>J@C.>.?KWJ_8^-](O;LVQ6[M
MY#$TT0N;=D\Y!R63^]QSZUQ&I^'M7US7?%2"PN;9+^SA,#R)\C2)AMA8<>V:
MTF34?$6H>&Y)-&O[&32<S74DT.T$A0-B?WLD=J -JR^)'AW4+RTMH)KC-W*8
M8I'MV5"X_AW$=3_G%=<.17C-KIVIIX4\.6<FBZCYUCK/VF9/LK<1;V.>G/!%
M>RCH* .9\6Z[<6$FG:3IY"ZCJDWE12'D1*,%GQWP.E+?^,=%\.RC3[Z\N))H
M$3SW$32>6#P&D(&!G^M9'C.WDMO&WA/66&;:.X:VE)X"%QA23]37,>.K#6-2
MUS7H5T?43&]K&+5[%/DGV\YE8?>QSA: /1M1\8Z+IDOESW$C$(LC&*%Y BM]
MTL5! S[UNJP=0RG((R#7C>JPW\T$%YIVEZUINLI:P0H#;F2&\4 #9(,8&,=Z
M]@MC*;6$SJJS%!YBKT#8Y _&@"MJNKV.BV@N;Z;RXV8(H"EF=CT"J.2?I7#^
M$/%GGZQXLN-0U2=M-LY4,/VI=AC4[LC;@$<X&.O2KWQ L=1^VZ!K5G:RWD.F
M77FW%O",N5.!N [D8_6N)U'2M9U^3Q9<6.C:A''<RV]S EQ&8C,(^H&>_.0*
M /1+CQYI+:/J=W9RRO/8Q>8T#V[JXR/E)4@';TYKB=&U>YO[31=6N?&NH6CW
M4@26UDM"4EDW?=3C 7&!W%6=+B@GT;7+ZT\*W^GR/ISP2/<^9)++(1@(@))*
M^I^E4;^*ZN/AWX2MUL;[[39WD9FB^RR90+NR3Q[C\Z .[N/B+X5L[N>UFU15
MF@D\N0>4YVMG')QZUH:IXKT;1F1;R\"ED\S$:-)A/[QV@X7W->9:G"\R>/-N
MG7KMJ!B-H?L<G[S'7'R\?C4$]FVGZM'<ZMI&M7EAJ6G6\0-HSJT;*@5HW5<<
M$\8- 'HWB7Q=I>FZ*[IJ8CN)[9I;9H4,I(QPV ",>YXJ7P'?W6I^"=,O;V=I
M[B6-B\C=6.XC^E>?6,%WX5U+46O=#NEM=2TT16@MHGG\HA?]4>20>>>V17:_
M#&.>#P%I]O<VTUO-%O5DFC*'[Q.<'ZT ;?B.6YM_#6ISV<Y@N(;:22.0*&P5
M4GH>.V*Y_P %>.-,UG3--LYM5BFUF2 -+&006;&3VQGV%='K\,EQX<U."%"\
MLEI*B*.I)0@"O)X]-F\0Z!X7TK3+*>#4].)-U-);M$+? ((+$#))QTH ]/@\
M6:%<ZI_9D.I1->%F41\C<1U .,$_0UA>%/$EP8O$$NNZ@ABL+]X5E=0@" <#
MBN,\)V%LNH:9I.I:%K3ZSIUSP[RM]FC ?)D!S@#O@=:AFL[]VUB[@MIY8+37
MEO)(1$0SQ\@LN1SCTH ]23QIX>DTZXOUU.+[/;D+,Q# H3TRI&1^56+?Q/HU
MU>V]G#?1M<7,?FPQX(+IUR,BN/@TZ#Q7XUU'4+5)1I5QI?V2XD>)D\R0G(P&
M )(&.:Y--%\90:;;:@H876@W!LK5 G,L9;:S>I&,?A0!Z)K/BK^SO(UFVN8[
MG15F^RWB*O,;9QO![X. 176HRN@=2"K#(([BN \;:>NE_"F?30-\K"*//4O*
MSJ2?J3FNWTV-X=+M(I!ATA16'N  : &:GJMCH]H;K4+F.WA!"[G/4GL!U)]A
M5#_A,/#WV.*[.KV@@E8HC-(!EAU&.N:P?B3<2P0:.RVQ*"]#-=B%I3;8!^8*
M.I/(YR*\XA$0LQ8O;7SE?$"W(:XM6!:'CYFXQ]10![98^(]'U*TGN[34+>6W
M@)$L@? 3ZYZ5S.E>+FUCXD2Z=8ZC'<Z4+$R!$CQMD! ZGD]?IS7&:M:W%W<^
M,?[,MY9$:XMIQ%'&0)HD/SA>F1TZ5OZ'J=MJOQ3BOK&UN$MFTORBS6S( X(.
M#D=AQF@#TZN2O_'.F#5M1T.UND34K>V9U:0?+YF#A,<9/?K76]J\OU2X73/B
M9K<MU%(J7>CB.W>.!GW,.N2 <?X4 ;O@CQI::UHVFPWVI6\FM3QL[PKA6.&/
M8<#@#BMN/Q5H<VH26$>IV[74>=T8;GCKCUQ[5Y+IA2RT?P-(MHQGM;J9KA4B
M(<9/&[BJNGW:_P!N>';A[6[A2VU"9I+-+1MMN&/&&QER3CF@#UOPUXPTWQ.]
MXMB^6MYF3!/+*,?/CL"370UY]\-)5MY-;TZ6*:*Z6_DE*O$R@*<8YQC/M7H-
M !1110 4444 <5J6CZG=_$#[9]C)TV33VLVF61<@MD[MI.>,XK&B\,Z]<>%[
M;PE=6*)!:W((U#SE*-$K%AA?O;N<5Z=D>M&: //[7PWJ=[#XPL;JW:RAU24O
M;3;E;MCD Y[#\,UD6'A'7=2TJ72-0T/1]+\N!H_[0MXT,DYQA<8&5YP2>IKU
M?(K/_MBW_MPZ2(YS<>3Y^_RCY>W.,;NF?:@#C-+7QX^C?V=-86-C+:6[1QW0
M99//(7"@+G"@X&2?RK"T_P .^);75;?4&\-F5_[/DMKD3WRMYSD=>O"]MH_2
MO8,T9% 'DUEX4UL:9KMC9V=U9:;=6++%8W,ZR!;C(^X0?NX!Y..M2:EI&LZA
MI^G"3P[>VU]:6BQVU[9W:"6*0#&&^;&PUZ)J>M6FE0137!D9)9A"OE1E_F/'
M./I6AF@#E-%UG6(-:M- U6P!<62R&]20$.X W?*!QS71:F'.EW2Q1M)(T3*J
M+C+$C'<@5(MM D[SK&@E< ,X RP'3)J;(]: /*X_#NOP>!-#@&EDZAI&H+<F
MW,B_O5#,>"#C/(]*CN/#WB'4['Q@SZ0;:34WBEMT>9"3L(^7@]<?X5ZQ10!Y
MW<V?B%O$&E:^FAEW^P/:36RW"!HSR023QSGMFLC1?#7B*UD\+)<:0Z+IUW-)
M.PGC8!7;.>M>MYHH \QU?PUJMKXQO[R#P]I^M6FI%65K@@-;L!@YS_#7HNGP
M-;:?! XC#1QA2(EVH"!V'855OM>L=.U.PT^X9Q<7S%( J$@D=<GH*TZ /,Y;
MJ\M_B3XEAL]+DOC<6,281E 4X(&[<1QS3M/\*ZOHM[X46&V,ZZ=!.+B574*K
MR X&"02 ?:NDN&T/1/%T$SBX75-5'DJPWLCA?7^$8_K739H \>MM \50ZKHV
MIR^'WFO+*>5[F0WD864-G&U<X4#/3%6$\,^(/^$2M-/;29!<1:S]M(\V,CR^
M3UW=>:]9JEJVJ0Z/ITM]<)*\46,B%"[')QP!]: .!N- UB3QHFIZ=IUQIDS7
M6;BXCN%,-Q!GJZ9SN(KTF3>8G\L@/M.TGL:$<.BN,@,,\C!IV: /(+?PIXH3
M4]-U&72(I[^TO7FGN'O //4G(VCHHJR?"GB%O"]QIIT\"XDU?[:/WZ%0F<XS
MGK7JV:,CUH \PU'PYXF@C\2:98V-O=66L2&=)GF"&%F^\"._3BO0-#MIK/0K
M"UN0HFAMTC<*<C(4#BK]% 'GNHW-[;?%ES86(O)#I0!3S1'CY^#D]LU7TWP7
MJWAN\T_6;41WEZOF+>6X<*"';=\A..G'6NX_LC3;?6'U@QA;UT$33-(?N\ #
M&<>E:6: /.M1\'ZI=Z;=7<<, U*YU..]-OOPJJ@P%W=,]R:AE\,>)+/7+R]L
MK'2+J/4V$DHNQO-LYZX)'S#_ #BO2\CUIB2QR;MCJVTE3M.<$=J .$F\.ZS'
MKNLW26\4T5YIBV:.'5,N%QG;V&>U0Z?X9\0:?/X:NDCM7FL+:2VG623 4,3@
M@@<\5Z)FHYY?(@DEV,^Q2VU!DM@= /6@#S:Z\+^*7BUI;58(TOM0%T4^T$&2
M/NA(' /%/M?!^NV^F^)+-+738(]44&*.*9ML9Z8^[7?Z9?'4=-@NVMY;8RKN
M\F88=?8BK>1ZT 4-$MYK/1+*UN HFA@2-PK9&0 .#^%<KXP\+7VOW3&&QLBX
M"BVO?-:.: CJ3@?,.O%=S10!P=SX8UZ+6-6FLI+26#4K1(9'G=@X8+M)X'X_
MC1<^%]<'@G2='@DMFEM'47$32-Y<Z ]">N.F17>9HS0!Y</ /B$Z/JECYNEQ
M+=7:74:1;PJD'[O3@?G6C)X=\6VFO2ZMIMWIHEOU5;I)(V*QD+@%>Y_SQ7H&
M:,T >4^)+._O/%<=I:ZE:+-:V"Q74EU,8#-N.2"5ZC'/M6E;V&J^(-*TC[/:
MV%I'IEYD>5*QCD5> 4X/'N?2NTO]$TK4Y4EOM/MKF1.%:6,,0/QJRTEM911J
M6CAC)6-%R%&3P /\* .+T[PMXBT74)[;3M3M5T>>?S6+QDSIDY(4]/;)HU#P
MCJ>I:];:@1I]M-;W/FB\BW>9)&#PC*  >PSFNLBO[B36)K)K"9((XU=;HD;'
M)_A'N*OY'K0!@^%[_5;^WNSJ@MR8YVCBEMU94D4=QGWXS1XOT:[U_07TZSDA
MC:1U+/+G  (/&![5O9'K1GWH Y34-!U>\UG1-126R#Z<CAU8M^\+#!Q@<"LA
M?!&M+H"Z;]NLPRZA]M#X?CG.*ZBT\0"Y\47NB&U>-[:)9?-+ AP?0=JVJ /-
M;_X>ZU?M?;]6L\74ZSF5H&:3*]%W9X7VK23P?JQN]9GFU"T=M3MQ"Q$3#9@8
MSC/]:[BL37-?.C7NF6XM?.6^G\G?OV[./3O0!S1\!ZM8+93Z)K26=]% +>X<
MQ[DE4=\'/-:MWX4OKF71)1JI>;3F:1Y9D+-*S=>AX'M75 T%E7&2!GCDT >>
M#X<:DK1!-?14AO?MB'[("Y;/5FSD_2NCT7PW/I>NZCJ<U^MPUZ%W((=NTCOG
M/]*Z NJXRP&>!D]:6@ HHHH **** "BBB@ HHHH **** "N1^)C!/ UTYZ+<
M6K?E<1UUU<=\403X O  23/;  =_W\= '7HVY%;U&:=3(@1"@(P=HI] !111
M0 4444 %<M_PF?VR_NK;1=)NM46T8I-/$R)&''559C\Q^E=#?)+)I]RD!Q,T
M3!#Z-CC]:X/X.SPCP=)8G"WMK=2+<QGAU8GJ1_GI0!UOA_Q!;^(;2:>&"XMW
M@F:"6&X4*Z.O4$ FM?-<%XNUB(:AI&DZ==_9XM1U'R+Z>U.U@0H^7<.C'@>M
M<YK^H:IH,_BG1K/5KTVT&GK>V\CREY(&W %-YR<'/KF@#U_(HR*\=M+;5Y/$
MNA:</%&K&#5=*^UW+><"0VTGY>/E&?2JR:[X@NO >D&/7+F.Y.L&Q:X51N=-
MPP3W)'Z]\T >V45Y#>:MK?A;4/$.B2>)'E5;-+FUN[Q-SQNS8*# Y)YQ]!6?
M%XF\0V=OXHM%U#4(196,=U";L(TRL2H/.#@')..HXZ4 >W45Y3IM[X@7Q+H^
MFS>(;J=-9TIIF+*@,$@7(9<#VI_A[Q'K%]$?"USJ$X\00:B8YY_ESY"_,7&1
MC! QT[T >F7MTEC93W<BNR0H781KN8@<\#O570]9M?$&D6^J66_[/."4\Q<-
MP2.1^%2:L/\ B2WP+$?Z/)R.WRFO(?!U[KFBZ?X+D35C+I^IS/;O9-"H6,;C
MR&ZD]Z /:Z*\A'C+7H/$EGG4I+N"?5?LDBQ6Z_9 A'"K)C<7'>M*T\2ZLOCI
M--U?4I]/D:Z816LMNH@N8>=OER8SNZ=30!Z9167XCO+BP\.7UW:300SQ1%DD
MN#A%/J:XGP%XKU75?$]WI5[=S74"V27*23VZQ,&) .W &5YX)]* /2J*X_XB
M:SJ^B:193:1<P033WD=NQECWC#G&?;%<MJ7B?Q9X;N=:TR^U2VNKF.Q%[:W/
MV8*%YP4*C]"<]J /6:1F5%+,0 !DD]J\PM=<\7+)HEA>:Q9^9KJ>;#<1VP#6
MZA S#;T8G(%9?BS7?$$6A>(=$O=1#76GO"XN88@OVB"0XVL.BGD=.M 'L@.:
M*\NU#Q+XFAU'_A'M+>>YNK2R6:2YAM(W,C,,J"I8!5P0,C)JU:^)/%/B"^CT
M>W,&CZC!8_:+KS8Q(6?.T*!V'0GOS0!Z-D4,P12S'"@9)]!7ED[^)YOB#X<M
M;_58H+DV4DK10PAXU89#=^<@=>W:EM?'&NIXLL+2[FMI(KN^>UDM88LK"N<*
M1,#AF[D?RH ]#TG7-.UV"2?3;I;B*.0Q,R@XW#K2P:UIUSJ]QI4-TCWMN@>6
M(9R@/K^8KQG0M4\2^'M!UO6--DLFTVTU20W%O*A,C@L <'MU%="_B&/2_'6O
MZ[Y#M&-%AG5.A.2N ?3DT >EW]A:ZG926EY"LT$@PR-W_P #[U6N+JP\.:.)
M;VZ:.UMU"F69BQ]!D]2:Y'PIXH\4:EK5M#J.E3?V?=0>9]H^RM$L38) R20P
M(Q@\=:VO'^J7.C>#KV_M8K:5H@NY+A-RE2<=.YY'6@#HXW2:))(V#(X#*P[@
M]Z?G%>8WGBWQ1/K=U8Z4VFQP0:6NH*TL3'*[0<=>O-4I/$.O^(==\&7%G>16
ML=[#)*T!C+*'4,&)YY!&<#M0!ZW28%>6I\0/$U]>M<:7HTMS9+=M 8EM'(V
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M Q^)KM-P]: P/0T <EX5\)RZ'K.IZI,;6)[[:#;V:L(EQU;![G^M==29!I:
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M>&GB4QJ%S+MS@GUZUM>$]9T>_33+9]%GCU33;1H;J22(HMN@7#9/1LD=/<T
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M"6:"Y1K\@/*$ZAB>I/I[5U%]<WOB?PSK3Q^&KBQN'M@F^9 )96!!V@8R0,4
M:<?B.QU&\T.X.JW5I+)&9#9"!PL_RY.<KT'.*T[;Q?HUWIESJ,-P[6ML_ER/
MY3 ALXQC&3UKE&:[O=7\&RC3+^*.T5DF:2!AM.Q5&?09%3+X9OX?'L\,46-!
MNW6^EXX\Q/X?Q8YQ[4 :L_B/3['5-5O/[3N[G[-:AWT](6Q'TY''4U4B\566
MM6.AW4FHW>FR7$XQ%'"V)3_=)*XV^]5+^ROKKQ5XI\NSGVS:8(87\LA9& '
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M==JEY&+=@T1! ;/'.2,UV?Q3NHK6+0Y)(0FV^!%[)&TD=MQU*C[Q/8'TKT(
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M:^";*\06D>H1>( %=2HD$0/3/7;7T.]O!(V^2*-B!U90:C%G9LN5MX"/4(*
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M(ZS8)>#";L+D<9&,G/J*ETWQ-K>K"SU*TTZWDTBXG:(X<^=&@)'F,<XQP>*
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M&LVFE:>D%OY<-Q;*&>9@,+G^Z.YQZT ;DWCRX2&\5O#][#<QV+7MNDC*5EC
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MZ5S7A'Q/-K_BK784O!<:?!L-OB+9MSUZ\G\: .VHHHH **** "BBB@ HHHH
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MID>C26XMU@^RZA;;DB ).4P.,YK<\,^'X_#]C-$IC,MQ*9I?)B$<88\85!P
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MAZ:EC>R7%I=P7=E*D,UG(JB0,YPN#G:0?7.*6?Q[%9>3]NT?4;8R7BV9WA"
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M=?4%W>6]A:2W5U*L4$2EG=NB@4 <N?AKX=^PS62)=QV\TOFM&ERVW.<@ 'H
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M=M?Z=/IR361O89)G5@\8&3G!XXKD_P#A!O$<$6N1VEAID$6IV<< BCN&Q&0
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MDGO-9^T0QFU<DJ74]AV ->J>%O#R>%]%32XKJ6XBC9F1I0 0"<XX]\_G6R2
M"2< =Z /--)L_P"T_'&O22:=.L-UI\,<$US:.JAU3!Y8#!!_E7+Z'H+W$%OH
M%[X=U8:S9R,%NYIY/LL8W']XOS8]. .:]HT[5K#5HGET^\AN8XW,;-$X8!AU
M'%7* /#T;4E\,:!X??0=4_M#2]35YREJ60H&8[@PX.<U[>K;E!P1GL:6B@!K
MD*A8YP!G@9KPZVAG30K.!=/OBZ>)C=%/LDA(BR3N^[Z5[G10!P7A%&3X@^+)
M/LL\<-P\3QR/ R*^% ."0!U-=[110 4444 %%%% !2<5YAJMC?:M\3=2L4U[
M5K6"WL8[J.&WEPI?/3'IQ6=X8N/$&JG2=?.N6T8>[:*[66[=C("^/*\G&U3Z
M8YYS0!ZC'HFF1:J^J)90B_<8:X"_.1Z9HN-%TR[U*'4;BRADO(!B*=ERR#.>
M#]:\G@N]:U>]^S0:EJ?]M+K#)<_9YG\A;4<'&/D ''/7-+K6K:C!J;ZE8:KJ
M%Q'%K<=J9C*4@5>AA$></CNW% 'L]8NL^([?1=4TFQFMYG.I3>3'(H&U&]ZX
M!!JDGB/Q;?C7-2,>B2F>"T$F4?Y"VTC^[QC%4)+>:6\^'VM2ZG<W<U]=AYO,
MF+(&;!PJ]%QR./2@#UC3-3?4);U'L+FU^S3F(-,H E&/O+ZBM#BO&M9U;6;?
MP_XL$6M7HEL]82&*7> RHVT8SC@>PQ6I%>:WHFM^)-+M=3N;YH=*6]@:\<,4
MD/!P>@'?'2@#U&BO+/"%SJ.I>(],DLM6U.XTYK!)M0\YBRBX(/R98<9]!Z5T
M'B?4)9/%VC>'C?36-K>12RO)"^QY&7&U W;N>.30!V?%%>827.KZ3XC\):<^
MO/?![JXMKEE?APH!57]6 8<^M5+75/$MQX<U-[2XN[Y[;6WB>*.4"=K=1RL;
M8Z].G/!H ]5EN(86199$0R-L0,<;CZ#U-2BO$Y9(==N_"5S#K.K3K)JDD+BX
MD*20D $*1TW#.,ULMJNJ:IX<U[7K;5[FUNM*N9%AM@P\L)%V=3]XMSDF@#U.
MCBO'9M1U[6=2U;?K=_9Q1:(FH)# 57:Y4-CIG&?Q]ZL:'JNLPZQX0N[C6+J[
M&L6THN()=NSY5R-H X/3GO0!ZU17D6BW_BK68XM=CU:"WC-ZT<HFN\(L>[:(
M_*V8##L<Y.:?H,'BC4M-UK58_$]V]W;7-Q:P6\FT1.1@+[ Y/'IQ0!ZU2,JL
M,, 1UY%</X#U<WMUJ%I<RZE%>P+'YUCJ!W-"><LK=U/%<]XZUO4X-1UF;3M2
MO&_LY(2$MVV16Y)&?,S]\G/3T/M0!ZU37;8C-M+8&<#J?I7ENJ2ZO?Z_K\"Z
M]?V\-KI27L20,% ?;G'3IQ4NDZO?>*K_ $72[K4+FW0Z2+R9[=_+>:0G:.1V
M'7% '<^'M?M_$>FM?6\,L2+,\)64 ,"IP>E:U<-\*4\OP=)'O9]M].NYNK8;
MJ:Y.4ZW/9^+=4'B;48Y-'O'%LGF (P4 X88P<YQB@#V6HI+F&*>*%Y566;(C
M0GEL#)Q]!7F>BZEJ'C6[U7[9?7FF26-M$88[>4QX9DW&1A_%SV/&*RM-N+K7
M?%'A?5-0FNDN)-/GD;RY2@<QYP0!T# <XZT >KW^C:=JDT$M[:13R6[;H6D7
M/EGU'H>!5^O(_#][XCUL6FN)K4$$;WACG$EX6&TO@1"+;A3TP<YJE-=:S;Z'
M=:Q)KVI-<VNN?94C,OR%-P!! ZT >PO>1+)-$I\R:*,2-$G+8.<?G@U'I5\^
MI:9!=R6DUH\@R8)QAT^M><VFG$>.O&1COK^%X8$D1H[D]2F><]<9X]*@74[^
M_P##7A>#^T;Z6\N+:662""4QR38SAVDSPH/YT >@:YXA@T*;3XYK>:3[=<K;
M(T8&%8^N3_G%;->/QW]YJ7@SP=<7L[32_P!MHA=SEF 9P,GOTKM_'FK2Z3HU
MKY<[6RW-Y%;RW*]8D8_,0>QP,?C0!U-%>9>)[:XT+P]KGV+Q'?3LJQ7$,)G9
MI+<%@"2^<D'G@U:N[V_7QY=6MKJ,B*^AF41R2GRTFZ!N3@=CGZT =_--';PO
M-*ZI&BEF9C@*!U-4KS3-*UZVB:\L[:\A(#QF6,,,'N,UX_J<KW/AW5[+5)-;
ML]4M[(2/;37+/%+@C]XIST/<=*Z>P7[3JNC^%Y+R]CL?[*%WN2X97F<XXW=<
M#GB@#T.UM+:RMU@M8(H85^ZD:!5'X"IZ\;GOM8EL(-/?6;^,6^O?8!<I)M>6
M,C/)[D?UI+N&^A'C!%U[5RFCF.2U#73$AB,_,>I'MTH ]EIJ1I&"$15!.2%&
M,GUKRO4]2U;7=;BTP7T-L/[,BN(A)=-;YD=02^5'S8].E"V6KZGXETK3+CQ1
M>XDTYI9);*7:C,KE>/7IU[T >I&&(S+,8T,B@JKD#(!Z@&I*\P6YOM'\56\>
MK7.IM;RW@2UOH[@O#,.@B= < ]><9R*Z3QAJ$\5WHFFI<26T&H71BFFB.U@H
M&=H;L2>,B@#I[B>.UMI;B9ML42%W/H ,FL+1?$TVL7B)_8]W!:31&6"[<J4=
M1ZX^Z3V!KDKV&XMY_%/A\W=W/I\6GF[B:2X8O$VT_+NSD@^AKIO -E%:>"].
M:)YG,L*N?-E9@#Z#/0>PH M7'BB/^TY].TZPN=1N;?'G^1M"1$]BS$#/M5K1
M-<AUR&=XK:YMV@E,4D=P@5@P&>Q-<E\+&\JSUFUN#C4$U"1IU8_-ST/TZU?\
M6ZM%;2V5E97"P_;+]+>]F@;:\8(Z%AT)&.>M '945Y9K\FH:)=:[IEAJ-[]C
M73Q=H3,S/ ^<8WG) ./6H[72KA]>T"T;6M7>/4M.\^[_ -,?+$ 'CT'/:@#U
M>BO'WO+^X\!Z4BZQ>QR'5S:&:*8A]FXC!/4_C3M5>;PI>ZQI,&N:C]DDM4E$
MCN9I8Y"V, DC&1].M 'KU%>*PW6HVT/BJS:YNK5(+&.:*+[:TCHQ[EL\$CJ!
M6QI6GFV\0>'[<:C?2)JNF.UTLETYR=F05Y^7GTH ]2HKRW1GO8;V7P1<&YEG
M2[\Z2[,C$FWX;.[/!/ _&O2[>YM97DA@N(I'A.V1$<,4/H1V_&@">BBB@ HH
MHH **** "BBB@ HHHH *XOXL#/PYU'_KK;_^CXZ[2N+^+!V_#G43Z2VY_P#(
M\= '80?\>\?^X/Y5)4<'_'O%_N#^524 %%%% !1110 AZ5Y=HU]J6OV5WXB_
MX222QN+34'66UF(\B.%3C8R8SDCOG.:]2KDYOAQX:G\0_P!MO9-]J,GFLBR$
M1L_4,5]<\T <O%JNL^(M!\0^(;;6[FRET^>5;6VCVB()&,_.I7)+#WJM;:QX
MA\2>(K6W37;G3H+O1EOC%#'&2C]#C(R 3SZX(KMKSP'I%YJ%W=[[R#[;_P ?
M<-O<,D=Q_OJ.M22^#-/?6_[6CGNX+D6WV51#( JQXQM (.* //T\3^(M0T7P
M6Z:R]O+J4\EK<O'$A+;6P&Y'7'X5)/XQU[2=-UG37OFN[NWU9+&"[<(CA&YY
MXV@\8!(QS761?#32(8-/ACO-2":?*9K4>>/W;$Y)'RU*WPZT6:'5HKE[JX75
M)!+<>;(.''1EP!@C)H Y#4?$OB_PRLUIJ=S$D-Y<1):74LL4DL*,<,2% !QZ
ME<9JSXXL-<M/"NO13^)GN+1;=9[=,()V7(5@Y51E,GM]*Z.S^&?AZUTB]TUD
MN;F.\54DDN9M\BA?NA3VQVHL/AIH=AI.H:>KW<R7T0AEEGFW.J#H%..!G'Y4
M 8\FHZOH5]X+MUU.:XLKT%)UDCCRW[O<!N '3T]JIGQ'X@NO!L_C2VU0HL$[
M,=.>-#%Y2OMVYQNW8[YKIQ\/K$-I+_VEJ;/I;[X&DF#G/OE?PP.*/^%>:6)Y
MU6ZOET^>?[1+IRR@0,^<YQC.,@<9QQ0!R%[XA\3WNI^(S::]]D@L+**^@A^R
MQEB&0/L.0>!G!/TKTOP]?RZIX<TV_G"B:YMHY7"] 64'BL6Y\!65SJ&K7GV^
M]235(?(G"E,!.F%RO' Q6YHFDQZ'H]MID,TLL5NFQ'E(+$=LX H Y_XAZAK6
MBZ"NKZ3=M&EK*IN8A&C;XB<$C<#@CCI7'I\2+V+7=4M%U*:[M;F'&D3>1&,R
M\#'"_-R<?A7K-[9PZA936EPNZ&9"CKZ@C!K"B\#Z+%#HL2P-MT=BUMSSD]2W
MKSS]: .<O-2\10>+AH+ZPK&31VG,R6R;EE&<D<>HZ<=:XZ--4G\"^$IH]3,L
M\NM 0^=&"L;EWY)'+<Y//K7J]SX1M+KQ2-?>ZN1.(#;^4I4(4(P>V>^>M8L'
MPOL[:*TABUK51!9W(N8(F=&2-P21@%?>@"UX,UC5KG5]?T?5[M+R73;A%CN%
MA$9=67/(''&*ZN[,RV<QMV19@A*%URH..,C(R*R-(\,1:1K6I:HEY<33:@5:
M99 NT$# (P!VK:FC,L$D8<H74KN7J,]QF@#QZU\8^,&T31-7;5K,_;[YK)H'
MM $7)(#D@YX]..U:T&O>+IK+Q1IT6HV\VK:*ZR12BV4"="K$H5Z#IP>M:Z_#
M2Q72K'3?[4OO(LKHW47^KSOSGGY>1FBXT^/P1>:KXC"ZCJDFHNBRVUO"K$$9
MP<#'% #?#/BZX\5SZ5_9]PHC2U,NHAHAD/G:$]CD,?IBNXYQ[UR_@;0H](TR
MYN?L1LY]0N'N9("02@)^5>/0=O<UU- 'E&L^-/$&BZAX@TRYU"W%[:JDVG#[
M,#]H1C]TC^]_A5F'XCSS:&VLPR)-#9Z<CW4?E@9NG.T)GL <D^PKLM1\*Z;J
MGB'3];N8\W5B&$>,8;/3=ZXYQ]:KVG@?1K31=3TE(";3497EF4GD%NP],=J
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M8P(BX4 _,0H(R>>!FMRY\=>(]/\ #TUSJ>DO9M%=I ;Q[9MGE,#^\\O=G(P
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M,L<=_%X@,GV<C#HN1DD=AB@#UG7/'-I;Z;KATB>UN;W2HP[I))\K'!) P<G
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M +A8AY@?'W]W7.>>M5I_$6JF\U#3/#]G:W7]CQ(+EKF0J9&*Y"( .N!U/&:
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MQZ5(_P 0+N&QM-:GT<+H%W*(DN%N,RIEL!V3&,'V)H [M(TBC6.-%1%& JC
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MCGDG2"-9I<>9(J@,^.F3WQ4M<CX4\:?\)!J=[ILUM''<6RB0202F2*13CHQ
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MW>IZAJ N+=K57N9=QAB/\*=AV_(5M:!HPT'28M/6\N+I(AA7G(R%[ 8 X H
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M(,BY!"D9[GH* )**3<,9KE_$'BJ?1O$>@:>EO#):ZI(R-.TA!3 SP,8[CG-
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M<<'=7J^>,U!)9VL]Q'/+;0R31?<D9 63Z'M0!E^$M$/A[PU9Z>[;YD3=,_\
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M=SU9OY5W]SK4XDTIM/TZ6^M+YAON$8*($(!#D$<@YK6=4DC*2*&5AAE(R"*
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M0W+0++J5R"SK(&R"%QR%P,D5V?PWO+Z[T_43>^1.4NMJ7T,/EK=C:/GQ@9.
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M#V-_$6B)>BR;5[$71?RQ#YZ[]WIC.<U):ZWI5[=-:VFI6D]PH):**968 =>
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MAU6UE^UQBY9]R! ?,SGY6YZBK_PIT97T*VU^74+Z>ZN$DC=);@O& )#C@]\
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M&QB*  ,&88YQVS6JGA_6X?%OA_4&TJ$06=M*D_V,QI'&SDD(BDC(&<$XYZT
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MTL)^S-& 05QUR20<^U=C"_F0I)@C<H.#U%4]:U!M*T:[U!(#.;>)I/+#!=P
MR>3TH X6ST#Q!X.M+*UTFYM"+G43)+9K$[((VP"J,>@ !.3BO2.<5GZ%J7]L
MZ'9ZD8O*^TQ"39NW;<]LUHT ><7_ (#UR6V\16%K?V L=7N#/B5'\Q"2">1Q
MV_\ U5>N?!5]J&LPW%[+:_9!I)TV58RVXY_B&1CK7<T4 <9X7\.>)M*DMK75
M-:@N--LABW2&,K)(,$ 2'T /3V%=7?VWVW3KFUW;?.B:/<.V1C/ZU8HH \RN
MK:#0/ ;^%/$-_:2W$T#)8Q6\;;W(.5Z]6W$>E,\6Z0F@_!PV)8M,OE&21^K2
M%@23_GM7I4EI;331S2V\3RQ?ZMV0%D^A[5A^-=1MM)\.2WUWI<6I0PLI,$FW
M')QGY@?7TH Q;KP7=>*':ZUZ:U ^PFVMDM-S!">3(2V,GIQ5[PSHGBBPE@CU
MG6+>XL[5"D*6\95I., R$]<#L.]=1"8X[1&55CB" @# "C'Z4EG>6]_:QW5K
M*)8)!N1UZ,/6@"IK^GW&JZ#>V-K<FVGGB*)*"1M)^GY5P<'@'Q'!+O2XT6)#
MIS6!2*.1<AOXB>Y[Y->CVU[;W;3K;RK(8)#%)M_A< $C]14] '!0^"]55/#,
M4LMD8])1TFVN^958%>/EXX]:H/X"\1KH\6@Q:AIQTNWNA/%)(C^;M!R%('%=
M?<^(A;^+[/0#:N3=0/,)]XP-O;'7M6[0 U=VP;\;L<XZ9KRWQ1X<UO0-#\32
M65_9'2+PM<R1S(QF5CRP4CCGWKU2H+NRM;^W:WO+>*XA;[T<J!E/X&@#BE\/
MZQ<7.E:SI-S9)NTE+25;I6. 0#N7;U/U(K.@\ >(;:VT> WNF7<=B)%,%Q&Q
MB&XDA\?Q,,^U>D6]O#:0)!;Q)%$@PJ(H55'L!4M 'FVD^!?$-@=&CGN],E@T
MVZ>X 0.K,&/(Z&IKCP)JUWIWB""2ZM%DU&]6[@(9B$(/W6^4?I7H=9M]?WEO
MJEE;0:;)<03EA-<*X @QT)'?- &#_P (]K<_B#1M3NYK$_8H'BE$1<;MW&5!
M'8>IY]JS;.RA\'>&[K2_$^HV/]GW+2+ (T;>^[DY]3[8_&NF\3^(AX;LK:Y:
MTDN%FN$@^5PNTMT)S_2M:>TMKHQFXMXI3&VY#(@;:?49Z&@#F_A_H(T'PQ"C
M;S-<'SG+CY@#]T'Z#''UK6\1:+'XAT&ZTR5R@G7 <?PL#D'\Q4^KW_\ 96D7
M5_Y+3"WC,AC0@%@.3R:CT/51K6B6FIB(Q+<QAPA.2OXT 8%IX;UFYNM'?6;J
MS>+2OFB^SAMTK@8!;/3IVJWX7T/4='OM7FO'MGCOKDW"B)F)0GL<CFMZTO+>
M^A,UM*LL88IN7ID'!_45/0 4444 %%%% !1110 4444 %%%% !7#_%__ ))C
MJO\ O0?^CDKN*XKXL_\ )-=4X!^:#@_]=DH ZK2O^019?]<$_P#015NJNF?\
M@FS_ .N"?^@BK5 !1110 4444 %8D=YI^I>))[%K*;[7IRK(+AX<*-PZ*_?W
M%;9KS#6]?UZUUKQE;VVIN/L&GQW5LIA3$?<@9'/'K0!Z=Q2\5Y19>(/$&EZI
MH4UYJDFIQZGI<EW);F%$"LL>\;< 5<T6^U^?1M/\6S:_&;.0R2WEG*JJBQY(
M"QX&=PQCDT >E\45Y+_PD'B)O \7CB/5V)$Q:33C&GD^5YFS8.-VX<<YJ:RO
M?%GB'Q3K4%KXB^PVE@T<L<1M$8[67<$/TZ&@#U2CBO$K7Q'XP'A*/Q8^O^>L
M-Z8'LFMD59$W;>2 #FMV/7=;\3:/KNN6&JR:<--=OL]H(U*L$7<?,R"3NYZ'
MB@#TN2"&5T>2.-VC.4+*"5/J/2I:\<TS7_%_C#Q%#!9ZR-*BDTY;T)]F5E^\
M!@9YP3WS5>3Q=XAM==MF.L378?5?L4IB@7['L/ "MC._J>] 'M0922 P)7J
M>E+Q7BEGJ^K>&[/QGJR:E<7<T&H_9D28(59B0H=N,\#H 0.E;MG<>/K1-0)0
MW"2V1DM?M4\+2^<!SL$?!'/0CTH ].HXK@OA]X@DU>XO89M5NYY843?9WT*Q
MS0-SN.5 !4G&*Y?Q%XRUZRUV]DLM0DDBMM02W$<$2M;)&3C$C$9WGGH>* /8
M9H8KB%X9HTDC<;61P""/0BG(B1HJ(JJB@!5 P *\EU?6?%4FK>+UMM?^S0Z,
MBSPQ):H=P(SM)(Z8JZ/%.K:-K>A:EK.I,="U6S#E?*3;%,4!P2%SCN/_ *U
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MW6E>+O%C:9),)(]#22-0Y;RSN )4$\8'/%5+J[T;3] EU7PGK$[:A-I9$EK
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M%AHMDMGIUJEO;J20B>OJ?6N.T7P6DWB+7;[6])RMU=^=;LTV5*^C*K8SWY%
M&#INGWGB3Q7*+[5=5MS'86]Z(K>Y*KYA ['('T'K21SS7?@&X\5C4[L:W;W!
M+$3L%!$@ B,>=N,$<8[UZ5!X?TNVUB75H;4+?2KL>;>V67TQG&.*KMX1T%]1
M:_;38OM#2>:QRVTO_>*YVD^^* .(O]0OO#OB:19OM<L>N68%M&TKD17!X*KS
M\O)S[5=UG[9H?B?PK;P75U(HAF\Z-IF82E5!R1GDY)KN[K3;.]FMY;FW262V
M?S(68?<;&,BH+S0]-OM1M=0N;?S+JU.89-[#9^ .* /);](=6\':7XBN[R:;
M4I=259 9SL3YF^39G P .U7;R:^UW5];:37;;3+FQN]L'GW+HT,:XP0@(5@?
M4@FNYE\ >%9[EKB31H&D9_,/+!=WKMSC]*LW?@[P]?ZC'J%UI-O+=1XVR,/3
MID=#^- ' SR#Q-!XJ_M:]=Y;"V MTBD:) NPG?M!&<G'45V'A6V2[^&^GVSD
ME)+,*=KE3@@]QR*O:IX/\/ZS=&ZU#38IIBNPON921Z'!&:TM/TVSTNRCL[&W
M2"W086-!P* /'] 9;'POX>LTGE@M]5OWCO)%G8':K$!1S\H/<C&:[;0HIM(\
M=WNC6L\TNEFT6Y$<LC2>1(6Q@%B3@CG&:UE\%>&TM[BW&D6_E7#;I%()R?4<
M\?ABK^FZ+I^D*XL;81&0@NVXLS8Z98DDT 7Z*** "BBB@ HHHH **** "BBB
M@ KBOBT,_#75/]Z#K_UV2NUKB?BX"?AIJ@ R2\ Q_P!MDH ZS3/^059_]<$_
M]!%6JK:<I33+16&"(4!'X"K- !1110 4444 !KE+_P !66H:AJ=[)J6HI)J4
M7D7 1TP8^RC*' KJR<"N9TOQUHVK:_?Z3;SIOLP"9&; <\[L?[N.30!%#X#L
M8;[2;LW]_*^EQ>3;K(Z;=F,$$!1G(XJMI_PQT#3=7%_$;MD60RQV<DVZWC<]
MPF/?O6_8>)M$U2[:UL-4M;B<#/EQR MCU [CWK4/2@#D8?AWI4*O;K<WQTYY
M_M!T\RCR-^<],9QD XSBKEKX8M-&U/5M9BN;R2>^4F9'(9>!QM55SP. .:YZ
M/Q1K>N>)-;TW2]1T^RFTV0Q16EQ$7>XQG+9R, ^P.*Z:+Q)::?HVGW'B"\MK
M"ZN(59XY7"?/@;@ >>#0!QG@#P>;KP]&NKMJD:PWSS?V?.OEQ%@V4;:5#$=#
MC.,UTM[X!T^[O;ZXCO=0M(]0Q]KM[:8+%-ZY!4D9[X(ZFM>Y\2:)9"$W6K6,
M(F3S(M]PHWK_ 'ASR/>GIX@TB32SJ::E:M8CK<"4;/IGU]J *%MX0L;/Q*NM
MP37$<JVPM%MU*B(1#HN-N>O/7K6'+\)]&D^0:CJT< N3<QVZ7($<;D]5&W_Z
M]=/;^*-"NU=K?5[&01J7?$ZY51U)&>!26WBG0KRUGN;?5[*2"#F603+A/KZ4
M 8H^&NB[]1$DM]+;Z@=TUM)<$Q[_ .^!U+>Y)J/3_AGI.G6-U;I>ZE*\\8B6
M>:X#20("#B,XPO0=NU;*>,O#4A?9KVFG8H=O])3@'OUJ[%K>ESZ9_:<=_;-8
MXS]H$HV#\>E &?HWA2UT?4KG4OM5W>WUQ&(GN+MPS;!T'  [5C77PNTF[^V*
M=1U6*&ZN?M3017"B-9,YR!M_GFNITW6],UA7;3K^WNA&</Y4@8K]1VJ\[JB,
M[$*JC)). !0!QR_#BP4:G_Q-=58ZE&([HO*C%U P.2GI69J.D2ZG]E\%)I-Z
M^FV,D+OJ5SMV-&O.%(QEN=OYUV%IXFT2_,WV75;.7R%+2;9E.T#J3[>],M_%
M?A^[N4M[?6;"69P2J).K$XZXYH UE150*H 4#  ]*Y./P!:6=U/+I>JZIID4
M[F22VM)E$18]2 5.T_2MN'Q%HUQ:7-U!JEG+;VW^ODCF5EC_ -X@\5?@GBNK
M>.>%U>*10R.IR&!Z$4 <_>^"M+NH+%8C/:SV+F2"Y@?$H8_>))!W9[YS5:[^
M'^F7NDRV$MS>9GN1=3W =?-F<=-Q*XP/0 5K:EXHT+1[C[/J.K6=M-@'RY)0
M&Q].M5=+U-KC5]4E;7=.NK"-4:.& KNMQCDNV>_O0!6_X0>W_M>]U0:MJ0NK
MVW%O,P:/E ,<?)P>.M0'X=V!\,P>'SJ6I?88)1+&/,0,"#D#.SIGGZUHS>*]
M)N[.Y33-:T][Q8V,2^8K$D#CY<@D?2LSP5XVLM8T'3EU#5;-M8FB9Y85=5;A
MC_".G S0 :E\-M,U*_N[S^T-4M9+V,1W2VTX19P!C+#;WJ*[^%FA7-OI\:3Z
MA;2V,9BCN(+C;*RDDX8X]SZ5HZ/X\T'65U%X;V*..QD*L\CXW*,?/SVR<#Z5
MLZ;K.G:Q&\FG7D-TJ-M<Q.#M/H?2@#"'@+3H]1L+VUO+ZUEL(#! (G7 #9+$
MY4DDDDDU7_X5MI8T:UTP7^IB.UNC=02"<"2-SG."%Z9)-:GC34+[2/"E_J>G
MRQQW%K'YH\R/>K =L9'YU/X6N[R_\-6%[?S1RW%Q"LK&--BC<,XQD]* ,:[^
M'&EW\VHRW5YJ$QOX5AEWRJ<!<%2#MSD$4RT^&FF6EX]V-2U>2=[8VK/+=;B4
M(QSQV'0=..E=+J.MZ9I/E_VC?VUKYAPGG2A=WTS6</''A<QJXU[3]K/L&9UZ
MT 3:-X<@T'P\-&LKFY$*A@DCLID3=SP<8ZGTK!3X7Z8FA2Z,NJ:K]ADG$[1^
M:GW\Y_N>H!_"NDU+Q)HVD-&NH:E;6S2#<HDD )'K]/>EA\1:1<ZDNG0:C;R7
MC)O$*2 L5QG/TQ0!CCP+;#4[S4?[5U+[3>6XMIGWQ\H !TV>U1K\.]*'AZ#1
MC<W[06TPFM93,!+;OURC <=3736E_:WXE-K.DPAD,4FPYVN.H/O7,?$#7;_P
M]8Z;>6=U'!"]_%!<;XPV48\\G[N #VH =<_#[3;W3;RTNKR_GDO&0W%U)*IE
M<)]U<[< #T JYJ'A"VU*YTJXFOKY9-+Y@*2*,MC&YOEY.*N6OB?1+VRN+VVU
M2UEMK;_72K*-L?U]*KQ^-?#<ME+>+K%I]GB<1R.7P%8],_7UH R'^&FF/IU[
M8MJ&I&"\N!<S#S$Y<'.?N<5'>?"W1[Z6[>2_U1!>*HGCCN JR,O1B-O)_3VK
MJEUO3GEM8ENXB]U&9(%S_K% SD>U0V/B71=2O&M++4[6>X7)\M) 20.I'K^%
M &1!X T^UU:+4H+_ %2.YC@%N6%SGS%'3=D<XXXZ<=*B3X;Z1'H]MIRW%\/L
MEP;FVN1(HFA<G)VL%Z9YQBNQK(_X2G0_[2&G?VI:_:R_EB+S!G=_=^OM0!E7
M7@#3;W2KNQN+N]=KR9)KFZ,BF64I]T$[< #T %.;P+;/JESJ3:KJ?VJXM3:.
MXE1?DQCC"C!'7/K6@?%WAX:B-/\ [9LOMA?RQ")ANW>GUK:H J:;8KINFP62
M333+"@023OO=L=R>YK)F\)03^+(O$;:C?B[B3RDC#IY83NN-N<'ZU<M?$NBW
MM\;*UU.UEN02/*24$G'7'KCVI8O$FC3ZD=.BU.U>\!(\D2C=D=1[GVH K:QX
M7@UG5].U*:\NXI=/8O L+*%W'J2"ISQQ61)\,M%GTS4+"XGO9DO;G[49'==\
M4O=D(48S^-;<_BS0+:\^R3:M:)<;_+\LRC.[^[]?:I)/$VBQ174LFI6RI:2"
M.X)<?NF/0-Z?C0!SK_##2'TJ.Q>]U)MEPMPUPTX:61E!"[B5/ R<#'>KOB+P
M%I?B6]M;ZZFO+>]MT\M;FUE\MV7T)Q]?SJ>?643Q/;C^WK".Q^QM+)9MC>W<
M2;NRXJ:W\9^&[L3M!K=C(($\R4K,,(N<9/XX_.@"A-\/]+-Q8W%G<WVGSV4!
M@CDM9@&*$DG=N!R223GWK,UBP_LK2D\':-X<GN[6^A97NFP8HV8\M(3U8?>_
M+%=CIFLZ=K,3R:=>0W*(VUS&V=I]#Z4S7+C[+HUW,+Z"P=8CLN9\;(V[$Y]Z
M )M,L(=+TNVL+<8AMXUC3Z 8KCW^%.CLR[=2U>.*.Z-U%"ER D3DY.T;>.OU
M]ZU[;Q7I.GZ79+JWB#3WNGMUE:4.$$HQ]X+Z&MNQO[34[2.[LKB.XMY!E)8V
M#*WXB@#E[?X=:;#+;&>_U*\AM6=K>"YF5DB9@<D?*#GDXR34EEX!L;2:.:34
M-1NY(;5[2W:XD1C C#!VX4<X]<UT6HZG9:3;B>_N8K>(L%#2-C+'H!ZFJ4'B
MG0[E[58=3MI&NRP@"OGS".H'J10!YUXF\&1Z6FAZ5';Z[=:+:B9C/8D//'(^
M, J!]W@\X[UH:-X)N=9MGCU/4]?73H9XI[%+R1/.W*#\Q!!VKTPO'>NXC\2Z
M++8SWR:G:FU@?RY93( $;^Z?0^U<QXQ\9FU\.6^J^'M2LY(Q?1V\[8#X!/(Z
M_*>.XH WM+\*V^E^(=0UJ.\NY+B_ $Z2,I0XP 0 HQ@#UK>K-TO7])UOS?[,
MU"WN_*;;)Y+AMI]ZTJ "BBB@ HHHH Y?6O&2Z9?75G::;=:C-90B>[$! $*'
MD<GJ2 3@<U%%XYBGO[FTCTZXW1:8-30L0OF1\<8/*MSW]*S=8TCQ7I?C.ZUO
MPY#9WD&HQ1Q7$%Q)L\ID&%<'N,=JJ:AX:\4P:^NI6Z6VHRW>D'3[N1Y?*V.3
MN+ 8Y'8 4 :R_$&*XL-*FL=,GN+G487GBMC*D;!%.#RQ )SV'-4HO'NIS>,K
M/3FT6:"QEL!=N9)$#A3CYVR> O((ZUCR>"M8D\):5I%_HEM>-:6[JDEO=B.:
M"4MD,KD8QCJ*MGP=XB_M?2I+@PWL;:,VF7T[S$,I8G+#C+<'\<=10!N1?$&W
M:2QGFTZ[@TF_F\FVU!RNQVZ+E<Y4,1P36;<?%>WM_MLAT'4S;6-U]EN9ODQ&
MV<=,\\Y_R:JP>%?$5[X<T[PIJEK;I965PC-J$<P)EAC.5"IC(8\#)_6J5UX-
M\22^'_$MBFGPF34]2%W#_I*X";LX/OP/SH ZNS^(%E)/J<.I6=UIDEA +EUN
M "6B/1AMS[<57M?B9I\]U+;26=Q',+5KN%4>.0RQ@$G[K85L G!K)U'P9J^N
M^(M8DN;=;2TOM(2S27S0Y612&Y YQD4EAH?BTZ1<VMUHFCVTD5G) LEL$WW;
M,I4'(QL'<^N* +]K\4H+BRBNI-#U*!+AD2T:555)V;. ') '3O77Z-J;ZK:-
M-+93V<B2-&\,^-P(^A((]#WKC!X<U(_#O1]%O="AOW@'EW5L\ZJ0H#89'S@-
MG%;/@+1]5T/0&M-4FD8^<S0122^:T,9Z*7[GZ<4 07GQ#L;+59;9[*Z-K%>+
M8R78VA5F89P%SN(]P*@U+XEVFG7FIP#2=1F73'5;N544)&#T;D\]:Y;7/"'B
MW4+W4))-+M[Z8:DES:W3W@&V$'(C5#]WMD\?C5R\\-^);J#QDO\ 8P5]:\DP
M;;J,A2HP<G(_E0!TGB3Q9;M97FGZ?;7E]<-8FXD-J0GDQLORL6)!![X'-3?#
M25Y?AUHTDKL[F)LLQ))^=NYKF5\.^*M*U&YN['38KJ/4],BM;B)[I4-O*B;<
MYZ$=^/6NM\ Z7?Z+X-T_3=3A2*YMU965) XP6)'(^M &3/\ %+3;=KMVTO5C
M;6=Q]GN;@6XV1'.,GFM'4_&]M9S7"V=A>:C':*KW<MJJE858;@>3\QQS@5PM
MC:ZMJT7C?1-/TU98KW5)(VNGF55AR>25/)('(Q6Y9>'-<\*W6M6^FV']IV6H
MQ*8W,Z1M%($V$,&ZCOQ0!?/CY[CQ=ING6%B]QIUU:&Y^U J-R_WADC 7G.>?
MZRV_Q*TB?4+> Q7"V]V[):7( 99V7L%!+#/;(YKG_P#A"M:TB]T&.QMHKN&/
M3)-/N9?-">6SDDL01DJ,G&/2CPAX8\0:/<6VG7?A[21#92%AJRA&EE0$D!1U
M#'IDXQ0!O6GQ+TR\DM"EAJ*6]S=FS6YDA"H)<X /.><=A]:J)XSGU*7Q/9ZE
MI5_:Z?8@QF: CS$&W)S@\$]1CI6+!X5\1Q>&].LCI+>=;:Y]O*">+'E;B< [
MNO-:4NC>(8]2\96\>E>=::LN^"83HO/E[=N">N>N<=/I0!I0>,=-TC1M(M[2
M#4;YIK$7*(Q#2B%1RSL2 3UX'I5+Q%JR:AK/@?4M/O+@6EY=_=5V19%(&-R_
MG6/=>%_$\MEH]I+I(N+2WTLVSP"[2/RY\8W,0?F7I@<T^Q\/^)HM/\%V]SH[
M Z5=%YV2=#A,C'?Z_E0!Z7J^KV>B:=)?7TOEPI@<#)8DX  [DFL"7Q]86]IJ
M,MU97\$NGJKSP21#>$;&&'.".?7-3>.]"O/$'AIK?3W5;V"9+F ,<*[(<A3]
M:PKN#Q;XL\+ZQ;:AI4&FM+:^5#!YH9I9 0=Q/8<$ >] '0MXRTZ/4OL<L=Q'
M_H!U 2L@VF(#)/!SGKQCM67J7Q"2#P]>:E:Z5?,\5N)XQ*@",C'"OD$\>W6L
M*#2_$]UKEMJ,WAM5BBT1K#R9;I#YC8/WN>A/&/0U7A\):\^E:]8:?:7=EI5Q
M9;(+"\N%DVSYR0AR<+]: .TM?&*OIFGM+I]V^I7=OYXLXD!<J ,OUP%YXR<F
MHF^(VA)I5IJ#?:RES,;<1I 6>.4=48#H?;O6#8:=X@T[6-'U]](=E6Q73[FS
M216EC48Q(.<'D=,U4N?"^M1+;72V$K37&O?VE-%&ZGR(P, 'GDXYXH Z-_B5
MI,4%Q+)9ZHGV60)=*UHV8 >C,>@'Z^U:6H^,=,T^38OGW3BW%TXMTW>7$?XS
MT[<XZ^U<5J.C:Y<0>.$32+DG5&C^R<I\P& <_-QTS45YX?U;3]6M-6_X1B+7
M(KJPAMYK:XV[[>1% [Y !]J .KO?B5X?M'MT5KRX:X@%Q%]GMF<,A[C^OI5N
MR\:Z=J%Y%%;0WKPRSFW6X\D^7Y@Y*D]1^(K#T_1]3M?'>DW3Z6L5K!IK02&W
M55AB=F+;5&>@SC.*IQ:)JT?C:*_TK3;W3=]ZS:ANE4VL\>3\X7/WB/;J: ._
MU;5K/1;![R^E\N)2!P,EB3@*!W)/:L@>,;21-0B6WNXK^SA,QLYHL2,N.&49
MY'T-1>/M&OM8T2 Z<@DNK.ZCNTA)QYNPG*Y]>:RKFUU#5];E\0C2;NV6WTQ[
M>*WE4"6:5\\8ST&>IH / :W&N6MKKTU]JJ7+!S/'(Q\B;).-JGC"^V*GFU*\
M\2>.;S0+>[GLK#385>XDMSMDED;&%W=EQZ5?^'MM>6'@RRL;^SEM;FW#*Z28
MYRQ.1@].:R[S3M4\-^.KKQ#8:?)J-AJ,2I=0P$>;&RXPP!^\./UH V+:SN?#
MNHW5Y=ZQ<3:,MMN/VN7<87!YYZD$5+;>,M*N+D0,+NWD>%IXA/;LGG(!DE./
MFXYQUK,UZWU;QAX7U&UAL7L$DC ACNB!)(X8-R <*.,<\\]L<YYM=2UZZT&6
M?2+JR_LB.1[CS%'SOLVA(^?F!(Z]* -./XF^&Y4@D$MX(9W*)*;23:6';..O
ML*MQ^/-"DTJ]U%I;B.*R<)<));N'0GIE<9YKB+'2-8A\/>&;5]&O5EL-5-Q,
MH4'$>XG/7W_2GZ[;WT>E>/KNZLKB"&[$3P/(H =5PO3UZ4 =EIOC[0-4NY+:
M*>:%UA,X-S"T0>,=67=U IUEX[T6^G\I&NHRT!N(S+;L!+&.K+ZBN5GMM5\1
M3:=J%AI,UJVFZ:X!O80!-(R8" 9^9>^>E96D6.MPZ]I>I/H&KD)I\EO<&8CA
MR"/E7/RKZ 8H [JR^(>@7\]K%!)='[4S)"[6SJCL/X02,9/I5RR\7Z3?Z9?:
MA$\RP6+E)_,A964CJ-O6N!M-/U6'0?"-NVD7WFV.H^;<*83\J;LY_(UKW?AV
M4_$4):2@:9J$:W=_;CH60\$C_:/Y\T =^;J%;/[6[;(1'YA9AC:N,Y/X5A:?
MXXT34KGR(9+A6:%IXC+ RB:-<Y9./FZ'WK6U4W"Z->?8XEEN1 _E1L,AFP<
M_C7D^D66LVNNZ-JDF@:PQ@M9(KC?C 8@C")G"J,\  4 =W9?$/P]?W=K;P3W
M'^E.8XI'MW6,O_=W$8S65X]\86]MH6IV^G7-\M[;D(TUK$VV-_[K/C _ YK
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MBD95&*JN<<8R*]&K/M=;TR]U.ZTVVO(Y;RUQY\2YS'GU[5H4 %%%% !1110
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M/^VR5VM<7\6"1\-]3(Z[H/\ T<E '4Z7_P @FRXQ^X3C_@(JW533/^039_\
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M6MGGR-9_,NWTPX'Z5+)\/;Z*XCNM-\0/8W,EDME>,EL'6=54*I"D_*<#KDT
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MJ/CWPUI5W<6EWJ:)<6^/-C5&8KGZ#_\ 56_;7$5W:Q7,#K)#*@='4\,I&0:
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MU+P9X>L_B+IFBQ6["S?3III(WN'.6&<'.?;]*PM'L;:V\,^'-6B=Q?\ ]O"
M3F4G;$&(V\GIP* /H#<N<9%9?]N6]S?7^G:?)%/?VD8=XRV%#'.%)'3IS]:\
M0\57UM/K&HZA;W$ >/6(X_.N)2+D!1@A%& L8Y]^E;VGVOAR3Q;XT=UL_P#4
MJ;1@X!.8R24Y[X[4 >JZ5=WLFD0W&L006=T5S+&DFY$_&KIGB$7FF5/+QG?N
MXQ]:\9T*6"YB\#6&J+&VC2VDI*R']V]QDX#=L@8QGN:S->LXUTO5[.)F.CP:
MY#'9#S#A=V?,53GH#B@#WJ.6.7=Y<BOM.T[3G!]*5Y$B0O(RJHY+,< 5YQX+
ML[32?B9XFTS3@L5FD$#I"C$@,5&3R3SS6M\1K1K_ $BTMHM0M+6<W2O%%=C]
MU<,H)V,?3Z\4 6?$7BJ?2-4T&"UBMI[34KL6\DQD)*=,D <=.^?PKI5N('A,
MRS1M$ 3O# KQUYKPQWT_5[3PY92Z?'9I_P ) \-W;)+NB+87=L(_@_'\:9)/
MI>FV?B?13N6U_MN..V@6;9$HR>')Z1^M 'KOB77VTGPI>ZSIPM[LVZ;P#)\A
MP<'D5EQ>+[]O$WAW3)+.!(=5LC<.^XED8+NP!TQ^=>;Z;=P1>%/B!8&^LI#A
M6B6U(6(C'S&-?3H*ZJ"2-_'/@7:PR-*?C(S_ *O':@#O?$.H7&D^'[_4+6&.
M:6VA:4)(Q52%&3R!Z9J'PWKT.NZ+9732P"[FMTFE@C<$Q[AZ=0/K2>, 3X+U
ML*,G[#-C_O@UX[%I%O:V?@ZY\(C;K<]N_P!I:VDW%@$&=^3QSD?_ *J /=UN
MK=YV@2>-I4&6C# L/J*+BXAM+>2>XE2**-2SNYP%'J37AG@R'2;F[T.Y;6[D
M:Y%<E9+*&V43%BQW^8_4KCDDU[-X@@BN?#NI131+(AMI/E9<@D*2./K0!SLW
MCM)[SPXVF"";3]5F>)Y'8AX]HST' _&NNAN[>>W\^*>*2'!/F(X*\=>>E>%:
M6FA:AI/@#3O]&D+7$AO8U(!+$<;\=^!4=X[66AZY:6L[6^E0>(56<1*'6.$_
M[/<9 XZ'% 'O5O<P7<(FMIXYHCT>-PP/XBB>Y@M8_,N)HXDSC=(P4?F:X+X=
M6^F1ZCK$VD:P^HP2^6TK1VRQ0*^#]T+WQUP!UJQ\1[<W7]D)!J%E!>QS/+!;
MWZY@N"%Y5B> <'CZT =D][:);B=[F%86Z2&0!3^/2N?\9^(I_#NAPZEI\-M<
M>9/'$?,8\JYQE<=:\W\/W]IJ>MZ!'K6GP66BFVGC@@E;=;F?>=Q4GUSQDU6U
M,>1X$U6."7.DCQ"JZ?EB1Y8/.TGJOI^- 'N37EO$T233Q1R2?=1W +'V!ZU/
MFO!M9-A>>)/$5MXDUN73Y=Z/:H+59&DB ^3RF(R#TZ8SFO;M/RNDVNXREA"F
M3+]\G:/O>_K0!(+ZT-V;07,)N0,F'>-X'KMZTAO[-7"&Z@#E]@4R#);T^O(X
MKYY_M73?[=L-1@NX;8#7&:1)F)N@IZM(W&$XX'OU-3WEMHKZ#XRU.!8#<0:R
MIM)E/S*AD&-OMC- 'MGBK7E\/Z#=WJ2VHN8XF>&*XDVB4J,D#N3]*M:!J+:O
MX>T[47V"2YMDE<)T#%02!^.:\>U>[TN[N/&8\126[:@;1#IIN./W?EY'E]LD
MX/')->G> )(I/ 6B>4X=1:J"1V(ZC\#Q0!NRWEK!*D4US%'(_P!Q'< M]!WI
M/M]GND7[7!F+_6#S!\GU]*\0UT:?=>,/$]KXEUF739FF5K5?LJR&2(?<$;$9
M!]AC.?K5GQA';6^I)J>G"=TMK2&+Q JN@9XF(X8=Y.N2/:@#V674+*"%)I;N
M".)_N.\@"M]#WK U?Q+=:?XPT+28H;=[34A(6E))<;1GCMCI7#:EJ?A2;Q5$
MFLM$?#LVDK'ILA&8HS_&!C.&QCW&*F9M.;Q%\/X[3SA9!9Q +IOG9,84GZ\8
M]L4 >J+?6CA"ES"P<[4(<'<?0>M!O;47'V?[3#Y__/+>-WY=:^?X+_38/!VE
M64LT$-_;^(B[PD_-$NXY)'4#I6Y)/::?X[6_B-AK-G>ZN K*0MW:3YQ@?WD_
M3'IW /3]-U.^6XU#^VI-.@A2X*6OE39)3'\>3PWM6Q]HA,IB$J>8%W%-PR!Z
MX]*\8MO#EMKNB>/+*T2+S[?5'FM<8^5DR0!['!%2W5QJ6N_#G6/%,<#174]M
M%:IY8&]8$($I'L6W'Z"@#V""[M[H,;>>*4*<$QN&P?0XJ:O*OAY%HC^)5O-(
MUN2^EEL<3PQ6J0QQJ"N-X7 W9_'K7JM !1110 4444 ><:W#K_A[Q]=ZU8Z(
M^LV&J6T<$D43 -&R<#.1T.?U/I56YT_7]+\76>L'16NA-I#6?DV( 2&0MN"G
M/10,#/M7>'Q#IG_"1#0?.8ZCY1F\O8V-OKG&.]:N,T >(Q:!J$?@[1K.\T#6
MK?4+**9H;VP(,L,A<D#:&Y4@\]ZTDTOQ.-:T&\U#39YYI]&DL+F2#;^YD8MA
MFY &%(_'->MX%9^J:WI^C/:+?2F,W<XMX<(6W.>@XZ4 >9P:#K-WX+T_P3<:
M5<PW-K=H7OL P>4LA;>K9Y)!QC&:I7FCZR^@>,K1-%U SZAJ2S6P\K[Z;NN<
M^U>TX%&!0!Y1J&B:GKGBG4PEA>6T%YH7V..::+""4$-ACVZ8JAX?TF\-H1)X
M$:PN[*TE22[9F9I6\LJ!$N>I)]QC->SXI,"@#RZWT=I/A5HVG:EH6HO)$P65
M+<;+BW(R1(H[X./KFG:+J^N^%_#T#:QIE]J44NH&.*:2,+/'$<*KR#DY)X&>
M??I7I^!4%Q8VMW) ]Q"LC0/OCW=%;UQZT 2NF^,KDC(QD5Y)H.B7U_\ "KQ!
MX6C(75+6[EB*%MN2&##\&'3UKUZJ0TJT753J21;+IX_+D=21YBCIN'0X['K0
M!YOI\VK:GXU\*7[^&]1M([*UDM[DRP[$1BNWC_9_R*UO#MNUY\6?$^JQ9^S1
M0Q69;LT@"D_EMQ^-=Y(@>-H\D;AC(."*KZ;IEGI-FMK90K%$"3@<EB>I)/))
M]30!R_Q1M+J_\$7%I96D]U<22Q[8X8RYX8$G [8%<O-#?SZYXMNO['U(17FE
M);VQ-H_[QPH&.G'->MXHQ0!Y(+6^4?#_ /XE.IYTW/VO%H^(OE"\\>H[=JD-
MCJ6GZ%XI\-3Z/>W4U_<S2VEQ%"7BD$N-I9NBE2.<^E>KXI,"@#S7PUI%]IWQ
M"F%W9W,EM%I$%M]J>%C&\B!<[6(]JY=])U$^"KBU71=2-PWB 7(B-E)N,77=
M]WI7N>!1@4 >1ZK:ZH=<\:W=IH=Q="[LX$MQ-:/LEQ][ (Y(SG'?%4=-L-0>
M_P!<VZ3K<@O]$:&*:\@P6D"'C_9&< +]*];U/6=-T:*.74;N.W21Q&A<_>8]
M *O8'I0!Y)Y-_/I_@&/^Q]41M/N%%QYEJP,84*"3CHN>YQTI$TZ_MO!^N>$;
MK2KN;4+FY=K>80LT4V]@0^_H,=3D]J]<.!5'3M8T[5S/_9]U'<?9Y/*E*=%;
MTH \U;2KNUUGQ8LMA>3Q-HL=K#/]D=A-(L84[3CGG_/%=UX)#IX)TB.6.2.6
M.V1'21"K*0,$$'FM[ JHVJV":JFEFYC%\\9E6#/S%!QF@#B([#[;\5M9::QE
M,$FFK!'/);$Q[^,X8C%<WX7TE89+/1-1\-:J^IVEV72X>606H^;/FYS@<=@.
M?QKV; H90PQV- 'A4=Y;+=76G7]O?Q:'!K#7HF6S:0E@<;2X. ,YYY-2>*$O
M=0GUF2+3=00-?PRPI9VC-%<1 \3.X!W$CH!TKT2W\!I:(UI;ZYJL>F,Q)L1*
MI3!Y*AMNX ^F:ZJ*&."%(HU"HBA54= !P!0!YKIMF-:\6^+)_P"SIHWN[2(6
M<EW:,FU@A!QN'!#;?RK$ANI3HWA+2O[%U)+[2M1C>[C%FYV@;LMG&#G.:]IQ
M4-S<06=O)<7$BQ0QJ6=V. H'<T >0ZS!</-\0$6SN2;H1"W MW(E((!V\<U>
M-LK>*M-9;:9;/_A'&AF>&(J-VUB5S@#=[5ZC;SPW=O'<6\BR0R*&1U.0P/<5
M%J6GPZIIMS87&[R;B,QOM;!P1V- 'C7A35-.N]3\.PZP6MO[+0Q6NZV=?-9B
M-N]B,#M[$U[1?.T>GW+I"9G6)BL0ZN<'Y?QZ5SVG^$KBU,,=[KU[?V<!4PVT
MJ(JC;]W<57+8P.]=10!X-I-YY&M>&[^6"^6"&.>.2!;-A';YW?(IQENO))-6
MK(0Q>$/#>+<I.FN"24>20ZJ')R>,XP17MV!4 N[9[Q[-9XS<H@=H@PW!3QG'
MI0!YYJ^CWUCXZ:RTU NG>(DS> <>64^^1_O*<?\  J](CB2&%8HU"HBA54=@
M*Q-&\,_V9J-Q?W.I7>HW,N5C>Y8'R8R<[5 _SQ6]TH \Q::VTV\\6:=KT+/-
M?2-+:L\1(N%*854XY(/85#:0R:;XC\#V^HG%Q;V<B3L_.PLORJ3^E>F075I>
ML_D313&)MK[&#;&]#CH:GP* (YX1-;2PY($B%<CMD8KSSPAKEKX-TZ7P]X@9
MK*>VFD,,LB'R[A&8D%6 P>O2O07N[9+E+9YHQ/("4C+#<P'7 HAGMKL,89(Y
M@CE25(;:PZCZT </XCOIKN^T#6'M9QHMM>,9]Z'H1A967&0H.>OU[US7B&"U
MN8?%VI6*AM+N8K=(F53LEG# DKQS@9R17L>T>E 55    '84 >4!-$_X36S=
MHK+[,NB<G8NP2<GZ;L?C62DUC_P@_A)K_P HV\.K%9A(F[:F\G!'IC!Q7MN!
M7/\ B;P[/KTNF20W4<'V*Y6YP\9;>1T'4<=: /,M;-M%?:WJ&EZ:)M!N'@C\
MV-66!)1C,F%^\!^54KK4+ Z;XTB>Z%RUR87@E:W\L2$$9(7  [U[R(T";=HV
MXQC'%*44@@J#G@T >7:='I3_ !!TFWM$M/LT^C>7(L04"0D<@XZG%6/#&EWU
MGKLWA6:V+Z3IDYO(9C_$&YC3\"2?PKO]0LY+JPF@MIS:SNA2.=%!:/W&:I^'
M]%DT>T=;F]EOKR4[I[J4 ,Y' &!T % $NO+ = U!;B22*!K=Q))&/F4$<D>]
M<7X$NY5\03::9['5((;0>3J=JFTA-W$<F.-W?UXKT8@'K34C2/.Q%7/H,4 .
MHHHH **** "BBB@ HHHH **** "N'^+S%?ACJQ'7=!_Z.2NXKB/B]C_A6.K9
MZ9A/_D9* .JTC_D"V&?^?>/_ -!%7:I:-G^P]/SU^S1_^@BKM !1110 4444
M %96L>&]'U]475=/@NMA^4NO*_0CFM4\"N&U'XIZ+I]W>VJV>IW$UDV+@16I
MQ&!U))Z"@#J[31]-L-/:PM;&WBM&!!A2,!3GKD=ZJV?A70M/BN(K32K6%+A"
MDH2,#>I['V]JYV[^*VA6\T,-O;ZC>/-")T%O;$[D/<9_'\JM7'Q%TJ%)9TM;
M^>SMR%NKJ*#*0,0#M;G.1D9QG% &F/!?AL111?V+9;(B6C'E#Y3[5+;^%M"M
M9I98-+M8Y)E*R,J<N",$'ZUA:C\3-)L=2^P066HW\YMQ<K]DMBX9#R"#W&._
M2I3\1]$;2+&]M_.GEO=WE6L8'FY7[V02 ,>Y^E &N?"6@'3O[/.D6AL]_F>3
MY0V[O7'K3K;POH5G9W%I;:39Q6]P,31K$ )![^M<Q-\7/#\=C:7,<5].]S(8
MA#% 2RN.JGL3TX&:IVGQ/N+[Q,;6+P_J2VL=F9WC:("8G(YVD\*.?K0!U\7A
M#P_!I;Z9'I%H+)Y/-:'RP5+>ISWJ2#POH=M=)<PZ7:1S(GEJZQ#(7&,?3%9E
MEX[L-0\.0ZS;6MU)'/<"VC@4*9&<G'3-=5VH Q%\(>'4M5MAHMB(5<R!/(7
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M>RV0LHIKNVMQ/<QM=K'LS_"I(^=L<X KK=(U.'6=)M=2MPPAN8Q(@88(!]:
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M_P!8/_1R4 =7H3B3P_IKJ<AK6(C_ +Y%7ZHZ*,:%IX_Z=H__ $$5>H ****
M"BBB@ ZUXY:W5TOC+Q]86>DW-[+>E8$>(#9$S(P&\DC YSGVKV,]*R=,\.:=
MI&I7]_:)*MQ?OON&:5F#L,X."<#J>E ' ^%?">J>'_&>E>99R26=KI?V5[I<
M;3(S%SWS@9QGVI8="UW1M*\2>'DTN6]34Y99+2\21-G[P8/F9.1CZ'->IXI,
M4 >064-SX4^)%K96^GW.IR0>'XX"("H)PV-WS'ID8_&J ^'>M:)'I^M#2K75
MIUDE>[TM\,%$A. O8D9_.O6$\-:='XB?7E6;^T'C\IG,SE=OIMSC'?I6OB@#
MRB70-:EU'PQ=KX>@LH8+]KJ6ULU0"W0A0 QXW-P2?2MF73-4L_BT^LI8>;IU
MQ8K \_FJJPX(R3GKTZ5WV!574M.M=6TZ>PO(_,MIT*2)DC(^HYH \]\+^%Q:
M_$+4VM;D2Z+:L+F")&RJ7$BC/Y+G\Q7IE<UH5SH.CZH_A+2[=[>:V@^T,GE$
M*5) W;C]XY[\_I5W5_$NGZ)?:=:7GG"34)O)A*1DKN]ST% '.WNG:IHGC^X\
M0VFGRZE:WUHMO+'#(H>)EZ$!B/E.*P3X-URST/2H([,7%S_;?]JW,<4B!85S
M]P%B,G&/UKUBC% #48L@)4J2.5.,C\JPO$$NLPWMB]AIZWUAB07L&] S# VX
MW=>_&>:WZ* /(U\(>(+:/Q)J/A^Q326OTC2WLC(N\@'YV[JA/.!GBJ-KX1\2
MQ7.M30^&Q%%J6F?9@CWZNZN0,LQ8\G(S7M6*,#TH \QM]!UFTU/PG=W.G&*U
MT>SDBNY'GCPN5QD8;D=S7':.NKZ?:V.JW^@RW6@VURUY:K%=($B+-PV,;C[
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MZP18LQMA]H4",$Y(7Y>.: ,/3_&NIV>IS?VWJEQ;WEJD\D^G3VZK',!G9Y+
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M7C#4[9]0N+^SL]%:ZCAGVY+@CJ0!GOSZ56GU/7-(T[PUKD>MW-Z=5D2.XMY
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M^P\7:#JE^;&RU.":Y^8"-3RV.NWU_"O/!?'3O%D%X=.NKM;GPVD,4<4#$RR
MC*GCCH<YKG?#5R]OXE\)W<D.HE(O/CDMULF$=MG.%3C+=>2<T >G> -;U/6%
MUJ/4[D7#V>H201OY83Y1T&!795Y]\,BS7'B=VADB$NJ23(&C904;.",BO0:
M"N'\?^,K;1M$U""PU-8=7BC5E58_,V$D8#<$#(SC-=Q7B&IS7NF:;XUT74--
MOI[_ %"Y,]M+%;M(LJ$C!W <8Q0!WEIJ[SZOX=6;7Q#+-I_G2Z>T0S.=@)=F
M_AQR?PK9L/%>B:E=-;6M\KR*C29VD*RC@L&(P0/45P$S!?$'A"6XT^\\N#2)
M8KA!;ON4M'M"GC@DYK'M=-UFX2YTG0&NKC3I]/F5([^W,<ED6()C#D<Y/'%
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M'<5) (*L.H(/(/L:OURO@*SMK;1IY;319=)@N)S)'#.S&5EP,,^2<$\\5U5
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MLP+NPED*2P(2?WL1Z;N#Z]*Y:ZGL-:UC61JVK1:21# ]C]LB+RQP^6"IC(8
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M<6UK;R6*^5:R>;"JNR[7_O<$9;W/-02^"]!E%Z'LF(OB#=?OY/WV#GYOFYH
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MX3M1X(_X1WR(I8C$%92QC5FSN+97D?-S6MHVG_V5H]G8&5I3;PK%O8Y+8&*
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M% !1110 4444 %</\7_^28ZK_O0?^CDKN*X?XO\ _),=5_WX/_1R4 =;I?\
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MXNH;Z9YO,CB\LQLQ!R.3GD UGW7AS5?#/A74KFYUJ_UN:*S:WM8UB"F)6X)
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M-E:6PN;F[@A@;&)9) JG/3!-<YXJ\2W6D2:&^G_99K:_O4MW<Y8X/=2#CL:
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M2]NMDD"PBS,G[A-O=5['_P"O6K5;^T;+[7%:?:X?M$R>9'%O&YU]0.X]ZLT
M%%%% !1110!R.O7^EV_C30H;N+43>E9FM3 2(F^7Y@PSR>!QCN*K6GQ/TJ[%
MI)_9VIQ6US=_8UN98E$:RY( )W>U/\5Z5JMUXO\ #>IV-@;F#3VF:;$JH?F
M QD\]*Y%/"'B4>$K/33I&+B#7/M^?M$>/+R3@'/7F@";4)H_$OCW7;/7+:_A
MT[3[=&25;E8_L>!N,G#8^;\3[5UMAXXM#-IUK/8:A;P7T?\ H%S<!2+G S@X
M)(8]@>N:P9/"VKZKXL\3275A+;:=K%D+=)C(C%&4#!*ACW%.@\/>(M5M/#FF
MZKIT=K'HD\<TETMP'^T",$*$ Y&>,YQ0!;B^+.FR6=S>?V'K9M+=G62X6V!C
M7:<<MNX/(_.IE^)MN]U':Q^']9:XGMA<VL?D+F=#W&#P/<UD6/AC7(OAQXDT
M=])\J]O;F66"(3H5*N1@9S@8QWJ>RT?Q!;^)?#>HMHTC16&E&RN!]HCR'QC(
MYY''ZT ;\'C[3KK1M*U"VM;R9]3E:&WMD5?,WKG<#DA1C![UAZO\36?3]%N]
M#TZXGBOKW[-(7"AD*GYH\9^\>QSCWKGX_"GBR#PSHVG/I!FM[:]EDNK,7:IY
MRL25.]3P!DY&:;;>"O%=GX9M+1-*A\[3]9%[&D=TO[Q#U STQ@=>?:@#L;;7
MM%L_$^OWMPVIVUQ:6L;W<=RW[E%/38N3\QQCC@]JO0>.[)]16PN=-U*SN)8&
MN+=)XAFX0#)"8)^;_9.#7*ZUX/USQ%KNOO-8BUBO]/ABBE\Y6431D-@\YVY&
M,XJ^-*U_6]5T.\U'2GLVT2%R_P"]1C<RE-N(\' 7C.3CTH T=*^)FD:M<Z;%
M'9:E#'J+M';SS0!8V=>JYSU_2NHU74HM(TNYU">.5XK>,R.L*;FP.N!7ENF^
M&?$UGX?\)V#:/*)=+U,W5PPGBQLW,>/FYX;]*],\0PW%QX=U*WM8#//-;21I
M&&"[BRD=3QWH YJT^*6B7EJ)TM-302E%MQ);;?M#,<;4.<$^N2*P_&WBNWUS
MP5?2:=-?65[87L44\+,8Y$);&#M."",]S1J7A'6;GX=>'HUTZ*35=&9)#8SE
M728#AER#@Y'-0:KX>U[4_ ]^L/A>TTVXN9H&CL;/RPX"$EG=N <]AV_.@#KM
M5^(&D:)>S6ES'>/]E$?VJ:*+<D&_[NXYSS[ U6/C:1O&UUH9TV\-K#:"7SHH
M]S')^_U^[C@=\UQGB_PWXHUV^U8_V'-.MQ;0FS9;A8TBV@;@RY^9\Y'.?:N@
ML+/Q'9^.+?5)M">2"?28[27;<(3&RG)W'N>.@]>M %C1O&6A:)X9TUTN=8OH
M;RXDBMWGB,DK,&^Z<?H.M;%MX]T:XTB[U%Q=6ZVEQ]FE@FA*RB0G 7;W)]*X
M"VT#Q##X?\.VQT&[\VPUAKN4!DXC+$\?-Z']*C\1:5?QVOBWSM(N$;5-2MVT
M_+JI9P<97!/S=P/2@#TW2O%VG:MK%QI,45W#?6XW2Q30%=@[9/(YSQS5+QKX
MM?PLNG>7937#7ETD.Y$W!1GD>[$=!_A7/> [F[A\2W)UK1]2MM5U&('[3<!?
M+<1@ J O3L<\Y]JV/B/I6I:CI^ESZ9:O=2V.H17+11D!BHSG&2 : -"_\:Z9
MISR))%>R>1&DER8;<N+<-R/,Q]TXYQ6]:W4-]:175M()()D#QNO1E(R#7G,-
MMKNB:MK^="NKRVUU?.C,15O)D*D&.3)Z#/7IQ77^#='GT'PEI^FW+%IX8AYF
M3G:QY('L,XH XG2?'EKH/B+Q+;:W?7\\<5_MC<QM(L"=.2!A1GBNW;Q=I*W5
M[;"61I;.V%U(%B8@Q'^)3T8<]JX:ZTO6+*Z\:Z<NAW5U_;<A:TGC"F+YEQ\[
M$_+@G/X4VYT36?#VK"*#2[O4XKG0%TX2P;<)*/[Q.,#W- ':2>-]&6SM+F%K
MFY2Z@-Q&MO SN(AU<J!D"JLVO:7-XFTN==6O8S)8/<)9K&WE31$;MYX^\ .G
M6N'_ +#U#_A&-!CFT?7++5+*S9(+RQ 9T?=]QU!^Z??%:C6FO0^(?"][J&F7
M,TMOI<L-W);Q;E5V4@#Y>,],XXH Z>P^(?AS4KVUM;:YE+73%(7>!U1G'\.X
MC&?:K<_C/0[:]^S2W+KB86YF\ES")3_ 9,;0?;-><VFF:O#X8\)P/HVH?:+#
M6#/.@@.4CWEL_DP_(TVS\.7=CJ]YH]_X3GU1I+LSVM_YKK;@,<AI "!D>PSV
MH ]+_P"$NT@ZHNGB64RM,;<.('\KS0,E-^-N1Z9I;#Q7I.IZA'96TDK22JS1
M,T+JD@4X)5B,$?2N"?3M2M?%@FT2RU2U>6_9KVRGCWV<R9.95<C"DC'OFK/A
M>RU"P\4Z>NEVNJ6^E,DIN[/4(3LM&(X\ISZGT[4 =[K>OZ9X=LA>:K<K;P%P
M@8J3ECVP!5#3_''AS5%O&MM3CQ9IYDYD!3:G][Y@,CW'M61\6!GP#<G!8K/"
M<#J?G%<_K-OJ&LZE>ZWI&A2ND6D?96BO+<H9W9@<!#][:/Y8H [BT\;:!>PW
M,L=]L6VC$LOFQ/&0AZ-A@"0?45C:C\5?#<%J'L+HWTIEC0I%&_RACR2=OIGC
MJ>E<=:?;AJNI3R:3X@FAO=$-L9+BV((E] J_=7/&!^5:U]IEQ_PJ?11;Z5<"
M[MI+9KB&.W(E^1OF)7&3W_.@#KIOB#X7MRZ2ZJBR1A2Z&-]R ^HQD>_IWK2O
M?$>DZ?;0W%Q>((IEWQE 7++C)8!03C'?I7G\CR:CXA\571TG48H+[21'$9K5
MPS.%(V@8//(K$-E>:6OAW4]0TW5[BP&F_8IX[,R12PN&Z$ @D'\C0!ZC>>-/
M#=A%!)<ZQ:QI<1^;$=^=Z^HQ3H_&&@2SP11ZG"[3E1&4R5);H-P& 3Z$YK@[
M?2Q#XA\(F/0[JVT^(7&8)4>7RD?(7>2" 223CMFC4+>XTOQ1(VA"Z4R7Z?:-
M'FLR\$R@C]]&V,+CKU[4 >F66J66HRW,5I<QRO:R&*95/*..QK.\2:U+IAL;
M*S5&U#4)O)@#_=7NSD=P!3=#US3]0UC5]/M;*:UN;24>>9(0@E)R X/\0XZF
ML;Q9#-#X^\):@,BW$LMNQ[!G7C\^?RH Z&]\0Z3HIBM]3U2&*8J,F0@$YXR<
M<*"?7 JG>Z[+I7B*QM[EDDT[4SY=O*, Q2@9P?56['UKA]?CCL/&.LQ:WI^K
MW-CJHC\A[!G*OA0/+8 ^HK5\76DO]A>$],@@,5S]N@*0F0N4"#)!;J<#J: /
M0+N58;2:1ID@"H3YKXVIQU.>PK!TWQ'866B63:OXATZ>>96(N5D5$F 8C*C/
M;I]16SJ8!TJ[RN[]R_R[<Y^4]N]>0:4UN+#P+#<1C-K<S"X22$_NP6.-V1P.
M: /0O$'C33M-\(W.N6%W;7:@%("D@97DZ8X].N/:H-(UM[>W.IZIXFT^YTJ>
M-/)=D6)ED_B'H1^M<.YB3P=XXM$0J);]VM80A^<97E!CGIVK<-XFGZ]X>U>\
MC+Z++IGV7S?+)2WFX)+#MG&,F@#N'\1:+'9PWCZM8I;3?ZN9KA0K_0YYJ >+
MO#C1AQKFG%2I;/VE.@[]:\HU#3[>&""62!5TBX\1B6VBDBPODG&Y@#_"?RXK
MI[VPT&Q^)-C$+&QALSIDBR 0J$!+9'; .,T =M!XCT6XN8;:#5;*6><;HHTG
M4LX]@#S4DFN:5%J*Z?)J-HMZW"V[3*'/X9S7CEFUA8^#O#LL<<4=Y;:QND98
M\2+'N;EB!G&"/TJ'Q5?PR76J-'FU>'6$E-K]F9VDQC,I<] >R@T >JP^,]'O
M]6U#2+2_MUN[5/OR. I;G..>=N.:LZ5J?V?P_!=:SJVG2,<A[N*4+"W)Q@GC
MI_(UQ>F7&FQ^-O%,,\2C[=;)/"9("H9=A+'D<?C6)X=O8[&S\(WU^\9TF#[3
M!-N&4@E+':S>F01C- 'KW]JZ?]C6\%];?96.%G\Y=A^C9Q3K34K*_,@L[RWN
M/+.'\F57VGT.#Q7C>OV]JFE>(KJW6'^QY]3MVM!M^1W_ .6A3V]<5U?AYM/M
M_BMJD&G&VCMY=.B8)!M"E@1G '?!H ]#HHHH **** "BBB@ HHHH **** "N
M(^+@)^&FI@?WX/\ T<E=O7%?%K_DFVI]_G@_]')0!UM@I33K9&QE8E!Q]!5B
MHK88M81_L#^52T %%%% !1110 'IS7E^K^&Y7UO5/$?@K5A::I;R.E]:RC,<
MK#D@@],^O3Z5ZA7.ZAX'\/:E/+//IR"69BTKQNR&0GKNVD9H \KE\47GB^\T
M&TO3:Z997%K(QCG=XX)9@Q7.4(/;(&<9J:VO6MM8T7PUKGB 7NB>9,KSQ.R(
M[@?)&TF<D GUQ7JU[X2T'4M,M].N]+MI;.V&(8BN!'],<BDN_".A7NC0Z1<:
M9;O80?ZJ';@)[C'- 'DWB?1])AMM"M[;4YM4BCUH6_G22'$:$ ^6&!P0,]1Z
MU>UF_N]!\8>*?[)FG*P:(CP+YK2!"2!N&2>F2:],F\):!/H\.DR:3:FQA.Z.
M'9@*?4=\_P Z?:^%]%LKXWMMIMO%<F/RRZKCY,8QCIC% 'F4D":;%X(U;1IK
M@7>IRQQW@\]V-P&4;V;D\@YY'3-<REDUOX2N-?2ZNO[2M]>$,4IN&.U<\C&<
M'ZU[CI_A30]*N9+FPTNV@FD!!=%YP>H'IGVJN? WAHVIM3H]MY#2>:4P<;_7
MKUH Z&N#EY^-T/\ V!C_ .C#7=1QK%&L:#"J H'H!6;_ ,([I']K_P!K?V?;
M_P!H<?Z1M^?\Z /%OB#:-K7BK7]0LD@MFT:*+[1'*2/M@SDY'0@8 QW KT37
M)T\0?#G;%J2:3--IZW#Q*5X0IG80>0IZ<5T.H^%="U:^6]O]*M;BX7 $DD8)
M..F?7\:;>>$]!U#4%O[S2K6:Z4!1(Z9X'08Z&@#%\,W,^H?#G3(KJ^&F7L]K
MA9$"JR@' 95;U4#\Z\Y>6Z7X>V%E=2K+86_B 6XG4;1-$K9W'U&<\U[+JWAG
M1==:)M4TVWNFB^X9$R5]L^GM2:KX=T_5=!?1WA6*T*A4$2A?+(Y!7TQ0!P_C
M^PL=3^(7A6TU ,;:1)U<"0IG@8Y%1>$H%M_"_C2S262;2+>6>.S:1MPVA#G!
M/49Q7:Q>'(;_ $NVMO$=M9:E-;95)6BSD= <'H2 ,XI-:\/-?Z&-$L&AL=/E
M'ESB-.1%W5 . 3TSV]#0!B?#+5H!X,T/3KJ\C_M"2V:2.!F^=HPY ./3 KH_
M%4BQ^$=99B!BQFZ_[AJH/!^GKXAT_58XXXSI]OY,"1H >A'+=P >!6U>V-IJ
M%J]M>V\5Q ^-T<BAE/X&@#F/A<P/PWT7':$Y_P"^FKEOB1;R#6Y=04V-]!;6
M0%Q87+E)(T))\R(GC=QV_*O3-.T[3],@,&G6D%M"6W%(4"C/X5%?:!I&I7*7
M-]IEI<SH %DEB5B .1UH \<O+;2M<\5ZU+-#OAB\/1S0)*YW(P1=I..I%5;N
M]M-2T?PY;S7$331:-+*9+Z7]POWAPO\ %)Q@?A7MLNA:-=2O--I5C+*XVN[V
MZ%F'3!.,TP^&M"+1-_8UAF'_ %>+=/E^G% 'D6GWL%QIWPR#7"S2QW+)(H8%
MD/& ?TKKO TBOX^\;;74YNX^ ?0&NP7PYH:A -'T_"$E/]&3Y2?3CBI[;3-.
ML9Y)K6QMH)IB=\D<2JS]^2.30!P?Q8M+*\D\,07?"RZHD;G<5_=G[W/Y5Q&H
M%],G\5Z?I>(]$BU&V^TQ0.<I$?O;>>A. ?PKW6[TVPU H;VRMKDI]PS1*^WZ
M9'%-BTG38!((=/M(Q*NV39"HWCT.!R* /)=<T[3F\47\7A]+9M,DT&::[A@P
M8MX5O+.!P&SM([UVOPR?3?\ A!M-CL#!YBPI]H$6,B0CG=CO746NG6-C"T-I
M9V]O$QRR11*BGZ@"GVUG;64/DVMO%!%G.R) HS]!0!YCXCLM$O?BYL\0) ;(
M:067SVVKN#=0?4#-<+:M<6JZ$FMWL]EX<=KC[)))")54$D*2K ]NA(XSQ7T+
M=:=8WS(UW9V]P8SE#+$K[3[9'%.N;.UO(?)NK:&>+^Y*@9?R- '+?#>WL;;P
MPZ:9>75W8_:'\F:X4+N'&2@[+G./QKDM?M=,U'XM:M'J*021Q:*642D85L9S
M]1UKUN.-(HUCC1411A548 'H!4,FGV4LIEDM('D((+M&"2#P>?P'Y4 ?/L5[
M&EIX.DU749K725LID$ZP"9$EWL/F# C[N.W%;<\>F6/AWPK%I]_<W%DVNAX9
M+O"%T&<LHXPF:]G?3[.2U^RO:0-;_P#/(Q@I^72E>RM)$1'MH61!A%:,$*/;
MTZ"@#P75[_3I/!?B6+5]B^(I-4W[)5_>;=Z[=O\ LA<U[II\JSZ+:RP,&5X%
M9"._R\5.]I;22^:]O$TF,;R@)QZ9J1W2*,N[*J#DDG % 'BNA:AH%Q;RZ-XB
ML9IO$J:JTHB5&$LSE_E.\?P@'G)Q@5;\):/X;O=4\9SW5G9RR6E](\+,.$C
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M#\P*E3C\3CZU[((T!)"+DG)X[TN!Z4 >.ZA%<:-H?A3QGHL2SW$-K%97,?\
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M%YI#$Q$EJH!*DDGY\X[ 8-53XSUF'3]-UZ:SM6T6^F6/RTW":!7.$<G.#VR
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M.30!VV*CD>*.-WD8*B@EBW0 =2:X2]\?7]AKL%K<Z?;16\U^+-8FF/VC:?\
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MEYH.Z8'L^.!CG.*S?!YN_P#A9WB8W>GI9RR0PLR1R^8I]\X&<]>E 'HM%%%
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MPDXX/'0TR\^(_A2PN)K>XU>)9H9/*D4*QVG\!T]Z )-&\#:7H>KKJ=I<7S7
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MD#@]*X#5K)OLGC35_MUZ;O3-55+0FX8[!O ]>>#C\* /?:3<*Y;QAJ6H:?\
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MPA@>E+7F'@.UCM?$$$UKX@M+J"[LBQLK3>R\$?O&W,=K9.#TR2:]/H ****
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M)Z'U%)IOAC0]'@N(=/TNUMXKCB94C&)!Z'U')XKC/ASXT@ET;0-&O4U WMS
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M-=S0YP)VSA0WJ!UQ7H%<EXF\*WU[KECXAT.ZAM]6LT,6V=28YXSU5L<CJ>:
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MZ!+;VUMI<L4D=G"SQPN[,P0'N<$9([YK&T_0M>L_#/AJ0:->F?3=7DFEMQ&
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MMO*T6\73[L.T%[E2A"G'S <KG'&:OZWXEM-%FMK9HIKF]NF(@M;=07?'4\D
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MVE\L"V6R0X\P$'>_KTQCW)JS;:!XSU?1;^S\0W]@N^R>V@C@!P[$<2.?7Z4
M<SJ=Y?ZG9?#K4-2BC%W)>(0XDW&0':<G@8SZ<UUMEX_E>+Q''?Z='9WFC\B
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M7#+(HR58'(./J* .>N/%FO:/JT.G:M8V$DEY:R36IMG90'12QC?.<]N1BI/
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MQ%-)N3<H?LO+DGH?F^M2VOP[N=.U.X:U\0W<.BS3FXDTY$ZG.X@-G(!/H.E
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M>"1I)(U&2 O1>1T."3Z5RO@OQE#HJZA::F-1EC?69+=;IU+QQ%FPJLY/M[T
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M&9'QT'7GVH R/"G@HV^MB_D\.PZ);B*2*2V%Y]H^T!@!AA]T*.M=9H_@_0-
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M=P4,W<GH !R3["@!@TBV776U@&7[4UN+<CS#LV@Y^[TSD]:OUQ'B_P 6'_A
M[K6O#>IQEHI$3S%0-@E@"I!Z'GN*G&K:FGQ'L]):[#V,NFF=HO*4'>#C.>M
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M2M/1M-M]#\<V]MILQMA<^'#-*[2$YDSPYSZ8H ];$B,Y0.I8=0#R*5B%4EB
M!R2>U>#^$(;36=9\-^68X9K0R/?SR70!NV))7 SN8YKO/B?=6Z:5IEG<%C]J
MOXE$9?9$X!R1(>R=,T =U&8V3=&5*GNO0T-+%&P5Y$5CT!8 FO-_A/<QB;Q'
M9+<6S"._)CBMV_=A>Y0$YVYQ^E8GB\?8/%M[JDJ6FJ:>;F!)D+[;FT<%<!,]
MC[<<T >QF:(*S&5,*<$[AP:CDO+:*2..2>)'D^XK. 6^@[UX;K=S86UA\1[6
M62))WOHFMXB0&)W<LH_$\BKFN2VT<[:NK6&KV7D6D-S:EL7%N0J[3$Q[$G)
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MD;7?<N3[G&37JM !1110 4444 <-XOM-8A\9>'=;TS3)-1CM%GBEB20)MWJ
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MUAIL5Q"OEA6+LRI\Q'7ELU?7X66$>G_9(]6U)2M]]NBD\P$QO[<=>>O6M)O
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M!4=W96E[%Y=Y;0W$><[94##/T-6 <BN?\<0)<>"M6#IN*6SR+@X*L 2"#[4
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M)"4F'G-EV("_+\O3 !YQ52Q\$Z__ ,)3;:U-!IUC=0QRK/-:2'9>$@A=T>T
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M1M;U6YU'[59K)IDS*%+R<J5XZ')'Y5T^F_#_ $G2[O3KFVN=0,FG*R0"2XW
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M'XKJ.&YFF%S.UP_F;>&;KC % &Q1110 4444 %%%% !110: ,_0O^0!IV/\
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MOVF>,Q3/)([^8IZA@Q(/3O0!XC9V\">)?AY>"[EGNKMU>X,LID.[S<9YZ?\
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M'=]'KUY=Z7XBN-/L-1?S+VUBC!WL?O%2?NYY^F:DO/A]=33^(98-7CC&L0K
MR&USY2J HP=_/ ZUW"2(Z;U=2OJ#D4HD0H7#J5'<'B@#A[/P%>V.LZ'J,&LJ
MCV%DME.!;C]ZBDD8R3C.<'Z5TVOZ??ZEIA@TZ^6SN!(CB1DWJ0#DJ1W!Z&G:
MGKVFZ0+;[9=1H;F=((AN&6=B /PYR?:M($$9'(H \SD^%ERUK)Y6I6T-Q/J$
M=],([<K$&0':JJ#P.234^L?#:]UC4-=N7UF.%=46(;8X#P8\8SECD<<UZ&TD
M:YW.HQZFAG1!EV51[G% 'GMO\/-7CO\ 4[R77X99-1LA;3@V@5<@8& #P *E
MC^'UZD/A2(ZG 5T%RP_<,/-R1_M<<"N]9U099@H]2<4-(B@%G4 ]"3UH JZI
M:2WVD7=I!*L4L\+QK(RY"D@C./QKBX/A_J%O9>%[>/5+?_B1RM(&,!/F9/3[
MWIFNAU/5-9LK^\\K38)=/ALFG29KC:S2C^#;R<8[T_PEKK>(_#-CJDD:0RW,
M9=HE;.W#$?TH Y2;X<:G/HFJ:8^L6XCO[_[<SB!LJV<D?>Z<"M=?"%^/$]_K
M)U&W+75A]DV"W(P0.&/S&K?A7Q'<:]<:S#=6L=L^FWK6V$<L& &<YP*Z165Q
ME2"/4&@#SZ/X<WD.C>';6+6$CNM%N'ECF$&58,<D%2>M=M?VUQ<Z5<6L4RI-
M)"T:RLN0"1C.!5MF5!EF"CU)Q4-U+(EK,;=4DN%C9HXRV-S8X!/8$]Z .)LO
M 5_9P^&T&IVY.B%]A\@_O W'/S>]0,++P!9:H?$%R;NWUJ\DD6*WMR2&<?,O
M7IC%=MI5S=S:3;SZG#%:W3+F6-) RH?0-WK'\;>(9?#>@IJ4%G%=@7$:,';
M4,<9'KUH 9\/O#R>'/"=O;;6668F>0/U4MT4_08'X4_Q9X8G\17&D307<<!T
M^Z%SAXRV\C&!U&*Z0NBL%+*&/0$\FJ":U8S:K<:5#.KWL$8D>,'[H/3/O[4
M9&L:%._BBU\2+<82PM)8Q;I#O>3<#G'/7TKRKPK]JLIK>^TC6[&ZU*>3+Z>]
M@3*"Q^8%L?+QG)&*]JT6ZU"XTF.?5[:&TNR6WQ1R[U49('/TQ5\"!<R@1C=U
M88Y_&@#@I_A[J$^DZQ8MJML!J=Z+QV%N?D;() ^;IP*U[3PI>6GC"378]4"K
M<6\<5S L(^<H !@D\#]:ZD.K D,"!P2#TI%=7&48,/8YH Q/%F@2>(]#^Q0W
M7V:=)HYHI2NX!E.1D=ZRQX0U.SU:XU+3=7BCGOHE2^$MON61@,>8H!&TX[=*
M[&H'NX4M9+GS%:*-2S,IR,#K0!5T/1[?0=%MM,M<^5 N 3U8]23]22:Y'4?A
M]J$DFM0Z;K2VVG:N3)<6\D&_:YZE3GC-7O#/B37->N+6\_LZU_L6[$C),DI\
MR':2 '!ZDX[5>\9>(I_#&E17T-JEPK7$<3AGV[0QQD<<T 5(/"%[#X@L-2_M
M.-UL]/-BH\G#$?WNN,YQ6?)\-UU:]DNM?N;>XE:V:W+VL'DM)G^-^3DBN\WJ
M"%+ ,>@)Y-'F(,_.O'7GI0!QFD>#-6M[26SU?Q%-?VJV[V]O&L838K+MRV/O
M$#IG-5M.\!ZM:7FB33Z[%)'I"O' BVV/E88Y.>3C^5=[N''(YZ<]:6@#AX_!
M&H2ZK'JE[J-M]O@MY88KFV@,;N7! :3G!(SVJ[H?A.XL?$DNN7LUJUT]L+=O
MLL1C$O.2[C/WOI75!E)(# D=1GI1D9QD9]* %HHHH **** "BBB@ J.?_42?
M[I_E4E1S_P"HD_W3_*@#.\,.LGA32'7[K6<)'_? K5K)\+@+X3T=1P!90@?]
M\"M:@ KB_BQQ\.=0/_36W_\ 1\==I7%?%@9^'&H_]=+?_P!'QT =C!_Q[Q_[
MH_E4E1V__'O%_N#^524 %%%% !1110 44'I7"GQ5XDU&:_N-!TRRN;&QO3:/
M'(Y$TI4C>RG.T=>,T =U17!77BO7=0?79M!2R^SZ,2CQW",SSNHRP&#\HZ@>
MM9X\>:_K6IZ-;:'%I\,>IZ>UR&NPQ*.I(8<'H"IQZT >C7EY;Z?:275W,D,$
M8R\CG  K$TSQQX>UC51IEC?B2\(8^48G4\#)Z@5YMXG\0:IXJ^%.GZE*\$$H
MU%8;A$CR'<-A2.>!ZCG/M747>M7.A^/+2TOH=/DSI<MU<7<5L$ED* G&<D@<
M=,T =EJFN:=HS6RW]TL+74@BA!!)=O08^M: .17BVN7NM^(8/".L7MS;K8WN
MK1M#:QQ8:(;L*2W<XS6G)XX\6ZA?7ESH>FR3VEK>FW%N+<,KJO#$OG(;/8"@
M#U>DR/7FO([OQEXS2V\2WOGZ=#'HEPBO ("Q<''R@Y]^M6[6[UK4/BPGE:HL
M,3Z2DZ0O#N55;!*#D=^=W6@#T/2]9L=:AFEL)O.CAF:!SM(PZ]1S3-<UW3_#
MNG&_U.?R;?>$W;2V6/08%>=6OC#74\)3W3264$L>LR6<URD(Q&@QRL?\;'GW
MK+U/Q1?^)OA+K4NH[&EMKY85D$?EEUW*02O8\T >R2W<$-FUW)(%@5/,+GLN
M,Y_*JVC:S9:_ID6HZ?+YMM*2$8J5S@XZ&G* =#7&"/LW!_X#7DWPIUR\U*UL
M]"L;V.S2P1Y+D.@=Y]SG 4'H!W/O0![/17C<_C+Q?'8ZIJS:A9_9]*U7[(]N
MEK@S+O"]2>!^M=!)X@U[Q#J?B"+1;Z.QCT;:JQM )#</M)(8GH,C'% 'HF:0
MGC->41^.M6FD\.:K<WB6>BZM&\,VV)3Y$ZY&03G@D9YI/"WCO5]:$>C27JG5
MCJ6WS# JYM0NXMC&,X''N: /1-(\0Z?KDU[%8RL[6<ODS!D*[6].:U<UXROB
M"[\.MXVN;%%:[GUQ+:(MC"EL\\\=N]7+_P 6^-/#5I<IJ5NC&Z>.*PGN&A#H
M['!+*A(('K],]: /18O$6G3>(9="25CJ$4/G/&48 +D<Y(P>HK5KR>!=2T?X
MH:I-<7C:E=PZ"TL>8U0OAA\N%'K3-!\7^(-0U#0VBUB&\AO+>2XOHA;+_HNS
M)V\8(!X'- 'K>:*\I\/>)_&NNRZ?K%O;B33)[DI/&_DI&D9; VG._</?KZ5Z
MMF@"O>WD.GV,]Y<MMA@0R.P!. !D\"HM)U6UUK2[?4K)RUM<)OC9E*DCZ&N%
MU_4M7U^[\5Z=9:@+"UTFT 95B5FG9HV8@D]!@8XYKG['7=7TSP;X7M=/O/(B
MDL))"MO )[AW4L1\AZ)ZF@#V8NH(!8 GH">M+FO&+34]9\2^*O!%X^K-"]U:
MRRE(X1L1U5@_!ZE@,>V>*L'QUKUMXKM('O8[B&;539R0Q0 PHA( Q+U+^HH
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M-*N].33[C3[:6R0 ) \8*+CI@'I7)>*_!<FK:KX;6QL-/_LK39F:>"3Y0R'
M*A=I'0&@#S^<MH]UJ6FVDCCPE_;MM$Y#ED"$$R(&!^[G /X5H^*;*VTZ]\56
M6DJJ:0VBBYEB@?\ =QW ?"D '@D#I7KL>C:;%IG]FQV%NMC@K]G$8V8/7Y>E
M11>'=%ATZ33X]+LTLY3F2$0KM<^XQS0!XSK'A;0--\->#=32W!>^O+7[5+-(
M2&4KELY. /\ "O<[5+=+.)+3R_LX0"+RR-NW'&,=L55GT/29]/BL)M.M9+.+
M!C@:(%$QZ#H*O(JJ@5  H&  .!0!XCJNC:)>>(_B ;V4JUI;K/;!YV&V3RR2
MP!//S<?C4WA97UW6XK3QL@:)M&C>SCN6PI'\3C)^_COUKK].\#^;XUUS5M;T
M^PNK:[=&M2Y\QH]HQR".,C'?C%=9?Z'I6J^7]OTZVNO*_P!7YT0;;],]* /%
M[.'5=1\.Z9-)/;ZG]D>Y,6G:A(1]JM@0N]6/&Y>0">W2EOYX+K1;34K2TBOM
M+M],C2XTR\D(N+9<M^]B8\$^X'8<5[+>>']'U".*.\TRTG2$8B62%2$'H..!
M4=SX:T.\EBEN-(LI7A4)&7@4[5'0#CH/2@#SDW,=S\0;N>W,JQ3>%S((Y221
MD#''8XQ6!X?TRPLM)\"ZGI4K1ZW<W_ESJDA)DBW-OW#/   _.O;#HNF'4?[0
M-A;&\V;//\L;]N,8SZ8XIEEX?T?3;E[FQTNSMIG^])#"JD_B!0!XMK=]<VD/
MB80S/#:R>)0EY*JE@L1!^\!R5)QZ>G>NZ^'=I9V.HZM#I^MQ:C;OY<Q2UBV6
M\+-GA?F(R0!D#VKKT\/Z/''<QIIEHJ76?/ A7][G^]QS^-3:?I=AI-O]GTZS
M@M8<[MD*!1GUXH P?B%H/_"0>#KVWC7_ $J%#/;D=0ZC('X]/QKE="G7Q-X7
MU7Q'/:_9RFDFRB.<'*(QD88Y'S8 ]A7J>,U4_LNP^PO8_8X!:/G= (P$.3D\
M=.M 'DGA^>.YD\$Z=JY631Y],=U28YCDN S?>SP2!T!]:JZD);;P3XELU9FT
MNVUN..P+-N 02 E5/H#_ %KUZ3P_H\NGI8/I=HUFC;D@,*[%/7(&,"G3Z'I5
MS9164VG6LEK$<QPM$"B_0=J /%?'MW!=:AKUY:S(EQ97L$0DN9CYZL#C$('W
M4[DGK72Z-9:/-\3?$)G6T#S6<,D." 273+LA]?IZUZ!+X9T*=W>;1["1G4(S
M-;J20.@Z5.=&TQIQ.=/M3*(O)#F%<^7_ '>G3VH \=\,7*2:7X.T_5&5M%GD
MNA+YI^1YPS;%?\^,U!KUBEOINOV<3,VC6NKVPL\2G;&SX\Q%YZ#(^E>RGP_H
MQT_[ =*LOL>_?Y'D+LW>N,8S[U(=%TMK*.S;3K1K6,Y2%H5**?4#&,T >8/8
M6EAK_C31;*]&F6,EE;L'+,R([$#)YS@YP?8UO?#Z80:KJVF3Z=!:7\"1&9[.
M3=;S#!"NH_A)'45U_P#8.CDR'^RK',B[7_T=/F'H>.1P*EL-+L-+C:.PLX+9
M&.66&,*"??% '+_$:\FL]*TUF9DTY]0A2_9201#GD$^AXS6&VEV=KXQU:TTM
M(3HD^CF:[MU(:%9<G:1V!P :]+G@ANH'AN(DEB<89)%#*P]"#UJI!H>E6UE)
M90:=:QVLGWX5B 5OJ.] ',?"JSM8/ 6G3P11I-,A,K(!EB&(&?PIGQ7*CP?&
M"P&;Z <GK\U=?8Z;9:9!Y%C:0VT1.[9"@49]<"B]TZRU&-8[ZT@N45MRK-&'
M /KS0!XIXTNXY=3UG4+*>-)[34(%\V>;;.I P1$!T3N2?2MCQ)8-:^*[B"SM
M4NK7Q39B--I^2.<$'?GTQ\W%>E3>'M$N)9))M)L9)) %=F@4E@.F>/85>^RP
M#RL0Q_N?]5\H^3C''IQQ0!YW\/4N=1E@AU*U\N;PZCV(<_\ +20G!8?10/\
MOJNQ\5W%Y:>$]4GT_/VN.V=HMHR00.H]ZU4ABB+E(U0NVYBHQN/J?4TXX(P:
M /*EMK*'_A#-3T*7%[>2QQ79BDR9XV3,ADP>2".O8U8^%VBV4Z7.L2--)>P7
ML\2.9F("],8S7?6FAZ383236>FVL$LF=[Q0JI;/7D"I;#2[#2T=+"S@MED;<
MXA0*&/J<4 6Z*** "BBB@ HHHH *CN.+>0_[)_E4E1W'_'O+G^X?Y4 9GA4D
M^$=&).3]BA_] %:]9/A;'_"):/CI]BAQ_P!\"M:@ KB_BN0OPYU$GIYEO_Z/
M2NTKBOBSS\.-1_ZZ6_\ Z/CH [&W_P"/>+_<'\JDJ.W_ ./:+_<'\JDH ***
M* "BBB@ /(K@)_A[J4&LWDVC>)+C3]/U"5I;RV6,,=QZ[#VSS]/>N_/ KAYO
M&>LMXQO/#EIHMM)<6\7GAWNBH=#T_AX/M0 Y_ 4]G>:B^B:M]AMM3C"74#P>
M9R!MWH<C!()IR> C::WI%]IVH);Q:;:-:QPM!OW!LY).X<Y.:O\ A3QC;^)8
M+T26[V-W83>1=02L"$;GHW0C@UT9EC!4%U!;[N3U^E 'GO\ PJ^3_A%?^$?_
M +>;[*+O[6'^RC<&SG'WNF:V+WP6VH>)].URYU'?):6S6TD1@&V=6#!L\\9#
M5U,LT4$9DFD2.,=6=@ /Q-1B\M28P+F$F7F,"0?/]/6@#@7^%;?Z+;P^)+Z+
M3K*Y^TVEJ(U/DG.<!CS^=32?"Z'^U[BYM==U&TLKMM]U8Q/A)3_%DYXS]*[:
M;4+.WADFFNX(XXSAV:0 *?0^](=3L%2)VO;95F_U1,J@/].>?PH Y&X^'*W$
M7B"$ZO.L.M2!Y4$0^3!R,<^PJ=/ ABU?3=4AUBYAN[2T6TD=$7]^B],@YP:Z
MX31&8PB1#*%W%-PW >N/2B66.&-I)75$499F. !]: .$7X8Q);*B:U=I/%J#
M:A#.J+F-V^\,=#G Z^GUIO\ PJR!M,U.P?7+]X=1G$\P8(?F!R3TZD]ZZZ77
M=-31[C5$O();2!"[R1R!@,#./K[5RO@GQ#X@\3&+57FTU]+G#[K>/(FM\$A0
M>N<X[T =A#9/%I:V1N&<K%Y7FE1D\8SCI7&V?PLLM/73GL]4NX+JP=FBN8U0
M.RMU5N/F'7KZFNFUNYOX;C34L;JPA$EP%G%TQ#.F.53_ &JY*Z\8:W#J'C&W
M5+3_ (E$"2VN48@@@GYN>3C\,T 66^&5N^EZAI[ZQ>-#?W0NYR53)DSG(X]:
MO7/@.&2]GN[35+RRFO+<07OD!<7  QN(((#8[CUJ_P"%]>75/#NE7-Y<6ZWU
MU;+*T08*3QR0O7'!JZVOZ2E@;]M1M1:!MAF\T;0WIGUH S[SP3HU[X:MM D@
M/V&V9&C4'D%3GK[Y.?K5F'PSIUOXEDUZ*$)>26RVYP %V@\'ZXP/H*S[[X@^
M'+&\T^V.HP2F]8A7CD!5 ,_,Q[#(Q6HOB71&NA:KJUD9R<!!.N3QGUH Q7^'
MFESKKD=U-//%J\GG2HV!Y<@)PRD#@C-5;3X6Z/#I%W87=S>7QN %%Q<2;I(0
M.FP]L'FNBC\4:'-;W,\6J6DD5JF^=DE!V+ZG%8<GBY-=\/VFH:%JNGV3/<J)
M/MK#A,D%<#^(X!% %"7X?_V-%?:S;ZAJNJZH+%[>-)IP/,4C 7@ \?7M7)>$
MO#D]E?V#:*_B.WNMZ?:HKZV$=OL_C!/?OCK7KE[X@TC3+J.UO=1M;>>3E8Y9
M I-%[X@TC396BO=2M+>14WE))0I"^N* .;T_X7Z-IVMF_@N;T6_F^<MCYW[A
M7Z@X[X/2KW@W0M0T4:I]KO+F6&XNC);Q7$OF-&ON??T]JZ2WN(;JWCN+>5)8
M9%#(Z'(8'N#7&ZWXKN-#^(&F:?>7=K!H]S;22.TB[2K*.,L3CKZ4 3ZY\/K+
M5]6GU*#4+W3KBYB\FZ^RN )UQCY@1Z507X4:;$+'R-6U6%[6!K?>DP!>,YRO
M3@<GIZUUR:]I4BVC)J-LPNR1;D2C]Z1UV^M9VM>-]!T33+B^GOX95@D\EHX7
M#.9/[N/6@##@^%6G6T=@(M6U19+)G\J03 $(W5!QP.O3U-0CX1::@A2+5]4C
M@@N?M,$2RC$3$Y...O3FN\L;ZWU&SCN[65)89!E71L@_C5*Z\2Z+8SO!=ZK9
MPRQXWH\R@KGID4 .UG0K+7M%ETJ_5I+>10"=WS CHP/K6%!X!CRTE_JUW?W*
MVK6EO-,%S!&V0< #EB.,FNAOM:TW3+>.XOKZWMX9.$>20*&XSP>]9FM>-M$T
M-+!KB[C?[=(JP^6X.5/\>>FT>M %OPSH*>&M"@TF*YEN(8,B-I0 0I.<<?C5
M'5O"(U/Q''K::E/;W$=JUJJJBLNULYZCWKHHY$FB$D;JZ,,JRG((]17"6?B/
M7;^\\862SZ?!-IKHEG+*-L:[@3\Y)]OSH 2'X8B'3-)L5UVY\O3+DW,!\E,A
MB<X^F:OQ^ ;?^U=7O+J_FN8]6C\N[MW10K #"D8&016XFL6EGI]NVI:E8I.8
M%DD82A5;CEER<[<]*ECUK3)IH88M0M7EF7?$BS*2X]0,\T <]IO@&.R>Q^U:
MO>7T.G;C8Q3!<0DC&<@9; Z9Z4VQ^'\-AX4U+P]'JERUK?NS.Y1-R;OO <=Z
MGO?$;:'?ZQ>:KJ>G_P!EVL2-%!$<SJQ[,/<]*T+?Q;HLVC6FJ2:C;06URH*&
M651SCE>O4=Z ,F'P&8-0TN^36[OSM,MC:P$QQ_<(QSQSQ_*J"?"NTCL[2&+6
M=0BEL[E[FWGC*AT9\;@.,8.!6_J?C70])O["SN;Z(2WW,9#C 7!.XGH!V]\T
M[2+^ZFU/5WN=3T^XL8G4VZV[ M"FW)\P^I_I0!SH^$NF?V7+8MJVILK7?VR-
MVE7,<G<@8P2>YK4'@.T;6Y=1NKZZO!-9_8IHKC:PDC]SC.<\YK=M-<TN_AEF
MM-0M9HXO]8R2@A/KZ4RV\0Z1>W2VUKJ=I-.Z[UCCF5F(]<"@#!T_X?6MB]GN
MU2^N8=/9FL89BI6W8]^GS8[9JD/A99#0HM(.K7QMXKS[9'D)E7_[YZ<YKOJX
M[QAXXM_"^KZ18SE(H[QR99Y$9@B#L O.XG ]!0!TFHZ7;:MI4NFWZ"XMYDV2
M!OXO?CH<\U@Z3X&@TV\M+F;5+Z]:QC:*R%PRD6X88)&!R<<9.:Y^U^+-@WAG
M5]<F*9M;CR8;)01)SPNXG@DX)XZ 5+8:E\0-1\-KX@A.D@RQ>=#IQ@?)0\CY
M]WWB.?QH Z3PQX37PPUZ8M2N[I;N9IY%GVX\QNK# ZFG^)/".G>)A!)<F6"\
MMSNM[NW?9+$?8^GL:;#XHLK#1]-EUZ^MK*\N849HY&VG<0">.H%7+WQ)HVFB
M WNIVEN)UW1&24 ./4>M &=I_@RUMW>74;Z\U>9HVB#7TF\*AX(50 !D<9ZU
M4TWX=:=IMQ:8O;Z>RLIC/:V4T@:*%SW'&3CMD\5;U3QOI%KX5O=<L[RWNX;8
M%1Y<@PTG9:\VT3X@^-M4DL;EKG0$L[N<#;+*J,H#89<;MW0CL3TQ0!V[_##2
MY--O-/;4M3^S7=U]KE7S(\F3.<YV9ZU'K_@^&RM==UN*YU"[O[G37M6B;:PD
M&W"C:J9SG!XIOQ%\=IX9TJ4:;?V9U:)E)M9!O)4^P/'K6QIGBVR3PCI6KZW>
M6MF]Y"K'+;5+$= .M '-^"/ \-UX?T6]UB74)Y;>V>-+.[^58"V0V%P#TZ9S
M_*K4/PGTVW>Q:+6=84V+LUMBX'[I3U5>./K757'B;0[/R/M.K6<7VA/,AWS*
M-Z^H]156_P#&N@6&@RZTVI02V4;% \+A][_W!CO0!@-\++,:,-*36=06T6\^
MVHO[O*R>N=M10VTOC#QG97E[H-S9V^AO)MN;L -</P%VCTXW9]<4C_$"75W\
M.2Z)<Z7'%>2C[=!<W*^9&IQ\H&1SR??.*[&3Q%H\&I+ILNIVB7K$*(#*-Y)Z
M#'K0 )HP7Q&^L?;;HEK?[/\ 9B_[H?,#N"_WN.M:E>?0>-=5;XOR^$I(;4V*
MQ^8L@5A(/W8<<YP>3Z5Z#0 4444 %%%% '+>*_'5CX2N;*WN;*^N9;PE85MH
MPV2,<<D<\C@5DS_%K1H87D^P:@3 @>[C9$1[?)QM8,P)/? SQ4_C;2M3U+Q1
MX3N+*PDGM["],UQ(K* @RHZ$@]B:Y[6/"VN6'C/5KVR\-:;K=KJNUTDN2H-L
MX&.=W;O@=: .HU+XCZ592LEI;W6I".T%[.UIL(AB/0MEASST'--TOXD:?JVJ
M65C;Z9J*M?0/<6SRQJHD503_ 'N^"!7GGB72=>G\67-GHEF;GR],@L]2-FZ1
MA\C)!#  =.,#@8K6M+;49[[PSKV@: [PZ7#/ILUFUP@>-AE,ENA&3G(]Z )O
M&7B:/Q/X+TS5]*>\M&&LQVN&?8<YYW!201P.M='JGQ-TG1]1N;.:TOI8[29(
M+FZC1?+C=N@Y()Z'H.U<7!X2\4VW@*UTN317>ZCUL7S!)XS\@.?7\JB\6^$?
M%>NZAK#OHAN9'N8YK.Y^TJJQPC_EF$S][D9)]#S0!U5OXXO-0\2^(=-N=)O1
MIMC  3;E?,48)+D[@?F&,8Z?G3_#OB[2-.\)Z+;:/;:C?37:R?9;-W#3D*6W
M%B2 !Q_]:JVF:/XDL/%>OW4FC*UOJMFAWI<J?+98]NSG&23]![UD:'X3\1:'
M%X8UB+2I'NM,26UN[(2(&D1V8[U.<'[W<@\4 =//\5-)M](^V/8:@9ENOL<]
MJL:^9!+Z-D]^<8ZX-:WA?QA%XCO+^RDL+G3[ZR*^;;7.-VUN5/'^>:X?4O!O
MB&YMKV^BT\&\U75X;V2W\U/W$462H))P6.3D#(KJ?#>EZK:^/_$6J76G-!9:
M@D/E2/(A;*+@@A6/7)_*@"]K/B\:/XHT[1)-.GD.H ^3.KJ%+ 'Y>3UZ?G6?
M8_$:VU'2I[J#3;HW$6H"P^R;T\PN>A// Z_D:L?$+PQ=^(M&MWTIQ'JUE<I/
M:2Y VG.#R?;G\!6+H/PT_L'QQ'J$,S/IB6ZR%&;EKH KO(^A8_5J ,^_\7VV
MAV/C'4]#TV\748+J-+G[7("J.V5#A<G ]O<=JIMXCU&U^(EAJLFDZA---H>^
M2SC=6).1\^ =JCC]>F:N7W@O7[ZU\>0BQCC;5IHY;-FF4APCYP<<@D#O4]GI
M'BN;Q5::O>:$L$4>DO9,J72,2<<=2.^* .[\,Z_;^)] MM7M4=(IP?D?JI!(
M(_,&N?U7XDV6EZK- ^G7DEG;726=Q>+M"I*PR%"DY;ZBK7PWTC4=!\&6^F:I
M;>1<P229 D5PP9BP(()]<?A7 >)O"/B_5KK5G?1H[N=[U)K6\-TJ[(5/"*F>
M#QR3S0!UVH?%&VL;W5H%T/4YETMU6ZE55"HI_BZYQZ>OM6G9^.K&\\60Z"EM
M<!KBU%U;W+8$<J%=W'.?4=.QKBY/#/BJYM_&AFT79-K:1" +<QD*5X.3NI_B
MO1)9]"\+16=R++Q19>39+&DRF0*R[7SM)XP"V?3- 'I&A:U'KVG-?0V\T,/F
M,D9EQ^\"G&X8)^4G./I7EFKS#Q/\1M9TS7K:^BTZRM5,;QSJ@M /F,QP<'/X
MG! Q7KUA9QZ?I]O9PKB*"-8T ] ,5YZWAW5K_P <^*'N--F@T_5K(6D=T)$(
M7"@;B,YP<?6@"UI'Q2T66\M;&X6>UMYH"UM=W$J-Y@4<EP#E"<$\]:Y_7_$T
M^L^,_!EU#87EII\E[F&YEEPERF1SL!XXYY[&F:3X)\1W6FMX?U#0])L8((FB
M.J1HK2S\$+M[C)QDD X]Z>F@^,[T>%K&YT*&--#N )+C[4FV1  H('7H/_K4
M =,?BEH_]J00B*1K":X^RI>B1"#)G'*9W!<_Q8JO_P +:L/M-X/[$UC[+9R/
M'<7 A!6-E'0X/&>?TK$T+PCXFT34#I$>BZ3):I<F6+6945I$C+9Z=2WIZ5=T
MSPWXHM/#OB^WM[,6=]J5T]Q:,9D8%6/*Y!.&QGD\<]: ->S\9Q>)8=2TJ?3K
MS3KK^SS=QJ\@R\3#A@5.0>1Q4WPHF>;X;Z6\DCR2?O-S.V23YC5RGAGPGXBT
MKQ"VH?\ "/PV\%QI)MI5-X'9I!SELG[S$#OC!ZUV?PYTG4-#\%VNF:G:"VN;
M=G! =6# L6!RI/KC\* *NK?$FPTNXO\ ;I]Y=6FG3+!=W,.W;'(W0 $@MCH?
M2K%[XZ2.7R+#1M0OKJ.!;FX@C"JT$;<C=D_>(YVBO-;^SUC5_$?B*33-'^W:
M')? 745O<K&DS1]VW<@YZXP#75Z3#JT&MS^)](TAKO3]=M(\VYE5)+:11M&<
M\%,=Q_\ K -VW^(FF7M[HL-K;7,D.K9$-Q\H16&=R-SD,,=/>GWOQ TVR@F>
M2"?<+UK&!<H/M$BG#%23@*.Y.*YZY^'=[;?#:VTRR:-]=M+@7D,J-M F+9(!
M..,<<^E3>)?!.IR:#H#:6EO=W^D.99(+D K=,^/,R3QR<GGUH LS?%C28=(:
M\%C?22QW0M)8(@K&.0],L&P0<'!'7%(GQ01[U;$>&=<6^:%YA;M"JL54XSR>
MG7G^=9.L>'?$^K^'X2-"L;2Y:_AN#:6SQKY21YR2W&YF)_"MS4]'UJ;XE6^M
MPZ?OL8=->V)$J;F<[CC!(QR0* !_B=8"QT6YBTS4IVU;<(8X8U)#*<,O4<@_
MI4<?Q4T_[+-<3Z/JL4=M<"VNW:-=MNY.,$[N>O:L+2?"WB.RM?"$,VCL3H]W
M--<%;B(@JY.-OS<]?TI+SPEXDNO#GBFP72@LNIZH+NWS/'C9N!.?FX/R_K0!
MU&O_ !*TG0[V:U$<ETULJO<F-T7RU;T#$%FQS@5#=_$VS2]GM;#2-1OVBM%O
M-\*J%,1 .[).0,'TK(G\,^(=*\57&JZ;HNGZE#J<<?F)>,NZUD"@'GN/7&<U
M9;PWKT'B+4[H62W$5QHOV!9(Y$0&7 R=O&%SF@"Q=>/;VXU_PU!I6G23V&J0
MM<%BRJ[ *V5&3@;>">>>@KK-?UN#P]HDVIW,<LD<6!LB7+,20 /S(KS^P\*^
M)=.'@^[BT^%[C28I;>XA>X4##9&X$=1@_6NP\;Z?J^I^&);716'VEG0O&7V&
M6//S(&_AR.] %&U^(NG&PUBXU"VGLY=)Q]IA)60\_=VE3@DGCZTMO\0+?^TI
M['4-,N[)H;7[8\CE618<9W$@YSVP >:X:[\-ZEH&E^*Y;O2K"VL-3@ACMX?M
M.X))N"A<]SDYR>,]SS5C2M&UAGFTOQ!ITB76K6C6,.H&[24QHJ;@-H_AXZ^M
M '3V7Q/TZ\OUMA9S@2P-/;F.2.0R!0200&^5L G!I^E?$FVU*YTQ9-)O[2VU
M(LEM<S*-C.,_+P?;K65X<\/>*+2U%G>Z1I-LEK;R1BYMPIENR4*J,_P]B3P>
M*BL?"_B"#2O"-G-IY/\ 9=Q(USB>/[C9 *\\_>H Z*'Q[!<75J(=+OI+&[G:
MV@O !L>0<=,Y"D]&-/T[Q[:7VBZE?O8W,,FGS_9Y;9BID+YP .>Y/%9'AO2?
M&.@/'H16S.C03EUU$N/,\K=NV[?7J,XXS21Z);7_ ,4GO]-OHY;!X4N;Z*)P
MRF9#B/..,]3_ ,!H [RXOH;/3I+Z[/D0Q1F60O\ P #)SCTKG(/'$37UA#=Z
M9>6EOJ0S8W$A4K,<9"D _*2.@/6MGQ!I0UOP]?Z7YAC^U0M%O'8D?RKC[7P]
MK>I6?A[3-6L4@CT:=)9+A9PPG\L87:!R,\9SB@#6\.^.H_$NHF"TT;4H[=6>
M-[J6,"-77JI()JYKWBE-&U&UT^&REO+VY1I%A1U0[%ZX+=3Z#O5/X?Z3J6BZ
M5?6VIVRPRRWTMPFUU8%7((Z=.E5?'F@7.NM%$FB+?1K"WE7$<XBFMYOX2"2,
MKZB@!9]9TRX\6Z)++IVH"_ELI)H&+;55,9*E<X+5!;?%"TGMK.Z_L751;7<Q
M@BE"*09,\+][/.*B30/$5OK7AN[GB^WMI]E)%<S^<H+NXP,;L$XXYK.LO"FO
MV_AK0;!M.'G:?J9NI<3(04R3P<]?F_2@#=F\7V&L>&M?%YI^I0?V>#'=VZX$
MH4CJI!].>M9UW-%_PDG@&XL9;A;::"4!9)"2R>4I7<,X)YZU(?#VM;_&S"PR
M-70+:_ODY^4KSSQUS0^@:XUQX,D2QV_V5 T=P6E3Y6*! <9Y'&>.WO0!J67Q
M!L+S5;2S^Q7D<5]))%:7#!=DK)UX!R/;(YJ70_'-MK^JM96NE:FJ)(\3W,D(
M$:LG4$@\&N,L_"OBB/5]&U.?2(Y-0L[R1KJY:\!^T*V<$#^%0.W7VKL? NEZ
MCI-IJ46HVAMWGOI;A/WBN"K'CH>M '64444 %%%% !1110 5'<?\>TO^X?Y5
M)45S_P >LO\ N'^5 &;X5.?".C'_ *<H?_0!6O6/X2&WP=HH)SBQAY_X *V*
M "N*^+! ^'&HD_\ /2W_ /1Z5VM<5\6?^2<:CGIYEO\ ^CXZ .QM_P#CVB_W
M!_*I*CM_^/:+_<'\JDH **** "BBB@ KR:\MTO?C9J<0U6;3Q_9T8,L$BJQ.
M!QD@_6O6:Q[GPGX?O+B2XN=&LIIY"2\KP@L<^_6@#RGPQX=BUN+QEX5\U;R!
M9A-#JH!W--SC)[X.>GOZUN_#R6Y\2W-K-JEH(G\/1?8E!'WI>A;\%4?B:[#5
M=+U#3]%2V\(1:?8SB4';)%B/;WX'>K?A[1_[$TI;>243W+NTUQ/MP99&.6;_
M #V H LZOIL&KZ1=:?<(K17$90AAG&>A^H//X5X#$FM6NDV=\NG1^=X.NC%(
MS+S."_ Q[?UKZ+ZBHOLT&R1/)CV2DF1=HPY/<^M 'B^OV=I9P^'&OXXH=2U*
M>6]GFNAN@0MR1(I^\0" !]?6JFCZ2NN_"=FL)$DU70[V2Y@PO( ;=M /12,G
M'M7M]WIUE?JBWEI!<+&=R"6,,%/J,US_ (@\-:E?+':Z)J%MI-C+N%XD5L-T
MH..A&,'&: *W@)KC6(;GQ3?0B*XU+:L2?\\X4& /Q.35+XIO/%9Z+*ZLVE)J
M$9U  9'EY&-P[K_]:NYM+2&QLX;6W0)#"@1%'8"I)(TE0I(BNC#!5AD&@#R6
M6+3QXF\37.C^1_8CZ*QN3#CR#-@[.G&['I72_":.U7X>::\$<2RLK"8HH!+!
MC]['?&.M=;'96$,+6<5K;I$PRT*QJ%/N5J6&V@ME*P0QQ*3DA%"@G\* //OB
MA]F34?"<SE1*FJ(=QZA._P"&<5AW]S$=?^)(\Q<FQC YZD+@X_'%>NRV\$V#
M+#')CIN4'%0F&P61RT-N)'^9\JN6]SZ]* /(+2_L-(N_AYJUU(8[&/398I)M
MI(#E,;3CW)XK+TU]-N?!\*)JB:;>QZS/<VLDT),3$?=#\8&0>,]*]W6"UE@0
M+%"\0Y0!05^HJ,1Z?.9+0);.8SEX<*=N?4=LT >$V-Y$-4\)ZMJ.E0Z?;1W5
MPDT\<9,4Q_O 8S@D\#\JO:18Z#<V_CW49M*BO?LUPSVRQJ4<(0P&W'('X=J]
MO-O"45#$A53E1M&!]*!!"F]EB0%OO$*.?K0!X#H5W9CQ#&$NEN%E\/O"J16[
M!4?!Q'ZL1_>-+<W&EW'PE\/6\/DB^MM0C2;<FUD)9B<DCD=,D>V:]WMEL90)
M+5;=@I*AX@IP>XR*D-I;% AMXBH.0NP8!H \>:XL(T\<:=XA56U.YE:6W,D>
M3*FS$?EGGIQ@#UJGI^GVJ>+[*#78H&GB\/9F^T*#^\P<9]6"X'KQ7M1:SDO%
MC8PM<HNX*2"ZCUQUQ4CVT$C;GAC9NF64$T <;\)9 _P[L!NR4:12/3YCQ^1K
M)\8"R3XI:!-K,4/]E+:3 R7" Q[^< Y&,]*]*CBCB7;&BHOHHP*;,L)C)G5#
M&OS'>!@>_- 'A$>GMI>GZ7J\T<D&DIXD\^W#(<16Y_BQU .!CZ56U.:#5-*\
M=W%BCRQ/J$%PK-&1\F2"PR/4_7!KZ"*12QX*JZ$=",@TQ(K<J\:1Q[<X90!C
M/N* *VBW=G?:/;7%BX>W>,;&"E0?P(%>2>((=)/C7QTUU#:EO[+3R6=1GS/+
M&=O^UG\:]I5550J@  8 ':HVMX'+%H8V+=25!S0!XQX:O(;+5_#=WKTD9TMM
M%\JWEE7=&DN[YE/4!L<<UF'38;33M(O+N,KH?_"1.\+2)G9;G'MD*2#Q[5[T
MUM T8C:&,QCD*5&!^%,N&M558[@Q!78*JR$88]@,]30 ^VEAGM8YH"#"Z!D(
M&/E(XX^E>,:E-;R0?%'<T3DO%L#8.2,C(]P?UKVS&!BH3:6QWYMXOG.6^0?-
M]?6@#QNV@T"^\7^&OM2V4\"^'@9MY5AY@&!N_P!H#L?2L'3H]*L_"'A.^B6W
MCO\ ^VOWTHQY@C#-U[@8Q7T!]AM/^?6'_OV*!868&!:0 9S_ *L=: /%_$20
M2Z[\1;:"-'=[*&154 Y92-Q'N,UG:MK&BWO]AVUJ8;<PZ.8WN9+<R(6V<HB8
MQO)_B]Z]\%M )&D$,8=N"VT9/XTW[%:$QDVL.8CF/]V/D^GI0!X-H=YIB0?#
M^YO #';&XBN'DA+8;<2BGCGJ,8S5C4%=H?'<>BH#;_VA;/+% N"T !WX'IGK
M7N8MH J*((P$.Y1M'RGU'H:5+>&-F:.)%9NI50": /(=:?2-6\2_VAH30"Q&
MC3_VB\:80J5/EJPX!?=C Z\"L30FTO3X?AY>(;>WG$DWVMT WX_V\<\].:]X
M6V@2-HTAC5&.2H4 '\*A\O3TN5A"6PG WJF%W8]0.N* *NA>(M,\26DESI=R
M)XXY#&_RE2K#U!YJ>_T;3=4DMY+^Q@N7MWWPM*@8HWJ*9I.C6FC1W"VP8M<3
M--*[D;G8]S@ >U:- 'F7Q/\  45]X/G_ .$?TV&.Z2Y%U)' @4S<$'ZG!S^=
M6?"WQ$T1/"6GV\LTO]HV]O' ]DL+&5G50N ,=\=:]$J-;>%93*L,8D/5@HR?
MQH \0\1_Z'\0M>O]<MS!;WVB.EF9EW#?Y:C8#TW Y''K7,:G9SVGA;P+!JT3
MJ!--(T<BGY8FD!&?0$9-?2TL$,H'FQ(X'3<H.*ABEL;X.L3P7 B<HP4A]C#J
M#Z&@#P#0'MH_#/Q#1 BQ3$&V0IPR[FQM'XC]*SKV6$> ?!D$(S=07LDDT:H<
MK\PY;CTQ7TR%55"@  < "C:,YP,^M 'S#J$GV.Q\:V6JQ'^UKNZB> &(L6'F
M%B5;' P15R_\^TO_  C?ZE+<0:3_ &:L(G6WW^4<,K#:PQG/Z5]'M!"[;FB1
MFQC)4$XHDABF7;+&CKG.&7(H ^=?$.G6%C_PAEHC7<VF"=W!OTPQB,@YV]E/
M/4"J^C6OVGP-X^M[>(R;98I8HPN<*)#\RCV7-?24D$,N/,B1\=-R@XI$MX(P
MP2&-0PP<*!F@#YQO=2TN>#X>&U0#[&RK=XB*8(9,G..>AYK!\1W4=U<:K_9T
M=U%9_P!I>=Y4BEV).[YRV/E]AUY]J^K/LMOM1?(CVI]T;1A?I3)EL[>*22=8
M(XVYD9P #]2: /&M&OK:[_: 2ZA=7AFL55'((R?(7IGOQBO;:A2"V9EF6&(M
MQAPHST]:FH **** "BBB@ J)[F".:.!YD667/EH6 9\<G [XKB/B-?:M8_V;
M-:_VC_9B-(U\VFL!.H &UAD'Y1R37%Z0AU?Q[X7N$\2ZA=K+932M-OVLNUF&
MW!'&< -Z\T >E:OX!\-ZYJ3:A>V)-TP >2.5HRX'3=@C-;.FQ:?:VOV/31"D
M%J?)\N+&(R.=I]^<_C7C^D^(-=D\4Z+OUF_N8-3O)X)9>!;.HR (01GC'WO6
ML[2]2U/0/"%]=6.HW375]KKV(:><;4&02^2/OG&-Q_*@#W[.:,UP_@I/$MEJ
MVHV.M7"R6Q19K=);L3SQYX(+ #*\=P/YUDRZAJGBG5_%<<.K7>E_V'A+1+=P
MH=L,2T@Q\P)4<=@: /3<CUK(\3>(;;POH<VJW<4TL,1 *PKD\G ^@KRJRU3Q
M-XRU;P_;?\)!=:4+[2Y)Y?(0 ;DD9,@<==H/7N<<5V?Q1B>+X5ZE'-*9G2.%
M6D(P6(D3)Q[T =K;SK<6T4Z@A9$#@'K@C-29%>86\]_XJU_4='35;W38-*L(
M#"+5]ADD9<[VXY P!BL3P]XMUKQEJVD:%?ZA<:>HMYFEN;1_+>Z=6*J0<<=.
M0.I!H ]KR*P==\4V^@ZEI-E-;3R-J5P((W0#:C'U)KSC7=2UF)M+T.'Q+<:E
M=V\%QYXTQO+E=E^XTC] %&,^N#4;ZI=:QX9^&]]?3&:XDU55DD;JQ#%>??B@
M#VFDR*XSXE:E=6.AVL5GJ$EI/<W<<06 $S3 GE8_0^]<):^)O$-MX/UZ*:[N
MHS8ZM':N\L@DG@@8X8!QU8<#/UH ]OS29'K7BUQKVO:/IWB?5]-U._N=(MA%
M#I[W>6#,^ S@L,D+S[<TMQ/XOTO2]1N6US99R::;B!3?+<3;EVY9#M&%.><=
M,T >TY!K'A\,:+;Z_/KD5C$NI3##S\D^AQZ9]J\QTS6M<T#4-&FEUB\U)-2T
M.6]D@N6W!9%C+C;^(Q6GH-IJ&JZ5HNMMXTND_M)&2[C:48:1L[5B ^ZRG(_#
M\* /4LBESQFO'_#^K:Q=2-X+OM3O_P"W(-3)FN0YW?95&[<&]#P/^!"NN\?Z
MS>:5::19VEPUNVHW\=K)<+]Z-#DG;Z$XQF@#L<BES7C7B?5-;\-W/B+1K35[
M^6%-/2^M[B27?+ =X4KN(S@]J[?P)I&H6>@K<7^NW>I&^@BF FZPDKR%.2>X
M_*@#J(;NWN))HX9D=X&V2A3G8V <'WP14V0:\#TZ^N_#FA>(KZRU"[6>7738
M>9))O6-6/,A!XW8&,FNXM;B_\.?$ZRT6/4;R_P!.U.S>8I<R>8T+K_$&/8XZ
M>] 'H$\ODPO)M9MJEMJCDX':N6L/'<&IZ+8ZG::7?RQ7EY]E"I&"8_FVEVQT
M%9>NW5SK7Q"_X1M]0N+*Q@TTW9%M+Y;S2%MH&X<X YQ7$:)J5[I/@'PL]M?7
M4*R:ZT,JQL,2IYAR&[]NGN: /4+KX?\ A>]U)]0GTN,SNV^3:S*KMZLH.#73
M*$1 B *JC  & !7D>H:MJ6E>.=VKWFJ003:A_H<]M+YEK-&#CR&0?=;(QGKG
MM5GP]=WNO:;8^*)/%36D_P!M9;JTDE_<K'O*B()QAL8P>O- 'JF11D5X;<>(
M]9@\#ZA=KJ]\;BV\0_9X9&F.[R^/E;N1CM6WK6K:EI_C9O[5OM3M+&:[C2RN
M[63=:A00#%*@Z,3G))SSZ"@#U?(J*>Z@MO+\Z5(_-<1IN.-S'H![UY=8ZMJ=
MIX[AM==O=2MWN+UQ:RK)OLKF,Y"QA1]UAQ^/6KWQ%L?M/B[P8IN;J,37K(1%
M,5 P <C'1N>M '7:%XEM]>NM2MX;>>%]/N/L\HF4#+8SQ@GBMK(KPRYMK[38
M/'>JZ?K5_;2V&HJ46*3Y9#\H._U/-;&JZIXC\1>(-4T_3;Y+22Q@A>WQ>^2,
ML S.5"GS!VY( % 'K;,J*69@% R2>@%1P7$-S D\$J212 ,CH<A@>X-<CKOV
MK4/A3=2W5U_I7]FF626TDPKL$SP1U4_R-<-83ZH+;PSX<T^]DCBN=,^UL9KU
MH2['@*K@$@#KM% 'M>11D5X[<_\ "1RWWA71KGQ/*L\TUQ;W$]A-D$*-PR<#
M+@''_P!>F7-MK,>J^*]-D\4ZO(FDZ:D\+K-M+/MW<X^E 'KFH6%GJME)9W]O
M'<6T@P\<@R#5#1O"NAZ!(\FF:?%!*XP9!DMCTR>0/:N#\/WFJP>(_"$TVL7M
MT-:T^1[F*=\H&5 P*J!Q3_">JWUOXO@T_7[C4(+^19/+WS&6UO@>59".%('8
M<?0\4 >I9I,BO./B%=WSZ[;V%A>79E%A-/\ 9+68PD$=)7?IM&"-O<UCV6H:
MOKC^!(9]9OX1J%K-]I,$FPN5!P2<=>* /7G571D<!E8$$'H17+^$KC1H]0UC
M1M(TLV T^91,-H D9@3D=^U<+IOB#5);;2]"N-4N%BN=:N+.2[:3$OE1[2%W
M^ISC/6N@^']H-/\ &7C*V%S-<K'/ !)-(7<C:3@D]<9Q^% 'HF117F\D]UXD
MUSQ+ =>GTN?3942T19=B(H&3(ZY^8$Y'/046][<>+M?UZU&KW=LFFP1BT-JY
MB#EE),I'\0SC Z8H ]'R*">*\<TG5=;\3ZIX5M[K5[ZU6]LK@7(MG\O>8RP#
MCCJ<#G\J?I'B'4[W3O#FCWFISI'=W]S!-=E]LCI$?E3?ZG.,]>E '>0^,([E
M==\C3KR272)!&\*J"\I(S\H%;4%_#*88W/E7,L7FB!SAPO&<CV) KRB(3:1I
M'Q$^R7]U'+;7"-'<>9NDSMXRW4^E7[/3S>?%.QDDOK\.^B)<$I,1AB0"/H>N
M/6@#T+1]4DU2UDFEL+FR9)6C\NX7#'!^\/8UH9%>2:;XCU672-+L;C4K@MJ&
MMS6LEWNPZQJ1A0W8GI3O$NIZYH2>)M,M-5NF@MK.&\M[B1]TL)9PI3<1D@\X
M[C% 'K.12YKS2PN=:T_Q0EBFL3W?VS0C> 7C K',#@$>@JUX%U:[EUF;3=5F
MU.'5([;=/9WAWHQ#8\V)_P"Z<XQTH ]!HHHH **** "BBB@ J*Y_X]9?]P_R
MJ6HKK_CTF_W&_E0!F^%"#X0T4CH;&'_T 5KUB^$.?!>A_P#7A!T_W!6U0 5Q
MGQ6&?ASJ0_VX/_1R5V=<7\5_^2<ZE_UTM_\ T<E '86__'M%_N#^525';_\
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MDME%$CN8HHPVXDMC+$D>G%-'A'Q,/$&DZI&=-B>PTDV _>LWS;2 WW.Q(.*
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MOY-?35M-GC4Q%H DD<F/F!P ,?AG^NOK'BC1-!EBBU34[:UDE!*)(V"1ZXH
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MOYHE\E@N6VM[D# 'OTH @\):;>7.J7WB?5M,CT^_O42)+<-N>.-1_$?4GMZ
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M(ZP-56WN'C6X4':!@':I).X#)YS[=JS?&WF1>._!FRXG19[F5'C65@K *,<
MXS\QYH [_(Q2U\[SV8M_#>HZZEU>&_MO$/DP2FX8@+N';/)]S7T,#E 1G!H
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M8KUV[N[>PM9+J[FCA@C&YY)&"JH]R:IZ/KVE:_;O/I=Y%=1HVQRG\)]"#R*
M/*H+:\\,^*'34+"^N&D\/1VJ2VT#2@R*H#<CL.:I:9;2QZ)\/T;3[J*XL[V0
MW)%K)F)2QY;COD&O;KJYM[*UENKJ5(H(E+R2.<!0.I-,L;VUU*SBO+.59K>9
M=T<B]&% 'B7AO2(K61/#6K>&]4N-7M[[SHI#-(+4C=_K#AMHP/0<X'/:MG0[
M.RDT3QN=0T2Y>&2^EFC5;=EF>)\@&,D=N3Q^/6O7<#TJ.>:&V@>>>1(XHU+.
M[D *!W)/2@#SOX;R:@-8U&#[1-J.D1P1K;:A<VQAEX)Q$2P!;:">>@_&NF\>
M6L]YX$UFWMHGEGDM6"1H,ECZ 5KVNI6-]:?:[2Z@GM^?WL4@9>.O(XIMAJVG
M:J)#87MO=",@/Y,@?;GUQTZ4 >5:1?SV-]X6\0W6GWO]F0:;_9LK-;,6MY!C
MY]H&=IZ9^M=3\.]-GMI_$.H&WEMK/4-0::UAD4J=G][:>F3VP.E=S@52;5M/
M35ETMKN$7[1^:L!;YROJ!^% '+?%:TN;OP/,+6WDGDCN(I2D:ECM5@2<"N5%
MS_:'C/7]3;3-0B@N=",$/GV;@F3 ^4<'DU[!UHP* /"(+.[TV#PMJ]]I&J76
MGQ:<UC<0VIDCFBDWL>5&&P01WP:]7\&6<5EX<@CM]-?3H'9I([:1RSHI.1NR
M3@GKCMFN@P/2J<6JV$VIRZ;%=PO>Q)YDD*L"R+G&2.U '"_$>TO8=;T'6Q87
ME_IUF98[B"RD=9EW@ ,-I![=OH>M49=.L+[PJNCV?AV[TZ/6;O,37"22/ 0!
MF9\DE3G@#(]3WKTR\O;73[<W%Y<100KUDE8*H_$TVQU"RU.W\^QNH;F'.-\+
MAES]10!X_=+J=[\,+_P\^DW/V_3)URT=NX6Z19 ?,4D<GU'7O4VIMY?BJ\U;
M4_#>M7NF:O;1I"(2Z.FW@HZJPX/7!KV3 ]*J6NIV-[=75K;744T]JP6=$8$Q
MDYP#Z=#^5 'FD-F;#Q>O_$KN+:W30#;)&D3R)$YRPCW<Y./?K6=I5O>Z;I'@
M2\GL+YDL)[F.XC2W8NA8MMRN.^1S7L^*,"@!J'<BG!&1T->.'2VL?$&N:3J_
MAS5-3_M"\,]I-%+(('#?=\S:P P>I->RUE3>)="MYWMY]6L8YD;:\;SJ&4^X
MS0!YSXQL;VYUU=>T[3'>;0FBB:)[>0_;5)YP>X7L>>N?2K$OB&U7XF6&IW-I
M=I%+H[$H;9V>)MW(*@9'<9QBO4(I(YHUDC971AE64Y!'L:P-1TC3K+Q#_P )
M9>:@]LT%N86WLJQ!#ZY&>OO0!YWI>CWFG3^$Q=65R(3J5S=F(0LRV\;\(&P,
M#U]LU-J.F)H_C#5[?4?#VI:E9:HZR6HL7=8CQC8X4@#!]:];MYX;JWCG@=9(
MI%#(ZG(8'H14G&.E 'DFMV=QINI^=HEO=VVI 6T4NG/ TMI>*JJ!AB, KZD]
MJGN4O;;QE%-I NQ]HU)3>Z5<6Y:$X/,Z.1@= >#UQ]*]*L]2LM0:=;2XCF-O
M(8I0ASL<=0:MX'I0!YKI&B#7K?QKI5Y#+%'?7\DD+R1,O4#:ZY'." :UOAY#
MJ=QI*ZEK)#7H3[&C YS'&2-V>Y8Y/X"N@US11K=M% ;^]LQ'('W6DOELW!&"
M?3FKMG:0V%G%:VZ;(8E"(N>@% $]%%% !1110 4444 %0W>?LDV/[C?RJ:HK
MG_CUE_W#_*@#+\)+L\&Z(@_AL(1_XX*V:R/"O'A'1L_\^,/_ * *UZ "N*^+
M!Q\.-2/_ $TM_P#T>E=K7%?%G'_"M]2S_P ]+?\ ]'I0!V-O_P >T7^X/Y5)
M4=O_ ,>T7^X/Y5)0 4444 %%%% !65?>'=.U'6]/U>YAWW5AO\D]AN]?7':M
M6LV]\0Z/IMU':WNI6T$\F-L<D@!YZ?2@"*Q\-:5IT>H106R>7J$K2W",,ARP
MP1CT]O>LS3/ 6DZ9=V\RS7DZ6K%K2">;?';D_P!T?XYK%U'QN^B?$N2PU34H
M(-$-B)D#1CASC^(#)[_G6YK.LP7":)=6'B*SM+:XN5.6 ?[4G]Q?QH ?:^!]
M(M-'U+2XFNOLVHN9+C,N26/7![9J!?AWH27-E<H+M)K2 6\;K<,I,?/#$<G@
MX^E:5[XMT#3=033[W5((;IB%V-G@GH"<8!/N:;J/B_0=+OTLKS4HHKAF5=N"
M0I/0,0,+^- &7)\/-(2WF*+<W,HMWAMUN;EF6'</X3_#VYK4\(Z')X<\-6FF
M37!GDBW%F))P22<#/.!FLW2OB!IFK>,;WP_!O+6ZC;+M.)&YW >@'')Z\UUU
M &3J/AO3=4U2SU*ZCD:ZLR3 ZRLH3/7@'!S61/\ #3PI<7+SR:;R\OFE%F=4
MW9SG:#@5?UCQEH6AW@M+^^$<WRE@$9A&#T+$# 'UIFJ^-M#T>X,%Q=,\BQB6
M001-((T/1F*C % #+_P'X:U/5X]4N],C>Z0@[LD!L=-P'#?C46H?#OPOJE[<
M7=UIJM+/CS-LC*"1WV@XS[U;U'Q7I%G86TYO2XO4W6HMT,CR#&=RJ <@5RG@
M3Q@J>#;K5-<U*:<#4)(87E7,C#C:H4#KUXH Z0> ?#BS>8MBP4E2T0F?RW*X
MP63.#T'44OAWPK%H.KZO?Q;4&H2A_)C)VJ 3SSW.?H.@K0T+Q!IWB*T>YTZ?
MS$C<QR*RE61AV(/2M">9;>WDF8,5C4L0HR3CT'>@#C_B;HU_K_AF/3]/M&N)
M#=1R, P&%7.>216A;>"- 72YK633]RW2KY_F2,SM@#"ELYP/3.*2T\<Z+>Z&
M=7@DG>T^T"VR(&W&0X&,?B*9?>/]!TZ_-I<7$B[)!#+,(B8HG/16;L: -"X\
M+:-=Z+%I$UBCV,./*C+']V1T*G.0>?6E@\+Z-;:9/IR6$36MQ_KUD^<RGU8G
MDGZFL/\ X6CX6.J"P6^D:3?L:00ML4XSR<=*GB\;Z-JUI>QPS7EN$M'N/.-N
MRDQ=/,3(YZ\4 7M-\&^']*TZXT^STR!;:X_UR,-V\>A)YQ_*HK3P'X;L=.N;
M"WTR-+>Y(,J[FRQ!R.<Y&/:L[2/%&E:5X1TR87VH:G]H5_LY:(O<3A6.3M'I
M[]JL2?$?PW#H\.IO>.()9?)V^4Q=''56'8C/^&: +B^"?#RV?V4Z<C)Y@E+,
M[%RPZ'?G=Q]:D?P?H,FC'29--A>S+;RCY)+?WMQYS[YJG9>/M#O;'4;L2S0K
MIQ'VA)XBCKG[N%[Y[5H:#XAM]?2?RK>ZMY(&59(KF/8PR,CZC% %?_A"/#G]
MFV^G_P!EQ"VMV+1*I92K'J<@YR?K4%SX)TR2_P!%EM[>&VBTJ0R1"-3NSUQG
M/0GDYR373UGZQK-GH=C]JO7*H6"(JKN:1CT51W)H O,JR(5/1A@\UCV?A/0[
M""Z@MM.B2&Z&)XR2RR?4$GGWK@_#WBT6OBKQ?J&I7-_'I]HL96"[!W1DG&T+
MVY.!^%;M_P#$NRBT'5;VUL;TWFGA?,M)X=C+N^ZS<_=]\T ;UIX1T&QM9[:V
MTV)(KA/+E&22R_W<DYQ[4/X0T"32H=+?3(38POYD</.%;U'/O6*GQ$L[?2-.
MFO;*^-[=6_GM;0V^7"*,L^,_<ZXYZ5T^CZK:ZYI-OJ5DY>VN%W(2,'Z$>H.1
M0!2/A#03)<R'38M]TGES')^=?0\T2^$/#\]I:6DNE6[P69S C+D1^P]O;I6W
M7*Z]X_TCP]JPTR[BO9+HQ>:J06Y?*^Q[]#0!=;P9X<:R%G_9%J+82^=Y:I@;
M_4XZ]:2Z\%>&KVXFGN=&M))9@!(Q3DX_K[]:Q)_BQX9AL+.[$EW*MV2J1Q0$
MLK#^%AV/M5AOB/I;VZR6MEJ5TXA\^:&&VR]NGK("<#H?7I0!I1>"O#D-TMQ%
MI-NDBLK  ';D=#MSC(]<4GA_PM;Z'J6JW\6Q9-0F\QDC7:B@=.,GDY))]ZKW
M'CS1H[:PEMC<7S7T;2016D6]RJ_>)!QC'?-9LOQ9\.1Z=%?A=0D@EE\E"EJW
M+^G.!G\: .IU;0]-UR.*/4;99UB;?'DD%6Z9!!!JN_A/0I-*CTQ]-@-G&V](
M\'*MG.X-US[YKG9/BMH:PK(EKJ<G[HS2JMM\T* XRX)X_#-6=2^)6BZ9=VUM
MY.H74EQ;BYB^S6Q?=&1G/)':@#:?PMHDFD#27TZ%K -O\DYP6]3W)^M))X4T
M*9+))=,MY5L<_9A(N[R\]AGM[&L2Q^)^@:A<V,4*7RQWL@ABGDMBL?F'^ MZ
MUH)XTL9-:.G1VM[(!<_9#<I%F$2XY4MGC'TH W#8VQO#=F",W!C\HR[1N*9S
MMSZ9[54G\/:1=:3_ &5-IUN]AVM]@"CG.0!T.3U%:=(S*BEF("@9)/:@#GV\
M"^%FCD3^PK(+( &VQ 9 Z=*N7_AO1]4TV+3KZPAGM(<>7&X^Y@8&#UK('Q#T
M7[7;Q,MXEO<RF*WO&@/D3.#C"MU//'2N1UOQS=Z_X4\5?9K>_P!.;3GVPSHO
ME]&4%7.>&.3P.U 'J5G96NGVL=K9P1P01C"1QJ%4#Z"J][HFF:E<0W%[907$
MT/\ JGD3)3Z'M7.>'?'FF7X73YEN[:XM[);AY+N+8)$ &7!SR*;;?$[0Y[KR
M9(KVW#PM/;R2PX%PBYSLP<YX. 0* -0>!O#0M9+4:3#Y$D@E:/+8+C.&Z]>3
M6^D:QQK&@PJ@ #T KE/"WQ"TKQ;>M;:?;7Z8C,@DGAVHP! (!!//-=5*YBB=
MPC.5!.U>I]A[T 9%OX2T&TU,ZE!IL*798OYF"<,>I Z ^]$/A'08-4;4HM,@
M6Z9S(7QQN/\ %CH#[XK#/Q/T==%;5FL]2%LEU]DD'DKN23T(W<#M6IJ7C32]
M*GO8KO[0GV..-W81Y#%_NHO/+'TH DO_  5X;U._DOKW2+:>YD #R.N=V.F1
MT[5-9^%M#T[4O[1L]/A@N_+\OS$R/E],=,<5D1?$32?+U#[7;W]E<6,7G26U
MQ;D2M'_>4 G(_&N*\7>.+/Q+IFF76CMJ=JUOJ5OEI5,22*^[OD@_=_G0!Z5'
MX2T"+6?[8CTFU74.OGB,9SZXZ9]^M))X/\/RZV-9?2K8ZB&W"?;SN]<=,^^,
MU3;QSI:V.HW_ )=T;&P;8]R(P4E;(&V,Y^8Y(]JNZ%XDM]?>ZCBM+VUEMF59
M8KN+RV&X9'&3VH V<<8K$C\':!%J!ODTR$3F3SN^S?\ WMF=N[WQFMLL%!).
M .I-<I%\0]#EOX+<&Z6"XF,$%Z\!%O+(#C:K_7\* -C3?#^E:1=W-W8VPBGN
MCNG?S&/F'U.2>:U*\CO=2O?%OQ%U'0_M6MZ=#;1(MLUK&4\MN"SR#/(/0$]B
M*]9B1DB1&<NR@ L>I]Z 'T444 %%%% ''>-/%VI^'+[2;/3M)BOI-2E,,9>?
M9A^,#ITYZUSS?%>[L1<Z9JFCI!KT5TEL(5D9HFW D/D G&!T&2<C%3?%.6X3
M7_!ALF@%V-08Q^>2$S\N-V.<4W4?AEJ&L?:]7N-1AM?$<UU'<136X8Q0^6NU
M5&>3QC)]J *\_P 4=<M/#]Y=S^'0+BVN4AWMYD<4JMG!7<,YR.E6)/&OC:VU
MG3-'N?#^F0WNH>88@UTV %'4XZ?KGVJ?5_!'BK7/#+V.I:Y:W-_)<1R-(8RD
M<:)D@*H'4D\GZ>E:FL>&-:OO%^B:[;W%D/[.@9&20-\[,"&Z=N: .:MOB;K[
M:7;:M=:181Z>-0&GW#+.Q<N3RRC& ![DU-XB\1W=KXB\4P6%AIUM?V>D^?'?
M\F5TXX)QV!X'J!S33\-->/AE]'.J6)#:G_:&\H^0>NW\ZV+SP+?:AXCU?4;B
M[MEAU'338E8T;<O& W7GF@#DHM>\:2)X'MTO;+%_\ZN6D+2[5_Y:GOP>W4UI
MK\4=4NKII]/T9KNQCN_LS116\K2LHX+AP-@Y_A/-6HOAUKJ:=X?!UFT%[HTS
M&%Q 2@C(Z8ZDTMA\-];TR\GL[3Q+)'H%S-YT]L(P)6)^\ V/E!]J ,+QYXCU
M3Q+X,U^6TM;./1K.\%HS2EC.[*RY88X R1U]Z]9T3_D :=SG_18^?7Y17GU_
M\,=6^RZKI.E:Y#;:'J,WGO;R0;W1L@D*<].!^5>C:;:O8Z7:VDDHE>")8RX7
M;NP,9QVH \GN;G7M-^*/B^?P[9V4[QVT$LR3E@2 @.%"]6/-:>D?$?4;O5M
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MM3:Q>1G5-49&\VUCVI 4^[M!Y/OGK43_  WU36M&N;7Q/XAEOKG:%LY8UVK
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M+NUNU!NV $(B5R?,#9Y.#T'->LZ;J-MJVFV^H6CE[>X021D@@X/L:M4 >?\
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MB@ HHHH **** "BBB@ HHHH **** "HKG_CUE_W#_*I:BN?^/67_ '#_ "H
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MNV^49EWY],9SFKP.:\D\$^'M#O?B#XJFFM;>6:TO$:W5@,Q\<L,<=:]; Q0
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M%<],XZ5Y!K4-GL^)<96/AH)4'??MY(]\Y_.MS1(-,TWXE:4FGK!"EUH666'
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MA=Y JXVD8X)QP.W2J^D_$S4M2OGTYM.LH[V6SDN8$6X+>45S\DHQE3@$\>U
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M4>JP6[12$M&\+M]UU.",^GO[UY/X@U[6_$/@/7KC5+./9::J%1XY<^4595V
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M\V0<+G^M 'H=%%% !1110 4444 %-D!:-@.I'%.HH RO# *^%-(#=19Q _\
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M?"!N+&=X[=9WN'1-RP&3.U21^OIFO3+?PW96WB>Z\0))<&\NHA#(&<%-HQC
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M2D;X81P:Q<3:;K=[8:7=L&N=/A^Y(<8(R3P#SF@#$L)O$2^*/&]\NK1L=/B
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M';O@]5![XK0T_P +6^F^)KW6X;F7?=PI"T! V*J@!<=^,?K0!O4444 %%%%
M!1110 4444 16J&*TAC8894 (_"I:** "N0^)S;/ ETWI<6I_P#)B.NOKD_B
M0,^"YP>ANK3_ -*(Z .IB.Z)#Z@&GT 8&** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $"@'/?O2T44 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<K\1/\ D3I?^ONT_P#2B.NJKEOB$,^$)1_T
M]VG_ *41T =31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 44CNJ*69@H R23C%06E];7R
M-):S),BMM+(<C/UH L4444 %%%% !1110 5S'Q &?"3_ /7W:?\ I1'73US/
MCX$^%' ZF\M/_2B.@#IJ*!R** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N7\0>(M0T?Q/H&GQ6UL]GJ4QA>1F.]2!G@=/YUU%<%XWF4>-/!@V2
M-Y=Z[/L0D*&4*"2.G- '>T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '#01R
M^.M8FGGD=- LIC%%"I*_:I%/+-ZJ#VKMHXHX4"1HJ(HP%48 KC/#>L6&@> ;
M2YN7V[GEPB\M(YD;@#UKH]'EU"ZA-W?QBW\W_5VV<F-?]H_WC0!IT444 %%%
M% !1110 5SWC9/,\.A,D;KVS&1U'^D1UT-8'C'_D Q\?\OUG_P"E$= &^.E%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !114=Q/':V\D\S!(HU+NQ[ #)- #V8(I9B  ,DD]*X/4/B!->:D=.
M\*V!U.=3AYN?*'X^GOTJEJ]]KOCJRNDT6&2VTB)3EY,H]X1_"O' KH? FJZ;
MJ>@QK8V<=C+;'R;BT7K$X]>YSZF@"K;:%XMOXA+J?B9K.8\^390KM4>A)ZU#
M_:GB30]271KIX-0ENE/V"\E'E@E1EE<#OCIZU;U&ZETGXB:?-*[&SU*W-H,G
MB.53N'YYQ1XP8G6O"L49/FG40V!_="G=^AH YSX=:#&FMZN-77SM4T^X&U"<
MQQ!\L"B^YSS]*]1KB)=VD?%FW<?ZC5[(HXQ_RTCZ'\J[>@ HHHH **** "BB
MB@ K#\6+OT2,#_G]M.G_ %\1UN5E>(1G3X/^OZT_]'QT :M% HH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'2M2L[6O^/*'_K[MO_1R4 :-%%% !1110 4444 %%%% !1110 4444 %%%%
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MT_Z?/_L*** *=Q\<Y8E!7P^F>>MV?_B*J2_'VY101X>B.?\ IZ/_ ,3110!
M_P"T#>88+X?@!'0FY)_]EJN?V@M5XQH=G^,K444 )_PT#JY.!HEC_P!_'I)/
MV@-9 &W1K $^KN?ZT44 5V^/OB+>0--TT#M\K_\ Q5)_POSQ(>FG:8/^ /\
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M7XQ\ULO/Y444 2#XX^,0.7L3_P!N_P#]>K2?'OQ2J@-9Z6Q'<Q/D_P#C]%%
M#Q\??$W?3]+/_;.3_P"+J6/X_P#B ']YI>G,/;>/_9J** )U_:!U@]=%L?\
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M]F!G[V:O444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>sgmo-20210331xex103008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"FNBR##J&'H1FG44 1FWB9MS1H3ZE108(F)+1(2>Y45)10!%]F@_YXQ_]\B@
M6\(.1$@(Z845+10 T1J'W[1N/4XYI<<@^E+10 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4$9&#110 @4 8'2F?9
MX?\ GDG_ 'R*DHH C^SP_P#/)/\ OD4GV: _\L8_^^14M% $7V6W_P">$?\
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M"K'_ ,!T_P *T** *']B:3_T"[+_ ,!T_P *3^PM(/\ S"['_P !T_PK0HH
MSCX?T8]=)L#_ -NR?X4G_"/:*/\ F$:?_P" R?X5I44 9O\ PCNB?] ?3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH :C!UW"G5%;G,(/N?YFI: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHH- $-J0;=2.F3_,U-5'1CG1[4^J5>H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "@T44 9VA'.AV9'>,5HUFZ
M,:#9?]<A6E0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR26T>QC$L\=U&8V"$9# 'J#0!T5%><6GB1KSXJ0JDE]#8MI;.\%VAC52#G>
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M3W]R]S:3V\>]&5G!.3[<<57\1V.NZHFKV\NA:D@>PMQ:K;I\KLH&3*1]YAR
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M5=H8#@''TK-\<3.WAVXTRVC,M]J*&W@C )SGAF/H #G- &GX?U$ZOX=T[46
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M!@8Z#WH ZFBBB@ HHHH *X'XIPQR:;HSNBDC4XER1D[3G(_05WU<MXWT&_\
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M+#U-3V]UBTA:\D@CN#$K2*K_ "@XYQ[9[UXU;S1+IOQ%LOM-D5\J.:.*R?\
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MX@N[J*X$XEEMYB@<)C'U^M6+6"RO+K6H-1UFXM9].N EM(\^#'$O0@=#GO\
MA0!WXN;PZLUN;0"S$6X7.\<OG[NWKT[U<R*X.2:X;Q[J<4=])&C:+NC:5L+&
MQ( ;';U/%<G=ZMJ/AZSOK$6\MMJIMT5I5E:6-D+?-+G)P3G% 'M.169XAU5]
M$T"[U)(1,;=-_EEMN>?6N8\&6OV35F*:Y!=1SVHD-K"S.%.0-Y))P>HK7\?'
M'@75R.OD?U% &W97/VJPM[DKM,T2R%?3(!Q4^17E!T&*VU;P[96%W=G^T+4F
M[43,Q50H._KQR<?A5[PW+>3WJ>$[GS=VEW!FFGWGYXP?D&<]R?TH ])SQ7.1
M>);G4M2N[;1[ 7,-F_ES7$DOEH7'5%X))'KTKH903"X7J5./K7#?#*6*TT.Z
MT^X81WEO=R><CG#<GK0!U6C:JVJVTLLEL]L\4S1-&YR016CD>M<5XHU**[O]
M&L4FSIEU>&.[DB)&XJ.$W#L3C-<_XA>YL(_%.GV5S/'86L$,D>V1OW4C,H*@
M_0DX^E 'JN11D&O+$T*U/C"RTUKF[^RSZ2+F=3<M\\F3\QY_&J0=]6\,^$H;
MB[N$66_:V=TE*EDW'^G% 'L&10&4C(((]17CVH21Z1<:_H]O/=MIHF@$:JY.
MZ5@-T9<G@>O/:JOVV:WT/Q?9/=+&L+Q^3%#,2L9)((4YR10![4'4D@,"1U&>
ME.S7FMIHUK'XR;2(WG^SW>D^;-NE9B9-P ?)/6CPT+J]OK?PU=1.JZ-,TUQ+
MDXD.3L'XY)^@H ]*I-RYQD9ZXJ*Y=X[25XUW2*A*KZG' KRY0O\ PA4&NQ7$
MO]O-=X:02'>SF0C9M]-O:@#L-6UVY.N_V5I5E;7=[;P_:)!.^W:"> O'WC71
MP-(T$;2H$D*@LH.<'N,UP=A86;_%BZ<Q*98K))3S]V0]3^5=GK$\=MHU[-*[
MQQI Y9T^\.#R/>@"V'4YPP.#@X]:/,0MM##.,XSVKQ?1'2UUN'SKA(;6YTJ2
M5H8KEB2>Q<Y^^<9Q4^BP06D'@^\C:07-]<O',Y<MYD?3:03TYH ]B#JV<,#@
MXXI:\N6VNM)UZ_\ "D<3F'59%E@FR24C_C_(#%>FQ1+! D2#"(H51Z 4 *TL
M88*74,>@)Y-4].GOY$N&U&&"$K*PB$;[LQCH6]#7"V_A_3=<^)&NF[,TBVPB
M>-1,P 8KSW]:R#,;7P-JH6X;[/'K6UE+\R1@C*Y]\9_"@#TS7=4?3- O-2M4
MCG:"(R*K/A6Q[BGZ3JB:AH]M>R-'&\D"RR*&X3(R:\V@CL9=(\4ZO!)##:RV
MI2VM%G!:-=O)*@D#)Z"C3]-L;/5?#\$$)\N_TF5KJ/>Q\WY">?QH ],T[6+'
M5-/%]:W"-;EF7>3@<,1_2KBNKJ&1@P/0@YKR30;2RNO =G:V=SIT6H-=-+)!
M<$[;@J6PC_@1CZ"NS\ WD-YH$K0VAM=ES(CQ;MRAN"=A_N\\4 =51110 444
M4 %%%% !37^X?I3J1_N'Z4 8WA$8\(Z2/^G9/Y5M5C>$_P#D4]*_Z]D_E6S0
M 5@^+&*V%@1_T$K0?^1EK>K \6\:=8_]A.T_]'+0!OT444 %%%% !1110!6N
MM.L;YHVO+.WN&B.8S-$K[#ZC(XJ!M!T=A*&TFQ(E.9,VR?/WYXYK)\=W=A8^
M'?.U(7WV59XLFS;:P.X8R?[N<54TCQ9J&H^/=2T5M,>.SM8HV$NY21N!8,W/
M1A@ #TYH Z)M#TEV5GTNR9E3RU)MT)"=-HXZ>U)_86D;D;^RK',:[$/V=/E7
MT'' K0K.UO6K;0K 75R'??(L4448RTDC'"JH]30 HT'1Q&D8TFQ"1L71?LZ8
M5CCD#'!X'Y4Z31M,EDGDDTZT=K@ 3%H5/F =-W'/XUS[^/[*VCU-+VPO;6\T
M^ 7$MJZJ6:,\;E(.",GGGBG:3XYL]:U6WTPV-]9O>6QN+:2X0*)DQSMP: -U
M-#TB-75-*L5$BA'"VZ#<HZ \<C@<4BZ%HZ,K+I5BK*NT$6Z @=,=.E>=^#O%
MXT/PO:G48[NZ2YU6:U2X+A@C%^ Q8Y]37H=OJZW.M7FFI;R9M41GFR-N6&0O
M7.<<T 6K2QM+"(Q6=K!;1D[BD,80$^N!59]"TB0RF32K%C*V^0M;H=[>IXY/
MO6A7"_%/6+O2O#MNMK'/LN;J.*:2)@"$SRN?5NE '7)I6G1W#7$=A:I.R[#(
ML*ABN,8SC.,4W3]&TW23)_9]A;6OFG+^3&%W?7%<CI^J6?A5;RTL--U:[9<7
M=U;[UD^Q*PX7)/HI. 2:LWWQ)TFV&G_9;6^OSJ$+36XMH=V\#J.O48Y':@#I
M=0T;3=5\HW]A;7)B;<AFC#;3[9HU#1M-U6*..^L8+A(CE!(@.WZ>E6+2X^UV
M<-QY4D0E0/LD7:RY&<$=C4K,$4LQ  &23VH HR:+IDKVSR6%LS6HQ!F(?N_]
MWTJN?"VA-%+$VDV9CE?S)%\H89O4_G67;>/=/N=1LX/LMW';7Q=;2\=/W<Q7
MKCG([X)'-1P_$72)KRSB$-T+>]D:*VN=@*2N#C  .1TX)% &ZV@:4S6C'3[?
M-I_Q[GRQ^ZYS\OI4,OA709[QKN71[)[AFW-(81DGU-<EJ'Q8LO[+OKC3-)U.
M=[=74R/;[8T=?[S9XZYK4_X3R*VL-.-UIMZU[=6INGMXT!98U&6?KTZX'6@#
M?N?#^D7>H17]QIMK)=Q8V3-&"RXZ<TDOAW2)Y+F273K9WN@%G)0?O!G//KR*
MY^Y\0:-J>J>%;U+G45^VF1K-8?ECDRO(E^GI40^*6B8W_9=1$"70M99VM\)&
MYXY.: .F'A_20]F_]G6VZS&+<^6,Q#_9]*A/A70C:/:G2K0P/()6C,8P7_O?
M6MBB@#%/A'P^R3(='LMDSAY (@ Q%6%T#2EO4O18P?:4C\I92N6"8QM^F.*\
MZM-5%OHGC%-9U/4Q;6^K-"L\#%IHUW<8/8< >G/O75WOCW1])O#ISQZA/<16
MZSD0V[2$H0#G/T/)H 9J>@ZA:)'IGAJSTVSTR[WB]=E(=0>"5 ZG&>M=3:6L
M5E:0VL*A8H46-%'8 8%<UIOQ"T/5;ZQM;;[4/MP/V>:2 I&Y R5#'J?I6)>^
M+[/0;'Q1J-A)J%_<6]VL<D-P#Y<#D8 7N$S_ $'O0!V-[X;T?4;T7EWI\,MP
M %WD<L!T!QU_&GW6@Z9>WT-[<644ES" (I6'S)CT]*R)_'.GV5G%)<6M\9C;
M_:98$@)>&,<;F'8<''M3M2\8Z:NFQFT:XNY;NU:>%+--\@3'W_8 ]_6@#:U/
M2;'6+5;:_MUGB5PZ@DC##H01R#S5*;PGH<^EIILNG0M:))YJQ\\/_>SG.??-
M8_PPU*[U;P3;7=[<2W$[22 R2MEB-W'/TKLJ ,6+PGH,-G=V<>EVRV]W_KX]
MO#^F:C3P;X?CTHZ8FEPK9&02M$I(W,.A)SD_B:K:SX]T30M3?3KMKEKI8O-*
M10,_'X58M?&>BWLFF);W+2?VFK-;$(<-MSN!]",=#0!;M?#NEV6H_P!H6]MM
MN_+$1E,CL2@Z+R>E%]X>TS4=0BO[NVWW4*E(Y1(RE0>H&"/6LN;X@^'[?3I;
MZ:YE2&*Y-H^86W"4=1C%5F^)_A91&/MDQ=\[8_L[[N/;% &BO@CP\MK':KIX
M$$4OG(@FDPK_ -X?-UXJS;>&=)M-3FU*&UQ>3*5EE:5V+CT.20:K0^-=#N-(
MBU."[,D$TABC1$)D9QU4(!G-.C\9:)+IDU^MT?+AE$,D9C82+(>B;,9R?3%
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M?01:=/\ \3":.>T+@#S2AY Y^N/6N^U'Q?H6E:D+"]OA'.656^4E4+?=#$#
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M"+&''&. ,4 67 *'=TQS7A=G# /!>G;[=?,'B+>P,?/EYSD\=,$5[J"#1@4
M>>:1I]KJ7BSQKI\R#R+H1+MV\'Y2"1]"13_ %EJ#S/%JB#_B2%[&V8?QY.2W
M_?.T5V&M:=<:GISVMIJ$UA*Q!$\(RRX/2GZ3IL>DZ=':I))*02SRR'+2.3EF
M/N2: +U%%% !1110 5PWQ!NEM[[0 Z&)3<,?MHC+^1QR N""3VSZ5W-13RP0
MJK3R(@+!5+D#+'H![T >*:(]L?#MO;O?W.G:C97]Q-;W$MN3&"?X7R.X[5IW
M%S+-H6EZC)+%I>K1V\QBC,&8+E-W*E>Q;K^->M[$(QM&#STH,:$ %0<=* /-
M(99;CQ9X,FGLQ9S-82"2-%P(LKA1[>PKFM U?3;FZTO3=4N8H+73K^2:.22,
M[I26.T,<8')Y->VSPB:"2(D@.I4E3@@$=JY2T\%W4-I'IMQJXGTI,?N/LJJ[
M '."_7K0!P]];VTWASQO)#"CR2:BGE,J9)7</NGTX-3:@;6V\2W\6NG4C8ZC
M;0F!K4Y610N-I ![YKV!8T10J*% Z "HVEM_/6%GC\XC<J$C=@=\4 >3VLR^
M&Y]:@UJTF7[78HMB'4R?(%($><=1D?E7;_#P2#P%I"RJRNL.TJPP1@FNAAEM
M[I/,A>.502-RD, 1UJ4 #I0 M>.3BZ6SUNUCMYV:VUS[=-"$.&A# Y]^QQ[5
M['4(F@,Y@$B&8+N,>X;L>N* ..LC'K/Q!MM8TS)LHK!DGE"E0SD_*I]2!^5=
MO2*H48  ^E+0!P_BVVN-/\5Z-XG2&2>VM5:"X2-<LBMGYL=^M:Z>(8=;ADM]
M'$DS/&P,Y1D2(X.,DCDYQP*Z'&:0* , 8H \G%O+J'@:S\,1VLJ:U;W*JZM&
M1MPV3)NZ8P>N:CU"W4Z;X^ @+2RSQB,^6<L,C./;->N8%&!0!YU#'CQA9RQ1
M,(4T$QE@A"AL @9QC.!6#HZQ:WX.T31]/MG;4(K[SI7$941J)"2Q;Z$"O7KF
M'S[:6$-MWH5W8SC(QFJ/A_14T'18--68S+#NP[+@G))_K0!Y1="];4+:X;3[
MY'M=;\Y[:" ^5$F?O XY8XJ]=0377A[QEMLKC[1=WRO"I@(9U^7&!CMS7K9V
M@8J"&_L[B*62&XB>.%BDC*P(4CJ">V* .'\5V5]!-HNK:.RI?3*MBX8XW*XX
MR/;DUW&GV<6G:?!9PC$<*!![X'6L#2K72-2U^XU6VU9]0D0_) 9MT=N3P2J]
MLUU% !7D&HV6J+I>MZ-%I%[-/-J_VD/'&2GE[@<Y^@KU^J-YJ^FV$RQ7=[!#
M(_W5=P"?PH XFYM+U]:\9RBPN3'<V"PP$1$^8VPK\OKR:JZ7!?\ AV[MK^XT
MN[G6?28K5(X8B7BD4<J1VR><UZ1;W%O=Q^;;31RIG&Z-@PS]14N!0!X_;Z)J
M-OX?\.ZA<:1<S)923_:K0$K(0[$A@!ST(_*M>ZT^>>TT4V?AV>T@&KI<M#MW
M,J+@%Y.N">?P%>DX%&!0   #B@]#2T4 >21V&L/X5TS1CHUWOMM4$LDA3Y=H
M=CD?GUK<N+"\.I>,I$TZXVW=LB6Y"']XP4J=OKDG-=]@48% 'FEYID__  C^
MF!-/U.'5+:P5(Y[=,_-T,;CT/OZUWVCB[&CV8OU1;ORE\U4& &QS5W JK?ZE
M::9%'+>3+$DDBQJ3W8]!0!//(8H)) C.44MM49+8'0>]<-;^$_[6T#4KO5EO
M%N]1+RRVV\J 5R$7;WP *[WK10!Y5?'56^&]A;WMC/%J=M>)';H1\S[>5;;W
MX_E47G74NDZ_:SZ7J0U[5HMVUXL!U' V@= ,G\Z])U;1;76(HEN#*K1-OCDB
M<HR'U!IFF:%:Z9*\RO//<.-IGN)"[[?[H)Z#V% '&^(?#]W/IOAJ]33#>_V=
M$JS61)5CE0/T(JCJ?AN^N;2SUB'PW%$D%QO;2D;YW3IDD?Q>U>IX%5&U*S34
MTTUI?]*>,R+'@_='?- 'GM_H^I7NFV+VOAU+!&U&*<VR %U1>K2'IGT%6;O2
M=4FO_&,T>GRE;V!([4G \P@;3CV[_A7<ZCJEGI5I]IO)/+BW!,X)Y)P.E6P0
M0".AH \QO= U.WFT74WT0:FL.GI:RV;L T;*.H/UK4MM(U&/Q%X=N6TN.WAM
MXYC+';XV0[P=JY[GGDUW>** /,1H&LCPU*G]G2&=-<%ZL61EH^.E=?8:_>7&
MOMI=WI3VA^S^<KF4/GD#'%;]1+;0I/),L2B63 =P.6QTR: ):Y'QSI]_J/\
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M'2M$-W)JMHUQ$KW 3:1U!X[>M2>*/"FK:QKLEW;2V4EO)9-:B.[#'R6.<NH
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M+2_M5GN74_MQ?YL8SG;C'O6F?#&HVC:O!I]S;+::HS/()0Q:)F&'*XZ\=,T
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M2M/O+^ZMK2RLQ''<?9?-5VSC&!T. *Z+1-,U6\TZW2XU2ZC@M[G="PB$3SQ
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M7\4F8_#W4X8U+RS*B(B@EF.]3P!UX!/X5S1GTZ]\:^"9'$4L::<ZRLR956V
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M[)JWF7EQL\R!&*Y"JI'*CG@C'UH ]KCECF0/$ZNI[J<BD:>))%C:5%=ONJ6
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M$6KVER^Q5E(6/:0%39TP1^=$-K;R>*?$]Y<AHISI22[&E/#NA+#&><'C'04
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M"&> #[24!EWD??W=2<\TDOB._-_>:5H=C#>2:5$GVIYIC'N8J2$4 'GCKTH
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MHHTET(QL]",'G((_*HX/B3YUOX>OCI;1Z?J[^2UP\O\ J)<D;3QR..#QW]*
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M?QK-OOB'H-A/(CR320Q2K#+<Q(&CC9NQ.<GWP#BLOQUXOMDT'6++3S>R7,,
M\RXM%)2 M@C<X/&1Z>M '2?\(CH7]CKI(TV(6*OY@A!8 MZD@Y)^II;WPIH^
MH7*W$]IF41B,LDC*73^ZV#\P^M3^'9'D\,:3)(S.[6<)9F.224&2:P++QY#/
MXDUJQN;2>VM--0%YY(\ <$DL>P/&!U- &Q?^%-'U*1)+FTY6(0XCD9 8QG"D
M*0".3Q4&I^"/#VL36\M[IL;O;H(XRK%,*.@.",BG6'C#3;[48;!H[JTN+A/,
M@6ZA,?G+ZJ3U_G2^-)YK7P;JUS;W$D$T5L[I)&<,"!ZT ;2PQK (511&%VA
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MX9UMYY53Y!WR?7!XQ6-K'B7^U=5\)ZOI^GW$LC2S)]G+;22 !C)X[]: .O\
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MTNJ1VRSW>Z<B.//10<9)/X5K>'=?A\0V#SQQ-#)%(8IHF.2C#MGO0!L4444
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M7ANS\1K!FZ%PLD6GP[\;(F!.WG@?,WZ5FV/AC7A%X,@GTHA=):1;IC,A&UN
M1SSQ7J616<-8A.O-I'E3^<L G\SRSY9&<8W>OM0!P,/A37QX3G\%2V2-9-<?
MN]1\Y=JP[P_W/O;NH_&O2XHQ;VRQHI(C4!5[X J6B@#R(^%?$2>$9+%-,D%S
M_;9OU431D>7G/KU]JG7POK&E^(M1MH/#>G:C:7]P9X+ZY"G[-NY(8')./05Z
MM10!Y6OA?5M(\0:C;0^'+#5;.^E\^&]N%3-N6^\&!Z@'L*@U'P_XBTNU\4Z/
M::0U[:ZPQF@N8&51&2,%64^F.,5ZM<7$=K;R3RDA(U+,0"3@>PJKHVL6>O:7
M%J-A(7MI<[&92IX.#P?I0!'X=AN+?PWIL%W"8;B&VCC>,L&P54#J/I7!:SX5
MUN^UKQ99P6G^CZQ'"\-V7 1#'SM(ZY)&*]0KGK?QIHUUK2:7#-(TLC,D<GE-
MY<C+]X*W0D4 8%K9:GXBU3PU->:3<6']CY>=YL ,^T*%3G)!QG-=)XRMKB]\
M'ZK:6L#SSS6[1HB8R2>*W** /*O!MEKW@]TL'TN\NM+O;83'$>6MY\896]CC
M^55[+0M:A\-^%+)])NUGL=4,]P HPJ;F.<Y]"*]-U36]-T6-'U&[C@#G" Y+
M,?8#D_A4>F>(](UB=X+"]2:9%WM'M*LJYQD@@$4 >?\ ]DZK::!K7@]]-N)G
MO;EY+2\5<Q,CN&+.V>"*O>(/!5_-JF@MI\SK&;8:=J$B<%H O)_'!'XBO1L4
M4 <-X#\+WWA^^U*.\=WMK=S!I^['$).\X_$C\JW?%UM'>>'9[>;3IK^*1E5X
M8#^\ SRR^XZUN44 >07.A^(I_"M[ L=Y>VUOJ,$UFMQ'MN'B3[V1U.. ,^E.
MU/1];\0:CXGNH='NK;[5;V[VWVE0"YC(.WKU./?I7KN** /,M4O-=\2>%=5S
MX6GLKB2T$#%H]TLS[APHZ[1\QYJSIMG?GQOX=N3IMW';VVD?9I97A*JKXZ$U
MZ'P!4%O>VMV\J6\Z2-"^R15/*MZ$4 6**** "BBB@ KB_B;9W>H>'+>UL[*>
M[D-Y'(R11E_E7).:[2HYYX;:!YIY4BB0;F=S@*/4F@#DX;Z&WU&*72_#%Y"S
M*1<RFT,>(P,[0.[9P!7/:38ZIHOBY-<31YS;:PC_ &F".W;=9G=P?QP"?QKN
M;;Q5H-U/%!!JEN\LI C4-RY]O6MB@#S30)-:TF1/#-QX>-Q)%=M-%J#@&$(7
M+;S_ +6">_6HKS1M3NU\?QK87"_;?+:V+1D"4(.=I[]*]/P*6@#R#4+#6?$^
MH-)9Z5?6T4FB_9!+,@0;\Y(Y[<8JS;C5-6O/"L']@W]I_9T<D%S*8\*A*!,@
M^G&:]6Q2 8H \A\/Z%<P"#0[GPK)]NMY25U*21O*49/[P<]?0"H)K75X?"D'
MAE]&OY+RUU)93*D68W3>3N#?C7LV.:3% '/^-$GN?!>J006TTT\UN42*-"S$
MGV%<LMI=S7'@)EL;K%G&1<9@;]U^["\\>M>E4G &: /-;'PQ<:MH/BNQN;.:
MW>YOY+BU:6,KD]589^GZTZ3P[K6I?#:\6[A+:U=[))(WX)$9&U/R7\V-=]I^
MIV6JP-/87*3Q*[1LR=F'!%6Z /*&TZ74/#>K/9^$+C3YWM# 6D+/+*Y(^5 3
M]T8ZUI6=C?'Q'X9F_L^Z2*VTEK>9VA90DA7&#GW%>BT4 >1_V9K ^'4.C#1[
MT7-O?HQS%G<N\L2/8<<^];T-MJ6AZUXCWZ9<WD&J?O;=X4W#=C&UO3K^E=]5
M/4]5L=&LC>:C<I;VX8*7;/4]!Q0!P&C>'=0T?7?#L<UK,\=CITJ2SHFY?,<E
MMN1Z9(JK9Z)-_P (G9VFHZ)J@F2ZN)4GMAB:W8L65@.X.?TKU0$$ CH:6@#F
MM"L=6N/!9LM9D87TT4D;.V-P#9"EL=\$9KG+?2-5O?#&E^&;G3I[>2UN$,MT
M"/+$:-G<ISU/3%>AW$\=K;2W$IVQQ(7<XS@ 9-1Z??V^IV$-[:N7@F7<C$$9
M'T- '-^#K&]L;[7VNK.2!+F^::)GQ\RD8_I^M'B+1[R/Q+IOB338#<36RM#<
M0*0&>,_W<]QS76T4 <5J=A?>,=4TY)K"XL=*LIA<R&X #S./NJ%!.!UR:Q+S
M1-=31_%>E0Z3)*+ZZ::&<2* P+ ]"<]J]0HH \ZU+PSJ&L:NJM:O%!)HOV0R
MMC"R<'!Y]J30=+UBWLC;S>&;.T>TM9(_M"!3)<-M*J%],]237HU(&5B0""0<
M'VH Y[P-87>F>#K"RO8##<0JP="0?XB>WUK/DL]33XES:LNFRR62V MUD5E^
M9L[NY''.*[*B@#RV+PSKR>%M,T]M,/G6^J?:I )4^YG([]>?TK>USPA<:CXQ
ML=2MY#'9NNV_0-CS0A#*".^3_*NTHH \_P!:T#5[7Q9<:KIVE66J0WL:H\=S
M@&)AQG)[5;31M5A\6PZD]JCQQ:4;9C"553(3G"J3P.U=K02 ,F@#S2R\,:_8
M:9X9:.SC>ZTVZFDEC:50-K^_T-6]2\*:GJ^J^)&EB2&*]C@^SR;P07BQ@'O@
MD5VUCJ%OJ,;RVK^9$K%!(!\K$=<'N,\9JU0!Q9TG6=7U73;Z_LHK8:9$Y1/-
M#^?*5P.G1?K69:^%-:MM)\,V1MHR^GWYN+AA*,;=^[CWY_2NRL]?M+[6KW2H
MA+]HLPIEW)A>>F#WK5S0!Y_/X7U.[\46>J164.GS13^9<7$4^5G0'A2GJ>AK
MH_"^JZCJEI=MJ5M%#+#<M$IA;*,!Z']*V7FB1T1Y%5G.%!."WTK-T77+35VO
MHK6.2/[%.;=PZ;?F'H/2@#'T?1=4M?'>K:Q<0Q):7D:QH%ER1MZ$C_/6K.M:
M/?7OBW0]1@2,V]B9#+N?!^88X%=+FDR* /-)/ FKR6\]TOV9+]-1>]MT<[T8
M-CY6X]JO:EX?\3ZQH0CO#9"Y-U%*L$/RQQ(GOU)-=]29% '(>(_#^K7.MV6N
M:0]K]L@B\EHKE<HRDD]>W6H[SP_KDMQHFI/);7-]922/-'DQH=W15X. />NT
MR** .*:PT_1=-U:;Q'>P)+J[LTH!^4 #"JN>20._K5_P)HS:-X;B$I=I[@^<
MY?J ?NC\!BMVZL+.]:)KJVAF,3;HS(@;:?49Z58R.E 'EWC6WN]6\9+!I]U:
M6[6]IME::4Q;@Q.5R#SQ_.KFEV6JZY)HDD=OI\%GHUP0&@=BDH Q\GM[^M=G
M=6&BZG>-#=6MI<W,:ABLB!F4'I4]Y<1:3IDLZP$PVZ;O+B ' ]!P* ./\1^#
M-5UC5M2N;>XLQ'=VZPJTZ%FA QD+V&<<FGZ9X4UNTU)[JYO;60'2_L**BL,8
M P?TKI?#^MQ^(-)BU*&WFAAESL$N,D#C/!-:F<4 <!%X'U.WTO0XX;RW6[TV
M9Y"S*2C;F)S^'I71^)M%FU[PY/IJS*DT@4ARO!(.?RXK0U.[GL].GN+6T:[F
MC7*P*V"_/K5B&1I($>1/+=E!9"<[3Z4 <C!X9UJRU9=7MKZU:\G@$-VLD1$9
MQT*@<\8_&MOPYH4>@:<UNLIFEED:::4C&]VZG'85K9%+D&@ HHHH **** "B
MBB@ H-%!H HZ,,:/:_[E7JI:1_R";;_<J[0 5RWC[_D7K?\ ["-G_P"CTKJ:
MY;Q\,^'K<<_\A&SZ?]=TH ZFBBB@ HHHH **** ..^*2Q'X=ZJ90N55"F>S;
MQT]^M<+=6&E:UXUU-KV&"91X?68 ME?,V?>]B/Z5[-<6T%W$8KF".:,G)21
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MIZM'J,KW4<VQ4G$,I07(7C]YCKQP:M:AX*L;_5)K\W5W!)-:?8F6%U"^5_=
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MM.F6W:+R?EG8 %F+'E1SP *2Y\2:NEUXJMQ<1*=-MDG@81@X)4L0?4<5=OO
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MZEDB"KMC4="<GJ>PK,U+QQXFL["[LA/:#4K'5HK%YS =LT;C*OC/RGCGZ]J
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MQP6 91A< ]_2IKKQS>_\)*^EVZV=NZB I;7VY)9PX!;8<@97.,=Z .^P/2C
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M:7EI81W&6M+22WWY0' WOG(SCL.*U[+Q&EIX=L[WQ'+!IUU(-LD;MM&\$@@
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M4O$WF%(8-06%K:3?G#QC W#WJQ8)XLL-(N;R\MM*MIK:V*PQ1X"RMQ\SMV
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M=R'TL-8SR2/*V]I+C?P68X].@KT>SBCM[.**.!+=%48B0 !/88XJ;(H X!_
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M:GR;[5KR_L$5EALY#B./(QGW(SQZ5VE9VMZW9>'],EU"_EV0QCH.2Q[ #UH
MP-'\#G2;M9&UJ_N+6 EK6U9L)$2",^Y&>.U:GA:TU&RTN2/4KF>>0SNT;3ME
MQ'QM#>_7CWJV==TR/38M0EOH([:4#9(SC!)[?6KL$\5S"DT$BR1.,JZ'((H
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MPWHUU;1O$VG2?:%5ROFR 'YC@@Y)R:]=,,14*8D*@[L;1C/K436%F]VMV]I
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M/3-;= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ]*]%L?"^D:=H\VE6UFJV4V[S(BS,&SUY)S5L:59+/:3"VC$EHAC@;'^K4@
M@?@!0!YYK.KZCH?B#Q,;6\GDBM-*A,4<DA81NS!=P![@'-5+B"+2_&/AR]MK
MJXO+AM-N)R9IFD+L(F(."3C)["O17\-Z5)J-U?R6H>YNHO)F9G8ATQC!&<=O
M2J6G>!?#VEWD-W:V.+B$GRW>5V*9[#)QB@#B/#+:C?MI.NR^([=)9K@+<1-.
M[-+N;'E^7T&.V.G6O61TK$L_"&@V&K-JEMIL,=XQ)\P9.">I S@?A6Y0 5Y+
M>O(-%^(<L5Q+#)'>[@\3;3P ,9':O6JQO^$4T79>H;)2E\V^Y4NQ$ASG)&:
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MX^G6A[^SB9UDNX$9!E@T@!4>_I0!8HI%970.C!E89!!R"*&8*I9B  ,DGM0
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MO&MM<30,@W!-I(R.Q-94>GZC>^#;#PB^F7<6HVER@><QGRE57)\P/T/'8<T
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MB@ K \7#.G6/_83M/_1RUOU@^+/^0?8_]A*T_P#1RT ;U%%% !1110 4444
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M:WX\\'-;'5]4%S82,Y:[LH%#(3PH8,,8[XXSDC->G^$]2;5_"NFWTEPMQ)-
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M[M/&^CZ*D,)M;Z.5VDR2X*J3].PH JO\.=%?0[S2BK"*ZN_M+. -RG=D*/0
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M[BW%O/\ :4GB?]Z9><L6(.2<]:U8=:TNXNDM8=1M9+AUWK$LH+%<9R!]*OT
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M9!\TC%<XXR #]: .NN[*UO[=K>\MXKB%L$QRH&4_@:D1(X8UCC5410 JJ,
M=@*?7,_$%I8_ FK30330S10[TDA<JRD$=Q0!TN11N'K7EL6HW3^*]"2WU1T-
MUX>:24O<$QB4)P[#.,CJ3[5A'Q!J?AK2M1BN?[1M]?6PRK27#7%O< NN9T))
MP0I/M0![?D&F3P1W,$D$R!XI%*NIZ$'J*\]\$KJ$.M6\C:Y:7%E=VF\6D=W)
M<NSC!\S+_=ZX(X%>C4 5-/TRQTFU^S:?:Q6T );RXEVC/KBK616!XVU6[T7P
M=J6H60/VB*+Y"!G;D@;L>P.?PKD[A+G2-9\._P!FZQ?36VLQ/%<>9.9"3LW"
M5=V=IY[<4 >B7ME::E:/:7MO'<6[_>CD7<I_ T^WMH+2!(+:%(84&U(XU"JH
M] !TK@?A=9WUUHMKKM[KFH7;S))&;>:3=&N'(! ]>.OO7H= !FL#_A*;?_A*
M9_#XMKDW45M]IW;1M=?1>>3_ %JK\0=7N-&\+M+;2F"2:>*W,XZQ*[8+#W S
M7,6^FIIGQ2NX(+V\E,NAEXYIIC(\9W'D$Y],_C0!Z%I&HG5=,AO&M+BT,F?W
M-PNUUP2.15W(]:\>@U77[CP9H.IO+?W]M']H:^2TN=EPP#$*^>K!?2M#3-9;
MQ+?VVDQ>(KN&%-*$T$ZL8I)Y2Q4LQ/)VX''<YH [B[\26]GXFL-"D@N#/>H\
MD<H3Y %&2"?7_$5LY%>;WDTL/BSP;/->)J$\5K>B2>(?+,RQ\X'3)(Q60VK:
MX?!=MXU@UF[-XUU^^L68& IYA7RPF.#C'/6@#UF]L[;4+.6TO($GMY1AXY!E
M6'N*2TM+6PM8[:T@C@@C&$CC7:JCV KS*[U[4]+\5!]9FU**"6^_T2>WE#6L
MD>#B%T'W6SWZU4T#4?$FL16?B)=;MH/],*7,4]VQ0INVB,0A,*>F#G)ZT >P
M44#I10 4444 %<%\5X;1] TV2\1#$NIPAG;^%#G=SVXKO:YOQGX=NO$NFVMI
M;36\8BNDN'\]2P8+GC ]<T >5^*;%[34]<E\,@KH!CMS?_8@&CZY.W'!XY('
MKS3M1MM#G\*^([W3M5DOEEMH2^VU6"&.0.H4;5 &_&>@]:]NAL[>"V,$=O#'
M$>L:( ISUXJ!++2F5[)+6S*@AW@$:X![$K_6@#RSQ-X>\/:3X3\.3VUE:Q-<
MWEJTSM\V\%?FY.>/7M5V2+1W\3^*;+7XK5(A:)_9WFA0JP!#_JL\ YYX[UZ7
M+IMC/'''-9V\B1C"*\0(4>PQQ27&EZ?=>6;BQMIO*_U?F1*VSZ9'% 'C&D:/
M!JWB'PC8^(HOM#2:9+O25R&(#-Y><$'.W%1ZCH^B(GQ""VMLILQ&+0YYC.W^
M'GKD5[5';Z==3_:HX;665#M\U55F4CMGMB@Z3II+DZ?:G?\ ?S"OS=^>.: /
M,?#ZZ=I7CS1'@,,$4V@[YS&?OO\ >);'4]>M>F:3K&GZ[8)?:9=)<VSD@2*"
M.1U&#R*<=*L5!\NSMD?;M#"%<C]*BT71K;0[#[):CY2[2.V -S$Y)P, ?0"@
M#DOB3<VB7.@6URL2M)=%DFNN;>/"\F1?XNO X^M>;VKZ;<^%M,LYI;:9X_$F
M-I &(6]%/1#Z5] W%K;W2!+B".95.X"1 P!]>:A_LO3S_P N-M][=_JE^]Z]
M.M 'C.LE--M_&UOHVU+);RU,D-LPP(BO[S ';. <?2MS0+O09?BW%)H1M5M9
M=)QB!0H+[LX('? _2O34L+./S-EI OF##XC W#W]:2&PLK0[H+2"$XZQQA>/
MPH 6_BCGT^YBE0.CQ,&5AD$8KPS0[+36\,>%9M*2W_X2,:FN[RF_>[-S;MX_
MNXQUKW!YEOK"8V$\$C,K(KAMR!NG./>L3P9X5'AG1HK6=;66ZCW W$4>&92<
MX)(SWH \JU6XL[+P?XATN62*.^'B NEOQN"Y7Y@/3 /-;NJV6@WOC?Q3)K0@
M*MI\+6KR, 2?+'*>IZ=*]4;3+!Y7E>RMFDDQO=HE);'3)QS2S:=8W$T<L]G;
MR21_<=XP2OT)Z4 >7:2;B#5_AY!J9 N5M+C>K]0"N$SGOC%8T<ZV.F7[%"VC
MQ^)F-]'&,CR1TR!U7('Y"O;)+*TFF6:6VADE7[KN@+#Z&FIIUE'%)$EG;K')
M]]!& '^H[T >4Z^WAX^ _$\OAV5FMII(9'(!$2N6'R(,#G')_"KOB&*;PMK^
ME>)])LUG6^@%G/&G\4C >6V?<X_+WKT<:9IXMA;"QMO(!W"+REV@^N,8K#_X
M1[4[CQ$+B]U&)]&MI!+9V,<(7:X&!N..0#DC\* -70=+31M&M[)0-R+F0@?>
M<\L?S)KE/&L\$7C'PZFLL@T-O,WB4?NO.Q\N_/&.>,^]=[56YCL;W_1+J.WG
MR-WDR@-^.TT >)R-II\"^.$LVA-LNJ VX4\;=P"D?AFM7Q6\4$G]HQ-8:C&E
ME;QW-A<@"55(^5X6/?G^'N._;U;^R]/\DP_8;;RBVXIY2[2?7&.M#:7I[NCM
M8VQ=  C&)<J!TQQQ0!Y$UEX;N]9\:RZK#!&RP1O;I*=KHS1DG:,_>W8Z=_K5
MVQ>>TUWP*VHE_M$>E3-(&/SX\LX'UQBNOTWPDT/BO5]7OXK&XCO'1H 4W/%M
M&!R1QD>E=*]E:R7"W#VT+3(-JR,@+ >@/6@#PO3+G3CXE\,W$+V\-O-<3B2
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M1K^H71A:WU&1&CVN2XVC SQW'-/\1:'J.I>)= U"T6W\K3I7DD\URI;<,8&
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M/=&:.Y,P8,0VW&/P/Y5GWSQV?Q<^U+"[,FBR2,J#+/A^@'KQBMWP/HU[X?\
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M49;J0/3I6GX6M=6M+>[75;N:YS<,8'G #^7VR!T]A0!OT444 %%%% !1110
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MLZI-IFHZ/XQN=;DA;58+EXX%F?#1H"-@0'\>E 'KNGW1O=-M;I@ 9H4D(4Y
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M$76]+UYG\FVM(WL$,C(JJ1\\B\_>SW[8]J]"MK:"SMX[>WB2*&,;4C0851Z
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M[GGGG>W2SCC'G;TY8$$XX'/7N*+CX@:7;V=K.;6_>:XC>46JQ#S41"0S,"P
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M66']]#$8V;<>,-G&..<G\ZZ+4?&FEZ1+<PNEU<"SC22ZD@CW"%6Z%N1]>,T
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M,?\ D&6./^@I9_\ H]*Z&N>\8C.F6/\ V%+/_P!'I0!T-%%% !1110 4444
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M-GI/V?1)T1P_F%I%;&,8(&<'/]*OVGCS4+35+BWURVM!$-+_ +2C:T+$JO\
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M"FJI:&U@@WQK$<X+2]I#C.W/'I6Y'\.K2/2M-T]=2O/*T^Z-U$V$R6SG!XZ
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M7.SS/*CF5FV^N : .0M/AM<VUWI+/XENYK729C)9PO;QY1<8VEN_UQ75>(]
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MZ[LY'XB@#UE'26-9$8,C %2.A%.JEI#RR:/9/- ()6@0O"!CRSM&5_#I5TT
M9NH>(-)TF9(K_4+:WD<9"2. <>N/3WIE_P")=$TQ(VO=5LX!(GF)OE W+ZCU
M%<C'/!H_BGQ-'KT;;-157MY#&7$L84CRUXZC^[6#I^CK%K/@JPUBV221+:?S
M(9DW;58_(K<=1SQVH ]=@GBN8$G@D62*10R.IR&!Z$5(>E,BBC@B2*)%2- %
M55& H'0 4\]* .-36M5\1>)=1TS2+F*RLM-(CGNFA$CO*?X5!. !@Y/-1GQ@
MWAO5KC2O$MQ$Q6#[1;W<<>WSE_NE?[WTJ'2,>#?$.N#4PR6%_/\ :H+H*S+D
M]4; X/-5+FRD\6^*KC6H;65=/L;"6WMVEB(^TR,K<JIYP,]>YH 74?'WVS3=
M"U33KQ;:UGOEBO%8 A%ST9B..!VKLK'Q%H^I64]Y::C;RV]OGSI V F!GG/3
MBO,5N(;KPGX2T\6ESNM;Z+[2KVSA5"L=Q)(QC)ZU)K%C?ZI/XR338)W62:VE
M545E\Y4^\%..3G^5 'H<?B[0)8YI%U6V"PC,F]MI ]<'!(^E3:1XDT?7I)DT
MN_ANFA ,@CS\N>G\C7GL*V%]I>JW]GI&M?:?[.>&2YU$NS%CC$:@YW?4=./6
MNW\%VT,'A332EL(9?LR+)F/8Q('.>_7- '04444 %%%% !1110 4444 %%%%
M !7+^/!NT*U7=MSJ5F,^G[]*ZBN6\?X_L"UR2!_:=GG S_RW2@#J1THH'2B@
M HHHH **** ./^*/_)-M:_ZY)_Z&M8UOHNN^(%TF^O;&WM(].TV2.UC6XW&>
M26()N) ^5<8]37?:CIEEJUH;34+:*YMV()BE7<I(Z<5/##';P1PPH$CC4*BC
MHH'0"@#SC_A"=7G^&6E:01#!J^E3+/"#)NC=D<D9('0@TNMZ1K&IRW_B/4K.
M.Q:ST:>VB@682,SLI+-D<!0,@=Z]*JO?V4&HV,UG<@M!.A2158J2IZC(YH \
MJT/0]2\7>%O"-G=Z>+33+)%G>X\]6,V%PH51R,YR<XQ3O#OA7Q%HL\>C3>'=
M%N+6&?>NKNB,YCW9QM(R6[#/2O3],TRST>PCL;"'R;:+A(]Q.T>G)-7* /.-
M T#5_P#A$?%5A=:>;6XU&>YE@#NIW"0' )!/(K+U+2[R3X46EKJ-N-+UC2#$
MUCF=6=I$(4$8Z;B2 *];K'O/"^CZAKMMK5W9I-?VJ;(9')(09)''3()/- "^
M&=-ETK0;:WN7\R[8>;<R$Y+RM\SG/U)_#%87C.QU ^)?#.LVEA->P:=+-Y\4
M!7> Z@ @,1GI78QRQR@F-U8 E25.<$=1]:?0!XUJW@36KIKGQ(NFQSWDFJ?:
MSI4KJ0T(&W!/3=U/6K.HZ+J%YX"UJ.R\'KI4UZ\216<!5I7VDDNYX&.< ?XU
MZY10!YMI\.J^&_$VJWW]C7NH6FKVT,J>4H+0RHI7RW!(P#GK67HOAG5=!USP
M@L^G7$T5C#</<S0KN6)Y<D+[XKTFZ\0:?9ZU9Z1-*RWMX&,*;"00HR><8K4H
M \,O+34M/\(VUJ=+NUU5?$#W=HA10[+\S;E3/S#'!';(J[;2R7GA?Q18+H^K
M#7]4B-S*D]N(Q+E@OR $X"Y[UZ;KWAG3O$2P&]$J36[%H)X)3')&3UPPYYJ3
M2/#]GHQDDB>YGN) %>XNIVFD8#H-S'I["@#@=,L[^W\3:5>S:1J'E6WAU;)F
M\GI..2#^&>?4BN<DM]6T;PSX/CM])NUUJSNKF;R1&&;;G<24R-P((Y![5[M7
M'^-8/#7G6=SK6HSZ;=J&2VNK>1XW&>J[E'/T- %3X:7-M]BO[,6VH6^H&<W5
MV+V 1,[29^90"<+\N/PI?&L5Y#XN\*ZG!87-[;6LLZRK;1AF4NH"GDCC_"NE
MT31[/2[8O:O/,\^'>XN96DEDXXRS<X'8=J?;:]IMYK-SI$%R'OK9 \T04_("
M<=<8H \PATW5X/!>K^#;G2+R74+F=S;W.P-"ZNV=Y?.%(Y)SS7J]I;R66EPV
MP<RR0PJ@9OXR%QD_7%6J* /"K6TU:/5=%O+C0-7%Q:ZM)-<000@6\0;.!$N>
M<]2Q/;K4EQ:WTO@OQ+;_ -F:A]IO-<^TQ1FU?+1EU;/3T!KW&D(H \P\4Z/?
M1^)M)U/0Y3#+K40T^\# @["N=X!Z%5!^F!7I-G:Q6-G#:PKMBA01H/0 8%8V
MG>$+#3M?NM9$]W/=3LQ7[1*76'=U"#MG'Y<5T% 'G%P9+OXD:]# MQ#)<Z/]
MDM[AH6">:-QX;';/7VK"2"XUCP1H/AB"RNK;6[&\B\W? P$ 1B6DWXQCZ')S
M7LE% 'D>F65I/8?$"ZNM-#SO<3O;R26A+%2A"%<C/7TJCIOV7^T/A]OLV5+2
MWD6ZW6S (^W W<=2>:]FGFBMH7FF=(XD&YG8X"CU)J*PO[74[*.\LIDGMI1E
M)$.0PZ<?E0!X?):7DWA.^GMK:[DAM?$3W<T$"E)&@.<,F1_+ZTNLP:1>Z%/J
M.G6>IR1WM[;+)/J09Y)BI);:,=E')[\BO91XAT@VEU=#4;;[/:/LGD\P;8V]
M"?QK0BDCGB26-E>-P&5E.00>A% %?3;.QL[-5TZWA@MY/W@6) H.>^!7CNNF
MQL_&?B.R\2Q:RT6I.CVQL\E+A HVQ]#R"*]MHXH \1D6PCU[Q<LULB/'H*0P
M+,/,99!'@KN(Y;. 34NAR:?'JOPZ6!(T=;>=+D(G\3*  W'4MGK7L%OJ%I=S
MSP07$4DMNVR9$<$QGK@CM4[@E"%(#$<$C.* /GZT@T>]\'WFE65LC^(Y-88V
MX2+]X@#C!#8X4+GO6KXE>^N]<\<PV&9;@VMJI6-26D5-OF!?4CO7I_A+PV_A
M?39[-K[[6);AY]WD^7@MR1C)[UOT >81#3?$OC/0Y]#A3[''831ZB$3:%C90
M%B?CJ#V[8J'PIHVIV^M7'ABY4-INAW#75I*>=^\'RE/^[EF^HKTC5;*:_P!,
MN+6VO)+*:5<)<1 %HSZBLC38=/\ "-LL6I:R);R\ER]S=NJ/.^   /8 #% '
MEF@VNE7L]MI&L'63XAM=0,C6BJ@5F+DF4OLSMV]<MSBNG^&&E:/<7>N7ZVEJ
MUY#JDODR!!NCC/ V^@/->G!4)$@5=Q&-V.<4Z@#AOB7++;VFBW$JEM)BU&)]
M04#(,8/&X=USU_"N(\6V]A=2>+=0TI[<Z3)IL?F.F/*>ZW@KMQQNVYZ>M>WD
M!@00"#P0:8;> PB$PQF(=$VC _"@# \%:1I6G>';.?2[:&+[5;Q/*\7_ "T;
M;U/YFO.OB5>6<WBC5+:1H+>>+22HDNE\WS<G<$A3HK9ZM^E>P375I9"..6:"
M -\L:NX7/L!21FSO&%Q&()B 5$BX;'8C- 'BNC'0M9\1:8;E;2X6/PV%D,^#
MNF4 <YZD#^5/L;-V^%F@>)[&-9M2T*5I"."6B$AW(?H#D5[,EO8R2-LAMB\?
MR-M525XZ'TX[5A:OX9O=1U&%(-36TT8IBYL8K=<S'.>6[ X ^GUH E\(6DAT
MU]7NHA'>ZH_VJ9?[@( 1/P4#\<U@>)YK9?B3H\6NQQ'1GM)! ;@ Q"XSSNSQ
MG;C&?6O0%4(H4   8 %07D-I<Q""\BAE1S@1S*&#'Z'K0!X=?6MM;V=I+*L3
M:''XFVV;RJ&1;<_> )_@)'TXJUKL6A:IJ'CN[1+.=(--MC9N,83]WCY/3!"C
M]*]IDM+>6W6"2")H1C$;("HQTXZ5 ]IIA,KO;VA(YD+(O'UH \/N)[&_U&VA
M\3:LUI97&BVXLYI(!,A^4>9M)!VON'4<\5K6.@Z'K'CG2],O4EN8$T($?:6V
MR2D/\A8#H=O('H!7K;Z=87$,<<EG;21(=T:M$I53Z@8XJ0V%H;H71MH3<#I*
M8QO'&.O7I0!-&BQQJB#"J  /04ZBB@ HHHH *H:MK.G:':"ZU.Y2V@W;?,<'
M )^E7ZX_XI@'X::T#_SR3_T8M '3VMS;:G8K/;N);>9?E;! 8?C7.V?@+3[$
M&&*_U0V!)/V!KHF 9.2,8SCVSBL:ZU;Q$FM:%HFE7=G;PW6E&;?+ 7*E%'OS
MU%9J^.M>'A+1M?EDA2W6_-IJ>V'.4W[?,7^[T_6@#U5555"@  #  '2C KSO
M6?&FIV%G>7MF4NH;G44T_3@L><''SOP?FY# #CI67J?C'QII.B7\T]FL?DW$
M*P75W;^4TJN<$;%8@$'OGI0!ZQQ5*]U>PTZXM+>[N4BEO)/*MT;K(WH*\XU#
MQ)XFBB\5Z/<:A:+>6%@+R*ZMX2-JD<I@GKZ&I[74M5TW2? <-P]I>I>S1(97
MM_GB4H"H!)/S8R-U 'IW6C KS2?QEKLWAR[\6V)M6TNUN&3["T9WO"K;2Y?/
M#=\8Q534_&WB9]0\0?V=+816FFV<-[&)(69F1U#!>O7!Y/Y4 >K45YEK'C[4
M87TMA+;Z7!>Z>ES#-<0F6.:9@/W18$;,9ZUZ/:.\EI"\I0R,BEMARN<<X]J
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M\N/8&.Y!RQY&,'O4DWC_ %:UT2*>_P!/_L]S>FV>\N(7$2I@E9-GWN<8QVH
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M,;A=3 XZ?>H [>BBB@ HHHH **** "BBB@ HHHH *Y7X@''A^VZ?\A.SZ_\
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MM>U"RNEU^R>WGAF*Q2/&(S,G9BF3@TGB#P/8:[HUA8+-/92:?M^QW$#?/%@
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M\0Z%;>(]#N=+NBRQSK]]?O(PY##W!H Y>?6]:L-731/$$=E/%J5I*UO-;(5
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M7=9O))+&.#4=)^P +([,C;?O?= (S^E58O"'B>:U\*1W3:6&T.<,VR5QYB*
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MD'''(JUX,\.7'A?1387%Z+HF1I-PCV ;CD]ZZ'(I<@T %%%% !1110 4444
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MT^]NTMA]L=0@"G'.?7UZXJOI.D6<M]X#C,ER/[2M)?MA6Y<&8!<A6(/3/'%
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M"MN%&_SA_P!]?>[FO7XW25%=&#(PR&!R"/:J_DV5K(6$5O$\QVDA0ID/I[T
M>=_!_1=(_L$:M';Q-J(GGB:8'Y@I;[OTP!^=4=:L_#;_ !9UA=>6R6!])1Q]
MH.T%\X)'^U@?7TKUB*&*!=L,21J3G"* ,_A7+)X4E?Q]>:_=M:3VL]LMND#1
M99-IR#D\9SF@#RB&?[/I6D0:F\45RFCW$D<NI$R)Y3,=B1QG&9".AST(XJ71
MUT77[[X?65X\%U&+2>"YC=OX@#M5N_4C%>]26MO*R-)!$[)]TL@)7Z>E,6PL
MT*%+2!2GW"(P-OTXXH \JTBT\/:1XJ\;::\5G;[846V@=5!\OR"6VD\X]>:Y
M:TNK9=+\&'5;^6VT86<Z><(EE1)][ [E96'W2.<9KW][.UDD>1[:%G==K,T8
M)8>A/<4TZ?9-;BW:SMS #GRS&-N?7&,4 >,W&GV$&CZ0^DZS#<"T%Q+;0ZVB
M^3>19&[;G 7G.._6O0-%O8+GX51W<5J;* Z<Y6%G)\L!2.IZCC@UT\VGV5PJ
M+/:6\H084/&&VCVR.*E:&)H3"T:&(C;L*C&/3% 'A>B0V&FVWPWO[98H;J>6
M5;F5"-TB],,>X[53LM1TE=;\/ZA;SV]O"=7E\U99-USM)Y:9O0]EQT[FO>1I
ME@-F+&V&SE<1+\OTXXI5TZQ4DK9VX);>2(E^]Z].OO0!Y5;:3+:>,=1\%);*
M=+O[F/4@^!A( =SI^+!5_.LG5(;*X\3^)+/Q%K9TZ=;A7M46V5I'B !C$+GD
M=AM'^->WA(7G,JK&95&PN -P'7&?Z5'-IUG<745S-:P23Q?<D>,%E^A[4 9&
MLZ#%XC\&/I=P'+36P"/-]]),<,<=\]?QKA/#=W)J>@7VK:Q:O -#TZ33AY6!
M(9 I\QUXX.W:![DUZW4"6]O&CI'%$J2$EE"@!B>I/KF@#Q?P7>6=IX]T/RKF
MPA@N-,*F.WF!)8D[1*V</(?H.W%5(_)?X96<NY0\?B/Y.>0"_(_*O:XM%TR
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MJ])N-"TR[U.+4I[*&2\B&$F9<LHJ*U\,:+97GVNVTVWCGW%@ZKT)ZD#H#]*
M,'XH^8O@J66*>:&1)HL-%(4/+ '.#SUKFW\.6$?C"_TSS;QK4Z2+IXVO)?GE
MY&]OFY/Z5Z7J6DV.L6PM]0MDN(0P;8_3/K54^%]$:XDN#IT)FD3RV<@Y*XQB
M@#S!]6O9/"G@^&[OQ#97#2K<W%QO,;;6(17VD$C ]?KTKM? $4=O;:A!!KD6
MJP+/N0PH1'#D9**2QR/QXK=/AS2#I/\ 99T^W-CG=Y!3Y<]<U:T_3;/2K1+2
MPMH[>W3[L<:X H M4444 %%%% !1110 4444 %%%% !7(_$?_D5X?^PC9_\
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M[31].FO[Z7RK:%=SM@G\@.ISQBL/P[X]T;Q)J,NG6PN;>]C7?]GNX3&[+_>
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M-%>1_#WQ!%J6OV5I=:AK%MK$$4BW=C?S.Z7#8^\H/"D8)Q@<?2O7* "BBB@
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M?>*K77O-TM98;-K;RM\A!W*RYSM_VOTH BF^*ER/!MOXB@T3S(FG:"X3SO\
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M[$YYKK/"UGXBM([W_A(;^&[=YRUOY2XV)Z=!0!T%%%% !1110 4444 %%%%
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MB@ KB?BNI?P-(JC)-Y; #_MLM=M7$_%<D>!)2.OVNV_]&K0!VHZ"EI!T%+0
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MP1XDN%U:]2>RU_RK=S<MN";E7;UR1@GB@#V^BO)M?U;4=-\3-=:C/J"Z6UU
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ME5+B1KL+E6Z$#:<GOCTK1TWQT]QK1L=2TQM/CDL#J$$K3!]T0Z[@!\IQSU-
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M#7@18/L.H:G/J#7EG([6D<UWYA@C;^!B.&..O7TJ_J_P[\/ZSKJZO<V\BW!
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M4/BK0I--EE:%MRRPS*,F.1?NMCO_ /7K<K/UK6K'P_I4VHZA,(X(ER>>6/8
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MHH **** "HYW>.!WCB,KJI*H" 6/ID\4LLL<$3RRNJ1HI9F8X  ZDURR^/\
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MKUR>=+>"2:0XCC4LQ S@ 9/2N<GMO#_Q)\.0NS2SZ?Y_F1NI:)MZ$KGL?44
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MGW"SVS,RK(N<$@X/7W% 'DEA;W<>C_#N%M.OP]A=NUR#:29B&X\M\O'6O9I
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M:37&Y'D7&"21N[#/-3^%M!N])U36KF:YNFM[N<-%!<3B4KC.6![ Y&!Z#GV
M+'CCSAX*U=X+F6WD2UD</%C=PIXY'&?SKS>&[\3Z?HG@;3M+UYH5U:((7EMX
MW\K" X'&2,'OS[UZ]J-C#J>G7-C<9\FXC:)\'!P1@XKE;3X<65I+I+C5=4E&
MEOOMEEE5@O &/N], # H XG7_$WBW0?[0677OMEQIWD<6EJICPQPQG./E)S@
M &M_Q!J6J>(6\66=IJ1L;/2;,H8DC5FG<QEFW%@<+CCC'K6IJWPQTO5KG4Y7
MO]2@CU)UDN((9@(V<'AL$'_"EN_AGIMQ/+/!J>J6LMQ;_9[IHIP3<+C'SY!R
M?IB@#D-$\0:Y+IF@>'M#$RNFCBY=X1%N9B2%!,G 4=3CDYQQ5\ZOXXN-8\/:
M/<:E:Z==7L4ZW!BA2;#1@\YR1NQC@=#6[=?"[29[72HX;[4;6YTR/RH;N"8+
M*5R3@G&.I/0"KR^ [*'4M+OK:^O(9--B>.$!E;._.]F+*26;)R: .$LO%/BX
M:+;:Q<:O'-';ZPNFO;+:*#<+NY8GL><8&.E6?&/C'7]%UJ^EMM05H[2YAC2S
MA@$D?EMU\Y\95CV .?YUTJ_#6T32_P"SEUC41!]M%_QY>?-SG.=G3/:F:C\+
M--U&6_)U34X8KV87$D$<J[/,'\6"M %&&[\6:UX\UK2[76[6"PTZ6(M$UJ"7
MC<$[<_3OGTZ5@_"_6[G4[>R\/6.H?8/L!EGN<QJS7(:0D*F0< =SUYKT#1O!
MD6B:CJ5_!JM_+<7\821YV1R"!A6!V]1[UEVGPMTVPBT_[)J5_#<6,KR17*&,
M2'=U4G;R/\30!G6?BC56\>OINHZH=/87CK%97%LJQ3P#(4QR8R6/!KTL&N0'
M@.-M0M[F[U>^NX+6=KJ"WEV825B23N"YQSTZ5;\&:3J.D:?=1:A=7,XDN6D@
M^U2B21(SCAB.,YR<#IF@"/XA:QJ6@>$+C4M+DCCGB>,$R1[^"P']:Y*34_&L
M?B*^T7^W[5F&FC4%F^PKE.OR*,]_4YKO_$N@1>)M%DTN>XF@@E92[18W':0P
M'(/<"LMO!*OK-QJC:M=_:)K+[$3LCP(\=OEZYR<T <I<^--;NO"GAR^2\CLF
MOHI6N'BA$TSNF0!'%W!(R3VS4+>.]>F\&^']4FD>TM[AI5O[^WM/.,10D+E>
M@!QR?RK?3X76MNFF+:ZUJ4!L(GMU=2F6B<DLOW>.2>:=8_#8Z5916^G^(]3B
M$2R(JR;)(]CD%EV%<=J .+UKQ5)HWC#0-8N;BWO+F7161;B'B)G:1@K'T7IF
MO7M%COH].C_M#4$OIV 8RQQA$Y'\(';WKDHOA5I44T1%U.8([%K(0LJD,&R6
M8G')W'/;&*Z7PQH+>&]'CTW^T)[V*+B)IP,HOIQV^M &5\1=4UK0_#AU71IT
M3[,ZFX1H@^Z,D D9Z8_K7,_\+)DC\3ZI:?VG#-9O8F73F6  &<J"(]V?F/(&
M/4XKTV]M(;^RGM+A \,R&-U/<$8KF;7X>:+;6&AVNQW&CRF:%FQEV.2=W'/.
M#^ H S8]:\2:GJMSH=G?VUO?Z;9QRW,KVV[SIG&[8!G"J 1SUK#_ .$_\4:R
M- ATI+"TN=1>>WE6>-F"2Q=6!STY! QU'4UVFI>$&N-=DUG3-4FTR]GA\BX:
M.-7651T.#T8=C[53C^'UO:WVA3V5])%'I!=D1HPYE9S\[.W')_2@#A=,U[4M
M,^(>MZ0\]K%KNI26T0N-O[E"J9<X/7(. .Y/:O:+5)H[:-)Y1-*J@/(%V[CZ
MX[5P^J?#.'5KK6+F?4F$VHO'(KK ,V[1D;2ASGID?C79Z=;SVFGPP75VUW-&
MNUIV4*7]R!0!R'C;7O$FG:]HVDZ";$/J0E56N48E60 YX/3GT[5FP>)];T_Q
M/J%IJ=I87-U9:*+N4VD1#NX(^7<>W/TYKJM9\,-JWB71]8^W&+^S&9DA\H,'
MW8W9.>. /I6+XE\.7=C>:[XIL[F>:ZFTYK5;2&(;L8&"K=<@C/3VH HZ#XOU
M_4-?T6TEET^YMM5LS>2>7"P-L!U3(8Y],GO7,^#/$6N:%X=T+RVLI-*N]4>S
M,91C*"SDEMV0!@]J3P99WME?6D?AO76N99647,$ND&-8TQR7D.#P>@SR:ZV'
MX8R0:-8:6FMY@L]0^W@FU&6?K@_-TS0!D:=K_B33QXTU22XAO6L;L1>4+=CC
M&%W* W"JN21U.#S79>"_$%QX@MKJ>2^L+V!&7R9K1"AY'(="Q*D&J!\!WL&H
M:M=:=XBGLEO[A;KRT@5@LH()R3RRG'3CKWK-OO!VL:-9WMYH^J2IKFHW4;.U
MG:*D+!01@KD[!R26S0!Z37":WXC\4IXY/AW1K732&L?M:RW);@;MIS@^O&/>
MNXB#B)1(0S@#<1W/>O-=9:[G^-$$6F:C;VES_8YC+S1>:"=Y;;C<.<8;KVH
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MO&.U:%U&TGBWQ7+>6T\<,^AB-FBC/+!,NJMT)&?6@#LX_&?AJ67RUUNQ#D9
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M >QZ@\\>GW$ELZ),D992Z[AD<\C(_G7,^#O%4VJ>&(=7URZL;?[1*8XU4>4
M02,99CDFNDU2>*WTNZDGD6.-8FW.YP!Q7B*S6<_PET>UDFA::+5 &B;!8+O)
M/7H,&@#V>/Q#HLUM+<QZM9/!$VV219U*H?0G/%3KJE@RV[+>VY%S_J")!^]_
MW?7\*\^TRTTK4?'WBW2HC;?8KJS@3RHL $A<$KCN/YXIO@Z+6+NWN;&YA"3>
M'H9;*U?_ )ZRG@.,],*%'_ J /0H]6TZ6^>QCOK9[M/O0+*"X^HZT@UC3&N(
M[==0M3-(2J1B92S$=0!FO'O"D6BWLFEV>H7FJ'7+.X.^P,*J%.?G+-LY7&<Y
M-4DCTNW\#6UW$ENEXFO_ .M7'F! Q[]<8Q0![!;^*-,OM7OM)L[N%KRU0$JS
MC!8@\#UQCGTS4NE7TYT)+K6;BP$HW&62W?\ <@9(ZD^G7WKBM/ET:U\>^+[6
MZ^SJUQ%#)"KJ/F7RB7(]N:YWP]<0QZ=X.EOVC;1$GN4FWX*+,2VS>.@[8S0!
M[)'>60M!<1W,'V;M*KC9UQUZ4^&\MKAY$AN(I&C.'5'!*GWQTKQ;Q/;6\>E^
M,)K)HSH[7$!@V$;//X\S9V]<XK9\G1M,\;7-K8M'9VEQX>9IC; <'D[L#J=O
M- 'HUQ?F>TF.DS6MS=1C(C,F0?8D=/K2:)J\.MZ:EW"K(<E)(V^]&XX93[@U
MP7@BX^R^*4TR1-.O&%AF'4=/(&^(,,"51_%D=:UO (D_MCQ:P!^S'5&$9[%O
MXOZ4 =Q1110 4444 %%%% !1110 4444 %<1\5R5\"R,#@B[MCG_ +;+7;UQ
MGQ0C$O@X1M]U[ZT4_0S)0!V0Z"EH'2B@ HHHH **** (;JZ@LK:6YN95B@B4
MN\CG 4#J36#'XYT25Y8Q)<K*L!N4C>W=6FC SN0$?-T[4GCW1KO7O!M_I]B?
M])<*Z+G&_:P;;^.,5SMY97WBO6O#D\>E7E@VFQR/<2W46P E-HC7^]SSD<8^
MM &5K/Q"GU3PGI&M64]QIJ-JJ0W"[2 8MQ_B(Y^5>=O?(KN],\:Z#JMG?7<%
MZ%AL/^/DS(8S&",@D$=#@UY:EKJ__"#>']$?0-4%QI^JK).WV4E"HE8D@CKU
M%6_$'AS5M=U;QL+73KQ5NTMI+9I(FC6<Q?>4$CKZ4 >AKX^\->7</+J(@^SJ
M))%GB>-MAZ,%(R0?:KFA^*M%\2K.='ODNA!M\S:C+MSG'4#T->8?9?[4T+5[
MJR\':K:7;Z;):R27#22R22-@!(P225&"2Q KTWPE:BU\):5";9K>1+2-)(VC
MV,&"@'(^N: ,NV\0Z;8:GXAO;SQ*)[6V:(26YB(6SX(P"!\Q)]/2K5MX]\-W
MC7*VU_YK6\!N&58GRT8ZE>/F_"N$U>SU$S?$8?V9?D7Z0K:D6KD2[05.#C&/
M>K=O;79\7>$)%L;Q4AT9[>9VMW55<I]TDCU% '3:!\0M'U?0!JLSM:(93%L=
M&)SN(4#CYF(&<+G%9_C?Q9O\!W6K>'-5*/;W"1.R)\P.\*5(894\^E<)!I^J
M0>$=!:31-4F_L2^E:\@7=$S;B<&,@[B1P<CUK3UC38Y?AYK,VD^'+^R&HW4#
M)'/ODGF(8,SLI)VCKCU_*@#K[;6-2'Q/&G37Q;3SI(N?)*JH5RV"2?PK>T_Q
M;H6JWGV2RU".2;89%4JR[U!P64D ,/<9K@M9TZ^UKQCJ4-E!<IY_ATVT<S1,
MJ&0\[=Q&!P<?C6-I.B-KFGQZ:OA_6+?6;.SDB:YOIY/)@)4KB/)ZL<<8P!GT
MH ]-_P"$\\-$R@:K&3'&TF K?,HX)7CY_P#@.:I:#\1]"UBPMKB2<VLES.88
MXY$;EB3M&[&,D<XS7.>&+Z74+32=)F\)W,>IZ7;M!+<W,6R.%=NTE&_B+8''
MUKGK2.^3X=^'XVTG40^CZM'+=+]F;.W<V=HZMC@'ZB@#UQO%6B(FHN^H1(NG
M,%NR^1Y1/3.1W[>M8VN^+K6\\%:W?^'M33[390EBXC.Z-N#RK =1[5Y[>2W]
MTWC*\C\.7LD=]<6LL0N;0D*B]7V]SR"!^=,A^T11>.$^R:Q<-J%G&89[FT96
ME;;SD <9)X'H* /7=%U/_BC].U/4;A5W644T\SD 9* DGL.:K67COPQJ-]%9
MVFM6LMQ*"40,?F_'&.U0:9_R3*W21&0II(1D=2I#"+!!!]Q7F>@0VFL^&O!M
MAIELWV^RO1<W<RP%1%&KDLQ?&#D8 Y.<4 >KVOC;PU?7AM+;6K.6X 8[%D'1
M02Q^@ )IVG^+] U2>2"RU2"62-/,9<E?E[L,XR..HKS32=!FU+X>>+(K6P*:
MM)>3-"SP%)'C.T@*2,X8!ACWK5^T1^*==\(MIUG/'/IVYKXO T8A38 8R2,'
M)Z#F@#L+;QYX7O+Z&RMM;M)+B8[8T5_O'.,9Z9_G5J3Q3HD6JC3'U*!;S=L\
MHM_%_=STS[=:\6T:*WUOP#8Z)I=L[ZT=4\T.L!'E*&Y<OC& />K6F:9%%-<>
M&M;TC6[W51?M-"$G=;:7+9$A.<+QSG!H ]0O/B%X4LFECFUNU\V/<&C1MS9'
M48'>H]"^(6@:U964GVV&"YNSB.V=\OG) '3K7)>&=.M+VX\<N=/#7#7,SVKM
M 0VTJP&PD?7IZU1M;#^TO@]I]W:136^J^'QY\4DD9C^9&+, 3U&W]: /7(=2
MM+B_N+&*=6N;<*98QU3(R,_4&LVX\8^';6^>RGUFRCN4<1M&TH!#'M4'@NUN
MDT,:AJ  U#4F^UW '12P&U1]%"C\ZY70+2PO/B=XMFO+.*9%\HQ/+#N7Y1AL
M$C&<T =-H6N1P:!=:AJOB"QO8$NI +J'"(BY 5/<C/ZUG^*/&=NW@_4K[PYK
M%H][:Q>9M&'91N .5/(Z]Q7FQG^P_#9;D1RK+!XD,T49C;:PR",C&2,>E3/J
MNDWOA7QA<_:%.MZMMD^R+ ZE%!& I(RW<G\* /4[+QOH3:,US/J]K)+:VZR7
M8C<,4.!G@>_'%&E>/="U'P_!K$MY#:0RML*2R#*MS\I]\#-<%(8)/$<45G$<
M2>$FM]J1$ RX)"].N*HV=Q9W/@KPNB7UWI6JV$<GE7;VK& /_$C\<YXYYZ4
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MZ*Z1<D,V=SX]0H7IZUI?#=A9^*KS2YK33Y+E+&-DU'33B*>('"[E' ;WX/%
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M/'I.LJJ3_(=T4I'3=G&"?Y&G7WC34[2SMF01ROJFH2PV#1V[-L@0GYRH.7)
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M(B+:-'5B,9^4ECR?TQ71>&?$L?B.WNF^QS6=S:3M;W$$I!*./<<$4 ;E%%%
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M3Z&J::QI$SO''J5D[+]]5G4D?49KPKQ-/XO\*>"K70-2EB@>_O''GV[?/)&
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M6K:<\(DMMK,DL98."P7'!&.N:M66N6UMI5D^L:E9QW<T E;+",'Y=QP">@H
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MEX;FL72:Y1)1=R;2(]Q! P>&/4#K71RWMK;R)'/<11N_W5=P"WT!ZT <;<>
MK^\T^U2[U^6XO8[R.[DN)8LAFCSL4*" JC)_.I;SP++?77B6274%":W"L9"0
MX,14 *<YY]_6NPDNH(B1)-&A W$,P&!Z_2D:Z@2(2O-&L;='+  _C0!R4GA+
M5IF\.-+JD#MI$F]C]GQY@QMP,'CY?UYJLO@&\BT^]T&+4HU\/W<WFF,QDS1@
MD,T:MG&"1UQQ7=(ZR*&1@RGH0<BFS&587,*JTH'RJ[8!/N<''Y4 <;+X)N_M
MOB&6"[MDAU:U2V2,Q,?)"KM!Z\\'^55[KP3J\WARVT8W.FW-M'8K:,ES Q"L
MN<2I@\-@C\JV?!GB:X\5Z9-?R6*6D23-"@$V\L5ZG[HP*E\7^()_#6D1WT-J
MEQNG2%@TFW;N.,]#F@#2T;3SI.BV6GF9IOLT*Q>8W5MHQFKU-5@1UH#J>AS0
M!R_BKP_J&NF6!8=-N;*6'RPEV&#0OS^\0@=>G'M6)#X'\1:%?17'AW68!YMO
M'#=B]0N&** '4#OQWKT3<,5B>*O$)\-Z,=0%J;@"5(RH<+C<P7/ZT 9;^&-5
MA\7:7K-M=V\HALA9W)N0Q9ANW%UQW.3]*[ 4Q'#*#Z]J=D4 +7#-X0U"]UCQ
M.U[]G2QUB)8D:*5B\>T$*2-H'.0<9KN:3- '$Q^&]<O[/1M.U<6(MM+E27SH
M9&9IS&I"C:5 7KSR:?H?A;4;70_$-A>FW5M2GFEC,4A8+Y@Z'(&,5VE,E<I"
M[JA<JI(4=6]A0!YW;>%_$Q_X15;JWT]8]%D^;R[ABSKM"YY7';-;_A71-0TG
M5M>N+Q(1'J%V;F(QR;L \8/ YK;TF^DU+3(;N:RGLY) 28)\;TY(YQ^=7: "
MJ.M0376AW]O;H'FEMWC12< DJ0.?QJ]2,0JEB< <DF@#S:S\-Z];Q^#XGTX8
MT=F^T,)TYSQE>>>.:W/!FDZEI>H:_+?V@ACO;YKF$^8K9!['%=7#-'<0I-$X
M>-QN5E.01ZT^@ HHHH **** "BBB@ HHHH **** "N+^*<AA\%&1<;DO;5AG
MU$RUVE<;\3V5/!X=_N+?6A;Z"9,T =B.@I:0=!2T %%%% !1110!D^)= @\3
M:#<Z3<2R11S@?/'C((((//7D"N3/PO=[JXN)?$VH2275C]BN"8X_G3& !QP,
M=O7O7::OJ]EH6ESZCJ$RPVT"[G8_R'J3TKD9/'C2>(_#:6SV@T?5;>26620_
M/$53=M+;MHQD9H D;P4FE/H^J'4;J;^P+=TABC@4M(FT@@CN2..*K^%K6T\2
M^+[CQI%I=Q9H;9;>$W*;&E;G>^WV 50>_-=JFIV$E@;Y+VV:T ),XE4H .#\
MV<4^ROK34;9;BRN(;B \"2)PRG\10!GZ_P"(+/0HH/MD=RRW+&-6@MVEVG'\
M6 <5Q/AWP-=:C\-M'L[J>73;^VNC>P/L#-&2S$;E/L>E>E3SPVL+37$L<42#
M+/(P55'N354ZUI0@2<ZG9B&0D))YZ[6(ZX.>: .&N/A0;JWU>.;Q%=R/JDL4
ML[/"ARR<Y_//3&!Q70>(O"<_B!-&$FI^4VG7"7)(A!\UU& >O Z_G70K=VSW
M#P+<1--& SQAP64'N1U%4;G5X)=*O+G3+JTNI;>-FPLH=0P&<-M/% '-WWP^
MDU>\B_M;6'O+&*[:Z2%H )!DD^7YF<[.>G\JSY?A3(UD-+A\1W46CQW0N8;/
MR5;RSG.-QY//2NC\&^)?[>\,:;?W\EM#>WBNPA5MN<,P^4$Y/ K<_M&Q^S/<
M_;+?R(SAY?-7:I]"<X% '+7/@"'4=<UB^U"[$]OJELEM) (MI4+C:P;/W@1G
MI533?AS<0VUQ;ZKXCO=2A^S/:VJ2 !8$9<$X[MCCZ5T.L:E>?9;.;1I].D62
MYC21[B;"E">=I'5O2M2.^LY ^R[@;RQ\^) =O;GTY!H XF/X>7W]D:!93:_Y
MC:/<K/$QMA@[0 J@ C@8/7).>U/;X>31#4+"QUE[;1=1D,ES:>2&89^\$?/R
M@_2NSEO[.W2-YKN"-93B,O( '/MD\U/D$9!S0!Q,_@&8ZCJMQ:ZI'!#?V2V(
MA^S9$42C"X.X<XKHO#NCOH7A^RTI[A;C[+$(ED$>S<HZ<9/.*RAXCOO^%EGP
MZ\, L_L!N5D!)<G<!SV'>NCAO;2XEDB@N899(SAT20,5/N!TH XV3X?3+'J>
MG6FL&#1=2E,L]KY 9T).6"/GY0?<&M#2/"#Z3XLNM9BO8S;S6T=JMJ(,;$08
M7#;OZ5TB75O+,\,<\3RI]]%<%E^H[4@NK=IV@6>(S+UC#C</PZT 9?BGPY;^
M*="FTRXE>(.0Z2I]Y''((KE[7X:W%YIE[!XFUVXU:YF01V\Q&/LX!R"H/\6<
M9/H,5M>&/$=YK6N^(;"Z@@B&EW"0IY3$[@03DD_3T%=+)+'$NZ2147.,L<"@
M#CX/!-W>W4=SXBU1+Z2"TDM+?R8?+"AQM9SR<N1QZ5CZ=\,]8L[C0WD\2J\.
MC.YMHEM  %;KDYY)KLKV^U(:IIJZ='9SV$SLMS*\N'7'38,\]\UJ?:8//\CS
MH_.QGR]XW8]<=: /.3\,;_\ X1Y-(76K<(FI_P!H"3[(<DY/!^?WJYJ'P^U"
MYO\ 7YK;6TA@UF)1-$;;=\X&#SGIU/KT].=70/%,VI>(O$&FWL=M;)ID\<43
M"0YDW GDGOQT%;!U[3AKZZ+]I3[:83.8]PX7( S[G/ ]C0!QNM7&G>'O!EKX
M/U427UW<V;6T$=K;-B5E&%]<'./RS5W^P[WP]\,H]+TFZEM;^*%?WL4'FNTA
M.6P/<DC/:NPN6MX8S<W#1HD0+&23 "#N<GI5?3=9L=4TN/4;:=#:N,AV8#C.
M.?2@!VD"\&CV@U$J;WRE\\KC!?'/3WKSVZ^&.K26&J:7!K\2:;=WGVI(GMMS
M!B022V1_= XKTU'21 Z,K*>A4Y!I6=5QN8#)P,GO0!P=[\/KG5]9U6[U._MW
MAU*Q2UD6*$JR%<$,"2>XJ[X5\*ZUI$L3:SXADU*.U0QVL0CV!0>"7/5CC@9Z
M<UUGGPA%?S8]C'"MN&"?:G,Z("68*!R23B@#G/&'AJY\10Z<UE>1VMU87:W,
M;RQEU) (P0"/6L%/A[K5EJMW+IOBF2WLM1;S+Z(VZEF<_>*'HN>>G3\*]"#J
MRAE8%2,Y!XIK31)MW2(NXX7+ 9^E '*:/X2O=+UW7M0^V6[IJ:!401MF,JNU
M<G//'7WK"M?AMJMMH6D::NJVA_LW4/MROY#?.<Y"GYN.I_2O1KB800-)E<@<
M!F"@GL,]JP?!?B67Q3HLM_/:I;.ES)!Y:ON'RXYS0!%X<\-WVD^(=<U.YNK>
M2/4Y4E\N*,@H5&.I-=11FFK(CKN1U9?4'- '.^,_!UGXST;[#<N89$;?#.JY
M,;?3N/:L^RT7QDME!IEYKMDMI$ C7=M$_P!J=1VRQVJ3C!/-=FKJXRK!AZ@Y
MI: /--:^&=Y-J.MR:/?VT%MK<02[6X1F9"&!+(0><\\'UKF-?TU?#GQ#\%Z3
MI<\!EM+41H]R3M+%GY;!R,DFO<JIS:7I]Q<"XGL;66<8(E>)688Z<D9H \Q;
M1]%\"^$K[2O$UZ))M?EE+O#$Q16VY&/H<8]S6IHG@FYM_A&^@VQC@OK^$M,\
M^<*SXSG'HN!]17?S6EM<A1/#%*$;<HD0-M/J,]ZYC5_%M_#K%WIFA:0-3GL(
MHY;I?/"$!R<*O'+8&><4 9X\$:D/A1_PB/VNU^U;/+\_#;,>9N^O2O-==T/5
M=,US1]!:ST[4I[+3"NU)FM@ZL[9R^Y"W';/<\5]"QN7C5F78Q )4GH?2H+S3
MK'4%"WMI;W '031A\?G0!X[#H6H?$3PCI]G866GZ,ND7CJT89GC<@#E&7.>I
MR<GZFM[3_ASJZ7OBF:]N[%4UV%TQ!O/E.3D=1R.37I4,45O$L4*)'&HPJ(
M![ 5)0!R?P\\/ZKX9\,1Z7JD]M*8680B 'A22>2>IR?2NLHK \5>)QX8M;*=
MK-[E;JZCM?ED"["QX)S0!G:GH.KS?$2QUZU%H;2WLGMBDDC!F+9.>%/&<5S:
M> =?MM!T33E-A(VGZI]O9UF90PW;MH!7W->@VVI7DVN7EC)I<L-K B-'>LX*
M3$]0!U&*T\T >:6W@[Q3I&J7]GI%_8IH=_<FX9I5)FMRWWO+QQGT)]JR=:^'
M?B>^OM2*-IERLE^EW!=7+,9B@)Q%GG:H_6O5]2O?[.TVYO/*>801-(8T(!8
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MG5X?%NKR6^AWK6;Z.+.%H8VD7>(47 8\D9!&37O%17-S%:6TMQ.X2*)2SMZ
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M"_M=4L8KVRG6:VE&4D7HPSBK(QVH \7U"X^R:5\1-+FM[E;JZG:6$>0Q#J5
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M8SC/3BJ[^']'D@$#:79&('<$^SK@'UQB@# \#^)-(N= TJSC*65Q-&YALI)
M6PK$';ZC(./85V#$!23T%8T_AJQGUK3M0,42?8$(@2.)5()!'7KM )PHXS6O
M-%'/"\,JAXW4JRD9!!ZB@#@_A&P/A6\4$?+J,XP.W(-2_%K'_"$G/0W<(.#C
M^*NLT[1M-TDR?V?906WF8WB) N[ZXIVI:5I^KVXM]1M(;F(-N"2J& /K0!Y=
MJPN/#5_XSMM$>6-5TZ"=4\UF8,3M9QDDYQG)^E1Z=96[EKRT\1VS+<:7*39Z
M=YB%BJ9WR'>=K XR3@D\5Z?!H&E6UV]W#80)<.GEO(%^9E]">XXJ&U\*:#8I
M<I:Z5:PK=#;,$C WCT/M[4 >5/9R:-X,\-ZG'JEZB:F\*7TMQ<.T2H1N (!!
M [<$<"K'B&T:U\'ZY;KK5M>023VLB0VQ9DMMT@'#,S=<9QGBO4D\/:2FCMI*
MV,7]GL"#;D97DYZ=JBMO"NAVFDRZ5!IENEC*<R0[<ASZG/)- '"MH'V7QK)H
M-AJ-Z;+4M,:2Y#7#N89 <+("3D$D#O4O@V_N]8:P\/W@N$N]#E=KYR[?.02(
M^<\Y)R<_W?>NM?1DT#2KIO#.FVQOF V+-(</C P6)S@#H,U)X<TNZM$N;_4T
M@&J7T@DN! /E3"A50$\D #KZDT :US(L%K+*\@C5$+%ST4 =:\?T6^U*+Q/X
M9NHKJ\DM]1-PLES<3DB[ YW>420@';Z=J]E=5="K %2,$'O7+)\.?"D<L4BZ
M2FZ*0R)F1R 3VQGI[=* .3T:\U"SU^&SU:>^@U"6&=K:\^UM+9WN5)#8)PI4
M<\#%2^&+N\@U.72=7?4[/5'L)2&-RTT-R<@^;&Q)"L #P!WKLK7P7H-E(KPV
M;?(CI&KS.ZQJPPP4%B%R/2G6/A#1M.<O;P2AO),"E[B1S'&>JKECM_"@#@;'
M6M1D\&>$7N;VZ:VN;J1+^5';SG 9MH!!W8]<>@IE[_PD%CX+U?4O[7U:!1?!
M+(2R<F#>%!Y&X9R?KBMCQ+X)BBMM)M--T:2]TJS:5GMHKHI*K/C!5F/3J<9J
M30O <$T%U#J%K?V^FR[-EC<7[2'<I)WDJ<#KTSVH ?X<:_TSXA7FCRZK>7UM
M)8)=?Z4^XJ^0#CT'M6_XW@:?P5JX666(K:N^Z)BIX&<9]..:F@\,6%OKRZRC
M7!O!"(,M,2I3T(-:MU;17EI-:W";X9D,<B^JD8(_*@#S;0KBX2/PSX<CU"]B
M@O;#[7)/YO[SA1B-&(^4=^.:Z+PC?7XU;7-$O;F6\73ID\FYEQO*.N0K$8R1
MCK[U,O@71H["UM8_M2&TD,EM/]H8R1-Q]TG/& !C&*UM*T>TTA)A;^8TD[^9
M-+*^YY&]6- &A1110 4444 %%%% !1110 4444 %<5\5AGP'./\ IYM__1JU
MVM<3\5\_\('.1VN;<_\ D5: .U'W1]*6D'W1]*6@ HHHH **** .7^(L(G^'
MNN(8]Y^R,P&,\CG->=VUQHFK>(OAW9JUI<6D5G(LL1P567RAU'3.X#\17M;*
MKJ58 J1@@]Q546VGP/#&(+>-E&(E"@$ ?W1_A0!X%;S"+PJ"D\BZ3:>))'NQ
M;J'\N([=C;"""N0<9&,UZ3\-X](^TZS<:)?WE];3R1M)-+&L<7F8.0@"CD#&
M?J*[6"&QDA=8([=HF)5PB@J2."#BIH+>&UB6*WB2*->B(H4#\!0!Y[\69I;>
M#09II)H])COPUZ\40DVC'RD@@@@'/7VKFFL_"EQX<UN"UOY]1_M*XC6TDD18
MT-T<_P"J   QD;CC&.*]IDC25"DB*Z$8*L,@U4*::+= 4M1"C[5!"[5;.,#L
M#GB@#Q7^T94\%>)=)D)D\60R!+^3S=\EQ"C#)0^@08('3DUU&FW_ (.OYKV_
M\.HRS'2'6X\I?+AA0#C>.!OSQ]!7I*VELLIF6WB$ASEP@W'/7FFQ6%G!%)%%
M:P1QR$LZK& &)[D=Z /#]"NK2SM/AM?W4T45O ;J.:9SA4)W8#'MU[^M)HK:
M;JVC:C%;ZO9VDO\ PD4MQ:QW29@E&W*!QT"G!_(5[>^FV,D2Q/9V[1JV\(8P
M0&]<>M#Z;8R0- ]E;M"V2T9B&T]NF* /%+J_M+SPIHT[65K920>)%1C"^8F.
MX%VC/]WI[<5K:]IUUH?CJ]TS3K8?9/%D2Q^8JX$# XD/O\I8_B*]5?3;%[=+
M=[.W:&/[D9C!5?H.U3F&-F1C&I9/NDCE?IZ4 >)>)X=,3QKJ>E:[J9TJP6QB
MAL"]J)$\H+\P0G[ISZ<FO6?"T8A\+Z;&)KB95MUVR7*XD9<<%AV.,5>N=/L[
MPH;JT@G*'<AEC#;3ZC/2K'"CT% 'DWC&>Z7XBZE_9CG[<OAV01B/[P.\'\\<
MUD^$H-%FN-.N]/\ $,W]H1Z?(DT-O:K&(!Y9W-,PZX;')R2<5[.MG9M<_;%M
MX3<$;?."#<1TQNZU4N]#MGT^_@L(XK&>\B9&GAB ;)! 8XZD9H \7\(SZ3JN
ML>' TEC"^F"5[F1IE,EZY)*X7[S'///2J=KJFGCQ'H&H6UQ!;0/K<C2>?)F[
M*EOF:9N %[!?3N:]#T[X?7Q:VM]3CT)+:V=&$UE9[;B3801ES]W.!DC)-=J-
M!T@,6&EV63)YI/D+R_\ >Z=?>@#CO ,D<GC/QPR.K*U]&5*G.1M-5_C/!!-X
M8TX2\%M2B0,#@@'.<5W\-A8V<TMQ!:P0RR<R2)&%+?4]Z+S3K'4D1;VS@N54
MY431AP#ZC- 'FVK>'M&\/^./!5MI426ZR7%P[#S"V?E4CJ?KBN/M/[-UJ\&D
MW-S9K?0ZRTMSJDUPJ&:$,1L&3N.> !7NUSI5E<-'(;6#SX5VP3&)2T7IMR.,
M5YW!\-]6,)TZ\_L":T);-^UF6NV!)).2<;N>N3B@#F=:TW3+J3XCWTJ1M/9M
M#]F?=Q&2/X1TSP!6OHPTG_A:%C<:DML)+C0[>6-Y0!ON#LP1ZMUKTJ+PSHD-
MN8O[*LF4@!MT"DOCH3QR:LII6FB:"5+&V$MNNR%Q$N8QZ*>W7M0!3\5VT5WX
M2U6&6)95-K(0K#.2%)'Z@5Y+X<ETDQ^"=.F-J-,N8Y6OHMPP]SM(02_T![U[
MDR*Z%64%2,$'H16:N@:*EDU@-,LQ:R.7:'R5VLWKCU]Z .4\ 1-:^(/%-G9D
MG18;Q1:@'*(Y7+JI] <<=JK?%JUM[F'P['<%PDFJ1Q.$D*DHP.[O[=<<?S]
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M8FGK?:DL*WOV\$2KN\WUSMKC;W1)F\7:E=7EOXMMM0ENF-M)I84PN@ 53O/
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MN[*2 (2MP%^8,"05*D@]*V*X;P%H.IZ)<ZBKQW5IH\FS['974ZRO$V/FP02
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M#EO83+9BX2ZO([5CYFWR]Y^]T.>]>36UQ96NC^#+%;NSM=.NH7DO3*IDB:?
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M-::=8'6;A)8M>.EO=(B@RI@88YZMR?:GZGXBU_PG<:YHYU*6_"M;&VO+G&Z
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MO7)QVIL'Q+MA9ZJ;VU"7FGSI;B&VF$JSN_W C8'XYZ4 =I<06=\K6MS'#.I
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MIN(5%R,< #..:ZK4_'6AZ1J<MA=3R^9!L^T/'$62#><+O8<#- %_PWHP\/\
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M\^R7NIHLVQ9-J(SY5NAR 10 Z+P)HD/A>?PZL4QTZ9MS(TQ9@<@Y!/3D4T>
M-$$NGR;;K=81-%"?M+_=;.[//).:W;[4K/3+![Z\N$AMD7<TCG  _P ]JR[3
MQIH-Y9WMTEZ(X[+'V@3HT;1YZ95@#SVXYH JV'@#1-/<L%N;C_1VMD6YG:01
MQL,,JY^[D>E01_#;0XM.M;!'OA!:W N(A]I;*N.A'ICL!ZFKT/CC09[:\F6Z
M<?8T$D\;P.LB)_>V$9V^^,5.OBW1#+91F^16OH#<6VY6 DC W%@<8X R: ,Z
M?X=>'KCQ"=:>WD$[.))(ED(BE<<AF3H3D9^M=97,V7Q!\+ZC?065IJT4D\[%
M(P%8!F';)&,^U9ME\4?#MQ>:E'<7)M8+.18UEF1QYG')Z<<\8//&: .W(R,5
MSK>!M!?29M+-F/LDUW]L= >LF[/7TXQ]*9;?$'PK>WL5G;:S!+<2R".-$5CN
M8]AQ5Z[\4:+82W,=WJ$4+6KQI-OR C/]P9QCF@"'6_"=EK=Y:7K37-I>VF1%
M<VCA) IZKG!R/:J%Q\/=+FMK"!+F^@6SNC>!HY1NEF)SO<D')_QKJRZJA<L
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M!=3BX/DD%,\?-QQU'6J-Y<I;^!6\.W-E='7K?6!-,/L[,9,R$[PP'<$"OH3
M-&T>E "1N)(D< @, 0&&#^([4ZBB@ HHHH *QO%S*G@_62[!1]BE&2<?PFMF
MF21),A21%=#U5AD&@#Y^MYHC-X9&L:G]ATF70Q#;SF%98UDS\X.X$ X YZ]*
MLWIT:*/3-.BNI'6/2[GR+S6/]6T19@/+C[L?X3G@8X/%>YO86DD*PO:PM$IR
MJ&,%0?8426-I*\;R6T+M$,1LR E/IZ4 >#:#9Z1XCU/P+97C172-I\\5RGF<
M[ESM4\YR.WTJ36-"T2W?XAK#:QC^SX;?[&0V?*.T9QSUS7N*:;IUL5DCL[:(
MQ\JRQ*NWKT...I_.F-HVE3&5GTZT<S\REH5/F<YYXYYH \9OKBVU/Q$;7Q+J
M\%E:W&C6WV.:XA612"@+E2>%;=GGVJ6PETN;4[W3/$5RTMI%HBC2YM14(63G
M+@9^\>,8YP!7L$^AZ3<Q013Z;:21V_,*/"I$?T&.*=>Z1IFIF,WVGVMT8_N&
M>%7V_3(XH YGX431R_#71PCJQ1'1L'.T[V.#[X(_.J'Q9A@N+/P[#=8^SR:O
M$LA+;?E*L#SVKO;6TMK&!8+2WB@A7[L<2!5'T J._P!-LM5M3;7]K#<P$Y,<
MJ!AGUP: /''\'0ZAJ/B_P[H[R&PMXXKBS8.66&YV\H&]^01]/2NI\ WDGBNY
MMM<N+5[<Z;:"P",, S?\M"/8  #ZFNBU?3M4L-&@M?!T6G6<B2C<DT>(]G.<
M!>^<5?T'21HVD0VAD\V8%I)I<8\R1B6=OQ)- %K44$FFW*$L T3 E6((X/0B
MO!=-T\+X>\%ZD+R^%WJ&J-:W$@NG!,9=E*CGC@?K7T!-$D\+PRKNC=2K+Z@\
M&L-/!7AN.WM[==(M_)MG,D*$$A'.,L.>O Y]J /*[W4KSP[HGC+3+"\F2UMM
M5@C2621G:*.3&_YLYQQ]>377>$?)TC6[N5_$MA/8W-LLPMX96:.#! #[G<[=
MV>AZGZ5UT?A?0XOMFS3+8?;05N?DSYP/][UK,N? 6A)X>OM)TW2K.WCNP-^]
M21N'1CSDD=1S0!U(((!!R#T(KS+QQ>:A>^.;+P^EY!;6LUDTL8FF>%9)=V/O
M)R2!R!TKT/3+%-,TJTL(V9DMH4A5FZD*  3^54]=\+Z-XEBBCU>Q2Y$3;HRQ
M(*^N"/I0!Y['+JMM?>";.YU^2],EU<VMQ);RD1RA5.,GJQ&<9]JY>?38K;P%
MXSD6:X9H=8, #RLR[1*G)!X+>_6O9W\):(YTS_0@HTS_ (]%5V41'U !Z\50
MO/A[X9O9KR2:P.Z\D\R8),ZAFZYP#CD@'\* .'NM9U/PEJ?B*WM;^]OA'HB7
ML0N7\SRY2P4L/0#.<=.*=I[>(K>T;41KL8L;S39'S]O-Q(\JHSAXP4 7IR.F
M,]Z]"7PAHZZFVH&"22X>V^R.9)F</%C&U@3@CZU0TWX<>&=(%Y]BLGC-U&T+
MMYS$JC=54Y^7- &?\-;74[C0[37+_6[N]^VVJ@V\V"L;!CRI^F!6UXXOYM,\
M)WMS;7\=C.%"QSNI;!) P ,Y)Z#WK2T71K30-*ATVQ$BVT.0BNY8@$YQDTS7
MM"L?$>DRZ;J",T$A!^1MK @Y!!]: /.+#5]3N[7QMI=[+>-!;V D@6]QYR;X
MSG./7&<=JD\+:G>:G%X>\+P7DVGPIHB7CW$&W?*<A0H)!  Y)XYKJK;X>Z1:
M37DT,VH"6\@\B9S=,2R].<]\?_6Q3CX#TQ+338K>XO;:?34,=K=12@2HAZJ2
M1@CV(H X>X\7>)H;:WL!J*K=6NO#2IKD0*1.ISAB#T/'(%6;CQCKWA^Q\1V5
MU=K?7EI?P6UK<-&J[1*,Y8<#@#\SZ5UMQX TN>QL[59[N,6MU]L$BNI>2?.=
M[D@Y/7\Z6;P#IET=9^US75PNK;3.LC+\K+]UEPHP10!7\*7/B===N[768W:P
M:(26\MPT7F[N RXC."O/7'%=%KVIC1= O]3,?F_98'EV9QN(&<9K*\+>"[3P
MN7=+V\O9F7RUDNI-QC3^ZH[#I^5=!=VL-[9S6MQ&)(9D,<B'HRD8(H X!O$.
MN:7'X>U2YOH;RRUB2.&6+R GV=I!E2ASD@=#GTJSX%U7Q1KTDE]?WEB;"*XG
MMGAC@*N64X# YZ=:OZ=X%AL?L4,VI7=W9V$GFV=O-MQ$W8D@9;&3C/2M#PMX
M;7PQ8W%JEY+<I-<-<9D4 JS=>G;- &K?+<O8SK9R+'<E#Y;NNX!NV1WKRR'X
MEZA#INC7-Y/;+*;U[;5(?LYW1!6QN'S< 94<^M>M]:Y6?P#I$\FO.4(;65 E
M.!\A]5]]PW?6@#&U[Q+J<?A^ZU:$6%Q8_P!IQV]NLL);,8D"%\YP3NZ'T&:S
M-0FU>X\6^-;>XOXI+6VTHXB,)QL:,LH'S<$$\GG/M76:UX+34?"%IX=M+L6D
M%N8OG,6\MY>".,CJ1DU6N_!-W-KE_J=OK A:_LUM;F(VP96PNW(^;@8[?K0!
MSO@WQ#J^EQ^#],NULVTW4[9DB\M6\U"JY!))P<_2O537#P> [J!O#1_M6,C0
MP0@^S']Z#QS\_''%=OVYH XBZ\7ZM<6.KZKI%I:3:?I4SQ/'*6\V?8 7*D<*
M!GC@YQ69;^(-5UWQ_;V]K+ =*N-)%TD,@89C=ADD=WXQZ=:V'\&7MK)K-OI>
MHPV^FZL6::&2 NT3,,.4(8#D>HIA\$7=AX@LM2T2_AMDM].&GF*>$R953D$$
M$8)XS0!R7@3Q1JF@^'O#MM-IT#Z3>7+VJSB4^:'+'G;C&,\8]JW9_B=(+Z9[
M73OM%C!=FV98Q(TS@'!D7"[< ]LYHC^'FJ0:#H>FIJ%HQTN^-T',; /SD#&>
M.I_2K5MX*US3-5O8M,UU+?0[V8S26_E9DB+'++&>BYYY[<<4 (OCK6Y]<U6S
MM?#J36^ER[;F1;KYMI!(*@@9/'2M+PMXLN/$DRL+:T^R-!YOFP7!D,;Y \MU
M*C:W)_*ETKPWJ.G:OXBOC=09U3#1; <Q,JE5SGKU!K$A\)ZOIFI7GB+SM+L;
MX63Q$VZN8II"<^9(N!@^PSSS[4 >BUB:]KK:7-8V5K;"ZO[^0I!"7V+A1EF9
ML'  ]JL>';C4;O0+.?58TCOGCS*J @9SQP>F1@XK+\4Z!J&H7^EZOH\T":CI
MSL42?(25&&&4D<CC^= '%Z+KT_A:/QGK$^E1ETU-%FMHI\;<KU#;>>3Z"NOO
M_&IL-9OM/?3'D-MIQU!'CE'[Q <$8(&#U[GI6&_@;7+[2_%$-[+IZ3:NZ31"
M(N51UZ9)'3C'0TLGACQ7=ZO<:G<1Z6LDVDMIYB29\ G/.=OX_I0!'J/C1=:\
M$WM]J?A.]_LIH8Y 6G4+*"X'4<C!QT!_"M:Z\<O9ZG+I5CH%W=/;V2W65D15
M\O [D],?CGM4-UX6U>;X5IX:6.W%Z(4A)\X[,*P.[.WOCICO3;7P_KT/BFZU
M5K.U\J72A9*OVGD. .?N]"10!HCQU;3Z?HLUE9RW%UK"%K>WW!<;1EMS'@8Y
MYJ]X8\41>)H;EHK*YMFM93#*)@N X/(!!.<?AUKSF_T;6].TSPGH-NEJ-9L_
M/E4K<[&VYX*N1WW<C':NR\"//9B\TBZTG[%<1$7$L@NA.)F<G)+ ##<=* -K
MQ3JT^A^&[[4K:V-Q)!$6";@,?[1SV'6N#U#7+TZSX(UB:QO3<S13A[6(AC*?
M+&"%SMP=V<]<?2N^\3Z=-JWAC4M/M]OG7%N\:;C@9(XKD(-&\12W_A*6YTA(
MDTE628I=(Y(*A<@<>F<<_6@#:L_'VF7>AC4C!<Q,;HV?V9U'F&;^Z.<=^N:T
M=!\367B"2\AMUEBN+.3RYX)@ RGL>"00<'D'M7GD_@;7'L;N==.A:Y@UAM0M
M[6XD1X[B-@ 5;GKP.M=MX0MKU$N+J[T.QT42A56UM@I8XSEG90/7@=L>] '3
MT444 %%%% !1110 4444 %%%% !7#?%U=_P\NQ_TW@/_ )$6NYK@_C$=OPXO
M#_TW@_\ 1BT =VOW1]*6D7[H^E+0 4444 %%%% '*?$DW*_#_6'M;N2VD2W+
M%X^K#NN>V?:N'DM-1_X27P!!;ZIBZ?3I2ET\*G8IC!P%Z' X&?QKU76-*M];
MTBZTV[W>1<QF-]IY /<5S5G\/(;35-,U#^V]2FGTZ-HX/.97 ##:1@C@8[4
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M;?7!K-L=VK_V>;?[&N&!/!)Z_@/SKTK3/"$&E:_J&KV]Y-YM[$L)CVJ$C5
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MKNZX7XO 'X=WF>TT!_\ (BT =ROW1]*6FQ-OB1L$94'!'(IU !1110 4444
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M-P,3HTAR N.O!]>O;%=-_;&KZ+K6O>%+K4;V>_O7C.D3O(21&YP<'L5Y)/\
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MXABMGE1<)*4.0V!]:WM4\5^*K[5=73P]:RNNF3K D*PQLDS#E][,P9>#Q@4
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MBZ=0N\@8  '  ';W-<3J7B/6Y=$TK4-?\/Z4]M<WUK]G_?,Q3?R&Q_>'/?\
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MKW<C7<(BN83,1'-A=NYE'4X_QJGI/PXT?1H[A;>ZU!O-B>%#)/N\A6^]L&,
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M-KR:AXJ\/)K/A:YM-0>:9;626X!$>%Y; ^]D>H^AH [R"UMK88M[>*(8QB-
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M>EQ=QWMX+8L('PN" _;);G@4 :FK^ ] UN^^V75JZSF+R7:"5HO,3& &"D9
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M(X+R.W$1:)BRA@N 02!]>E>967PZ\56EQHMRHT?[1IUW).\S.Y>X+G.YSC\
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MP?#I5G&'/G+-&0%4]U"]\^M7+'P[8VWAR/1;B)+FV"XE61<B5B=S$CW8DXH
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M-)U*:^MI$T^Q^Q;$A8%U_O9+'!H @L_&>IW_ (BDTM+2PAEMYTBGM99B)]I
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M&DPVJV.@Q!I?.4L9VW8(!!&WOCZ4 >L45Y-J/Q*UR75/#\&D6]DL>L68F"W
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M'OR>M>A5%;W,%W")K::.:(]'C8,#^(JGKVL6^@Z'>:I<D"*VB+D?WCC@?4G
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M 8_@[PM!X1T3^SX9FF+2-+(Y& 6/H.PJIX[\(2^,M,M[*/47LUBF$K@+N60
M=&'?GFK]MXLTJ[\33Z!!<*]Y!%YDFTC:ISC;G/WN^*U;VY-G937"P2SF-"PB
MA7+OCL!ZT ><0_"FXMTUV./76*ZM$L;EK=<@[@2>,#U  ]?:ETSX67-AJNB7
MDNL1S1Z4GE)%]GQO0LQ()W=?G-=!X%\:_P#":1:E,+(VJ6MQY*JS98C'?T-=
M#JLUY!I5U+I\44UXL;&&.5MJL^. 3Z4 >9W?P>GETR?1[;7/)THW?VN&)H-S
MJQ7!!;// %>IVT30VL43/O9$"EL8R0.M06UVRV-N^H26\-R\:EU5_EW8Y"D]
M15S(QGM0!S/C'P;:>+;2#?*]O?6K^9:W*<F-N.W<<#\JR=0\$:EXGN+ >*=3
M@N+*R?S!;6L)C$S=BY)].PQ7<"XA:4Q"5#(!DH&&1^%/8D*=H!/84 <3>>!;
MAOB!!XHL-26UVPB*2$PAL@#&!Z @?X5R9^"5T;&:T&OQ^5+<BY(^S'[X!'][
MWKJ]+\7ZWK7AJ\O;'2K4ZA;7[6K0//M3:K ,=QQSC_/:NT,\2R"-I460C(4L
M,D?2@#SVY^'>J0^+'U_1M>^PSW4*Q7G[D-NX 8J#TZ @'H15N3P+>_\ "P=-
M\31ZDKI9P+;F.92SNNTJQ+=R=Q.:ZK3M;L-5NKVWLKA97LY?*FVG(#8!P/7&
M<?6M!F"@EB !U)H 6N$^(?@>_P#&KV"0W]O;06A,@5XR69S[@], <5J:%XIF
MU?Q5KVD26T4<>FF,)(DFXR!P3D_E72K(CJ65U('4@T ><:QX US5O%-KKYU'
M3X[B&U-OL$+;.58$]?\ :J30_AJ]A\/M2\+7UW%<+<NSQRQJ1M; P3GT(!KT
M-9$==RNI [@T*ZLN58$>H- '!7/PSMKCX:V_A47!26'$HN .LW))(].2/I52
M3P-XHU'P5<Z%JFM6;LT4<$ CB(145E;<QQDM\N/3%=KJ.H:C;ZAI\5AIRW=M
M,SBXE\T+Y.!E< ]<GBL_P;XI?Q3I]Y<2V@M)+>[DMC'YF_.W'.?QH Y30?AS
MK6D^*=#U6:_L9HM,M/L>Q%<,R889'O\ /52'X7Z]9Z-XDTFWU&Q:UU20/%O5
M@P.\'+$#C !&!G.:])MKZ_EUN\M)M-,5E$B&&[\P$3$CD;>HQ6CD>M 'EEC\
M-]:TBYT;5+&ZL7U*RL7LI4E+B)@0P5@0"<@-R,=JSKKX/ZDOA+2]*LKRS-U!
M=/=W,LI<*SD  +@'@ >U>R9'K2T >36GPZ\2VFHZ_??:-*>3575S$Q=DP) S
M(P*\@C(I=,^'_B;P_I^L3>'[RVTV[OIHFBM@YDCB1<[AEE/)S^0QFO5F;:A(
M!8@< =37"R?$ZVC\-R:R=*N=B:@;!HBZY#YQDG/3Z9H [:T6=;.!;IU>X$:B
M5E& S8Y(]LU-110 4444 %-=TC0N[*JCDEC@"G5S_CA8F\#ZV)MNW[%*1NZ9
M"DC]<4 2:SJET; OH-QILURLD8?[1-\BHQ]CU]*U);ZUMY4BGN88I'^ZKR!2
MWT!ZUXEK6C:-IOP@T34+*WA2ZNY+,SRA\EV )/4]B3_D4GC2_LF\6>*-.FN+
M>62_BMH[>>>0*MH1@G!/;^+*^M 'ID_B::V\?IHDXMDT^33S=K/N.[(8+@GH
M!U_2M74?$6F:7+817%S'YE]*L4"JP)8GO_N^]>7W&EZ+<^.]'L7GMKVSA\.$
M+M8,C,I/(QZ\MS6)IXL9/#_P[N=1$+0)?SP3238("!SM5B>WL>* />_M5OYP
MA\^+S2,[-XW?E4M>+^;;Z?XPAOUELM8L;W65$<D1VW=I+T"\\F/'&.F!VKV@
M<B@#,2ZU(^(Y;5[2$:8MN'2X\T;S)GE=O7&.]:*R(QPKJ3C. >U>1>)Q&OC_
M ,6@RE-WAPN,.1ALC&.>#P*H^&K>'2]<^'MU9L\<NI64@O#YK,)<(, @GUZ?
M2@#VVDW+NVY&>N,TIZ5X+XUOE?5M9U"PNY/.M-2MX6GFN-DD1'!2)!_!ZD]?
MS- 'O517$Q@MY)50R%%+!0>6P.E>+:Y##J&O^/IEO+IH[.RBN+4QW3A5<H&W
M#!P1G\.:LZ;?GQ-J45AK]]+]GAT&*XMT\UHO.D9/GD)!&XC_ #WH ]#\/ZE9
M^./"UMJ-UIT7DSL_[B=1( 58KW&.U:TLEAHFF/*YAM+*W0LV %1%'L*Y'X/L
MI^&>F ,"5:8'GI^\;K47QCMHYOAW>2ONW0R1,N'('+@'('7@GK0!WP8, 0>M
M+7FMFL6K^,[_ ,-RWEW!86%BCV:0W;JTA?[\A;.YL'  S@>E;/PSU34-6\()
M+J4K3SPSRP+.XYE56P&/KZ9]J .QHKF?'?\ :Q\.;-%D5;MIT'E^<(FF7.61
M&SPQ [<]:\\;Q-<?V1IK6%_JMO-_PD45M/;7<C&2!&49B8G[RY!(^M 'M.:R
M_$6NVWAO0[C5;N.:2"  LL*[FY.*\PUGQ=JFB:YXIMXM1E6W6^M((Y)3Y@M5
MD&790?3GCI5_QG:7.F>#/%,$FNMJ%K-:QRVT$S[Y8AO56);NI.,?C0!Z=;7"
M75K%<1YV2HKKGK@C(J8UYKX8O=5L/'5GI-SJEQ>VEYHJ7>V=5 C<''R8 P,5
MZ5VH Q-.\5:;JFM76DVWVC[9:?Z]'@91'GIDD8Y[5MUY;92S6OCCXB36TWE3
M16L$B2%=VTB,GIWJ#1/$?B-;[P6][JYNHM=@E$T?D(HC(7*D$#.[US0!ZS17
MEMCXIU\76I>&KN_+>($U)(+63R8P# WS>9M"XP$!)^HI;KQ/XNU34=8&@6SN
MNE7?V98BL6R8KC>9&9@PSR1MH ]1I,CU%>57OBSQ5)<^*5M[NRM5TBUBN53R
M!(3E-Y3=G!],_3&*=%JVKZM\1_#+"_$,-SI'VL0>7N12?OC&1G..O:@#T;3]
M8L-5DNX[*X69K28P3@ C8XZCD?RJ]7F%IX]O+8:E"]O8K>2:X--MBD96/) &
M^3G)Q]<U=O\ Q?KGA_4=4TJ^6SNKB+36U"TG6,HK!3AE=<G\"#0!Z$>16)I/
MAN+2=<U75([N:1]297EC<+M4J,#&!GIQ7*:-XTUU]6\.0ZG;V+V^MV;31BW#
M!T95W<Y..<]*M^%/&U[XAU9+=_L* "3[3:%7CN+9A]T$,?G![D#B@#NZ* <T
M4 %1M-&DJ1,ZJ[YVJ3@MCK@=ZD/2O&O&7B-AXGC\1VNHPB'0[Q+7[(LJ[YD/
M^N<+G..0OX'TH ]EHKE/$WBVYT>31%T^RAO5U2<0QLTVP#(!';OGK6/+X_UB
M#0M8NWT:!KO1[OR;N%)B5*8!W*<>_- '?7,4DT#I%*89&4A9 H)4^N#5;2=*
MMM&T^.SM0=BDLS,<L[$Y9F/<D\U1LO$ U+4[2WLDCE@DLUNYIMY&Q7^X ,<D
MX/I@"MLG H " 3D@4A1",%5(^E<.GQ"?^W+"SFTSRH+Z[>TBW3?OD*G 9XR.
M%)Z<]*N:?XT?4]9EM;:Q22VBN9+:9A-^]B* _.T>/NDC ()ZB@"U#H&IR>(S
M>ZAJWVC3H)#)9V0@5!$2, L0,MC)Q^==$DB2KNC=77IE3D5R.B^-9==F0VVE
ME[.7S@)(YU+H4S@.O&PMCC)[BL_0/%6CZ;X3TY]+TR>%;^]>WM;-I<LTA<@D
ML3@#- '<W5G;7L1BNK>*>,_P2H&'Y&EM[6"TA$-O#'#$.B1J%4?@*XF;XF1V
MUIJLT^A7P.ERB*Y"/&P5B<  [LG/TJ];^.XWOK^SN](O;2XM+/[<(Y"A,D7<
MC#8!]B: -[^R[6UBN&L+*UAGE4Y94";B?[Q S6!X'\'KX;T:&&^M-/?48F?_
M $N%,LRLQ(^8J#WQ^%5;?XEV\YTMO[#U18M3#?9'V(?,8=@-WOU-7+7X@Z5+
MHU_J%U'/9FQN3:S6\RC>),X"C!P<_6@"QH^DZV^K-J'B&YLYI( Z6:6J$*BL
M1ECGG=@ ?3/K6P-(T\:F=2%E;B^*[?M'ECS,8Q][KTXKF/\ A96E1VVIR7-M
M<PS:>BR2P?([,C$ ,I5B",D9YXS5BU\>V=W-<VZ:=J$5Q%9&^CCGB$9FC]5R
M: '>(?"<-UI-^FCVME!>WA4SM(A G 8,58CD9Z9K#TGP#&^K6]U<^'].TI(=
MQ<6MP\AFRI!4C  7G-=)X*\0S>)_#L6I3VDENTC-C(&UAN8#;SS@ #ZUM7M[
M;:=937=W,D,$*EWD<X"B@#*_X0[0!!;0#3D6*UD,L"*S 1N3G(P>*M6_A_2K
M35[C58+...^N/];,,Y;\.@_"J5IXOT^ZU)-/>.[M;F:,R0+<P%//4=2GK].M
M<EH.H7GC+7-1E^WZM8/9Z@5MQ%&RP^4N,QN"-NX]\\T >FT444 %%%% !111
M0 4444 %%%% !7"_%[_DGMS_ -?-O_Z-6NZKA/B]_P D]N?^OFW_ /1JT =T
M/NCZ4M(OW1]*6@ HHHH **** ,[7=7M]"T2[U*Y8!((BX!/WFQPH]R<#\:\C
MU_P[J_\ P@*>(#JUD9HIAJZE(,/YSD$C?NYQD #'\(%>ULBN,.H8>A&:#'&4
MV%%*=-N.* /)->UW3=7U;P!XB8*+:229;@E-VQMJC80!USG K ?4-.T[3?'=
MI<:>]S<RZB66$(Z[8B1AF8#A <<9&:]X\F(*H\I-JG*C:.#ZBHH)+.[61[=X
M)E+%)#&0PR.H..] 'SW<W$LT_BQ-/F^VFX@M92+6W:-)8D.9 J@<*!QGO75Z
MIJ_A?6?#GB#4=$LY8Y)-+\F><QM&B'("1!>A8GT]*]?$<:\A%'&.!V]*@CEL
M9)9+.-K=I$PTD*E25ST)7M0!XU!%%!K7A%-':"&[F\/2H3%@$S-%D;L=]V>O
M<5G^%ETN]M]+MX+C5V\46'F".S5$C6-^=Q=MF2O7()R>E>]BWA#*PAC!7H=H
MXI$MH(Y7E2&-9'^\X4 M]30!\^"_TE?"GA:T=536[;6E:^5HSYP/F$LS<9(.
M5_+VKZ%DECC@>5W5(U4LS,<  =2?2FF" 2;_ "8]^<[MHSFE62*8,JE7 )5@
M"",]P: /GS2X["V\(^%KY1#%>_\ "0Y>;@,%#<Y/IC;^=2I#IUQJ.L:=XAN]
M4CUO^TC-#:V\2[[@Y^38^TD?GC&*]]-K;D &"+ .0-@I3!"9?-,2>9_>VC/Y
MT >*V?A_3]6UCXAR6UG'-?VQ#6)4_-&^U\[<'KN _&H/!UKX>U:31T%QJ%UJ
MMI;R+)9FV54C^4[C(0@W+G&,DG)%>XI#%&Q*1(I;J54#-)':V\+N\4$:._WF
M5 "WU/>@#P/1;RW@\)>$EE"FPMM2=M739D*2Q$?F<?7K7?\ A-(3\2M>FT9D
M;1'MH]Y@.83<<9VD<9QUQZUW4L%I';2B6*!8#EI R@*>Y)[5)!'#%"JP(B18
M^4( !CVQ0!P7Q.N;5)/#\$ZPJSWI=9KHG[/%M4Y+@?>]AZUP&AR6&H>#SIK:
MY;V=_%K<L]JT\8\DX7@,&X53SC/>O?9(8I@!+$C@'(#*#@U"=.L6B:)K.W,;
M,69#$N"3U)&.M '+?#.]6]\)^8MA'9D7,JL(B3'(V>73_9)/;C@UG^.+O^WM
M>T_PI8-9W$JDW=Y;SRE595QM0D<\DYQU^6N_CBCAC6.*-411A548 'L*B^Q6
MBW)NOLL(N#UE$8W_ )]: /&/A7?'PYXJUGP7JDL!$KDQ /E"XX91GKD$<?[-
M<WHEGIP\.>/+22U1]1A8M;AH\NJ*Q!(XXZC\Z^AEMM-W?;$M[7.2_GA%Z]SN
M_/FGV\5C+YD]O%;MYW^LDC53YGU(ZT ?.TVI:/#X.\(1VY#7J2NUPC+B MGK
M)Q\Q (Z=C65:7E_'\.]1M+>61H%U5&NHT!P(MIZCLI;'Z5]._P!EV 6)196P
M6%M\:B)<(WJ..#3ETZQ2.6-;.W"3'=(HC&'/J?6@#P_Q)!X93X<>(+OP]?22
M"]EMI9;?I'"Y8':HP,'KD<\"H? \-A8_$ZRAMS'';RZ(C2J'X9S &?=^.2:]
MU&F6 MQ;BQMO(!W"/REVY]<8QFDCTK3H7WQ6%JCX(W+"H.",'MZ4 ?*RV]BO
M@U+L.%U$ZN8U82$-Y6P'@9Z9/4>M=;8E]-UGQ[:Z [Q*FGYA2%\GADW,/H"W
MYU[NVA:0R[3I=D5]/LZ_X5+#IFGVTKR06-M%(Z[69(E4D>AP.E 'A7@^*QDT
M=[R#68/.CT6XBN;&*W89 5CNE<DC.2,'Z"N9\.);6DG@Z]BE"7<FI.)W\SD*
M'0 'T&"?SKZ:@TG3;:.:."PMHTF_UJI$H#_7CFHCH&CLZ.=*LMT9RI\A>#^5
M 'DOA2WTNW^._B!;F.%'!)M$8<^82N2H]<;C7M,CI'&SR,JHHRS,< #WJN--
MLEU Z@+2$7A789]@W[?3/6IKBWANH'@N(DEBD&UT<9##W% 'E7P0EB:W\1*K
MH6-^6 # DKSS]*[+XAI&_@#6O,. +9F4[L?,.GZULV.BZ7IDKRV.GVUM(XVL
MT404D>G%3WEE:ZA;-;WEO'/"Q!,<B[E./:@#Q;6H@-,L=45K+4$MM#B2XLIY
M-DB(03YD1_O?KQBO8M)FCGT2SGB21(G@1D63[P&T8S[U6G\+Z%<&$RZ39OY(
M CS$/E .0/ID]*U@ !@  #M0!X FH6C>)=,UFTN8H(9_$;!Y9Y2+AX\C=NYP
ML8'&#ZU[^&!4$$$$<$5E-X7T%Y))'T>Q9Y'\QV,"DLWJ>.O-:A564J0,8QB@
M#P*Y$?\ PK75G1F^3Q(VTJQY!?\ 7BMGQC$+7Q7?ZM,D.HZ:US;03^5(1<63
M +@*/0]>ASGL:]0'A?01;FW&D67DE]YC\D;=W3./6A_#&AOJ"7S:5:FY0AA(
M8QG(Z'ZC H X7X9PZ59^*/%<<:PPW0U&2*&/=A_*&#@#TR!6I\2;TQ-X?LKB
M39I5YJ*1WQ)(!08(4D= 3UKK[?2-/M;^>^@LH([J?_6S*@#/]33[_3[34[1[
M2]MXYX'^]'(N0: /!=4NH=%O/'$6B2K%:M<V:,T#%@D1SOP0<XSP<>N*V8=/
MMTT[68-'\663)>V\1\B!&2WC8NH4$[CM+<C&<]<XKU6T\,Z)8P3PVVE6D4=P
MFR94B #KZ'U%1P>$?#]MITVGPZ3:):S$-)&(^&(Z$_2@#R$ZVEG;-I-U82:3
M'_:UO'K"PRDPK&5/W6ZJK;03SVJSXQM])LO#M]'X?UJYFA.I6[E;>?=#;[\@
MHK X/<X[<?CZS'X8T2'3)=.CTNU6TE.9(M@PQ]3[U!_PAWA[^S8]/_LFU%I'
M)YJQ!?E#_P![W- '#ZGHEOX6\9^"K/3KB\,,MW<%Q+.SYRH_#N:X^+3Q;>$M
M<\0VEW<0:M::XZ6P24A6S(!LV]#G.?PKW.YT#2[R]M;VYLHI+FU $$C9S'CT
MJO'X2T*'5#J4>F0"[+F0R8/WS_%CIGGKC- 'G.HS77]M^.]]U<(Z:)%<*JS$
M>4^S.!Z<CI2>&H[G3/$?@UX[ZX?^U-*E>Y$LY<.RIN4X/3''Y5Z'=>#=!O;F
M]N+C3T>:]7;<OO8&1>.#@].!4$_@S2H+=)=/LHH[ZU@:.RED9V$1(..IZ9H
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M]O!"D!:29T^]L4=0.>>G%5I?B1X:ALK6Z>[E"W,S0*@@<NLBXRK #@C(X]Z
M+-QX%\.W$%M%_9_E_94*0O#*Z.JGDC<#DY]\UMV-A:Z9916=G"L-O$NU(UZ
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MU#4FNVM9)3\T; _*&V_*P.W!QZT =SH.JW&K64DUU8&RE25HS&9!(& QAE8
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MKGKVH ]4C=9(UD4Y5@"#[&G56T\SMIMJ;F-8K@PH98TZ*V!D#V!JS0 4444
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MHH **** "BBB@ HHHH *X;XN''P_N?\ KYM__1JUW-<+\7O^2>W('_/S;_\
MHU: .Y'W1]*6D'W1]*6@ HHHH **** ,OQ#K T#0;S56MWN%M8C(8T(!;'N:
MGTK4%U32+._"&,7,*3!"<E=P!QG\:R/B!_R(&N?]>;_RKSJVTZ\T>3P?_9NJ
MWTPU>S>.XM'N&8;?*#;D QM ]NF!0![1D>M&17B%AJU\WAGX>32:E<M<3:HT
M<Q,[9D3S2"&YY'3K6A%=ZEI7C>R_MB6ZFAO=386FH6]VSPR*25$31YP,' _
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M$NA2^(='NM6BGN+3R)8;^6)00DC $!!U;DX'/2@#UEF5$+NP55&22< "@$,
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MBEU2WU0::GD[O*=F&0V.6Z=@"3Q1>?$;6M/T76+R71E<V#Q&.9HY88ID<X)
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M7NI^"C=W]S<73FZF"23G<Y0-P/YC%<]KWCZYUGPEXK:PCOM/DTV39#,L94D
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MMP8Y2T!#H/,R&;&&*@8.*B6]B2#Q]$T]Q<&^L87AF:T:(2D(02%"@*,D >M
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MY8=B:T:!CM10 4444 %1SSQ6T+S3R)%$@+,[G 4>I-250UN-)="U!'4,IMI
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M_:WFG\^&/S<"U?.=R<?>]SGBMK2/#$6FZA)J5S>W&H:B\0@^TW&,K&#G:
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MC CV>-<F1XF,C?(JL>O'7% %[2_%&M:G\39=.6. :8E@EPJ>800KD$.>.6Y
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M0,X'4T >60>!?%6D0Z)?Z1>V*:K8VAL9XY2QAEBW$J>F<\U<D\)^*;'7-/\
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MYX5L'T[RS;"%4PBX&X*-PZ<\UX_=7&EVOP_\8V):WCU ZJX$1 #[!,I''7&
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M*WU'4F35&1R&,89MBOCD*2?;I[UV6A2V_ASQ_KEE!<)!H"VL4Y#2?NH)F(7
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M?'P8TYLYQKP(_P"_K5ZM:^ /"UF8V@T:!'B#!'!;<,]><Y^GIVJ3_A!_#?\
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MM<,+G+9.?NC'7Y30![+4#_9=SEQ#E?ODXX^M>;ZO\5I++QBVB6VFI($>*/\
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M<=/LC>"[-I;FY P)C&-^/][&:X^R^(\-[H4-TFFRC49KXZ>E@9!EIAC=\W3
M!SFM/0/%;ZIK%WHNH:>^G:I:HLK0M()%=#_$K#WH Z6J3:-I;RO*VFV;2.P=
MG,"DLPZ$G')K&\4^+1X>NM/L8;1;F]OV80J\RQ(-N,Y9O7/ JM9^-9[C7M.T
MFXT66UGOK:2X3S)1E=A(VD8[XZ^XH Z.+2--@N6N8=.M(YVSNE2%0QSUY S3
M(='TFS9G@TVR@9QL9HX$4L#V.!R*Y>Q^(L.IZ3I\]GIDLM_?SRPPV0E /[O[
MS%SP !@_C7,>-O$S:AI.A:I]@O+>YM-96*:T)(8LO)4=FS@8- '5>)/!DEY<
M:=/H]OI*16CNSV-W;#R)"ZX+$*/O"C0O ]C8SSW>IZ?I/FSJL8MK:#]RNTDY
M&[DL<]>.E:/A7Q6/$IOX9-.GT^[L91%-!.02"1D'(K$^(3,OB+P4%D=0VK*"
M Q (XZCH: .NATC3(;I[B&PM4G9!&TBQ*&*^A/I19:'I>FI,MEI]K;K-_K1%
M$%W_ %QUKC8O%&B:+K/BN_:#44N+>6".X61@5D<C:@C&>,^IIGB3XAZGINFJ
M\&@7$-R;V.U;S71E^;D;<'DD=.U '76GA;0["=)[32;.&9"661(0&4GT-:]0
MVTKRVL4LD#PNR@M$Y!*'T..*X?2?%>A:=;:O>6ZZI(\NJ&%X;@#<9V_A0$X5
M>#UQC% '4)X8T..UN;9=*M!#=/YDR>4,.WJ?\\50U3P9IEUX=N='LK*TMX;A
M@S9C)P?[W!!+#MDUIZ-JPUBSDG^RSVKQRM"\4X 967KT)K'UOQ]I>AZA<6<T
M%Y,;5$DNI((MR0*QP"QS].F>M '16-I'I^GVUE$28[>)8DR><* !_*JVKZ#I
M>NP+#J=E%<HARN\<J?8CD?A7*7?Q"DM_%TVF0Z/>75I'IXNUD@CW-)D@AASP
MF"1GUIVB?$:&\\,VNJW^GWD4UU<&WAABAW><Q8@!.>>!R>.<T =18:#I>F6L
MMM:6,,<4W^L7;G?QCYB>3QZU6L/"6AZ8\CV6GQPNZ&,L&8E5/4+D_*/IBJ5O
MX^T6ZTR*\A:=GEN&M8[7R_WS3#JFWU]\X]ZY;QCXVBO?#MC?Z7>7EH8-7BM[
MR( HZ]2RL!R>G;K0!UP\">&EM(;5=+C$$$IFB02. CG&6'/7@5F^+?!\,_AW
M6UT73PVIZF@21O-QO^8'+;FQQBK]EX[T2[L=0N7DFM!IQ N8[J(HZ9^Z=O?/
M;O2V7CG1KO[:LKS64EG")YH[N/RV$9Z.!W'(H ;H7@_2K'3%$FG 3S6JV]PL
MTAEPN.4!).%SZ5$OPU\)))%(FD(K1 A2)7'!_P"!5@6/BN76?BIID%G-J$.G
MR6,DKVUQ'Y:L?X6 [@CG->EGF@#FQX(T"WM[1;?3@/L+F6T3SY (WZY'S>M4
M] T_6=3US^W?$5A:V5Q;1-;VL,+!SACEG+>^  /KZU2N+S4E^+]MI"ZG<C3Y
M+ W;6_RXW!BN,XSCC-=?K&K6>A:7-J-^[);0C+L$+$?@* +U<Y%HMQI?BZ?5
M;%5DMM255O(B0I1U!VR#UXX(ZU5M_B3X8NXRUO?/*WF+&L:0.7D9N1M7&6_#
MI3I/B/X6BL(KR34U6*20Q &-MRN.H9<9'XT =6:Y23X=>'9=6EU5H;H7\I)>
M=;R4,<\=0W3%$7Q'\+RZ7<:C_:(6"WD$4H>-@ZL>GRXSS@_E2P?$3PU=6IGM
M[UY5\TQ*B0.7=@-QVKC)&.<XQ0 O_"OO#_\ 9\MB(;GR)9_M$H^U2$ROZL=V
M6Z=#3+3X;^&;+[8(;)]EXA2XC>9V60$YY!/7/3TJXWC705L+.]2]\Z&\+" 0
MQ.[OM^]\H&1COD<4EUXW\/V=G:W<VH 174?FPXC=F9/[Q4#('N0* ,RS^%WA
MVRTR[L(ENS%<H8V+W!)1202J=E!(YXYIT_PRT"XT;3],=KQ8M/D:2VD6?$D9
M8Y(#8Z9YJ]=>/O"]DT:SZS; R1><FPE\KZ\ _EUJEJ_Q)T'3+72KB.Y6YBU&
M94C>,$A4SAF/&1CTZYH BM_A9X<MM&U'2E%T]M?,KR"27<5=<X93C@\FG:5\
M,=%TK6+?55N=0N+N&+R@UQ/N#+MVX(QTQQBNQ25)(5E5@8V4,&]C6/9>+M U
M">:&TU:UEDA0R. ^,*.K9/! QU% &)I'POT31=1:XMY[U[;S#*MC)-F!7[';
MCG';.:SKCX-Z//');KJ6I0V1N#<I:QNNR-SP2,CTXKK;'Q=X?U*\BM++5[.>
MXE4ND:2 EA_D=*P/B'XV_P"$;TIETR\LFU02QJ8)#N8*QY.,_P Z .U@C,-O
M'$9'D**%WN<LV!U/O4E(F[8N[&['./6EH **** "HYYXK:"2>9UCBC4N[L<!
M0.234E9GB'37UCP]J&FQR^4]U;O"']"PQ0!B6WQ$T>[NXK:*"]+W$+S6A,0
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M3P7K-NFBZC]JN]?-VD1@.?*WA@WY _C0!Z7J7C+1=*N9X;J:7%N4%Q*D+/'
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M)J?V\.489YR%_4UR^KP2:CXRUS5%UK1(HX[S:]CJ3M'YGE *I9!PPR#CKZT
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M=:@76+34)+VUN!"54;_O*W7.<#M[<UT^N>*[RVU\:)HNG1W^H1VIO)HY)_+
M0$ *.#ECGOBNDLIY;FP@GN+=K::2-6>%CDQL1DJ3[=* .$U7P3XAUC3;%KS5
M[:XU&*_BO)2R,D2A!@1H!G Y))/7-;&A^&]0T[QGKFMW$ML8=26(+'&6+)L&
M.<C!S75T4 5K\7#6$ZVJQM.R$(LC%5)]R ?Y5Y_<?#-M8T'PW::F\$=QI++'
M,\+$^? !RN<#&2!].:])KGSXH0>.4\,&SD#M9F[^T%AMP&Q@"@#G+[P3J6I>
M,=6OKE;1=+U"P^P$1S-YB(""' VXSQT_6FP>#=<N]+T71-6DLFL-(N4E6XB=
MC)<+&"$4J1A>#R<FNPUK5;K2UM#:Z5<:@9KA8G$)'[I3U<^PK4S0!YWI?A#Q
M%9^%_$UA]IMK6]U.YDN+>6"5B$WGE2< CCC(]:S=(\%^)--UG[<NGZ3#')I3
M6,L<4[99NN\DCEF."3Z5ZC=7 M;2:X,;R")&?8@RS8&<#WK/\-:]#XG\/VNL
M6\,D,5QN*I)C<,,5YQ]* ,[X?Z->^'?!EEI&H(BW-L7!,;[E8%RP(/XX_"JW
MQ*T74O$7A"?2=,MTEFN)$R7D"! K Y]^E=A10!YU/X7UK3_$5CXET*WBCN98
MUAU.P>8*LH ^\&'&?_K>]9VMZ=?:=)XXUS4K*&.QU"Q2*%9)0275< $#U)X^
ME>K5BW%Y9:MJMYX<N].FEC%LLLCRQ9@=6.-H/<_X'TH \PT*/7M!U"TEUKP]
M<74[6PTZRG6\C?RDVG"A1CJ>I)X%7=-\+Z_9>%_"-BVEN;C2]2-S<;9D^YEC
MD'/)^?\ 0UWVC^#= T*Z-UI^G1Q3GHY)8J/1<DX_"MZ@#R]-#UVT'BNQD\/P
M:C9:CJ)NE\RX"B6-W7*@=F !.21@@=:ATUO$'@/2;^YM].NKC2?M4:VUE=W"
MF:&/'SD$9!^;  _&O4XI8YE+1.KKDC*G(R#@C\P16%JNO:-#J4=A/$][?0XG
M%O!;M.\?HV #MH W8F+QJQ4J2,X/45YEXYT?Q!JFOZC#'IL]UI\^G>7;&VD6
M,"7GF4D@MC)P.E=[HVOZ?K\$TVG3&189/*D!0J4< $J01G(S6G0!Y3X9TW6(
M?$^AW]WHEU!%9:$;-RP4_O 2>.>X_GBLO0-!\0^'[/PWJC:-<3-IUQ<QW-H@
M!DV2XPZC.#Q_*O:J* .#^'MIJ=OJOB>ZU#3;FS6_OOM$(FQRI'3@]1Q6WXY2
M_D\&:DFF6B7=VT8"0O&'#?,,_*>I R1[BNAHH \=\/V&IVGB75[M]'UK[/=:
M/Y*274>YC(%&0<=,D8"CVXI;'3=4B\*^ ;5]*OA+8:GYMTGV=\Q*';D\=,,#
M7L-%  >E>5SW$_A_Q9XCL]3\.WFJ66M2(\$D$.\2?+M,;$G  _2O5** /+=:
MCO(O'=K<_P!E&80^'I83;HC-$TAW'RMV/3BL?PM/,GB_PM<RQ7S0BPDMRIM2
MD<#=T48^Z.,DYKVJB@#P9=K>$X('MW+_ /"4F=HVA;_5?WB".F"!6GJGV(ZC
M\1G2WB83VL*P'ROO,$VL%X_O8S[BO96(52Q(  R2:@LKZUU&V%Q9W$4\))42
M1L&4D'!Y% 'D^JRV\>BZ!?VNJ?8]4M]%1%6>'?!<KC#1$?WL@UZ7X:EEF\-:
M;)/9_8Y#;)FWY_=\#Y>:U" >H!^M+0!YIX^O8(?&.EP2HMNS6<P6]DC:4#<"
M#&B="QZ<^HKC_#YTV_'P]LYEBEDMYKF.XC=/5B4!SU&3Q7O+A,;G"_+SENU1
M0_9IXDFA$3H1E'3!!'J#0!X@MP+70=3A3)TB+Q0&O88N0+4XSP/X21].*ZKP
MS/I3?%W5WTM[8VTVG1E3!@*S94G&.,^M>D&"$JR^4FUQAAM'/UID%G;6I)@M
MXHB5"_(@7@=!QVH GHHHH **** "BBB@ HHHH **** "N<\:?\@NP_["ME_Z
M/2NCKG/&G_(+L/\ L*V7_H]* .CHHHH **** "BBB@#(\4@CPKJLB22QR16D
MLB/$Y1E95)!!'/45QWASQ9;^'? GAZZU:34;VYU0X#_-,Y<]N3P.F *[/Q-'
M<3^&=3M[6!IYYK62*.-2 6+*5')X[YKSA=!\0'0?!ED=$G$VC7:2W&98\%5/
M\/S4 =.?B5IJ:+J6HRZ?J,9TR80W=LT:^9%GHQ&[&#[&MB3Q78PO!YJR+#)9
M&^:;Y2L40QRV#GOV!KG]%\-7;ZYXRCU*R9+#6''EN74[EVE3T.1US5#PSX U
M*/P5J^F:M<8O;R,VL3%MPCA3.P?0DD_C0!J6_P 4-(DN/)FM;R'?;-<P$JK&
M5 "3@*20<#.#BETOXFZ9JL^G1+IVI0+J.X6LLL2A)&49*@[NO;TKG]"T/Q%#
MIDUC<^%=-M9+>SDA%Y%Y?F73%"J@?W<YR3FDL/#>O16O@2!]*D5M'F=KMO,3
M ![CYN?6@"U%XS;6_"_B:;6=/O[:QMI7B+6I7>B@@;<Y^\.I/3WKI%\566G0
M66GV=IJ%_-]@2Y$<2AG2''#.6(Y..G4FN37PYXC@\/>,-&_LH2+?W$LUM,LZ
M_/O88&#T &22?RJWIFC:_P"'O$D6LPZ4UY#>:9#;7$"S*)()(U4#DG!!QUSW
MH UI?B=HBQ:7)!#>W/\ :3,D*PPY99%ZHP)&&SQBI8?B-I,VBR:CY%VC1WGV
M(VKHHE\[CY<9QW]:Y6S\%ZWI&J>'+E;/[0(+ZYO+L12+B/S< *,D9P*;;^&]
M2CTW6H-3\,O>6U[K!N3")5\P1,#\R$-PP('YT >BZ7KRZKIMS=QV%Y$UN[QM
M;RH!(649P!G!ZX'->7ZYXRU'Q#\/)M4$-UI[1:HB(\3[5=-Q&W(.21W[9Q7<
M_#_2=6T?0I;?5))2GVAC:QSN'DCAX"JY'!/'J:X/_A&?%*^!I_#@T-S)'J7V
MA)UG3:Z[]W0D<8H [ZT^(&DW%OJTLT-[:?V6BR3I<P;6*-G:RC)SG%4+OXFV
M4>F:C+#IMZ+RS@6?[-.@4E&'ROP3\O(SWYK&UW1/$]UXB\2WNFZ<46^TZ*WA
M:5HR&8$;AC)YQG'O6);^#M?:\UH1:'<0I?:0+8/<72NQD&TDDYZDKC'\J /4
M-"\0F_\ !]OK=[;S0?Z.)9E,9R<+DE0,D@\XK#A^+7AR>2U54U )= B*4VK;
M7?\ N#'5OI6CHW]H_P#"O$MKO3)K>ZAL?LX@+*S.5CVY&.F37#V&A:[%HO@2
MWDT:Y672[]I+D?+\J%B0>OO^E ';Q?$/0I-"N=59YXX[:X^S2PR1$2B7LNWU
M-5_^%FZ&NDW>H31WT*V<PANHGMSYD+'IN&>AQ7'W&C>)8+3Q3]CTJ9A>ZRLZ
M;E1G:#)RR;CPW3!ZC.:N>$O#=P-3\3V&J:-=VVEZJJ;9+J978G!'+9)+$G/L
M: /0D\06<FHV%BJS-+>P&XC(3@(!G+'MU'YUEZ]\0=!\.:E_9]]+.;K8'\N*
M!FX/OT/X5D?"[2KZWTR6]U&Y%RR$V5HXZ>1&Q (^K9_(5-<V&H?\+AM=26QG
M:P73F@:XVY57))Q_GUH T/\ A8?A[[7%#]ID\N27R%N3"PB\S'W2WKS63IVO
MG2?%WC)M7U68Z=8_9WC67YA&'!)"@#U('Y5RVF>%[^PU"\TB^\(+J,KW9EMM
M2DE/DA6;.Y^>WH!FKVO6&NI=>.+BRTF><7KVOE&6 .)$0$.5'0D<8_.@#J+[
MXCZ5;^']3U&WBN9)[ *)+62!DD5F'R[@>BGUJU%X[TI=&L[ZZ,R2W%OYY@2!
MV<*!ECC&=O\ M'CWKS9-#U:X'C2*'2M7/]HV41@DO<%W*XR"<]?0#Z4^>TO8
M;_2M8OO"VIW^GS:5'8R0QDK+&R@ G:ISM//7'6@#UBZ\2:?!X8DU^.0SV2P^
M<K1 L6'8 ?7CV[UE:)X]TS4O"UOK=VQM!*_E^448G?SA5&,MQZ9HT[2WA^'L
M]E#IBZ<\MM/Y=FC%_+W[MH.2<GD9]ZX#14U&TTOP5?SZ;J'V71GFBO$:$Y4O
MT=5') SU_P#KT >M:1KFG:[:-<Z;=)/&K%&QD,C#LP/(/UKF=/UO5?%^M:DF
MD7HL-*TZ7[.9A"LCW$H^]C=P%''OS2^$-.D;Q3XCUV"!X-.U!XA LBE&D*+\
MS[3T!)[UA>&KM_AYK6K:/K-O.MC=W375G>QQ-(K[NJG:"<\"@#KM+OM3TJ#5
M9/$UY"8+64>5=>6(U:/:#G [YX^M7(/%>@W-E<7D>JVWV>V_USL^WR\],@\B
MN1\:WFH:QH=EJ5GIL[Z=::E#/+"Z'?<1*3D^7UVYQP>3UP*Y[Q?'#K5QKFNZ
M1&3I_P#9/DW$PB($TQ<;5 (R2,#)[8H ]+7QGX:=92-;L?W0#/\ OAP#_.K1
M\1:.NFV^H/J=JEI<<0RO(%5_IFO+K"/1X_%WA)GMH/)AT3]^#","39GYN/O=
M>M8<,MG_ ,*Q\/QZA$OE0:_B3>N=L99F;(ZX(/2@#VRT\1Z-?6,]];ZG:R6L
M!*RRB0;4/N>U20:]I%S9->PZG:/:HVUIO.7:I]"<\5XUKS6$=WK^IZ9IHET&
MY:U@#QJ4A$RG)?:.2!C'3!)K+O;VR?2O'%O]L%RUU]F>VD-OY0E(8;F5< #
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MUT,WELIB7"/D<CCGN.?6MFY^&.B7R77VE[S-VZS3+'<,J&4=7"],D_SJY<^
MM,N;FXN#<7JR7%E]@D/G9S#Q@<@^G7K0!Q^A:[XB@UKP8;K67O(=;LW::&2)
M55"J;@01SGD9/>H=/UW6;ZYN]-U/6]0T[5C;W#2VLD*!'QDHT#8Z #GUZ^]=
MK'X#TZ.?191<79.CQ-%; NN-K#!SQSQQ3+#X?Z=:7%I-/=WM]]BC>*U2YD#+
M"KC#8P!GCCGI0!5^$T<X^'VG3SW<LWG*S*CA<1_.P(! R<GGG-9_PED-S%XD
MN;IMU^^JR"<M][@# /L.<"NM\,>&;;PMI[65I<74T.[*+/)N\L?W5'0#DUGW
M_@B&;6)M5TO4KS2;JX_X^3:D;9O=E(QGWH J>)[^/PU<VT&E!(+W7]2CAFGP
M&$1(52^T\9V@?CS6-K?B/Q#X>EU[27OEN9H-,_M&RO7A4,%!VLK 87J#@XKJ
M+OP1IM[HS6$\EP\QF6Y^VM)F?SEZ/N]1T Z8J*?P-%>6.I1W>I74]YJ$*V\U
MXP7<(A_ J@8 Z^_- ',PZMXME\3:3I/]N6X75=-%WYGV)?W! Y"C/)/O^54T
M\<^([OPAH%Q;7-M'J%WJITZ1WAR).<!_0>XQ]*[6/P7'%KFF:H-2NC)IUK]D
MB0JF"F,<\=?\*XWQ1X53PWX<T32+.[O9%.MQW1G$0=H!SN?"CMD'F@"[)XK\
M2Z0_B+2;VXL+K4+"WBN;>Z91$A1F .X=,C/ [U2/Q UJ'1_%+1SQ74VEK!+;
M3S6AA,D<G!)3MC@CU!KI;_X=6VJV5^+[49YM1O'C=KT(%*^7]P!1QM'/'?/M
M5.Z^&#WLFIO<>(KUVU..-+HF-,OLZ?0>P_6@"*Q\2>*)/$/]C7#V!GO-*%]:
MM'&=L3C'RG)^8'UI^@^,M5UO1M.B1K9-<DU!K:[B,9Q$B9+G&<_=QSZFK]WX
M=70]5A\5W&H7$PTS3_LQ@BMP3(@')X/7O3/!VFVE_K^J^,+>RFMDU$(D*SIM
M9E &Y\=MQ'X[<]Z -3Q9XCFT0Z99VD:/?:I<BV@:7[D9/5FQR<>G>N>U+QOK
M.@MK>GWEO9SWUA:+>P2J'5)HB<'*\D,#[XKI_%/AF/Q):6X$[6MY:3+<6MRH
MR8I ?3N/:L?4O D^L6FJ/?:BC:EJ%NEJ9T@PD42MDJJYZDYY)H T_"5]X@U&
MQ:\UNWLX4G5);46S,3M9<D-GN.*YJ'Q_KQN-:N9=*LO[*T>>2&Y=)6\P[0?N
MYZ\X'3O7=Z39RZ?H]G9S2K+)!"L9D"[0V!C.*YO3/!3PV/B*SU"ZCFAUJ9Y7
M\E"IC+@@@$D^V* *6@>.-2UC6;.RN]*4V=] 7\V&*3$+8SM<N "".XXK&\&:
MU=:%\.-*^Q6D4AGO9TDFG?9% H=CN<CGM@5TGAOPMX@T?RX+[Q +VRM%*V<7
ME;#TPID/4@#MS67:_#W5K+2M%MH]1M)6TV[EF\N:-C%*'R<LO]Y23B@"AJ7C
MS6=4T72;C3X+>V>;5ULIBLI(<JP("MC[C=SU]N:UM7^(\NFW=Y;P:?%<MI^Q
M;I5D;<[D LL>%(./]K'2J@^'6LQZ4MNNIV3S0:N-2MRT3*IY)(;'KQP.F*N2
M>$/$UAK]W?Z'K%K!%J6UKV.6,D+)C#/&.?? )[T /UGQ7+K&GZI9:1IHNEAT
M_P VZ,\GE[!(FX(!@Y;!SVJ[\.WF'PRTAE17E%J=BEL!N3M!/;M6==^$/$%C
MJVIW&BW=K-!JEJL-Q]L9@ZNJ;-X(!R<<\^M=)X1T>YT'PG8:3=R1236T?EEH
ML[3R?6@#D_"WCV^F\-+?ZM:>9<75\UO9QQ.N97+D! .P7U)KIM(\4_;M<N=#
MO[%[#4X(A.(BX=9(R<;E8=>>",5R5KX URUT*WM4EL1=:7J)OK"0,V)<L25<
M8X_6NCTS0]0NO&#^)=4@BM9%LQ:0VT<OF<;BQ9FP/PH ZRBBB@ HHHH ****
M "BBB@ HHHH *YSQF,Z78?\ 85LO_1Z5T=<[XS&=,L/^PK9?^CTH Z*BBB@
MHHHH **** "C KGO&^O2^&O"-_JL"!YH4 C#=-S,%!/L,Y_"N4O+_P 3:-J.
MAQQ:X-0AUI6C_>P)F%]FX.FW&5]C0!Z9BJU_>PZ;83WMQO\ )A0N^Q"QP.N
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MIOGCMRCYQ*2PW!1MYX[BF-\4+@^%KG5H-)2XDMM0^Q.L4^48DC:R''(.1^=
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MAJ&Z4NTK 1*2=JH <*  />K]M>R^#;+3?#D:RZOJL[S/#&)-I,>\MN=VZ8!
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MVZS@9,1E4,.,],YJR>E>/AX;#QI;O$;/5[.[UB0@;=MW:3$D'/=DZ]>, =*
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M.;Q3H4&K)I4NJ6ZWKMM$6[G=Z'L#[&@"C_P@^DQW^EWELUQ;2:9$T5LL3C:
MV=V<@Y)R<FJEO\.["RC5;+5-4MV6X>Y5DE7(=QAC]WG(K;_X271?[7&E?VC!
M]N)V^3NYW>GIGVZUJD@#)Z4 <<WPVT06]DD,M[;S6DKRK<PS;979_OY.,<^P
M%36G@#2K73]7LFN+R>+5CNN?.D!);U& .?\ "M:U\3:)?7<EK::I:S3Q@LR)
M("0!U-</I_BG5O%OB._CT36K.UBL;I8X[62(-]IB'+N3U^F,4 ;%A\,]*L;Z
M*[:_U*Y=+9K0B:<$-$1C;P < =JL:7\/]-TV:QS>7MU;Z>Q:SMKB0&.%CW
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M?#F[CUN74].\27=G)>*HOPL2_OSW88P%)^G%)??#>9+N\?0M7;3[;4+86]W
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M7UM;7YMQ;7,5P"T;KG.1CG@_3I3#X5UZ/Q-H6K/=V]\UA%*)WF=D:1Y,YV@
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M#:+:ZM9QW4".)%1R>&'?CZFN=\;W-QX>^'++'K$D%U&D4"W94M+*W .,?Q,
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MZ[H&F3Z/H=KI]S?2WTL*[3<2_>?G_(JM+X1T2;7+;67LQ]NME589%=@$ Z
M'&.?2MR@#R&#=_PTA<"0 '['\N/3RUQ7 WGB#Q%';:]=1^)-3!T[4$CAB\XE
M2&=^ISVVCCWKW;_A M _MDZO]GG_ +1+;OM NI=^?KN_2J#?"GPE(9]]A*PG
MD\R13<R88\^_N: .(\1>(=9\,^)]"UJ\U#4)M'U*U666VBD(593'R%'3&2#B
MDU_5O$FCW/AGPV^H7S3Z@@N+J3[1LE+L2!$'/W0.!]:]5N_#&E7UE86=S;^;
M!8.CVZNQ.TH,+DGD\>M1>(_"&C>*H(H]5MO,,)S'(C%77Z$=J /(=?U/QMI%
MAX<M+_4[BTNWO'M7E@N _F)E-I;'5AN(YZ\4U-8UB[\)>/K*]UB^G73W589"
M_P Y!9E*D_W3@9%>HW?PY\.WMI8VTD$XCLF+P[)V!WD@EB<Y)X')I]E\/?#]
MC'J4:0321ZDNVZ6:9G$G.<\]\D\T >1W<]_X>\!>"KC3]6OE-U-N:)G!1.1P
MHQQU_4UH:EXM\0W4?BW6H]4NK,Z-=QPVEJF%CVEV4[U(^8X KT%OA;X8;3;6
MP\BX\BUE::+$[9#MCG_QT5/J/PX\/ZGJ,]Y<1W -RR/<PI,5CG*]"Z]Z /-]
M4\2^(]7\7Z1;VFM7.G1:CI"74B1X*H_ELQP.V=M4_P#A-O%MU\-]-O([V:1X
M[R6.YEB;$[QJH(.?09.3]*]6U7X=Z#J^JKJ4Z7$=RL0A0P3% J 8V@#@#!/Y
MU3MOA;H-E;PQ6=QJ-OY#N\3QW."A; ;MC!  YH R_"^EP>/_  CH6HZK="\E
MM+EY'=XAO<ACM0GL/NY ZXKK/#GA6U\/3ZA<Q>6UQ?S>;*8HA&@ & JJ.@'/
MU)-7="T.Q\.Z5'IVG1&.W0D\G)8DY))[DUI4 >?^,K_7%\<^'M'TS6&L;?4$
MF$FV!7(*J3GGK_3%<='XG\66'AV[UJ77VN(]*UC[&]NT"CSTW $LW7OP!TKU
M/5?"MIJVOZ?K4EU=Q7=@&$'E,H4;NN05.<UCR_#/2Y-(N=,&H:@MM<W8O)5+
M(<R9SG[G3CI0!S6J>*?&.L^(-:M_#:.L>E2JB1KY6'.,DR;SD@\XQZ56\1^/
M?$UB;NZ@NHX_L]K;3_9+>%;A!O\ O^;)_ ,\#!YXKKM8^&>F:MK)U/[=?VLT
MJ*ETMM+L%P ,?-@=QP:K:C\)M)O9[\PW]]9VUZJ"6V@<",LGW2<CD#TH Q+[
MQ3XMNM<UJ"RU2VM;>RTI-213:*YY0-LR?KC)_*G7OQ U8Z9X>NI;N/2H;^R,
MKWAMO-B:?. C?W%XSD9/-=!:_#>&UGU"8:U?2O?6'V&0RA&(3  (..P&*CF^
M',IT:WTF#Q!<1V4=H;22)X%<2)N+ X/ 89QF@#L-*GDNM)LYYI(I)9($9WB.
M49BHR5/IGI5RJ6D:7!HND6FFVQ<P6L2Q(7.20!CFKM !1110 4CJ'1E.<$8X
M.#^=+2.P1&9C@*,DT <[;^!M M=.OM/BLC]DON;B)YG8.?[W).#[CFJ<'PS\
M*V_F%-.8M)#Y#N9WW%.XSG//3Z<5GZ/XTT#1=$DNKSQ#=7\,^HRQ)//"V5;C
MY ,<*/ZFNFT#Q3I7B47/]FS.[6SA)4DC9&4GIP1GF@"M-X)T.?PW'H#VK'3H
MV#QQ^:Q*$'(*L3D=3^=0Q_#_ ,/PR7$D-M-%)<0?9I72ZD!:/&-OWJ3Q=?06
MUUHD,NM7&G/-?H(XX8]WVDY^X3V7D9_K4%U\3O"UG<W-O->R"2VF$,N('(4^
MI..F>,T /O/AOX9OM)M--EL#Y-GD0,LK"1 220&SG&3TJQ%X&T2"\TNZ@@DA
M?3%VVJQRD*N>N1W)[D]:I_\ "P;%O'(\.+!-@0AS<%&VEB1C''W<'ECQ5VU\
M>>';RZ:"*_&?+:57>-E215^\4)&&Q[4 :&O^'[#Q+I+Z;J4;/ S!OE;:RL.A
M![&L2'X9^&(GNV:RDF^UQ"*833NX;'\7)^][]?3%267Q)\):A)(EOK$1\N(S
M.65E 4'!ZCK[=:M6WC?P_<V-Y=B^$4=G@W"S(T;QYZ94C//;CF@#/MOACX:M
M-(N]-AMIA#=X$SF9B[*#D+N[+D=*D;X=Z*;U;Q);Z*86HLV:*Y*^9&!@!L=>
M,#\!5/7_ (HZ'I.C_;+=I+F4RK"(?+9"K$ _-D<8'-=A:7UO>:?'>PN3;R+O
M5F4KQZD'D4 <U'\.M$BATN&)[U(M+D:6T47!PC'DG_/J:?)\/=$DOIY\7*6]
MQ*L\UDDQ6WDD!!#,GU'T-2Q_$'PI-<Q6\>MVK2RR^2B@GE\XQG''XU;U3Q=H
M.BW@M-1U**"<J&*MD[03@%B!A?QQ0!-J/AW3-4U'3[^[ME>XT]R]NW]TD?KZ
M_44EGX>L; ZHUJK12:E*TT\BD;MQ&,CCCU^I-5M0\;>&]*G6"]UBUAD:,2A2
MV<J>AX]<UL32E["26WD7)C+1R ;ATX/N* ./E^%VA2:%;:6DEY']DE:6UN5E
M_>PLQ!.& '&14UQ\-](ETFWLXY[V*XMYS<1WZS$W'FGJQ?N3@?D*@\$>+C=^
M [;6O$5_#'))*Z-*^$!.\@  5TO_  D.C_V7_:?]I6OV'.//\T;<^F?7VH X
M'Q'X$31/"VHQZ9_:^HS:G<PF^?SO,EV!MS.J\!FXZ'UJGX6\.2WMR;&WGUZ3
MP_+%(E[#JT0B5MP('E]RV<'.,#'6O1XO$^A3VLES'J]BT,0W2-YZ_(,XYYXY
MXK,U[Q/$?!>J:QX?OK2X>TB9@X_>*".2" >N* (_"_@*T\,W0G74;^],2&.W
M6ZEW+ AZA!VZ=:->\!VVNZXVJ?VG?6;RVIM)TMG $L?/!R/?\:VO#M[-J7AG
M2[ZX(,]Q:12R$# W,H)X^IKG-$\7RGQ3XBTS7+RQMXK&>&*U.1'OWJ6_B/)Q
MB@!FF?#==*O-*NH-<O6DTV)XH1(B%=K=1C' Q4)^%]O_ &8MLFKW27,-ZU];
M7:HH>&1OO=.""0./:NSNM6TZQ:-;R_M;=I/N":94+?3)YJE=7=^/$EA%#<V"
MZ>\+M-$[_OW;'RE!_='>@"AX8\'?\(YJFI:A)JMS?7&H%#,95502HX/ Z\FL
MC6OAG_:MUK/E:Y<6MIJSI-<6ZQ*P,B8P<GG'?'';TKLX]6TZ4L([ZU<J"6VS
M*< =2>>U2VUY;7D?F6MQ%.G]Z)PP_,4 >*>(]-1O&,RZGK5Y9S6<$$=M//I_
MVA;G:O+# P,L>GK78Z#X:UC5;W0_$6KZD1=:>)8XXS:!3+$Q(#,,_*Q7'&.*
M[N:[M[<XFFCC."?G<#@=3S2?;+;<B^?%ND&4&\98>WK0!Q5U\.ISKU[>:;K]
MUI]CJ+;[VTA7/F$_>VL3\N?I3-1^'5V=9GNM$\07&EVM]@7L$:YWX&,J>Q(_
MSVKJ;7Q)IE[KEYI%O<*]U:*K2@$8!.>/J,<^E7OM4<T4GV:2*5U!P ^0#VSC
MI0!GZYH$>L>%;K0EE,,4UOY"OC)48X/OTKG-.\#:O9ZUI.J7&N0W,FG6AM40
MVFT;2,8R&[<=:Z?0+K4KG1K>768(+:_;<)(H7W("&(&#] #6F&##(((]J /,
MK;X6ZA96NFI;ZY 9=/NY+F+S+3<A,F,Y4MU&.*</AIJL>A-8IK<#2QZLNIV[
M-;[5##.0P![Y[<#'O7I98*,D@?6C('<4 <[XJ\/WOB+P9<Z*+N);FXC1))V0
MA<@@DA1TSCI[UB7/@&[U#6[6ZO;JV:UCTDZ9+&BMN92#E@>QR1^5=[N&,Y&*
M6@#A_#GA7Q)I;P6VHZ[%=:;8$_8X4C*NX (02-Z+GIS^E9"_#?6$\-06*ZA8
M_;+75?[2A?8VQF)SM;OUKJ_&?BO_ (0_2%U*2P>Z@WA'V2!2I/3@CFM1-9L6
MT$:SYZ_8?(^T&4] F,Y_*@#CCX'UF6Y\3W$]W8M)K=HD&5#@(RKMW8QWR35>
M/P+XDTB;3]0T/5+2&_CLDLKN.4,T,RH,*P&,YKI_!WBM/&&D-J<%E);6_F&.
M/S'!9\=3@=*Z*@#BH_"6K1^-M'UF2^BN8;.T>"9Y<B21G+$L !@#)&!V%7/'
M_AV^\4>%WTNP>".229&9IB0 JG/& ><@5U-8'BSQ.GA;3H+N2UDN!-<QVX",
M%P6/4^W% &/)X8UF7Q7J6L,+,)>:6;(1B9LJ^,Y^[TSQ]*Y_4],L]'^&4/A'
M5[VV&L1H7LD@<EWD\PF,J" >IQ],UZJQ*H2!N(' '>O/AX\T6Y%SK5UX>N\:
M5.UK-=F*-S P.#@AMV.>H'>@#K_#VF'1] M+%F+RQQYED)R7D/+L3[L2:X_5
M_!^J:KXG@U!+2UM)X+U9$U.";;(T (^1T ^8X&,DUU=[KX@L=/O+&RGU""]E
MC0-;C.Q'_P"6A]A6P* /)]3\$^*'TC7-$M(;![2^U(WR7#SE6P2IV[<<?=ZY
MK5&C>+]#\1ZC=Z+%87%OJY6687$I MI@,$CCYE_G@=*ZO_A([7_A+?\ A'#!
M.+O[+]J$A4>64R!P<YZGT[&M66>& QB61$,C;$#'&YO0>_!H X"71?%GA_Q/
M?:AHT=KJ<&IQQ"?[1)Y9CE1=N_Z=3@>OM5.;POXAT?Q)/J%OING:['J,4?VC
M[5M0Q2J,%AD?=// _I7I],FD$,+RE68(I8A1DG'H* /,_$?A74[P1+!IA74;
M:WC6RU2PD6'9(/O*ZY^X#T]JC\0>'M;N-8CO+'3KB#6XW@1-3MIE$4R!5#^:
MI.>#N[<@"O1-&U6'6]*@U""*:**8$JDZ;'&"1R/PJ_0!YG;:-K6E:/XD\.MI
MKWBZC+-);7:%0A\T8._)!7!YZ&I] \/7^C^/K4M;3265OHT=E]K(&UG7D]\X
M[5Z+BB@#R^+2=1A\607&BV>I6*2WS'4+>9-ULR9.9HV/ 8CD8YY_/L-#\.WN
MD7<LT_B#4=0C=-HBNF!"G.<].M=!@44 %%%% !1110 4444 %%%% !1110 5
MS?C7=_9-CMQN_M2RQG_KNE=)7/>,<_V98X_Z"EG_ .CTH Z&BBB@ HHHH **
M** ,GQ3&DGA/6 ZAA]BF.",]$)KS70?$-_X8^''A"+2+&TGFU.<P'S6*@,S'
M!X_7Z5ZAKEE<:EHEY8VTB127,+1;W&0H88)Q]":XF/X>ZK'HV@:<-3M"-&N1
M<12>4V7(;(!&>E #%\;^(H]%\3%[&QDU30IE\Q4+&*2,C/'.<@ U?7QX9+)-
M0BCAELX=+^W7K)DE6/W(UYX)(/7L*T-%\*SZ?KGB"]NYH)[?5V4O"$/RX!&.
M>H()JMX=^'EAHOAW4]&F8W$-_(^]NA$9X5?PH P+7XD:[,8V_L:.:&6T:?>D
M4L:Q,%+;69AAA@=1ZT:1X^\2W5QX<FOK#34L]<\R.$1,^Y'7H6SVS^AJ_IO@
M3Q#;6<EA=^)FFL(8'ALH!&!MRI4>8>K  ]*+/X?ZG;1^&83J-JT6A2-(A\IL
MR;CT/- &'I>N>(T\*>+=4U(6&I16]W+&T-P&VG80I '3;CM^M;]IXKU/5IH-
M&T"UL;>X@TR&[F,P;RTWJI6- /8]:4^ -173?$.G0ZQ&MGJTKRJCP9,9=@3D
MY]!C\:DA\"ZCIVHV>IZ3JD5O>I9)9W(>(M',$4!6QG(( 'Y4 9$?Q(UK4%T.
M'3M,LA=WUQ-:3K<.VV.6/KC';&#GGTJ5/B+JD?A?4+RYL;5+ZPU/[!,Z[VA4
M9&9"!\V /\]JNCX<26]QH4MI?QJ=-NGNY6>(YGD<Y8\'@=L4ZR\$:UIR:B+;
M5[8&]OVO'5[<LCAAAHV&<%: -_PEJUYK6ER7=V]E)F9EBELF)C= !@C)R.<\
M&L'5_$<MAX]OK2/2;)Y[?1I+N.Z;/F,%/W"<<+G/%:_@OPF/"=C=PF9)'NKA
MIW$2;43/ 51Z8%4=:\':CJ/BJYUBVO[:)9M/:P$<D18A6ZG(/7- &-H?C[7[
MJ]\-R:G86$=AKF]8?(9C(A7N<\8]J[#Q?J>I:-X;NM2TN"">>V7S&CFW89!U
MQCOWKF;;P!JEO_PBZ_VC;,F@LQ4>4P,H;&<\\=*] EC2:)XG4,CJ58'N#0!Y
MQ9?$QI/$&E6MV]@FG7U@+HSINW1OLR4/.!R#6/?WVNZAX[\'ZC':V2ZC<6MP
MT4;EE385;!;J?NG.*W%^$6E#PZ=+,S>9]M%RMQCYE4'A.O\ =X^M;FJ>%KF^
M\9Z-KL-S%''IT3Q^2R'+;@03D'L#0!R]UXWEU'P;9ZC>Z+87$J:N+*:.3+1H
MX;AT!]CWZ5N77B_5[BZU*31-)BOK+3+@6]PN\B:5A]_RP..,CKUK,'PVU$>'
M6TD:I;%3J@U$.86Z_P!WK5JY\#Z];Z_>W6A>(!86.IR>;?0F/<P<\,T9/0G\
M,<>E '+2ZSJ?AOQEXVU32M-MYXH1;RW"S.4*KMYP!U/)KUW3;V/4]*M;Z($)
M<1+* >V1G%<+<> M8:7Q0(KVU,>LPI"C2EBR*HV\\<DC//K79Z#83:5X?L+"
M=D>6VA6)F3.TX&,C- '#_#JUM5\;>-WBMHXS'>K&A" ;5^;('H,BI_B?^XO?
M"MY#:+<W4>IJL:$[=V5)VY[<@5H^%/#.KZ'XAUS4+N6R>'59A,5A+;HR,X'(
M /WNOM5GQ=X>O]=O=#GLWMPNG7?VF1)F8;\#  (!]Z ,I/B/.ND:C-/HKK?V
M-\MC) DP:,.>C%\<+QR<>GK5<_%&4^'=3U6/11(=,NA;W2I=!E )P'5@/F&<
M=JSM1^'_ (GNFU?R;C3EBO=36^,+2OB0#/R-A>G0_A6OX;\$ZE9KXCM=6&G?
M8=8)<QVH;]V2,8 (   /'T% &O?>-K;3FFEG@S90:>EY+<))G!<X1 ,<D]NE
M5/#7Q"@U_6QI<EFL$TD'VB%HYUF#+W#%?NL/2J.G?#J:'X?:AX?O+WS;R[/^
MO!)"A"/*7Z */S-7?">F>*H+B'^W(M-@AM8S&K6JY>Y/0,Q[ #TQDT ;7B#Q
M'%H;V=NMM)=WUZY2VMHB 7(&223P /6L";XF6EGI&H75[I5[#=Z=.D-S9_*7
M3?\ =8'."I.1D?E5WQ;H6IW6L:+KVCI%+>:9(X:"1MOG1N,, W8XS^=<SXB\
M#ZUJ]KK5^MM$+_4YH-EL)5 BCCYRS="Q]OSH [SP[K<FO:>UW)IEWIY60H(K
MI=K,, [A['/Z&N:OOBE8V5SJ40T;595TR4)=RK&H6,$X#?>SBNX@:1[>-I8_
M+D*@NF<[3CD9[UY??^%?$4MMXV2/3<MK4B-;'STX"D_>YXXH ZC2O'VGZGJD
MMBUG>VC):&\1KB, 20C^(8)/?-0:?\1]/OYTA&FZC')/;O<VJM&N;E%SG: W
M7 )P<5BG0?$@UVSOK2P^SNFAFQ$LDJ$1S8&"1DY&1Z5C>&O"OB/2_$^@ZI/H
M1B%M')%>SR7BL7W @OUX !X ]* /0-.\<:;J?A^+6(8+H0RW(M5B9!YF_=MQ
MC/K4WCAY8_!&L2P3RP2QVSNDD3E64@9X(KE_#N@B'XBZF+*[6718&%ZL*,&6
M.YD4J1_WSN..V175>-+6ZOO!FK6EE T]S/;-''&I ))X[D#WH PO!WCFQNK3
M3=*NEO8KLV"S">ZC(6<*OSLK'KC!YJ]8?$71-1N!# EYEXI)H&: @7"I][R_
M4^U<K'H_B"+4_"US!I$H:PTB6V<R["JS&,JH8 ],X_.LSP]X>U^S\2>'M0DT
M"^$EN94O7DE0)N?/**#A4&>P&?>@#T2S\=:1?Z)!JUN+EK:>Z%I&/*^<R'C&
M/2F7?Q T*RU3[#-+, )_LSW(B)@27^X7]:PM!\%7NE^/+YB<:"DIOK://'GN
M-I'_  $;OS%<YI_A.\TW4;[2+[PB-3EFNS-;:D\I\D(3G+\]1UQU- 'L-[>P
M:?937=U((X(4+R.>BJ.IKG[#Q_H.H1W3)-/";6 7,BS0.K>4>C@8Y'(JWXQ2
M_D\)ZBFF6L-U=M%A(94#*W(SP>"<9Q7D]IIVLQ:U<7/]BZ[,EWH3VK/<*,F0
M@]@<*N<87]* /3-)^(7A[6]4@T^QN97EGC+PN\+(DF.H4L!DBM#Q5=6]GX9O
MI;G49-.C\LJ;N-"S1$]" .:\WTC3K^"^^'N=+O8UL(Y4NBT#8B9@1SQZGK7?
M>.XI[CP-J\%M!+//+;-'''$FYB3QTH HCQ[X<T>"TLKO5I;BY-HDP?[-(S2I
MMSO("]QS4.J?$G2[670OL2RW<.J2<2QPLP5!G/ &2V>W4=^U<UI-O>VWB_1;
MF;2;_P BU\/_ &:1OLS8\P DK_3\:S=,T[5].T#P;=OHM]*VF7UP;B!(CY@#
M'Y2%/;!ZT >FWGC?0+"_-G<WVR176-V\MBD;MT5G VJ?8FH1\0?##:L-+758
MS>&7R=@1\!O3.,?C7F::%<V>K:IINK^$;S5;F]O&N;:X29E@;<?^6F" ,'\>
M36]H>@W%UJ'CNV:RDMIKO"VD[P,JGY&4[&(Z9]^E ':67C?P_J%ZMI;WX,KJ
MS1[XV19 O4JQ #8]JJS?$7P['975S'<S3"WA,Y5+:3+IZ@E<8R0,]*\[\*:9
M#+%;6=YX.U0ZGID4@FEFFD$04(1^[RV-S<# &.<T_3K34XX-5TS3(M0NM&?1
MYU5+ZV*2V;D'$*L1\V2!P.* /4O"WB&'Q-H-MJ40VF1073:1M;N,D<_45I7U
M[;:;92WEY,D-O"I:21S@**\_\)^,K72?#_AK2;W3]1AEG5;02R6Y6,2# P23
MG&3CI6U\3#-_P@.H""Q^V,P0-'M+;1N!+8')QC/X4 :=AXNT'4[2ZNK34X'A
MM &G9LIY8/()# 8%6-)\0Z5KHE.FWL=QY6/,"Y!7/3((SVKQ6R$+:EXFBOX]
M;OK+4;.W_P!)6T9';!&7"X  4YP/;%=M\-;R]FU/5K>60:A:Q+$L>K&%HWGQ
MG".#U*@XS^'/% ';ZIKFF:*L;:E?06HD)">:^-V.N*YOQGXYMM%\-VUYIMW:
MR37TJ16TI8,@!.&D..H'\ZS==NDT;XJ1:EK08://IC6T,S(7CCDW993@'&1^
M=<5J-O'I_@U!<_)97/B7S]/AD7&VV#<D*>0OL?4>M 'K_AIM7:UF_M.^LK^,
MR9M;JU&/-C_V@. ?H:W*CA\KR4,&PQ%04*8VD=L8[5)0 4444 %(QVJ2<\#/
M S2T4 >"PZ;JB>&[.U_LG4?/C\3&^9?LC\0_WNGZ=:ZFPT"_U7QMXN,4^IZ3
M!=M \-Y%$8R^U<, 6'3-=MJ'B_P_I5]]BO=5@BN<9,>22H_VL#Y?QQ6E8ZA:
M:G:)=6-Q'<6[Y"R1ME3@X//U!H \W\7Z'J&GV7AJ!)=3UJXM=72Z>XDB,C)&
MO7.T=.GOUK"U*RU"ZL/B&$TC42VI30M: VCYE ;DCC\:]NHH \@NK#6IO$#>
M7I=XXU+PTMC#.(R@BEQSO)QLP<]?PS5+PE81@V,%QX5U.+5-(1OM%W<22M$B
M@$'RE#?,S<84#%>V48H \+@\+:C-\&K>.+29UU*UO_/FA:(Q321AB< D G@J
M>/3VJ]]DT/5=+U343X8URV@F2*&>ZGDD>X+[Q@H"6)"8!S]!7LQ&:3 H \)U
M@:[?^#]16:.?4;6UU2VD@O\ [*8Y;B, @EEQEMORC.*]MLKU+[3H[P130I(N
M\).FQP/<=JLX%5+S5=-TYUCO=0M;9G&56>94+#VR: /!YK1S\/=06*PN#=-X
MC\Y,6[AC'U##CI@&NFBN8=)G\9:?KUK-,^K$SV3B%I/M2,F$12 >0<8!QC->
MN(R2(KHP96&0P.012X% 'BWAO1]GC?PUI^NV@GFBT(QR+/%N"N68A3D8R$.*
M]BN3';V$S'"1QQ,3Z  5/M%+0!\\62R6?A7PEJEQ%>G3;&\N5N_LN1)$SD;6
MQ]._^-7=9CT?2_"-OJ>E17RV7]N17$,EYN_TM@K%F*X^5>H!QSBO>2HQSTKE
M?%N@QZ[=Z<L&L"PU.U9Y;52%D#\8),;?>P._;- 'D<FHZ%<>&]?U$"WO-0U/
M4H[A[95<"S3<<.QP"X!/('&2*M6-_;Q67Q"M3?FY%Q:)+'+]G\I93MP2%QA1
MD@ =^.M>LZ'X7DL;F2^U6[CO[YXO)W+;K$B)G)4*.N2!R?2M]K>%MVZ)#N !
MRHY Z4 8_@IT?P/H91@P%C"I(.>0@!'YUY!KT>G7%U\3YITMY[A/(^SRM@LO
M8A2>^< X]*]Z1%C0(BA5'0 8 J%K*T.[=;0G?][*#GZT >#3?V?-K\Z^)=5F
ML[&^TJW6TN/)69601@.JL0VT[L].<YKHK.'3K3QWX.C;S AT65'-YM#M'@[
MX]<9XKU633K&98UDM('$1S&&C!V'VXXI\EG;3/ODMXG?&-S("<4 >%^&O#N@
M7?PON-2NGBLKPWCPI>XW;,R+M##."O3.>Q-=Y\-[@M?:]:S6=I%>02Q">>Q(
M^SSY7Y64#@' &1[]J[0:98"W>W^Q6_DN=S1^4NUCZD8P>@I]K:VEBGD6D$,"
M?>\N) H^N!0!YKXUTO3-6^+/AFRU&))()[6=9$+;=V =H)!SUZ5R+V6E+J/B
M#3-;U=M,N+6Z LD%N'E,*8$0B<_,. !@$9S7N\NG64]TES+9V\EQ'C9*\8++
MCI@XR*;-I>GW%TEU/8VTMQ'C9*\2LZXZ8)&10!XTDFBZ)XC\:OJ"F*8647D%
M%"SDO%\Q3T8DY)'J:B\%&WM_&<%E+<Z?%;7FA!)(;:;"%B> [=Y,9)(]?:O:
MGTNPENFNI+.![AHS$96C!8H>JY]/:JR>&]$C"!-)LEV(R+B!1M5NH''0Y- '
MBUE#!=^$OAU'<LY674I89 LK*2ID;T/TYKOOAPD=GJWB[3+<E;2UU/$,6XD1
M@KR!^5=0GA?P_&8]FC6"F)MR8MU&T^HXXZ5;M-*T^PN)Y[2S@@EN&W3/'&%,
MAY.6QU/)_.@#SWXC/%=^+=%TUF$DGV>>8074FRU P1O<CDL,' _E7(Z.%URQ
M^'MM?7T\BRSW<,RBX8%D4G:#@Y]OIQ7MFHZ%I6KS02ZCI]O=20',32QABOY_
MRJG;>#O#EE)#);Z-9QR0DM&XC&Y23G.?6@#RVQT:YU7P)XCM+&>=I]%U:9K%
M?-.=JG)3.<D$9_&NV\$:DWBRZE\3>7+#;B!+.")F(!9?FD;&<'YCM!]%J[J6
MDZAI"HOA#3=-B:ZG+7KS9'!'WL#J<DFMO0]*CT31K73HB"L*8+ 8W,3EFQVR
M23^- &'\0+6"]T?3[:Y"M;RZI:QR*QQE6D (_6N(\/17INI/AQ<I)):V-X9Y
M)B.&LP0ZH?7<V!]"?2O5-3T;3]86);^V$ZQ/O0%B-K#H>#UIS:38O)-*ULOF
M30B"1QD,T8SA<]<<G\Z /%_#NIW-A\/=%MHIGM[*]UU[>\G1BI2(OT##[N?6
MK_C!KO0KKQ+I6FWUV+$:2E\ +ERUO+Y@3 8G.&!SBO2H_!V@1:1<:5'IL2V-
MP<R09)7/J,G@^XH3P?H*:=<6'V!6M[C;YP=V9I,= S$Y('IF@#SR[TU=,M/#
M5E'JVJW4VJD3R6;W943$1 G,F040'D]<UE37EY??">T^VW)GEMM?2+<\N]M@
MD( W=^O7TKUF]\(Z#J-G9VMWIT<L-G_Q[AB<QCT!SG'M58> O#"V,EFNE1+;
MR3"=D5F'SC.#U[9./3- '2=J^>V&JC0O$[0R?\2)]?E34EB0&81[ERP)[=!@
M5] F)3#Y7S;=NW[QSCIUZUCZ7X2T71H;N"RM"D-YG[1&\C.LF>#D,3UH Y3Q
M7=K8Z#X1.@7LL5@U_;0)Y$F!)"<  GJ>!_C6/XFUO57U_P 26,%[?1:I;FW_
M +'AMF;8V<%@0."3GG=VKN%\ ^'DLX;1+29;>"7SHHA=2;8W]5&[BN/U+PE/
M-XDU"ZOO#E[=W%S<%X+JPOQ$H0*H4-E@01C)/O0 [4=,O+SXEV%I+J5U#=KX
M=+23P,JNS>:<C(&,9]!VK!AO=1\1CX?7-YJ-VLMQ<7$,CQOMY0X#@8QNQGFO
M1M'\%PVZ6%[J,T\NKP6IMGN5N'R5.>.O;/7UYH/P[T$:;96,:W4<5E<&>W9+
MA@\9.-P#=0#B@#G9=;U33_&R6NLW=]9Q3:@%LI5PUK/#G C.!P_OZUZ'JC31
MZ3=O;OY<RPNR-@'! ..#Q6,?!6FO?1SR2W<D4=U]K6V>8F(39)W8_'UK>NK=
M;NTFMG9E65"C%3@X(QQ0!Y58^(_$FIV'@4KJYADU8W"73B!#NV9P<8]/Y5U'
MP]UG4]4@UFWU.X^TR:?J,EJDY0*748QD#C-3V?@'3K$Z1Y-U>;=)9VM5+J0N
M[[P/'.:T]!\-VOA^6_>UEG?[=.;B42D$!SU(P* ,'QEK6J:?JMI:V-ZL$;V\
MLGEPQ"6>1P/E^4C 3N2<=ZPK7QEXBU"R\%M!<6T4FLF:.X9H-P!0D;@,^@SC
MUKK]<\'6VM:U#JGVV[M;E(&MG:W<#?&225.1QU-9MC\.8-/;1_*U6\9-*E:6
MW1PI W'YATZ'F@#&_P"$K\5'PCK5W UK/?Z-?O#,?*^6:%0"2 #P1G\A77:7
MKCZUJD+6$D<FF_8TFD<+SYCGY5!SZ DCMQ64T%AX"AO)+DWM_'K%XSM'';A\
M.PY''8XQ6GX&\/CPYX:AM3#Y4LC--(A.2A8\+GO@8'X4 =)1110 4444 %%%
M% !1110 4444 %<]XP_Y!MA_V%+/_P!')70USWC#)TVPQ_T%+/\ ]')0!T-%
M%% !1110 4444 0W5U!96LMS<R+'#$A=W;HJ@9)KG9O&"?\ "4Z#I=M );75
MK=[A+DMC "[AA<?3KZU!\3X89OAWK'G(7"0[U /1LC!KADT?1[WQ1X)TV$AK
M9M.E:9(9SG<8\D9!R.>U 'LY8 9H!!KY\BU2ZB\):'9/?^3I4VL7$<KW!9D2
M-2I17((.W))ZUZ=\.K**PM]2BMM=&JVWG@KY:$10L1DJC$G(Y'?B@#MJ;)(D
M2EI&"J.I8X%./2O+O%-[IEU\1&TCQ/.8=+.GYM"[%$\TGEB>F0.F>* /3VD1
M%+,P51U).!2A@PR#D'GBO([&6SOO$^AZ#>W-Q=Z"-.<VDEVQ473AB-QZ9P!\
MN>V#WKGKN&22PMK![BX;35\2_9+)_.8;H,_-@YY'3GMS0![UYT6W=YB[<XSG
MOZ4\L "2< 5X+J^AV%J/'Z0>:L>G>3):QB=L1,0"2.>O7K6U+IUKK_CWP[!?
MR3RP7.@+-,IF8!VP>3S^- 'KPFC.W#J=_*X/7Z4ID0,%+ ,W09Y-> :'!!9Z
M)X0U-9KA;V36_(\[S68+#NP5 )QC'MZU)*R:UK.M?VUXA&FZI;W_ .X0P.TR
MJ/NB/# 8/IC^= 'O;2(F-S 9.!D]Z1YHXP"[JH)P"QQS7@VJ:7:W1^(%Q<//
M)-I_E-;LTS#8YSEL9ZY_*M22^TO6/$ LO&-X(K7^QH)+*1Y=BAF52[C_ &\G
MCZ4 >S-(B+N=@H]2<4%U ))P!U)KPS5YK74O$5EI=[K)M=&32U%C-J"$K+VW
MG! W$#()_*IK/0[.^\3:!IUSJ%QJ-L-'F<R,S1B4!F"8&<XQ@@]P : /;!*A
M( 8$D9 SU%.R*\$T.Q%IHG@W6(+JX&H2ZS]D\R29B/*WLNS!XQ@?J:=J-P=:
MUKQ$VI^(;?3+ZTO<6RS!Q+&B'Y?* 8 YQTP2?QH ]YR*K/J5HFI1Z<TR_:Y(
MFE6(==@(!/MR17AFJ6#M!X[O)=1O99M,>W:W=IW4I(<9.,XZY^E=%86=C/\
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MNND")%$1]EDD&4.<_./7Z=JX;4;O6;SX=:O<:C?)=,NNB-=R$'>& SG. O;
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M*1K34(D,X@G=X,+;L3C#G-6-8^)FEZ3JMYIGV#4KFZLU#RK#!D!?[V<],=Z
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MWD*3V\@P\<BY5A[BN?OO'FDV;1*D=W>&2U%Y_HL._9$>C'D5TL4@FB61?NN
MP^AH RK#POHVF6]Q#962PI<)LEP[$LN,8R3D#GH#4^CZ%IN@6S6VEVPMX&;<
M8U8D9]>2:ONZQHSL0%49)/85QWAKQ"VK6>H>*[R[\C25:2.VBS\@B1L&1AW8
MD'\.* .SK'O?#6G7^LP:M,LHO8(S%'(DS+M4YSC!]S7$VWB]M2^*>G);7-_#
MIDMC)))#<H8HS@$K(H/4<9R:Z>T\?:#?7OV2&>4R,CO"3"P6<)U\LX^;IVH
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MPM]5TVYL+I=\%Q&8Y%SU!&*+74K&^MFN+2\@G@4D-)'(&4$=<D5R]CXMEO\
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M!Y\:R.QWGYC\K<#GM@4 >VSWMK:JK7%S#"K\*9) H/TS2R20,,/)'C ;!(_
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MT71K/0-*@TRP1DM8 0BLQ8C))/)]S6A10 4444 %%%% !1110 4444 %%%%
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M;U/6M(NQJXB:\L;R2SDFA'R2E,?,.W?MZ57\?^+KKPY:16NGV-U<7MT"!)#
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M3K\]J(M25(6+LTD@*Y*#N,XSU]:L>'-:U:6[\7Z?::K+80FQ,MLEQ=;A"^Y
M ')."0Q'7J?:@#Z(K%\3^)+;PKHSZG=6]S/$KJA2W3<W/?V%>&Z+J7B$Z1K^
MCI?7>GZU%! JP7$[#=AL-L9C\K-D<#KGBJ<OB/5AX!U@/?ZG;W]MJ-O&T4L[
MYB!60%02<X)4\'IB@#Z4@F6XMXIE5E61 X##!&1GD>M25\_^)]=UPZ_<07.J
MZC;H-'BETZ.TD;][,53&[;U))?K4FKW'B?1]&\$VUQK&J6M_J,S"[+3DL TB
M[<@]PI'% 'OE5=1ODTW3;F^D1W2WB:5E098A1DX_*O$M*\4Z_:>&O&EN==82
MZ;=!+>[NVW,%+E2!P>3CCWIWA;Q%JFH:WXATA[R\EL9=(DF2.\?>RMY:_,">
M0#N)Q[B@#USPQXFLO%FC)JE@LJP,[)B5<'(/-5](\9:;K/B'4M#@2X2]T\D3
M"1,*0#C(.:\(T74-4\,> ]%UW3-2N@SZH\+6._,3C XV]\XY^HK8GUVZ\.^,
M_B#J5B +I(P$+#.PM(HSCOC- 'T!4-U.;:VDF$,LVP9\N(99OH*\R^'5YXHN
M-1L;J^N))](OK(-FYND=S,!DL@SD#D@CMQFO4Z .8\+>.M+\827"Z7!>%+?_
M %DDL050>PZ]>OY5T]> ?#NXGL?AWXVGM9Y(9X6#QR1MAE(4XP:G\,>)?$']
MO^#_ +;KMW<0:O%*)XG(PIWR(N/?*@YH ]XHKQ#3]>\10>(=9\&WVJW[:K-<
M11V-P"#LCWAF;I_SS.[\,4^[\5^+=2\7:W8Z*UTTFF%([:!0NUPK8=I0>N?;
MIF@#VRHKBXAM('GGD2*)!EG=L #W->,^(/%GBJ/QIJ.GP:LUG!#IGVWREAC?
M:PA#E02.FZL7Q;XBUO7?A9X?O[N^=6N+IX9UC "S;2=K-CZ=.E 'N,GB'3(O
M$,.A/<@:E-$94AVGE1GG.,=C^5:E>0ZYK]_H'Q4LH)Y8[V.'37E=S;()7PCD
MC<!D#*C]:@LOB#X@AT?0?$-W/#/:ZG?O;2V8B"^6@8A2C=<C!ZY[4 >RT5XK
MK/CSQ9::GXKCMKZT^SZ.ZM'NM@6(:0*%_P#'N3[59U_XG:U86FA7<44-O;W^
MG+.\K0EU,QSE>O X^O- 'L-%4-%NWO\ 0["\E,9DGMXY',9RNXJ"<>V:OT !
M.!5:VU"SO'9+6[@G9/O"*0,1]<58/(KSGX=0I'XU\= (BLM^@&T8P#O.* /1
MZ*** "BBB@ HHHH **** "BBB@ K/U9/,CM!QQ=Q-R<=&S6A5>Z&6M_^NH_D
M: +%%%% !1110 4444 <_P"--:O/#OA:\U:R2"22U4.4F!PPSCL1SR*R=-U/
MQG<V^DZA*FE/:7AB:6&)'$B1N 2>3C@&I?BHZK\-=:W$#,2@9/4[UXK!T<>'
M-#M=#U9==FGGC@6,6?VH2[GD0+@)GY2/Y4 >AC5M.-N\_P!OM3"C;'D\Y=JM
MZ$YP#1=:MIUB8A=WUO 9?]6)) N[Z9ZUXS?2:3IOC<ZE"#+X3NKU8[M%8>4M
MTHX?;_=!/XX/:KL^I^'I/$WBRS\5OF*Y,4EC(1DO$%^41'\1TZT =O/XCO[?
MXCQ:-(;==,;3VN6<\,I! R23T_QKHQJFGD0$7UL?M!Q#B5?WO^[SS^%>=M)%
M_P +/M$\IXPWAU@L,O+COM.>IP.:X[2]3TMM \#VCW"FYMM48RQ_\\UW'[W<
M<[: /2_B!XT/AG1I'TZZL6U))8U-O,VYMK'^Z"#TYKI[G6=-L'BCO;^VMY90
M-J2RA2WT!KP34;_39_A]>PZAL/B0ZONG$B_O?O\ 7U"XXJYJ9TF?Q7XBM_$^
MJWMK'>,KVA2$.)H3RH0D$CMC&* /8/%.OV^B:'=S"_M+:[$#O;B=Q\S $C )
MYI/!>K7.N^#M,U.\9&N;B+=(4&!G)'3\*\J>YT[3]1\36?B$D.VE(FF&]&YB
M@BX4''WLX_'->C_#21'^'.B["#M@VG'8@G- %+0/%6IW?BWQ!8ZI/8Q:?I)
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M%=*@^2%(/)! YQC&?KWK@?ASJ5KX1T6Y\/:_<16%W9W#LOGML$D;<AE)Z]Z
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MD36\ "XY0O@\=  13-/\5>+O&$S6NGR-;W-OIL,P5)EAWR.,F0AE.Y>G P*
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M[>6,$<US#$TB)(^U3@9Y->.WFKZMJ-A\/M9OK$3Z@][F/9( UP.HZ@!?U]:
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MQ;>(=:@&HC4)8(UE C8J& 48 P*ZZ\\4:)I]\+*[U*WAN"5&QFZ%N@/IGWH
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ML<_,!V7(R!74TCNL:,[L%51DDG  H \2/@?Q3"VI?9/#UI#'?Z6MFR+>*=K
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MKG'J:]3M[B&Z@2>WE26&10R.ARK ]"#WJ7% 'B5Q8Q7OA77KO3O".HZ?<26
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M8)6N/LOV,EYW(:+;MVD9YXJSX>\,:9X7LY+72XGCA=]Y5Y&?GVST'M0!Y_\
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M3_:VMQ:?\/=+T?5$M(M2LECE;R5<@K$,GGTYX]17I/B'14\0Z)<:7+<2P0W
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M^"2.6SBM@?*#H<[GSU)Z>U7=%T'Q$_Q!_P"$EU:*QA4V'V1HX)2QSD'(X]:
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M9WWB=KNQGM_M&JR7$1ECV[T;H0>_3]: .XHHHH **** "BBB@ HHHH ****
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MV-])I^IP(8O.1 ZR1G^%E/!ZUDZC\.(+[0#IB:C)$\UW]LNK@PJS3RYSDC@
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MI)[2ZTU;: I+&"SC;V+# Z_E0!S/@N[LHM+TWQ7?Q:I_:\\KPJ%N PU.5V8
M!2W11Z[0,5VMQ\2--L;+4Y;ZQO[>ZTW:;BS9%,@5NC @[2N>^:Y2R\'^(K;P
M?X9*Z>PU30;UIC:M,FV=&8DX8$C./7WJ;Q%X:U[7QK^M0Z0\,]_81V%O9O*@
MD(W!FD<YP,8P!F@#7'Q=TG?;*VC:X@N7V0%K3'FG (V\\YSVI=8\9:-KG@35
MKF=M4L([:46]TL2;;F!PP(Z'Y<D8R?I46N:1K-_=>!KF'2I2NG2B2\7>F8N%
M&.O/0]*Y^^\/Z_)H/CRW&BW7G:O>":T0;3N42<DX/'TH [*]^(&C:"([61;Z
MZ6"UBFGFCCW>3&V K2$D<G(Z>M=?;SQ75M%<0N'BE0.C#NI&0:\0\4>'_$.H
MG4()- OK@/IEM':&!@B(RJ"WF8^^P(( .<5ZWX4%ROA32X[NUEM9X[9(WBE(
M+*5 './7&?QH R/B;/=67@'4[ZRO+BUN;95DCD@D*G.X#!QU&":V?#"R#POI
MCS7$UQ+);1R/+,^YF9E#')^IK'^)EM>:AX#U'3["RGN[JZ"QHD*YQ\P))]!@
M&L^TU_7(_#NEZ9I_AO4HKX10V[3W4(6&' "LYYR0 ": -.U^(F@7NM1:9#)<
M%IIFMXK@PD0R2+U56[FN2\.^/[/0-2U^R\0:C?3F/6)8DGDB9TBC&%7<P& #
M@\#T-<Q;:9X@BU?2KR?PSJINK36&GG$,>V!4.,")/NXZDM^M;M[IVK?V=XP\
M/+H%[+=:QJDLUM/Y7[@1N1AC)T&,$XH [_5O'&C:/=M;S-<3-&BR3O;0M*MN
MC?=:0C[N>W>J^J?$CPMI#VZW6I<W$0FB,<3N'0]""!BN4T?3-0\$:OKUK=:;
M?:I::A!&;>XMX#+N94V^6V.G7OQBJ'A_POJ6C^*O!EG>V%Q/'8V4ZW,WDEHH
MWD+L%W=.,XH ]?M;F*\M8KF!M\,J!T;U4C(-<MXS\2WFFWNDZ%I!B75=5EV1
MR2KN6%!]Y\=R.PKKE4*  , =!7 ?$'2-0CUO0O%FFVTEX^DR$3VL8R[Q-P2H
M[D9/% %Y[#Q9I5_IK0ZU)J=D]PB7B36\:NJG@LI ''3/>M23QGX>AU0:8^J0
MB[,@BV\[=Y_AW8VY]LYJE9>-(-=>"WT.UNIY78"9Y8'C2V7^(L6&"P[*.IKS
M5(I/^%<:AX,N[&9_$:WA\B/R&W.6D#";?C&,$_-GI0!Z)X\\7P:%H>H16FJ1
M6VKQ0>;$AC\S'H",$#/09JQ9>,=-L?#.BW>MZC%#<WEE%,Q<8+$H"S8 X&3U
MZ5YI=W4OA^Q\;:)KL-S/J-]#OMKGR6D$Z^7M'.. N,^W-4_W6CW>DWWB"WU<
M:3=Z'%9H]J&4HX&&1AQP<$X]P: /?+>XANK>.>"1)89%#(Z'(8'N#3+R\MM/
MM)+J[FCA@C&7D=L!1]:R?!MK!9^$["&VLKBR@"$QV]PY:1%+$@-GH<'..V<5
M2^(D5A/X1EAU&ZGM8))HE$\*[C&VX$,1W (YH U8/$NC7.GSW\.I6S6D!Q+-
MO 5#Z$^O2IHM;TN?3VU"+4+5[-?O3B9=B^Q.>#[5X+J-SJMQ9+/>H\VFV.L1
MM>:EIB "X4( ) ,8)4+UQC)&>:MW(TZTLDUK0TU._P##T6K6]SJ4MTO$I&<E
M4VC(&1G/<CTH ]:U7QUH&E: VL-?PSV^[RXQ"X8R/_='O_*I?[2NKCQ-9+9Z
MAIDFE2VSLR"0-,[@\%,'E?7Z&O+_ !=+X<U3P)XAO_#UFYMWNK>::Z*D(9"X
M#!%/3"]2/[U7]4N;23XH:5-X=\C=+H=S]E:!0%:3$FWMCJ* /5H]2LI;EK:.
M[@>X7[T2RJ6'U&<TAU.Q641->6XD+;=AE7.?3&>M>(%K>Z^&WA^;2]J>*H;]
M8QLP+@R[SNW=R",$YK.U73-..D?$2]$$9N;34U6VEW9,8+_P^GUH ^BZQ?$F
MKWNEV<2Z9IKW]_<2>7#"&VKT)+,W8  _I6CI[F33K:0OO+1*Q;/7(%4_$/B#
M3_#6D2ZCJ,PCB3A5S\TC=E4=S0!SFF^/V?2=>FUC3)+&_P!$7==6RMO!!!*E
M3[XJOH7Q$N+[5;.SU'3%A&H6+7UJUO-YOR#)VMQPV!^?%4;35]*MO#?B/57G
MM=7U:]MFO+NUA?>JQA0JQDC. H('KUKFOAS:2>&O&VCVX\JZM]<TO[1$X)+6
MO!<H.3A<@C\J .O7X@>((;S38K[P=/:P7]S';Q2/<KN^8]2N,C R>?2K5Q\1
M88)[NZ6R,FB65ZMC<WWF<K(<9(7'*J2 3G//2I;B0ZS\4K:V S!HEH9WYR/.
ME&%X]0N3^-><"-[3X2>+=&<;[\:V8?+(^9F9X]N![X.* /8I_$$9\00:-91B
MYN3&)[@AP%@B/ )/<D]!^-;!?(8(5+@=,]Z\U^'VZ#QAXV^V,1/#);J=_)$:
MHV/PKA_#UW)%XK\+7T%VRP7E[<*\TDY,URF?O2KDA1S@?C0![7H/B"+63=P/
M!):WUG+Y5S;2$%D/4$$=5(Y![ULUYY:M)%\>+Z*!CY,VC(]P >-ROA2??'\Z
M]";I0!C+XB@GU^?2K9#)]C3?>3YPD&1E5SW8]<=A67J'CJUAF\/FQA^V6NL7
M9MDN ^T(0V"<$9/(/Y5RO@B WG@_QJNH+NN9+Z[%QS@E@M<K8:?:7'A/X=P!
MW5KK4V$YCE.X'<1QS\IQZ4 ?05%>$3ZQJ6AZ1XFTZUOK@6D&O1VPFEE<F"$D
MDC=]X#@ D'U]:[OP/:WVG:YJ%M-K5I=VDT2W$-I!,\H@'3(9LG!],T =V3@9
MKG;7QKI-Y'9O"S-]MN6M[<$J"^WJ_7@?KR..:Z(C(Q7,K\/?"Z*BQZ5&@2Y^
MU+M=AB3UZ]..G2@"-_'EB;G48[6QOKR#37\NZN+= RHW< 9R<=\"N@TS4(-6
MTRUU"UW>1<QK+'N&#@C(R*\:U+1-6TV\U'QCX#OVEM9)Y?MEDX_B5CO!4\$=
M2.X!J*Y\3:EJE]X'73[ZYT:PU.+R)8+9\(I5]AV@]O0T >ZT5X!-\0_$>AZ/
MXDTUKR6ZFL]0%K!?2 ,T:DOG)/4G9QGU/M6QJ7BSQ?X6\/W]U.LLMI<)%_9U
MU<M&[H6');;U[D9]J /7-2U&VTG3I[^\?9;P(7D8 G 'L.:S[CQ;H=IH=OK,
M]\D=A< &&0J<OGH N,Y_"N#OW\66/@?6+^;58K[3Y-/BN+:61%9P6"EU8$8*
MD$_ABN1\1276J:!\.KA[A%^T.(A$L2A5;S%&[ X]./;W- 'M&B>,- \1SO!I
M6HQ7$R)O:, @A?7!%;M>+VWB1?"GC_Q7"NG60MK"R,R>1 (W8_(0N1V)>NJ\
M&Z]XKU6YT^ZOH+:;2=0M#<>=&FTV[Y.$Z\]OS]J .^HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "D(S2T4 %)@4M% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1&V@,XF,,?FCH^T;A
MVZU+10 4444 1RV\,Y4RQ(^TY7<H.#ZBGXXQ2T4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 )@"C I:* &E%8$$
M@\$'O2E0>HI:*  #%(RA@01D'L:6B@!@AC$?EA%"8QM XQ]*001"(Q"-1&01
MLP,8^E244 0?8K7[,;;[/%Y!&#%L&W'TZ4@L+02QRBUA$D8PC^6,J,8X/;BK
M%% %5-,L8[LW26=NMR>LRQ*'/XXS4$F@Z1*LBOIEF5D8.X\E?G(Z$\<UHT4
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M]B-HI?"7@F\\+,8%UVYN-.C9F@M"@4+G^\>I^G KLJ* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#$\27^L6=K#%H=@EU?7$FQ3,2(HA@DNY';CIW)K-\'>)-4U:]U72=;LX;?4
M],=!(;<DQR*X)5AGGM6EXJ\3V/A319-1OFX'RQ1@X,CGHH_Q["L/P'J>D7L]
MZUMJ,-_J]T?M5[) K;$_A5 3V4<#\30!V]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!7NK"TO@@N[6&X"'<HEC#;3ZC/2DM=.LK%G:TM((#
M)C>8HPN['3.!S5FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "H;J?[- 9=N[&.,XHHH SSK>#C[/\ ^/\ _P!:FC7<G'V;
M_P ?_P#K444 *=<PV/L__C__ -:@:WG'^C]?]O\ ^M110 HUO+$?9_\ Q_\
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M_P!M@9&?^/6+_P")J(_&+QT#C^V5_P# 6+_XFBB@!!\9/'7_ $&%/_;K%_\
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G "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>sgmo-20210331xex103009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@#E5
M^&WA!0!_8L+'U+N3_.G?\*Y\(XQ_8=L1[EO\:ZBB@#EA\-_!XZ:!:_K_ (TO
M_"N?"'_0!M?U_P :ZBB@#E_^%=>$,?\ ( L_^^3_ (T[_A7GA+&/["M/R/\
MC7344 <P?AUX/(P?#]EC_<I__"O_  CMV_\ ".Z=CV@&?SKI** .=7P'X308
M'A[3OQ@4T\>!_"H.?^$>TW/_ %[K_A6_10!ACP;X:"[1H6G[?3[.O^%*/!_A
ML=-"T_\ \!U_PK;HH R%\*^'U&!HFG$>]LA_F*</#&@ Y&AZ:#Z_9(_\*U:*
M ,@^%O#S-DZ%IA/_ %Z1_P"%._X1G0<?\@33>/\ ITC_ ,*U:* ,O_A&]"QC
M^Q=.Q_UZI_A2CP[H8Z:-I_\ X"I_A6G10!F_\(]HHZ:18?\ @,G^%'_"/Z+C
M']D6'_@,G^%:5% &<- T9?NZ38#Z6R?X4[^P](_Z!=E_X#I_A5^B@"JFFV48
MPEG;J/:)1_2G_8K3_GVA_P"_8J>B@"#[';?\^\7_ 'P*7[';=/L\7_? J:B@
M"'[';?\ /O%_WP*/L=L?^7>+_O@5-10!#]DMO^?>+_O@4?9;?_GA%_WP*FHH
M A^RV_\ SPB_[X%/6)$^XBK]!BGT4 ,:-7^\H/U%/HHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *:R*XPZAAZ$9IU% $?V>'_GC'_WR*3[-!_SQC_[Y%2T4 1?
M98/^>,?_ 'R*/LMO_P \(_\ O@5+10!%]F@'_+&/_OD4?9X223$A)[E14M%
M$?D1 8$: >FT4>1$3DQ(3_NBI** &>3&%VA% SG %.  S[TM% !1110 5A^*
M54V5@64$C4[0CV/G+6Y7/^+7*6FF '[VJVBG_OZM '04444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7->,SBUT?WUBS'_D45TM<OXV.+?0QZ
MZU9_^C!0!U%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R7
MCMBJ>'0.C:Y: _\ ?==;7)>.VV_\(YQG.N6H_P#'J .MHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "N/\?$#_A&L]]=M/\ T*NPKC?'^-WA
MCI_R'K7&?]XT =E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<;\0/]9X6_[#UK_,UV5<7\0)-L_A6,'EM=MCT[!O\ Z] ':4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7$_$''VKPIG;G^W+;''/WJ[:
MN*^( 7[7X4;.&&MVX ]MW_ZJ .UHHHH **** "BBB@ HHHH **** "BF3"0P
MN(F59"IVEAD ]LBN!\%^-=4U[4M7BU8:?;6VFOY;N@9=S;B,Y9L <?K0!Z#1
M5&+6=,GG\B'4+22;:7V),I;:.^,]*CC\0:/+!)/'JMD\,6/,D6X4JF>F3GC-
M &E15&;6=,MI88I]0M8I)P#$KS*"X/3 )YS4=SXAT:SEEBN=5LH98AF1))U#
M*/<9S0!I45S/B3QQI/AS3K:ZEN(YC=,H@5'!#J2,MG^Z!SFH[#7KN_\ &<UK
M;W6EW&CBV#QM%.K3;^,\ YQSUQZ4 =516=;:]I5[>/:6NHVD]RF2T4<RLPQU
MXS58^+_#@(']NZ;N+; OVE,[NF,9H VJ*S;OQ!I%A=?9;O4K2"? /ER3*K8/
M3@^M1^))KVV\/7MSI\Z0W,$+2JSH&!V@G!!]<4 :U%<5\,]?U3Q/X;;5-4GC
M=S,T2I'$% VXY]\YKHM1\1:/I$HBO]2MK=R =LD@! /0GTH TZ*RI_$NBVMU
M':SZG;)/(@=(S(,LIZ$>H-11>+= G@:>'5[1XED$1=9 0'.< ^YP: -JBO.X
M]2\9&")OM5K(Z:GY0"VQ'VN$@?=S]T#YCNZ<=?7?TG6;J/Q/>>'M2D62=(Q=
M6LP !DA)(PP'&X'CCK0!TM%(3M&3TK)L_%&BZAJ!L+34(9;H D1@_>QUVGHV
M/;- &O163:>)=(O]1.GVM]'+= ,=@!Y ZX.,''M4^J:Q8:/$DE_<+"LC;4!!
M)8^@ Y- %^BN!\$>*1+HFJ7VK:L)H(M1DBAGD&-R\;0!COZ5H:S\0M'TW28;
M^WE%V)IQ JID;6S\P;C*D#L>: .NHK!N/&?A^T:,7&IQ1ET5QN!&U6Z%N/ES
M[XIDER)/%?V>'7=KM9$BP5%;'/$F?Q'!H Z&BN(\'>)]OA".]UR^9Y6NY85=
ME)9R'("A5&2?8"M[_A*=%;2#JBW\;6@?R]XSG?\ W=O7=[8S0!LT5P_@?7[C
M6O$/B:-KY[JS@N$^S%EV[%(/&,#TKH=5\3:3HLHBO[H1R%=^U49R%]3M!P/K
M0!KT5A7GC'0;!;5I]2A'VJ,R0;<MYB^HP*OZ3K%AKEBM[IUPL]NQ*AU!'(."
M,'D4 7J*XWXD^*IO"OAQ9[,C[9+,J1@C/ Y8_EQ^-:H\4V"^$$\1R,PLS LQ
MVC)&>WY\4 ;M%>9O\7+)/!G]JB+.H2.Z1V^QMH.X[26Z$8P3@UTLOCW0+6R@
MGN+P@RPB?:L3$JG3<1C@9]: .GHK%O?%>C6&G6M_->I]GN\&W*@L9>,_*!S7
M$^./',EO:^']5T'4\6-Q<LD[(@(901D$$9!ZT >H45SEIXZ\/WNDWFI0WN;:
MR8+<$QMN3/3*XSBJT/Q*\*3N$354R8S(-R,,@=AD<GVH ZRBL&W\9:#=:%+K
M45_&;&([7<Y!#?W<=<U&/'&@'2KC4C>XMK9E28^6VZ,MTW#&0#Z]* .BHKG=
M+\<>']9N9;>POQ--'%YNP(P++W*C'/X51\'>.K?Q9>ZE##$R);S8A.QAN3'5
MCT!SVH ["BO._B+<>+-.L[O6-+U**TL;-4(A"!GE)(!)R/4]*Z_PU?W.J>&M
M.OKQ EQ/ KR*!@9(H U:*** "BBB@ HHHH **** "BBB@ HHHH ***ANE+6L
MH#,IV'YE."..QH FHK@/"OB6+2_!46JZ[J5Q,;BZ>(/+ER"&*A1C_=K5N?'6
MG_V)JM]9QS23:>F7@>(JPS]TD'M0!U5%<U%XQLX](L+JZCG\^Y@\[R8X26"@
M99L'HH]:S]3UA=1U3PE?:==R?8[JZ=6",0'&P\,/8@T =K17$:-K$6D7/BFX
MU&ZF>"#4 BER7(RJX4?B< 5K0^,])DAOGD:6W>Q"F>*9-KC=T '<D\?6@#H:
M*XW5_'D5KH^HS6]E="[M0N8IHMNP-T<]L<UIZ?XG@N;JST^:WN8;ZXM?M"I)
M'@, .<'/KZT ;]%<ROC?3I+"TNH(+N8W<KQ10I%ER4^\<=@*QO%>M0ZOX=T;
M4M-N)EA?5(4."5R,D$,/PH [^BD/W:\EN+D6VI>+1+K-W#<6;J;%/M+9R1N
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M'<>E '6T5%<W$=I:RW$S;8XD+N?0 9-<I%XNU"&UL]1U#38HM-O9 L3QRY=
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MWQMX;TZ:>"ZU>VCF@.V2,M\RGZ5//XJT.VNK>VFU.W2:Y56A0MS(&^Z1ZYH
MV**IV&JV>I^?]CG67R)#%)MS\K#J*N4 %%>??%+7]9\-6-A>Z5>B$33B"1&C
M5AR"01GZ5T3>)])T>*VM-6U>%+PPJY\WY6?(ZX _E0!OT5Q7B_QU;:9X)?6M
M'N8;AI6$=NX^9=V<$D>WO57POXHNK32([WQ/J]JZ7H5[,*N)",?-E5';]* .
M_HK'N?%.AV=G;7EQJ=M';7/$,I?Y7]<&JS>./#*KN;6;4)O,>[=QN';- '0T
M5SK>._#"PR3?VS:E(V"MALD$^W6KM]XDTC3;6WN;J^B2*YYA(.=XQG( ZC%
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MKI/#GA%7N-1NM6@FS+?--' \G[LKD%6*C@GZUM7?@[0[ZXGFN+/<\Y#28D8
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M^DHP5B56;<P !/K7,^"?"+>#])DT\WOVM&F,JL8MA7.,CJ?2NHH *\@\(/\
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MQ/,WY )&>@[@UY9XBTV\MK_0-";4-)M;W3M.V&2XG:)),G&%;@GA>G;FO1?
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MK6I3M 8-0:,HJ,Q9=B[1G(QR*H:-:'4O'NI^( O^BQP+96S]I"#EV'J >,T
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MI:G;64:3I]K4FWE< +)CKT.1^- '3-M92&&01@@U'#:6UO"(H+>*.,'(5$
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MPLY_A5P3^53.BR(48 JPP0>XKP:RF@GT4:/96YCUBZU-A'=GY%C4'^]W^@H
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MM7GM=3:U:+2DE>2W4-YA SQGMFNT\,7TVI>&["\G)::6$,Y(QD^M &M1110
M4444 %%%% !7+>-P-F@$@Y&M6F/^^ZZFN:\9_P"HT3C/_$YM/_0Z .EHHHH
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MY9V?:0@;<OIR<4 =QK'BZVTVSTV[@A-Y;7UTMNLL;X5<DC/3GH?RKHEP% &
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MC.,U-532BITBR*?=,"8QZ;15N@ HHHH *IZL"=(O%52Q:!P HR22I[5<HZ4
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M _\ X0OP_P#9+*U_L\"*R<R0!974HY.2V0<D\=327/@S0KJ/4$DLVVZ@P>Z
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M*ZT:TO-#_LB=6>U\I8L;N<#&.?7@4 >?Z3KNKBZU>WDN[W8FDF[C:Z4;P_\
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MSZU7=K(^%/"/D+'F.^B63:NW!&-V?TS7J2V\*N76*,,PP6"C)'I3O*CP!L7
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M<:-J$1N7$64*IQN5NASG/X5[+10!Y/\ V<[2^-H=1T74IK6\OHY8_(C*NR9
M+H<<E?O8K/6P\76TEKK @NM6L])ORT"SQ&.YN(64*201DD8&,\UZU?:QI^FW
M-I;WEW'#-=R"*!&/,C'L*O4 >8>*6U+7? FI/!X=N+1KFZB:&W$/[Z3!!9Y
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M [JS\4:/?M<"WO WV=/,DRK+A/[W(Y'TJK8^./#VHW,-O:WX9YFVQYC90Q]
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ML3R:[#5[:2]T>]MHCB26!T7ZE2!7'6&AZM>IX=M+RR-K;Z3B25W=6,K@8 4
M]/K0!M1>--/FTJ#4$@N3%-=_9%7: P?..>>E0Z!XFO=7\1ZK8S:=)!!:%51F
M(R#_ +7N?;/2N77PYXD&G6VCIIJ""'4_M;7#3*-R[N@&?<FNKT:QU&Q\4ZS)
M)9K]DO'61+@2#L, ;>M %7Q3J%Q<^(M(\-6\KP)>[I;F6-MK^6O.T'MG!YK3
M7P]!8W]K=V=Q+;QPDF6-I&9)!M(YR>O/6J_B+1+R?5-/UO2PCWMD2OE.0!(A
MZC/;J?SJ0'7=85H+JS72[5XV61A,))&R",+@8'UZT 0_\)I;A%NVLIQI;S>2
MEYD$,V<9V]=O7FJ5S\0/+FOQ!HEY-#8$?:)=ZKM!]CSGVJL/#>L2^'8_#,L$
M26B3#-Z'',8;/"]=WUI)O"^JBW\4V]O#&!J3)Y#/+G@9R3WS0!JV'C&2[U#[
M--H]Q;B2U-U;EW4M*@]AT/XUFV7Q%EN#!<W&A36VERS_ &?[8\P(5LX^Z!T]
MZMIHNI1ZSIMY(D2P6FF&VD._DMMYP/3(KG/#.EZIXA\*6NGLD,&FK>-*]P'R
M[J&)P%[<]S0!T-SX[^S:C DNG-'9S7/V5)))-LC-_>$>,[?>H;_QQJ-O<ZHM
MOH8DM],<"XE:Y X/H,=:SKGP3KTMP7\ZRFD6^6X%U<%FE=!T0G' 'H*TF\*:
MM+:>(TDFM/-U5D9""VU,=<\9H O6_BN23Q);:;/:+#;7=M]HMYS(<N,9QC&,
M]>_:MK2+V74+0W,D2QHSGRMK;MZ=FZ#K7(>(;;3KVVTKP[]J#:S 8HQY&2T:
MX <GT&,]?:NZ@@CMH(X8E"QQJ%4#L!0!)1110 4444 %%%% !61XA.+6S_Z_
M[;_T:M:]9'B'_CTL\?\ /_;?^C5H UZ*** "BBB@#%\(E3X0T@J"!]DCX)S_
M  BMJLKPRK)X7TI7"AA:19"]/N"M6@ HHHH **** $/ KR_4O'^KZ9XC6"XD
MM4C&HI:FR6(NWDMTD,@. W/W?TKU$\BO/+GX822++%;^(+B&W.H+J$,9A5O+
MD[Y)Y;V]/>@".\\;ZU;Z/XMN56S,NBWBQ19B;$B$@8(W=>>OZ4UI]9N/B5J4
M+7T9LH](\WR/+XV-V'/WL\Y_2KFI_#9[^76%BUZXM[75=KW$*Q*VZ0?Q9]#C
M.*N7'@J\;6TU2TUZ6"5K);.<- K^<%Z$],>^* .-\'>(M9T'0_"PFDLFT:_N
M)+8*$;S4^9CN)Z=<]NE;=UXTUU?#K>+;46<FD)<%#9F,^8T(?9O#Y^]D=,8J
M[:_#V>TTK0+)-74_V1=M<H[6V?,R2<$;N.IJ0?#]H[6ZTF+5670;F;SGLC#E
MDR<E%?/"D^V: *!\5>*[SQ%K$%@NEC3]+\N:3S%<.\3*6 !S][ ]!S573?'W
MB"?[#J\NF2RZ/<*[W"QV;#[,@SAA)G#].>!75Z9X4.G^(]9U)KM9;?4XTC:V
M\K 0(NT<YYX)[5CZ5\-FT^06DVNW5SH<;,T.FNH"KG/!;J0,GCB@#G=6U'6-
M;;P7K=W):K87>L0M%;I'\\8W':2V3G(!STKU\=*\Z'PRO(X+&RC\2SC3M/NQ
M=6D)MU9HL'(7=GG'TK?\+6VMV]_J_P#:>H37=HTX^R&:$1LHQ\V!_=R0!ZX-
M $>M:WJ4GB6/P]H[V\%R;1KN2>="X49VJH7(Y)[^E4;?Q'X@NK_3] DAM+/6
M6M7N+QW!D1 K;1M (SN//7@5?\3^#Y=;U&UU73M5FTO5+93&+B- P>,]58'K
MS51O 4D%SI^I:?J\L6L6H<2W<T?F"Y#G+!UR.,],'B@#%N/'_B"/3XHEL;)=
M4BU<:9=*^[RR6&5=><@'\:G7Q[JFGC7+/4HK66^LKN&VMWB!6-S+]W=DD@"M
M"]\ 2W-K;A-4"W@U%=1N+AH,^;*.@"Y&%'IS3+SX=#4KCQ ][J.5U8QNHBBV
MF!X_NL#DYH 74O$WB#PQI^JW&L6UM<1Q-&MC/ I42L_567)(Q^M4H_%/B1K'
M71?Z0LEO;VC3P3W%H\,;X'S1LK$Y[]^<597X=7%_I-S:>(=?NM3F=!'!-M">
M0 <@@=VR!DGTJS9^"]471KZSU+Q'-J$T]LUK#++%A8HVZ_*#\S<#DGM0!0@\
M8:A977A+S8;*WT;5K<*S*A'E3;>%'. IR,<>M+=^.M2@M;#9;(TVIW$QM"D#
M2$6Z=&**<L3]1Q6E?^ X=4\"6WAJ[N]QME01W*1X*E3P<9/;CK4OB/P3'K%C
MIJZ?>OIM[IA'V.XC&=@P 5([@@"@##L/'6O7D%EI]SIB6.L7EVT,37,+I&T2
MC)DVGG/08SWJ;X<K=)KWC%;TQ-<_V@I<PJ0I.WJ :FO/A]>7D-K>/K\QU^VG
M\Y+_ ,H;3P!MV9QMP/7N:KR^%?$6AZ;K=[I^N>;J>H2I-^ZLARXXP!DX!]>U
M 'H3L$1G8X51DFO.Y/'6LIH4?BD6MFVA&?8\/S>>L6[:'SG!.>V*[VT$SV$*
MW>#.8E$H'3=CYOUS7&Q_#^>/3IM".I(WA^2?SEMVB)E0;@WEALXVY'IF@"+3
MO%'BC6/%M]8V5KIITZPGC69V9@[1N"01[XK9\<>(+_PSX=;4K&W@G=941DF)
MQACC(Q[D5)H?AJ71_$&L:D;J-XM19&\E(MOE[ 0.<G/!IWC'P]/XGT%M,AN8
M[</(CL[H6X4YP,$=P* .9?QGXDMM171KVSLHM1:)KGS((I;A/+Z*-J\@YSD]
M.E6K3QGK&K-IVFVNF1V>KSPO-<I>JP2)5.,@<$[CT]*M^(/!U_J&IV.L:3JW
MV#5;:'R'D,>Y)$]"OU^M077@?4%U"PUC3]:*:U K)//<1[TG5N2-H/RX/0"@
M#EO"6O7_ (?T"(K;6Y:Z\1/9SI@_*6/)3!]CU]JZ:X\=W5I<>(8);2!Y-/N(
M8+;:2!(TO"[OIWJ _#J^/A^2Q.KQ&Z&I_P!I12B A0^<X89Y!H?X<7M^NNG4
M]82235#$^Z&#9Y4D?W2.>@Z8H LZEXOUOPY::C)K>FPL(VC6SGML^7,S_P )
M!R>,'-4XOB)?6UOJ9U#3U)MTC-K*D4D:3.YP%PXR.3U] :LS> ]3UK19[3Q%
MK[W=Q@"VDAB\M82#D-@?>/%/D\#ZKJV@SV.OZ\;JXVJMO+%%M6(@@AR/XFR!
MSZ?6@"GIG]HI\7U.K)9I<2Z,2GV8$ CS!P<]2,$9] *O_$K4=7T[2+%M*E2+
MSKV**1CD'D\#(Z D8/UI^E>%M=B\66VN:KJUK<-#:&U*16Y4LO7.2>N>:U/%
M_A^;Q)HJV=O<I;S1SQSH[KN&4.<$4 9C^(=<N]0U"RTJ+3Y)=*B3[5YN\"65
M@3M3G@8!Y.:W/#6N1>(] M=4B0QB9>4/\+ X(_,5AKX7UFRUB[U+3[^S$FI1
M(E\DL3;0Z@C>@!]SP?SK?T#18/#^B6VF6[%HX5QN;JQ)R3^))H X:]\=^*(G
MUR>UTBPDL]'N?+F)E;>RCKC\.:MIXVU_4_$!L=$TJRN+<6L-WNEF*L4< X],
M]?RK*TK2[_7=5\::?:WMM#97.H%)RT9=\$<[<''3(YKJ])\)3:3XGN-0AN8O
ML<EG':)#M.]%08!SG% &/8_$*^DUZRLKZSM8$N[F6#R Y\^#;T9^V#S^5:6F
M^)M<U1K._M=-MY=(NYGB5D<F6)1D"1NV"0<CMQ6):_#;5[1[ KK-FPLKU[E'
M:U.]PPP=QW<FM30O!>KZ%<BSAU[.A1S>=';^5B3KG9NSPN>?>@#G[#Q!KK^$
M/%.H:I%8ZA#;W4D?DRAL'!4$8Z;0.G?-=%_PDVKW(>UT&PLY);.QBN)DD9L%
MG&5C3!] >3[5$/ NH)I/B#2TU* VFJ2O+&&B.Z,N03DYYQBFGP-K%G>VM]H^
MMQV5U]ECMKO,.])0@P& /?% #-3\=ZE#>?8;.P1;V&S2XGAEBD<[V&1&NP<'
MW-=?HFHOJ^BVE]+;R6TDT89X9%(*-W'/O7+W/@?5+75XM4T+6S;W;P"&[:Y0
MR";'\6/6NOTZS:PT^"U:9YVC3#2N?F<]R?QH \JTS7M:\,VGB._L=.M)M)M]
M8E\_<Q$@^90=H'& ,5U=IXSN1KVIV.H16\,$5G]MM'3),T1_'&1[5'_P@UZ8
M=5TTZC#_ &3J5XUU,HA/G#<02H.<=ASBJNJVFB^)_%^D6E@QDN-)D=;O8A"Q
MQK@>6Q(Y^8#'XT =MID]W<Z3;3WD21W4D8=XUR I/..>:\]D^(7B.*POM2;2
MK VEEJ'V.51*V\_-MR.W<<^_2O3<<5P4O@&_DT'5--_M&WS?:A]L\SRF^7Y@
MV,9]0* )8O&]]I]UKMOKUG!&^F6RW2FU8L&5NBG/?.!GI4GAOQ7K.J:O;V]W
MII^QW-OYRSI;R1B%O[C%N&XQ@BII?!DM]K6KW=_=1/;ZE9+:R1QH0RX ^8$G
MUR>E0:=X;U_1]-F2Y\2M.EM Z66+?)C." S=WP.@H [8]*\ZO/'NKO?WO]DZ
M:UW;6ET+<Q+;2,TF,;CO'RKCT]J[#PVVI2>'K-M7P;[9^](&,\\$CL<8R*Y]
MO U[!K=W/INNS6>FWSF6ZM%0$EC][:W\.?TH S]9\0ZD)_%<-G;VEK<65G'*
MEQLS(P(R0Q]0.GI64#JW]N>"7B>U>_DTZ3;)(K;<%1@MSDFNOE\&F?4==N9+
MT;-5MEM]HC.8PJX!SGG\JKV'@S4;74](O9]8BG.F0-!&GV;:"I&.<-UH SHO
M'VH/I.F(;:,ZG=W<MO)Y432*HC)W,%!R>,<9I;SQ;XIM]+M6_LVWANYM1%FO
MVB-T616'RNH)R.^<U.WPZF.EI#'K#Q7T%X]W;74<6WRR_P!Y<9Y!JY<^#;Z[
ML+&.?6WENH+M;N2XEBSN91@!0" HH Z+2?[2_L^/^UQ;?;.=_P!FSLZ\8SST
MJ]0.E% !1110 4A 8$$9!I:AN[C[+:2S^6\GEJ6V1@%FQV&: *EGH6E6%RUQ
M:6$$,K$DLB8(SUQZ?A3/["TNWOI-1M]/M4U!@<3E.2Q]365!XYL)X=&E%M<K
M'JLABA<[<*P)&&Y]JAU[6=-N85@U"UOE@34H[=)8B IE##&3G[N?Y4 7=!T[
M5/MDFJZ\UJ;XQ^3&EL#LCCSD]>Y./RK2N=%TN^NEN;FQ@EG7&'9,GCI]:Y"0
M._C#Q<AFE6%=-C_C.$)4G(YXZ=JW? ;O)X'TEW9F8P<LQR3R: -672-/FNFN
MI+.%YV0QF1ER=N,8SZ5&= T@V269TZV-LC;EC,8(4^H]*T:YJ+QA#/?P)%8W
M4EC-<&V2]4 H9.1C'7&1UH W;2PL[!66TMHH%8[F$2!03^%1W&E:?=W N+FR
MMYI@NS?)&&./3FL*\\:PVHGNEL+B;3+>;R)KQ",*V<'Y>I /!-5=0\?K:7U_
M;6^D7=S]BB6:61615V$9W YZ8- '3II.FQF(II]JIB.8R(5&P^W'%.73;%+U
MKQ+.!;IN#,(QO/X]:Y_3O&T-_JUI9'3KN!;RW,]M)(!^]P,D 9K-M_B7'- E
MY)HM[#IYN?L[W3E2J'.,X'6@#N)H8KB)HIHTDC889'4$'Z@U#)IEA-'''+96
M[I%_JU:($)]!CBN2O?B3IUK>2)'%Y]M%.())DE7.3U*IU8#UHO?B"]O+JHAT
M2YFATQE$\ID51M/<#J>N?IZ4 =C]DMOM N/(B\X#:)-@W >F>M(;.U.[-O$=
MQRWR#D^IKFKKQBXU86-A8"Y=88YG5IQ&Y#\C8N#NP.M0ZOX[&D:I-!)8,;:&
M>.!I&E"NS/W52.5'KF@#K!:6P?>((MV-N=@SCIBD6SM5(*V\0*G(P@X-<8?%
MU_9>)?$ U"*-=,TR!&^1_FYR01QR3D#MCWJWX=\;C7-8^P-9[-T/G)+%)O7_
M '6.!@T =2;6W8.##&=YRWRCYOKZTX0Q#=B-?F&&XZU)7/\ B'Q!=:/>Z9:6
ME@MU+?RM$NZ;8%(&>>#0!NB*,;<(HV]..E*(T#%@H#'J0.37GY\?:JEG=W,N
MC0I'I]V+>[87&>I ^08Z\CK5O6?'4UKJES8Z;:"X>UB62165RTA;!"KM!P<'
MJ: .UV+S\HYIW2J]C<F\L+>Y,3PF6,.8Y!AER,X-32,51F )(&0!WH 7:!SB
M@!>H%<'IOCF^O=:M].>&T\VZBE<(C,3;E02%<]">.<8J_P##R]U/4?#\EWJ5
MQ',TEQ)M*@Y&&((^GI0!UI -&!2UPOB_QEJ'A^[G6*.V\N%$9(W!9Y\GDC!^
M4#U- &_'X<C'B.36);NZF8C]U!))F.$XP2H^G\S6W4<$GG6\<N,;U#8],BB=
MG6"1H]N\*2N[IG'>@!^!1BO-;;QGXFC\,+KMU#8R0SR>1!%$K!@^X@,>>1P>
M/I6C'K_BFVL-2FO;")4AB5X)YP(AG@'*[CTZT =K<P?:+:2'<R>8I7<O49';
M-5-%TB'0]*ATZ"21X81A#(02!UQQ7%VOC+5Y8=>CA5;R2QCB>&06[1E@WWCL
MSG Y(IZ>-K@Z?"D%_:W5W=W<=M"QB*&$L/F+IG/!Z>M 'H&!5/5-,@U;3I;&
MX,JQ2C#&)RK=<]:Y#4_$.MZ%-J6GRS17,R61N[:Y,6W&" 591]>.:72]>UU-
M5TN*_NK6=-1L&N0JQ>6(B%R,G)_&@#KM/L+/1=.2VMD\N"($\DDGN23W-&E:
MK::S9?:[*0R0%BH8J1R#SUKA-"\7:M=^*M/L9[F.YM[V.5G*0[8XV4$A4;JW
M3DUD:!J6MZ)X1M]6@O87L_MIB-FT/W@S'G=US0!Z?::S9WNI7>GP2,UQ:8\Y
M2I&,^_>M"O.-0U6;0M:\7ZG;HKS1BUC0,.,LN,GZ5M^&I_$XU)HM:"&U>+<C
M.Z>9NXX 7MS0!UE,DBCEV^8BMM.Y<C.#ZT^N.\77FKC7-$TW3-1-B+QI [^4
M'Z $<&@#L:;YB>9Y>]=^-VW/./7%>5ZWXAU[2KBY2'59KZ2Q>&-VBA58ESC/
MF9ZL?05;N;NXT[Q=KVL&ZN)&L].C=("P",6' (_N@G- 'I=%<'X4;Q1-?V=]
MJ-]"UE=PEC&\H9BV,C8  !_A7>#I0 55U#4+?2]/GOKI]D$"%W..U<]XXU"Z
MM;6QM[*>99[B<+Y5L<2RC'13V]S7'3WE[J7PLU3^TKB62:WOC#\TFXX#+PQ[
MXR: /0-'\1'4KI[>XL)[&38'B6?&95]1CTX_.MO(KS>338['Q_I!-S>RB'3&
MGRTY).W^'Z''2JFAW6MZVEMK#^(8;19+@QR)YA;()P$6/&![=: /475)49'&
M588(]0:BLK"UTZV%O9P)!""2$08&37#^ ;>XU26XUFZU?4+B6&XEA$,DG[O;
MV.W\37H% !D9I,CUKC/&BO/X@\.V/VJYABNII$D$$I3( 'I7'361M]%\0W27
MUYOTV_$5J#<-A!N'..YYH ]>6UMDN7N%AC$[@!I HW,!ZGK4X.:\ZU^:[\-:
MW:^(H%FNH;N#R9(BY(60@;2!Z$XX^M=EX?L&T_1X8I"QF?\ >2[O[[<D?AT_
M"@#3HHHH **** "BBB@ K)\0#-I:?]?]M_Z-6M:LS7%+6MM@$XO;<G_OZM &
MG1110 4444 9OA[_ )%O2_\ KTB_] %:59OA[CPWI?\ UZ1?^@"M*@ HHHH
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M7Z+%8>&_'\(AE%K93:&EQ<;Y3L+;OO$DUZ5:7EM?VJ7-I/'/ _*R1L&4_B*
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M,ELO[)NI3()I4S+ #R0OK^/'>I;OPIJURGBM%%N#JI00,TAZ* /FXXX%=X2
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MG]13HM#TJ"VFMHM/MD@F.98UC 5S[CO7-Z9\1M/O]2L[2:PO[%;Z(R6DUS&
MDV!D@8)Y]/6EL/B)9ZC=PV\>GWJFZBDDLRP7_2-F<@<_*>.^* .@C\.Z-#8R
MV4>F6JVLQ#21",;7(Z9'>M)5"*%4 *!@ =JX'0OB&T_AK^U=7LI8#+<M#;!=
MO[\ECA5Y[8P2<#C-3_\ "T-%&ER7C17>^&Y6VE@2,,R.<XY!P1P><T =C=V=
MO?VS6]W"DT+?>1QD&J">%]"C$032K0")M\8$0^0^H]*Y;5/B5'#HVM2VNF7B
M7^G; 8;A I ?[KGGI[=>E=9H>HRZAH-M?75O);R/$'=),9Z9SP3P>M %BTTR
MQL99I;6UBADG;=*R* 7/J?7K3+W1]-U&>&>]L;>XEA_U;2QABOTS6#IWC_3-
M3U*WLXK:]07<<DEK*\8VSA"0VW!)['&0,U0M_BIHUQ);G['J45K--]G-U+ !
M&DF< $@F@#IW\-Z+)9K:/I5F;='\Q8C"NT-Z@8ZTXZ!HYL)+#^S;7[)(Q9X1
M$ I8]\>M<S>?$_2[2XO8_P"SM6D6PE\NZE2W!2+G&2<]*BBU!7^)\[1W,TMG
M/H@F5%<E?O#E5Z9(_G0!U,?AS18K6:VCTNT2"?'FHL0 ?'3/KBI&T+2F:U9M
M/MR;08MR8Q^Z_P!WTKF=!\2:19>'-/735U*\-U+*MM!+AIY"I)8G)P /<]*M
M+X^TZ33K2XAM;V:>ZF>!+1(AYHD098') X]<T ;<>@:3%:3VL>G6RV\YS+&(
MQM?ZCO0FA:3'8O8II]L+5CEH?+&TGU(KD=5^)"K9:+=:18W%RFH7?DL&4*5P
M<,G7[QR,=NO-7;36]'M_$FOW4DNHP3VUO%)=I<-^Z08XVJ">?\B@#<F\-Z2^
MYTTVS$WE&)7: -A<8QCN/:I-!T6WT#1X=.MB3''DY/<DY/TZ]*R[?QK92WT=
MG/:7UI-/ 9[99X@//4 DA<$\X'0X/-4K#XCZ;J-UIL<-CJ"07\K0QW$T05!(
M/X>O/X4 ='_86E?VA_:']GV_VS.?/\L;\_6KYQBN<L/%\.HZHEK!8W9MY)9(
M$O,+Y;.@)(X.1T.,CFLOXFZO?Z=X?BALH9S]JN$ADEB8#"D\KUSENGYT =BE
MI:I$(E@C$:MO"A1@-G.?KGFHIM+L+J[CNY[2&6XB&$D= 67Z&N'T?3M&TSQG
M#:PQ:S;WUY:/*L,LW[J!#P0,$\Y';-5_!WB>+1?!<)NY)[JYGOYH;>+?EY"&
MZ98X 'N: .[.@Z0;>6 Z=:^3*_F2)Y0VLWJ1ZU>1%CB6.-0JJ %4= !7)0_$
M+3+K3XY;>&>6]DN/LHL!M\WS.>.N,8&<YQ6?\-YYKC5?%;3I<1,+\?N9Y-[1
M\$XSDT 7_!_A!-&6YFU&SLWOFNY)HYT&Y@K<@9(R,5U,5C:03230VT,<LIS(
MZ( S_4CK7G-SKLWA_P")>OM'8W^HQFSBE,4#;O+&,EL$X%=!9>/K#4-8TRQ@
MMKGR]2A,UO<-M"' Y4\YW C!% '20Z98V\SS06=O%*_#.D2JS?4@<U&-&TP1
M>4-.M/+W;MGDKC/KC'6H]*U7^U/M16WDB2"=X [XQ(5."1CMFN9NOB5:6HOI
M#I&I-!8W0MIY@B[4.<9^]Z_SH V]?\/1:AH6H6EC;VL-S=PF+S2@7@^I S4O
MAW1(M%TBVMC!;K<I"L<LL*8\P@8SG&3^-4-.\:VEW?7UK=VESI[6D'VD_:5
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M80^_'E]=V<CKCFO37;8C-@G S@=37-6OCK2KCPW<ZZZSP6L$S0,LB?.7! P
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MC>9J>H+<09FCP%#@\G=P<"N^N=:MK:ZT^#9-+]N8B)X4+H,#.2PX YZUI9H
M\_NO#>IZOXEU*:>V>TL[S2?L7F&5"5?KT!/')%/\(:9XFLYK2UU33-,M+:S3
M9]IAVM)<X&T?[OJ3Q7>T4 <GX@TG4D\4Z9X@TNW6[>")[>:V:41Y1LD,">,@
MU@ZKX/UJZL_M$4<#7ESJJ7\T0EPL:JN H..3[UZ55+5=4M-%TV:_O'V01 9(
M&223@ #U)(% %Q>@..:6LO2-7DU-KA)M-N[*2$@%9U&&!&05()!K4H ****
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MD\50W'@_5KS0M2V75FJECY9#)DCJ&'?UK4\/^)],UA([6"_2>]2!))5VD$Y
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M9W,^C7L,,6B_926C_P"6@_QQ5/2]&\0Z%9:%J=MI4D\]FL\%Q:%@K%7;<"*
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M\5Y<:(L5D+L6DTJW.YE<G'RKCD"I;/P=>Z5JFB36;P/#80R"5G8AI'?.<#'
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M2:]HD6MZ8M\TDUH(9H+PQ+G8[ %6'3OU]JTHM2U72M?U6PN]8$J_V6+Q)[A
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M<MI.BQ3:WXRW75\HCD'"W+ /E"<MCK53P_))8^%/#EG#<W,4&IW+)<2B4Y0
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MI;:E9Z=-!//=22,JGR]NR,$G)8]@.!46G6-XEK\.M^G7:264LOVK_17'E@D
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MT/<T =!X$\:P:UHMDFJ:E:G5YVD_<@A6.&./E^E=H\BQH7=@JJ,EB< "O"+
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M4 %%%% !5:^.($R,_OHO_1BU9JM?$+ A(S^^B'_CZT 6:*** "BBB@"CHO\
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M &/X:AGB\*Z=;W$4D$T=NJ,K##*0,5ROA]/$FEI'X<;1@R03EDU)SF)8R<Y
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M+W%VH\LQ2C9,PX.S)Y&:Y.X\5ZY%#XT99+/S-&*FV!B)7;M+'=\V2<8YS^%
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MLH(ST"C/KFNZ=T"$N0%[YZ5SO@SQ!)XATZ\GEM([7[->26PCC;(PN.<_C[4
M.\:>&IO%>A_V9'=I;(9%D9VCW'CH!R,51'A/5'\2+K,^H6KR"Q-D4\EL$'^+
M[W7-=B#D9%% '%0^ V;X>/X5N[Q)"-QBN$CV[#NWJ<9['/X5-J_@6+4/#&G:
M7:WLEG<Z:5>UND'*R <DCWYS70SZK:0:C!IS2K]LN%9HHL\D*,DGT'O67X/\
M22>)=)DNI[=+:5+F2#RU?=G;CG]: ,34/ VLZKH'V34-?%S?-<12O,\&U L>
M["JHQCEB2>]27O@2[U&[\037&H0J-8MTB(CB/[MDQ@\GD<5W&X;MN1D]!2T
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MW'2M#P]#J%OH%E#JLHEODB F<=V_J?>N-\3:%JM]XE>\TS3I;74$DC$.I0W
M5'CP-PE4GG'/0>E &A>_$BQL[B_C&EZI*MA($N9$@^6,'N3GI4^I?$+2K++P
M))>0QQI+/) R_NE;E>"02<<X'2N7A&HW>K>.-+LM.-PUY,L33B552(E",D'G
MOGBG6O@O6?"^IR)IFEZ=K%I<QHI>[ !A=1C//:@#J[WQQ9P122V5K<ZA%#"D
M\[VX&(D;E<YQDXYP.:8^JZ;-XOLVCM+R349--::!MVU&C.#C!.-WUZ5DV^B>
M*/#NNW-QI,-E?6^H)'YWF$1"&11C( _AZ\"K\^EZVGC33M5\A;N&WT]K>60.
MJ%Y&.<@=AG% '%VYLM7\.:MXA\2:1>2M!=2'SH;C:V-P7R^&Z+^5=E?^/=,T
M.*&TB@>5H[-)VC,RJ40J-HRQ^9L=A699>&M=C^'NM:)-9Q?:[J:1H09E*[78
M'KV(Y-.?P_XFTW58=1TRTTZY-Q9PP7,%T0?*9%VY5NX^E &IJ'BV'5-.DM]'
MLY-0DFLC<2*DHC\I",#)_O=>!Z5+\,VW?#_3"<YP^<G_ &VK*F\.^)-)UJ;4
MM,-I?-?6HAN4E;RPCCHR_P"S[=:Z+P7I5YHGA:STZ_$0GAW9\IL@Y8G\^: *
MWB"ZT^+Q3H,-WITT]S(\AM9U?"QL!D@C//&*RX/B.TICN)-%N(M.:]-DURTJ
MG:_0?*.36MX@TC4K[Q-H5_:1PM;Z>\CR!Y-K-N&../:N;/@O6SX8_LS;:^:-
M6^W;O.."G)QTZ]* /2F)"$J,MC@9QFO)=:UG5M:\&>)FU.WA6.UO!'"4?.TJ
MRC:!CGZY[UZRI)3)&#CD9S7GMUX.UZXTW7=*2:P6UO[PW44CEMPR02" /]F@
M#5TGQ3>3:A+I-_I7V>>.Q%U$HG#^8O3!QT-96E>,+>U\.Z.-/T^ULOM\LRQI
M+*5B3:QR"V/O$D5K)X>U(>+CJ[FU$0TW[&$61B=V<Y^[TS6=;^#M5M?#%KHL
MBZ9>0)YHECF+8)9LJRD+D$9- '::;<7%UIT,]U!Y$[KEX@V[:?3/>N;UCQ/K
M5MXG.B:5I,%U)]F^T!Y)]@QG'3ZUL^&=)DT+PY9Z9-<&XDMT*F3GGDG'/89Q
M^%<MJ7]H'XJ[=+DM5G.E?-]I#%?OGT_"@!X\>7EQHUC>064$#RF5;A[N0K%"
MT?5<]23VJ#_A/M7O+'09-,TB"2?5?,0)+-@*Z9S^'&:?_P *^NK>739;/4(3
M)!YAN/M$)=6>3K(J@CD9P,^@HT?P+JVFW&BF35+::'2Y9&1/)()#YW<YZ\T
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M+NYEF$EG]D>(A0K+Z\#.<\U6T_P)!812QG5=0N%,+P0":0,(%88.T8ZX..:
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M0!Z!%XJT2:&>5=1A"0+ND+Y4J/7!&<5DZEXNT/4=+G2Q\2PVCJ5S<(A<KD]
M.^>E86OQG7]1N-5L+:Y%M#I<D;2&W96ED;A4 QDD9Y/04NH:=Y7PFMH(-.87
M4L<0:..W(<G=DY &>W>@#KKSQ;HFE-)%>7Q5H5!D;RG8+D=R 0*6X\6Z-:V\
M4\EV=DL(G7;$[$1GHQ 'RCZXKC?$%VWB#6+.PNM/U)-"M )IBEK)_I4@'"8
MZ#U-5;Z"X_X2&YO=3\*:A=V>HVZ"*&VE;,84<(ZJ0/3@]* .[U/Q/I=K:1_Z
M4[O<Q&2$6R&1RN/O@ '@>IXJI\/[ZYU'PC;W-U/+-*\DF7E.6QO.,USVGVFH
M^%];DO?[ GD@N+%8XH;$>;]G8?P$D_K6_P##VWOK7PK'#J%E+:3B:0[),9(+
M$@\?6@#JJ*** "BBB@ HHHH *KWHS"G!/[V/I_OK5BJ]XP2%2?\ GK&/S<"@
M"Q1110 4444 5M/8-IUJ1WB3^0JS5#13G0M//_3M'_Z"*OT %%%% !1110 &
MO(-?(\,^+M5N_%.C'5-$U)E\J_$?F-:#&-OJH'MCU&37K]<K>Z5XD234H[2X
MTZZL[V0E8;Q'S &4 \C(89R<8'7K0!A_\)/<Z$- \/\ ARQBUB*[M"UM<O<A
M X7.<\>E$'Q1']GB.]L4M=86]^Q26\DN(T8=7+ $[1],UF7NBW'AOQ%X$TO3
M)8)KJUANP&N"55R0"W3D9).*NWGPYU*6V_M6UU&&W\2_;FOO-53Y62,&/!YQ
MCO0!>M/B4MS&UN+#=J1OA90QI(3#*2"0X?'W< YXS4?B'Q'._@S6_P"W_#3N
MMI*(9H?.*Q3*<$.CX!(Z=.:35/!_B;7-#CGO]6MDUZVN4N;0PH1!$5!&,'GG
M.2?85+>^'?%>L>#=3L=4OK*74;Y5B5(\I#"@/)'!)8]_P]* ,?77O-3^(N@:
M6VG6UQIK6+216L\Q\M@5P68;3AE'3KTJ;0-:T/PQ#KJ:;H#V4\-_%8K#]H:0
MW$IR%Y).T=?PK6/AS77\9:'K3)9"*PL_LTJ"9LDL,,1\O;/%9M]X U?4&UYS
M<P6TMSJ$>H6,JN6*2)D .".F#VZ4 ==H>MW]_?WMAJ6E265Q:E3YBDO#*K#(
M*O@9([BN9\301M\6_# *?++#*T@SPY4?*2.^/>NB\-VWB7>]UXCN[-I"@2.W
MLT(1>>6))Y8_I6?KF@ZO>^/-(UJUBMFM=/1T*O,59]PYP-IQCZ\T 9US\39[
M:&\N7\/7*V=A>?9+N?SU(0YQD#OV_P FMI?&&/%%_H<]EY#VUJ;N.5Y@%F3V
M&./?TP:Y>^\%^(KC0/$5@L5D)-4O_M<;?:#A!N!P?EY/%:_BKP==Z_+HEY#*
MMO>VY$-XRO\ ?@8?O%SCGO\ F: )+GXB6]O!8JUJD=Y=VYNA!<720JL>2 2[
M<9..!58?%&"Y?2H]-T>\O)=1C=HT5T3:ZG!0DGMZ],$4>*?#&N1^)+/7O#4=
MC-(MM]DFM+S[C)G((]/P_P :1O#VO-KGAN_FM[:3[!YTEP('$:AI.-J+CHN!
MR>M %75/B+J<FDZ7<:7I+PS7&I?89TN'0&*13S'SW(_BZ"KZZ]IEKXWU.:^L
MKRSNK73%EN)I)@T6S(. H.,Y.,]ZPG\%^(_[#,*VMN;B+7O[3C1[GB1#G*EL
M<'IS[UI:IX0U7Q!XAU*>]ABM;6]TH69>.8.4D!# XP#C(Q0!L0^.0NH6-M?Z
M3=V::C&9+*4LCB8XR$.#\K$8P#ZUG6/Q1M[TV<O]B:C#97-W]C^U/LVI)V&
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M^JVVM:3:ZC:%C!<1AUW#!'L?>KU97AS1D\/^'[+3$?>+>/:7QC<W4G\R:U:
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ML-/@D-G*)VMA$ZW4C2,BXY09) 'L*L:;X2T;2;A9K2V93&28E>5G2+/7:I)
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MB#,+[05NWL8[7482\SC=F)AGCKZC%4-;O=3U/5_#%_:QVGGRW4WV4LK*IC&
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MM9O[.X\<02ZY-$ML8%MI9?F,>X'Y4 [GH,?_ %Z /49IHX(7FE=4C0%F9C@
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M.OI7=;DL0\*O]X;,8/MR.]=[D49% '(Z/X;N]*\6W>H*L/V)K*.UA&\[SL
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M<D?K5B/QQH$M^EH+PJTF[RI'C98Y2O4(Q&&/TJG!\3/"EQ<P01ZBQ,TIA1S
MX3?G !8C SVH EUKX?>'];^R&:VEA>TC$44EM*8V"#^$D=16]%I]M!I:Z? A
MBMEB\I50D%5QC@]<^]4?%-S#:^&;^:?49M/C$7_'U"N7C/8@?7'_ -:LQO'&
MA:3%;V5UJ$]Q="T2?BW9GD4C.["C&<9/MS0 ^'P#HUO%IT47VI8M.G,]NGGG
M"L3D_A_]>FK\._#R^(9-:%K()Y)/-:(2?NB_7=M]<\^E=!IVI6FK:?!?V4HE
MMIUW1N 1D?C68?&6AC5(].-X1-)*8%8QL(S(."@?&TGVS0!4_P"%?:!_PD+Z
MS]FD$SOYKPB0B%G_ +Q3H3GGZTV7X=^'I/$9ULVT@G9A(\(D(A=QR&9.YS^'
MM5N;QIH,&I?8I+PJWF^09?+;RED_N%\;=WMFH+OXA>&K*YN+>:_(DMI!',%B
M<A">Y('3WH 3_A!=*;4OMD\U[.HG:X2WEN"8DD8DEE7MU-1Q_#[0Q&L=Q]JO
M(TA:")+F8L(D;J%Z8K*\6^)&;Q5I&A07U[:VUS$\TTUG$S.W V;2 >.I.*N>
M&-2M]*L]7;4_%;:I]BD5+B26'RQ;GD;?<GVS0 #X8Z"&B;S=1,D4)@5S=L3L
M/;Z8XP.*N7$=QX1T&RTS1-(N-4BW&$(TP'E*<\L2/N]JQM%\5_;OB%JX.H3C
M2H-.6;RKB,QB(Y&3@@'IZ^M=!%XW\/3"<F^,?D0^>WFQ.A,?]]01EA]* +GA
MO1H=!T&UL(HXT,:YD\L<%SRQ_.HM4\*Z9J^L6FJ722_:;52B&.4H"I[''456
MTOQWX<UB_CLK&_$DLD1E3,;*& ZX) R1WJ6S\9Z%?ZDMA!>$S2!C$6C94EV_
M>V,1AL>U $5KX(T>SN_.C2<PB;STM6F)@CD_O*G3.>:T]9T:VURP-G=-,L>]
M7#0OL96!R"#5"T\:Z%>ZC#8Q73^9.S+ [1,J3$=0C$8-7=8U[3]"CA:^D<-.
M_EQ1QH7>1O0 4 9<_@/1;G2IK&1;@M-,MQ)=&8F<R+T;>>_;\:2#X?Z!!;:A
M;_9YI8]051<^;<.Q?;@@YSUR <TK?$#PXFGV5\]ZRPWCM'%^Z8G>O52 ."*L
M6GC70+S2KG4DO@EM;2>7,9$*LC=AM(SD]J &6G@O2+>WN(G%Q<F:'[.TMQ.S
MN(O[BMV'TIB^!M'^QWUO,+FX-["())9YR\@C'(4,>@!YK'\+^(;C6/B+KL"W
M%V;".UB:*"XC,?EL>N%(!_.NBN_%.FV>M'2)/M!O?),XC2%CN0=2#T/2@#*?
MX:^&W*E[:Y8^3Y$A^U29E7L'YYZ5:LO NA:?-#/;1W,<L,)@1OM4AVH>HZU8
MM/%VDW^F6]_:M/+!<7'V:/;"VXOSQCKV-<=K.K,G@3Q#?Z5X@U">6"^V^8PV
M&([U!C7(SM /M0!U/_"!^'AIUM8BUE$%M,9X0+B0,CGK@YSSZ4^7P+X?G6_6
M6TDD%_M\_=.YR5^Z1D\$>U8]K?ZA_P +.M;-KZ9[272%G:W+#8'SC('X?J:W
MM<\7:3X=NK6VOWF$UUGRDCA9]V/H* *R_#_PTOVG-@S&YA\F4O/(Q9?Q;K[T
MEY\/O#-_:6UM<:=O6V&(W\U]X'H6SDCZFIX/&>C7.AC5HY)3"TQ@6/RCYK2@
MXV!>N:R=9^(UC9>'K^^M+:Y>\M'$4EK-$4>)FZ%QV7W[]* .PM+2"QM8K:UB
M6*")0J(HX %353TN^_M'3H+HPRPM(@8QRIM8'Z5<H **** "HYG:.%W1"[A2
M0@.-Q]*DJMJ%H;[3KBT$KPF:-D\Q#RN1C(H X#3?B#J=QK8T^XM[%I)K.6X2
M*)FS Z D)(>0<@<XZ9INF^/?$$MMH>IW^GZ>FFZI-]G'DR,71BQ 8Y[9'3GI
M1!X U'219WDNNP.NG6D\./LNW*,"3D[NO)Y-5? 7A^ZUGPIH$MW?0'3;*9KB
M.WBC.\N&. [$XP#SP.] $\GCWQ/#87NJR:3IYT_3[YK6Z"2L9" P!*]N,CKZ
MUI2^,]4U"UU34- MK6:RTPX=9]V^<A=S;<?=P/7.:PO#6C77B6#7[-=1METB
M;697GB6,F5UW C#9P <#MV-=(W@FZLKG44T74HK2PU)<7%O)#O*'&"4.1C(]
M<T 53XM^W:_H\EGIMHXO-,ENH9YL^9&0#E,XX&1@U5TCQWKU['H=[=6=@ECJ
MEPUJ%B+EU?) ;GC''2M:3P-)#JNFW>G7T<$-A9/9QQ20E]P8'+$AASS5:S\
MWEEIVBV:ZK R:7=FZ5C;'+DDG!^?CJ: ,&T\3^)]-TCQ/K#O97@L]0,1CD#+
M@ A?EP>G(XK43Q5XNDU>?3!;Z.)OL OD?+E47T/J:L77P_O9K77;.+68X[/5
M;DW!C-KN*$L&Z[AGH*NIX/OX]9?4EU.WWMIXL-AMC@*,?-]_KD4 97_"Q+J[
ML-#2TM@E]J,#S28A>98@I*\*I!.2#]*8OC3Q0Z:##)IEM9W.H7+V[BZC<?=
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M444 %%%% &?H//A[33_TZQ?^@"M"LWP]QX:TK_KSA_\ 0!6E0 4444 %%%%
M"'I7F]UK>L0ZKXVL8]3EVZ=:+<VK%$W1L4WXZ<CMS7I-<KK'@'3-9U2[OY+J
M_MY+R 07*6T^Q)E P-PQSB@#C+_Q=KL&DZ+J5Y=WUII]UIZ,U]:6T<B)<$G)
ME!!.W&W@8[U:D\1>)]>U2_M= N#(+&WA,<D!A5)G=-V]Q(,E3V"XQ71?\*ZT
MY;,6D.HZI#;FV%K)&MP"LL8S@,"I_O'IBH=2^%VA7UU!<02WNGR10K QLYMG
MFH, !N#G@4 =%I<M[J'ANWDNI$@OI(0)7MF5U5^A*DY!Y^M>3^%]8OM'\(P+
M!J(DN+_6VLHC+$A6 E_FDX&<D'OQSTKV2"RCM=.2RM<PQQQB*/;R4 &!C.>G
MO7+0?#?2HO#\VC27-Y/;23?:$:1D#PR==Z,%&#0!AZKXA\0^'=1U71GU-+MA
MIK7]I=RP*'C*M@HP'#<9QQ70^!9O$%_H\6IZUJ4%U'>01RPQQVXC,61DY(Z]
MJD/@>TEAOOM6H7]U=7EM]D:[F9#(D7=5PN!GN<5LZ+I4>B:/;:;#-+-%;H(X
MVEQNVCH#@ 4 >;>(?&VO:3J]TT5]#)##J*6ZP16X>(1'M))U60^F>/2IM3\1
M^*DU+Q:+;5+6*'142:.,V88NI7=MSGT[_P JUK[X6:=?&]3^U-1BMKJZ^UFW
MC==BRYY897FK1^'D 35P-7U!GU:-8[EYBCDA1@8^4=N* ,S_ (2W5=-USP_<
MZI<P+HFLVP;_ %8'V>8H#M+_ -WGC//Y5UOAJZO;_15OKR3+7+-+""@4I$2=
M@..IVX/XUQ^LV4>K)9^ _P"S;^>.T\@OJ$R 1A%'4$=3C*_B:]'1%CC5$4*J
M@  =A0!Y1+XJ\:RZ5KFK6]WIGD:->/$T'V8YG1",G.XXX/:KT7C759[?Q5-#
M- 8]/LX;NT+0YQOCW%6YYYXJCX:\.-KM[XILYM2N[?3Y-5D,MFL87S4SD'<1
MD X[>E=+JOP[@O[Z]GM=5O+"*^MEMKF"':5=57:O4<8'&/Y9H Q?^$J\6:EJ
MVAZ;IDVF1MJ&E+>N\\#':V.>C=,]*@D\3>.)3XA-O=:.?["?]ZAMG'G#:2<'
M<<=*Z;3_  )'INMZ9J46JW3_ -GVGV2..14.Z/T) '^17*Z-H\VM^+O&=J-3
MN;.UN;@"6)8A^_CY#$,PX],CUH U])\8:IXRFEBT.6VL7M;2*:3SX3)OE<9V
M=1A1C&>M8[_$O4KC3],N)FCTJ&8217%X;5IHEN%; 0\C:I'.>3762^!DMM5C
MU#0M0?2I?LZVTR1QATE11A>#T8>M13> WBT^&PTS5I+:S6V:WEAFA$ZR[B27
M()'S9/6@#$O_ !GXDN;N33]'MXY[BTLX9I9+:#STEE=0V =PVIVSR:[&'7;B
MW\&_VUJEH;>XAM6FGMP>C*#D>W(_6N;F^%EO!-8W&B:O>:3<V\ MY98,$SH/
M4<8/O_A78P:/:0:(ND[6DM?*,3"0[BX(YR>Y.3^= '%#Q7K]A9:)K=W)9W&E
MZG*D<L,<!5[??]W:VX[L=\BK?A#6_%6OZE>2W,FEKIMG>RVL@CB</)M'!7+'
M'4=:LZ=X#%H+.UN=5FN],L9?-M;22,#:>HW,/O =AQ6CX7\,GPS'?1K>M<I=
MW+7)#1A=KM][IUZ#\J ,[6=:U*\\5OX=TF:WMS#9-=7,TT1D)!.U4 R/7)-<
M9X=U>]T?X>^&3'%:RI/K!MIA-%NQNE;!7G@C!YYKO-=\&C5-<AUJQU.YTS4$
MC,,DL(#"6,_PL#^AK,'PUB3P_9:2FL76VTO?MJR,BD[\DC'H,G- %7_A-[]?
M&MSH]U=6MD(+K:EO<6[ W$&/O))NP6[XQ^=6=!UKQ/KL%CKEJ]BVF7-PZ26C
MIM:&(,0&#YY;CD=.:M3> FOKJ$ZGK$U[:PW9NT@DB7*MUVA^6"Y["H=-^&T&
MEZB7@UC4!I?G?:%TS?\ N@^<\^HSVH YBQU^;PY?^*8[,1FXN]?CMH7FY1&D
M!RS8QD#!K;O/$?B;1-8U#1Y5@U6Y.GM>V,D<.QB0<%&4'GU&*NR?#:RN%U=9
M[V9O[1N5NPRJ%:"52<,I_'O5T>#3)]IN+K5KJ;4IK=;=+U55'A0'(V@=\\D]
MZ .1/Q&N[?PS<7L%]!J%PTL,"(T'E2P2/NW!TSR!CCUKJ?".J^(KJ_O;76K.
M5;=55[:XE@6%G[,I4,1QZU5N/AEIVHIJ3ZK=27=W?*BFY5%C9-OW2 O!;/4G
MK6OX8\+'P]'*T^J7FIW+J$$]T^2J#HJCL,T <C<:SJ6F_$GQ#=37[R66FZ<L
M_P!F\L89#@[0<\')^]5K_A*/$&GPZ#K-Y/;7.GZM+'%);1P;6@WCY2K9RWOG
M]*W[SP;!>>)YM9^V3QK<VWV:ZMDQMG49ZGJ.W3TJOIO@.*P:QAEU.ZNM/T^4
MRVEK*%Q&W8E@,MC)Q0!3^)CZC'9:*;*^-LLFJ0Q2 )G=G)&>>@(Z=ZY_4'UV
MR\<^*KO2[RU@EMM.@GE>6 OYNU,D 9^7.#_GFO0/$_AR/Q+I<=F]U-:O#.D\
M4T6-R.N<'GKU-9'_  @3_;-3N3KEW(^H6GV24RQH3LQC.0!SC/YT 9\/BK4;
M[5/!T@BL@FJVSLY:(LT;A"3M.>%)QQ^M95KXW\4QZ!>^(KUM,DL;>1[58(XV
M5VEW!5;.3@9//L*Z6/P'Y']A-%JLH?1D9(&,*G<&X^8?2GV?@"SA\+W^@75W
M-<VUY,TQ?:$9&)!R,>X!H P[)=5A^+FG#5+JVGEFTEVW00F, ;L[>IR >AK6
M\5ZWKUGXHT71])FLHUU$2 O/"SE"HSGAAGZ4_2? DNGZ[:ZO=>(+Z^N+: P)
MYJJ,IZ$XR?YUF>-[>>Y\>^%!;W#VKQF8FX2/?LR  ".F#TY]: *G_";Z_:Z9
M=6U[)8)?V6IK:7%P4)!B89#I&#EF]A^50?\ "P/$4GA);Z!;%;I=6_LYFG@9
M0P/1BN[Y3ZBMZ;X:VLL4,HU.Z35([LWAOP%WLYXZ8QC&,#M59/A:BV\\!U^^
M:*2^%\$9$($@[GCD_E]* *4)\5+\3+&QU'6+1Y/L,LJB*V/E[2W3&0<\#G/:
MHO\ A.=9M](>,00-J,VM2Z>CV\' "XRP0M\S>F378ZEX374/$-EK<>HW-K=6
M\1A?RMN)4)S@Y!QS63/\,["ZTF[L9[^[8S7C7L4Z[5>"4]2I Z>W\J ,>?Q7
MXOTW1IY-1LIHUBO$0W8M5,@MR#E_+!(R" ,].:[7PMJ3:OX?2Z_M&"^W,X6Y
MA3:&&>,KV.,9%9EOX(N+6Q C\1:DVHB42->RL'+X! 5E/!4 GCWK7\-^';;P
MWITEI;NTGFRM-(S #+MUP!P!QTH \XU+QOXBTFSURVN=0@_M73KU%CC^S#,\
M# G('^Z-V>U;.H>+=0O/#6NZYI5S;O86UO&8/-@W!G*@N.HZ9QSWKK)?"^FS
M>(9-;>$-=26IM6ST*'K^../I5-O!&FKX.D\,0/-#92?>=2"Y!?<>2,>W2@#F
M[*;4M1^)<'G7_P#HK:,DQMUC 4!\;E'U/.>O05A^#-7UK0]&\+;+J"33=1OG
MM3:F##("Q^;?G.<YKN9/ L3ZG:ZA%J^H03P6@M&:)E!D0=,_+P?I5:V^'%M;
M6.E6B:M?>7IER;F#(3(8\\_+0!D7'BKQ#<>&]0\5V-[;BSM+ET2P>W&'B5]I
M)?[P8]>.*27QAK+_ /"4M%=I&ME90WEH#"I*;T#[3GKUQFN@D\ 6C2W<:7]Y
M'IMY,9[C3U*^6[DY/.,@$XR,TW5OA[8:KJ5U=B^OK-;N!8+B&UD"K*%&%SD'
MH.,4 <]H]YJVK?$/3))-4D57T6.Z>)(EV L1N7'OC.>O:M_QOJ^L:=J/A^UT
MF[A@.H79MY#+"'X(&#U[58M? MG9:AIM[;ZAJ"26-N+7_6C][$#D*W'0'TQ6
MAKGAN#7;S3;J:ZN(9-/E\Z'RBN"_')RI]* /.+OQ)XOL].\07+:U#)_8EZL/
M%DH^T!B 0>>,9[<^]=#<^)K[0/&,8UJ^']BW]D9;7,:JL<JC)3.,DXZ<]Q5Z
M?X>6ES;:O;SZI?-!JDXN)U'E@[A@\';["JU[9_\ "1:O::!/HUT;32)HY6O[
MK&V0*O&WU+' /MF@#I_#ZZA_8ML^J2&2\=-\F5"[2>=N!Z=*U*!P** "BBB@
M IDL4<\312HKQN,,K#((]"*?3)94AB>20X1%+$XSP* ,V/PUH<0B$>E6BB)M
M\>(@-K>HJIJNC7T4.?#+6&G74L@-Q*]ONWKSZ=\G-96F?$.'4=12T?2KN'[1
M!)<69+(S7")G/RY^4G!P#^=1Z;\2H-1N=)7^Q[^WM=2D:&&YFV[=X[8!)(]Z
M .KTG38M(TR"RB)(C'S,>KL>2Q]R<FI+W3;+4H?*OK2&YCSD+*@8 ^O->8_$
M#Q(=7T8_8;&[:RM]0CA_M!9@J%PPR-H.67MGIFO5)69(6:-"[ $A00-Q],F@
M"$:=9"R%E]D@^RXQY'EC9C_=Z5%_8>E?98K;^S;0V\3;DB,*[5/3(&,9KB_#
MWC^]N=-O+O5=.D1VOVM;2.-U)D?.!&.>HZECQ71:)XG.IZI=Z5>6$NGZE;*)
M&@D<.'C/1E8<$=J -,Z+I?SG^S;3]X-K_N%^8>AXYIJ:)I*.Y33K169 C8A4
M94= >.E0>(-=BT.VAQ"]S=W,@AM;9#AI7/.,GH ,DGM7G_AS75T;7_&&I:E9
M36C++ IM1)YK>8PP%4]#DG/TH ]*_L?3,H?[/M,Q_</DK\O.>...:MLBNI5@
M"I&"#T(KG=,\527&O'1=4TR33KYXO.@5I5E65.^&7H1Z5>\0ZU_8.F?:Q:37
M;LZQ1PPCEF8X&3V'J: +;Z?8"T%N]I;_ &9>1&8UV#WQC%2Q+;P*D40CC7'R
M(N ,>PKSGQ!XBB\4^!/%%O-8FWN=.PCJ)1(N[(*E77@TMHL:^/\ P?(J!6ET
M4[@.0,)Q_A0!Z++:V\[J\L,<C+]UF4$CZ4IMH"S,88RSC#$J/F^M4]=UBWT#
M1;G4[K/E0+G:O5CT 'U) KGIO&&I6NH)I][I$=M<7=L\UD3=;DD91DHQ"\'Z
M9H ZF2.SCC6.1851FPJL  6]AZU*\$4BA7C5E'0, 17C%QJFKZOH/A+6+RU@
MGO#JI,!67#2 EOE.0 HXQU/2NQ_X6$UII6HS:GIHMKVSNUM/(6;>KNP!'S =
M,')X[4 =N\,<@ =%8 Y (SBCRH]I78,$Y(QUKS^7XE3V^F:M<-I*S2Z>8SF*
M5A'*CG (9D!R#P1BNL\/:CJ>IV;SZII7]G/N'EQ^<)-R$ @D@#!YZ4 7S+:_
M:E@,D7VG:65"PW[>Y ZXZ5%'IL*:G)J!+O.Z>6"QX1?0#ZC-<AJ92U^+=I<)
M 6<:/*Y5!\TA#' ]SQBFZ=X]O]0U6'2QI]K'>75K)-"@G+F)USA)1@;<@=NF
M: .^(S3)&2.,O(RJBC)9C@ 5YTOQ)N_L&BWLUG:0Q7EZUI<JTIW0$-@]O3^E
M)X[UK4KOP?K#6ZVRV<=VMLLFYMT@# -CC'WN/H#UH [NPU73=55S87MO=!#A
MO)D#;3[XJ:XN[2T,0N;B*$RN$C#N 78\ #U-<=I]Y<Z=XIN-.?3-+@O9],^U
MM-;;@'96VJIR.1UK'U/6&\2:!X-U>ZABBFDUF-7$?(7#LIP3SR #0!W6HI;:
M[:7FEVNJO;W"8$CVDH\V+GCZ=*LZ1I4&C:?':0-(X7+/)*VYY&/)9CZDUP(N
MKW2?$OC>^TFV@DN($@E,4@.' 5BWW><UT6E>)Y]:?1!9&UD6ZMFN;S ;]T!@
M +SUW$CGT- '58I,"L;Q7JUSH7AF]U.TCBDEMTWA)<[2,@'I7*GQQK6B7-JW
MB.TM/LM[:-/ ;,L2C*N[8V>N?ZT >AX%&,5YWIGC3Q%>W$$JZ8)+2YMWES]G
MDC6!@,KESD.#Z@"J2^,O&(\'-XE>+2/LC "./#[\F3;ZX_6@#U*J=]J=GIS6
MRW<ZQ&YE$,0/\3GH*XB7Q!XN35KC23)I0G&G_;4E6)R%'/RX)Y.1UI[^+[^X
MT/PGJ @M2^I7:0S[D+;"202G/'0T =_D>M+7D=W=>)4M_&TYUI0;)E3Y;?EA
MMXV\_+P?>M>3Q!KMD=)T.U)N;I]/%W)<16@8A>BKM+@=1R<_A0!Z(S*BEF.
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MY;!6! #?3G!Q0![0?$6BB"&9M5LEBG_U3FX4"3Z'/-4-7\;Z#I&AG5FOX+B
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M:QP@S:)(9Q;L%:5MG0D<EB01ZY^E8_A?4K"+Q3X7N!/;K;O]H1[>&(L\1?<
MLK8R[$D?08H ]4;Q;%KNAW-QX<U#3XYX;CR@][)A"H;!/'.#VKH+G5;+3TB&
MH7MK;N^ /,E"!C[9/->%[=+7X4:I:/\ 9TU.VU(EXRH$B_O,#WZ9_*NL6[TM
MO$_B:#Q-);O'<VL36,EP!MDAV'/EGUR0<#G- 'I5QJEA:8^TWEO#E2X\R55R
MHZGD]*G@GBN84F@D26)QE71@P8>Q%>)Z+81-XA\%V^O1PRL-/G#)=X/R9<QA
M@W7@C -=I\)I5?P=)&A&R*]F15#9 7.1]!S0!T'BC7H=#T>ZF%Y9PWBPL\$=
MS( )"!T SD_A6=I6LZIJ-EX;NVN--C6]@$EU%(2LCDJ"/*'YUQ7B"\L(]>\:
M6WB+R5NI;5/[,:X3(,84\1Y!YW8SCO197=BUY\,YQ+&KK!)$[' 880* ?;=D
M"@#U:'5M/N+I[6"^MI;B,D/$DJEUQZ@'--CU6RNWG@L[ZUFN8E)9%E#%#_M
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M$+QI;7*$O<([ X]P$Y_&MC7M,M$E\%G5H(//O=0:ZO4D Y+X8@Y'W1D#GTH
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MTJU@GF\U59))-BJA/)^H]* .;TGP-?Z;']ED\27%S81*PM;:2$ 1$@@$G.6
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MA8(1M*QH-O0A1Q2+:P*<K$@.<Y"CKZUQ\WCB9?$,VD:=ID5P;58C*AN0DN&
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M214NJ?%:VM+V865M'=6MML$Q,I25RV"=B[2#M!YR10!Z"EM!&[/'$B,W5E4
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M9V6YM?'+K9SEKDQFW#6[!G'?''J:]:P!5:TU"SO9;B*UG25[9_+F"G[C>AH
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M)X?U6SCTS4IC/.EPA+P.WWF3'![=ZC'A#Q/HVMW;^'M7MUT_4"&N1=J6DB?
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M7M=GX;T73S,;32[2 S*4DV1 ;E/4?3VJ%/"/AU+>.W71;+R8W,B(800K'&2
M>AX% 'G-Y.^E^-EO;^-+ZRN-6*P7]K<,);=\@>3(G=1@C&/>O8*R8O"^A0:@
M+^'2;2.[!W"58@&SZ_7WK5R* /-O%&GZ9+\7?#SWD<8#VLS.[N5R5!V]^QKB
MVM8['PM<Z[;S7$=_#XC,43+.P5%+#/R@XYKV[4M"TK6'A?4;"WNFA.8S*@8K
M]*I+X,\-I;_9QHEEY._S-AB!&[&,X/>@#RCQ=J#3:OK.HV=RYDL]0@A2XDN3
M&\+ D%(XQ]Y<]2<5U/AJST[_ (6SXBF!3S%CA>)A,<,SKEB!GGOQSBNNG\&>
M&KF:6:;0["224 .[0C)QTJW%X>T>#4([^+3+5+N*,1)*L0#*H& !Z<<4 :5>
M.ZO=V^M7?CA]6NREQI:F/3X//*>6 I(=0",DG%>Q5R?B_P (6&M:=>S0:19S
MZM+"8XII %8$C .[';K^% '&Z-,L7B?2$NKADANO"X></,0';:,DY/7 K+T^
M]&I>&?"VEF[:ZGD:Y9[22X,4;J&?#22=1MZ@#K7I.D>$[2;P]HUMK^F6EQ>:
M?;K""X$@7  X..AP*O-X/\./!# VB6+10,7C4P*0I/4T >4P7MQ>_#7PR;FX
M,\J:TD8+/N(4,<#/T]>U=+Y?VWQ-X\L[F:>:W2TB9(WF;"'8S<<\#/85V'_"
M'>'/LRV_]C68A20RK&(P%#G^+'KP*E?POH<EQ<SOIENTMT-L[E>9!Z&@#R:#
M0OLWPGT7Q%I8F^U63+<W,*S/MN(U<[@5SCC /'H:](\(3'6!=>)&BEB34"OV
M>.1C\L2@#..@)()^F*KZGX?U6UCBTOPO#I=CI,Z,EWO1MZ9X)0#CI^M=3:6\
M5E9PVL("QPQK&H Z # H F90ZE3T(P:\7BT338=+^(5S%$RSVES((7$SY3"Y
M'?U[FO::RK7PUHUBUPUMIMO&;E2LV%_U@/7=ZYH X#2=0CE^('A0Q7P=KC1
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M(S$I53Z@8P* ,_P?$L/A73T2YN+J(1XCFN%VNZ9.TD?3'X8K<I    . *6@
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M+5JJFH?\>R?]=X?_ $8M %NBBB@ HHHH Y[P("/ FB ]?L<?\JZ&N=\!D_\
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M/:7%U'J<7E6ZAIB58%%/1B,9P?7I5]-=TV2"RF2Y#1WS;;9@K?O#C/''H":
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M&LHREIHER=4TZ8IRQ8;A$O'09?IW J_X@MG'AOP]>:M$!>WVL0WMW'L)50<
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M]K_4_LVH3_:+E?-3YWSDG.S(R>U79/!MI->Z3=RWU^\NEKMMRTB\^N[Y><C
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MH@"+$H8-G:#\Q)49)YXI\O@G5C>Z/J,.OHFHV5LUI+,;0$/&?[JYX([$Y]Z
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M]*/B+3M(CM;MSJ*H]M<!5$;JW0CG/8B@#M:*XN;XCZ?!;1LUC>FYGNGM;:U
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MO"S@2-@  =>G)'IWH VRZA@I8!CT&>M+7C2ZEJLWB'P1JLFF)<:G/83;46Y
M,WR##,Q4!>I..:ZFW^(4]YX?LKZVT=C=7%X]F\<DVV*!ESEGD .%]\4 =Y17
MEE[\0]8U*ST&XTBQAC%SJ?V.X1K@'<ZD?(K 8VM_>Q7J$1<Q*9%"N0-R@Y /
M<9[T /HK"\2:[<Z-]C2UL!<R7+LN^27RXH@!DEVP<#CTKG+?XF)<Z'IMZ+."
M&>^NI+4"XN=L*,G4F0*>#QCCO0!Z!16=HE]=:CID=Q>V1LYR6#0[]P&"1D'
MR".0?>M&@ HHHH **** */\ 8NE>7<1_V;9[+@[IE\A<2GKEACD_6I;+3[/3
MH!!96L-M$#G9$@49]<"K-% %*\T?3=1.;W3[6Y/',T2MTZ=11)I&FS6\5O+I
M]K)!"<Q1O"I5/H,8'X5=HH SO^$?T7(/]D6&0V\'[,GWO7IU]ZR?$?A--0TL
MPZ1%8V<YG2=P]N#'<;3G;(!@D$UT]% '&:+X,:/5%U#5;+1(7CB>)8-,MMB2
M!NOF$_>X' QCZ\5T7]@:,%"C2;':$\L#[.F-N<[>G3/:M&B@"B-$TI6C9=-L
MP8QA"(%^4=<#CBG#2M.6"6 6%L(9?]9&(EVO]1C!JY10!432]/CLVLTL;9;5
MN&A6)0A^JXQ5E$6-%1%"HHPJ@8 'I3J* "BBB@ HHHH **** "BBB@ HHHH
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MX P1BO0Z,T >):A\.O%5Q%XEA@M+39JMVD\;-=<H%=FYXYSNK>MO"&O1>.M
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MBB@ HHHH **** "BBB@ HHHH **YGQ'XINM(NH[/3=$NM6NS'YTD<!"B./.
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M)FU.]\@W$D<;8VI[<$D\&KVN>,(]%M-+W6C&^U-UC@MI&V;6(!.]NV,@'WH
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M **** "BBD)Q0 M%)D49S0!S_BCQ%;:!;1HLD U&\/E6J2N%!;U8GHHSD_\
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M-7\S^T3<*BF $ J/F!]@ *WH/#>FWGQ"UT[)6:QAMIK9%G? DV[O7GD"I?\
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M D5"!G&#T]16QKVDW?B";Q5J^E6-R+6YTM($5X&C:XD#!B0K $X QG'7@9H
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MA,B-%*B[<G<1E3UXR: -2\^)^E0+8&UT_4[\7\!F@^RPAMV.J]<[AW':G/\
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M@#M],OO[2TVWO1!) )D#B.7&X ],X]JFN;B.UM9;B4XCB0NY] !DT]$5$"J
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M'G:&^7Y..I_ 5UOB*:]AUS0(+;4KBWCNKAXIHXT0[P$+9RRG'('3UH KZ?\
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MOA]HE_KCZJZSQR2L&GBBE*1SD=-ZCK_6K,_@VPGFU25I[I7U*(17 60 %0,
M 8XP.*FC\8:%(ER_V]$%M&)9?-1D(0]& 8#(/J/6FZ=XR\/ZMJ*6%CJ44]RZ
M%U10?F Y."1@_2@"G-X$LY;:& :CJ<:);"T8)<8$D0S\K#'/7K27_P ._#]^
M]N_D36SP1"%7M9FB9D'\+$=:T1XLT,WPLSJ$0E+%5+9",PZ@.1M)]@:I+\0_
M"CW1MAK5MY@W9SD#@9/.,4 +?>!=&O)8)46XLY((?(5[.=HB8_[I(ZUI>']
MLO#>F#3[#S?(#EQYLA<Y/7K5:P\4Z1KK3VNF7X:Y2/=MV%6 /1@& R/TJMX!
MU&]U3PG!=7]P9[@R2*TA !(#D#IQ0!TU%%% !1110 4444 %17'^K7_?3_T(
M5+45Q_JU_P!]/_0A0!+1110 4444 <M\-_\ DGFBC '[CM_O&NIKFOAZA3P#
MHP9=I-N#CZDG^M=+0 4444 %%%% !7G]X5;XXV2D\_V,XX.#]\UZ!63-X7T.
MXU-M2FTRVDO6ZSNF6Z8ZGVH \/:SBA\"7&NQRSC4H-?\N.4W#Y"[A\HYQ_6N
MI\1&7PCX[N)(+9YH/$-H8(%/*I<D@'W"\Y->A'P?X<:V-L=$L?(+^88Q"H7=
MZX]?>M"73+&=[5Y;6)VM&W6Y*_ZLXQD>G% 'D?B"UM[;Q3:>&+Z_L['3(-+4
M6SWJ,\;RD_,_#* _N3_.F6&DV5[XK\+Z9<ZE<:G:2Z?<*\QDDC$ZJS <;ON\
M?CC->LZKH&DZY&B:II]O=K&<IYR!MOTI&\/Z0UW#=-IMJ9X$$<4AB&8U'0+Z
M#Z4 >&1V]M<^$/#GVW$L</B"2V4RN3LBS]W/IQ72ZS++I/C+Q$VA;@\?A\/
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MG0=6\,WU_>O>M/;W*S2"V;<<AVP0!C\ZFU.WG?3O'T T^Z,MU=1FWVVTA\T
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M)IM>CF.D[A"K6>,JRA<'#>@^M56^'-X',T6M)'.NIMJ,1%KE0S#!!4L<].*
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M5_;H-2M!:[6A),:@8!SNY/6H;3P7J-L?#N=2M6&CA@!]G;]X&&#_ !<<?K0
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M7*_Q+ZK[T 4/ ]IJ>G>%+'3M4LDM9K2)80%F$F\ ?>X&!GTYKHZ,T4 %%%%
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M00<@BO$;VQLK#1]+?3-3A;[-:3^39ZV@"W=LTAR5) VL< CH<$5Z?I<\]SX
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MA]OO9VB06DF8_O'!R3T QD^M<AIFI>%KKXG6O]DM9_89]$>*01H%3(;.&_X
M._I7-69TF/0/!%Q=+;&U@U6XCN'=051=Q8*WMSG% 'L]G=:@^OWT<\EA_9RQ
M(UN(W)FR?O%QT ]*O07]G<EQ;W<$IC^^(Y VWZX/%>,^("8=;\;C12B%K.U8
MI!@%H^/,P!['FM*]&CZCXBT*Z\.+:"V?3I_[1$2J$$&P8$H' Y]>: /5([^S
MEE6*.[@>1AE460$D>H% OK-KK[*+J W'_/(2#?Z].M>(^&X=+L=,\ WT,5M'
M>R:A+'/*H&]@2PPQ_P"^:U=#GBT_QKIZ126.K6]S>SM!+& MY:N0P82 <E>>
MI]O:@#TS6O$6G: ML;^=8S<S+#&I(R22!GZ#.2:Q]-\52S>,M9TN]>RBLK6*
M&2WF#XWAQD9).#^%9OQ3CM!INB7-Y%"T46KV_FO*N0L9SN!./NGO7*ZM%H.L
M^(O&,Q6SN8H=)B:T;Y2J$)U3TQQ]* /9)[JWMHQ)//%%&>-TCA1^9J0$, 00
M0>017A'VR"63P^-=U)K739]#2*&X>W6>/?GYP=X(#8&,CD<5ZMX'AAM_!]E#
M;7%S<6RAA#-<KM9TW'!QV&.F>V* -L7EJRAEN82I;8"'&"WI]:<UU;I.(&GB
M$Q&1&7&XCZ5X->7.G6'A+4=+DFMUO;;Q*SK"<;@@8#<!_=P*WM5GMK;Q=-J4
M36&LVD^HPH\1(%W:R#&TQGDLG X'8F@#US[1!Y_D>='YN,^7N&['TIY( R3@
M5X7I:V-W>30ZOJ\]OXAMM3,GD"T7SY7W?*$?J5(P,9  ]J]&^)$M[#X)NY+1
M7.&3S]AY\G<-_P"G7VS0!U,5U;SAS#<12;#AMC@[3[XZ4])HI3B.5'/7Y6!K
MR_4(-(_X2:UDT!;4:?>:7.VH);X$10+F-F X!R>_-:WPKT+2;7PK8:O:P 7U
MU;[)Y@Y.[YCQC..WIVH ['4[Q;&PFFWPK(J,8Q*^U68#(&:YW0?$>KZ]H>C:
ME!:62_:9F6\5Y2-B D93U/'>L#7+K3I?'NK6/B80"U_LT'3OM1'E]#O*YX#Y
M[]>*P-%DM3H'P_D22,NFJ-&2&SM&22#_ .._G0![,UU;H[(T\0=1DJ7&1573
M=:L-6MGN+.X1X4D:,ON&,J<?E7F"0VEOXM@^T1:?K-A?:E($N0/]*@D(92DB
M]608(^@!XXK ^S:$WPWABVV:ZB-6$<^TJLPC,I'S?Q8V^M 'M-]=:BM]8C3X
MK2:UD=A<O+*590!\NW .3G-4?"?B*77+2\>\2W@G@O9;4)%)N#!,<@G!/7TK
ME=2T#2?#GC+P?#I-N(8I;F=F'F,V<HOJ37+'1])E\->(;_[FO0:O(MH4D(EW
M;EV@*#W)/;^5 'NGF(,Y=?EZ\]*I2ZQ91:M#I;3#[7-&TJH/[HQR?SKS'59[
M:PF\?6VH30Q23V=LR+(0/,D\LY*CN=Q'3O4>C0:/-XH\+RWRVS++H@)><C#R
M [1R>K#&/6@#U#2[B_E2Y.HV\,!2=EB\N3<&C&,,?0^U7Q(C+N#J5]0>*\6M
MITM;+[,QQI!\3O%>Y8E=F%VAC_=R.]6O$=I:V<_BN+3"BZ0=,2>2.%OW4=QN
MPI&.%)'84 >OK(CDA75B.H!S2L0 22 !W->8:%8V.E>//#W]GIY*WNCEY]KD
M^8V <G)YK=\=W/DW6@171VZ5->A+PGA",?*'_P!DGKGB@#J;F\MK"PGO9'40
M1(TCLI'0#)K!\-ZWKFLM#>7&GVB:7=0F6*2&8F2,YX5P>I([CI7)WNFVUI?>
M+K"TAC;1/[-%R8L#RHKC!QM[ XY_*NK^'EK96_@G3)+2&&,S6Z-*T8 WMC!)
M(ZF@#J-R[MNX9QG&:7->4ZB(].\7G4+NWM=4LI]52-;F*3;=6<N0!&0?O)GM
MZ<^E8VIS65MX3\6VAGBCN(]9W0Q%P' ROW1UQC/3WH ]N9E7[S ?4U@6OB"6
M;QE?Z)-;1Q1VULLZ3"3)<,<<C Q^M<1-+H&JZ[KMGXINT@D6.)K&:68+MBVY
MS%VW9Y]3FBZTS3=9\5:N;OSIXX]"BEC\UV4Y"Y#-@CYNA^M 'J]-WJ&"[AN/
M;/-<]X#N)+OP/I,TTC22&  LQR3@D#]!7$Z;/H.HM=RZW?M:^(;75&8%7Q.0
M&PB(.I4CC H ]8+*" 6 )Z GK4-Y<&ULYIE"LR(656;:"0.F>U>8[;+6M-\5
MW.KDQ:Q8W$AA=F*/ JKF+9SP#CMUJ.PNEUS4Y;7Q>L8,6CQR6\<[;5)(^9^W
MS=/<4 =_X7UT^(?#EMJLD*VYFW90/N"X8CK@>E;6<]*\)TN]0:3X6T^?4;>T
MTR6.<,UQ'YD)E\QL!QD#.,8R>,UZ?X%MH[/0I+:#5QJD$4[+'.JX11@':IR<
M@9/.?;M0!T]%%% !1110 4444 %17'^K7_KHG_H0J6H;K_5+_P!=$_\ 0A0!
M-1110 4444 <_P"!O^1%T3'_ #Z1_P JZ"N=\!_\B'H?_7G'_*NBH **** "
MBBB@ KR;QM%>:-XY;7]5T7^VO#SVPAVXW_9.FY@IX!Z\^_45ZS7,7]EXEM]9
MO;S39;"YL[A$46ET74JP&"0PR,'TQ0!SVG:[::#X3L7\+I%>65[=R%)IW*0V
M:$[B)6.2N.F*@;XIWC^%;75;72H9YY-1_L]XQ/\ *6[%3CD'MFFCX9ZG9VFF
M-9WEB]Q%?R7MS;S1M]F9G & H/(7''UJ*'X;Z_\ V>+)[[31#'K U)"L;@DC
MM[ ^G.,=30!JP_$.\LX_$HUO3(X9]%C20I;2[PX<?*,D#GD<TZR\;:X?$=OI
M%YI5G(TUC]OWVL[$B/'W0"/F;/'IS61XNT>_T2V\7ZY=3VWDZM!% B1HTAC(
MPH+9&,8SD]JQO#>GZA8WBZ=8:EH5_P#VC";9[JPD>2XMX]OWL[CM53CCC)H
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MZE+<7=DML9KAP)88B.44;1MST.1GUH Y.SUGQ5'9^&OM7B'S#XB*)O%J@-J
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M1;$W5P&;+!$C3[TCDX"CWK*3Q9YDM]8OIEU!JEM#YZVLI3]ZG]Y6#;2,]>:
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MPRGA>P..P]J /2]%U9=1\/:?J5R8X&NH4D(W8 )&<#-9>M>)+S3/&.B:0EO
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MG>1*&G6W*!80>@9F( )].M6-#U^+7/M:K:75K+:2"*:*Y0*P; /8G(P>O0T
M<7IWA7Q!9Z1X3MI;2V:32KMI9A'<?P'..HZ\G@<<5,OAC57\86FK6^G1Z7,M
MRS7=S;W \NZAR<!H^I8\<_CS7HN1ZT9'K0!Y,?"7B=?"YT-=.MV$&J_:XYQ=
M >8FXMTQQU]:Z[7M-U2_\2>&[ZWME:VL97DN 9 "NY=N!ZXS75Y%&10!YC%X
M5UUM%U3PO+:(+:^OVN#?B4%5B9E8@+UW?+TZ<]:?K/AWQ%'J'B2VTO3X+FTU
MFVC19Y+@)Y112I!&.2<\5Z7D>M&: //[+1=>T_Q!H6HC3XIA'I@L;E!<@"(@
MCYLX^;@=/4UGP>$-=2P>X6W2._M=:;4K>%IAMF0]5)&<'%>H44 >=ZMH.L:V
MVL:HVF_9Y[G318P6IE5F.6R68C@5H6VE:HOB;0;Z2Q98+.P:UF;S4)#G'. >
M1Q7:9HH YKQKHU]J^F6KZ:R_;;&ZCNXD8X60K_"3VSFJ TS4M4\0GQ!<Z?+9
MO;V#VT5J949I6;))R#@#GCFNTHR* .6^'^GWVD^%8-/U"T:WN(7?(+*0V6)R
M,$^M8_C'1M>U3795CL%O],DLFCA3[0(A#,?XF_O>W6O0:,T >8^'=&\16>J>
M')[[271-.L9+:1DF1LYSMXS]*FM=!D/PYU33-;C%E*99KF)I&4[3G>K#![&O
M0[>YANHS)!*DB!BI9#D9!P1^=9NL:!I&J3V]_J-BMS+8YDASDD'KT'7IT- $
M/A*PN;+08'OY3+?W $US(PY+$#C\!@5G>--).K&VC;2)[M$#,ES:S".>WDXP
M5)(XZ_E70:3J2:MID-ZD$]NL@/[NX38Z\XY%7J /-]&T;Q/H&IV6L7D<FKS2
MV7V2ZC61?-CPVY3EB W& >:BG\*ZQ:Z;!J,%DDU\FL_VF]FL@!"\#8&Z9XYK
MTVD+*JEF8  9))Z4 >5WF@>(KNR\5H^C%&U62*2$)<HV,=0<XK?\06&N+=Z+
MX@TFR$]S91-'-82.%9E<#(#=,C%=HCI(BNCJR,,AE.015%-61]<DTK[-=!XX
M1-YYC_=$$XP&]?:@#A];T?Q%JIT_79]&L;F6!WW:/,RL/+8 ??(P7R,Y[5U/
MA.TGM].E>?1K32#+)N6TMPIVC&,LP !)YK?R/6FQR)*F^-U=3W4Y% #J***
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M :](%1.]O;!I)'CB#'EF(7)^M<[XI\27.AW>A1VT$,T6HWJVTCNQRH/=<=:
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M1T^7V_J:UJ** "L37O"NF>)+BREU%9G%HY98UE*H^>H8#J.!6W10 U$6-%1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)81XR7PX;:83-:FY$QP$*@XP/6N#TZ_N_$&J6.CWNM7=DBZ##<1/%<&-I9F
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M10 5YEXE^'FN:SJFO2PWVG&WU-(U1[E7:6 +@[%/15)';\J]-I"0" 2 3TH
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M37=^Z7%U#::@P>[LXG"QRD?AD9[X(S4L?C/3+SQ5<^'8+C;>11XW%3_K.?E
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MP=XC/B?P];Z@UO)"[KE@T952>?ND_>'O5;5_B#H&AZO)IE[-.MS&JLX6W=@
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M_P 1O#.F7EU:7-\XFM'"3A('81GW('3WKJ$ECEA6:-@\;*&5EY!!YR* /+]
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MC'J<UF3?#32)]"MM+DNKYELY"]I/YW[VWS_"K8Z>QJXGQ%\)21+(NMVV&#$
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MO<++PWHFFW(N;+2;*VG VB2*%5;'ID"E7P]HZ:J=473+47QZW B&_/KGU]Z
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M;VG@ZQAL_M9M0&,)N\>84+$@D #&1R!Z8KE/!FV/PEXPCU1Y$*W]U]J,8^<
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MZ-JUQ;VP2TL#;R[)C]\CL".@J]X+TG4-&LK^"_BB1I[V2Y0QR;AASG!X'(H
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M#U7-9NEZS#JL]]%';74)LYS"QGBV!R.Z^H]Z\^MHO$VJ>.M5T:+Q7<P0:;#
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M,TC:BJ,1(1O4$@ ^N,4D6GR7,OCG5X+J]?4=)O)#9$7#$)M![$\\?RH ]J#
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ML%<^G3\_>M#6[:V9?B<J(C;'MW48W;3GYB/0\M^= 'LD&L6$^GV][]JAC@N
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MU5GTZQN;J.ZGM+>2XBQY<KQ@LGT)Y%>:ZI?7_AKQAN#W-Y#X@LMEH-[[4NN
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MKIXMNK=GE6.TL;:-0F68*BY/))SD_C7H5C'+#86\4\IFF2)5DD/5V P3^)H
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M#?4;O5?!%E>7UP]Q<2-)ND?J?G./TH M7W@?P]J-PD]S8LTJQ"$NL\BET P
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MM!\NQF'7) /Z5E^)[PWK:LR65W:E=8CN&LQ:-EE_YZR.1U/91ZFOH<C-&T4
M>*ZS]MO=>\<Z?80W?VO4[:WEMD2)@70(I;)[<<8/<XHT7^Q=2ADN!HVO2S6F
MF20WC7,I_<IL*^7'GJ3S@<8%>PV][9W=Q/#;W,4LMN0LRHX)0GH#Z=ZL@8H
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M.'F3S'GD!XC5 <@=RQX%5V\;ZKJ+^'+2T%O8S:K8/>//*A=5*C.Q02*N^(O
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M@OXWUZ\2"\NUO6B2- !*#DG)R3[#/'O0!%?>+]2T'Q-KNFZI>)Y8LS<:7B$
MNQX"^Y!XJ.]\1>*Y=2ET.R#/?65E'+<2V\,9WS.,A?G8 )VR!FNIU+PA9:KJ
M6C7]U)))/I;;D=L9EXXW'Z@&J7B+P(FLZU'J]EJUWI5\(_*EEM>LJ=@?\: -
M[0KJ_O-&M9M3M5M;UD_?0JP(5AP<$$UP&NZ]XJ_MGQ5#9:K:VL&C0)<QH+4.
MSJ5+;><]AR?7'05Z-IUA!I>GP65L&$4*[5W-N)]R>Y)YKF[KP/\ :KW7KAM5
MF4:S&L4P6)<HHX 4_P"[D?C0!FVGB#6/$^J6FG65\--*Z3#?3RI"KEY) ,*
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MX,TMM812V,6Q1M9NN#CD]<9KEM;UIM6^'?B%6U6[N)81:"2TOX@DMO)YHW=
M 5)Q@UZ-?>!;*_U34M0DOKY)K^)8I/+=0%"D%=OR\8*_K5>[^'.G7]E?0W=]
M?33WQB^T7+.N]UCY5?NX S@].U %3PW?ZM:>/;W0KW4I+^W_ +/BND,B*NQB
M<$#:.E:GCO7;G0](M19L([B]NX[19BN1%OSEL>HQ5FT\*06GB4Z[]LNI+IK9
M;9@Y7:R#&. !SD9J[K^@V7B/2GT^_1C"Q#!D;:R,.C*>Q% ' :]K6O>&=2U/
M24U66[1]*DO;:>6)#) R'!!( !!P>H[BG>%]9UY/$/AE+_6'O8-8TYYI(GB5
M1&RKD;< 5TP\"V3VM['<WU]<W%W;"T>ZED!D6$?P+Q@ ]^.:2/P+9076EW*7
MM]NTRV:W@ =>5.<Y.WN#CMT% '5YS17.>"]$N]!T,VEW/-(6F>2-9I/,:)">
M%+=R.^.,FNCH **** "BBB@#R.#Q!XOUVYN-7TN14LK347B='FB6W\E#@[@?
MGSCG.?I534]<\4V^D>)-43Q%(#I6K?9HHOL\>UURHP3CIAOTKM5^&NAIK<VH
MHUVL<\GFS6:SD02/G.67OSSC.*=-\.].N-.U2QFO[]H=2NOM4XWI]_.>/EZ<
M#\J ,>SU+7K7Q-K>BS:O)=$:2+Z&9X4'DR=, #C'L<UBZ1KGBJTL/"FOWFMF
M\MM6NDM9K1XE4+O+ $$#J,9KMKKPM;6%W>Z^+B^N+TV#6Q4X8,@7@;57).>:
MQOA_X3#>'-#NM4DOFFL@S165T-J029(R%P#TZ9]: ,"PURZT>'6;:RE$%QJ7
MBF2T6X*AA"#MRV#QG'2M:^NO$UKXAU3PO::O<3RR:<+ZSNG1-\;J<%#A<$,1
MZ<5OK\/-,.GZE937-Y-'?77VMF9U#1S9SO0A1@TMQ8#PC:W6M1P:CKNHLJ1,
M20TIC!X   &!DD\4 87ACQ+J'BK3M+CMM1GANK.VE?5&\M2?-'RJK9&!DACQ
MV%<YIOB#Q;<Z/X;U'_A()"VIZ@UDZ&WCVH-Q ;IR>#7H7A70GAT_5+R>U_LZ
M\UB=YY(XR"T0/"CIC=CD^Y-5X/AMIUM8:99Q:AJ"Q:;=-=VV&3*N3GG*\@'/
MYT <S-XPUS2-*\067VS[7>6>J165O=SJBD+)W/1<C!Z\<C-+JNH^-M$T#7[B
MYNC!%%"DUF\TD4LX^8*P^48QSUQQ76R_#_2KF'6(KJ>[N(]6<2SK(Z_+(.CK
MA1@BJT?PSTJ/0KO2VO-0D6[")-/).&D\M3D("1A5SV H Y74-3UV"YU?29]<
MN)XY]!_M!9=BHT3@C(7 X!''XUV7PUBEC\!:2\MU+/YENKKY@'R C[HP.GUR
M:>_@2PEU,WT]W>S.;'[ R.ZA6BQ@CA1ST.1Z5H^'/#T/AK2UT^WN[NXA3A/M
M,F[8.RKP !0!YWK?B[7++Q-(]OJ4DL$>KQ6GE10J;98FQ\KN1GS.3T/&.U:G
M@&*Z/C;QB\VI7,_DW:QE)-I#\-@GCC'0 8%7;SX5Z9=R7!_M/5(HYKO[8L4<
MP"1R]V4;>OUK:TGP?9Z-KM[JUO=WK27F#+')+E&8#&XC')^OJ: .<U2<R?&_
M1;>]_P"/=-/D>T4XVF4YR?K@?RKK]92SMD76)XPTVG1RRQ'."?D.X?B!^E0^
M(_"MAXECMS<M-!<6KE[>YMWV21,>N#3+#PM%;SBXOK^[U294,:->,I" C!PH
M &3W/6@#CO\ A)M=M/#>D>+VU$7%O?3QK<V/EJ(XT=MHV$#=N7CJ3FL>\\5^
M+;?1]7U,:S&?[+U?[)Y1MDVR(3CGOW'3\Z[JS^']A9FWA6]O9-/MKC[3!8NX
M,4;YR,<9P"<@$U7F^&UE<:5J>GR:G?M'J-X+R=LIN\P'/'R\ G'Y4 9T&M^(
M;76?$6EW&J17+0:4+^UG,"KY3$'Y<=Q]:R-)\3>++:U\+:YJ&K17=AJ]PMM-
M:_9T3R]Q(5@P&3TS^%=7J'A..RDU;6CJ%[-/-IC6CQ[5(90A P N<YY^M8G@
M/PC%JG@[0Y=6N;R>.U1FBLID")$Y+ G[H8X!R,GB@"CI/C77_P#A*-'AN;Z.
MYBU&YGMYHD@ @B*D;?*D'+X!YY-1'Q=XMMM+76)]2M9((=:;3Y+=;8#S%W8R
M6[=.,?C70V_PKM;==/4:]JVW396DLP'0>4&Z@?+^M67^&]J^ARZ4=5O3%+??
M;V?$>[S,Y_N],\T 9\GBS4_#_B/6M*UR_1T^R&YTMQ$J&3.0$X'+9X_"NYT=
M;U-(M5U*59;WRQYSJNT%N_%<5)':>,_&=@9-)NX_["GD,US<Q^6)&'"*O]X%
ML-]![UNSV6KMX]M+RWO+D:6MLRW-NP'E$\[2O.=V2,\= .>: *OCS7-4\-PZ
M;J=I*HL%NTBOT,6\B-C]X'MCI^(K#A\>WKZKXCTM+RWGN8F0:6R0_+)N;:1U
M^8@L!^!-=[K6DV^N:-=Z9<Y$5S&8V(ZKGH1[CK6)!X"TJWO-!ND#"31HFCBP
M!^\R,9;WSD_4T <3>W&N:=XX\7WFF7-G'/:6$$]P\L)(EVQY( SQGG]*Z%/%
MEW<:UX4N)8;5+/4;":YD_=YDC9(]QVMV'3\JO77@>2YU77KX:IL.L6PMI$^S
MY$:@8!!W<G&?SIMGX%EM;K09'U42QZ/"\$:&V \Q'&U@QW>G'% $'A_6O%6L
MQZ;K")8RZ5?2/YEN!M>VCR0K;L_,>.1BN+\.ZYK7AO19=0MY+4Z:VO/;RV[1
MDR-O;DAL\8[5VVC_  \;1KTI%KEV^D)(9H-.;[B/G(R?X@#SCCH*A_X5LW]@
M/I7]L$JVH#4#(;89W]<8W8QF@#IO%.H7FE>%]1U"Q\K[1;0-*OFJ2IVC)X!'
M:N''B_Q=:Z3I$EY'92SZT$>U^R0L[QIL#.2I(#-R, 'UKOM;TN36- NM+^T^
M2;F$Q/-Y>[ (P2!GZU@:EX#&H>%]*TL:G+%>Z4$^RWR)AE*C ^7/H!^5 &9:
M>+O$A6STR]LDM=1O+QH+>YN(2BM$JEBYCSD-T&,XR:MS^(?$>F16VFZC%9C4
MK[4#:6ERG^K:+&?-*YZXR-N1SBENOAV;_2$2\UR\EUF.99X]4P Z,HP %' 7
M';UYJ23P ;C2D2YUJ[N-7CN%NHM2<#<DB\#"]-N.,4 9.M>,_$&@)KNGW#64
MU]96JWEM<B(A9(F;:0RYX8$_0U9M->\6->:5IMW/IBW.J@W,<L,;'R(%4%@0
M<98DC'X^U7K_ ,"S:M8:HNH:H'O]1BC@DN([<!4B0Y"JN>YY)S4VJ>"GOH-&
MEM]5EM-3TI-D-W'&"&7 !#(>"#@=Z .*TC6-3\.:;XHNE"/<#6]ES/% 72)3
M]Z0(#G ],]Z]"\(ZM/K.D/=RWMI>H9F6&>V4J'3 QN4G*MG.0:RM/\"7NFPW
M30>([@W=S>_;))6MTVL=I!4J.H.>>>PK6\+^&8_#=O=J)5DEN[AKB4I'Y:!C
MQA5R< 8]: .=U/Q=K6E:OK^FSRV*RV]H+S3BT#?O5)(*$!N3G X^M3:'XOO_
M !#IUE-8O:.ZV+S7PDC.$E!VJO!XR0WX"M[5_"UEK&O:3J\_$VFNS( !\^1P
M#]#R*CT?PC8Z!%JJZ<2C:A*TK%P&"$C@ <9 R>/>@#AI-3DUKPGX(U"XA@CE
MDUN/*PQ[%&'<<#MTKH?#@ ^*7BW&/]7;?^@T6WP]EM]$T73%U?Y=*N_M4;_9
M_OG)(!&[IR?SK:TSPV^G^*=5UMKWS/[05%:$1;0FP8'.3GC- '/>,EU)OB!X
M:&CM;)>M;W05[D$HHPN3@=3BLV#XD:H0FBW$$8UX7TEI*\$+2)M09+JN<D^V
M:[+7?#MSJ6KZ=JUCJ'V2\L1(J;XA(CJX ((R#V]:QKWX;6MSIP\G4)X=6%T;
MP:@/O>:W7C^[CM0!J>#=5UO4K"Y&N6+V\\$Q2.1HC%YR=FVGI7.>+?'6K>']
M5O ILDAM3$8[9T+O<JQ^9MRG]WCH,]:['0-'GTFU<7FI3:C>2D&6XE 7..
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MTGVIE8<JA_U:GZ+C\2:XJX_LR_U7QS;>(?*6_A^>T,K?,D 3*&/)XY /'<T
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M(RG[2HX E*XQM.>* /2=HH(!ZUYM:^./%^K'4VTKP[921:?<202,]R<DJ,X
MX)/^(K8T7QG-K=AX>DMXK=KC46<W"!CB%$!WX[Y!VCGUH [#8N.1Q1M4\US7
MQ!U34-&\$ZE?Z8R)/%']]B<HI."5]^>*Q].\4ZRT6DZ'!!92ZS-8+=N\LK^6
ML. %+'&2['/';KF@#O@ .E+7/^$_$A\1V%PTUM]EO;.X:VNH-V[9(O7![@UT
M% !1110 4444 ,$,8=G"*&;JP')I(X8H01'&J G)"C%244 ,>*.1E9T5F4Y4
MD9(^E(L$2@!8T !R %'!J2B@"/[/%M9?+3:W4;1@_6E6)$4*BA0!@ #%/HH
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M444 %%%% '(?"]P_PYT<@8Q&P_)VKKZX_P"%BA?AMH^#G<CM^;M784 %%%%
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M']A^'K2Q=S).J;IY&.6>1N68GOR36/XKT'5KWQ-H6M:2+622P\U7BN9&0$.
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MP1LL9$:(&#%B!C<YVKSVY]:T/^$2U9_$TFL/>V>9-+-@45&ZXSN_/MZ5VE%
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M;AM9-O\ "N/3Z]36=J_@2^UK3M6>>]MH]3U,PJ[HC>7''&00H[GIR3ZUWE%
M''CPMJO_  D\^LF\M?WNG?8O*VM@'LV?3/:N6U+1[_P[_P ()I$=U:O=6UY*
ML<K*0A!&>1G/<BO6<U#);6TTJ/+#%)(G*LR@E?IZ4 <-J7@+4+\RZ@=1MCJD
MUY%=2*\1-NRQ@JJ8ZD 'KW-03?#[6IK+5K9]5L6^WWL=X6^S,"K+@GOTR.E>
MBY [CTI<C.,\T <;+9MX>\3:AXKU>^MHK*>VCMW15<E"#P>G/.?SIO@31;*U
MFU75K(/]DOKAFM%8$!(NIVCL&;<?IBNQECBF0QRHCJ>JL 0?PIRJJ*%4!5'
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M#LUA!82Z1:FUMV+11;,*I/4CW]Z?;^%-!MKV:\@TNW6XF4I*^W)<'J#GJ.*
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ML=SH\>R],<4@9%NW##.1Q]W<?;(KL/&>@OXE\(:AI$4@CEN$&QFZ;@0PS[9
MH SH?'D8O8K34-(OK&6XMWN;02;&\]57<5&#PV.Q]:;X2\?1^+[A1:Z-J-O:
MLC,+J9!Y9(."N0>O-9#Z/K_B*[T2ZU/1Q9'1HI6*?:%;[5*R!55<'Y1QDD^O
MXUL_#;1]2T#PA#I>J6H@G@D<C$BN&#,3D8)]: &^);O3(?&_AF"[M;U[QVF:
MUDB?;$"%^8,,_,>.GO6;;?%>SG2"=M%U**RDO?L+7+A-J2GH, Y/]*O^*]*U
M:\\9>&=1LK#[1:Z:TTDQ$J*WSKM  8C/3-<?+X.\2GPF--CT@+,-?.I ?:8R
M!%D\9SUYH TOB3XI6]\,Z_86%C>7$5EMCGO89A&D,I(^4\Y;&1D#(YJS:ZGI
M=OXBT#S;.^EU2+0A*CQR#RVC" D;2>3G//%9.J^$_%5OI_B?1-.TV&[L=9G^
MU13M<*C0L2"RL#UZ "M5]!\0QZWH-Y_9:2K9:.]G.8[E<>8RX& V.!CD^_M0
M!):?%RPN=-;4)-&U.WM"F8YI$79+)OVA%;.,^YXX/I5RS^*&E30ZD;J*2">Q
M5&:&.1)C+O("A&0D$DD#&>":PE\":W/\*;30Y(8X=4L+HW$4;NKQRD,Q /;&
M&[]Q3I_"WB77O#]Z)]+TO1;N/RFM8;5$_>RQL&W.PZ#C 'OS0!=\0_$F\T_0
M]7\K1+NUU2SC1BLY0JBR<+)D$@X/;U_&J.L:E=W7B[P-J4MG<PW,T<[-:^:/
MGP@(P-VWG/\ C5G5M)\:>+/"&JVNIV-G97$D")#;12AO.<.&+,W;@8 SW.:D
MN](UZXUOP7J$VE"--+6072K<(PC!4*#DD9X&3B@#9L?B!:7WANZUA+&Z7[/=
MBS:U8KYID+*N,9ZY;I[5M>(-:70O#%]J\L?_ ![0&01L>K8X4X]3@5P>EZ!8
MW_Q3N[K3+Z.XT=-E_/#"VZ,7?S*O(XSU:NR\<:/-K_@K5M,ML>?- ?+'JRD,
M!^)&/QH QM*U>30/".GZMJ?VJ^U369(OW:'):6095%!.U% 'MTIUQK)\6^&M
M1NM+-YI^I:3,X"NP!6:,9*MM)#*>GXUDS#4_$/@'PRVD1FX2W:%-1LXYA%(P
M1=K)N/W2#U'!YI/"MCJ/@WP]XHEU73H[.V:62Z@"SB3.Y<!!CKC@>I)H [3P
MIKR>)?#%CJZ*%-Q'ET'\+@D,/S!K$E^)FC0WWEM'.;/[5]D^VKM,?F^F,[L9
MXSC%6OAOH]QH?@'3+*[0I<>69)$(P4+L6P?< BN0T?PGX@T;4+C1UT'2KFQE
MNVFCU>949XXV.3E3R6'0=L^U &[-\4]-A,[MIFJ"WMKS[)<3F)=L39QD_-Z]
MNO%:>L^.K'1[R^MOLEY=MI\*SW9MU4B%6Z9R1DXYXSQ7$:CX4\13>&_%%E%I
M+F;4M6^U6_[Z/_5[LY/S<'C]:KZ_9ZSJOC;63I&EW%Q:R6\-MJ26]U$C.2@8
MJQ8$9' ROH: .XN?B)80Q6[0Z?J$[2V37[1JBJ8X!_&VY@.>P!S5IO&]A)#I
MALH+F\GU& W,%O$JA_+ Y8[B /3KUKA[RSU7Q=#:SV6ARG2&TN2TAM'NEC6W
MN%+)EB.7  &.WTK-DLO$UE<^%=/L],\O6--T^3S!!=(9/*)"\[AM /.!SS]*
M .\B^)>DW&FVUW!;WC/<S&""!U2-G91\QRS 87H23UK:\,>)['Q5IC7=F'1H
MW,4T4F-T;CL<<'UR*\R70[V6UT\Z5X>!O/#TSK<Z=?3)-]H690Q;?]TMWQVS
M7I'A*VO8=-DFO],L],EG?>+.U5<1+@#YB!\S'D_CB@#*U+7=+T[QM>-);:G)
M?VNEF8B-LQ-$&R=J[L%L]\=J=I'Q%L=6U'2[8:=J%M'J<;/:3SHH20KRP&&)
MK/\ $6A:U=^-;_4+/3S+;2Z,]BDGFH,R-DC@L#CFJ.G>&]?ME\#+-I?.BF1+
MHK-'@!P%!'/..IH [SQ#KMOX=TA[^YCEE 98TCB7+.S'  _&N=F^)-E:Z=J5
MS=Z=>Q3:;.L%S;KL9D+?=.0V"#G%7O'^GZQJ?ALVNC#?,TR&:,.$,D0/S*&/
M0].:X*X\'^)38>*+2VT&WAAU0P/;HETA\HH5.,GKT.3ZF@#L5^(2,VH1-HFH
MQW-I:B\6"38'FAS@LO/;KCK6A8>,;;4=-T6\M[:9_P"U9-D<89=T>,EBW/0
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M?4CJUK+9B\BFDB"LF6VE2!VZU)\*;B7^Q=5T\EFAT_4YK>!FYPF00/PR?SH
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M[Q#>:;<WJ%GT^?SHQV;V/MD _A6Y5.[U;3M/FBBO+ZVMY)3B-9954L?;)YH
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M=: +VL:-8Z]IDNGZC )K>7[RDX(]"#V-9%MX$T&VT>ZTS[*\T-VH6=IY6=W
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MM%($4$D#KUH X?X8WUW>Z=JGVN&U+1WK+]LM$*QW9V@%P#].H&#7=4F #2T
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M !1110!ROPU_Y)WHO_7 _P#H1KJJY7X:G/P[T4_],#_Z$:ZJ@ HHHH ****
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M5@UM?(S1ACTD '4C^E<]%\//$47A32M&>;3)18ZC]LR2ZY4$G&<'KN]L8[T
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MC<<+WQGT% 'H8Z45F:''K,=G(-;FM9;@RL4-LI"B//RCGO6G0 4444 %%%%
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MU(]: -*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVI7OB*#2=3L]1(2-@YG55^ZB#< 5/3&/KUKH/#7ARRUKQ[XHDO;R^<Z=>(8
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M 92.X/2@!]%%0W=U%96LMS.Q6*)2SD*6P![#F@!MU8V=^BI>6L%PJG*K-&'
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M=<&F27$,./-FCCSTW,!0!)14;SPQ@%Y44$9&Y@,TCW5O&5#SQ*6&1N<#(]:
M):*KB_LRP47<!)X \P<T/?6D;E'NH%8=5,@!% %BBH7N[:.-9)+B)$?[K,X
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MBB@ HHHH Y;X<?\ )/-%_P"O?^IKJ:Y?X<[O^%>Z)N7:?LPX_$UU% !1110
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M-[MC/Y>] &3=> _"][>RWESHMM)<2L'=V!^9O7&<9KH(XTBC6.-0J( JJ!@
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M<NTG< "3CH>U5?A]X6G\+66I0R22^3<79E@BD<,R)@ 9QQD]_P * .QHHHH
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MPE:1I,L6+ 8R:[BJ&E:/8:):FVT^W6&(L68 DEF/<D\D_6K] !1110 4444
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M/U- '5T444 %%%% ',_#U2O@#1023_HR\D8KIJYWP$H7P%H848'V1#^E=%0
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MEN;VXNK^'R)KR>4--Y>,;0<8 _#GO7.ZSHUS!I-MX"T[1+BZTR:$*=2GE!6
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M1)A(9%?[H' &<X'XU0M/BRTT-Z6TF.22"R:]3[/<ETVKU1V*#:P'L10!Z/\
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M!=RY]<<C.*G:*-V5F125Z$C.*\:M]=OO"OC'QMJ$&BQW(06\]TJW 18@5)8
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MCIFL^/[*]W*]]:1&U3RR?,8)U&/?%9]Q-:IKME+XAGU.'2KK1H8+>6"'(.%
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M%.EZ]J;>']3LH-.U:<SSM.A:6!C]XIZGTS4-SX$U]SXM2.;3W36XXXHI)9Y
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M,: .KHHHH **** .=\!N)/ NBL#G_14&?H,5T5<WX !'@/1@01_HR\$YKI*
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MN;&X)) Y(#8R:SG^)'B*"RFU*:QTP65MJ_\ 9\Z(SM(1G&5Z#CU/7TH ]5
M)ILTT5O"\TTB1QH"S.[8"CU)->6+XJUK2/%_BZ_U*>":PTJ",&"-6!P02@3G
M )+#<35S2?&6L:Y--::AHYDL)[!IO.BM)%6)]I.QM_#<=".M '9KXET1XK.9
M=5LS'>-LMCYH_?-G&%]>:UB-RX/>O#+%,_#_ .'KE>1K"\_\#>NGD^(VLW6I
MS-H^C2WEE;7AMI(4MI&D=5.&<./E'/:@#TVBN C\6>)-7:?4= LK.YTRVO\
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MNV<?K7J^J:58ZSITUAJ-NL]M*,.C=_\  U4L/#>D:?;S006H9)D$<IE8R%T
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M:/XATVUT_5+RXT_6+&X2X1YRY&V/<LJGJO7M6E\([>)/ %C<))(SS;MX:0L
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M[H7J1T_.@#7KB/%7@O4O$TEQ;RZE;#3II(W59+?=+!M !\ML\9Q^M=IYBDL
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M_P"%6M+I&K0R7EM#>7US%<(;:';#$T?3"9[Y.:]'WKNVY&?2CS%+;<C<.V:
M//KCX9S:K<:Q<ZSK"W$^IP1QEHK8((G3!5EY[8QCT/6I3X$UJ[T:]M-4\1_;
M)Y;8VL#M;A5BC)&3@'EB!C-7-:\6:FOB270O#]E;7=Y;6OVJ=9Y=N1N "+C^
M+G//%=;:O++:0R3Q>5*R*SQYSL8CD9[X- '(67@R_@\2:)JTVHV\G]FV7V/R
MU@*[UP1G.X\X(KM*PO%^N7'AOPW<ZM!:I<_9@&>-I-GRYQQP>>15K0M3EU30
M[*_N84MY+J%9A&LFX $9'.!V(H P]5\+:K>>.;+Q';7]HBV<#0Q02PL<A@=Q
M)!'K6++\-M3ET"_TO^UK4?;=2^WR/]G8D'.[:/F]0*](1U=0RD,IZ$'(--,J
M*X0L QZ#/)H XF]^'TM_JVM33:KMLM8AC2YB2 ;]R# VL2<#OTS_ #IVC>#]
M?L(#%?>)#>QV\#PV49BVJFY=H9\<O@=/QK;\5Z\_A[P[>ZE##'/-;QF00O+L
MW =:FAU9Y/#$&JLD?FRVBSB,OM4L4W;<T <I;_#N^A\-:!I)U6$G2+S[4K^2
M<28)(!&[U8T1?#W5;/4;N.P\2S6^C7MPUQ<6@B!;+'+!6/0'BK^@^*M8U_PU
MI&K6FEP,;NX*7*F;:(8PQ&X9^\>.E;1UZ&\AU2+1VCO;^P!4P[\ R;<A=W3T
M'M0!R?\ PK:^M=3NQI7B*>QT:]F,UQ9(@)R>H5NP/3_&K%W\.YKK4/$)&KE-
M/UI!YL'D@LK@84[CV'7%==87-R=+MY]3CCM;ED!FC#@JC>F>]7&=5QD@9.!S
MUH \YC^&>I2W-C->^(A_HFGOIZ+;VH3$9&WKNZX/6G:1\.=5TS4M%O#KT)_L
MR*2!$6T &QL\=>ISR37HJL&&001[56U*:XMM.GFM(4FGC0LD;OM#$=LX- &'
MX*\,3^%=,N[2:YAG,]T]P&BC* ;L<=3Z5TU<UX(\277BOP^FK7%G':I*S")$
ME+D@'&3P,<UTM !1110 4444 ><&_N8/B;XDM;C4;T6$>CB<*C%O))(RR*!U
M'/:GZ7X^T;1="T*U-QJ^IO>Q.T$KVY>60!B/FQU.1C R>F:@O+748OB-XBU
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M?-'INJ6\<22N/E?";6Q^9JAX5\#ZO#X=U[3M6N3YTD#Z;8RM_# -Q!X[$O\
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M[*"LD^WYF!Z@GTJQ8:=9Z5:BUL+:.W@!+".-< $G)XH YSXG?\DWUOW@ _\
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MKR";7M6\/>,O&FIW>HBZ@TZW@Q;>5@,''[M1S\H!?D\YZU=L_%GC-+2_GN;
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M]"<'\#0!W%8-QXQT.UM=4N);P"/3)/*NOE.4?T]_PKB/#'CW5]=A73S=6O\
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M1(H=@B)C!(S_ !#!')]*;?>,_$-EX;U^]MY;);BSUTV8(MP 4R!TSU)Y).:
M/7J*\PN?$7C2SUQO#SBWN+[[*UXL]G;ALJ3M52K$ #(Y/6IM.\6>(=9O;'P^
MZII6L?9))[J26(,"RMM4*I]>I_&@#TC('<<TN:\FO;CQ/)XU\'0ZE>PVMS(E
MP9(HT#HK*#EL9Y)4_A5F?QEK]UX;OO%UA-:KIMG<,@L)(OFEC5MI)?J&[\4
M=E<^$=*O/$D6O3B5[N( *ID)C!'0[?4=:WJ\WMO$?BC7?&%Q9:3+80Z?#;VU
MV%GC.]DD 8C([X)KTB@ HHHH **** "BBB@ KC_'@S)X8'_4=MOYFNPKDO'/
MW_#7_8;MOYF@#K:*** "BBB@#G? :JO@310HP/LJ'\>IKHJY_P #8_X071,?
M\^D?\JZ"@ HHHH **** "N?D\::%%?:A9-=2&XT^,RW*+ YV*.IX%=!7F_C7
MPSJUQXQL-0T3Y%OX&L-0=5SB(_Q'\,@>X% '4?\ "9Z&]E8W2W4A@OU<P.D+
MG(7J< 9&*X74-:F@\'Z-=Z-XAO[R*37%B:YE&UG0L?D.1DK_ )]JO> O"VIZ
M'=ZC'J;S36FF[[?3=Z]4;YF91[\?J*YFWTS4C\/-!M#IE_\ :(-=\Z6(6SEE
M16)+$8]Q0!W>DWU\_P 7-=L);V:2SBL8GB@8_(A.W.!^?YUV]<'HL-TWQ:UN
M_:RNH[.:QB2*>2%E1R-N1DCK_A7>4 <QK7CW0]"O&MKJ69FC8+.\,1=8,]-Y
M'2DD\>Z)#?WME+-+'/:0&X*M'@2Q\<H>C9R,5P6H:)<:=XOUR*_\)7.N0:E<
M?:+6>)G$:[L_+)C@ <=?2K'C+1]4UBX2]L])>.YT!(A#%]G9EO.1N53W4?C0
M!V][XZTBQAM7<74DEQ#]H6&. M(D?=V7L*;=>/M"@LK>Z@GEO5N(C.B6D1D?
MRQP7(_A ((YK@M:MM0N_$MOXDN?"M_?V5[9+;S62[DEMG!YZ<D>_0YI\.F:U
MX/\ $=KKUIX7::QN;0PR6%CEFMSG(!SG)Z9[=: .^L?'&BZE?65G:2S227EN
MUQ"1"V"BYS^/!XK!U7XIVD-AIMUI=A>72WE]]ERT# +A@& ]6(Z ?CZ50OEU
MG3_$WAWQ ?#LC*+6>%[.Q3/V?<<H&(&,\\G@9S6#9:'X@M/!^@ROHEWYMCKK
M7<D"J#)L)ZA?KQ_];F@#T+4/B+H>EW?V>[^UJ4\OSW$.5MRXR%<YX..H&:ZN
M.1)8UDC8,C#*L.A%>,W&@7MKXCU=;WP8^KC5;C[1:3ER$A+\[9"#@!3U^E>A
MZ!X@>ZUN^T";2YK)]/C38['*3)T#+QTXH Z6N;MO&NF7.HZQ8JERLVDHTEQO
MCP-H_N\\]*Z2O-_%OA#4KSQQ97VE*1::A']FU5@0!Y2LK?J!B@#9U#XB:/IM
MO;RRQ7C&:#[0T:1 O#&>C.,\9[5!?_%/PY93P0J;RZ:>%9XS;6Q8%#T/:N7\
M2Z!=:?XYNK^3PHVOZ9?11I$D;$&%E4#!QT'UXK5TC1]2MOB5IUU-I0M[:'1_
ML[-;IB"-]Q;:I^G'UH F'B:QMU\6ZK87&JW%W;01L]M<QG9"Q0[=JGH,_>^E
M8?A#6K&SOM$U.];78KO6(A PG^:"XF+?>!)X [#C@_G=EL-3M[_X@2?V3>R+
MJ<0BM"D>?,(1DR/Q.:DU/0&G^#-K!<I)9WVF6R31F48:.5.?UY'XT =];:M#
M=ZI>Z?$DOF6>P2N5^3+#( /<XZUH=JP?"&GW-CH$3W[B34+H_:+I_61NWX#
M_"MQ]WEMMQNQQGUH Y.#XB:-/K<&FHMUMGF>WANC"1%)(O55/4^G2JTGQ3\/
M1SNNV^,4=Q]FEG^S,(XVSCYB>0,^V?:O/X-'U]-<TG4KWP_J37MOJSSW)B4>
M2J%LXC4<<]=W\ZMW&CZQ+X.\162Z-?&XO-;^TQ(82,Q[@<_I^M '5?$+Q?!;
MZ%JVGV(OY+N& %[BR4[;=C]W>X/&:ZKPI))-X2TB6:1I)7LXF=W.2QVC))KS
M74[;7M.M_&&F1^'[NZCUDF>UN+=,@%E *OZ8]/K7I?A>":U\*Z7;W$31316L
M:/&W52% (H O7]_:Z98S7MY,L-O"I=W;H!7GEGXJ_M#XHPR%M0L].32GE>*\
M_=QGD$2!>F,=S70?$;1[_7/!US9Z:H>X#I)Y1./-"MDK_GTKB]5L=:\8:^\J
M>'[ZQA?1I+,M<@*!+DL!],@#/OF@#M--\>:-KFIMI=N]S#-+$9+=Y8]@F7'5
M"?SYQ7&Z/JD3?#.QEUG6=6C=M49$GMF9I782$!"W3!]S5CP9IMREU:)<>#1I
M]S80LDU]*Q?S"$V_NQZD^F162VAZPGPMTS36TF]^V)K G>(1$E4#EMQQVP10
M!Z/:>-M+NKG5;=8[J.72T+W2R1;=H'ISSTS4-]X_TJQMH96@OI&>W%T\4<&7
MAB/\3C/RBL+Q1X2O[[QO:75@I73]4B%OJFT8^1&#<GMD +6;XHT*YT_QW<:G
M+X8DUW3+VVCB1("=T+( ,''8^_K0!TNI_%'PYIDUO$9+JY:> 3QFV@+@H>AS
MQ_\ 6P:[*&59X(Y4SM=0PR,'!&>E>;Z5IM[:?$;23+HC6UE#HYMSY$9:&%V<
MOLW>W3/K7I= &+K_ (EM= :UBDAN+FZNG*PV]NFYWP,D\]@*H)X\TNYTFPOK
M*.ZNVOV=+>VBC'FL4SO!!.!C'K65X_L=3O=;T7R=,N+W38Q(9OLC!)=Q& -Y
M(VJ>,X]ZXO3=!O%\(V&G:KX8UB*2VN+AHKRS;]] Y.054')!P!D_A0!Z1+X\
MT^.VL9$M+^::[A:=;:*$&1(U.&+ D8P:J#6-)OO'6D2K=:C'=3:<TL<!&R$Q
ML-VY\]6^F>E<?>:-K^HZ+I?]KZ;J::Q;VKM;ZA8D>8DA8X24 ]P%)/J?K6K#
MIVMCQCH5_K%D[+:Z*\-Y< @1B0AB02.G'4],F@#=_P"%E:/]JMT\B_:WNY6B
MM;F.W+I.RG!"XYZ^U02?%;P_%-(CQ:@J17/V::4VI"1-V+'L#S[\'BO//#DU
MSIPT6ZUG1]3.BZ?,\UE)#&ICC+MPS-U8<C'3^E:%[H>MW'A#Q-:KH]Z;N_UD
M74(,?WXL@YS^!_.@#O-3^)6AZ7J%[92QW\LUD TWDVI8*I_BSZ=.?<8S5C2?
M'^B:SK$6FVS7(>>$S6\LL)1)@.NTGKC^AKDY[;4)=<\8W@TG4/)O=(6"W#0'
MYY FW 'KD_H:AL=(U6XU+P6KZ9=0I9Z=+;7,C1$")FC*C/XXH Z]/B'H3ZE%
M9[[A4G=XX;IHOW,K+U"MW].G-5X/BAX?G>,!;](GN/LIG>U81I)V#-VS^?K7
M'>%=!N;.]L='OO!2&\L[C<VK2;C"8P<[ASR^. /7'TJ!](UF7P//:#2+\3OX
MA^UB/R2&\K.[=C\* .RT_P"(L,VK^((KVSNK:RTM@OG-"<# .=WH2<;1WK?T
M/Q+!KES<VZ6EY:S6ZJSI<QA#M;[I&"<Y%<(]A?1ZSXSANO#=[J%CJC12J%.Q
M70#G!_O=, <\<XK8^'EKJEE>ZE;.E_\ V+&J"R.I1[9U.,LGJ5&3_2@#OJYB
M^\=Z-I]S,DYN3;02B":\2 M!%)_<9AW'&?3-=/7D$>E:M:>%_$GA!M'O;BYO
M+R5[6Z\O]RZN1AV?HI&,X- &CXIU.37/'=MX<<:LFG?9#+NL1M+R%AMDW#JB
MCOTS7H6E63Z=I=O9R7<]VT2[3/.<N_N37"V%C>Z;\2=+$EG=RV=KHRV!O!"Q
M1I 5/7L..M>C#I0!@ZWXML-"O$M)HKNXN&B:<QVL/F%(QP6;T%5K?QWI%Q>7
M%JHNA)#9+?MF$X:(@'(]3STKGO'VG2W.MB[M+/58M0M[/-K?V"%P[Y;]TXQT
MZ'/OS69<6/B.Q\2IJ%UHLU[->Z"+-Q:JNQ)NX;LH_3TH [1_'6D?V997EL+J
M\-]&TMO;V\!:5T7@MM[ 8ZFN8UWQ9;OXD\':U9W]V^E77VA7@A5SO*J0,QCD
MG<<=.U8NBVGB+PK:^&M:&@WEWY5A+87-FB?OH\R,ZL!Z=/\ )K=:#5;CQ)X/
MO[G0FLTAEN7>*VCW+;HZ[45R.-V>3]: .T\.^(K'Q-IOVZP,@C61HG25-KHZ
M]016O7#?#2UNK*WUZ.[L[BW:359IH_.B9-Z-C!&1ST-=S0 4444 %%%% '$Z
ME\.X=5U_5KZXU&86>J1)'<VB1J-VP *0_48(!XJK9?#>ZAT^:TO/$EW>(+62
MTM!+&,6Z.-K'&?F;:<9/2O0** .(NOA\USX7T70_[698]*F69)?(!,A7.T$9
MXZFBZ\ SW=UXBN)-6"MK<:Q2A;;_ %:KP,?-Z<'-=O10!QG_  @TPO/#MTNK
M'SM$A,,9:W!$H(V_,-W'RX'%4&^&#'P[_8XUN0Q_VC_:/F-;@G?Z=>F>:]"H
MH \XU/X62WT>HQ1:_-%!>W@O7B,"G$N>3NSDCK@?3TK4M_ US:ZMJM]%K<V-
M1MUBF1X$;<XCV;R>/K@8YKLZ* .!M?AS+IEIHKZ?JHCU/24>**Z>#(DB<DE&
M7/.-QP:DO?AQ'>62H=3D%V^HKJ5S<&('S95&  ,C:HSTKNJ* .;TCPO+IGBO
M5M<>^$[:D$#Q>3MV;  N#D]LYJIJO@RYN/$USKNF:LUG<7=L+2</")!Y?'*<
MC#<#KFNOHH \P\1V.CKH\7PWL;"]>X=(VBE6/*1Y?)D=_;DGBO2+*TAL+&"T
MMUVPP1K&@] !@5/BB@#BY_!-[9:W>ZGX;UDZ8U\V^Z@:!98W?^\ >A]?K3[_
M ,!IJ&F1K-J=P^JQ72WB:BZJ6$HQC"] N !M'%=C10!Q%YX EU6SU,ZCJ[RZ
MCJ,"VTMPL("QQ*<[$7/&3U.:GC\$S0Z]9:O'JO[VTT[[ J-;@J5Q][[W7.#7
M844 >-^*O#C^%?#GAK1X-5#2C7$GBN)(@/*SDEB,G(#'/XUT-_\ ##^U5N;V
M[UB236I[B*;[8(0%01_=4)G&/K7H+QI( '16 Y&X9IU 'F]S\*YKM=92;Q#,
MRZL8WN2;9,LZDG/&,>P%:%[HZ>&-6;QA>ZA--%:6"V3V]O:Y+ID8/WLYW8-=
MQ10!PG@C1K9]1USQ/:VLUFFK2#R(Y8]KJ@'+[3TW/N./3%:G@J/74TZ\_MJY
MFN,W;FV>>,)(8N,94=.<X'I73T4 <OHWA.?2?%NJZZVI"8:D%\V#R-H4K]W!
MW'H/SJUXN\+6OB[1/[-N7,8$J2K(HY4J><?4$C\:WJ* .>MO"&GVGBS^WX5V
MS"S6S6,#A0#P?K@ ?A60? -Q+:^)8I=6&==<-(1;Y\L#C ^;GCBNXHH XVT\
M"O;:KX>OFU0N=%M3;1IY  E4C:2?FX.,?E6AXA\,2:[JNC7POS;_ -F3^>J"
M+=YAZ8)R,#'\ZZ*B@#A)/AK#-;:HDFI2&6[OQJ,,J1A3;S#H1R<CM5BX\!G5
M(]2EUC43=7U]9?8A,D0C$*9S\J^I;DYKLZ* . M=#\2Z-J_ARVM];N;NV@0Q
MWB/ JP^4HP.0/O< #OU/K6OXG\)2Z[JVD:I:ZB]E=Z<[%7$8D!5AAN#QGT-=
M110!P&F> -6T6T\BP\2N5^T23&*>U5HWW]0P'7_.,5T'AGPO#X<\-G2(YBX=
MI'=PNWYGZX'8#M6_10!YI9?"V^L9-&:/Q'(5TB:1K4&W7Y4<Y(]R?4TY?AA<
MIX>325U="D>IC458P?Q#L?FZ5Z310!B>)O#=OXGT;[#<R-%*KK+%/&.8Y%Z,
M/\*SX/"5R]U<ZCJ&IB?59;0VD=PL 584/7"]R3ZUU=% '!2?#8R>"K?PN=8<
M6L$WFK(+<;NI;!^;U)K6U'PB=5\0Z;J]U?;FLX'@:$18657!#YYR,@_I73T4
M <+HGPT@T6Z"_P!KWMSI2.TD6FS$&)"<CGUZFFZ3\-4T>Z*P:W?-IL<AFM[!
MR#''(<X)]0"<XKO** ."7P?=>&OA[J.D:;JU\\KL98)8(OWB,2#M !Z$]?0$
MUT5OI$FH>#X])UMS/+-:""Z=3@L2N&.?6MNB@#@['X=W-I>Z)-+XAN;F/1V/
MV:-X4&$(P5SWXP*9<_#(7.F:G8OK$OEZA?\ V^1O)&0^22!SC'3\J[^B@#DO
M$?@@:[J-CJMOJEQIVJ6J&/[5;CET.<@C/J3^=4]1^&\5S!I\EEJ][9ZK9AA_
M:"-F24,<L&]>2?IFNYHH XR3X?H9-%GAU>[CN],DDD-PX61IS)C>6W<9.*A/
MP[2,7UC::C)#HE_()9[ H&PV03L;JH.*[FB@#FK#PDNG>*+[68+QE6ZMDMEM
MQ'@1*@ 7!SVQZ4>";76K/2;B+6KN:ZD^U.;>2< 2&+C;N]^M=+10 4444 %%
M%% !1110 5R?CEBK>&\=];MA^IKK*Y+QUP?#A/;7+7^9H ZVBBB@ HHHH Y[
MP+_R(NB<Y_T1/Y5T-<[X#8/X$T4@Y_T5!^E=%0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5:WT^VM;BXN(8E6:X8-*XZN0,#)_I5FB@ HHHH
M **** "N>UCP;I>NZY9ZI?\ GR/:KM6'S/W3\Y&Y>_/_ ->NAHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ J.>"*YMY()D#Q2*4=3T((P14E
M% '+Z?X#TW3Y8L7FI3VT+;HK.>[9X$(.1A.G!Z9KJ*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KEO&Z[HM .XC&MVAX[_/74UR_C89AT(^FM6G_ *'0
M!U%%%% !1110!S_@48\"Z*/^G1/Y5T%8'@C_ )$?1?\ KTC_ )5OT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 17%Q#:6TEQ/(L<42EW=C@* ,DF
ML+0?&VB^(]0GL;&>7[3"NXQS0M&67^\N1R.:WIH(KB)HIHUDC8<JXR#^%<):
MW-S#\8I(]2L8D^T:>4T^:)LYC5BS;O<D_A@?6@#OZ*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %34[2:^TVXMK>\DLY94*K<1 %HSZC-9&C^%C8:DNJ:AJ=SJ>H+
M"8$FF55")G)VJ.A/<UT5% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5DZUI5]J8B%GK%QIVS._R4!W@X]>F/ZUK44 <B?!=[E67Q;K88#!W3!E/U4C
M%;7A_0X/#VE)I]O+))&K,^Z3&<DY/3H*U** "BBB@ HHHH **** "J&KC-E'
M_P!?5O\ ^CDJ_5>\YA7_ *ZQ_P#H:T 6**** "BBB@""QXL+?_KDO\A4]061
MS8V__7-?Y5/0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-U_JE_ZZ)_Z&*FJ
M.=]B*< _.HY]V H DHHHH **** /F]?CQXFCC6-;/3OEXSY;<_AFE/Q\\3D+
MML].&!S\C'/_ (]110 X_'WQ+Y87[#IV[.2VUNGIC=4@^/\ X@VG.F:<?P?U
M^M%% $O_  T%K>.=&T__ +Z?_&C_ (:#UK_H#6'_ 'T_^-%%  ?V@]:QQHUA
M_P!]O_C1_P -!ZW_ - ;3_\ OI_\:** %_X:#UG_ * MA_WV_P#C3A^T'J^[
M_D"66/\ KH]%% !_PT'J_P#T!+'_ +^/4D/[0>I DRZ#:L,<;)V7^8-%% $H
M_:%NRP'_  CL'/\ T]'_ .)I3^T)=@'_ (IV'_P*/_Q-%% $O_"_[KY?^*>A
MY'_/T?\ XFHQ^T'=%]O_  CL/7'_ !]'_P")HHH F'Q]N<X_X1Z+KC_CZ/\
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M_P B?_6HHH /^$CX_P"/7_R)_P#6II\2X _T3K_TT_\ K444 .'B/G_CU_\
M(G_UJ;_PDG./LG_D3_ZU%% #O^$C_P"G7_R)_P#6IH\29!/V3_R)_P#6HHH
M>/$65S]E_P#(G_UJ5?$&XD?9<<?\]/\ ZU%% #AKV?\ EV_\?_\ K4O]N_\
M3O\ ^/\ _P!:BB@!Z:P9&4>1C+!?O^OX4UM;VNR_9\X)&=__ -:BB@!/[<_Z
M=_\ Q_\ ^M2OK>Q4/V?.X9^_TY(]/:BB@!O]O<9^S?\ C_\ ]:@:]G_EV_\
M'_\ ZU%% !_;W./LW_D3_P"M33X@QG_1>G_33_ZU%% "?\)%_P!.O_D3_P"M
M0?$.!_QZ_P#D3_ZU%% #?^$DYQ]D_P#(G_UJC_X2C#$?8^G_ $U_^M110!G7
MOCPVEU%#_9V_S._GXQR!_=]ZBO\ XA&Q21O[,W[&08^T8SN!/]WVHHH S_\
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AEU36_$>GZ4^F6<4=Q=PQ,ZLQ(!< XS110![91110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>sgmo-20210331xex103010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M;;DL+56'0K"H/\JMT4 4SI.FL26T^T)/))A7_"D_L;2SUTZS_P"_"_X5=HH
MI#1],4@KIUH".A$"_P"%*VE:<Q+-86K,>I,*DG]*N44 4?[&TO\ Z!MG_P!^
M%_PIO]A:1G/]EV6?7[.G^%:%% &?_86D#_F%V7_@.G^%#:%I#?>TJQ/UMT_P
MK0HH SO[ T;&/[)L/_ 9/\*/[ T;.?[)L?\ P&3_  K1HH H?V'I(Z:79?\
M@.G^%*-%TL?=TVS'T@7_  J]10!633[.)=L=I J^BQ@?TI_V2V_Y]XO^^!4U
M% $7V6W'2"/_ +X%.6&-#E$5?H,4^B@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS@CVX-7M6MI;S2+RU@?9+- \:-G&&*D TZVTZVM;NYNHT/GW)!DD8Y)QP![
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MM[R.,Q332+YAF!ZDY/7_ .M6GX9T >'-(^PBY:XS(TA<KCEJ . M;[7=+O\
MQ;?:6;3[+:WQDFBD4EG]<>@Q6[9^,[R#6%&L>1#87-E]IMBB$$GKC)/)QD8J
MY-X)9[K5 NHLECJ<HEN853YS[!L\ _2J>JP6'B;7M/T>WLY2ND7 >:0KB-%
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MXSD\UUFB:);Z%926MM)(ZR2M*S2$$[FZ] /2J$_@^SFN[F1;BYB@NV#7-LC
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MHO& H/? % &X.E%%% !1110 4444 %%%% !1110 4444 47/_$^A'_3M(?\
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MNXD\!%M0N2;N"5+@B8_O,*<$\\D'O69I:W4?@74-?NO$NJ13"66W4&4NI^8
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M(&>1^F*RO'S!? NL9_Y]S_,5:\-NJ>#=,<DE5LT)V\GA: -83PM*8A*AD'5
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MDM)I_M#*T,HA>%T(E#GHNWKDT 3GPOHIM9K8V"&&:432*6;YG'\77K6L %
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M35[?PE<^%GT34)KZ#4A.)XX2\<R;]V[=7M^*7'- 'D^MP:E::UXOC32+^?\
MMFQC^S-##N (0@@D=""?\YIED^M>&=4M=0F\/WM]:7^E0VK01)EX7C4*58=@
M<$_C]:]8ED2*)I9&"H@+,Q[ =34-A?VFJ645[8SI/;2@E)$Z-SC^8H X&:*]
M@\:>%]1DT>>"&"PE2:.V@9T@+ [5X'45@6FEZG!X2T:$Z7?>;!KWVJ2,6[9$
M8).XC'H:]FJI!JEC=7]Q8P74<EU; &:)3DIGIF@#QK59Y5U[Q!8-I]])H4^I
M++=200&0ADP6PPX&2!QU&*]GTZ\M]0TZWN[5MUO,@>,XQP>G':N=/@:W6]N)
M8-4U.WM;J4RSVD4^(W8]>V1GO@UTUM;PVEM';P((X8E"HHZ "@"6N"E6X\.^
M.]6U&[LKBZT_5($"2P1&0HR#&Q@!P#^72N]HQF@#R/0?#E_HNO\ A1;JPFDC
M6*Y\T^662$R,2JDXP#7K:J%4*H  X %5=0U*QTJ!)[^YCMXV<1JTAP"QZ"K?
M6@ KR'4]-FT[QGJ\.H^'+S5+;5)EGM9(';R\]"L@!Q@'UKUZDR#0!Y9<V%_!
MK/BL_P!F702YTF*W@\J!V1G$84JI Z#I^%5-._M?PO<Z5JDNAWE[:7&EI93Q
M)$?,AD4G@@C.#^1KU^B@#S:S34=%\60:[>:3)'87MC]G\FUB+&T(;*J5'J,9
MP.IK)GT'4M)M-*U<V-R4CUV2^DMXDW21Q28 ^4?3I[UZ_BC&: /$[^SU2YT+
M7XSH>HH]WJT=W$AMV.4XST%=#XP@N;K5[9(=*NULY].=4ELH?WC2,.(W/9<8
MR#[UZ7VI,"@#Q!Y=3TBT\)W%KI=ZFK6-M-&\30EOW?(SL'/?K5TPQ77P]AT[
M2[+4);RTU**>XA>W*R!B2Q;:/X<9KT76?"\6JZA%J$5]>6-['&8?.MI-NY,Y
MVD'WJ[I6CP:3%((WEEEE;=+/,^YY#ZDT >=7UE>7'_"=!-.O2=02,VQ^S./,
MP,$#BLS6KC4+35-.:QL+IK@Z(EI>J(&<HIXY7L>#UKVG(KGM3\)PWVJ/J5OJ
M%]87<BA)7M9=HD Z9!!H 3P/-8/X5M8-.\X0VH\AEG38ZN.H(['FNBJGIFF6
MVDV@MK56";B[,[%F9CU))ZDU<H X7QXEZVJ:28[&ZFLU\SS)K-,S(Q& H/8'
MO7)Z)::I':^%X)='OE.G:C*\N;=L!&/!S^?Y5[-UK+U'Q#I&D3I!?WT<$KC<
M%;)XSC)P.!GUH X[3_#CZI;^,K&]MY8([R^>6WDE0J#UVN">V16G\.[>_?1!
MJ6JL7O)\1JQ_YY)\J_GR?QK:UW0+7Q%;P1SW%S''&V\?9YBF\$=#ZBK$][IN
MA6<27-Q#:PHH2,.V.!V'<T :%8GB_2Y]:\*:CI]J0)YHB$SW((./QQC\:NZ=
MK.FZN&-A>17&P L$/*YZ9':KU 'E=A:3WFDW97PC<65W%I\D,D\VYG=BI4+'
MD\@]:GTW3+U+_P #L^GW*K96\B3DPG$;$%1GTYKTVB@#Q?4[>;3O"4GVVSFC
M'_"1"94DB(+H22, ]:Z*ZT^YU:[\2:W;6-Q%#/IOV2&-T(>=\'G;U]!77Z]H
M$'B""WAN)9HU@G6=3$0"67..H/K6L!@4 ><:);:CH&H:;J-SI][/;SZ7':R+
M'"6D@=.Q4<X-1S^&)H/ %]+*3:7D=W)J5HK$;H3D$+]2!C\:],K%U7PQ8:SJ
M=I?7GG,UM]V(2$1MW^9>_- '(:SX<U.[\&:?=& WFHBZ34+N '!E)4@J/H"!
M^%9^I:#>:E91ZK9>%FM!;W"2/9.Y\VY ^]S[=!^->LC@49H X2RU,:#H]UK,
M7A.>T1Y$5HMW[TCG+MGL.!7<12"6)) " RAL$8(S23017";)HUD7(.&&1D5)
M0 4444 %%%% &+XLTJ76_#%]I\#8EEC^3GJ00<?CBN>MK+4-:U'P]++I]Q9#
M2%)F:4 ;VVA=J^H..M=S(ZQ1O(YPJ@L3Z 5!I]]!J5C%>6K[X)1N1B",CZ&@
M#F_ -E>:?IM_%>VLMN\E]),HD&,JV,?RKJIE+0NHZE2!3Z* /*+/2M<AT?0[
M"71;@'3]2\Z20$,&7<3D#\:UKG1M4FA\:JEE*&U H+?.!O &#WKT&B@#S/5]
M%U&ZALS;:5>V^KVMK#'!=0N-K,,95^V!7I%N)5MHA.P:4( Y'0MCG]:IZCK-
MEI4EK'=S>6UU*(8A@G+&G6NJVUWJ-W8Q%C/:;?-!7 ^89&#WH R/$EC<:S?Z
M=IC6TQTYI/-N94.!\OW5_.L6?PY<:#XYL=3T>SN)[:6-H[S,F>#T.3Z<'\*[
MXD#K2\$>U 'C)749=8U2?^S+FYT :@;ATB9=I*'DY/;UKJ]%L+W5/$>N:G):
M26^G:G9I'#))C=TQTSD=2:WAX/T9;F29;>0"1B[1"5A&2>OR@XK<5510J@!0
M, #M0!YMH7AS6(H/[#NM%L8;>(LK:EL5G=#G[O?=[]JG\-Z'K>E2PZ=+HNG"
M"VD+?VAA2[KG.!WW'IGM7H=% 'F:^%M:;PHEBUF%N/[8^V$&1>(\Y]:MZIX/
MU#5]1\2,R)%'>I%]G8D$,R>H[5W5Y=1V5I-<RDB.)"[8&3@#-1:5J4&KZ9!J
M%J6,$Z[DW#!Q]* .,MM&UV7P_?6\VCZ?9RFT-NB6X7=,QQ\Q;L..E7+'0]4A
MUOP].\"I;V-BT$S;P3N(QC'X"NSJE;ZG'<ZG=V*Q2J]L%+.RX5MWH>] &/X)
MT[4-(T5K"_MUB,4K&-E<-O!).?:M'Q%I(US0KK3]Y0RKPW;(.1GVXK4I,B@#
MCO[&U;59M*;4;:*!=,5F79)N,TFW (]!TZUI>#-)NM$\-PV-XJK,KNQ"G(^9
MB?ZUT&:,T 07D<LMG/' ^R5HV5&_NL1P:\ZTOP?K]AJ6G7J6UBLMLLBR.TA+
M2EL_,Q_I7I>11D4 <#;^$-3M]!TFR9H-]IJ!NI3O.-N<\<>].;3=/U_X@Q:C
M8W GAMXPUUY9RAD'"#/0G_"NGM==M[W7KW1Q%();6-7=F VL&]*KR:CIVA:Q
M8Z/!8^4U^69&B153('.??I0!O5SFNZ)>W&N:?K.G-&;FU5HVCE.%93[CZUT6
M12T <-?>#[ZYT+6$$D7]HZK.DDO)"1A3P!Z]_P Z[2U1XK2&.3&]456QTR!2
M74S6]K+,L3S,BEA&@RS8[#WI+2=[FUBFDA>%W4,8W^\OL: ,GQ=H]SKN@O86
MK1K(\B,6D)P #FLVX\/ZS%XCNM3T^XM$6XMDB<3*6P5 '3\*Z.^O9;0VXBM)
M;CS91&WEX_=@_P 1]A5O- '*>'/#$^FZU<ZE*L-J)8@AMK8GRRW=N>GTKJSR
M"*,BC(]: .$3P+J"Z4MJNHQ1S6MV;FSD1#P2<_-_];]:M:EX8UK5M$:VO]3A
MEN7GCD.$*QHJ'.% [GUKLLYH) !). * .=N]!N9_%.FZLDR"*T@>(QD')+ C
M/\JR8_!5\N@VFFM>0YAO_M;L 2&&<X%=A:7UM?0>=:S++%N*[EZ9!P:L YH
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M %*;RH6E!\M .K'')^E=$,X&>M8/BCPT/$"64T-TUI?V$XGM9PNX*W<%>X-
M'*ZEX[US1+;6K2\MK*34M.6*5)%#".:)V"YQG(.3ZUUOAFXUZYL7EUZ&TBE8
MAHA;$D;" ><D\YK%U/P)/K.GZI]KU"+^T=1$:23)"0D<:'(55SGKW)KK[.&2
MWLH(97$DD<:HS@8#$#&<4 ,U*62#3+J:)49XX7=5?[I(!.#[5YY9>,=9DT'P
MJ^FV.F0'5I)8BA5E2,JQZ 'IQFO1KR W5E/;AMIEC9 V,XR,9KBK'X?WEE;>
M'[?^U8VBT:9I4'D']YN)//S>YH JVOC[41I!ANK>W.KG53I:.F?*+\?.1UP
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MR+J,:)JT*P$>228U4 #G=SP*?;^!Y[76-%U*#4]DMA:"TE A!$R ]LG@D<4
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M'49=3EEN9P^H,CL1CY&3[I'_ ->@#C+SQ-J]]H7B6Q:]D(M(HWCN##Y<CJV
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M\B/<*+F5-K2(  #C)_#UKG+.\@_X2'0[^"=%MKG5)DDEFF_?RQG /FCH%Y(
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M>XYH ZGQ3XKC.D6E_H^I*(5O(X[AD'12>0<CBM6\\;:1;Z)>:G!,;E+8["B
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M=G\*Z#<S22S:/8R22*JNS0J2P&,#I[#\JL+H6E)>I>+IUJ+B.,1+((AN5!T
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MHHXA%I]]<7+6WVI[:.,;XH\XRV2,'(/'7B@#8DT?39I+>22PMW>V $#&,9C
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MEJ[W5Y=2ZIY<%JK;FV[0<C/ ')R<UW-[J5OINFRW]ZWD01)OD+<E?;COVXH
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M74=P]S=QJS2Q[BJ,QS^/!YK3.O:SJ<.L7^G3PP6^FR,BP/%N,H49)8]N^,4
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MK#RE4,!LV'KP>IYIWAI-7\0>++Z:_P!7O[=;)HW6U0A5.X9VD8Z4 >ET444
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M+@W8&(1C$:CMTY-7]8\&Z[JNI^)H%M88X-5CAGBN&FXCD0+\A &3R"*]2HH
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M^,[03T%9$OB#5=/U3Q/X:EU&YF-K9->65X2!*N%#;6.,'\J /5JKSWUK:_\
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M[117E0\8W^NZ9JNJ:%/.T\>G(QL_O>3+OP^!CKM&1]:U/ 'B"/7+MF@UJZN
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M4 %%%% !1110!POB9&;XI>#,*3A+PG';Y%KNJXW7_P#DIWA#_KE>?^BQ794
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M:U/#>C:]82!]:U=;T11^5"D2;!CU;U/%=*:Y_1/$K:SK&JZ<;%H&TZ01R.9
MP8GICCTH A\1^'+W5-;TC5-/NX;>>P+_ .M0L&# #M]/UK&_X0+4I="U739K
M^V+7]]]L,BH?E.0<8_ 5W^::751DG ]Z /.;SX<:K=G4$.LP>7>2QS.6M\ON
M7MG/"C'2NAT[PS>6'BB?5_[2$B7,2)<1F$ NRC (/8=ZZ;-(9$&,L.>G/6@#
MGO%?ARY\1"P6&[2W6TN%N/F0MN8=!UZ5T0S@9ZTUI44@,P!/ R>M/H ****
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M]!N-0GD,,4=TZLEK S%(L9S@GUS3=;T'59O$T6L:7):AA:&U99\\ DG(Q]:
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M8 ]ATKUV?P]I-Q?2WT]C%)<RQ^6\K#DKZ?2JK^#/#<L5O$^BV;1VX(B4Q@A
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M8^(X+> =3"D@E4P1_P!=%KF;DZIHE\EA#K5]<0W&DO<'S'^:)D&05X^4'&*
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MP'<1VZ]* /6]PW;<C/7%&]=VW<-WIGFO)-#C%A=^%+ZWED>ZOTE6??*QWX!
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M_AA00(&M4C;@JY(R7)QT/K5XZCXBEUOQ1.NO21VFBL)$@\A&\P;"VT\#CC%
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MJVUO91J"C0'^+:1CIR2: /7Z*\NN9?$TOBW7;2'Q+,D6F6\=RJF!,2?*&*D
M#%1Z/K7BM].L/$DLZ/8RAWNHYKA-C#G C4+E2,8QDT >JTUW2-"[LJJ.22<
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MRQ$<4F3A@I&>X/7&<U-X_P#&RZ5:Q0:/JL"ZBMW'%+"%#G:3R.> ?UKO^@H
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MX>:%H>HO>6BW!!W;())BT4>[KM7Z$COUJ/3OAQH6EW<]Q:_:E\P.$C,V4AW
M@E!C@X)ZYK:U#Q)HVE7*6U_J-O;S/C".V#STSZ?C4-WXP\.V$\D-UK%G%+$0
M'0R#*YZ9H @M_!UA:^%V\/QSWGV(DD-YV'7)W8! '&?YUOPQ"&".)22$4*"Q
MR>/6N<N/'.CP>)K/1?/5I+F+S1*IR@SC8/?<#G\O6NCDE2*)I9'5(U!9F8X
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MUK5=3M1-I$GV"Z#$3)$X$.,XRQX.<=J .XHHHH **** "BBB@ HHHH ****
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M4X,0F7<#],U=P* !6W*&P1GL:XW5%N-)^($6M3P3RZ?)8&WW01-(8W#9Y Z
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M,\6OVC,3?O$")0W52G0+TP!P*9J?P^OKJ"QO;?Q!/'XAMG+G4&3B3< "NP<
M8'2@"DWQ&U*/3K(WUE'I-Q/<20M<WT$@@^494@<$;L]^F*L:KXXU2Q?2K5O[
M,M+F[M/.\ZX9F@EDSCRT=6P,]<DXY%7)O!^L2:<D,VLP:A+(&^V+?VV^*8D
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M"Z(]Q"T09P2!D8SQ7-7G@N]N?#FCVT.I);:KI.#;W21Y7@8P0>Q&/RH J?\
M"P+N+3XVO=/%E.UV+<W%PCK;X()#Y(!P<8YJK?>(/%,_B'P];Q?V?$ET\S*L
M<C.DP48R2.Q!R*VO^$>U]]/5+O5;:_GE<FYCN8/W#IMP%51]WUR*S[;X?W>E
MKH\VG:A"+BPFFD*3(S1XDQE5&<@#''- $5OXP\3:A-JL8\/V,EII[RPW)-SC
M<5!Z9'(X]*L:-XCGFT;1K'1-/M(+R[MGN?)8D10QJQ';DDMQ5[1?#&HZ=8Z]
M%<W5M+/J<DDH=$8!6<$'(]/I68O@/5+33]'DTW5H[;5M-C> 3>66CDC8DX*G
MZT ,N=?\4SZ]X9@-I;V7VLRF6WE9LED4YS[8.0/6I/\ A+K?3+[Q%(=*ACO8
M;N*W4QMS<LPPI8XXJU=^#]6FGT6^36@^HV,DCS33Q[@^\ $*HZ 8X%1W?@.?
M4)];>YO8U-]-'<6[QH0T+I]TD=QZT /N_%VKZ1<WEAJ5C:M=I9O=VSPR,(Y
MHRRG/((_6H=)\:ZO<:EI,6H:=;1V^J6KS0&"0LP91GG/8U=O/"VH:JL]SJ-W
M;-?&R>T@\J-@B;QAG.3DD^G05!;>#=0M[KP_+]N@ TFW>'*H<ON&,CZ#% $W
MA3Q;>>(;K#K9B,JYDAC8B:W8-@*ZGKD=P*OZWKEW!K5CHFEK ;ZY1IB]P"4C
MC7O@8))/O5'2_"-W'XDAUO4;FU:ZAA,1:UB,9G)ZM)SR?I5[6_#UQ>:S8ZSI
MUVEO?VBM'^]3<DD9ZJ<<^O2@#B?%?B74M5\&WUK(D-M>V=_':WBJ"5;)RI7V
M..<UZ+9:;Y.GR[X[:&]N$Q/+:Q[ S8(!]>!ZUSFH> GU#1KFU;44CNKR\%W=
M3^1D,PZ*J[A@#\:Z\PO)9&"60;V3:SH-O)&"0.<4 >46#+X;6#P]XLTI5L_M
M&^UU6)<@L6W#<W8GIZX_.MR\\=:Q/JE_%HFF_;(+*98B@MY',W]XAU.U?;(-
M:5QX/OKW3+?2+[5UGTV)E9O]'Q*X4C"[LXQ[XS2/X&E@UJYN]+UJ>PM+L@W-
MI'&"'/?:3]W/M0!6M_$_B#6VO+C1;.W$5E.L+VMP"))3@;OFR N/I5*VU#7S
MXH\5L]Y;21V5NI$#Q,4QM9@!S^?K6F? #0:I<3:9K5U8V%T0US9Q@$.>^&)R
MN:MGP>Z:UJ=];ZF\4.H6_DRV_E!AD*5!SG/&<T 9.D>)K[4+/0=.L!:6EY>V
MK7,C^3F.-02,*@(Y)'K5+4/'.NV]I+;(MDNHVNI)932%&*.K9PP&<CISUK<A
M\"_9;32?LFI-#?Z8C1Q7(A!#H2<JRD].:?<^!8+K3_)>^D%P]X+V>X\L9D<9
MP,=@/2@#)'B;Q';+XEL6,-]?Z=Y;0M!"1\KXS\N>=H.:W/!NLR:Q;7+OJD=^
M$8!3Y(BE3CD.G8YIH\'2+J6IZA%J\\-S?^66>*,#84(QC.>..0:OZ'X<AT6X
MO;LS-<7EZX:>8H$W8Z84<"@#"\5Z5JMCJ$OBC3KY',$(#V<\8*-&.3@]CWKJ
MK6X;4=&CN(RUN]Q '4XR8RRY[]<9K+O/"[W^I3S7.L7[6,V-]B' C..V>H![
M@5OHBH@10 H&  , "@#R2X\8ZU9Z:([C4;@ZGI]^4O8DB0AH 1\WW>GO6IK?
MB/5'\*:AXBTW498K=[F-+1#&A'E@A2>G<Y_*NQ/AC2FOM1O'M]TNH1"*?)X*
MXQ@>F:CO?"FFWGAZ+0\2PV,>W:L38. <@9(/>@# NCN^*,.>#_8SD_\ ?1JW
M\,VW>"8 /X9YA_X^3_6M>3PU:2ZRNJF:X%R+8VN0PQL.>V.O.:ET+0K3P]IH
ML+)I3"'9_P!XVXY)R: . 2[U][GQ-JB^()RFD3R+':-&I1P >N,5+H\WBB>.
M"_?5?+L[JTD+>9<I*S2;208UV_+C'3FNVL/#5AI[:EL\R5=1D,EPDK;@Q.<X
M'XU0TSP%H6DO.UI%,#*C1C=,Q\M6ZA/[N?7K0!Q&GSZW):>%[EO$6HL^K3-%
M,"RX11_=&.OO5G^WM2A\.:S:MJUP9+?4UM8)FYGD4D952/XO?ZUVD?@K1X4L
M$1;@+8,6MAY[?NR>3WIC^!="D@FA>&9EFG%PY,[9\S^\#G@\T <0NMZS%X7\
M41O?7D,^GSH(2\H>1%/\);O5[43J=WXHEM&UF_AMDTD72I#*%)8#UQW(KIQX
M"\/B&ZB%M+MNL&;_ $B3YR.Y^;DU8'A'2_M;W1%PT[P?9R[3OGR\8QUH C\#
MW]QJ7@S3[JZD,D[1D,YZM@D<_E7$ZOJVJ0:=XI":O=J]OJ444+AAE5;JHXX'
MTQTKTK2M)M-%TZ.PLD9+>/.U68MC//4UE3>!M"N#<&2"5OM$OG2CSWPSYR">
M: ,;PQ+>V7CC4-'DU&YN[<6D<X-R^]@QQG![#DTSQ;>ZG<^++71K6\6UA:T:
M8$W!AWODCEAR<8Z5U-IX<TZRU:35((Y!=R1B-I&E9LJ.@Y/M2:YX8TCQ$L0U
M.T68Q'*,"58>V1SB@#SV_P!+ENKKP@NHZH]W=/=2123V]P=N%Z;3V/J:N3VT
M>F>/]:NK<W#RV>D_:(T:=VW-V!R<D>QKLI/"6CR&PQ;M&+ ?Z,(Y&4)^1Z^]
M3)X=TZ/6I=7$3F\E38[M(Q!7TQG&* /.--U#7([&#7TUNW??$Y>V>X:5IFYX
M"=%(]O2M?08;74[#3KZ7Q)=-=7<92ZM_M.3*Q!^4*/NXYZ#I74Z=X/T+2=0D
MOK+3XXKA\Y;).,]< G _"G6'A+0M+U%M0LM.BANVSF0$GKUP"<#\* ,'X76E
MM!X7\R'=YDDTGF R$XPQ XSQQ5">SBB^*>HW4$4CSP:=]H1%D8;G]",\CVZ5
MVVF:%INC/,VGVJP&9MTFTD[C^)XH30].CU>354MP+Z1=K3;V)(],9QB@#SLR
M,/!VG>(XKNX;69;A1(1.Q\PLQ!3;G P.P%6/ NC&_P!=U+4KZ_O9+JRO"BQ_
M:"R?B.<UV]OX9T>UO!=PV,:3!BX.20&/4A2< ^^*L6&D6.EO.UE;I"9WWRE<
M_,WJ?SH X_X@S0O?6%H6:64QRR?9WF\J' 7AW;KQ@X'>K_PTO9+WP7:O-/YT
MBLZD[LD#<<5O:CH6EZM+')?V,%P\8PAD3.!4UAIMEI5N8+"UB@B)+;(UP"?6
M@#R)M,M'TCQ#JTM]<B_LK]EM3]H;Y,%< #/)-,#S:S?Z@/$&MPZ9=QJAA^T*
MPD1<9_=\@9/'8DYKMO#'@Q;2\O[W6+*VEN9;HS1/NWX!]NF172W>AZ7?7D=W
M=:?;37$?W)'C!(H \\L-!T[6?B!=6]Y)=W,<%I%,ADF=2S<<D=>_3M5'[1]D
MTW4;>,N--.N>5<E6)_<^F<YP:]5BTJQ@OY;Z.UB6[E&'F"_,P^M*FEV$<4T2
M65NL<QS*HB4!SZL.] 'F'B>:;1K_ %"#PLVVU>R5KI;8;EBY(R,?=)'>I=-&
M@6WC[PT-)DMLO:/YWE-DEBA'/N37IEOIUG:0O%;VL$4;_>5(P ?KZU#:Z+IE
ME*);;3K2&09^>.%5;\P* +]%%% !1110 4444 %%%% !1110 4444 <;KI_X
MNCX2';R+W_T!:[*N.UTD?$_PF N08+W)]/D6NQH **** "BBB@ HHHH 8\T<
M0S)(B#U9L4>=$)!'YB;R,A=W./I7F.N^']+U_P"+B6.H*\D+Z8961967+A@
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M-I>I/]HTI[8R3J%"N>P]%'3%,72]5.FZ!--X?O+J#3%>*> ML=MQY90#GC%
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MOB+:Z;JLEI)IUP8(KQ+-YRZJ=[#@JAY*^]1:C\1C8W^KVR>'[Z=-) :YE$B
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MI?)97"O>2M';PSO'&7V_>)8M@ =.>] &XO@_PVH4+H6GC:21BW7@_E3QX5T
M0I"-'LO*1MZIY(PK>H'KQ4?AGQ39>*-->[M%>,Q.8YHWQE&';(X(]Q65+\0;
M6-1>#3KEM&^T?9SJ09=@;.W.W.[;GC.* .CM-)TW3[F6XM+*W@FF_P!9)&@4
MO]3WINH:+I.JO&^HZ=:W3Q_<::)6*_3->>SH_BSXD:EI.IZ?</9V]J@A:.X
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MO0]+@O+304CN(H/M01F,-NH5%)R0B]!QTS^-:=% 'EFF^%/$-KH_AVTDT_\
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M=7UNS7$*E4ECE>-@IZC*D<>U07W@OP]J6DP:7<Z9";. [HHURFP^H((/U]:
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M9T/\#'/W>V!BIX/ &B6L=@D/VM!8RF:W_P!(8[&/?!XH X.?6/$,&FZIK/\
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M"-W?Z;<""XA*88H&R"P7'/UH Z>BO,)]0\7V.K6FAMJ1O9[B!KOSH(HHW"]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N8T30+ZQUG7
MKF[%JUMJ<@<)$[$KA=N#D#J.>M=*[K&A=V"JHR2>@%8,WBNV76-'L[>(SP:H
MKM%<JX"C:,GCJ: ,2S\%:A&VEZ;=36SZ/I=RUQ 5+"63DE%8=."?7FNKTX:J
M)KS^T6M3$9?]%\@'(C_VL]Z36=0NM.L/M%II\M_)O5?)B(!P3@G\*OJV5!((
M)'0T 8'B6QUB^FTTZ;'9LEK=+</Y\C*25!&!@'UZU2\0>"8=8\1Z3KL+)!>V
M<JM*>TJ#M]1V-==10!Q,/A?6- \0:KJ.@O9R6^ID/)!<LRF.3GY@0#D<GCWJ
M;1?!LFA^%M2L(IHY]0U 2--,^54NX([ G S6M?>)M/L/$=AH<TA%W>JS1^@Q
MTS]><?2MG/% '&:!X4U/2?AY/X>EDM7N7CE1)%9MGSYZ\9XS[UC6_P -K]?"
MVDVK7-M'JVDSF6VF7+1L"V[## Q^%>F9HR* .?%KXBOK.YCOFL(=]N\2PP%F
M#,PQN+$9 'H!WKE]!\#^)M#T5-+M[[3(@7.^[C5_.",064<8[5Z3FC.* //[
MSP+J>LVEM8ZO<V,T=O.'2\56^T; 20F3Q^.:Z#P_H^JZ9?ZG+J&K/>V\\H:V
MC?K"O/'\NGI6_FC< <9YH 6L36=(N]4U'39!-"+.UF\Z2&1"?,.,#OVSGZUM
M;A51-5LI-4?34N$:\CC$C1 \A2<4 <_K_A*XU#Q#I6KZ9<V]G-8;NL.?,!Z@
MX(XQG\ZSI_ FHW.FZ[:2:C;_ /$UNEN681'Y"#D@<^PKO::\B(,NP4>I- 'G
MNL0:9XOUK3M%"RR7FDSJ]U,L95%0+\RY/7<<#'UKT,  8%,#1;R%*[CR<=:H
MSW-__:]I%;16[V#HYFE,GSJP^Z%'>@#+N_"CW/BF?6UO0AELS:>48<X!'7.X
M<YK-M/A^^G6VFM8:JT-_IX=([D0#$D;')5USSSWJM-X\U-?"VJ:JMA;+/9ZA
M]D$32%@%R!DGN<GVKT '*@T <E=^!H;G2#:B^ECO'O1?27@0$O*.^WICVJ67
MP9%=ZQ-?W]Y)=">R^Q21,@7<O<Y'?//%=37)^&O%AU*?4;?5)K&VN+>]>VBC
M63!<+_O')/TH KZ3\/+:P22&]U&\U*U\MHH;>Y?*0J1@X'KCC-2:3X!ATMG!
MU;4;B)8VCMHY)N+8,",K[X. >U=-/J5C;3I!/=P132?<C>0*S?0$\U:H P-,
M\,1V6K#5;F\FO;Y81;I+*%7:F<]% R?<U9\1:%%XCTB339YI8H9&4L8\9.#G
M'/OBM:LZ;7M(M[O[)-J5I'<#_EF\RAOU- &9KW@RRU^.S::>YM[RS $5W;OL
MD [\BH+SP#I5S#9>7->V]S:9VW<,Q$S9^]N;OFKPUB.'6;R2XUG3AIT<*%8O
M,4/&Q/+,<\ \5IKJ5B_D;;N!OM&?)Q(#YO\ N^OX4 <#X8\)I?Z#J^EZE#?0
MQG4VF@EDRLI /RN&(Y/^-;]KX%T^U&I$7=_)+J,7E7$LD^YB.GIUK8BUO29[
ME[>+4+9YHP2R"49&.M1P>)=$NKB.WM]6LY9I20B),I+$=A@T 4;+P?:V-_I]
MVEY>.]A"8(%=EP$/8X49J"Z^'^BW6N/JC"X1Y6#301RE8IB.?F7O755%=7,5
MG:RW,[[(HE+NWH!0!RM_\.M(OY[I_.O8(KI@\UM!-MB=AW*XKJ;6VCL[2&VB
MW>7$@1=QR< 8ZUBZ-XPTG5]&.IBYC@@$A1O-< @Y(&?<@9Q6M8ZC9ZE"9K*Y
MCGC!*EHVS@^A]#0!D:AX/L+^_N+OSKNW-RH6YCMY=B3@?WA4\/ABPM]=BU:$
M21S10"W2-6P@0#@8K:KG/%>OW&DBQL=/1'U/49O)MQ)]U?[SM[ &@#HF.%)]
M*\[\&^#TDLI'U5+]-M\\ZV<Y*Q$Y^5MO?K6^EMXGL;JS,FJ1:A \JK<J;98R
MB]RI!Z?6M)_$.CQ7_P!B>_@6XW;"I;@-_=)Z ^V<T 9L_@+0+C6_[4DM6$I8
M.8UD*QLPZ$J.#5^U\-:?93ZE-#YPDU$DW!,I.2<]/3J:CN?%_AZSGF@N-6M4
MEA($B%\E3[U+:>)]$O[F2WM=2MY98UWL%;@+W.>A'TH I1>!]&AM[2",7*I9
MRF: >>WR,>XJ1?!^E"VU&WQ<%-18-<YF;+G.?PHM_&WANZO8[.#5H'GD;:JC
M."?3.,9J9O%>AKJ7]GMJ,0N=_E[<';O_ +N[&W/MG- #&\(Z0]S9SM#(9+2(
M0QGS6&4'0-SR/K54^ ?#AL[FU-B3%.V\@R,=A_V>?E_"II_&_ARVNY;674T$
MT3[)%".=A]R!@?6KEKXBTJ]U6;3+>ZWWD*[GC",,#USC!ZCH: *2>"- CT5M
M)6Q'V9VWL2Q+EO7=US5C2/"NCZ%<27&GVICGE78\C2,Y8?B36A8:A;:G:K<V
MDADA8D!]I7.#@]0*LT 5[ZQMM2LY;2[B$L$HVNA[BL6'P)X9@!\O2HP2I4L7
M8DCT)S4VH^+]&TJ]:TNKAQ(@4RE(F=8@3@;V POXU4'C&)_&0T%+2X9/)#^>
ML;$$G&.@^[C^+I0!>3PIHL<ME(EGM:R.;?$C_N_H,U!)X(\-27;W4FD6[2NV
M\D@XW>H&<"N@JGJLT4&E74LTTD,:QMNDC!+(,=1CO0!4N/#&AWFH1ZA/IEM)
M=1X*R,G(QT^M6K?2;"TU"XOX+9$NKC'FRCJ^.F:Y"S\;0VUYH6F6MOJ-Y;W<
M3,;J6%B[ #@^_/4]A716WB:SN]2%E#!=MEVC6X$/[IF4$D!OP- &U1110 44
M44 %%%% !1110 4444 %%%% '&ZX3_PM+PF >MM>Y_[Y2NRKCM;#'XH^%2O0
M6MZ6^F(_ZXKL: "BBB@ HHHH **** "BBC- !1110 449%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 449HS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!B^+K>*Y\(ZO'-NV?9)6X8CD*2.GN!7F-CI5A<IX MXGG5)HY6E\
MNX8,#M&<$'Y1GTQ7LLL4<T3Q2J&C=2K*1P0>HK#MO!7ARSFAFM=+AADA),;(
M6!4G\: //%OKV+X;7D@U"[7['K8AB;SCN\L2*-I/4CDUIZS/<:?XM;4+YKJ7
M3YKN%(+NTN6_T4X&8I(\XP3S^-=JWA+0GM);0Z=']GEE$SQ;FVE_[V,]?>E'
MA71!>_:_L*F;>)"2[$%P,!B,X)]\9H V:;(ZQQL[L%51DD]A3JAN[2"^M);6
MY3S(95VNN2,CTXH \?U^TU75=,NO%T.GL)HKI;NTNC. Z6R=%VX[\GKWKI/$
MVOQW5CX:OS*_]CWDN;J*)R)&!0X'RG) /7'I79KHU@NDG2A!_H.SR_)+$C;Z
M9SG%<;XD\%#_ (EL6EZ%97VF6QD+V$LQB^9@/F5CGCCI0!S>I6U]9^!TNCJ.
MI0-<ZPJPYO'W"W8G:"-QP<>O-6;W3YK;Q7-X<.N-':1VOG6S:A<29W-U964K
MDKVS^5=)HG@+3PL\FH:3#!%,R.E@D[2)"5!^;/&6.:Z/5?#6C:YY/]IZ?#<F
M'_5F0<K^/7'M0!Y=]JOM6U2WT:^UZW,4=A_HUS.9(EG;<09%(*Y88[U>6Q;4
M?%.@6%[J]U?1-I<N^:*9XQ*5+ -C(].O?'>O0=1\+Z)J\5O'?Z9;SI;@+"&7
M[@]!CM[5*WA_27N8K@V$/G11^5&X7!1/[HQT'- 'DNCI.FC>%=3&HWC7\FK_
M &0M)<NRF+<1MVDXQP/SJ:"8ZQ>:I=ZCX@BT_4[/4CM4([3HJL J*-X4J>!C
M!]Z].7PMH:111+IEN(X7\R-=O"-_> ['WJ5_#VCRZF-3?3;5KT<B<QC=]<^M
M 'D^IV4;V'C?4#-=?:K"\C%O(;A_W?(SQG'<]:Z70X-,'Q3OYI8HEO'L8)8V
M;J78'<1[G(KL7\-:+(MPKZ9;,+E_,F!0?O&]34ZZ-IJWD-XME +F"/RXI=@W
M(OH#V% %ZN?\:Z(->\*WUFH/G!#)"1U#KR,?7I^-=!2'!XH \3M]4U,76G>)
M[73D$6H0_P!E^5C!:;;MWX[#</R!KJ6TZWT?XB^%+*#"A+*=6QQO(7J?<\UW
MRVENB*BPQJB-N50HP#ZCWY-1R:;8S7274MG!)<)]R5HP67Z'J* /(+F6,?#_
M ,2G>/FUTXR>O[Q3Q7M"G*@CTJC_ &'I7E-'_9MIL8[F7R5P3ZGCK5U$6*-4
M10J* %4#  ]* '5XA<6&C7>D>*Y)88FUHZK(MI@'S@2X*X'YU[?5<V]HMTLI
MBA%PWW7*C<?QZT >++#;B^U;2?%NI7Z:C)+&T:10*YG  V!'*D@Y]P*]KM%*
M64"G?D1J/WARW3O[TYK>%Y5E:)#(OW7*C(^AJ2@ /2O"XK_2Y[R;0]1N[>"&
MWUEKIKJX5C)(,XVXVD?B3C%>XS,BPNSR!$"G+DXVCUSVKCK'PA>+8FR;75NM
M*D);!M4,C*3G'F9.>IYQWH S8+"PU'XC>(].*QBWN--CB8(H SWQ[CBH_"EC
MK-SI-];7L.R?28)K"S;)RSD'YQZ<;0#]:]'2-8U 50 !@4X#% 'CWA"#1[I]
M/@N(-6DU/3@WGQ7&%A@&#N8G'(]L\U5L1:P^%_"KI'&EP-8+2,% 8+O/4]<8
MV_I7M6P<\=>M&Q?0?E0 X=*ANU+V<ZA=Q,; #UXJ:H;BZM[2+S;F>.&/(7?(
MP49/ &30!Y#H]P]KI7A>9K:=K73+J9;]3"Q$3,?E8C'..>><5V/A6$S^*]<U
M:R!72;KRUB.-HED ^9P/3W[UV0 Q@4H  P* "N*\;V%W%JFB^(;6&2X739B9
MXH^6\ML D#OWKLI98X8FEE=4C0%F9C@ #N320SQ7,"302))$XW*Z'(8>H- &
M#!XLM-6:.#1DENI7X=S$Z)",=6+#]!UKB(X97\&7'AF>SG&NM=<9C/SL7SYN
M_&,8SSFO6  !Q2T >2W4 BE\:![=Y)'@BBC<Q$F1@H!(XY^;FM'1T"^)?#@C
MMV2--),<A\HJ-V.AX]J]"M+VUOXC+:7,4\:L5+1.& (ZCCO4KJ7C90<$@C/I
M0!XYIJ0ZMX(M-&T^S9]3>^+EQ"0(P')+E\8Z<=:K:G#J$UVKOI-]#Y&J"9[6
MUMR(@H."^>K,?R%>L>'=$3P_I":>EP\ZH[,&< 'YCG''UK6H \AN8;BZT[QG
M(FFWD;WL\;0(\#;G&1GM6IKNFZC9C0-4T4^5?W$4=A,KC!8,O4@]Q@_E7I58
MT/ANTCU^36))[J><Y\M)I2T<.>NQ>V<4 :-C9Q6%C#:0C$<2!5S5BBJNHZC:
M:59/>7LRPP)]YVH \Q\8V6L:CJ6LP)HU^RNL8M_LBJL<V#RTIZM[#Z5LZ,FJ
M0^-H;^;1KQ+>XTZ.VW';^[88)+<\=*[N">.X@CFC8-'(H96'<'I4E  .E4=:
M2271+Z*&-I)7MW1$7J25(%7J* /-K/3]6TT^$;H:1<S&RMI(9XD*AD+#&3DU
M-8Z;JL7BFTN].L+[38Y96;4(9)%:W*^J\GYC["O0Z*  =**** "BBB@ HHHH
M **** "BBB@ HHHH X[7 #\3_"A[BWO?_04KL:XW73_Q=#PF/^G>]/\ XZE=
ME0 4444 %%%% !1110!RGBGPQ%K$QO[[6=1M+2UA)\JTF\H#'+,3WX'Z4WX<
M6=Q:^#;62YN+B>2Z+7 :>4NRJWW1D^V*O>,;"_U7P]-IVG@;[IDBE8MMVQ$_
M.1^&:LWDNHV4FG6^F:?'/;%Q'<,TVSR(P.H&/F^E &M10.E!Z4 >(^*-6\2>
M$/&]]JNGW%W=:+:31QSVTT[2(N^,-CDG R3@]JWK#Q3IL5QK_B>&_OKK3[>T
MAFBMGN7*J[[MR[22 <@#T':NATRPO+O7O$:ZKH[II^HF,1M))&ZNJH$.0&)&
M<9%<UIGPOELM/\6:(9MMCJ'EFSFR"1C<0&'L<9]: +%SXV\3Z;X3M/%EW;:=
M)IT[*SV<2N)8XV. =Y.">G;O76ZGXFAL_!4WB.W0R1"T%Q&C<;L@;0?Q(KA[
M[1?$^I^ K7P8=*,,\92*:]>5# 8E.01@[B>G&*[FX\+P7'@H^&VF80_9!;"7
M'(P  V/J,XH X_P7I.I^+O#RZ_J^OZI'<7;N84M+DQ1Q*&('RC@G(/7VJ>?7
M]9\++I/A@SQ:CK^H3OMN+AB42/<<.P&#T[#T-,\(#Q5X.T<:!=:!)J"PNQMK
MBVG0(RDYPVX@CDG\ZDU_PWKUWK7A_P 416\$NIV)Q=6<<@52A).%9N,@$CGO
M0!9/C'5],\4OX;U=;'[5<6K3V-U K"-F /RNI.1]T]#_ #K&\/\ Q6O-6TG4
MX;JWMK76K2 W$2,K>7,@&3@9SG\>]7+C0-5\1>.5\2W6ER6MK86;1VMO*Z&6
M>3#8R Q"\MW/855\3?#R?Q#X.TF6WM?L>O6%ND14LH\U54!E+ XYZ@Y_G0!;
MU7QKX@T_Q7#H;3:/$LME]K-S+%(%3 )(P'.?NFEO/&7BC3=6\/Z?>6^EA]4G
M,)**Y 7( <?-T(.<'%4]=\%WFN?$2UN+S2GFTA; 6TDPE3Y7P<, 6SP2.W;I
M5WQIH&L7/BCPM>Z7ILEY;Z6XDF998T) (X&YAS@4 =%X[\07GA?PM/J]E%!+
M)"R@QS X8$@=B,=:Q9?'&I3SZ'H^GV]I+K6I6RW,I?<(;="-V2,Y)QVSV]ZH
M^,X/%7BC1]6L(="GBMWCB6WCDFAW,X?<S'#<<8&,GI49\.ZWI&MZ!XEL]/>X
M:WL4L[ZRWIYH 7;N0YVGUQG^? !O7&H>.X-6BL(]/TJ>*0 _;0'6-?7<N[(/
M\\UD^$_&7BWQ,]S+'8Z4(+:[%M* 7# =W&3@@>E=G8:C?W;3RSZ5-:VZH#&L
MKJ99#W^4$@?B:Y'X6:/JNB6^M)JFGS6YN+LS1;V4[E(Z<'K0!0@^(OB&?1]=
MO$LM.>;2KI;<0JK_ +TEBO!W<=*TM&^(<_B'2M/EL8[2&^>[%K?6T^[,.03N
M7&,CY?Z5@Z/H>NZ9:^(#<:+=DWFIQ74*H8V)02;CGYN#BM;5_A\Q\=:7XDTA
M/)C>93?VXPO&#\_7\"/QH OZ5XLUSQ5?:B= @T^+3[.0Q+-=[F,[CT"GY1[\
MUU&@W>H7ND13ZK:):7I++)"A) (8C@GL0,_C7G&FZ/KW@W3=>T6WT^_N([IW
MEL+ZP9<JQ'RA\D%<'&>O>NU\%6^M67A:%=?DEFU,EFDWR!VZ\#/3I0!SGQ/\
M;W?AB738M.!9Q*L]U@<>4#@*3VW'/Y5T>O\ C*PT+PDNO8,\<RK]GC4_ZQF&
M5&?Y_2N.NO"=WXLM/$&HZK#K%E>3$K!:*\81XU'[H8YR<C)Y')K*T[PAXDUG
MX;-X?U&REL[[39Q/9/*R[)%Y^3()QW_2@#NX=1\9(FFW,]EIDL%U+&LZ0[]]
MNC$<\G#8!YKGKGXB:_!?^)(5L]+>+0V!<L[HTJDX^7DC-27\OB_6]7T*.QL]
M6TN&$JNIF21%C9<C)4Y^;^+GZ5R^K?#W6=?\2>)KH6ES:M,WFV32,H24@\JV
M#W'2@#J]=^(NHV>G^&K[3[.T$.L_+MNBP,39'4@].?TJUJ'B_P 1:;X6U36)
M;73)5M1&]O+"7,4ZEBK#D@@@_A7+Z_IOB'Q#I7ABWO/#%R)-.E_TN) FQD&T
M?+\W<#I6CJ]IK5WX+U'P_IGAV]@L$A6.T6?9YKN9-QSAL!0!B@#H?#OB;7=9
MEMG:+3)+66 22O;E]UNY3<JL#U].*SO!OQ.;79-5@U:VAM);&(SCRR<21C.2
M >_3\Z@\'6^H^'K:RL+/PU?VYEVOJ,TVPIE4/W!NZL0.M4;?P!<W^J>'-4>T
MEM5AA:+487V@L%)9>_(8G!H =9?%#7+_ ,-ZYK26%A''ILB*(7WEG#''7/6M
MW1_%7B+5%BD6WTJ2![3SG>%W_<.4WHKY/0].#7&0^'M=C\,^+K#^PKSS=4N5
MDMAL7&T-GGYN.*Z#P[%J.A:7;V%CX7O8S/"O]H-,J!-RQ8.P!LDL?7^M ":%
M\5+G6-(U-9+.WM=9LXC/'"Y/ES(.3CD'.,U-XF\:^+?#%FEW=:=I30R70MH\
M-)N;(SO^G'UJCXA\ SZYX0TN^M;62UURRMTC:-L*TJKP5./Q(_*M3XJZ3J6M
M:%I=MIMA/<2I=K*ZQ@?(H4CGGWH ZS1[S5I(;K^V;>W@DB?Y'MR3'(FT'(SS
MZC\*Y6S\<ZWX@M-3U/0--LWTVQ8JOVEV$EQM&3M X''KZBN[51<V05E91)'@
MJPP1D=#[UYGH.F:UX*T77-!32KN\,KR26-S;!2K;UP-V3\I''ZT 6+[XGW$F
MG>'[_2+2VDCU64V[1W#,&AD! /(ZCD=JW/"OBZZUG7-6T34;2&&]TY@&>W<M
M&X]LC(/2O/=3^'^JZ?X5\.:1%9W-U+%>-=7KVV,1[MH(!SU %=-X"T75O"7B
M;5--GL9KC3KM_.AU$@%NF=LASGOCZ_6@!?%WBG4[CQ_IO@[2+O[$)0KW5RB@
MN <G:N00.!U]Q5;Q%KNI?#[Q9I2-J%Q?Z1J!*RQW;!WC8$ LK 9[@XZ5=\5^
M$]0B\>Z9XPTF#[48,+=VRD!V49&Y<D G!(Q["J^OZ!?^//%FD3R6-S9:1I^6
MD:Z4(\C$Y*JN<XX'- $%[\4-9LKC75_LW3I$T><1R_OV5I06V@J,=:V#XYU*
M7QGHNCV]E;K:ZG:+="27<'0;22,>O!K@M7\&ZQ?ZOXH<>';F:6_N@]A<$JHC
M^<DDG/&170RZ7XBLO&?AK4KK3KN__LW3_)NI8%4[G(;[N2,XW ?A0!U'C_Q7
MJ'A+3[*[LH+:<3W MW2;<,$@D$$?0TD_BS4+CQ8/#.E6]K)>P0":\N)BWE1Y
M X"CDGD=^]<OXVB\2^+-/,":#>1QQW\4MNC*H8(JG<6YZDD8%:8T74] \>W/
MB.VL+B]L-2M1'/'$5$]NP"XX)^;[HZ>I]* .JT6_UF22_CUVUM;?[,R^7- Q
M,<J$$EOFZ8Q69X:\=1>*4UI;&#,]A(RPH3_KEQ\I]LD?RKGK"S\8?\(]JRZD
MFHS-J$X@MXFE1WMX&)W.1QR!Q5?2_"&L>$/B-;7>F17=]IMQ ([J1@BX].A'
M3"F@#3'BWQ>OBNW\.RVFC)>36OVG/[TJO!^4\]>.O2GQ>.-:@\6PZ-J5K90(
M+'[;<,JONC !+*.<$\=:?=:1J4GQBM=7_LV5]/BL_),X*X#'//)SQGZU#JOA
MK4K_ .)TFH&QE_LN;3FLI+@2)P65AD#=G'([4 +:^-?$6J^';WQ-I]C8C2[9
MG,=O*6\Z:-?O-N!PIZ\8/2JNK_%2XL(M'U.UT^.XTF]A$MQC/FP?-M;D'!P?
M:H-,TOQ-H'@G4?"2Z/)<S2&2.TNXG3RF1^I;+94CGC%;&A>$I-+CTK1[FS^T
MV$6GRPW,IV[&DD96(QG=CY<=/2@#?T?7)-7U>Y6WEM9M-6VBFADCSO._/!YQ
MQM/YBM^O+M)\*^(/ =KXD.@0I?-,\+6*S-_!EMRD9'*Y]L_I7H^FRW,^FVTM
M[$(;IXE:6-3D(Y'(_.@#C_BI/=6?AB&[L[RYM9UNXH]\$I3*L<$''6NV@B$$
M$<09V"*%R[%B?J3UKDOB/I>HZUX>BL=-LGN9C<QRG:Z*%53DYW$5U\3F2)79
M&0D9*-C(]CC(H =1110 4444 9/B@N/"VJ.DLL3I:R.KQ'# A21@_A7,>"O&
MMG/I.DZ=>M=I>26?F":XC(27:/FPQZX%=7XAAFN?#FI6]O$TL\UK)%&BD EF
M4@<D@=Z\Y_X1?5YO^$7M7TZ>%;73Y[2XDW*PC=TV@\-R,G- '7VOC_0[K48[
M02S1"96:">6(K',%SG:>_0U+I7C?2=6U&.RA-Q&\R-);O+%M2=5)#%3[8/7%
M<;X;T37+*UCL&\)Z?!?6*.$U1]KB7"G;@=<DX!.>.:SM.\.^(6U;2KF31;U9
M5MKBWN))IT"JSJ1E%!^5!G@ <T ;GB'Q>=0UOPXFE2ZA%;2:D(VF"[(;A0<$
M ]3_ "KH-0\?Z1ITLP=+N6""86\MQ##NC20_PDYZUQT6F^)GL_#&D3:!,K:/
M>J\EPLB>6Z+W'/I5#5X-8\/>#-3T*]TQW@;4%F74!(NQPTJL..I/&,4 >DS^
M,]+MEU8RBX']E%1<CRN@;H1ZBHM2\=:3IKJ)%NI0+=;F5H82PAB;HS>E<EXD
MT77#J'BRWM-(ENH]7@B,,R2*%7;U!SW]JHZYH?B74X[BVFT.=E;3(H+40W"*
MJLH^;S"#\W.<#I0!VNJ_$/1=*NTM66\N)GA6=!;VY?<AY!!JMHWQ#M]0L=2O
MKRSN+.VM9_*CWIRYX 7K]\D]/>J'ARQUH>,M/O+[29;>*+1ULWD8J0'!!['O
MBLBX\*Z]<:1K-@NF*[QZN=1@,SCR[E<_<QG/()ZT =A+\0M'M["_NKA+R%K!
ME6>!H?WB[ONG )&#ZYID7Q"TVX&V"QU.2?YF$'V;:Y0#)< D<?K[5SE_H^HZ
MGX0U&.U\)1:7/<F)%MXBGF2$-EF8\ +Q@=^:U/&&DSZJ+'9H]Z9H[<M;W=I*
MJS6TW96Y V],_C0!UD]PFH^');B)Y8DGMC(C*2CJ"N1]#7*^$_$WV7P1H(N/
MM-_J-W$YCA0AI9-K-DDL1P!W)KHK&'4D\'I!?XGU+[*4D$9'S/MQU.!FN+T/
MPUKVC+X9U$V+2W%A:R6EU:"9,[2Q(923@]1QGM0!T\7CG2Y].^TQI<F<7'V4
MV?E_OA-_<QG&<#.<X]ZB'CVQ:S:1;.]^U"[^Q_8S&!(9?3.=N/?-<W?>#]=6
M]E\36$,0U7^T/M*6+N ICV[=I8'&[')^IJ[J]EXOUBRM);C3[=8C=*\^F0W
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MH7\L$3%X+.6;,,3'/(7UY- '5CI10.E% !1110 4444 %%%% !1110 4444
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M!((]ZDU'7?$'AO5=9T6Z\0QS;K%;JVO+F,(8FW %0%!SD9QQUQ0!ZW17BO\
MPEGB.'2_%$7VZ]BDLK>">!KN-/-7<0&[=#R1GD5N6$WB ^)SHTGB"XF;4-%%
MW'*41?(ER!E0!T]?K0!Z=17FOA7Q%J&N_P!G:+-=W$>K:?<2?VHPQRJ$C!XQ
MAB0/P-=#X]URZT+0(VLG$<]U<QVRS,,B+>>6_(&@#0@\265QXHN?#ZQS"[MX
M1,S,F$()QP>];->-:M=W7A#QEX@OH[NXOIX=*C\N2YPS*6D"CH,$#.?TK4UC
M5];\&7^FR1:A<ZO;W]M(SPS@,5D5-V]2!POM0!ZCQ17EOA^Z\73C3M8;4+=K
M6]A;S!<7:M&\C E/+0*-A!&,9/>K7@?6KR7Q"=-U>\U&'5! QFLKW#)(V00\
M+#MC/% 'I'%%<)XXGU-?$_AJQLM6N;*&^EDBE$(7G !SR.O-<Y:^*=6CL(-&
MDU*65I==?3O[0) E$((YSC[QSU- 'K<LL<$3RRNJ1H-S,QP /4FE1U=%=6!5
MAD$'((KQOQA-J5E9^)O#\^I7MU:P6L5[;S._SJ&<*T;MCYASD?05Z=X=MULO
M#-@GVB:91;HV^9MQ *@]?04 ;%%>.:;K^LMXLTB5=4O;BUO[Z>%Y&.+:11T$
M:'GY?7'6HA?ZW%I4VKMXBU!Y+3Q!]D,3.!&\6\ @CIT_ 4 >JZ_KEOX=T>?4
M[J*:2&'&X0KN;DXJ]:W"7=I#<Q@A)4610>N",BO(?$EW>>(O#WC*\FU&YACT
MV?[-#:Q/MC**1DN/XB<UZGH)SX=TP^MI%_Z * -"BBB@ HHHH *1F"J6)  Y
M)-9VOW366@7]RES';/' [+-(,JAQP2._->3OJ6K3VNN:;<WVIB!]$%VK7$@W
MEQU*X^ZK9/R^E 'L\4L<T2RQ.KHXRK*<@CU!I]<WX"MOLW@K20;B>8O;(_[Y
MLE<J/E'H!VK!\1-J]U\0?[+M=;NK.V;2VN-D.T88,0.<?K0!Z%67KN@V7B*P
M%E?F3R-XDQ&^TDCI7FFAZWKQ7PCJ-UK-Q<#4YWM)X&"A-HZ, /XN^:MQ:SK&
MF:CJ_A.[O[N?4KBX0Z=<$Y;R6ZG/^R ?UH ]2C39&J;BVT ;FZGW-.XID2^7
M"B%BQ50-S=3[FO)+[Q)J\/B"*[MM1NKF%]9%HQCP+7R_^>8!Y+]<D4 >D>(?
M$%IX;TW[=>),\6]8\1)N.2<#/H*FU;5X-'T>?4[B.5X($WNL2;FQ]*\F\175
MWXE\$7VNSZC<HBZF(DLE8"-$5P &'=N^:UM;N+OQ+8>+Q_:=Q:0Z3$T,5O"P
M"OA-S%_[P/(]J /2M.O8M2TVUOH01'<Q+*@;J P!&?SJSQ7DT$>KZGJ^A:+9
MZ_=:;;MH45QM@4<, HIFBWWBC6(CJ\6JQ1&VO#'/]HNR(_+!P4,(3 )'?.:
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MQT5_M'V[R3,L:P,0R@9.T@<_A45KXQT>^TN+4;:::2UEN!;(P@?)D],8S^-
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M*.'SAO?V]^E7--\5:)K#W:6&HP3FTYFVMPH]<^GOTH QM.^&NA:9:7EM;&\
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MFV]O*1C=&F#C^E9B>.M,9[=VM[V.RN9O)AOGB @=LX&#G."1P2*99>/=/O\
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MB/JI++U'MUJYHGB[6+O7-+L]3L+2&'4K=IX&@E9F&!GYLC% ';T444 %%%%
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M).0YP0!@=33M&TL6EU/X?UGP[JMY?K?M-;R++)]E;)XD/S!1CGG&:]LP*,4
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M?\*LF%M;Z>GB6Z72[6Z%U;6WV="8VY.-QZ\D]N_2K'Q;;R_!")YG[QKN$*Q
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M![O_ $,-NC9>L9))#''I3;#QUXAO[O0A!!ICQ:P)"J /N@"'^(ACGCO@4Y?
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M@@D=N:UX/"VCVU];7L5IBYMD\N&0RN2B^G)Z<U:U71K#6[06NHP>? &#["Q
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MB?Q-K.HZOI]I.ES.LENS'>5 SU&/H:ZF;2K"XNX+J:S@DN(!B*1HP60>Q[4
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M&D1B8(  W.XJFT_B&('UJ?5(Y].\,^$?%>DPI/=6-O%;RH/^6B.H7!^C?SH
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M@?@* .)^*XM3X6MQ<I&V;Z$#<.@W?-C\,URE_IOA[_A(?%\26MDL4.FH\"
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M<F>._O$1I+;=UX/+8[#&*9?^%_$D^G>+[-=*+MJMRDEM(+B-00IZL-W' Z4
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M0UP&I^"M>N[6[O(X;;[?J&JPWLT)F^6)(@=J[L?,?\:]17[H)&#WH 6BBB@
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M<K#-NN6+/D@?+\HYY%:=EXLU7^V[O3-0TR!9ULOMD$=M*79O]AB0.?I5*_\
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M0-XA-S<6%HD@^R6JMN)/+3Y!"#L,')ZXK6ENFO/B9X+NI,;Y],ED;'3)C)-
M'I!Z5F:7KMIJUW?VUNDZR6,WDR^9$5!;_9)ZBM(]*\EO_%?B*#0O&$T6HH)]
M+U)8('\A>$)QC'XCDYZ4 >M\45P'A_4];@\>R:-J6HB^@N--6^0F)4\MB0"
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MK%VL]]?F-(4B1;B:(<#R_EX)ZDMZB@#T#Q%X:T+74BDUBVC<Q'$<I<QLF2.
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M+"%OB3;::TLKVT^CL&1IF8$[B,C)]!6?X42YEU%?"%W;LRZ/=/<2SMG$B?\
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M** "BBB@ HHHH **** .+U['_"T_"&>OD7N/^^%KM*XKQ ?^+J^#O^N%]_Z
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MUT_$-I(98$$TF(W/\0^;K70UYCX$\5)I_@_3UO!?7U]?WDZ01*=\K;6R<EB
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M10 4444 <3X@_P"2K>#O^N%]_P"@+7;5Q/B$X^*W@WWAOO\ T6M=M0 4444
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MC!&68=!D#GVJGJ/A;Q7%X>U/PO::7#<VD]Y]HAO?M"K\I;=AE/.1Q^M>OT4
M0VOF?981,BI*$7>JG(!QR :Y;Q1IFJ/XIT'6M/LA>16/FK-"LBHY#@#(W8!_
M.NOHH \YN/#5M#X<\1'7[BVM+C6)7N@GF#]R5&4 /\1!Y./6NA\#:7<:;X:M
MWOI#+J%THFN)6ZDD# /T7 K4U+0=+UB>UGU"RBN9+1B\)D&=A/M^ _*M'H*
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M4N5CUBX1=[EC@;>YY-=M/)Y,$DNUFV*6VJ,DX[ >M $<=G9VV&CMH8MN<%4
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M-XTL];U46,-E?Q>9#]H@FFAVQS1YQN4Y/!]\5TM 'AFNZ9XC\/\ @T:#=Z;
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MD_B_0;;28-5EU*(6,YVQSA692?3@<'ZT ;=%9L^NV%N]FLDS9O%+0;8G;>,
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M%<'+$  ' ]>]7-4U3Q!X;UJYTMM8EO(;G2YKJ">:)-\,D:Y/0 8/N.XKH'\
M:7.-86YGNYUU9Q).K.H"N/NLF%!!%/A\#V8BNOM=_?7EQ/;&T^T3.N^.(]57
M"X'N<9- ''^&]=\1QZQX2>^UM[V#6X)&EA>%%";5)!! SFO6*Y*T^'VGV<^D
M2QZAJ+'201:J\B$*#U!^3GCBNMH Y+QEK%W9WVAZ1:7#6IU6Z,3W*XW1HH!.
MW/&3D#-<KJ]YJ<</BSPQ>:E<W4-K8B[@NCM$NTCF-R!@CGT!ZUZ#KWAVP\16
MB07JN#&XDBEB;:\3CHRGL:H_\(7I[:9?V<MQ>2R:@ MU=O+F:0#H-V, 8XP!
M0!!\.;-[3P-I7F7-Q-YELCA9BI$>1T7 ''US75'H:H:+I,.AZ7#IUO+-)!"-
ML?G,&8+Z9 %:!&1CI0!XE=ZKXE31==U=/$EZ'L-8-K#%M385W ?,-O(YZ=*Z
M+3TUQ_%>M^'7\0WDI;34N(IVVAHI21]W P%]O2M\_#S1FT^[L7EOGM[NZ^US
M*9S\TGKG'^<"I+[1$T2>Y\0Z9976HZOY @$1N<>8@(XYXXZ_A0!S/A/7M0UU
MM,T.:\NH]4TV5WU5B>6"' 4GN&)'X"O3A7,^$](GMWO]9U"TBM=1U.022PH=
MWEJ!A5)[GJ3[FNFH X;XC:YJ.F)I%CI\@A?4+KRGE\SRR%&#@.00I/3.*Y+6
M+CQ7I&GF"?Q$\;/J,,<:6\XF>*.3=D.Y0$GCBO5-<T#3?$>G-8ZI;+/ 2&')
M!4CN".0:QE^'/AQ-+CTY+:98([@7(Q</N,@& 2<Y.!TH X'4I=;@N/%]HGB7
M5_+TB%+BV+2KN+$ _,VW)7V&*T[NZUC6_$GA6P&OWUE#J.D"XN/LS*I9]F21
MQQFNPG\":+<S7\TOVQI-00)='[4X\U1T!YZ5SFK>#WF\<:!##97PT>PLFA^T
M13E60G.T;MV[ H YF\U&_N?#UM9:A<2W9T_Q0EK%=2<M*@+8R>Y%;YO;_7K/
MQ;JG]JWME=:1/*EK%%+L1%C7(W+T;=@YSGVKKIO!.ASZ;9:>ULZVUG+Y\2I,
MRGS/[Q(.2>3R:6\\%Z)?:A)>S6\GFS;?/5)G5)\=-Z@X;\: .#/B74=!U+0O
M$FI37KZ9JMCB:!W8K'<;<@JO8-@8'N:LS:=JH\3>&--N==U6$ZA;W$UW''=D
M%6"[L#K@#./P[5T5]INL:WX@AL+S2K&'0+*=)XIO,W/+M!PH7^'GK],<UMWW
MAG2]2U:#5+F&4WL"&.*5)Y$* YS@*P'>@#R2TU#6K?PWIVL?V]J,D\6N_85C
MDFW1F+)X88^8^Y-6M2O=?USQ/XA2UUV'3GTZXV0I->O#Y<:<EO+'#@]R<]:]
M"'@#PV+-;3[%+]G6;[0(_M<V!)_>^_UI^I>!?#FKZM%J=]IL<UW&!ARS#=CI
MN .&_'- 'G&IOJMS_P )?<OK^J(VFV\$L"P7)1-[(&/RC!VYSQZ'FK^@VB7G
MQ&TF\O)YS-+H45R6^TR#<^5'KTSGY>GM7=S^"M!NIKZ6:S=FOP!<_P"D2 2
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MRT?0K&U>!HF<@J6)Q@=P.._<T <%:7C36MGH-S=W%W%#J5U%:17,QB@N(5&
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MS45$\P$'S 3D8SG@&J]MX4UK2;[7X(=.GNH)]&2PMYO,3$CB/!)RP(&2?RH
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MT:34(;?]Z()YS;PW7RE'D!QC .X#/0D8-<Y8^'M;CB\%0RZ3(HTII!=-YD9
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M+?B%JGAS5[N/R+%;>W:(1Q2EC+<JW5A@_*![BIY$!^,%YDJ/-T/IZY;H?RH
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MHWPFS):E@8&3S2GE[,<8!Z]:JZKJ.ME/&%[#KVHQG298VMX5*!>>H8;>1[4
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M/Z5U_@RQOX-'AO+[6;K4&O((I@LX \K*Y(&/K^E '12S16\+2S2+'&HRS.<
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M1CACA_6K>B>*Y]5\8ZWHSV\*6^G*A29'+%]PSSV%=,;F (SF:,(O5BPP/QH
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MS6NH#4IKG49]1B$4UQ<$!Q&.BJ !MP>?K5*P^&6EV6D7FGM?:C/]JB$#323
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MQW<CQO/]G6-87,ID_N[,9S^%))X_\-Q:9#J$E\RP2S&W&8'W+(.JLN,@CWH
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MQ#JMKI=VIU%[6."UV?.PC.6=E'3IWKUZB@#S6>WOCXTUF^_LN^-M<Z(+:-A
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M:S<Q7UQ:12SL\,7EAE4%@,>N!65=?#NRN['R&O[M9GO!>SW(V>9-*/NDG;@
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MY$XE1;QY996*EN%(PC#';I0![+17G/PKTV[NM$MO$-[K.I74UPLB>3-<%HP
MY .T]^/UKT8]* "BO%=9CNKF_P#'MP=8U1#I822UC2[955B">@[#' J_I1GT
MCQIH4C:K?2I?:&UU=M<SF0;@N[.#Z>@]* /6Z@M;RWO83+;3)+&'9"R'(W X
M(_,5XKX<N)9/%V@>;=3O9:E%=">>:\8O=KM.&9,_NQTP.M9FEW":7X&TM+6]
M2T_M#4WCO7>5]HB!. P4Y"GN1C/K0!]"5F7U_>P:I86MOILEQ!.S>?<!PJP
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M--N;?X?3ZP+=K8?:4EEFP054DHK$]@>WO5);W3O^$@TS5K2XM;>%]?)W2/\
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M,?AL='U#Q+KNLV<EBDMVRF*TB8,\* 8).!QN/.!7IU %2ZU.QL61;N[@@9R
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MB!X<U>SDN5U".T$4GE21WA$+HWH03['I6W8ZOINI[OL%_:W17[PAE5\?7!H
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M$-]:Q-9V;2@3SQ%HTQR54#)_#(_.O+O%B7DGQST1=.FBANC9?))-&70?ZSJ
M1GCWKT/3O">DZ7J(U"VAE-T(O)626=Y"J<<#<3@<"H+SP3HE]K*ZO/!,;]6W
M+.MQ(K+],'@>PH \T\:^"X?"?PYU.1KM[R\O;V&6>9DVC.3]T<X^\>]1>';N
MYOO'NH70M(M(U.TTAD@L8QG[2VP[6R  ?X3^7I7KFN>'=.\1V*V>J1--;JP;
M8)&7)'3.#S5:3P;HDMYI]X]IFZT]52WF\QMZJO0$YR1]?6@#SSP?9Z=>_!35
MY[Q(Y)Y!<R7$LG+>8,E23UR/EK&N8-1D^&7AOQ>0S:CH\W^L8<O!OPN?7& /
MH37J]QX%T&ZEN6>UD6.Z<23P1S.D4K#NR [3^5;5SIUI=:;)ITL"&TDB,31
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MR'^][\UVJ,QC4NH5B.0#G!^M+N![B@#S^#P-J\-AX8M!?66W0Y3+DQL?-/(
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M&=%E6278%C)^9@>Y'I0!R.I?#ZYU+3-4$FH0C4M4N(Y;FX$)VA(R"J(N[@9
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MTV&2VNK58CYJ;N-P7O5+Q#X>U6]LM8U*#2K[&J:K;RQV8B)<1QYW.Z]LYZ4
M=RGQ.\-221QI-=M)*6$:"TDW/M&>!CFG6WQ*\.7;VJQ3W&VXE$ D:V=420]$
M9B, ^U4]8M;Z3XF^'M2CL+F2QMK2422(F0C." /KTKD+?0]:7P59:=)HM_\
M:4UX7LB^6/\ 59)SG/7F@#T2]\=Z-8:E)93-.1#*D$UPL),44C8VJS>O-9?_
M  G4=QK?B#2[FRO[:UL(@#<Q0L73(.YS@' Q@K],_3B/$NC>)=5O-1>3P]?2
M2'44G@\N4+"(A@#Y0<,Y&,L>?RKHVM==@UKQ@YT*XD75K1/+DC<%580[=O7Y
MCN;'X&@#<TGQ+I>E^&='2VN+_5)+J(M;(5+W$R@\L1V ]Z?-\2= ATF'4"UT
MRR7'V4Q+ QD24=58=C_/M7):)H.N:%+X7UHZ7<3FTL7L;NT0CS8_F8AU!.".
M?6H[WPEK+A+Y-,E$U[KRZC);(R_N(5! #'.-QSG H ]%\/\ BBQ\1/>16T=Q
M#/9R!)H;B,HZYY!QZ&EUGQ+:Z/<16IAN+J\E1I$MK:/>^Q>K'H ![FL+PCIV
MH6WC7Q3?W5E-!;7TL;0-)CY@H(/0U#XIL?$&F^,[/Q/HVGKJ48M#9SVHD"-@
MMN!!^N* ->+QQIMW:6,NGQ7-[/>HTD5K"@\P*OWBP8@  \<GD],U4F^)6B1:
M=97GEWD@NK@VPB2$EXY1U1AV//3OVK(72/$>F>)['Q5-8I=-):M;W%A:$!K=
M2=RA2<!L="?K64W@S7(9=-O$T_=)+KC:I=11RK^X3C"<D9.,]* -O7/B4L7A
M34]0TW3[D7EG<+:RPW"A6@9NC,,]/ZU>O?B+:Z:CK=:9>B:V@2XO44+BW1B
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MK>SO+6ZM%BLVN9ROV1@/FVI@C+$=?>@#:O/B 8]4:PL=$N[R06*WP82(@,9
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M@T2:&X-Y%;DR2(RX?!!4@X;(R,]N]0OX<UL:CXHN3I%I=0ZI+ R6]S*I5T7
M=6_NG&2#SC%9)\!Z_'X;N[>UC*QIJ4-Y8:?/<[_)1,[EW=!G/3VH Z=OB%MU
MJ31QX=U9[Z$1F6.-4<(&[DAL8]ZF7X@V!TFWU%K*[$<M^;!E 4F.7..>>GN*
MK^'-(UV+QOJVM:G8PV\5];11@13A]K(/PSGGFN;F\)>*4T]M(@TRU>&'6?MZ
M7376/-4N6 *XR,=Z .KU3XC:1I=_+ Z220V\P@N9T9,1.>/ND[B!GD@8%8_C
M_P 6QS^&=8MM+AO)UME5)KZUD"I"YP0"<Y/7G&1S54>&/$6F^(-4BM]%TJ_L
M]1NFN([VX"E[4O\ >X(R<=A5>]\,>*--TGQ%X>L]+BU&SU21IXKP3)&4+8R&
M7U&.,<4 >H::Q;2[1F)),*$Y_P!T5SVH^/=-TW4I;:6WN6A@G2WN+I%'EQ2.
M,J#SD^Y P*W]+CGBTJUCN8Q',D*JZ*VX @8Z]Z\I\5>%O$VJ7VK%M*^VRF\C
MGLKK[2%5(00-@3^]ZDT =YJGCC3M*GN%D@NYH;5U2ZN((MR6[-T#<Y_('%+J
M7C?3=-FF5X;J:&W9%N;B"/='"6QC<<^XZ9Q7,6EEXPT'7-4CM-(MKVUUB;[2
M)'GPMJ[?>#<?,![=<4ZUL?%GAO7]3M+'2X-1LM3F%P+J20((G( ;<,=,\XH
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ME5_#&@7EE>VVD7WA&%IK2?>NKELQE0V=V.[=A0!ZP.E% Z44 %%%% !1110
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M5#.9+5)I(VA)0,R-@E>,X./2@"O#I&F6M]+?06%M%=S#]Y,D0#O]2.M/&G6
MO#=K96XNCUF$2[S_ ,"QFO/_  >!X^N=4UK5WFD@BNFM[2T69ECC11][ (RQ
MSU-;<7E> [.>-IKB_-]?;;&W+YD+, !'ECT&.O84 .T'P=]@\1:UJVHQV5R]
M]<+- ?+W/#@$8R1].E3'P[JUYXF-[J6KK+I4,HFM;%(@NUP."S=\=?K6;/\
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MML4\,AD4@]$8X #G(&/>GIXSU"WO-,BU31T@BU2,FUDBN=_SXR$?*C!([C-
M'9LBL"&4$'J#0%4    #H!7F$/Q1U2:QL[\>'HC:W-Y]B3%Y\YDZ#C;T]ZOM
M\0-1MM(\137>D1+?:+(BR1)<91E?H0V/Z4 >@XI,"O.[?Q_K27\=KJ.APVIO
M+&2\L6%QO#[5W;7('' _E4MIX]U"\M_#$L6G6X_MHR(RM*P\MESWQTXH [_
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M<O;SKO1F4J2/H>14[L$0LV< 9.!FO,D\7:_J-OHEA9!Q>7.G_;)Y;6*-FZX
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MMJ$2>( X:-^26/7!- 'H=% Z44 %%%% !1110 4444 %%%% !1110!R.L?\
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M8R) 2\C?>9R0<DUNKK6F.+0K?0$7F?LV''[W'7;ZU%:>(='OM0>PM=2MYKI
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M0"$'4_3I75:8NDZ%HR6\%W EK Q1I'E4#>3DY/0$D]*TGAAFP9(D<CIN4'%
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MB.6>U8).BG)C)&0#5O H \I\2VFH:?J>@ZWHHV2ZM:IIER&&#EERCD>H /\
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M )KJQ%J4\@X! &&^]ZCI67;?#:6V\+6&FC5!]NTRX-Q8WBQ8\LDY(89.0>:
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M5&26Y# @*X^[@>M=7HT>JQ6)76+BWGNO,8A[="J[,_*,'OB@#0HHHH ****
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M:C.T#MY*N00!SS]>E<KJOBKQ7I.D:U8G5TDO=-U&"!;O[.NZ1)<D CH,8]*
M/9J,5Y3>ZEXNM_$<?A;^TFO)S;M=?:;=8H)&SPJ_-D8!!/ R:@^W^-[S7]$T
M6YUF&RGN()O/:VC20*4X))YRW3T H ]=P/2BO';;Q7KDEK_9%UJ\GVFVU9[-
MY;>(&YND ) 08P#D<D\#(JJGBCQ-?>$=,=-7FM[J76FT]Y-B%BG&"W'4>V*
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M7!"NZ1L$[1]!S0!:HJ&TNHKVTBNH'W0RH'1L8R",BIJ "BBB@ HHHH ****
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MU+4);.-BUO92RYBA)]!WZG&: .K'2BBB@ HHHH **** "BBB@ HHHH ****
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M6DDLEK96\+R\R-'&JE_J0.: /#M/\/Z)-\+_ !'K#6T;7\%Q<1QS%SE1N7
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MOQ'N&CM3/'=Q_97XW*2>=A_/I0!Z+XJ\63P>)+'PWI5]8VEY<1/+)<7.&6/
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MI]UJEU/+*\HRX8-]T9(!  X_"NUKC=6\=RZ-HE_J=WH-Y'':WGV8*[!?,4G
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M]V,XR",_K7 Z=X(U6?1M%T/6/L@T_3)#(7@D9GG(SMX*C:/FYY->BY'K2Y%
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MQ'XA/A];!OL;7"W=W';%E<+Y9<X!.>M6K;4+V77+RRETYXK2%$:*[+Y68GJ
M,<8H XK1_ NNZ;JVD7S7>E[K"%X7"1N#*&ZL3W8^O\Z=)X$UAO#,VDK<6"M)
MJ/VWS,O_ 'MVW&/6NGG\1/#XRM?#_P!B)6>V:X%SO&!M.,;:EL];E&GQW&LV
MHTR62X\A(FE#EB6PN"/6@#FM0\&ZVMSKJZ3?6266LKF>*Y5RT<A&&*$>OO5S
M28/$6DZWH^DM<VMQID-ELN D)5E(!"MD^I &,^O%=CD48YS0 M%%% !1110
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MO'IQ34TG3HHIHH["V6.8YE18E ?ZC'-<IJGQ!DTQ-*5_#NH/<:GN,$*LI8X
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MN^-T;]#CFJ7_  B^C;IV^P1[IX?(E;)RZ?W2<]* //I]5N=,TKPEXRNI[F:
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M+ &)<C.T9[8KUH\ UXC>:3JLW@WQ?;1Z/J/G7FL>?;Q_9GW2(6SN QTP/Y4
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M ;+)@GJ3GG]*D_X2W6[/P_I?BE#9G1;B58WL(X<&")FVJ0X/+#H1C'M72?\
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M^TS W#$O)USF@#CO$-S<>*;3QM]IU"ZMHM(B,4-G"VU7PNXNX_BW$8'M7?\
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MU:+299DL&'VZ*W!BG(.1G(PV0<]^])>A(-.@O=%\-WMII]SJ44KWMRAFN58
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MJ*[L[=(D>V<*^ NYL8&2/Z4 =EKWC&SU3P9KD_A_4WCO+.V\TGRF1U!&0<.
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M32&[WW$)G$*VDC2+&#@LR@949[FMS3M1M-6L(;ZQG2>VF7<DB'@BO.;.]O\
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M&TN^U"2W6;S#Y@8MU Z8%=%>?$6_M/%$5A+I]O':R:A]A"/,?M'/ DV] IH
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M*[!A<'/Y\4 = BA$5% "J, #H!2T44 %%%% !1110 51L_\ D(:C_P!=4_\
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M%=&M6FE:%_$DD7[N4C]T>W7\OQKVZ?PSHES:VUM/IEK)!;',,;1@B/Z"F?\
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MK&D>,?#%G;S6<\9LIH;8!5DW?<88XZX_(5Z:FF6,=D;-+2!;4@@PK& A_P"
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MPS;:G<QQQRRM("L>=HVN5XS]*\\L)--TWQ%:6&O/)+HJZ2PT]M048<E\DXZ
ME>!GG&*ZSX4R1-X LTBX"23#;_=_>,0/R(H Z&WN;Y=5OQ=O9K81JC0%'/F
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MMGXM!O\ A7M\5/(>(X]?G'% #(_BCIGF7D-WINIV=Q! ;A(9X,--&!G*C/\
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M;?%7PO<M;[)KM5EE$!D>U=4B<G 5VQ@&KNJ_$#0-'OY;2YFG8P,JW$L4#/'
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MJ X.=[ 9R",=>*Z+0M;L_$.CP:G8.S6\P)7<N""#@@CU!H O21I)$T<BJT;
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M#H<#./<5>T7XBV>KZY:Z=]F,8O(V>WE6429(!.U@/NG )YH [6BBB@ HHHH
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MJ(F.56?GY,E>A..!VK<UN^O=9\>'PPFIW&EQ1Z>US%);OL>:4D <]P.3@=:
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M#GKS^E>C:AXBLM,UG3=*G\W[3J#,L&U"5RHR<GMTJ;6=7CT32Y+^6WN;A(\
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M@>V9&EC/1ES_  ].:U_".O-XD\-V>I26TL$DJ NKQE 6QR5SU7T- &Y1110
M4444 (S!49CT S7EVF^.?%.NW5I>Z7IDCZ=<3O"Z?9#MA3.!)YA;YB.I& .V
M:]18!E(/0C%<'IGPWDTK4&$'B"\_L;SC.FF$?('SN&3GE0<'&!G% %6S\5^)
M)/%<WA.Y-HFHI/YHN_*Q&UKMSD+NR7/Y#\*E_P"$A\5:S/J=WH'V)K;3K_['
M]DD3#W 4C>Y<GY>O QT%/N/AM/.MK=?VX8]9M[M[K^T4M0'?=CY2-WW0!C&<
M8XIUU\-Y9=8N+NU\0WEE9WS"34+.!<+._P#$0<_+N[C!H RKWQQXIO-7U/\
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MZ56L[W6_%/B80+K=WIT,NCQ7HCA5<(Y(&!QG&>?TKL;KP5I5SJ-U>@W,+7@
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M!NKO3YA##X@:></ 2%C(ZD8Y'^%:NK69;1_'VMVEJ\6E7L<2VZF,J)67&Z0
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MO[6U@UC:Y\E&+1Y!.WG/<8[URM[\.+J[EAN_[0@^WMJ2ZA<R&([6*XVHHSP
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M8?%+Q+>>'].MKI_L$$TBS2;/DVJQP!U8T >J37^G07D&G2SPK<7 /E0$C<X
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MF]HXO+)4G"@L<D<>GK74^%_%3ZWX3EUF^LI+)X-XFB8'^ 9)&1G!% '3  #
M&!2-&C_>4-SGD5YCHWQ-U36=1LH(=)C,-_O$3*)"83SM,A*X(..2O2K^B^.-
M;UC5)-$_LNWMM7M9W%XDC,8XXAC:ZGODG&/QH WM>\,SZ[J,#/JUS#IJILN+
M&, +/SGD]1V!]A71  # &!7D^E>-]:TJS\5:IK1@N%M;[[-%#&[#$GRJJK_L
MXY/?K4T_Q,U>VL=9E.F0RFRC6:&<+)'&Z$@$889R"1]: /4B!UHP*\[A\9^(
M)Y[[3[FQLK2[?23J5DPE+C'3:W'7.36KX#U:\E^'MIJFK31R!;<R^8A8L44'
M);/\7!Z4 =?@4;1Z5QFE^*=9O6T_4I=.B_L2_C>421L2]JJ@D&3L00.W0FJ#
M^/\ 4H-(M?$LUA ?#US.$^5SY\498J'8=#DCI0!Z%M7(.!D=Z,"O,=0^(FO6
MP\03P:38M;:)<)',6G;=(K' V\=>];%GXOU@ZK=:??:=:K,=,_M*T\J<E2N<
M;'..N>XH W_$>@KXATM;3[5+:NDJ31S1@$JZG(.#P1[55TGPW<6U[#?ZMJ;:
MC=VZLL#>0D2QAN"<*.21QDUR.F?$37WBT+4M2TJV32=5E%LKP2$NDA8@,0>V
M>WM5F/XA:D/$EEIMS96T7VRZEM5@+GS8"OW'?L0WI0!WU]?VFG6<EW>SI!;Q
MC+R.<!>U,AU33[B]-E#=127*QB4Q*V6"'&#].17F-AX@UA/ 7B75-5@L]46"
M]E5[>4D+\K*" ,$;>X%.^U:L?B*UUH-G9?:;K0H9629BJ 9!XQU/0"@#TVXU
M&QM+RVM+BYCCN+DD0QLV"Y'7%6@BC. !GK7EEQXAC\3WG@76/(^SRG498I$)
MR48+@C/<<5H6_P 0=0O+FWN;/2Y+C39KPVQ"12;T0';YN[&TC/:@#T2B@=**
M "BBB@ HHHH **** "BBB@ HHHH YG4F(^(FA*,X:RN\_G%735S&I?\ )1M
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M6NRX> QL^\_+CG.!ZT 87A3PKXIT6XMK&]UN"71+%B8(XDQ+(,':KG'09S^
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M;<YX_E4D_@[Q5J_A>_TW6]>M[BXGB2"(I&0B*&#%FX!9CC'_ .NO0LCUHR*
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MJEWJ6C:A+XA1KC24"0,;3.['0M\W-=)H>@7NG7VHW]_JGVVZO=@R(?+2-4!
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M;-W9B,%HSS\T7YGC_(M0?#S3-6^']II-NE[ILD<PN!)<1XE\X<%F7O\ _JH
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MXDD;LYQD]* )?!<M];^$F36-2@O+BS>2.6YC)887U) R1T)]O6O.M U74O\
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MX/AWIKQ!]]Q&6ES(QYW,. 3QT[8K@]?BO=*U#Q%X4@_M&:[OWCO-)D%RV54
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YZ]0/X]T@GJMC=$?]
M]1#^M=#6#=C_ (KK3#Z6%S_Z'#6]0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 55U'4+?2]/GOKM]D$"%W;V']:M5B^)_#__  DFFQV9OI[,),LN
MZ)5.XKR 01@C.#^% ',?#_6=:U7Q)XD76"\;1M \5JQX@5E)  ['&,^]>@UY
M]X-\,:OI'CCQ!>7=_>3VTOE!99D0"Y.SDG _AZ<8KT&@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **,C.,T4 %%%% !1110 4444 %%%% &'=?\CKIO_7C<?\
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MD?\ %9Z<?^G&X_\ 0XJVJRYHU;Q1:R$?,MG* ?J\=:E !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8Z=X\M+OPU/]M34Y!'J-K!EE'( E'8$9.:[G6]#M]?M8[6[(-N) [J%&6QT
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M%/&+;3?^_3?_ !5!^._BK/\ Q[Z;_P!^6_\ BJ** &GX[^*_^>&F_P#?EO\
MXJD_X7MXL_YXZ;_WY;_XJBB@!I^.GB[<#LT_'IY!QW_VJA/QO\9?\]K,?]NX
MHHH /^%W^,O^>]G_ . XII^-OC/_ )^;0?\ ;LM%%  ?C7XT_P"?NU_\!EIO
M_"Z_&O\ S^6W_@,M%% $4GQD\;NVX:I$G'1;6/\ JM1GXP^./^@PO_@+%_\
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M<R#)\/Q#_MZ/_P 35A?CI,&7=X?0C)SB[([?[E%% %A/CAO8C_A'<8_Z??\
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-G.[-7:** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>sgmo-20210331xex103011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M2(W(C$Y0>8(\[0V.<9[5S=[XAU.X\17FBZ);VKS64"RSO=%@"6^ZBX[XZDT
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MB@ HHHH **BN/]6O^^G_ *$*EH **** "BBB@ HHHH **** "BBC- !1110
M5R":5J*_$Z36?LF+!]/%KYIE7.X-NSMSG':M:[\36%EXDLM!F$PO+Q&>(B,[
M,*"3\WX5LT >;7T7C^3Q1-J<>BZ=<0P[H[%)KH 1*>K8'5CZ]NE=2USXEAN(
MXUL+.XA%EN>03%";@?PXP<*?6N@HH X:UTG6->\5Z5KNK:9#I8TZ-PJ+.)9)
M788Y( PHR?QK4\56_B![K2KO01#(UO*YN(9Y2B2QE<8/!_#T-=(2 ,UQMU\3
M="M98U\G4)8I9#'%/%:EHY&!P0I[X- &)!X%N-0\73ZVVE0Z+&UE+ \*3!S-
M)(I7=A>  #^)[5R-K\.O&45IH]F^GVK0Z5?/,'%RH:4,RDX![?+QWYKWD2QE
ME3<H<KN"D\X]<4^@#RJP\+>*_"_CC5KO2+2SO-+U1RY\^;:(B6R">,G&3P.H
MIB>%_%WAOX@:AJNCVUIJ%GJV3,LLGEK&Q.[)')X.<8SD'%>L<4<4 >/ZCX#U
MZV\=3:U#I6EZS;WR#SXKA@J1R$#<0&R<9&1UXXJKK?PZUK4+]?)TNUM[J.6/
MR-1M)1$BH ,AH_8YP1S7J^OZ]9>&])DU._\ -^S1D!C%&7(R<#IT^IJ_!,EQ
M DR?<=0RY]",T >0:KX$U[5?%L&I)81V5['>"1M1MYP$DB!X)3DA\ =.#WJ&
MY^'WB.UTW7?#=I:Q7%EJEXEQ#?&8+Y2A@3O7J3C'3WKV&\O8+&WDFF8XCC:0
MJH+,5'4A1R>U5="UNS\1:1#J=CO-M-G:9%VG@D'CZB@#@9?!FL6OQ"\-ZC:V
MPGTW2K*.T>5I55FPK*6"YS_$#5'QSX%U?Q%XAN;FVTQ4N#)']DU&*=4 0 9$
MJ]3@YP1ST%>O4AZ4 <UXML=9N? US9:4T<FIF%4!D (?&-V,\9(SC/>O/O"'
M@;Q-HOC+3]<GTV#R?LICN%^U[G#%<$G/<G' X%>G:+XFT[7[O4;:R,WF:?*(
MIQ+$4PQSTSSV-;- '@"_#;Q?_P (D=)_LR+S#J(O-QN4P%";<=>O-='J?@WQ
M':^(]=O-,LH[JWUVP,$BO.J&WD*C.?4#!Z>M>N44 <G\.=&U'P]X+MM+U2&.
M*X@>3 CDW@J6+ Y_$_E62/"ESXBU36KSQ)I\\7G+Y5JL%[@&$#A"%."<\\\<
MUVNJZK::+ITM_>R>7;Q ;B 222<  #J22!6)I/CK3-7U]M%CM=0@OE5F9+BV
M*!0/4T <!X?\)^,]'\+:GX?GT6TO+.ZE61$EN4P!D;@<'C(&0>Q%,T_X?:W8
M:7J-K'I0N-*O+J(_V9=W*^8J -N<.I # XQZ]Q7M"2))G8ZMM)4X.<$=J=0!
MX?/\,_$2^"+K2;1699M1%Q;VT\RYAC"D99@<;CD<#TK'U\S+XPUF*30]2V2V
MT,-[#I\@;>=JL=[;6 R0.F.GUKZ&9E12S$  9)/:N AN?"'B+Q*@BL;Y;F^1
MG2ZC66&*Z"<$[E(W=.XH YNZTR\\81>#-:\,Z48].TPY:&2=49-D@!49Z_</
M/O3-*\$>)K/3-<MKO0[6ZCU&]2<P/<KS'\^X!A]UAN7!KU6232?"NB;G,-CI
MULO88"\^@Y))_$FJ"^-=)\^TAF6]MGNW6.W^T6<D8D+=,$KC\Z .$T'PKXW\
M*^&[N+0C#'+<7RR1VUU(KF&'!SD_=W$[<X]*]:B\SRD\W;YFT;MO3/?%/HH
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M5REYX=U.U\43Z[HD]HLEW"(KB&Z#;21]UAM[^U=73)79(F9(S(P!(4'&3Z4
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M.]T]V>WG@VDKN&""&!!!%9U[\/-(U#0I]-NGN))9Y_M,EZ7'G&;H'SC P.,
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MHW5N]K9FSC0!6&PY))W DG))SZU0D^%VG-X?M=+74+U);*=I[2\1E66%F.2
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MY, +DDLPQRO)''I6UXG\.7,WAJPTO19KNVDMGC6%[>41A0HP"^>JCK@9.<4
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M4[?6=,@U"TW^1,-R;T*G&<=#S0!<HHHH **** "BBB@ HHHH **** "BBB@
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M6[-G&#7%6W@3Q#8:3I<MJ(7N=/U1KNWL9[DLL<)&/+WXZC&?3FO5Z* /*I_
MOB34M*\50W8L89M4NH[J )*6&Y3G:3C@>];!T#7]4U1M=O;2TM;RVTY[2SM#
M)YJ.[#YF=L8QVQCH:[VB@#RJV\#:Q%!XB-KI\&FQ7]C]GCL(KPO$TQ/,@X^4
M8[8]:LV?A3Q-HM[H^LV$%E->PZ<FGWEK+,54A>CJX'L.,5Z910!Y&/ OB<>
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M+3M9T2+4=33:!=/)M)(Z$9  ^Z/2@#M-6^(^A:1?7EI(;J=[( W+6\.Y8L\
M$Y'/-1W7Q,T&QL].NKH7D,6HH7@+6YY ..<?YY%>2^([_34\;>(;6Z^W6=E=
MNGVE(X%DD)&&/)/R\_6NMU73O[<U+P-?>'M.N+C1+(H3(5'RKO48(/.1M.:
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M'>2SI;2K'+*)I+83-Y#R Y#%,X)S^'M5ZV\,Z9::CJ%_#'*+C4!BY)F8B3C
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M$UMJ-O)%<M%J,OGW*_:'P[^O6@#(O;[49OB)H5DNHW$-M>Z7+))'&0%5]O#
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MF7/WE[G/;BO5(--L;6XDN+>SMXIY/OR)&%9OJ1UI4T^RBNWNX[2!+EQAIEC
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M.3_UT6KE !7-?#\%? NE C'[LG_QYJZ6N:\ 9_X0;2MQR?+8?^/-0!TM%%%
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MW"]Q%;K"/,\I<Y<C. /E)Z]JY+XB>,FOO!^CZ[X;U&\@62\\LF-S'VY5QZY
MJ7Q_X;UV_P#$.EVFCZ,'TZ&S:$3PNL;#((VLY^ZO3CODURLOA3Q.WPVM-#;P
M_=_:8=2:<8VD%,?7U- 'T#&28U).20*=7)Z-JGB>Y\675G?:.EMHR0AX+@_?
M+<<'D@GDY Z8KK* "O.OB1IE[9^'-;UV/6]2BF14-O#;W#1QQKE5(*@\DY)S
M7HM<G\2+2[U'P/?Z?8V<]U<W(5$2)<X.X')]!Q0!R/B/1KVR^'#Z[;^(=8+-
MIT3O')>.P+L4.X<\<%@1[BNKT'QKI^IR#23%?Q7<5DMQF: J9D  +)W//M6?
MK]IJ-_\ !_\ LR#2[LWSVL-O]G*C<&7;DGGI\IJ*SM]33Q]IFIOH]\MM#HOV
M61BJ\2 [L?>]L?4T 3Z!XJT;3?#MDMA)JVI->7,T=O'<$//(RDE^I  ';I77
MZ/JD6LZ7%?PQ2Q))N'ES+M=2&*D$=CD5Y-9>';MO!UCIVK>&M38QW=Q()K4A
M;BV8D,CI\V"#T.?2O0_ UMK5IX7MH=>D9[Q2V#(<OLS\H?'\6.M '25Y=:^+
M]2_X6G!Y\CKX?U'S+.S)/R-)&<%A[ELCZ$5VWBV[U"T\.W1TJSGN;Z13'"L*
M@E21]XY[#_"N&\3> $C\%V4NBPZI)JMDT<MI&\S,4;(+90MM7N3CO0!W>L>)
M;+1[N"R>.XN;V=&DCMK9 SE%&2W)  'UK$?XH^'DTJWU$+J#03R^2A6T;E_3
MT)^A-<KXKO-<GUW0-0T[2+Q-:AL7-S'&4>1%;Y2"F2,9)(/^%58DDN-'T/2=
M)\.ZPDFCZI%<WB7$:A\<L6ZXR<\"@#LW^)VB_95FAM=1F81M--"L&'@0'!9P
M3Q[=:O7GCS1K:&"6W^T7XFM_M(6SCWE8O[S<C Z^_!KD?%'AZ_M/'-QK0\,1
M^(K#4(40PDA7@=0!U.1@U0U+PCJ>DZW::H?"EIK-I-:+#)8P$*+9@<@+D=.<
M9[\]* .XD^(V@":SA@>[NI;R SP);VSN7 [#CKP?I@YQ5>W^*'AZY:R\L7OE
MW4H@\YK9E2*0]$<GO],U@6^CZI9>,_#-Y_8!M[:VM91-'9QCRX6<L0N<\XR,
MGUK&CT;7$\%P6+:'J'VA-?%\4$8_U0.<]>M 'HVJ^.M'TBZN()Q<R+:E1=2P
MPETMRW3>?Q[9JI=_$O0+6YN8$6^N6MXEF<V]LS#81G=GCC'?I7%W/AV_T[Q9
MJYD\'KKD&JRB:VN)#@0%AR'ZX /7Z5HKI>JV?B+Q,XTBY:"YT=+.%H(?D>18
MPN%&>F<X]J -Z_\ 'Z1^)M#TZQL;BZM=0B,YGCC+90KD;1WQP3Z"NV!R*\CT
MK2=:TV]\#WQT:\E^QV<MI<1@ -&QR 6R<!><YKUL9(Y&* .?UCQEIVBWLEK+
M#>7$D,8EN#;0EQ AZ%SVS7&0>+U\,^.O%*:K<ZG=6D9A:-54RB%2"2<#A5Y%
M2>.]'O;K7YKW2=/U2#5HXHUMKRU&Z&?/5)0> !Z^]49M+UV:3QK)<:3=^=J-
ME#'$8XLK)(J[6V^V3^5 ';ZGX\T72VA#&YN/-MOM>;:$OLA_OMZ"L;7]:ED\
M9>"KC3K^8V&H&4M&LA6.5=@*DCN><X-<EJ.E^(+R"ULYM#U(P_V"+:$6RA")
M@ ")6R"5R"0N?3@YK5LK'6-_P_>71;]?[-#QW.Z,$Q@J%!// _7 H W_ (>W
M=Y/J?BNVNKZXNDM=4>*$SR%BJC/ ]!["NX9@BEF. !DFN'\!V=]::WXJENK&
MXMX[S4#/ TJ;0Z'/(KL[LLMG.R1>:XC8K'G&\XZ?C0!S</C_ $B>WEG$-\L2
MV[W,;O;D":-/O,A[XZ^M65\::0]QI4*M.3JD+3VK"(X957<<^^.U>?Z7X?U9
M+F[L])LM2L]+N]-N%GL]07Y()F4A5B;OEL?AUI='M];:\\%2OX>U*.+1H98+
MEGC R2FW(!.<?S[9H Z8_%GPY^]*1ZE(D6[S'6T.%V]<YK<C\6:?/%IDD<=T
M5U*-I8=L62%49)8#D<?6L/X?:9=+X6U+3]7T^: SWD[LL\>WS$DYSBJWP^\-
M:KH<E[_:RM)'I^^TTW Y,.XN6 ]SM_+% "Z-XQT;1/#D-T)]9O[2YOY($N+A
M S"0M]TY(P/3/O737WBO3=.GU&.Z\Z-;"))9I=F4^<X501U8GM7$:+X2O=4^
M&>JZ-J%E-:7DEW-<P"48PQ.Y"/Y?C3KOPAKFJ?#":.X4R:_=3)>31R$#>RD
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M\*ZY!XET/4KEK!H].T_[(RQNX+'&,C*UI^"?#M]X=M=0BOI+>1KFZ:X4PLQ
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MR'MWGBMI[K4HEC(*)'T5<MP2?7/K71ZKX0M=9N='N;^5IKC39!)YA4 S$=F
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M+?@.!7/?$36]1\/>$IM2TR6*.>.1%_>1[P0S >OO[T =717E]WKOC33=:M]
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M%DNKC3$OIY88!-M).-H5F48SWR:[/PO>ZI?Z!;3:U:?9=0P5FB'3(.,_B.:
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MKJIU6Y:9;$V.TQI@IC&>G7/-<?XK\-?\(_HWA?1K.]NG6'5?,2?R@SPH<DG
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M?;-2O9+^>>.X:]!57#1C"  #  R>,5V#;0,G@>M<CX2\=0^*-8U>Q5%C^R2
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M0>154>._"Q$F-<M/W:[S\_4>W][\,T :<^C6%QJUMJDT"O>6R,D4A_A#=?\
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M/_0Q4]0W7^J7_KHG_H0J:@ KF/AYQX$TL>BO_P"C&KIZYCX>D'P+IF/[K_\
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MN[6;.-ZG[S)@9YXQ7L1M8#NS#'\S;C\HY/K]:!9VXN/M @B$V"/,V#=S[]:
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M *$*FH *Y;X<#'@+3/I)_P"C&KJ:Y?X=?\B'IG&.)/\ T8U '44444 %%%%
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M[5M.\*VNFZS]F$T$8A46Y)&P  9)[]: ,6?XB3Q:?_;D>CM+X?$_DFZ68>8
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MWN;:%8!<03;'>,< ,1UXJ]%X/TVWUBQU*W:>&2QM_LT,:.-@CYR"",G.>N:
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MD;>N>.U %FBN87XB^#V.!X@LNN.7(_I70VMU;WMM'<VLR302*&21#D,#W!H
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MWC>5]<4 6Z*** "BBJE_J=CI<*S7]W#;1LP4-,X4$GL,]Z +=%%% !111G-
M!1110 454_M6P_M/^S!>0F^">8;<.-X7UQZ<U;H **** "BBB@ JGJ.EV&K6
MWV?4+2"ZASG9,@8 ^O-<MX_OFC?1;"*[N%FNKP+]DMY/*:Y7!^4R9&Q<XR?T
M-<1;:WK$?@4-<7]QY<'B#[+<;9BTIM\@E%?[S<^G.* /7M-TC3M'A,.G64%K
M&QR5A0+D^IQUJ]D>M>+7T>I6WA+Q3JUE?:Q;:<LB_P!EJ]PZX3<-Y /.,GC-
M2:C!?:,?#VG)K5P\&L_Z1<RZC=NJ,ZQC";U^902>G?CTH ]ER*,BO$KC4=<T
MS4--\.W7B"TDMY+QS).;F4(O (A:7ACC/KW&34FI1:C:0:=IW_"47%PS:TD#
M-9W,G[I)!G86)^8CMDG&: /:<T9%>':CIGE-XXCBU34VCTA8Y[13=OE)&&68
M\\\BK5_=7WB3Q!INFWFIVUO')HT4T8NG=$DE<<L-K#+#/&?2@#V?(]:IZAJ=
MGI<4<EW,L:RRK$F>2SL<  "O*;;3#?>*/"FG7FMW.I0265R)9HIW19MA(&.>
MF.">^*R1#!J/A3PV+^628Q>(6M$>29LK#NY&<_3GM0![Q14-K%#!:Q16X A1
M J8.?E XY[U-0 F1G&1FHYHX;B$QRK')$W!5P&4_A7EWC2W&A>.EO_LSW4&N
M6CV0B&3MGP I'/&>.GO4?@.UN+VY@\.ZG;D'PW-*TKY.V5V/[OZC[S?@M &W
M>Z_=^$?#=QJ3^%[*S?[;Y A@E504)PKDJO)]N*W(_$TS>/9?#;V2I&EE]J6X
M\W)?Y@,;<<=^_:O*IF9OA1J3/([!O$!"[V+$#>.YY-=[%M/QLF)'31>#C_IH
M* .[J.=WCMY'C0.ZJ2J$XW'TS4E17/\ QZR_[A_E0!B>#O$3>)O#MOJ4T<<$
MTK2 Q(V=NUR!UZ\ 5MR>3)^YD,;;A]QL'(^E>"Z9I5M#X!TO6=.:5?$!U3RH
M"CG<V7/R 9Z8YZ5+9K#K!NI]8UR*QU^#42VS[.?M>X-A40EAD=L 8H ]U@MX
M+="L$,<2DY(10H_2I:;&"$ )W$#D^M.H ADN[:&01RW$2.>BLX!/X4?:[;8S
M_:(MBG:S;Q@'T/O7DWBORM/\47NIR+8ZM:->01S0'Y;NU<!=HC)Z@^@X//O6
M1K,^GV7AWQ]93R0Q7DVHJT%NQ 8C<IW*OT)YH ]OEO+6 D37,,9 W$.X&!Z\
MT3WUI;0">>Z@BA/2220*I_$\5Y/%:>'+WXA'^V$LGM9-"BF0SL KMQE@>YVY
MKF]-DN+:W\-/K]S+9Z($N!:3O LJJ2YVEE8$?=Z$CITH ]ZEU&QABCEEO;>.
M.3[CM*H#?0YYJ%];TF,1%]4LE$PW1EKA!O'J.>1]*\<N]*T+_BC[&VE:]T^?
M59 )+A0#)'E<XP!\A;-6O%5IIGAW5M1DTP:=<6Z)#!<:-.,. <$-">N><\=\
MT >N7.JZ=9W"076H6L$S_<CEF56;Z G)K.\4^(+;0]'NI?M]G!>B!G@CN''S
MD#LN03^%>3WS:;+K7B&V\67&HVMU<W"RV]O%"KM+'CY%5BI((Z<$"KCW5GIM
MQXKMO$L92^GLE2P%R-Y:(1D*JL!UW8)QCF@#T#P_XJMW\':3J>MWUM;S7<08
MM(PC#-WP*VKO6M,LK%+RYU"VBMY,>7*THVOGI@]_PKPZTN(+5_#UUK-U>VNE
M/I7V>*>"(,J/DAP05/XX'I6WIG]GZ#KOA^\NX;J/PZMM,ME-=C=MD9B0S #Y
M<KT&.X]Z .T^'GB*^\1Z=J5Q?30RF&]>&)H4VJ4 &,?G78UY[\)Y8WL-;\M"
MB/J<DD8V%1L(&,9'3BO0J .6^(.K:AH?A*?4--GCAGB=!EX]^06 P,\ \Y[]
M*MVOB_09[2>9-7M'6V \]ED!"9P,_3)ZCBLOXI6T]WX"O8[>!YG#QL412QP&
M&>!6/96.G:_XTL[G2+=/[*ATQX+R2*,I'(6X$?09('/MQ0!W*Z]I;V=M>+?0
MFWNG$<$@;B1CT _(UHUYOX*TO4(M8ET2^(>P\/S,;9NOF-(,IG_=4G_OJO2*
M $)P"3T%>=:S\1K>[T/7I-$O$ANM..(V=-QF'&2%/3DXR<]*]&KQ._NDLO#_
M (YTN>"47UQ>-)%'Y+'<IQ@@@8['O0!Z=H/B73-8M%BAU*WFNXK='N K#Y21
MR3VZYZ=*J:-K]M::&]WJGB&UOD-R\:W,<>U3SPB@?>(]17+Z?)96WC[0W01Q
MP+H860JF%W=<''?%8NCBV7PI9I<WEYI5W%J5S);72Q';$<#&\8^Z0: /8=/U
M&TU6S6[L9TG@8D!UZ''6K5<SX#NKV[\,I-?V<=M*9I,&.,QB49_UFT]-W)KI
MJ &NZQQL[L%5022>PKA_!/C>7Q)KFK65Q$8E1O.LMR[2\'0'WYYS[U?\>7LB
MZ7#I-N9DFU.46YECC+>5&3\[''MQ^-<GXAT>Z\)>(_#VN6]S>ZB83]EEC2 9
M$&,?P =,]_:@#T#4_%&C:/="VO[Z.&8KOV8+%5Z9. <#W-4KGQ_X6M$C>;6K
M4+("R%26R!] :\[\8:J+'QAK4%N)!#JME#%<S26[R>6"."@7_9[''-:=JVDZ
MAXK\'K8127FG6UG+ 7DMV(5MNU=^1@-Q0!V\_C3P];/$LFIQ?O4612JLP"M]
MTL0,+G_:Q3M2\7:)I-U]FN[T+*%#.$C9Q&IZ%BH(4?6O-[S3TTW7-=T[5M U
M>]M]0N3+:+8,PBD4]%8 @#&!R>F*@.F/H^JZE8Z[X>U2]CU#8\":=*[1'"@"
M-N0.,8R<]* /1[_QWX;TVZDMKG4HQ-&@=E16?@^FT'-/LO''AW4=1@L+34DE
MGG&8]JMM8XSC=C&<=LYKC8[.:S\9ZF#ID\<0T,0Q+'$[J6"CY%;'S>E5+#3[
MP:3X$@;3+Z.6SN7>Z'V1QY0)X+?+]* ._N?&>A6NI&PFO=LHE$+/Y;>6LA_A
M+XV@^V:IW'Q&\,6MQ/ ^H%I(&"R;()&"Y[Y"XQ[]*X.QT=K6]N]#U3PO?ZE>
MM>M/;7)=_LN&(^=L, ,>PSVK1O;&[-KX]1-,O"]\Z?90MJ_[W P=O'K0!UDW
MC>TB\8V_A];:=S+%O,ZQL5R<;0,#D8/+=!755YS:Q7UIXUT*^?3+R2"32$MF
M9(O]6^1G?G&T#WKT4=* %HHHH **** "BBB@"*X_U8_WT_\ 0A4M1S L@ &?
MG4_^/"I* "N5^''_ "(6FXZ?O?\ T:]=57*?#88\ Z;[^;_Z->@#JZ*** "B
MBB@ HHHH **** "BBB@ KBOB3%&VF:.[(I8:Q:@$CD O7:UA>*/#C>)+:T@%
M^UHMO<I<@I&&+.ARO7M0 _6K;1;?S=9U6&%_(@,>^9=VU>I"@]STXY/ K-^'
MFB2Z'X8\J:+R&N;B2Y$'_/%7/RI^  _'-'BGPA>^))[)E\07-E':X<10Q*0T
MH/#G/\J2+PEJD>B/9MXIU![V2Y2=[T@;MJX_=A<X X_6@##\:Z7K.D:O<^+K
M<6.I64,"K-874 RD2\DHW/.<G_&O0+.>.]T^"X1<1SQ*X4CL1G'ZUS>J>$-0
MU>_NEN?$=T='NL>;IXB7E1C*B3J <<X%=)+;.NGM;64BVSB/9$^S<(^,#Y<\
MX]* / ?AI>3Q:Q?:>NGK+97VI)#<SL 51<283!'\7K[5W/BKQ!J'@B;PYI'A
MU[-[2X8VH6X!;:58#E@1_>Y^E3Z'\,M1\.K>C3/%#1&\8/(S6*,0PS@KEN#\
MQI]_\+S>VNB1?VW,KZ6[2>:T <S2,^]F//K]: .3G^)GC&"QUS>NF>=H]T(Y
MG\ILN"Q7 &?4$YKH=<\<>(8];\,66EBQC76[6.3]_$S>4SCU!YQFFR?""62'
M5XCXBDV:I,)9R;0%LABW!W>IK"\9V=QI/C'P18QWX62QA2$WAA^5 &VJS+G'
M3WH K>)?%U_XB^'OB73-7BA%_I5Y%$\L(PKCS",X['Y36W8>,]7<6>@:*UK#
M_9^A17=Q/<QE]S")3L !&!R.:U'^%$4OA_5;"35Y&O-4NEN+F[\@<X8L%"9X
M&2>]32?#6:-X+BPUK[->?V=_9US(;0.L\8&T';N&UL <Y/2@#GK_ .*.N_V!
MHOB"VBM8M/N9C;7JM"SF&13R0<C(*Y(^F*T=<\<:]:^%]3\1Z=<V,VGQWBQ6
M9:W.9(\X+?>]3CISMSQ4/B.QTG0/"]O\/DLKZ[DNX6>VN%3(,Y?()/;YOR%=
M+K/@*+5O MEX8AO/L<, CRZQ!]VT>F1U/.: .0B^(?C%M873GATGS+G3?MT1
M".%C'EF3UR3@$8Z9J0?%G4%^'UAJKVL']IW5VUID@F,;<$OM'/0CC/6M5?A=
M>KJT&HCQ&/.ALOL*_P"@C'E["G]_K@U&OP@MCX/&@SZO*[PW37-M<I"%,9(
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M#UD]_/%-,\*,&C0K\I48SDDD^IKB;/Q'K&D:QXOOM2O8KJUT]HT$ C*Y8CY
MO)"CGGKF@#T[ ]*6N+CU[7=*US2;76?L<]OJI*(UM$R&%\9"G).X<]>*[2@
MHHHH **** "BBB@!DA8*-O7</RR,T^BB@ KE?AO_ ,B#IF?27_T:]=57+?#C
M_D0M,^DG_HUZ .IHHHH **** "BBB@#/UO6K'P_I4VHZA,(H(AD^K'L .Y-<
MXGC4OXUM=-,EHFF7&G&[69F^<-G&TG.T=Z/BM#'+\-]79XU=D1&4E<[3O7D>
MG&:XF$>&=8\?^'K81Z?-81:.WFJ OEAP"3GMD<F@#V)KVU2V%RUS"L!Y$I<!
M3^/2LW5O$^EZ.ED]S=)B]F2&#:P.XL<9SG[HZDUXUIU_82>$/"ME<M"6%[<>
M5)>/_HL0#'_6+_$<'@<=>N*I:?=:4_ASP_#<2V<JVWB$BX,B+M2$MGG/1#R<
M=* /HI6#*&!!!&01WJ&:\M;<D3W,41 W$.X7CUY[4MH]O)9PO:;/LS(#%Y8P
MNW'&/;%>7>(-/T6\^+ETM_;VDJ#1&E99L8\P-P2/7;^E 'J+W=M';_:'GB6'
M&?,9P%Q]>E9^K^)-*T72UU"[NX_(=E6,HP/F$G V\\UX[X6NXFM/!D>LO$^@
M 7,>V;!B%QO;8'SQT/&?6H-<L;>/1_$36T<;Z##K%O\ 8WVYCCR?WH0]EZ X
MX- 'JT/BB=_'LVBO]D&GKIZW<<X<[B2X7D],=>GYUI:Q=ZG$^G'2Q8M%)<*M
MRUS(1B,]=F.K>E>97</A?6OB+>+LTZ?3(-#)B"D>4K!CR,<# )_G6;;RPR>#
M/AS/,\;3)J8CWLWS!1(>/IT_2@#V]KVUC8*]S"K%MH!< D^GUI9KJWMRHFGC
MC+G"AV W'VS7@NH:=H[:+X_O3';BYMM3 MI,\IEQ]WTSST]*T?%>J6,'B+.J
M"&]^VZ D<"2NJB"1OXLM@#/7(YH ]O!!&0<BLCQ#-JD%C&VDP6DT[3QJZW3[
M5"$\GW(_SZ52\!Z?;:9X-T^UMKFVN=B?O9K9PZ._\1R.OI^%8?Q9CA.A:9))
ML5UU2W5'8\J"><?E0!W3W5O$<23QH1@$,P'7I4P.>E>*ZQIFBWGBOQ_)=6]K
M,T.FK- Y?.R3RR21_M9Q]/QKTKP+.USX%T25Y/,8V<>YB<Y(4"@"YJ6NZ=IE
M_8V5U.JW-[)LACR,]"23Z#C&?>L?PWXKGU77-?T^_2UMQIUTL$.QSE\@]<]3
MQV%<[\1[733XV\)3ZA#;+ TTB3RS@!2H (5B>,=?SKCM7L=)O+7XAZF%@EGM
M[B$V<RL#L!(Y3']* /:9[K5U\1VEO#;6S:4\3F:9I,2*XZ +W'2M&.Y@F9EB
MFC=E."%8$BO+;R6'_A8WAB[EFVO/HDK33 Y)_=M\W\Z@\ ^7I'BNPTY[>PNS
M+92&VU/3VQYL60W[Y?[W Y/K0!Z]7+>+/&]CX2N]+@NEW_;IMC$''E)W<^O)
M'ZUT[NL:%W(50,DDXP*\GU/0]1\?PZWJ-JFF26EQ_HUI).[^8BQ,?F3 P-S9
M- 'K.X;=Q(QUS3$GBD4LDB,HZE3FO';[Q,VN_!(3M>K'=VLD=O<QE\&4JP&T
M_P"\.>?2JD&E:#?VGB[6[9+&*![#-M9I<1N\3!/F?",0N3C_ .M0![;Y\6"?
M,3 &2<]*<)$9=P8%3SD'BO!KS1].T7PMX2U&W8P6>H&+^U+A]TT9( *[TSC:
M"6XXZ4_4/LVD:4D6G:\UYH<NJQF]ECMO]&A!&=H4-RO0D9QP* /=1-$4WB12
MG][/%'G1;2WF)@'!.> :\%\2V.DV?AV^ET[65O[:34;>1H[1/+MXF;=N5,,1
MD@ D=N*OWOAW0X_%7B^QBMD6VMM'^TPP>:VU)=F=V,]1G\,T >V-(B+N=PH]
M2<4;TP#N&#T/K7AL]\+BV\#Q:Q?0PZ-)IY)ENHO.B:<#&'&1R!C&3Q0FC:6-
M5\(Z:-2DU6Q:\N(A(^41X]H.U0&.5#$C/KD4 >QZKK>GZ-IQO[VY2.W!"[NN
MXDX &.IK05@ZA@00>A%?/=[:V?\ P@VMVQB5HM/\0A( YR(8V(! ST!Q7O.E
MK8)IL":9Y'V)1B+R""F,]L<=<T 6C(@?877?_=SS09$"@[A@]#GK7FOQ(M8M
M%US2/%XLA<QPN;6]B"Y\R-P0./49(_$5@^$=/OH]8;P;?67EQK=IJSD#*B+:
M"(R3_M;1^!H ]"U77M;TG3]?OIM,MOL]B@DM&,_,Z@$L6 !QCTX_K53_ (3*
MZ;4/"EJ]C"(M<M_->3>3Y9\O=M Q[CDUR4R+'_PM&-&Q$(E(4N3@F-B>OOFK
M8:,:I\+F8GFT8=/6!<?K0!ZA';P0Y,4,<>>NU0,T\NH(7< QZ ]Z=VKQ>TF\
M.ZM-JSZ]J$UIXAM-39DD5MLY4-A$B'<$#&!WH ]#\.>)Y=;U77+*XM$MCIMR
ML *R;M^0>>@]*Z,R(I + $] 3UKPC5].L[F+XAZ@ZO\ :[2ZBD@8.5,9)ZX'
M>F^,[R'5Q>3I.DUW;:1;O(UW-L$3'#9@ Y+G//UH ]Z+* 22 !U-(74+N+ #
MKFO&8;*SU_Q=IWVR5[J.;PT)YOW[$/(/ER<'VZ>HJG;ZH(_ W@N34YC<:>+J
M9;FUDD ,RJS!3R?F"^A- 'N88$9!&/6A75P"K @]"*\'EA;2_"T5Q]JCCTV]
MUG]_B7SU@M3RB.%; &<Y /XUW_P_L[6PO-6BL=7MKZWD9)?*LH\6\#$$84[C
MR0 2.U '==*;YB$L-PRO49Z5S7Q$C$GP_P!:)9E*6KNI5BI! XZ?RKSJP\-Z
M6?%OABS=)6AU/13+>(9W_?,%W MSZ@<>PH ]K# @$'(/0BC(KP^RT.75OA2M
M_!NDU#1KR5[?))W1(^3&?48YQ[5Z#X-FB\0W-SXL$!C%XB06X88(C4?,?Q?/
MX** .PICR)'&SNP55!))X %8_BZ[BL?">IW,]Q<6\:0-F6W&9%SP"OODUXWI
M$4*7.I6$IM4M;GPYYWDQW&_S)!@J[]O,[X% 'NNG:A;:KI\%]:/O@F7>C8QD
M>M6<BO-/"<NIZ5X T9_#.D6E_)- )+H-=>6P8]\'_P"MTK-\5P2Z)XIL]9N=
M-,JZW9M975K&Y<+<,!MP?<X&?8F@#UW/I7'ZUXLUG0O#5_JU[HD:M;W7E1QB
MX!#1$@+(2 >YZ5RG@.UOKJ^MO#NIP,DGAR>265\G$A?_ %>#WZL?P%95TXA^
M&?C.'S))$_MLQHSN7.!(F.2?04 >G)XEG;QU_P (ZUFJQ_8?M8G\S);Y@N,8
MX[]ZZ.N#0@_&I.?^8%_[5KO* "BBB@ HHHH X#XHS1VL7ANYDC>1(M8A=D1=
MS,!DX [GVKE?%FDWVKQ>*-:LM+O%AOXK>V@A-N1),RLK,Y7J  N,D<UZ=X@\
M-0^(FL&GN[F V5PMS%Y!7[XZ$[E/2K5AK.FZA>75E:WD<]S9D+<*O)0G/7MG
M@T <AKEK>6?B/PSXCAL)Y[&U@>&XABC)DAWJ &V=>. <<C%8=WH!NGUS5;O2
M]1-EJ=_"T*VRE)[=45OWX7KU/3K@UZ?<:K86FI6FG3W")=W88P1'.7VC+8^@
MJY@'M0!XA=MJUA:>'Y=86YN8XO$*M;RR0;;BXB"_>9.I;COSQ5K7_"NJ>(+G
M7/$-AITJQO<6TD%E.OEM=+$,.2N<C/;.">:]+UWPS;Z_=:=/-=7,+:?.+B$0
ME<%QT)RIS6E+>VMM<V]M-/&D]P6$,;-@O@9.!WP* /*;O1=2U_1+NZTCPM_8
M]U"\,FRY;][=/&^XJ"3PHQQGJ?3%:>I2:_XN\.:WGPN=-D>R,*^=M,T\@8':
M#P0HP>O4D5Z7@>E+@4 >7"#5-0U+P/<_V)?V\5@&6<S*"5&P*&."< G/7G%7
M'\(7\7Q(EF@4#0+\I>W:XX,\>=H_%B&]Z]%P/2C H \BN?#NHZ=XGUB*7PC%
MKMOJ-PUQ;7;. (BW57SV%=%::7>P_$Q+E]/<6"Z0MGYZ(%BWA@< 9X&.*[O
MJEJNEVNLZ7<:=>*S6]PFQPK%3CV(H X7P?X<FL?%^J6_VD2Z3I<S/91#I'),
MN6'_  $<?\"KH_'>AW7B'PC>6%D5^TG;)$&. S*P8+^.,5J:-HMCH&FQZ?IT
M(BMX\X&222>I)/)-:% 'G-W9ZMXCUG2]5FT6YLO[)MYB\<A3?-,R[0B8;E>^
M3@5D66@:]!X>\&V3Z-<^;IFH&XNL-'A5WL>/FYX;]*];9D3&X@#.!GUI>"*
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M9[TM !7+?#G_ )$+3/I+_P"C7KJ:Y;X<_P#(A:9])/\ T8U '4T444 %%%%
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MTQ[96C:269YY3%&(TWMUVH/NC@#%:5S9VUXH6ZMXIU!R!*@8 _C570[RZO\
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MAM_#Z0R/ISJRF.20L<$YX)Z<\T <'KFOZC#H(UBUO98[?6=42&$R3LBQVV"
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MM9FN-0\BV^PF>V::YBN)O,4C.TA1\I!]..*2"]UZVU32+:Y\0W=S'K6CRSR
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MVJZA:V#W,-W%$VR2+;R"N[Y6YXYQ7':II^HM\*_#5Q<7-DR-/;I"!:_.BD\
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M^69+0^80XPNW(S@^U9%[?2:%8> ]1BMKB2[M;*6.2&2%F &T*P8 ;@03Z8H
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MO:3!?"QEU*U2Z+!1"THW9/08]336\1:*M_\ 8#JMG]KW;/)\Y=V[^[C/7VH
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M#EOK;ZQ%I4"7[DDRC/!/4@9P#[@4P>!/#8LC9?V</LIF\_RO.DV^9_>QNZT
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MC0U@<S7UK"LT37)/)((()P ,D9J[)I.EC2-+DT;7%V17-Q-8C6(U^SW. N\
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MH'_"9^*=EM8>1'HP\D*BA0^W^'MGITKUQWA,@A=XR[#(1B,D?2E1XI 3&R,
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MM]6LHO(6\2)0#$.B;!@8'N3GO7H)(4$G@"H(+ZTNE=K>YAE5.&,;A@OUQTH
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M)"BNY=E4 N0 6/KQ7G-[\+;FY:^BA\1RPV5S>"]$)M48K*#D9;.2/;BO2:*
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MP%>'6.J:;!K/AZ^M[FSMX/[5=V1B6ND4MR9G]#V'IZU]$1QI$@2-0B*,!5&
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M& S?4U);VL%HK+;PI$K,78(H +'J>.] $U%%% !1110 4444 %%%% !1110
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M_P#'Q\W\J /;^**\KU#4M>\2^*=4TC3KM+=[.UA>%1>- 0[+N+X"MOP2!@\
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MB@ HHHH *Y7X<'/@'2_I)_Z,:NJKE_AT O@+2P/[LA_\B-0!U%%%% !1110
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M5K-_JI7E 5_H>] '//X"/VO69HM6DC35;=;62+R%(CC5=JA<]P#C--M?A_\
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MK$L.P74H5D7HK#=R!GO6\;6$V9M!&%@,?E[%X 7&,#'3BL&X\;Z1;7!5S/\
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M7L$EMJ+&RD"7#K;';&#_ !$GH/U]JZ:>_2+3'OHXI+B,1^:JQ %G7&>,X[4
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M_P#?0KO=9TZ?4M(GLK*^DTZ:086XA4%D.?2J6GP:=X2L(H+W4PUQ=39>YNG
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MCPQ>PZ==S6MHDWGS11%E3>I4<UWF *H:1K6G:]:O=:;<">%)&B9@",,O4<T
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M^V-1U6?6K::ZO;'[&<V9  ]<!^O6H(?A]?10>%H3J<!709=X(@.9>>GWN.*
M#0/&VIZSXF:P+:="([F2*>QD#)<QHN<,"2 ^<=AQFO0:X9/ M]<Z_IVHZIJ5
MO<_V?.9HI4M=L[CG:KON.0/IVKK]0BNIM/FCL9DAN67$<CIN"GUQD4 >,^/_
M !"DWB+^V;748Q)H%XD4%F#DS$<RL?0=%_ UZ%XA\8_8-!TJ^TQ8I6U2>*""
M24GRTW_Q-CL/3BK&E^%Y+#P9)H4LMO/(\<B-,82%<MGEAG)//7-<#XE\/WOA
M[P'IOAW4=9#6AO1B\%J2D$8!.'&23R>.G2@#6G\=>);6R\3.]KILK:(ZH91O
M42[CQA<GIW&:BG\=^*K*+3H;ZRL([C55$ELUNDDQCCVY8M&/F)Y'3WK.T+2=
M2UG2+[PSIVM:;>Z3-"?.O(;!HQ&^X8&00'8COSTKKM8\"W&I:)HT5OJK6>K:
M0H6"\CCX/ !RN>A '>@#%;XDZO;Z;:PWNC2P:G<W;01NUM)L= ,^8(_O'K]V
MFWGQ"\36>A/=/HD4<J7Z6JRW"21),KDX94;D=.<GC(ZUJZA\/+O4=)@:;7[E
MM>@G%Q'J)7 1L8VJ@Z+CL*9?> =7U+18[6^\0F[NS=QW,LT\)V_N\[450P"C
MDY]?:@"A+XP\9PZAK^GM:Z1]HTN 79D+.5\LKNV@=S[DBI[WXC7<BZ-;Z?:!
M;F_L1>R-Y$EP(P?X0B8)Y[U<F\$ZQ)J^O7XU.S4ZO:BV=#;N0@QC(^?T)JJ_
MPVU"*ST:73]>-GJ^F0?9EN8X,I+%DX#*3[__ %J (&\=^)W7P] ND6UI=ZH\
MD3K=AUVLIQD#K@Y!_,>]8^M>,/$>H>&1&9H+*]M]8%A=- K8DPPP0<\#@Y'>
MNJE\"ZB^HZ)>G61//ISM-*]Q$6,\C=3PPP,   =,54E^'%_-I.JVKZM"L][J
M*Z@DBP'".#D@@MR* ._M!<"TC%V\;W 4>8T:D*3WP#SBO/=5\;:WI6J^(-/G
M?3HIK*W%U8^9$X$Z$],[_O=N.]>A64,T%E#%<3F>9% >4J%WGN<#I6#KG@VQ
MUWQ)I6LW+-YFGYQ'M!$@Z@'V!YH Q]$\7W_B2TTTV7V"9I+*2>_1E8"-L[53
MJ<9.>#G@9KE-2U$:OX"\,WQL;:TQK*H(K9-L:_,W0>^*[_0?!L/AN+6AI\^'
MU&5I5+)Q%D' P.H!)/:L ?#C4T\*:?HBZM;8M+[[9YAMCR1D@?>]2?TH M:1
M'Y?QHU[&W#:;"QP,<Y%6OBLB/\.=4W*#M52,CH=PYJ]8^&[VV\<WGB"2]@>*
MYMEMS L)! 7D'.ZK_B?1!XC\.WFDF<P"Y3;Y@7=MYSTH X:W\=:UX<;3XO$E
MC:BQN[$S6TMHY+ H@.UL]SQTP.:M^'?'NL:OK&GI+I+M87REO,BMI5^S\9&Y
MV&UQ[C%7H? <M^+<>([V*]6TM6M;:.WB,:JK+M+').6P!SVQ4?ACP-J^B7%O
M#>>))KS2K1BUM:^7MP?X=S9)(&>G2@#K]5NI[+2KJZMK9KJ:*)G2!3@N0.F:
MXKPGXZO]8\4_V+>BPE)M!<^99EL1'C*-G(8C(Y%=;XCT@Z]X>OM*$[P&YB,8
ME7JO_P!:N4T'P'JVE>(--U2?6X)%M+7[(T,5IY89.P'S>N"30!U/B6]O]-T"
M[OM-@2XN;=/,$+YPX'4<=\9KBK3XD3R:QX<BN9+ 6&JVWF22*K!HY.1MY. ,
MC'/O7I+J'0JPRI&"/6O/7^$VF-X?OM+6=E-Q>_:8I=@)A4'A![8)'U- $5WX
MUUZSTNTNY+?3K6WNFF>.ZFW;!&OW%V Y+-U&#4<_C1M4\.>%-6FT:RE_M"_6
M%EF^?R6WE=R9'7@GV]ZV/$7@BYU'5]+O=,OH+9;.W:U,4\'FJJ$8W(,\,*Q[
M?X:ZO;Z!I>F?VS:M_9]_]L1FMCV.0/O=^<T 7?\ A-]2M+_Q)I^I6]K#<Z;!
MY]H5W$3JQPAQGU*CCN:@UCX@ZCIU])IL5G%)?VEFD]THAED5I&&?+78#MX(^
M9CCFMW7/!=OK7BK2-;DDV-8Y$D>W(F Y4'Z-S5+6_!FJR>*'U_P[K0TVZN(A
M%=))%YB2 #"G'J * ,@_$#Q/J&IV6G:5X>@CN+JS^U*MY*RD '##! ]#C\*]
M($S1V8FN $98]T@!R%.,GZUQ]AX+O['Q?8ZTVIQW"6]H;:02QL9)=QRS%LXS
MD\<=.*[.2-98FC<95@0P]0: //)O'VJPZ-;^*#8VK>'YIO+V!SYZ)N*B0GH>
M1]W'XUG107NM_%S5;6[33[JR-A'OCF1F'V=B" OHW/6M.W^'NIQ:0WAN7589
M/#QN/-">4WGA-V[R\YVXSWQ6K8>%M2LO'EWX@%U:&VN(%MOLXB8,J+C&#GKQ
M0!NW\K:+X?FDL+(SFU@_<VT?&[:.%%</H_Q%U"\N=3M)8-/N+BUT_P"VK]GE
M944C[T3$YY&>HXKM/$NCOK_AR]TM+E[9[F,H)4_A/]1V/M7#VWP\\10W/G-K
M&G '2_[.*):$*$]OFZ]\_I0!/I?CO7;RXT 7>FV4,&N0R?9FCE9V1U7(+#'3
MIQ^M/TWQWJD^C:FMY;6B:_:7Z6:V0+ ,690#UR<C<<CTHB\#ZC90^&7FU*S$
M7A_>Q80M^\4XSWXX%1Z';:-XM^(;^*]*\Q[:WMQ&\C1E4EFY (! R57^8H ]
M&7?Y8W8WXYQTS7EI^)'B4V&J:I'H-B^GZ7=M#<,MV2Q48!V\<]<Y_2O5.U>-
M^&](O_$B^*]*M=0LH=(N-6E^T!4+3%=P/R'.T @8SCM0!NGQYX@O?$%]::5H
M]I+8V*17$TTEP0QA=0V0/[V,G'M5*R^*E_>7=K=1Z1)-I4S,)!!!*TD"@G#L
MVW8>G0=/6NCTGP;/IWBC5M0:XMWL+^W2W^SK&P9%10J\YQTZ\5G:/X!UC3)?
M[,?Q TOAI9&=+,)B0@DG87_NY/..OM0!:TSQ3X@U$Z9J<>E0/HM_(R_(Y,L"
M#.)&[8..@Z5EV/Q-O=1O+6>UTF6?3;BY\@K%;S&2),X\PMMV'_=!X]:LZ+X
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M:TJ&^LX]%N-6F\YMK&XVAP3C^'G Z^] &]-\0M7?6]2M;'08I[/3DCGN)S=
M$0LN[< 0,G;SCVIND_$F]U;4K*"'2E:&_5O*9/,)A;^'S"4"X/?:3BM/3O!M
MW;>(M>N;F6U;3=4MTM_*3=YBJJ;!R>.F<U!X8\'^(]$DAL+OQ L^B6C[[>*.
M/;*P'W5=O[H]!_*@!NE^/+_4M(+FPMXM6&IC3VLS(WRGN2<>@)_"HF\6V6B^
M(?%US>:3#!+8QVY>>%]TEUN!" \#'4?2M:S\%1VGQ!O?$PE4I<0A5@ /RRX
M9_3D#]36;J'@"ZU?5O$TM[<VZVFKQ1I&(@V^)H_N,<\'D9(H FF\8:SIVI6%
MEJ>F6L9U.%VM)8IBRK(J[MCY'TY'K5>T^(-[<Z7X6OS80*FM7GV61/,.8CN(
MR..>!5JU\(:M>7NE2^(+ZUG32HV6W%M&RM(Y7;O<L3SCL.]8UG\./$-O;:)9
MMK5C]ET>^-Q !;,69<EOF.[D\XQP/<T :^D>-KG6_$#V$,%F(HKJ2WN+=Y2+
MF)5!PY4@ @D=LXS7):3K]_X1T;Q+?Z?86\]I#X@FCN Q*^4A*@, .PZ8]ZZ9
MO FHWGBFRU74+FP(LKEITN+>%DN95R2L;G."!D#/7 ]ZJ_9['P5IVL6OBF^@
MFM]=NIIHXX8'+,S#YD[^V* .NLM;DU#Q"]I:K%+I\5JDSW )SO?)51V^[S^(
MJ+Q?XF7POI,5R(#//<3I;PQC."[9Y. 3@8/09JO\/?#W_".>$;6VD#BXE'G2
MA_O*2!A3]  /PJQXQ\,?\)3HRVL=T]K=0RK<6TZ?\LY%Z'Z<T <C<?$C6[+1
MM5N9M$#O8M'LN&26"*97(' =0V03TK3L_&6K6NM7^GZ[I]O&8=..I1_9)"V$
M!QL8GJWN.*K7O@3Q'J_AN\L=6\1)<WEUY:;S$1'$B'=\J@C+$XR32ZQH6KZ9
MJ6H>+)[N&0QZ4UJ;>VMF9NF0RY)_BY^F: (K+QYKUU?: !I]A);ZVCR0JLKA
MH0O)#'!R<=\ 9J'2?B5J%YXHT[3KFUM(UOIY8&MD9C-:[>A<_=.<=!BN4\*P
M36#V$.B^(=(OYYP('BAM7\^.-F^?#_P8R3DX'%=39?#+6;"31G&OV[1Z5<23
M1!;+YF#\L6.?F8].: 'WGQ$UE;:;4K.RLFM$U4Z8MO(S"5F[.2.!VXP?K3M4
M^(6LIJ&H6^EZ;]I;3I%AEB2UFE\Z3 WA74;4 SQGKBN%@D*:U=:U9Z]8Q:I)
M>S21Z;=6+O,K[B ,#^+& #CC/6O03X$ULZM+JVF>()=)_M)$?4;5(PX\S'S%
M#T!Z\]: $U;Q+J7B&QUVSTN"W@AL+#-X+Q&+L[QEMB@$8P.Y[]JW/AM_R3K1
M/^O<?S-9=Y\/;R*^OI=!UG[!;ZC;"WNX)(/-#87:&4Y&&QG\S72^%M$?P[X;
ML])DNOM)MDVB38%XZXQ0!D7>OZKJGB:_T709+2!M/A5YYKF,R;W;H@ (P/4\
M_2N8?XB^(-2CT"/2;6QBNM0EEM9TN Y$<R<'!';!![^E=9?>%+Q/$\VO:)J*
M65Q<PB&YBE@\Q)<'AL C#"J*?#I;2\T.;3]2\E-*DDEQ+!O:>20_.S,&'4<=
M.* .KTG^T/[)M_[5\G[?L_?>3G9N]J\Y\2>/=<T36KD&2S6&"\CA2R$9D>2$
M]9&D4X0GL#@UZH>E><ZA\+9;P:G%'XAN(;2^N_MA@%NIQ)G/+9RP]!Q0!6U?
MQ9XHCO\ Q7'9W-A%%HJK*N^W9F=2N[;][KCO5S2/%&OCQ-H,&IR6DMIK=F;A
M(H8BI@(4,/F)^;@\U.?AY<M_;OF:[)(VLQK',[VRY '&1@@=/:K$'@6XBU70
M;Y]7W_V/ ((T-L!O7&.3NX.,4 =E)N,3;" ^/ESTS7DEMXT\2MX<TZ[MCIJ2
M7.L/8OFW(7&>#@'CH<UZTX8QL$(5B."1G!K@H?AHT6F6=D-:EV6U\;\$6Z\R
M$_7I0!H>#]8U>[UKQ!I&KW$-S)IL\82:*+RPRNN<;<GIBJ?Q6DOXO#,#6=\U
MLCW<44BJ@.\,PQSV (Z=ZW-'\,G2=?U35OMTDSZD5:6,QJ%!487&.>E3>*/#
ML/B?1FT^:>6#]XDJ2Q8RK*<@\T <!J-IK4/Q,=;/58%U$:('>ZDM\AL.>B X
M&<"G6OCW7-8LO#]E9QR+?WMF]S<36\*2-A79,*CD+R5R>>*ZF+P0\>M-JKZW
M>37369M-TJ(?E.3GIUR:S9/A;:?V1IMK;:M>6UYII86U]%A9%5B25..HR3^=
M '0^$;S6[S1@?$%JMO?QR,C!2OSJ.C$*2 2#TKE_B':WLOBSPD8-1,&^]*Q#
MR581OC[W/7TQ7:Z)H\>B:<MJD\]PY8O)/</ODD8]2QK/U[PM_;NJZ;?-J$]N
MVG2&6%(T4C>>YR/2@#EG\0ZY92>,K3[?&[Z5#'/;RBV53E@6.0.#TJIIMSK.
ML>.=$FDUEXVGT7[3A(%VKEE#* >.2.M=)JWP_M]4U/4;Q=4OK5=1A$5U%"5"
MR8& >13K?P!;6E_I5Y;ZIJ$<NGVPM<AES+&&W;6XZ9].U '-1^,/$ \&0ZF]
MZGVE-:^Q.3 H$D>_;TQP>O(J>76O%UWXC\1I:ZM:06.BL)#$;4,9$P6VYSGH
MO7^5:$OPMLY8YK?^U]2CLWO/M<=M&RA(WSDXR.?QZ5M:7X1ATW5-5OFO;FZ_
MM, 3Q3!=IP"!T [$B@#E_#GB+QCJ<VD:E);M)IEXW^D*RPI'&K'"E&#;SCC@
M]:[O7=2.CZ!?:D$\PVT#RA,XW$#.*YW1?AU9:)J$<L6J:G+9PR&6"PDFS#&_
M8X[X[5UMW:0WUG+:7"!X9D*.I[@C!H \\T35_&]W+:74D9;3[JV:2229(@L3
M%25*!6W$=.#S6=IOB7Q2--\.:[>:O'/!J%]]EDLUME0;2S+G<.<_+73Z/\/+
M;1ILQ:OJ<T$:N+:WFEW16Y8$;E7H3@GK21?#NVBTG3=-_M6_-OIUQ]IA'[O.
M[)(S\O3)/YT <YK7C'7D;5Y+74$M;VSU!+6VTMH5<RHP&&Y&XDYR,$#BI/%G
MB+Q!I,UZD6LL9;*SBE6*VM5<LW\;3<'RU[ 9K(?3YCK^I7,LGBRPU>:XD=8+
M*'?&PS\N'Z'CU(%=6WPY75H9;K4]3U"&\O[6.._BMY0L<KJN,D8YQZ=,T 5]
M4\4:@]YIL$NJ)I$$^D_;1<A%(EF('R?-P .N.IK-7Q3XLFT[P_8M*[:CJH>X
M9XHXXW2->B+O^7G&<GUZ57\1^&$M-:MK:ZD\2"RM;2.&VNK,><78$Y!_NXXX
M [5OVO@F3Q!H<<>MW>J+-;W+26%U,ZK=QH0.&(SWR<=1QTH HP:_XMAN=-\-
MZI(EKJ%[<N!> QR2"!5SRHRH8],_I5[X?6\UIXN\8PW%T]U*MS#NF=0&;Y6Q
MD#BM&7X<Z6^G6\ N[\7MO-Y\>HF;-QO]2Q'(P ,>U7_#OA"T\.7M[>0WM]<W
M%Z09WNI0VXCOP!S0!B_%I9&\+62Q,$E.I0!&(R <G!Q6<]SXMM]?U#PW_;S7
M-R]@;RTN1;HI5P0-A&,;23C\J[?Q%X>M/$NEBPO))XT$BRK) P5U9>A!(-94
MNF1^%([O6HH-3US4I56)B2'E* \    #N<"@#)\,>)KSQ(FB6D5]*MY;J[ZL
M/+7(*G:%/&!N;T[5Z#7,^$-(%I'?:I+IXL;O4YS-);\9C4<*#COU)]S734 %
M%%% !1110 4444 %%%% !7,?#W_D0]*_W&_]#:NGKF?AZ<^!-*_ZYM_Z&U '
M34444 %%%% !1110 $X&:A%U;LF]9HRN<9##&?2L/QS ;KPE>VRWR63S;(TF
MD)";BXPK$<@'H?K7D6M&-/#&M6]QI4.GZC9WMH9S;2;H&SG#)_=R,Y'TH ]]
M\Q=^S(W8SCOBFK-$[,J2*S+PP!R1]:\6UW6=GC'Q=<Z%=PR2-HZ>6]M(&);<
MNXK@\L!D\=,5<6?P_%I!U#PC<2R:P^D/&UM9MG!"Y,DHZ[@<XSR3C% 'KRRQ
MNS*KJ67[P!Y'UH$T;2,BR*77[R@\CZUX]:76@#0K/4O#UU.?$ TQXWM[1\L7
MV?,\PZ_*<G/KBL_08[-M/L=3TGQ"9-;6SD4V5G:XED<J2?-.XDX;^(CTQ0![
MB)HVD:,.I=>J@\C\*YOQ=XHG\._V=]F@@N#=7<=NZO+M9 QQD+W[]Q7EF@"V
MFL=+U6V\0YU^'?NLK:TS<3/DDK*=V6'')(Z56F?2)O!>BZO-<1GQ =60W+N^
M9L[SD'/( &/:@#V^UN-8?6[R*ZM+>/3453;3I+EY#W!7'%:!>&1S$61FQDH3
MDX^E>0ZMY#:Q\1 DH*?V='*A#G&[;G(.?6F^'K&TTOQ;X-FM&\B2_P!)E-PY
M<GS&V9!;)YY_E0!Z_&\"N88V0,O)12,C\*;>RRP64\T"+)*D;,J.VT,0.A.#
MC\J\%TT:?KDEEI\DUO\ VC#J[RWFH37*(+B+>>!R';/  KWFZ4+I\RJ.!$P
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M)/&?>J\FB6-U>^#=*DU2XU*RDGN(3.6>(2HO("_,<J"2 1UH ]O9CY;&,!F
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MI 8R0(RQ:8AR00V.3U.*HZ9I=G;>'?!.JZ*=VO37RI(5F+%TRV\,,\* !Z4
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M>&]&32GTY=*M$LYOFEMQ$NUCUY]:QM=^(6GZ'?W=N]E>W"67E_;)X479!O\
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MS#)SV&30!K:?IECI5M]GL+6&VASG9$@49]>.])J6DZ?K%N+?4K."ZA5@X29
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M,!0, #Z5R;Z7I/@>?4_$$>+:P-L@>VC!P&#'[HZ#.X# [TA\97MEJEE9ZMI
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MU._LH[/3+>6$VMP8WD=URSL1RV.!CI^==&?A_P"&RE^AT_Y+\[IT$S@$Y!.
M#QD@$XZX%27?@?0KQK5Y;>436L(@CFCN)$D\O&-I8')'UH \UT_4]>UF_P##
M%C=ZSJ$'FW-W9326TNSSUB'$G3J<D9]J[7X8W][=Z-J<%[>379L]2FMHI9VW
M.47&,GOU-;#^#=%:YTZX6V>)].4K:^5,Z",'KP#SGN>]6=$\.:;X>6X73HI(
MQ<2F:7=*S[G/4_,3S0!P7B)=2;XV:>-)>U2[_LM\&Z5B@&3G[ISFLW6/#>I>
M$-,T>VAU^[BNM5UD?;);3]VI,G7 ]L=_RKTJ;PII<_B)=>:.8:B@"K*MPXPO
M]W .,>U3:OX=TW77M7U"%Y6M7\R'$KIL?LPVD<T <-96-Q>^+;GPG>:[K'V?
M3K-)HI?M!CFG9FR7+CJ%R !7*I+>Z]>^#Y-2O+IY8M4GL#*LK(950@B08/#<
MD$CTKU[5_"NDZW<PW5Y;M]IA4HD\4KQ.%/5=RD$CVJ&[\$^'[W3;/3Y=.06M
MF_F0)&S)L/?D'//?UH \WMKOQ'KG]J:E::[!9R6%^ZXFOY L4:'&UH@I# CN
M>2:T[6[N?%$.MZE)XFGTJ\TZ^*1JDC+#'$F#\T?&[=SR>?Y5UTWP]\+SZQ'J
MKZ3%]JC(8%68*2.A*@X.,>E/O_ 7AO4]<76+O3(Y+P$$MDA7(Z%E!P3]: .*
MT73D'BWQS-;W]]$T**\;+<OG+1$Y(/7';/3M5/PWK5YK,?A'1K_5+KR+VVN)
MIY5N&62:178*A?.>@Z UZ1-X/T2?6+C57L_],N(S%+(LCKN&-O0'KCC/6J[>
M _#S:5::=]B86]G(9;8B9P\3$Y)5LY'YT >8ZOJVLVNG:KI*:Q?A=/UN&WAN
MO./F-')GY&/?;C]:VHWU>SUOQEH.FZO<$1VL4EO-?7!9HY6QG#'IG)'UQ7;S
M^!] N=-BT^6QS;1S>?M$K@M)_?9LY9O<FG3>"M N9[R>:Q:26]01W+-<2'S5
M&, _-VP/RH Y3P08=7EU;1-6AU2WN(UB,^GWET\JC!.2KYR5;(RI_6O0(--M
M+>\ENXH0)Y55&?).%'11Z#V%5-'\-Z9H4D\MC RRSA1)))*TC,%Z#+$G ]*U
MJ /,_'\]U<>)H;"SN[J5TT^6=K*&<P*AY E:0$=.R\].U<[IM_J.NS^ X;K6
M=1!OH)Q<^1<E"^TL 3COCJ>M>IZOX1T/7;^&]U+3X[BXA78K,2/E]" >1[&J
M5G\//"^GS6\]KI@BFMV+1.D\@*$]<'=0!YQ:>(-1@T2'2)M3N5LW\0OI\EV\
MI\U(!@[=_49SC-=-X.T^WTOXI^)[6VEEDA%K;LIEE,C<C.-Q.2*Z@>!_#@L+
MJQ_LR-K6ZD$LT;R.VY_[V2<@\]1BI-(\'>']!NS=:;ID4$Y7:9,LS8],L30!
M8U#PWI&JZG::E>V,<UW:@B*1NP/8^HY/!K!UZWM_"7A5],\-V:0W>H2F"UBC
M.,R/U;)]!DY[8KLZS=0T'3=3OK6]N[;S+BT.8'WL-A^@.* /+])BN_ _Q T]
MKC34TW3-6A6S95F$H:5  &) &"3C\S5SQ-=7NG>)+N_U W%SHWVB%4O+*X8-
M8L",H\8."#GGCG/X5W^L^&=(\0>3_:MDEUY))CWLPVD]^"*KR>"_#\M]]LDT
MV-Y]RN69V(9EZ$C."1@=10!P?VN\T_Q?#<ZHUS/97>J 6FJ6ETQCR3M\B2/.
M ."/P/6JDNI:C'H?CH6VH7(DMM45%:6X.X19 *(Q/!QG %>E0^#]!@U'^T(]
M.C%SYIG#%F($AZL%)P#[XK%\3>!X9=&NX]"L+/S[JX2>[BG9L705MQ7=D[2?
M7W- '.:?8/<W.OZE83:K;:(FG;K5&NI(_P!^%)8A=V3@CDGN:I:")[:\\ WH
MU"^DFU*.1+GS;EW#+M) P3@5O:+\/[>345GN?#EIH]LB,LD,%X\S7&X8VMT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!Z\BL#3_  2EGY,5QK6J7]G 08K2YE4QC!RN<*"V., G'%=310 @'%+@444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM%-:_NT_=DX) XYZXYJI=ZMXITV+P[ ^N37LFMA)&&R* QC8#M60@@$D]<4
M>OY%1S3Q6\32S2I'&O5W8 #\37DHUCQ7IE_8>'-8U6&W:_O-JW22K+/%#MX4
MG  8G@,1FF^.M/U"T\."SNO$,UX8]5@$05AYB1N>!*>Y&#@_Y !Z/_PDMG_P
ME8\.F*<7A@-QO*8C*^QSS^7:MC(]:\SN=/D_X6I;:>E]<B8:$R"[+ R9W'YB
M>YJGX=UK5=5MXO"MU?WD>O6U^QOI@Y#>0N3D'I@Y4 #ZT >LT4@(Z9S67XEO
MFTWPUJ-XES%:R10,4FE&51NQ('7G% &KD49'K7CWAK6M>EU:ZLI;[4HDFT0W
MBR7C*[>8#_K$4CY%.3A3VJ'0M5\012^"[RZUN^N5UHRQ3PR$; ,\$<=><YH
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M+K]MX5T6;59[6:>)& <0*"03P"<D<=!FMDUXCXDN;CQ3X*\3ZS=7]TC65_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<K\-_^1 TOZ2?^C'KJJY7X;_\ (@:7])/_ $8] '54444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7*?#88\ :7])?_ $:]=77+?#C_ )$+
M3/I)_P"C7H ZFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MY+X9R^;X!TX[2-IE'_D5JZVN.^%^!X#LP.GFS?\ HQJ .QHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N,^%F/^$"L\?\]9O_1C5V=<7\*@
M1X!M,_\ /:?_ -&-0!VE%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5QGPL&/ 5H/^FTW_HQJ[.N,^%F1X"M >TT_P#Z,:@#LZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC?A=_R(MKCIYTW_ *,:NRKB
MOA2V[P#:'_IM/_Z,:@#M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KB?A/SX M?^N\_P#Z-:NVKB_A7@> K4+T\Z?_ -&-0!VE%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5QOPN '@6V Z>?/_Z,:NRK
MC?A=SX%MO^N\_P#Z,:@#LJ*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KC/A;_R(MM_UWG_]&-79UQ/PH);P#:D]?/G_ /1C4 =M1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<5\*B#X"MB.GGS_\ HQJ[
M6N(^$Y!\!6^#G_2)_P /WC4 =O1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %</\)@!X"M^,'[1/DXZ_O&KN*X?X2_\ (@6W_7Q/_P"C&H [
MBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XKX4C'@&U'_3
M>?\ ]&-7:UQ?PK_Y$*UYS^^G_P#1C4 =I1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<9\+%V^ K08Q^]F_]&-79UQOPNY\"6A]99C_ .1&
MH [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOX5'/@"S
M_P"NTW_HQJ[2N,^%:[? 5H/^FTW_ *,:@#LZ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KB_A6<^ ;3_KM-_P"C&KM*XOX5?\B#:?\ 7:;_
M -&-0!VE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QGPK&
M/ %G_P!=9O\ T8U=G7&_"T$> ;+@_P"LFQ_W\:@#LJ*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KC_A@<^ [/'_ #TE_P#1C5V%<9\+ !X!
ML\?\]9O_ $8U '9T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7&?"LY\ V?_76;_P!&-79UQGPK.? -G_UUF_\ 1C4 =G1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<7\*@1X!M,_\]9O_1C5VE<=\+QC
MP'9C_IK-_P"C&H [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *X[X7C'@*RS_STE_]&-78UR7PT39X$L?]II3_ .1&H ZVBBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Y#X9$GP)99)/SR_\ H;5U]<?\
M,3GP)9_]=)?_ $-J .PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N0^&(QX%L_^NDO_H9KKZY#X9?\B+9Y_P">DO\ Z&: .OHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N/^&)SX$L_^NDO_ *,:NPKC
M_AB"/ MIG_GI+_Z,:@#L**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KC_ACQX%L^?\ EI+_ .C&KL*X[X7$GP'9DGGS)?\ T8U '8T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?"XY\!69_Z:2_^C&K
ML:X_X8#'@.RS_P ])?\ T8U '84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7)?#2,Q^!+ $@DM*?I^\:NMKD?AF&'@2Q+ \M*1G_KHU '7
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)_#5"G@6PST8
MR$?]]M765R_PZ_Y$/3/I)_Z,:@#J**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KE_AT<^ M+_W7_P#1C5U%<O\ #KCP%I?^Z_\ Z,:@#J**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF/AY_R(>E?[C_^
MAM73US/P^&/ FE?]<V_]#:@#IJ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KFO  QX&TL?[#?\ H;5TM<YX#);P3IA))_=D<G_:- '1T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6'X-4+X.TH  ?Z.IX
MK<K$\(?\BAI.?^?9/Y4 ;=%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%(03C!Q@_G0 M%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6+X2&/"6E#_ *=D_E6U67X;C$7AG2U&?^/6,\^Z@T :
ME%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5GZ%QX?TW_KUB
M_P#0!6A5'1?^0%I__7M'_P"@B@"]1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %4])0QZ/91MC*P1@X_W15RH+'_ (\+?_KDO\A0!/1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %060Q8VX_P"F:_RJ>H;/
M_CS@_P"N:_RH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"HK92EM$C##*@!'X5+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-9U12SL%4
M=23@"G5YS\3[75+K[$?[(FU'0K<--=QP3A)"PSCWP!D\"@#T575U#(P93R"#
MD&EK"\'S:1/X7LWT-2FGD'RT8DE3DY!R2<YS6[0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4449Q0 45E7OB31]/NA;7-]&+@D#RD!=LGV4$UJ]: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YG7[WQ
M5!J<,&BZ79W-I)'AIYY2OE/GN.XQCI7344 8_A;05\-^'K;3!)YK1[F>0#&Y
MF)8_ADUL444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<CXDU#4-0UF/PSI,AADDB$U
MU=@\PQYP /<X_6NNKBXM0M-+^(FN/>SQP))902*\C  A<@X_&@#<T3PUIF@0
M8M8 9B/GN).9'^I_I6K%+',F^)PZY(RIR*XNWO\ 4/&MTPM/-L_#ZDAI\;7N
M?8>@ZUV=O;Q6L"00H$C0855' % $E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBB@ _MSG_CW_ /'_ /ZU3-JNVU6?R>K;=N[_ .M110!#_;?_ $[_ /C_ /\
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MS_T]_P#V%%% $1^,I!_Y (QQ_P O?_V%1R?&:0/A-#0#_:NL_P#LE%% $/\
MPNFXP?\ B1Q<?]/!_P#B:C?XW7*H6_L.+C_IY/\ \3110!5'QXN21_Q((>?^
MGD__ !-*WQWNE(_XD$//_3R?_B:** (Q\=[Y<E]"MV'8"=A_0T-\>[L9QX?A
M_P# D_\ Q-%% "CX]W1(_P"*?A_\"C_\33_^%\7//_$@BX_Z>C_\3110 A^/
M-R& _P"$?BY_Z>C_ /$T[_A>]SC/]@1?^!1_^)HHH !\=[G'_( B_P# H_\
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4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>sgmo-20210331xex103012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1E#8R <<C-+10 4444 %
M%%% !1110 4444 %%%% !1110 4444 -9%?&X X.1D4WR(MH7RTVCMM&*DHH
M A^RVY_Y81?]\"C[);?\\(O^^!4U% $/V.V'2WB_[X%'V.V_Y]XO^^!4U% $
M7V6W_P">$?\ WP*46\*D$11@CIA14E% !1110 4444 %%%% "%0V,]J88(F)
M+1HQ/<J*DHH B^S0?\\8_P#OD4?9H/\ GC'_ -\BI:* (?LEO_SPB_[X%'V2
MV_Y]XO\ O@5-10!#]DMA_P N\7_? H^R6W_/O%_WP*FHH @^QVIZV\/_ 'P*
M/L=K_P ^T/\ WP*GHH @^Q6O_/M#_P!^Q4#:-ICDEM.M&).23 I_I5ZB@"@=
M#TD]=+LC];=/\*:= T8]=)L3_P!NR?X5HT4 9I\.Z(>NCZ>?K;)_A3#X9T$_
M\P33?_ 5/\*U:* ,H>&=""!!I%CM'0>0N/Y4\^'M%90ITBP('K;)_A6E10!E
MKX:T)5VC1M/Q[VR'^E.'AW1%Z:/IX^ELG^%:5% &>-"T@=-*L1_V[I_A3TT?
M3(W#QZ=:(PZ,L"@C]*NT4 0_8[;_ )]XO^^!1]DMATMXA_P 5-10!&+>%3E8
MT!]E%2444 %%%% !1110 4444 %%%% !1110 4444 ,:&-SEHT8^I&:<JA0
MH  ["EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*W8O;1.QR60$_E4
MM06)W6%N?6)3^@H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
MCG.(Q_OK_P"A"I* "J>DRK-H]E*OW7@C8?BHJY67X;_Y%;2/^O*'_P! % &I
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<_ZI?^NB?^A"IJ@NO]
M2O\ UTC_ /0Q4] !61X5;=X0T5O6P@/_ )#6M>L+P6YD\$:&S'G[#"/R0"@#
M=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:C+Y5JC8SF>%?SD4?
MUJW6?K1Q8Q?]?=M_Z/2M"@ KG_ W_(B:%_UXQ?\ H(KH*Y[P)SX"T+_KRB_]
M!% '0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9NN'&GQ'_I\M1_
MY'CK2K,UXXTZ+_K]M/\ THCK3H *Y[P'_P B%H7_ %Y1_P#H-=#7.^ SGP%H
M7_7E'_*@#HJ*** "BBB@ HHHH *RO$>J7&B:#=ZG;VB71M8S*\32^7E0,G!P
M><5JUA^,V5?!.N;B,?89NO\ N&@#C;/XH:Q?^&Y->M_"J26,3%7VZ@-X QN.
MW9R!D59\7?$^7P?X@ATZ]T<26\P$BW$=SSL)P25V]1@\9_&N*^%:?V?90^(+
M[4D72+5+F.6"1P!$QV$$#N6Z?A70>,--M?&NK,D:XFG\.BZM5;&X/Y@91]2"
M1^- '3^./B#:^#M,L;M+;[<]XW[N-9=F4QDMG!XY'YUAZO\ %/5-%T;2]5NO
M#D!MM27=!LO\D< C=^[XX/O7G,MM>ZA\)9]9U-@6MWBL+/>,$1*Y)QGJ<MCZ
M)[5H>.ID?X5>"L.-P7UY&%% 'I-G\1)IM=N_#UWI MM;BB,L,/VG?%,-F_&\
M+D';D_=[5)X"\?7'CB2[9=)CM+>UP'<W.]BQZ +M''!YS2:+X$M;#47\37VI
M3ZEJLEN5$\H5$0;=O"@?W>.OK7&? FY@MAX@26>-/GB(W,!D#?DT >B>,/&U
MIX3CMHO(>\U"[<);6D9PSG.,D]A67>>/[SP_J=C;>*-'2PM[TXCNH+GS40_W
M7^48QD9(K@_&>HQZAXV\-^+55QHJW MQ.>5S',V6]@1R/I6S\<9$OM.T2PM"
M)[R:Y+111?,S#;C@#W(H Z#4_B-=:/XVM?#M]HJ0QW4BK#>-=?(R$X#8V=<\
M8SU[]ZU+OQ1J@\73:#IVC17?E6ZSO.UWY80'H&&PX)[#TYKEOBOH2M\-K.\N
M#C4-+$060'DD[589^N#^%;GPK3S_  ;#JT\AGO\ 4':2YG?EF(8J!]  !0!D
M:/\ %/5M>BOWT_PJLALL"5#?@,2<X"@IR>#Q5O7OB=-H?AO2-<.BB:VU!1E?
MM.UHI,$E2-O/0\^U>:?#O3+Z\\37-S;7:QVMCJ4,]U"S!0Z!G^;)_N\\>]=-
M\8M7L];\"Z7>:>2UJ=1>-&Q@-M#J2/8D'% ';Z9XQU6Y\06.EZAX>^Q)>1L\
M=PMVLJ@JNXJ0%&#C''O78Y%>>^#G;PO:?9-;NA=WNJ:B&M'3:6D5HD^;;GY0
M,$'Z59\ PZ3;ZCKZZ=XADU65[O?-'(K+Y!RW SU[C(]!0!W5%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!#=74%E:RW5S*L4$2EW=S@*!U)K
MFX/'^D3+:2-'?P0WDJQ6TTUJRQREC@8;I[\]JO>,8+&Z\(ZE!J=P;>SDBVR3
M 9V9(P<?7%>1Q77B3X?7&FZ7XDM4U/P^+J,VLR<^6RG*E&'0]]IZB@#VG5]9
ML="LEN]0N%@A,BQ!F[LQP!_7Z TFKZO!HVF2ZA/'-)!$-S^0F\A>YQZ"O*OB
MY=C79Y](@^U,-+@^T'R8&=6G8C"L0"!B/<><?>]JV_#WB*/Q%\&[YW?-S:Z?
M+;S@G)RL9 /XC!H Z32_'FBZUH=WJVGM<3Q6A_>Q)$3*/?;Z>_L:D'C71E\-
M)X@N)WM;"3_5FX38TGIM7J<]L5XUJ^CWWP\^R>(M#W3:3J-F(YXWR0"Z<@^W
M<'UJ7Q:6DM?AS#< _P!FFVAW*3\I;*!L_AB@#U&;XC:7:10S7MCJMI!.0(99
M[,JLA/0#_P"O747]];Z9I]Q?74@C@MXVDD8]E R:XWQWXMTO0S;Z=K>B7-W:
M79'DO&4*LRD<?>!!&1^=4?B7J/V^PL?#Q^U0-?H9[D0PF9XXU'"D)GJ^!GIP
M: .]M]2@O-)34K4M/!)%YJ>6,EQC. /7VK"\.^/]#\3:I/IMB\ZW4"EGCFCV
M'@X..>QKE/@EKSW6A7.A7+,+C3I"45@0?+8]/P;/YBN"N([OP;J>D>,K(>;'
M=7-S'+&O&XB5UVD^X_E0![)J'Q%T+3O$?]@L;F?4-RIY=O%O^8]!UZU9U;QM
MI>E:M%I(6XO-2D&?LEI'YDBC&<L,\<5Y(=*GTSXO>&/MC;KZZ1+J[8G.979R
MP^@X'X5M?#T2?\+E\4G4 1=E9=@?KM\Q<8]MN,>U 'HVB>,-+UR]GL8FEM[^
M#_66ERGER+^'?\*76O%ECH5_;V4\%Y/<3QM*B6L!D(5>I..@KSC6D<_M#Z9_
M9Y)D\I#<;>PVMNS_ ,!Q^=>KW]M";>XN3&OG"W>,28Y"D9(_,"@#D+3XM:#>
MQ^;;VFJ21"583(MK\H9C@ G.!UJ]9_$72K[6Y=&M[/4WOX=WF1?9N4QUSS7&
M? VV@N_#NL0W$22Q?:T;:XR,@9'Z@5G:"-3;XX^(_P"RGM%G'F[C=*S+MW+_
M '2#GI0!Z!IOQ*TK5M3N=/L[#5);BV!,J"W'R8.#GGUXJK;?%?1KV&ZFL]/U
M>XBM>9GCM-P3ZD'CH>M<;\)?.7XD^)C<LAF"2>84X7=YHSC/:L?X71ZQ+K3"
MSR=+_M%?M@7J?DDVY_V>OZ4 >IZM\3-'T:UTZYN+:_:'4(Q) \<((;...O7D
M<5;TWQ[I5]KBZ--%=V&H.NZ.&\A\LN/;D_Y%>=_&&6TDL/"_]EM$T$=Q+'%L
M^YE2HP/;(J'19KG7OC6DGB@)8:C9)BWMH5.R1E!(^8GI@EO>@#V'7==L/#NE
MOJ.HS>5;JRKD#)))P !3]2U6/3M+DU 0S7,4:>85@4,Q7KD<CC%>6_%B6X\0
MWIT*S@O)EL(?M$@M83(#,WW%;'W0%R?Q%:G@/Q#_ &W\*;V&=LW5A;2V\@)Y
M("':?RX_"@"];?%WP_<017+V^HV]G++Y(NI8!Y8?T)!/K5G4?B;I.G:VFD/8
MZE+=2X,(AA#"4'H5^;D&O-/ _A'4O&G@6'3C>6]KI$6HM+*0I:9W"@8'8#!J
M?X@VES8?$WP]9:-M%S#9Q16V_ID%@,T >FP^/;6:WU23^RM4C?355[B&2 *X
M4@G(!;D<&ET3Q]8^(-'O-4L+#4&MK7[VZ-07/<+\W.!S68I2W^'TUC<@?V[)
MHC/.C ^8RA",L?J>,^]8?PD>./X5ZJ['&UYRV>@&P4 =&/B;8LD+IHVL.);8
MW0V0*=L0.-Y^;@5'I_Q4TS5$BDM-)UAX)9A LWV==F\]%SNZ\U):6Z0_",3-
M$%G.C ,Q7#$",D _F?SK&^"$23>!91*BN%OF90PS@@*0: .AT?XA6&M^))="
MM]/U!+N#=YQEC0+'C@Y(;UHN/B!9OJ\^F:/87NL36P_TAK-04CYQ@L3R?I7G
MWAL3GXF^.?LA_P!)^SW'DX&?GW<?K6O\"&A7P]JD1 %V+O,H/WL;1C/X[J .
MH?XD:1%IMW>2P7T1MKA;4P20@2O*?X5&?KUQTJ_IWBU+S5XM*N=,OK&]EB:5
M4G1=I4>C \UA^/-)T'7;%-+^UQ6M]>7H\J6+!_?JG1\=./QY%<WX5UCQ#X;\
M96^@>+!%./L\CV]ZY!:*, DG=_=^7OTH ]CKB(?B58W'B*;08M(U1]0B+;XU
MC3@ 9)^]76:=J=CJ]H+K3[J*Y@)($D3!AGTKR/P^,?M#:O\ [LG_ *"* .WT
M'XC:-K^KW&E0BXM[Z'/[FY55+D=0N"<FKNG>,K*^@U.XGMKK3X--<I<2WBJJ
MAAU P3GM^8KRC4_!5Q=:)-XIT/>NJ6NH7#R!#RZK(<$>XQ^-5K^\U+6_@M?:
M@?O2ZNTMRJ#&1A?TSB@#TNS^),&H6T]]:Z#K$VFQ$XO(X 58#J0,YQ75Z1J<
M.LZ1:ZE;AUAN8Q(@<88 ^N*QO LUE+\/M(>#RUMUM%5O0$##9_$$UHV^H:/
M;;2K.]M8Y'AW6\,<BDE,<%1W% &KG-%<AX#M)[:+4S/XD76R]R3E'W"$CJO7
MC^5=?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9/B)@-.@!.";ZSQ_X$1UK5B>*,?8++/_ $$K/_T>E;=
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M2+BZGT^QAMY;I]\S1KC>?\DUI44 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!1UG2;;7=(N=,O-_V>X7:^QL'&<\'\*PX_ E@)K0W-]J%Y
M;63B2VMKF;?'&PZ'IDX[9S7544 <]HOA2+14U)4U&]G.H.9)6F8,P8C&0<=<
M8_(5D6GPNTC3K"_L["_U2WAOEV3JLX(8?3;Z$C\:[BB@#)C\.V7_  C0T&X,
MEU9^5Y)\\AF*]N<=NWI@55N_!NC:AX:MM!O(#-:VT:QQ,Q^=-HP"&[&N@HH
MXN7X;Z??2V3:OJ6HZDED<V\=Q*-J].N ">@[]JV;7PS;VOB2YUT7EY)=7">6
MR22 QA>P QP!]:VZ* ..MOAOI-GK=SK%M>ZE#>W.[S'CG"YW=>-M6[7P)H]M
MI$>ER?:+JUCN1=1K<R;RK@YX..A).?J:Z:B@#D]0^'VEZEXD37Y[O4!?QD&-
MTF $>.@ QTJUJO@S3=3U6/5DDN+/4XUVB[M7V.1TPW8\>M=%10!A:)X3TS0K
MJXO85DGO[@YFN[A]\K^V3T'L*U+^S74+&:U>66)95*EXFVL ?0]JLT4 <WX9
M\$:7X2$ZZ7+=JD_WTDEW+GUQCK56P^'>E:;KLVM6UYJ*W\V[S93.#OW=<C%=
M=10!QNG_  UT?2KRZN[*[U.*XNE99Y!<9+@G)SD>M,L?A?HNF07$%A>ZM;17
M/^N6*[*[_K@>YKM:* .-O_AEH&HVMA:SM>""PCV6\:3X">K=.I[FK6J> =%U
M>\L[VY^TB]M%58[J.8K(<="Q'4^]=110!AZ/X5LM#^VM:SWC27K;YI)IB[%L
M8W<]ZQK3X7Z%8+=K:7&IPB[4K/LNB/,!ZYX]Z[6B@#!\,^$=.\)6\UOICW/D
M2MN,<LNX*?4>F?Z51U3X>:-J^O#6KF6^%\N-DD=P5\O'3;Z5UE% &#H_A'3=
M&O+J[B:YN+FZ01RRW<QE8J/X>>U9\'PW\/VTLOD+=QVTS[Y+-;EA Y]T[CVK
MKJ* *&IZ3;ZKI4NG3-)';RIL80ML.WTX[5G^'O"&F>%[.>UTMKF.&8Y96F+8
M.,9'H?>M^B@#F=+\":)H^L/JMFEREY(29)&N'/F$\G=D\\TESX!T.;4);Z%+
MBRGF_P!<;.=H1)]0IKIZ* .>G\$:!<:=;V#V6(;>4S1['8-YA'WBP.2?<FF1
M>"])M?M4WDS7ES/;F!I+N=I&*$?=!/W0?:NDHH YOP3X77PIH366Y2\LS3.J
M$E4+=%!/) &!GO4$7P]T.#5I-5B-ZE_*27N%NW#MGKDYKJZ* ,G1/#EAX?MI
MK>P$PBE<R.LLK2?,>IY/&:=9^'=*L=.N-/@LXQ:7$CR2PD95BW7@]O:M2B@#
MD[?X=:!;2,(DNEMBVXV8N7$!/^YG!K2;PGHS:]!K7V-1>P0^3&PX55P1C;TZ
M$BMJB@#(T+PUI7AN.X32[80BXD\R4[B2Q^IK7HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,'Q6<:?8_]
MA.R_]*$K>K!\6?\ (/L/^PI9?^E"5O4 %<]X$_Y$+0O^O*/_ -!KH:Y[P'_R
M(6A?]>4?_H- '0T444 %%%% !1110 5C^*()9O#6H&"ZGMI8[=Y$EA<JRLJD
MCD5L5E^(FE'A^_C@MIKF66!XTCB +$LI ZD>M '#_!F]O]6\/WFH:AJ%W=S_
M &@PCSYBRJH / /3K5S3/&VLWWB[7=#:VT]!I<3R"7+_ #D8V_3J,U!\'])U
M/0- O-/U73KBTF-P9E+@;64JHX(/7BL6'PG-=_$/Q/J&K>'I[BPN8G^RNR @
MN,8(YXS@XH ZKP#XSO?%6@7NKZA!;6\5O*T86'.?E4,223[U/X0\;CQGHE_<
MV$"QWEL[HL,K?*>IC)(Y /?Z&N"\-:%XBLO 4_AN72K^UDU"_P S7"QJWE0%
M5R<;N2=N,>A-:/AGP]K/@WXGW"P6]Y?:1?Q@37(B"JKG)!(''!!Z=FH U_#G
MQ$O=7\/>(+R]M+6TOM)SF EL< _>[]01Q4.J>//$NEZEH&FS:;IB76K1AB))
M7"PL3T;CC'X]ZK7W@:[;XN+>6\<BZ+>QBXO=IPC.AR$/U8(V/K[U#\3-(FU?
MQKH+MH]]>Z=;*1=F"!F&TMT!'4X]* .Y\+ZOJVK6MU)J-K;1;''V>:V9FBG0
MJ"&4D XYQ7%'XF^(!-XAQI&GRQ:&^VXQ.ZLPW%<KD'/0UU'@FYN1:MIHTV\M
M=-T^&.&WEO8C'+.>=QQG@ !?S->3W7@C6==U3Q?/#:ZE;/+,UQ:AXFCCNEWL
M2ASCG!!&: /0M;^)4]CH>@ZM8:;'-#J[>6JSRE&C;..< @BN@\-ZUJ^J7-Y%
MJ-C;110X\JXM93)'*=S*R@D#E2N#7E_BJ+6?$/A#PU:OX9OXKFTE/VF"*T8(
M$'&1CID#I6\FL:GH>C3:)H'A_6%LUAE%O/+9N'2220E<#GY55FY/)(% '6^'
M/&UEXCU_6=*MQAM/D 5\Y$J]"P^C9'Y5SJ_$?6YM6UZSM=!M9UT4L9\79#.B
MD@E?DZX!XKFT\,ZKX#\<Z/J6G0W>IVLD(CN_LM@R80\'<!D%OXO7*\U)H[ZK
MI/C'Q??1:#JTR:FKBS/V-U#.6)&[.-HYZGTH ]3\,>([+Q5HD6J6.\1.2K(X
MPR,.H-8_C[QA>>#;2SNX;"&[AN)A V^8H58@D?PG(P#7%:/-K_PNT/1-/DTQ
M;A=1O-UX^21 6*J$!'&[ SGD5T?Q@T?4-8\*6PTVUDN9;:[6=TC&6VA6!('?
MJ.E &OK?B+5]+U.SL8;"SE:>SFN&=IV4*T8!91\G(.1@_6N=T/XLC7/#^J7,
M6G1Q:II\1G-H\Y DB'5E;;U'ICTYYJ_<WQUZX35;:SOEM[#3KF.1I[9T9Y)%
M7"JI&21M.3C'(KD?$/@:?6?!.E:_HUO<0:Q;62074 C*/.JIL88ZEA@CW'X4
M =-/X^\0Q>*XO#D>@V4M[+;_ &A<7C!2-I;&2G7@BDG^*8;P?=:Y9Z9NN+&<
M0WUG-+M:$DX!R%.1GZ5CWTEQ8_&*TU@Z7J4UG;V AD:"T=\.48!>!SR0/2L2
MY\.:S8_#_P 3W5WI]P+O7;R)X;2.(NZ*LA?+ 9QP3U]* .^TWQMK5[Y9?1+7
M;-9FYC>&]+*K; X20[/E)4^]8]I\89&T6VUJ]T'RM-EN_LC2Q76]T8+DG84&
M1CWJMX3EB\/Z/]@LM-U9O[0A\VZ:>SE5;8K!A@"5^?+@  >M<#IOA76K;P[:
MZLVG7]RECJ(:YTJ:%PK+\N'5<<YY4XSCB@#V6^\=7/\ PD-]I&D:9'>S6$*S
MS+)<^4\@*[L1KM.X@=>E9NN_$S4M&TC^U#X;9;3S(8PTUSM9FDB$F NSH,XS
MGJ*Y7Q1;V7BJ6\U9M*UO2=8CVFPFCLI?])PB[5;CA@V5R".W7%:7Q!MM9N?A
M)HUG?V]Q<:P98FF2.,R-\JL"6*@\\C/O0!W^@>(;W4UNCJ6E?V:L,4<RN9Q(
MDB."<AMHZ8YIOAGQ=;>+-%N;_3(\O!*\1BD?&2/N\XX!&#T[^U8GB.^FE\"Z
M5IEHL\<VII%;-(;9V\J/:/,+@#(XX[=:Y7PS%>^ /B%J%A<QR2Z7?1!WEL[.
M0112=5  SC&2.">HH Z7P[\5;7Q%:ZBL=@8-1LX6F6UDG&)E49.UL>WI23?$
MG48M8TK2E\-J]WJ=LMS HOP!M(8X)*<'Y37)7_@NXUGX?:7K6CQ3V^NV$+1S
M+M:*25!G*X.,D \>H)'/%/OYI;/X@>#M2GM+PP6.EQ)<M';._EMM?C@'GYA0
M!Z3X1\96OBM+N-+>6TO;*3R[FUE()C;)'!'4<'\JZ6O%=-N-8\,3>*?'*Z+.
M\%]<8M[:0%'V%R?,88R ..W>N_U#Q:5\ +X@M[:437%NK00["Y#L.,X'0=<^
M@H MZ+XML-<UW5])ML^=IDBH[$C#YZD?0@@UCZ9\2+2[\97/AF]LVLKN-RD3
MM(&29AV!P,''2N @T;5?A_X]T?4]S7]O>1;+R2TMY#\I(#,_7))PWO@\5LWW
MA6#QM8^('LM\.K6FJR7%G,Z%"P*I@9('!*G![$ T ;.I_$^XTJSL[FX\/.4N
M[F2VB NUW;T;:<C;QS6[H/C6VU;6KC0[NSGT[5[==[6TQ4[EP#E6!P>M>2:^
M+T>"O!ZWT4YODO[B:Y4QDL/WI+,0!ZUU^GV=QXE^,2>)K*&=-(LK?RA<2QF,
M3-M884, 2/F].U 'H/B'68= T"^U2;&VVB+@$XW-V'XG K(\ >+1XN\,17\F
MQ;N-C%<(HP X[CV((-8?C:[;Q!XITKPM8W<4,D,GVJX,\#21,Z@%(R. <Y)(
MSV%<;X*EF\&?$#5/#MQ.7L[TF%9X(V$:3'[I[XQDKUH ])A\=IJ>IWUGH>E7
M6IK8G;//&R)'G^ZI)^8^W%12?$?3X]/T^46-Z^H7\CQP::JKY^5=D.X9P!E3
MS7)_#6_M_ L>L:'XD<65VMQYJ,Z'$R[0,J0/FZ=.O-)XAN)+3XE>'?&<EI<K
MHC0^4TDD1!A)\P$LO51\P;\: .NOO'SZ9)<Q7V@:A#);VAO&&Z,JT8*@[6#8
M)&[D4S3/B&NIIILR:'J$=KJ$GEPSLT97.2 2 V0,C&<5#XJ\3Z3K'A'7H-/D
M-QML7'VA(R8]S<! V.6/H/2N-^'&IV?A^PLYYKZ>ZO+N..T73V5LP'SFYSC"
MKAMWYT =3_PM[34:[:?2=1BMK.X%M<S@(RQN20,@-G'RGFI+OXK65JMI*-&U
M*6VO9FAM)@$ G((&5!;..1@FN'\$^&;'Q=KGBBUU"\NTM?MPN!:Q.$6<;W^9
MLC) R.F/O5N_%O[/:ZGX.MH]D:6]WNV+P$C#( <=AP?RH [JW\612:#J.J3Z
M?>VQT]G2>VD0>9E0#QS@Y!&.:PC\4(QJLNEGP[JWVV*'SY(<1[@FT-G&[T(X
MKO1M=01@J1^=>2VTT0_:+NR9%*M:>6#G@MY:Y7Z\'B@#K--^(%IJGB9M"BTZ
M^2Y%N+C+A,;"JL/XO1A^-4H/BMI,^B:AJRZ=J?V6PD6.<[(\AF.!@;^>:Y7R
MX[OX^ZJD>IS6*FT"B6V=025CCRF6!'8Y&.U<EI<\$?PN\7VC7"F>2\B,:,PW
MR#>.0._3M0![&OQ"LIVTZ&STZ^N;R_MS<Q6J! ZQ<_,V6P,XX&:W]"UF#7M+
MCU"WCFBC<LNR9=KJ5)!!'U%>+7-KH.LZ/H4<FJMI&KV>F1/#?[CY;'D&-L<A
M@1ZYY->E_#.\U6_\%V]QK"$7#.VUV3:94SPY'J>>>_6@#L**** "BBB@ HHH
MH **** "N/U/QY:Z=\0-/\+L@8W,>7ES]QS]Q?QP?S%=)JNIVNCZ9<7]Y*(H
M(4W,Q/Z?4GBO _%6CZI?>&(O&LD^G"26Z-TK1.QG&X@+&3T.P*!@=,&@#W#Q
M#XET[PS8+=:A(PWL$BBC7=)*Q[*.YJC;>,[>2_M[2\TS4M.>X5WC>\B5$VJN
MXY.XXX]:\Y\3ZQ_;I\%>+MIDTVUG OE4%A;R;D+9';I^@]J[GQ/J-AXG\.ZA
MI6BW45YJ$UF[P^1\X48Q@L.%)!(P2#S0 ^'XB:?=6UQ=V6FZM=V%NS![R&W!
MC..I&6!('L*8_P 2-.&L1Z7%INJ7%U) MP@BB0[HRNX-RP[5E?#OQ'H^G?#V
MUL[^>*VN;/?%/:R<2%MQ. G5LY':N/\ &,,>H_%26VM]233%.E^6)&(11\G^
MK;/W<]/:@#T2^^)6EZ=IME?7%AJ82\E>"-/)7>LBL5*L"W!R*2#XF:3<R_9H
M+'4Y+]9S ]DL \U& ))(W8QP><UPOQ&UVPUVQT!M+G")!JAB24* KD!29 #U
M 8XR>^:]$\.>$[+PRNHZG)>O>WMZ3-<WLV!D<G@#@#O0!4TKXFZ9K*H]IIFJ
MF)Y_LXE:% HDQG:3NXJ&W^*NEW5E/>P:3K#VMO)Y4LH@0JK?]]UA?!:6(>$-
M8#LF5O'<@G[HV+S].#7*_#R[T_23-K&H:P(X;2YG)L&()E+( &5>I)Z4 >H7
M/Q&L+;6[O2/[+U66[M8S+(L4*-\F =P^?T(KH-!U_3_$>EQZAILWFPOP0>&0
M]PP[&O*;77M/LOC1K.IWLRQ6QL ,-SEMB'9[G@C%;GP=T>^TS1-3O[V)[>*^
MN/-ABD&TJ@S\Q!Z9S^E ';:CXBT_2]9TW2KF4K=:@S+ H''RC//IGH/>LSQ-
MX\TSPIJ5C9ZE'<!;S[LZJ-B<X.><\?2O+O&J:EKHG\;V30_9K"Z5+.43X<)&
MV!A<=V);KG&*ZN>?0_B%?:-#>.CB[TJ9O+S\T4NY.GH>&_ 4 =5JGC2TTRXO
M(C8WMP+6T%X\L(0H8CG!!+#/0]JS=/\ B?I-VEC+=6E]86U^Q2VN+B,>7(0<
M$9!..?6N TS3M8T'3O&.FZU*S_9=)$%K(Y^5HR6VA3WZD8_"J,[CQ!\,?"_A
MK2HVN=6%RSNB(3Y"[GY8]%!W _A0!]"9XS61H'B73O$D=W)I\I<6L[02;A@[
MAW^A[5G>,-5ET?PNMK;2J-0O"EE;,S8P[?+O)[ #)S7FWA6.]\"_$"ZT&Z:.
M.#5+<!3%(65),?*23WZC_@5 'HT/CF#4+V\M](TR^U*.S?RYI[<((PW<*2PW
M'Z55U+XE6.F:)I^JOIM^T-]*T,:;4#JRDC!!;U!KC/!^LS>!O!^NZ5=B*VUN
MTG>>.&Y4D3Y4 ;<8S]WL>]4/'6J:AKG@?PM<WZ1VNH7%VTICCC*^6N2 VTDG
MT.?>@#T[2_'-IJ=_J&FFRN[;5+*,R/9S!0S#_9.<'MW[UEZ=\4;;5+-+VWT3
M43:M<"W,N8^&X[;LX&17)^$KO_A'?'&OKXJF:34KF'=#J##Y)(P,\8'&1MQ]
M,5D_#:]L?#UI+K%]?RM*GFQ1:7L;<Q8H591CJ=N"?84 >E3?$:&/Q'>Z)'HU
M_-=6:%Y"IC VC'/+=\C\Z;>_$JTLX]%/]E7TCZMQ!$NP,&W;<')ZYQ^=>=:B
M(;SXOZI//JC:=;Q^4[/M)1V0H3&2/<'\15OQKXBM-6\3>$=4A1XK6*X9R63D
M(L@ 8CMG!.#VH ]0T3QEINL37ULPELKRQYN;>Z 5HQ_>ZX(]ZU].U.RU>R6\
MT^YCN+=R0LD9R#@X->46MNNK^./$?BQK"=M 2Q> Y4J;KY0#M'!P<'GZ5W/P
M\GTRY\'6TFD:=-I]D7?9!*26SN.3DGG)H ZFBBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH P/%H)L+#'_ $%++_T>E;]8/BS_ (\+#_L*67_H
M]*WJ "N=\!_\B%H7_7E'_P"@UT5<]X#Q_P (%H6/^?*/_P!!% '0T444 %%%
M% !1110 444R:5(())96"1HI9F8X  ZF@!]&:\<\'>.;BY^*%Y;W4\;6>LH)
M+55E#"+:OR*<$@,5'(]<58T*:'QIXR\477B"1WL=(<PV]J794C7+@L0#R<)^
MOTH ];R/6C(]:\,\7IHUO\/-0ET'5Y+Z-=31XW$CDVX=0#'N)Y'R_P JE\ 7
M::C\01;:/+<)I*Z<!?VUS(WSR;<,55CG[Q'(]_6@#V[-&17SEX7AAUC6+W1+
MJ&^+W5\\,%^L[A;8!'8 #=@G*C@]@:T?&\D6D_$G:]M<ZA;KIPD>".5U#N$(
MWG:P( P"<=A0![YD49'K7C'C?PU<V/A'2+32+FYDN7N9)8OWK;U0QF0QYSSC
M'%87B;QMJ/B3X=:>UI<2QO9!!J<JN5+2$E$&>^=K.?PH ^A,T9KP/Q7/'I/B
MCPRICOI[2324FGMH)Y-TS;7]&SV&3Z"M[6?#^H3^"-(&DZE=QW>HWL<L!ENG
MS")(2QCW=2,KQG_&@#U[(HS7AVE:Y>^,-7TSPYJDEW8ZU;+<VUS)'(R;L1'8
MY (&X,,__6-3PZ$TOQ8O/#)U35EL4L/,0_;7W!]J_-G/J3Q0!Z[>:59:A<VM
MQ=0B62U<R0[B<*W]['0GT)Z=JNU6L('L].M;:6=IY(8DC:5NLA  +'W/6K-
M!1110 4444 %%%% !1110 4444 %%%% %34]-M]7T^6QN]YMYAMD5'*%AW&1
MS@]ZG@@CMH(X84"1QJ$11T4 8 J2B@ HHHH **** "BBB@!C1([!F56(.02.
ME.(#*58 @C!![TM% #4C2-=J*JKZ*,"G444 -5%5F8* 6ZD#K39((I2#)&C$
M=-R@U)10 #BH_(B\SS/+3S/[VT9_.I** (1:P!RXAC#')+!1DYZT?9+?IY$6
M/38*FHH B-M"R;#$A7^Z5&*E P,"BB@ HHHH **** "BBB@ HHHH 9)$DJ[9
M$5U/4,,BFFV@,8C,,9C!R%VC /TJ6B@");>%8S&L2!#U4*,'\*2"TM[52MO!
M'$&.2(T"Y/X5-10!7-A:-<"X-K"9QTE,8W#\>M-?3;&21I'L[=G8Y+&)23^.
M*M44 5CIUDR!#:0%!T4QC J8Q(T1B9%,9&TJ1P1Z8I]% $$5E:P;_*MXH]_W
M]B ;OKZTP:;8B3S!9VXD_O")<_GBK5% $)M+<N7,$18G.XH,YJ7 *D=J6B@"
M$6L C\L0Q[,YV[!C/TI4M8(V#)#&I'0J@&*EHH 8\4<GWT5OJ,TD<,41/EQJ
MF>NU0,U)10 QXHY""Z*V.1D9Q2&")GWF-"X_B*C-244 1R6\,K!I(D=AT+*"
M10\$4A!>-&QTW*#BI** (V@BD(+QHQ' W*#2?9H<@^5'D=#M'%2T4 1_9XOF
M_=I\W7Y1S0;>)L9C0XX&5'%244 ':D5510J@ #H *6B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** .<\8L5M-* /#:O9@_]_E/]*Z.N8\;
MG%IHW_8:LO\ T:*Z>@ KGO ?_(A:%_UY1?\ H(KH:Y[P)_R(6A?]>47_ *"*
M .AHHHH **** "BBB@ K+\0Z0^O:+<::MY):I.-KR1J"2O<<^O2M2B@#B-?^
M'%KK5UI=U!>G3Y]/ V26UN@+,,<G\NE69O YBUN?6-(U6;3;R[3;>;(E>.<_
MWBIZ-GG(]3ZFNNHH \[?X2V7_"(_\(_#JES'%)<_:IY2BL9&Q@#'85:/PVBA
MUK3]9T_59;+4+6!8))(X5*S@#;EE/&2.#^%=U10!YWIOPRO-(2]2P\43PK>2
M&24BTC9@QR,J3RIP3T]:>?AI-'KEKJUKK\D<]M:I:()+59%,838003R2,_G7
MH-% '%6_@6_AU"VO9O$4MQ+%>-=L9+9?G)C\O;@'"C;QQ534_A797/ARZT;3
M[S[%%=7INYG,(<GKA!R, =J] HH \]O_ (;W]YK.EZJOB!([C3;9;>'-B&!4
M CY@7YSN-68O VKK=17,GB022)>17)'V(*@$:E%15#8488UW-% '.3^#K&3Q
MG9>)X<0WD".DH5>)PRE03Z$9Z]ZHIX*O$^(;^+/[6CR\?DFV^S?\L\8QNW=>
M <XKL:* .9T_PO>67C+4-<DUJYFMKE,)9.QV1GC/?';CCO73444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!S'C<$VFC8'_,:LO\ T:*Z>N;\
M9'%KH_\ V&+/_P!&BNDH *YWP'_R(6A?]>4?_H-=%7/>!/\ D0]"_P"O*+_T
M$4 =#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S7C-=]MHXSC&L6
M9_*45TM<UXS.VUT<_P#48LQ_Y%%=+0 5S_@7_D0]"_Z\HO\ T$5T%<_X&_Y$
M/0O^O&+_ -!% '04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <OXX
M_P"/31?^PW9?^C1745R_C<$VNBX[:U9'_P BBNHH *Y_P-_R(FA?]>,7_H(K
MH*P/ _\ R(NA_P#7E%_Z"* -^BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!DSF.%W"[BJD@>M>0>"_%7B&/6-+O-7OC=:=X@EFBCC(_X]Y$8@ >@([5["
MPRI%>-7-JNC>&/#T(&Y].\4F)6/<>8Y_48H ]F%% Z44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQJ<6NC?\
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MTNC6<=C<OY6G6S0+M6)>-^TCJV.OUKTBWTZRM-OV:T@AV\#RXPN/R% '!?\
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M** "BBB@ HHHH **** "BBB@ HHHH YGQIC[-HV3C_B<V?\ Z,%=-7+>./\
MCUT3_L-V7_HT5U- !6/X2V_\(=HNW&/L$'3_ '!6Q6%X+Q_PA6BX.?\ 0HO_
M $$4 ;M%%% !1110 4444 %%%% !1110 444=* "F^8F\)N&XC(&><52.H"Y
MD>"RR[+D-.%W1H?0G(R?85/:6HMD.7,DKG+R-U8_T^@XH 6]E$%A<3%MHCB9
MB?3 S7B:--I<_@*ZAMI[F1(KNX\J(?.X)+8&?45ZQXON_L7A#59^XMG4?B,?
MUKS#Q-.=)U#PI NY9H=%D6/&"3+(H0#\S0!K^$?'*F"\N?\ A']:ENM0NWN
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M&VW/_"*66<]/[4&?_0* .NHKCQK7C?'/A&T_\&B__$T#6_&^>?!]M^&J)_\
M$T =A17(?VWXUQ_R)]O_ .#1/_B:!KGC7OX/@_\ !HG^% '7T5Q_]N>-L?\
M(FP9_P"PHG^%']N>-O\ H3K?_P &B?\ Q- '845R']M^-<?\B?;Y_P"PHG_Q
M-)_;GC;)_P"*.M__  :)_P#$T =A17(?VYXV_P"A.M__  :)_P#$T?VYXV _
MY$^W/_<43_XF@#KZ*Y#^V_&O/_%(6_\ X-$_^)I?[;\:?]"?;_\ @S3_  H
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M'R9[O<AW.!R,<UH7'PHM+VZM;NY\1ZY+/:X\B1YT)CP<C:=O'(K7\9*]U?\
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M4 .?P5X@%XUS'XNP[$;I#I<&\X]3BK+^&O%@8"'QO,J8Z-I\)_D*XOPO8?\
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MG-='10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%174C0VDTJ+N9(V8#U(% '):KXLNI+[48='A$L&CQF6_F/.Y@"1"@_O'')
M[?6LG0M;\6:SHNEZQ;7^GW$-Y<*ES"MO@VB;CNPV>H QSZBJGA[4Y?"7@30+
MI@9I=7O1/>2%"VU'RSN<>@ YJ+36M]&\;:Q?>&I&GT :>]S>1P#="MP,X5.V
M[ !P.Q- '::9XFCF&J7EY?:8-,@G$=O/#/G(QSO)X!SVJ5?&WAED9O[<L1MZ
MAI@"/P->0%[?1? ?A759PSSG4GNWM+A"B3,W5SUPJ@#!P<^E:6I6$=[X9O;R
MQNK/4=4\3ZDEN9K9-RVRYY4$C=@ #.<=: /6K7Q!I%[?+96VHVTURT0F6))
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M*O8O$NGIF6$;+V)1_KH.Y_WEZ@^F:Z2VN(KNVBN(6#12J'1AW!&0: ):***
M.7OF:\^(FE6ZD%+.TEN6! ZL=@KJ*YG3"USXZUJ<KA;>&&V4[>O!<\_C734
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M4M% "8&,5G76BV][JEO?7+/+]F&88&(\M'_OXQRV..>G:M*B@ HHHH ****
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ML;W4HE;[,C!HU+ KC&\[0<*3W-7M5\8:!HKP)J&I10M,H=%P2=I_B( X'N:
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M.XMKV%95 ;/ ,G"D8SQF@#Z+HKAK+QG>V>H>'='U.TCD?4[96744G'EN^W+
M#'7..AYR*T#XLNWMI[BVT*ZN8X]0-DGDN"7 8JTGLH((H ZFBD'(I: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** .;\9'%II'_88LQ_Y%6NDKF?&I
MQ9Z/_P!AFR_]'+734 %8/@K_ )$C1/\ KRB_]!%;U87@LEO!.B$G/^A1?^@B
M@#=HHHH **** "BBB@ JM?SBWL9Y#'+)M0_)$A=C[ #K5FB@#PC2=,@A^'=Q
MI%_X+U&?6G:18Y!8$-DGY6\PC@#^GO6_KOAW5-/^&VBZE=7 _P"$@T+;,CLV
M[/S?ZHGOQM'7M7K%<[>^#=.U'Q+%K=W+=2R1;2ELTI\D,O1MGJ* ,^WW>%O!
MT,U[ID^HWEQ*LMW';Q!V:60Y)(]!P/P%=B.E+7*S^$=1DGDEA\7ZU%O9FV9C
M95SV *]!0!YY\5M&N;C739Z+I^HK/?(C3"",F"Y;=_%CHPX))]!6+XGTO5=3
MU&]&LZ%>6EY;Z<D=LNGQ-*MPP YD<9! 'IC]*]WT?3I],L!;W&I7.H2!B?.N
M N[GMP!Q6A0!X-= #3K&ZTV'5M.UB#2H8##)8N\%^H&#&5 ZY]>#^M=!H=W<
MZ'XAUJ3Q1ILZ+JUI \7DV[2H-J8:$8!((W8Q[5ZS10!XCH&CW>B>(O T.J6\
M@,%O<M+F,L(0^\HI(&,Y/3L377?"=C'HNJP/#)$1J4TBJ\;+E&Q@C(Z<&O0*
M* /(AHFE>)/BYX@BU6S>6UFMD2WD9&4>8JJ&VMTR.?RK3UF%O"_CSP_?W,<T
MVAP6!LEF*&06S_WC@<$@ 9QZUZ510!X#JNG.NGW5W]CD32[KQ(EQ;1- W,(!
MWR;2.%.1U]*O:S$;C6/B%!8VS/%/8Q-$(XSARFT-M '..>E>X44 >#7-];C4
M]$U>^76(]$;1TL?M%I&R%)0/G4@CE3[=?PJS!:Z;8^)O!,:64MOI\9N75;WY
MG5&8[&?(&,GD ],U[A10!X#I;7$.FPW@AD?3-/\ $CW%W;JI.V-MNQ]N/NCY
MJT_$%M_:]WXTU;1HC-IDVEQHTD:$++,&4Y7^]A0<GM7M=% &%X.OK:_\*:;)
M:[RB6\<9+1E/F50#U SSWK=K U'2O$5Q>O+8^)4L[<XVP'3TDV_\"+9-5?[#
M\6_]#C'_ ."J/_XJ@#J:*Y0Z'XO!&/&4?OG2H_\ XJI[+2?%$&HQ27?B>&YM
M5.7B&G*A?VR&X^M '24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 5M0$YTZX%K$LLY0A$
M9]@)/J<'%>::5X7\7:7X"N?"ZZ?IDIG\Q3<R71*JK]?DV=1GCFO5** /*?$F
M@Z?IW@33O#46K1MK^GO$]EAP)O,:3'RKG('S'Z  ]J[)['5=!\.Z=8Z'!;7,
MT3QI.;ABNY3_ *Q\Y^\3S^)K5?1=-DU9-5>QMS?HNQ;@QC>!Z9J_0 W<%')
M^M'F)_>7\ZI:MHNGZY:BUU*V6X@5PX1B1\P!&>"/4UB_\*X\)?\ 0&C_  ED
M_P#BJ .GWI_>7\Z-Z?WA^=<P?AQX2(P='3'M-)_\51_PKGPG_P! A?\ O])_
M\50!T^]?[P_.CS$_O+^=<S_PKKPGC']D)_W^D_\ BJ8?AMX2./\ B3H,'/\
MKI/_ (J@#J?,3^\OYT>8G]X?G7,?\*Y\)8Q_8Z8_ZZR?_%4?\*Y\)_\ 0(3_
M +_2?_%4 =/O3^\/SHWK_>'YUS'_  KGPG_T"%_[_2?_ !5!^'/A0X_XE*\?
M]-I/_BJ .GWI_>7\Z/,3^\/SKF?^%=>$SUT>/_OX_P#\51_PKKPF!@:/%C_K
MH_\ \50!TWF)_>'YT>8G]Y?SKF?^%=>$R<_V/'_W\?\ ^*H_X5UX3_Z T7_?
MQ_\ XJ@#IO,3^\OYT;T_O+^=<S_PKGPG_P! :+_OX_\ \52#X<^$Q_S!X_\
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M\>[^= &V;^S'6Z@'_;04?;[/_GZ@_P"_@K"D^'WA*5MS:!8YZ?+'M'Y"G1^
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M** "BBB@ HHHH P_%()L;''_ $$[,_\ D=*W*Q/$_P#QY67_ &$K3_T<E;=
M!7/^!O\ D1-"_P"O&+_T$5T%<_X&_P"1#T+_ *\8O_010!T%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYA"T7V:5WG<'Y]K+\J8'KZ5U]A>:W=ZJKRV4$&DR6B2H78B=93@E&7IQS^5
M&U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW1=6Y_Y;Q?\ ?8IM[96VHV<MI=Q+-;RC:\;=&%<^/AUX2#,PT.WR>O+8_+-
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MUU^P_P"_PI?^$[\*_P#0?L/^_P *USIMB6+&SMRQ[F)<_P JD^RVX_Y81_\
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MX_\ "Z@DZO%P,\*Q_I^E=%Y,7_/-/^^11Y,7_/-/RH P#X[\,#KJ\'3/1O\
M"HS\0?"P<+_:J$G'(C<C\\5T?DQX_P!6OY4>3'_SS7\J .;/Q"\+*2#JJ_A$
MY_\ 9:3_ (6'X6QG^U!_WYD_^)KI?)B_YYI^5'DQ_P#/-/\ OD4 <T/B'X6.
M/^)H.>F89!_[+72Q2I/"DL;;D=0RGU!Y%'DQ_P!Q?^^13Z "BBB@ HHHH **
M** "BBB@ HHHH **** ,;Q)G[%9X!/\ Q,+3I_UV2MFL;Q*2+*SQ_P!!"T'_
M )'2MF@ KG/ )!\ Z%C_ )\XQ^E='7-?#U!'\/\ 0P.]JC?GS_6@#I:*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** ,;Q(,V5IDX']H6G_HY*V:QO$H
MS8VG_80M/_1Z5LT %<S\/6W_  _T,YS_ **@Z8Z<5TU<Q\.QCX?:)RI_T5?N
MCZT =/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !12$@$>]+0 4444 %%%% !1110 4444 %%%% !1110
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MQVKU*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTD7.<.H(JL=(TTIL.GVNS^[Y*X_+% &;_P )SX5_Z&+3/_ E/\:/^$X\+?\
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M_P#?F+_XY2?\)C=?]"CXB_[\1?\ QRNIHH Y4^,;L$8\(>(2._[F+_XY4?\
MPF>I;P/^$+U[;GD[(\@?3?7744 <G'XROBI\WP=KZG/ 6*-O_9Q2R>,[Q4S'
MX/\ $+-Z&&,?^SUU=% '+?\ "97/_0H^(O\ P'C_ /CE'_"8W/\ T*/B+_OQ
M%_\ '*ZFB@#E'\97@0E/"'B!F[ PQ@'\=YI3XQN]A(\(>(2W8&&+_P".5U5%
M ')OXQU#"^7X-UUL]=R1KC_Q\T'QCJ 08\':Z7QR-D>/SWUUE% ')1^,M18_
MO/!FNJ,?PI&>?^^A35\9:IN&_P %ZV%[D",G\MU=?10!RD?C&_93YG@[7E.>
M (XC_P"SBA/%^I%\/X.UP+ZA8B?_ $.NKHH Y67Q?J"X\KP?KC>NY8E_]G-1
M_P#"8:M_T)>L_G'_ /%5UU% '*#Q9K!Q_P 49JW/3]Y%^OS<4T^+=84X;P9J
M^?9XB/SW5UM% '*-XMU4?\R;K!].8O\ XJE_X2G63T\&ZI^,L(_]FKJJ* .6
M_P"$GUK'_(FZG_W_ (?_ (JC_A)]<QQX,U+/O/#_ /%5U-% '+?\)/KG_0F:
MC_X$0_\ Q5'_  D^M_\ 0F:E_P!_X?\ XJNIHH Y8^)];'_,FZE_W_A_^*J,
M^*]<W[1X*U3IG/G0_P#Q5=;10!RI\4ZV%S_PAFJ>_P"^A_\ BJZ2UF>XM8II
M('@=T#-$^-R$CH<<9%344 %%%% !1110 4444 %%%% !1110 4444 4-8 -E
M'G_GZMO_ $<E7ZS]8_X\H_\ KZMO_1R5H4 %<I\,_P#DG.B?]<#_ .A-75UR
M?PS_ .2<Z+_UQ/\ Z$: .LHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH S]9_X\8_^ONV_]')6A5#5_P#CRC_Z^K?_ -')5^@ KD_AG_R3G1/^N)_]
M":NLKE/AG_R3G1/^N)_]":@#JZ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS_\ 6KT@=!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %/4VV6B' /^D0#D>LJ"
MKE4]34O:(!C_ (^(#R?2535R@ KD_AG_ ,DYT7_KB?\ T)JZRN3^&?\ R3G1
M?^N)_P#0VH ZRBBB@ HHHH **** "HKJVAO;66VN8UDAE4HZ-T8'J*EHH H6
MNB:;9:8=-M;.**R(8&%%PI!ZU2C\'>'(M/GL(]&M%M)V#2Q",88CH3]*W**
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M$Q_:VAD^ILY/_BZZZB@#D_LWCW'_ "$M!_\  27_ .+I!:^/@/\ D):!_P"
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M97)_#+_DG&B_]<3_ .AM0!UE%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $%W_ *E?^NL?_H8J>H+K_4K_ -=(_P#T,5/0 5R7PQS_ ,*YT;./]4V,
M?[[5UM<G\,O^2<:+_P!<3_Z&U '64444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (;G_ %2_]=$_]"%35%<?ZH?]=$_]"%2T %<G\,_^2<Z+_P!<3_Z$
MU=97)_#/_DG.B_\ 7$_^AM0!UE%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% $5Q_JQ_OI_Z$*EJ.?_ %8_WU_]"%24 %<G\,O^2<Z+_P!<3_Z$U=97
M)_#/_DG.B_\ 7$_^AM0!UE%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5R?PR_Y)QHO_ %Q/_H;5UE<G\,_^2<Z)_P!<3_Z$U '64444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7)_#/_DG.B_\ 7$_^A-76
M5R?PR_Y)SHO_ %Q/_H;4 =91110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<=\+-__"N-)WDGY&VY&.-YKL:XKX3L6^'&F98G&\#/;YS0!VM%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% " @YQVZTM%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%(1FEH *Y'X8(
MJ?#C1MH S$Q..YWM775R'POS_P *XT;/_/)L<_[;4 =?1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<5\)B3\.-,SVWC_Q\UVM<3\)3GX<:
M;]9/_0S0!VU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'
MPC_Y)QIOUD_]#-=O7#_",8^'&G?[TG_H9H [BBBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *X;X0G/PWT_\ WY?_ $,UW-<+\(/^2;Z?_OR_
M^AF@#NJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA/@_\
M\DWL/^NDO_H9KNZX3X/G_BV]A_UTE_\ 0S0!W=%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Y_\&7+?#NW!Z+/*!_WUG^M>@5YY\%O^2>Q_
M]?,O\Q0!Z'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>?
M!;_DGL?_ %\R_P Q7H=>=?!0Y^'J?]?4O]* /1:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KSOX*X_X5ZF/^?J7^E>B5YU\$SGX?+[7<O]
M* /1:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGX)?\D^
M'_7W+_2O1J\Y^"7_ "3X?]?<O]* /1J*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KSGX)C'P^'_ %]R_P!*]&KSGX)_\D^7_K[E_I0!Z-11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>=?!08^'J?]?4O]
M*]%KSOX*'/P]3_KZE_I0!Z)1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>=?!/_ ))\O_7W+_2O1:\Y^"7_ "3X?]?<O]* /1J*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGX)?\D^'_ %]R_P!*]&KS
MKX*?\D^3_KZE_I0!Z+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>=_!3_DGJ?]?4O]*]$KSSX+?\D]C_Z^9?Z4 >AT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7GGP6&/A[%_P!?,O\ ,5Z'7GGP6_Y)
M['_U\R_TH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M/?@N,?#R+WN9?YBO0JX#X-X_X5W;8Q_KI.WO0!W]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5P?P>(/PZL@%((DESQU^8UWE<-\(?^2<:?
M_OR_^AF@#N:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD) ZG%+
M0 5PWPA&/AOI_P#OR_\ H9KN:X?X1?\ ).-._P!Z3_T,T =Q1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 R4A4!(!^91S]13ZCG_U8_WU_P#0A4E
M!7#?"+_DF^G?[TG_ *&:[FN'^$?_ "3C3O\ >D_]#- '<4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 17'$8_WT_]"%2U%<?ZH?\ 71/_ $(5+0 5
MQ'PD_P"2<:;]9/\ T,UV]<1\)1CX<:;]9/\ T,T =O1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!%<?ZL?[Z?^A"I:BN/]6/]]/\ T(5+0 5Q'PE.
M?AQIOUD_]#-=O7$?"48^'.F_63_T,T =O1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!'/_JQ_OK_Z$*DJ.?\ U8_WU_\ 0A4E !7%?"<8^'.F<@YW
MGC_?-=K7%?"<8^'.F<8^_P#^A&@#M:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** (Y_P#5C_?7_P!"%25'-C8,G'SK_P"A"I* "N-^%B;/ASI7WOF1
MC\W^\:[*N,^%6?\ A7.E9;=\K8YZ?,>* .SHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 9(I=0!_>4_D0:?3),[1C.=R]/J*?0 5R'PO<M\.='RI7
M;&PY[_,>:Z^N2^&((^'.BY.?W)_]":@#K:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** &NVU0<=P/S.*=37V[1NZ9'YYXIU !7*?#/_DG.B_\ 7$_^
MA-75URGPT_Y)SHG_ %P/_H1H ZNBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!&&1^([TM-=0ZX/J#^1S3J "N3^&9_P"+<Z+_ -<3_P"A-765RGPT
M_P"2<Z)_UP/_ *$: .KHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N4^&O/PZT3_K@?_0C75UROPV_Y)WHG_7O_ .S&@#JJ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KEOAO_ ,D[T3_KW_J:ZFN6^&__
M "3O1/\ KW_]F- '4T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7+?#<8^'>B?]>_\ 4UU-<Q\.P!\/M$QG_CV7K^- '3T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7-^ &W> =#SCBT0=<]JZ2N?\#+M
M\"Z(,8_T./\ E0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5@^"?^1(T7_KSC_\ 016]6%X+_P"1*T;_ *\X_P#T$4 ;M%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5B>#@1X-T8''_ !YQ=/\ =%;=
M97AA=OA31QZ6,(_\<% &K1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %9GAT8\,Z2/2SA_\ 0!6G6=X?_P"1;TL?].D7_H H T:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO8*%T^V & (EX_ 58J"S_X
M\H/^N:_RH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !2,JL,, 1[TM% $-S:P7=M);W$*2PR*59'&00:X#1H9_
MOC2/0C,TFAZKO>RWDDP2CDH/8Y_E[UKO:>.+R0L=4TW3U!(5(;<RD^Y+56D\
M,>([[5M*GU;5[.YAL+@7"M'!Y<A/IQQB@!WC;3-0AU#2_$VC6IN+[3V*2PJ,
MM-"W!''7')'UJSX3T2Z6>?Q!JXSJMZ!\A&/(C[(/3MFNK'2EH CEMX9VC:6&
M.1HVW(64':?4>AJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXP3_ &!%_P"!1_\ B:** &'X]W'_ $+\7_@4?_B:=_POFXP/^*?B_P# H_\
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M\8_,;']@X_[?/_L*G'Q9+*#_ &+U<K_Q]>@'^Q[T44 =2OBC<?\ CS_\B_\
MUJ>/$F?^73_R)_\ 6HHH >/$.?\ EU_\B?\ UJO:?J'VYI!Y>S;C^+.?THHH
M O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>sgmo-20210331xex103013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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MV/\ R[Q?]\"C[);_ //"+_O@5-10!";2W/6"(_\  !1]CMB"/L\6#_L"IJ*
M*8TG3@.+"U_[\K_A2'2--8 -86K = 85X_2KM% %'^QM+_Z!MG_WX7_"E_L?
M3/\ H'6G_?A?\*NT4 4/[#TDCG2[+_P'3_"H_P#A'=$_Z ^G_P#@*G^%:=%
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M'H<&EJ./&^7G/S\^WRBI* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/;.>K5WU% #78K&S!2Q R%'4^U<!X/\ #^M:1XRUW5+ZR5(-4D+J5F5O+Y)
M(!YZUZ#10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 10_ZR?_KH/_05J6HHO]9/
M_OC_ -!6I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BA
M_P!9/_OC_P!!6I:BA_UL_P#UT'_H*U+0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>
M*]<E\.:!<:K':"Z6W&Z1/,V?+TR.#WQ6W7*_$DX^'>M_]>__ +,* ,*+XI-%
M9:1J>I:.UOINI,4CFCG$A0@X^88%=A/XHT*UN&MY]5M8YE^\C2 $=^E>;>"?
M!DGBCPGH4^K7V[3;4L]O9Q)C/S'.YOJ*S?%5[+I7Q<U:Z@TU;[R]-YB.  OE
MC)Z=J /89M=TJWL$OY=0MEM'.%F,@V$_6EDUS3(M-749+Z!;-QE9BXVM]/6O
M%5@AB_9\N6CN%G,MV)"H_P"63%U&S\ ,_C5UHWN/&O@&TO?FTPV$3QQMPADV
MGJ.A.0OZ4 >NV&N:9JAD%E>1S-%_K%4\K]0>:I#QGX;)(&M665;:?WHX/H:X
MOQ$LEM\;O#IT_*R36Y%TJ#&Y,MDMZ\?R%>=7-W):Z9XPM(;".6TN=3$;W/7R
M!O8C ]\=: /H^25WM3):E)&*YC);Y6XXY':N&\'_ !!NO$=YJ8O+.WL[73@3
M*ZNS,>3R!CIP:ZKPS#;6WAG38;2X^T6Z6Z+'-_?&.M>5_";_ )"'BY3R#GK]
M6H ]5M/$FD7^F2ZC:7\4UI%GS)4.0N/4=:A'B_06U"WL!J,?VJXVF*(JP+[N
MF.*\?O--U'P-H]OKVCAIM,U2R$=["W(1F7&?S/!_"NB^(NE7%MX9T#Q+8J4O
M=*6+>P7G9@=?H1^IH ]$O?$FDZ=<R6UW=B.:*/S778QVI_>.!TJK:^-O#U\T
M"VNI)+Y\@CB*HV&8]LXK%A9M4\':]X@GB\N74+*7RT/5(5C8*/Q.YO\ @5<O
M\+GEC\-VEQJRPKHUNC/ [#.V;SAR?]KTQ0!Z59^)]'O]6FTJWO4:^ASOA(*L
M,=>HYJM+XUT&)MOVQF;<ZX6!SROWOX>W>N"\1^&;RYU/6/$>AR.FK:?>;MJ?
M\M$V*2![_P ZWO!EV-8\!WFJSVZ1W,K739"@$;LYQZ#C]* -FV\?^'+S9]GO
MFE#DA2D+D$@9(Z5;L/%NB:EIMSJ-M>J;.V.)9G4JJG\:X[X1QQR?#EF=%)CN
M9BI(S@X'(_ UY_'#=S?!R^%N#Y2ZONG"G^#_  SC]* /;8/&>ASO:@7+QK=\
M6[RPNB2_1B #3Y/%VBP^(5T*:[\O4&QMC=" V>F&QBN#^)MQ!+\-M%M[/#3S
MR0?98X_O$!.V/J/SHUCP;)XENK\/*RZW8V=J8Y W_+38<@GW(H [VZ\5Z79+
MJ#7#RH+%TCES&?F=ONJO]XGVIVF^);/4M1:P6&Z@NEC\TQW$)0[<@9_6O+M-
MSXA\,:G;>)KAK2]FU**!9RN/+E1,*6Z=E//O70^#9?$&F^,6T+5[F+48X[+S
M([M1N9$W# +=>?0T >DT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!%#_K9_P#KH/\ T%:E
MJ*+_ %D_^^/_ $$5+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %1RM(NWRT#98!LG&!ZU)10 4444 %%%% !1110 4444
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M.0:TJ* ,FT\,:)8SK-;:="DB<(Q!;9W^7.<?A5R+3;."^FO8K=%N9@!)(.K
M=,U:HH I3:1IUPKK-8V\@=_,<-&#N;&,GWQWI;'2K'3 XLK6.#><ML&-WUJY
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!%#_K)_P#?'_H*U+4<8(>8GN^1_P!\BI*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T4 %%&:,T %%%%
M !1110 4444 %%%% !11D>M% !1110 4444 %%%% !113=Z[PFX;B,X]J '4
M49HH **,T4 %%%% !1110 4444 %%%&10 44@(/0@TM !1110 449%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!%%_K)O]_\ ]E%2TQ#EI!C&&Q]>!3Z "BBB@ HHHH ****
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MR>N?PH VM(^(NEZMK%MI?D75M/=Q>?;&91ME3G&""<'@\'TK.?XLZ8C7T?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <A\38;F\\"7]C9VEQ=7-SL6-((BYX=6.<=!@&N$2
MR\0:E\+].\'VFA7T-VS8N9KN+RHHU#E^IZ]N@KVJB@#S+4=%EL='\/\ @N.W
MU%['*M>WMI 2HP2PY[9?D^@%<]XD\-:MX=^(&G:WH<&K:M(F'NG:,MD=,;@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ '>BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $  )//)S2TU6W%A@_*<?I3J "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKV&U N('G3?;FXA,8F7U7/6JNG_$+0M3U==+MC=&Y:0Q@&W8#(&>3CCOU]*
M.JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP(T.G7U\\]E W5(>BGKW _("L_7Y-7M_BW;MHEE:S7<FD$$W+E4"^9R3CD]
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MM.*Z687?.0H.W:#UP$Z#UKH-;N]9TG6O#]EI!LVLG<13VS F4H."P]%4<YH
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M-BTMW#,1\\FS<#%@<#/Z#O73W&D07VAOI5^S744D/E2L_P!Y^.IQW[USN@>
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MY'L:[? I<8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@_,N3U% 'I-(&!8KGD=J\FM?&OBQ?#NC^([R336L+J[6WDMXHF\PJ792V2<
M\=/I6OX9_M=_B?XE2XU)9H+?R59#%C*LA957GY<$GZT >A,P7&3C)Q2UY]\1
M(]3;5_#$=KJ?V:";440IY>1O&2&)SDC@C%.77/$.M7&NKI%U;P#1I# JO!N-
MU*H^8,<_*N00,>M '?UG:OKECH>GS7U]*R00X#E$+D?@*I>$_$ \5>%K75(T
M$,LR$.O4(X.#]1FO.;,ZI-X?^(<E]J/V@1RS1,&B +%5 # YX&!C% 'KME=Q
M7]C!>0$F&>-9$)&"589''T-3UY=HFO:[H<OA2VU">TFTS4K/;'%%&=\(2-2"
M6/4D$9J*V\:^*=52VU72["XGM)+G#6@M/E\G.,B7/+?I0!ZM16/XHU"]TKPQ
M?WVGVYN+N&+='&!NR?7'? R?PK@_^$PUB3PSJ>K:=KUE?)9VJ2X:V"2))NPR
M,F>!CH: /499%AB>5\[44L< DX'L*S= \0Z?XEL'O=->1H5E:(ET*G<N,\'Z
MU@_V]J:^)_"ML9XC::M:2231^5R'6(-D-GH2>GM7!>'+SQ5H_A/4]9TJ>R.G
M6FH322VLD9+RC<-QW=L#T]Z /78]=LI?$,VAJ9?ML, N&RAV[20/O=,\UIUP
M$?BR^_X2QC)]G_LHZ'_::JJ8?&1@,Q_'VYJCI?BOQ;J%QI5_#I\T]A=L#<Q&
MU")#&QX9)-V6P.N?2@#TVFAU,A3<-P&2,\XKSRSU[Q5XAL3KNA-;O;+?&%=/
M=5&^%3@LSGD-WP/UH\-_VI-\4_$2W.JM*EM'"OEF%0"C*6"C^[@M^/>@#T6B
MN+\<:OKNF7^A0Z1=6T2WUXMLXFBW9)[Y]/IS[USZZUXU-SXBTS^U;$R:/$+@
MW1M1ND!0L$"]!T/- 'JE-=UC7<[!1TR3BO/'\5ZO?Z#X<OEN8M.AOX7:YG1%
ME?>!\JQQG);)'. <"N<O/$.M>(O!^BW,U^T#_P!L+9SB.%1YI5LJY!Z$8'R]
M,T >S&10X0L-Q&0,\XI2JE@Q W#H:\P1M3LOBM=_:M9GN8K/2?M#!HD&Y-P)
M0 # SCJ.:33O$OC34I-)U*TLKB:SNY,W$#6\:Q1Q$X!1]V\D#GF@#U&BO.?#
M-_XQUCQ#?B?5+/[!IVHO;31+  9% ['DCMW[FMOQ/KMU:ZUHFA6,PM[C4Y'W
M7!0-Y:(N3@'C)X'- '5,P52S$  9)/:N;LO&VGW^IVUI!:WS0W3.MO>" F&4
MKG.".W!Y(KGEU;6?MOB;PO?W[/-;61NK6]2-5<QD?=88QGMG'K[5H?"RVGB\
M!:;))>22QR1DI$R*!%\S9P0,G/O0!VU%>;75[XGO/'&NZ1;:\MI;6UHMQ%MM
M59ES@@<_J3^59=OXG\4+H'A[Q)-JL3Q75W'9S68@ 5U)*ERW7<<$\<=* /7:
M*\WFU_5/#_BW6-/U;5I9+>2R-QIF8XP2W/RCCE@> .]=MHT=];:#;+J=PUQ>
MB+=-(0!ECR1P ..GX4 :5%>2VFN>-M>L$UO2(K@AKIBEN6@%N858C:<G?NXZ
M\5:>]\4W_B#Q39P^('M8M-B66)1;1DY*E@N<=.,$]30!ZA17DUKKWB,:=X4U
M^?63*NHW26LUH(56/:203Z[LKG/O3[<^+M:U#Q1';>)I8!IET5@40)\Y )"G
MCA>/\: .[O\ Q+:V'B/3]$FM[@S7P8QR!1LX&3DYS^E:4&GV5M(TEO:01.W5
MHXPI/XBO+K75)?$&N?#[5+M!]IFBN/-.W&64 9'MG)_&ITU/6M=\*ZMXJM]7
MN;2:SGE-O:(0(1'&1PXQEB1GKZT >IT5YA)K]_8Z]X=\07VHW$6AZK:YF@9_
MW4,QCR/P/\Z@UZ;6K/PCI>H0:WJ$$VH:DAVNP;9'(Q*+SR, #C/.30!ZM17F
M$&DZO+XUU3P[_P )3JOV/[&ET7+#S-Q)&%;' SS@?2LRR\3ZSJ/A[POIB323
M7%]-/'-*9S"\JQ$X7S.Q(QGOQ[T >Q4$X&:\?U^T\3:#X1U0W.MRQ[;J%[5(
M;MI)(D=B"KL5!(]/H:U(K6;2?'G]C2ZK?W=A>Z0\UQ]HN6)W@G+*01M_#% '
MH=E?VVHP&:TF66(.R;E.1E20?U%8MIXDN+CQS>>'I+18HX+47"R^9N+@L!TQ
MQUK'^$EE!;^!;2XB9S)<-(T@,A(!#L!@9P. *S-3T&#Q#\6]0M;BYNH(UTJ-
MLVTIC).[C)'89SB@#TZDR-V.]>)O::D_@MM4^U7-W+X>U.2(,TK#[3;(PR&P
M><?RS7H?A*6WUJZOO$T4;JEXPB@+9&8D&,X]2V?R% $WB'Q)+INKZ9H]E%"]
M]J!;89V*QHJCDG')/H!4FC:OJMSK-_IFJ6,$#VT<<B2P2%EE#%AD9''2LWQC
MH6C^*;^UTFYN);75HXFN;2XB.&0 @'Z\X./:N;L]8U;2(/$6@>)[YI#9Z>)8
M]2MAF7RR=H'8ELMQGW^M 'J*7$,A81RHQ7[P5@<?6FB]M24 N(B7)"_./F(Z
M@>M>3:%:+;>.-!A>WM[.VN]*D5[>.7+NNWAI2,#<<YXK M]*L8?AC'K"QE=0
M750L<X8[E'F8P.>/6@#W:XU"SM&1;FZ@@+_<$L@7=],GFB;4+.V@\^>Z@BAZ
M>8\@5?S/%>:Z]+;CQMK]K?0+J+7&GHEI'D,(#C[IR?DR><U%-IUIHEOX0T5H
MK1]4$<L@>>0?902HWNX_C/IR.10!Z8^K:?%:+=/?6RV['"RF50A/H#G%0?\
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MWQA=3:5J"PWK^9;'[.V9,!AP/Q'6@#2L?B19WIL9/[*U&*SNYA MU*@"!R<
M=>>>XJ[J?C6&QFO/L^GW-Y;6+!;NXB(VQ,<<#/+$9&<=*XX6FJ1?#WP[8?V3
M?_:+:_22>-8"2JK(6S^1%:%G-KWAG5=6LXO#UQJ-OJ-P;FVE3 52PZ29Z =Z
M /1H)DN((YH\[)%#+D8X(S4E8]IJ&HC58M.N=.?8+42R7B']WYG *@?G6Q0
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MS7=5@^(?$H\/W6E1/933)J%TEJ)4("QLQP,]_7\C0!;\/:';>'=#M=+M23'
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M$GB)Y=!MI!)#;B,"7 ;<J%_[N>W?VK6\2Z];^"],CNHM*,L,LZQN+?:@0L<
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M$<BFU!$:@87;\W8<5UX(-<QKWB+4H-:71-$M+>XU#[(UVWVARJA0=H QW)H
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MXKMYO*62#57$*.1E#N0#;Z<9Z>]>C67P[\,:?=6]S!IH,UNVZ)I)7?9] 3C
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M%K,GGW@E5E>-#D;%!SD].17I%% ''Z#IVJ6OC37-0N;#RK2^*>4_FHQ&P8Y
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M/ID5XK9:996GPVT'7((@NIKJZ*+@$[MN]OE^G'2NZ\*6^G6_Q4\6(8K:.8-
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M/L[X'&<!]^21].:Z"+6+--,M+N]N8+47$2N/.D"<D XY^M-C\0:1+I"ZHM_
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KO_R$(?\ KE)_-*L57?\
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M;$Y)!4>G!JH/ ?AL64UD--_T:=Q)+%Y\FUV'<_-UKHZJ:C'>RV3KI\\4-U_
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M&QV=S>W-QHUMIEM=0"!M.2X-PKC.2SD\9[#':NHD\0Z+%*L4FKV"NS% K7*
MEAU'7KSTJ2[UK2[%F2[U&T@= &999U4@$X!()]: ,^R\&>'M.L[FTM-*MXH;
ME=LP7.7'H3G./:D_X0KPZ;:WMSI4!AMV9HHSDJA/4@9ZUH7>MZ787$5O=ZC:
M032_<CEF56;Z FDFUS2[?48]/FU"VCO)" D#2@.<]..M %>'POHT&I3:BEA%
M]KF4I)*V6+*1@@Y/3%5[+P1X;TX7 M-)MX?M*E)2N<E3U .<@?3%:)UK2_\
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MO1?'6AZVNHO#>VZ16,C*SO*!N0 ?O/9<G&?:M?3M:TS5PYTZ^M[KR\;_ "9
MVW/3..G2@"G:^$/#UG<_:(-'LTDW;LB(8!]0.@/TJSJ?A_2M9>)]1L(+EXCF
M-I%R5]L^GMTK2HH S+GP[H]ZD*7.F6DR0#$2O""(Q_LCM3/^$8T,SR3G2+(R
MR@AW\A<L#UR<<UK44 >?^(_!;W>K:+'IFC6 TJQF,\\+%464L,$;0#R ,\UU
MZ:%I2Z<]@NG6@LW.7@$*[&/J1CDUHT4 9+>&-"< -H]@0$\L?Z.O"^G3I2GP
MUH>%SHVGD)]T?94X^G%:M% '*^']'UW^U7U+Q)>6MQ-$KQ6D=LF%C1B"Q.1]
MX@*/H/>NBDL;2:[BNY+:%KB$$1RL@+(#UP>HJQ10 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !5=_^0A"/^F4G\TJQ5=_^0C!_URD_FE %BBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#E?B1G_ (5[K&.T2G_Q
M]:Z.QYT^V/\ TR7^0JGXBT=?$'A^]TIIC"+F/9Y@&=O.<X_"N:C\)>+8K>*-
M/'4X" +C[#%P .U '<5QWP] %KKX'_0:N?Y+33X5\5\8\>7/O_H$5:WA7PZ_
MAO3KBWEOWOIKBY>YDG= A+, #P/I0!NT444 %%%% !2$@#).!2U'/!%<P/!,
MBR12*5=&'# ]0: /+K3PQ+K'@71]8T:40Z[IWF-;2J?]8!(^8FQU!Y'X^]8E
MSKE_>_#?7M1%O);22ZPHO85SE$P@<'N!D8^E>R:=I.GZ1 T&G6<-K$S;V2)
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M 4444 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 55D!.IV__ %QD_P#0DJU5.5\:O;)CK!*<_1H_\: +E%%% !1110 4444
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M_IX94NE&\RACEM_KDY/XUW=% '#:IX!O-3T6&R?7Y&G-TMY<7,L 9I9% "X
M("J,=.:MS^#[N#79M:TC5$M+Z[B6*]#V_F1RD8&]5W#:PQZD5UU% '.0^#=/
MA\'3^'%9V@GC<22MRS.W)<^^>?PJ@WPZTPV'AVV$A!T:42A]O^N/5\\_Q, ?
MTKLJ* ,FYTN]F\066H1:M-#:01NDMD%!28GHQ/8C\>G;FM:BB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J,V/[<M/7[--_Z
M%%5ZJ$W_ "'K/U^RS_\ H45 %^BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *SYO^1ALO^O6?_T.&M"L^;'_  D%GZ_99_\ T.&@#0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBD)"C)( ]Z %HIGFQ_\]%_.CS8_P"^OYT /HIGFQ_\]$_.CSHO
M^>B?]]"@!]%,\Z+_ )Z)_P!]"D\^(?\ +5/^^A0!)14?GQ?\]4_[Z%'GP_\
M/5/^^A0!)14?GP_\]4_[Z%'GPC_EJG_?0H DHJ/[1#_SUC_[Z%-:ZMTY:>(?
M5P* )J*A%W;D9%Q$1C/WQ2+>VK+N6YA*YQD.* )Z*KF_LPNXW<&/7S!3?[2L
M/^?VV_[^K_C0!:HJNM_9N<)=P-]) :0ZC8KC-Y;C(R,RKS^M %FBJIU.P!(-
M[; @X(\U?\:0ZIIXZW]J/^VR_P"- %NBJG]J:?\ \_UM_P!_5_QI?[3L/^?Z
MV_[^K_C0!:HJI_:FG_\ /_:_]_E_QH_M33_^?^U_[_+_ (T 6Z*J?VKIW_/_
M &O_ '^7_&D_M73O^?\ M?\ O\O^- %RBJ?]JZ=_S_VO_?Y?\:/[6TX]+^U_
M[_+_ (T 7**I_P!JZ=_S_P!K_P!_E_QI?[5T[_G_ +7_ +_+_C0!;HJI_:NG
M8S]OM?\ O\O^-)_:VF_]!"T_[_+_ (T 7**I_P!KZ;_T$;3_ +_+_C2?VQIG
M_01M/^_Z_P"- %VBJ7]KZ9_T$;3_ +_K_C1_;&F'_F(VG_?]?\: +M%4O[8T
MS_H(V?\ W_7_ !H.LZ6!DZE9@?\ 7=?\: +M%9S:_HR8W:M8+GIFY09_6D?Q
M#HL;;7UBP5O0W* _SH TJ*RSXET$==;TW_P*3_&D_P"$FT#)']MZ;D=1]J3C
M]: -6BLK_A*/#^<?V[IF?^ON/_&D_P"$I\/?]![2_P#P,C_QH UJ*R/^$J\.
M_P#0>TO_ ,#(_P#&C_A*_#HZZ_I?_@9'_C0!KT5C_P#"6>'!_P S!I7_ (&1
M_P"-,'C'PR?^9@TS[N[_ (^DZ?G^E &W16"WC;PNBACX@TW!QTN%/7\:9_PG
M?A0_\Q^P_P"_PH Z&BN>/COPJ/\ F/V'_?T4A\>>%!UU^Q_[^B@#HJ*YMOB!
MX35<_P!O61^CYI&^(/A,8_XGUG_WWF@#I:*Y=_B+X20\ZY;G_=#'^0I@^)7A
M$KN&LQD>T,G_ ,30!U=%<L/B+X5/35,_2WE_^)IC?$CPNK;1?RMQU6TF/_LM
M '645R?_  LCPUQ_I5P<^EG-_P#$T'XC>'@H)DO<'D'[!-S_ ..T =917)K\
M1?#[?=:_;G'&GS'GT^[3QX_T5AE8]38>HTV?_P")H ZFBN3D^(6E(P"V.LR>
MZZ=+C]0*9_PL33\?\@G73_W#GH Z^BN1'Q!LF8*NBZ^Q/0#3VIX\=PM]WP]X
MB89QD:<W^- '5T5RG_"<ID@>&_$G'_4./^-(?'#X!7PMXB8^ALP/_9J .LHK
ME4\97,I(3PIKW']Z!%_FU*GB^^D!*^$==X.#E(A_-Z .IHKF/^$KU'&1X0UO
M_P @_P#QRD/BK5,\>#]9(QZP_P#QR@#J**Y/_A*]:./^*+U7..?WL/\ \52G
MQ3KI("^"M2.?6XA'_LU '5T5RI\2Z^'V_P#"&7^3_P!/4./SW4[_ (2'Q%_T
M)EW_ .!L'_Q5 '445RY\0^(_^A,NO_ Z#_XJHCXB\69X\$2$>IU*(4 =;17)
MGQ#XL[>"7_\ !G%_A2KK_BMFP?!A4>IU./\ PH ZNBN8.M^*N<>$4X_ZB:<_
M^.THUCQ4?^93A'_<43_XB@#IJ*YG^V/%F?\ D4X/_!JO_P 11_:_BS_H5+;_
M ,&H_P#C= '345R[:MXP(^3PM9J?5M4!_P#:=-;5?&FP!?#5AN[G^T>/RV4
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M8%ED>J<?E72T4 <VG@#PFC;AH%EGWCS_ #H?P!X3D*EM LOE&!MCQ_*NDHH
MYO\ X5_X2QC^P++_ +XITO@+PG* &\/Z>,?W80O\NM=%10!S7_"O?"/_ $ +
M+_OBE'@#PD%*_P!@6.#_ -,ZZ2B@#FO^%?>$L?\ ( LO^^*F7P1X510H\/:;
M@>MLI/ZBM^B@#"_X0KPM_P!"]I?_ ("I_A2?\(3X6_Z%W2__  %3_"MZB@#"
M_P"$*\+_ /0O:7_X"I_A1_PA7A?_ *%[2_\ P%3_  K=HH PO^$+\+_]"]I?
M_@*G^%'_  A?A?\ Z%[2_P#P%3_"MVB@##_X0OPO_P!"]I?_ ("I_A2?\(7X
M7_Z%[2__  %3_"MVB@##_P"$+\+_ /0O:7_X"I_A1_PA?A?_ *%[2_\ P%3_
M  K<HH PQX,\,#IX?TSU_P"/5/\ "E_X0[PS_P!"_IG_ ("I_A6W10!B_P#"
M'^&L8_L#3/\ P%3_  I1X2\. 8_L'3<?]>J?X5LT4 9+>%_#[+AM$TX@<8^R
MI_A0GA?0(\[-$TX9]+5/\*UJ* ,P^'-#.,Z-I_'_ $[)_A2_\([HG_0'T_\
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M *]+C_T.&@#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M10 4444 %%%% !1110 4444 %9L__(S6/_7G<?\ H<-:59L__(RV/_7I<?\
MH<- &E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9L__(S6
M/_7G<?\ H<-:59D__(SV'_7G<_\ H<% &G1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %9D__(T6'_7E<_\ H<%:=9D__(T6'_7E<_\ H<%
M&G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %07EW#8VDMU<.$@A0N[D$[5')/%3T$9ZT <K_P +(\)'
MIJZGZ02G_P!EI#\2?"2C)U8 ?]>\O_Q-=4%5>@ H*ANH!^M '*/\2?"B*6&I
M,WLMK*2?_':=_P +'\*?]!1O_ :;_P"(KJL44 <K_P +&\*_]!-O_ 6;_P"(
MIO\ PLGPMN(_M"7CO]DFY_\ '*ZRB@#C_P#A9WA8?\O=S_X!3?\ Q-*/B;X7
MQG[7<X_Z\IO_ (FNOQ1B@#D/^%F>&,9^TW7/_3E-_P#$T?\ "S/#/_/Q=_\
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MIRW7CIER=+T)3Z&[E_\ B*ZJB@#EC<^.NVG:#_X%R_\ Q%'VCQU_T#] _P#
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M **** "BBB@ HJMJ&H6FEV4M[?3I!;1#+RN<!1G'\R*P3\1/" _YF"Q_[[H
MZ>BN7/Q&\'@X_P"$@LO^^C_A6WI>KZ?K=F+O3;J.YMRQ421G(R.HH NT444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;/_R,
MMC_UYW'_ *'#6E6;/_R,UC_UYW'_ *'#0!I4444 %%%% !1110 4444 %%%%
M !1110 4444 <C\3@&^'>K C((B_]&I6S#X=T541ETBP!QU%LG^%8_Q.X^'>
MK?[L?_HU*ZJ+_5)_NB@"@WA_1F4*VDV) .0#;IQ^E<]\-E5-(U9$4(JZO<@*
MHP -PKLZXWX<_P#(+U<^NL77_H0H [*BBB@ KAO&_CIO#&KZ7:QQ,\+2+)?.
M%SY<).T?0D\_A797MY;Z?9RW=U,D,$2[GD<X %>8)H5_XS\/:SJJZM8P6NLL
M7*R6^]DCC.(QOWC;PH)XXR: /49;B&&W:>65$A1=S2,P"@>N:\_@\8?VC\4-
M.L=,UN.[TN>VD9[>-!A'5>[=3G&:Y0^)I-8^%%K#(RW$NF7D46HP1MN9[=#U
MP.JD <]*O:SKNC:C\1M%N=%O;=Y#ID\43Q=!(R,(U/OD]/<4 ;WQ#\916-@;
M?1M?AAU.*=%D@C579P6 *Y/0C.?6MB348[7Q?=2W/B2%;6WL=TFF@#,9!YD8
MCG\/>O+[G7M#?X26^ER/%'K%M=(9K>12)/,$OS,>.X)Y_"NNM-1T^?XSSO!<
M0,+C1PJ%&'S.6!Q]<"@"[)XXTWQ-X9N)K#7XM%F2?:LT@W,%#\<''W@.E=;?
M:]IFC0PG4;^&(R+E-QY? Y( YQ7C,>J:8/@GJ&F274(U"*Y.8&.'!,P/0]\9
MKJ-/U6VTSXB"\U6XC73KS28H[&[D8>4-H!= W0$G)H [JX\4Z'::=;7\^J6J
M6MR<0RE^)/I_GBDTOQ7H6LM<KI^J6\YMANFVMC8/7GM[]*\8U6&"W\)WSNR)
MIEWXC$MA')P'@!.YE!_AY%;FNZQHMGX]U>2!;6ZMG\/&/[/ X"S-NSLRO?'I
MSB@#TBP\5Z)K-TUCI^IQ27)0LJJ#DCIN7(PWX9K(^'&I7^IZ9JC:C>274T&I
M30K(X .U<8&  !7GFE:]80^,/".H2:N)H$MI(I!'"4AMB4P(EXR<9Y))/>NS
M^%%Y;SV&N)%/&['59Y JL"=AQAOH?6@#J=6\6:)H=R+?4=0C@E*;]I5F(7U.
M <#@\FN/NO%46B?$J8ZGKTHTB331<0QN/D#,W&T*,G@<<$\FJ'CJ6QM_$>J7
M6GZVEAJ\5HJW5G>*#!?Q[<A ">N./Q_&F:7K&GR_$NVN[\6UIMT%%>.0@"%^
MI3GH0O;KB@#T5_$^C)H\.K&_B^Q38\J5<G>?0 <D^V,TRU\5Z)>Z7/J4&HQ-
M:6YVS.<KL/H00"#[8KQ+3Y8X= \/ZG-)=OIFGWURMX+-V22#S#\C?+R!S^/2
MMG5K'2KKP]/JOARPU2>PCU""XO)VD??=!=^XIN.[Y<CGW]J /0KGXB:!%H]_
MJ$-R\QLQ\\(A=9,G.W*D9 ..IXI^G^.=*GT#3M1NYC%)>)D1)!(S;@N6 4*2
M0/7&/>N'=-"UC2/$&H>&[75+JZETV1)[NXDE))(&(\-G<< _3%0OJ6B:GHWA
MD1ZM=Z/J5I9[;?4?*98E8*H>-LX!!_+C'M0!ZUI>JV6M:='?Z?.)K:3(5PI7
M."0>" >H-9,OCGP_#J0L7O2)#-]G\SRG,7FYQLWXV[OQJ'X?W=W?>$()KRVC
M@E,DF#%'L64;B?,"]MV2:\CUK5A=:?<%X[NSN+?6Q-+IL,#>3"N[EW;'S,3C
MG/T% 'I__"R-.77-6L7@NO*T^)6W+:RL[O\ -N& O P!@G&<U)HGQ"TV\\+V
M^KZ@SVK32^4(O)D)9R3M5./G. /NY_"N>TV_4?$'Q.&MKQ6U.RB>U4V[Y=1&
M>3QQZ<]^.M<W8Z^8/!/ANP>SN;?[%=LEUJ!M&8V9W-C9D8WD'&><>F: /6;;
MQCH5SI%UJ8OA';VC;+CS49'B;^Z5(SGVQS6!K_BNQUKPIKJZ9?7MGJ%A;-,R
M!6@F7 R#@C.T^U>;S)>O_;?V#3]4NI(-6@U';=0MODA0-RV1R23G&.E=IJWB
M/3_$/AS7[S3=&NHVFT\PS7,MJ5>20\)$,9W8YSV'% &UX-\<:1J-KI>D&^DE
MU(VBL3(C8D8+\V&(PQ'.?QK3E\=Z!#?QVKW;@/+Y"W'DOY)DSC9YF-N?QQ7G
MTLJO-\/U@CF0P0/',1 W[DLFT;N./FJCX>L]/M+$>'M8\)W]WKEO<%8]WF""
M0EB0Y8':  <YQTH [GQYXHL[?0]6LK>YOUO;>'+RV*-_H[D$H'<?=!/XX]*Z
M+PG+)-X0T>65VDD>SB9G8Y+':.2:\PDU6;1++QGX?U+3+Q[V_EN);62"V:19
M@Z\?-CH./I79^$_$,4.B^&]+:PU%99[7R][6S*D;1J =Q/3..* .THH'2B@
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M,:)&D60K\ZYP<^M #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$[/0O^$PDU'3->DU*\N;/,RP)$D00$8+A  &]!UZUV,>AZ5$]T\>G6BM=_\
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M)P.NUB%_F17F\VE:S\,[ZPFL-0.I>';FZCA-G<?,\98\%??J01^(H ]?+J"
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M=7-Q'$S1MS<1LN6W\_-WR>U8:^'M+N-$\?WLT)::QNY1;,9&_=$<@CGKGN:
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M/F"QVRHZO%(#\SL>F/XCD]NE;?PVO;*'4?$VDJP2Z36+F41!3Q'E0#Z <<4
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MM;M-&A3>R;X+M0O,+#!^8$$8QWZ&O3--BOK_ .&\<'V46-[-IQC6$#;Y3%"
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M._CIG/3M0!OXK%\1Z!+K]K!##JU]IIBEWF2SDV,XQ@J?SKF=%\<ZA+K?B/\
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M:+[.?E$>23GI@Y&*TE.N>'?&&N7,.A7FHV6NHDL+P@!HG"8VOD_+U/7TKT[
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MY4'KC\<&O2O"2-*;B]7PW!HD$@58XC$J3/C.2^WH.F!73X%+0 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** &JX8L!_"<'\L_P!:=447^LG_
M -__ -E%2T %9TW_ ",5E_UZ7'_H<-:-9TW_ ",5D/\ ITN/_0X: -&BBB@
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M&ZO46[6^:&XL4C1H5C^7: X'7EOXB>!0![W4%Q>6UHT*W$R1F:011ACC>YZ
M>_!KRKQ#XC\7+\5&\-:/JL4<=Q$#$)X4*QY0L>0N>U8>N6WBD?$3PKI6K^(#
M)>M&LJRPQ+LA<LXR%P QPHY(H ]XJEJFJV6C6$E[J%PL$"8RQR<D]  .23Z"
MO*9O&'B#PQXVOM$U[6))K7[)(UE*+>-3(Y7*'A>N01CUI=6?4YO''@70=;NF
MNW"B]N"RA0TN6(& !PNW% 'H,/C+2Y?$=MH+"YCO[BW%PJ21$  C.T^C8!XK
MH:\GU;Q/?Z1\8GM))TDL([-YV7R$WA1$6VA\;L97/7O69X;\9>-M=GLM4M4N
MKJWDU Q7-NEN@@CA^7H_7<,GD^U 'M,K^7$\FUFVJ3M49)QV'O5'2-9LM;L_
MM-E*64,4=&4J\;C@JRGD$>E>5>'?'FMW?CN+2=6OI;28W\B26DL2"-H]K;54
MXW!LX[_-D?CMZ-.^F_'#6],A8BUOK1;IX^PE 7YA]<G\Z /2J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :[;5)P3@
M=A7*1_$CPY-=S6D<UV]S!GS8ELI2R8ZY&WC%=;7@0U]O"_Q:\4:F+"2[2,/O
M2)@"H)3YC[9Q^= 'M.B>(M)\16K7&E7L=RBG:X7(93Z$'D5ILVU2>>/09KQG
MX8;-/TCQ%XVFFC9'$I-I$>4VDO@^A]/8U)X;\?\ BC5+[3+MHY+NTO+IH;FW
MBLB$MDR K+(!R>3G)[4 >D:#XLT?Q++=1:9<M+):D"9&B9"A.?[P'H:VZ\(\
M%:CJ>E3^.[O2[,W=]'(I2(G_ *:2 D^N.3COBMCPG\0=:U3QG8:/+?PW<%Y:
MEG8VX0P2B,L5&W[P!7'XT >LO=V\?FAID#0IYDB[N57GDCTX/Y52T+7]-\1V
M'VW2[D3P!RA;:5(8=00>?2O)O!4_B&[\0^,;QM8C,ML2MP)+8.)BOF!=O(V@
M8Z>AIFF_$>[TKX<QW5K96,=_<7\D$:PP".- %4EBHZGD4 >WT5YI;>,]8MO$
M.M^&KZXAFN[6T:YM;Q80N2(P^UDS@]>WI7)K\3_&">';77I9;!K8WIMGA$&&
M?Y=W7MQQQ0![O6.?%.CKXC&@/=[=3896!HV&X8W<'&.F>_:N!\8_$+5='\4R
M:=#-%90"U$ML\L'F+,Y&?F.1M'49'?K6;XG_ +4G^,FB-I<ENFHO8*4>8909
M63<2!UXS0!Z[J>I6ND:=/?WTHBMH%W2.03@?A3M.U"VU73X+ZSE$MM.@>-P"
M,@_6O)[;QKJ^N?"O6[Z[6SENK"81OYD >.9"5X*=._Z4V]\;Z[I/AWP@^D?V
M>HU&+RS;^1A%=6 XP1@?-T[8H ]CHKS[PMXMUH^.+_PGX@^SRW,2>;#<6Z;5
M(P&P1]&%>@T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP#>>%Y=51Q)="ZAG$&-K8 ((R>..WK7;^&]+N-&T"TT^ZO3>2P($,I0*,#@
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MV\,6J#=<,%0M$ZKDG !)&!^-<+HNI6D_Q!BN(;K4+U;W1W@2>>W*JTF02$
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M2&XL&59PT9 !8$C!/7I6G0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $<?^LF_W_\ V45)447^LF_W_P#V45+0 5EW'_(T
M6'_7E<_^AP5J5A7YQXUT5?6SN_\ T*"@#=HHHH **** "BBB@ HHHH ****
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M]>=Y_P"A05O5@W__ ".^B?\ 7G>?S@H WJ*** "BBB@ HHHH **** "BBB@
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M$,_A1K?P[<:?:Q:F;LVL=NSM'%\HW28R Q()V]ABO8:* $4Y&:6BB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &J@4L1_$<G\
ML?TIU(""6QU!YI: "L&_/_%;Z(/^G.\_G!6]7/ZC_P CSH7_ %YWG\X* .@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*U+0 5S&KN5^('AI0?OVUZ.G7B(_TKIZY;6A_P 7#\+'T@OO_08J .IHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **.E)D4 +1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0P_ZVX_ZZ#_ -!6
MIJBA_P!;<?\ 70?^@K4M !7+ZS_R4'POP/\ CWO?Y15U%<MK7_)0O"W_ %PO
MO_08J .IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!#!_K;G_KH/\ T%:FJ&'_ %MQ_P!=!_Z"M34 %<IK8_XN
M+X3_ .N-]_Z#'75URFM_\E%\*?\ 7"^_]!CH ZNBBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@""#_777_74?\ H"U/5>W_ -?=_P#74?\ H"U8
MH *Y;6L_\+#\+?\ 7"^_]!BKJ:YC6,_\+!\,>GD7O\HJ .GHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH JVI!N+T \B8 _P#?M*M51L?^/S4_^OD?
M^BHZO4 %<KK1/_"P_"H'0P7V?^^8JZJN7UD?\7"\+?\ 7"^_]!BH ZBBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"C8#%YJGO=+_Z)CJ]5&P/^F:G
M_P!?(_\ 14=7J "N6UK_ )*'X6_ZX7W_ *#%74URVLG'Q"\+?]<+[_T&*@#J
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *-@/],U3WNA_P"B8ZO5
MG::VZ^U<?W;M1_Y B/\ 6M&@ KE=:&?B'X5/I!??^@Q5U5<QK )^(/A@CH+>
M]S^45 '3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9FE,K7^LE3G
M%Z ?KY$5:=8VA$&^U[';4<'_ +\Q5LT %<QK'_)0/#(_Z87O\HJZ>N7UC_DH
M/AC_ *][W^45 '44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8?A\
MYO\ Q!_V$O\ VA#6Y6'X>_X__$/_ &$S_P"B(:W* "N=U,@>._#^<<VEZ/UA
MKHJYS5!GQYX>]K6]_P#:- '1T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 87A[_C_ /$/_83/_HB&MVL'PZ<W_B+_ +"A_P#1$-;U !7,:P"?B!X9
M(!P+>])_**NGKFM6?;X^\.#&=UM>CZ?ZD_TH Z6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#"\/$&^\0X'34R#_WXAK=K!\.?\?WB+_L*'_T1#6]
M0 5S&L$CX@^& .]O>Y_**NGKE]8_Y*#X8_Z][W^45 '44444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 8/AS_C_ /$?_84/_HB&MZL'PX<W_B+VU0_^
MB(:WJ "N7UC_ )*#X8_Z][W^45=17.ZFRCQWX?!(R;2] _.&@#HJ*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** ,705*W^OY!&=1R,_\ 7"&MJLW3,?;]8_Z_%_\ 1$5:5 !6;/\
M\C+8_P#7G<?^APUI5G3C_BH[(_\ 3I<?^APT :-%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% &=IHQ?ZQ[W:_^B(JT:S]._P"/[5_^OM?_ $1%6A0
M50F_Y#UH?^G:?_T**K]59$SJEN_]V&4?FR?X4 6J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHIGFIOV;AN],\_P">#0 ^BBB@"K:($N;YAU><,?\ OV@_I5JH
M+<?OKK_KJ/\ T!:GH *B=3]JC<#@(P)^I7_"I::4!D#GJ 0/QQ_A0 ZBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ JCJND6>M69M+Z-GA+!MJN5Y'N#5ZB@
M#EQ\._"VT!]+$AZ%GF<D_P#CU;>EZ38Z+8K9:=;K;VRDD1J20"3D]:NT4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !5._O_L7E_N]^_/\ %C&,?XT44 4O[>_Z=O\ Q_\ ^M2#7L_\NW_D3_ZU
M%% !_;W&?LW_ )$_^M2C7<_\NW_C_P#]:BB@"=]4*1JWE9R<?>]R/3VJ_NPR
MCU-%% #Z*** "BBB@ HHHH **** &NVU2?2G444 (>E4[>^,XB/E[=^[^+.,
M444 3P3^;)*NW&PXZ]:FHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
; "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>sgmo-20210331xex103014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 sgmo-20210331xex103014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I 2<Y&.>/>EHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I .O.>?RI:CB!#R\<
M%^/^^10!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNUO<PI+"PPR.,@U,.!BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBC- !11FFAU8D @XZ^U #J*:74,%) )Z#UIU !12$A1DG
M I0<C- !1110 4444 %%%% !1129YQ0 M%&>:* "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHH)Q0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 44C,%&2< 4 YH 6BD) QGO2T %%%'2@
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MBJ5GK&GZA=W-K:7<4T]L<3(AR4/O5V@ HH)Q10 4444 %%%% !1110 4444
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MXD3=K.K(MPR#NJE=J#_@*]/4T ==8>-=%U'48+**6=);E"]L9[=XUN%'4H6
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MZMX)HKS_ (]E@1I'F]=JJ">._''>O,[]AH'B^:]\7PZAY&I6,""XLI'4>8J
M.C",C/.:FEE'A+4?#GB"/1+FUT".WF@:(9D>#S')#$$Y!(P?TH ZG5_B;I-M
MHMG?Z9YEY]JNEMP%B?\ =G(W!AC(8#HO4U:34M+O/'UIY6M7@O/L1QINQUC*
MGYM[ CAL'OSP*Y/Q)=VESX/@U;3M(EL].76X;HL(2K2H"=TI4= 3TJQ>:A#J
M?Q9TR>U,T8FTAXE9X64J[;BH((X."#0!UTWCSP_;W0A>[?R_.^SFY$+^0LG]
MTR8VY_&FZEX_\.Z5J<NFW-W(;R) [11PNY.>PP.3SFO/+>XQ\++OP9=6L@U^
M.1K=+0QG<[-)N#@]".<Y]JUM+FBTKXG0PWLC2/;Z(EJ\HB+#S5P2,X] : /1
M='UFQU[2XM1TZ;S;:7.UL$'(.""#T-<=XJ\/ZW/8ZIK3^)+JSFM5>:TAMGVP
MHB#(##J6..?K2_"693X7NHO+>-UOIGV-&5PK'(QD52\6^+K2XUIM$O['5!I4
M;?OS!:LWVM@0=@/]T=R.O2@"KXA\3:HOA+PE?ZC)<6ME>.AU.:V)5\8XY'(!
MZG%7?#3:UKNF^(H-/U.X72Y;@1Z9>S%F<1YQ(4)Y( '!/?O4/BN^?6].\/7,
M^FW</AJ2Y;[;"T1#J@X0LJ\A>"?RJW\-+"ZTZ?6[>W-S_P (\MP/[.%PA4\@
MEBH8 [>1_G- &:OAS4-*\?Z+86GB35;S]V]Y<I<S$H$7A00/5N*?XLT/6M#T
MK_A(XO$=])JR3QL;<2'R)"S >6J>G-=#X42>\UO7_$5U%(JSS?9K564AA!%D
M9 /9FR?PKG+KQG%J&O&[O] U][6Q;=96Z6+%7?\ YZ,3CGT';K0!ZBDA%NCR
M@(VT%O0''-<ROQ T9I('*7B6-Q-Y$.H/#BW=^F-V<@9XR1BM;48+C5O#%Q %
M:VN;JT90I;F-V3H2/0G%>9"VOM1^&,'@PZ7>1:Q%*D#!X&$:JLF[S?,QMVX]
M^: -/Q)J3:I\2;/0+S3K^;35M)&:*,8\QF./,X8?*.F3[UN:Y>M\/? 3-:)=
MWYMD*1R2MO*$GY2Y_N@D#\A63([0?%O3Y!;WKVT&F_8GN!:N5,F[(&['TYZ5
MT'Q$L;G4? .K6MG"TT[Q*5C3DMAU)Q^ - '):[K;IXI\&:O/'?P&5)1+;E6)
M<[!C;&">I8^_/-=A:>.M'NM)O+]_M%L+.7R9H+B+;*LG9=O<GL*Y.?4)M4\6
M>#;O^Q]62&U67SVFLV!4L@56X[9__563?Z+J>LQ^*OLNEW+,VK17T,5S;O&M
MS&@(*@L .<].M 'HVD>,++5=8FTA[:ZLM0B02>1<H 60]P02/PK&\>ZO>?VM
MHGABPN'M9-6E(FN$X9(EZA3V)YI?!S6][?\ VNU\'_V,L<966:>$1R%SCY4Q
MR1UR3[4>/= O[G4-'\1:3";F]TJ7<UN#S+&>H'O_ (T 3:MX"M7TQ%TB2:TO
M(F1A()W_ 'N""0_/.<5-JWCZTTNYOT33[NZ@T[:+RXBVA82W0<D$GD=*EMO%
M5SJD4<6GZ'J,=RX!+7D!BBBYYRQZX]!UKA/%5EK^J3^([2ZT*_NY7Q]A>'Y;
M=47^+K\SX^I[4 ;VI&*3XP>&[J$L5N+"5R<G!&#@X[<&IM*U?3X[/Q=?:'IM
MY'>PSNUS',P!:7!.X G  Y.*S;9=4G\9^%;^70M1A@M+ V\S/&#M8C )P>/Q
MZ4_0X-2A7QP\FC:@K:C/)):JT0!<,&4=3[T 9_A273+3POHWB/4]-N/[4\QE
MMYHY 7OI9&8$8!_]"QBNSM_&T7VR\T^^TRZM=3MX/M"VFY7,R=RC X-<G!X>
MUQ? 7AP0V$J:EH5R)WM9< S#))"D$CH>]:DUAJ&N>)F\2-I5U:P6FFR6\$$H
M4332.#GY<\ 9(Y(H 9%\5A-IDNIQ>&=4;3XXC)]H.T+D-C&>G?\ ^M6EIOCT
MWVKZ?97.B7=C%J,3/:33LO[W SC:.1^-8,.E:S_PI>70'TBZ&I;#"(ODYR^[
M.=V,8_6K%W:ZO-K/@^Z30KWR=+A(N"3'D$H%P!N]J +>E>(M'TK3?$>IVFB7
M-J;:\*W,8(9YI3@9X) Y/KWK:TGQ6U]XCFT*\L#:7L=NMR )A(K*?< 8/-<;
M%I7BI-,\5&QL+BUN;^_%Q"&= SQ$_,H()PV*L^'=$UFR\=P:I'X=2PL);(0.
MIN%9DP<EF(Y+''O[F@#0^+]O%+X%FD>-6=)XMC$<KE@#@^]=IIUO#::;;PP1
M)%&L:X1%  XKE_B/IVI:UX<&EZ78M<S32H[-YBJJ!2#SDCDU9DOO$DZV=I:Z
M,]F#(@FN9IXF$<8(W84$Y) Q^- &?JWC^733>71TS&GVMT+5GFFV22MD E$Q
MR!GUK&O[F^TSXM7\NCZ/]ON9-,0M&LBQ@?-DLQ/T_&J>L^%/%6IVNL6\NEVU
MQ<S7/F1W\MR-[1!LK&@_AX^E=&EEXBL?%SZ]_9,=S]IT]()(8;A1Y3@YZMC(
M^E !:?$6.]TZU6'3V_MFXN6M!8/)@HZ\L6..% [XJ?\ X32\MKC5-/O]+":G
M96YNDBBFRDT8ZD,0.GTK#/@#4[,66N0&&77(;Y[R:'?A&#]8U)]!W/O6G=>'
M]5U+4=6UV:R2*ZET]K&TM#,,X;JSL./H* -'PAXGU7Q+&EW<:)]BL)80\4_G
MA][9P1CJ!6+JW_%1?%JUT.]P^FZ=:&[-NQ^660D $COC(X]C74>#=.O-(\*V
M6G7\21SVR;#L?<&YSG/XUF^(O#5^_B*T\2Z')"-1@3RI89N$GC]"1T//6@#6
MU#PY87EY87WE1PW%C*)4D5 #@9RI]N:P7\:ZA<:9>ZWING0S:/9R,A9Y"LLR
MKPS*,8 !SUZXK6MG\0:G-$+VSATNU7F55F$TDO\ L],*/?K7/6OAC7M*T75?
M#=FEO+87C2?9[N27'DH_W@RXY/)QB@#5;Q;)J]];6'AZ*"XEFM!>227+%4BC
M/"@@<EB?RKE/#/B(^&/"6H2SP1_;)]:EMTB!(17(&2<<[0 >@S6T/".J^'-5
MMK_PR;68?8DLYX;MF4,$Z."/Y50B\#>(O[%N?,O+2/4X]3.I6KQ$E2Y'*MD<
M#TH Z'PIXKO-;U2^LKJT 2 !HKN&*18I1T.-PZU5\47VNP^-_#UG83VR6UPT
MIV2;OF94.=V.P!X'K6MX=C\2M(\_B&6T0[-D=O: E?=F8]_8<55\5:+JU]K.
MB:II#6OG:?))N2X)"L' !Z?C0!RXO];T[QAXPFT>QM95B\J29YW(  C)P%')
M8\_E70/XNO[C3M(O;6WM;:VO+<S3W=ZY$4)'&P8(RQ/2HK+P_P"((+[Q)<RG
M3R=5C 15D?"L%VC/R],$UG6?@SQ+8OHLT=QIDLFG0- L<^]D7)_UBC'WN: *
MNM>*=7USP-I]_8O#:M/J*VLP7=\Q#X!4]0IQSWKTZW\[[.GV@H9L#?Y>=N>^
M,]J\\@\#Z]#X6DTPWUB\\>HB]MW*L%8ABQ#>F2>@KT"Q%TME$+YHFNMH\TQ
MA=WMGG% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK&\57]]IGAG4+W3HXGN((6D
M'FDA0 ,D\=2/2@"_<ZE96=Q#!<74,4T[!8HWD :0^@'4U:KQ+4;O4[KP[X%U
M:]LH[S43>H(F27]Y.N"0"Q VDGZUVEK\0)+:/78]>TW[%=:1&LKQPR^8'1_N
MX/KG _&@#N:1F"J68@ <DGM7 Z'\1SJ'B6VT>[M+93=QEX)K2X\U5."=C\#!
MP#TJU\5+K4+;P#J+62)M9 LTAD*LB$@'&!SG..W!H Z;3M:TS5FE73[^VNC$
M<2"&4/M^N*OUYS97,.E7^F"+P_9?\)/?6VU%AGPOD*H.]VV\=,=">*N2_$-[
M;2M9>?26&IZ0P^TV:S@C8>CJV.5_#- '=45Y['\3)X]-CN]1T&6P%T8ULC-.
MH28L,DEOX0.I/H14NG_%"PGMM9>[MO+DTI/,D^SRB9)%)P-C8&>2!^- '>T5
MQ4?CB_36M+TR]T$Q2:G'YL#1W*L%7JV[(&"!S@9IMS\076QGU>TT6:ZT2VF:
M*:[64!B%."ZIU*@Y].E '8M=6Z726S3QK.X++$7 9@.I ZD5-7$7&JZ/=>/=
M$D&DRSWMQ8O+97X<!#'M+$ 9Y//?INJDOQ2<V-_>?\(S?_9M/G,5U)YB8CP0
M/7D\]!0!Z)17-W?BU5U2VTW3;&2_N9[3[;A7$86+. <GN3VJ;PGXHA\6:8U_
M;V=Q;1*YC_?;>6'7&">GO0!O45@>+[^6ST)X+0_Z?>L+6U Z[WXS] ,D_2L'
MX77]RND7OA_47S?Z-.8'RV=R')4_3J/PH [VBN1U+QY!9-JCV^FW-[;:4P6]
MFB91L)Z@ GYL#K5.\^)MM:'31_8>JNVHQF2!5B4E@!G@ G/;\Z .ZHKA[GXD
MVL-J98M*NY'A@6>ZB9DC:W5AD ACRV.<"K4GQ!TN6VLWTR-[^>[A-PD$;*C+
M&#@EBQ '/&/44 ==17"R?%31ET:QU-+6^EBNIS;;8XP6CD'\+#/7GC&<TD?Q
M-@>[N[$Z!JXU"W7?]E\D;V3&=W7 'U]: -SQ-H%[KL5LEGK=WI8CD)E^S_\
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M0FN^HH \UM_A]K\U]IEU?ZY:;;:U:S>&&VPODL-I"G/4CN15>7X;^))=%AT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ('_X_P"'_KD_\TJ>J[_\?\/_ %RD
M_FE6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW]KSS!4;CRVQM8#T.#S5#4ITM/BGKD/FR07>H:2D%B0C$/(1@8P.Q[]L&O4
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MD37-HR#<H&03R!T]:XC7TU;4K"^^V:%K+ZK!J(?;!"1;1Q!LY4#AF/K@^N:
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M;5C 0 PCQ\[=%QD@\U5\,QZ;?)I^DR^#;V/7+38DT]PC"*''60,3UXR!CDT
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MGJ,'U'%:5% &9H&E2:)HEIIKW1NA;1B))2@0E0, $#T%:=%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <YXI\+2>)7L"
M-3DM%LYUN$5(E?,B]"<_4\5T**54!FW'')QC-.HH **** "BBB@!KKO0J20"
M,9!P:K6&FVNF6_D6D7EIDL>22S'J23R3[FK=% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-+]H=2 _[Q?E3O@<GUJ9O%7BR]\2QZ-9:=86CSZ>MXAO-^Z+)P0P'<-D8_\
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M6.+RSAFVIEF[8'O6_P""_$6IZZE]#J>GR026L@1+D0O%'<J<X95< CIR/<4
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M% !BBBB@ Q1110 4444 %%%% !1C-%% !BBBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !111GG% !103CK10 444PRHJLQ90J?>)/3ZT /HHZT
M4 %%-9U4J"0"QP 3U-.H ***"<=: "BBB@ HHHH **,@44 %%%(6 (!/)Z4
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M-)X<U'2DTD":RU=M2MY)I%,=USP@7W!)YX[5N0C6K[P[K,A\&PZ4TME+;K!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-89(/I3J
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M8A5))P!5+2]7L-:M3<Z==Q7, 8H7C.1N'45S]GJGB[^UUM+[2K&6VGLS,EQ
MS(D4G_/-R2<]AD =<XKF].\>/IWA&"6'2;&WO;G4I;.*WMD81*0?F<JH+-^
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M?A&V6RL6;19A-+_I9'F;> !\G&1SWJQ8>$M>EN/%QO([.V37(SY928R&-L$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7(?\*[O#9Z_;'7EQK<OFW#"SY4YY"_/0!GV&L>)K+7/"<NH:NEY;ZW$1);K
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP/F;U)! '08'Z]J ->BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN_"^M7RZDBVOVJ&Z$81@,@8('XU:&L:GX-T*[U#QGJ]M=G<!;);0["QP?E'
MR3^F*I>"O$FAZCK$LR7ZWNN:D-\JQ1-MMXU'"9(' Z9[F@#T.BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "F21)-&T<B*Z,,,K#((]"*?10!#!:V]K$8K>
M"*&,G.V- HS]!45MIEC9RF6VL[>&0C!:.)5)'U JW10!!<V5K>*JW5O#.JG(
M$J!@#^-,MM-L;*1GM;.W@=A@F*)5)_(5:HH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BDR!5=]0LHYA"]W LIX$;2 -^5 %FBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+Y:E3DCN>3TKLJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *U]86^H
MP"&Y$A0'=A)60Y^JD&N=G\#0EB]EK6L6;$\B.\8C'T-=710!F:#H=OX?T[['
M;22RJ9&D=YFW,S-U)K3HHH **** "BBB@ HHHH **** *.I:C_9T:-Y7F;B1
MC=C'Z5GKXEW#/V3'_;3_ .M110 O_"2<?\>G_D3_ .M2/XDV_P#+IG_MI_\
M6HHH !XDRN?LG_D3_P"M0?$F!_QZ?^1/_K444 ._X2+C_CU_\B?_ %J1?$>[
M_ET_\B?_ %J** '-X@Q_RZ_^1/\ ZU-_X2/C_CU_\B?_ %J** '?\)!P#]E_
M\B?_ %J3_A(?^G7_ ,B?_6HHH 4^(<#/V7_R)_\ 6IO_  D?_3I_Y$_^M110
M +XCR<?9?_(G_P!:GC7\_P#+M_Y$_P#K444 +_;_ #C[-_Y$_P#K4'7L?\NW
M_C__ -:BB@"R-3S9M<>3T(&W=_\ 6JS:7/VJ'S-FWDC&<T44 3T'@9HHH K6
M]UY\$4FS;O)&,YQU_P *;?7OV,(?+W[B?XL8HHH K-K&V"*7R,[\\;^F/PJ/
M^W?ES]F_\?\ _K444 )_;W_3M_Y$_P#K5--J_DK$?(SYB[OO]/THHH C?6]L
M<;_9\[P3C?TYQZ4S^W_^G;_R)_\ 6HHH GCU??=>1Y&/FVYW^_TK1D?9&S8S
M@9Q110 (V\9QBG444 %%%% !39&V1LV,X&:** '4444 %0SW'DL!MSE6;KZ4
M44 #7&V&23;]P9QGKQFG02^? DFW&X9QFBB@"G-JGE7+0^3G;WW>V?2FQ:KY
MJN?)QM_VO8GT]J** (?[=X_X]O\ Q_\ ^M0VNX_Y=O\ Q_\ ^M110 W_ (2#
M_IU_\B?_ %J9_P )'_TZ?^1/_K444 ,_X2?DC['_ .1?_K4@\3\?\>?_ )%_
M^M110 ?\)1_TY_\ D7_ZU-_X2KYL?8O_ "+_ /6HHH 7_A*?^G/_ ,B__6JM
M>^-/L=N9?[/W\@8\['4@?W?>BB@"'4_'?]G6XE_LWS,OMQY^.Q_V?:L8_%G!
MQ_8G_DU_]A110 ]/BMO\S_B2XV+N_P"/KKS_ +E,_P"%L_-C^Q/_ ":_^PHH
MH 0?%O(_Y G?_G[_ /L*?'\5_,W_ /$EQM7/_'U[@?W/>BB@!)?BSY5R\/\
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8N?%_A@:I=P102F9X]D6<8&/7ZT44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>sgmo-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20210331.xsd" xlink:type="simple"/>
    <context id="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i453fc7e4d39e485696880a0068f3ac91_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i55deba83f3ac420da3d9b6ec9427676b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iab4e0c85a3d84ffcab1a0012cecf66ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifd883257c84a4687a5494a39e124d667_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i53e0b5e6680f4291908d2acc03c5a95a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica34d212b8dc4e4eb77a34ebc1cc8e1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02e3ad207ffb4b27a99cbe2bb6344955_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b75390260714bd093b27d2888f6731f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i279bd903b27f4b1883910ef6730e4837_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id4d81ef37b6f41dc8f6b9d2391fe86ea_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4c6e8db148e24765949ce24f00ae55c2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i231e4a76d123433c8564b93e35aa1d22_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i82edc27b271d404c8f4a64dd3f6d09f3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if1bce859227c48ec937b364b0c755fb6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id569692232f44b089c8390de87c4cada_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6c0f9028eede4cde8866b5ae5aa57301_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2de66a8952c648ea9920beb1f440b1dd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic0ac77a17de44bb29cd358c8e38c4a67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81f6dd582b9643c0aaccfd23d753ec9b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib14881f3db284ea58af6d0401f231170_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fe452484de4488eb4d2377e776c52ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6cfe10b5a20e4fa2b3b9874ee8383060_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd84aa923eee4c089192240132cbdce6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib311ed9a02b24bb49e4b526d0c3068c2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i66fbbaa5c12e4acaa46d80bf7f899b95_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8adf3f5cfd514160ac3dc95f5c7ae73b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic79f4436f8484b2bbe53cd473de9e52e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i67bf00db7caa48c4a6d8cf45da387715_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2ae1200701864b2592f8e63d6320339b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i86ebacde06924391a242a1ad5478841c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7af747e9403b4e1ba505b3f4ba6cee05_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i563dfbe34ad4474ea0cf1df69ce7d40e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7c16f4045ec2486c9655bc30dbea465c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i873c9f5644134b289bd2510df3750392_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i024dc19eb24b4daab222db22932603df_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i91dfabbfcb6c42b6bb0bf2d326d97a54_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i332314e60491404688c2fb0fef961934_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i61dbb95b254048c5aba2eb7163863213_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i797c92907973403a9443e0c27091c0f5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic5b3cce32d374c0cbcc1ed41e9b476bc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3ef830db3b5a4c42bce46b64a5716cf5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic54f8c76b5c842219a02086497ccdcf2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie0d66e275ba74d119f72575fcbff978a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1fc652101e3c4c20b3cf3a98ba873683_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i635047121e6c4458b824262db0945d4e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i82295ac670bb4f48911ed7686079294d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icfd3e7b1c54840f38d767f4d886e6a20_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1d2bc412b074d02b1f276ca18f76761_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ide8966338ebc438da839ad284fa2d835_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id7db582e5de644bcb1b85a92b0e5f562_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i271e9f7a598345499ec311df587568ef_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i78163204b2e442aea1bef8ca15bd3185_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2e7ce110dc7a4abc917e9ff1f848c5c9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i106cafb1122d4c0e9f548d6e74623320_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i05e6eb66bd26477ab90813ade9edfb03_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i46865ce5446e4b3581efb803f5308180_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i89889f9b7a0f46bebb2b75f129454b9e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if04c5d46d250473194dd874c126bdbc8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5dc8108057d44225a1ea75bd1ff54b19_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i419d0e887e054403af4e6b64c3884a5a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i51edc4e56f8e4a7cb40c8d663d6c17d7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i33962be218df46e4bb2551730a919275_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i41dd293fb24a49c58c23d0ed05154696_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic8ef26cb1f0244fd88cc3a23ee2cb867_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4bc5de5ccb1a4b8aaffe4d2996876f39_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if45973c1fb6444ea88b6e3c888274698_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic2c1ad6d704e41659c0fd0df2e944744_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib7d4134488184de8a1fa41faf29af748_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic8f6a626ca824ba0a50ba08002bf41f3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7b36af6a83fa481bace8cd4e6fc87589_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1526a93629134bf5a457c273f64476aa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ida4abef0acf44596a26f1a6b9c75bcdc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i049f3221e84245a9b058bae1da73bc95_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i162a782c6f754612b1731de6c5d3c0d2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iceb962d8a3b8454e9d31307a65f31666_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic31c2d44d30d4f72b00d4d3dc2f0ea0e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2068f55b1b64c409a3faa26ee2644cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic7da0f47f5194d899b2a75cec012f983_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb9fa3dbd2e0444181f5a6e3e7046acb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e460cd7328340128515c28a0c9286b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27ac6cc477e44273a668068859113a3b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86ae0a19620647ba86b490ea19afde52_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0eb74ef8efdf48d992458b94198588ac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i09b72198ef2049a59d0032b521440eab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4829f8fd2ceb499a88d1a605878ef324_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ad0091ec4e44a5c95e0c234a8797e30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6857d704b93459f901a1ad318f49bde_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa573862768c47788f0353badcc8a2c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if80129c7bc444c6c89ddf9cfc902a3bb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8cbb561c5be14e16a7780931e372eeaf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i648e5da489e74498abd8b5eb03f88c29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17aabe1f736146ce8ab6b6adf624da61_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5951cf3812f84d1b880568d902f8ffb0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i02a6ede247654801b23070be6fe9771f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i927cfac1568340718ec2370561ddff86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c77548671c64b518a9d84a96771bd0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieebfdbf5d1314dbf8980ccd6c0efeb45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifba723c7ee42434e90ebc7232841e8db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i15841938ea744133a39ee8f0276f4e94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8a7cf6c983f4c9589afcfe337a84376_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85fee7acc1c942e3a814f2d4a0f959b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79b7c87fda55463998db819047f79ca3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bc5cd0ff3e2431cb254b14fb4219da8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9866ab5b25c94734a96e173d3df99684_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0cffbb4314d64ee4b5119c285bb1bdf8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i468e13f71bb44158bc1ebf6b962f54ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icce97d825f8b420eb0fba22b6d0a786f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1129259eb0a649868776568fa4898425_I20180720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-20</instant>
        </period>
    </context>
    <context id="i91b1a80eaeeb470bb98449ced38f5857_D20180720-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-20</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1087025adac9402fa10512e9bbce394b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i373acdae6305402aa0be5cf76855d613_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3a2f2e458499460c9d2f8569ded9b145_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ad2a2e3a84b4100b7319b30812c47e6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icef8cccbf6ca4534ae5c619f394063a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6869d31d7a094145bfb28ac75b1e9b65_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i280b535896024bcd95cb6e05701ce4a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ad1dcdb92f74b6aa8153279f247ec2b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i672e278ea9d9400fb2d871ecc0490a9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i096af9793db343b0815caa338ffd63a8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic336725f5f2a462798de6f9160210fdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1004bec248ae4ca1ba8a9c29ad354f09_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i46c3138c0eba415ea37d06436df62854_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i859a69b7c32743829ed4f102732a1722_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i39b2e0222b2542508d6cd3681b08a431_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i434d6421401646d8819ebb7f70ca4def_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie037112c32294882bba7e7dbbf15ae0a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iddf917e0cbb043a6a5d13564bd385789_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1b613add127642da88c0f1e731060ffd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i53804a6be8344f08a5725ae1fe862146_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ad382cd550f476288b6b8449774030a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id08febcafb084cb3800af6dd3c8ae060_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00b352c0d2ab458ebc5713e73ef66c30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic558cd205e844605965ec5e4461a1ba5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81c0ac6823a34b509afee459208f16b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i64c74fee69544d6fba7898340eefc923_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if88ebd43c71848c89734b2715f66361b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7dc2e857539f4ef4ba7daadf58df7f59_D20171201-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3acb6e7ece7c4264be4a73e7e4f9a1d1_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="id33584313d634d6ebb308bbe8e5d106b_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i7809379654904198b0f40fede3b357a4_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="if7f4f202adee470e8770f3ce345ea450_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i757166e143b64a41ba577ebe4be02b45_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i34fb2fbe43f84642b4ef2537c5369e1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3a7d845e25d44dda4758f9bcaba97fa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0431659b3584e55b72f8e5b04fcf870_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i15ffb4ef28e24434bf448ba66f1f1afc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i005c57a24e8f443ca9c1180106705ef2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54a4cf97110343f3a88212e70424cd96_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3542eb13ee6148b8b4bcdd99fef16454_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="idcd855b9275c4a8eb8f323a68bbf1d77_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i9cb99906f06b46e8b267391bde6b0830_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ic36d2806042d4050b552799fc92519e9_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ia4bf6163ffff418c83013f140a3d867b_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i3274c4f79e0340a5ae43580f04c8e34f_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i1492cd406dd2436db6296241d9022d11_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i3e07997bca414cf2953b42b65cb1fefb_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i4f7ac715a9b948b18839034f530a5ddd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1f78e88d6b69472e839f423e5b345307_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="ib69b2d9da4aa46f294f132d7d0fd52f0_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f5f5ec067c64bd38439f1f0e454a1a3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0ce08d1f25be4729bc3e45da23cef7b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2118dcb01a3143bb92d2503658c8e4de_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i98afd062347644fe9caa179181f1d6bb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if1f36c6406ec47d0a03002619c66f091_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i828c0aafea3d4fdfb8f588e64d921e4c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53a6386cca364200a895bc9cda07eadd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6cf45da81af341b5af253ace0465bd98_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i868c9fe32a52452dab9aa2f991f5ac1f_D20180405-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="i6d691cfac5fc48f6ae86378e6b4a002a_D20180405-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="i5161917923e141dba34488ab948e41a6_D20180405-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="iad0d9faf81c84a81aa9b16164821cf1d_D20180405-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-05</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia8ba008f3a5a42be83d38ba385bbc8d9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i184e9ab5d0b74ca68b16888bb4007dc0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a3d9c81024248b1adfc4a25b7c4d391_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icb423d0affaa4d709010389b445356c0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i01acb0b530634a9f92961bce1668f40d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0d076890fcfc4f4cae05e8d5e034c7b2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iba7559393313442091af1abf5c735f2b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2d499b745bbd4aca82c6887941eb2f4b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iad9f9edf27124c6a8611cf6dcc485c06_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i11db6cb00c9c4e91a017c15c76688b71_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i607adea8b9544c9a857fd7049243e384_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="if807a38abb434889be2ed63115c6d893_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i2b355d6fe77d457698c955bfed974e53_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i0739b227da3b4bca85dcba2a54effd31_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ie9c5e3edd0db4669b6958fb4f83b506b_D20170501-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia108ccb69cd546219ec3a5224afff3d6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icc1d6a7d7d9648f297ef3f74c21f27f5_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib02a2a6eb3a3422dbca515f54079ab86_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b75336922ca48acbeec35795e3f89c0_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idc16c1fdcccf4d5798400ac9fd30c32d_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibefa2eee1d224a5a8a3a002053b6b569_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id906fae1befa40139b59199d084644fb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2c5af769a3724b79ad162f6dc82b9325_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5e53a9d7d29f4ca7a15cc2342c452633_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0794a490e25b4316b034257c060699e8_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iad9117357d274e389ec4bb2d954d40a3_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie71a3d375d8949d28e7d537186c4fba5_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i552e02bdf7ff40bd9f7d8d307d5ed4a0_D20171201-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i12192197df6e4c748c74e75b895766dd_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i263f5e49eb104d2b951703a42c48374c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81052728a07f4234a17255473a25eb02_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2b8e1d577cdc4e909e22ace81ac93119_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i2c2127ce4c454d39bf4876ba0fcacebf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4bcae7d19c204753a2408edcca187aea_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i85f4919f9c0c4473b1ebc3b0d83ed945_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ic69d4938e11f4400912ca470c0f2df17_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ia3d256269518436384e6a844f9460eb3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id2f0c509626e41d2b12512c505830612_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icb3452b189334360b2eae0dc8a8f906d_D20140101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie081f263ba514369a864fc04ab2755ef_D20140101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i900c9e6b08d34f609332901a02f4e019_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i70098c2ae44f43d0b6cc32e42dc76aff_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibfb4fcf9f2374b178f3f64eb7492ba62_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8946000fa68f43baa5c040af17dd5bd5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3cf33b15cb6f4155a7c06a66148748b1_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i3e1b297e2e824a43b69317d3cf60c21c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if64ca9e8294649218a45ade74be60132_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia042567c5f69499ca3310b43148a2dc4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7a483e7e113b40b4932319e4d56036a0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i412d6af141ea4a5eaff0bd4986d51146_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic2a5a95ecafb44a7874d3bd37d807e3b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic2ec745d260041b8a59a2e8dc45ffa91_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie63bf8b36b024460a56259f11296d885_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic51c2ae6d077473d8293fa2b46203655_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i6dae3ccf0cd54c5fb3e19ed6a18b06c8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i55f0be7b4249420ab4cc66f467c2f873_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic886d255bdf04e18ab350c75c4128994_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31a1ce4b0e414b9186ddc9401df9e1ca_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i08adf079a35e4e43a2b4ac18b46404b4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i53f2a73e9b4a48b496f08bbeb4ae0cda_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i002c88e9975348a9b63cef46a46fe8bd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4389a31659b5435cbd086cba9f72cb06_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if674a30905aa4701b577fea5cdd38927_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i49ed718922c34bacb4fe8ab46f011d3b_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="i4bb8843fb3d341009157555d58c1790d_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i62fb65868a04407c87a0eefd5094126d_I20210129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="ied0c47637c5a4c5786b8ac57faeb569b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie59ea076e227497193dff8217d78482e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:LonzaNetherlandsBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i21a9537a071b45a490485e4e675afbda_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia7879f7c1ca14257a286f0937f160d6a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic7121386b2ac42788064446ea02e0293_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i689dc02e331246b1b5c7ee22451f278f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5d2cd66475ef461e9c805c9eaaaca699_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i29077b179cb747c6af600e5610999238_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4031384af7314ae98be13e046f877228_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i628ef7e645dc4f99a3b94a2aa9545377_D20181001-20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="i25f4525748b042cb9cf63d0d356cdd37_I20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product_target">
        <measure>sgmo:product_target</measure>
    </unit>
    <unit id="option">
        <measure>sgmo:option</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="royaltyfee">
        <measure>sgmo:royaltyFee</measure>
    </unit>
    <unit id="program">
        <measure>sgmo:program</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF8yLTEtMS0xLTA_36d0feb9-34fa-4de9-9f62-e44e49d37ac7">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF8zLTEtMS0xLTA_8a9dce33-38f0-4a11-b71f-32c2ae101f6f">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF80LTEtMS0xLTA_6cd9371a-0eab-4652-bc0a-338844c158b3">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF81LTEtMS0xLTA_b78f0396-d3ed-47c6-8f66-9a44750aafd2">0001001233</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80L2ZyYWc6ZDg4MjJiNTQ3NjFjNGQzY2JkMGVhYWRhMmIxNDhlODgvdGFibGU6MTkwNGExZTYyNTA4NGZkNzhmODNhMDNjNTk3MTY0Y2QvdGFibGVyYW5nZToxOTA0YTFlNjI1MDg0ZmQ3OGY4M2EwM2M1OTcxNjRjZF82LTEtMS0xLTA_fccca1f6-af3b-4287-84f5-8829250d8161">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i002c88e9975348a9b63cef46a46fe8bd_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjY4_d3ea0c69-cbb9-4d34-80ee-4f04096945c8">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjY5_20be905a-0f66-4e8d-9b33-3ffce6705d35">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6ZmRhOGVhMjBmNmQ4NDZiMzkwOWM2ZTYwMTUwMDFhOTQvdGFibGVyYW5nZTpmZGE4ZWEyMGY2ZDg0NmIzOTA5YzZlNjAxNTAwMWE5NF8wLTAtMS0xLTA_d47931cb-fb74-43f1-b30f-38f6784ba2e3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMzM_027739b5-30ce-4484-aa49-66853c503aa4">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6YTc1NmZiZmFkOWQyNDU3MjgxYmZmNmIwYWU4MjQxYmQvdGFibGVyYW5nZTphNzU2ZmJmYWQ5ZDI0NTcyODFiZmY2YjBhZTgyNDFiZF8wLTAtMS0xLTA_86d9d692-1a61-4f8c-8344-6a333c45adb5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjc1_30530f6d-1e3e-4505-9d4c-aeda873c7d73">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjc3_6d3bbb03-cf5b-4dcb-acdd-6db4119b8c34">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18wLTAtMS0xLTA_1d905462-0bb8-4e6f-b31a-13d4a1210055">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18wLTQtMS0xLTA_d70f8ff5-c445-41da-8d57-d0ced463be90">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiOTEyOWI3MTcxZTc0N2M5YjhjZDgzYWI5YmZmMzRmMV80_e8a248ce-57a0-4ff7-9dff-9b8a9506c2e5">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiOTEyOWI3MTcxZTc0N2M5YjhjZDgzYWI5YmZmMzRmMV84_b82405a4-b845-4405-8d61-032c22e2b3f8">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiOTEyOWI3MTcxZTc0N2M5YjhjZDgzYWI5YmZmMzRmMV8xMg_14fc50b2-0cda-408f-b2d5-211c1fd33192">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6NDRhODBhODQwNTViNDJjZmFlMTkyNjE1ZTE2NDA0MzcvdGFibGVyYW5nZTo0NGE4MGE4NDA1NWI0MmNmYWUxOTI2MTVlMTY0MDQzN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjpiOTEyOWI3MTcxZTc0N2M5YjhjZDgzYWI5YmZmMzRmMV8xNg_f3c1f4d8-6fd0-4def-9b6b-ce449b88f59b">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjcy_5dcb8e8f-1b55-4a3a-9358-a35ddfb99e49">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjcw_6e585944-3795-419e-8a11-69560dbb8f35">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6Mzc5YTgxOTM5N2VjNGNkY2JkM2MyYzdhMWRjOWUzMGIvdGFibGVyYW5nZTozNzlhODE5Mzk3ZWM0Y2RjYmQzYzJjN2ExZGM5ZTMwYl8xLTAtMS0xLTA_17afae51-4539-4cc9-80c9-80d0185dce81">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6Mzc5YTgxOTM5N2VjNGNkY2JkM2MyYzdhMWRjOWUzMGIvdGFibGVyYW5nZTozNzlhODE5Mzk3ZWM0Y2RjYmQzYzJjN2ExZGM5ZTMwYl8xLTItMS0xLTA_56b02673-d9ae-428a-aebf-ace3e634e450">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6Mzc5YTgxOTM5N2VjNGNkY2JkM2MyYzdhMWRjOWUzMGIvdGFibGVyYW5nZTozNzlhODE5Mzk3ZWM0Y2RjYmQzYzJjN2ExZGM5ZTMwYl8xLTQtMS0xLTA_415a3e59-ae5b-4ebe-a2e4-10d0c42768cd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjcz_4a5eb67a-0928-4420-ba40-05d41226a4cc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjcx_8cdcd4d5-ec9c-4c62-affd-7d7cb74011da">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6YWYyYjlmYzdlZWU5NDZhZTk3MmNiYTVhY2NlNDNmMDAvdGFibGVyYW5nZTphZjJiOWZjN2VlZTk0NmFlOTcyY2JhNWFjY2U0M2YwMF8wLTAtMS0xLTA_4209385a-a71e-4f68-8e93-2a36190d5dad">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6YWYyYjlmYzdlZWU5NDZhZTk3MmNiYTVhY2NlNDNmMDAvdGFibGVyYW5nZTphZjJiOWZjN2VlZTk0NmFlOTcyY2JhNWFjY2U0M2YwMF8xLTQtMS0xLTA_b5c755ce-1040-4de5-9f1f-6228985a28f6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGFibGU6YWYyYjlmYzdlZWU5NDZhZTk3MmNiYTVhY2NlNDNmMDAvdGFibGVyYW5nZTphZjJiOWZjN2VlZTk0NmFlOTcyY2JhNWFjY2U0M2YwMF8yLTQtMS0xLTA_3f71df62-f056-43fb-896d-135042812324">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMjc0_d92a763b-be91-41d1-8a7d-750fe12f7841">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i453fc7e4d39e485696880a0068f3ac91_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xL2ZyYWc6ZGQ4ZDQ0Yjc3NjgwNDljMWIxYzExMjcyNDY5OTNmZTMvdGV4dHJlZ2lvbjpkZDhkNDRiNzc2ODA0OWMxYjFjMTEyNzI0Njk5M2ZlM18yMTgz_c98828f1-f3c1-4da8-9200-848a68ffeeec"
      unitRef="shares">143881477</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMy0xLTEtMS0w_ca8f4747-5f9e-4901-aa3e-3ca93f590adf"
      unitRef="usd">122975000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMy0zLTEtMS0w_b8137237-4f2b-4e7b-b059-d29f183c16c9"
      unitRef="usd">131329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNC0xLTEtMS0w_4aa9e00d-4087-4be9-97be-5a186d11601e"
      unitRef="usd">464109000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNC0zLTEtMS0w_fa85f019-1aa3-42a1-aeb1-de6e92125607"
      unitRef="usd">510094000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNS0xLTEtMS0w_d1204586-b44a-4357-a10a-c526bb1c56e4"
      unitRef="usd">974000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNS0zLTEtMS0w_21909382-e893-4572-966f-c26aa11d1410"
      unitRef="usd">1035000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNi0xLTEtMS0w_78d5bf01-efb2-4e70-94f4-bd391a65caf3"
      unitRef="usd">6746000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNi0zLTEtMS0w_8f00ab41-0fbf-47f4-8f24-5d25c40df162"
      unitRef="usd">5224000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNy0xLTEtMS0w_ccacadb2-1292-43f1-af6e-d6ccf2c5ca66"
      unitRef="usd">12140000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfNy0zLTEtMS0w_2ebb503e-89f8-44c1-9c14-c0e328070684"
      unitRef="usd">11986000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfOC0xLTEtMS0w_d5a8ab29-b5cf-4ae9-b41a-0238771d467f"
      unitRef="usd">606944000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfOC0zLTEtMS0w_e3ad8b1e-b0da-4437-a5d1-fc6d991210b9"
      unitRef="usd">659668000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfOS0xLTEtMS0w_48ff6d20-40ce-41b8-aa5f-bc039bb6fe45"
      unitRef="usd">42431000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfOS0zLTEtMS0w_94e0fe59-3061-4e58-83fe-09b214a71ee2"
      unitRef="usd">50530000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTAtMS0xLTEtMA_faa2b25f-e309-451d-9cc0-85ee177208ee"
      unitRef="usd">45222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTAtMy0xLTEtMA_e8b7a7d9-9dc8-434f-8271-81922235cb58"
      unitRef="usd">41324000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTEtMS0xLTEtMA_5c22efb7-3554-474b-96d7-7d689ff6e0b2"
      unitRef="usd">55583000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTEtMy0xLTEtMA_9d27fc08-a9ce-49e1-883c-0c2372e6acf2"
      unitRef="usd">58128000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTItMS0xLTEtMA_4fe04845-cef2-4f14-bc84-b158dc81b59f"
      unitRef="usd">40994000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTItMy0xLTEtMA_3ae3b7ff-20b6-43b3-a8b7-18b1935d3742"
      unitRef="usd">42798000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTMtMS0xLTEtMA_3fbb9043-7823-4ab2-8891-a622471433d0"
      unitRef="usd">70324000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTMtMy0xLTEtMA_a8ae27fc-9e24-45cd-aa9c-d11a0c8d8b8a"
      unitRef="usd">71045000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTQtMS0xLTEtMA_6a087290-92ac-471c-a882-29275f11b158"
      unitRef="usd">14097000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTQtMy0xLTEtMA_4baa94d2-41e1-4207-bc46-02d2c6f43ced"
      unitRef="usd">13557000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTUtMS0xLTEtMA_d7e236f1-5b90-4411-a13c-e7516886e8b3"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTUtMy0xLTEtMA_5fd02efe-2992-4920-8a47-a63db78f65c4"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTYtMS0xLTEtMA_07b55dfb-7921-40d4-8141-e92b3da945e4"
      unitRef="usd">877095000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTYtMy0xLTEtMA_f9c4383a-5939-4a4c-960b-c68cadb635fb"
      unitRef="usd">938550000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTktMS0xLTEtMA_e1bfdd4f-0640-487b-a285-0ae0a4bcf6de"
      unitRef="usd">11638000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMTktMy0xLTEtMA_94852f02-8e20-47ec-ad1f-288a37e75b91"
      unitRef="usd">12553000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjAtMS0xLTEtMTg0NQ_48c98c4f-53db-4770-b78e-8b6ba54b8365"
      unitRef="usd">13077000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjAtMy0xLTEtMTg0NQ_181a0c8d-3247-4639-8cd0-ba42239adcae"
      unitRef="usd">20738000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjAtMS0xLTEtMTQ1_0453a3f7-dde6-494e-b749-f36908103d8e"
      unitRef="usd">13760000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjAtMy0xLTEtMTQ1_4b63e814-c4cc-4ef1-bb8f-b4ef8d084d89"
      unitRef="usd">18612000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjEtMS0xLTEtMA_9b98b078-7ab9-49ef-9e4a-9c6805480c7f"
      unitRef="usd">94364000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjEtMy0xLTEtMA_98ec157d-6cc2-4448-b217-df464a384005"
      unitRef="usd">91644000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjItMS0xLTEtMA_1bb82e28-efb8-414a-983f-f94a69d4ed43"
      unitRef="usd">132839000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjItMy0xLTEtMA_c0fbe4e4-c836-4d16-af48-dfc6058899ae"
      unitRef="usd">143547000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjMtMS0xLTEtMA_c249307d-19d1-450e-80ea-2e72d6aa35aa"
      unitRef="usd">222278000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjMtMy0xLTEtMA_3dcec622-c15d-470b-b454-5b96087a17db"
      unitRef="usd">245045000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjQtMS0xLTEtMA_9fb24952-e77b-4f18-bf80-8de468c0e99f"
      unitRef="usd">38463000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjQtMy0xLTEtMA_6a8be7de-79e4-466d-b21d-3526ce61d812"
      unitRef="usd">38396000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjUtMS0xLTEtMA_2a9d62b4-0f85-406c-b1b9-25cdaccc7df3"
      unitRef="usd">6870000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjUtMy0xLTEtMA_c3668feb-f735-4a7a-801d-0939006d6969"
      unitRef="usd">7185000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjYtMS0xLTEtMA_0ef46ef0-a036-4dc7-bcd9-58d86dd7fcbe"
      unitRef="usd">7228000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjYtMy0xLTEtMA_013022ac-47b7-4a18-ba2a-94d4e171b1af"
      unitRef="usd">7011000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjctMS0xLTEtMA_eba99778-ce03-4fda-9c9a-90cada7930ad"
      unitRef="usd">407678000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjctMy0xLTEtMA_e79bb91a-53f8-43b8-8127-28329816451c"
      unitRef="usd">441184000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjgtMS0xLTEtMA_7243f50c-0707-4097-a72f-6c399747ec39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMjgtMy0xLTEtMA_84a364a1-c775-45d1-adea-6c8b6db64127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzAtMS0xLTEtMA_db07df4c-56fa-4e9b-882a-2b4c03cc9ec9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzAtMy0xLTEtMA_95ef544c-7daf-4e73-bea3-0462043527a9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzEtMS0xLTEtMA_a4982fec-b731-4e39-8a2d-5493b8e3f81e"
      unitRef="usd">1437000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzEtMy0xLTEtMA_fbc2aade-bc68-4524-974e-9a67c6185b0e"
      unitRef="usd">1421000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzItMS0xLTEtMA_b9583a76-65ed-410c-bc2b-cefb17405857"
      unitRef="usd">1292118000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzItMy0xLTEtMA_66825401-f5a4-49b1-8b06-59cddc6831f1"
      unitRef="usd">1269375000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzMtMS0xLTEtMA_9b3b15c1-f6f0-4cb2-8732-3749caa8d1a6"
      unitRef="usd">-823914000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzMtMy0xLTEtMA_999f5b55-829e-4db8-99e3-71a140fecfa5"
      unitRef="usd">-777981000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzQtMS0xLTEtMA_be53a351-2e17-4e49-b241-393eee55019b"
      unitRef="usd">714000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzQtMy0xLTEtMA_b8f7deb1-1fde-476a-a1a6-aa9ada6e8ced"
      unitRef="usd">5419000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzUtMS0xLTEtMA_57d75c0a-4fb6-4f42-8de5-d928e9835fcc"
      unitRef="usd">470355000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzUtMy0xLTEtMA_aa19d098-e6e6-4e1b-81b2-99601d0abda3"
      unitRef="usd">498234000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzYtMS0xLTEtMA_c0406e02-9364-42d7-85cb-91f38eed1555"
      unitRef="usd">-938000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzYtMy0xLTEtMA_69ab08d0-ca3d-478b-b3f2-d541bf674191"
      unitRef="usd">-868000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzctMS0xLTEtMA_003da965-5bde-4253-a5ff-88dc00b38c0b"
      unitRef="usd">469417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzctMy0xLTEtMA_532f953f-da96-487d-819a-209656d11c2b"
      unitRef="usd">497366000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzgtMS0xLTEtMA_caa82941-d98f-4113-86fd-2e8389cbf57e"
      unitRef="usd">877095000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8xOS9mcmFnOjFkOTkyZjQyNmU5NzQ3MDM4MzE2NDI0ZGQ4YTE2ZmFmL3RhYmxlOjkwMGM2N2RkZTg5MTQ4ODlhOTgwZmE2MGQzNDk1MTVjL3RhYmxlcmFuZ2U6OTAwYzY3ZGRlODkxNDg4OWE5ODBmYTYwZDM0OTUxNWNfMzgtMy0xLTEtMA_57d45cb0-2a3f-4596-96e3-28bbac321d82"
      unitRef="usd">938550000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMi01LTEtMS0w_a5449d37-0cb2-440b-9a82-a8ab890dbe4f"
      unitRef="usd">26280000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMi03LTEtMS0w_973cb0af-6dee-441b-990a-b4b18238e010"
      unitRef="usd">13076000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNC01LTEtMS0w_ea55b675-d190-4685-ac18-c18fa4c1b40b"
      unitRef="usd">56434000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNC03LTEtMS0w_954a76ab-ffd1-4c0c-9499-588b2a121937"
      unitRef="usd">41479000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNS01LTEtMS0w_d101e201-588b-4fae-950c-feac63384b0d"
      unitRef="usd">16148000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNS03LTEtMS0w_ec36b26b-ddec-4012-ac93-8a17867bd620"
      unitRef="usd">16119000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNi01LTEtMS0w_6ca66601-2e7a-4777-9b2c-c457c8a5378b"
      unitRef="usd">72582000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNi03LTEtMS0w_e8093038-29cf-46c2-806b-74a788895547"
      unitRef="usd">57598000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNy01LTEtMS0w_6ab247bf-0215-42a2-ae6e-81cc60db6faf"
      unitRef="usd">-46302000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfNy03LTEtMS0w_2110cceb-faa3-4a6f-9f99-6fd7c64d1274"
      unitRef="usd">-44522000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfOC01LTEtMS0w_5e4a33c6-3821-4c7e-aaf6-efa3fb849c66"
      unitRef="usd">625000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfOC03LTEtMS0w_95678a7d-179d-4b5c-a346-6f2a5a6e1235"
      unitRef="usd">1548000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfOS01LTEtMS0w_2b08d7c8-7b29-4012-b056-485b7f0c4144"
      unitRef="usd">-45677000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfOS03LTEtMS0w_870b359a-e916-4fc2-8374-7aabf762878f"
      unitRef="usd">-42974000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTAtNS0xLTEtMA_3eaee0ad-1cc2-4199-8ac0-25d2ffba164b"
      unitRef="usd">262000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTAtNy0xLTEtMA_92b78116-6918-4b11-977a-2554b650eb33"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTEtNS0xLTEtMA_684ea2c2-f277-4ae7-8c0c-88c6974bb243"
      unitRef="usd">-45939000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTEtNy0xLTEtMA_a77e1840-3707-469a-be17-b43097b8c163"
      unitRef="usd">-42974000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTItNS0xLTEtMA_2d8f9764-e786-4f39-8207-c40f63f54e76"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTItNy0xLTEtMA_da97e928-35de-44f1-84be-7fde6ddd253d"
      unitRef="usd">-61000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTMtNS0xLTEtMA_6a4d2734-d152-4769-9073-f414ab8e3257"
      unitRef="usd">-45933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTMtNy0xLTEtMA_8516d294-18c0-411a-a160-90f459ce4f6c"
      unitRef="usd">-42913000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTQtNS0xLTEtMA_f32e37da-1018-4e3e-b7c5-152208bd6406"
      unitRef="usdPerShare">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTQtNy0xLTEtMA_e76735c0-c6a7-4aee-aac3-20e3eceb6796"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTUtNS0xLTEtMA_1da0c37e-fefe-4409-86b3-86717df66017"
      unitRef="shares">143112000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yMi9mcmFnOjQwYzhlNDYyOTNiODQ2ZTliYjFlNTdkOTZlNDI1MWM1L3RhYmxlOmEwNzJkY2IxNWJlYjRiODE5OTAyMmFmYjczYmMwN2Q1L3RhYmxlcmFuZ2U6YTA3MmRjYjE1YmViNGI4MTk5MDIyYWZiNzNiYzA3ZDVfMTUtNy0xLTEtMA_a4fa6928-8446-4e1f-856d-68793927f71e"
      unitRef="shares">116060000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfMi01LTEtMS0w_684ea2c2-f277-4ae7-8c0c-88c6974bb243"
      unitRef="usd">-45939000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfMi03LTEtMS0w_af1a3c1f-0a86-489a-90a5-133d95e27a54"
      unitRef="usd">-42974000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfMy01LTEtMS0w_f8d51b91-cab1-482b-bf53-3bdaec8bc8e3"
      unitRef="usd">-4749000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfMy03LTEtMS0w_1cb85838-736c-4065-8f95-a40b499b7bdf"
      unitRef="usd">-1633000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNC01LTEtMS0w_e55b730b-5434-4de6-8c66-ee0ac7082216"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNC03LTEtMS0w_84d0878f-44be-47f0-97ed-1d99fcf5b8a2"
      unitRef="usd">254000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNS01LTEtMS0w_ee9a7069-8876-4028-b104-134cf5b910e9"
      unitRef="usd">-50644000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNS03LTEtMS0w_3e15d444-95db-4cbe-814d-b9ce5b6a3116"
      unitRef="usd">-44353000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNi01LTEtMS0w_f7f27081-b0c7-4561-8f87-5a4fecf2c875"
      unitRef="usd">-6000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNi03LTEtMS0w_f8d502b3-3743-4715-9853-01150583d0bd"
      unitRef="usd">-61000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNy01LTEtMS0w_ab828e88-7447-4c51-8d7d-04794ad15ea6"
      unitRef="usd">-50638000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yNS9mcmFnOjQzYTg1YjBiNmQzMjQzN2JiOGM4YjY5N2MwNDE4NjE3L3RhYmxlOjNlYjQxODAzZjMzYzRiMzBhMGNkZDBmNWYxZTdjMDc0L3RhYmxlcmFuZ2U6M2ViNDE4MDNmMzNjNGIzMGEwY2RkMGY1ZjFlN2MwNzRfNy03LTEtMS0w_c65fe698-da7d-47d3-8b9d-7cdb4b8be200"
      unitRef="usd">-44292000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="iab4e0c85a3d84ffcab1a0012cecf66ca_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy0xLTEtMS0w_f43e15b2-c1fe-4049-9e2e-0eb1359e1487"
      unitRef="shares">142063203</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab4e0c85a3d84ffcab1a0012cecf66ca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy0zLTEtMS0w_19752b17-0558-49d4-a66c-87428f5219f3"
      unitRef="usd">1421000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifd883257c84a4687a5494a39e124d667_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy01LTEtMS0w_d7524f9b-1e94-4c07-bf80-b0fbb68b179b"
      unitRef="usd">1269375000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i53e0b5e6680f4291908d2acc03c5a95a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy03LTEtMS0w_d87fb179-907d-4435-93ee-4eb7a7edff7f"
      unitRef="usd">-777981000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica34d212b8dc4e4eb77a34ebc1cc8e1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy05LTEtMS0w_44bceb6b-5df6-4d22-8c14-0345031b18bb"
      unitRef="usd">5419000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02e3ad207ffb4b27a99cbe2bb6344955_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy0xMS0xLTEtMA_45f9c08b-747b-4496-99e5-374b2a85e796"
      unitRef="usd">-868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMy0xMy0xLTEtMA_5ee661e3-372d-40be-a2e4-27729fea492c"
      unitRef="usd">497366000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4b75390260714bd093b27d2888f6731f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0xLTEtMS0xOTAz_82f6ed45-155a-4add-8584-d70fa27c2bf3"
      unitRef="shares">1034762</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4b75390260714bd093b27d2888f6731f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0zLTEtMS0xOTAz_686af727-1a12-4bed-a771-4f22612522a0"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i279bd903b27f4b1883910ef6730e4837_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC01LTEtMS0xOTAz_0959732b-50ee-4b7c-93c5-d4486338d579"
      unitRef="usd">15641000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0xMy0xLTEtMTkwMw_7a80ed1d-5c68-4ed6-bd81-2893fe33aabb"
      unitRef="usd">15651000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i4b75390260714bd093b27d2888f6731f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0xLTEtMS0w_70cbf323-92ef-480a-8af6-95076d7323b6"
      unitRef="shares">615800</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4b75390260714bd093b27d2888f6731f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0zLTEtMS0w_49cdcc3a-e48b-4239-9925-d90b1b38398c"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i279bd903b27f4b1883910ef6730e4837_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC01LTEtMS0w_48b63b92-302b-4104-ae66-feee4c66089d"
      unitRef="usd">-422000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNC0xMy0xLTEtMA_ea9f59d6-e96a-4881-b232-1eca25467a84"
      unitRef="usd">-416000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i279bd903b27f4b1883910ef6730e4837_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNy01LTEtMS0w_eca6d5ba-0595-45d5-bdc1-a0518c33f1d8"
      unitRef="usd">7524000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfNy0xMy0xLTEtMA_d3661b2f-e580-441d-8a2f-d283274adc8b"
      unitRef="usd">7524000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="id4d81ef37b6f41dc8f6b9d2391fe86ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfOC0xMS0xLTEtMA_af7c6a45-67b4-4c2f-8b36-fed7cf5b5224"
      unitRef="usd">-64000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfOC0xMy0xLTEtMA_58d98446-071b-44b6-ae72-b28bed46426a"
      unitRef="usd">-64000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i4c6e8db148e24765949ce24f00ae55c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfOS05LTEtMS0w_7674cffa-afdf-4215-8443-f0d4b15dc3c7"
      unitRef="usd">4749000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfOS0xMy0xLTEtMA_bf09e460-2047-488e-bf02-bedee39ad7b4"
      unitRef="usd">4749000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4c6e8db148e24765949ce24f00ae55c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTAtOS0xLTEtMA_86870d34-ff03-4b20-a5bf-a3745c599175"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTAtMTMtMS0xLTA_75e29756-0bb1-4a25-aacd-60b2819a9745"
      unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i231e4a76d123433c8564b93e35aa1d22_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTEtNy0xLTEtMA_ddda627e-55df-459a-a65b-7999a1cebb6c"
      unitRef="usd">-45933000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id4d81ef37b6f41dc8f6b9d2391fe86ea_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTEtMTEtMS0xLTA_2c3249e8-ed78-477b-870f-44df1779575c"
      unitRef="usd">-6000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTEtMTMtMS0xLTA_7ffec78e-dd2f-4a9f-ad44-d916b560010a"
      unitRef="usd">-45939000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i82edc27b271d404c8f4a64dd3f6d09f3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItMS0xLTEtMA_e6359452-19ef-4375-929c-c0830c127df1"
      unitRef="shares">143713765</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82edc27b271d404c8f4a64dd3f6d09f3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItMy0xLTEtMA_a8f7e082-6248-49b7-a047-62d69f1bba81"
      unitRef="usd">1437000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1bce859227c48ec937b364b0c755fb6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItNS0xLTEtMA_11faf270-923b-4e4a-ac52-d1ab3bcad7c5"
      unitRef="usd">1292118000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id569692232f44b089c8390de87c4cada_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItNy0xLTEtMA_5b456dc0-7395-4a5e-a6b5-2ea3f6a03545"
      unitRef="usd">-823914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c0f9028eede4cde8866b5ae5aa57301_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItOS0xLTEtMA_caf98dd7-5b61-41d9-afc0-0e2e45fc10a8"
      unitRef="usd">714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2de66a8952c648ea9920beb1f440b1dd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItMTEtMS0xLTA_44a1b135-0c5f-485f-b82c-9959e454b74d"
      unitRef="usd">-938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOjkxOGIzYjE2YWQxMDRkNTJhODNjYjlhZTJhOTRhNWZlL3RhYmxlcmFuZ2U6OTE4YjNiMTZhZDEwNGQ1MmE4M2NiOWFlMmE5NGE1ZmVfMTItMTMtMS0xLTA_223ae074-1270-4238-8e55-2ffa9f144582"
      unitRef="usd">469417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic0ac77a17de44bb29cd358c8e38c4a67_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy0xLTEtMS0w_053ae366-3bb4-4459-87d5-1c97fcb94683"
      unitRef="shares">115972708</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0ac77a17de44bb29cd358c8e38c4a67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy0zLTEtMS0w_b3681633-db7a-4c80-9a6a-2965885d5743"
      unitRef="usd">1160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81f6dd582b9643c0aaccfd23d753ec9b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy01LTEtMS0w_8c576cc5-895d-4ea9-8d26-e42d0f5c8299"
      unitRef="usd">1090828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib14881f3db284ea58af6d0401f231170_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy03LTEtMS0w_47996545-ef4b-4567-907e-2ea635962274"
      unitRef="usd">-656985000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3fe452484de4488eb4d2377e776c52ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy05LTEtMS0w_51db46d0-4c89-44a8-afc3-cfdad906ac8a"
      unitRef="usd">-2449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cfe10b5a20e4fa2b3b9874ee8383060_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy0xMS0xLTEtMA_8e072042-19cb-4f5c-8a4a-4cde57ad23ea"
      unitRef="usd">185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMy0xMy0xLTEtMA_80069392-89a7-4fca-8fca-e9725c13a2f4"
      unitRef="usd">432739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ifd84aa923eee4c089192240132cbdce6_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNC0xLTEtMS0w_a8c76ede-f334-454c-8d10-2b278bce10e2"
      unitRef="shares">305845</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifd84aa923eee4c089192240132cbdce6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNC0zLTEtMS0w_a8dc3b88-d823-4c5a-8233-d69315b80ff0"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib311ed9a02b24bb49e4b526d0c3068c2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNC01LTEtMS0w_f41f678d-ebb0-4a04-8776-b16e55e43112"
      unitRef="usd">406000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNC0xMy0xLTEtMA_5364ee91-cc8f-45d9-b6d8-d70fc6e0f8c0"
      unitRef="usd">409000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib311ed9a02b24bb49e4b526d0c3068c2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNy01LTEtMS0w_df674349-b708-42b4-854e-f1e039f26751"
      unitRef="usd">5620000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfNy0xMy0xLTEtMA_de01cf1f-dc4a-4d8a-b1eb-393910e6823c"
      unitRef="usd">5620000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i66fbbaa5c12e4acaa46d80bf7f899b95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfOC05LTEtMS0w_abd574ab-3f1a-4be8-9e46-e88e990df720"
      unitRef="usd">1633000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfOC0xMy0xLTEtMA_9499faa3-3f2d-4c3c-a68c-7cc5ff2dc0df"
      unitRef="usd">1633000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i66fbbaa5c12e4acaa46d80bf7f899b95_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfOS05LTEtMS0w_1437cd09-3e2a-4380-8d58-754bd0992642"
      unitRef="usd">254000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfOS0xMy0xLTEtMA_c6b359cf-ce32-4e6f-8105-a0c79a0ed113"
      unitRef="usd">254000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i8adf3f5cfd514160ac3dc95f5c7ae73b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTAtNy0xLTEtMA_095f9f5b-4206-4f45-aec9-836b3533378f"
      unitRef="usd">-42913000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic79f4436f8484b2bbe53cd473de9e52e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTAtMTEtMS0xLTA_0cd37792-9199-41cc-9b6f-addb58595c46"
      unitRef="usd">-61000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTAtMTMtMS0xLTA_d994d1ab-19e3-4bf3-834a-535815ffcf6f"
      unitRef="usd">-42974000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i67bf00db7caa48c4a6d8cf45da387715_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtMS0xLTEtMA_a795ed95-b742-4f20-ba36-31acdcacb306"
      unitRef="shares">116278553</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67bf00db7caa48c4a6d8cf45da387715_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtMy0xLTEtMA_534bff49-3b54-4ba0-816a-c774e4ad44a0"
      unitRef="usd">1163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ae1200701864b2592f8e63d6320339b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtNS0xLTEtMA_efe09f8e-6a2c-4b34-b9fe-b0ac0952b464"
      unitRef="usd">1096854000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86ebacde06924391a242a1ad5478841c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtNy0xLTEtMA_6730a320-9ba6-4f8b-9e2d-27b3985089df"
      unitRef="usd">-699898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7af747e9403b4e1ba505b3f4ba6cee05_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtOS0xLTEtMA_ea3a05fa-3222-42f2-ad7f-1f196cb2f07b"
      unitRef="usd">-3828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i563dfbe34ad4474ea0cf1df69ce7d40e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtMTEtMS0xLTA_fe69e9a8-404d-4a76-8cc8-f455efacd145"
      unitRef="usd">124000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8yOC9mcmFnOmM4ZjE3MGI4MjNkYjQzZTRhMDQzMTkzZThkM2Y2OTQwL3RhYmxlOmMyZjRlOGZlMWNiMDRkZWNhNTRlOTE3MjQwNWEzMDVhL3RhYmxlcmFuZ2U6YzJmNGU4ZmUxY2IwNGRlY2E1NGU5MTcyNDA1YTMwNWFfMTEtMTMtMS0xLTA_da0b17da-7d69-4ddc-b367-59ad0d96350d"
      unitRef="usd">394415000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMy0xLTEtMS0w_a3a4903a-9c0e-4bbd-8d05-513ecf0941c7"
      unitRef="usd">-45939000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMy0zLTEtMS0w_7e1aed8b-83c8-430b-b72f-5c81532c726b"
      unitRef="usd">-42974000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNS0xLTEtMS0w_d311a144-5530-4bf8-bc2c-ab59427287f3"
      unitRef="usd">1875000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNS0zLTEtMS0w_9e608cbf-3a26-416c-884e-0cba5ce18e44"
      unitRef="usd">1311000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNi0xLTEtMS0w_3b2c482a-fccf-4dff-a751-320bb274a973"
      unitRef="usd">-824000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNi0zLTEtMS0w_7ba60adf-f9f2-479b-b57e-e6e901beaf9f"
      unitRef="usd">744000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNy0xLTEtMS0w_26a45d37-3d00-4293-8458-136fd926dea5"
      unitRef="usd">-2023000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNy0zLTEtMS0w_b5913dcc-9ed1-4e53-80c8-b5615b8f08cc"
      unitRef="usd">-1886000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:GainLossOnFreeShares
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfOC0xLTEtMS0w_19a80508-2ef9-4cc2-b087-2dd0bfbd33c2"
      unitRef="usd">-27000</sgmo:GainLossOnFreeShares>
    <sgmo:GainLossOnFreeShares
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfOC0zLTEtMS0w_6673e5f8-e480-47de-a815-8b0d8e2b12a7"
      unitRef="usd">-73000</sgmo:GainLossOnFreeShares>
    <us-gaap:ShareBasedCompensation
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfOS0xLTEtMS0w_20ce0974-bf0f-45ba-acb8-de9e7294de40"
      unitRef="usd">7524000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfOS0zLTEtMS0w_e5d5faa0-dfc7-4ddf-9999-4b23c5b7885c"
      unitRef="usd">5620000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTQtMS0xLTEtMA_fcb71a9b-67f7-43af-89e6-3a84a7a1cb03"
      unitRef="usd">-61000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTQtMy0xLTEtMA_873363b3-ad9b-4ab9-89fe-23bb78e7d8b4"
      unitRef="usd">244000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTUtMS0xLTEtMA_df14ac62-85e6-40c1-8273-6d25471b88f9"
      unitRef="usd">1522000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTUtMy0xLTEtMA_afbc2f09-36b2-4293-91fb-ae16f16ef5a4"
      unitRef="usd">-29939000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTYtMS0xLTEtMA_822e1e93-dd48-4c26-bbb2-b0c26c9d4ef2"
      unitRef="usd">1741000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTYtMy0xLTEtMA_204f68c6-5f65-4141-a6a8-f97f11933d28"
      unitRef="usd">100000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTgtMS0xLTEtMA_67de5709-d26a-4282-a2fc-97320bd070b2"
      unitRef="usd">-3829000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTgtMy0xLTEtMA_0f6327bb-7896-4d55-b9c3-500443cc5c2a"
      unitRef="usd">345000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTktMS0xLTEtMA_6b66436d-c8c2-4ed2-b4ea-5a61bb0f86ea"
      unitRef="usd">-7561000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMTktMy0xLTEtMA_e3be6e26-3601-485b-b2ab-ecf8ca89d032"
      unitRef="usd">-4965000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjAtMS0xLTEtMA_a142d33a-bef2-4646-967d-20b4d478e1e1"
      unitRef="usd">-20047000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjAtMy0xLTEtMA_ee510cc4-e99e-4aed-adae-51c12f5b6581"
      unitRef="usd">-8319000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjEtMS0xLTEtMA_20565221-9cfd-4cbe-811a-2ff5b289b456"
      unitRef="usd">-1045000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjEtMy0xLTEtMA_10b2ca00-7e59-4e1f-8f3e-5e285a36d53a"
      unitRef="usd">-887000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjItMS0xLTEtMA_fec4fbd2-8b41-43a6-a0b0-42c2182bb32f"
      unitRef="usd">800000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjItMy0xLTEtMA_a64224a4-2fc4-4caf-a003-8b5782e7ac73"
      unitRef="usd">169000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjMtMS0xLTEtMA_0f02c2a2-9444-4bcc-b90b-ea9e8f1551b0"
      unitRef="usd">-68550000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjMtMy0xLTEtMA_edb49f6a-39d7-45d9-90c3-5ab81444100c"
      unitRef="usd">-18890000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjUtMS0xLTEtMA_3c4c6d36-890a-462b-8705-ed48a8b10f95"
      unitRef="usd">97935000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjUtMy0xLTEtMA_1db0ca71-e27d-4f94-a16e-a869eb552656"
      unitRef="usd">43580000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjYtMS0xLTEtMA_8b66cbf8-a98f-4f0a-bf78-686fccfe95c5"
      unitRef="usd">144369000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjYtMy0xLTEtMA_af40d57d-f12b-48ad-a5cb-53e88ee368ac"
      unitRef="usd">71075000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjQtMS0xLTEtMjMzMQ_1a34c233-07af-42cf-b9f1-b9312bcab9dc"
      unitRef="usd">6870000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjQtMy0xLTEtMjMzMQ_b613c710-e5ab-463b-a88c-4e92a8100d3e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjctMS0xLTEtMA_5d17216d-f314-42ff-9055-83f68169acbd"
      unitRef="usd">7950000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjctMy0xLTEtMA_9bbc76b9-9217-4a7c-8620-dbd0954e402b"
      unitRef="usd">3775000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjgtMS0xLTEtMA_7591a3e2-f5e9-434e-ac07-be26ffa63a1d"
      unitRef="usd">65000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMjgtMy0xLTEtMA_5d716608-0af6-4e84-bdbf-157bc17020fb"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzAtMS0xLTEtMA_0b8c151a-041c-46cb-a8c5-679e1c87225e"
      unitRef="usd">45289000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzAtMy0xLTEtMA_793363dc-58be-4498-8623-832802b26399"
      unitRef="usd">23720000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzItMS0xLTEtMA_edcb4284-49a5-417f-92ad-59e90ae5594e"
      unitRef="usd">15651000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzItMy0xLTEtMA_1edfb66d-5c41-408a-a69c-26e28f641490"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzQtMS0xLTEtMA_71cf6a22-4493-457f-abbb-d50ce51805a8"
      unitRef="usd">2234000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzQtMy0xLTEtMA_2a2d9c4f-c9be-4b9c-84f0-71a5ac30de70"
      unitRef="usd">411000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzUtMS0xLTEtMA_a4047943-897c-4e03-a9dd-8b657caa8593"
      unitRef="usd">1818000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzUtMy0xLTEtMA_cc1402db-ca97-4e8b-9361-ad88fe40682f"
      unitRef="usd">820000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzctMS0xLTEtMA_87e6f0aa-c5e9-4029-8261-9f7dd8c69f79"
      unitRef="usd">15235000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzctMy0xLTEtMA_6f3f86ce-78f1-4c1e-853a-1bb6a185da4c"
      unitRef="usd">409000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzgtMS0xLTEtMA_b3e01172-4469-4f1b-b6a4-c727c00ed387"
      unitRef="usd">-328000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzgtMy0xLTEtMA_34feb890-f0fc-4d3f-9ecf-224cd89ccb14"
      unitRef="usd">82000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzktMS0xLTEtMA_2d5927eb-4ef7-4b29-91b1-d8006dc39f84"
      unitRef="usd">-8354000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfMzktMy0xLTEtMA_6bb8b679-a2ca-497d-aa10-d1a0a4fa1c89"
      unitRef="usd">5321000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDAtMS0xLTEtMA_3bfc90ee-1397-455f-9174-9460e9af0816"
      unitRef="usd">132829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDAtMy0xLTEtMA_8384f319-85a2-4cf4-805d-aa4773fb27b3"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDEtMS0xLTEtMA_9a3e66e3-b0ba-4790-a345-c570906f933d"
      unitRef="usd">124475000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDEtMy0xLTEtMA_27415d17-eb97-4623-b576-6e569228b848"
      unitRef="usd">87249000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDMtMS0xLTEtMA_ae7664f9-616d-475f-9791-56e736dd5fc3"
      unitRef="usd">2953000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDMtMy0xLTEtMA_ae0ecd19-c38f-4026-9dbc-3c234a8b86bb"
      unitRef="usd">1080000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDQtMS0xLTEtMA_13169ca1-eb72-4d30-b262-f07fe03f2e11"
      unitRef="usd">1356000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl8zNC9mcmFnOjFjOTkwYzRhNWNmMzRhYzBhMjFiOWE0MWZhNGE3MTg4L3RhYmxlOjk2YmEwNzg1NjQ3MTRjMDc4NGEyNmE4ZWFiZWUyNTk5L3RhYmxlcmFuZ2U6OTZiYTA3ODU2NDcxNGMwNzg0YTI2YThlYWJlZTI1OTlfNDQtMy0xLTEtMA_6e2ad12a-13e1-421a-b07e-15f93d93168e"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTQ_0ab8b639-31c0-4f9a-9ff4-446a8b09486f">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#x201c;2020 Annual Report&#x201d;) as filed with the SEC on February&#160;24, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#x2019;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of March&#160;31, 2021 and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#x2019;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#x2019;s stockholders, and any debt financing may include covenants that restrict the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in estimates during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#x201c;Sanofi&#x201d;) and Pfizer Inc. (&#x201c;Pfizer&#x201d;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $0.1&#160;million, decreased net loss by $0.1&#160;million and had no impact on the Company&#x2019;s basic net loss per share for the three months ended March&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of March&#160;31, 2021, the Company had not incurred any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received from the Company&#x2019;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of March&#160;31, 2021, no impairment of goodwill or indefinite-lived intangible assets was identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of March&#160;31, 2021, no impairment of long-lived assets was identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#x201c;AOCI&#x201d;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#x201c;IND&#x201d;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDU_de5758b9-fda7-4af2-bac6-9c76eae5e662">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#x201c;2020 Annual Report&#x201d;) as filed with the SEC on February&#160;24, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#x2019;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTI_52de2e73-e161-455c-9efa-784a86005118">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in estimates during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c16f4045ec2486c9655bc30dbea465c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMTA5OTUxMTY2MDY0Nw_d271669c-d1c5-4e79-83da-547c99a44fcb"
      unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i7c16f4045ec2486c9655bc30dbea465c_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMTA5OTUxMTY2MDY2Ng_babd330d-9a62-444c-8aa6-f51f7fc3d57c"
      unitRef="usd">100000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i873c9f5644134b289bd2510df3750392_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfNjU5NzA2OTgxMDIwOQ_f1d95512-027a-4173-b5d2-00cf0c7adb1e"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDc_96605206-4801-4ab6-839e-850a37c20a73">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of March&#160;31, 2021, the Company had not incurred any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received from the Company&#x2019;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTc_02695ca2-9286-4743-a301-9f5620aef611">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i024dc19eb24b4daab222db22932603df_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfMi0xLTEtMS0w_80a8bc8b-bbec-453e-96ca-9e48db796ebe"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i91dfabbfcb6c42b6bb0bf2d326d97a54_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfMi0zLTEtMS0w_0f8a784d-13be-4450-87ff-daaabe8ebe39"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i332314e60491404688c2fb0fef961934_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfMy0xLTEtMS0w_9925c68e-44b8-4de0-aa64-c3387659b71d"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i61dbb95b254048c5aba2eb7163863213_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfMy0zLTEtMS0w_cd86b038-bcd1-416d-a956-3e1ce70035f7"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i797c92907973403a9443e0c27091c0f5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNC0xLTEtMS0w_93a2ae52-3417-42ea-98f7-d78279e9aece"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic5b3cce32d374c0cbcc1ed41e9b476bc_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNC0zLTEtMS0w_632d6a79-f0f6-4a6a-bb41-639f0a350c38"
      unitRef="number">0.55</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3ef830db3b5a4c42bce46b64a5716cf5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNS0xLTEtMS0w_f938517c-5f4e-4649-bb62-d82240054cde"
      unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic54f8c76b5c842219a02086497ccdcf2_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNS0zLTEtMS0w_5cfef66a-2061-4664-a8b8-1746311e8bd5"
      unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie0d66e275ba74d119f72575fcbff978a_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNy0xLTEtMS0xNjg4_5c54b0a8-c45d-4266-8fdb-988730bb74cc"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1fc652101e3c4c20b3cf3a98ba873683_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOmM4MjAwNzcxMmE2MzQ4MDI4MDM4YjI0YTYzMGM1ODRmL3RhYmxlcmFuZ2U6YzgyMDA3NzEyYTYzNDgwMjgwMzhiMjRhNjMwYzU4NGZfNy0zLTEtMS0xNjg4_c4752ed6-8fa3-49da-a2bd-8b50999c345c"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTg_70f90c5c-682a-419f-8a68-cc9ed5a7b72e">&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDg_220f0240-889b-435f-ae68-2fe380b1e642">Goodwill and Intangible AssetsGoodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfNjU5NzA2OTgwODE0NA_93495b9a-9f25-4ab2-a54f-5afb83b97d5d"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0Njg_46b7bf24-c13f-46e9-bf2c-1261cfb716d9">Valuation of Long-Lived AssetsLong-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfNjU5NzA2OTgxMTgzNA_e805b270-96a4-42ae-92dc-5b6ff3efcff2"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTk_4ea59db0-5067-4b18-9afc-94b24f53da39">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDM_96654823-6b15-4a4c-945a-777343753b7b">Cash, Cash Equivalents and Restricted CashSangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMTYyNTU_26804864-7dac-4ecd-876a-db188d74ca3e"
      unitRef="usd">1500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDk_1833ce89-748f-45ed-8075-86ce6a7135d8">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDk_9e58a4e4-2c5d-4dc0-95f9-fb1e9eb68c0e">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.515%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMS0xLTEtMS0w_393efed3-3f3b-4a2b-8249-2227beb1dd0b"
      unitRef="usd">122975000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMS0zLTEtMS0w_cd83ca78-91c2-4a7e-9563-8749ac117eef"
      unitRef="usd">131329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMS01LTEtMS0w_a0f7bb46-fa14-4904-8dd8-a44fee38e0c5"
      unitRef="usd">85749000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMS03LTEtMS0w_05d82cee-2d4a-4600-b5bb-a9b5eee9c5f5"
      unitRef="usd">80428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMy0xLTEtMS0w_8d73c8c9-cf99-4c82-9fde-67cc97703ad8"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMy0zLTEtMS0w_7d179ab8-103d-4d0f-8b93-ab304eaedb93"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMy01LTEtMS0w_6db18224-dc84-4414-b860-fede9f3551ae"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfMy03LTEtMS0w_b8a8935f-3d3e-4212-a41d-53b86e5bb6e7"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfNC0xLTEtMS0w_2f5bc009-8b71-4e3f-b997-e8c057233ae4"
      unitRef="usd">124475000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfNC0zLTEtMS0w_cf58aed8-da93-44eb-b8b8-f0034d929965"
      unitRef="usd">132829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7a27e84ff3fd40bb8532801e30d09cb2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfNC01LTEtMS0w_29c9708f-440b-45d1-8799-374477450ef9"
      unitRef="usd">87249000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iafd05447c88a4175a7c9abd3cd4a4dbf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RhYmxlOjkwZTRkZTY0MjRhYzRmYmRiMzBhMjgwMjIzYzQyZDM3L3RhYmxlcmFuZ2U6OTBlNGRlNjQyNGFjNGZiZGIzMGEyODAyMjNjNDJkMzdfNC03LTEtMS0w_8a703f4e-d9ba-4757-bc0c-396be4d9fc75"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NjA_0b69d1e3-4a9d-4de3-b12a-9281a0898930">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#x201c;AOCI&#x201d;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NDQ_e78ce17e-cd1c-4d5a-a8a7-3c52c16efccc">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#x201c;IND&#x201d;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0Njk_3894528e-8df1-4002-9c76-ed968c82b2aa">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NTU_538d9b9d-1336-4ebb-afce-62ec46c9d5e9">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80MC9mcmFnOjFiMDYxOWFmNjRiZjRmNTNiMjdiNzI1ZWY1MjMwNmUyL3RleHRyZWdpb246MWIwNjE5YWY2NGJmNGY1M2IyN2I3MjVlZjUyMzA2ZTJfMjY0NjI_4b24c084-06f0-41e6-bef3-6f2b3b46ccbd">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfNDA4Ng_fa58ec9c-9436-426c-86fc-696111d8c6b7">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally classifies its marketable securities and some cash equivalents as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Free Shares Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the July&#160;20, 2018 Share Purchase Agreement (&#x201c;Sangamo France SPA&#x201d;) to acquire Sangamo France (see Note 10 &#x2014; Acquisition of Sangamo Therapeutics France S.A.S.), the Company entered into arrangements with the holders of approximately 477,000 &#x201c;free shares&#x201d; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). As of March&#160;31, 2021, the Company purchased approximately 453,000 shares of the 477,000 total free shares, for a cash payment of approximately $1.1&#160;million, upon exercise of the put options. As of March&#160;31, 2021, approximately 24,000 free shares remain outstanding and subject to purchase by the Company. The fair value of the free shares&#x2019; asset is immaterial at March&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Free Shares valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR / USD exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated correlation between Sangamo and Sangamo France stock prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR / USD exchange rate volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate and cost of debt by expected exercise date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfNDA4OA_50426843-bb1c-491b-bd69-2bf1f837227a">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i635047121e6c4458b824262db0945d4e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNS0xLTEtMS0w_b72ee3af-085e-4778-adb3-57fcc2c945bb"
      unitRef="usd">47635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i82295ac670bb4f48911ed7686079294d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNS0zLTEtMS0w_b8f05ddf-cc9b-4e69-8549-386d7e31abab"
      unitRef="usd">47635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icfd3e7b1c54840f38d767f4d886e6a20_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNS01LTEtMS0w_e9f67db4-9586-450b-b19a-c0d13ce8ed3d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie1d2bc412b074d02b1f276ca18f76761_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNS03LTEtMS0w_df1075b8-b1a5-41c6-a3ad-321991300d42"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNy0xLTEtMS0w_8c859faa-d037-4534-9412-d7c30f9df513"
      unitRef="usd">47635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ide8966338ebc438da839ad284fa2d835_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNy0zLTEtMS0w_bc4ce320-7e1d-4a35-b69a-363d0f765d64"
      unitRef="usd">47635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id7db582e5de644bcb1b85a92b0e5f562_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNy01LTEtMS0w_e896bbe0-4122-411a-8e30-00bd1db7c433"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i271e9f7a598345499ec311df587568ef_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfNy03LTEtMS0w_701b0505-041f-4a14-9ffb-d312e8cb739b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78163204b2e442aea1bef8ca15bd3185_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfOS0xLTEtMS0w_8c0522ce-534b-4c92-8ad3-1667958df312"
      unitRef="usd">177154000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e7ce110dc7a4abc917e9ff1f848c5c9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfOS0zLTEtMS0w_70f14404-1eaa-460c-b8f0-7efba4d4c4ef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i106cafb1122d4c0e9f548d6e74623320_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfOS01LTEtMS0w_a5c48f5f-6bbc-4436-91bf-f01580f8b24e"
      unitRef="usd">177154000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05e6eb66bd26477ab90813ade9edfb03_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfOS03LTEtMS0w_be8a865d-4ed4-4db2-92bc-e8d39dc2638d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46865ce5446e4b3581efb803f5308180_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTAtMS0xLTEtMA_3bcb0e33-3335-4a5c-8a18-7f153fcc2b52"
      unitRef="usd">39022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89889f9b7a0f46bebb2b75f129454b9e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTAtMy0xLTEtMA_8e4f9d62-1342-4ca8-87a2-0628f99f6945"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if04c5d46d250473194dd874c126bdbc8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTAtNS0xLTEtMA_b4f41d7b-4c06-4b58-ad9a-4598e569e78e"
      unitRef="usd">39022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5dc8108057d44225a1ea75bd1ff54b19_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTAtNy0xLTEtMA_8793ddc1-d342-4780-955b-afe59fdfa8b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i419d0e887e054403af4e6b64c3884a5a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtMS0xLTEtMzA1_838c8dc8-7016-437e-8519-1637e6be5dd6"
      unitRef="usd">11494000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i51edc4e56f8e4a7cb40c8d663d6c17d7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtMy0xLTEtMzA1_414d5308-2075-4f35-b9dc-d59f2f14f19a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i33962be218df46e4bb2551730a919275_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtNS0xLTEtMzA1_b2211be7-ab78-41e1-b887-a13aab422bb4"
      unitRef="usd">11494000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41dd293fb24a49c58c23d0ed05154696_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtNy0xLTEtMzA1_c3867013-b684-4912-ac47-f3e38ca18fe9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8ef26cb1f0244fd88cc3a23ee2cb867_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtMS0xLTEtMA_8968da6f-57a7-4b0a-8d79-22c36a694a16"
      unitRef="usd">36410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bc5de5ccb1a4b8aaffe4d2996876f39_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtMy0xLTEtMA_edcad7d4-1eb6-4d44-8aeb-9e91ab012b24"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if45973c1fb6444ea88b6e3c888274698_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtNS0xLTEtMA_a3d08003-2044-4eee-8e2c-bb24419092c4"
      unitRef="usd">36410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2c1ad6d704e41659c0fd0df2e944744_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTEtNy0xLTEtMA_536e0d8b-0871-42ce-9dff-cb457294c72c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7d4134488184de8a1fa41faf29af748_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTItMS0xLTEtMA_c9ff3469-0b10-4ddc-9e0c-eb61ea81502e"
      unitRef="usd">242460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8f6a626ca824ba0a50ba08002bf41f3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTItMy0xLTEtMA_38ed92ed-172b-4a37-bba4-ead03592f501"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b36af6a83fa481bace8cd4e6fc87589_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTItNS0xLTEtMA_1d035658-b01d-4947-932e-2f9d7e9865f8"
      unitRef="usd">242460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1526a93629134bf5a457c273f64476aa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTItNy0xLTEtMA_a665a338-6b3d-44e9-99a3-da1582c16a3d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTMtMS0xLTEtMA_6dec7127-b00b-40e0-a6a7-7fa20ea9ca0b"
      unitRef="usd">506540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide8966338ebc438da839ad284fa2d835_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTMtMy0xLTEtMA_3a6c41b2-9edf-4e46-b760-a26e57a65227"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7db582e5de644bcb1b85a92b0e5f562_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTMtNS0xLTEtMA_981f577d-e47c-4ffe-a582-f68612bfbd28"
      unitRef="usd">506540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i271e9f7a598345499ec311df587568ef_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTMtNy0xLTEtMA_3314fcde-9050-4a15-9024-e320e83e2b2e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTQtMS0xLTEtMA_b70f6234-f5a3-4031-b61d-56d04a547db9"
      unitRef="usd">554175000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ide8966338ebc438da839ad284fa2d835_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTQtMy0xLTEtMA_3a33449f-8227-4c3c-8d33-c1e7f5f6435c"
      unitRef="usd">47635000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id7db582e5de644bcb1b85a92b0e5f562_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTQtNS0xLTEtMA_e3a0bb34-854d-43a1-b852-14ed764b4ad6"
      unitRef="usd">506540000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i271e9f7a598345499ec311df587568ef_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTQtNy0xLTEtMA_ff705ad7-a493-4f13-9b33-ce4a7ad4cbde"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ida4abef0acf44596a26f1a6b9c75bcdc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTYtMS0xLTEtMA_e077f391-8235-47d8-86e7-826024cf430e"
      unitRef="usd">38000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i049f3221e84245a9b058bae1da73bc95_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTYtMy0xLTEtMA_129e329d-80f9-4a51-925c-6b6f6b24bd0a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i162a782c6f754612b1731de6c5d3c0d2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTYtNS0xLTEtMA_31bb92b7-60c7-47ed-86ea-d3c3c54fe52c"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iceb962d8a3b8454e9d31307a65f31666_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOmNmNTljNmI2NmM2MDQ0MmM5ZmNiMjNjYWRhNjBjNzFmL3RhYmxlcmFuZ2U6Y2Y1OWM2YjY2YzYwNDQyYzlmY2IyM2NhZGE2MGM3MWZfMTYtNy0xLTEtMA_efc375e6-2bb9-4ddf-8f25-e107547d5c22"
      unitRef="usd">38000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic31c2d44d30d4f72b00d4d3dc2f0ea0e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNS0xLTEtMS0w_da0fd66f-631d-4691-8adb-9de6ae9ae761"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie2068f55b1b64c409a3faa26ee2644cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNS0zLTEtMS0w_4f0bc83f-d77d-4c22-a15f-ee7ab2f9948a"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic7da0f47f5194d899b2a75cec012f983_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNS01LTEtMS0w_9eed939a-b734-4f8c-bae1-e1bd16a3bc47"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icb9fa3dbd2e0444181f5a6e3e7046acb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNS03LTEtMS0w_34ce5469-3a49-4c27-a338-e6080294ddc1"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5e460cd7328340128515c28a0c9286b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNy0xLTEtMS0w_c8eda0dd-a34b-44ca-909c-38831128e4ea"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i27ac6cc477e44273a668068859113a3b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNy0zLTEtMS0w_bf6a9670-a2c8-48e1-bfff-089d94caf74a"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i86ae0a19620647ba86b490ea19afde52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNy01LTEtMS0w_58f75636-bd4a-4d16-9d0e-97430b05fbf4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0eb74ef8efdf48d992458b94198588ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfNy03LTEtMS0w_942c149c-55ae-44fe-9029-2561c9f32a86"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i09b72198ef2049a59d0032b521440eab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfOS0xLTEtMS0w_95f084e7-3f6c-47e0-aeee-860bad3d59a6"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4829f8fd2ceb499a88d1a605878ef324_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfOS0zLTEtMS0w_51343a00-5d73-446a-b083-149d56dcb047"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ad0091ec4e44a5c95e0c234a8797e30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfOS01LTEtMS0w_461909a3-7ae0-4fbc-b717-eeb7e3b18ba0"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6857d704b93459f901a1ad318f49bde_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfOS03LTEtMS0w_a6955dcc-be8d-41b9-a097-b4669349ec10"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa573862768c47788f0353badcc8a2c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtMS0xLTEtMA_b9667772-c933-4883-8db7-e1572516807d"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if80129c7bc444c6c89ddf9cfc902a3bb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtMy0xLTEtMA_255ac27d-295a-498e-be8d-48180c74763d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8cbb561c5be14e16a7780931e372eeaf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtNS0xLTEtMA_d0ee3348-f3ca-4d3f-8e08-e0c333d8e19e"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i648e5da489e74498abd8b5eb03f88c29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtNy0xLTEtMA_7c64facf-aa3c-4b21-8f50-3ae072ba73c3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i17aabe1f736146ce8ab6b6adf624da61_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtMS0xLTEtMzE5_b61b4c08-4678-436c-83ab-044acb567245"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5951cf3812f84d1b880568d902f8ffb0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtMy0xLTEtMzE5_fab8bd3a-ba87-4b26-8a34-4cab2f828989"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02a6ede247654801b23070be6fe9771f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtNS0xLTEtMzE5_daf705ee-c113-4b49-996f-0085df347fb1"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i927cfac1568340718ec2370561ddff86_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTAtNy0xLTEtMzE5_c16f367c-4a13-4cce-97bd-78ff3635721c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c77548671c64b518a9d84a96771bd0a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtMS0xLTEtMzE5_8a17cd29-434c-4db0-b1d1-126fba316c31"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieebfdbf5d1314dbf8980ccd6c0efeb45_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtMy0xLTEtMzE5_2b8c3404-22e5-4afa-8af6-ba211d7a93d4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifba723c7ee42434e90ebc7232841e8db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtNS0xLTEtMzE5_4dce357d-f2ca-491e-ada5-95eff7c95a57"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15841938ea744133a39ee8f0276f4e94_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtNy0xLTEtMzE5_4552b050-c47b-4600-a184-bad4266f414e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8a7cf6c983f4c9589afcfe337a84376_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtMS0xLTEtMA_3238306d-9810-460e-b9ed-c5cfc65f7844"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85fee7acc1c942e3a814f2d4a0f959b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtMy0xLTEtMA_d8bdd229-b2e3-4b73-8745-1322acc39278"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79b7c87fda55463998db819047f79ca3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtNS0xLTEtMA_71957f5f-8955-459d-ac04-a8a2d6d9ed27"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bc5cd0ff3e2431cb254b14fb4219da8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTEtNy0xLTEtMA_8e79b245-9ee0-4d3d-8054-3e2ea3a00d44"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5e460cd7328340128515c28a0c9286b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTItMS0xLTEtMA_23c2bf34-e474-4f0a-bd9d-39410f1ec8fc"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i27ac6cc477e44273a668068859113a3b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTItMy0xLTEtMA_9aabfa28-b1fd-4ec2-a5da-5d045626cc21"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86ae0a19620647ba86b490ea19afde52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTItNS0xLTEtMA_19b92929-d044-4ff3-be95-ee6823b4185a"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0eb74ef8efdf48d992458b94198588ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTItNy0xLTEtMA_cf9baf83-0d49-4d41-951d-ef79b2293c95"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5e460cd7328340128515c28a0c9286b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTMtMS0xLTEtMA_2494c29f-f728-40c4-bcbf-1446033bda8c"
      unitRef="usd">613789000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i27ac6cc477e44273a668068859113a3b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTMtMy0xLTEtMA_67c2da4c-0a9e-433b-879b-89a6991e5a60"
      unitRef="usd">53165000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i86ae0a19620647ba86b490ea19afde52_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTMtNS0xLTEtMA_655fb0a4-59f5-4a72-9581-4917ccf0b468"
      unitRef="usd">560624000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0eb74ef8efdf48d992458b94198588ac_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTMtNy0xLTEtMA_cdae48e8-8382-4a42-8f57-51c511ac0e73"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9866ab5b25c94734a96e173d3df99684_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTUtMS0xLTEtMA_5459cfb3-0a93-4da0-b995-991c22090faf"
      unitRef="usd">70000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0cffbb4314d64ee4b5119c285bb1bdf8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTUtMy0xLTEtMA_af8a6c63-81a1-48b0-8f1c-ae7be7991e78"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i468e13f71bb44158bc1ebf6b962f54ce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTUtNS0xLTEtMA_241a5725-f4e3-4ea9-8f2a-cd68445e5161"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icce97d825f8b420eb0fba22b6d0a786f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjQyNzc0MTU3YjlmYzQyZWVhZTgzMDk1NWNkODBiNTRjL3RhYmxlcmFuZ2U6NDI3NzQxNTdiOWZjNDJlZWFlODMwOTU1Y2Q4MGI1NGNfMTUtNy0xLTEtMA_a44447bd-aa42-46ea-a17b-0d3746fa9330"
      unitRef="usd">70000</us-gaap:AssetsFairValueDisclosure>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="i1129259eb0a649868776568fa4898425_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMTA5OTUxMTYzNjc4OA_af754001-f9fe-434a-bb35-f35b6928cf74"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i91b1a80eaeeb470bb98449ced38f5857_D20180720-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMTA5OTUxMTYzNDE5Mg_6bf7b1f8-136f-4c27-92a2-6ca7602ca12c"
      unitRef="shares">453000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="i1129259eb0a649868776568fa4898425_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMzU1OQ_9adea93d-c5ff-4eb9-a0f2-3354c59447c6"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i1087025adac9402fa10512e9bbce394b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMzYyNA_e36257cf-f873-4081-b943-24cc4e63da10"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase
      contextRef="i1087025adac9402fa10512e9bbce394b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfMzY5OQ_926bd635-04ce-4c20-93dc-b7602efcf126"
      unitRef="shares">24000</sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RleHRyZWdpb246OWUyMmFmODEyMTIyNGIxZmEyYzU2ZjI1NzRjZjBiODdfNDA4Mw_38a4d4ab-a1b8-45cb-91ce-504215c75d10">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Free Shares valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR / USD exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated correlation between Sangamo and Sangamo France stock prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR / USD exchange rate volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate and cost of debt by expected exercise date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="i373acdae6305402aa0be5cf76855d613_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMS0yLTEtMS0w_02622810-b424-4b61-acf5-e8dcc99f378c"
      unitRef="usdPerShare">11.83</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i3a2f2e458499460c9d2f8569ded9b145_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMS00LTEtMS0w_a03b5438-cd8d-4e91-85d8-8b8d6ca1a3fe"
      unitRef="usdPerShare">15.61</us-gaap:SharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i3ad2a2e3a84b4100b7319b30812c47e6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMi0yLTEtMS0w_6e1ec399-c853-42f1-a8ef-1e4388dfc3df"
      unitRef="eurPerShare">2.92</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="icef8cccbf6ca4534ae5c619f394063a1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMi00LTEtMS0w_2425f39e-bed8-4cb5-a20b-26e7a6c1dd54"
      unitRef="eurPerShare">3.85</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i6869d31d7a094145bfb28ac75b1e9b65_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMy0yLTEtMS0w_06742d19-79ce-4e80-ab3a-54f336284c9d"
      unitRef="number">0.84</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i280b535896024bcd95cb6e05701ce4a5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfMy00LTEtMS0w_1a4e2232-a828-40bd-a21c-442859d22796"
      unitRef="number">0.82</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i0ad1dcdb92f74b6aa8153279f247ec2b_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNC0yLTEtMS0w_ddaf990b-2977-4390-8185-9bb1a7092801"
      unitRef="number">1.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i672e278ea9d9400fb2d871ecc0490a9c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNC00LTEtMS0w_2f244093-e4f9-4c2e-a7ce-4ee24ecbba99"
      unitRef="number">1.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i096af9793db343b0815caa338ffd63a8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNS0yLTEtMS0w_97b70b59-994c-4978-b6f7-f79bff541bb3"
      unitRef="number">0.913</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ic336725f5f2a462798de6f9160210fdb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNS00LTEtMS0w_39bf3cfb-36c4-4e46-b212-e4292631db97"
      unitRef="number">0.889</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i1004bec248ae4ca1ba8a9c29ad354f09_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNi0yLTEtMS0w_ce9386ee-dd21-4d7a-bb21-29d783135249"
      unitRef="number">0.913</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i46c3138c0eba415ea37d06436df62854_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNi00LTEtMS0w_6b4bb703-5b0e-48c7-9864-94e578f9ae52"
      unitRef="number">0.889</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i859a69b7c32743829ed4f102732a1722_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNy0yLTEtMS0w_e8ff0c83-6bea-4ee0-9dc1-3650317e7a95"
      unitRef="number">0.063</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i39b2e0222b2542508d6cd3681b08a431_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80My9mcmFnOjllMjJhZjgxMjEyMjRiMWZhMmM1NmYyNTc0Y2YwYjg3L3RhYmxlOjJjOGJmMGM4NWY4ZDRiOTZiZDVhZDQ4ZjNkNTgwYzFlL3RhYmxlcmFuZ2U6MmM4YmYwYzg1ZjhkNGI5NmJkNWFkNDhmM2Q1ODBjMWVfNy00LTEtMS0w_cb7ba3d4-4d08-4b49-88a6-acaa787222a3"
      unitRef="number">0.063</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTU2Mw_edb9eef0-3ad8-4922-bbcc-a2e02bd59f13">CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.565%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2021 and 2020. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews the marketable securities for other-than-temporary impairment losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than &lt;/span&gt;&lt;/div&gt;not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#x2019;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#x2019;s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at either March&#160;31, 2021 or December&#160;31, 2020.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTU2NQ_cf5939df-8e98-4868-8438-e4ba125b926b">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.565%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i434d6421401646d8819ebb7f70ca4def_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNC0yLTEtMS0w_02b2483d-83db-47f1-9c22-b4da5e230e6f"
      unitRef="usd">47635000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i434d6421401646d8819ebb7f70ca4def_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNC00LTEtMS0w_0df09fc1-d356-42a1-8c66-21279964f7b4"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i434d6421401646d8819ebb7f70ca4def_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNC02LTEtMS0w_ceae51ea-aca4-420c-9536-9fbbc8676da2"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i434d6421401646d8819ebb7f70ca4def_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNC04LTEtMS0w_ecb00d35-4f7d-4e5f-a1fe-5404d27db749"
      unitRef="usd">47635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie037112c32294882bba7e7dbbf15ae0a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNi0yLTEtMS0w_ec3b6e8e-e427-4fbf-9e65-d1ea0940cb32"
      unitRef="usd">47635000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="ie037112c32294882bba7e7dbbf15ae0a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNi00LTEtMS0w_fb6216b1-fe67-4b9a-aad5-e469c03c1e42"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="ie037112c32294882bba7e7dbbf15ae0a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNi02LTEtMS0w_3283866c-ea65-4c75-8ef6-d142dbb7a92f"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie037112c32294882bba7e7dbbf15ae0a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfNi04LTEtMS0w_15deeae9-e101-46b6-bff8-e3d15049f7e8"
      unitRef="usd">47635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iddf917e0cbb043a6a5d13564bd385789_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOC0yLTEtMS0w_09eb9f9b-59d7-44eb-a679-58b6213e2567"
      unitRef="usd">177101000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iddf917e0cbb043a6a5d13564bd385789_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOC00LTEtMS0w_7d5ce0e8-0e7f-4d17-9bd6-d2d6a8f9c891"
      unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iddf917e0cbb043a6a5d13564bd385789_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOC02LTEtMS0w_9e1951d0-f143-4913-a888-2fa106c3f8d7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddf917e0cbb043a6a5d13564bd385789_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOC04LTEtMS0w_e3353e7e-caed-44c9-ab60-1c4dd1a702c0"
      unitRef="usd">177154000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOS0yLTEtMS0w_a93e8346-b802-4597-baa6-a630a7b285e3"
      unitRef="usd">39031000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOS00LTEtMS0w_d9b1ae35-f9e9-42fe-b35d-4b1ede454488"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOS02LTEtMS0w_42a9a9a7-6201-42ab-bb49-9c95b5c9abeb"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccd3a0ae10b5494d9f2589c18ef4f889_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfOS04LTEtMS0w_4c50210d-3f45-49e2-aa07-a12d5941a17b"
      unitRef="usd">39022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1b613add127642da88c0f1e731060ffd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtMi0xLTEtMzgz_c24e239c-b11e-4574-9363-6b848d866097"
      unitRef="usd">11495000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1b613add127642da88c0f1e731060ffd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtNC0xLTEtMzgz_e6bcb4c5-947a-4568-9f4b-9d9b2cae348d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1b613add127642da88c0f1e731060ffd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtNi0xLTEtMzgz_f910c3aa-3f95-4c53-8306-b991ad789b42"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1b613add127642da88c0f1e731060ffd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtOC0xLTEtMzgz_9377e2ef-cdd1-4313-ae0d-16c6a6fd079a"
      unitRef="usd">11494000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i53804a6be8344f08a5725ae1fe862146_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtMi0xLTEtMA_dbb46eed-5f44-4b6b-93c3-5571c63c855b"
      unitRef="usd">36419000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i53804a6be8344f08a5725ae1fe862146_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtNC0xLTEtMA_2162c242-f620-47a1-8496-56b35c44ea49"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i53804a6be8344f08a5725ae1fe862146_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtNi0xLTEtMA_ecd38838-ea95-439e-bd7a-590f14c9d850"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53804a6be8344f08a5725ae1fe862146_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTAtOC0xLTEtMA_4da345cc-cc18-4929-9f5b-18d6308d614b"
      unitRef="usd">36410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTEtMi0xLTEtMA_73684941-5f0e-4399-b042-e36a639c2619"
      unitRef="usd">242401000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTEtNC0xLTEtMA_715c389f-1c75-4435-9339-2fe322875c4e"
      unitRef="usd">59000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTEtNi0xLTEtMA_c8b89999-6d2d-4792-8714-0949de36c845"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8736f8df5d91428fbe929d51fd7ce0ab_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTEtOC0xLTEtMA_d194716b-acb1-4cf6-86c3-8165c220faa0"
      unitRef="usd">242460000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTItMi0xLTEtMA_915d8135-9c1a-4131-808b-a9edcf76be41"
      unitRef="usd">506447000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTItNC0xLTEtMA_b4056541-3dd6-4139-be2f-03d62ea92afb"
      unitRef="usd">124000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTItNi0xLTEtMA_bed9ff98-70ca-4187-9597-6c8f5aee74a3"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTItOC0xLTEtMA_2714db83-fdee-4fd5-8d83-0e268dc1e2ec"
      unitRef="usd">506540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTMtMi0xLTEtMA_d6bd36d2-26df-46ab-9206-c1f8fb33171b"
      unitRef="usd">554082000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTMtNC0xLTEtMA_e8e46b62-9d0f-4543-a70f-7af62bf4d496"
      unitRef="usd">124000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTMtNi0xLTEtMA_ececd9a6-1957-4fe0-9acb-e184a10f56b3"
      unitRef="usd">31000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTMtOC0xLTEtMA_53aabeef-a99f-4a5a-94c8-d14502232635"
      unitRef="usd">554175000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0ad382cd550f476288b6b8449774030a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTgtMi0xLTEtMA_630cb017-f416-4c67-b8ad-3fe7cfa767d1"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i0ad382cd550f476288b6b8449774030a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTgtNC0xLTEtMA_813dbcd0-c0a6-446f-9aea-e8925ec991ab"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i0ad382cd550f476288b6b8449774030a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTgtNi0xLTEtMA_524a7c1d-d21a-4dc4-a4b3-d50f2ab7926a"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0ad382cd550f476288b6b8449774030a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMTgtOC0xLTEtMA_1c587fcb-5a6e-4658-a577-605975ff92a0"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id08febcafb084cb3800af6dd3c8ae060_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjAtMi0xLTEtMA_ccdc8002-6dbe-460c-868f-924c50d20e3b"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="id08febcafb084cb3800af6dd3c8ae060_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjAtNC0xLTEtMA_04bb42ab-284f-4972-a0d9-1495f05c6c9b"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="id08febcafb084cb3800af6dd3c8ae060_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjAtNi0xLTEtMA_c7f2adc3-1de2-41fa-8d68-537437d31d11"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id08febcafb084cb3800af6dd3c8ae060_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjAtOC0xLTEtMA_4c52d209-0d58-4aa0-a8b2-e4100918924a"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i00b352c0d2ab458ebc5713e73ef66c30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjItMi0xLTEtMA_d7b6de10-4dcf-457c-a7b7-4718ccc0590f"
      unitRef="usd">213500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i00b352c0d2ab458ebc5713e73ef66c30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjItNC0xLTEtMA_f55ebd5f-48f7-42ad-b93f-6500291d633e"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00b352c0d2ab458ebc5713e73ef66c30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjItNi0xLTEtMA_da344757-9b87-4bf8-ae37-cbe277571c0e"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00b352c0d2ab458ebc5713e73ef66c30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjItOC0xLTEtMA_514d5990-f808-4ef2-a87a-0f2a919a2f34"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic558cd205e844605965ec5e4461a1ba5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjMtMi0xLTEtMA_36f05169-6cfb-48d6-baa3-59843072ecc3"
      unitRef="usd">59575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic558cd205e844605965ec5e4461a1ba5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjMtNC0xLTEtMA_497ff521-5f8e-43ad-8bbf-01adfec96fcf"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic558cd205e844605965ec5e4461a1ba5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjMtNi0xLTEtMA_09de1191-3807-4c1f-9f75-d0cf3606df72"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic558cd205e844605965ec5e4461a1ba5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjMtOC0xLTEtMA_5a048071-54c8-4e7c-984b-83aaee921a98"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i81c0ac6823a34b509afee459208f16b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtMi0xLTEtMzg5_9d0ba7aa-5002-4366-b628-8975b0f6e471"
      unitRef="usd">12311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i81c0ac6823a34b509afee459208f16b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtNC0xLTEtMzg5_5d6d4a96-2007-42ce-a5b3-187b2876895f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i81c0ac6823a34b509afee459208f16b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtNi0xLTEtMzg5_665e6401-c2ea-4caf-bb34-7328f9435674"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81c0ac6823a34b509afee459208f16b2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtOC0xLTEtMzg5_a1e81276-6521-42b7-86cc-77f19ca3cad0"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i64c74fee69544d6fba7898340eefc923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtMi0xLTEtMzg5_ed9a8167-8acb-40c9-b9ef-19883b779aca"
      unitRef="usd">17905000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i64c74fee69544d6fba7898340eefc923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtNC0xLTEtMzg5_1654576a-08a8-4c5c-bc90-b11c9e1a1759"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i64c74fee69544d6fba7898340eefc923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtNi0xLTEtMzg5_fcff054d-71d7-4ba3-b1cf-0a6d6fd46497"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64c74fee69544d6fba7898340eefc923_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtOC0xLTEtMzg5_d745c12f-43d9-4f65-8ce4-2b790262ec77"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtMi0xLTEtMA_8e51fc0c-165b-4cff-bdb4-cae6dd48ff5e"
      unitRef="usd">257284000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtNC0xLTEtMA_97f4115e-fef8-481d-b674-2e77e5495be4"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtNi0xLTEtMA_9277ed18-e715-440e-92bf-2480ee6f157d"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80f656d41c73409ca3afd6dd2aff8f8e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjQtOC0xLTEtMA_f13288de-b65c-427a-b734-8d40cd1b4a3a"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtMi0xLTEtMA_68e0a300-c26b-4ae5-b45b-55a6134d5fea"
      unitRef="usd">560575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtNC0xLTEtMA_994638e8-0787-478d-9e89-dc2237b6a081"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtNi0xLTEtMA_68a143ca-3eaa-4544-ac6b-1d2dfcdd7a87"
      unitRef="usd">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjUtOC0xLTEtMA_1459898b-9897-466e-bb5c-43ca35c9dbac"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjYtMi0xLTEtMA_35ef8173-8ba6-4b06-94e7-e2e269f43afe"
      unitRef="usd">613740000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjYtNC0xLTEtMA_f9c105d8-e41c-4c63-a6c2-0190b43b9187"
      unitRef="usd">86000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjYtNi0xLTEtMA_77b93e9a-5383-45be-a55c-732f289a1969"
      unitRef="usd">37000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmI3YTJiMWU4MDkxODRkOGY5YmUwMzQ4NzI2ZDUyM2FkL3RhYmxlcmFuZ2U6YjdhMmIxZTgwOTE4NGQ4ZjliZTAzNDg3MjZkNTIzYWRfMjYtOC0xLTEtMA_a9a501ec-e484-433a-b735-b38610d80e3c"
      unitRef="usd">613789000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTU2MQ_89c62e11-a401-4b38-8eab-246f9abab4a4">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMS0yLTEtMS0w_ec1235bc-044c-49f8-b06d-490e5af713c7"
      unitRef="usd">464109000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMS00LTEtMS0w_077ce745-e869-4a41-a161-4bbbac0de334"
      unitRef="usd">510094000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMi0yLTEtMS0w_22705731-098c-4bab-a185-13afe88677be"
      unitRef="usd">42431000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMi00LTEtMS0w_dc1df223-d8d8-46a5-a5ec-00152aed21b1"
      unitRef="usd">50530000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMy0yLTEtMS0w_e1a6260a-19f4-4c75-ad5e-61564dc7b7fc"
      unitRef="usd">506540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RhYmxlOmQ0YWU3ZGYyMzZjYTQyMjRhMzUyZjkzMGQwZDA1ZTU5L3RhYmxlcmFuZ2U6ZDRhZTdkZjIzNmNhNDIyNGEzNTJmOTMwZDBkMDVlNTlfMy00LTEtMS0w_60a066d5-3017-4fde-9774-e0fe49838114"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTM3NDM4OTUzNTIxODA_e6b7e5ba-c7d8-458e-89b6-15bae8d8a97f"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="if88ebd43c71848c89734b2715f66361b_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80Ni9mcmFnOjYzOTdmMjdiZDAwNTRmMjc4N2IyZmFhN2JjZTU3MWM4L3RleHRyZWdpb246NjM5N2YyN2JkMDA1NGYyNzg3YjJmYWE3YmNlNTcxYzhfMTM3NDM4OTUzNTIxODA_f625b17b-d73f-40ac-a177-d9d62e5e54a8"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80OS9mcmFnOjkyNzQ3ZTkyYjA0NTQ0ZTc4NWNkYWNiOTgxMjUzMjAwL3RleHRyZWdpb246OTI3NDdlOTJiMDQ1NDRlNzg1Y2RhY2I5ODEyNTMyMDBfMTA3NA_0b832f53-659b-40c6-b9af-9774e4a2bd28">BASIC AND DILUTED NET LOSS PER SHARE&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares subject to stock options and restricted stock units (&#x201c;RSUs&#x201d;) outstanding and the employee stock purchase plan (&#x201c;ESPP&#x201d;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of March&#160;31, 2021 and 2020 totaled 17,614,376 and 14,849,728, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80OS9mcmFnOjkyNzQ3ZTkyYjA0NTQ0ZTc4NWNkYWNiOTgxMjUzMjAwL3RleHRyZWdpb246OTI3NDdlOTJiMDQ1NDRlNzg1Y2RhY2I5ODEyNTMyMDBfMTA1MA_1c17aafa-cc3e-4074-8b16-052beb07d609"
      unitRef="shares">17614376</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl80OS9mcmFnOjkyNzQ3ZTkyYjA0NTQ0ZTc4NWNkYWNiOTgxMjUzMjAwL3RleHRyZWdpb246OTI3NDdlOTJiMDQ1NDRlNzg1Y2RhY2I5ODEyNTMyMDBfMTA1Nw_f2050796-3fe1-4bea-97c7-67e83eff4544"
      unitRef="shares">14849728</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i7dc2e857539f4ef4ba7daadf58df7f59_D20171201-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjI_ad7493e4-6c9e-4384-aef6-1ba627a50dce">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#x201c;Novartis&#x201d;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#x201c;ZFP&#x201d;) transcription factors (&#x201c;ZFP-TFs&#x201d;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company will perform early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, IND-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#x2019;s proprietary adeno-associated viruses (&#x201c;AAVs&#x201d;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All payments received under the agreement, when earned are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and estimated research costs of $20.1&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its performance obligation. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $64.7&#160;million and $70.9&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and 2020, the Company recognized revenue of approximately $6.2&#160;million and none, respectively, related to the upfront license fee and approximately $1.7&#160;million and none, respectively, from research reimbursement costs related to the Novartis agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $1.5&#160;million for financial advisory fees during the year ended December 31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company amortized $0.1&#160;million and none during the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (together with BIMA, &#x201c;Biogen&#x201d;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#x2019;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#x2019;s common stock (the &#x201c;Biogen Shares&#x201d;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.45&#160;billion in first commercial sale and other sales-based milestone payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12&#160;neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#x2019;s disease, ST-502 for synucleinopathies including Parkinson&#x2019;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#x2019;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e. through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to ten targets. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#x2019;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#x2019;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock purchase agreement also provides that from the first anniversary of the effectiveness of the collaboration agreement, through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule&#160;144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#x2019;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i)&#160;the two-year anniversary of the effectiveness of the collaboration agreement, (ii)&#160;the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock and (iii)&#160;the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $204.6&#160;million includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#x2019;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $175.9&#160;million and $183.2&#160;million, respectively, related to this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and 2020, the Company recognized revenue of approximately $7.3&#160;million and none, respectively, related to the upfront license fee and the excess consideration from the stock purchase, and approximately $3.1&#160;million and none, respectively, from research reimbursement costs under the Biogen agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the transaction price of $204.6&#160;million, as a contract asset. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company amortized $0.1&#160;million and none during the three months ended March&#160;31, 2021 and 2020, respectively. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#x201c;Kite&#x201d;), which became effective in April 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#x201c;ZFNs&#x201d;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#x201c;NK-cells&#x201d;) including the insertion of genes that encode chimeric antigen receptors (&#x201c;CARs&#x201d;), T-cell receptors (&#x201c;TCRs&#x201d;), and NK-cell receptors (&#x201c;NKRs&#x201d;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the effective date, the Company received a $150.0&#160;million upfront payment from Kite. Kite reimburses the Company&#x2019;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial research term in the agreement is six years. Kite has an option to extend the research term of the agreement for up to two additional one-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $3.4&#160;million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $75.3&#160;million and $81.4&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Giroctocogene Fitelparvovec Global Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia&#160;A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia&#160;A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $134.0&#160;million, which represents the upfront fee and research services fees of $79.0&#160;million and two unconstrained milestones achieved of an aggregate amount of $55.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company entered into an amendment to the agreement, pursuant to which the Company transferred the IND for giroctocogene fitelparvovec to Pfizer. Upon this transfer the Company achieved a $25.0&#160;million milestone as the conditions for achieving the milestone were met. The cumulative revenue recognized in connection with this milestone was $25.0&#160;million during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia&#160;A collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the giroctocogene fitelparvovec product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $2.4&#160;million, decreased net loss by $2.4&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.02 for the three months ended March&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company determined that there was a high probability of achievement of a $30.0&#160;million milestone with Pfizer for giroctocogene fitelparvovec. The milestone was subsequently achieved upon dosing of the first subject in a Phase&#160;3 clinical trial in early October 2020. The cumulative revenue recognized in connection with this milestone was $30.0&#160;million during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three months ended March&#160;31, 2021. The Company recognized $2.2&#160;million of upfront license fee and research services and $1.0&#160;million milestone achievement as revenue related to this agreement during the three months ended March&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C9ORF72 Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal lobar degeneration linked to mutations of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;fifteen years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following termination by the Company for Pfizer&#x2019;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time. Following termination by Pfizer for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pfizer agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $17.0&#160;million, which represents the upfront fees of $12.0&#160;million and one unconstrained milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $5.0&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December&#160;31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three months ended March&#160;31, 2021. The Company recognized $0.4&#160;million of upfront license fee and research services as revenue related to this agreement during the three months ended March&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#x201c;SCD&#x201d;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#x2019;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#x2019;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#x2019; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $93.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones in the amount of $13.5&#160;million and estimated research costs of $59.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $0.8&#160;million and $1.2&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company achieved a $6.0&#160;million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $5.9&#160;million as of March&#160;31, 2021 and included $0.1&#160;million recognized during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company achieved a $7.5&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $7.3&#160;million as of March&#160;31, 2021 and included $0.1&#160;million recognized during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(729)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This adjustment decreased revenue by $2.2&#160;million, increased net loss by $2.2&#160;million and increased the Company&#x2019;s basic net loss per share by $0.02 for the three months ended March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;California Institute for Regenerative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#x2019;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of March&#160;31, 2021, the Company had received $5.2&#160;million under the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of March&#160;31, 2021, and December&#160;31, 2020, $6.6&#160;million and $6.4&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i3acb6e7ece7c4264be4a73e7e4f9a1d1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTc4NA_65fa7973-a583-4f2b-a1d6-45a6d0f81068"
      unitRef="usd">75000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="id33584313d634d6ebb308bbe8e5d106b_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk1OA_079702a3-ff71-4cd3-9f30-231718ba2fe5"
      unitRef="usd">420000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i7809379654904198b0f40fede3b357a4_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk5Nw_a208f736-3e45-4abf-886d-0bd18d09ecd9"
      unitRef="usd">300000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="if7f4f202adee470e8770f3ce345ea450_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjk0MA_54afdc98-26e0-4c04-9bc1-3c47ae066490"
      unitRef="usd">95100000</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementLicenseFee
      contextRef="if7f4f202adee470e8770f3ce345ea450_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjk3OQ_717bc127-453d-45a3-b230-390762ce4342"
      unitRef="usd">75000000.0</sgmo:CollaborativeArrangementLicenseFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="if7f4f202adee470e8770f3ce345ea450_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzAxNA_cf8dd13f-cb62-4d90-baf3-69d5d9a3c71e"
      unitRef="usd">20100000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i757166e143b64a41ba577ebe4be02b45_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDYyNw_9440c3ba-4a4f-4ade-afcd-7c28208c04f6"
      unitRef="usd">64700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i34fb2fbe43f84642b4ef2537c5369e1e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjI3MQ_4bf2ada3-f3bc-47c3-91d1-1a8d4b45297f"
      unitRef="usd">70900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3a7d845e25d44dda4758f9bcaba97fa_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NTQyNg_5963fc08-ad7b-43cb-af56-6c6f5f1a26de"
      unitRef="usd">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0431659b3584e55b72f8e5b04fcf870_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzYxOA_82b308b9-8c22-4b50-8e7b-aa23250bc546"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15ffb4ef28e24434bf448ba66f1f1afc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NTQ0Ng_549de850-2a93-42af-9a1f-0d45a6894c11"
      unitRef="usd">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i005c57a24e8f443ca9c1180106705ef2_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzY4MA_ecd7889a-4204-49de-89d1-9faf015a2d1b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczNw_0687e4f3-6bab-4297-a871-55274530e247"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDgwNg_d0eb9294-eb19-4d6e-8140-8e951350e776"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDgxMg_d55666bf-a09a-4e41-acbd-4c8e7f5ffcb9"
      unitRef="usd">75000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="i7283d3c5f03e48df91803ba6f5d86094_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0MQ_0687e4f3-6bab-4297-a871-55274530e247"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i54a4cf97110343f3a88212e70424cd96_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NTYyMw_ff14de3a-fc58-4d0c-887a-ab5576552bd7"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i3542eb13ee6148b8b4bcdd99fef16454_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTk4Mw_1430c7c8-e74a-4bf4-8e0e-48c87ced1ec5"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNTg5NA_2b956dc5-5df9-4993-a620-d65e35e405b8"
      unitRef="shares">24420157</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="idcd855b9275c4a8eb8f323a68bbf1d77_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNTk4MQ_509534f2-90ea-497d-bb6a-84e6fa394aed"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjAzNA_02a24daf-a32f-48c6-b667-14263af58fef"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjMwMg_803d7282-ba7c-4da4-a3d5-130b1f4530bd"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i9cb99906f06b46e8b267391bde6b0830_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjQyOQ_a69ac5d8-66b5-4e13-b790-d2b9c396f942"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="ic36d2806042d4050b552799fc92519e9_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjU5MA_196dd90c-9441-48a8-b32d-27685c06d7c7"
      unitRef="usd">2370000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="ia4bf6163ffff418c83013f140a3d867b_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjc1Mw_a0980b52-4a6a-4f71-9071-b575ad5e483e"
      unitRef="usd">925000000.0</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i3274c4f79e0340a5ae43580f04c8e34f_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjgwMQ_5efd2ee6-7c7e-4eb2-a3a6-d5d193271bd3"
      unitRef="usd">1450000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementNumberOfProductTargets
      contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNzUxMg_15af1a1b-3920-4665-9ee1-1d06e38bfc8e"
      unitRef="product_target">12</sgmo:CollaborativeArrangementNumberOfProductTargets>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="ic36d2806042d4050b552799fc92519e9_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNzU5Nw_00c892c1-f7be-4dcd-b083-ac71a701c36e"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationAgreementNumberOfAdditionalProductTargets
      contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNzgyNA_bee6a386-61ab-42ff-bf41-53559af91dec"
      unitRef="product_target">9</sgmo:CollaborationAgreementNumberOfAdditionalProductTargets>
    <sgmo:CollaborationAgreementTargetSelectionPeriod
      contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNzg4MA_3a139834-58b3-4266-9fa3-acc97260ed02">P5Y</sgmo:CollaborationAgreementTargetSelectionPeriod>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="ic36d2806042d4050b552799fc92519e9_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfODQ2Ng_f699eac4-daac-4adb-9cc9-00b096677399"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="ic36d2806042d4050b552799fc92519e9_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfODcxNw_0b7b97a1-c25f-4cd5-9dfa-c41c368cf81a"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationArrangementResearchPeriod
      contextRef="i3e07997bca414cf2953b42b65cb1fefb_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfODgyOA_b296b354-3543-4850-b9c3-234752ab6230">P7Y</sgmo:CollaborationArrangementResearchPeriod>
    <sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace
      contextRef="i4f7ac715a9b948b18839034f530a5ddd_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfOTQ1Nw_6a89725b-2a56-40e1-a698-816d772fb499"
      unitRef="product_target">10</sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace>
    <sgmo:CollaborativeArrangementStandstillRestrictionPeriod
      contextRef="i1f78e88d6b69472e839f423e5b345307_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjU_baa00ea5-9d95-4029-b9a4-3a4eebf3a1aa">P3Y</sgmo:CollaborativeArrangementStandstillRestrictionPeriod>
    <sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage
      contextRef="ib69b2d9da4aa46f294f132d7d0fd52f0_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA0MjE_2323b309-3660-415c-b3f6-9cc1e032f47b"
      unitRef="number">0.05</sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage>
    <sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld
      contextRef="ib69b2d9da4aa46f294f132d7d0fd52f0_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA3NDE_ab0c0934-d2c0-4b41-ad41-f94ecb0ad238"
      unitRef="number">0.50</sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld>
    <sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod
      contextRef="i1f78e88d6b69472e839f423e5b345307_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMTk_58f628c8-fe4a-40c7-b66a-6c9e2d562c86">P2Y</sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod>
    <sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage
      contextRef="ib69b2d9da4aa46f294f132d7d0fd52f0_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTE2MzY_293b1140-37f8-4df8-abfb-50fb28906a8a"
      unitRef="number">0.05</sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjE5Ng_1d398edf-04c4-4238-bada-2c32d6cd8367"
      unitRef="usd">204600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTIwODc_cb04605c-f574-4a13-9d13-ed6d15301479"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction
      contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTIxNDY_af3299c7-f15d-4254-9724-0005c1e24d85"
      unitRef="usd">79600000</sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTIxOTQ_19cf3cd2-3687-4043-b757-90b7001269f5"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTIyNTI_2b194fc4-3fbe-40a5-b800-cb60d82bcabe"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7f5f5ec067c64bd38439f1f0e454a1a3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQyNjU_99e09286-18d2-408d-bcda-677fdd48d4ac"
      unitRef="usd">175900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i0ce08d1f25be4729bc3e45da23cef7b0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjIzNA_77c9bd3e-73a2-47cd-b4a1-8429cdaa722b"
      unitRef="usd">183200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2118dcb01a3143bb92d2503658c8e4de_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjE2Ng_fee621c4-d802-4e80-b9f7-0ab4e6c3532c"
      unitRef="usd">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98afd062347644fe9caa179181f1d6bb_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzQ2MA_895bec06-b666-4958-a0da-03b33d59ed80"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1f36c6406ec47d0a03002619c66f091_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjE4NQ_324940a6-353e-4d3b-af84-d36c3d64c49b"
      unitRef="usd">3100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i828c0aafea3d4fdfb8f588e64d921e4c_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzQ2OQ_d7b048b8-4095-457f-bd89-1ac842d6e12e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ0MzM_fb16a5dd-56b7-41f4-82e6-4d172db63c0d"
      unitRef="usd">7000000.0</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ1MDY_a391ecd9-c3f0-4ccb-85d9-d615a43063d0"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iaee2adb3bcb4418d9c71c6bce8427a96_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ1MTI_19cf3cd2-3687-4043-b757-90b7001269f5"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ1NTE_71d3c437-00c4-4ef5-8b9d-9748a55894dd"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i1492cd406dd2436db6296241d9022d11_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ1NTc_cb04605c-f574-4a13-9d13-ed6d15301479"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i53a6386cca364200a895bc9cda07eadd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ4Njk_840681c0-87c5-444e-b2dc-956783cf3324"
      unitRef="usd">4100000</us-gaap:ContractWithCustomerAssetNet>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTQ4OTA_5b40cd5b-57b2-411e-bbaa-5f6252677e9d"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTY2Mg_2320af8d-2c2c-4cbd-afd2-203c5f15b345"
      unitRef="usd">204600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i4f7ac715a9b948b18839034f530a5ddd_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTUyNTk_77b1c9e1-9c12-4a72-8ec5-8b340496f466"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i6cf45da81af341b5af253ace0465bd98_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTkzMw_edacfe5c-22a1-4cde-8640-5ab363b8f4f5"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTUzNDY_d09b6420-44b5-4c3c-9a4a-56a11d1943d3"
      unitRef="usd">2900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i4ea21dddba944fae95f081e6e9953e91_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTUzNjc_37e6dd58-aa3e-4b50-96fb-915ed9359e43"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="ibcd9e729b2b04d48ba191bad15f4bb37_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTUzNzc_2b194fc4-3fbe-40a5-b800-cb60d82bcabe"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <sgmo:MilestonePaymentsReceived
      contextRef="i868c9fe32a52452dab9aa2f991f5ac1f_D20180405-20180405"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTc3MDA_af62d61b-0f42-4b03-9939-96b9f5b33db7"
      unitRef="usd">150000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i6d691cfac5fc48f6ae86378e6b4a002a_D20180405-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTc5MzA_732e0026-1cc0-408b-a5a1-dd33afd71b50"
      unitRef="usd">3010000000.00</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="i5161917923e141dba34488ab948e41a6_D20180405-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTgwNDA_09417a48-acea-4c79-9222-296bfbf08141"
      unitRef="usd">1260000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="iad0d9faf81c84a81aa9b16164821cf1d_D20180405-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTgxODI_1e37da87-45b2-4164-ad8b-eaddfe40f6e4"
      unitRef="usd">1750000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTkxMzY_ef5e6340-6264-45d0-890c-bbdc3b637a33">P6Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:NumberOfOptionsToExtendInitialResearchTerm
      contextRef="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTkyMTQ_d29aa5ec-b46e-47a4-a08c-569313fb7ab1"
      unitRef="option">2</sgmo:NumberOfOptionsToExtendInitialResearchTerm>
    <sgmo:ExtendedResearchTermOfAgreement
      contextRef="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjA_917b356b-fab0-4dca-b9f4-e139a3de0f05">P1Y</sgmo:ExtendedResearchTermOfAgreement>
    <sgmo:SeparateUpfrontFee
      contextRef="if89351b164f142b5be5c21c71d0eec80_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTkyNzQ_dd8b5b70-0c89-4ea6-88ae-c4fb72b624c3"
      unitRef="usd">10000000.0</sgmo:SeparateUpfrontFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan
      contextRef="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk1ODc_8e9d9e2d-a994-461a-98e0-7cf549a97b3e"
      unitRef="usd">3400000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk3MzQ_f9120245-0ce1-44db-a883-b69b8b5d482b"
      unitRef="usd">189300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk3Nzc_db8ebdaa-9028-4015-8fd5-381403b42365"
      unitRef="usd">150000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="idafbd726ab0f4fb09384c2cbffff74e0_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTk3ODQ_3eeec428-af18-4332-bdcd-46083f774759"
      unitRef="usd">39300000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia8ba008f3a5a42be83d38ba385bbc8d9_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjIyODE_c7e4b3ab-1712-48fb-b9f0-34cea7ef11f6"
      unitRef="usd">75300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i184e9ab5d0b74ca68b16888bb4007dc0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjIyODg_cb5eaeb4-8c06-4167-97ef-c1544a4846d8"
      unitRef="usd">81400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i2a3d9c81024248b1adfc4a25b7c4d391_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjc_c3847f46-7b40-40de-8c8b-310d6349c148">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb423d0affaa4d709010389b445356c0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfMy01LTEtMS0w_5a5277eb-6b0f-481f-a0b3-b351d7c46447"
      unitRef="usd">6159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01acb0b530634a9f92961bce1668f40d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfMy03LTEtMS0w_2fdeed6c-74e8-43f8-83f2-77bd72fced94"
      unitRef="usd">6227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d076890fcfc4f4cae05e8d5e034c7b2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfNC01LTEtMS0w_2fb373b4-576c-40e6-8e69-ffa91b209d80"
      unitRef="usd">129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba7559393313442091af1abf5c735f2b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfNC03LTEtMS0w_64e449e5-508f-42da-a8e8-dd43463e0b55"
      unitRef="usd">992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a3d9c81024248b1adfc4a25b7c4d391_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfNS01LTEtMS0w_9156eb22-1561-4559-92e9-99c583a542c5"
      unitRef="usd">6288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d499b745bbd4aca82c6887941eb2f4b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOmUzNzQ4ODc1MjM0YTRjMGQ5NWRkZTdlOWRkYTRkZTg4L3RhYmxlcmFuZ2U6ZTM3NDg4NzUyMzRhNGMwZDk1ZGRlN2U5ZGRhNGRlODhfNS03LTEtMS0w_f168f1ab-cfed-49a2-95f9-1f7eb5fa566c"
      unitRef="usd">7219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm
      contextRef="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjQyNzM_bcd5a05e-ec39-4625-8743-a9111e194bdd">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="iad9f9edf27124c6a8611cf6dcc485c06_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjUxNTI_4e68f986-98c3-4f60-acbb-fdc9d25b91c0"
      unitRef="usd">70000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i11db6cb00c9c4e91a017c15c76688b71_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU0NDI_3834b228-f549-4394-9aa8-e512acee5fbe"
      unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
      contextRef="i607adea8b9544c9a857fd7049243e384_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU1NzE_4209e013-acf3-471e-b063-3659dee35fb0"
      unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="if807a38abb434889be2ed63115c6d893_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU4Nzk_bafd5bd0-e1f2-4380-b1ca-b9427b65cd12"
      unitRef="usd">475000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i2b355d6fe77d457698c955bfed974e53_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU5MDQ_66afe849-c93e-4e18-9e04-dd8dd98f6d34"
      unitRef="usd">300000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i0739b227da3b4bca85dcba2a54effd31_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjU5Mjg_fe829ab6-61b6-4dd5-88c9-a415fb00fb59"
      unitRef="usd">175000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="ie9c5e3edd0db4669b6958fb4f83b506b_D20170501-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY1MDc_a9c06782-402a-459e-bea8-63925472505e"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <sgmo:MilestonePaymentsReceived
      contextRef="ie9c5e3edd0db4669b6958fb4f83b506b_D20170501-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY1MjQ_5e77f5c4-e319-4e60-b5a5-2dea1fbf94ad"
      unitRef="usd">55000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="ia108ccb69cd546219ec3a5224afff3d6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY1Njg_6e4d4ec4-c6a9-4424-8aa1-5accf783f3e4"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="ia108ccb69cd546219ec3a5224afff3d6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY2MTM_0e392f5b-9b3d-472f-92d1-f51257a3a1e4"
      unitRef="royaltyfee">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY4NTA_1af649f1-9ced-4d5c-b3e6-c7ac85ccf9b4"
      unitRef="usd">134000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementResearchServiceFees
      contextRef="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY5MTc_1ad26e8f-d6b3-48af-8625-504bf213358f"
      unitRef="usd">79000000.0</sgmo:CollaborativeArrangementResearchServiceFees>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="ie9c5e3edd0db4669b6958fb4f83b506b_D20170501-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjU5NzA2OTgzMTcwMw_0ad206e8-6451-4bf4-96a5-875245b16138"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i9352eaf9a370449e9c56e7e9e87116e0_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjY5ODg_ced4270d-d383-408c-8d24-005ce79c23fb"
      unitRef="usd">55000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="icc1d6a7d7d9648f297ef3f74c21f27f5_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjg4OTY_8f4d4946-98c5-452a-b824-e46882041308"
      unitRef="usd">25000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned
      contextRef="ib02a2a6eb3a3422dbca515f54079ab86_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3OTA5NA_b7da49d9-99b7-497f-911f-4f2b2cb298c5"
      unitRef="usd">25000000.0</sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue
      contextRef="i6b75336922ca48acbeec35795e3f89c0_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NDUyMA_fecf2a9d-f39d-4c66-9bb0-f83ecd226b3e"
      unitRef="usd">2400000</sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
      contextRef="i6b75336922ca48acbeec35795e3f89c0_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NDU0Nw_217ddf25-7b14-42dd-883c-1288d39869a1"
      unitRef="usd">-2400000</sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss>
    <sgmo:CollaborativeArrangementNetIncomeLossPerShare
      contextRef="i6b75336922ca48acbeec35795e3f89c0_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NDYwOA_89603dd6-de7c-433f-b913-5335f4ef0985"
      unitRef="usdPerShare">-0.02</sgmo:CollaborativeArrangementNetIncomeLossPerShare>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="idc16c1fdcccf4d5798400ac9fd30c32d_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjkzNzE_05d4db1f-e79a-4737-afb4-0db400b05bb4"
      unitRef="usd">30000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned
      contextRef="ibefa2eee1d224a5a8a3a002053b6b569_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMjk1OTE_d5203b87-60a7-49da-ae66-a90416ce1d4c"
      unitRef="usd">30000000.0</sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id906fae1befa40139b59199d084644fb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NTYxMA_4977adb3-1ddb-4034-85a9-e763fa1bfcd6"
      unitRef="usd">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c5af769a3724b79ad162f6dc82b9325_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDk0NzgwMjM4NTY2Mw_f192e2c2-090b-4e89-939b-407e19087ab5"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm
      contextRef="i5e53a9d7d29f4ca7a15cc2342c452633_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzI2MjU_6f7660c4-14d4-4d2f-b20b-0057960ed1b5">P15Y</sgmo:AgreementTerminationTerm>
    <sgmo:MilestonePaymentsReceived
      contextRef="i0794a490e25b4316b034257c060699e8_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzQ0NDI_c24336cf-b831-4ebd-b577-601b29dfaad6"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="iad9117357d274e389ec4bb2d954d40a3_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzQ1MDY_39f1d009-e90f-4b24-9e49-b64edd0fb80d"
      unitRef="usd">60000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ie71a3d375d8949d28e7d537186c4fba5_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzQ2OTI_ba14a468-eba5-4860-aa3b-cb0cb24935f4"
      unitRef="usd">90000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i552e02bdf7ff40bd9f7d8d307d5ed4a0_D20171201-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTg3OQ_5f6334ec-ef83-42e3-848c-9d0ffc869630"
      unitRef="usd">5000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i552e02bdf7ff40bd9f7d8d307d5ed4a0_D20171201-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjU5NzA2OTgzMTc1MA_3b624a7c-eb78-4509-aca7-45b719086259"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i552e02bdf7ff40bd9f7d8d307d5ed4a0_D20171201-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNjU5NzA2OTgzMTc1MQ_30af641c-2edb-4063-bf4c-f877ef2f3e7f"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i12192197df6e4c748c74e75b895766dd_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzU0ODk_070c1eb8-df1b-46f8-8350-cd29b62fceca"
      unitRef="usd">17000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:MilestonePaymentsReceived
      contextRef="i12192197df6e4c748c74e75b895766dd_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzU1MzA_9e1813ab-af93-48a5-a486-56b128d64c9f"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i12192197df6e4c748c74e75b895766dd_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzU1ODI_0e6b1f08-19d3-4b10-b10e-bef6cdfa4ff2"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i263f5e49eb104d2b951703a42c48374c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MzgzMQ_2f455116-33bc-4cc5-bd36-5f8d2675a5d6"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81052728a07f4234a17255473a25eb02_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4MTM5NA_4ab090ed-c8d4-4386-bea4-06ccc6c78530"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:NumberOfResearchProgram
      contextRef="i2b8e1d577cdc4e909e22ace81ac93119_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMzg4Nzg_1681ffd2-2b16-42bd-b8d5-1a26284420ff"
      unitRef="program">2</sgmo:NumberOfResearchProgram>
    <sgmo:AgreementTerminationTerm
      contextRef="i2c2127ce4c454d39bf4876ba0fcacebf_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDA5MDI_09cf16ca-5c94-4f40-a820-a6795c66c7a1">P180D</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i2b8e1d577cdc4e909e22ace81ac93119_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDEyMTk_f58164fd-0fb9-4b98-bf5a-ad3493fb9747"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i4bcae7d19c204753a2408edcca187aea_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDE0Mzg_d6d16117-191a-4b2f-9276-76ee8b7d9ed2"
      unitRef="usd">115800000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i85f4919f9c0c4473b1ebc3b0d83ed945_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDE1NTI_2734d90f-a6f0-4e12-8e2f-8687fe3abc28"
      unitRef="usd">160500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ic69d4938e11f4400912ca470c0f2df17_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDE3OTI_7cd188f6-1fce-404c-97d9-09af1846ae07"
      unitRef="usd">276300000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ia3d256269518436384e6a844f9460eb3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDIxMDE_b1ed2490-243e-41e2-a052-d24409173fa1"
      unitRef="usd">6000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="id2f0c509626e41d2b12512c505830612_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY4NTkxNA_ac918ce0-7e5f-46b8-811f-af44d805bf27"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="icb3452b189334360b2eae0dc8a8f906d_D20140101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDIyMzg_1ebcf43c-6248-4faa-8f07-7a9f8b872075"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="ie081f263ba514369a864fc04ab2755ef_D20140101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDIyODM_ea6dcbf8-2459-4160-9153-a428b65bf009"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i900c9e6b08d34f609332901a02f4e019_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDI0NzA_bff5ae7a-729d-47a3-93ed-e041d590896e"
      unitRef="usd">93300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i900c9e6b08d34f609332901a02f4e019_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDI1MDk_5929e5bd-8537-4e49-8a10-08f6a2591d4f"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i70098c2ae44f43d0b6cc32e42dc76aff_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDI1NTk_957dcf11-a2c7-47cc-ab15-8a0b341f4e56"
      unitRef="usd">13500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i900c9e6b08d34f609332901a02f4e019_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDI1OTQ_1bcf6653-a611-41cd-bd6f-7a73f4a0efd7"
      unitRef="usd">59800000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibfb4fcf9f2374b178f3f64eb7492ba62_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ0Mjc_88483716-ca66-4918-8984-83462cf4be8a"
      unitRef="usd">800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8946000fa68f43baa5c040af17dd5bd5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ0MzQ_e09f3fae-fa77-4569-8621-e9270ff0d8bd"
      unitRef="usd">1200000</us-gaap:ContractWithCustomerLiability>
    <sgmo:MilestonePaymentsReceived
      contextRef="i3cf33b15cb6f4155a7c06a66148748b1_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ1MTg_4f818673-4f65-41a9-8f5a-dc270c660dfd"
      unitRef="usd">6000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="i3e1b297e2e824a43b69317d3cf60c21c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ2OTA_a343282f-aded-4e71-9c21-6c14096a6435"
      unitRef="usd">5900000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementMilestoneRevenueReversal
      contextRef="i3e1b297e2e824a43b69317d3cf60c21c_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjU2OA_66da8893-83b3-48b3-a71e-4e237bb0deed"
      unitRef="usd">100000</sgmo:CollaborativeArrangementMilestoneRevenueReversal>
    <sgmo:MilestoneRevenueReceivable
      contextRef="if64ca9e8294649218a45ade74be60132_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDQ4OTM_d1d8d634-cb47-4360-97a0-034a03f6a9b7"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="ibfb4fcf9f2374b178f3f64eb7492ba62_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDUwNDU_f11b6dca-377a-4718-8aa8-31fd05c52b44"
      unitRef="usd">7300000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementMilestoneRevenueReversal
      contextRef="id2f0c509626e41d2b12512c505830612_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfMTA5OTUxMTY3NjgzMg_6f5977f7-67fc-4cac-b5b0-3c53ea0342e6"
      unitRef="usd">100000</sgmo:CollaborativeArrangementMilestoneRevenueReversal>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i2c2127ce4c454d39bf4876ba0fcacebf_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDczMjE_c5fad739-0269-47a8-a876-e244f32c973f">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.434%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(729)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia042567c5f69499ca3310b43148a2dc4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfMy01LTEtMS0w_835f885f-97c6-4baa-879f-afa39f460771"
      unitRef="usd">227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a483e7e113b40b4932319e4d56036a0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfMy03LTEtMS0w_83551598-e553-4ace-b051-2350d515c5e6"
      unitRef="usd">-729000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i412d6af141ea4a5eaff0bd4986d51146_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNC01LTEtMS0w_a9ca4d13-887f-4aff-8efe-225820e53c12"
      unitRef="usd">679000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2a5a95ecafb44a7874d3bd37d807e3b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNC03LTEtMS0w_a7aeee02-4849-4acb-95a8-540f76a9c7a4"
      unitRef="usd">1720000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2ec745d260041b8a59a2e8dc45ffa91_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNS01LTEtMS0w_f5bb98f8-10a0-4a08-a7d7-a05da5dff1a1"
      unitRef="usd">154000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie63bf8b36b024460a56259f11296d885_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNS03LTEtMS0w_cc260216-57a4-4254-8668-a48b52c35dd0"
      unitRef="usd">-492000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c2127ce4c454d39bf4876ba0fcacebf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNi01LTEtMS0w_811554b0-dc37-4291-870d-6636f4ea6b6b"
      unitRef="usd">1060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RhYmxlOjJkOGZlMzI5MmY3MjQ4OGY4NzYwYTVmZjhmOTQxMGE4L3RhYmxlcmFuZ2U6MmQ4ZmUzMjkyZjcyNDg4Zjg3NjBhNWZmOGY5NDEwYThfNi03LTEtMS0w_6be83e0d-0e31-4883-9083-1e80e0df316c"
      unitRef="usd">499000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue
      contextRef="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDU3MjI_304413b1-1cd3-42eb-b55f-b839ca206b64"
      unitRef="usd">-2200000</sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
      contextRef="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDU3NDg_fd831f0b-339e-4828-a639-d4b5b05aa6f6"
      unitRef="usd">-2200000</sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss>
    <sgmo:CollaborativeArrangementNetIncomeLossPerShare
      contextRef="i48e7c2f705a242ceb3a1aa70af0bd8ad_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDU4MDg_d3564f5b-6367-47ae-aff0-98b5a566613e"
      unitRef="usdPerShare">-0.02</sgmo:CollaborativeArrangementNetIncomeLossPerShare>
    <sgmo:GrantFundingAmount
      contextRef="ic51c2ae6d077473d8293fa2b46203655_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDYwMDE_c1ba8d41-b2f3-4f91-9542-7975dbdbd50b"
      unitRef="usd">8000000.0</sgmo:GrantFundingAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dae3ccf0cd54c5fb3e19ed6a18b06c8_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDY0MTM_7b989f22-8530-4af1-bc09-abfc94d83f92"
      unitRef="usd">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i55f0be7b4249420ab4cc66f467c2f873_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDcwNjE_6451eecf-31d2-422a-af3f-c3557a16c683"
      unitRef="usd">6600000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic886d255bdf04e18ab350c75c4128994_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81Mi9mcmFnOmQzMTMxYjljNGIwMTQ5NGU5MDlhM2UzMDAyNjBkZTg2L3RleHRyZWdpb246ZDMxMzFiOWM0YjAxNDk0ZTkwOWEzZTMwMDI2MGRlODZfNDcwNjg_d9d07b91-2662-4dce-90d1-eca15edf095f"
      unitRef="usd">6400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81NS9mcmFnOmE3OGUyOTc1OWE3MTQyOGJiODZkNmY0NjY5ZjlkZWI1L3RleHRyZWdpb246YTc4ZTI5NzU5YTcxNDI4YmI4NmQ2ZjQ2NjlmOWRlYjVfMTM1OQ_19ba4026-b6ee-4b38-89ca-9039f074a96b">INCOME TAXESThe Company&#x2019;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. During the three months ended March&#160;31, 2021 and 2020, the Company recorded income tax expense of $0.3&#160;million and nil, respectively. The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three months ended March&#160;31, 2021 was primarily due to foreign income tax expense.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81NS9mcmFnOmE3OGUyOTc1OWE3MTQyOGJiODZkNmY0NjY5ZjlkZWI1L3RleHRyZWdpb246YTc4ZTI5NzU5YTcxNDI4YmI4NmQ2ZjQ2NjlmOWRlYjVfNTEx_6750f9a2-4916-4331-99f6-6d459c9fb207"
      unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81NS9mcmFnOmE3OGUyOTc1OWE3MTQyOGJiODZkNmY0NjY5ZjlkZWI1L3RleHRyZWdpb246YTc4ZTI5NzU5YTcxNDI4YmI4NmQ2ZjQ2NjlmOWRlYjVfNTE4_053993fe-806e-4716-9bc7-d36989488a9c"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMzM4Nw_a798d60f-ecd7-4ce3-83d6-ae0e27be1607">COMMITMENTS&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 59,200 square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company leases approximately 25,600 square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through January 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjY4_d3ea0c69-cbb9-4d34-80ee-4f04096945c8"&gt;five&lt;/span&gt; to ten years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the three months ended March&#160;31, 2021 and 2020, the Company incurred $2.7&#160;million and $2.6&#160;million, respectively, of lease costs in relation to these operating leases. These lease costs were included in operating expenses in the Condensed Consolidated Statements of Operations. For the three months ended March&#160;31, 2021 and 2020, variable lease expenses were $0.7&#160;million and $0.5&#160;million, respectively, and were not included in the measurement of the Company&#x2019;s operating ROU assets and lease liabilities. This variable expense consists primarily of the Company&#x2019;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#x2019;s election to not separate lease and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March&#160;31, 2021 and 2020, was $1.7&#160;million and $1.6&#160;million respectively, and was included in net cash provided by operating activities in the Company&#x2019;s Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine months ending December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as of March 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities - current (included in other accrued liabilities on the Condensed Consolidated Balance Sheet)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the weighted-average remaining lease term is 7.5 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.2% for the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into an amendment to an existing lease to acquire approximately 5,000&#160;square feet of research and office space in Richmond, California. With this amendment, the existing lease expires in August 2026. Total lease payments over the life of this amended lease are approximately $0.9&#160;million. Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On February&#160;1, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company also entered into a new lease to acquire approximately 5,800&#160;square feet of research and office space in Valbonne, France, that expires in January 2030. Total lease payments over the life of this amended lease are approximately $0.8&#160;million. Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On January&#160;29, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $0.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any financing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of March&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total commitments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lonza Netherlands, B.V.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contractual commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also had $0.9&#160;million of license obligations related to its intellectual property as of March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i31a1ce4b0e414b9186ddc9401df9e1ca_I20210331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfODA_f06b7e0f-8d78-4c8f-a6b7-e2884e6bdccd"
      unitRef="sqft">87700</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i08adf079a35e4e43a2b4ac18b46404b4_I20210331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMjU3_3ae64539-9f46-4f9f-b8ed-ebe7b36d0d82"
      unitRef="sqft">59200</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i53f2a73e9b4a48b496f08bbeb4ae0cda_I20210331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNDE5_7abe622d-7811-4d6b-ab56-f80c28c4045c"
      unitRef="sqft">25600</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i4389a31659b5435cbd086cba9f72cb06_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjc0_0264dc6f-f5fc-4562-b386-b57c40c36d97">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA3OQ_e98f7405-454a-4afe-a9fa-e52283653e5b"
      unitRef="usd">2700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTE2NQ_fe1cc423-7365-4617-9cce-1bc069752974"
      unitRef="usd">2600000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTMxMA_fe91038c-09a8-450d-bdb0-6ab5eaf29810"
      unitRef="usd">700000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTMxOA_0b229076-31c6-44a0-b4be-4926648ca331"
      unitRef="usd">500000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTc2Nw_8adad3a0-1073-4056-b167-ec45b50c3e42"
      unitRef="usd">1700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTM2Nw_03858125-f5ce-4dcf-addf-c98c65ec778c"
      unitRef="usd">1600000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMzM4OA_402decbf-379c-40b4-9dd7-10c1c16daa34">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nine months ending December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as of March 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities - current (included in other accrued liabilities on the Condensed Consolidated Balance Sheet)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMS0xLTEtMS0w_52bf8b47-3ada-406e-bc6d-5a701841320b"
      unitRef="usd">4663000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMi0xLTEtMS0w_00647a82-7522-40ea-b263-4c0a582cc26b"
      unitRef="usd">6991000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMy0xLTEtMS0w_c750ba63-7dcd-4348-a86e-4483fdaa6fc8"
      unitRef="usd">7089000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfNC0xLTEtMS0w_9964d017-9fa3-4c75-bd8a-8ed7b6a5fc82"
      unitRef="usd">7237000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfNS0xLTEtMS0w_9f684cfb-ddf8-4388-b1e5-42ce0e551899"
      unitRef="usd">7308000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfNi0xLTEtMS0w_7522f705-a920-4841-b3c1-c32ef0970984"
      unitRef="usd">20037000</sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfNy0xLTEtMS0w_b2602aee-8d20-4ca6-8b5a-e97fda69cd1e"
      unitRef="usd">53325000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfOS0xLTEtMS0w_356dbbf8-a7af-411d-9c80-022650aa2c57"
      unitRef="usd">10980000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMTEtMS0xLTEtMA_b468a24d-1c48-41ae-89fe-39cb566c07f2"
      unitRef="usd">42345000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMTQtMS0xLTEtMA_b0fca8d9-5310-4456-ae92-5b27816813ca"
      unitRef="usd">3882000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMTUtMS0xLTEtMA_f8ed2baf-ec63-4a43-8c28-dd079ba89c50"
      unitRef="usd">38463000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOjcyNzUzMzc3ZTBiMjRkODlhOGRlMWRlMmQwZWE3YzgzL3RhYmxlcmFuZ2U6NzI3NTMzNzdlMGIyNGQ4OWE4ZGUxZGUyZDBlYTdjODNfMTYtMS0xLTEtMA_81721604-7c6a-4a78-8aae-93237ff1d80b"
      unitRef="usd">42345000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMjA1Nw_20567e2a-af47-4cd4-a104-865a98f92a0f">P7Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMjE2NA_581bc419-439a-4c2a-9621-c6c6b99dc013"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <sgmo:LesseeOperatingLeaseAreaOfRealEstate
      contextRef="if674a30905aa4701b577fea5cdd38927_I20210131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjU5NzA2OTc3NDI2MA_1d03b1ac-ee37-46eb-9177-c9013552f8ba"
      unitRef="sqft">5000</sgmo:LesseeOperatingLeaseAreaOfRealEstate>
    <sgmo:LesseeOperatingLeaseAmount
      contextRef="if674a30905aa4701b577fea5cdd38927_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMjQ3Mg_b15036c5-2ff5-47cc-9ed2-d3d3b24ec852"
      unitRef="usd">900000</sgmo:LesseeOperatingLeaseAmount>
    <sgmo:LesseeOperatingLeaseAmount
      contextRef="i49ed718922c34bacb4fe8ab46f011d3b_I20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNDM1NQ_b6881517-02cf-4641-b1c8-248ce249ec4a"
      unitRef="usd">700000</sgmo:LesseeOperatingLeaseAmount>
    <sgmo:LesseeOperatingLeaseAreaOfRealEstate
      contextRef="i4bb8843fb3d341009157555d58c1790d_I20210131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjU5NzA2OTc3NDI1Mw_16b2dd43-f736-4427-85e6-fac25c26365a"
      unitRef="sqft">5800</sgmo:LesseeOperatingLeaseAreaOfRealEstate>
    <sgmo:LesseeOperatingLeaseAmount
      contextRef="i4bb8843fb3d341009157555d58c1790d_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTEwOQ_ce6b9e61-856a-4ee0-8241-e3ad7ee272f5"
      unitRef="usd">800000</sgmo:LesseeOperatingLeaseAmount>
    <sgmo:LesseeOperatingLeaseAmount
      contextRef="i62fb65868a04407c87a0eefd5094126d_I20210129"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMTA5OTUxMTYzNTEyNw_3fe8542f-aa72-4fe6-a3bc-d9f1fb359221"
      unitRef="usd">600000</sgmo:LesseeOperatingLeaseAmount>
    <us-gaap:OtherCommitmentsTableTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMzM5MA_1a2ff623-2650-4d9c-adc5-f47966f90173">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of March&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total commitments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lonza Netherlands, B.V.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contractual commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCommitmentsTableTextBlock>
    <us-gaap:ContractualObligation
      contextRef="ied0c47637c5a4c5786b8ac57faeb569b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOmExZTI5NTUxOTQwZDRlYTE4NzAxNGRmZGRmMmYxOTIwL3RhYmxlcmFuZ2U6YTFlMjk1NTE5NDBkNGVhMTg3MDE0ZGZkZGYyZjE5MjBfMS0yLTEtMS0w_1a070a7d-e513-4066-a936-3b47d460c665"
      unitRef="usd">6157000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="ie59ea076e227497193dff8217d78482e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOmExZTI5NTUxOTQwZDRlYTE4NzAxNGRmZGRmMmYxOTIwL3RhYmxlcmFuZ2U6YTFlMjk1NTE5NDBkNGVhMTg3MDE0ZGZkZGYyZjE5MjBfMi0yLTEtMS0w_16838e2a-c445-42df-9720-e401ef34b1a3"
      unitRef="usd">11804000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RhYmxlOmExZTI5NTUxOTQwZDRlYTE4NzAxNGRmZGRmMmYxOTIwL3RhYmxlcmFuZ2U6YTFlMjk1NTE5NDBkNGVhMTg3MDE0ZGZkZGYyZjE5MjBfMy0yLTEtMS0w_c2df82b3-c509-48eb-a8ed-98f6f4aac61f"
      unitRef="usd">17961000</us-gaap:ContractualObligation>
    <sgmo:LicenseObligations
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfMzEwOA_717484a3-e142-4ec6-bcdf-57eebec2eb53"
      unitRef="usd">900000</sgmo:LicenseObligations>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RleHRyZWdpb246Zjg4NWI4NzZjNDEzNGQwOWI2ZDM0NDcwZjlmYmFmMDdfMjE5_78f775f6-b99b-4f52-ba46-dd5cab044a1a">STOCK-BASED COMPENSATION&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three months ended March&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RleHRyZWdpb246Zjg4NWI4NzZjNDEzNGQwOWI2ZDM0NDcwZjlmYmFmMDdfMjE4_5cc92469-d4b1-4474-aa65-1e10f947dd0f">&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three months ended March&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.275%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21a9537a071b45a490485e4e675afbda_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfMi01LTEtMS0w_63f11ca6-fa79-4ab3-97a4-7ad6e9f20fd0"
      unitRef="usd">4252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7879f7c1ca14257a286f0937f160d6a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfMi03LTEtMS0w_fe615d90-e0ae-4245-bc55-149e38d4dcb3"
      unitRef="usd">2839000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic7121386b2ac42788064446ea02e0293_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfMy01LTEtMS0w_1aac2692-cdf3-4b9c-a735-1f1fe0e54178"
      unitRef="usd">3272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i689dc02e331246b1b5c7ee22451f278f_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfMy03LTEtMS0w_f7afe84e-9851-4edc-9567-71a2bce19961"
      unitRef="usd">2781000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfNC01LTEtMS0w_17c94131-dd7c-4084-8d12-42a14c9eb44a"
      unitRef="usd">7524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82MS9mcmFnOmY4ODViODc2YzQxMzRkMDliNmQzNDQ3MGY5ZmJhZjA3L3RhYmxlOmJjMjYyNDU0ZTA2NjRhYzM5MjkzMWZmOWRhNDY0YzBlL3RhYmxlcmFuZ2U6YmMyNjI0NTRlMDY2NGFjMzkyOTMxZmY5ZGE0NjRjMGVfNC03LTEtMS0w_310de181-8203-4503-b60c-075d2ed7866e"
      unitRef="usd">5620000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82NC9mcmFnOjRlM2IyMmUzODg5MjQyY2JiNzAwMGJhOTFkZThjZTg3L3RleHRyZWdpb246NGUzYjIyZTM4ODkyNDJjYmI3MDAwYmE5MWRlOGNlODdfMjYyNg_43127351-1a85-4c4e-84e3-cd78bee33f94">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#x2019;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2021, the Company sold 1,034,762 shares of its common stock for net cash proceeds of approximately $15.7&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <sgmo:StockOfferingProgramMaximumValue
      contextRef="i5d2cd66475ef461e9c805c9eaaaca699_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82NC9mcmFnOjRlM2IyMmUzODg5MjQyY2JiNzAwMGJhOTFkZThjZTg3L3RleHRyZWdpb246NGUzYjIyZTM4ODkyNDJjYmI3MDAwYmE5MWRlOGNlODdfMTE3OA_5caa2402-aee5-4395-9849-1075cc0d45f0"
      unitRef="usd">150000000.0</sgmo:StockOfferingProgramMaximumValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i29077b179cb747c6af600e5610999238_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82NC9mcmFnOjRlM2IyMmUzODg5MjQyY2JiNzAwMGJhOTFkZThjZTg3L3RleHRyZWdpb246NGUzYjIyZTM4ODkyNDJjYmI3MDAwYmE5MWRlOGNlODdfMTA5OTUxMTYzMzE3Mw_39025409-520f-4fbf-b6a3-f04cf9b54fbf"
      unitRef="shares">1034762</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i29077b179cb747c6af600e5610999238_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82NC9mcmFnOjRlM2IyMmUzODg5MjQyY2JiNzAwMGJhOTFkZThjZTg3L3RleHRyZWdpb246NGUzYjIyZTM4ODkyNDJjYmI3MDAwYmE5MWRlOGNlODdfMTA5OTUxMTYzMzIwOQ_fb2ec7e5-f9c2-427b-8ec6-1ee9a3f6004d"
      unitRef="usd">15700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMzM1MQ_d44e6332-ed4e-43b3-9d24-e32a2b4cc038">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#x2019;s share capital, including arrangements with the holders of approximately 477,000 ordinary shares of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders, and such holders have the right to sell to the Company such shares from time to time through mid-2021. As of March&#160;31, 2021, the Company acquired approximately 453,000 of the 477,000 shares, increasing its ownership of the ordinary shares of Sangamo France to 99.9%. The fair value of the option to acquire the remaining shares was estimated to be an asset with immaterial balance as of March&#160;31, 2021. See &#x201c;Note 2 &#x2014; Fair Value Measurements-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Free Shares Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; for information regarding the valuation method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic&#160;805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in exchange for total consideration of approximately $45.9&#160;million at the October 2018 acquisition date. The operating results of Sangamo France after the October 2018 acquisition date have been included in the Company&#x2019;s Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no goodwill impairment during the three months ended March&#160;31, 2021 or during 2020 and, as noted below, substantially all of the non-controlling interest on the October 2018 acquisition date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of March&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Controlling Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the remaining non-controlling was determined based on the number of outstanding shares comprising the non-controlling interest and the $2.99 acquisition price per share as of the October 2018 acquisition date. The non-controlling interest is presented as a component of stockholders&#x2019; equity on the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-controlling interest as of March&#160;31, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(938)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire
      contextRef="i1129259eb0a649868776568fa4898425_I20180720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMTYy_eca2201a-0394-4755-8266-fd92e10dc1ed"
      unitRef="number">1</sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="i1129259eb0a649868776568fa4898425_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMTA2Mg_1d69ea2f-1987-4ec6-bcab-49bc204b75a8"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i91b1a80eaeeb470bb98449ced38f5857_D20180720-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfNTQ5NzU1ODE0NTQ4OA_6bf7b1f8-136f-4c27-92a2-6ca7602ca12c"
      unitRef="shares">453000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="i1129259eb0a649868776568fa4898425_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfNTQ5NzU1ODE0NTQ5OA_9adea93d-c5ff-4eb9-a0f2-3354c59447c6"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i4031384af7314ae98be13e046f877228_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMTc4OQ_8c06c933-4e03-429a-b123-943491d76846"
      unitRef="number">0.999</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i628ef7e645dc4f99a3b94a2aa9545377_D20181001-20181001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMjQxNg_4afaa552-9a51-4b31-b3b5-a3a3a78b3fb3"
      unitRef="usd">45900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i939670888e0a47a28486f5f7cd1bfc6b_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMjYwOA_1ffe8611-19de-49d9-867c-7da20a378610"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMjYwOA_224bc123-9b9f-4ffe-9bf4-0c6a831edadc"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i25f4525748b042cb9cf63d0d356cdd37_I20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMzA4Ng_b73b931a-76ae-4c7d-8dc6-bc2473070fe2"
      unitRef="usdPerShare">2.99</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RleHRyZWdpb246MzVhNGI5NWU1ZGRkNGIwYjkwYmE0MDRjNTg5NGU2NTdfMzM0OA_ec94d9af-0429-4a10-b410-ac017d5ef9a9">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-controlling interest as of March&#160;31, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(938)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="i55deba83f3ac420da3d9b6ec9427676b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RhYmxlOmUyN2JkZWU4MWM1MzQyNGE4OTlmNTRkODIwODgwZjY2L3RhYmxlcmFuZ2U6ZTI3YmRlZTgxYzUzNDI0YTg5OWY1NGQ4MjA4ODBmNjZfMS0xLTEtMS0w_54b177cd-e3f5-4e82-8d53-2e14767db852"
      unitRef="usd">-868000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RhYmxlOmUyN2JkZWU4MWM1MzQyNGE4OTlmNTRkODIwODgwZjY2L3RhYmxlcmFuZ2U6ZTI3YmRlZTgxYzUzNDI0YTg5OWY1NGQ4MjA4ODBmNjZfMi0xLTEtMS0w_cae56ae8-a1d4-4eef-82ed-f6b465598994"
      unitRef="usd">64000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RhYmxlOmUyN2JkZWU4MWM1MzQyNGE4OTlmNTRkODIwODgwZjY2L3RhYmxlcmFuZ2U6ZTI3YmRlZTgxYzUzNDI0YTg5OWY1NGQ4MjA4ODBmNjZfMy0xLTEtMS0w_48d83f86-9e6c-4400-8886-f73453f8ebca"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl82Ny9mcmFnOjM1YTRiOTVlNWRkZDRiMGI5MGJhNDA0YzU4OTRlNjU3L3RhYmxlOmUyN2JkZWU4MWM1MzQyNGE4OTlmNTRkODIwODgwZjY2L3RhYmxlcmFuZ2U6ZTI3YmRlZTgxYzUzNDI0YTg5OWY1NGQ4MjA4ODBmNjZfNC0xLTEtMS0w_3dfbfa57-9d0d-42a1-a20c-f662ee81e460"
      unitRef="usd">-938000</us-gaap:MinorityInterest>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650650262040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,881,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650645245096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 122,975<span></span>
</td>
<td class="nump">$ 131,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">464,109<span></span>
</td>
<td class="nump">510,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">6,746<span></span>
</td>
<td class="nump">5,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">12,140<span></span>
</td>
<td class="nump">11,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">606,944<span></span>
</td>
<td class="nump">659,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">42,431<span></span>
</td>
<td class="nump">50,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">45,222<span></span>
</td>
<td class="nump">41,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">55,583<span></span>
</td>
<td class="nump">58,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">40,994<span></span>
</td>
<td class="nump">42,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">70,324<span></span>
</td>
<td class="nump">71,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">14,097<span></span>
</td>
<td class="nump">13,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">877,095<span></span>
</td>
<td class="nump">938,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,638<span></span>
</td>
<td class="nump">12,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">13,077<span></span>
</td>
<td class="nump">20,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">13,760<span></span>
</td>
<td class="nump">18,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">94,364<span></span>
</td>
<td class="nump">91,644<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">132,839<span></span>
</td>
<td class="nump">143,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">222,278<span></span>
</td>
<td class="nump">245,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">38,463<span></span>
</td>
<td class="nump">38,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">6,870<span></span>
</td>
<td class="nump">7,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">7,011<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">407,678<span></span>
</td>
<td class="nump">441,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">1,437<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,292,118<span></span>
</td>
<td class="nump">1,269,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(823,914)<span></span>
</td>
<td class="num">(777,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">5,419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</a></td>
<td class="nump">470,355<span></span>
</td>
<td class="nump">498,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(938)<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">469,417<span></span>
</td>
<td class="nump">497,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 877,095<span></span>
</td>
<td class="nump">$ 938,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650646290360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 26,280,000<span></span>
</td>
<td class="nump">$ 13,076,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">56,434,000<span></span>
</td>
<td class="nump">41,479,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,148,000<span></span>
</td>
<td class="nump">16,119,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">72,582,000<span></span>
</td>
<td class="nump">57,598,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(46,302,000)<span></span>
</td>
<td class="num">(44,522,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">625,000<span></span>
</td>
<td class="nump">1,548,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(45,677,000)<span></span>
</td>
<td class="num">(42,974,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">262,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(45,939,000)<span></span>
</td>
<td class="num">(42,974,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(6,000)<span></span>
</td>
<td class="num">(61,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</a></td>
<td class="num">$ (45,933,000)<span></span>
</td>
<td class="num">$ (42,913,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)</a></td>
<td class="num">$ (0.32)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">143,112<span></span>
</td>
<td class="nump">116,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650649385736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (45,939)<span></span>
</td>
<td class="num">$ (42,974)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(4,749)<span></span>
</td>
<td class="num">(1,633)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(50,644)<span></span>
</td>
<td class="num">(44,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="num">$ (50,638)<span></span>
</td>
<td class="num">$ (44,292)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650646641208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Non- Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,972,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2019</a></td>
<td class="nump">$ 432,739<span></span>
</td>
<td class="nump">$ 1,160<span></span>
</td>
<td class="nump">$ 1,090,828<span></span>
</td>
<td class="num">$ (656,985)<span></span>
</td>
<td class="num">$ (2,449)<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,633)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(42,974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,278,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Mar. 31, 2020</a></td>
<td class="nump">394,415<span></span>
</td>
<td class="nump">$ 1,163<span></span>
</td>
<td class="nump">1,096,854<span></span>
</td>
<td class="num">(699,898)<span></span>
</td>
<td class="num">(3,828)<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,063,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2020</a></td>
<td class="nump">497,366<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="nump">1,269,375<span></span>
</td>
<td class="num">(777,981)<span></span>
</td>
<td class="nump">5,419<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with at-the-market offering, net of offering expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with at-the-market offering, net of offering expenses</a></td>
<td class="nump">15,651<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">15,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">615,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="num">(416)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">(422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(4,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(45,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,713,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Mar. 31, 2021</a></td>
<td class="nump">$ 469,417<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
<td class="nump">$ 1,292,118<span></span>
</td>
<td class="num">$ (823,914)<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
<td class="num">$ (938)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650650605784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (45,939)<span></span>
</td>
<td class="num">$ (42,974)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (discount) on marketable securities</a></td>
<td class="nump">824<span></span>
</td>
<td class="num">(744)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets', window );">Amortization and other changes in operating lease right-of-use assets</a></td>
<td class="nump">2,023<span></span>
</td>
<td class="nump">1,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GainLossOnFreeShares', window );">Loss on free shares</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,524<span></span>
</td>
<td class="nump">5,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="nump">61<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,522)<span></span>
</td>
<td class="nump">29,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,741)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(3,829)<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(7,561)<span></span>
</td>
<td class="num">(4,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(20,047)<span></span>
</td>
<td class="num">(8,319)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities', window );">Long-term portion of lease liabilities</a></td>
<td class="num">(1,045)<span></span>
</td>
<td class="num">(887)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(68,550)<span></span>
</td>
<td class="num">(18,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(97,935)<span></span>
</td>
<td class="num">(43,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">144,369<span></span>
</td>
<td class="nump">71,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Sales of marketable securities</a></td>
<td class="nump">6,870<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(7,950)<span></span>
</td>
<td class="num">(3,775)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional shares of Sangamo France</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">45,289<span></span>
</td>
<td class="nump">23,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from at-the-market offering, net of offering expenses</a></td>
<td class="nump">15,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(2,234)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and restricted stock units</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">15,235<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(328)<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(8,354)<span></span>
</td>
<td class="nump">5,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">132,829<span></span>
</td>
<td class="nump">81,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">124,475<span></span>
</td>
<td class="nump">87,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in unpaid liabilities</a></td>
<td class="nump">2,953<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 1,356<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization And Other Changes In Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AmortizationAndOtherChangesInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GainLossOnFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GainLossOnFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long-term portion of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650645397560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;2020 Annual Report&#8221;) as filed with the SEC on February&#160;24, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#8217;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of March&#160;31, 2021 and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in estimates during the three months ended March&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#8220;Sanofi&#8221;) and Pfizer Inc. (&#8220;Pfizer&#8221;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $0.1&#160;million, decreased net loss by $0.1&#160;million and had no impact on the Company&#8217;s basic net loss per share for the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of March&#160;31, 2021, the Company had not incurred any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of March&#160;31, 2021, no impairment of goodwill or indefinite-lived intangible assets was identified.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of March&#160;31, 2021, no impairment of long-lived assets was identified.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"/><td style="width:53.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.515%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,975&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,749&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,475&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,249&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#8220;IND&#8221;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650643192392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities and some cash equivalents as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Shares Asset</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 10 &#8212; Acquisition of Sangamo Therapeutics France S.A.S.), the Company entered into arrangements with the holders of approximately 477,000 &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). As of March&#160;31, 2021, the Company purchased approximately 453,000 shares of the 477,000 total free shares, for a cash payment of approximately $1.1&#160;million, upon exercise of the put options. As of March&#160;31, 2021, approximately 24,000 free shares remain outstanding and subject to purchase by the Company. The fair value of the free shares&#8217; asset is immaterial at March&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:73.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Free Shares valuation assumptions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.61</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation between Sangamo and Sangamo France stock prices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate volatility estimate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650643078584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.565%"><tr><td style="width:1.0%"/><td style="width:54.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,022&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,447&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%"><tr><td style="width:1.0%"/><td style="width:73.065%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three months ended March&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three months ended March&#160;31, 2021 and 2020. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews the marketable securities for other-than-temporary impairment losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than </span></div>not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at either March&#160;31, 2021 or December&#160;31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650643163800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
<td class="text">BASIC AND DILUTED NET LOSS PER SHARE<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of March&#160;31, 2021 and 2020 totaled 17,614,376 and 14,849,728, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650643207272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<br></strong></div></th>
<th class="th" colspan="1">40 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#8220;ZFP&#8221;) transcription factors (&#8220;ZFP-TFs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company will perform early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, IND-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement, when earned are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and estimated research costs of $20.1&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $64.7&#160;million and $70.9&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, the Company recognized revenue of approximately $6.2&#160;million and none, respectively, related to the upfront license fee and approximately $1.7&#160;million and none, respectively, from research reimbursement costs related to the Novartis agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $1.5&#160;million for financial advisory fees during the year ended December 31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic 340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company amortized $0.1&#160;million and none during the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.45&#160;billion in first commercial sale and other sales-based milestone payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12&#160;neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e. through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to ten targets. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock purchase agreement also provides that from the first anniversary of the effectiveness of the collaboration agreement, through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule&#160;144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i)&#160;the two-year anniversary of the effectiveness of the collaboration agreement, (ii)&#160;the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock and (iii)&#160;the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $204.6&#160;million includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $175.9&#160;million and $183.2&#160;million, respectively, related to this agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, the Company recognized revenue of approximately $7.3&#160;million and none, respectively, related to the upfront license fee and the excess consideration from the stock purchase, and approximately $3.1&#160;million and none, respectively, from research reimbursement costs under the Biogen agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the transaction price of $204.6&#160;million, as a contract asset. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company amortized $0.1&#160;million and none during the three months ended March&#160;31, 2021 and 2020, respectively. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in proceeds.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), which became effective in April 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the effective date, the Company received a $150.0&#160;million upfront payment from Kite. Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term in the agreement is six years. Kite has an option to extend the research term of the agreement for up to two additional one-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $3.4&#160;million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $75.3&#160;million and $81.4&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia&#160;A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia&#160;A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $134.0&#160;million, which represents the upfront fee and research services fees of $79.0&#160;million and two unconstrained milestones achieved of an aggregate amount of $55.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into an amendment to the agreement, pursuant to which the Company transferred the IND for giroctocogene fitelparvovec to Pfizer. Upon this transfer the Company achieved a $25.0&#160;million milestone as the conditions for achieving the milestone were met. The cumulative revenue recognized in connection with this milestone was $25.0&#160;million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the hemophilia&#160;A collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the giroctocogene fitelparvovec product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $2.4&#160;million, decreased net loss by $2.4&#160;million and decreased the Company&#8217;s basic net loss per share by $0.02 for the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company determined that there was a high probability of achievement of a $30.0&#160;million milestone with Pfizer for giroctocogene fitelparvovec. The milestone was subsequently achieved upon dosing of the first subject in a Phase&#160;3 clinical trial in early October 2020. The cumulative revenue recognized in connection with this milestone was $30.0&#160;million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three months ended March&#160;31, 2021. The Company recognized $2.2&#160;million of upfront license fee and research services and $1.0&#160;million milestone achievement as revenue related to this agreement during the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;fifteen years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $17.0&#160;million, which represents the upfront fees of $12.0&#160;million and one unconstrained milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $5.0&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December&#160;31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three months ended March&#160;31, 2021. The Company recognized $0.4&#160;million of upfront license fee and research services as revenue related to this agreement during the three months ended March&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Genzyme</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $93.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones in the amount of $13.5&#160;million and estimated research costs of $59.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of March&#160;31, 2021, and December&#160;31, 2020, the Company had deferred revenue of $0.8&#160;million and $1.2&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company achieved a $6.0&#160;million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $5.9&#160;million as of March&#160;31, 2021 and included $0.1&#160;million recognized during the three months ended March&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company achieved a $7.5&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $7.3&#160;million as of March&#160;31, 2021 and included $0.1&#160;million recognized during the three months ended March&#160;31, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(729)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This adjustment decreased revenue by $2.2&#160;million, increased net loss by $2.2&#160;million and increased the Company&#8217;s basic net loss per share by $0.02 for the three months ended March 31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Institute for Regenerative Medicine</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of March&#160;31, 2021, the Company had received $5.2&#160;million under the award.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of March&#160;31, 2021, and December&#160;31, 2020, $6.6&#160;million and $6.4&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644445464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESThe Company&#8217;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. During the three months ended March&#160;31, 2021 and 2020, the Company recorded income tax expense of $0.3&#160;million and nil, respectively. The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three months ended March&#160;31, 2021 was primarily due to foreign income tax expense.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650643129912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text">COMMITMENTS<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 59,200 square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company leases approximately 25,600 square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through January 2030.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRiZTlhMDMwNmQ5YzRmMjliYTgyYzJhODNkMTM2ZGViL3NlYzo0YmU5YTAzMDZkOWM0ZjI5YmE4MmMyYTgzZDEzNmRlYl81OC9mcmFnOjQzN2FmNGM5ZWNlOTQ2OTJiYzAwZDM0NzUwOTcyMzZkL3RleHRyZWdpb246NDM3YWY0YzllY2U5NDY5MmJjMDBkMzQ3NTA5NzIzNmRfNjY4_d3ea0c69-cbb9-4d34-80ee-4f04096945c8">five</span> to ten years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the three months ended March&#160;31, 2021 and 2020, the Company incurred $2.7&#160;million and $2.6&#160;million, respectively, of lease costs in relation to these operating leases. These lease costs were included in operating expenses in the Condensed Consolidated Statements of Operations. For the three months ended March&#160;31, 2021 and 2020, variable lease expenses were $0.7&#160;million and $0.5&#160;million, respectively, and were not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. This variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities for the three months ended March&#160;31, 2021 and 2020, was $1.7&#160;million and $1.6&#160;million respectively, and was included in net cash provided by operating activities in the Company&#8217;s Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ending December 31, 2021:</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,663&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,089&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,308&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,325&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,980)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of March 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities - current (included in other accrued liabilities on the Condensed Consolidated Balance Sheet)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the weighted-average remaining lease term is 7.5 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.2% for the Company&#8217;s operating leases.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an amendment to an existing lease to acquire approximately 5,000&#160;square feet of research and office space in Richmond, California. With this amendment, the existing lease expires in August 2026. Total lease payments over the life of this amended lease are approximately $0.9&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On February&#160;1, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $0.7&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company also entered into a new lease to acquire approximately 5,800&#160;square feet of research and office space in Valbonne, France, that expires in January 2030. Total lease payments over the life of this amended lease are approximately $0.8&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On January&#160;29, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $0.6&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any financing leases.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of March&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,961&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had $0.9&#160;million of license obligations related to its intellectual property as of March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650643207272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three months ended March&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644567816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three months ended March&#160;31, 2021, the Company sold 1,034,762 shares of its common stock for net cash proceeds of approximately $15.7&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644408328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</a></td>
<td class="text">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#8217;s share capital, including arrangements with the holders of approximately 477,000 ordinary shares of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders, and such holders have the right to sell to the Company such shares from time to time through mid-2021. As of March&#160;31, 2021, the Company acquired approximately 453,000 of the 477,000 shares, increasing its ownership of the ordinary shares of Sangamo France to 99.9%. The fair value of the option to acquire the remaining shares was estimated to be an asset with immaterial balance as of March&#160;31, 2021. See &#8220;Note 2 &#8212; Fair Value Measurements-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Free Shares Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for information regarding the valuation method.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic&#160;805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for total consideration of approximately $45.9&#160;million at the October 2018 acquisition date. The operating results of Sangamo France after the October 2018 acquisition date have been included in the Company&#8217;s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no goodwill impairment during the three months ended March&#160;31, 2021 or during 2020 and, as noted below, substantially all of the non-controlling interest on the October 2018 acquisition date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of March&#160;31, 2021 and December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining non-controlling was determined based on the number of outstanding shares comprising the non-controlling interest and the $2.99 acquisition price per share as of the October 2018 acquisition date. The non-controlling interest is presented as a component of stockholders&#8217; equity on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of March&#160;31, 2021 was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(938)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650650029624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three months ended March&#160;31, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;2020 Annual Report&#8221;) as filed with the SEC on February&#160;24, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#8217;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in estimates during the three months ended March&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e. cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of March&#160;31, 2021, the Company had not incurred any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible AssetsGoodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text">Valuation of Long-Lived AssetsLong-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed to approximate fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashSangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#8220;IND&#8221;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644560040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"/><td style="width:53.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.515%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,975&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,749&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,475&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,249&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.850%"><tr><td style="width:1.0%"/><td style="width:53.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.365%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.515%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,975&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,749&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,475&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,249&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644609176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value of Free Shares Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"/><td style="width:73.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Free Shares valuation assumptions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.61</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation between Sangamo and Sangamo France stock prices</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate volatility estimate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650645436888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.565%"><tr><td style="width:1.0%"/><td style="width:54.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,022&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,419&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,447&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,905&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,575&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair value of investments available-for-sale</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.855%"><tr><td style="width:1.0%"/><td style="width:73.065%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,540&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650645444232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement for the three months ended March&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.434%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(729)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650660793176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nine months ending December 31, 2021:</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,663&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,089&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,308&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,325&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,980)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of March 31, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities - current (included in other accrued liabilities on the Condensed Consolidated Balance Sheet)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,882&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,345&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsTableTextBlock', window );">Other Commitments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of March&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,157&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,961&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about obligations resulting from other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644725992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations for the three months ended March&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.147%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.275%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,252&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,839&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,272&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,620&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650649579752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock', window );">Summary of Non-controlling Interest</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of March&#160;31, 2021 was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(938)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650645824232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenues</a></td>
<td class="nump">$ 26,280,000<span></span>
</td>
<td class="nump">$ 13,076,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Decrease in net loss</a></td>
<td class="nump">45,939,000<span></span>
</td>
<td class="nump">42,974,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill or indefinite-lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit established as a deposit</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember', window );">Change in collaboration agreement scope | Collaboration agreement | Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Increase in revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Decrease in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650656252584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail) - Revenue from contract with customer - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644638312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 122,975<span></span>
</td>
<td class="nump">$ 131,329<span></span>
</td>
<td class="nump">$ 85,749<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 124,475<span></span>
</td>
<td class="nump">$ 132,829<span></span>
</td>
<td class="nump">$ 87,249<span></span>
</td>
<td class="nump">$ 81,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650648058392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 506,540<span></span>
</td>
<td class="nump">$ 560,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">177,154<span></span>
</td>
<td class="nump">213,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">39,022<span></span>
</td>
<td class="nump">59,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">11,494<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">36,410<span></span>
</td>
<td class="nump">17,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">242,460<span></span>
</td>
<td class="nump">257,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">506,540<span></span>
</td>
<td class="nump">560,624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">554,175<span></span>
</td>
<td class="nump">613,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">177,154<span></span>
</td>
<td class="nump">213,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">39,022<span></span>
</td>
<td class="nump">59,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">11,494<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">36,410<span></span>
</td>
<td class="nump">17,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">242,460<span></span>
</td>
<td class="nump">257,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">506,540<span></span>
</td>
<td class="nump">560,624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">506,540<span></span>
</td>
<td class="nump">560,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">177,154<span></span>
</td>
<td class="nump">213,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">39,022<span></span>
</td>
<td class="nump">59,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">11,494<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">36,410<span></span>
</td>
<td class="nump">17,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">242,460<span></span>
</td>
<td class="nump">257,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650645720424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Narrative (Detail) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">32 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share purchase agreement and tender offer agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase', window );">Number of free shares outstanding subject to purchase (in shares)</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650650520344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sangamo stock price (USD) (in dollars per share)</a></td>
<td class="nump">$ 11.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember', window );">Exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">EUR / USD exchange rate</a></td>
<td class="nump">0.84<span></span>
</td>
<td class="nump">0.84<span></span>
</td>
<td class="nump">0.82<span></span>
</td>
<td class="nump">0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Stock price volatility estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility estimate</a></td>
<td class="nump">0.913<span></span>
</td>
<td class="nump">0.913<span></span>
</td>
<td class="nump">0.889<span></span>
</td>
<td class="nump">0.889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility estimate</a></td>
<td class="nump">0.063<span></span>
</td>
<td class="nump">0.063<span></span>
</td>
<td class="nump">0.063<span></span>
</td>
<td class="nump">0.063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France stock price (EUR) (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France stock price (EUR) (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock price correlation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimated correlation between Sangamo and Sangamo France stock prices</a></td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">1.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock price volatility estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility estimate</a></td>
<td class="nump">0.913<span></span>
</td>
<td class="nump">0.913<span></span>
</td>
<td class="nump">0.889<span></span>
</td>
<td class="nump">0.889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650646031352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 122,975<span></span>
</td>
<td class="nump">$ 131,329<span></span>
</td>
<td class="nump">$ 85,749<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">506,447<span></span>
</td>
<td class="nump">560,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">506,540<span></span>
</td>
<td class="nump">560,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and available-for-sale securities, Amortized Cost</a></td>
<td class="nump">554,082<span></span>
</td>
<td class="nump">613,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">554,175<span></span>
</td>
<td class="nump">613,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">177,101<span></span>
</td>
<td class="nump">213,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">177,154<span></span>
</td>
<td class="nump">213,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">39,031<span></span>
</td>
<td class="nump">59,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">39,022<span></span>
</td>
<td class="nump">59,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">11,495<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">11,494<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">36,419<span></span>
</td>
<td class="nump">17,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">36,410<span></span>
</td>
<td class="nump">17,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">47,635<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">242,401<span></span>
</td>
<td class="nump">257,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">$ 242,460<span></span>
</td>
<td class="nump">$ 257,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644578568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing in one year or less</a></td>
<td class="nump">$ 464,109<span></span>
</td>
<td class="nump">$ 510,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Maturing after one year through five years</a></td>
<td class="nump">42,431<span></span>
</td>
<td class="nump">50,530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 506,540<span></span>
</td>
<td class="nump">$ 560,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644436088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporarily impaired investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644692328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options and RSUs outstanding (in shares)</a></td>
<td class="nump">17,614,376<span></span>
</td>
<td class="nump">14,849,728<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650547873512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="13">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1">47 Months Ended</th>
<th class="th" colspan="1">87 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>product_target</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>option </div>
<div>product_target </div>
<div>royaltyFee </div>
<div>product</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>milestone </div>
<div>product</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>product </div>
<div>milestone</div>
</th>
<th class="th"><div>Feb. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,280,000<span></span>
</td>
<td class="nump">$ 13,076,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,011,000<span></span>
</td>
<td class="nump">$ 7,228,000<span></span>
</td>
<td class="nump">$ 7,228,000<span></span>
</td>
<td class="nump">$ 7,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California institute for regenerative medicine agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California institute for regenerative medicine agreement | Research grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">$ 95,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementLicenseFee', window );">License fee</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,900,000<span></span>
</td>
<td class="nump">64,700,000<span></span>
</td>
<td class="nump">64,700,000<span></span>
</td>
<td class="nump">64,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Financial advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of specified preclinical development clinical development and first commercial sale milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">420,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of commercial milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargets', window );">Number of product targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected', window );">Number of product targets selected | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets', window );">Number of additional product targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementTargetSelectionPeriod', window );">Target selection period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace', window );">Maximum number of product targets replaced | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Financial advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Portion of contract asset recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and license agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementResearchPeriod', window );">Research period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and license agreement | Pre-approval milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and license agreement | Sales-based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,200,000<span></span>
</td>
<td class="nump">175,900,000<span></span>
</td>
<td class="nump">175,900,000<span></span>
</td>
<td class="nump">175,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod', window );">Standstill restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage', window );">Standstill restriction, ownership threshold percentage ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld', window );">Agreement restriction, percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod', window );">Voting provisions expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage', window );">Voting provisions, ownership threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction', window );">Excess consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementEquityIssued', window );">Collaboration agreement, equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Recognized portion of equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,288,000<span></span>
</td>
<td class="nump">7,219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,159,000<span></span>
</td>
<td class="nump">6,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
<td class="nump">992,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400,000<span></span>
</td>
<td class="nump">75,300,000<span></span>
</td>
<td class="nump">75,300,000<span></span>
</td>
<td class="nump">75,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Initial research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm', window );">Number of options to extend initial research term | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExtendedResearchTermOfAgreement', window );">Extended research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SeparateUpfrontFee', window );">Separate upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan', window );">Collaborative arrangement estimated reimbursable service costs for new research plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration and license agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,010,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned', window );">Contract to perform for others, cumulative compensation earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue', window );">Increase (decrease) in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss', window );">Increase (decrease) in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare', window );">Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Maximum | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Maximum | SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Maximum | Other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned', window );">Contract to perform for others, cumulative compensation earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Achievement of specified clinical development intellectual property and regulatory milestones | Maximum | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Achievement of first commercial sale milestones | Maximum | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Achievement of specified preclinical development clinical development and first commercial sale milestones | Maximum | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Achievement of commercial milestones | Maximum | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementResearchServiceFees', window );">Research service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved', window );">Number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | royaltyFee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,060,000<span></span>
</td>
<td class="nump">499,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue', window );">Increase (decrease) in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss', window );">Increase (decrease) in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare', window );">Increase (decrease) in basic net loss per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
<td class="num">$ (729,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="num">(492,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">679,000<span></span>
</td>
<td class="nump">$ 1,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved', window );">Cumulative milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMilestoneRevenueReversal', window );">Milestone revenue reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | ST-40 Beta Thalassemia Phase 1 clinical trial milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMilestoneRevenueReversal', window );">Milestone revenue reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved', window );">Cumulative milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Achievement of specified clinical development And regulatory milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Achievement of specified sales milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementEquityIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementEquityIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Additional Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementNumberOfAdditionalProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementTargetSelectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Target Selection Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementTargetSelectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Research Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Percent Of Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementPercentOfInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Cumulative Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementCumulativeMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Increase (Decrease) In Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Number Of Product Targets To Replace</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMilestoneRevenueReversal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Revenue Reversal</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMilestoneRevenueReversal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Net Income (Loss) Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNetIncomeLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets Selected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementResearchServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Service Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementResearchServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExtendedResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended Research Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ExtendedResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GrantFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Extend Initial Research Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfOptionsToExtendInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Excess Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SeparateUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Separate upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SeparateUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650646925880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 26,280<span></span>
</td>
<td class="nump">$ 13,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,288<span></span>
</td>
<td class="nump">7,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,159<span></span>
</td>
<td class="nump">6,227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,060<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">227<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="num">$ (492)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650646187608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">$ (262,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650646022904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 29, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities included net cash used in operating activities</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted-average remaining lease term</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted-average discount rate</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LicenseObligations', window );">License obligations</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember', window );">Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseAreaOfRealEstate', window );">Area of real estate | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseAmount', window );">Lease payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember', window );">Valbonne, France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseAreaOfRealEstate', window );">Area of real estate | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseAmount', window );">Lease payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember', window );">Office and laboratory | Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember', window );">Operating lease one | Office and laboratory | Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="nump">59,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember', window );">Operating lease one | Research and office space | Valbonne, France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseAreaOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Real Estate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseAreaOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LicenseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LicenseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650649938280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Nine months ending December 31, 2021:</a></td>
<td class="nump">$ 4,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">6,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">7,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">7,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">7,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">20,037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">53,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(10,980)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">42,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current (included in other accrued liabilities on the Condensed Consolidated Balance Sheet)</a></td>
<td class="nump">3,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">38,463<span></span>
</td>
<td class="nump">$ 38,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 42,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650644640536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 17,961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember', window );">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">6,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember', window );">Lonza Netherlands, B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 11,804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650657186936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7,524<span></span>
</td>
<td class="nump">$ 5,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,252<span></span>
</td>
<td class="nump">2,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,272<span></span>
</td>
<td class="nump">$ 2,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650645312360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Detail) - Jefferies LLC - At-The-Market Offering Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockOfferingProgramMaximumValue', window );">Stock offering program, maximum value</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockOfferingProgramMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Offering Program, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockOfferingProgramMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650650757528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">32 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share purchase agreement and tender offer agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share)</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share purchase agreement and tender offer agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire', window );">Percentage of equity interests agreed to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, percentage of equity interests agreed to acquire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140650643019160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Balance at December 31, 2020</a></td>
<td class="num">$ (868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Fair value of additional shares acquired</a></td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to non-controlling interest</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Balance at March 31, 2021</a></td>
<td class="num">$ (938)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M$G_#FW9J2K7B-627W;EO4YV8 2,X#$:R+58X2V.[[K37G7IUWTO%BG=(3,W
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M/8L!2M1GGGJ@^,X<&]9<P2'$7&9P3J1"&\#S#>?J,- 3M"?/Q;]02P,$%
M  @ )(*D4LAO+ !" P  W0@  !@   !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6RE5FUOVC 0_BNG:!\V:6T@"6\3(+7 M$KKBYJV^S#M@TD.XC6QF>V4;K]^
M9X=F% +:M"_$+_><G^=\YV.XENI19X@&GHM<Z)&7&;/ZX/LZR;!@^E2N4-#.
M0JJ"&9JJI:]7"EGJ0$7N!ZU6UR\8%]YXZ-9NU'@H2Y-S@3<*=%D43/T\QURN
M1U[;>UFXY<O,V 5_/%RQ)<9H[E<WBF9^[27E!0K-I0"%BY%WUOXP&5A[9_#
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M-<@1Q]&@G1E&W;&T%TMG&TNG5+);8@FU!WVNX.@UQ*^\>J/F?#GU%B*)>%[
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M9 ?CD,&)%C%_/M+;D+TC/3<A7D+@)TW0/#4C+8+6AG7C+324VK"CQCP=6 _
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M[57+H4-&+!&O3 !8\:#GATJT,>U(]"@1%Z'W@ZT_;VP+#IJ?\19@)1)5X0/
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M_.&]K0WAG4R*%/DL!-=@V4(1CV)5%&:(%A EF"_4/M-M9.KWK*3H!A'8HY[
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MHU069/,Y^1A,'37CVM4)NHZ!<:[>?\HNA)$\OP2D!VD3%\-9 $AJJ6DYM4-
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M1STOF 5]9*#Q#K2^UW3(VX$/T'VV+/X#4$L#!!0    ( "2"I%*(HJ8>Y2
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MA(EB@W295XX..Z]XA@=OQ+;,"M$]1,%"T/3,(51.<(<*N9_#"Z1L(*O[C91
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MF\T%<%.3"U-UUBYT RD[.HH,%#5F!(0L4J/C:.;K<TS%YJ'.<1C^[OSZ(OD
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MW@9106[E=JFR&T:GL<TS Q.SL8S,\29$3 ?X<J_7^:S,M'4M+U]#JS4<[%T
MN,9'^Q9YV6MHG';KUIU?8;"],--IGAP^">X-16BA:W4LS4'.M>W5X6[O8*O(
M"-70(;#@'K+)X\>;B+FO<7Q?=,AFV((!L>O:S+W-,/:!&PP&@QF!!W=8[JX]
M;[?0E)->=P-KS'HZ_S;4_^__S$OPXQKA);7K;H^+?TYC&S[:J^-.NY<+QDSU
MK=RIW!RJI,-]S[A4^3F;EU'WV(:[_@I,$9LP?_.<:]-[T>C5>#<'9?[WG<J@
M)VU:TFG\VR)!(]H:!6XU1PUFJ@V&T<:?UD?^+&WDRN* [JI0K-&>G72N-?07
M@OHN@D,9,%W*G[W&(]=N#<$+]O>63/6QEGBZ'1]VP;N,SJ>:7[T8V,SM&Q2!
MT]NU1>'CY-Y)ZIW[H4?'?7/0.>L<^I3H0**KX/ I"SXYW3E_#5L(85+0EPIM
MO=TH@L<&>^GM;;3AH_@H5IS**[ZFN# %4?-'YZ= A&]+#JW,AJ#FM\]85?@N
MB>@'PL+30%0-MCLR<T(?WGP#LK1 U%O8(PM9\EF/1O\->J]__5'F<+G$P[]%
MC_:^SMS]';FP&?<U_W"']=^[_FQ')U'Y0[_BX;L&?\:O>/@&AA&=:!UN@6OV
MX@$_\+'^YS.^[H80Q'FN\W,?1JH,T%==$1BJ[4=YN#DT5QOM>O/NY;V1M)-<
MFT.3Z;2G[Z(4U\4XD">%,5& T-'6V%M'1-4$>M$RRC]-':.%- $,V([6')>L
M73?(R;4:0JH!I<%H,'E,UY8'6T?<G$$)'3YM7//),",X=F?J?LM*&'-(QM68
M[V'*953RVWQ\U6X/G<<,:*!S:Q93'K;4,<W)Z$8D+B%D-=_ RZ4Z4A&=0>3K
M.M_Q)0H4MJ1!=0U">X01S-J")*I[-'.3=/6[/D[>4CZ]6\U<!(@KX*T6Y-V8
M;.,&%O!'RS?T1Y8K$)O -/2Y9<?S)G)*-ZP'753+J9PR&_J-PLXSICUB'QNR
M%%CHR_P _J<%<"A(<2=;]U99,$-T95<X<\E5G<"/U=+(!=UB#IR:VL 2 ]Y.
M,H]9]Z >A]G"/0:$E3=60]_B*@*S0>%6SK\;4(57R]HLD4JTW*$[ZO;G*%Q!
M"_X>Z+#<^(R&(V+$+H8C,.S=[6'W94.=T"6LR6FB.Y4QT0_#( ^MV"X2X.C#
M7IK7@Q6L#1!49TT&..RQ&CXQ"&;;Y7#TIE/0_C>@0$367<DP %>A&RF&?5(@
M]$(/F>U.CKK#4D $+L[>7[T^G7B,P99H@# @V @)\,CQH,#\,&R ,ST['EH>
M;EQQ3P[FLC>.-_:'W,5B534UNK>,&TM8;LP*R.ZPZ>1^X_BGZ^@H,>TUS+D
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M9-Z_=J"X4C:0YAK0T?#]VX)\_X+TD^C:W+67+N(-R,,&CR[[9(#]VKFXFZ0
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M#(>(-C,93:AO<G#V.SGX<DY_?L)IC]Y_+KMF_[_L:MQR_-=AU^3)G=OGD\S
M<)JQ5BC'C)XLI$:PMTOD575,*1'=[:\(I">V=5KM0X3"=(IR%>J4"&-:2MQ1
MX2U%%Z%4S<FG#-=/*DNPPI)[RP6]M5!\& X4%,>R*)2D[FA!QV4UQNSJO"^&
MC&^<)M7(S^WM/A*5-R$,..=S1,:R2VG8S06Z(P^S T[MU])14[Y+93R)I<C/
MM$N'5B<S28$^P#0R&$^?9I: XK/1_^7LBZ"63GS"U'S9_=YE@P%2\:BU>-B
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M%9 $L$0V5U1.Z=1),DKPE%FZK"P=+FT&U!86!6I/8\BX]CB;:43(ZY9 UQ)
M!4VRIJ+ 9.J$-KSSIE1IZ,6\'U(,#GK<337 *S]1"CR/@Z?X0FNE\.6[@&XK
MZD5T1JU!_ $^H22GA-=C*8T.=]5U.P#B5M2/2*T_Z,#ZW])R ?U6+^K2V6M=
MDQM_:Y'P: QSU#N_; SQE=+6$]F\-OML6H_Q;_5Z&5*J=IRR*7!+T/95OQ>
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M+(#W,P/2J!?L8/DM=O(O4$L#!!0    ( "2"I%)YAPT,@1H  (E4   9
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MQ&FSG&)]J^J>*$4?ENAFP>,S)>*3$G;,X50 HZ!$Z9F@R< %IV]UVVMR$6M
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MA_5/6$!R1LYH=W%Q5HYCS!1[8U#)S"<?NH3M&F(%W 521N52-1UZCZ:@PU5
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M+:X 08.C]' );+SK@T3@H;>Z(NZ&PI8\_BA__-\&_-;[C0*-E,OGC^'R#S_
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M^?A$MO'[;MPT#5!%!>OX7B_B.Y\-09M6\$X1\<Z((4LLKM*P/[:$X8#[8_E
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M!KB.GSH*?^ &\>NCS_\?4$L#!!0    ( "2"I%+@C1R+(00  ",,   9
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;.U7;6_;-A#^*P=M'5I C6S9SMML
M [*;I,9FQ["<#=NP#[1\MKA*I$M2<=-?OR/U4@=-O.S#]JE 0I&\M^=X#YE+
M?R_5!YTB&OB49T(/O-28W640Z"3%G.D3N4-!DHU4.3.T5-M [Q2RM3/*LR!L
MM4Z#G''A#?MN;ZZ&?5F8C N<*]!%GC/U,,),[@=>VZLW%GR;&KL1#/L[ML48
MS=UNKF@5-%[6/$>AN12@<#/PHO;EZ-3J.X5?..[UP1QL)BLI/]C%9#WP6A80
M9I@8ZX'1YQ['F&76$<'X6/GTFI#6\'!>>[]VN5,N*Z9Q++-?^=JD ^_<@S5N
M6)&9A=R_QRJ?GO67R$R[$?:5;LN#I-!&YI4Q(<BY*+_L4W4.+S$(*X/0X2X#
M.93OF&'#OI)[4%:;O-F)2]59$S@N;%%BHTC*R<X,;Q<WT6SR>[2<W,Y\&$7Q
M)(;;:Y@OKN*KV;+:CF;O(+Z;3J/%;U883VYFD^O).)HM(1J/;^]FR\GL!N:W
M/T_&DZL8WL+K)5MEJ-_T T,8;:0@J?",2CSA,W@Z,)7"I!JNQ!K7C^T#RJU)
M,*P3'(5''4Z9.H%.VX>P%;:/^.LT!]9Q_CK/^(N21!;"<+&%N<QXPE'#']%*
M&T4$^_-(@&X3H.L"=)\)$-.]6Q<9@MS  N]1% @;)7,@)69PRQ.8,V4$*HN!
MV)BQE22)Y7BT58AT98P&)M9DKI&I)(7(<I^;![A1S GI!^:H$E*EJV=#+:5A
M61U0/U6XX[!KRQ)KSOZ2"I)'X-AC<*H&QVIPVP-PNT?@C .GZA![5&C5-N1?
M[O4E+%-R_8@YKMQV:,&(RRT*F$8^3$1R MT6O((?OCL/V^&/,)/W=)A<DT@;
M;@IC,R#H9#3%-4_<F91 *_/.H?E/W"#,4T;O0R4.NR3N]6B(F9 ;#C<H/C_D
M"';?_LXW_#.J4KEV$Y[!JR/4Z374Z;V8.F.F4W?.;G+UL>#W++.'_U1IC[JU
M?Q<N]8XE./!VMFKJ'KUA1.5(I$AXQLOR4LR$0OEN!/P2L*ZV43PQ5!DG5[B3
MRJ[VW*1<@$F1N$R5$YHV::;I<JV9U1BQC(D$(;:/G"8N.&66VVNHGW3$Z([F
M.R8>RAORI-?8T*=D8WU:UY9,L&?Z@%OPVOF4A:8L])M+F#K.V@?E'2:8KZB4
M=O',=E.%KP[E>VB'H7]QUK,S4NV$%S0[[_EG73=I^=WPG.@IWB:%4F3RU1&V
M_5ZK]<0X?GD5V']P?C:QKM^M$@O]\S*Q,S\L$VO[%Y38$;:?-FP__8<7ITR&
MR$<8Q+]C_%'7WQC_C?'_"^.#@\8M1[5U[:D&UV&4/5RSVW3 4=GX?5$OVV<J
MQY;31<AP0Z:MDS-ZTU79DI8+(W>N#5Q)0TVEFZ;4Q:.R"B3?2&GJA0W0_%\P
M_!M02P,$%     @ )(*D4HT*%T+\!   W0T  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&ULO5?;;N,V$/V5@;LM-H!BZ^K;)@:<Q$$7V!2+.$D?BC[0
M\M@B(HE:DK:3O^^0DF79:[O;HNB+R!G.?0Y%\FHCY*M*$#6\96FNKEN)UL6P
MTU%Q@AE3;5%@3BL+(3.FB93+CBHDLKE5RM*.[[K=3L9XWAI=6=Y7.;H2*YWR
M'+]*4*LL8_+]!E.QN6YYK2WCD2\3;1B=T57!ECA%_5Q\E41U:BMSGF&NN,A!
MXN*Z-?:&-Y&1MP(O'#>J,0>3R4R(5T-\GE^W7!,0IAAK8X'1L,9;3%-CB,+X
M5MELU2Z-8G.^M7YO<Z=<9DSAK4A_YW.=7+?Z+9CC@JU2_2@VOV*5CPTP%JFR
M7]A4LFX+XI72(JN4*8*,Y^7(WJHZ_(B"7RGX-N[2D8WRCFDVNI)B ])(DS4S
ML:E:;0J.YZ8I4RUIE9.>'MV//S_"R_C+\P0>)N/I\^/D8?+;TQ0NX>,3FZ6H
M+JXZFOP8Z4Y<V;PI;?HG; ;P('*=*)CD<YSOZW<HOCI(?QODC7_6X .3;0@\
M!WS7]\[8"^JD VLO.)4TXQ)>6+I"N.,J3H5:253PQWBFM"2<_'G&1UC["*V/
M\(2/:8ER$ MHN'M 9GP1JK4R2[=,)3#YMN)KEAJ> ^,UXZFI_"7MN,LIL8'2
M?T5M>##%>"6YYA0MR^=P+Y%X"9,(8Z50=[YP-N,IU^_'NG8V8+/[AZI@,5ZW
M:'LKE&MLC9X2A(4)?VW#SP["U[1\*[*"Y>^__-3WO=XG!;%)"9LI9;OXU7[\
M1G]A<E F!^*9),"DP^>DRQ<<Y\!T*2=2^H/P? DIKC%5M%%TPO-R;1=BPE$R
M&2?O\-$NBI4B3^IB:,H8)S6,3G;E26B6PA?C [QJ]*LQ*,NLAF7C&ED.#>;Q
MO<H5%BOR"1\@[#G=(&I.;)W\3XU9Z; 2J(;MVG9\.%;"H:E]AC+FI%^P F6S
MOEZOYWA16)LXI&^%+(1D&NDG-M--S6#@N+Y?"QZ0MRA-8V+2M!B88R$4U^!Y
M3CAHN-LG;=TN9RQ^I8XV?76=T'-WOO;)Y_:T#4NQ1IF;YERJ0N1*2#)AT*'?
MOPO=#WTG[.X,'-)EK2.WZT3ACGM(EU*'0+:(/8[E#Q!%H>/U]CJ]M;KK]/UW
M4/\ 0?\H*.S"'<:8S:BM%6C=_P>T4>!XW:@Y.07:2J :_@/0^E[@1$&PZ]\!
M?1JTT<")>CN\'9 -T#8P2YO$=P+/VX%VGSP%6J_G#-Q^8V?MD?\<M%'/\0<[
M X=T5>NNZW3]1H8']+\ ;9>JV^L/]EI>63T/VIY[ K2T<.;LC.JS,_K1LW.B
M-*>[%Q6O 7USIM8GG[),9N]XU+!55IBI.G8 GO?:-+FN3;*=R<8)\OW.G+)\
MR3(!=&.+7Z&0/$;X^#R]NZ"J>%Z['Y@Q:G>]6O)>LIR$]A0FSX\7IIQ!-R0<
MM =^303M?@2T#!T@JX!O<4)V$.QF<-O]T'S\1KUB(26F91(SU!O$O'9M0'$Z
M# *XZ[9=^+D>3R>W%L:%N7$ 5JYAX+4#4NKWVX.&[LET_][$J;2/:7:M8OE]
MY.JUO%]8<9-U+)0N_P"T!V>D]U;0^\#LS3?S3U+T8S&B+TQRBRPS'$-TIW'E
MIK_9TCXLZ/(C5KDN;]\UMWZ[C,LK^TZ\?/@0JI:<T)7B@E3==H]@*LO'1$EH
M4=@+_$QH>@[8:4+O+Y1&@-870N@M81S4+[K17U!+ P04    "  D@J12,'0W
M;($$   '"P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R=5FUOXC@0
M_BNC'#J!E):\$F !B5+VMKKMJE?HWH?3?3#!(5&3.&L[L.ROW[$3 NT6I.T7
M\(P]S\PS'D]FM&/\6<242OB>I;D8&[&4Q;#;%6%,,R*N64%SW(D8SXA$D6^Z
MHN"4K+51EG8=R^IU,Y+DQF2D=0]\,F*E3).</G 09981OK^A*=N-#=LX*!Z3
M32R5HCL9%61#%U0^%0\<I6Z#LDXRFHN$Y<!I-#:F]O#&5^?U@:\)W8F3-2@F
M*\:>E7"W'AN6"HBF-)0*@>#?ELYHFBH@#.-;C6DT+I7AZ?J _E%S1RXK(NB,
MI?\F:QF/C;X!:QJ1,I6/;/>)UGQT@"%+A?Z%7776]PP(2R%95AMC!%F25__D
M>YV'$X.^=<; J0T<'7?E2$=Y2R29C#C; 5>G$4TM-%5MC<$EN;J4A>2XFZ"=
MG,RFBT\P_^?I[NOT\_S+<@'3+[=P/WW\>[Z<WGR>PV(^>WJ\6][-%W %[259
MI51T1EV)KA5 -ZS=W%1NG#-N7+AGN8P%S/,U7;^T[V+(3=S.(>X;YR+@/>'7
MX-HF.)9C7\!SFSRX&L\]@W>7;ZF06&U2F'!+5Q)(OH;YMS*1>UC0L.2)3*B
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M:#E!*#"QCH'1\H(S%,(1D8S?!\Z@#NF I_:1_9//G7+9,(,S)7[PU&:CH!]
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MVKKI=0/0U6BI-E85OITWRM)P\&9&TQBU<Z#_6Z7L<>,"U/-]_ =02P,$%
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M!"#- =S?"J%/$Q.@_(LQ_A=02P,$%     @ )(*D4G.0N"@G P  A0@  !D
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MX(XPPP*^$XC0 %A?<:X>)_JB:+\\AO\ 4$L#!!0    ( "2"I%+/<B7=&0D
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M"!5WCI6B!#M"X9YSS-DK-93=-T3T-GM."L5[C@DU0H_>/\".4)KG6*E)L%A
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MY8)',YY5!N7G\S0M7MY4SW-K'^!W\3]02P,$%     @ )(*D4C<&*?E) P
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MIM1VH78':'^IE-U.G(&ZD1O]!U!+ P04    "  D@J122U(IW2@$  !B$P
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MTT7@*-X-,6Q$H,.X^A#<*@2W3PC+C(="WH3OGX(P!3^":$]UWKNZ++*)U0A
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M,!#^5TX\M=)6"-"FJP@2^3$U4MM%H=T>ICTXX 2KQF:VT[3__<Z&L*Q*JKV
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M&J[4NCVSLL=4.)?[9&F5]^(/]]E\5BE<)0+Q'4=_EK]4%>5JKNYI,H% @EQ
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M"&W"4U7KA1WR^O4(4C@KK_[0K!2D4?ZT;=2/!2D'W=9++P_[8(B+4*[,;*O
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M%0>IFY5VK'22]5(0</63)M)%3 =$L/TQ><L.N9Q&"HT98M8?*OS3?BXN^'(
MG\6QZ8P+'@97(PLF\4]E56N2@_. :**TTW6" ?LN#)9I, +ON6CXOG8G,1P0
MDRA.QM1>'2F,)H%70VX:SGJ&? <;AY30?G1#><;JW'8%"0UK O;-3-9PHQ\
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M4!8[F!^6^,L [0)P?ZF4?9VX-M;\A+*_4$L#!!0    ( "2"I%(5T5AN[0(
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MW>[\ILQ@DFE$*K0ED\?%)1P?G< 1< FWO"BH=&886B)WYX?)EO*BHHS?H.S
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M@G]/=$KC6$M"'M]*H5:E4P-/WP_2Y\9X-&9#))WR^'<6JFADW5@0TBW)8_7
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M*NDY]P[$>(,RJA;\\(B+>-J&+^)4VB\<BKUU!Z),*IX68*T@)2S_H[<B#R<
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M8922*$3ZCF2;.,2%3KS%&YRN(F1 >@"D-PDD*?0EB5(#T@<@_0DA__(,R "
M#*:$] W(:P#R>DK(P(!< ) +NY!9?H?3^$]<Q%GZ7(\7$A.4W:)M'I$H+; !
M^0* ?&$7\A;'.;K'FUV$D@B37=X/EX(8<"\!N)>6FQF3-8K^V,4:L*=". U1
M@O-W48'?;B(#\A4 ^<HN9-^PJX$LC#>[OANF48$V&2%H&^5F?'3G4!2?V\5,
M\.]9CE8[4F1)E)/G:(OS(M5WZWBK*];$!&5CV39QNM)\J,#O([,3NI!;7.MR
M29*X^.^X<"&3N)95HEMQ]>Y*=[TA!"9;'0R'.&/R01)Q+5MDX%MGFU!WL%^&
M(5Q\,-D@=[B6Y8%7&H?$?77U\9C@] XG&2K648ZWT<[$A.SA3JF/T6S!A?SA
M6A8(C&G.%US()*YEE?S <^@*/=/3_]K$A%SB6I8):+Q1HWN03+PI93+&A&3B
M65^Z? O<EX9FW:\F';ADL:R5'\7PKZ@F)J0:S[)JP' Y;FO(.)YEX\!QR%P2
M>)!\/,OR@3&O34Q(/MZD\EF8F)!\O&E6+WH$D5/34!,3DH\WF7Q2*N4($Y*/
M9UD^8&V.1KH/R<>W+!_8D>:,PX?DX]N6#XAI!B0?LI!O>W$#8IH!R0>WSBQ;
M"%QEC_LF9"'?LH7@B=&H;T(6\BU;",8<]4W(0KYE"YF; >A9R!3E]6C^YD/R
M\2W+9SR[Q%7%^U=HC>*V+\_$A.3CV]Y$&V$.7I2?D=BCA*J3Y"8F)!_?]LIG
MA)F*]JJD;:G?U!@:U=P<A^036)8/,&DG2I0F)B2?P+)\OK?_<IEN*/YH8D+R
M"2S+!UY;F.$R@.033+H$,L-E )[<#/*974X/*[;G+:M2_8E.YY>T+K<2]9?S
MCF=PW6]%[$]UO=)Y6;L1M+H<1EX.4M_\ U!+ P04    "  D@J121QQ@N:0!
M  ";&@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=F[;L) $(7A
M5T%^ ):966X14*6AC7@!"Y:+,-CR;A1X^R HX%@ITJ ]E;6V//X+ZY.UGGV%
MJDR'^ASWAR;V+J?J'.?%/J7FP[FXWH=3&?MU$\ZW*]NZ/97IMFQWKBG7QW(7
MG X&(]>^SB@6L]>9O=6U"?^96&^WAW7XK-??IW!.?PQV/W5[C/L04M%;E>TN
MI'GA+M7S='3W@_1ODXO><C,OVN5&"I<[2"%(\P<9!%G^( ]!/G_0$(*&^8-&
M$#3*'S2&H''^H D$3?('32%HFC](!BCC@""I@S6!UH)<"X'7@F +@=B"9 N!
MV8)H"X':@FP+@=N"< N!W()T"X'=@G@+@=Z*>BN!WHIZ*X'>VOG8)M!;46\E
MT%M1;R706U%O)=!;46\ET%M1;R706U%O)=!;46\ET-M0;R/0VU!O(]#;4&\C
MT-LZFR4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>GO4VQ/H[5%O
M3Z"W1[T]@=X>]?8$>OO.9O<[]8[I6H7X['FL\?GOI#K=[@W/Q]^7CY.=M_>.
MLX-_48M?4$L#!!0    ( "2"I%(NTOC K@$  ,H:   3    6T-O;G1E;G1?
M5'EP97-=+GAM;,V9S6[",!"$7P7EBHBQG=(? 9>VUY9#7\!--B0BB2W;4'C[
M.N%':D6C(BIU+K$2[\Z,O=)WR?1M9\@-MG75N%E4>&\>&'-I0;5RL3;4A)U<
MVUKY\&J7S*ATI9;$Q'@\8:EN/#5^Y%N-:#Y]HERM*S]XWH;/KM3-++)4N6CP
MN"]LO6:1,J8J4^7#/MLTV3>7T<$A#IU=C2M*XX:A(&)G'=J=GPT.?:\;LK;,
M:+!0UK^H.E2Q;<6<WU7DXGZ),QEUGI<I93I=UZ$E=L:2REQ!Y.LJWHL.^YU]
MN&':/_G5_IU,GV&H7%AM7)B8I<OMCB-INT<F")'U9?\13XY!^NKS43OMC+)?
M>H?K_=!VU<W#L6ZY_HZ_SOBD?V$. 9)#@N1(0'+<@.28@.2X!<EQ!Y+C'B0'
M'Z,$02$J1T$J1V$J1X$J1Z$J1\$J1^$J1P$K1R&K0"&K0"&K0"&K0"&K0"&K
M0"&K0"&K0"&K0"&K0"&K1"&K1"&K1"&K1"&K1"&K1"&K1"&K1"&K1"&K1"%K
M@D+6!(6L"0I9$Q2R)O])UG>M5W_]=Z5=XUJ5S=&?=;^PYI]02P$"% ,4
M"  D@J12!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( "2"I%+=')S0[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "2"I%*97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ )(*D4K)0Q_XZ!0  8Q4  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "2"I%+K$T^6
MD 8  ((;   8              " @7T-  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  D@J12<-<INTD$  "%#@  &
M@(%#%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ )(*D
M4LAO+ !" P  W0@  !@              ("!PA@  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( "2"I%)M-,K".@8  *8:   8
M      " @3H<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  D@J12+FG#ZEL'   ]'0  &               @(&J(@  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ )(*D4N^EOSS#'0  OUL  !@
M             ("!.RH  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( "2"I%*!J%YM&PD  (@8   8              " @31(  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  D@J12,J<!%^\%  "9
M#@  &               @(&%40  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ )(*D4HP^J3IR P  P@@  !D              ("!JE<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  D@J12B**F
M'N4@  #^A0  &0              @(%36P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( "2"I%))^LPAA ,  -('   9
M  " @6]\  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M)(*D4IR^K&C5!P  T!4  !D              ("!*H   'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  D@J12V%_X2KX"  #Q!0  &0
M            @($VB   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( "2"I%(%_[#(0@,   8'   9              " @2N+  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ )(*D4HI[.L*0!0
MEPT  !D              ("!I(X  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  D@J12>8<-#($:  ")5   &0              @(%K
ME   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( "2"I%+@
MC1R+(00  ",,   9              " @2.O  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ )(*D4HT*%T+\!   W0T  !D
M     ("!>[,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "2"I%+I)&H*GP(  'D%   9              "
M@3#(  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ )(*D
M4HFKH<JU P  HPH  !D              ("!!LL  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  D@J12L0EJ6GX#  !N#   &0
M        @('RS@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( "2"I%)SD+@H)P,  (4(   9              " @:?2  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ )(*D4L]R)=T9"0  S$\
M !D              ("!!=8  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  D@J12-P8I^4D#  #4"0  &0              @(%5WP
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( "2"I%)+4BG=
M* 0  &(3   9              " @=7B  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ )(*D4H^($M!W!@  [R4  !D
M ("!-.<  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  D
M@J12='*G2:@"   P!@  &0              @('B[0  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "2"I%*C3^=*;@(  '<%   9
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M970S-RYX;6Q02P$"% ,4    "  D@J12O#6P\/4$   Z%0  &0
M    @($'$0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M "2"I%+[,'CM80,  #(*   9              " @3,6 0!X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ )(*D4KL0_4*  @  D 8  !D
M             ("!RQD! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  D@J12%=%8;NT"  #P"   &0              @(&"' $ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( "2"I%+4&X0AZP(
M -0&   9              " @:8? 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ )(*D4DR\E#N\ P  <@P  !D              ("!
MR"(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  D@J12
MZ5=>Q],"  #^!@  &0              @(&[)@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( "2"I%*%.8YL40,  /04   -
M      "  <4I 0!X;"]S='EL97,N>&UL4$L! A0#%     @ )(*D4I>*NQS
M    $P(   L              ( !02T! %]R96QS+RYR96QS4$L! A0#%
M  @ )(*D4KXL^6?X P  S!T   \              ( !*BX! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( "2"I%)''&"YI $  )L:   :
M  "  4\R 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M "2"I%(NTOC K@$  ,H:   3              "  2LT 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     T #0 (PX   HV 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>265</ContextCount>
  <ElementCount>329</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2107102 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2119105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTS</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2135110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - COMMITMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSTables</Role>
      <ShortName>COMMITMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/COMMITMENTS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/INCOMETAXES</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - COMMITMENTS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail</Role>
      <ShortName>COMMITMENTS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail</Role>
      <ShortName>COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sgmo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sgmo-20210331.htm">sgmo-20210331.htm</File>
    <File>sgmo-20210331.xsd</File>
    <File>sgmo-20210331_cal.xml</File>
    <File>sgmo-20210331_def.xml</File>
    <File>sgmo-20210331_lab.xml</File>
    <File>sgmo-20210331_pre.xml</File>
    <File>sgmo-20210331xex102.htm</File>
    <File>sgmo-20210331xex103.htm</File>
    <File>sgmo-20210331xex104.htm</File>
    <File>sgmo-20210331xex311.htm</File>
    <File>sgmo-20210331xex312.htm</File>
    <File>sgmo-20210331xex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20210331.htm": {
   "axisCustom": 1,
   "axisStandard": 20,
   "contextCount": 265,
   "dts": {
    "calculationLink": {
     "local": [
      "sgmo-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "sgmo-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 431,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 6
   },
   "keyCustom": 63,
   "keyStandard": 266,
   "memberCustom": 46,
   "memberStandard": 27,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sangamo.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7dc2e857539f4ef4ba7daadf58df7f59_D20171201-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7dc2e857539f4ef4ba7daadf58df7f59_D20171201-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - INCOME TAXES",
     "role": "http://www.sangamo.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - COMMITMENTS",
     "role": "http://www.sangamo.com/role/COMMITMENTS",
     "shortName": "COMMITMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i2a3d9c81024248b1adfc4a25b7c4d391_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i2a3d9c81024248b1adfc4a25b7c4d391_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - COMMITMENTS - (Tables)",
     "role": "http://www.sangamo.com/role/COMMITMENTSTables",
     "shortName": "COMMITMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "10",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i024dc19eb24b4daab222db22932603df_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i024dc19eb24b4daab222db22932603df_D20210101-20210331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i03bfd7b3de0b4cadb36dcbf7df43380f_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i1087025adac9402fa10512e9bbce394b_D20210101-20210331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i373acdae6305402aa0be5cf76855d613_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i373acdae6305402aa0be5cf76855d613_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "ic51c2ae6d077473d8293fa2b46203655_D20180501-20180531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sgmo:GrantFundingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - INCOME TAXES (Details)",
     "role": "http://www.sangamo.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - COMMITMENTS - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail",
     "shortName": "COMMITMENTS - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail",
     "shortName": "COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail",
     "shortName": "COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i63e63da1fd9e4d59a1f37f4cfcadbb42_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i29077b179cb747c6af600e5610999238_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail",
     "shortName": "STOCKHOLDERS' EQUITY - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i29077b179cb747c6af600e5610999238_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i55deba83f3ac420da3d9b6ec9427676b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDecreaseFromRedemptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "ic0ac77a17de44bb29cd358c8e38c4a67_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "ic0ac77a17de44bb29cd358c8e38c4a67_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107102 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210331.htm",
      "contextRef": "i7df956b618a845de9a1fd3c49ec7ae8b_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 74,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Commercial Milestones.",
        "label": "Achievement Of Commercial Milestones [Member]",
        "verboseLabel": "Achievement of commercial milestones"
       }
      }
     },
     "localname": "AchievementOfCommercialMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of first commercial sale milestones.",
        "label": "Achievement Of First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Specified Clinical Development and Regulatory Milestones.",
        "label": "Achievement Of Specified Clinical Development And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development And regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones.",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development intellectual property and regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones.",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "verboseLabel": "Achievement of specified preclinical development clinical development and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones.",
        "label": "Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.",
        "label": "Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]",
        "terseLabel": "Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Specified Sales Milestones.",
        "label": "Achievement Of Specified Sales Milestones [Member]",
        "terseLabel": "Achievement of specified sales milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "label": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "terseLabel": "Acquisition of additional shares of Sangamo France"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive.",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones"
       }
      }
     },
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Termination, Term",
        "label": "Agreement Termination, Term",
        "terseLabel": "Agreement termination, term"
       }
      }
     },
     "localname": "AgreementTerminationTerm",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_AmortizationAndOtherChangesInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization And Other Changes In Right-of-Use Assets",
        "label": "Amortization And Other Changes In Right-of-Use Assets",
        "negatedLabel": "Amortization and other changes in operating lease right-of-use assets"
       }
      }
     },
     "localname": "AmortizationAndOtherChangesInRightOfUseAssets",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering agreement.",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "At-The-Market Offering Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BiogenMAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen MA, Inc.",
        "label": "Biogen MA, Inc. [Member]",
        "terseLabel": "Biogen MA, Inc."
       }
      }
     },
     "localname": "BiogenMAIncMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrammerBioMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brammer Bio MA",
        "label": "Brammer Bio MA [Member]",
        "terseLabel": "Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary"
       }
      }
     },
     "localname": "BrammerBioMAMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrisbaneCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brisbane, California",
        "label": "Brisbane, California [Member]",
        "terseLabel": "Brisbane, California"
       }
      }
     },
     "localname": "BrisbaneCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, number of free shares held by the holders.",
        "label": "Business Acquisition Number Of Free Shares Held By Holders",
        "terseLabel": "Number of free shares held by the holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesHeldByHolders",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "label": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "terseLabel": "Number of free shares outstanding subject to purchase (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, number of shares acquired.",
        "label": "Business Acquisition Number Of Shares Acquired",
        "terseLabel": "Number of ordinary shares acquired (in shares)",
        "verboseLabel": "Number of shares acquired (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSharesAcquired",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, percentage of equity interests agreed to acquire.",
        "label": "Business Acquisition Percentage Of Equity Interests Agreed To Acquire",
        "terseLabel": "Percentage of equity interests agreed to acquire"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CNineORFSevenTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C nine ORF seven two.",
        "label": "C Nine O R F Seven Two [Member]",
        "verboseLabel": "C9ORF72"
       }
      }
     },
     "localname": "CNineORFSevenTwoMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California institute for regenerative medicine agreement.",
        "label": "California Institute For Regenerative Medicine Agreement [Member]",
        "terseLabel": "California institute for regenerative medicine agreement"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAgreementMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities.",
        "label": "Cash Equivalents And Available For Sale Securities",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax.",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "negatedTotalLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "label": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "label": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Cash equivalents, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ChangeInCollaborationAgreementScopeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Collaboration Agreement Scope [Member]",
        "label": "Change In Collaboration Agreement Scope [Member]",
        "terseLabel": "Change in collaboration agreement scope"
       }
      }
     },
     "localname": "ChangeInCollaborationAgreementScopeMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAgreementEquityIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Equity Issued",
        "label": "Collaboration Agreement, Equity Issued",
        "terseLabel": "Collaboration agreement, equity issued"
       }
      }
     },
     "localname": "CollaborationAgreementEquityIssued",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationAgreementNumberOfAdditionalProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Additional Product Targets",
        "label": "Collaboration Agreement, Number Of Additional Product Targets",
        "terseLabel": "Number of additional product targets"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfAdditionalProductTargets",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationAgreementTargetSelectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Target Selection Period",
        "label": "Collaboration Agreement, Target Selection Period",
        "terseLabel": "Target selection period"
       }
      }
     },
     "localname": "CollaborationAgreementTargetSelectionPeriod",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "verboseLabel": "Collaboration and license agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements number of products approved under agreement.",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "label": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "terseLabel": "Financial advisory fees"
       }
      }
     },
     "localname": "CollaborationArrangementCommissionFeePortionOfGrossProceedsValue",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationArrangementResearchPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Research Period",
        "label": "Collaboration Arrangement, Research Period",
        "terseLabel": "Research period"
       }
      }
     },
     "localname": "CollaborationArrangementResearchPeriod",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Axis]",
        "terseLabel": "Collaborative Agreement Milestone [Axis]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneAxis",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Domain]",
        "terseLabel": "Collaborative Agreement Milestone [Domain]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneDomain",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborativeAgreementPercentOfInitialRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Percent Of Initial Recognition",
        "label": "Collaborative Agreement, Percent Of Initial Recognition",
        "terseLabel": "Percent of initial recognition"
       }
      }
     },
     "localname": "CollaborativeAgreementPercentOfInitialRecognition",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "label": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "terseLabel": "Agreement restriction, percentage of shares held"
       }
      }
     },
     "localname": "CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementCumulativeMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Cumulative Milestone Achieved",
        "label": "Collaborative Arrangement, Cumulative Milestone Achieved",
        "terseLabel": "Cumulative milestone achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementCumulativeMilestoneAchieved",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement estimated reimbursable service costs.",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs for new research plan"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)",
        "label": "Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)",
        "negatedTerseLabel": "Increase (decrease) in net loss"
       }
      }
     },
     "localname": "CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Increase (Decrease) In Revenue",
        "label": "Collaborative Arrangement, Increase (Decrease) In Revenue",
        "terseLabel": "Increase (decrease) in revenue"
       }
      }
     },
     "localname": "CollaborativeArrangementIncreaseDecreaseInRevenue",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, License Fee",
        "label": "Collaborative Arrangement, License Fee",
        "terseLabel": "License fee"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseFee",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "terseLabel": "Maximum milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePaymentReceivable",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "label": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "terseLabel": "Maximum number of product targets replaced"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementMilestoneRevenueReversal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Revenue Reversal",
        "label": "Collaborative Arrangement, Milestone Revenue Reversal",
        "terseLabel": "Milestone revenue reversal"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestoneRevenueReversal",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementNetIncomeLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Net Income (Loss) Per Share",
        "label": "Collaborative Arrangement, Net Income (Loss) Per Share",
        "terseLabel": "Increase (decrease) in basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeArrangementNetIncomeLossPerShare",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Milestones Achieved",
        "label": "Collaborative Arrangement, Number Of Milestones Achieved",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfMilestonesAchieved",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets",
        "label": "Collaborative Arrangement, Number Of Product Targets",
        "terseLabel": "Number of product targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargets",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargetsSelected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets Selected",
        "label": "Collaborative Arrangement, Number Of Product Targets Selected",
        "terseLabel": "Number of product targets selected"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargetsSelected",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementResearchServiceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Service Fees",
        "label": "Collaborative Arrangement, Research Service Fees",
        "terseLabel": "Research service fees"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchServiceFees",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "label": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "terseLabel": "Standstill restriction, ownership threshold percentage ownership percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction Period",
        "label": "Collaborative Arrangement, Standstill Restriction Period",
        "terseLabel": "Standstill restriction period"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionPeriod",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Collaborative arrangement transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "label": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "terseLabel": "Voting provisions expiration period"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsExpirationPeriod",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "label": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "terseLabel": "Voting provisions, ownership threshold percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments to be received.",
        "label": "Contingent Development And Sales Based Milestone Payments To Be Received",
        "terseLabel": "Contingent development - and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer contract liability milestone payment eligible to receive.",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "terseLabel": "Development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ExtendedResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended Research Term Of Agreement",
        "label": "Extended Research Term Of Agreement",
        "terseLabel": "Extended research term of agreement"
       }
      }
     },
     "localname": "ExtendedResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_FreeSharesAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free shares asset.",
        "label": "Free Shares Asset [Member]",
        "terseLabel": "Free shares asset"
       }
      }
     },
     "localname": "FreeSharesAssetMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_GainLossOnFreeShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on free shares.",
        "label": "Gain (Loss) On Free Shares",
        "negatedLabel": "Loss on free shares"
       }
      }
     },
     "localname": "GainLossOnFreeShares",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_GrantFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant funding amount.",
        "label": "Grant Funding Amount",
        "terseLabel": "Funds due under the agreement"
       }
      }
     },
     "localname": "GrantFundingAmount",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in long-term portion of lease liabilities.",
        "label": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongTermPortionOfLeaseLiabilities",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_InitialResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial research term of agreement.",
        "label": "Initial Research Term Of Agreement",
        "terseLabel": "Initial research term of agreement"
       }
      }
     },
     "localname": "InitialResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kite Pharma Inc.",
        "label": "Kite Pharma Inc [Member]",
        "terseLabel": "Kite Pharma, Inc."
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LesseeOperatingLeaseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Amount",
        "terseLabel": "Lease payment amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAmount",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LesseeOperatingLeaseAreaOfRealEstate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Of Real Estate",
        "label": "Lessee, Operating Lease, Area Of Real Estate",
        "terseLabel": "Area of real estate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaOfRealEstate",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LicenseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Obligations",
        "label": "License Obligations",
        "terseLabel": "License obligations"
       }
      }
     },
     "localname": "LicenseObligations",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LonzaNetherlandsBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lonza Netherlands, B.V.",
        "label": "Lonza Netherlands, B.V. [Member]",
        "terseLabel": "Lonza Netherlands, B.V."
       }
      }
     },
     "localname": "LonzaNetherlandsBVMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputExchangeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Exchange Rate [Member]",
        "label": "Measurement Input, Exchange Rate [Member]",
        "terseLabel": "Exchange rate"
       }
      }
     },
     "localname": "MeasurementInputExchangeRateMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputStockPriceCorrelationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Stock Price Correlation [Member]",
        "label": "Measurement Input, Stock Price Correlation [Member]",
        "terseLabel": "Stock price correlation"
       }
      }
     },
     "localname": "MeasurementInputStockPriceCorrelationMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneRevenueReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone\u200b revenue receivable.",
        "label": "Milestone Revenue Receivable",
        "terseLabel": "Milestone revenue receivable"
       }
      }
     },
     "localname": "MilestoneRevenueReceivable",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NovartisInstitutesForBioMedicalResearchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Institutes For BioMedical Research Inc.",
        "label": "Novartis Institutes For BioMedical Research Inc. [Member]",
        "terseLabel": "Novartis Institutes for BioMedical Research, Inc."
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of clinical or regulatory milestones included in transaction price.",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "terseLabel": "Number of milestones included in transaction price"
       }
      }
     },
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfOptionsToExtendInitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Options To Extend Initial Research Term",
        "label": "Number Of Options To Extend Initial Research Term",
        "terseLabel": "Number of options to extend initial research term"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendInitialResearchTerm",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research program.",
        "label": "Number Of Research Program",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "NumberOfResearchProgram",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory.",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office and laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "terseLabel": "Other products"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer Inc."
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerSB525Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer SB-525 [Member]",
        "label": "Pfizer SB-525 [Member]",
        "terseLabel": "Pfizer SB-525"
       }
      }
     },
     "localname": "PfizerSB525Member",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PhaseThreeClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase Three Clinical Trial",
        "label": "Phase Three Clinical Trial [Member]",
        "terseLabel": "Phase 3 clinical trial"
       }
      }
     },
     "localname": "PhaseThreeClinicalTrialMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PreApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-approval Milestone",
        "label": "Pre-approval Milestone [Member]",
        "terseLabel": "Pre-approval milestone"
       }
      }
     },
     "localname": "PreApprovalMilestoneMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PropertySubjectToOperatingLeaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property subject to operating lease one.",
        "label": "Property Subject To Operating Lease One [Member]",
        "terseLabel": "Operating lease one"
       }
      }
     },
     "localname": "PropertySubjectToOperatingLeaseOneMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned",
        "terseLabel": "Contract to perform for others, cumulative compensation earned"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ResearchAndOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and office space",
        "label": "Research And Office Space [Member]",
        "terseLabel": "Research and office space"
       }
      }
     },
     "localname": "ResearchAndOfficeSpaceMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services [Member]",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk",
        "label": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RichmondCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Richmond, California",
        "label": "Richmond, California [Member]",
        "terseLabel": "Richmond, California"
       }
      }
     },
     "localname": "RichmondCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveAndOtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S B Five Two Five And Other Products",
        "label": "S B Five Two Five And Other Products [Member]",
        "terseLabel": "SB-525 and other products"
       }
      }
     },
     "localname": "SBFiveTwoFiveAndOtherProductsMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SB five two five.",
        "label": "S B Five Two Five [Member]",
        "terseLabel": "SB-525"
       }
      }
     },
     "localname": "SBFiveTwoFiveMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone",
        "label": "ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone [Member]",
        "terseLabel": "ST-40 Beta Thalassemia Phase 1 clinical trial milestone"
       }
      }
     },
     "localname": "ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Excess Consideration Received on Transaction",
        "label": "Sale of Stock, Excess Consideration Received on Transaction",
        "terseLabel": "Excess consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockExcessConsiderationReceivedOnTransaction",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based Milestone",
        "label": "Sales-based Milestone [Member]",
        "terseLabel": "Sales-based milestone"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SangamoFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo France",
        "label": "Sangamo France [Member]",
        "terseLabel": "Sangamo France"
       }
      }
     },
     "localname": "SangamoFranceMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi.",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi Genzyme",
        "verboseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest.",
        "label": "Schedule Of Noncontrolling Interest Table [Table Text Block]",
        "terseLabel": "Summary of Non-controlling Interest"
       }
      }
     },
     "localname": "ScheduleOfNoncontrollingInterestTableTableTextBlock",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_SeparateUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate upfront fee.",
        "label": "Separate Upfront Fee",
        "terseLabel": "Separate upfront fee"
       }
      }
     },
     "localname": "SeparateUpfrontFee",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement and tender offer agreement.",
        "label": "Share Purchase Agreement And Tender Offer Agreement [Member]",
        "terseLabel": "Share purchase agreement and tender offer agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementAndTenderOfferAgreementMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_StockOfferingProgramMaximumValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Offering Program, Maximum Value",
        "label": "Stock Offering Program, Maximum Value",
        "terseLabel": "Stock offering program, maximum value"
       }
      }
     },
     "localname": "StockOfferingProgramMaximumValue",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock purchase agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ValbonneFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valbonne, France",
        "label": "Valbonne, France [Member]",
        "terseLabel": "Valbonne, France"
       }
      }
     },
     "localname": "ValbonneFranceMember",
     "nsuri": "http://www.sangamo.com/20210331",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r37",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r230",
      "r232",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r369",
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r230",
      "r232",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r369",
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r140",
      "r215",
      "r217",
      "r370",
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r140",
      "r215",
      "r217",
      "r370",
      "r406",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r220",
      "r230",
      "r232",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r369",
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range",
        "verboseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r220",
      "r230",
      "r232",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r369",
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range",
        "verboseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r215",
      "r218",
      "r409",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r215",
      "r218",
      "r409",
      "r420",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r15",
      "r144",
      "r145"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium (discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r29"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r41",
      "r43",
      "r44",
      "r394",
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r40",
      "r44",
      "r45",
      "r85",
      "r86",
      "r87",
      "r292",
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r233",
      "r234",
      "r247",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r200",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Recognized portion of equity issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r234",
      "r239",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options and RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r159",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r129",
      "r132",
      "r138",
      "r166",
      "r287",
      "r293",
      "r312",
      "r374",
      "r392"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r36",
      "r81",
      "r166",
      "r287",
      "r293",
      "r312"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r299"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities and free shares asset"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r151",
      "r173"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r147",
      "r152",
      "r173",
      "r377"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total marketable securities",
        "totalLabel": "Total",
        "verboseLabel": "Available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r149",
      "r173"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r149",
      "r173"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r229",
      "r231",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Sangamo France stock price (EUR) (in euros per share)",
        "verboseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r272",
      "r273",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S."
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r78",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in unpaid liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r24",
      "r72"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, Estimated Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r73",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r66",
      "r72",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r66",
      "r314"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r93",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r93",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r277",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper securities",
        "verboseLabel": "Commercial paper securities"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r32",
      "r197",
      "r378",
      "r399"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r194",
      "r195",
      "r196",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50",
      "r54",
      "r382",
      "r403"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Sangamo Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r49",
      "r53",
      "r283",
      "r284",
      "r297",
      "r381",
      "r402"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r47",
      "r49",
      "r52",
      "r282",
      "r297",
      "r380",
      "r401"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r143",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r118",
      "r119",
      "r143",
      "r309",
      "r310",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r118",
      "r119",
      "r143",
      "r309",
      "r310",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r114",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r118",
      "r119",
      "r143",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r118",
      "r119",
      "r143",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r203",
      "r205",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Portion of contract asset recognized"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r203",
      "r204",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r203",
      "r204",
      "r216"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r203",
      "r204",
      "r216"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r221",
      "r228",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r254",
      "r255"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r70",
      "r127"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Volatility estimate"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r55",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r101",
      "r102",
      "r103",
      "r107",
      "r108",
      "r383",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r111",
      "r167",
      "r200",
      "r201",
      "r242",
      "r243",
      "r244",
      "r260",
      "r261",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Free Shares Valuation Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r300",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r299",
      "r300",
      "r303",
      "r304",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r227",
      "r228",
      "r300",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r227",
      "r228",
      "r300",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r300",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r342",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r305",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r175",
      "r176",
      "r177",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "EUR / USD exchange rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r178",
      "r180",
      "r373"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Impairment of goodwill or indefinite-lived intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r182",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r70",
      "r179",
      "r181",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Research grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r70",
      "r188",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r187",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax",
        "totalLabel": "Loss before taxes"
       }
      }
     },
     "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r262",
      "r264",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r96",
      "r97",
      "r128",
      "r256",
      "r263",
      "r265",
      "r405"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax expense",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r184",
      "r186"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair value of investments available-for-sale"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r371",
      "r389",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Area of space leased (in sqft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Nine months ending December 31, 2021:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease agreement, extendable lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit established as a deposit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r81",
      "r133",
      "r166",
      "r288",
      "r293",
      "r294",
      "r312"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r81",
      "r166",
      "r312",
      "r376",
      "r397"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r81",
      "r166",
      "r288",
      "r293",
      "r294",
      "r312"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Recognition of license and stand-ready fee"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Stock price volatility estimate"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Price volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r34",
      "r81",
      "r166",
      "r312",
      "r375",
      "r396"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at March 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r201",
      "r285",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Fair value of additional shares acquired"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r66",
      "r68",
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r46",
      "r48",
      "r51",
      "r71",
      "r81",
      "r88",
      "r90",
      "r91",
      "r92",
      "r93",
      "r96",
      "r97",
      "r100",
      "r129",
      "r131",
      "r134",
      "r137",
      "r139",
      "r166",
      "r312",
      "r379",
      "r400"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Sangamo Therapeutics, Inc. stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r46",
      "r48",
      "r96",
      "r97",
      "r290",
      "r296"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r201",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r129",
      "r131",
      "r134",
      "r137",
      "r139"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r331",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current (included in other accrued liabilities on the Condensed Consolidated Balance Sheet)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - long-term",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r328",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities included net cash used in operating activities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r84",
      "r124",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table Text Block]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r38",
      "r42",
      "r313",
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r39",
      "r41"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized gain on marketable securities, net of tax",
        "verboseLabel": "Net unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporarily impaired investments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Purchase of additional shares of Sangamo France",
        "terseLabel": "Purchase of additional Sangamo France shares"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from at-the-market offering, net of offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r63",
      "r241"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and restricted stock units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r60",
      "r148"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r60",
      "r148"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.",
        "label": "Proceeds from Sale of Held-to-maturity Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r46",
      "r48",
      "r65",
      "r81",
      "r88",
      "r96",
      "r97",
      "r129",
      "r131",
      "r134",
      "r137",
      "r139",
      "r166",
      "r282",
      "r289",
      "r291",
      "r296",
      "r297",
      "r312",
      "r384"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedLabel": "Decrease in net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r25",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r190",
      "r398"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r251",
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Revenues under agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r250",
      "r431"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r12",
      "r72",
      "r77",
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r12",
      "r77",
      "r421"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r201",
      "r245",
      "r395",
      "r414",
      "r416"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r167",
      "r242",
      "r243",
      "r244",
      "r260",
      "r261",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r125",
      "r126",
      "r130",
      "r135",
      "r136",
      "r140",
      "r141",
      "r143",
      "r214",
      "r215",
      "r370"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Increase in revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r118",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r155",
      "r158",
      "r161",
      "r162",
      "r163",
      "r164",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Revenues Recognized under Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r234",
      "r238",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r234",
      "r238",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r9",
      "r77",
      "r372",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r236",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Sangamo stock price (USD) (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r33",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r97",
      "r111",
      "r167",
      "r200",
      "r201",
      "r242",
      "r243",
      "r244",
      "r260",
      "r261",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r85",
      "r86",
      "r87",
      "r111",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock in connection with at-the-market offering, net of offering expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r200",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in connection with at-the-market offering, net of offering expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r201",
      "r235",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r19",
      "r20",
      "r81",
      "r146",
      "r166",
      "r312"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Sangamo Therapeutics, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r81",
      "r85",
      "r86",
      "r87",
      "r89",
      "r95",
      "r166",
      "r167",
      "r201",
      "r242",
      "r243",
      "r244",
      "r260",
      "r261",
      "r280",
      "r281",
      "r295",
      "r312",
      "r315",
      "r316",
      "r321",
      "r412",
      "r413"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r201",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions",
        "verboseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r221",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored entity debt securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r112",
      "r113",
      "r115",
      "r116",
      "r121",
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r332",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Estimated correlation between Sangamo and Sangamo France stock prices"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121578510&loc=d3e41551-112718"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r432": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r433": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r434": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r435": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r436": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r437": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.18)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001628280-21-008878-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-008878-xbrl.zip
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MEV9XZ8KR#]>;P//3SG2V/%_@90E_35#*IY<E?-[X0M/1#H1)62+.%X6XE\7
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M;:<-.!F.YM=;><1("GES>JF2R?M[!B](,%'E.JV!ZJ@;Q#Q\TEEC^')N%?/
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M_H@SS?L-:HR(A26"6N-)$B1!!.ZYU$XT"KN=/JM=HW*-ROVPRB%)%0FOZ"*
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M",L"NN*\T"776O.*6<4$C18Q'ND\FYW-6=U/#?S5A-U55G?3)1%7,/HCPU=
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M^ [^G,M\C_[1^@5AV\JXO2;(J5%&R?2E[U#A,Y-8+\'55L5_:.;O]$\9@S>
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M3;1&*%?U)Q^W3ES9^N!Z$VC]_V2-T+S\H#4ZNO-,CD89OJL,,XL\-<B-)MQ
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MYML.M7:*T?O&RM9&E_D/YELW5O9.)",N6EG16-D':F6G4P/C$H586=@WY3!
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MZ!3P<[@@UCGY?XP-3HHQ2O"B6YE%^JCXF4_DI\CRQD:SB<ZOA'7G?/?+]@T
M[LK7S&+IRI*7PX^9PZ5++J7I^H5V/1JWX^G(Y.=<@,LY /ASM01K$*#I^X7V
M_3EWG070O:H,8EF,WH^JO-.FMQ>*])X;5!'&\307-,_P5J/R%\*-HDHO._^:
M)^6GHTL7LE?&1^YSALM1,<(HIAKUR$,/WT@L_49&[G+RM"IY;>$=AWW(?C5W
MR.EPDFE.J\C/5:1J,^NO9?U4$VG5#/8LI6G*M-##^CPQ5O9'LPF.T=-YYM?G
M0?G1U8QK#[T"/GSY>TX>*_+@_9<')KUX]<=S)O'%@4K27_Q<R3M^\?/_8^]+
MF]I(MFW_BH+[XL6Y$4HZY\%]'A$T8#?W&N$V<COPEXX<C6PA<21A&__ZEUFE
MH1B-D! ER#-@C:6JW+E6K;USY]ZG^EJ.>#E[KKPX]/[K]1=/;CJS[YUN]^IK
MW<Y7W[WV2_W>YWZ2)%=/H"3JJR_KX?#\]%K^^BA.-G_ML]&8/AKZVNN?SZ.L
MC?1^[4PF4+GVHYW3:\?HZVXU97[8B;-5%\HL95,4D"I'N_2_[C'#;DRE"]V)
M)SJ)'G[K^.^EHSE)]$['OY)FE_!J=%K_32EQ:<S.JJC_UN]&M^)K+\43TROG
MO?)QP<7-^-1&WS1%JB89'24KC-=A2TI(67!6%Y!(DJ9T:\>Y(LWJ731!1-N3
M--W'C-)OF!2^C*")-]SN1<-U0K$I8E3Z)(F&QM=ST_&&UPXX'O1R T9THR*T
MBH7OI*I^/=[%18^'H7K=TQ2_B5-?I/>5^;SKE,QW<UYN3>]<'WTQ=_4TN@ZB
MP:) -IU^):W EAM;2A3T^M?SQQJ50.ID.72S<5CL3K$V16J</TM46.Q6&>DB
M%!]G8D3+Y36Q:?:3\Z<1/Z.Q9!R6-4S2I/'):=,SE^T6;_R7&3.3@,XP_L(P
M(6WB\%<BN>=Q(I;9NO%BIK'>,CP0 7W+J9>!Q1O"S9WAV)-,G!?E6._SZ.0B
M^I0G<2Q\&;TJ81'AY3JVV*<UCF)?1 ?S6Z2$OK4IR3<A,MKC^K7?+A#J (VU
M$G4'A3R[?9)5*;\7T="].SDG45Q!Y"<Z3IT+7]Q&+CJ^6^K *:1FT<*(CV^=
M8@Y4I^\$<MG2RR3!PBC1?.FFG]3%YUXGT4Q*N9WZK=W^,.50#3OI)IO^G$W[
M)\Z49V.B*-WD\Y/^]$D>1457&+2\W6XV/OH*MHVW22M' X=.@?ULXF6:>!RR
MJP;<)M&\0M"-(W17TCTFYJS&+^([$V1.PD9)W$1ZO^'8A7VC*Q<EF/ZFHV@M
M -U/68)%JMVW_J!\J7!I$K%']Z_;S5L(IU.*W+Z%,.\&K.=&NI>V&S#S\4/X
M. J<$Z^_=<:.P.4\R<+7Z*9 PR!Y(V<G.KJCMM! Y2:7>"6%INH7:[+%VO T
M$[.2Q]6<KN/>E@%R?8WV]$[IM]G8#^F^$+J=8@UOD(H2E/D@UY)4DH,<QD4*
M+EU>HOM.+YWT1,Q'[AJF#2-E0EKE0B9G4$U,BTY,?Q!__'L*!J5[2\]_+FX
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MY0G,PH956BR\M2(8F"?3,B5<U;<=N[7EO&K.$F^+F&VJLFJ32$FQ8#VX&!/
ML%/ZOC>GZHWS @OFF$S)>]S%$A]%FBH/'R?IE\A=0S=.\FPVOI]T[$FC6-Z+
MLRY.MF&B4ET$A0NA%B%P/MTY>^WW?D%68S&9#M[IV23IRF23<M&C'PIZ[%Y,
MH[_E0'32C+5ED"G*AC)#M924EX/!XQ!SGL5+F\4WK5'$L8\L4^1MI9GYN9*W
M,O"358!*J&=\UXX$UNV$M!8V_-J)TSG.^WB'[U]X/[SRW<G:XE=_$6_'WIX7
M"0,E5"9?F<S4A+&(K^HBP>=.XO%"$5Y*,"P#C>,*:=\Z[GR\Z% LC YS.'%Y
MLZ:=]ERF5=UDCNO;R$H"F(8.(RW.F&:2=KKT;6;795^YBCP]RF2+1.&_5G>3
M32+/DR7B.7U0FWW05<VYL;0Z&Z32==-I<!HU3SS#OOT:U76RIB]ONRDII%%F
M@5R:C-%4<>Y&4W5]F9E:Y.445NRFJA'I[ID6=/5@-*D=TNE%@AH59N_TKOWL
MFF4E;<^H.]YZ[7F1/S+9%'K/G(RH+NR@8Y*+9OK)=8L#_SWMW=?C\I.WYCE,
M4#9Q?2;X;!:I428%A,Z++[EXD''Z2[5=YB0-)MKA7;+0?K-1-&A!VY,9L=WK
M)2%UO;KE_TX7HRY\2IXILF5VHR@[-?&W"&HV,,0P74+H=">;G(JR57L[Q7&\
M&9Q'^586%L.T^#PJYU#T*:)/&7\^B?<TH>+E3<M8EM&+FX9]L_%F?#>;YH;\
M<O#+1+(R$:K0GV=='?$01^R\""MVRC28R4'O2DG9[@[[S5]^+I4:2XMWO9*W
M;TKUFV:&W9GUU^\EK3F<S#4W+@I35)R,0QY_=;-Q/+NVJ!]=^>:TUEF*&8P*
MQ=JKV*>8+"FO8IS<KD?5+*'+R3U7M[?%WR_3F"92X_9,H>_IP-\GY0:F=H_S
M-EEA5J'U<YPD.EZU'QN^=T<>5LE2QD_J&;@BTI%VQ9N)I+HH&:F<W'>G#):6
MM/J\F&C1T:@8>\U8:N]'\I_3;)EN+(H7V-7?FVG,"XN/]->4)UK9UE:L+)Z5
M\VI0!F'\>"?SG=F69^?Q$#8Y)F5D\<9C%/181*DG\<A+66CC6T@Y9ZJS:.RX
M%[>62MV$SJ\!VBRF9@I9I&V[G5FSCK%D&5;65,<5_29+ZPE&16J3^Q:GI&LV
M3OK?TS)[L]Q V"M"5V7JVZ @%S=KD)0&^#2-;;\W+J_G4N)2@GODC#6;1]5:
MB>,<N^&5^]Z8;1LW5I<:URHH5Y@3N_2CBSSH],^'-ZZ-3)(JRP.,+L[2 1-?
M15M,%<5T8:?OBH66Z0_'@^A+/U7HU)L"41,6JUQ)(HUX%6/R-$4NQK#CBKZJ
MX]DQ*14])N KIY%^/:KCV::<YI4S*P/PQ40H=OD54[TL&QQG^UGR\,9AAL*7
M2W/W^TGZXXL\TO%!AK.M1Z/R&L\*ZY3I:)-,M]\B^,I<M72#+$I@IY&[-A;-
M6U+6IM&9X4DZ[<2=92[K)%YV0T)$<7[]P7AEHC<+"D8&'O4_^P24G)DPA19=
M2G%CDHL;USP3X*6E,]2UN/&[[??MQOYFX_5^:[M5E#G>;[T^?'^PW=X_;%VG
MI7OBCV_<8P@NN>3B:BEDD%YYHD'9;^\=E X9VBS_O?YW-F!WU7R^YWBI7XP7
MK]&,.=INO=D^.&RT_]Q[O_UN[T-[?^<H^LNMG?F\@1I<R<YA:W>O=;2WVXB/
MC@[?[N]&0^XV_MA^&RV[USCZ<V_OCCK>=;F*?WWHZ:@,HZ#^O91D449&/3+\
M[U^98ZP22AE=+H9,]<,@\B$HHJ%G0_]J\N#WJ RCIW[QJM,KSJ/XT@T=WF9W
MS4U8WCG'38G&QQ^_O5F\-6EZ<^D]P3:1(K>^#3?1K>_==5@$-XFB#SKLW>\Q
M)!_G9-F]#GO/'GUS])6ZH<]0.<MO[32TU+DO?S7UBVEU4%08(ZCY;S/X;2L%
MSJ9S?JE-MM9B,*I!Q\EXP$OC\8M98K3]^GF0(J5@?,K6^N@N_3[W,$S;T:V8
M#XMQV#XZJM+V[=:]]7K']%<(E;/H[/6['=>8G/@<T^>7 [K(,>8_R;G-'XK_
MW&7^.UN/K=A]+(R_,RE0-QSZT?#5@V;!E<M^D)$>^QB/ .7ZV5*/J_D6)612
M9.6;[I;NUF6KSG/1L+$.E_Y_%KK$ZJ45I;9J=6W_[OQ(+?A>#\8;1,][G='[
MY'.?#]W&))I8O-#AQ'/B- I.>>J8BH^("-0&JYTQ%/^SG^[YD!"TT8C>?.=4
M=X?_;P-$')11[7B('Z-7O?-3UQ^-W]\HFI>E'P.?M3Y[E2;9=L^E?_9F,VQ[
MM*,'@XLXHG^GU*6(JSAXOD!8X=$Y\O>%V>U_>XO??SLF!^?NR]ZW3V_4E\,O
M[SN?VMV3@]V#[ZW3O]CQS_>G!U^ZG>/VYXOCG_]S<KC;^GK0/L"?WOS=>4M:
MW>.??7A\^H$=M[=_'NQ^^GKX\0!^^K+/CD_WZ,'IP47\WL]/NWL_6Z?ON\==
M^>/P2)W:T]>]PR^OOQZVOUY\^O+712M^O_7S+Q)_DQ[\W,.MW7WXZ<U?]+B]
MAS^=OCY]2]Z?')_^Z!Y^^?K]X,T!;N'W7S^U/[.#]E_T<+=[<MC^_/W3Z1X^
M>//7S];N5W30_OO+Y#OQM\X_X0_\L+W]_?CG,?GTYGWW</?KC];N9WKX<8\=
M[OYQ>MP^_OYI]P >MC_\:'ULA8,+^.-M>V]T< 2__V.U#%10 5A0'E %$=":
M>$"L5B0P!;4+&UL(XZ82[-^_79X:6Z6GO0@6TJUQ3DPL\X:>F>F9,A-CSALM
M22#:4@R=)DX9[JVB6'#!3<%,$.',3/5BII]39C(2$8&) #1@ Z@7!AC(%'!8
M!22)1=RJR$S1F2)8U8B97H**/RARLLJ(U+2[VZU:'L]W\3?R[%J3T0IDTO8D
M)^!U?W 4"6?6=&_7F]'LV=C_RK0T!RVU=BJ"B6JM/(0.4"@C-QFO@!+& Z:1
MY Y%UD%^8XMRVD1P85JZF1H>53#=US%^\:!>@<+(H'Y44,^T1M"2!8@40-'Y
M 13KZ 5Y@X#SW"N,,.-0;&PQ!)M0T1J!^B5$F?93 -L/4Y$MZZ/*CG!XD-*X
MKT>WUJ3T<*5QF7DF@_Y^.N:98Q[ ,4<5X> 0AI1)#@RE&E#"!- (:F 9YL8@
MR[BG&UM*+,PO]8NR9'RN4#1DZ"X)NC-Y@)&"BD@,O%11'C"!@>(\ (NYU@@Y
M1!'<V$)-2.H4(GT)@8AM:^,5%+M5%A('+\)C64488FR/&?FT_"CSSP/XIU.1
M#D(Z9J)_ GPP.(5"(5 T4& <44AS9G4@&UN\*2BOD7.2(P[K)QXR?I>'WYE^
MD %";2@",)@ :.1<( .F@#G,+(4N((XWME@3XQQ<6"WZW@W\F>ZX:;>CRL9;
M>RE3*8<<GE!5C*VT5QIIN^<.DX6V"\-D<GH .5W* +$Z60H#A%44%R0@H /W
MP'%K [917'">,D":B,(:>3<Y-+%^ZB+C>.DXK@0IO#$,$@^D"A)0:A%0%E%@
MH2=80@&YI!''J*GDPEY"_:(4)1SQ)F8U5QSM?JJ0O@1Q,1Z'>Z69/T_&6D4\
M(W/3 [GIL)HTX9B6VF %#+/1 =(^/J)( XB)% (YRD78V.*0-Q5=E@MT;V"L
M47SC!8-]%<&/#/:'@WTF1#S13AKD@8E6BD*$"*"90R!8[I1"D9&-BF!GJLFY
M7!>POX1@R(U9G<U&M X8ZY4<!5F#%,]6OV<SA\W/8=5D#2I#X Y#0*'U@"(C
M@=8L &,A4<;PX"G;V**X20FJD3.5@R)KJ#HRK!\9UC-IHJB'P3,%".0(4,\D
MB+;U "J#$=4">9\68F"3D3K%.E]")L>[20G\HHK<?\X[1<'EJ#[\PU3'BU@1
M7LG:2VF7=UW=&VWWW-[$-"V?B6BNS6WM[41"I<;8_B=HC0V.DL(3J !ER %E
M+022>8^$P%#ZM(\D+0KC&BT*YZ2.]5,8&<++A/#%%,)>&J&%4T Y*P$E- ")
M!0(2J0A:PJQA,D(X;5#->1TKWS2B>Y\[13/QG+_QU!IB9HTRQ!IY9^]'JLH<
M1_5-O^]2.?1,1',1T5Y52S"+L0]& ,(8!510 Q1W @C'I0J!>VB26\.:3)(:
MN34Y6K%^6B)#^3&@/-,4RF$1+)1 JQ1X5#[*"4DL@!83@3W7-B0HRR;""Z^=
MY C%7$"<3.\<CGA"*9$YYD$<LU^5"S1X2"5EP/J  0V( F-E_(.8C)X,,DR%
MZ+? IJK59O<<>E@_N9#A^E"XSB0!T9X8$0+ T'! B2% RRCVD31($>:(H+A8
MBQ1J6>D4.<QP/[ =E@TJ4P_;HNUM,2R@'\#Y, <>:J 6IO9YF\SS/IWG8?@P
M+'V7S$ES<=)!54*08(R"E  A,0%4&QS=%(6 YAA3@2@A#FYL";B,T&>..-07
MPRN0$!G#2\7P3%=HJ7T*-@#E,06460>T5A8XA#2TTDDC=<0P:D*:RUJL6%<4
M.U KB9=+V"CRO(EH%6)BMEDMYV(]D(#^JHH(KJ$46$&@L+8@R@8;'1N) 598
ML(!0BD=L;"':A$K4R+')<8@U%!$9N\O [DP\4!.U G484.01B%83P%C* <0.
M6QXHL=ZEZMQ-QNJ$W9<0E'COAZ-!QZ8&SJDQ2PY /*%FF-DBM0G(U/- ZOE0
ME0U.>$QX0("9J!TH10AH1"SP@B$N)??2D%2-C\$ZY7#GT,/ZJ8:,WF6A=R8<
M6' 0^^"CRD_E9A2&0&HJ@(Y4;(0,G%E:/_2^S"H5-P<='G>3>NV&XOX-E>:^
M_F?#Q2NKQ)&9=R[F/:[J)BA,O&<& X3"T66#C@*)* )>81.-IRA+!<BE$$VH
M%@[XKED1CLQIF=.>JN!(YK1Y.6VF)H.RE$BB 5-$ :JI!8I# RR7Z=;#"0MF
M8TL1V61L83VYQK5&:M@&_.W^]A_[;_?;^WM'C>W6;N.H?;CSOW\>OMW=>W_T
M?_]+8B1^;^S]]6&_?;RD5N$DFL/US].>H!KW"K_O6;Z$9=!)L_!N1YM.MZB"
MD#N&KW-H>MJNX4Q?W-2K8>&(5NVN.+?C777KB7?EU,IEW!XBKKY6'4:/3'".
M!@ YA8!*88#&D@&H/=34V,"=+RK*<E*GO4BY-7CFHJ=V[#(7+86+*OLBJ60X
M0 RD3U79A+= .Q0 EE(3X04S"A55ZAFKTQ;GEZ#2XV0?G*=D@_YIJNNN"_P5
M59Q.S[K]"^\;QO=\Z.3TQ:?61\E,>V.C_#&V2>:F!W#3ETHII_9GV/KK'RJM
MDC9J)4:<B?PD(#!">B --YI1(PEG13X4%'7*A\JYC&LI+C*0EPCDBTM 1K+<
M_0 (I@)03A20UD4T:XHQ4=I9'9T>#)MB<:<G)S8^8%>$'LN-2E PIS@^O:YX
M.S-'9J)%)<5?Z!](&=$D"."<YX JZJ.@H H$PA64T61.^D)0"%ZG1*F<YKBV
M@B(C>(E:(B*8FLB^,G7@HM8"Z@,"QL@ 3'PH'9342141+)L<+5SA-8<LYL+?
MK@\^SG#7&/AOOG?^0 7Q(AR:%2B(G?A[Z4P^=D8G.^?#."Q^,"&CBTQ%#Z&B
M2^4AE5'20"&!T$:EFG(!1%MJH"R7D%$);>J^I6B3\%SOZ1E#>052(D/Y,:!<
M60:1WB(F'.#68D IE<!@%)V$0#G51,8YPB*449,OK8]>C:(3:[9]PEY/7UHD
M4O&"F_^M0(1D[V=!GKI48A)%3P=[+($/1@**DMJ(-QX0%-5<.>H=37LT"6Y*
MHI;D_-1FK\$28QLO&/,K4"L9\XMC?J9-+ S&4T^!E80#ZA '.D2!XH+ED$FI
M5%HY090T&5UX#715F'^1T9#%>WZ^"'_JJ4,C>4/Z VGK4BE+BZDB,+I42#D$
M*(,>2.@UP%Y@Q[4F3.N-+8QQ$XLZK?CF\,CZ"8X,YT>"<Z5:MK/><HR!1<P!
M*J !AC*:BL5P*(5&PID(9\J64=:R?B&26@N-M_W>9S#R@]/&67]0P+$?QI6S
M<S9'/03'Y6J[F9L6Y:9+!2]5,%%L, R\$"8UWI# ! F!=)YR::%7J?$&D4W*
MZY3$GG,ZUD]I9!PO'<<7E<*UTGCA/!"1AP'EW*55& <(P]QZCIQ$N, Q4;Q&
M.'Y1L8Q.ST9UW1CI'SF \81Z8F*/_<(<;?VC$G/-[8?G9:%+=3"Q5HYC0P$,
MD@$*N04&&04PLTY;:X4+9&.+-Z585N63'+:H(8A7("8RB)<,XLJB">%<!F]
M$"2"6 L-)(Q2 BJB(.2.*ZXVMD03R1RL>.H>'#E&40]-45BF2D'9J7D8$UTN
M#^D#Y3Y H&&Q?&M317^G )-.<N=$L,8G)L*U:CR<8Q/K)R<R?I>'WYF2@(A
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M% DGE>_5V %&%3'2DR!1VH3>I"27X7[&J%W)7LZ,VL506VGC:"S6VGE@+)>
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M6CJD^<:6Q*2IT/4\J?_.,8KG .>':XL,YSK N;+,H51@AC$@L?* .B.!4IX
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M\,.'+<^LK]>UXN69RU1TT.GU!Y& ]L=CGXEH+B*Z5-[*0@JYAY%Y"*> 8B>
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M^3R,Y>;J;545IJ7B6^N->&O"B3]G9:"48-@@ 2!C$E#E*-#1M$ *BF5@&*E
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MWZ_VKJ+9?;\DNUQ%;"?'^PV0V/BDG']<?04Y0N+H8@=_^G=USXPT$L* +4#
MG+-C&S2:Z>GN]:QG77HM)P25.6#/V8[0W=GQ>Q'-?3NM]_EFV<>3"!G<*?D8
MCV!*P^3G\>ATL6BE\D4%8GO#\,(.!I/#]-]Q$(Y&]47G'9)](Y(M%[)Q4GJ7
M-+)&)T RX"<N*8TD:"?O4S3" S4!RWN';56@H0L3;E^8L)/Y;9;Y=O4]CH,
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M1H8<=F"?*H.195P@+Q0V6";#6 #*1OD.__Y65#>2GWOV>G4(V"'@(FQ@J8I
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M_=$$T&/H8S.^? ,+&VY\#MJ,J-WYI?U)S_8\O&LQ+2=3H.>]XS@<G0)FGL8
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MU:E'T ,OVA;^WMS K]I6%M? 7AU ^:5XT/<F>[_-3](?IJ-L+C4F?-E33SI
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M7)JI\XG$I'-)'.:$Y=D[ZR.73G(KP'KR':6Y1[1ZVZ(TR3 MB/)()!X1E]P
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MO_/BE[HFKG]0OGKU:_>F6EL]8KLFY;]N[^6WN'3 [?N!V W\0.OMP;WIBSH
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M5)LCCW_-V&$K=KWK;M"[CG6]Z[9@+%WONFOUKKM&+[JUW[N2Y'Y%E=R38%:
M6;A>U6$[9E.R\4^L4H!A<8$-<J1O7#O>J^C*G!P4,E2WMJJ4,/QSTH>1VW$O
M=Q<9G8*-%H>?^N/1,-_ULIC+BGMG9W[G^;@J_]%TE'%_E3?-&Y%.YF0M1V/J
M^,;B%>HNI1XHJQV?U^$F,#S]K/9A?5W_U1IHP8@FQ>AMV,SHK/)49%=6]O2$
M3%\J7==HG.JKY;']:66F9T,:1 \FH_:8+&FF_F  -XMCWY]4=&DR\R?-DW)
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MS',?&<5( 8U'W#*!G 1;E$D6,/!W$23O$*!#@+4(H((3FD81HN3<>4><%M:
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M2J8WE^JY*1%^4D<-7XS&N=G\-+<3=]/O-?*OF\7Z<!&)2]C//@K.9>2."4V
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MSH1=-&$;13E&EX)+(A!&8/T3&(?8^R ]CBDZ+CIZL9U2W*87U&D/W) C2J,
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M-$6=$O::(>FBS2<*&)G@"1BZ C.BHK)&O'@I6R]8BQ4/AQ7,.!HQI=11P:G
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M5B)B1.ZD'C$RUCL4B>:6X)2SW9;SQ+4HUZ+<"J/<$[5E6XQ;$N/FW)>"6>N
M@I$U!O0Y*RPRW.O<0%I@2AF53%3F*U$/WD3V/OV:S2@: J^P[,[=06_72)3!
M1,)@DOV-9^?9OO,?>N</Y.]6%Z+W)N@K1RX..XRL=0!]\8,FO[7/^+&>L5Q<
MYRIPP165DNZE,%)[Z367WF?F\<K'"+\Z<XYXDR[N3Q,)VF<\-KH^C5S\[4$_
MGM9'Z9T$"W$7U+UI)9#56H++W 0_H,&/;6":^B $3EQ)JK7+==>Y48ICAFTQ
M^#&A=PA7RA +AOY9TW_\R@Z'I["<?]G>)+;&_E+&_L'\6;5DV#M,%$J<2,2]
M5,AIFUN#1.6355*%TK%ZC<C5[G[5HL6S0(NS.<@7>0;;@]Y[Q(JY@UY-6' ^
M8.2Q!:S@,B%CHT51&RJBSP6\W2W3C%NP:,%B)<"B/2F]$UC,% M!N56>!!1H
M3A,,GB/+'4,!=I1:IPR5M@6+%BQ6!BQN88>\L=UAL4 VNR/?&XPFP]86618R
MY@X>B1=:)>^0L#(B+H5&5BB%)!9&B90,S<4/'L46>59^S9O6/GC06BV7G@C_
MR E@ >L4G;?)8<V]8QICFV0(S&L;L<2M1V454>SS0B,"[X.'?:-(!I=1#'ND
MI093B>:^JX'BR-SM4.R.O/)4JC2UG']KSF^](_\PW\]Y1S#/06[6(:IY0J!\
M4F1Q,(AP(Q(67GIS6^](R_@MX[>>CM5B_#F!KQ*UP3-$0J2(DV21#E(CP11G
M*C 2"&D9OV7\5='U6Z_%W=E_O@^$%Q2T>H-P$!IQ:S&RVE$4.9"$(1KT?OMT
M]/T?L9;C]D6E'6X2K'6[Z.-+MN3!HIW;]SVSCB>O!D='<>B[MM<YML=QV#8W
M^4=.&;!C@GH<P,;C0H/H%HJPJ%A,4GIV'_*Z+6/ZH&)[H8QI4$Z&2' ^FLQ9
MZ\HCJYQ"7!'MO<>Y=]J+EY2P-8%7IM)RR]&KP=%M7=/'Y^4YUUL2(KH@@(UU
M @X&:QPYPQ*2P+K4D" 9BR]>\K9'T=-AXV6J*SPV'[>>M#OQ\9Q,MHQS)10R
M3@,?NZ21C4PA[R)5*C?RQL#'^N[%%5H._D$$<5OW]+'9=[YP ,EE'PQ&26.-
M>$P46:TLR@%_AAA+$^.U2LW8JLCB'S$-Z]5@>#P8@J2Z1>_3):#J!T8D+X3V
M@6(1-><Y_DR*Z$6$WXDESHK6V%]U9%JHR,EDPH)(@Z1/#JR$()&SEB%A-&=8
MT>@]R]T/U\2R%4T>OUAZRX6M@;Z2_#=GH'.C4A(T=Q+6N9,P&.C:N80PL2%%
M;V3RZ<5+(EO>6QVK^K&9K[6J[\1\,^&'38B$&(*8QF!5>Y*024J@@'UB$LN0
M% 7F.]^KZS*SNN6[E91YK2W\V$PW;PM;S('=0.+ETGD\*H] UW1(,VMC-)18
MHVN-<\FZR"N5R[+ZIG >2(*A@#$\2, QQX-1]T;%H%IGWNT 3!./K9>:,LNX
M$]C8%",7AF*=B'2T-9U7'<C>SDSG[P=BWP3LK+(6Y=,T4-XE&,^2:J2-$@XG
M&;DBN;[[&B/M"5O+TC>.46^M\\=D\:EUGEE<!!FX-1)1G$T$ZB.RPC%$M')4
M*ZF-2/<=PM[R>,OCK1/@87E\7HQ+,"0EQP1Y&BWBWB;D'.-(,:J3X4Q(Q5L>
M;WF\]2VL)"_OSLMK2Z(F5$DDLU.=4Z>0EMXCI1(QWC)O UXUE?Q'/&@OE:51
M7K,8VF/V6[0,X5YQP"!I!.=!)K SM=&,8R Y;RAK?06K#DP?%GT%,1BKB00X
MREV1./8&.1,3(D9KYI0RUMM\UK!F<'O0_B/P86O*/SX'+ICR1 HNE+0(:ZM!
MS1<>.6\P<H1X$XDE2AC@P"536EKN>\BC]L=FO];*OA/[S0O Y%/"@@>D2,@A
M[)8!Y_F$L)6PL8%+;M2+E^U9^Q,7>ZT]_-A<MV /!\6%)S0ASH)!/$F!M(\<
M@6%L,)4T>J5JM?-\]DA[VGYOO/=A_?UZYV  X^D?Q7SO\: _ K$2.O!7=WQZ
MBWCTUM=W2U\?!BZ0@1.O -"R4\BF($.@-B6==&Q-ZU7'N+?S$>PZ"I(\]@CT
M>S"L0<M +CB.O(VPJ5RG).*+EU2H-:KOJ]%ZZ[W_03BZ-=(?GY?GHN&-2IP0
M$5&*"4QT30)R4H&V$I6*@AOA(@=MQ;1L_&38>!EK_['YN+7V[^5,'?B8 K\&
MHE%41" .9B,RU"5$N08+4B8B5'CQ\KR?NTU77T$.7FW5NG4;W/<Q^L9^(HQJ
M'2((7^$1I\HB!QN*=.#8!^(X[&NM4ILEO08K=8J^\O49;]IO8AE8NJQ\X ]>
M5%:($)W5+#'K.<7!LF"<C-X >4LE76OUKSI$?5CHSJDCM@QCY*D$J]]&@1P'
M^U\(*PGC0:28:\M*O'SB^HTYY'%.'5H&7I:!6R/_\5EWWL@W7#(=-<(JU[)2
M.B 3M4'!4\J4DQ9K\N*E7C+EO>7:U;3I'YMM6YO^7D[PL\2UA#-O$8O6(BXX
M1]:#["6!AN1#4%:K%R_9S0_P6X[]P>1L:\,_-KO.MXSDPFBC'8*?(&6E!&O>
M96L>6)@);P)8XI6"+.FRQV(/RKCW%!:PXD9]Q]O182?.>H]T;#]TCB[JQ_ 0
MH0#7W5=OL1N,QX.CGQGL8QA,\K":Y;D;.J[6AES6$/B?6)U69EPC,R[JU[71
M#Y>+D 4_2RM!EI(@'Q=* XJ8-%$,:6<EX@Y+9'A4*-)(I4F<V11?O)2$K2E^
M7WT [H^S'O,TJ$77%EU7 EUO":&MY^L>$76^&X/Q!(N@<P<TT,2]9,A*3Q$F
M!CO.G"'9A%[:\]6":0NFSQM,_TF'Y%W1M'5(W@E-9_JI4LZP:"P23#/$A<NE
M>83/93L2U<82(\UR#LD62%L@?=Y ^D1M_A9&EX31.4>Q-59@$CTHI9HCSE@)
M]A+(,2T)#AI'YFLS7]]7X/4C VIQ,?^[^%GAOZ'[]64SKYW)$3".;_B@_G.1
M\%5(1D@GB;:: Q. I$F!>6ZB5S9JM[\)A$\P_ ^57UCF@,4#D*W^US@:YT2P
MT:N>'8VZJ1O#KZ>OX#5Y82>VMVW'F;9/-^T8] 08Z!Z\_]?>P']YFA3>B_]]
M=_KI[W#L*)<[G[?%#OUX"M=\V=[<(#N_P>_?#]C'S[\???S[-?MXM-/;V?/?
M/GX_3-M['^CVVWUMO*21$&1SH2X.Q(ETM [!TY*QSCIN^8M.!!@XAG4>#R<1
M-AMVMB'%(SL\Z/8K@J*-8.KV VS!STP6.?D/XRTM9P&'L9-L=]CYFMN.YSJ\
M%QX!=-QIH<&:.."BBCHZ)W$8.W8$D-KK#4Y&G9^Z_<[X<#"!,871OV:=G N-
M7[P<<E%,>UB1.(3EJ,>P<.0#R]*SQZ/X<_/++Z$[.N[9TY^[_3*Y<M,%G/?+
M23>,#W\V9ET+D>5,?<!3/[[ZEJP7$70&1*KO%%O'4ESZ-5XGM_Q.T-L]]:K!
M$KQNN'PJ@R7KE)D;/?:&(;;WV^_ZBG.]BE;/DELE5>Z;H?49?E:7-53WAQU&
MUO[CAO]^F>'_?INI/ZG%V(P^'KDXG%\/O+ >]YD"OO+!W)5([Q]T *,'_=@Y
MC7;8&0P[O3AZS#/>>S3G'H;8'MBBNP^#[5$GODQ9#Q8E"UE?-3%W)(3?F$K<
M)V^#<[PJ<UEKK \2VU.KM?#7W]WQ8;>_VX\?@0U^Q#/;M_CCWQ_8)U!MM[]_
M^OQQ[^WI]N=WA]O?/YQ^^OSE^_9O;T_@603N$V>-N4^;[PX_[84O,#88R\[A
MSN;6Z<YO,*Z]WX]V][;AOE]!;?X+5.1>VGZ/3XLA]QZ?[$</YK9P'F'./>(F
M:>2P#/ ;CL(F19A7+UYRR=<(OF=3[CXMM2DWM6C8HN'3]&"U:/A8:(BG:(B5
M\E%Q@:*6!G'+";)$9N>! R[ (;+<=%<0O(;-?14&>7 T7%IC3N6?)ZXQVP2F
MS4QI'A_"% \..ZG[M?KD=OKSF:6Y54[W!<M[\WCPIP*4*Z0V;F1* )S<JTC@
M#5! ALP?,NKO'\+,[IP&2:G"0C&"L-$^%VET@)E:()*#_;262KD(&B1=X^S.
MY=.O0*:'TA%;CG]ZJE'+\0_ \3,M*7@2$J4,!1TTXM(*9$4$$Q(306T,E#@"
M6A)>$^S.0;[WR/'/RG-XTS(0;4A(&Q+RK/7$'RXBY!\2"*?S3D1B)978(F(2
M1]PK$ A!1"2)D#QXY53*B8-8KHDV[:-%TQ9-?U@=O$73VZ+I3+T&(,52!H$8
M)@KQ%"(R2G$4<8K<:*8)X;=-PUY1-+U!=-W3",QZ-3B"-Y]VX&'V ![MAS%T
MQYUA=_2E8T>C@>_F>B.=D^[XL-,=CSK=:51?YQALTP3+.ICZ*L]=T.OZT[7.
MR6'7'W9ZW:/\_?%DZ _M"%XU'G0.833H?R>PO./33G<TFL1AE20.;#YH[AC#
M,.T1T, XQXZ59\R]V8X['I;.Q?K-,-ANOV,[(]A?((?JH>N=^;D&H(3^ "89
M/1 )O ]>UQN<V+Z/&5::->@-1GF8\,$ AC#L=.'N[K#,#&8PS*LUC*4<2YY*
M'M?%<6WYD7D.L$HQ=HY@6PY'G0B['SHEE*9B $;6.EES+-//H+=^D\"V526G
M0QL ]IMTD&8I'W2Y\A:/X@5O+?&#>;_M>#SLNDD]@@5*AX?488:+) \;W<\;
M#215C3:++[@-@&NT2%3'L&B#D-&B=PH3_=J-)Q7I7C[+0E8(2!CV,AX!4=OA
MZ3R55>-?? V\?M0-F4T2X.< _CN: '/9ZEUA,K1Y;&OUFP] \DY"+//+G\#2
MC$ @-TL,$C-O8YY=B<VL;CL>C'._!MLK# (8V$QNK5ZS$V"_0[AO-,H,F6]I
M6+?^<VZ>^<T5+.2'YG4?Q5YOO0/"^.*568/+*_:?3?7D,!8._*G[KVKWX9(N
MT,\ =JS7_1)AQ?,J=A8Y)@-R5C:Z_4E9E 4>JBF7TZJGQO%@5#;UYT*BW:_Q
MER;*L2@T<S?6$@?/;K$.A M0U:6W7!1Y^A@,2N29!9K[>3B<A=\=1.2 4KZ@
M<B3UL^V=V-/1BW\O8A  T)DU/#O]2R>9TH--LL+"D(&][/G/H#G$8;X*QF17
M9BP=P#90?_]/E[MH+&98!N-YH@9T8>HI*,2!, FJ\;X"7"T< JSUGW_;)SN)
M'/:?4P'*'"Z@PLO%VR,QRW_.H$=E$RCK6#1$\B!@JL&:*(6,L  ,.ZL(??$R
M"YJBE8SG4/NDV^ME%668B^$,*_F3<;!&X86N.'!=3IR<@6\%JMUA5H*JTP"
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M.YO;?'?O ]C=6]]V-S?VHW0J"F>15_GT2NB(M'$2$?@LZJ"M46DIITO2.KK
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M.1Z"C=F=F3J?WLPLG3',9^2'W6(D3,.5YJY$>V]F&SC.$75U:%:UY#"32F+
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M$[6&(4YSJKXE">&0 ]NTX9X04$%O9.XM02$8"R^4I3QJH WFK8'W:* (J;
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MD?EZ0^ZY.HOM#:,-I[/+;D=#MS/8;A@4<@NR>E]/YSF35RY!B['7P-T$)>5
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MM%8R?0:3BTMG@[S,;HIA=SS.2PR"L8G%F3O4G*'5+-2W:APR%:=KM03K%8J
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M+\S%.=C*\\HI-&LVYS;FA WEPX,78^^7L::NFJ<TK!]8/WG>ZCMS3ERZZ8E
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M42M+3.5\QKA3>HPL/Y;/&] %I@[:7,]&V4E5EW2F6== OL<7UNI"K1N)QE%
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MTEW^\627P_723T=O:>_H^&3O;SC?T7\B7"O9>WM 0%@XIA)9&0+BEB6*"6=
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MS:VG_M9]9^_=Y^ OCD' =DY.CX=7(;P/9_^ QQ[+55ORMLJF7GB5Q@'<\'
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M0#>O)_/HCE6Q%S:G=:XC*5@A&'_NWQ!P*ZQ04%)/E*5YQP1%2R8A(D$+C&W
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MJ1 ]HV2W  '$3=:"]C<JD< 9+A-_DF+7J-P_$FFEF8G#-<GT;,%/@BDM)D\
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M8H.F#DBI0&.SD)EY W*&4PO2'$4"?W,I+_TOSH6EEQ+MMTW:(R=:Y/ KN,'
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M['0)U#YB^9_,C^F^2M;62/B+1M&9@H;B9:"\4>#88Y4N9D4.7@-Z4P([!A^
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M$B(BXL.)S)B3!?[\T_\#4$L#!!0    ( "2"I%)>>S4<+R   $1- 0 5
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MXVS:I\:%)*1#5LN\84PT+)D^H !1HX*H0GE>Q=0LAB_#Q&U2$E9X(3%%F.?
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MN]=Z=P*AW0'\?6_#?8H5GURBB?P&/.Q(<)M'56L]?V="K!)WK3;T[<QYY**
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M7H&RN2HJ6]6EA491<P]*1^!#!,1%X,A8*E"B1BL+CK+%5:[<+KH]LLOKN^K
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MKC^YPT%$OVT,K^'JOX>#T\DP_OYQ>)[0!SSXYV5_\N5D>'[^9CCZPX]2CSD
MI4S$^:*[(*7+Q)J(1B_5)DD>0+G88N8KXOQ:++?<WAO-!'1M ZYI)!;/MBI+
M)L/MZ>6*&SB_'W\8CO!Q?_N1;DJC_>'%Q? *XNE'/X+QX7A\":F7A8[<RT"2
M$)3(E!+QF@M4, 5J!2CJ6 NZ+,&S?5HTU>.POA+N<X-MRHW[$T:AG%^6B-+[
MX6@J_LEDU ^7$Q_.X6SX;CB(P\$$I8Q/_' XF !.9=*C,8?@(9*0$D/)<$8L
MIXK@MA!2% 'EQ=NLN37@/V_F[4#%]XG*JQ#UZIUY?3DJV&'4'Z:K=^D=_#']
M:MSCEDOJ B,L0UG6C2,6'"<"GZAT\7VE:4;$1^&] *+55=%](HE&1/K-GU_"
M+<C,(",62JQ-@L@@%;%,H40 !-K 5$;IM\BCK]&]2!IMH*#[+))-EZ/IGZ]0
M3 EW_4\P&$]/!'H*)&)5B3B*DI&6&N(<S42'E+F2W*G4Q-Y: ^N+9%@UY=WG
MFVJY:BU!+$,$H! (-5P1:4PBP6FT+$7PU#*JO W;7L*^LZVZZNZ336]*MKWT
MOY?C2?&7QV?#O92FRO#G[WT_'0[V_:?^Q)]/D8=YY"> HAOW)W *H\_]"%=3
M/8$X_'"ETNFL>^CE!"JT0UM2 Y'4&N(A<0*:@Q J)N9H"VJVGMCS)O*3HL5]
MVIMU:5_"M9TFMQ>OIH'?'.<E;A)W,>;('!$B:B*=X<1ZIX@Q0/&_'J=@'XL6
MUP3T/"FY,Y7=IYW==+4]GGR$47E;1O"Q'*)_1HG%X04<#<=CE!'T/PSV+T<C
M&,0O9R,_&)]/7ZG;R9_Y/WO6\A0A!N)I-$3JK(F-(>$2B)N%< +?JR:1WPK8
MGR=!=Z7<^_QTK?CYZP"E=][_%Z1?4'+X0OV,PB_S.AZ<0D1+9]*'\=X(W[[!
MA[N&SSN8'.<R+R94D"8HPJU#%XX[3AQ+GB2NA<8WSS'>Q,=N-:&7R>2MTF!!
M!'SCXY'WHV'N3PKBGO&62I442<XX(GV2Q'LT0'R6WENG::1-HH>W$)XWA]84
M]0*M;WSPL>P\1C'/DTF1""G1&) 6T,\/AD!0,3,3D@2QLT.QW9WO")NE8NB&
MFA"(M!)-I%#^D$!3HF!9;G2F7O]\9X,D@[,R2B]3';P!Y+U4Z*88BA31V1-N
M7!!@E L^-4TPF,*HN%+<20AN?G:^@2P7'7_^<)7>^==X/D2?\V\_3D:7</LA
M4@'^G!R<3P=$3PL^E+]4H\,5(\N>.!P4+V3OS_ZXYY6PEGI<SJRTN( $(%X*
M27*.B2=K\(-&)P</H*I(E@<RM1\@SQK:7D:<C:7>X!A]#M/KZ=;;"51O+G>\
M)B46HJII82Q+@'^ ")MK;]A*]%OCA?62TLB!A)P5D> #L8(Z @S?B^P,1-%D
M ]DB'[ZZ8+![.JPB\08TN&/<O9V:XSUKM!2)6L*C]42*P,O!DB:9HG$5J$ZJ
MS2YQ#\GV'8X*&EJ>6[6&>!MDW"T)1EZ#8SRC,8TN4T!3Z2K>Z-'C)2FGXOT(
M*XQL<_KQ *KGP(-Z8F^P!IS !.<'Z<"/!NB;C*]1"4=ER:PB.5A<ZT1RQ%EM
M2/&-8W+**=5D(5@,YSFPH(*@&^2O[<5X>7%Y7F[A+HND70-5BN)&QQC)UC(B
MN:'$,X%>=\H\),T<M'$O.R-\#B1IHXX&Z6J+(QK7V)*&Y"(N9#C7$HN3D007
M-$F,9O2N6/2J2;SR(5#/@1W5A+XT\^S??YH3SQ'^V.SFV=[I+V^.CO_1Z,;9
MS=.W<=-L\53F+RJ)8 P/T@BJI3+.6YME2)PYZ6VDO,,-LT636DDKQR<_[[T[
M_/^FMPI?[9T>XD/?GQR<XN.G'^V]>WWZZ]NW>R?_<_SF]/#G=X=O#O?W\+O]
M_>-?WYT=OOOY/<+:/SQ82V?5QMY<HVW$,*=OZY)QP6>N?9219\>]DMKJ$,%R
MDV6OA4!VPH;WP_-^[,-XEZRXP?!TV+%8+',L$0&TY4RFF"6N"KC7 KJ#N!=X
MJ=!A5-58LDA .V'+-.JZ4ZY<(W@Z3%DDDCF>:(_. 4]*>V-ER0'B.F9/'8N<
M*R.@&D_N"V<G++EUFP\'>3BZF*:@O"Y>5(<Z,>VH\Q"LI\.GSL*;+R*16526
M <<_I1;&:2U3$!Q" )%HKD:RAP!ND"]Y//K@!_U_7:4K#=+IY<6%'WTYSJ?]
M#X-^[D<_F*"/-;P<3*9GM5<+XNT1HO79 )-HD^N23L^8)\XD172VTG$!!NRC
M1*N 8_.@SF<87,(;]$GVB\/@X^0?_<G'_<OQ!#W(T<&?UX?5>^,QX/_3-)T+
MC'?H49*<M"<R:$8<*IZPI 0+GC+M;9N(S\I8M^?+;9M3]X-&;179(,A\)YDF
MLFC0P\T$;5[T=5VIT*:9)=QSH[SFQ@O]7/*6=LV4-<7>XG#Q.L#Y'D:S>R3]
MV'/:>\_!$8]^+Y'",1+0!R+6H7_DLS!:- DH+T3S<FBQN3(:!)U_'@[3'_WS
M<Y3%X6"")E ?#<ZRA$T.+S[Y_JB<P/94LIPS9TA RI:,MT@"I$BHM=$P147(
MN05ANH![.?RIKJH&L>A;),?Y:#CX<-3_#&F*<?P+G*<WP]&O8^B%Z)FE*1#A
M#7(>#5KBN*-$JA"<,(JC8]6"3YW0O1Q"U5=6@VO41S"9P&A\G/='@&[*\>6D
M%%^=&EH712J]**3PV0D2:"H2*$NI]Y2(J*-/F>F@70LR/0;LY?"HJHHJWHQ>
M7RY7N8A&&Z8MTR3(+(GD);E9.4F,<UR"4-I"0P]T*RF\NZ+.-E7S5)*"]S_B
MG@V'@]LY'8PG_0L_@5=?SO 9T\2V"(Q2R"@]D3.1V5+BG<L$I)-H#]I(;9,R
M25W ;3M%>*LDF4\8JZVL%CF#2S$6A->'W%TPMLPP[@)R-PG']57<F4,;ZF=7
M7%+>6,%](.B@TE+<WQ!G>2;)*V.H2KB--PDB[8Y#CR0I/PT*K:*6BM29+L\S
M@/O#<_QJ.+I:IS^,8+IWGL;AIUF65$[H*V2C"&.JE&,*N!HSS0A'^P]!6LEU
M-VNJ\Y#;SS.JKZYA<UDWB#N7R1[GO=&HX"W8IN\!1)8BNI)H'09.I.81'4G)
M2=*.:T<9IZI)%&DAFI=DRVRNCA;9KK=PQBB+=\.!O_UD6NC QR*G67)N%[@M
M[9@5\>[&I*F@Z?DLV"VHJ8$YLRKL'$R.5D="A4787.($5-+$>T'QS7)1)O5L
M6?6(D;-[4JVBG29WLV[VV\]P!_LU.NI]:4H 1"=FB/32$:]=())YW()U-,(T
M.:U_&-;VC9^F6KUWGZN:2BK:/^/1!)%=EF3P3WXT^?+.7URY -Q[[2U:>\)(
M1B0X(-9D0Y)@3'!I2J6$#A3!Y]^A!_XT3XUE %Z"M5-%^!6/Q J>$_AT.8H?
M_1ANS/1YB-=.01>0*Y@WG9C2&=UVC9DZBAQN2PLU/>J5P#HO/1/)$EH@2F$5
ML39J8J+6WFF0/':IZ/8M4&6)A;)#IJPB_-HQE_>Y_R\8G;Y27%WO=S):$[)6
MA*NLB:34$T?QQY"5<[C=91?F2A(MB:W<>_063S';R7]837A+C86:M[5JY?5>
M9RR.BXQ/)V@KP8=^?(^"'$ ILK8XC(1HT@F, >?X<0_MM<_]R9>?T;Z:C'>?
M[]UF0D\G4WP+"IO+,7? G<^*F9RE=-0[9JT(608?8I*:5LLQ;S.U3?VZ0822
MR3LM0-P?_WY[IJU$X.CA6A*XF&8L<.(M$X0YFX!;CQY$FV/8I9 V=V+GGOP>
MS7C\P'\ UA,R>E-*UYOD$I$J,^*LR$1%$Y6/5IC<YF#G 5 [B-[7X<-]7[62
MY)LT_IK#=NU_<:D@6$984!G]+UN:&CA'K(K #(@LZ';HO]4Z=MO2_^HRWG4*
MRU)#VSLTO4 :HD!2(DOAML!M($H*]-$CMZ"Z5'W\9@(;-77Z6-QB%=GNS GM
M O*EQRU64N1:WN@Z6M@99;("0R.B,XP+(M'R)%8C8F_0E\M)9LFZ).Q^"U19
M-6[1GBFK"+]VW.)5?_@!!F_W#@=Q=@0 U -5E+#(<%LUFA'T/"@:0];:K"E^
MWZT5QKU'/]6XQ4KR'U837LU#CH+FW? S3JP_/AR,)_W)Y01*JP*$^!92/_KS
MF=-V"S9:&P$QE:074VHD02D(+ C8(),US(60.VEZU9&?'1&:BK[V*__W_@3>
M?_2C"W^'MR)YKY@DI4H2D5)G8BD+)"0TCX0":^93G)=08<'#GYVV-Q5@Q<R=
M*9Y3/QCF_C40SJT(AC.2?+G7H0S%[<H7>BE45HXJS1<76Z+)NT]]=BI<6V0U
M#R-O0]^S1!WNG+&>$\M+3PV)6TB@+!.EO;("LG4B=-+=W:<^.]VM+;(&-^'N
M^9ROOKR"0?QXX4>_7R4:YZ"\8,4"<.A]*OS#!RV)\,Y[IIGPM%'%X(>!/0,G
MO8D.&F15WL<W0S>[;M !7]/K((\ W-%5D*IJ?90S%732),WM$9R<Y@P1@(CH
M)9$"5U''J"6Q5+/@+N=L&S6^V05G'KOZL5/*K***)I6J'ZR%,RNQ'HQA6C)B
M@D=;)V1!/$.D&CU32J-G()LD_'="]P2.ES92ZFK5B=;0R#9.F^[<DF*"!_ Z
M$>"E<(4U'LTLH 1MS<R4BI:))B7O'\#TO.V6M23?H&3(_=G>7I7J FVKULK.
M[ZS6TN.C9Y2;*6$;YLD=B!9].,]](K&4E9!6)G3MO";1X"XK$^-YOE+#-\J/
MU8V2YO181?:UPXM?[7H+,XBNTH7V!NFH'XL02ZK1W%QF1=N99"&7AI4"')$Y
MXCP4)**2UKC$"H-K;Z> 2$503\!(65?3PR>@IF\L6S/BE/OG_>F,AWG?CS_Z
M02K_*>T+/OMS>"))F"O@?$JYE>N*=RYETB@5:';66C3(C.&>">>C%]:&#*QB
M)?EU!;T2>]_L'9[\MG?TZ\';@[W37T^NFANL0Z_%#]I<_QT SBE("6XULRY(
MS:3)X(2W3"4*2E) 'ZOW*-3-);A^6?6''M=(FAT*GH,6"%!R[<!+JTTP(+D,
MI:DO%5[JQ3+=L'KYPF=>7R,;YC>^/_K-GU_"6_#CR]'5/G+UEMQY/?8^X]M1
M8.3AZ!0_>HON-DQ; =^V'L>7Z@UN1-.BG-/R=T=]'_"]FWQ9?[5],M@;<6;G
M:I@C*%>6!X4L+:?: A=C<%)&&81WP()GBPFZBUELY@7= +VJTSBUF*Z>CV-?
M@T_'@Y."IR367UW$'<U^+#5G[Y1NXRPRSR1%GZ"4I@%@)%!NT=.Q#*@5S/K0
MPF^J.HN-'4M4\MZ]??4&XNO^N*38(J*>B<!E%I&D<O$=;>%,/#.)T)0TM=[S
MR+O<N%O=S>R*</O^PN[X>,]';:+&!E'0FU7DS=4J<KMVO(8PN?VI%ZQ/6913
MZUCNKAMT=2QNOP1HIE:*9"4TB9]W!?B2V=9$B2T*H4P%M>@MT"!8D%D1-.@4
MD3KXXD@[PI-&!\=(*76;'K/+$+UH.E514X.$@AHBNCJ^L(9JS3D0YV3$55=H
M$@R/Q =G M.> 32Y8U9M!MNZAO1T6+D;Y>_ZLM.]V;_Z<L<K0./^GY<PB%^F
M0?6DDW89EW,MID>V:$6@_2!(#D;'I*A3IBVIEV/;U>GECDBSC+J5E-=@:U[D
M<]X O ZY=X'8\@"T \;='(16U^\R_E16SHYX9" PIS@GNE1FERZA%2&L*/65
M'"0;&9TOOOJ-\^>1@]*G0)]5=+(EVHQO5N59:W.;0"='B;'%>E @B4UHC%JA
MA,I2)C]_*-J.-_/@=N@OU-)J!]9LI)(&T8L[;\[-7W_IPZC<.?IR!)_A?/KR
M2"5*QEH@E*+9(('BMLU4(B$)#@J]F)2:Y*)W@_?=-JJLPI:>Y]V7X3[>Z]>N
M"]AM&TI+T>[<9*JF]BX+6%6=;6LC7 HZZ #:,4<XIP*M@J")BZ")\MF:)+F(
MK,D9P!,@6'>;ZFGP:Q55M>35X>#3Y60\E0"[WL2#S;A-RTP$("H9/>[?P!+A
M6>#V'I*DC0_>[F-Z&N94)6TNX\V&JFAI3]V!QJ^A"66$-FC;B<!G%9(S6&),
M3%1X%;1LTMKN 4POC27KJ&)+:XFXAN948,)R3YBB 1T"SLI-<%[ZR^ '*(*4
MV_KV]S&]-):LHXH6)G-_X >Q[\]+;8C1Y4VM?L&B2@;010&*2QPZ"L1*0%A4
MZ8R?L6R;'/4MP?/"O:\*2FIP#6=:H#_#J(CE%$:?^Q&G?)P7H!V7E/#QXJ^N
MWZ\N<VGIC=6<S(Z<M1HLF>\#M&L5-]@8J\XI*6V<<H&P%#.1N%@33V/$M]S:
M;&SP.30I>_GTZ?J8Z_?4V;J*9ANP].UP %^NLD7?7 [2K .*2]1+DTM7;:D0
ME2IA8A:(#3PJGZ+5\T6QZO!M,9SM&VV[4_&PNGZ:7)>^N$#K!F?[WG^ZN</-
MN8[6.T\$U8@L%'_5H<GI)&2'(N T-*KRL@#-"^;,YMII<DEV]*E<KH.OLQ!G
M;9&$%\X;0Z@"!!<9(SY[1G10R0JC$'.C,M\/H'K1%*JEK1:EA& TF;9IFA0)
MO(9/PW%_UE\K1J&E8Y8H$4I+6X/^3V9 6/ F 0O6N"8;UP.87C*-*FFJ@5<Y
M];1?^?@[I'O\]EYS;X,@619H,B TC3K'S37I%+F7L<EJ] "F%TRB6IIJ4/CN
MU].?AY]A-"A3/?TT'(R'(T@'TSI_H_YX/N-^MA%+QJ8U%I,M 5N?,W$^.F*C
M5@Y?"><8:\&N=<"^8-HUU^U]/JJ-2D[<7.X;3]^8:T0Z&@O, AI[4A")C@&Q
MFFEBC(B*!54BRH]=&5W^^!?(CTJROJ]]7;\"Q,*KI>]*\]/2G;3R'>+YYS:Z
MW_L@_+F[MU;Y8 !?.INTS(ZZZ+4$:W62G''A%]^]G1]ALSWB-'Z$='E>&A4O
MO9EU=',I(B>ELM* Z[>21#*%#EH 0S25@7J3 S5-DCA60KE9K?W+,3YG/-Z+
M_[SLCZ>D>'=97A]\4V_>JE_@/+WZ\LOP'-^,<0^TD99;23QZ&.BZ!EZN11J4
M3)+"QL03[U:7>_6QM[_ M>/+UU7[VZJA=EG_!^!>K\/E"]RA42),@8N*,.MQ
M3:>"$L>3(D['(#5 BDQN2I:OAWR)'-E Z V"2^_]EZL=?WB-:"^E*=RRZ:/%
M!N/)X>#T,HS[J>]'Y?(K$XI[[DMK^,+E!)8$135Q1J,3$2G/ODF<8&6DSY%<
MVU%;[08#G5;,X\O)>.('"8U2!/Z_$"=GP_?7M>![G$LA -%;D4NOMF2)I=(2
MK2AS++F(*VB]?>PA*,^153M04H.X5!<Y7:5Z.!6\S!3A>5J*WHE$G)6:2!,L
M5PHB54VB5)T1;NM:\O86K#;*>2K7BA>\.].S<BI5E*7OM,H"-W<G+/$A:8*V
MH%5.1O2W4@NB+<&SJR2M1LH?UE=" PMK$:RK/7M6@[,+P):958\BW$VZ5!5]
M=N#(YLK8"6NLH#Z5%O=@3$"@(1,+"JVZ8,%[3D.CS@T[8LLCV4J[(<LJ.JA=
M)_GT*N;W9N0'$:[#J(P'(TM-(FW*;*GUQ*=8N@*(R)CG@!MX)S-YP<.W;_A6
MEO^PHO :9 :5F#MND".$] %NLNVD9S9FAT8TE U1VD!LHI$8G7$W]$%IV^3(
M:R&:YVT_;*Z !AD;=^",KW+7_>TGTQ,='XL*9L=H7>"VM"56Q+L;RZ*"IN=/
MVK>@IA:5Y%:$G81"5X\'PHPHZRTWQ"HKB%0V4IR0D(H^6U8]8H'LGE2K:*>Z
M-5+"0^_G6S<BZK-RJC@ZSAE&-Q_/4G$=Y*B")I$'1V2,@3@.@)LYCYD&F846
MW:R5U0??OC735)O#+:IB*QT8'B[M?#">]"_\!-+-]:_AG2!E^>"J%\5X?'GQ
M:2K45E6_UT;2NH9W'1'-906DA M6MN L+45IF+7<*2T]3RYEYM0C%;G7QK3[
M>I<WX,X@?AST_WEY-S"J=936<TYL-KC(,^>)8UF35 +A*3LOVK0J:CVQC2/R
MTY5HU(_0HU%YIK,@+I7ZS-0H$J*5A ;!G7%HM4.3X@BW$+[-4K35>'<O(+^>
M;AHXO@O<_#O@0F:E4Z(EV3)1.N1%8J5P!'=!Y9/(X-NDI3^(ZCN7&FFP19F%
MX0CZ'P;[*(A2TNW@3[2+T.HZP7UH:G6=3T7">ADTEY MFEK.($QAB9,YD:B$
M5HYIAO)ILHAWP_>=<LVUVB!\\X^IC3\5WDG_P\?)W0/T.U4MIF4G>L(FJZVQ
M)&F)@&-)T0@NHP- 8U!9>W096S!P%9#?:;@=_3;(CW@-H_[G:7;N3?N:>Q !
MLM:.:V(CP]<E!GQ=DA?$!(XO$3"C9),#ZP[8OC.OJ38;W/%I)+^K2#_CG@8?
M&?%4ELO<Q7SUUA"FK<_4ZR1TVYI]#2;U+74C:+>S/Q76//7D(MPZO$4CFBA9
M[!NJ+?&*:<)% NLDI8WN6CZQY**GPY>.^4BKZ&TGF25= '[/1UI/GRNGF*RC
MC)VP1@I%K8^<2(,FKE0,K5MM/(G <,EGFL<V0=!O*Q^I+5E6T<$V\I&$MJ7Q
M7B":9;0#M%;$QY(6KBQB2T:JV*W_^C>2C[22_!_+1UI%> W"LO/>1#G?GE)8
M)VF-ET!4+C=)./.DW!4E&J+A401*VX0IE@'Z;GC,5[ZJH;D&P;!%N*Y?G"[(
M6IH<RZ'MQM:HH\(.O-A _BUJZCV L!1.<CFC!G&[E!D"L0"R%%+28(/.N$H^
M!V8\8E=LG1@KB'T+A+@]5KK>)"VHX"@-A'+<&F4Y9O).4Y+!VAB$%#29;=!B
M'MCVK9-:2GR$&QMIH/;=]GEP=X^!9G6.(J=9&$F""Z7B&J4D@,2Y@U<VR9B!
MNDXFZ.-C??,Z;R'3VF[&/3Y.AO'W*1_WAZ,17)W[S:KM(0^55(ID6?IV)1N(
M-RH2;G300COE=#?W8X5!GR<):DEY"U;E\31S[+=AP7AU*G+%V>!2,-:1($H1
MSZQRN9R,JY;6&1 NVM-J&QO%8GC?/&L::J/!4>@\RBFS[X$,RJ$Q)0T:4I 0
M) ?B.3BBDO0L.2MLF^[6G= ]6\9LKHNE1YDU$Y3W]TY_.?BO7P]_VSLJ.:Y[
M[UZ_W3OY^\'9WJNC@].#??SW9X<'I^LD''=\\N8)Q.M,82XAF(>D PL"E:*D
MR=*&Q+26,07G,PNFM_ID&FAA&E(9M]/%]?.WI9%%TYG3B[>!"ID-#3[+4A+6
M"1&2DXEJ5).#CGJY/[$&VKE)#]_WXX\'_[SL?_;GY9*$'Z2;ZWYY_KK?^OG\
M[4%MBP?5!#=''ER_N69@F+%2,@F..Z.D1TL.:,*WNB-Y-H&WS<*!U(5L0Y"$
M91I+*4M)K'1 DF/194!WAN^L&LQ1K53\ZQAU&$]&/DYZP@6K+5@BHF9$>LZ(
M2P)(%!&4TI)SWZ0KRM<PGGHMI568L;#V\GH";]%V E_!O4&:>Q/W)OM^-/K2
M'WR8GF/TJ*%@J?%$0S!$AD2),VAD">^,+6VPA&O24ZP3NAW<V-M A?/EW*O+
MOW9<90[:SZ/A>/SK8 3^O/\O2#^CO%Z5U1K._)\]K9DST5L2%;K]4D1!/*.
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MP+4O6BV8#$;Q4D"29M?;8'HM-;5^$9?U!MJZUCJ4=;&,%_/%I9 L^FG1"1X
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MCHX.]][M'YQ>=^L;GT <?ACT_P7I<H#0;@Y97\/$]\^_GL&X?_'I_-%3Y#9
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MS40((DJ+&T8Q(+PTQ%$9B'::6FZBHO,-'"O=$UN&:-,C\3M2O$W=[RDMF+>
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M#X/<4&KO_.A*WQM&.A]\: N9/@A\OOD<TXGFB.)EN-DJY;P71EL;O1)6,+I
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M[?J>5(?8($FAER 4H=0+42A,]O_W$'YN%D5'?9!+4*YE!J76#.J3+@=/&PQ
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MP=1+& PBDB0)#S@E1CXNP_GFQEQK<=6;5<<O5#U1!X/P-:,HAZB-S$H;P-J
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M<,"L<HE-T#@CI[AW^,ERBTV4[.88&WW^S-22VN1;6WH+/^841TCWNA,!Q&G
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M2H[''MSF5(JB$+P^V-1%[18B0@&F*(8D#(7:,+& *8\%I!2A&),0$6G5.NO
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M??.V@-:]&J8UPAE)DH@'"*9^Y$.,/ P3QBGD:4P3[L524*M$]>-3S8T+]\K
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M<NJK-9QZ6B^M'1Y[_EG+Q]U=,S7)Z,U_=:6 NE# PJ.8HX3[D#&*="\U"9.
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M+FTO)W)-:I>Y1/*MS>9T;#=!4+NQ")=/>5%E_Q!<.P=U^_!RD4:<T90AZ.-
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M;^Y78X_%/$A]&$J.M<\FA@F)$90(B81+$878R-<[7(2Y,<O=O>)1H-4 '3U
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M'0'5D'S.AFILIK%'R9Y3>D%P2B"'9YJ6+7JUW:.&_D\/K.=8'[07DL72XUC
M4"8"XB2-(>%A E'BA8QBSGB K0IBU\-:O><3E+ENS+\AOJX6)K,WV5[YD=_<
MRWZ-[<L+[BCHM#Y@,_*T!?YVM-FKT+?[UZ%M2+Z)U8OXK.9>5\/_MZQZO'HI
MJ_Q)%&T87X E\1"BD 1"G1?B4$#B20PYH6G@(X34G^WZC!C,.K>]N!4:Z'72
M#J>F[43M;F*MX+:M04RP-WNSG2,Z\HN_ ^;5#IAKF<$'L6*/VH5W.EYU0 </
M"[S<MN@PF7CB'AP66.PWV;!YV+Z,0EMS]!7Y]#ZKE,T:42E$G& H0EWC*>6A
MSN AD+(@ILHT" @W*M-W:/"Y44XME'98(_\'^N.ZIN^K>3F$/?3ZV>1<3$8F
M#5LXK$H;'-/[C$(&>T-.5K;@F#+=(@5'/S,@E^:7_!LIJJR\7I555KU4HOR<
M%Q^R_&?!=<#TNA//]8JMTVA"PGD:J.,\2A.(?1'#A#,)DS0D22092XE92\,A
ML\_M-5_+#[8*U#VLMBJ M0X7.MSC>%E#!RO3SQ"CXSTRA1R"^O-AJ&NDAZ3*
M6$-ND24S)O03)<C8+H&CS)BAR/4FQ5@/.ET^S%!]=U)A!@]R7M[V<R$>Q:K,
MOHDFP&I;7OYO^5*7S]%5YK_D97FSZM2D+[)2_:E[J_F+J&ZD;@1!")8)83$,
M(Q*K[8:GD'*2PHAX-/4((@&V"JL<2]"Y[4Q7C[I77M,,?-,=XD'I!/(5:*(K
MZD9%W?8?;8Q%U=,V8MK%9P2Q(" ,DDCJ<DBZ4T#LA9 P=8((TX@%G-G==LYA
M^:>Y'-69/YVE7^I&(?\'+;V9\V0.RSFRW7-S=7T!3C2&N:L;PW3:P+1:U^U@
MP ]:\1\W76$N^7^H(WY35)A(Q45N^\2,O21C5%5P+NN[%&48"_%C-1U&FV]H
M7L8WT7RO2_VZM+6$J]?.W.O$3R:(3P-!H(QBHO85Y,.4276DY9$O0E_M*IYO
MEZMA.O7<S(2.Y"W+K,N.ZV8(&_$']Z>Q6!0SQA\'ZI$YW"'* Y)"; %SFRAB
M//O$R2.VJ.PGE%B/,(S7?A9$!^?HF:Y7SR]579'TMLC8NE1'&DCF,^U7]X6$
M.,8<IG$@(>=AE"8>\[AG5=OOU(1SX[ FL/E9"VA'3B>1-:,DEWB-3$0=44$M
M:UMP&-3BCG!;9XJ-2\XY.>>D3&.*P%M^,7[.4;#>52%X5NF?%H0A+)4-!"5#
MVL4?84A]$D OH0'B$58\8Y7 UC/7W+AD1]12'XFUE&>&['6@-6,41X"-3";[
MP7L7H!&T_<=MOLS8*_BM_=][\;T"']2[\?N8T7W[4(T:XM>9[GWC_/;U/AGL
M=^"1 3>(5_E2_9PWPUZNNZ'_\J))ZD9><C6%^@-9WA8Y?V'5/2D>=-Q;&"4^
MCB2#8:B.7YBQ"-(4(>CC.,1>R&02&9',&3+,C7P:>37ID(W$RJZI1095([/%
M;=; A3&X1AP?[M&IJZ, V&AP =HEN)%@JP5HU0#W4RV!Q;7B^$LQT>7B.$MB
M=]-X'IB]]XT#AY[NUO$\W7?N'L\<:F ^-EF*&UF?!=5&5V9<M!N=8$+W@KM9
MW1=D59(ZUWC!?1^IW2>!J0P\B'FJSLR)#*$,&1.^1'Y K>)BK6:?V[ZS(S$H
M6I'U;5&U%=HRT=IJ-<RLXM$P'GFST7+K3;WM\+.+]M<.VO<&:-OG7P]!S6D>
MMI4 T^9C#\%F+R][T"##2.ZC>%:O9];T$1'/2U$S[(I?/N5%E?VCM1<2/Q*Q
MGT 6IP'$^L(\]1"&.$VQB'"*0U_:<)O)I'.CM*[,M;.==(2UHS(CS,T8S#62
M(Q-75UQ];]$*7.-Y:8*G-5G9 .22HXSFG92:;)!XRTA6SPXX\=\4#V35CJ.&
MO7MY>B+%J^+ [&&5R8SI3JZ,Y2\K78^O=OYDHMO)PT^9P)Z R!.A8B5MA?DX
MA1X.4IX(3@)DE ?@0):YT597&Z#4 :T^^O33T0AL50)KG09T!7&QF ;>@NF6
M:&0^_#]O=2P<"=.MTD0.A9W5TEM6V:Z6,L7+SFJ1[6H]MVJYBEQV@VFO7^',
M*:;S+[C!8L?/X&A(RQVPJ!:MX^*FN!/%MXS57<H7#"4Q(SB&*=4%8-,H@4G
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MOO='/C4D 447$5H7F]^T %)\<2]67-=.4SSRMA\5B9*(A8A#7Z21.L8S#I.
M*LN'>3)D5(0LD.8Y*?8"S(T3:A7 \[IB_Z9O5;WI5K4:31++]D\V61<#5LC@
MN#XR[B-33P/YIDG"M@.;4@ T&C29&N<U9QN"O4T2S+AK,%5>C/W7W]4Q_ P
M^S-G!HP[83+-<*UW\VO.&&=@_&EM?UXU=U7;MFZ"2(QH KG'?(A%D,*$"P29
M( $CH1<BWRKE^N L<]LT6O':$[%M;[6#.)J9DV>C,S*U-_)=@#5 H_0CZ\/
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M-$EXIBE3XBR * LQ9 D6,(Q$0"B+0B2M.MO833<V\EQ+"V9E2MNLEM=4Y8>
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MH0P%@XADPO0RXE#),$L#&N"8.'5R=Q=A;'RS2?C9R/IOSJYJUW6P]E7WB.X
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M2XLYQV96[S39$QNA?;0]W 7;CED]0]@S=9YL45@+W,-IVP&@_AL)[DX[@O:
M1W&P:_IW_-'N_4WX8OE:5UTHPRZNS=WB\M?U0L@I%2)-#=,@&F<0Q41"C&@
MDRQ$81PF,B)6AWG+^<9&.C=-^XXMF<L0SI4TAE\M.3"BNW<^:<.]G8-Z0+-G
M_O$!9*>>*!;P>&B-TC;+X!U2+%0^UBC%YK&.OOS%0OS,9[/;EU>:+PV%F89O
MT\@$>:H0P9!F')JL-4CUW[6-(\. !*G^5Z=PJN/3C(U2&BE!OA;3U<U_'$Y+
MC__%(/7M_*\%O (;$8&1T>,]0"L&7J\$CL\T[.U J[8'%P7MG^X<+&#(I'B4
M7.8_S&'+5-%N0@588LK"8M/RW02!IR%DG.JS34PC07 8ZO]W#!4X.=G8R*"1
M%2S7PCI'!)Q&UM)%Y FOGGEA#=5&SBM E5ZETK'SD^J7H>RG?KV4(J\HHY]
M@;-H>0X3.#W?T$$"9S4_$B)P_IENG/(EGR^638<W6:R.Y+!\^/5 JV:-4J4Q
M2P)(D @A2C3%T) PF#&$" T12R.G  *'N<?&.'L=E)OFU1?DEW99$#MFZ@GF
MGHGJ1(_JJZ,I?*9I2*6!/XKJ )M/QG*9?E "ZX#+/I]U&:(;O7V612'E;ACX
MYYRR?*:G?Z"_RG/#QS<Y55&6)"D64"8T,#4I(XA1Q&"82AY)$L4ABJ>KQ8K.
M[+C-=F(G8EM/W]]K]VSFJ!)1P&LMIAN!64-NQUY] -DS=54B7X&#3).UW%=@
MM0!,EN4K_3&6*U0^Z<IZ[D&YRA61?:)R?KYC"IT)9GC^3N?/\L4XCY:_=L^-
MY@IM<Z&V?]4V%5C%"4HI9#04^NC'&20L1C 41- TPVFBK+S+?L09FZE6:@-7
M6AVXJO7)9[]JOU'99NR'WH(Z$-V%JV9'?\.M1<^D>&09?NW[IJ[ F=B$@K:<
M[-WS\+Q@ZS4K[S*)ALW1\X+>0<:>GU$[!.7^1[Z2#]_I\H7>SGE]A\V0D)DA
M51R;'KN4*$AYBJ (%4M5(A@E5K[U4Q.,C2N-B*"2\<K<,OW5(3[T&'[M'.<#
ME9Y9:PL0@T>7N-ECN#C$R5Z(ST!QL7LXG?[>N,7 MBC?&O-Z[+GA8EQ;I-Z)
M:6W[7,=Z,>L>Y2<ZDQNNW#1=Y'%*]=%6:G,QBR"*I:8WDQN$$54\(E1EW*UP
MC-/T8R._1GI3ZJ1L26N"?,H?ME1P+!WCMAYV)F%_*/=,IE8 @Z^E_*"?AIB=
MH/-:8<9-@F%+S71"YZ#F3+=1.D=]EI6Y9#F+\1G7EW9$$I72.(&*(FYJ8B40
MTU!"'E*9*A5)@IWN*DY--#82V\@)N!;4.:SS.)IVQ.0#HYXI: L>(^,5V$CI
M-62S%0?/<9K'YQHZ.+-5XR,1F>V?[\8&#\L%EU(4NVVP%LMBRH(@"ZF*M7T3
M$M/N!>F#7!Q#$DO]_[&421"[T,')F<;&!XV@P"P:X-NBNG'#:6SMR,$+8CVS
MPRY8UU9@.;/#62!\TL/IR0;EA[,Z[Q/$^0?\)/GMN9,XKYJ)2/'[<E$4?\R7
MDLY,@HIQ/7V0:K&4S_3/J4PI8RB35?$ZI((8,J;)A0242L00HXQ,Y_*;&<B.
M3[S(9?4FD>I-VI:NQVBC ^\M*+:<NZ4R8*,-^,WH(XN_7)8&V&U1[6ALN(4:
M13)@424#;M0Z7+/*<<]*W8!6KK^<OXNP[C/MKYM@[YKY=Q&6YY+_+AN\&[/K
MJ67^;5Y%Q?%?STLZ+VA9LMDT/2W_.BN=H,7#8I;K#VR\8)DB(A$":ON0F*QM
M"FD:*YA)R1(<QD11[&(;=I9D;+9CK0AH- %;LKLQ=/?%L6/E02#OF8F/HUUK
M4;K*MO4 E2+@:_W?7MQE%\/JDW2["S,HT5Z,V3ZY7CY@Q[N$-U;D(J?+7X;2
MZP+2DS_S8II($4<,"Q@K4\LT(@QB@3,H%(\%BI(@)<KIVN#43&,C1"/>NA Z
M^&I$=*TE?Q)42]^_#ZCZ=O.[H.3NPC^'@%=O_<G)AG7,G]/YP =_]H&N><X3
M(?1W15--L:*S_YV_5NG-.$T9#Q(H8XTABO6AF,DD@C1),Y5106EDY5UKGV9L
M;% GX]:B7H%*6*"E[93)?!39=E;PAU?/E- 5J@ZYRFU(7)RB?'3P@3.3VQ0\
M3$AN_70WPV"OC/K=FPE<T!SSG2[E_=NJ,&US\OFW#[3(N2FYD,_>]*>G218'
MC&81E"S#IORH@IA@?<S"/)0JRN*,.55 [R;&V$BD%+< ;T49B5J6.GXK0\:9
MD;NJTE))#N9R!6;&^?(JEZ PSP&Z6BUS]K8J;\Q7"_"DAZ8O"_#\76/R*O5(
MO*@"N4"QU?\#_*:G*D=P=;5U7'L[XZ;_%>V9Y@XZ250JE,90M<Y;:ER!#^LE
MKE7Q9R5=!J5/$ZJC)(/:5Y>AM6]\73A:1_<7S9?_16=O<E(4<F5.ADV>0BZ+
M+Y(6;TLI[N>/QBMGBN_I#]PMYLOFKT:8PCQ?GB2?)?\^S__G35;!&E.54(*"
M!$,I4V'J9BE(1(JT?1>F(DG"1$1.U-VGL&,C>*,K*)4%M69EN/OM7/-\Y=99
M:P(VJM114(ZGRUZ_!):>N)$L;=_.NGY6U=U#-P#<7IUX?<H[K)]O .0/7(%#
MS'E9<:)I&"B18L%@A 6%B*D,4AHDD,>99$@F:2J=ZI T X^-UQNYNA4=<BPS
M-"+F.ZMWYSI"??#->NQWJ15TZCT^^/VET?ZGJZ]^7O?'$ISQ*&4)9#31+R9/
M%*02<1@A%J5!C!,:N7GM768?V]MK$?9P09<RMX6Q]/SW!7?/?.$-Z0N"_1T0
MZR?6WT: =PKU=\#F=*2_RR#C.]]NA8*DE/$8F96,$409Q9"A-()IB'& DDS&
MR6@.NJ,-&WEZ>WDQR=T+!6Z*5?Y2AHUM'9CTOW]:2MFXQ#8')0W2V\MK>94]
MGG.O<RC*V)9\S"?AGL)6AER"?Y;3\7N%PPRY%D.>ER\-LS%7=!_KY.PRB"<O
M>XO*U\5R-8VSB 8<9_H+DIJ^GR2"!%,$2: DS5(<<V9UB&Z;9&S;1B,GV @*
M*DGM;])/ GK^'MT'3'V;TNX(.5V@GX/@@NOSDT,/=GE^3KGMJ_.SG^V8?++4
MXWTK]\>BHAJZ^9?MN+ZZ2D3"XUC$0A, "Z5F 1Y JK)80XMEQ .1I#1R*NGK
M-O_8"&);_-*PT K +0UV F8=,T@<5\;.%.P1[YZ99I-R5;:XV\+8X+[]]ZKU
MG2GK!'8?^OIQ\4+SN4>SKB.<7A,_'$48-L6C&SX'R1P=A^G&B4W;XR>Y_)%S
M69X)M=UE6D)MFG[7+<?T3_=*&VN+;W.3/?(@E_FB;!VUY4Q3"O%41 I&<6QB
MD[,(,AD@O: 9B8,0(:&<.-.S?&/CU%(?R(Q"8%NCG7><_0+;GZOK'H+)3[H4
M5[N/&6TO<)SZ_C;8\?0[KG'//'YTV38K>]7TK1)U*9;7?%5E9I4- -_FEFOI
M3.4](>Z3ZGV+..A6T!.^^UM%7]-<Z"*N?$^?3:NOJ#&EPY"%$94PB(@VI3&E
MD B90:;?(!3C2/"0=W+L'LXU-HHO90-11X_J$2P=_:"7(328]_*J=EE>@1JP
M'GKY66#2BSOQR'3OXP0\K?=)UUW+(]T=;O_Y1I?ZW9O]JMU#2F&D2(RA2*2
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M"':FN#=@>]X_UXA.MA$M1:TB+/T9WU:0^+3$VR<<U"RWTGW?1K=[J.M5Z?$
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M&M''\X@Z^V%<(/+IE+&:=U /C0L2^^X:IV>[5L;3+V]%D551$.-I/RP5L@X
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MN,%4I5C*[WI(?2ZH8M_OY.I>/=,_M[,-GA>[!<N;FM?3D#*$4)A!*02!2*E
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M0924O:7UCJY(J'F!2BZP4ST>BSE'2 >ER%>@%+K\YJ_%O@)&<+>MWP9W.V/
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M!CJ))#2.((H2!BE.M>NC@@=8ZJ /V=-%#23DU/QCK84YE_12ZE'TS5D6FEP
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M\.A $WM([=[LL#N#CDP*>TBA]URP![]UOK:(YOHBC+R7_&DQ^]]7V6B2)\-
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MZD]__TO]%_V/*?__^U_^'U!+ P04    "  D@J12\B=11>)X  "'2@4 %0
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MZ0.9#1RW%)P/1"NI<'VH3-!9M431TE>!>@EF129Z=TRM05L_O4OJ0:MK=32
ML(?$0RSDB4R8+ZZCLYZ$&"2)62<EN95:N"KV:6/4='[N5=$@;2WB[?$QF?O1
M7AWSCY-QO.%0>BF,=Y:P4J4L!3?$N2@(34!3\M)XYOOTS>]);<$][R;74%=+
M#=BI3]/)!4SG5Y]&'I?E.)70]Z(D^G!S'V \"]0&1Z)0D<A$*?$"16<U,"37
M*!=6% UWL04^3U0+#GHGV.I,\@V@"*,,/_XRQ(5R+2!DX>A['%V6BJ5?)I/T
MQW T&EC'G-4ZD=(6ADCJ%?$:;77@C#L:$XNR2CIT'>):<-8[057GFF@ 77=T
M&R>L,B&0G!UZ"P%#5A]Y(#P%(:A+SJUJ*KH[@C9"266_NQ.4;"71!I!P@A;3
ME]M;[\'/X'-IZ'Z2?YM=8WT0,H"4T1!T*M$%M%$21XTD3#$5%4L&5)6#NA>I
M:L'K[@0SW<F^!2#=!YA+OAO* XS!\$-I40XPO2>X/BSQ8+43SB2IJ]B7E=3T
MTV:P!G!VEG4#@/D,*(EAG,/B@&B)CVAE5.62L0^+N-4"L=0RPI@'S:/#OZJ$
M]L\1U$^SP0JPZ43B#2#G6B0#;IF4+&JBLD&?BX,D7I7B?60FB6B4]"NNW'65
M NJGOV"UT_^-I-E MN?]T(?A:)$JP$AO<;/CZV2$0I^5J&]^=2>:5"X/1MPW
M5>! )+B(+"5&@J4FTZPD>NPU4+(N@?UF=JI7(5714P,V:(FOQQE8H[-PEG/"
M62EH8$(0QY&=$+R7I3.CAA5%U9TBKJE*I3H0>!YGN^BC 63=G@I^\E?+A\N6
MRAQM B)D#*7U:R:>15IN.;)$%<NX2FL>R#XDIQE$[:3L9\YC=Y!\&_B97D(Z
M.K\83:X WL 8\O#^5(=Y:FT(E%CO&?IZ.F&4D!WQ7-D0E5<LUCK8?X&L?G?!
M>GCJ2A/MX.JIK 81O*,F46+ (", FKC@.0$)46MI#<]5-KQG*>KW1*,NFG:4
M?P- .IR,%]+XQW#^]?!R-I^<P_26J]NF4H. L@&#;H 2R>#BD)Z$I ,!KP6C
M- <05;:[=8CK]VBC$KPZUTH#2%NQ5C(#87SP1#E:!G\)17S$S5P+&;@%#YGO
MR3GO]^BC$HIVE'@#B847U\%2SHP*E3@&+"2;G(B4+I# >+D;OKCBJ;.D:>\&
MJI6"D;V$?#4TU8#1>G@JM(HAIJ5VKAP%:5R;,BJ4%QA-E/=9(:_&LRHN_ \I
M:\;OJ@>Z;K73:T.16Y;>WKRXS*\ZAS/_?4F0I7*&&UM"7$%L3&C D](8L6A&
M>,A6:BZIX%7*=G] 5S->6#VP=:F9%BQ;.;9<9F&IQD^7/BLF$%/F#4@O#-IH
MY,F"%2&QG)6K4A?W/$G-N&<5;5DW^F@ 64M,%/OKI2IC;2*C1%KT/+W-GE ,
MDSG7WHDZCMD2#?U6J.P[W[Z1Q)OP\,_/A_/SQ5W4<2I>)&[G,(Z%E9**BTPR
M$IE!BRI-N1.1-7$R:QJ5,GG5R-0NO/IG:>JW:F5/GGPW&FG $CV5$&[>U\6B
MGTJ;=-3:?#X=ALMY.6(XFQ2;6^*8R0B?^.7V;N&=5*,%[2S+)$8>B=0L$)^E
M(*!,8LY)'625 KQNV>BW@F8O$.Y1[PV@_M/M>Q=BN+[7S[P+G E*(%&,@TK!
M0'!E:@0$BSQXF5.5PHL5M/3=Z:4_:#R]%KB3GAJ VE(KUVOZ S7:4<\(.J7E
M>-8A_3DA,C(MTXI  %3;LI<)Z;N0IQF0[:2A!A!VD-*B_LF//ODAQMZ'_F*(
MON<26P/M.(N<E7EH):==QL&'K!=-8T6PS*L8ZUP<_"%I_:;@&D)AQUIL )>?
M8>Z'8TA'?CI&:<T.8KP\OQSY.:2WD(=Q.!]XT($9ZM!9EIS(,K\K,)6)$N5Z
M=\@AK)K-WD7I](](ZS=;UQ N.]9B [A<XF"142HM^:?P%<:SX3>X3EV^G\Q*
MPO(DG_GO@ZB9$B@DXDP9;Z\D2@^8)CSXB.QIFL6*9M6=E(ML0F>_"<"&$%M3
MOPW ]ZFD!\90+FF9)J)+F]:L%+$L&N*5IIYF:T!5*3YY2DJ_F<2&0+BCEAI(
M.WX8CB?3VVEH*):!T!$IQ4@K<EV: 4=<,4)[HI3*$$T(BE8Y5WM,2+\)QH8P
MMI.&FK1DVXAR(*R,AN9RF2C),G_-$9<,H)>LO)#!2^_V9/VV(;_?7&-#:.X!
M#0U8V1\E>P=@-%B-WK27SA,)P9<K;@F]$R.$MEE%6^5&\H\(Z_<^X;[/#'?7
M36=8VT-[_-,S_//#T<>STY-W)Y^./A^<'>-/'W*R0Y_\9QY?K6'^.NQTU#G_
M.KRXNZ5X!T/ ,$(8W)0AV4"D<88$QQ-160%C.CE?IS'%,_3LGMKY!N-+>(?K
M<E55XUV_F7)7%_]+)<RRRD+V-J*_&W&Q,,,QS-) F).2<>>"M55*9K:@M=_S
MERXP]#2+4U=A#7B3=Y6.-TTD[V^;FV2S*8%74BE?%]3ZG!6)GB*I*J7(JYRX
M/$M1OT<O-?#5C? ;0-%GU 424/K O\4U,YHL&K+=<#5(&LK45@S<M2U7#:C&
M$-YF8KU2*"^FW*K99)VT^GB>JGZM54>:?]KZHR,U-("I7V",,AHA+P?I?#@>
M%OF4X?*W['#%O+08J!AJ2S,V9XGSZ*UR]%&9$]F KQ+ _H"N?JU4'5QUJ8H&
MD/5$2 //8G(Y4F("10:<0.%XEXD"*:+A4E-9Q4(]H:3?@]TZZ-E-W UD&^X8
MN#\&&00?D&PKB16E%23W@K@R&3('JKTV+&5;Y8;A"EKZQ4Q5OVA+@3> F;LD
MWTU3]FM.< \.%NE51#,*1'I< RX!(XA[!M)QZ^K<LEE-3K_']360TX'8&]B@
M[F&_53+7<VNDTX;HDEN3SI?3,D6)T(9K3HL?6"7YN1O9_9[$UP'CWM38A,6[
MN;YVL\W?-$(9Q#*H@&D@5'-9&J!8$E3V1!EEC F@<!'60^,3>OH]:Z\'L]T$
MWX#1^S2=(-6+O9XEK3WZ@,1!Z9D#*1)OO20LQ,1LD%'Z*AW/[TGH][2\!DJV
M%&\#AN4CS.\MZ5J6TRD#-FM9G$-*9 3T%95.Q#L'R7!OHJR2NMR8TGZ/L6O
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M">OAFGT7(NSAJCW0D*QD)"+,2[ANB#.ECX4M]6,"D5ZG1\W^KMJ_'$W>--G
M[_XQG'\=CD_&\%_@IP_=>YJ% B,%@1)B2J<$\1D<8<YFEXS"4+/*9>C=27\]
ME_,WP.%F^8+.-=SDV=5S/!]DM#O(\MG7Z>3RR]=WPV\+[A_%K\(R&DN^C@I
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M)T;8<B7=TD2K7+AYEJ)^350GB'ALD+J1_JNT-1U[=]N_K+Z%VK<W]RQ4I<4
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MPHPN^#5;9*[UOIYGUM74]Z2N\/MON'XZG\3?/SWV,VY8D=%KEC0GC$L45:!
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MD+2Y@%:8D>/Q'$8CB',4#\K@ J;S8E#NK<L3.Q*=Y]I!)M)2C5N\M<1Q-";
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M?X8;.U<C,40G<K5R N5I0R$&!RB$#>1T16>:C'/8 H9-R&L&R-<78>I0B .
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M[3;GRREC><23*EES33LC;JF4$_C:E,,P.BN2V>1D,R=\\[6;(>[5!D,Z%=6
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MODZ[WT48#".7.7D-R(H )>D<QN +2"NP)%3$U$X>BG<GO=^Y(0.Y8_<+@"%
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M7$JB&9*HT+K,ZA;%V"ZN1*$X?@8/286".?16\1JP8';:K5W8/^Q"R?4XU?!
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M#@-)'/[#*'ZU=%<1IYN)[M;C+U!+ P04    "  D@J12$<[\ .U)  "<[@$
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MJ&'1],2L"A=IPXB/?_&]D"A>%(=W194X^Z^SJ%)G$:(UI6I'$G0<Q(F$S^&
M"4'/8$3,+"@*T?S^J.)</'"L XR"\--U#B<0[*6)"C]Y80(: .X0W\.CM1B#
M+H/0KUQA1 =W#ETGR!GW"MA#L,M:5>E$7<,1RHG!@E'3>^-C2BZ^RQ+7<\_7
MW?K1S,.O,)JY=]1E$$+69B1GC([E'VT$FVX64-IV_+FGF#VUG,.J+O4)B)E5
MUQ,/I:?K2L=?M'!M9K^Y$A/WS@G"M[6L+8(I-.-S2?A)#%["&J^2R )1:LV<
M!)&H@([1DH5TUD1R BQ*\']\N__BE3FI?&^2W6*__&9<Q((?FD-#WATS%J"9
MPCOP",1K$6H^CK%Q,";:\:3][+BK\7N,[*8E*PMX.#4'4 XXQK Z0Q>G:#3!
MN,13?1+KPX]10+6!:,8KGAY@W3-75!^=R:(2]D45UHX4=[V3ZJ758*/#7L,?
M.5F#KM+'FUM9-8N5Y 6DXZS*BRI(&ZIHBQ7,KR,[N%AHJ&Q.1ZT-/'(K)&QR
MTP:")F 3K_-@VG"RC3$!$AL0?%*-&PC<1.<KRJB;(!2TG$&",PB>5  ^P[GG
MQ23+RRWLC0=G),-(HHK> @W&T#Y#.EU,'A[II$Q"!\]<*(F334Q-M*TCG2.J
M)/T3<23&'W";>1L[F]ZM4I\*P9_G!G:"O=8GQ !T!AT9K'<>+@IN0 FB&6 T
M/>KCY,:1'#=U[V3%!Q,KNR1">B16>NCA/H4I+N<="Q5SZF8U-]6/>2R+B'*6
M,6#D$^AU3/LY\,H\(",0KN*,9><+,<U<6_>G'.6(FTZ).C'[[NCT;T%VN:A<
M.+@U$&O%,F>[59OKI&04AFG#@F)M8XR?F%NM0F4L6WN1)1I8SP-W37?.LPJ&
M*MU"EW!9D=%0E!D8'=F,;7@0&"!@PPGZU:H9?CSB.!\\)5=-86S,"WPUM."2
MGG4/7T'S.3O;PR./ER"Z,O LN1&=$2?NR[?^'BK@'>URS5WB^%-\S@1.\;S+
M0]1.81&P0YM'6H*B,H28\P,2.?^D2CA1DDJM-0^R>9R%Y2[^]S3C)E,'SX]5
MBQ@D>W/Q*9ZGV,P3LL)$1A$0;U9D-G$%Q]H?%3[,/HD=R=P6JT*@4@!/-08
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M]PPK:>[[GP@4@%K!V^"V5[O=T5Q FYSEH!5%'! M\PK_9#P#NV.T1A6)9>E
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M39PEQAMB* 6PC.Q.K7,!D[G"AK8TMB9-$.RK1%+I*96IBIV++&.%A8F-.8-
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MYVZN===*MC49_6;$KIEI:[WZM4#?ZFK5M"0_II2%?UER^:_[!@,<3,B"$?J
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M+5^3:M'X"XS,)]?UPGB!_"0DHJYH0D5<*1\(9S:3MXU,@1G-;DIV[>>2&1?
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M%PJX7^;]G] 37!K[?LPM#@P5"%"&IPW&TQS;1+6D2<Q0O*7$BFLG+LQ,]=O
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M@6FW>=RAB;B4#AL!A"ODM$]CJ4[I-N&EVUZ%\MY8 A?52#&3FM*B _#33+G
M>I"2>>B'2N857ZYSKI6:!Z!5J70%EGK%Q]2HP)VPQ1FM1-B.NG+LE%#<*G)
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MZ3NU&>L_G\U8.%T4RT527_$4T>8Z4%>415#;.NKUS4+VSCJ.8M8;Z^XR?GB
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MV" >R\_DQ@=5J^4<\G9[I<+'6-.EWU3YQ#=8U6_\(BQ\FW;V*U!+ P04
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MY8<K^PGM]$]02P$"% ,4    "  D@J12&J$CUUCC 0 U^!( $0
M    @ $     <V=M;RTR,#(Q,#,S,2YH=&U02P$"% ,4    "  D@J122 S2
M@:H4  "?U   $0              @ &'XP$ <V=M;RTR,#(Q,#,S,2YX<V10
M2P$"% ,4    "  D@J127GLU'"\@  !$30$ %0              @ %@^ $
M<V=M;RTR,#(Q,#,S,5]C86PN>&UL4$L! A0#%     @ )(*D4J/N(!GJ40
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M;6\M,C R,3 S,S%X97@Q,#(N:'1M4$L! A0#%     @ )(*D4MN>'4;- 0
M_!   !<              ( !,-L# '-G;6\M,C R,3 S,S%X97@Q,#,N:'1M
M4$L! A0#%     @ )(*D4A'._ #M20  G.X! !<              ( !,MT#
M '-G;6\M,C R,3 S,S%X97@Q,#0N:'1M4$L! A0#%     @ )(*D4E\PMDC_
M!P  ]B8  !<              ( !5"<$ '-G;6\M,C R,3 S,S%X97@S,3$N
M:'1M4$L! A0#%     @ )(*D4H? B0P6"   8R<  !<              ( !
MB"\$ '-G;6\M,C R,3 S,S%X97@S,3(N:'1M4$L! A0#%     @ )(*D4D]8
MB9M4!@  G1L  !<              ( !TS<$ '-G;6\M,C R,3 S,S%X97@S
<,C$N:'1M4$L%!@     ,  P * ,  %P^!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
